<SEC-DOCUMENT>0000950170-25-069311.txt : 20250512
<SEC-HEADER>0000950170-25-069311.hdr.sgml : 20250512
<ACCEPTANCE-DATETIME>20250512163346
ACCESSION NUMBER:		0000950170-25-069311
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250512
DATE AS OF CHANGE:		20250512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neumora Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001885522
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				844367680
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41802
		FILM NUMBER:		25935417

	BUSINESS ADDRESS:	
		STREET 1:		490 ARSENAL WAY, SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(857) 760-0900

	MAIL ADDRESS:	
		STREET 1:		490 ARSENAL WAY, SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RBNC Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210929
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nmra-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-12T16:28:12.2078+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nmra="http://www.neumoratx.com/20250331" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_bf414cc1-70d4-4935-87df-a16b97268b94" name="dei:EntityCentralIndexKey" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1">0001885522</ix:nonNumeric><ix:nonNumeric id="F_7d6d31ed-6274-48c4-83c9-f284145996fd" name="dei:CurrentFiscalYearEndDate" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1">--12-31</ix:nonNumeric><ix:nonNumeric id="F_4dad036f-1f70-4e65-9ecb-159d2eb2d837" name="dei:AmendmentFlag" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_2a904c58-ad37-4d3f-85f9-392846bafecb" name="dei:DocumentFiscalPeriodFocus" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1">Q1</ix:nonNumeric><ix:nonFraction id="F_45e7c1f7-f3df-4a26-b1ce-361952795a76" name="us-gaap:CommitmentsAndContingencies" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_61c6ee64-fa23-4de8-ba82-cf50486e9efd" name="us-gaap:CommitmentsAndContingencies" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_5ef6507a-991a-417b-a92b-153ec2aede3b" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonNumeric id="F_c244de65-f8a1-4f33-b839-be154c63280c" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_c9441c9e-5777-498d-b6d5-078a3f0763f0" format="ixt:date-monthname-day-year-en">May 31, 2029</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nmra-20250331.xsd"/></ix:references><ix:resources><xbrli:context id="C_807f1ef6-efe1-47cd-a1ac-f6eebc286522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8546d344-f5a5-49c0-b25a-d7761e6c965c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8581f7af-0c61-4b18-9fa5-437addc36bcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88db6b5d-3162-4950-a605-ff7e73170e5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8930b52e-d90e-4036-b728-884065a23c99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8983212a-31bb-40e6-aad9-72c31bd8b3ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89c9cc8c-f7d3-4aa1-8971-7f4acc54dceb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89d8aeee-2789-4a1f-a31f-e532505c7bf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a4d11b0-e864-40f5-af40-5075fb6dcc55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ae50382-fe31-444e-adfd-c5c5cf08f02f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d55cf2a-ccb9-488d-99f3-88abc8c63dc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8df9e453-1166-43a2-b750-45ffb91958ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e618d30-af12-4d65-8977-21df83d2cdd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:FirstVanderbiltSponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_900e0f63-0ee4-40ff-a668-3acce016bc69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9061b628-1cbb-40d6-878c-d538a8e5434f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9118ec0b-0a0b-4f37-8864-d70d86430dc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91940b71-4a64-44b8-8e19-43b82923017e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93d4bd12-ee53-4993-8268-9e9637ffeca1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_945e63e7-24e2-41e4-b69a-b13ccda12454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_948e3436-40f4-4902-9557-b188a3de6f02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_957f0675-75da-45b6-8d5a-5d4c59c2f42a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96e4575f-22fb-4510-8c56-dcf2ef26b887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9725a19f-6026-4597-becd-68b62f258eb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97e950d4-ad65-4370-8e70-5ec2021370e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:Nmra511Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_998e1d41-951a-4a8a-8f7b-eacf68edbd89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99f5cde7-7246-4eb9-9076-bb614ce418b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nmra:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a04f240-c069-4dc2-8d21-d62bfc7e531e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b4cda2e-b933-47c6-a24f-6f190752e6c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9da9e2d3-d2c9-4624-9a0f-41478107481a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9daa6341-c6b6-4510-aaef-1aaad596df55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:AchievementOfSpecifiedCommercializationEventsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f0723d9-5254-4d08-bff0-43148bf1192a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2d3f823-77c5-4f3a-8379-db86ade0a660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a449de6c-c7c4-4d8d-971a-f9c39a05240e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:ParkinsonsResearchVenturesFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4715f31-d2a5-4cb7-8365-aeeabb7b9c1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a55ca487-0567-4505-9f6f-f91c988a8506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a586780a-a629-48b7-9844-e31954befa7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6afc305-12c7-42a2-8ee0-0a5d36ab752d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:Nmra511Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad0401b2-4d75-4075-81f0-1c16e959518e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b021f8a3-fac7-453a-93f0-4243983b574b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b09a7f2f-554f-4ab7-a516-b0464c7db20d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1e412fe-b620-42a7-889f-eea848ba3fcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:TwoThousandAndFifteenTsriLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2225424-d630-4726-95a9-a1c8ebfb3755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b67f54a8-a954-4dea-9fa6-8d6747046679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7741931-52c1-4814-ba2a-d45dd587fcc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b89706ed-11c0-4574-9fec-db2b478b98ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b98e4b10-ee87-4bcd-aba7-dfcce8c3e11f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:NavacaprantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb5db30d-8a29-4c0f-9230-7f59a4cc1240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:ParkinsonsResearchVenturesFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb874d5c-ff29-4fda-8629-e1343f9f7d96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornCarveoutPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbcc59cc-72ab-42ea-869f-9a969577ae6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc5bd643-a814-479f-a13f-0894453ba0e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdb2f4d2-eed9-41ee-954a-8febbe7f4b55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EarlyExercisedStockOptionsSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be0b1b72-5d49-463b-ab77-61e5bac1a983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bec87db7-aba1-42c1-89de-287859477b6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bedae046-3671-4278-8b1c-24865ff68f64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf4dcd0a-343d-4af9-b2ff-82d99b4a270b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfc6fdc3-c7bf-44aa-8118-ceab97da4350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1c1147c-6515-43d5-9a5a-39bdb8587234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nmra:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5716e30-2845-4e75-9c82-0ead8f11e3d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6ca0beb-621e-45be-9f36-bcb1a9eadb66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7784c8e-e600-439e-b7df-863d51173fcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7f8c769-dcee-4641-8788-0ecdfd5e085d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c862b521-4d47-4fe1-8a29-5956f0f3aafd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9441c9e-5777-498d-b6d5-078a3f0763f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-09</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cac684c1-58c1-4056-87fb-85dffbb9e345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc122612-07fc-43ba-9703-dd266daba6d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccb36bdc-b5f6-4cd8-9f8d-4b1d849d2f44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd3670e7-bb95-4a95-9b48-6251aef56387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdd08ec8-fc48-459d-ae7a-3d50a476e424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf3b1219-8ac1-48e1-966f-2ba7c5539861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d182de24-0601-4e16-8128-a87852d11d16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltSponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d23263c4-414c-41f5-b6d7-7e3e8f52cb59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3ac0816-6766-4808-8c6b-73bdf51bb772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4678025-d799-4a17-bfbf-952b85ed2d13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d572c7f7-2d65-449d-822a-730cba140e6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:VanderbiltIprDAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6cdf9f5-5dbc-45cb-b827-e5ec44728d50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da5dfacb-16f9-419e-9ea3-8176113c5d89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dca1c4c1-2e7e-4f8b-8535-f8ba404884cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de855e05-78f1-4034-9dd2-99edd71f6a01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df815232-6d0e-46d5-858f-73dd8e96a6b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0b073e0-9ae4-4fbf-ac18-8ac5ee41c4c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e34013cc-ec03-4b59-921d-284dfd9952b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nmra:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5572f63-a9f0-46b3-8d24-1600baa94c52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6152824-6482-450d-a1ed-1cd75cb82a46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7491852-40a1-4eee-b2b1-7b6c1fafa82d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:SecondVanderbiltSponsoredResearchAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e899c8c7-d7d0-4f74-ac13-bf387dd80ce7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e911e4aa-353a-44c7-8d53-12528baf8f7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eba48cde-044c-4cf6-83fc-6f6426dd681f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebff40d6-3768-4f98-8eb1-4e6b12753e80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecb47253-5967-4e68-a907-ee441a95567a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee1bf88c-a716-432c-9927-f73c12f7dabe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef2557ce-7b57-4e87-830c-4493b126211d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:AchievementOfSpecifiedDevelopmentEventsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f164d19d-7ff7-4491-8078-1f6420964b6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f17f2417-a74c-4179-81fe-cbc4a177ea8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f31ea84f-b25c-49d3-b5e0-ea4d01b60c1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f56f8fbd-ff2d-4bcf-9a02-48dfad75f890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f63b1f37-86a2-476e-9394-a9737eb501a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9669214-3f77-4f65-8703-5b733c4987c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EmployeeStockOptionAndAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa6eb452-286f-470e-bfaf-790490cd6700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc26cf16-194d-42e9-bd78-03837763f10b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd27dd1d-0143-49e6-bae8-7ed81f1fc545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">nmra:ServiceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe1ba1ef-7e15-4e74-8545-43b5c9422c97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff586993-3393-4df1-a26e-92ffb8e44664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff6c1c0c-dab0-4730-8b13-70db93c2b6cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffa0d7b0-15ec-4da1-b744-c829194fe468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0073ad06-94e6-4b3b-840a-a087ad92d314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:CommercialMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nmra:CaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05cc4820-f2b7-4d8d-a300-c73727f10eea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05db645f-f4bf-46f3-bf4e-7f20ec31940c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_061cf2c5-5b6a-43b7-9349-feb9de83c3de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_069e0991-79db-49f3-896d-022fc3b13a5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06e547db-6799-4ce2-99ec-f971505c46d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07657077-ad7d-435a-b4d6-1b88f79c2724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0765bb7b-af0d-4ddb-abe8-4e7b1ecfd1c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:SharesReservedForFutureIssuanceUnderThePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_097e4542-80e5-445f-9968-c8d2e3c75940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a97a9b7-374a-4ba2-8c70-91464eb57c67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c70cc8c-7dc7-4484-8ee0-c0f1aacfc08a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cbb0a62-efc0-4cdb-94b9-ad0c8c0323da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cd17fb6-6272-4a76-8980-45ff567d9207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d5d9e12-40b5-47d8-9d2b-14dd033fa5f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e450f30-40c2-4a41-84cf-da509f4dece6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nmra:TrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e64685c-4df1-4cfc-8090-786dde3ed56d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f91fe01-be96-44a4-a1f4-fc84be3ec675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0fa32b7d-f446-4078-9cee-2d0078041367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:TwoThousandAndFifteenTsriLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_107c6cfe-84dd-41a5-a2a4-ae925e0ea374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12814edb-2555-40ce-8b79-cd767af2d069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_139308af-4183-4890-bc4a-2ef55df09c62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19eb528f-0c9a-4741-8410-ab696e22ae8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a39b2a9-d6a6-4b5e-bafa-1411d170d3dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1aca905f-ee26-4555-b248-631ec9df757a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bc0b95c-7620-484e-a74a-a6ff2b9e28be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bef601d-1919-4e4e-87a0-ea9d5c9cb986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1de420c3-74a2-46db-8f45-5e14a2cb894c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20182b59-d390-49de-939f-92e912503780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_247cd15b-eac5-41fa-89ce-c12599a45e39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24e1bd61-fe0a-45a0-b4e5-7e09d0a6cf7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27e8bd25-1d8a-462a-a5a8-60599bc36dcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27ed8d77-f3bf-4069-b960-220c0a09b3fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nmra:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-09</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2872bc3f-ac79-4fed-ade2-77671074619e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28c76f06-1cc1-4845-8c93-25ddca00f65e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nmra:CaseOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28c81270-b763-4f43-9e26-86aed60a8e6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29d4b3f4-84bc-4e37-a42c-c5ddac7501e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a459aad-9b00-4fcc-9e37-26666bf29cc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ab6c9e7-ed9e-4fb0-969f-343343d0a2c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b244c9b-1ded-43bc-820f-3c639a651b27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c7eaaa1-bb2c-4bb1-811e-b3ed93a9e5b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_319051d1-d908-4b4b-a4e2-c1ec01693b5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nmra:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33520c04-a8f9-4978-85e4-d1ef14e55fac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_345b87e2-e0de-4a5f-bd10-8a06638a2087"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34728959-32a0-44fc-a13c-2f71e43ae7e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3484d184-2e57-4ae8-ae41-4d03630e1535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34c399d6-b754-4a45-afe8-4f0160c2d7d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35521780-703a-4201-9415-b3fff9017474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3565ca70-6698-469e-afc8-c1986c5cf118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_357567a5-de51-4303-afa8-40e33e156b88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_380c3204-a040-4430-aff2-cdc8bf414df7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:ParkinsonsResearchVenturesFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_389f4cfd-1035-4a63-8472-a8b0535f9979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39f31af5-0a63-4d36-b5c4-aa045096d63a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-09</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b83541b-7d35-4924-a941-cdc46db3b104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3baa7dbd-2e2b-4e86-9a5b-5cbbc95835cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:SecondVanderbiltSponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c5a3125-1df8-4cfd-82c2-6439f4fce770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d315f3a-94bd-45c2-a9f2-a8597bd60111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmra:AdditionalSharesOfCapitalStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3dcb2394-89b3-4597-ac19-7d6a28943660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_434aebe9-f88b-42f1-a3a9-60444626ef43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:NavacaprantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43d828f3-9822-4b63-a7d7-23b01fed21ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_453a453b-8844-4a63-a3ea-cec4fbf05356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45866c85-796b-42f6-a180-2cc89ed0ddd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45cdde70-3358-4569-a949-fee006c59617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_467a3e0c-fcaf-44b2-b119-58d8725c65ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49cf2bec-a0f7-4364-9f41-4d0d4dd7485d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a09c9c7-6948-412c-8311-1564f533ec6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-09</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a189432-6771-4924-b99e-f1ee33b187a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d3885b7-eb3e-4bdb-9e6c-4fd241fd9a03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4da76cd5-5865-4083-a0ab-47c7fb41907e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4dc3cc35-4428-4ddc-abab-0af3843650aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e37b9ab-9112-4171-96d3-a28df5c5f26d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ef13920-7a05-4ac0-99bb-9c2e976e10f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_504593b3-57d4-4b02-8b18-4bdd29a7ac8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50810541-9cdc-4d75-8385-8446d34bf249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_567b6948-dab8-40c8-9463-dba168ab7953"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:NavacaprantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_572b967f-2f74-487f-ae14-180bdd868be9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59e023c8-7631-4420-9721-fe4e193d844b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:ParkinsonsResearchVenturesFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a79bd11-7094-4ffc-951c-6a83cbffb588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b2a4e5c-222a-4ad2-8abc-8bf73b709b4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c0b10fb-50d4-4b4e-b9aa-33b20ed8cf2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c2c1eeb-3a09-4d7b-9795-a097550eb2bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EarlyExercisedStockOptionsSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cbec31a-e68a-41aa-a5e6-626bf079aa0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d02fd90-893f-4a41-a4e0-50545ee339fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_609a5a5a-15b7-4aa9-b8b5-78d98fae8999"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60c0ef16-d311-4eff-b99d-ea396190548b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6167264c-1f42-4063-b5e7-f295414754c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmra:LiquidityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_624b06cb-3eb6-4c5a-b6f8-d5c6f733459c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EmployeeStockOptionAndAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62cf7b31-5216-483b-b0b1-4177e5c19093"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_635b097b-2010-46d5-b9db-42a97113defc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64494bd4-6ab5-4895-bf3c-bef01605a51f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:TwoThousandAndFifteenTsriLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_674b4626-69f1-4f21-a46c-b4994d0e271f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67e82a6b-31f5-4d3a-8d28-c6d447c17553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69427e48-5aaa-40a8-b2f4-3bbf2e2277d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cc3140f-0593-476f-9bc0-70f418f9f63e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d975b6a-1d37-4354-bb12-b6e8b427cd7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76739724-db36-40d3-a0e9-ef80e990e67b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornCarveoutPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b7d5dac-7754-4da3-bb2b-8b1d57fcd91d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c050cf9-993c-4fb3-aeca-b255bac5106d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornCarveoutPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e9a4d20-f83c-40d6-a5ea-7a0380c08cf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f20fb03-a67c-4772-9d37-ac7b4fb27bce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:VanderbiltIprDAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Agreements"><xbrli:measure>nmra:Agreements</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Milestones"><xbrli:measure>nmra:Milestones</xbrli:measure></xbrli:unit><xbrli:unit id="U_GBP"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="U_Program"><xbrli:measure>nmra:Program</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>nmra:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Tranche"><xbrli:measure>nmra:Tranche</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">0</span></p><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, DC 20549</span></p><p style="margin-left:216pt;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:5pt;border-bottom:0.5pt solid;margin-right:3in;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3bc3f219-be62-4833-a49e-655490b0a154" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p><p style="margin-left:216pt;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:5pt;border-bottom:0.5pt solid;margin-right:3in;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:4%;box-sizing:content-box;"/>
      <td style="width:96%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_5d7536cb-ba3a-423b-800f-07c469f5a826" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_772c5c81-7e89-4c65-bd6c-e35c44229ded" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_015bb14e-8a96-46f0-9de7-5543e4f62956" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:4%;box-sizing:content-box;"/>
      <td style="width:96%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_628cabf7-2353-4539-9051-f4110dbbd138" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from ___________ to ___________</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_385183fb-0bb0-424e-8435-a630a9e4a608" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-41802</span></ix:nonNumeric></span></p><p style="margin-left:216pt;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:5pt;border-bottom:0.5pt solid;margin-right:3in;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:22pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78fc4316-23fe-4946-81a6-52657f20dae6" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p><p style="margin-left:216pt;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:3in;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:50%;box-sizing:content-box;"/>
      <td style="width:50%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_371a24a5-bcf2-4114-bbc3-cdb3e4bf6126" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7c8a5672-8b8c-494e-a519-c97706ac12dd" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">84-4367680</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_3a856f4f-f064-49d4-af9b-bf9f9d3d33eb" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">490 Arsenal Way</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_c50e33bd-1f1e-4d19-b51f-384ca7c9d49e" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 200</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_eae7aa30-a562-44b9-8864-204058ef9129" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Watertown</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_96aa3b6a-2b3d-4165-a773-3ed46cda81cf" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_23bdf6ec-9348-497c-8f65-931d493aa156" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02472</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_952d4e12-eaf5-45c6-a651-529f79cd488b" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1eef9c5d-f422-4971-892b-07cfa0326b10" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">760-0900</span></ix:nonNumeric></span></p><p style="margin-left:216pt;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:3in;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:38%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:15%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:45%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
     </tr>
     <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_6daf5ed7-1ea9-4bd7-bd2e-55f8568831dd" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_7d39104f-4ff8-444d-8d95-ef3d26031797" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NMRA</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_31a3825a-cac5-4d84-a8fa-83978b3a0965" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ffc11f2-1100-4586-a130-7ea155c64819" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746; </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   No  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed6d140c-8690-4f8a-be66-27ecf5ccb200" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746; </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   No  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:18.9%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:55.84%;box-sizing:content-box;"/>
      <td style="width:1.06%;box-sizing:content-box;"/>
      <td style="width:20.1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:2.1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_cdbcf534-7261-4ccd-92fd-06432deced5e" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     </tr>
     <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_20bb26f7-a6e3-4fac-ad09-286c9720afac" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_00e1eb78-9595-4ad5-95fd-828d6d5f8378" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   No  </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a41955d-1afe-4abe-bf45-b46532f07f0a" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.     Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744; </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   No  &#9746;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of May 5, 2025, the registrant had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90f3b421-25f2-4b3d-bf35-4c1023169235" contextRef="C_6cc3140f-0593-476f-9bc0-70f418f9f63e" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">161,747,922</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, $0.0001 par value per share, outstanding.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the potential market size and size of the potential patient populations for our product candidates and any future product candidates, if approved for commercial use; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our clinical and regulatory development plans including any related anticipated program milestones; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations with regard to the results of our clinical studies, preclinical studies and research and development programs, including the timing and availability of data from such studies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates of the number of patients that we will enroll in our clinical trials and the timing of their enrollment; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of commencement of future preclinical studies and clinical trials and research and development programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to acquire, discover, develop and advance product candidates into, and successfully complete, clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to reduce the time or increase the likelihood of success of our research and development relative to the traditional drug discovery paradigm using our precision neuroscience approach; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to improve, and the rate of improvement in, our precision neuroscience approach, or to realize benefits from such improvements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations related to our precision neuroscience approach, including but not limited to whether it will have the same impact as data-driven precision medicine in the oncology field; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to achieve our mission to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to scale our company; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of milestone payments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our intentions and our ability to establish collaborations and/or partnerships, and whether such collaborations and/or partnerships are successful; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our commercialization, marketing and manufacturing, including any capabilities and expectations related thereto; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to keep pace with new technological developments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impact from future regulatory, judicial and legislative changes or developments in the United States and foreign countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our intentions with respect to the commercialization of our product candidates, if approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pricing and reimbursement of our product candidates, if approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the implementation of our business model and strategic plans for our business and product candidates, including additional indications which we may pursue; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain our technical operations infrastructure to avoid errors, delays or cybersecurity breaches; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to effectively manage our growth, including our ability to retain and recruit personnel, and maintain our culture; </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected terms of patent protection; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expected use of our existing cash, cash equivalents and marketable securities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the period over which we estimate our existing cash, cash equivalents, and marketable securities will be sufficient to fund our future operating expenses and capital expenditure requirements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the performance of our third-party suppliers and manufacturers; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact to our business from general political conditions, including but not limited to, disruptions in U.S. government operations and funding, geopolitical conflicts such as the war between Russia and Ukraine, the war between Israel and Hamas, and any sanctions or other repercussions that may result therefrom;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact to our business from general economic conditions, including but not limited to, inflation, tariffs, trade controls, recession risk, low consumer confidence and increasing interest rates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments and projections relating to our competitors and our industry, including competing products; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These forward-looking statements are based on management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management&#8217;s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements contained herein for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by applicable law.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investors and others should note that we may announce material business and financial information to our investors using our investor relations website, Securities and Exchange Commission filings, webcasts, press releases and conference calls. We use these mediums, including our website, to communicate with the public about our company, our business and other issues. It is possible that the information that we make available may be deemed to be material information. We encourage investors and others interested in our company to review the information that we make available on our website.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table o</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:95.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:10.526%;box-sizing:content-box;"/>
      <td style="width:83.874%;box-sizing:content-box;"/>
      <td style="width:5.6%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;text-indent:6.85pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">FINANCIAL INFORMATION</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements (Unaudited)</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Balance Sheets</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_operations_and_com_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statement of Stockholders&#8217; Equity (Deficit)</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#organization_and_liquidity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Part II.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unregistered_sales_of_equity_securities"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#defaults_upon_senior_securities"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Information</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Financial Statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Cons</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">olidated Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:67.393%;box-sizing:content-box;"/>
      <td style="width:1.6%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.703000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.6%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.703000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(unaudited)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c7762c3-c155-446b-ad3a-8600b2b00c02" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,860</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78f92e4d-d243-4e13-982c-bb51f00cc6b1" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,148</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97f18eb5-5773-4519-af47-6d4f451a7e0e" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_696c60c9-bb3b-4738-a3e3-0296c036a964" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_547ccb8e-52a6-49d1-923e-aebd1243516c" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,493</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efc74190-74b6-4a4a-884e-4ab6d4999772" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,430</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8cf4bff-93b0-4624-b83d-8c8525c1a5ba" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,300</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a24b037d-7b7a-49c2-9861-c441284a9a1a" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,264</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e622c93e-71b4-4c56-8ce5-b54815b7ca6b" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">254,866</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6333c106-ebe9-44ba-82cf-756b36b1b24f" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">314,055</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f55f5bc-8372-4df9-8604-effb354d7982" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">982</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f37ed48-9427-4b19-bd20-c4c3b13145c5" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,140</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c43d2f2a-2fb5-40f7-a4ee-aef4e64fda49" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">900</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0a9f8d7-9f85-4f10-8492-e481a78783c0" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,777</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b209e760-0e34-458b-bc10-9d34f0219b82" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256,748</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41015d79-8dd8-4d12-affb-a2dacc336c0b" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">316,972</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b4bf8c5-ffb0-42c2-a11a-9ab574cfdba0" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,052</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22067218-48ca-46f1-914e-1ce06cb5aa6f" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,307</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c7b278e-61f5-4c95-8dcf-0962e7102f01" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,272</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23c17a00-3e4b-4887-b5d5-d9f963b3ebfd" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,593</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Early exercise liability, current portion</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eddb0e1a-94f4-42b2-a090-1ec94ed0629a" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="nmra:EarlyExerciseLiabilityCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4be2f14e-a0dd-40cd-aebe-c423c3c7293c" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="nmra:EarlyExerciseLiabilityCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_633bacd2-f1af-4c62-aef0-5cc7c54b1b0e" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">938</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30be4811-532a-4fbc-b806-28446aef6f76" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,853</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74e64543-61d4-43fd-b8a7-d1bc12321c12" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,384</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b448e1b-d9e7-4d8f-b62b-ede52547a29a" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,886</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Early exercise liability, net of current portion</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00fe8ded-e9fc-4aa0-a31c-9fe776117b05" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="nmra:EarlyExerciseLiabilityNetOfCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6af33d6b-60ba-4b69-95f8-c8f69bf256c0" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,384</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1df33c3-6ccd-4f68-9f74-3f31463a45c9" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,908</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_45e7c1f7-f3df-4a26-b1ce-361952795a76;"><span style="-sec-ix-hidden:F_61c6ee64-fa23-4de8-ba82-cf50486e9efd;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 7)</span></span></span></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfb6e7fe-ecf6-46ba-8e0a-2979d80fe903" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd19bdb4-ae0c-47a7-a4b8-da424f343568" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41b15df7-2f8c-4fca-b939-bc6f27f64f08" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,243,564</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e9f7831-a8cf-49a7-880d-85b7c5d47f1d" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,234,207</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive gain (loss)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb0ff829-2181-4eb3-991a-a9d8563cb1d7" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f54e55ec-b526-420a-a547-9815d83398bf" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51951d06-9df2-4e0c-8d21-85e6f1890ec9" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,015,213</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57c000e9-39c7-41ab-94e6-9b80fec9d997" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">947,221</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35a79b29-7818-4d0e-95bc-a0fc82b64aa1" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">228,364</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8a85215-b90b-457b-a604-c3199dbcba07" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">287,064</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17b6ec15-43e9-47c2-9b2f-60c76fd3b4e6" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256,748</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3f33148-23b6-49a9-82bb-c4bd44271b84" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">316,972</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_operations_and_com_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Operations and Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited, in thousands, except per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1777fdbf-0ff4-4ecf-a336-5187185125f3" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,151</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_088a8b54-aba8-4fc2-9781-b6470cf23672" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,757</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29aaeda2-2569-43ae-8c75-834a818c8c16" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,785</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb880d5e-f3ac-484a-8bc9-53387961f1ce" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,317</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8294971d-6f1d-4644-a9f3-4bdff8410b5c" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,936</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a2f7871-b205-457f-b3d5-6799250da55e" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,074</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f7ce1bc-0995-4ad1-a72f-51eb015bdd7b" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">70,936</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_660056fa-09dd-488a-8efe-84c9822b3ac9" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60,074</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c559b19b-6a10-461e-ac26-916e9017a935" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,074</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95613611-01f4-49fd-b1ab-17a6299e76c7" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,365</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e96c2702-5f90-469a-b4df-0989be79a971" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d18e3758-cd5e-4e2f-be91-0fed2f332601" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc709e29-2087-4d77-8fdb-b816b7d8326a" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,049</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ea9dc4c-9235-4c43-81e4-0a3a117404fa" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,353</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss before income taxes</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81a1daf3-72d1-4da3-8fb6-cc93a9715937" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,887</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ab4a247-4fde-4cb9-bcf1-53719a6b4425" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,721</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7878be9a-3a80-48aa-b55e-e557fcd59f5d" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93770844-4614-47a8-b31c-bfe8140d2d36" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,992</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea92c1ae-20eb-4295-9a88-ad2428577677" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,721</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be2e27ee-13d0-47d1-ad09-539d25fbc605" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91f10e3d-adeb-4f2b-a171-35cf291138e9" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09a3e384-6761-415b-be15-a50709e7c0e1" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,057</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c1ffc72-faab-4745-a2e0-7c68bd212eaf" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,793</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32d0d27f-f8dc-4988-9315-cf7a3701073c" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3e38aac0-495b-4ad1-8704-d4792e9cfdb5" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.42</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ada7d270-88c0-4249-8703-1e2ceda460d5" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d1abde46-6048-4027-b014-84004aa8af7b" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.34</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares outstanding, basic and diluted</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7180f85-445b-46bb-88c4-b5c481015197" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4e48208a-29ad-4800-8485-d21c7fb8b172" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,451</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd0bdd46-c401-48a6-8506-56ce9353f416" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_40ec7b2d-e782-437a-9f24-835d9f19cffd" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,943</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:10in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:10in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:10in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Stockholders&#8217; Equity (Deficit)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited, in thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:34.833%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.479%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.059%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:8.018%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:9.898%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:8.018%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:8.698%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c03825e7-317d-4e95-aa3c-4982f9131d4d" contextRef="C_cc122612-07fc-43ba-9703-dd266daba6d5" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,710</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a6ead74-34eb-4233-a466-313bd874a0a4" contextRef="C_cc122612-07fc-43ba-9703-dd266daba6d5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f770d5e-4926-4edf-a971-91fa061cd93d" contextRef="C_900e0f63-0ee4-40ff-a668-3acce016bc69" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,234,207</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f93ea06-c741-4a08-8ffb-9c641d58d9ba" contextRef="C_cf3b1219-8ac1-48e1-966f-2ba7c5539861" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a57b59a-567d-41a7-8e55-7eb24d28e021" contextRef="C_d6cdf9f5-5dbc-45cb-b827-e5ec44728d50" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">947,221</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bb9ec17-c0e2-4281-bb6b-c1e2a502de53" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">287,064</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeiture of unvested restricted common stock</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5640b99e-3891-4e39-a8e9-9870cd420ea7" contextRef="C_b67f54a8-a954-4dea-9fa6-8d6747046679" name="nmra:ForfeitureOfUnvestedRestrictedCommonStockShares" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">231</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d3f93ed-e3df-4b03-b5a3-fc0a1cc979f3" contextRef="C_b67f54a8-a954-4dea-9fa6-8d6747046679" name="nmra:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of common stock subject to repurchase</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52cf5843-a38c-4b14-b924-b2ca7102f56e" contextRef="C_467a3e0c-fcaf-44b2-b119-58d8725c65ac" name="nmra:StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf4e5002-d5c5-44ae-82b0-79a4c7e8de92" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on marketable debt securities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26d26045-9568-4b4d-80e9-9af279aa40f4" contextRef="C_5cbec31a-e68a-41aa-a5e6-626bf079aa0b" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e655c32b-ce9a-4540-9266-933dda047180" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27e987ce-688d-4f03-a75e-4151cace42cf" contextRef="C_467a3e0c-fcaf-44b2-b119-58d8725c65ac" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,324</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4876e977-7615-4d35-aa99-37dd92148757" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,324</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1a8da1a-b328-4129-be53-a654b547ea02" contextRef="C_a4715f31-d2a5-4cb7-8365-aeeabb7b9c1e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,992</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e97f4e49-fcc2-430e-9eea-3ef493a275f3" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,992</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of March 31, 2025</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3b56af9-2c65-4d0f-bc23-453613e153da" contextRef="C_df815232-6d0e-46d5-858f-73dd8e96a6b8" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,748</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01f7184f-78d1-4e96-8eba-56f20a34e321" contextRef="C_df815232-6d0e-46d5-858f-73dd8e96a6b8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faf1cf26-4cb5-480d-9d73-ef0180be28ab" contextRef="C_139308af-4183-4890-bc4a-2ef55df09c62" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,243,564</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0be0fc7f-37e4-4e49-9c80-e1f4087b9ea9" contextRef="C_1a39b2a9-d6a6-4b5e-bafa-1411d170d3dd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dfe8c2a-ab47-4cce-b6db-f6f3547dc591" contextRef="C_3565ca70-6698-469e-afc8-c1986c5cf118" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,015,213</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abf99b77-247c-4175-8ce8-cf18c6b41f6a" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">228,364</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:35.44%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.64%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.22%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7.64%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:10.1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7.64%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:8.32%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08aae8bf-2551-4923-a75d-1cd7881a7570" contextRef="C_bfc6fdc3-c7bf-44aa-8118-ceab97da4350" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,832</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_346ceaa8-0fc5-4946-885b-dc01d5ff685c" contextRef="C_bfc6fdc3-c7bf-44aa-8118-ceab97da4350" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a839262b-a79e-4a00-adaa-51d412431d53" contextRef="C_bc5bd643-a814-479f-a13f-0894453ba0e4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,172,570</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_667b1d93-9dea-4799-a886-8dfeef971dd4" contextRef="C_20182b59-d390-49de-939f-92e912503780" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faf85d89-ce40-4d25-9635-b536d54f9923" contextRef="C_e6152824-6482-450d-a1ed-1cd75cb82a46" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">703,434</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd97cea6-2586-4d63-bde3-1f36fe6fd809" contextRef="C_807f1ef6-efe1-47cd-a1ac-f6eebc286522" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">469,076</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of stock<br/>&#160;&#160;&#160;options</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6b016f0-7765-42c5-9277-f7245f3165ea" contextRef="C_4da76cd5-5865-4083-a0ab-47c7fb41907e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">525</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c775485-8402-412a-a50a-e514f6e72bf5" contextRef="C_069e0991-79db-49f3-896d-022fc3b13a5c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,845</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d4b3fe9-8b0b-4911-b277-dc1bfedb2c3e" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,845</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd0d3575-fd82-49b5-9da1-75e8b8e168ca" contextRef="C_069e0991-79db-49f3-896d-022fc3b13a5c" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c1fa898-2214-45fd-be8b-a955c372cacc" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on marketable debt securities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7feff954-d84b-41a1-841c-21be8254c1f6" contextRef="C_33520c04-a8f9-4978-85e4-d1ef14e55fac" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52426f68-b0b9-4276-b11b-8763407feb83" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c881f494-32fe-4941-af56-8b1e9d349a7e" contextRef="C_069e0991-79db-49f3-896d-022fc3b13a5c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,373</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55721930-bf7c-4a81-9576-bac126db69c8" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,373</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_422e6d45-b422-48f3-a913-7c4d9de758d2" contextRef="C_8df9e453-1166-43a2-b750-45ffb91958ef" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,721</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0eaf5a49-6c47-4a03-b8fa-7ef2a7bd2c17" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,721</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of March 31, 2024</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a632714-be1a-4264-89ec-1c3f1f782a06" contextRef="C_1bef601d-1919-4e4e-87a0-ea9d5c9cb986" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,357</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5c81a4e-540d-4df9-be1f-8e9031309bd0" contextRef="C_1bef601d-1919-4e4e-87a0-ea9d5c9cb986" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1658f6c-8b88-4818-b671-dd18d6445015" contextRef="C_9118ec0b-0a0b-4f37-8864-d70d86430dc5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,181,829</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_744ed7ed-85e0-469b-aaf0-1b985cd04800" contextRef="C_bbcc59cc-72ab-42ea-869f-9a969577ae6b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">148</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_909c4df0-594b-458d-9266-230fc953356b" contextRef="C_5b2a4e5c-222a-4ad2-8abc-8bf73b709b4a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">757,155</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d337ae8-cd72-4c99-84f8-c9a2e9a8fb61" contextRef="C_d23263c4-414c-41f5-b6d7-7e3e8f52cb59" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">424,542</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:10in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:11in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidate</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Statements of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited, in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:73.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"/>
      <td style="width:1.58%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.923%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.58%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.923%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64e31c0d-24bf-466f-9221-63a78150b730" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,992</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_feafa436-56d7-4294-8fbd-bca98b29c600" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,721</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99e173c5-acc5-4410-ab88-eb276a58f342" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,324</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe3e5a86-a2e7-4c54-9e0d-03d132bdee3c" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,373</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2803fe57-8213-4b9f-8f74-24ede2b295a5" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:NoncashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">877</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78d33da1-274d-4675-9954-95ad3268d54b" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="nmra:NoncashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">791</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45b003f1-fd42-46f1-b0c7-fc292e0d47ac" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b19fa76f-1f73-4d35-8d13-79020cd31e6d" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net accretion of investments in marketable securities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_862dafa4-d42b-49d9-946d-f0375b6812b2" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,289</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc895e70-9a2e-441d-a9fc-ae7a7b6f359c" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,147</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32bb8818-ddfb-4a2d-9c3c-7280aca90bcf" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">966</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13f79ecc-81a1-4bbe-b48d-3f1841a29052" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,351</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_874c28ac-87c1-4331-a67d-75298bf78d31" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,255</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b26fdd3b-a628-4356-9f9c-6ced4faeda78" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,155</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10f10d4b-5f78-46b0-b8f4-e9f0356bd6da" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,679</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3425961f-6cf3-4c53-a956-54a3c29a04af" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,113</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28014d62-ff70-48ff-90d4-0e18393a8468" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">915</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c284669d-dd43-46de-97ae-d9443364c47d" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">802</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91fba0f8-c2b9-4663-890c-6567601810e8" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,448</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e121ae40-a87a-44a2-aab6-ab010c8df7fa" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,955</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of marketable securities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8c853fa-e074-4587-9436-60ee03b9040c" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,385</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5b794bd-e31f-4679-99be-c1428ff5d16a" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,804</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for acquisition of assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89c37a14-608a-4ab2-9f30-97104fc02d0d" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52846d03-06d4-44f8-9343-b8f6324140b5" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">775</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb20802b-a5cc-41f6-94ad-cf0ac34171ef" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:ProceedsFromMaturitiesOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,545</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36177244-3b62-4062-a000-4529606e79c1" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="nmra:ProceedsFromMaturitiesOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,578</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e269eda0-c9e8-466b-810a-1f1f04b16af3" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,160</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_735c95ac-7e22-4162-a98d-abaf307fc6c4" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">150,001</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db3cdb6e-d3ec-4793-93d2-5fbac1fc1b45" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cc4c8aa-71e6-457e-ae20-83291e00b7a7" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,845</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_654f65c2-f052-400e-b5ff-5dcc51b42fee" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f92d3fd-b745-4253-8bad-3f93ea0b9803" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,845</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net change in cash and cash equivalents and restricted cash</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32cbe34c-5613-40ac-91fb-f66daad395cc" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,288</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f422ee89-d92e-46ee-9589-2ee83a08ba56" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">191,111</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents and restricted cash at beginning of year</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d49b854-9ef5-4247-844b-24c696e21d50" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,361</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ce2cd79-5e37-45cb-a257-5970c1e69299" contextRef="C_807f1ef6-efe1-47cd-a1ac-f6eebc286522" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375,251</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents and restricted cash at end of period</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8283713-3084-4da6-b17f-cfdbb7d9304e" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128,073</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_126d729b-1047-4e94-b5bc-08307c14130b" contextRef="C_d23263c4-414c-41f5-b6d7-7e3e8f52cb59" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184,140</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Components of cash and restricted cash:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fad22d3-8cec-4e87-bfe2-f8ed593b6c4c" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,860</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43e0f5c2-a408-480f-af1d-00677f25487a" contextRef="C_d23263c4-414c-41f5-b6d7-7e3e8f52cb59" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,927</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45860af2-fda4-4d00-b4c2-9ae1f5ede103" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17f9bc40-16d0-4990-942c-bfc6562068e8" contextRef="C_d23263c4-414c-41f5-b6d7-7e3e8f52cb59" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash and cash equivalents and restricted cash</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8fd7fad-b205-40ba-b770-0a8a44e3a8aa" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128,073</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f40246fe-127f-42ef-952e-943b73249a99" contextRef="C_d23263c4-414c-41f5-b6d7-7e3e8f52cb59" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184,140</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_282dcd20-d41e-4e6b-aec4-3def916e031e" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="organization_and_liquidity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization and Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neumora Therapeutics, Inc. (the Company), was originally incorporated in the State of Delaware in November 2019, and is headquartered in Watertown, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. The Company&#8217;s therapeutic pipeline currently consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06df7f0e-77f4-4e64-85c0-8122244d9c14" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="nmra:NumberOfClinicalAndPreclinicalNeurosciencePrograms" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">seven</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The Company&#8217;s most advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of major depressive disorder (MDD), which the Company believes has the potential to provide significant advantages relative to the standard of care, if approved. Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company&#8217;s next most advanced product candidate is NMRA-511, a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer&#8217;s disease (AD). The Company is advancing a Phase 1b signal-seeking study investigating NMRA-511 initially in healthy elderly adult participants and then people with agitation associated with dementia due to AD. The Company&#8217;s M4 positive allosteric modular (PAM) franchise comprises multiple novel compounds that each have different chemical composition and what the Company believes are optimal pharmacological properties, which have demonstrated robust activity in preclinical efficacy models and high selectivity for the M4 receptor subtype.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company has devoted a significant portion of its financial resources and efforts to building its organization, acquiring technologies and companies, executing clinical and preclinical studies, conducting research and development, identifying and developing potential product candidates, building its precision neuroscience tools, organizing and staffing the Company, business planning, establishing, maintaining and protecting its intellectual property portfolio, raising capital and providing general and administrative support for these operations. The Company has not generated revenue from the sale of products.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred net losses and negative cash flows from operations since inception and as of March 31, 2025, had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0452064d-047a-4d3c-8982-0c1a4dd77983" contextRef="C_6167264c-1f42-4063-b5e7-f295414754c1" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1,015.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of March 31, 2025, the Company had cash, cash equivalents and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98ee860b-7db2-44da-8d4e-5bffb46937b3" contextRef="C_6167264c-1f42-4063-b5e7-f295414754c1" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">249.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which are available to fund future operations. The Company believes that its existing cash, cash equivalents and marketable securities as of March 31, 2025 will be sufficient to support operations for at least the next 12 months from the date these condensed consolidated financial statements are issued.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects to incur additional losses in the future as it continues its research and development efforts, advances its product candidates through preclinical and clinical development, enhances its precision</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neuroscience approach and programs, expands its product pipeline, potentially seeks regulatory approval, prepares for potential commercialization, as well as hires additional personnel, protects its intellectual property and potentially grows its business. The Company will need to raise additional capital to support its continuing operations and pursue its long-term business plan, including to complete the development and commercialization of its product candidates, if approved. Such activities are subject to significant risks and uncertainties, including clinical failure which can impact the Company&#8217;s ability to secure additional funding. The Company expects to finance its cash needs through a combination of public or private equity offerings or debt financings or other capital sources, which may include strategic collaborations or other arrangements with third parties, or other sources of financing. However, there is no guarantee that any of these financing or opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_a316f933-a014-4d67-9987-e9c813519092" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_a316f933-a014-4d67-9987-e9c813519092_1"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	Summary of Significant Accounting Policies and Basis of Presentation</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90e33afe-590a-4aa9-90c1-22b3633ffbed" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a316f933-a014-4d67-9987-e9c813519092_1" continuedAt="F_a316f933-a014-4d67-9987-e9c813519092_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d36a4791-6823-4c45-b08b-470662a5c504" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unaudited Interim Condensed Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The condensed consolidated balance sheet as of March 31, 2025, condensed consolidated statements of operations and comprehensive loss, statement of stockholders&#8217; equity (deficit) for the three months ended March 31, 2025 and 2024, and the condensed consolidated statements of cash flows for the three months ended March 31, 2025 and 2024, and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s consolidated financial position, results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2024 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 3, 2025.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5cc2f84e-7476-4b7c-8858-d12d44a42ab8" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management&#8217;s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, the fair value of the Company&#8217;s common stock, stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company&#8217;s estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2bedbc3-926a-4764-852d-493187d04945" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:RisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the Company's ability to successfully develop, manufacture, and market any approved products; the Company's ability to obtain regulatory approval from the U.S. Food and Drug Administration or foreign regulatory agencies prior to any commercial sales; new technological innovations; dependence on key personnel, protection of intellectual property; compliance with governmental regulations; uncertainty of market acceptance of any approved products; product liability; and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6fa6560-22a8-449a-8312-70b3a44213f1" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All highly liquid investments, including money market funds, with original maturities of three months or less at the time of purchase are considered to be cash equivalents. All of the Company&#8217;s cash equivalents have liquid markets and high credit ratings. The Company maintains its cash in bank deposits and other accounts.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3432e995-3f1b-4ef8-884b-f86fc150cac6" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash consists of a facility lease agreement collateralized by a letter of credit pursuant to certain banking and lease agreements. Restricted cash, which is unavailable for a period of less than one year from the consolidated balance sheet date, is classified as a current asset.</span></p></ix:nonNumeric></div><div><ix:continuation id="F_a316f933-a014-4d67-9987-e9c813519092_2" continuedAt="F_a316f933-a014-4d67-9987-e9c813519092_3"><div><ix:nonNumeric id="F_b528968c-4095-4a70-8bf2-710533f4dab1" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:MarketableSecuritiesPolicy" escape="true" continuedAt="F_b528968c-4095-4a70-8bf2-710533f4dab1_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests its excess cash in marketable debt securities with high credit ratings including but not limited to money market funds, securities issued by the U.S. government and its agencies, commercial paper and corporate debt securities that are accounted for as available-for-sale and carried at fair value. Marketable securities are classified as short-term or long-term based on the maturity date and their availability to meet current operating requirements. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income in the consolidated statements of operations and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_a316f933-a014-4d67-9987-e9c813519092_3" continuedAt="F_a316f933-a014-4d67-9987-e9c813519092_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b528968c-4095-4a70-8bf2-710533f4dab1_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">comprehensive loss. Realized gains and losses on marketable securities, if any, are included in other income (expense), net. The cost of securities sold is determined based on the trade date using the specific identification method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company periodically assesses its available-for-sale debt securities for impairment. For debt securities in an unrealized loss position, this assessment first considers the Company&#8217;s intent to sell, or whether it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#8217;s amortized cost basis is written down to fair value within other income (expense), net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security is considered, among other factors. If this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded in other income (expense), net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as provision for (or reversal of) credit loss expense. Losses are charged against the allowance when management believes the un-collectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. These changes are recorded in other income (expense), net.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb24736c-7b65-4ae4-81a0-4cb69a4c430c" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company measures fair value by maximizing the use of observable inputs, where available, and minimizing the use of unobservable inputs when measuring fair value. Financial assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized in the fair value hierarchy based upon the lowest level of input that is significant to the fair value as follows:</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_d140766e-af4c-4a46-9fd8-d3ef30188da7" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_d140766e-af4c-4a46-9fd8-d3ef30188da7_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses primarily consist of internal research and development expense, including personnel-related expenses (such as salaries, benefits and noncash stock-based compensation) and other expenses, including laboratory supplies and other non-capital equipment utilized for in-house research, research and consulting expenses, software development costs, license fees and allocated expenses, including facilities costs and depreciation and amortization; external research and development expenses incurred under arrangements with service providers conducting research and development services on its behalf, such as contract research organizations (CROs), preclinical testing organizations and contract manufacturing organizations (CMOs). Payments made prior to the receipt of goods or services to be used in research and development are capitalized, evaluated for current or long-term classification, and included in prepaid expenses and other current assets or other assets in the consolidated balance sheets based on when the goods are received or the services are expected to be received or consumed, and recognized in research and development expenses when they are realized.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to estimate expenses resulting from its obligations under contracts with service providers in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in cash flows that do not match the periods over which materials or services are provided. The Company estimates and records</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_a316f933-a014-4d67-9987-e9c813519092_4" continuedAt="F_a316f933-a014-4d67-9987-e9c813519092_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d140766e-af4c-4a46-9fd8-d3ef30188da7_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accrued expenses for the related research and development activities based on the level of services performed but not yet invoiced pursuant to agreements established with its service providers, according to the progress of preclinical studies, clinical trials or related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and services.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the course of a clinical trial, the rate of expense recognition is adjusted if actual results differ from the Company&#8217;s estimates. The Company estimates accrued expenses as of each balance sheet date in its consolidated financial statements based on the facts and circumstances known at that time. The clinical trial accrual is dependent in part upon the timely and accurate reporting of CROs, CMOs and other service providers. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its estimate may vary from the actual results. To date, the Company has not experienced material differences between its accrued expenses and actual expenses.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p></ix:continuation></div></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a316f933-a014-4d67-9987-e9c813519092_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_219e8103-94a6-44b1-82c1-8c3c2091fc62" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity (deficit) that are excluded from net loss, such as unrealized losses on the Company&#8217;s available-for-sale marketable securities.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e80b321-c55a-4c70-9b7b-f12a2d6b4dc7" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:EmergingGrowthCompanyStatusPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company was an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) until December 31, 2024. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has evaluated whether any accounting standards which it previously delayed adopting would have a material impact to the consolidated financial statements or disclosures and concluded that there is no such material impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc209ae5-e1ea-4593-8846-ae2292b8e1f8" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the Financial Accounting Standards Board, or FASB, issued ASU 2024-04, Induced Conversions of Convertible Debt Instruments, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard is effective for annual reporting periods beginning after December 15, 2025, and interim periods within those annual periods. We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which is intended to improve disclosures by requiring additional information about specific expense categories in the notes to the financial statements on an annual and interim basis. The standard will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The standard updates may be applied on either a prospective or retrospective basis. We are currently evaluating the disclosure requirements related to this new standard.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ASU 2023-09), which requires issuers to make additional disclosures on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, and disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 will be effective for the Company as of January 1, 2025 for annual periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_197b756b-216d-46d7-aeb6-dcecd9d6aac0" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	Cash Equivalents and Marketable Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d789624-11b0-4dd7-a361-3615d76ad771" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the amortized cost and fair value of the Company&#8217;s cash equivalents and marketable securities by major investment category for the periods indicated:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d12d58d2-0283-47b4-99d1-b5c08a8a01cb" contextRef="C_9061b628-1cbb-40d6-878c-d538a8e5434f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,347</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e72748fc-d30c-4cb2-81d1-1ae08f6788f2" contextRef="C_e5572f63-a9f0-46b3-8d24-1600baa94c52" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09f099af-b85f-4ced-8ea1-e7c1e53330df" contextRef="C_e5572f63-a9f0-46b3-8d24-1600baa94c52" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4b18ff9-68ea-4f40-8129-01a2a5641813" contextRef="C_9061b628-1cbb-40d6-878c-d538a8e5434f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,347</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b57e7dc-4bb8-4a57-9ae3-0f57cac7daf8" contextRef="C_ffa0d7b0-15ec-4da1-b744-c829194fe468" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,347</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a04b4743-1709-4899-92f6-cbf11b0f8a81" contextRef="C_34728959-32a0-44fc-a13c-2f71e43ae7e3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0e5d716-ec4a-4264-9eda-15c0cc6818bd" contextRef="C_34728959-32a0-44fc-a13c-2f71e43ae7e3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_273d5660-39f5-49f7-a85a-34de641fa168" contextRef="C_ffa0d7b0-15ec-4da1-b744-c829194fe468" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,347</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2def81d6-2f9f-48d6-8448-0977764916a5" contextRef="C_2872bc3f-ac79-4fed-ade2-77671074619e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,630</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_750255af-8c8c-4a80-a64d-f3eed127184a" contextRef="C_e899c8c7-d7d0-4f74-ac13-bf387dd80ce7" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_080616dc-16dc-44ad-9da1-6f3f5310ced8" contextRef="C_e899c8c7-d7d0-4f74-ac13-bf387dd80ce7" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0841a631-df83-4fcc-9766-4072b5c02f3d" contextRef="C_2872bc3f-ac79-4fed-ade2-77671074619e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,627</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9cbea89-08de-4b20-9a89-20a1ec649d28" contextRef="C_4ef13920-7a05-4ac0-99bb-9c2e976e10f2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">607</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5c843c8-684c-4eee-9545-432f4326366d" contextRef="C_3484d184-2e57-4ae8-ae41-4d03630e1535" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b167686-afbb-4d01-bfd9-46de8aa6c081" contextRef="C_3484d184-2e57-4ae8-ae41-4d03630e1535" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46cb08da-7862-4896-8f58-f8af21b7a694" contextRef="C_4ef13920-7a05-4ac0-99bb-9c2e976e10f2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">607</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de07d57e-dfe5-468f-8b4a-2be4419ad3dc" contextRef="C_9b4cda2e-b933-47c6-a24f-6f190752e6c8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,969</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12d66d1b-7332-43a7-a8ca-cd07dc0d7d26" contextRef="C_e0b073e0-9ae4-4fbf-ac18-8ac5ee41c4c1" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8311e92-92a8-4355-bf8d-9d89ba92bc67" contextRef="C_e0b073e0-9ae4-4fbf-ac18-8ac5ee41c4c1" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0fff5b7-07ec-4880-971a-deec5cf484a3" contextRef="C_9b4cda2e-b933-47c6-a24f-6f190752e6c8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,970</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b549b10b-e592-4dbe-ac20-fb1a39c5256c" contextRef="C_f17f2417-a74c-4179-81fe-cbc4a177ea8b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,290</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7645174d-5ea4-466b-838b-75fbda3592f2" contextRef="C_fc26cf16-194d-42e9-bd78-03837763f10b" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0ee2ab6-ad95-4e6a-983a-883144d6ce4f" contextRef="C_fc26cf16-194d-42e9-bd78-03837763f10b" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2fb6647-6a1c-48df-a61b-f0f7fca46cf0" contextRef="C_f17f2417-a74c-4179-81fe-cbc4a177ea8b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,289</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6af4793e-af3e-4d3b-89b1-6397b51d064b" contextRef="C_0cbb0a62-efc0-4cdb-94b9-ad0c8c0323da" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,496</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3163dd1-b86f-4554-a248-625fc6c91f85" contextRef="C_8ae50382-fe31-444e-adfd-c5c5cf08f02f" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa5f6c9c-d64f-4eec-8d6e-ff0b7ef688b0" contextRef="C_8ae50382-fe31-444e-adfd-c5c5cf08f02f" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3080a179-5fef-490c-b1e3-a8f322151a31" contextRef="C_0cbb0a62-efc0-4cdb-94b9-ad0c8c0323da" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,493</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e215e1a-19ec-497e-b8ff-58424018757d" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198,843</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c961b09b-fde8-497a-9297-d0091ff85d36" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94ff201a-c189-4411-b5d7-52622fe2314d" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86b5778d-a88f-4d49-9305-010b863e2e0d" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198,840</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_523c1dc2-4c55-47a4-8d13-c3e63ed921e0" contextRef="C_d3ac0816-6766-4808-8c6b-73bdf51bb772" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,411</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9307d7b3-202c-45c0-b437-c33a3e488ec1" contextRef="C_67e82a6b-31f5-4d3a-8d28-c6d447c17553" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93323323-7172-47f6-b09c-7f08176ea472" contextRef="C_67e82a6b-31f5-4d3a-8d28-c6d447c17553" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea529026-bba8-4c60-842c-33fb159d1671" contextRef="C_d3ac0816-6766-4808-8c6b-73bdf51bb772" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,411</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_527b2bc2-d3ec-4f53-9aad-9a716f115e63" contextRef="C_1aca905f-ee26-4555-b248-631ec9df757a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,875</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac653eb6-9d39-4e58-88a5-f741b63f354b" contextRef="C_0cd17fb6-6272-4a76-8980-45ff567d9207" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bd40c81-8e30-49f5-b3b0-d24cbfc888bf" contextRef="C_0cd17fb6-6272-4a76-8980-45ff567d9207" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb37fd59-fb30-4cb3-9185-9112a29421aa" contextRef="C_1aca905f-ee26-4555-b248-631ec9df757a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,881</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a117a334-bf01-452d-8d05-809c17dd709e" contextRef="C_d4678025-d799-4a17-bfbf-952b85ed2d13" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,286</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d60bcbc9-8b76-4d80-bb4e-75e06160f24d" contextRef="C_4d3885b7-eb3e-4bdb-9e6c-4fd241fd9a03" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5c7268b-3f7d-4c70-b759-5e2eac3b356c" contextRef="C_4d3885b7-eb3e-4bdb-9e6c-4fd241fd9a03" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b30d2aee-172b-4528-83ec-b1940808a086" contextRef="C_d4678025-d799-4a17-bfbf-952b85ed2d13" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,292</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d90b62e-df9a-44b1-b025-a2f073a281dd" contextRef="C_572b967f-2f74-487f-ae14-180bdd868be9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,374</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1865044-e2bd-4096-8919-be8e1341bd7b" contextRef="C_69427e48-5aaa-40a8-b2f4-3bbf2e2277d4" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7d7babc-16ac-4678-80a7-3099340ca31a" contextRef="C_69427e48-5aaa-40a8-b2f4-3bbf2e2277d4" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_741a2f88-6887-47b3-964e-c4206367e013" contextRef="C_572b967f-2f74-487f-ae14-180bdd868be9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,383</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abaf6705-8407-449f-acd5-12ea02f8fb3c" contextRef="C_cac684c1-58c1-4056-87fb-85dffbb9e345" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,918</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_620c8990-8120-4510-a8db-6fdd5eeb21c1" contextRef="C_609a5a5a-15b7-4aa9-b8b5-78d98fae8999" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a73043a3-a219-434c-8ba2-7ecd7a9b0abe" contextRef="C_609a5a5a-15b7-4aa9-b8b5-78d98fae8999" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14bc3e7f-dfde-4a9f-b3e4-4176889c0100" contextRef="C_cac684c1-58c1-4056-87fb-85dffbb9e345" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,918</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1d69e9c-bcb8-4071-a6d4-87826ad02f3d" contextRef="C_45866c85-796b-42f6-a180-2cc89ed0ddd6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,411</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_313788a3-b613-40ad-be8b-e9a1c38664f4" contextRef="C_05db645f-f4bf-46f3-bf4e-7f20ec31940c" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1b04699-2596-4543-8247-5849601a2938" contextRef="C_05db645f-f4bf-46f3-bf4e-7f20ec31940c" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57cb4d51-2f01-4a6f-ad71-268a4d149e02" contextRef="C_45866c85-796b-42f6-a180-2cc89ed0ddd6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,444</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4a10dab-23f9-4fbb-a44e-00103ac32cf3" contextRef="C_bf4dcd0a-343d-4af9-b2ff-82d99b4a270b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,671</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a65be563-c326-4e28-9a7c-80a89893280d" contextRef="C_91940b71-4a64-44b8-8e19-43b82923017e" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c0e9d92-be08-4295-807e-ae6f1bb1c405" contextRef="C_91940b71-4a64-44b8-8e19-43b82923017e" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38373d98-d4f4-4ebc-99c7-ab57f5c7719e" contextRef="C_bf4dcd0a-343d-4af9-b2ff-82d99b4a270b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,685</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e58d8db1-9ea6-4bbb-a30e-a207fe438e81" contextRef="C_3c5a3125-1df8-4cfd-82c2-6439f4fce770" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,374</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d961727f-3355-4536-bd62-cf5bbd66c313" contextRef="C_2c7eaaa1-bb2c-4bb1-811e-b3ed93a9e5b0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b2182f1-2d64-4db0-b583-f9cbe23de869" contextRef="C_2c7eaaa1-bb2c-4bb1-811e-b3ed93a9e5b0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe6abfa9-e6e8-4c24-a73d-e8dd90cfb4f4" contextRef="C_3c5a3125-1df8-4cfd-82c2-6439f4fce770" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,430</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cd8f73a-29c3-4d90-97fb-9aab9ff7b779" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290,660</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e9a59a6-8f58-4d3e-936c-1edc9e7a78b0" contextRef="C_cdd08ec8-fc48-459d-ae7a-3d50a476e424" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4aabac67-35cd-4637-93aa-57958b73b9e1" contextRef="C_cdd08ec8-fc48-459d-ae7a-3d50a476e424" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f09eb14c-b3ca-4ec8-a797-3e999dd1306e" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290,722</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company has not realized any material gains or losses on its marketable securities, including any impairment charges on its securities related to expected credit losses. As of March 31, 2025, the aggregate difference between the amortized cost and fair value of each security in an unrealized loss position was de minimis. Since any provision for expected credit losses for a security held is limited to the amount the fair value is less than its amortized cost, no allowance for expected credit loss was deemed necessary at March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (see Note 4).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c98d713-4ebf-46de-8873-1e34e10dfa8a" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" escape="true" continuedAt="F_9c98d713-4ebf-46de-8873-1e34e10dfa8a_1"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amounts of the Company&#8217;s financial instruments, including prepaid expenses and other current assets, accounts payable, accrued liabilities and the current portion of operating lease liabilities approximate fair value due to the short-term nature of those instruments.</span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_9c98d713-4ebf-46de-8873-1e34e10dfa8a_1"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c641c61f-69c2-467a-a4a6-968086f0c7e0" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true" continuedAt="F_c641c61f-69c2-467a-a4a6-968086f0c7e0_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company&#8217;s assets and liabilities measured at fair value on a recurring basis by level within the valuation hierarchy:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af5c1100-87fa-46a2-ad28-0b68d565a601" contextRef="C_5a79bd11-7094-4ffc-951c-6a83cbffb588" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,347</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fd88428-9265-4385-ab33-a8d1b1273960" contextRef="C_a2d3f823-77c5-4f3a-8379-db86ade0a660" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82a71fd9-86f9-4a7a-9c46-24d03cff87b7" contextRef="C_60c0ef16-d311-4eff-b99d-ea396190548b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0976b9c0-e4af-49c0-a29e-c0c105f08c45" contextRef="C_8983212a-31bb-40e6-aad9-72c31bd8b3ec" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,347</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0252935d-44e7-46cb-aabb-3c89ad7370d8" contextRef="C_2b244c9b-1ded-43bc-820f-3c639a651b27" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f415ae7d-95a5-418a-aa7a-069dacf4140f" contextRef="C_8930b52e-d90e-4036-b728-884065a23c99" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,627</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98a5a348-a580-4d19-870f-b0da0a81e24c" contextRef="C_be0b1b72-5d49-463b-ab77-61e5bac1a983" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de710dde-e69c-4232-b173-57e1279d0657" contextRef="C_f31ea84f-b25c-49d3-b5e0-ea4d01b60c1a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,627</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f51d93a-d9ac-4a90-ae31-5c6e93abe677" contextRef="C_dca1c4c1-2e7e-4f8b-8535-f8ba404884cc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d983a82-3744-4437-864c-7dbd8a7af741" contextRef="C_c5716e30-2845-4e75-9c82-0ead8f11e3d5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">607</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e414534-deda-467a-b37c-d952c5a9f19c" contextRef="C_4e37b9ab-9112-4171-96d3-a28df5c5f26d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2e1d2e2-e7ed-40f2-8a60-f57036b86cd0" contextRef="C_0a97a9b7-374a-4ba2-8c70-91464eb57c67" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">607</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e62846f5-8d20-42cc-beff-50f0f7708a6c" contextRef="C_2a459aad-9b00-4fcc-9e37-26666bf29cc0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,970</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bc6c208-0ef8-48b9-90c4-e0114cd58103" contextRef="C_8a4d11b0-e864-40f5-af40-5075fb6dcc55" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4c6f855-fe25-4290-9a1d-4d138e2b7dd7" contextRef="C_8581f7af-0c61-4b18-9fa5-437addc36bcf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dab1eaa7-4c4e-4932-96a4-13727c3d7139" contextRef="C_f63b1f37-86a2-476e-9394-a9737eb501a9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,970</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_242614fd-2cae-410e-83ff-050a2769b49f" contextRef="C_4dc3cc35-4428-4ddc-abab-0af3843650aa" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f26d5fb3-fc78-470d-b4ce-2e0c3822476f" contextRef="C_1de420c3-74a2-46db-8f45-5e14a2cb894c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,289</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a6aa5e1-ae38-4821-a775-527cc1d2a83e" contextRef="C_1bc0b95c-7620-484e-a74a-a6ff2b9e28be" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa3e3dfa-5376-4a4f-bcde-f87c95de4e75" contextRef="C_f56f8fbd-ff2d-4bcf-9a02-48dfad75f890" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,289</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d51dd7a4-0f6b-4f4e-9dc8-389bfe3c298f" contextRef="C_96e4575f-22fb-4510-8c56-dcf2ef26b887" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,317</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca9c6844-80e6-48f0-8edc-529260ac1892" contextRef="C_345b87e2-e0de-4a5f-bd10-8a06638a2087" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,523</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfe21d95-07ed-4cf6-aa39-7c211f5e73a3" contextRef="C_ccb36bdc-b5f6-4cd8-9f8d-4b1d849d2f44" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23709699-4570-4939-af4e-5cf741c5a27e" contextRef="C_27e8bd25-1d8a-462a-a5a8-60599bc36dcb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198,840</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c641c61f-69c2-467a-a4a6-968086f0c7e0_1">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.22%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.184000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecfd3923-2fa7-457e-8082-541e6ad91228" contextRef="C_453a453b-8844-4a63-a3ea-cec4fbf05356" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,411</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e5361a2-1a7c-49a9-85d2-bf95196b7f11" contextRef="C_89c9cc8c-f7d3-4aa1-8971-7f4acc54dceb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9419917-e618-41cc-901f-8cb6c010ea7c" contextRef="C_389f4cfd-1035-4a63-8472-a8b0535f9979" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30488188-a88e-40c7-85ad-df43b653cf78" contextRef="C_29d4b3f4-84bc-4e37-a42c-c5ddac7501e7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,411</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9846ff60-e870-4289-91a0-a59f76237e96" contextRef="C_93d4bd12-ee53-4993-8268-9e9637ffeca1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a8feb07-a14f-4b21-9f15-e08246133922" contextRef="C_12814edb-2555-40ce-8b79-cd767af2d069" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,881</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8596dc5-7770-4381-bc4c-2097b357ffcf" contextRef="C_107c6cfe-84dd-41a5-a2a4-ae925e0ea374" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b0a6c9b-09d6-4a6e-8035-748eed9841ba" contextRef="C_957f0675-75da-45b6-8d5a-5d4c59c2f42a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,881</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50c3371d-bffa-463c-ac09-6bc4167ba060" contextRef="C_674b4626-69f1-4f21-a46c-b4994d0e271f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b338c0e-66ae-4bdd-94a9-a02fdde66343" contextRef="C_bec87db7-aba1-42c1-89de-287859477b6e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,383</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0108a3f5-b95b-417c-8197-ad147fdaf75e" contextRef="C_05cc4820-f2b7-4d8d-a300-c73727f10eea" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f54eef6-a68e-4817-be86-e9536ebf6ecd" contextRef="C_7b7d5dac-7754-4da3-bb2b-8b1d57fcd91d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,383</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2b107bb-bafa-41bd-8401-ce4409d6b7ea" contextRef="C_07657077-ad7d-435a-b4d6-1b88f79c2724" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a21aa15f-9354-4048-87ec-20669d87a907" contextRef="C_b89706ed-11c0-4574-9fec-db2b478b98ff" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,918</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88667cbb-e8bd-415e-aa52-282baca21268" contextRef="C_c7f8c769-dcee-4641-8788-0ecdfd5e085d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05d90979-5e96-4565-9ae1-b7e10f0eeff6" contextRef="C_9a04f240-c069-4dc2-8d21-d62bfc7e531e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,918</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3f643ba-385d-4935-adb0-8727e98b6d60" contextRef="C_62cf7b31-5216-483b-b0b1-4177e5c19093" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,444</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e016191-6edb-4874-b6ae-6e9772f18c7c" contextRef="C_7e9a4d20-f83c-40d6-a5ea-7a0380c08cf8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1829398b-8d8b-494d-988c-813557433e11" contextRef="C_4a189432-6771-4924-b99e-f1ee33b187a1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa6beda2-7ad3-41ea-be4e-5c3e16873d98" contextRef="C_45cdde70-3358-4569-a949-fee006c59617" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,444</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db8d6743-9348-4f47-8d34-2e901c135aa8" contextRef="C_247cd15b-eac5-41fa-89ce-c12599a45e39" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_264bd2ae-4f3f-44e4-9390-b1cbf6c11f4d" contextRef="C_de855e05-78f1-4034-9dd2-99edd71f6a01" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,685</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2136da1-4c0e-4574-968f-ca1b7ad28e99" contextRef="C_ff6c1c0c-dab0-4730-8b13-70db93c2b6cd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e2d5ec0-4949-47b2-b74a-8d7e05f70777" contextRef="C_061cf2c5-5b6a-43b7-9349-feb9de83c3de" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,685</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fde979bc-52f0-4fef-a9ea-9fd2096d171b" contextRef="C_43d828f3-9822-4b63-a7d7-23b01fed21ef" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168,855</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01f9d530-0260-486c-ae27-95c18322c7a1" contextRef="C_28c81270-b763-4f43-9e26-86aed60a8e6a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,867</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50e7146a-0566-4068-972c-409aa07288e5" contextRef="C_948e3436-40f4-4902-9557-b188a3de6f02" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b99a55b-a4d5-4018-a607-c012498edc4d" contextRef="C_9da9e2d3-d2c9-4624-9a0f-41478107481a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290,722</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are highly liquid and actively traded marketable securities that generally transact at a stable $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bdf12f7-9fb8-4127-b81b-f51e3ab7df0b" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:NetAssetValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> net asset value representing its estimated fair value. The Company estimates the fair value of its commercial paper, certificates of deposit, U.S. government and agency debt securities, and corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data, and other observable inputs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4c66987-8497-4777-a400-251297578891" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	Balance Sheet Components</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e79c852b-ce62-45c8-bfde-8738f2e73b5f" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:63.473%;box-sizing:content-box;"/>
          <td style="width:1.86%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.943%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.7%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:15.023%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial and preclinical costs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85928805-d636-4f90-8cd9-6f212b31fc55" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="nmra:AccruedClinicalTrialAndPreclinicalCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,482</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2dabe00-ac43-4725-8e06-84cd28a37a4f" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="nmra:AccruedClinicalTrialAndPreclinicalCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,606</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development services ($</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70ca5226-1720-438d-a9d6-3c5b024d18eb" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;million and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_799daa3c-660f-4efb-9111-152ca83557d1" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;<br/>&#160;&#160;&#160;&#160;&#160;million due to related party in 2025 and 2024, respectively)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aa8e5a8-e65e-407a-9912-bed5bca6e4fc" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="nmra:AccruedResearchAndDevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,250</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation and benefits</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e017b20-506d-4341-b1be-3bcaccda9259" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,159</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3142399b-a154-471c-8eff-9a71c8587891" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,975</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bd030b3-3ed5-401b-afb2-0cfa370ae95f" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,972</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36a38e8f-3744-46aa-aefa-05d508e551cb" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,686</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7acc35b6-3b8d-4d4b-b126-ef300c7906e3" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">409</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9993c16e-9144-43a3-8155-a8085d39787e" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued liabilities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41023eb6-2a4d-498a-9a82-667d25aec423" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,272</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f151547-cfa3-406e-9727-14fd6c2c4405" contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,593</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8dd9c54-1565-4ac2-b2e4-640324695bda" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true" continuedAt="F_e8dd9c54-1565-4ac2-b2e4-640324695bda_1"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.	Acquisitions of Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BlackThorn Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2020, the Company entered into an agreement and plan of merger (BlackThorn Merger Agreement) to acquire all of the equity interests of BlackThorn Therapeutics, Inc. (BlackThorn), which became effective in September 2020. The Company acquired BlackThorn for its in-process research and development programs, including an antagonist of the kappa opioid receptor (navacaprant (NMRA-140)) for the treatment of MDD and an antagonist of the vasopressin 1a receptor (NMRA-511) for the treatment of agitation in AD. The Company also gained access to a cloud-based computational psychiatry and data platform that was being developed to support drug target identification, patient stratification and objective clinical trial endpoints. Both navacaprant and NMRA-511 were exclusively licensed to BlackThorn by The Scripps Research Institute (TSRI). The acquisition was accounted for as an acquisition of assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The BlackThorn Merger Agreement requires the Company to pay the former stockholders of BlackThorn contingent consideration (i) with respect to navacaprant, in the form of development and regulatory approval milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec01fb94-bd55-4a02-8eff-29d3c08246c0" contextRef="C_434aebe9-f88b-42f1-a3a9-60444626ef43" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">365.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which includes a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f0c8da0-69c4-469a-b3fa-4977c88b85fc" contextRef="C_567b6948-dab8-40c8-9463-dba168ab7953" name="nmra:MilestonePaymentDueDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant,</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and sales-based milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c855e073-08db-474f-8af0-6f09bc171212" contextRef="C_b98e4b10-ee87-4bcd-aba7-dfcce8c3e11f" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">450.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and (ii) with respect to NMRA-511, in the form of development and regulatory approval milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8174ef86-c070-40f5-9b27-c8cb5ad3bf7a" contextRef="C_a6afc305-12c7-42a2-8ee0-0a5d36ab752d" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and sales-based milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1540e9d5-95ce-4c20-8fab-f62d0be909a7" contextRef="C_97e950d4-ad65-4370-8e70-5ec2021370e9" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (BlackThorn Milestones). At the Company&#8217;s sole discretion, the BlackThorn Milestone payments may be settled in cash or shares of the Company, or a combination of both, subject to the provisions of the BlackThorn Merger Agreement, other than one development milestone in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ded6ee91-ba0e-48ff-b1c4-72f158dd1d74" contextRef="C_635b097b-2010-46d5-b9db-42a97113defc" name="nmra:ContingentConsiderationMilestonePaymentSettledInCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which must be settled in cash. None of the BlackThorn Milestones were subject to liability classification and/or derivative accounting and any such contingent consideration will be recognized when the contingency is resolved, and the consideration becomes payable. The Company settled the Phase 3 navacaprant dosing milestone in December 2023 by issuing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d2ee0f6-83c3-4cde-a0f8-3f4b39cb7e48" contextRef="C_998e1d41-951a-4a8a-8f7b-eacf68edbd89" name="nmra:SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,072,445</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock based on the volume weighted average price per share prior to the date the milestone was met and paying cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5336aabe-ff05-4b03-855e-d5330b90b920" contextRef="C_fa6eb452-286f-470e-bfaf-790490cd6700" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the former stockholders of BlackThorn and participants in the carveout plan (discussed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">below). As a result, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fefc8743-9b00-4ff5-8a5c-833d8b9304fb" contextRef="C_50810541-9cdc-4d75-8385-8446d34bf249" name="nmra:AcquiredInProcessResearchAndDevelopedExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in acquired in-process research and developed expenses in the fourth quarter of 2023 related to the BlackThorn Milestones. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e07c876d-8e78-4ec7-b12f-b6147bdfc7c7" contextRef="C_06e547db-6799-4ce2-99ec-f971505c46d0" name="nmra:NumberOfMilestoneAchieved" unitRef="U_Milestones" decimals="INF" format="ixt:fixed-zero">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of the other Blackthorn Milestones have been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d1bd066-9864-491d-8065-be47abb4e063" contextRef="C_ecb47253-5967-4e68-a907-ee441a95567a" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were deemed due or payable as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BlackThorn Carveout Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The BlackThorn Merger Agreement required that the Company establish a carveout plan (the BlackThorn Carveout Plan), pursuant to which each BlackThorn stock option holder as of immediately prior to the closing date was allocated a certain number of units (the BlackThorn Carveout Units) based on the number of shares underlying the outstanding options held by each participant at that time. Each BlackThorn Carveout Unit represents a right to receive a portion of the BlackThorn Milestone payment (the BlackThorn Carveout Payments) upon the later of (i) the achievement of a BlackThorn Milestone and (ii) the vesting of the BlackThorn Carveout Unit.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e8dd9c54-1565-4ac2-b2e4-640324695bda_1" continuedAt="F_e8dd9c54-1565-4ac2-b2e4-640324695bda_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The BlackThorn Carveout Units vest based on time-based schedules that mirror the vesting schedules for the original option awards held by each participant. As of the closing date in September 2020, a portion of the BlackThorn Carveout Units corresponding to the pre-acquisition service periods were fully vested (Vested Carveout Units). The remainder of the BlackThorn Carveout Units had vesting subject to the continued service of the participants, the last of which became fully vested in May 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vested Carveout Units represent contingent consideration for the acquisition as they are attributable to pre-acquisition services rendered by the participants and continuing service is not required for the participants to receive future payments upon a BlackThorn Milestone being achieved. The Company recognizes the contingent consideration obligation for the Vested Carveout Units when the contingency is resolved, and the consideration becomes payable. The BlackThorn Carveout Units that were unvested as of the closing date are dependent on the continued service of participants and were deemed to be a compensation arrangement. The Company recognizes compensation starting from the time payment becomes probable over each participant&#8217;s service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company settled the Phase 3 navacaprant dosing milestone in December 2023. The Company recognized contingent consideration related to Vested Carveout Units, which was included in acquired in-process research and developed expenses in the fourth quarter of 2023 related to the BlackThorn Milestones as described above. In addition, the Company recognized and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11920318-3f32-48d5-b370-b453b6e5be93" contextRef="C_76739724-db36-40d3-a0e9-ef80e990e67b" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in compensation related to the BlackThorn Carveout Units that were a compensatory arrangement in 2023. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c5c4d1d-43e4-44d4-a63b-311c6e60b801" contextRef="C_bb874d5c-ff29-4fda-8629-e1343f9f7d96" name="nmra:NumberOfMilestoneAchieved" unitRef="U_Milestones" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of the other BlackThorn Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23806b17-2713-449a-9788-9d60ad47e311" contextRef="C_7c050cf9-993c-4fb3-aeca-b255bac5106d" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were deemed due or payable as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e8dd9c54-1565-4ac2-b2e4-640324695bda_2" continuedAt="F_e8dd9c54-1565-4ac2-b2e4-640324695bda_3"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amgen Inc. Licenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, the Company entered into two license agreements with Amgen Inc. (Amgen) pursuant to which it obtained exclusive, worldwide licenses to develop, manufacture, use, commercialize and distribute products containing compounds that are directed to, in one case, CK1&#948;, and in the other case, glucocerebrosidase (GCase), both for the treatment of neurodegenerative diseases (the Amgen License Agreements) and related know-how and clinical material (collectively, the Amgen IPR&amp;D Assets). The Company accounted for these transactions as acquisitions of assets. Concurrently, the Company also executed a research collaboration agreement as well as a stock purchase agreement with Amgen. Both agreements were deemed to be separate transactions and not accounted for as part of the acquisition of assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total upfront consideration transferred to Amgen of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f84dcd7e-2fc8-402b-96b6-46d20628b4ff" contextRef="C_319051d1-d908-4b4b-a4e2-c1ec01693b5c" name="nmra:UpfrontConsiderationTransferredShares" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of the Company&#8217;s Series A-2 convertible preferred stock, with an acquisition date fair value of $1</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1661c701-fd3a-41ec-8e09-e67c86dcc727" contextRef="C_319051d1-d908-4b4b-a4e2-c1ec01693b5c" name="nmra:AcquisitionDateFairValueOfSharesTransferred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">57.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the Amgen IPR&amp;D Assets and expensed in 2021.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under these </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58d1e050-047d-484c-9a80-cc8ac86e731a" contextRef="C_eba48cde-044c-4cf6-83fc-6f6426dd681f" name="nmra:NumberOfLicenseAgreements" unitRef="U_Agreements" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> license agreements, Amgen is eligible to receive contingent consideration up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1939e71-edd9-44f3-94ab-4a26eb8e7118" contextRef="C_28c76f06-1cc1-4845-8c93-25ddca00f65e" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">360.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in commercial milestone payments per product payable in cash with a compound directed to CK1&#948; and up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6504d70a-2971-41ba-a9cf-f91f05a6ff45" contextRef="C_0073ad06-94e6-4b3b-840a-a087ad92d314" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">360.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in commercial milestone payments per product payable in cash with a compound directed to GCase, in each case, upon the achievement of certain sales thresholds and single digit royalties on potential future net sales, related to CK1&#948; or GCase (the Amgen Milestones). Such contingent consideration was not subject to liability classification and/or derivative accounting and will be recognized when the contingency is resolved, and the consideration becomes payable. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a51d85f0-84db-4cdc-bbbd-1d74f5e768ad" contextRef="C_fe1ba1ef-7e15-4e74-8545-43b5c9422c97" name="nmra:NumberOfMilestoneAchieved" unitRef="U_Milestones" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of the Amgen Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8140c207-d041-4966-bee7-c7a262ffb0c2" contextRef="C_a55ca487-0567-4505-9f6f-f91c988a8506" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were deemed due or payable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, until a specified period of time following the achievement of the first successful Phase 2 clinical trial for any licensed product, if the Company chooses to sell, transfer, sublicense or divest rights to a licensed product in certain major markets, Amgen has a period of time to enter into an agreement with the Company for such rights. The Company determined that these rights of first negotiation were not freestanding instruments from the Amgen License Agreements and did not meet the definition of a derivative.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vanderbilt License</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2022, the Company and Vanderbilt University (Vanderbilt) entered into a license agreement (Vanderbilt License Agreement). Pursuant to the Vanderbilt License Agreement, as amended, the Company obtained an exclusive, worldwide royalty-bearing, sublicensable (subject to certain restrictions) license under certain patent rights and a non-exclusive, worldwide, royalty-bearing, sublicensable (subject to certain restrictions) license under certain know-how covering small molecule positive allosteric modulators (PAMs) predominantly of the muscarinic acetylcholine receptor subtype 4 (M4) to develop, manufacture, and commercialize products, processes and services covered by such patent rights or that incorporate or use such know-how, for any and uses (the Vanderbilt IPR&amp;D Assets). Concurrently, the Company also executed a sponsored research agreement (see Note 8) with Vanderbilt. The sponsored research agreement was deemed to be a separate transaction and not accounted for as part of the acquisition of assets. The acquisition of Vanderbilt IPR&amp;D Assets became effective in February 2022. In May 2024, the Company and Vanderbilt entered into a second sponsored research agreement with Vanderbilt and concurrently entered into an amendment to the Vanderbilt License Agreement (Second Amendment to the Vanderbilt License Agreement), to extend the rights granted to the Company under the Vanderbilt License Agreement to the data and patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research pursuant to the second sponsored research agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensed patent rights are subject to Vanderbilt&#8217;s right to use the patent rights for research, internal non-commercial use, and educational purposes. The Company intends to develop the PAMs for the treatment of schizophrenia and other neuropsychiatric disorders. The Company has agreed to use commercially reasonable efforts to develop and commercialize licensed products, and to achieve certain development milestones.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e8dd9c54-1565-4ac2-b2e4-640324695bda_3" continuedAt="F_e8dd9c54-1565-4ac2-b2e4-640324695bda_4"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid Vanderbilt a non-refundable, non-creditable upfront cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5288ea01-b9b5-46c5-b847-de262c224148" contextRef="C_7f20fb03-a67c-4772-9d37-ac7b4fb27bce" name="nmra:UpfrontCashPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the Vanderbilt IPR&amp;D Assets, which was immediately recognized as acquired in-process research and development expense in the condensed consolidated statement of operations and comprehensive loss as it was determined to have no alternative future use as of the acquisition date. Under the Vanderbilt License Agreement, Vanderbilt is eligible to receive contingent consideration payable in cash up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d67e331-0217-4414-ba3a-582dd4cc7971" contextRef="C_ef2557ce-7b57-4e87-830c-4493b126211d" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">42.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specified development milestones and up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc47a8f4-294e-4262-baf2-9197ea3fc7d6" contextRef="C_9daa6341-c6b6-4510-aaef-1aaad596df55" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">380.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of commercial milestone events as well as tiered royalties at mid-single digit percentages on potential future net sales, subject to specified reductions for the lack of patent coverage, generic entry and payment obligations for third-party licenses (the Vanderbilt Milestones). Such contingent consideration was not subject to liability classification and/or derivative accounting and will be recognized when the contingency is resolved, and the consideration becomes payable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In October 2023, a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f90def0d-e9a3-435c-94dd-dc63d3bb4feb" contextRef="C_8546d344-f5a5-49c0-b25a-d7761e6c965c" name="nmra:ContingentConsiderationMilestonePaymentSettledInCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million Vanderbilt Milestone was achieved and settled in cash in November 2023 and was recognized in acquired in-process research and developed expenses in the fourth quarter</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e8dd9c54-1565-4ac2-b2e4-640324695bda_4"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01c09771-d537-4ef1-b2f3-b2788fcdd3fa" contextRef="C_c862b521-4d47-4fe1-8a29-5956f0f3aafd" name="nmra:NumberOfMilestoneAchieved" unitRef="U_Milestones" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of the other Vanderbilt Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1c4db9f-a88a-47a5-b958-7b6672b52a85" contextRef="C_d572c7f7-2d65-449d-822a-730cba140e6d" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were deemed due or payable as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company also had an exclusive option, exercisable for a specified period of time, to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research pursuant to the sponsored research agreements between the Company and Vanderbilt, the first of which was entered into at the same time as the Vanderbilt License Agreement and the second of which was executed in May 2024. The Company determined that the right to negotiate was not a freestanding instrument from the Vanderbilt License Agreement and did not meet the definition of a derivative. The Company exercised the above disclosed exclusive option under the first sponsored research agreement and the parties executed an agreement in December 2023 pursuant to which the Company licensed certain patent rights in return for a payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cdbd122-f01b-4d3b-8c4e-a8326cf6aa49" contextRef="C_5d02fd90-893f-4a41-a4e0-50545ee339fa" name="nmra:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5d94ffa-a690-4d50-8125-35ebb6dbf10f" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.	Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware law. The Company currently has directors&#8217; and officers&#8217; insurance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Commitments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has various manufacturing, clinical, research and other contracts with vendors in the conduct of the normal course of its business. Such contracts are generally terminable with advanced written notice and payment for any products or services received by the Company through the effective time of termination and any non-cancelable and non-refundable obligations incurred by the vendor at the effective time of the termination. In the case of terminating a clinical trial agreement at a particular site, the Company would also be obligated to provide continued support for appropriate medical procedures at that site until completion or termination.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_78ab11e9-4b4a-4ad4-959b-757b45cd5cdd" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_78ab11e9-4b4a-4ad4-959b-757b45cd5cdd_1"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.	Strategic License and Research and Collaboration Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2015 TSRI License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the acquisition of BlackThorn (see Note 6), the Company gained certain exclusive rights to intellectual property related to Kappa Opioid Receptor and V1aR Receptor Antagonist programs as well as an oxytocin receptors positive allosteric modulator program (collectively, the TSRI Programs) under a license agreement between BlackThorn and TSRI originally entered into in November 2015 (as amended, the 2015 TSRI License Agreement). The technology licensed under the 2015 TSRI License Agreement is used in the Company&#8217;s navacaprant and NMRA-511 research and development programs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the 2015 TSRI License Agreement, the Company is obligated, among other things, to pay TSRI (i) a nominal annual license fee due and payable on the first day of each calendar year and after the fourth anniversary creditable against any royalties due for such calendar year, (ii) development and regulatory milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be67f819-32bb-4328-9bf1-2c64dbace3a2" contextRef="C_0fa32b7d-f446-4078-9cee-2d0078041367" name="nmra:DevelopmentAndRegulatoryMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate for the first product from each TSRI Program, which are contingent upon achieving specific development and regulatory milestone events, (iii) commercial milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96d00e40-f734-4826-9375-5d2f34b0003e" contextRef="C_0fa32b7d-f446-4078-9cee-2d0078041367" name="nmra:CommercialMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate for each occurrence, which are contingent upon achieving specified commercialization milestone events, (iv) tiered low-single digit royalties on future net sales of each royalty-bearing product and (v) a percentage in the mid-single digits of any sublicensing revenues the Company receives. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the Phase 3 navacaprant dosing milestone was met and the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f036f314-93a9-4f08-aa6f-94b189ff900c" contextRef="C_b1e412fe-b620-42a7-889f-eea848ba3fcf" name="nmra:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to TSRI, which was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86d70340-4d57-441a-9532-2047549c1bbf" contextRef="C_64494bd4-6ab5-4895-bf3c-bef01605a51f" name="nmra:MilestonesAchieved" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of the other milestones have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_316adf3f-1a9c-4991-96b2-55e94f60ff9d" contextRef="C_64494bd4-6ab5-4895-bf3c-bef01605a51f" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> royalties were due under the 2015 TSRI License Agreement as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025.</span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_78ab11e9-4b4a-4ad4-959b-757b45cd5cdd_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Collaboration Agreement with Amgen</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, and concurrently with the Amgen License Agreements (see Note 6), the Company entered into a research collaboration agreement with Amgen (Amgen Collaboration Agreement) to collectively discover drug targets, biomarkers, and other insights associated with central nervous system (CNS) diseases utilizing Amgen&#8217;s deCODE genetics and human data research capabilities. The Company received exclusive rights under intellectual property generated in the collaboration to exploit therapeutic compounds and diagnostics for use with therapeutics in the CNS field and Amgen received exclusive rights to exploit therapeutic compounds and diagnostics for use with therapeutics outside of the CNS field.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In return for Amgen performing research and development activities under the agreement, the Company committed to making non-refundable, non-creditable quarterly payments over the first two years totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_120fdba5-7e61-442e-b2f4-9a396e7356d3" contextRef="C_e911e4aa-353a-44c7-8d53-12528baf8f7d" name="nmra:ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and for the third year $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a743553a-11f1-4f9d-a021-3989e200de3f" contextRef="C_5c0b10fb-50d4-4b4e-b9aa-33b20ed8cf2d" name="nmra:ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025 and December 31, 2024, the Company was obligated to pay Amgen $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7a102fc-fd37-4a87-a12d-613f2de3d16f" contextRef="C_c6ca0beb-621e-45be-9f36-bcb1a9eadb66" name="nmra:RelatedPartyTransactionObligationWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and nil, respectively, under the Amgen Collaboration Agreement, which was recorded within current liabilities on the condensed consolidated balance sheets. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24133a10-1b5c-4e20-bf00-60148094282f" contextRef="C_e911e4aa-353a-44c7-8d53-12528baf8f7d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and nil of research and development expenses during the three months ended March 31, 2025 and 2024, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a43bc030-11f9-4f00-8da6-80734685c207" contextRef="C_e911e4aa-353a-44c7-8d53-12528baf8f7d" name="nmra:CollaborationAgreementTerminationDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> On May 1, 2025 the Company made a final payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e4bc458-a83c-4cc6-86e8-2780d5ce008e" contextRef="C_e911e4aa-353a-44c7-8d53-12528baf8f7d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Amgen under the Amgen Collaboration Agreement for research and development activities. The parties agree that this is the final amount due under the agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sponsored Research Agreement with Vanderbilt</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2022, concurrently with the Vanderbilt License Agreement (see Note 6), the Company entered into a sponsored research agreement with Vanderbilt (First Vanderbilt Research Agreement), pursuant to which Vanderbilt agreed to provide the Company research services to develop a M4 PAM back-up program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In return for Vanderbilt performing research and development activities under the agreement, the Company agreed to make quarterly payments for research up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b976eb1-098c-4fad-988a-46cdb4ba0d65" contextRef="C_8e618d30-af12-4d65-8977-21df83d2cdd6" name="nmra:ResearchAndCollaborationAgreementQuarterlyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on an annual basis. The term of the agreement ended in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f11a484-1b22-4658-b1c7-86fb487d77a9" contextRef="C_d182de24-0601-4e16-8128-a87852d11d16" name="nmra:ResearchAgreementExpiryDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, the Company also had an exclusive option to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research (see Note 6).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, concurrently with the Second Amendment to the Vanderbilt License Agreement (see Note 6), the Company entered into a second sponsored research agreement with Vanderbilt (Second Vanderbilt Research Agreement), pursuant to which Vanderbilt agreed to provide the Company additional research and development activities on the M4 PAM back-up program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In return for Vanderbilt performing research and development activities under the agreement, the Company agreed to make payments for research up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fab97e10-c34a-47d8-9e75-2063fe5d376f" contextRef="C_e7491852-40a1-4eee-b2b1-7b6c1fafa82d" name="nmra:ResearchAndCollaborationAgreementPayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The term of the agreement ended in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d00a7175-df89-4247-b572-b7bb2fbce686" contextRef="C_3baa7dbd-2e2b-4e86-9a5b-5cbbc95835cb" name="nmra:ResearchAgreementExpiryDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, the Company also has an exclusive option to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored r</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">esearch (see Note 6).</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Parkinson&#8217;s Research Ventures Funding Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Company entered into a research funding agreement with Parkinson&#8217;s Research Ventures Limited (PRV), pursuant to which PRV agreed to provide the Company funding up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd904aec-73f6-494b-b0fc-422031131c55" contextRef="C_a449de6c-c7c4-4d8d-971a-f9c39a05240e" name="nmra:FundsProvidedForPreClinicalResearchAndDevelopmentActivities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in two tranches to carry out preclinical research and development activities related to the Company&#8217;s NLPR3 program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The first tranche was due upon execution of the agreement and was received in March 2024, for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_194b4302-5bb1-49fd-a763-25d4d3f17f5d" contextRef="C_380c3204-a040-4430-aff2-cdc8bf414df7" name="nmra:PaymentsForExecutionOfAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company notified PVB of a successful drug candidate nomination, the trigger for the second tranche of funding, in December 2024 and received payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6e715e7-80c7-4c81-88da-c862119e2ecc" contextRef="C_9725a19f-6026-4597-becd-68b62f258eb7" name="nmra:FundReceivedUponCompletionOfCertainDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in January 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded the funding arrangement was an obligation to perform services and the funding received is recognized as a contra-R&amp;D expense as project costs are incurred. $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_519ea4cb-9ee0-43a6-90c0-bb4da27a831d" contextRef="C_bb5db30d-8a29-4c0f-9230-7f59a4cc1240" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c964ad1c-39f6-461f-93e6-0d3bfc662d96" contextRef="C_59e023c8-7631-4420-9721-fe4e193d844b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and nil of costs were incurred during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon achievement of certain development, regulatory or commercial trigger events, the Company agreed to pay PRV in aggregate an amount equal to no more than four times the funding provided by PRV, i.e., a maximum repayment amount of up to &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_155f8a51-63ad-433a-94df-950a341c0af5" contextRef="C_bb5db30d-8a29-4c0f-9230-7f59a4cc1240" name="nmra:MaximumRepaymentAmountAgreedToPay" unitRef="U_GBP" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The trigger event payments meet the derivative scope exception under ASC 815 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and therefore do not need to be bifurcated and separately accounted for.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:nonNumeric id="F_35af6c7b-58f1-4709-a8ca-481479e12c91" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.	Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's board of directors has the authority to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_627b82b2-8c27-4552-ab8d-9ce50f8feb0e" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock in one or more series with rights, preferences and privileges to be determined. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a32671bf-e245-45ea-8125-f24778e2e77f" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_68bf5f45-811f-484e-94a0-43f28215e3c7" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock issued and outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025.</span></p><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock outstanding in the condensed consolidated balance sheet and condensed consolidated statement of stockholders&#8217; equity as of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d964ed4-cc25-4a56-9266-cf26d674c70a" contextRef="C_fd27dd1d-0143-49e6-bae8-7ed81f1fc545" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">136,920</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of restricted stock that vest based on service conditions and are subject to the Company&#8217;s right of repurchase upon termination of services. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f961e3de-bc20-416e-83bc-cc4a070c67ea" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true" continuedAt="F_f961e3de-bc20-416e-83bc-cc4a070c67ea_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_f961e3de-bc20-416e-83bc-cc4a070c67ea_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:75.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:78.02%;box-sizing:content-box;"/>
          <td style="width:1.7%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:18.28%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for options and restricted stock units issued under the equity plans</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af8e4a50-21ba-42ff-9cde-02df44cb175c" contextRef="C_ee1bf88c-a716-432c-9927-f73c12f7dabe" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,187</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future issuance under the equity plans</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b82b0662-0a20-422b-8f01-2a6594d51f98" contextRef="C_0765bb7b-af0d-4ddb-abe8-4e7b1ecfd1c2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,389</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future issuance under the employee stock purchase plan</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_729d019b-895f-4c69-9436-506d55101841" contextRef="C_6d975b6a-1d37-4354-bb12-b6e8b427cd7f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,681</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd2258c7-0688-47c6-8367-77ca2d5e1b9c" contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,257</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company may be required to issue additional shares of its capital stock if certain milestone conditions are met pursuant to the contingent consideration associated with the Company&#8217;s acquisitions of assets (see Note 6). In December 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6a6e228-ac4c-4519-af6e-3767391b9964" contextRef="C_b021f8a3-fac7-453a-93f0-4243983b574b" name="nmra:SharesIssuedUponAchievementOfMilestone" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,072,445</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were issued related to BlackThorn Merger Agreement upon achievement of the Phase 3 navacaprant dosing milestone that was met in October 2023. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dc37b11-5d57-4c6a-ae6c-0ca80061e85a" contextRef="C_3d315f3a-94bd-45c2-a9f2-a8597bd60111" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been reserved for potential future issuances as no other BlackThorn Milestones have been achieved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_a29b31d9-0c7b-422c-95b5-4c87bed249a4" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_a29b31d9-0c7b-422c-95b5-4c87bed249a4_1"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.	Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the Company adopted the 2023 Equity Incentive Plan (2023 Plan). The 2023 Plan provides for the grant of stock options, restricted stock awards, restricted stock unit awards, and other stock-based awards to employees, directors, and non-employee service providers of the Company. The 2023 Plan replaced the Company&#8217;s 2020 Equity Incentive Plan (&#8220;2020 Plan&#8221; and together with the 2023 Plan, Plans). The Company no longer grants stock options or other awards under its 2020 Plan, but any stock options outstanding under the 2020 Plan remain outstanding and effective in accordance with their terms. Awards granted under the 2023 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ce2fc9b-34b1-41fe-8118-d2ca5008da54" contextRef="C_0c70cc8c-7dc7-4484-8ee0-c0f1aacfc08a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant. The price of stock options shall not be less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_249dd7ec-9742-4248-9f57-2a347a9e1639" contextRef="C_b09a7f2f-554f-4ab7-a516-b0464c7db20d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the estimated fair value on the date of grant and typically vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6e3baa7-479e-4dfe-828f-274b1e62644d" contextRef="C_0c70cc8c-7dc7-4484-8ee0-c0f1aacfc08a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period although may be granted with different vesting terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2023 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc6623ae-b357-4bba-a4bc-5840cede6a2b" contextRef="C_b09a7f2f-554f-4ab7-a516-b0464c7db20d" name="nmra:Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s outstanding shares of common stock as of the last day of the prior year. On January 1, 2025, the number of shares of common stock available for issuance under the 2023 Plan increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1f5930d-2c7f-487a-b036-1c42b9bc940a" contextRef="C_34c399d6-b754-4a45-afe8-4f0160c2d7d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,085,495</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares as a result of the automatic increase provision of the 2023 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Employee Share Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the Company adopted the 2023 Employee Share Purchase Plan (ESPP). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may hold one or more offering periods each year during which employees will be able to purchase shares under the ESPP through payroll deductions made over the term of the offering. The per-share purchase price at the end of each offering period is equal to the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9743ab6-e533-436d-b5d9-188a62fc4898" contextRef="C_8d55cf2a-ccb9-488d-99f3-88abc8c63dc6" name="nmra:Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the closing price of the Company's common stock at the beginning or end of the offering period. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2025, the number of shares of common stock available for issuance under the ESPP increas</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ed by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b6c08d6-ef1c-4084-9e0e-c2e6c1d67145" contextRef="C_19eb528f-0c9a-4741-8410-ab696e22ae8b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,617,099</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares as a result of the automatic increase provision of the ESPP. No shares were issued under the ESPP during the year the three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_a29b31d9-0c7b-422c-95b5-4c87bed249a4_1" continuedAt="F_a29b31d9-0c7b-422c-95b5-4c87bed249a4_2"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51d2826f-850d-42b8-95b1-38c996013269" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option Activity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:41.7%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.88%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.42%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:10.06%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:11.36%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:10.58%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding<br/>Stock Options</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic <br/>Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except per share amounts and years)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62687563-0229-40a6-8b86-3b561f0d4f0a" contextRef="C_504593b3-57d4-4b02-8b18-4bdd29a7ac8f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,927</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b36c41f-c9a4-465c-8c88-92ce790f2cf8" contextRef="C_504593b3-57d4-4b02-8b18-4bdd29a7ac8f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.20</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b7b2f553-d258-4e6c-8634-27bfed77c101" contextRef="C_2ab6c9e7-ed9e-4fb0-969f-343343d0a2c0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_179a1b71-5c40-49e2-98e0-2aa469779f6c" contextRef="C_504593b3-57d4-4b02-8b18-4bdd29a7ac8f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,953</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_534b9394-dd3d-4e90-8fd9-f57b75042fc3" contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,995</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d19dbc6b-7ce8-407f-ad48-403834e48cbc" contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.68</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e53a34d-a1ea-4412-b46b-9828da92c1fc" contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0acf88c4-ef97-44ae-b3d1-90210029bd82" contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Canceled and forfeited</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e9ad7ce-0030-47a1-9532-5060da7c0866" contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,166</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d39747b-f962-48ad-96ce-4ad39fea4e15" contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.16</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7a70e2d-9020-46ed-a488-fc0338da337f" contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_593b2038-1c45-4850-974b-8ff40025a960" contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.58</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8213a50-7156-40c4-b858-49f2beee4c4b" contextRef="C_b2225424-d630-4726-95a9-a1c8ebfb3755" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,635</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2df767c-6888-44e2-855f-540d90ae2cff" contextRef="C_b2225424-d630-4726-95a9-a1c8ebfb3755" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.51</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5956a6ed-a691-447b-ba5b-9df033b833ec" contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.9</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f055c60-0a77-497d-93a9-55aa7afcddd8" contextRef="C_b2225424-d630-4726-95a9-a1c8ebfb3755" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable as of March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4803b81-95cd-45f2-889c-93bb88a87f63" contextRef="C_b2225424-d630-4726-95a9-a1c8ebfb3755" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,490</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9128318b-dcb2-4069-a213-873aa612515b" contextRef="C_b2225424-d630-4726-95a9-a1c8ebfb3755" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.54</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_23836285-a2de-4206-afe1-292616830435" contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98eefbcd-cc14-417a-a15b-7480d9f05bb3" contextRef="C_b2225424-d630-4726-95a9-a1c8ebfb3755" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The stock option activity table above excludes options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d93b4751-0bfc-4cd5-a774-c4fe49e1cc9f" contextRef="C_0e64685c-4df1-4cfc-8090-786dde3ed56d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">446,068</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock that were originally granted with market conditions to one of the Company&#8217;s executives.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Activity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Plans allow for the grant of restricted common stock and restricted stock units to certain employees, executives, non-employee scientific advisors, and third-party service providers. The restrictions lapse over time primarily according to service-based vesting conditions of each award. In the event of a voluntary or involuntary termination of the holder&#8217;s continuous provision of services to the Company, any unvested portion of the restricted stock award is automatically forfeited.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eae948f1-1123-4e6a-af83-4ad7c47c9e69" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s restricted stock activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:45.46%;box-sizing:content-box;"/>
          <td style="width:1.06%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.74%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.28%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:11.64%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.86%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.16%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:10.8%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares of<br/>Restricted<br/>Common<br/>Stock</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares of<br/>Restricted<br/>Stock<br/>Units</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average Grant<br/>Date Fair<br/>Value Per<br/>Share</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except per share amounts)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding and unvested as of December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25a796b2-8575-494b-9af1-425378fc4cd9" contextRef="C_097e4542-80e5-445f-9968-c8d2e3c75940" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">371</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52f91698-d02d-4192-b1a8-545a67505bbd" contextRef="C_097e4542-80e5-445f-9968-c8d2e3c75940" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.82</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4646330f-c1c7-4061-81c2-3970ff674e8f" contextRef="C_ebff40d6-3768-4f98-8eb1-4e6b12753e80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,441</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfc81987-ba3a-4f8f-bb7f-292a1ccea9c9" contextRef="C_ebff40d6-3768-4f98-8eb1-4e6b12753e80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.32</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88eefb45-2d6e-4d4e-8a97-6e15fc6c4012" contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ceba66be-06c0-495c-ac1b-86267b06cdd4" contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d740ed64-9e33-4933-86eb-bdbd0086dc81" contextRef="C_35521780-703a-4201-9415-b3fff9017474" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2072702a-ca69-4425-8d6c-a7ab42a390ff" contextRef="C_35521780-703a-4201-9415-b3fff9017474" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12b2315d-e902-4bf6-942d-099c454928c4" contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8611a7c2-bf7f-4c90-948e-bdc520e99cd3" contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.50</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dc11f71-6902-468b-a797-2c1f0961d02b" contextRef="C_35521780-703a-4201-9415-b3fff9017474" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5189fe1b-d321-44ce-974f-2b1e6db9c633" contextRef="C_35521780-703a-4201-9415-b3fff9017474" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.07</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited and expired</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b5b20aa-e3bb-4ceb-bf76-299aba73e911" contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8" name="nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c65bbcb1-edcf-4f1c-be89-c7bf89359100" contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8" name="nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.87</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ee339df-a967-4dda-b98e-7849f6a71476" contextRef="C_35521780-703a-4201-9415-b3fff9017474" name="nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9db4f39-3311-4b75-ad37-628e91dc9160" contextRef="C_35521780-703a-4201-9415-b3fff9017474" name="nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.07</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding and unvested as of March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_391df976-7b3a-4fd8-8699-1cd601b2af34" contextRef="C_9f0723d9-5254-4d08-bff0-43148bf1192a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c42b57b3-88c3-49af-aaac-eb96a2ed78ff" contextRef="C_9f0723d9-5254-4d08-bff0-43148bf1192a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.67</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98c6625d-4918-466b-a3c5-ea51f55021d6" contextRef="C_ff586993-3393-4df1-a26e-92ffb8e44664" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,106</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4151b746-9581-4a85-993e-e7afd233bed8" contextRef="C_ff586993-3393-4df1-a26e-92ffb8e44664" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.08</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_389cbeed-1d44-4b2e-9f28-e649c63eec51" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes total stock-based compensation included in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.434%;box-sizing:content-box;"/>
          <td style="width:1.163%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.911000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.465%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:14.027000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_231e5ee5-e0c4-42fb-ab02-e2c6aac222e3" contextRef="C_3b83541b-7d35-4924-a941-cdc46db3b104" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,748</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f3d6c47-b60e-48a2-a82f-c66a015a4105" contextRef="C_945e63e7-24e2-41e4-b69a-b13ccda12454" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,812</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59653870-751a-41e9-a1ac-369c34db57d0" contextRef="C_89d8aeee-2789-4a1f-a31f-e532505c7bf2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,576</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_898d03c1-fd7e-436b-85d6-8d0bc491688e" contextRef="C_88db6b5d-3162-4950-a605-ff7e73170e5d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,561</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5577d24e-c81d-4dfc-bcdc-c1f1720dda6f" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,324</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee983b67-5f06-4524-92f8-43412dd2f0ec" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,373</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a29b31d9-0c7b-422c-95b5-4c87bed249a4_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2572f38-788a-4ca2-ab76-6fc72972fefd" contextRef="C_357567a5-de51-4303-afa8-40e33e156b88" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">73.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42f3d6bd-ef5b-4975-9475-4cec97cbb3e6" contextRef="C_9f0723d9-5254-4d08-bff0-43148bf1192a" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation related to stock options and restricted stock outstanding, respectively, including stock options and restricted common stock for which achievement of milestones was not probable, which were expected to be recognized over a weighted-average remaining service period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9896afbc-0fb7-4683-9acf-2f81b510b08e" contextRef="C_0f91fe01-be96-44a4-a1f4-fc84be3ec675" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81973bf6-b38f-4ee1-9d44-8c773ab589bd" contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80707aff-2f93-4ef6-8311-3f840bbe84ca" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Segment Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e59d2f58-bcc5-4220-a836-76c206417c46" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment related to the development of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5ef6507a-991a-417b-a92b-153ec2aede3b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (CEO) serves as the CODM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_227a2bb3-3530-40ae-ac92-9a2a08d6c1cd" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CEO manages and allocates resources to the operations of the Company on a consolidated basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#8217;s strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, cash forecasting, allocating resources and setting incentive targets. The CEO bases this assessment on the Company&#8217;s consolidated net loss. Through this analysis, the CEO assesses performance by comparing budget to actual results, and then decides how to allocate resources to invest in the Company&#8217;s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22071d19-6358-4399-ae71-660dbd09fad7" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below is a summary of the segment loss, including significant segment expenses (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Program expenses</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Navacaprant (NMRA-140) program</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72b3e118-3c6a-4bad-93f1-d9e52a20e704" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:NavacaprantNMRA-140ProgramExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,493</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37810957-ba77-4d50-a4b4-e7c83253302e" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="nmra:NavacaprantNMRA-140ProgramExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,319</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;M4 PAM programs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24edb14c-9f8f-4908-aa89-00eee9f698e3" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:M4PAMProgramsExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,882</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2da78c1-2806-4068-b5fb-24a185928ce8" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="nmra:M4PAMProgramsExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,524</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;NMRA-511 program</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ce561fb-37e7-406f-8f04-eb6d4556e7aa" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:NavacaprantNMRA-511ProgramExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,580</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd136785-352d-47c8-97ac-6fb9f96d23b0" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="nmra:NavacaprantNMRA-511ProgramExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,887</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Preclinical programs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_344e0853-d5fc-470f-b410-edca55971544" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:PreclinicalProgramsExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,002</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d9f4f8d-6fe5-493e-878a-0c3f09c528ea" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="nmra:PreclinicalProgramsExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,409</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development personnel-related costs</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10a91ede-bf1f-4ddb-9c84-5050e7bd9d86" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:ResearchAndDevelopmentPersonnelRelatedCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,326</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ab12f41-2e90-480c-983b-598b6c79580e" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="nmra:ResearchAndDevelopmentPersonnelRelatedCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,875</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_034b0471-de22-4444-9f31-c48cf24bed0b" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,785</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb7abb83-d468-492c-83e1-bc4e266a6600" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,317</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14dda382-8264-4beb-b17b-d944f118a099" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,074</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b19ec3c2-a0cd-4a1e-824e-d820b49170de" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,365</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_338b5abd-d5ba-4acd-9834-3af999a45efe" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="nmra:OtherSegmentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,998</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afd64794-3f3f-44b3-a05c-f17ef3eabec5" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="nmra:OtherSegmentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,755</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7438873d-54a3-4536-9775-c03692263e32" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,992</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90611b52-ec38-4c7b-a41b-b07140656bd1" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,721</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Includes other research and development costs, provision for income taxes, and other income (expense).</span></p></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_40991cf4-f17e-4b90-a5c9-6d2039d09ff8" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="F_40991cf4-f17e-4b90-a5c9-6d2039d09ff8_1"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.	Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ae5773e-4e0c-47d5-807b-0d86f6fa84f1" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58.42%;box-sizing:content-box;"/>
          <td style="width:1.94%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:16.279999999999998%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.94%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:17.419999999999998%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except per share amounts)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4c178e3-c2f1-402c-a58d-6ecf7e55d721" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,992</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd4b775b-833b-430b-b756-222c9b37c9cc" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,721</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6675b482-8136-415d-8ff3-63698ed4b95b" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1598f811-2987-4fb7-9177-3ba3b1c288d6" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,451</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b3c5527-a96c-4011-b791-7746e8a7bae7" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_04168446-e1ce-4db3-a881-86f9b90d925d" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,943</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75c17561-7d17-4a28-9c63-bd7cb232b7ed" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c4f4b542-cf51-47c3-8ce0-a65b9d9ee7ce" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.42</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4f4bc77-772a-448d-9b87-6f50a92afd2b" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3e8a70c7-c2b4-414e-92d3-a5db7bc047c6" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.34</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><ix:continuation id="F_40991cf4-f17e-4b90-a5c9-6d2039d09ff8_1"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f572e454-baaa-428f-82d6-eab5f24eaec6" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_f572e454-baaa-428f-82d6-eab5f24eaec6_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;box-sizing:content-box;"/>
          <td style="width:1.16%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.357%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.16%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.357%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options and restricted stock units</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4fe711a-2cec-4260-9887-5f40a1acb7c8" contextRef="C_f9669214-3f77-4f65-8703-5b733c4987c2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,187</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2696f5c-e516-41fd-a256-25e642d18ba7" contextRef="C_624b06cb-3eb6-4c5a-b6f8-d5c6f733459c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,084</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Early exercised stock options subject to future vesting</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90fc4c7e-08c8-40b5-9a7a-113d79366f0f" contextRef="C_5c2c1eeb-3a09-4d7b-9795-a097550eb2bf" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a77d8c3-895c-4cc6-9b81-4c7dac12494b" contextRef="C_bdb2f4d2-eed9-41ee-954a-8febbe7f4b55" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3094e629-1591-49c8-8781-09cf671f6718" contextRef="C_da5dfacb-16f9-419e-9ea3-8176113c5d89" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d686e93d-bd7b-46e6-bc80-01b5dbbdb178" contextRef="C_b7741931-52c1-4814-ba2a-d45dd587fcc8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">650</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Performance restricted stock (with performance conditions to be established)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_381b2813-4954-4d18-9140-65a68f1fe9d3" contextRef="C_0d5d9e12-40b5-47d8-9d2b-14dd033fa5f5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">255</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fef22623-ef1a-434e-86fa-948f02c97beb" contextRef="C_24e1bd61-fe0a-45a0-b4e5-7e09d0a6cf7f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">272</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe21f909-fd49-42e7-a8ab-29d156513efb" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,596</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_683f8c15-daa0-43a7-a96f-e31c1469e184" contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,044</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_f572e454-baaa-428f-82d6-eab5f24eaec6_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aae49879-c595-4c0a-a2fa-f7d7599aaeda" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.	Related Party Transactions</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025 and December 31, 2024, the Company was obligated to pay Amgen $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ae6ae2f-d65a-410f-a518-ffeb5a8a6bbb" contextRef="C_c6ca0beb-621e-45be-9f36-bcb1a9eadb66" name="nmra:RelatedPartyTransactionObligationWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94fd2344-c59a-4865-96d5-3589b780661c" contextRef="C_c7784c8e-e600-439e-b7df-863d51173fcb" name="nmra:RelatedPartyTransactionObligationWithRelatedParty" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, under the Amgen Collaboration Agreement, which was recorded within current liabilities on the condensed consolidated balance sheets. During the three months ended March 31, 2025 and 2024, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ebf712e-6a31-4eb6-b4ba-eae5cd727c17" contextRef="C_e911e4aa-353a-44c7-8d53-12528baf8f7d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43ed7e5a-d9f7-4bf3-8545-2f18ce0b0a58" contextRef="C_bedae046-3671-4278-8b1c-24865ff68f64" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, of research and development expenses with Amgen.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_07594a85-9a35-4339-8f32-6efd0798b426" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:SubsequentEventsTextBlock" escape="true" continuedAt="F_07594a85-9a35-4339-8f32-6efd0798b426_1"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.	Subsequent Event</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 9, 2025 (the &#8220;Closing Date&#8221;) the Company, entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with K2 HealthVentures LLC (&#8220;K2HV&#8221;) that provides up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c67afe6-76d3-42b7-b1b5-17073376a4d5" contextRef="C_cd3670e7-bb95-4a95-9b48-6251aef56387" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million principal in term loans (the &#8220;Term Loans&#8221;) over </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_330746ad-6634-4665-8371-9e365055d6fc" contextRef="C_c9441c9e-5777-498d-b6d5-078a3f0763f0" name="nmra:NumberOfTranches" unitRef="U_Tranche" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> tranches. The first tranche consists of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a72b7a16-5b60-4cd1-87c6-8fb9d286a417" contextRef="C_99f5cde7-7246-4eb9-9076-bb614ce418b2" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">40.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million with $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e283c3b2-27e6-4bc2-9d07-860a238561ee" contextRef="C_99f5cde7-7246-4eb9-9076-bb614ce418b2" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million funded on the Closing Date and an option for an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c797c971-3ec9-4f2e-b523-f88a9060f260" contextRef="C_99f5cde7-7246-4eb9-9076-bb614ce418b2" name="nmra:LineOfCreditFacilityAdditionalBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at the Company&#8217;s request through December 31, 2025. The second tranche commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2bba2a1-1e90-40e0-8904-f4a1ab8a1432" contextRef="C_c1c1147c-6515-43d5-9a5a-39bdb8587234" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is available to be drawn at the Company&#8217;s option through September 30, 2026, subject to the achievement of certain clinical and regulatory milestones and receipt of not less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1507c87-e000-4c1b-a14e-8030391f14e9" contextRef="C_27ed8d77-f3bf-4069-b960-220c0a09b3fc" name="nmra:NetCashProceedsFromFinancingActivities" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">175.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net cash proceeds from certain financing activities, with at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2315a3b0-0707-408b-8ca5-150a0547b16f" contextRef="C_27ed8d77-f3bf-4069-b960-220c0a09b3fc" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from an equity financing. A third tranche commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2439587-8562-475a-852c-e9d22b678279" contextRef="C_e34013cc-ec03-4b59-921d-284dfd9952b9" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is available to be drawn at the Company&#8217;s option from December 1, 2027 through December 31, 2027, subject to certain regulatory approvals. A fourth and final tranche commitment of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_249b09b7-7441-4866-b5ae-8f5db24c1524" contextRef="C_0e450f30-40c2-4a41-84cf-da509f4dece6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is available subject to K2HV&#8217;s review of certain information from the Company and discretionary approval by the Lenders.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loan matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c244de65-f8a1-4f33-b839-be154c63280c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 1, 2029</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a528946-d477-4295-9c91-12f81b89aab7" contextRef="C_ad0401b2-4d75-4075-81f0-1c16e959518e" name="us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company is obligated to make interest only payments for the first 36 months, or 48 months if the second tranche is funded, and then interest and principal payments for the next 12 months.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc019c2d-aa9f-40d7-9937-e3dbc01ed823" contextRef="C_ad0401b2-4d75-4075-81f0-1c16e959518e" name="us-gaap:LineOfCreditFacilityInterestRateDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loan bears a variable interest rate equal to the greater of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac7875dc-08a9-4370-b494-1694ea7c6469" contextRef="C_f164d19d-7ff7-4491-8078-1f6420964b6a" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">10.45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and (ii) the sum of (A) the prime rate as quoted in The Wall Street Journal and (B) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40abd0b7-044a-4ecc-b990-f6e4d580a20c" contextRef="C_49cf2bec-a0f7-4364-9f41-4d0d4dd7485d" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our obligations under the Loan Agreement are secured by a security interest in substantially all of our assets, other than certain intellectual property assets. The Loan Agreement includes customary affirmative and negative covenants, as well as standard events of default, including an event of default based on the occurrence of a material adverse event. The negative covenants include, among others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying cash dividends or making other distributions, making investments, creating liens, selling assets and making any payment on subordinated debt, in each case subject to certain exceptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd4bb77f-5dee-42e2-b234-7f9377c56b1c" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="us-gaap:DebtInstrumentCovenantDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beginning January 1, 2026, the Company is subject to a minimum liquidity covenant. Depending on the Company&#8217;s achievement of milestones and/or exceeding a specified market capitalization, the minimum liquidity amount will be one of the following: (i) four months cash runway, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69112e18-2528-40c9-b224-d3e06278c76d" contextRef="C_39f31af5-0a63-4d36-b5c4-aa045096d63a" name="nmra:MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding obligations under the Loan Agreement, (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_196c6c0e-3f5b-4cf0-a56b-ab4ab9d8b347" contextRef="C_39f31af5-0a63-4d36-b5c4-aa045096d63a" name="nmra:MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">105</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding obligations under the Loan Agreement or (iv) waived (i.e., zero).</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may prepay, at its option, all, but not less than all, of the Term Loan then outstanding plus the accrued and unpaid interest on the portion of principal so repaid, subject to a prepayment premium and end of term fee. K2HV may elect prior to the full repayment of the term loans to convert up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_519afbab-c0da-4a03-a628-c116f31fab74" contextRef="C_4a09c9c7-6948-412c-8311-1564f533ec6d" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of outstanding principal of the term loans into shares of the Company&#8217;s common stock, at a conversion price of the lesser of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_390a31d2-72ce-4b15-b74d-a48f47beb46c" contextRef="C_a586780a-a629-48b7-9844-e31954befa7a" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.8774</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and the lowest effective price per share of the Company&#8217;s next equity financing. There will be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_902dcadf-d210-4bf8-b660-317ee5e58266" contextRef="C_c9441c9e-5777-498d-b6d5-078a3f0763f0" name="nmra:PrepaymentPenalty" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> prepayment penalty for any principal amount converted into common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_07594a85-9a35-4339-8f32-6efd0798b426_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company granted K2HV the right, prior to repayment of the term loans, to invest up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e15aa5c-22d5-4aff-b4ce-10c226e8b093" contextRef="C_cd3670e7-bb95-4a95-9b48-6251aef56387" name="nmra:MaximumFutureCapitalStockOfferingsInvestment" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate in future offerings of the Company&#8217;s capital stock subject to certain exceptions and conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/> </span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7_managements_discussion"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Management&#8217;s Dis</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cussion and Analysis of Financial Condition and Results of Operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and notes thereto and the related Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 3, 2025. This discussion and analysis contains forward-looking statements based upon current beliefs, plans, and expectations related to future events and our future performance that involves risks, uncertainties, and assumptions, such as statements regarding our intentions, plans, objectives, and expectations for our business. Our actual results and the timing of selected events could differ materially from those discussed in the forward-looking statements as a result of several factors including those set forth in the section titled &#8220;Risk Factors.&#8221; See also the section titled &#8220;Special Note Regarding Forward-Looking Statements&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. We have rapidly scaled our therapeutic pipeline, which currently consists of seven neuroscience programs, including two clinical programs, that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our most advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of major depressive disorder (MDD), which we believe has the potential to provide significant advantages relative to the standard of care, if approved. Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. We expect to report topline data from KOASTAL-3 in the first quarter of 2026 and KOASTAL-2 in the second quarter of 2026. Our next most advanced product candidate is NMRA-511, a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer&#8217;s disease (AD). We are advancing a Phase 1b signal-seeking study investigating NMRA-511 initially in healthy elderly adult participants and then people with agitation associated with dementia due to AD, and we expect to report data from this study around the end of 2025. Our M4 positive allosteric modular (PAM) franchise comprises multiple novel compounds that each have different chemical composition and what we believe are optimal pharmacological properties, which have demonstrated robust activity in preclinical efficacy models and high selectivity for the M4 receptor subtype. We expect to progress an M4 PAM into the clinic in mid-2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As shown in the table below, our current pipeline includes seven programs, two of which are in clinical development and five of which are in preclinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img236770017_0.jpg" alt="img236770017_0.jpg" style="width:720px;height:347px;"/></p><p style="margin-left:5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALS = Amyotrophic lateral sclerosis; CK1&#948;= Casein Kinase I Isoform delta; GCase = Glucocerebrosidase; IP = Intellectual Property; KOR = kappa opioid receptor;  M4R = Muscarinic Acetylcholine Receptor M4; NLRP3 = Nucleotide-binding Domain, Leucine-rich&#8211;containing Family, Pyrin Domain&#8211;containing-3; NMDA = N-methyl-D-aspartate; V1aR = Vasopressin 1a Receptor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in November 2019 and commenced operations thereafter. To date, we have focused primarily on building our organization, acquiring technologies and companies, developing our precision neuroscience approach, identifying and developing potential product candidates, executing clinical and preclinical studies, organizing and staffing our company, business planning, establishing our intellectual property portfolio, raising capital and providing general and administrative support for these operations. We do not have any products approved for sale, we have not generated any revenue from the sale of products, and we do not expect to generate revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings, and receive approvals from the applicable regulatory bodies for such product candidates, if ever.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisitions of Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed various acquisitions. For details regarding our acquisitions, see Note 6 &#8211; Acquisitions of Assets to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Strategic License and Research and Collaboration Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have assumed license arrangements with certain third parties as a result of our acquisitions and have entered into several additional license, research and collaboration agreements with various parties. For details regarding these agreements, see Note 8 </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8211;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Strategic License and Research and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to our condensed consolidated financial statements included elsewhere in this Quarterly Report </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on Form 10-Q</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Consideration</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BlackThorn Contingent Consideration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the BlackThorn Merger Agreement, we are required to pay the former stockholders of BlackThorn contingent consideration (i) with respect to navacaprant, in the form of development and regulatory approval milestones of up to an aggregate amount of $365.0 million, which includes a milestone payment that became due and was paid in the fourth quarter of 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant, and sales-based milestones of up to an aggregate amount of $450.0 million and (ii) with respect to NMRA-511, in the form of development and regulatory approval milestones of up to an aggregate amount of $100.0 million, and sales-based milestones of up to an aggregate amount of $100.0 million (BlackThorn Milestones). At our sole discretion, the BlackThorn Milestone payments may be settled in cash or shares of our common stock, or a combination of both, subject to the provisions of the BlackThorn Merger Agreement, other than one development milestone in the amount of $10.0 million, which must be settled in cash. In December 2023, we issued 6,072,445 shares of common stock based on the volume weighted average price per share prior to the date the milestone was met and paid $2.3 million in cash in satisfaction of the Phase 3 navacaprant milestone to the former stockholders of BlackThorn and participants in the carveout plan. As of March 31, 2025,</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">none of the other BlackThorn Milestones have been achieved and no such related amounts were deemed due or payable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vanderbilt Contingent Consideration</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the Vanderbilt License Agreement, we are required to pay Vanderbilt contingent consideration payable in cash up to an aggregate of $42.4 million upon the achievement of specified development milestones and up to an aggregate of $380.0 million upon the achievement of commercial milestone events as well as tiered royalties at mid-single digit percentages on potential future net sales. We achieved a $2.0 million development milestone in October 2023, which was paid in cash in November 2023. As of March 31, 2025, none of the other Vanderbilt milestones have been achieved and no such related amounts were deemed due or payable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Operating Results</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of external and internal expenses, and primarily relate to our discovery efforts and development of our precision neuroscience approach, programs, and product candidates. External research and development expenses include, among others, amounts incurred with contract research organizations (CROs), contract manufacturing organizations (CMOs), preclinical testing organizations and other vendors that conduct research and development activities on our behalf. Internal research and development expenses include, among others, personnel-related costs, including salaries, benefits and stock-based compensation for employees engaged in research and development functions, laboratory supplies and other non-capital equipment utilized for in-house research, software development costs and allocated expenses including facilities costs and depreciation and amortization.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we are working on multiple research and development programs at any one time, we track our external expenses by the stage of program, clinical or preclinical. However, our internal expenses, including unallocated costs, employees and infrastructure are not directly tied to any one program and are deployed across multiple programs. As such, we do not track internal expenses on a specific program basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense research and development costs as incurred. Amounts recorded for external goods or services incurred for research and development activities that have not yet been invoiced are included in accrued liabilities in our consolidated balance sheets and often represent estimates. We estimate accrued expenses and the related research and development expense based on the level of services performed but not yet invoiced pursuant to agreements established with our service providers, according to the progress of preclinical studies, clinical trials or related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and service. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as prepaid expenses or other current assets or accrued liabilities. Nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to incur significant research and development expenses for the foreseeable future as we further develop our precision neuroscience approach and advance our programs and product candidates through clinical development and pursue regulatory approval of our product candidates. The process of conducting the necessary clinical and preclinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result of the uncertainties discussed below, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development expenses may vary significantly based on factors such as:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">per patient trial costs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of trials required for approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of sites included in the trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the countries in which the trials are conducted;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the length of time required to enroll eligible patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients that participate in the trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the drop-out or discontinuation rates of patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential additional safety monitoring requested by regulatory agencies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the duration of patient participation in the trials and follow-up;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of manufacturing our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the phase of development of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy and safety profile of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and scope of preclinical and IND-enabling studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our precision neuroscience approach at identifying target patient populations and utilizing the approach to enrich our patient population in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee-related costs for personnel engaged in the design, development, testing and enhancement of our precision neuroscience related technology;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we establish additional collaboration or license agreements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we choose to partner any of our product candidates and the terms of such partnership; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of general economic conditions, such as rising inflation and increasing interest rates.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates. We may obtain unexpected results from our preclinical studies and future clinical trials.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses include, among others, personnel-related costs, including salaries, benefits, and stock-based compensation for our employees in executive, finance, and other administrative functions, legal fees, professional fees incurred for accounting, audit, and tax services, recruiting costs, and other allocated expenses, including facilities costs and depreciation and amortization not included in research and development expenses. Legal fees are included within general and administrative expenses and are related to corporate and intellectual property related matters.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our general and administrative expenses to increase substantially in the foreseeable future as we continue to support our research and development activities, grow our business and, if any of our product candidates receive marketing approval, commence commercialization activities. We will also continue to incur additional expenses associated with operating as a public company, including increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with the rules and regulations of the SEC and standards applicable to public companies, additional insurance expenses, investor relations activities and other administrative and professional services.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income (Expense)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income consists of interest earned on our cash equivalents and marketable securities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">For the Three Months Ended </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">March 31, 2025 and 2024</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our result of operations for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:57.7%;box-sizing:content-box;"/>
      <td style="width:1.4%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:10.700000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.4%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:10.700000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.4%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:10.700000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,151</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,757</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,394</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,785</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,317</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,468</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,936</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,074</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,862</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(70,936</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(60,074</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,862</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,074</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,365</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,291</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense), net</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(25</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,049</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,353</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,304</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss before income taxes</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,887</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(53,721</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,166</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,992</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(53,721</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,271</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses by program for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:55.84%;box-sizing:content-box;"/>
      <td style="width:1.46%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:11.26%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.46%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:11.26%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.46%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:11.26%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct external program expenses:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Navacaprant (NMRA-140) program</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,493</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,319</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">M4 PAM programs</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,882</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,524</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(642</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NMRA-511 program</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,580</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,887</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">693</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical programs</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,002</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,409</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,407</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal and unallocated expenses:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related costs</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,326</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,875</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,451</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,868</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,743</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,125</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,151</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,757</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,394</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses increased by $6.4 million, or 14%, to $52.2 million for the three months ended March 31, 2025, from $45.8 million for the three months ended March 31, 2024 primarily due to the final $6.3 million of costs incurred under the Amgen Collaboration Agreement. Direct external program expenses decreased by $1.2 million, primarily due to a decrease in pre-clinical program research. Internal and unallocated expenses increased by $7.6 million, primarily due to an increase in external research and development activities of $6.1 million, attributable to the final costs incurred under the Amgen Collaboration Agreement and an increase in personnel related costs of $1.5 million, primarily attributable to an increase in stock-based compensation and a one time bonus payment for a key executive.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses increased by $4.5 million, or 31%, to $18.8 million for the three months ended March 31, 2025, from $14.3 million for the three months ended March 31, 2024 primarily attributable to higher personnel-related costs, including severance pay and one time bonus payments for key executives of $2.0 million and increased stock-based compensation expense of $1.0 million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income decreased by $3.3 million to $3.1 million for the three months ended March 31, 2025 from $6.4 million for the three months ended March 31, 2024, which was attributable to less interest earned on our lower balances in cash equivalents and marketable securities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, we had $249.4 million of cash, cash equivalents and marketable securities. Prior to our IPO we primarily funded our operations with the net proceeds from the sale and issuance of our convertible preferred stock and convertible promissory notes and raised gross cash proceeds of over $600 million including from the sale of convertible preferred stock, borrowings pursuant to convertible promissory notes and cash acquired in our acquisitions of assets. In September, 2023, we completed our IPO pursuant to which we issued and sold an aggregate of 14,710,000 shares of common stock at a price to the public of $17.00 per share. We received aggregate net proceeds of $226.5 million after deducting underwriting discounts and commissions of $17.5 million and other offering expenses of $6.0 million. Since our IPO, in October 2024 we entered into a sales agreement with Leerink to sell shares of our common stock, from time to time, with aggregate gross sales proceeds of up to $300.0 million, through an at-the-market equity offering program (ATM) with Leerink as the sales agent. We received aggregate net proceeds of $13.7 million under the ATM after deducting commissions and offering expenses of $0.8 million during the year ended December 31, 2024. There were no sales under the ATM during the three months ended March 31, 2025.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have not generated any revenue from the sale of products and we have incurred significant net losses, which are primarily attributable to acquired intangible in-process research and development intangible asset (IPR&amp;D) costs pursuant to our acquisitions, which occurred in 2020 and were accounted for as an acquisition of assets, and negative cash flows from operations. Our primary use of our capital resources is to fund our operating expenses, which consist primarily of expenditures related to identifying,</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquiring, developing, and in-licensing our precision neuroscience approach, programs, and product candidates, and conducting preclinical studies and clinical trials, and to a lesser extent, general and administrative expenditures. We have not yet commercialized any products and we do not expect to generate revenue from sales of any product candidates for a number of years, if ever. As of March 31, 2025, we had an accumulated deficit of $1,015.2 million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future Funding Requirements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses and operating losses will increase substantially over the foreseeable future as we continue our research and development efforts, advance our product candidates through clinical and preclinical development, enhance our precision neuroscience approach and programs, expand our product pipeline, seek regulatory approval, prepare for commercialization, as well as hire additional personnel and protect our intellectual property. Furthermore, since our IPO, we have incurred and will continue to incur additional costs associated with being a public company. Our net losses may fluctuate significantly from period to period, depending on the factors described below. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. The expected increase in expenses will be driven in large part by our ongoing activities, and our future capital requirements will depend on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, timing, progress, costs and results of discovery, preclinical development and clinical trials for our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of clinical trials required for regulatory approval of our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of any of our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with acquiring or licensing additional product candidates, technologies or assets, including the timing and amount of any milestones, royalties or other payments due in connection with our acquisitions and licenses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing clinical and commercial supplies of our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our precision neuroscience approach at identifying target patient populations and utilizing our approach to enrich our patient population in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to access additional multimodal patient datasets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses to attract, hire and retain skilled personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of macroeconomic trends including tariffs, trade controls, inflation and rising interest rates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing any potential supply chain interruptions or delays, including those related to geopolitical issues;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competing technological and market developments; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or invest in business, products and technologies.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements through at least the next 12 months following the issuance of the condensed consolidated financial statements. However, we anticipate that we will need to raise additional financing in the future to fund our operations </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and pursue our long-term business plan</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including the development and commercialization of our product candidates, if</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approved. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We may also raise additional financing on an opportunistic basis in the future. We expect to continue to expend significant resources for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To complete the development and commercialization of our product candidates, if approved, we will require substantial additional funding. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through public or private equity offerings or debt financings or other capital sources, which may include strategic collaborations or other arrangements with third parties, or other sources of financing. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to raise additional capital on terms acceptable to us or at all. If we are unable to raise additional capital on acceptable terms when needed, our business, results of operations, and financial condition would be adversely affected. The amount and timing of </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our future funding requirements will depend on many factors including the successful advancement of our precision neuroscience approach, programs, and product candidates. Our ability to raise additional funds may also be adversely impacted by potential worsening global economic conditions and disruptions to, and volatility in, the credit and financial markets in the United States and worldwide.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:67.318%;box-sizing:content-box;"/>
      <td style="width:1.176%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.917%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.506%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:13.081%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by:</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(59,448</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(42,955</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,160</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(150,001</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,845</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net change in cash and cash equivalents and<br/>&#160;&#160;&#160;restricted cash</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,288</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(191,111</span></p></td>
      <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $59.4 million, which consisted of a net loss of $68.0 million and a change in our net operating assets and liabilities of $0.5 million, partially offset by noncash charges of $9.1 million. The change in our net operating assets and liabilities primarily resulted from an a decrease in accounts payable of $2.3 million due to the timing of our accounts payable and a decrease in current operating lease liabilities of $0.9 million due to the upcoming expiration of our office and lab lease agreement, partially offset by a decrease in prepaid expenses and other current assets of $1.0 million due to less interest receivable on our cash and marketable securities and an increase in accrued liabilities of $1.7 million related to our ongoing clinical trials. The noncash charges primarily consisted of $9.3 million of stock-based compensation, $$0.9 million of noncash operating lease expense, partially offset by $1.3 million on of net accretion of discounts on marketable securities.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities for the three months ended March 31, 2024 was $43.0 million, which consisted of a net loss of $53.7 million, which was partially offset by a change in our net operating assets and liabilities of $3.6 million and $7.2 million in noncash charges. The change in our net operating assets and liabilities primarily resulted from a decrease of $7.4 million in prepaid expenses and other current assets related to our clinical programs and an increase of $1.2 million in accounts payable primarily due to the timing of our accounts payable, partially offset by a decrease in accrued liabilities related to our clinical programs and a decrease in operating lease liabilities of $0.8 million. The noncash charges primarily consisted of $7.4 million of stock-based compensation, $0.8 million of noncash operating lease expense and $0.2 million of depreciation and amortization, partially offset by $1.1 million of net accretion of discounts on marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by investing activities for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was $44.2 million, which primarily consisted of $88.6 million in proceeds from maturities of marketable securities, partially offset by $44.4 million in purchases of marketable securities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities for the three months ended March 31, 2024 was $150.0 million, which primarily consisted of $185.8 million in purchases of marketable securities, partially offset by $36.6 million in proceeds from maturities of marketable securities.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities for the three months ended March 31, 2024 was $1.8 million, which consisted of proceeds from the exercise of stock options.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligations and Other Commitments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, our contractual obligations and commitments relate primarily to our operating lease for</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our office and laboratory facilities located in Massachusetts with a noncancelable lease term expiring in June 2025.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into a number of acquisitions of assets that are summarized in Note 6 &#8211; Acquisitions of Assets to our condensed consolidated financial statements. As part of these acquisitions of assets, we are obligated to pay cash and/or stock for future contingent payments that are dependent upon future events, and in some cases, vesting by the recipient of the contingent payment, such as our achievement of certain development, regulatory, and commercial milestones. We have also assumed license arrangements with various third parties, primarily as a result of our acquisitions, and have entered into additional agreements that are summarized in Note 8 &#8211;Strategic License and Research and Collaboration Agreements</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to our condensed consolidated financial statements. In accordance with these agreements, we are obligated to pay, among other items, future contingent payments that are uncertain and dependent upon future events such as our achievement of certain development, regulatory, and commercial milestones royalties, and sublicensing revenue in the future, as applicable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of the financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with the U.S. generally accepted accounting principles (GAAP). The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosures. Our estimates are based on historical experience and on various other factors that are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no material changes to our critical accounting estimates from those described under in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8211; Critical Accounting Estimates&#8221; included in our 2024 Annual Report on Form 10-K filed with the SEC on March 3, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 2 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JOBS Act Accounting Smaller Reporting Company Elections</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were an &#8220;emerging growth company,&#8221; as defined in the JOBS Act until December 31, 2024. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until those standards apply to private companies.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the date we lost emerging growth company status. As a result, our condensed consolidated financial statements may or may not be comparable to companies that comply with new or revised accounting pronouncements as of public companies&#8217; effective dates.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were also a &#8220;smaller reporting company,&#8221; as defined in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Exchange Act of 1934, as amended (</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act) until December 31, 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7a_quantitative_and_qualitative"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Quantitative and Qualitativ</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e Disclosures About Market Risk.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We had cash, cash equivalents and marketable securities of $249.4 million as of March 31, 2025. The primary objectives of our investment activities are to preserve principal, provide liquidity and maximize income without significantly increasing risk. Our primary exposure to market risk relates to fluctuations in interest rates, which are affected by changes in the general level of U.S. interest rates.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the short-term nature of our cash, cash equivalents and marketable securities, we do not expect that a sudden change in market interest rates would have a material impact on our financial condition and/or results of operations. We do not own any derivative financial instruments.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We contract with vendors in foreign countries. As such, we have exposure to adverse changes in exchange rates of foreign currencies associated with our foreign transactions. We believe this exposure to be immaterial. We do not hedge against this exposure to fluctuations in exchange rates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not believe that our cash, cash equivalents and marketable securities have significant risk of default or illiquidity. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash, cash equivalents and marketable securities that are in excess of federally insured limits at one or more financial institutions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our results of operations during the three months ended March 31, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9a_controls_and_procedures"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Cont</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rols and Procedures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of March 31, 2025, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II&#8212;OTHER INFORMATION</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Leg</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">al Proceedings.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 6, 2025, a purported stockholder of the Company filed a lawsuit against us, certain executive officers, and certain underwriters in the United States District Court for the Southern District of New York (Case No. 1:25-cv-01072). The complaint is a putative class action alleging violations of the Securities Act of 1933, as amended (Securities Act) related to our initial public offering on September 15, 2023. The plaintiff seeks compensatory damages, as well as fees and costs. The complaint claims that our offering documents contained false and misleading statements and omitted material facts about the prospects of navacaprant. We do not believe these allegations have merit and intend to move to dismiss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, from time to time, we may in the ordinary course of business become involved in legal proceedings. Regardless of outcome, litigation could have a material adverse effect on our business results of operations or financial condition due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">k Factors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISK FACTORS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before making an investment decision. The risks described below are not the only ones facing us. Many of the following risks and uncertainties are, and will be, exacerbated by any worsening of the global business and economic environment. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect our business, financial condition, reputation, or results of operations. In such case, the trading price of shares of our common stock could decline, and you may lose all or part of your investment.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary Risk Factors</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our substantial contingent consideration and related obligations from our acquisitions of assets and license and collaboration agreements may result in dilution to our stockholders, may be a drain on our cash resources, or may cause us to incur debt obligations to satisfy the payment obligations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our limited operating history may make it difficult to evaluate our prospects and likelihood of success.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully identify, develop and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition and results of operations will be materially adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were founded with a mission to redefine neuroscience drug development, a field that has seen very limited success. The ability to successfully develop drugs in this field is extremely difficult and is subject to a number of unique challenges.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have invested and expect to continue to invest in acquiring product candidates, technologies and assets, as well as research and development efforts that further enhance our product pipeline. Such investments may affect our operating results, and, if the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have experienced rapid growth since our inception in November 2019. If we fail to effectively manage our growth, we may not be able to execute on our business objectives.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.	 	</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical and preclinical drug development is a lengthy and expensive process, with an uncertain outcome. Our clinical and preclinical programs have experienced delays and may experience additional delays or may never advance, which would </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adversely affect our ability to obtain regulatory approvals or commercialize our product candidates on a timely basis or at all, which could have an adverse effect on our business.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and commercialization of drug products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis or at all, our business will be substantially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend on intellectual property licensed from third parties and we are currently party to in-license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our proprietary technologies and product candidates. If we breach our obligations under these agreements or if any of these agreements is terminated, or otherwise experience disruptions to our business relationships with our licensors, we may be required to pay damages, lose our rights to such intellectual property and technology, or both, which would harm our business.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a clinical stage biopharmaceutical company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical&#8209;stage biopharmaceutical company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We have incurred significant losses since our inception in November 2019, have no products approved for commercial sale, have not generated any revenue from product sales, have financed our operations principally through proceeds from sales of common stock, convertible preferred stock and convertible promissory notes and expect to incur significant losses for the foreseeable future. We expect that it will be several years before we have a commercialized product and generate revenue from product sales, if at all. Our net loss was $68.0 million and $53.7 million for three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025, we had an accumulated deficit of $1,015.2 million. Our losses have resulted principally from acquired in-process research and development from our acquisitions of assets, expenses incurred in the research and development of our product candidates, as well as from costs associated with our preclinical studies and clinical trials and management and administrative costs and other expenses that we have incurred while building our business infrastructure.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses and operating losses will continue to increase substantially for the foreseeable future as we expand our research and development efforts, advance our clinical candidates to potentially registrational trials, identify and acquire product candidates, complete preclinical studies and initiate additional clinical trials, seek regulatory approval and commercialization of our product candidates and operate as a public company. We anticipate that our expenses will continue to increase substantially as we:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue clinical and preclinical development of our current and future product candidates and initiate additional preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory approval of our current and future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire additional product candidates, technologies, multimodal patient datasets and other assets for our business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical and preclinical development, manufacturing and commercialization efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to develop, perfect, maintain and defend our intellectual property portfolio; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur additional legal, accounting or other expenses in operating our business, including the additional costs associated with operating as a public company.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have devoted a significant portion of our financial resources and efforts to building our organization, acquiring technologies and companies, executing clinical and preclinical studies, conducting research and development, identifying and developing potential product candidates, building our precision neuroscience approach, organizing and staffing our company, business planning, establishing, maintaining and protecting our intellectual property portfolio, raising capital and providing general and administrative support for these operations. We have not completed development and commercialization of any of our product candidates with most still being in relatively early development.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To become and remain profitable, we must succeed in identifying, developing, conducting successful clinical trials, obtaining regulatory approval for, and eventually commercializing, products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, continuing to discover and develop additional product candidates, obtaining regulatory and marketing approval for any product candidates that successfully complete clinical trials, accessing manufacturing capacity, establishing marketing capabilities, commercializing and ultimately selling any products. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is sufficient</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the price of our common stock could be materially adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with biopharmaceutical and biotechnology products and drug development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA or comparable foreign regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in commencing or completing our clinical trials or the development of any of our product candidates, our expenses could increase and commercial revenue could be further delayed and become more uncertain, which will have a material adverse impact on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our substantial contingent consideration and related obligations from our acquisitions of assets and license and collaboration agreements may result in dilution to our stockholders, may be a drain on our cash resources, or may cause us to incur debt obligations to satisfy the payment obligations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our acquisitions of assets in late 2020, we entered into arrangements whereby the former stockholders of those companies are entitled to substantial contingent consideration payments upon the occurrence of certain events. For example, in connection with our acquisition of BlackThorn Therapeutics, Inc. (BlackThorn), a privately held company, the former BlackThorn stockholders are entitled to contingent consideration (i) with respect to navacaprant (NMRA&#8209;140), in the form of development and regulatory approval milestones of up to an aggregate amount of $365.0 million, which includes a milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant, which was primarily settled by issuing unregistered shares of our common stock in December 2023, and sales&#8209;based milestones of up to an aggregate amount of $450.0 million and (ii) with respect to NMRA&#8209;511, in the form of development and regulatory approval milestones of up to an aggregate amount of $100.0 million and sales&#8209;based milestones of up to an aggregate amount of $100.0 million (BlackThorn Milestone Payments). With the exception of one development milestone in the amount of $10.0 million that is required to be settled in cash, the remaining BlackThorn Milestone Payments may be settled in cash or shares of our equity, or a combination of both, at our sole discretion. In connection with the BlackThorn acquisition, we also became obligated under its license agreement with The Scripps Research Institute (TSRI) for, among other obligations, development and regulatory milestone payments of up to $1.5 million in aggregate for the first product from each of the TSRI programs and commercial milestone payments of up to $3.5 million in aggregate for each occurrence.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of our September 2021 license agreements with Amgen, we are obligated to pay Amgen up to an aggregate of $720.0 million in commercial milestone payments upon the achievement of certain sales thresholds and single digit royalties on potential annual worldwide net sales related to the CK1&#948; or glucocerebrosidase (GCase) programs. In addition, under the collaboration agreement with Amgen, we committed to making quarterly payments to Amgen for their collaboration activities over three years totaling $62.5 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of our license agreement, as amended, with Vanderbilt University (Vanderbilt), we are obligated to pay Vanderbilt up to an aggregate of $422.4 million in development and commercial milestone payments upon the achievement of certain development milestones, which includes a milestone payment of $2.0 million that became due in October 2023, and sales thresholds, and mid&#8209;single digit royalties on potential future net sales.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to satisfy our obligations to make these payments, if and when they are triggered, we may need to issue equity or convertible debt securities that may cause dilution to our stockholders, or we may use our existing cash or incur debt obligations to satisfy the payment obligations in cash, which may adversely affect our financial position. In addition, these obligations may impede our ability to raise money in future public offerings of debt or equity securities or to obtain a third&#8209;party line of credit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See the sections titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Acquisitions of Assets&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Strategic License and Research and Collaboration Agreements&#8221; in this Quarterly Report on Form 10-Q for additional information regarding these agreements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our limited operating history may make it difficult to evaluate our prospects and likelihood of success.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical&#8209;stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. Since our inception in November 2019, we have devoted substantially all of our resources and efforts to building our organization, acquiring technologies and companies, executing preclinical studies and clinical trials, conducting research and development, identifying and developing potential product candidates, building our precision neuroscience tools, organizing and staffing our company, business planning, establishing, maintaining and protecting our intellectual property portfolio, raising capital and providing general and administrative support for these operations. All of our product candidates are in either clinical development or in preclinical stages of development, and we have not yet demonstrated our ability to successfully complete any late&#8209;stage or registrational/pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from period to period due to a variety of factors, many of which are beyond our control. Consequently, any predictions you may make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by clinical&#8209;stage biotechnology and biopharmaceutical companies in rapidly evolving fields. We also may need to transition from a company with a research focus to a company capable of supporting commercial activities. If we do not adequately address these risks and difficulties or successfully make such a transition, it could have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time&#8209;consuming, expensive and uncertain process that takes years to complete. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek regulatory and marketing approval for, our product candidates. If one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. To date, we have funded our operations principally through private financings. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the clinical and preclinical development of our product candidates, continue to develop and deploy our precision neuroscience approach, commence additional preclinical studies and clinical trials, and continue to identify and develop additional product candidates either through internal development or through acquisitions or in&#8209;licensing product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Accordingly, we will need to obtain substantial additional funding in order to support our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future regulatory approval or commercialization efforts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to expend significant resources for the foreseeable future. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day&#8209;to&#8209;day activities, which may adversely affect our ability to develop our product candidates. Our future capital requirements will depend on many factors, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, timing, progress, costs and results of discovery, preclinical development and clinical trials for our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of clinical trials required for regulatory approval of our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of any of our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with acquiring or licensing additional product candidates, technologies or assets, including the timing and amount of any milestones, royalties or other payments due in connection with our acquisitions and licenses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing clinical and commercial supplies of our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property&#8209;related claims, including any claims by third parties that we are infringing upon their intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our precision neuroscience approach at identifying target patient populations and utilizing our approach to enrich our patient population in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to access additional multimodal patient datasets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses to attract, hire and retain skilled personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company;</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third&#8209;party and government payers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of macroeconomic trends including inflation, tariffs, trade controls, and interest rates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing any potential supply chain interruptions or delays;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competing technological and market developments; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or invest in business, products and technologies.</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to raise additional funds will depend on financial, economic, political and market conditions and other factors, over which we may have no or limited control. Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, future commercialization efforts or other operations. Because of the numerous risks and uncertainties associated with research, product development and commercialization of product candidates, we are unable to predict the timing or amount of our working capital requirements or when or if we will be able to achieve or maintain profitability.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives and adequate additional financing may not be available to us on acceptable terms, or at all.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations with our existing cash, cash equivalents and marketable securities, the net proceeds from our initial public offering, any future equity or debt financings and upfront and milestone and royalties payments, if any, received under any future licenses or collaborations. If we raise additional capital through the sale of equity or convertible debt securities, or issue any equity or convertible debt securities in connection with a collaboration agreement or other contractual arrangement, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. In addition, the possibility of such issuance may cause the market price of our common stock to decline. For example, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in October 2024 we entered into a sales agreement with Leerink Partners LLC (Leerink) to sell shares of our common stock, from time to time, with aggregate gross sales proceeds of up to $300.0 million, through an ATM with Leerink as the sales agent. During the year ended December 31, 2024, we received aggregate net proceeds of $13.7 million through sales of shares of our common stock under the ATM after deducting commissions and offering expenses of $0.8 million. I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n December 2023, we settled a Phase 3 navacaprant milestone owed to BlackThorn stockholders by primarily issuing shares of our common stock. Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends or acquiring, selling or licensing intellectual property rights or assets, which could adversely impact our ability to conduct our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating results and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi&#8209;national financial institutions, and our deposits at certain of these institutions exceed insured limits. Market conditions and changes in financial regulations and policies can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. In addition, changes in regulations governing financial institutions are beyond our control and difficult to predict; consequently, the impact of such changes on our business and results of operations is difficult to predict and may have an adverse effect on us.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to successfully identify, develop and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition and results of operations will be materially adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue from sales of any of our approved product candidates, which we do not expect will occur for at least the next several years, if at all, depends heavily on the successful identification, development, regulatory approval and eventual commercialization of any product candidates, any of which may never occur. We have never generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize, a marketable product. All of our product candidates will require significant clinical development, regulatory approval, establishment of sufficient manufacturing supply, including commercial manufacturing supply, and may require us to build a commercial organization and make substantial investment and significant marketing efforts before we generate any revenue from product sales. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The successful development of our product candidates will depend on several factors, including, but not limited to, the following:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful and timely completion of preclinical studies and clinical trials for which the FDA, or any comparable foreign regulatory authority, align with the design, endpoints, or implementation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receiving regulatory approvals, allowances or authorizations for conducting future clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiation and successful patient enrollment in, and completion of, clinical trials on a timely basis;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate is safe and effective as for its intended uses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate&#8217;s risk&#8209;benefit ratio for its proposed indication is acceptable;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timely receipt of marketing approvals for our product candidates from applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing any potential supply chain interruptions or delays;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent of any required post&#8209;marketing approval commitments to applicable regulatory authorities; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing, scaling up and scaling out, either alone or with third&#8209;party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates are approved.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which would materially adversely affect our business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, clinical or regulatory setbacks to other companies developing similar products or within adjacent fields may impact the clinical development of and regulatory pathway for our current or future product candidates, or may negatively impact the perceptions of value or risk of our technologies.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We were founded with a mission to redefine neuroscience drug development, a field that has seen very limited success. The ability to successfully develop drugs in this field is extremely difficult and is subject to a number of unique challenges.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug development in the field of brain diseases, and neuropsychiatric disorders and neurodegenerative diseases in particular, has seen very limited success historically. We estimate over $110 billion has been spent on neuroscience research and development since 2019 in the United States alone, representing approximately 33% of all disease&#8209;specific spending. However, only approximately 12% of all new therapies approved during this time period have been for the treatment of brain diseases. From 2011 to 2020, clinical development success rates for new drug candidates that employed patient selection biomarkers were approximately 16% compared to approximately 8% for patients without patient selection biomarkers according to the Biotechnology Innovation Organization; however, clinical success depends on a number of factors and employing a patient selection biomarker approach does not guarantee that our product candidates will be approved and commercialized. Developing a product candidate for treatment of these brain diseases is extremely difficult and subjects us to a number of unique challenges, including obtaining regulatory approval from the FDA and other regulatory authorities who have only a limited set of precedents to rely on.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to work closely with the FDA and comparable foreign regulatory authorities to perform the requisite scientific analyses and evaluation in an effort to obtain regulatory approval for our product candidates; however, the process of developing our product candidates may be more complex and time&#8209;consuming relative to other more well&#8209;known approaches to drug development. We cannot be certain that our approach will lead to the development of product candidates that effectively and safely address the underlying brain diseases.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, given the history of clinical failures in this field, future clinical or regulatory failures by us or others may result in further negative perception of the likelihood of success in this field, which may significantly and adversely affect the market price of our common stock.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have invested and expect to continue to invest in acquiring product candidates, technologies and assets, as well as research and development efforts that further enhance our product pipeline. Such investments may affect our operating results, and, if the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have invested and expect to continue to invest in acquiring potential product candidates to enhance our product pipeline, technologies and assets. These activities and investments involve significant time, risks, and uncertainties, including the risk that the associated expenses may affect our operating results, such investments may not generate products that can be successfully developed or technologies that can be effectively used by us, and may cause significant drains on capital resources and commit us to substantial financial obligations. While we believe that we must continue to invest a significant amount of time and resources in the development of our product pipeline, if we do not achieve the benefits anticipated from these investments, or if the achievement of these benefits is delayed, our business, operating results and prospects may be materially adversely affected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have experienced rapid growth since our inception in November 2019. If we fail to effectively manage our growth, we may not be able to execute on our business objectives.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025 we had 103 full&#8209;time employees. We will continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to the complexity in managing a company that has scaled very quickly, we may not be able to scale our headcount and operations effectively to manage the expansion of our product pipeline or recruit and train the necessary additional personnel. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any future growth would impose significant added responsibilities on members of management, including: identifying, recruiting, integrating, maintaining, and motivating additional employees; managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and improving and scaling our operational, financial and management controls, reporting systems and procedures.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely on certain independent organizations, advisors, and consultants to provide certain services, including strategic, financial, business development, and research and development services, as well as certain aspects of regulatory approval and manufacturing. There can be no assurance that the services of independent organizations, advisors, and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants or contract manufacturing organizations is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on reasonable terms, or at all.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to develop product candidates, leverage our precision neuroscience approach and our future growth depends on attracting, hiring and retaining our key personnel and recruiting additional qualified personnel.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends upon the continued contributions of our key management and scientific personnel, many of whom have been instrumental for us and have substantial experience with developing therapies, identifying potential product candidates and building the technologies related to the clinical development of our product candidates. Given the specialized nature of brain diseases and our approach, there is an inherent scarcity of experienced personnel in these fields. As we continue developing our product candidates in our pipeline, we will require personnel with medical, scientific, or technical qualifications specific to each program. The loss of key personnel, in particular our neuroscientists, would delay our research and development activities. Despite our efforts to retain valuable employees, members of our team may terminate their employment with us on short notice. The competition for qualified personnel in the biotechnology and biopharmaceutical industries is intense, and our future success depends upon our ability to attract, retain, and motivate highly skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions, and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement our business strategy, which would have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical operations and research and development programs depend on our ability to attract and retain highly skilled scientists, data scientists, and engineers, particularly in Massachusetts and California.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is powerful competition for skilled personnel in these geographical markets, and we have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications on acceptable terms, or at all. Many of the companies with which we compete for experienced personnel have greater resources than we do, and any of our employees may terminate their employment with us at any time. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees often consider the value of the stock awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, it may harm our ability to recruit and retain highly skilled employees. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not realize the benefits of assets that we have acquired, or will acquire in the future, or other strategic transactions that we have consummated or will consummate.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our approach represents an aggregation of innovation and assets from multiple companies and academic institutions, including BlackThorn, Amgen, TSRI and Vanderbilt. Further, a key component of our strategy is to acquire and in&#8209;license assets and technologies to support the growth of our product pipeline and to enhance our Precision Toolbox of translational neuroscience tools, methods, and data science capabilities. As such, we actively evaluate various strategic transactions on an ongoing basis. We may acquire other assets, businesses, products or technologies, as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions and any future strategic transactions depends on the risks and uncertainties involved including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated liabilities related to acquired companies or joint ventures;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties integrating acquired personnel, technologies, and operations into our existing business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">retention of key employees;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of management time and focus from operating our business to the management of acquisition and integration efforts, strategic alliances or joint ventures challenges;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increases in our expenses and reductions in our cash available for operations and other uses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruption in our relationships with collaborators or suppliers; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">possible write&#8209;offs or impairment charges relating to acquired businesses or joint ventures.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. For example, less than one year following the acquisition of Propellex Bio, Inc. (Propellex) in 2020, we terminated and are no longer developing the program we acquired from Propellex. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses, impairments or write&#8209;offs of goodwill or impairments and write&#8209;offs of in&#8209;process research and development assets, any of which could harm our financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have relied on, and in the future will continue to rely on, third&#8209;party datasets and databases to build and enhance our precision neuroscience approach. If we are not able to access additional data sets or develop enhancements to our precision neuroscience approach, our ability to execute on our strategy may be limited.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to execute on our drug development strategy depends in part on our ability to enhance and improve our precision neuroscience approach. As part of this approach, we interrogate public, partnered and proprietary datasets across neuropsychiatric and neurodegenerative diseases, currently encompassing genetic, imaging, electroencephalogram, digital and clinical data. We rely on these datasets and data analytics for identifying or validating some of our biomarker&#8209;target relationships. The success of our precision neuroscience approach and any enhancement to our approach depends on several factors, including access to and generation of additional multimodal patient datasets, whether public, partnered or proprietary, development of more advanced proprietary machine learning capabilities and increased computational storage and processing capacity. If we are unable to access additional datasets or they are not available on acceptable terms, or if we are otherwise unsuccessful in enhancing our approach, we may be limited in our precision neuroscience capabilities and not be able to fully utilize a precision neuroscience drug development strategy.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, access to public data sets may be limited by governmental or other restrictions, including restrictions on commercial application by government or government sponsored organizations or privacy related restrictions. See the risk factor &#8220;We face potential liability related to the privacy of health information we utilize in the development of product candidates, as well as information we obtain from clinical trials sponsored by us from research institutions and directly from individuals&#8221; for additional information on privacy related considerations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and biopharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain marketing approval for new and innovative products on a cost&#8209;effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large biopharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research organizations. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing, and marketing of products that compete with our product candidates. Mergers and acquisitions in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the proliferation of new drugs and therapies for our target indications, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and biopharmaceutical industries could render our product candidates or our technology obsolete, less competitive or uneconomical. Our competitors may, among other things:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have significantly greater financial, manufacturing, marketing, drug development, technical, and human resources than we do;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less severe side effects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain quicker regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish superior proprietary positions covering our products and technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implement more effective approaches to sales and marketing; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">form more advantageous strategic alliances.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these factors occur, our business, financial condition and results of operations could be materially adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any collaborators may decide to market and sell products that compete with the product candidates that we have agreed to license to them, and any competition by our collaborators could also have a material adverse effect on our future business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in developing or acquiring technologies complementary to, or necessary for, our programs.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs, therapeutic platforms, and product candidates that we identify for specific indications. Additionally, we have contractual commitments under the agreements for various product candidate assets that we acquired from third parties, as well as our license and collaboration agreements, to use commercially reasonable efforts to develop certain programs and, thus, do not have unilateral discretion to vary from such agreed to efforts. In addition, we have contractual commitments to conduct certain development plans, and thus may not have discretion to modify such development plans, including clinical trial designs, without agreement from our collaboration partner. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, therapeutic platforms, and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely upon third&#8209;party providers of cloud&#8209;based infrastructure to host our platforms. Any disruption in the operations of these third&#8209;party providers, limitations on capacity, or interference with our use could adversely affect our business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We outsource substantially all of the technological infrastructure relating to our hosted platforms to third&#8209;party hosting services, such as Amazon Web Services. We have no control over any of these third parties, and while we attempt to reduce risk by minimizing reliance on any single third party or its operations, we cannot guarantee that such third&#8209;party providers will not experience system interruptions, outages or delays, or deterioration in their performance. We need to be able to access our computational platform at any time, without interruption or degradation of performance. Our hosted platform depends on protecting the virtual cloud infrastructure hosted by third&#8209;party hosting services by maintaining its configuration, architecture, features, and interconnection specifications, as well as protecting the information stored in these virtual data centers, which is transmitted by third&#8209;party Internet service providers. We have experienced and expect that in the future we may again experience interruptions, delays and outages in service and availability from time to time due to a variety of factors, including infrastructure changes, human or software errors, website hosting disruptions and capacity constraints. Any limitation on the capacity of our third&#8209;party hosting services could adversely affect our business, financial condition, and results of operations. In addition, any incident affecting our third&#8209;party hosting services&#8217; infrastructure that may be caused by cyber&#8209;attacks, natural disasters, fire, flood, severe storm, earthquake, power loss, telecommunications failures, terrorist or other attacks, and other disruptive events beyond our control could negatively affect our hosted platforms. A prolonged service disruption affecting our hosted platforms could damage our reputation or otherwise harm our business. We may also incur significant costs for using alternative equipment or taking other actions in preparation for, or in reaction to, events that damage the third&#8209;party hosting services we use.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that our service agreements with our third&#8209;party hosting services are terminated, or there is a lapse of service, elimination of services or features that we utilize, interruption of internet service provider connectivity, or damage to such facilities, we could experience interruptions in access to our platforms as well as significant delays and additional expense in arranging or creating new facilities and services and/or re&#8209;architecting our hosted platforms for deployment on a different cloud infrastructure service provider, which could adversely affect our business, financial condition, and results of operations.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our security measures are breached or unauthorized access to our other data is otherwise obtained, our data may be perceived as not being secure and we may incur significant liabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use a set of proprietary tools to generate, analyze, and derive novel insights from our data. As a result, unauthorized access to or security breaches of our data, as a result of third&#8209;party action, employee or contractor error, malfeasance, or otherwise could require us to make filings with the SEC and provide notification to individuals, governmental authorities, supervisory bodies, the media and other parties pursuant to privacy and security laws and result in the loss or corruption of, or other damage to information, claims and litigation, indemnity obligations, damage to our reputation, and other liability. Our collaborators and other third parties we work with may also suffer similar security breaches of data that we rely on. Because the techniques used to obtain unauthorized access or sabotage systems change frequently and generally are not identified until they are launched against a target, we and those we collaborate with may be unable to anticipate these techniques or implement adequate preventative measures. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. In addition, if our employees or contractors fail to adhere to practices we have established to maintain a firewall between our internal drug discovery team and our teams that work with external individuals, including our collaborators, or if the technical solutions we have adopted to maintain the firewall malfunction, our collaborators may lose confidence in our ability to maintain the confidentiality of their intellectual property, we may have trouble attracting new collaborators, we may be subject to breach of contract claims by our collaborators, and we may suffer reputational and other harm as a result. Federal, state and foreign laws and regulations may also expose us to enforcement actions and investigations by regulatory authorities, and potentially result in legal claims or proceedings (such as class actions), regulatory investigations and enforcement actions, fines and penalties, negative reputational impacts that cause us to lose existing or future customers, and/or significant incident response, system restoration or remediation and future compliance costs. Any or all of these issues could result in reputational damage or subject us to third&#8209;party lawsuits or other action or liability, which could adversely affect our operating results and the further development and commercialization of our products. Our insurance may not be adequate to cover losses associated with such events, and in any case, such insurance may not cover all of the types of costs, expenses, and losses we could incur to respond to and remediate a security breach.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our precision neuroscience tools utilize third&#8209;party open source software, and any failure to comply with the terms of one or more of these open source software licenses could adversely affect our business, subject us to litigation, or create potential liability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our precision neuroscience tools include software licensed by third parties under any one or more open source licenses, and we expect to continue to incorporate open source software in our precision neuroscience tools in the future. While we have a process in place for monitoring the use of open source software by our employees, we cannot ensure we are aware of every instance of such use or have validated the quality or source of such software, or that we are in compliance with the terms of the applicable open source licenses or our current policies and procedures. There have been claims against companies that use open source software in their products and services asserting that the use of such open source software infringes the claimants&#8217; intellectual property rights. As a result, we could be subject to suits by third parties claiming that what we believe to be licensed open source software infringes such third parties&#8217; intellectual property rights. Additionally, if an author or other third party that distributes such open source software were to allege that we had not complied with the conditions of one or more of these licenses, we could be required to incur significant legal expenses defending against such allegations and could be subject to significant damages and required to comply with onerous conditions or restrictions on these solutions, which could disrupt the distribution and sale of these solutions. Litigation could be costly for us to defend, have a negative effect on our business, financial condition, and results of operations, or require us to devote additional research and development resources to change our precision neuroscience tools. Furthermore, these third&#8209;party open source providers could experience service outages, data loss, privacy breaches, cyber&#8209;attacks, and other events relating to the applications and services they provide that could diminish the utility of these services and which could harm our business as a result.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of open source software may entail greater risks than use of third&#8209;party commercial software, as open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code, including with respect to security vulnerabilities where open source software may be more susceptible. In addition, certain open source licenses require that source code for software programs that interact with such open source software be made available to the public at no cost and that any modifications or derivative works to such open source software continue to be licensed under the same terms as the open source software license. The terms of various open source licenses to which we are subject have not been interpreted by courts in the relevant jurisdictions, and there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to market or provide our software and data. By the terms of certain open source licenses, we could be required to release the source code of our proprietary software, and to make our proprietary software available under open source licenses, if we combine our proprietary software with open source software in a certain manner. In the event that portions of our proprietary software are determined to be subject to an open source license, we could be required to publicly release the affected portions of our source code, re&#8209;engineer all or a portion of our precision neuroscience tools, or otherwise be limited in the licensing of our precision neuroscience tools, each of which could reduce or eliminate the value of our precision neuroscience tools. Disclosing our proprietary source code could allow our competitors to create similar products with lower development effort and time and ultimately could result in a loss of sales. Furthermore, any such re&#8209;engineering or other remedial efforts could require significant additional research and development resources, and we may not be able to successfully complete any such re&#8209;engineering or other remedial efforts. Any of these events could create liability for us and damage our reputation, which could have a material adverse effect on our revenue, business, results of operations, and financial condition and the market price of our shares.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Development and Clinical Testing of Our Product Candidates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical and preclinical drug development is a lengthy and expensive process, with an uncertain outcome. Our clinical and preclinical programs have experienced delays and may experience additional delays or may never advance, which would adversely affect our ability to obtain regulatory approvals or commercialize our product candidates on a timely basis or at all, which could have an adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to obtain FDA approval to market our product candidates, we must demonstrate the safety and efficacy of our product candidates in humans to the satisfaction of the FDA. To meet these requirements, we will have to conduct adequate and well&#8209;controlled clinical trials. Clinical testing is expensive, time&#8209;consuming and subject to uncertainty. Conducting preclinical testing and clinical trials represents a lengthy, time&#8209;consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are directly conducting preclinical studies may cause us to incur additional operating expenses. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including, but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to generate sufficient preclinical or other </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">data to support the initiation of clinical studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timely completion of preclinical laboratory tests, animal studies and formulation studies in accordance with FDA&#8217;s Good Laboratory Practice (GLP) requirements and other applicable regulations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent Institutional Review Board (IRB) or ethics committee at each clinical site before each trial may be initiated;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching a consensus with regulatory agencies on study design and obtaining regulatory authorization to commence clinical trials; delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs), and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in identifying, recruiting and training suitable clinical investigators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in recruiting suitable patients to participate in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insufficient or inadequate supply or quality of product candidates or other materials necessary for use in clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a temporary or permanent clinical hold by regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments on trials conducted by competitors for related technology that raises FDA or foreign regulatory authority concerns about risk to patients of the technology broadly, or if the FDA or a foreign regulatory authority finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in recruiting, screening and enrolling patients and delays caused by patients withdrawing from clinical trials or failing to return for post&#8209;treatment follow&#8209;up;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty collaborating with patient groups and investigators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s good clinical practice (GCP) requirements, or applicable regulatory guidelines in other countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits, or occurrence of adverse events in trial of the same class of agents conducted by other companies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes to the clinical trial protocols;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of our product candidates being greater than we anticipate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">transfer of manufacturing processes to larger&#8209;scale facilities operated by a contract manufacturing organization (CMO) and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third parties being unwilling or unable to satisfy their contractual obligations to us.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials must be conducted in accordance with the FDA&#8217;s and other applicable regulatory authorities&#8217; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and ethics committees or IRBs at the medical institutions where the clinical trials are conducted. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays in the completion of any preclinical studies or clinical trials of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate product revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any delays to our preclinical studies or clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For example the EU Clinical Trials Regulation (CTR) which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application (CTA), to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR transition period ended on January 31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such as contract research organizations (CRO), may impact our developments plans.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is currently unclear to what extent the United Kingdom (UK) will seek to align its regulations with the European Union (EU). The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 17, 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA), launched an eight-week consultation on reframing the UK legislation for clinical trials which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The MHRA published its consultation outcome on March 21, 2023 confirming that it would bring forward changes to the legislation. These resulting legislative amendments, which are yet to be published, will ultimately determine the extent to which the UK regulations align with the (EU) CTR. A decision by the UK not to closely align its regulations with the new approach adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Results of preclinical studies or clinical trials of any product candidates may not be predictive of the results of future preclinical studies or clinical trials.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain the requisite regulatory approvals to market and sell any of our product candidates, we or any collaborator for such product candidate must demonstrate through extensive preclinical studies and clinical trials that the product candidate is safe and effective in humans. Before an investigational new drug (IND) can be submitted to the FDA and become effective, which is a prerequisite for conducting clinical trials on human subjects in the United States, a product candidate must successfully progress through extensive preclinical studies, which include preclinical laboratory testing, animal studies, and formulation studies, certain of which must be conducted in accordance with GLP. We cannot be certain of the timely completion or outcome of any preclinical studies. We also cannot predict if the FDA or comparable foreign regulatory authorities will allow our proposed clinical programs to proceed or if the outcome of our preclinical studies will ultimately support further development of our programs. Additionally, we cannot be sure that we will be able to submit INDs or similar applications with respect to our product candidates on the timelines we expect, if at all, and we cannot</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be sure that submission of IND or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, success in preclinical studies or early clinical trials does not ensure that later preclinical studies or clinical trials will be successful. A number of companies in the biotechnology and biopharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier preclinical studies. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. The design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. In addition, clinical and preclinical data are often susceptible to varying interpretations and analyses. Notwithstanding any potential promising results in earlier studies, we cannot be certain that we will not face similar setbacks. For example, in January 2025, we announced that our KOASTAL-1 study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-&#197;sberg Depression Rating Scale (MADRS) total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) scale. In addition, the results of our preclinical animal studies, including our non&#8209;human primate studies, may not be predictive of the results of outcomes in subsequent clinical trials on human subjects. Product candidates in clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to receive positive results in preclinical studies or clinical trials of any product candidate, the development timeline and regulatory approval and commercialization prospects for that product candidate, and, correspondingly, our business and financial prospects, would be negatively impacted.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates may have serious adverse, undesirable, or unacceptable side effects or other properties that may delay or prevent marketing approval. If such side effects are identified following approval, if any, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects that may be caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign authorities. The drug&#8209;related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk&#8209;benefit perspective, which may limit the commercial expectations for the product candidate if approved. We may also be required to modify our study plans based on findings in our ongoing preclinical studies or clinical trials. For example, in a rat study, at its highest dose (100 mg/kg/day) navacaprant was observed to have skin&#8209;related phototoxicity of erythema, edema and flaking additionally ocular phototoxicity (corneal edema). While no phototoxicity has been observed in our Phase 1 clinical trials, we monitored visual acuity and corneal integrity in our Phase 2 clinical trial to confirm there was no phototoxicity in humans. Though we did not observe any phototoxicity effects in our Phase 2 clinical trial, if phototoxicity is experienced in our later&#8209;stage clinical trials, the labeling implications of such safety warnings may limit any future product sales, if navacaprant is approved.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, may be reported by subjects. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw or limit approvals of such products and require us to take our approved product off the market;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies, or issue other communications containing warnings or other safety information about the product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a risk evaluation and mitigation strategy (REMS), plan to ensure that the benefits of the product outweigh its risks;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change the dose or the way the product is administered, conduct additional clinical trials, or change the labeling of the product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be subject to limitations on how we may promote or manufacture the product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of the product may decrease significantly;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be subject to litigation or product liability claims; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of any products.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, topline, or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then&#8209;available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, prospects, financial condition or results of operations.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on enrollment and retention of patients in our clinical trials for our product candidates. If we experience delays or difficulties enrolling or retaining patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful and timely completion of clinical trials requires that we enroll and retain a sufficient number of patient candidates. Any clinical trials we conduct may be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, patient withdrawal or adverse events. These types of developments could cause us to delay the trial or halt further development.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clinical trials will compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this competition reduces the number and types of patients available to us, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. The eligibility criteria of our clinical studies, and in particular, any eligibility criteria we may establish using our precision neuroscience approach, may limit the pool of available study participants as we will require that patients have specific characteristics that we can measure or to assure their disease is either severe enough or not too advanced to include them in a study.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient enrollment depends on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and nature of the patient population;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the severity of the disease under investigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eligibility criteria for the trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity of patients to clinical sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the clinical protocol;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to obtain and maintain patient consents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our product candidates or trial completion;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of competing clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of new drugs approved for the indication the clinical trial is investigating; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost&#8209;effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process, and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The estimates of market opportunity and forecasts of market growth included in our public disclosures may prove to be smaller than we believe, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to initially focus our product candidate development on treatments for various neuropsychiatric disorders and neurodegenerative diseases. Our projections of addressable patient populations within any particular disease state that may benefit from treatment with our product candidates are based on our estimates. Market opportunity estimates and growth forecasts included in our public disclosures are subject to significant uncertainty and are based on assumptions and estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inaccurate, the market opportunity for any product candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if approved, our products may not gain market acceptance, in which case we may not be able to generate product revenues, which will materially adversely affect our business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the FDA or any comparable foreign regulatory authority approves the marketing of any product candidates that we develop, physicians, healthcare providers, patients, or the medical community may not accept or use them. Additionally, the product candidates that we are developing are based on our proprietary approach, which are new technologies. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of any of our product candidates will depend on a variety of factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of the product candidate as well as competitive products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which a product candidate is approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of any approvals and the countries in which approvals are obtained;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and clinical profile of competing products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential and perceived advantages of our product candidates over alternative treatments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to provide acceptable evidence of safety and efficacy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of an approved product candidate for use as a combination therapy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative convenience and ease of administration;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cost&#8209;effectiveness;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient diagnostics and screening infrastructure in each market;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of sales and marketing efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval of other new therapies for the same indications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">marketing and distribution support;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse publicity about our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability of coverage, adequate reimbursement and sufficient payment from health maintenance organizations and other insurers, both public and private, for our product candidates, or the procedures utilizing our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of patients to pay out&#8209;of&#8209;pocket in the absence of coverage by third&#8209;party payors and government authorities; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other potential advantages over alternative treatment methods.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates fail to gain market acceptance, this will have a material adverse impact on our ability to generate revenues to provide a satisfactory, or any, return on our investments. Even if some products achieve market acceptance, the market may prove not to be large enough to allow us to generate significant revenues.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently have no marketing, sales, or distribution infrastructure and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given our stage of development, we currently have no marketing, sale, and distribution capabilities. If any of our product candidates complete clinical development and are approved, we intend to either establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates, or to outsource this function to a third party. There are risks involved if we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or that our collaborator&#8217;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator&#8217;s business strategy.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses, which would have a material adverse effect on our business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of biopharmaceutical products. While we currently have no products that have been approved for commercial sale, the future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any prospects for commercialization of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects or patients who should not use our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even successful defense against product liability claims would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: decreased demand for our product candidates; injury to our reputation; withdrawal of clinical trial participants; initiation of investigations by regulators; costs to defend the related litigation; a diversion of management&#8217;s time and our resources; substantial monetary awards to trial participants or patients; product recalls, withdrawals or labeling, marketing or promotional restrictions; loss of revenue; exhaustion of any available insurance and our capital resources; the inability to commercialize any product candidate; and a decline in our share price.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain product liability insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our product candidates. However, we may be unable to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims, and our business operations could be impaired.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Regulatory Environment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The development and commercialization of drug products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time&#8209;consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis if at all, our business will be substantially harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing, distribution, adverse event reporting, including the submission of safety and other post&#8209;marketing information and reports, and other possible activities relating to our product candidates are subject to extensive regulation. In the United States, obtaining marketing approval for a new drug requires the submission of a New Drug Application (NDA) to the FDA, and we are not permitted to market any product candidate in the United States until we obtain approval from the FDA of the NDA for that product candidate. An NDA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing, and controls. Outside the United States, many comparable foreign regulatory authorities employ similar approval processes.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not previously submitted an NDA to the FDA or similar marketing application to comparable foreign authorities, for any product candidate, and we cannot be certain that any of our product candidates will receive regulatory approval. Obtaining approval of an NDA can be a lengthy, expensive, and uncertain process, and as a company we have no experience with the preparation of an NDA submission or any other marketing application. In addition, the FDA has the authority to require a REMS as part of an NDA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe&#8209;use criteria and requiring treated patients to enroll in a registry.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, or regulatory authorities may not accept a submission due to, among other reasons, the content or formatting of the submission;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or those of third&#8209;party manufacturers with which we contract for clinical and commercial supplies; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. For example, regulatory authorities in various jurisdictions have in the past had, and may in the future have, differing requirements for, interpretations of and opinions on our clinical and preclinical data. As a result, we may be required to conduct additional preclinical studies, alter our proposed clinical trial designs, or conduct additional clinical trials to satisfy the regulatory authorities in each of the jurisdictions in which we hope to conduct clinical trials and develop and market our products, if approved. Further, even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any comparable foreign regulatory authority.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post&#8209;marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, FDA and foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may, however, have a significant impact on the pharmaceutical industry and our business in the long term.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if our product candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, testing, safety, efficacy, labeling, packaging, distribution, import, export, adverse event reporting, storage, advertising, promotion, and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post&#8209;marketing information and reports, and registration, as well as continued compliance with current good manufacturing practices (cGMPs) and similar foreign requirements, and GCPs for any clinical trials that we conduct post&#8209;approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post&#8209;marketing testing, including Phase 4 clinical trials, and additional surveillance to monitor the safety and efficacy of the product candidate.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP and similar foreign regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, quality control, and distribution.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue warning letters or untitled letters;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue, or require us to issue, safety&#8209;related communications, such as safety alerts, field alerts, &#8220;Dear Doctor&#8221; letters to healthcare professionals, or import alerts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impose civil or criminal penalties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend, limit, or withdraw regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend any of our preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refuse to approve pending applications or supplements to approved applications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impose restrictions on our operations, including closing our and our contract manufacturers&#8217; facilities; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seize or detain products, refuse to permit the import or export of products, or require us to conduct a product recall.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off&#8209;label uses. If we are found or alleged to have improperly promoted off&#8209;label uses, we may become subject to significant liability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about drug products. These regulations include standards and restrictions for direct&#8209;to&#8209;consumer advertising, industry&#8209;sponsored scientific and educational activities, promotional activities involving the internet and off&#8209;label promotion. For example, any regulatory approval that the FDA grants is limited to those indications and patient populations for which a drug is deemed to be safe and effective by the FDA.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While physicians in the United States may choose, and are generally permitted, to prescribe products in their independent medical judgment for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote any of our products candidates, if approved, will be narrowly limited to those indications and populations that are specifically approved by the FDA or such other regulatory agencies, and if we are found to have promoted such off&#8209;label uses, we may become subject to significant liability. For example, the federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off&#8209;label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages, staffing reductions or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, reductions in staffing, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or modifications to approved drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, the current U.S. Presidential administration has issued certain policies and Executive Orders directed towards reducing the employee headcount and costs associated with U.S. administrative agencies, including the FDA, and it remains unclear the degree to which these efforts may limit or otherwise adversely affect the FDA&#8217;s ability to conduct routine activities. Further, during the COVID 19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, during the COVID&#8209;19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points, and more recently there have been FDA staff cuts under the Trump administration. If a prolonged government shutdown occurs, or if funding shortages, staffing reductions or renewed global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti&#8209;corruption laws, and anti&#8209;money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended (FCPA), the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti&#8209;bribery and anti&#8209;money laundering laws in the countries in which we conduct activities. Anti&#8209;corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government&#8209;affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed, or become more expensive.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business operations and current and future relationships with healthcare professionals, principal investigators, consultants, vendors, customers, and third&#8209;party payors in the United States and elsewhere are subject to applicable anti&#8209;kickback, fraud and abuse, false claims, physician payment transparency, and other healthcare laws and regulations, which could expose us to substantial penalties, contractual damages, reputation harm, administrative burdens, and diminished profits.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, healthcare facilities and institutions and third&#8209;party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, healthcare facilities and institutions, principal investigators, consultants, customers, and third&#8209;party payors may expose us to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti&#8209;Kickback Statute and the federal False Claims Act, that may constrain the business or financial arrangements and relationships through which we research, sell, market, and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and regulation by the federal government and by the states and foreign jurisdictions in which we conduct our business. The applicable federal, state, and foreign healthcare laws that affect our ability to operate include, but are not limited to, the following:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Anti&#8209;Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, including through civil whistleblower or qui tam actions, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease, or conceal an obligation to pay money to the U.S. federal government. Pharmaceutical manufacturers can cause false claims to be presented to the U.S. federal government by, among other things, engaging in impermissible marketing practices, such as the off&#8209;label promotion of a product for an indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti&#8209;Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items, or services. Similar to the federal Anti&#8209;Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires, among other things, certain manufacturers of drugs and devices that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare and Medicaid Services (CMS), information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous U.S. state laws and regulations, including: state anti&#8209;kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements, and claims involving healthcare items or services reimbursed by any third&#8209;party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">similar healthcare laws and regulations in foreign jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our product candidates, if approved. Compensation under some of these arrangements includes the provision of stock or stock options in addition to cash consideration. Because of the complex and far&#8209;reaching nature of these laws, it is possible that governmental authorities could conclude that our payments to physicians may not be fair market value for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">services or that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties, damages, fines, exclusion from government&#8209;funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of noncompliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time&#8209;consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of employee fraud or other misconduct. We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition, and patient privacy and other privacy laws and regulations. Misconduct by employees could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self&#8209;dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, labeling, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, individual imprisonment, disgorgement of profits, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of noncompliance with the law, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and pursue our strategy.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the ACA), was enacted, which substantially changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA of importance to the biopharmaceutical and biotechnology industries are the following:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturers and importers of certain branded prescription drugs are required to pay an annual, nondeductible fee according to their market share of all such sales;</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% of the average manufacturer price for most branded drugs, and to 13.0% for generic drug;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs, including our product candidates, that are inhaled, infused, instilled, implanted, or injected;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extension of manufacturers&#8217; Medicaid rebate liability to covered outpatient drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expansion of the entities eligible for discounts under the 340B drug pricing program;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a new Patient&#8209;Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA remains in effect in its current form. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the IRA) into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. It is unclear how other healthcare reform measures of the Trump administration or other efforts, if any, to challenge, repeal or replace the ACA, will impact our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price. Further, in August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect until 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional action is taken by Congress.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, heightened governmental scrutiny is likely to continue over the manner in which manufacturers set prices for their marketed products, which already has resulted in several Congressional inquiries, proposed and enacted legislation and executive orders issued by the President designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Most recently, the IRA marks the most significant action by Congress with respect to the biopharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (which began in 2025). Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and the list of the subsequent 15 drugs that will be subject to negotiation, although the program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated, and while the impact of the IRA on the biopharmaceutical industry cannot yet be fully determined, it is likely to be significant.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, individual states in the United States have passed legislation and implemented regulations designed to control biopharmaceutical product pricing and costs. Similar developments have occurred outside of the United States, including in the EU where healthcare budgetary constraints have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. To obtain reimbursement or pricing approval in some EU member states, we may be required to conduct studies that compare the cost&#8209;effectiveness of our product candidates to other therapies that are considered the local standard of care.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict the likelihood, nature, or extent of government regulation that may arise from the IRA or future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we are able to commercialize any product candidate, coverage and adequate reimbursement may not be available or such product candidate may become subject to unfavorable pricing regulations or third&#8209;party coverage and reimbursement policies, which would harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulations that govern regulatory approvals, pricing, and reimbursement for drug products vary widely from country to country. Some countries require approval of the sale price of a drug product before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription drug product pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third&#8209;party payors, such as government authorities, private health insurers, and other organizations. Even if we succeed in bringing one or more products to the market, these products may not be considered cost&#8209;effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. Because our programs are in the relatively early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of coverage and reimbursement. Increasingly, the third&#8209;party payors who reimburse patients or healthcare providers are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for drug products. If the price we are able to charge for any products we develop, or the coverage and reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There may be significant delays in obtaining reimbursement for newly&#8209;approved drug products, and coverage may be more limited than the purposes for which the drug product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drugs product will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interim reimbursement levels for new drug products, if applicable, may also be insufficient to cover our costs and may not be made permanent. Reimbursement rates may be based on payments allowed for lower cost drug products that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drug products may be reduced by mandatory discounts or rebates required by third&#8209;party payors and by any future relaxation of laws that presently restrict imports of drug products from countries where they may be sold at lower prices than in the United States. Obtaining coverage and adequate reimbursement for our product candidates may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third&#8209;party payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time&#8209;consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor&#8209;by&#8209;payor basis. One payor&#8217;s determination to provide coverage for a drug does not assure that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third&#8209;party payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the demand for our product candidates, if we obtain regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to set a price that we believe is fair for our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain coverage and reimbursement approval for a product;</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of taxes that we are required to pay; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of capital.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our inability to promptly obtain coverage and adequate reimbursement from both third&#8209;party payors for the product candidates that we may develop and for which we obtain regulatory approval could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face potential liability related to the privacy of health information we utilize in the development of product candidates, as well as information we obtain from clinical trials sponsored by us from research institutions and directly from individuals.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The global data protection landscape is rapidly evolving and we and our partners and vendors are, or may become, subject to various federal, state, and foreign data protection laws and regulations that address personal information, data privacy and security. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. If we fail to comply with these laws and regulations, we may be subject to litigation, regulatory investigations, enforcement notices, enforcement actions, fines, and criminal or civil penalties, as well as adverse publicity and a potential loss of business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations that govern the collection, use, disclosure, and protection of health&#8209;related and other personal information could apply to our operations or the operations of our partners. For example, most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009. HIPAA imposes obligations on &#8220;covered entities,&#8221; including certain healthcare providers, health plans and healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. We could potentially face substantial criminal or civil penalties if we violate HIPAA. For example, we could be subject to significant penalties if we knowingly receive individually identifiable health information from a HIPAA&#8209;covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information, or otherwise violate applicable HIPAA requirements related to the protection of such information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the Federal Trade Commission (FTC) also has authority to initiate enforcement actions against entities that mislead customers about HIPAA compliance, make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement policies to protect personal health information or engage in other unfair practices that harm customers or that may violate Section 5 of the Federal Trade Commission Act (FTC Act). Even when HIPAA does not apply, according to the FTC violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute a violation of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Additionally, federal and state consumer protection laws are increasingly being applied by FTC and states&#8217; attorneys general to regulate the collection, use, storage, and disclosure of personal or personally identifiable information, through websites or otherwise, and to regulate the presentation of website content.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may maintain certain sensitive information about individuals, including health-related information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws and regulations governing the privacy and security of personal information or requiring notification of affected individuals and state regulators in the event of a breach of personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act (collectively, the CCPA) requires covered businesses that process the personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; (ii) receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and (iii) enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. Although there are limited exemptions for health&#8209;related information, including clinical trial data, the CCPA may increase our compliance costs and potential liability. Similar laws have been passed in other states, and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complying with U.S. federal and state data privacy and security laws, regulations, amendments to or re&#8209;interpretations of existing data privacy and security laws and regulations and contractual or other obligations relating to privacy, data protection, data transfers, data localization or information security may require us to make changes to our processes, incur substantial operational costs, modify our data practices and policies and restrict our business operations. Any actual or perceived failure by us to comply with these laws, regulations or other obligations may lead to significant fines, penalties, regulatory investigations, lawsuits, significant costs for remediation, damage to our reputation or other liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. Any clinical trial programs and research collaborations that we engage in outside the United States may implicate international data protection laws, including, in the European Economic Area (EEA), the General Data Protection Regulation (GDPR), which became effective in 2018. The GDPR imposes stringent operational requirements for processors and controllers of the personal data of individuals within the EEA. Among other things, the GDPR requires detailed notices for clinical trial subjects and investigators, as well as requirements regarding the security of personal data and notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects. If our privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices, enforcement actions requiring us to change the way we use personal data and/or fines. In addition to statutory enforcement, a personal data breach can lead to adverse publicity and a potential loss of business. Further, from January 1, 2021, companies have had to comply with both the GDPR and the United Kingdom GDPR (UK GDPR), which, together with the amended UK Data Protection Act 2018, imposes separate but similar obligations to those under the GDPR. The UK GDPR mirrors the fines under the GDPR, imposing fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA and the United States remains uncertain. Case law from the Court of Justice of the European Union (CJEU) states that reliance on the standard contractual clauses &#8211; a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism &#8211; alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case&#8209;by&#8209;case basis. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (DPF) rendering the DPF effective as an EU GDPR transfer mechanism to U.S. entities self&#8209;certified under the DPF. On October 12, 2023, the UK Extension to the DPF also came into effect (as approved by the UK Government), as data transfer mechanism to U.S. entities self-certified under the DPF. As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could suffer additional costs, complaints, and/or regulatory investigations or fines, and/ or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. These laws and regulations may apply, not only to us, but also to vendors that store or otherwise process data on our behalf, such as information technology vendors. If such a vendor misuses data we have provided to it, or fails to safeguard such data, we may be subject to litigation, regulatory investigations, enforcement notices, and/or enforcement actions, as well as adverse publicity and a potential loss of business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are likely to be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time&#8209;consuming to defend, and could result in adverse publicity that could harm our business. Moreover, even if we take all necessary action to comply with regulatory requirements, we could be subject to a hack or data breach, which could subject us to fines and penalties, as well as reputational damage.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we use artificial intelligence (AI), machine learning, and automated decision-making technologies (collectively, AI Technologies) throughout our business. The regulatory framework for AI Technologies is rapidly evolving as many federal, state and foreign government bodies and agencies have introduced or are currently considering additional laws and regulations. Additionally, existing laws and regulations may be interpreted in ways that would affect the operation of our AI Technologies. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or market perception of their requirements may have on our business and may not always be able to anticipate how to respond to these laws or regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Already, certain existing legal regimes (e.g., relating to data privacy) regulate certain aspects of AI Technologies, and new laws regulating AI Technologies entered into force in the United States and the EU in 2024. In the United States, the Trump administration has rescinded an executive order relating to the safe and secure development of AI Technologies that was previously implemented by the Biden administration. The Trump administration then issued a new executive order that, among other things, requires certain agencies to develop and submit to the president action plans to &#8220;sustain and enhance America&#8217;s global AI dominance,&#8221; and to specifically review and, if possible, rescind rulemaking taken pursuant to the rescinded Biden executive order. Thus, the Trump administration may continue to rescind other existing federal orders and/or administrative policies relating to AI Technologies, or may implement new executive orders and/or other rule making relating to AI Technologies in the future. Any such changes at the federal level could require us to expend significant resources to modify our products, services, or operations to ensure compliance or remain competitive. U.S. legislation related to AI Technologies has also been introduced at the federal level and is advancing at the state level. For instance, California enacted seventeen new laws in 2024 that further regulate use of AI Technologies and provide consumers with additional protections around companies&#8217; use of AI Technologies, such as requiring companies to disclose certain uses of generative AI. Other states have also passed AI-focused legislation. For example, on March 13, 2024, Utah passed the Utah AI Policy Act, which took effect in May 2024, imposing certain disclosure requirements on the use of AI, and on May 17, 2024, Colorado enacted the Colorado AI Act, which will take effect in February 2026. Further, the California Privacy Protection Agency is currently in the process of finalizing regulations under the CCPA regarding the use of automated decision-making. Such additional regulations may impact our ability to develop, use, procure and commercialize AI Technologies in the future.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Europe, on May 21, 2024, EU legislators approved the EU Artificial Intelligence Act (the EU AI Act), which establishes a comprehensive, risk-based governance framework for artificial intelligence in the EU market. The EU AI Act entered into force on August 1, 2024 and the majority of the substantive requirements will apply from August 2, 2026. The EU AI Act will apply to companies that develop, use and/or provide AI in the EU and includes requirements around transparency, conformity assessments and monitoring, risk assessments, human oversight, security, accuracy, general purpose AI and foundation models, and proposes fines for breach of up to 7% of worldwide annual turnover. In addition, on September 28, 2022, the European Commission proposed two Directives seeking to establish a harmonized civil liability regime for AI in the EU in order to facilitate civil claims in respect of harm caused by AI and to include AI-enabled products within the scope of the EU&#8217;s existing strict product liability regime. Once fully applicable, the EU AI Act will have a material impact on the way AI is regulated in the EU. Recent case law from the CJEU has taken an expansive view of the scope of the GDPR&#8217;s requirements around automated decision making and introduced uncertainty in the interpretation of these rules. The EU AI Act, and developing interpretation and application of the GDPR in respect of automated decision making, together with developing guidance and/or decisions in this area, may affect our use of AI Technologies and our ability to provide, improve or commercialize our business, require additional compliance measures and changes to our operations and processes, result in increased compliance costs and potential increases in civil claims against us, and could adversely affect our business, operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that further new laws and regulations will be adopted in the United States and in other non-U.S. jurisdictions, or that existing laws and regulations, including competition and antitrust laws, may be interpreted in ways that would limit our ability to use AI Technologies for our business, or require us to change the way we use AI Technologies in a manner that negatively affects the performance of our business and the way in which we use AI Technologies. We may need to expend resources to adjust our operations in certain jurisdictions if the laws, regulations, or decisions are not consistent across jurisdictions. Further, the cost to comply with such laws, regulations, or decisions and/or guidance interpreting existing laws, could be significant and would increase our operating expenses (such as by imposing additional reporting obligations regarding our use of AI Technologies). Such an increase in operating expenses, as well as any actual or perceived failure to comply with such laws and regulations, could adversely affect our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We contract with third parties for the manufacture of our product candidates. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third&#8209;party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. We do not have long&#8209;term supply agreements. Furthermore, while the raw materials for our product candidates are sourced from multiple suppliers, in some cases, the drug product is sourced from a single&#8209;source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to rely on third&#8209;party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third&#8209;party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third&#8209;party manufacturers, reliance on third&#8209;party manufacturers entails additional risks, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third&#8209;party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the termination or nonrenewal of arrangements or agreements by our third&#8209;party contractors at a time that is costly or inconvenient for us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the breach by the third&#8209;party contractors of our agreements with them;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of third&#8209;party contractors to comply with applicable regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of the third party to manufacture our product candidates according to our specifications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or study drug or placebo not being properly identified;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the misappropriation of our proprietary information, including our trade secrets and know&#8209;how.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP or similar foreign regulations for manufacturing both active drug substances and finished drug products. Third&#8209;party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or a comparable foreign regulatory authority, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third&#8209;party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2024, there was congressional activity, including the introduction of the BIOSECURE Act (H.R. 7085) in the House of Representatives and a substantially similar Senate bill (S.3558). In September 2024, the U.S. House of Representatives passed a version of the BIOSECURE Act (H.R. 8333), however, the Senate did not approve that legislation. If Congress takes up the legislation again and it is passed and enacted into law, the BIOSECURE Act would have the potential to restrict the ability of biopharmaceutical companies like us to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology companies &#8220;of concern&#8221; without losing the ability to contract with, or otherwise receive funding from, the U.S. government. We do business with companies in China, and it is possible some of our contractual counterparties could be impacted by this legislation.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Supply sources could be interrupted from time to time and, if interrupted, there is no guarantee that supplies could be resumed within a reasonable time frame and at an acceptable cost or at all.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on our manufacturers to purchase from third&#8209;party suppliers the materials necessary to produce our product candidates for our preclinical studies and intend to continue to rely on these third parties for any clinical trials that we undertake. There are a limited number of suppliers for raw materials that we use to manufacture our drugs and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our preclinical studies, clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event a new supplier must be used. The time and effort to qualify a new supplier could result in additional costs, diversion of resources, or reduced manufacturing yields, any of which would negatively impact our operating results. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third&#8209;party manufacturer could considerably delay completion of our clinical trials, product testing, and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have the ability to independently conduct any clinical trials. We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third&#8209;party CROs, to conduct our preclinical studies and clinical trials and to monitor and manage data for our clinical and preclinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third&#8209;party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations (or similar regulatory requirements outside of the United States). Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, that they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third&#8209;party service providers may require us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors, or if we are liquidated. Further, some of these agreements may also be terminated by such third parties on short notice, or under certain circumstances, including our insolvency.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a limited number of third&#8209;party service providers that specialize or have the expertise required to achieve our business objectives. Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If any of our relationships with these third&#8209;party laboratories, CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative laboratories, CROs, or investigators or to do so in a timely manner or on commercially reasonable terms. If laboratories, CROs, or clinical investigators do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements or for other reasons, our preclinical or clinical trials may be extended, delayed, or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed. Switching or adding additional laboratories or CROs (or investigators) involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new laboratory or CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our contracted laboratories and CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Intellectual Property</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on intellectual property licensed or acquired from third parties and we are currently party to in&#8209;license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our proprietary technologies and product candidates. If we breach our obligations under these agreements or if any of these agreements is terminated, or otherwise experience disruptions to our business relationships with our licensors, we may be required to pay damages and/or lose our rights to such intellectual property and technology, which would harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are dependent on patents, know&#8209;how, and proprietary technology, both our own and licensed from others. We are a party to intellectual property license agreements and in the future, we may enter into additional license agreements. For example, with respect to developing our product candidates, we have licensed or acquired, as the case may be, certain intellectual property from Amgen, Blackthorn, TSRI and Vanderbilt. These license and acquisition agreements impose, and we expect that future license and acquisition agreements will impose, various diligence, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under these agreements, we may be required to pay damages and the licensor may have the right to terminate the license. Any termination of these licenses could result in the loss of significant rights and could harm our ability to develop, manufacture and/or commercialize our product candidates. See the section titled &#8220;Business&#8212;Intellectual Property&#8212;In&#8209;Licensing and Collaboration Agreements&#8221; in the Annual Report on Form 10-K for additional information regarding these key agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the agreements under which we license or acquire intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed or acquired prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Our business also would suffer if any current or future licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully obtain rights to required third&#8209;party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant research programs or product candidates and our business, financial condition, results of operations and prospects could suffer.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disputes may also arise between us and our current and future licensors regarding intellectual property subject to a license or collaboration agreement, including those relating to:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license or collaboration agreement and other interpretation&#8209;related issues;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we are complying with our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of patented technology;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights upon termination of the license agreements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope and duration of exclusivity obligations of each party to the license agreements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount and timing of payments owed under license agreements; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the allocation of ownership of inventions and know&#8209;how resulting from the joint creation or use of intellectual property by our licensors or collaborators and by us and our partners.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The resolution of any contractual interpretation dispute that may arise, if unfavorable to us, could have a material adverse effect on our business, financial condition, results of operations and prospects. Such resolution could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, increase what we believe to be our financial or other obligations under the relevant agreement or decrease the third party&#8217;s financial or other obligations under the relevant agreement. Furthermore, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend, in part, on our licensors to file, prosecute, maintain, defend, and enforce certain patents and patent applications that are material to our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain patents and patent applications relating to our product candidates are owned or controlled by certain of our licensors. In some circumstances, we may not have the right to control the preparation, filing, prosecution, maintenance, and defense of patent applications or patents covering technology that we license from third parties. In such circumstances, our licensors generally have rights to file, prosecute, maintain, and defend the licensed patents in their name, generally with our right to comment on such filing, prosecution, maintenance, and defense, with some obligation for the licensor to consider or incorporate our comments. We generally have the first right to enforce our exclusively licensed patent rights against third parties, although our ability to settle such claims often requires the consent of the licensor. If our licensors or any future licensees having rights to file, prosecute, maintain, and defend our patent rights fail to conduct these activities for patents or patent applications covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, or selling competing products. We cannot be certain that such activities by our licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and, even in the circumstances where we have the right to pursue such enforcement or defense, we cannot ensure the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. In addition, even when we have the right to control patent prosecution of licensed patents and patent applications, enforcement of licensed patents, or defense of claims asserting the invalidity of those patents, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that took place prior to or after our assuming control. This could cause us to lose rights in any applicable intellectual property that we in&#8209;license, and as a result our ability to develop and commercialize product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Given the breadth of the application of our precision neuroscience approach, in order to increase our ability to exploit our technologies, we may enter into collaborations and/or strategic partnerships in the future, and we may not realize the anticipated benefits of such collaborations or partnerships. If we are able to enter into such transactions or realize the potential benefits of such transactions, we may be forced to alter or delay our development and commercialization plans.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development collaborations and strategic partnerships are prevalent in the biopharmaceutical industry. The breadth of the application of our precision neuroscience approach is an attractive technology for potential collaborations and/or strategic partnerships. Our existing and any future collaborations or strategic partnerships are subject to numerous risks, which may include the following:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration, and may not commit sufficient efforts and resources, or may misapply those efforts and resources;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not pursue development and commercialization of collaboration product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results or changes in their strategic focus;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay, provide insufficient resources to, or modify or stop clinical trials for collaboration product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could develop or acquire products outside of the collaboration that compete directly or indirectly with our products or product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital and personnel to pursue further development or commercialization of the applicable product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may own or co&#8209;own intellectual property covering our products that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. We may form or seek further strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop, including in territories outside the United States or for certain indications. These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write&#8209;downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into acquisition or in&#8209;license agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction or such other benefits that led us to enter into the arrangement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time&#8209;consuming and complex. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of our technologies, product candidates and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of these risks, we may not be able to realize the benefit of our existing collaboration or any future collaborations or licensing agreements we may enter into. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates may also require specific components to work effectively and efficiently, and rights to those components may be held by others. We may be unable to in&#8209;license any compositions, methods of use, processes or other third&#8209;party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. In that event, we may be required to expend significant time and resources to develop or license replacement technology. Even if we are able to obtain a license, it may be non&#8209;exclusive, thereby giving our competitors access to the same technologies licensed to us. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies, which could harm our business prospects, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, some of our owned and in&#8209;licensed patents or patent applications or future patents are or may be co&#8209;owned with third parties. If we are unable to obtain an exclusive license to any such third&#8209;party co&#8209;owners&#8217; interest in such patents or patent applications, such co&#8209;owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co&#8209;owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Furthermore, our owned and in&#8209;licensed patents may be subject to a reservation of rights by one or more third parties. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights for our product pipeline which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own or license from third parties certain intellectual property rights necessary to develop our product candidates. The growth of our business will likely depend in part on our ability to acquire or in&#8209;license additional proprietary rights, including to expand our product pipeline. In that event, we may be required to expend considerable time and resources to develop or license replacement technology. For example, our programs may involve additional technologies or product candidates that may require the use of additional proprietary rights held by third parties. Furthermore, other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. Our product candidates may also require specific formulations or other technology to work effectively and efficiently. These formulations or technology may be covered by intellectual property rights held by others. From time to time, in order to avoid infringing these third&#8209;party rights, we may be required to license technology from additional third parties to further develop or commercialize our product candidates. We may be unable to acquire or in&#8209;license any relevant third&#8209;party intellectual property rights, including any such intellectual property rights required to manufacture, use or sell our product candidates, that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, and as a result we may be unable to develop or commercialize the affected product candidates, which would harm our business. We may need to cease use of the compositions or methods covered by such third&#8209;party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license under such intellectual property rights, any such license may be non&#8209;exclusive, which may allow our competitors&#8217; access to the same technologies licensed to us.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third&#8209;party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensing and acquisition of third&#8209;party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third&#8209;party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be dependent on intellectual property licensed or sublicensed to us from, or for which development was funded or otherwise assisted by, the U.S. government and/or government agencies, such as the National Institutes of Health, for development of our technology and product candidates. Failure to meet our own obligations to our licensors or upstream licensors, including such government agencies, may result in the loss of our rights to such intellectual property, which could harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. government and/or government agencies have provided, and in the future may provide, funding, facilities, personnel or other assistance in connection with the development of the intellectual property rights owned by or licensed to us. The U.S. government and/or government agencies may have retained rights in such intellectual property, including the right to grant or require us to grant mandatory licenses or sublicenses to such intellectual property to third parties under certain specified circumstances, including if it is necessary to meet health and safety needs that we are not reasonably satisfying or if it is necessary to meet requirements for public use specified by federal regulations, or to manufacture products in the United States. Any exercise of such rights, including with respect to any such required sublicense of these licenses, could result in the loss of significant rights and could harm our ability to commercialize licensed products. For example, the research resulting in certain of our in&#8209;licensed patent rights and technology was funded in part by the U.S. government. As a result, the government may have certain rights, or march&#8209;in rights, to such patent rights and technology. These rights may permit the government to disclose our confidential information to third parties and to exercise march&#8209;in rights to use or allow third parties to use our licensed technology.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates and approach, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected. We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors have filed patent applications, and we anticipate that in the future we will file additional patent applications both in the United States and in other countries, as appropriate. However, we cannot predict:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if and when any patents will issue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the degree and range of protection any issued patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether others will apply for or obtain patents claiming aspects similar to those covered by our patents and patent applications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we will need to initiate litigation or administrative proceedings to defend our patent rights, which may be costly whether we win or lose; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the patent applications that we own or in&#8209;license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and approach. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining and enforcing patents is expensive and time&#8209;consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into non&#8209;disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to enforce patent rights also depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or service. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. If we initiate lawsuits to protect or enforce our patents, or litigate against third&#8209;party claims, such proceedings would be expensive and would divert the attention of our management and technical personnel.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Composition of matter patents for biopharmaceutical products often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain, however, that the claims in our pending patent applications covering the composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO), or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off&#8209;label&#8221; for those uses that are covered by our method of use patents. Although off&#8209;label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement can be difficult to prevent or prosecute.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The strength of patents in the biotechnology, biopharmaceutical and data science fields can be uncertain, and evaluating the scope of such patents involves complex legal, factual and scientific analyses and has in recent years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. The patent applications that we own or in&#8209;license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability, or scope thereof, which may result in such patents being narrowed, invalidated, or held unenforceable. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, this could dissuade companies from collaborating with us to develop, and could threaten our ability to commercialize, our product candidates. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not identify relevant third&#8209;party patents or may incorrectly interpret the relevance, scope or expiration of a third&#8209;party patent, which might adversely affect our ability to develop and market our products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third&#8209;party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third&#8209;party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One aspect of the determination of patentability of our inventions depends on the scope and content of the &#8220;prior art,&#8221; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Further, we may not be aware of all third&#8209;party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third&#8209;party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third&#8209;party intellectual property upon our freedom to operate, is highly uncertain. Because patent applications in the United States and most other countries are confidential for typically a period of 18 months after filing, or may not be published at all, we cannot be certain that we were the first to file any patent application related to our product candidates. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For U.S. applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the U.S. patent laws, including new procedures for challenging pending patent applications and issued patents.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third&#8209;party pre&#8209;issuance submission of prior art to the USPTO or become involved in post&#8209;grant review procedures, oppositions, derivations, reexaminations, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Any failure to obtain or maintain patent protection with respect to our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or in&#8209;license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if enforced, a court may not hold that our patents are valid, enforceable and infringed;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose;</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know&#8209;how, and a third party may subsequently file a patent covering such intellectual property;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may fail to adequately protect and police our trademarks and trade secrets; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know&#8209;how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our product candidates, technology and product discovery and development processes that involve proprietary know&#8209;how, information, or technology that is not covered by patents. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third&#8209;party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade secrets and confidential information, however, may be difficult to protect. We seek to protect our trade secrets, know&#8209;how and confidential information, including our proprietary processes, in part, by entering into confidentiality agreements with our employees, consultants, outside scientific advisors, contractors, and collaborators. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, outside scientific advisors, contractors, and collaborators might intentionally or inadvertently disclose our trade secret information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time&#8209;consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, or misappropriation of our intellectual property by third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations, and financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third&#8209;party claims of intellectual property infringement against us or our collaborators may prevent or delay our product discovery and development efforts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and biopharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review, post&#8209;grant review and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Furthermore, patent reform and changes to patent laws add uncertainty to the possibility of challenge to our patents in the future. We cannot assure you that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. We cannot provide any assurances that third&#8209;party patents do not exist which might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. As the biotechnology and biopharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Third parties may assert that we infringe their patents or other intellectual property, or that we are otherwise employing their proprietary technology without authorization, and may sue us. There may be third&#8209;party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture, or methods of use or treatment that cover our product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product candidate. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties, our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may obtain patents in the future that may prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates, and may claim that use of our technologies or the manufacture, use, or sale of our product candidates infringes upon these patents. If any such third&#8209;party patents were held by a court of competent jurisdiction to cover our technologies or product candidates, or if we are found to otherwise infringe a third party&#8217;s intellectual property rights, the holders of any such patents may be able to block, including by court order, our ability to develop, manufacture or commercialize the applicable product candidate unless we obtain a license under the applicable patents or other intellectual property, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non&#8209;exclusive, thereby giving our competitors access to the same technologies licensed to us. If we are unable to obtain a necessary license to a third&#8209;party patent on commercially reasonable terms, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biopharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties asserting their patent or other intellectual property rights against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates or force us to cease some of our business operations. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, cause development delays, and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, or redesign our infringing products, which may be impossible on a cost&#8209;effective basis or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents are of national or regional effect, and filing, prosecuting, maintaining and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or adequate to prevent them from competing.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biopharmaceutical products, which could make it difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, or the marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such proceedings could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims of infringement or misappropriation against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. In addition, certain developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. In addition, many countries limit the enforceability of patents against government agencies or government contractors. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, geo&#8209;political actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. For example, the United States and foreign government actions related to Russia&#8217;s conflict in Ukraine, the ongoing conflict between Israel and Hamas, and other matters may limit or prevent filing, prosecution, and maintenance of patent applications in Russia, Israel and other countries. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia, Israel and other countries. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees from the United States without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, Europe&#8217;s Unified Patent Court (UPC) may, in particular, present uncertainties for our ability to protect and enforce our patent rights against competitors in Europe. In 2012, the European Patent Package (EU Patent Package) regulations were passed with the goal of providing a single pan&#8209;European Unitary Patent system and UPC for litigation involving European patents.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Unitary Patent system and UPC launched on June 1, 2023. Under the UPC, all European patents, including those issued prior to ratification of the EU Patent Package, now by default automatically fall under the jurisdiction of the UPC. The UPC provides our competitors with a new forum to centrally revoke our European patents, and allows for the possibility of a competitor to obtain pan&#8209;European injunctions. Such a loss of patent protection could have a material adverse impact on our ability to commercialize our technology and product candidates and on our business, financial condition, prospects and results of operations. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the current EU Patent Package, we have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, but doing so may preclude us from realizing the benefits of the new unified court. Moreover, if we do not meet all of the formalities and requirements for opt-out under the UPC, our future European patents could remain under the jurisdiction of the UPC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patents, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk&#8209;adjusted cost of bringing and enforcing such a claim or action, which typically last for years before they are concluded, may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings and that the more prudent course of action is to simply monitor the situation or initiate or seek some other non&#8209;litigious action or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, in&#8209;license needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or other intellectual property or the intellectual property of our licensors, which could be expensive, time&#8209;consuming, and unsuccessful.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe our patents or other intellectual property or the intellectual property of our licensors. To cease such infringement or unauthorized use, we may be required to file patent infringement claims, which can be expensive and time&#8209;consuming and divert the time and attention of our management and scientific personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. In addition, in an infringement proceeding or a declaratory judgment action, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to, or the correct inventorship of, our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation, interference, derivation or other proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign authority.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim we infringe their patents or that the patent covering our product candidate is invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent, including lack of novelty, obviousness, non&#8209;enablement or insufficient written description or that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re&#8209;examination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review, post&#8209;grant review, and equivalent proceedings in foreign jurisdictions, such as opposition or derivation proceedings. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167; 271I(1). With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates and such an outcome may limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Such a loss of patent protection could have a material adverse impact on our business. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time&#8209;consuming, and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. Patent reform legislation in the United States and other countries, including the Leahy&#8209;Smith America Invents Act (Leahy&#8209;Smith Act) signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy&#8209;Smith Act includes provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost&#8209;effective avenues for competitors to challenge the validity of patents. These include allowing third&#8209;party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post&#8209;grant proceedings, including post&#8209;grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review, and derivation proceedings. After March 2013, under the Leahy&#8209;Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Because patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (1) file any patent application related to our product candidates and other proprietary technologies we may develop or (2) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. However, the Leahy&#8209;Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on decisions by Congress, the federal courts, the USPTO and the relevant law&#8209;making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how future decisions by Congress, the federal courts or the USPTO may impact the value of our patents.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non&#8209;compliance with these requirements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. Although an inadvertent lapse on us or our patent maintenance vendors, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non&#8209;payment of fees, and failure to properly legalize and submit formal documents. In any such event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The lives of our patents may not be sufficient to effectively protect our products and business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. The launch of a generic version of one of our products in particular would be likely to result in an immediate and substantial reduction in the demand for that product, which could have a material adverse effect on our business, financial condition, results of operations and prospects. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. A patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co&#8209;inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co&#8209;ownership of potential joint inventions. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors may have relied on third&#8209;party consultants or collaborators or on funds from third parties, such as the U.S. government, such that we or our licensors are not the sole and exclusive owners of the patents we in&#8209;licensed. If other third parties have ownership rights or other rights to our patents, including in&#8209;licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self&#8209;executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive, or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our stock price has experienced volatility and declines and may continue to be volatile or decline, regardless of our operating performance, resulting in substantial losses for investors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock has been and may continue to be highly volatile and may further decline substantially as a result of a variety of factors, some of which are related in complex ways. The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including the factors listed below and other factors described in this &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commencement of, enrollment in, or results of current and future preclinical studies and clinical trials we may conduct, or changes in the development status of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse results or delays in clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated serious safety concerns related to the use of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in laws or regulations, including, but not limited to, preclinical study or clinical trial requirements for approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative clinical outcomes or other adverse events related to product candidates being developed by others in the central nervous system (CNS) field;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publication of research reports about us or our industry, or CNS programs in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any adverse changes to our relationship with manufacturers or suppliers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing, supply or distribution shortages;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure to commercialize our product candidates;</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general political conditions, including but not limited to, disruptions in U.S. government operations and funding, geopolitical conflicts such as the war between Russia and the Ukraine, the war between Israel and Hamas, and any sanctions or other repercussions that may result therefrom;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic conditions, including but not limited to, inflation, tariffs, trade controls, recession risk, low consumer confidence and interest rates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions or departures of key scientific or management personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variations in our results of operations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our cash position;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements made by us or our competitors of new product and service offerings, acquisitions, strategic relationships, joint ventures, or capital commitments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to establish collaborations, if needed;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to effectively manage our growth;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the market valuations of similar companies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">press reports, whether or not true, about our business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales or perceived potential sales of our common stock by us or our stockholders in the future;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall fluctuations in the equity markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ineffectiveness of our internal controls;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes or developments in the global regulatory environment;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impact from pandemics or other public health events, on us or third parties with which we engage; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other events or factors, many of which are beyond our control.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the stock market in general and biotechnology and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance, which may limit or prevent investors from selling their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to maintain the listing of our common stock on the Nasdaq Global Select Market or another reputable stock exchange, the trading price and/or trading volume of our common stock may decline and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">it may be more difficult for our stockholders to sell their shares.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is currently listed for trading on the Nasdaq Global Select Market. One of the requirements for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) is maintenance of a minimum closing bid price of $1.00 per share, and failure to comply with the $1.00 minimum bid price requirement could lead to the delisting of our common stock.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our common stock is delisted from trading on Nasdaq and we are unable to obtain listing on another reputable national securities exchange, a reduction in some or all of the following may occur, each of which could cause the trading price and/or trading volume of our common stock to decline and make it more difficult for our stockholders to sell their shares:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the liquidity of our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the market price of our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain financing for the continuation of our operations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of institutional and general investors that will consider investing in our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of market makers in our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of information concerning the trading prices and volume of our common stock; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of broker-dealers willing to execute trades in shares of our common stock.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our operating results to be subject to quarterly fluctuations, which will make it difficult for us to predict our future results. Our net loss and other operating results will be affected by numerous factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timing and variations in the level of expense related to the current or future development of our programs, including but not limited to, the timing of the milestone payments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to enroll patients in clinical trials and timing and status of enrollment for our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of clinical trials, or the addition or termination of, or changes to clinical trials or funding support by us or potential future partners;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competition from products that compete with our product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any delays in regulatory review or approval of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock&#8209;based compensation estimates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in general political conditions, including but not limited to, disruptions in U.S. government operations and funding, geopolitical conflicts such as the war between Russia and the Ukraine, the war between Israel and Hamas, and any sanctions or other repercussions that may result therefrom;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in general economic conditions, including but not limited to, inflation, tariffs, trade controls, recession risk, low consumer confidence and interest rates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under potential future arrangements or the termination or modification of any such potential future arrangements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions and departures of key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin&#8209;offs, joint ventures, strategic investments or changes in business strategy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if any product candidate we may develop receive regulatory approval, the timing and terms of such approval and market acceptance and demand for such product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and cost to establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with current or future collaborators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with any of our product candidates;</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to commercialize our product candidates, if approved, inside and outside of the United States, either independently or working with third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaborations, licensing or other arrangements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to adequately support future growth;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential unforeseen business disruptions that increase our costs or expenses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments affecting current or future product candidates or those of our competitors; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impact from pandemics or other public health events, on us or third parties with which we engage.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates owned approximately 49% of our outstanding voting stock. Therefore, these stockholders will have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. In addition, certain members of our board of directors were originally designated by our principal stockholders, including Amgen and ARCH Venture Partners. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could cause our common stock price to fall.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our existing stockholders sell, or indicate an intention to sell, or if the market perceives that such existing stockholders might sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline. As of March 31, 2025, we had outstanding a total of 161,747,922 shares of common stock and approximately 49% of such shares were beneficially owned by our directors, officers, and holders of 5% or more of our common stock. In addition, approximately 47,261,405 shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or there is a perception that they will be sold, in the public market, the trading price of our common stock could decline. Further, certain holders of shares of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in the future, we may issue additional shares of common stock, or other equity or debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement, or otherwise. For example, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in October 2024 we entered into a sales agreement with Leerink to sell shares of our common stock, from time to time, with aggregate gross sales proceeds of up to $300.0 million, through an ATM program with Leerink as the sales agent. During the year ended December 31, 2024, we received aggregate net proceeds of $13.7 million through sales of shares of our common stock under the ATM after deducting commissions and offering expenses of $0.8 million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, we settled a Phase 3 navacaprant milestone owed to BlackThorn stockholders by primarily issuing shares of our common stock. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not currently intend to pay dividends on our common stock and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation of the value of our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in the foreseeable future. As a result, any investment return on our common stock will depend upon increases in the value for our common stock, which is not certain.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay, or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:</span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a staggered board of directors divided into three classes serving staggered three&#8209;year terms, such that not all members of the board of directors will be elected at one time;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize our board of directors to issue new series of preferred stock without stockholder approval and create, subject to applicable law, a series of preferred stock with preferential rights to dividends or our assets upon liquidation, or with superior voting rights to our existing common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eliminate the ability of our stockholders to call special meetings of stockholders;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eliminate the ability of our stockholders to fill vacancies on our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at our annual stockholder meetings;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">permit our board of directors to establish the number of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that our board of directors is expressly authorized to make, alter or repeal our amended and restated bylaws;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that stockholders can remove directors only for cause and only upon the approval of not less than 66&#8209;2/3% of all outstanding shares of our voting stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require the approval of not less than 66&#8209;2/3% of all outstanding shares of our voting stock to amend our amended and restated bylaws and specific provisions of our certificate of incorporation; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limit the forums in which certain stockholder litigation may be brought.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a Delaware corporation, we are subject to the anti&#8209;takeover provisions of Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years after the date of the transaction in which the person first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at least two&#8209;thirds of the outstanding disinterested shares. The application of Section 203 of the Delaware General Corporation Law could also have the effect of delaying or preventing a change of control of our company.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides an exclusive forum in the Court of Chancery of the State of Delaware for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a breach of a fiduciary duty owed by any director, officer or other employee to us or our stockholders, (3) any action asserting a claim against us or any director, officer, or other employee arising pursuant to the Delaware General Corporation Law, (4) any action to interpret, apply, enforce, or determine the validity of our second amended and restated certificate of incorporation or amended and restated bylaws or (5) any other action asserting a claim that is governed by the internal affairs doctrine, is the Court of Chancery of the State of Delaware (or another state court or the federal court located within the State of Delaware if the Court of Chancery does not have or declines to accept jurisdiction), in all cases subject to the court&#8217;s having jurisdiction over indispensable parties named as defendants. In addition, our amended and restated certificate of incorporation provides that the federal district courts of the United States are the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act but that the forum selection provision does apply to claims brought to enforce a duty or liability created by the Exchange Act.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may result in increased costs to stockholders to bring a claim for any such dispute and may have the effect of discouraging lawsuits against us or our directors and officers. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition, and operating results. For example, under the Securities Act, federal courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our net operating loss carryforwards and other tax attributes may be limited.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three&#8209;year period, the corporation&#8217;s ability to use its pre&#8209;change net operating loss carryforwards (NOLs) and other pre&#8209;change tax attributes (such as research and development tax credits) to offset its post&#8209;change income or taxes may be limited. We may have experienced ownership changes in the past and may experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership (some of which are outside our control). As a result, our ability to use our pre&#8209;change NOLs and tax credits to offset future taxable income, if any, could be subject to limitations. Similar provisions of state tax law may also apply. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and tax credits.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the trading price or trading volume of our common stock could decline.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock is influenced in part by the research and reports that securities or industry analysts may publish about us, our business, our market, or our competitors. If one or more of these analysts initiate research with an unfavorable rating or downgrade our common stock, provide a more favorable recommendation about our competitors or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If any analyst covering us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the trading price or trading volume of our common stock to decline.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Global credit and financial markets have experienced extreme volatility and disruptions due to a number of factors including concerns about declines in consumer confidence, declines in economic growth, inflation, tariffs, trade controls, borrowing rates and changes in liquidity and credit availability, and uncertainty about economic stability, including in connection with actions undertaken by the U.S. Federal Reserve Board to address inflation, the failure of banks, the military conflict in Ukraine, the war between Israel and Hamas and supply chain disruptions. There can be no assurance that future deterioration in global credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive, if at all possible. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">An active trading market for our common stock may not develop or be sustained.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to our initial public offering in September 2023, there was no public market for shares of our common stock. The price for our common stock may vary and an active or liquid market in our common stock may not be sustained. The lack of an active market may impair the value of your shares, your ability to sell your shares at the time you wish to sell them and the prices that you may obtain for your shares. An inactive market may also impair our ability to raise capital by selling our common stock and our ability to acquire other companies, products or technologies by using our common stock as consideration.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are no longer an &#8220;emerging growth company,&#8221; and, as a result, we now must comply with increased reporting and disclosure requirements, which may increase our costs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We no longer qualify as an &#8220;emerging growth company&#8221; within the meaning of the Securities Act, as modified by the JOBS Act and, as a result, are subject to various disclosure and compliance requirements that did not previously apply, such as:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley Act);</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement that we adopt new or revised accounting standards when they are applicable to public companies, instead of delaying their adoption until they are applicable to private companies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding obligatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement that we provide full and more detailed disclosures regarding executive compensation; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement that we hold a non-binding advisory vote on executive compensation and obtain stockholder approval of any golden parachute payments not previously approved.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that the loss of emerging growth company status and compliance with these additional requirements will increase our legal and financial compliance costs and cause management and other personnel to divert attention from operational and other business matters to devote substantial time to public company reporting requirements. In addition, if we are not able to comply with changing requirements in a timely manner, the trading price of our common stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities, which would require additional financial and management resources.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The requirements of being a public company may strain our resources, result in more litigation, and divert management&#8217;s attention.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes&#8209;Oxley Act, the Dodd&#8209;Frank Wall Street Reform and Consumer Protection Act (Dodd&#8209;Frank Act) the listing requirements of Nasdaq, and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly, and current reports with respect to our business and operating results. The Sarbanes&#8209;Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control and procedures on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, changing laws, regulations, and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time consuming. These laws, regulations, and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations, and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue&#8209;generating activities to compliance activities. If our efforts to comply with new laws, regulations, and standards differ from the activities intended by regulatory or governing bodies, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By disclosing information in filings required by us as a public company, our business and financial condition will continue to become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#8217;s resources and seriously harm our business.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self&#8209;insured. We rely on third&#8209;party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a man&#8209;made or natural disaster or other business interruption. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes&#8209;Oxley Act, our management is required to report upon the effectiveness of our internal control over financial reporting and we are required to have an independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex, judgmental and require significant documentation, testing and possible remediation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations, or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if we and/or our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our condensed consolidated financial statements, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well&#8209;conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision&#8209;making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our estimates or judgments relating to our critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, our results of operations could be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP, requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, as provided in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Estimates.&#8221; The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Significant assumptions and estimates used in preparing our condensed consolidated financial statements include but are not limited to stock&#8209;based compensation and evaluation of acquisitions of assets and other similar transactions as well as clinical trial accruals. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the trading price of our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we regularly monitor our compliance with applicable financial reporting standards and review new pronouncements and drafts thereof that are relevant to us. As a result of new standards, changes to existing standards and changes in their interpretation, we might be required to change our accounting policies, alter our operational policies, and implement new or enhance existing systems so that they reflect new or amended financial reporting standards, or we may be required to restate our audited consolidated financial statements, unaudited condensed consolidated financial statements and related notes. Such changes to existing standards or changes in their interpretation may also have an adverse effect on our reputation, business, financial condition, and results of operations.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our information technology systems, or those used by our third&#8209;party research institution collaborators, CROs, CMOs, or other contractors or consultants, may fail or suffer cyberattacks or security breaches.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information, clinical trial data, and personal information of our employees and contractors). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third&#8209;party contractors who have access to our confidential information.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures, our information technology systems and those of our CROs, CMOs, and other contractors and consultants are vulnerable to attack, damage, or interruption from hacking, cyberattacks, &#8220;phishing&#8221; attacks and other social engineering schemes, computer viruses and malware (e.g., ransomware), malicious code, denial or degradation of service attacks, sophisticated nation&#8209;state and nation&#8209;state supported actors, unauthorized access or use by persons within our organization, natural disasters, terrorism, war and telecommunication and electrical failures, employee theft or misuse, human error, and fraud. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the continued hybrid working environment, we also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and certain of our service providers are from time to time subject to cyberattacks and security incidents, including social engineering and phishing attacks. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. Although to our knowledge we have not experienced any such material system failure, accident, or security breach to date, if such an event were to occur and negatively affect, our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Further, we cannot ensure that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Likewise, we rely on our third&#8209;party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their information technology systems could also have a material adverse effect on our business. To the extent that any disruption or security incident were to result in an actual or perceived loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information or patient information, we could incur liability and the further development and commercialization of our product candidates could be delayed. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. Further, our insurance coverage may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered and expect to enter into collaboration, license, contract research and/or manufacturing relationships with organizations that operate in certain countries that are at heightened risk of theft of technology, data and intellectual property through direct intrusion by private parties or foreign actors, including those affiliated with or controlled by state actors. Accordingly, our efforts to protect and enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, and we may be at heightened risk of losing our proprietary intellectual property rights around the world, including outside of such countries, to the extent such theft or intrusion destroy the proprietary nature of our intellectual property.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or biopharmaceutical companies. Although we try to ensure that individuals working for or collaborating with us do not use the proprietary information or know&#8209;how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information proprietary to these third parties or our employees&#8217; former employers, or that we caused an employee to breach the terms of his or her non&#8209;competition or non&#8209;solicitation agreement. We may be subject to claims that patents and applications we have filed to protect inventions of our employees, consultants, advisors or other third parties, including those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are currently subject to and may be subject to additional future securities class action litigation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. For example, on February 6, 2025, a purported stockholder of the Company filed a lawsuit against us, certain of our executive officers, and certain underwriters in the United States District Court for the Southern District of New York alleging violations of the Securities Act related to our initial public offering. See the section titled &#8220;Legal Proceedings&#8221; in this Quarterly Report on Form 10-Q for additional information regarding this matter. This litigation could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, results of operations, or financial condition. Additionally, the dramatic increase in the cost of directors&#8217; and officers&#8217; liability insurance may cause us to opt for lower overall policy limits or to forgo insurance that we may otherwise rely on to cover significant defense costs, settlements, and damages awarded to plaintiff.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="unregistered_sales_of_equity_securities"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities.</span></div></div><p style="margin-left:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Proceeds.</span></div></div><p style="margin-left:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 19, 2023, our registration statement on Form S-1 (File No. 333- 274229) relating to our IPO of common stock became effective. There has been no material change in the planned use of proceeds from the IPO from that described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on September 18, 2023.</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities.</span></div></div><p style="margin-left:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="defaults_upon_senior_securities"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Defaults Upon Senior Securities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tem 4. Mine Safety Disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Other I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nformation.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_a2ecbe52-b123-4ab1-88c2-8a6e9d824920" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c562ae46-4928-4564-ab1a-0684ecef7691" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_bcdc8240-7dbe-4327-896c-1e46a9a9b823" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_97e5dcdd-6c1f-4c34-b5e1-7e22dc9f9ef3" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_fecf18a7-b0e8-4210-8f81-87adaa8eda38" contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this Quarterly Report on Form 10-Q.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 6. E</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">xhibits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:8%;box-sizing:content-box;"/>
      <td style="width:1.3%;box-sizing:content-box;"/>
      <td style="width:60%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:6.4%;box-sizing:content-box;"/>
      <td style="width:8.22%;box-sizing:content-box;"/>
      <td style="width:6.86%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7.22%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Herewith</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1885522/000119312523237644/d541406dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation, as amended, currently in effect.</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/19/2023</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1885522/000119312523237644/d541406dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Bylaws, as amended, currently in effect.</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/19/2023</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reference is made to Exhibits </span><a href="https://www.sec.gov/Archives/edgar/data/1885522/000119312523237644/d541406dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.1</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;through </span><a href="https://www.sec.gov/Archives/edgar/data/1885522/000119312523237644/d541406dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.2</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1885522/000119312523231902/d241143dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Certificate.</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/11/2023</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nmra-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nmra-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nmra-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nmra-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
     </tr>
    </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:6.5in;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ This certification accompanies the Quarterly Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIG</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NATURES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:45.22%;box-sizing:content-box;"/>
      <td style="width:4%;box-sizing:content-box;"/>
      <td style="width:7%;box-sizing:content-box;"/>
      <td style="width:43.78%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neumora Therapeutics, Inc.</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 12, 2025</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Paul L. Berns</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Paul L. Berns</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 12, 2025</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Milligan</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Milligan</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Principal Accounting Officer</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>nmra-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Paul L. Berns, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Neumora Therapeutics, Inc;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:45.2%;box-sizing:content-box;"></td>
      <td style="width:5.06%;box-sizing:content-box;"></td>
      <td style="width:3.06%;box-sizing:content-box;"></td>
      <td style="width:46.68%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 12, 2025</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Paul L. Berns</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paul L. Berns</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>nmra-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Michael Milligan, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Neumora Therapeutics, Inc;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:45.2%;box-sizing:content-box;"></td>
      <td style="width:5.06%;box-sizing:content-box;"></td>
      <td style="width:3.06%;box-sizing:content-box;"></td>
      <td style="width:46.68%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 12, 2025</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Milligan</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Michael Milligan</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Principal Accounting Officer)</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>nmra-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report of Neumora Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the period ending March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:45.2%;box-sizing:content-box;"></td>
      <td style="width:5.06%;box-sizing:content-box;"></td>
      <td style="width:3.06%;box-sizing:content-box;"></td>
      <td style="width:46.68%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 12, 2025</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Paul L. Berns</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paul L. Berns</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>nmra-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report of Neumora Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the period ending March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:45.2%;box-sizing:content-box;"></td>
      <td style="width:5.06%;box-sizing:content-box;"></td>
      <td style="width:3.06%;box-sizing:content-box;"></td>
      <td style="width:46.68%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 12, 2025</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Milligan</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Michael Milligan</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Principal Accounting Officer)</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img236770017_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img236770017_0.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" E7$UD# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=?U_PZ^\U:*RO[=T3_H,Z5_X,;3_ ./4?V[HG_09TK_P8VG_ ,>HY)_RR_\
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MO[=T3_H,Z5_X,;3_ ./4?V[HG_09TK_P8VG_ ,>HY)_RR_\  7_D%UW7]?\
M#K[S5HK*_MW1/^@SI7_@QM/_ (]1_;NB?]!G2O\ P8VG_P >HY)_RR_\!?\
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M  Z^\O451_M/3?\ H(V/_@7;_P#QRC^T]-_Z"-C_ .!=O_\ '*.67\LON?\
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M7\LON?\ 75?>%UW7]?\ #K[R]15'^T]-_P"@C8_^!=O_ /'*/[3TW_H(V/\
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M %U7WA==U_7_  Z^\O451_M/3?\ H(V/_@7;_P#QRC^T]-_Z"-C_ .!=O_\
M'*.67\LON?\ 75?>%UW7]?\ #K[R]15'^T]-_P"@C8_^!=O_ /'*/[3TW_H(
MV/\ X%V__P <HY9?RR^Y_P!=5]X77=?U_P .OO+U%4?[3TW_ *"-C_X%V_\
M\<H_M/3?^@C8_P#@7;__ !RCEE_++[G_ %U7WA==U_7_  Z^\O451_M/3?\
MH(V/_@7;_P#QRC^T]-_Z"-C_ .!=O_\ '*.67\LON?\ 75?>%UW7]?\ #K[R
M]15'^T]-_P"@C8_^!=O_ /'*BM];T:[D:&UU?3+F5%9GBM[^UFD15959F2.5
MF559E5B0 &903D@4<LM^65N]G_EYK[PNNZ^\TZ*@^U6W_/Q!_P!_H_\ XJC[
M5;?\_$'_ '^C_P#BJ5GV?]?\.OO"Z[K^O^'7WD]%0?:K;_GX@_[_ $?_ ,51
M]JMO^?B#_O\ 1_\ Q5%GV?\ 7_#K[PNNZ_K_ (=?>3T5!]JMO^?B#_O]'_\
M%4?:K;_GX@_[_1__ !5%GV?]?\.OO"Z[K^O^'7WD]%0?:K;_ )^(/^_T?_Q5
M'VJV_P"?B#_O]'_\519]G_7_  Z^\+KNOZ_X=?>3T5!]JMO^?B#_ +_1_P#Q
M5'VJV_Y^(/\ O]'_ /%46?9_U_PZ^\+KNOZ_X=?>3T5!]JMO^?B#_O\ 1_\
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MY^(/^_T?_P 51]JMO^?B#_O]'_\ %46?9_U_PZ^\+KNOZ_X=?>3T5!]JMO\
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MZM9I=V[W2M&"9%:W60RJ4 )<% 5 );&*O4VFMTUI?56T>SUZ %%%%( HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXB_X*7?\H[?VY_\
MLTK]H+_U5GBBOMVOB+_@I=_RCM_;G_[-*_:"_P#56>**Z<%_OF$_[":'_IV!
MR8__ ''&_P#8)B?_ $S,_F!_X-O?^2(?M(_]E5\+?^HBU?TAU_-Y_P &WO\
MR1#]I'_LJOA;_P!1%J_I#K[W,O\ ?L1_BC_Z;@?)\+_\B#+?^O53_P!/U0HH
MHKA/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBBD]OG'\T!Z]H_P#R"K#_ *]8?_01
M6E6;H_\ R"K#_KUA_P#016E7E3^.7^*7YL[H?!'_  Q_)!1114E!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7":C_P C=IO_ %]Z5_Z41UW=<)J/_(W:;_U]Z5_Z41UM
M0^*?_7N?Y&=7X5_BC^9[G1117":!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YE
M\*_^1NU;_L%7_P#Z<].KTVO,OA7_ ,C=JW_8*O\ _P!.>G5M'_=\7_U[C^;,
MI_'2]9?H?0M%%%>2:A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q?Q#_ .1-UK_K
MG:?^G"TJU\#_ /D39_\ L.7O_I+855^(?_(FZU_USM/_ $X6E6O@?_R)L_\
MV'+W_P!);"NQ_P#(LJ?]A2_](@*/\:/^"7YH]BHHHKRSI"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /E[PQ_R6_4O^PKXE_\ 2>^KZAKY>\,?
M\EOU+_L*^)?_ $GOJ^H:[\P^/#_]@E#_ -N.?#?!/_KY+\HA1117 = 4444
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M9B__  =1_P O7^GI_J_T5_E ?\/%_P#@H/\ ]'V?MD_^)/?&W_YN*]>\#?\
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MO"OC:QN_"\GB[5=#\5^)M4LH8_ >I:IIWC9M2L;<ZK:P>'YTM8[Z.>XTN_\
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M5C$SNT=I8VD$",[%8P6.?W _X-@OVB_V@_C]_P -P?\ "]_CM\9?C7_PB?\
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MK5)*,)59QJX9RE9*+KQ4'!MNRE4I0I]7--V/ZWZ***^6/N0HK_* _P"'B_\
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M:"_]59XHKIP7^^83_L)H?^G8')C_ /<<;_V"8G_TS,_F!_X-O?\ DB'[2/\
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MS58;&WU/6OB+X^\5^-M6U&#3$ACTV"_U'Q+JVIWEY#I\=M;I8QW$TB6B00K
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M?-?\1)P/_0LQ?_@ZC_EZ_P!/3_5_HK_* _X>+_\ !0?_ */L_;)_\2>^-O\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^7O#'_ "6_4O\
ML*^)?_2>^KZAKY>\,?\ );]2_P"PKXE_])[ZOJ&N_,/CP_\ V"4/_;CGPWP3
M_P"ODORB%%%%<!T!1110!^-O_!P'_P HB_VM?^Z#?^M-?!BO\TFO]+;_ (.
M_P#E$7^UK_W0;_UIKX,5_FDU^E\&_P#(KK_]A]7_ -1\*?BWB-_R/,+_ -BJ
MA_ZEXX_T0_V7_P#@A;_P2O\ B)^S1^SO\0?&/[+?]L>+_'7P+^$GC'Q5J_\
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MIOB/P7X@U.XOM?\ %O@VUUB^6W\0V6OW>H^*/#%I=6NN3:IKN@0:_?\ AO\
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M^QM\%+7]JK]EK6O$.A>!M"\0^'O"GQ)^%OC37KGQ,+4>)KF#1]!\4>"/$%[
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MN6_7FMU/'\-57YLV?O?5^7")WOR^WO7MRK;FY+\]M;<G-]D]"K\I_P#@M/\
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MZ\_^M-?&>O\ -)K_ $MO^#?S_E$7^R5_W7G_ -::^,]=/&7_ "*Z'_8?2_\
M4?%'%X<_\CS%?]BJO_ZEX$_9*BBBOS0_:0HHHH **** "BBB@ HHHH ****
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MH_\ $QUB\^S?;/L=G]GL+>UM8/MS_@WS_8@_9>_;@^-?[0'A']J'X8_\+/\
M#W@CX6^'_$?AC3_^$T^(?@K^S-9OO%D6F75Y]K^'GBSPE?7OFV+-!]GU"YN[
M5,^9' DP$E>$?\' ?_*73]K7_N@W_K,OP8K])?\ @U$_Y./_ &JO^R)>%/\
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MA/\ L+_]PU3X3PW_ .1MC?\ L72_]2<,?IM1117YP?LH4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBBO)-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"4@_[=G_9Y/[3W_J[?'%?U%?\ !IG_ ,B#^VW_ -C?\"__ $R_%"OY=?\
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M=N_\]'_!UW_R<?\ LJ_]D2\5_P#J=S5_*17]6_\ P==_\G'_ +*O_9$O%?\
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M"?\ U\E^40HHHK@.@**** /QM_X. _\ E$7^UK_W0;_UIKX,5_FDU_I;?\'
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M0DF^JEKN=G#S6>\9X[,=94J:QF(I2DGI3Y5@L(I)WM*-*I"2C=6=-VLHV/\
M-:K_ $MO^#?S_E$7^R5_W7G_ -::^,]?YI-?Z6W_  ;^?\HB_P!DK_NO/_K3
M7QGK7C+_ )%=#_L/I?\ J/BCG\.?^1YBO^Q57_\ 4O G[)4445^:'[2%%%%
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M/CN+M-,N(=3U3PSXB:"RU"X_X1?Q%K@L[&XO3; ?P#5_IR_\$,_^44O['O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\1?\%+O^4=O[<_\
MV:5^T%_ZJSQ17V[7Q%_P4N_Y1V_MS_\ 9I7[07_JK/%%=."_WS"?]A-#_P!.
MP.3'_P"XXW_L$Q/_ *9F?S _\&WO_)$/VD?^RJ^%O_41:OZ0Z_F\_P"#;W_D
MB'[2/_95?"W_ *B+5_2'7WN9?[]B/\4?_3<#Y/A?_D09;_UZJ?\ I^J%%%%<
M)[X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M -2L"?@!_P $?/\ E)S^Q9_V6W0?_2/4:_U(Z_RW/^"/G_*3G]BS_LMN@_\
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M>K:C\'OBMXHU:ZN[W5O$&NQ6":EKWP[\5:U?7:W^M^)?"NF:]HVJSVT]U>^
M9_$>N:OXJD_DO_:7_P"".O\ P43_ &5FOK[Q_P#LX>+_ !5X0LI(Q_PL#X01
M#XK>$7MI(F?[??/X/74-?\,6$<T<EG)<>,] \-8NQ!&%9-0TR2]_K._8T_X.
M,OA9^V!^U=\*?V9K+]G'Q3\-+3XKZMK&AZ7\0O$GQ)TG58].U:Q\':YXATFQ
MN?#&E^$$:>;Q#KND6OA6P\KQ B17&KVNHW#K''-:C^D*OH:><YWD3I83'4HU
M(>SC.G3Q$E*HJ-W&*A6I3E9)P<5&I[1P2MRJ/*?(U>'.&.*8U\?EE>=&I[:5
M.K6PD)4Z4L1RQJ2=3#8BE"[<:D9.5'V2J2;;G*7.?XX6H:??Z3?WVE:K8WFF
M:IIEY<Z?J6FZA;365_I]_93/;7EC?6=RD=Q:7EI<1R07-M/''-!-&\4J(Z,H
M]5^"/[0/QL_9M\;V7Q'^ _Q0\9?"KQI8[537/!VM76ER7EL&+-I^L6:,VFZ]
MI$Q)%SHVMV>H:5=*2MS9RJ2*_P!5GXZ?L??LL?M,V%_8?'O]G[X3?%-]0M/L
M4FL^*_!.B7GBRSA$(MD?1?&D=I!XN\/7D-NH@M]0T'6]-O[:',4%S&A*G_/E
M_P""WW_!.GX<?\$[OVF_"GAKX,:UJUY\)?B[X"_X3SPMX<\1WDVI^(? VHV&
MM7N@^(/#4NLRQAM>T(36UEJOA_5;R0:PD&I76B:M'=2Z+%X@U_Z7*^(<)F]1
MX.IAY4JTZ<G[.?+6HU8Q5YQYK1;?+=\LZ:BTGJWH_B\\X1Q_#U)9A1QD,1AZ
M=6$?;4E/#8FC*;M3GR<\K)RM'FIU924FGRJ-VO[ /^"+7_!5)?\ @H_\&?$F
MD?$FUT#P]^TK\&7TFS^(VDZ&);+2O&WAK6(YH_#OQ.\/:5<9^P1ZA=V.H:-X
MMT33[O4K70->M+2_WZ1I7C#PWH]O^U-?YPO_  ;F_$+7/!?_  53^#OAO29&
M2P^+?@/XT?#WQ.JS/$)M#TWX9^(/BM;QNB@K<*/$OPR\/3"&0JBO$EP#YD$:
MG_1ZKXGB/ 4LOS*=.@N2C6I0Q%.FMJ:G*<)07]U3IS<5]F+45HDW^E\'9K7S
M?)85L5)SQ&&KU,'5JO>JZ4*=2%27>;I5J<9R^U.,IO65D5_#=_P==_\ )Q_[
M*O\ V1+Q7_ZG<U?W(U_#=_P==_\ )Q_[*O\ V1+Q7_ZG<U:\*_\ (ZP__7O$
M?^F9F''?_)-XO_K]A/\ U(IGYM?\&_G_ "ET_9*_[KS_ .LR_&>O]+:O\TG_
M (-_/^4NG[)7_=>?_69?C/7^EM77QE_R-*'_ & 4O_4C%'!X<_\ (CQ7_8UK
M_P#J)@0K_&WK_9(K_)8_;:^#VJ_ #]KW]I3X.:Q8/ILW@/XT?$'2-.@>Z^W>
M?X;E\1WVH>$M3CO"L<ES;ZSX6O=&U>UEN(;:[>VOHC>6EI=^=;1=G!,XJIF-
M)M<TX8::5]7&G*O&3MO9.K&[Z77='G>)=*;I9/62]RG4QM*3L[*=:.%G!7VU
M5";MN[.VS/[9/^#7"\L+G_@G9\08;.U^SW&G_M9?$BSU67R(8OMU^_PQ^"M_
M'=>9$S27.S2[[3;+S[D),OV/[,JFWM[=W_I#K^+/_@U2_:5TK2?%7[2/[)>N
MWNEV=]XMLM"^-_P\BF;[+?ZK?^'8U\(_$33(II28=3N%TF\\$ZOI^EP-%?VU
MAI/BC4U@OK&*^GTG^TRO!XBI2HYQC5)-*I.-6#>THU(1DFO)/FCY.+70^KX0
MQ%/$\.Y:Z;3=&E+#U%I>-2C4E!J5MG*/+-=7&<7U"O*?CQ=V%A\#OC-?ZI;?
M;=,LOA1\1+O4;/R8;G[786WA#6)KRV^SW+);S^?;I)%Y,[I#+OV2LJ,Q'JU?
ME?\ \%I/VF-,_9=_X)Q?M%^)Y;[3+?Q3\3/"MS\!?A[I^I1R3-K/BGXNV=[X
M:U&/3859(9=3\.^ W\:>.K=+QS9>5X2N#<6^H(/[-O/,PE&=?%8>C!-SJUZ4
M(I=Y32N_))W;V23;T1[6/Q%/"8'%XFJU&G0PU:K)OM"G*5K=7)I*,=Y-I*[:
M/\P>O]$G_@VF_P"48V@_]EM^+?\ Z6:+7^=M7^GA_P $2?@C=? ?_@F/^RWX
M<U?1#H?B3QEX1U+XO>(8I+B.XN[V7XL>(=5\;^'+Z_\ )PEM=_\ "#:MX4LG
MTYHXKO2XK*+3=23^U+6]=_T3C&I&.64H-^]4Q=/E76T*=5R?HKI/SDC\?\.Z
M4YYW7JI>Y2R^MS2L[7J5J$81OLF_>DD]U"5MC^<;_@Z[_P"3C_V5?^R)>*__
M %.YJ^8_^#9#_E)3<_\ 9NWQ3_\ 3SX$KZ<_X.N_^3C_ -E7_LB7BO\ ]3N:
MOF/_ (-D/^4E-S_V;M\4_P#T\^!*FA_R1\O^P'$?^G:I>*_Y.''_ +&F$_\
M3-$Y_P#X.!?^"=LW['_[4UU\;_AYX>73_P!G[]IW6==\5:)'ID=P^E^!_BH3
M!JOQ"\%SJD L]"L=9O\ 49_&/@?2UE@LVT>[UO0O#MFFG>";N*T\*_X(H?\
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MMZ,:T(MQYU&M1ERR@M(2YG&<3_'#_P!/TB__ .7S3-4TR\_Z;65_I]_93?\
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M2QE6K@*=:O0E[KK8>C+$X;$4E)\GUBA%3E1FK_:Y90E*4:=649-S_L2\<_\
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MG3DFE.Z=G^2G[+7[,/Q>_;"^-O@SX#?!/PQ?>)?&/BV^C%Q+!"3I?A7PY!/
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M1Q;PS_;U"G6PTHT\PPL91I.>E.O2E)2="I+5P<7S3I3UC&4IQDK3YX?Q._\
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M,69MK4WEVRM>ZGJ-U/)<:CK.LW[)&U_K6LWE_JU^8XS=WLQC3;\6_P#!8/\
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MDZ5%QY5'5<'_ ,0_G_!(S_HTK_S//[37_P ^>C_B'\_X)&?]&E?^9Y_::_\
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MAS8?&X>.!P=6I0H5J<DIT7&A3<()U*3J>SM&/LZJBE:Y_HD_M+_\FX?M ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\;?\
M@X#_ .41?[6O_=!O_6FO@Q7[)5^:7_!8/]G[XN_M2_\ !.C]HCX$? CPE_PG
M7Q6\=?\ "I/^$5\*_P!O>&/#']J?\(Q\<_AEXQUS_B>>,=:\/>&['[#X;\/:
MQJ/_ !,=8L_M/V/['9_:+^XM;6?MRV<*>8Y?.<HPA#&X6<YSDHQA"->FY2E)
MM*,8I-RDVDDFV['FYU3G5R?-J5*$ZE6IEN/ITZ=.+G4J3GA:L80A"*<I3E)J
M,8Q3<FTDFV?Y<E?Z[?[-'_)N'[/_ /V1+X4_^H)H-?YVW_$/Y_P5S_Z-*_\
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MR[<RRQ>7I5UYTR1P/Y"2M<P_S:?\0_G_  5S_P"C2O\ S//[,O\ \^>IK?\
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M?Q=U#Q)I;-##*T5_=?#3P?\ $/PA))&\CVSG3/%6HQ&:WF:.22W:">?^7/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI5KX'_\ (FS_ /8<O?\ TEL*J_$/_D3=:_ZYVG_IPM*M? __ )$V?_L.7O\
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MJ/</;Z?J%O=S) DDD4;3-'"RQ+)+$C.5#R(I+#^]#_B*A_X)\?\ 1'?VR?\
MPWWP2_\ HAJ_FD_XA_/^"N?_ $:5_P"9Y_9E_P#GST?\0_G_  5S_P"C2O\
MS//[,O\ \^>OJ<QCP_FCHO%YAA)>P]I[/DQ]"%O:.'->U1WO[.-NVO<^'R>?
M%F1K$+ 91F$5B72=7VN4XJI?V/M.3EO27+_$G?O==D?TM_\ $5#_ ,$^/^B.
M_MD_^&^^"7_T0U'_ !%0_P#!/C_HCO[9/_AOO@E_]$-7\TG_ !#^?\%<_P#H
MTK_S//[,O_SYZ/\ B'\_X*Y_]&E?^9Y_9E_^?/7F_P!C\*?]!^'_ /#G1_\
MD_ZN_*WL_P"L/'O_ $*\7_X9<3_\K_J[\K?VG_\ !/[_ (+(_LQ?\%'_ (F>
M,_A7\#_ OQX\*^(? _@63X@ZM>?%;PQ\/M#T:XT:/7]%\.-;:=<>$?BAXYOI
MM3-]KMI*(;G3K2U^RQW+F]$R103?,?\ P<8?L7^(/VH/V);;XI?#_1DUKXC?
MLIZ_JGQ-%A#;13ZQJ?PGU725T_XM:;HKLJ2)<:;;Z;X7^(%]"+E5OM(\ :A9
M6UEJ.M3Z- /C3_@W\_X)F?MN_L1_M+_&7X@_M/?!/_A67A#Q7\"[CP=H&K_\
M+(^$?C3[?XD?Q_X+UM=.^P?#WQ[XLU.USIFDZA<_;+VRMK ?9_)-T+B6"*3^
MLZOF<9/#93G%.ME=2%:CA_95(2C6C6A-N%JM-U8-JTDY0E;6/,[:H^UR^EC<
M_P"':V'SVC4PV(Q?MZ,XSPTL-4IJ,T\/65&HHN\)QA4BVE&3BNA_CG>']?UK
MPIKVB>*/#>IW>B^(?#>KZ;K^@ZQI\K07^DZUH][#J.EZG93K\T-W87UM!=6T
MJ_-'-$CCE:_NA_8S_P"#G3]FKQMX+T70_P!L_0/$/P4^)FFPZ)I>M^-?!_A[
M6O'GPV\5W#VT\>J^+;?2?#MC?>,/"$*W-M%/=^&4TKQ2]M_:,*:7JNJ)%<I:
M^0?\%&?^#9_3O&VOZG\5O^"?^L^'?!-[J]WJ&I^)/@%XYU*?3?" OM0U%KII
M/A;XEM["Z3POI\4=Q)'#X,U^%]%LH8$CT?7M*LDMM&3^<+X@_P#!(?\ X*9_
M#*>6W\1_L4_';4I(6F1V^'WA0_%N F"\%BYBNOA5=>,[:=6F(>%X9I$N+/.H
MV[2Z>IN1]G5JY#Q%0I>VKPIU(7Y(RK0P^*HN5N>*C-N,T^57:C4AHFFGJ?G&
M'H\5<(8JLL/A:E6C4Y?:2AAZF+P.(C"_LYN5-*=*2YVDN>C5U<9)Q/[4/BE_
MP<<_\$NO OANYU?P5\4_'7QJUM;>]:S\)^!/A%\2/#U_-=P0A[."ZU/XK>&_
MAYH=I;WT["'[5#?WTELJ332VAVPQS_Q&_P#!2']OSXB?\%&?VD=4^.?C?2++
MPEH.E:-!X&^%O@'39!<P>"OAWI>K:OJVEZ;J&J>3;R>(/$M]?ZWJ6K>)?$4\
M$!O]2O6M-/M-+\/Z=HFC:9EZ%_P3&_X*+>(IS;:?^PW^U9;R":V@+:[\"?B/
MX7@WW;O'$PNO$WA[2+4PHR,;FX$Q@LD*27DD$<D;-^K'[(G_  ;1_MJ?&;5M
M"US]I*^\-?LN_#.X6RU#5+?4=1TSQW\7K_3;NTN+RWM=$\%>&;^Z\/Z-?3-%
M:6.J_P#";^+] U;PN=32ZD\+:]?Z;?\ A\3A,+P_D3GB5BX2J\CBJE;$4ZU9
M1=FXTJ5&,6W*RUC3<VM+V;O6/Q_%O%*IX.67U8T.>,W2P^%K8?#N:TC.O7Q$
MYI1C=M*I6C34O>Y>:,6MG_@V-_99\4?$S]M'7OVGI8/L?P__ &:/!FN60U.>
MSCF_MCXC?%GP_K?@S1?#VFR7!C,?V/P;=>-=<UO4=.>XN-*\GP_I=];QVWBZ
M"X7^_&OGK]EO]EOX+_L<?!?PI\!O@-X4A\+>!O"T+2RRRM%=>(/%?B"ZB@36
M?&?C/64@MY-?\6:_);PR:EJ4D,,$,$%EH^CV6E>']*TC2+#Z%KX7.LQ_M3'U
M,3&+C248TJ$96YE2@VTY6NN:4I3FTF^7FY;NUW^H\-Y-_8>5TL'*<:E>4YXC
M%3A?D=>HHIJ%]>2G3A3IIV7/R.?+%RY45_#=_P '7?\ R<?^RK_V1+Q7_P"I
MW-7]R-?RI?\ !P9_P3:_;3_;@^-?[/\ XN_9>^#'_"S_  ]X(^%OB#PYXGU#
M_A8OPH\%?V9K-]XLEU.UL_LGQ#\=>$KZ]\VQ99_M&GVUW:IGRY)TF!CKIX;K
M4:&;4*E>K3HTU3KIU*LXTX)NC-).<VHIMM)7>K=D<?&>'Q&*R#$T<+0K8FM*
MKA7&E0I3K59*->#DU3IQE)J*3;:6B3;T/Y]O^#?S_E+I^R5_W7G_ -9E^,]?
MZ6U?P[_\$??^"/O_  47_9:_X*+_ +._QW^._P"SO_P@OPI\"_\ "V_^$J\5
M?\+;^!GB?^R_^$G^!GQ-\':'_P 2/P=\3?$/B2^^W>)/$.CZ=_Q+M'O/LWVS
M[9>?9["WNKJ#^XBNGBS$4,3F-&>'KT:\%@J<'.C4A5BIJOB6XN4)22DE*+<6
M[I23M9HXN <)BL'D^)I8S#8C"U99E6J1IXFC4H5)0>%P<5-0JQC)P<HRBI)6
M;C))W3L5_'7_ ,'+W_!-[Q%XCU+2/^"@7P8\'WVL_P!G^&[7PI^T[8^']/LY
M9[/2_#,26W@OXPZC;VT:ZQJ2V.B21^"/&6J,;Z#0_#/AKP/=20Z?I&F:WJ*?
MV*57N[2TO[6YL+^VM[VQO;>:TO+.[ACN;6[M+F-H;BVN;>97AGMYX7>*:&5'
MCEC=D=65B#X^6YA5RS%T\522ERWC4IMM*K2E;G@VMKV4HNS49QC)J25G]%G.
M4T,ZR^M@*[<%/EG2JQ2E*C6AK3JQ3:3M=QG&ZYJ<IQ4HN7,O\?KX8?$_X@_!
M?X@^$OBK\*O%NL^!?B'X%UFUU_PIXKT"Z-KJFCZI:E@LL3%9(+BVN())K+4M
M-O8;G3=6TVYN]+U2TO-.O+JUF_MQ_8V_X.??V</&GAKPYX7_ &S?"'BWX,?$
M2TTZQM/$'Q)\&:#=^._A/KU];I;6U]KIT70?M7Q#\)3:C*\FH)X<L/#/C2SL
MH(KJ)/$4DHL[6X\Y_;__ .#8[0OB#XKU_P"*'["/CGPW\-+G7[G4];UCX%_$
MN:^MOA]9ZI=7,%PUG\,?$WAW0=3U+PCHTL1OFL_"NOZ7KFFV6HR6]GIWB#P]
MX;-O8:+_ #D?%'_@CE_P4X^$5Y?6GB/]C7XQ^(%L9H(OMGPNT6V^,=G>)=LP
MMKBQ?X57OC"6XA=%$DZ^2EQIJLJ:M!83;HE_0:M7A_B&E3=:M3A6C&T>:K'#
MXJDY;P7/[M2*?95:=W=:L_):%#BWA'$5EA\-5JX><KSY*$\9@:_+\-1^RM.C
M)QTNY4*K2Y9745;^R;XS?\')'_!,KX<>&SJ?PY\;_$;]H+Q#/;ZB++PQ\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /E[PQ_R6_4O^PKXE_P#2>^KZAKY>\,?\EOU+_L*^
M)?\ TGOJ^H:[\P^/#_\ 8)0_]N.?#?!/_KY+\HA1117 = 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5\1?\ !2[_ )1V_MS_ /9I7[07
M_JK/%%?;M?$7_!2[_E';^W/_ -FE?M!?^JL\45TX+_?,)_V$T/\ T[ Y,?\
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M-2%6*?9RA*2OY7"BBBH-@HHHH **** "BBB@ HHHH **** "BBO%OCY^T/\
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M  COBSQ1LU;6GFCTRT_LKP9H7B+6V^TO!*//336MH=F;B:(,I/P3_P /S?\
M@EE_T=%_YA/]HK_YT=;T\+BJT>>CAJ]6%VN:G1J3C=6NN:,6KJZNKW5T<6(S
M++L)4]EBLPP6&J\JE[/$8JA1J<KNE+DJ5(RY6TTG:SL[/0_6BBOR7_X?F_\
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M]UZ:,****Q.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***^=/C]^US^S)^RS:Z/=?M#?'+X<?"5O$/G-X?TWQ=XCL[/7M=AMI(X;R[T
M7PW"UQX@U73["6>WBU'4;#3+BQTZ2YMDOKBW:Y@$EPISJ24*<)U)R^&$(N<G
MUTC%-O371&=6K2HPE4K5*=*G&W-4JSC3A&[27-.345=M)7:NVD?1=%?DCHG_
M  77_P""4NOW\>G6/[6NDP7$FS;)K?PI^._AJP&^:* >9JGB/X7:5ID6'F1G
M\V[3RX5EN'VV\$\L?Z;?#WXG?#;XM^'(O&'PI^(7@?XF^$I[A[6#Q3\/?%F@
M^-/#DUU'#;W$EM%K?AO4-2TR2XCM[JUG>%+HR)#<V\K*$FC9M:V$Q6'2>(PV
M(H)Z)UJ-2DF^R<XQO\C##X_ XMM83&X3%..LEA\31KM+NU2G)KYG<4445SG6
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%_$/\
MY$W6O^N=I_Z<+2K7P/\ ^1-G_P"PY>_^DMA57XA_\B;K7_7.T_\ 3A:5:^!_
M_(FS_P#8<O?_ $EL*['_ ,BRI_V%+_TB H_QH_X)?FCV*BBBO+.D**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ^7O#'_);]2_["OB7_P!)[ZOJ
M&OE[PQ_R6_4O^PKXE_\ 2>^KZAKOS#X\/_V"4/\ VXY\-\$_^ODORB%%%%<!
MT!1110 5\T?$#]M']CKX3>+]7^'_ ,5/VL?V:/AGX]T#[!_;W@CX@?'?X6^#
M/%^B?VKIEEK>E_VOX:\1^*M-UG3?[2T;4M.U>P^V64/VS3+^RO[?S+6Z@ED^
MEZ_B^_;D_P"#>+]O7]JW]KW]H?\ :(T/XI?LGZ5X<^*WQ0\1^)/"FF^(_B#\
M95\0V7@_[0NG>$;;7H+/X%ZS86>LQ>&K#2EU33]-U;4]+TZ^$]CIFH7EA;VU
MQ)Z>687!8JM4CCL8L'2C3YH3LFYU'.*44G?3EYFW;2RZ'BYWCLSP.'HSRO+G
MF-:=;EJ4^9Q5.DH2;FVK.[GR16MK-NSMI_3Q_P /%_\ @GQ_T?9^QM_XD]\$
MO_FXH_X>+_\ !/C_ */L_8V_\2>^"7_S<5_&!XF_X-@?V[?!WAOQ!XN\1_&[
M]C;3O#WA;1-6\1Z]J'_"<_'>[^PZ-H=A<:GJEY]DL/V<KJ^NOLMC:SS_ &>S
MMKBZGV>7;P33,D;?C/\ L8?L@?%3]NK]H+PG^SA\';WPEI/C/Q9IWBG5X]=\
M>:AK6E^#=#TWPGX<U+Q'?WFOZAX=\/\ BK6K:&[&GQ:-IQL?#^HM+K>J:9!<
MK:6<MS?VOT='AW)\12K5J.;SJ4L/'FKU(PARTX\KE>3:72,GI=Z=]_CL1QAQ
M%A*V&P^)X?ITJ^,G[/#4I5:G/6GS0A:"3?VJD8W=E=[^[(_TU_\ AXO_ ,$^
M/^C[/V-O_$GO@E_\W%=E\/\ ]M']CKXL^+](^'_PK_:Q_9H^)GCW7_M_]@^"
M/A_\=_A;XS\7ZW_96F7NMZI_9'AKPYXJU+6=2_LW1M-U'5[_ .QV4WV/3+"]
MO[CR[6UGEC_BI_XA7O\ @H/_ -%B_8V_\.#\;?\ Z'FOT]_X)%?\$'/VDOV%
MOVQ=)_:0^/GQ%^ _B/P]X2^'OCG2?"VE_";Q/\1==UZ7QGXMM++PW#)JEKXM
M^&'@/3(= A\+:CXKDGNHM3O[Q=5&D01:3)#/<7^G>?B<LR*EAZU2CG#K5H4I
MRI4E"/[RHH^Y#:Z4I63ZI7[,]7!9UQ37Q>&HXGAU8;#U*U.->O*I.U&BY1]I
M4LY6;C#F<4]Y671G]6%%%%?,GVP4444 %%%% !1110 4444 %%%% !1110 4
M45^"O_!P5^WA\7OV)?V5/A[;_L^^.!\/_B[\:_B?+X2C\2PZ1I6JZQI?PVT/
MPEK>H^.;WPS+J\=W:Z/XA;6+[P-I5MKBZ9>7FF:?J^J7.D3Z1KR:1J]ETX/"
MU,;B:.%HN*J5I\D7-M1CHY.4FE)VC%-NR;LM$<68X^CEF"Q./Q"DZ.&I\\XP
M47.5Y*$804I1BY3G*,8WDE=K4_=2UU[0[[5M6T"RUG2;S7=!ATVXUW1;74;.
MXU;18-92ZDT>?5M.BF>\TZ'58[*\DTV2\AA2^2TNFM6E6WE*:U?S\?\ !MIX
M$UG3?^"?NK_&3Q9J^O\ B7Q?^T7\>/B3\0=6\3>)=0U?5-5U>U\-MI7PQMWG
MU+5I99-5<:OX)\0W5QJHENKBXO+ZZM+N]E>PCMK+^@>GC</'"8O$86-3VJH5
M)4G4Y>3FG#W:EHWE9*:DEJ]$F++<7+'X#"8V5+V#Q=&->-+GYW"G5]^E>?+'
MF;IN$FU%*[:6@5\\^%OVN?V4/''Q%3X0>"OVG?V>?&'Q:?4==T=/A=X6^-/P
MW\0?$5]6\+VNI7WB72T\$Z3XEN_$K:CX=LM'U>\UVQ&F&YTBUTK4KC4(K>*Q
MNGB^0_\ @K[^W+:?L%_L5?$#XD:5J/V7XL^/=_PH^!]O%'+-<+\1/%6EZG*G
MB1EA_P"/:S\#>']/UKQ>]Y=;+"74])TC0Y9?MFNV$%Q^2'_!L]^P[J?A+X?^
M/OV^OBM:WE[X]^.?]H>$_A7=>((=1EURW\ V^M/>^-?&MQ=:Q9I<7=Y\1O%-
ME:)::O;7=W]JT?P]+="]F3Q!<Q+UT,O@\LQ.98BI.G"-2-#"0BE?$5WK+XO^
M7=-:RE'?EFD^:-GY^)S>K'.L%DV#HPK5)TIXK,*LW+EP>%BTH-*.]6J[QC&5
ME%SI2:<9Z?T)>-_VW/V,/AGXJUGP+\2/VN_V8/A]XW\.W$=IX@\&^-_C[\*?
M"GBK0KN:V@O(K;6?#VO>++#5]+N);.YMKJ.&]LX)'MKB"=5,4L;-[GX%\?>!
M?BAX4T?QY\-/&GA/XB>!O$4,]QX?\9^!?$>C^+?"FNV]K>7&GW,^C^(M O-0
MTC4X;>_M+NQGELKR=(;RUN+:1EFAD1?\G_\ :@^(OB']J']IK]IWX\Z=;W.O
MVOC+XE_$;XJW5QI]M>F#2/!&L>-WM]#F6WOH8-3M]&TC3]8\/:1;_;[:.]M+
M,6QU%(WBN73^[?\ X-KOB%/XT_X)@^$_#<US#/'\(_C'\7OA[:Q11VR/9P:E
MK-C\5VMKAH)9)99FN?B=<7:R7J07(M[J")(C9Q6D\WIYMP]#+<OI8N->=2JZ
ME&%>G*,5&FZE*4I6:]ZZJ*,4I6]V5WJM?$R#BZ>=9M7P$L+2I4%2Q%7#5H3G
M*=54:U.$.92M%*5*4YMQVE%):79^^M%%%?+GW)YI\5/C3\'/@5X>L_%WQN^+
M/PT^#GA34=9M_#FG^)_BIX[\+?#WP]?>(;NQU'4[30;/6O%VJZ1IMUK-UIND
M:MJ%OI<%R]]-8Z7J-W' T%E<R1<9\*_VKOV6_CKXAO/"/P1_:4^ /QC\5Z=H
MUQXCU#PQ\*_C'\._B%XAL?#UI?:=IEWKUYHOA'Q'J^I6NC6NI:OI.GW&J3VR
M6,-]JFG6DDZSWMM'+_"G_P %^/VZ-?\ VSOVP;S]F_X<ZREW\#_V6;WQ;HUI
M_9TUR^E^(OB'HVD-=_%_X@:PNGRWB:O8^"+30=5\.Z!/#9WEQIVCZ+XGU#0D
M<^+K^WNON'_@T]^$0NO&/[7WQZO+2%&T3PU\-OA%X=OF@TV:XN!XHU37?&?C
M.TBN?-;6-.ALSX/\!33P>3#INLO?6\AEN+K0@EK]15X?CA\F>98FM4A7]G3J
M1PZC'E2K5(PHQDW[RDXR4IJUXZK[+9\10XNGC.(XY-@\+3JX7VU6C+%RG)2;
MPU&=3$3A%>XX1E!P@V_?3C)?$D?VDT445\N?;A1110 4444 %%%% !7SIXQ_
M;!_9)^'GCZY^%7C_ /:D_9T\#?%"RO-'T^\^&_C'XV_#3PSX^M+_ ,166GZE
MX?L;GP?K7B:R\0P7FN:=JVE7^CVTNG)-J=EJ>GW5DD\%[;22?1=?YO\ \.4T
MW]O3_@OW97TRC6_!_CO]M_Q)XLM(8;>^G36OA9\&M?UCQ5I-K>Q)=:I/%#JG
MPY^'-I;:U-;72V-E%<7MQ9OI>FP0BT]C*<LIYA]=G6JSHT<'A98B<H14FVKR
M46I:6<(5'WNEYGSN?YU5REY;2P]"GB,1F6.AA*<*LY02C)QC*:Y4VVIU*4>R
MYM;Z'^D!1117CGT04444 %%%% !1110 4444 %%%% 'DWQ8^/GP+^ MAI&J_
M'/XT_";X,:7X@O+C3]!U+XL?$;P?\.K#6[^TA6YNK'2+SQAK.CV^I7EM;ND]
MQ;6<DTT,+K+(BHP8[_PX^*/PS^,7A6S\=?"/XB^!?BGX(U"XO;2P\9?#CQ=X
M?\<>%;Z[TVY>SU&VL_$/AG4-4TBYN+"\BEM;V&&\>2UN8W@G6.5&4?AS_P %
MOO\ @E_^U5_P4MO?V>=)^!OC+X"^$/!GP?M?B)J.N#XJ^)/'VB:YJ_B?QQ+X
M3MK<V$?A+X8^.[9M)TG2O"H$;RWVFSRWFK7BW%I<QV]E-%^FO_!/;]E[4OV,
M/V,?@#^S1KFLZ-XA\1_#'P?<V_BO5_#D,\/AZ[\8>*/$.M>-O%XT)[RSTV^O
MM&MO$OB75;33-7U+2]*U36K*"#5]3TK3-0OKFPM_0JX?!PR_#XB&*Y\;5JRC
M5PJ2M1I)U+3;M>[4:;M?[;ZQ:/(H8O,:F;XO"5,![++:%"$J&/E)WQ%>2H-T
MXP;^&+G63DD]:2U]Y7^RZ***\\]<**** "BBB@ HHHH **** "BBB@ HHHH
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MG^+;+PM_PE/]B_\ "1?V']KBGD^W?V)_:VA?VGY?D[?LO]KZ?OW9^T+MP?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS+X5_P#(W:M_V"K_ /\
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MKOCKP=X8\<^+M.MK$)&D=OIOBWQ'KEA#+"BV]U';+=VRBWGBK_0W_81UN_\
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MC0KB6>(>)_%.JWSPZ'X/\/-+;26]D^IW,FNZW<%F\/:!JUE8:U?:3_-CX_\
M^#IK]K+4M;DN/A9^SG^SMX-\-EIC%I7C^7XE?$O6T1G!MUD\0>'?&7PGL)6B
MCRLSKX9A$[D2(ENH,9[L'D>98ZFJM&A:E+X:E64:<9_X%)\TEO[T8N-TUS7/
M+S'B?)<KJNAB<7S8B/QT:%.=:=.]M*C@N2G*S3Y)S4[._+9G]R%%?Q:_!O\
MX.H?BM::W80_M!?LO?#WQ!X;F6.#5-1^#?B3Q)X/UO3W9['S=3L-%\;7OCBP
MUA8HX]2\O0[C7]#-P]W8AO$5LNGW!U/^J?\ 9$_;'^ W[;_PDLOC)\ /%;:_
MX<DO9]'US1M4MXM+\8>"_$%KAI_#_C'P^MS=R:/J@@>&]M2MQ=6&IZ=<VNIZ
M3?7^GW,-R^>-RC'Y?%3Q-!QIMI*K"4:E/F>R<H-\K?134;]+FV6<093F\I4\
M%BE.M&+DZ%2$Z5;E5KRC"I&//%77,Z;FH_:M='U'117YA_\ !07_ (*R?LM?
M\$\;*VT7XC:KJ/CGXRZQIUKJ_AWX)>!U6X\576BW-X;3^W_$.JW*#P_X-T0-
M'.UI+KM[%JNMFWN!X<T?6([+4I;'CH8>MB:L:.'I3JU9?#""N[=6^D8K>4I-
M1BM6TCTL5B\-@J$\3BZ]/#T*?Q5*DE&*;VBNLI2>D813E)Z13>A^GE%?PW^/
M_P#@Z:_:RU+6Y+CX6?LY_L[>#?#9:8Q:5X_E^)7Q+UM$9P;=9/$'AWQE\)["
M5HH\K,Z^&81.Y$B);J#&?<?V=/\ @Z9\1-KUKI?[6'[-_AUO#M[<:?%<>,_@
M)JNKZ=J'A^$1M'J5T_@#Q[JOB!/$D<]P\=Q!'!\0/#\VFVL,T!CURXFC>+V9
M<,YO&GS_ %>$FE=TXUJ3J>:MS<K:[1D[VLKNR?S=/C;AZI55+ZW4@F[*K4PU
M>-)M[-OD<HIO3FG"*6\FE=G]C]%>6?!CXV_"?]HCX=:!\6O@GX[T'XC_  Z\
M3I<MHWBCP]<22V=Q)97,EG?6=S;W,5M?Z9J>GW<,MKJ&E:I:66I6%Q&T%Y:0
M2@K7J=>%*,H2E"<91G%N,HR3C*,D[.,HNS33T::33T9]5"<*D(U*<HSA.*E"
M<)*4)QDKQE&46U*,DTTTVFG=.P4445)1^8?_  5D_P""@ME_P3Q_9:U7XC:+
M;:=K'QE\<ZBO@?X)>'=7M;RYT6Z\57"I<ZKXAU_[(8V&B>#?#XO==EM&GM_[
M;U6+1_#@N+*/6)=2L?XGOV)OV#OVLO\ @L;\?/&_CCQ5X_UZU\.)J=YJ?QC_
M &E/'>FW?BNTTW7-26;4+'POX<T0:GX?M_$7B*Y>YBFM/!NC:MH&B>%?#CI<
MSSZ+8MH.G:I_65_P6$_X))?$_P#X*5ZQ\*O%'@GX_P#AKX??\*@\->(]&T#X
M>>,/!FL7^@ZEK'B[4K2^\1>)9O&>C>()[O1Y;ZTT'PII1TZ'P)JC-'I!O)-4
M?,-E%]?_ /!+/]B*^_X)_P#[(7A7X">(]2\+:_\ $!O%OCGQO\1O$W@T7Q\/
M>(O$?B/7IK;1[ZSDU72=%U:5['X?Z1X*T"Z?4K+SENM&FBMYI-/CLPOU.#S'
M"97E#GA)TYYKB*CA4<J<G*A"\N5KG@HRC"$8M).475J7DIQCRKX7,LGQ^><0
MQI9A2K4\AP=)5**A5C&&*JI4^=2]G-U(3J3G*#;4)QH47[-TYS<G^+GBW_@U
M:^"LWARXC\"_M5_%'3?%J:9<"UN_%O@OPGK?ARXUD0Q&U>XT[1YO#^IV6F27
M"S+<1QZI?W4,,\3QRS/:LEY^#7A'XA?MG?\ !"K]MW6?"=U<V\M]X>N+1O&'
M@9-8N[KX5?'CX7ZQ*)=-UNS*INM1K%E:?:?#?B1M.M_%/@W6[6?3=4L ]IXA
M\-7G^DY7\-?_  =*^(/#-]^UE^SWX>T^]LKCQ5H'P"GNO$EK;Q%KNPTW7/'W
MB-_#D-_=K%Y6Z=M/UNZMM.:X>ZM()EOI;:WMM7LI[WJR/-,7F.*G@,?)8S#8
MBC4YHU*<+PY8WO>$8^Z_AUVDXRBXR6O#Q1D67Y/@89ME499=C<)B*'LY4:M1
MJISS4.5QJ3FE*-^>\4E**G&I&<97C_:)\$OB_P""_P!H#X0?#3XW?#N[FO?!
M'Q5\$^'/'?AM[HV0U&VTWQ'IEOJ4>F:U!I][J5I8^(-&DGDTGQ#I<5]='2=;
MLM0TR69YK20UZA7XZ_\ ! ^Q\76/_!*[]FP>+9+DB[G^*]]X7MKZ">"]LO"-
MS\8/';:/',+FTMII+:\<7FKZ-/YE[!+X?U+27LKO[";:UM?V*KY7&48X?%XF
MA"7-"CB*U*,M[QIU)13?G9:]+WM=:GWF78B>+R_ XNI'DGB<)AJ\X[*,JU&%
M227E>3MUM:]GH%%%%<QV!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '%_$/_D3=:_ZYVG_ *<+2K7P/_Y$V?\ [#E[_P"DMA57XA_\B;K7
M_7.T_P#3A:5:^!__ ")L_P#V'+W_ -);"NQ_\BRI_P!A2_\ 2("C_&C_ ()?
MFCV*BBBO+.D**** "J]W=VEA:W-_?W-O96-E;S7=Y>7<T=M:VEI;1M-<7-S<
M3,D,%O!"CRS32ND<4:,[LJJ2/#?VF_VE/A+^R)\$/'7[0/QMUZ70?A]X!TZ*
M[U![&T.HZUK.I7UU#INA>&?#FEK)"=2\0^(M7NK/2=*MI)[2RCN+D7FK:AI>
MCVNH:G9_YX'[9W_!2']N/_@KC\8V^%'@O3?'$?PV\4^(;6R^&G[*OPK.JZGI
MMU;V>J"70-0\=+IL<4GCOQ+:2-9ZCJWB3Q!%;^'-$OH6U'1M+\,:? %C]G*<
MEQ&:.<U..'PM)VK8FHKQBTKN,%>*G-1:E).48QBTY25XJ7SF?<2X3(U3I2IS
MQ>.KJ^'P5%I5))MQC.I*TG3IRDG"#4)SG)-4Z<E&;C_<G\6?^"P7_!,_X)ZG
MJNB^/?VPOA4VK:)>)I^K:=X&D\1?%F[L;]I9();&>'X4:#XU<7EC/%);ZK;*
M&FT>XC>#54LYE*#C_ W_  6]_P""5GQ$U*UTK0/VQO >GW5Y?0:?#+XY\,_$
MSX7Z:EQ<3VEM')=ZQ\2_!'A+2+"Q62]A:?4[Z^M]-M8$N[JYNX;73[^:V_F4
M^!'_  :S?M8>._#6B:_\=?C;\+_@'J6JLLM_X)TW2K[XO^*_#5F9;6,Q:S<:
M#K7ASP3<:RL9U"?[%X>\9Z[I!2'3D'B'S;^\32.O^-G_  :G_M!>%/#U]JWP
M'_:>^&_QEUBPTF\U >%O&W@36/@QJ.LWUI%//'H6@:A;>*?BCH4FHZFL4-KI
MMQXBU/PSH_\ :%RD>K:GI.G1S:HGK?V9PLI>QEG-=UK\O/%1]A?9OG^K2IJ-
M[M/V]K?:>[\#^VN.91>(AP[A8X>RE[*;E]:Y7K;V;QL*SG9I-+"\R=[PNFE_
M;OX;\3>&_&6@Z7XI\(>(-$\5^&-<M(]0T3Q'X;U6PUS0=8L)L^5>Z7J^EW%U
MI^H6DN#Y=S:7$T+X.US@UMU_F.?L7_MW_M?_ /!(']I?5_!WB+2_&%MX>\+>
M)+CPQ\=_V7/&VJ7]CH&JP^? ^HWFDV;O?:7X;\:16WD:MX/^(>A6UW;ZA;2V
MDDLGB3P9K-YI^J_Z5_PV^('ACXL?#OP#\4_!-ZVI>#/B7X+\+?$#PCJ+Q&!]
M0\,>,M#L/$>@7KPL6:%KK2M2M)VB+$QF0H22,UY.;Y/5RJ=-^TCB,-73E0Q$
M$DI62;C)*4DI<K4HM2<9Q?-%Z2C'W^'N(J&>TZT?8SPF-PK4<5A*C;<&VXJ<
M).,'*//&4)1E&-2G-<LXV<)3[2BBBO&/HPHHHH *^=/B5^V#^R3\&?%$_@?X
MP?M2?LZ?"GQK;6=GJ%SX0^)7QM^&G@7Q1;V&HQF;3[Z?P_XH\3:7JT5G?0@R
MV=S):+#<Q@O [J,U]%U_)I^W?_P0>_:\_;;_ ."BOB[]I[6/B7^S7X=^!OBW
MQU\+[:31)=>^(M_\0]-^%'@C1?"'A35<>&'^$K>%=6\7WVCZ%JNKQ:+?>.(]
M$O=7U!-,F\0:=I)66S]#+</@\36J1QV+^J4849351)2E.HI04:<59W;BY2ND
M[<OF>1G.+S'!X>E/+,!_:&(J8B%*5)R<8TZ4HS<JLI)JRC)0CJ[>^V](L_K#
MM+NTO[6VO["YM[VQO;>&[L[RTFCN;6[M+F-9K>YMKB%GAGMYX726&:)WCEC=
M71F5@38HHKSSU_7^OS"O.OBA\8/A)\$?#<?C+XT?%+X<_"'PA-J=KHD7BKXH
M>-_#/@#PW+K-]#=7%EI$>N>*]3TG2WU.\M[&]GM;!;HW5Q#9W4L43I;RLGHM
M?R-?\'7'QP?3/AC^RM^SIIVKS*WC#QIXS^+_ (JT:W$"QFS\#:19^$O!USJ,
MK6_VQX;R]\;^+OL%K;7@L9;C1[FYU.TENK/1)[?ORS!?VACL/A.9P564N><4
MFXPA"524E?2]HM*^EVEU/*SO,O[(RO%YAR1J2P\8<E.3Y5.I4JPI0BVM;<TT
MY6NU%-VT/ZFOA7\:?@Y\=?#UYXN^"/Q9^&GQC\*:=K-QX<U#Q/\ "OQWX6^(
M7AZQ\0VECIVIW>@WFM>$=5U?3;76;73=7TG4+C2Y[E+Z&QU33KN2!8+VVDE]
M+K\8?^" 'P@_X5)_P2W^ ,UU;7%KK?Q6O/'GQ?UR*8VQB;_A*_&&JV'A6YM#
M#96D_P!GO/A[H/@V\<7TFH7(NY[H0WIT\6-I:?L]6.,HT\/B\3AZ4W4A0K5*
M,9R23G[.3@Y66FK3:MTL=&6XBKC,!@\77IQI5<3AJ.(G2BVXP=:G&HHIR][1
M22=];W"BBBN8[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M7O#'_);]2_["OB7_ -)[ZOJ&OE[PQ_R6_4O^PKXE_P#2>^KZAKOS#X\/_P!@
ME#_VXY\-\$_^ODORB%%%%<!T!1110 4444 ?F=_P6-^,DGP,_P""9O[7WC&T
MN-/@U/7/A5??"O21?7%W;RO=_&?4M.^%$\VDFPFAO6US2],\8:AK>E- S1VM
MWI:7]^ATRTOB/YD/^#5/X*2>(_VF/VC?C[>:=;W.F?"WX/:/\.M,N[RSM)A9
M^*/BSXJMM72_TB>XB:XM]4M?#GPRU[2[JZTV2.2#2O$EQ8WKBWUB..?]%?\
M@ZC^,:>%OV2?@+\$H%A74/B_\:KWQ;/*U_/#<'P]\(_"\Z:C;1:;%"(KZ&77
M?B)X4N)[JZO!%I[V=O&FG7EQ?PWND]Q_P:\_!?\ X0?]A3Q_\7K[2M0LM6^.
M7QPU^;3M2N[3[-::SX'^&VD:7X2T:;2I6#-J%I9>-)/B18SWRNL*ZC%>Z<D$
M<VG7$]U]?A_]DX3Q=7:>/Q2IP?\ -!2A3E'?^6EB-=[MZ:7/S[&?\*''V P_
MQ4LIP3KU(_RU90G5C+;^>OA/*T5K=V/Z4Z_'W_@J1_P6'^"7_!-C1](\,RZ0
MOQ>_:#\6V,FH^'/A#I&O0:/_ &%H;17,=KXR^(6LK9ZI)X=\/W.H0K::38QV
M$^M^)98[S^RK>*QT_4]5T_\ 8*OY-_VDO^#=OX[?M1_MX^(?VB?C'^U1X4\>
M_!WXD_%F;Q/X]L(],\4>#?BEX>^%BH)M&^''P^M+BV^(/AA?^$7T^&Q^'OA^
M\U/7[2WM_#NGP>*IX)]6>;PZWBY12RZIB92S.M[/#TJ<JGLTJG-B)K:FI0B^
M56NW[T92=HP>K<?I,_KYQ2P<89)AO;8RO5C2]LW2Y,)"6]:4*LDIN]DFX3A!
M<TZBM%1E^+WQ*_X./?\ @J+XVU6[O?"/Q.^'WP>TZ75+J]M-'\#?"'X?ZY#9
MV$V5MM'>]^*.B?$*]N;>S3:PNVECOYYM[RW'DLMNG:_ 3_@Y9_X*+?#3Q7IE
M_P#&+5/AW^TCX,$UO%X@\,^)_ WA7X;Z[=::-2CN[V3PWXL^%F@^&K70/$,M
MBLFE6&IZUX5\8Z'90R_:KOPIJEX@F/\ =]\"OV8/V>?V9/#5GX2^ /P;^'_P
MJT6SL1IV/"7AVQL=6U"V\X7#?V[XC>.;Q%XCN9;A5GGOM?U74KVXF1)9[B1T
M5A^(7_!PGH7[#%]^Q)\:O&?C72?@3?\ [4NGZEX TWX7:[8S>$K;XZOXL;QG
MHWAR\TU-0TF\LO&>KZ-IG@FU\62ZWX>UN>_\/0:=X<DO)M*FU7P[H_V3Z'#9
MIDV,Q-/ QX?HJE7J0HQK1C2=>*G)04YJ%)3@E?FG*.(;BDVFSY#&Y)Q'EV#K
M9G/BW$.OAJ53$3P\Y5UAI>R@ZDJ=/VE>5*<I<O+"$L&HSDTFHW/UH_8/_;A^
M$/\ P4%_9]T?X_\ P>36=-T]M9OO!WC3PEXBMA#KO@/X@:-8:3J>M>%-0N8
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MJ1KV9(/#G@O2[J2TC\3^,[V&ZATF&YC@TO2O$7B"XTSP]J7\:'QP_P"#E?\
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M_B?K%E;W&FCRXX]3\._#'6=,U*/5)(=,OM&O-3TV4S7-[:6MQ_+A_P $/?\
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MJ'C#7==T?PGX0TW6[/2=9\/ZG<Z=J/B77M*L;B*PUK3;MDN#Y%RLFT-^%?\
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MT7"V9XW'8+.LUQ-6MB*7UW$O!X>37[NC0INNJ=)):*7M8TUK+6FETN_Y;/\
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M4P59U*ELNPDJL8X>,9\M.-6G1Q-#V<9)7A*5.M*4.64JDZDII?@C_P $F/\
M@OWHO[;GQ(@_9T_:7\&^$/@_\<O$<<]Q\,?$7@J;4[7X7?$:ZL[:"2]\$K9>
M)]=UW7_"WCJ9%O-4\-6MSK&MZ-XHLK6_TE-3TCQ+:Z#I?C'^D.[N[2PM;F_O
M[FWLK&RMYKN\O+N:.VM;2TMHVFN+FYN)F2&"W@A1Y9II72.*-&=V55)'\DC?
M\&T_CCPW^W#=_'CX,?'SX>_!GX'>#OCAX)^+?P7\,:;H?C7Q=X^\+6&@:YX<
M\8R>'KB+5;[2[#3Y?#.OVNJZ7X6U >,?$LVI:5IVB:IJ;:9>WUYIFF?T#?\
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M_K9HHHKXP_1PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _S\_P#@YZ^,'_"=?\% O#7P
MQMH?)L?@=\#_  ?H=T7C_>W/B3QS?ZOX_P!0NDF,<9:S_P"$>UKPC9Q0 S+#
M=V=_*)MUR\$']F__  3A^$'_  H;]@S]DCX5S6UQ9ZIX<^ _P]O/$MG<FV,E
MKXS\4Z%;>+_&]LAM;+3T-O!XOU[6XK0RVWVPVB0G4+B]O_M-[<?Y_?[2%TW[
M>G_!:3QKHVG:O_;&D_&O]M30OA/HFMZK:26L+> M'\<:+\*M!U"XT_5HY+E-
M.L/ WA^RFBT^]LUO9+"UCM)-'ANW_LM/]-FOK^(?]FRS(\ M'&A[>K'6ZJ<D
M%>WG4J5M]58_/>$?]NSOB;-WK&>*^JX>:LU*E[6I*UT^E*CAMM'>]PJO=W=I
M86MS?W]S;V5C96\UW>7EW-';6MI:6T;37%S<W$S)#!;P0H\LTTKI'%&C.[*J
MDBQ7P-_P5+^,:? 3_@GA^U[\2RL)NK+X*^*/"6D-/?SZ9'#XA^)R0?##PU<B
MZM89KDS6OB#QCIMS;VL!M9=0N(HK!-1TMKD:C:_*T*4J]:C0C\5:K3I1_P 5
M2:@NW5]S[O$UXX7#8C$S^##T*M>=]%RTJ<JDKM)M:1?1^C/X(_V+HK[]NW_@
MM)\*_%NKZ7I^JCXO_MD^(/V@?$&@^7#=:%-X;\->+/$/QY\0Z%]B\7SM]I\,
M0>&/#-_IG]CZD]Q?SZ#%_95O:7FH/;V<W^FK7\"7_!KG\(K3QG^W1\2?BGJ-
MG<3V_P &?@/KLVC7211FVL?%WQ!\1:#X6LI+B=V9T>?PBGCJW@MXH@T^^65K
MJ)+5K>\_OMKZ7BVJGF%#"PTIX3"4X*.]I3<I/_RG[+[K]=/B_#^A)93B<;4U
MJX_'UJKE_-"G&$+O3?VOMV]6M5:SN%%%%?*GW9_'-_P=B?"WQ)/8_L=?&NUM
M[BX\(:9=_%/X6ZY=K9S?9=)\2:Y#X5\6>%;>;4%+VYN/$.F>'O&4EM9RBWF6
M/PQ=SP&\1KD6'Z&?\&[/[7GP$^)W["7PN_9G\.^)M+T3XW? 2/QEI?C3X;ZE
M+9Z;K&K6/B7X@>,_'&F^./"%L7B;Q1H&I6.N'^W[NQA:_P! \20:E:Z];0VM
MYH.L^(/V._:?_9C^#W[8/P3\9_ +XY^&_P#A(_ 7C2S1)C;3+9:[X=UFS?S]
M$\6>%-6\J=]&\3^'[X)>Z7?>3<VLN)M-U>QU30[_ %/2K[^##]MK_@@A^W!^
MQAXDU#XA_ .U\1?M"?"K1[N?4] \<_"6WU"#XL>$[)4UBZ3_ (2?P+H\TGB.
MVN]+TO3@VH^(_"!U;0I#=VI:;3+B[;3+;[#+ZV!S7*:638K$K!XC#5G4PU6:
M7LZG,ZC2=Y1C*2]M.#@Y0D_<E"4GSQ/SS-L/FF1<05^(\#@GF.$QF&C1QM"F
MY>VHJ$:$9-<L9SC%O#TJBJJ%2"_>0J1@N2;_ -$ZOAS_ (*1?LL7G[9O[%OQ
MT_9^T+3_  E>>-O%WA=;OX<77C.,KI&C^/\ 0;ZUUCPYJ2:E%:7MWH=TT]I+
MIBZS96[RVMMJ5U'/'/83WEM-_&5^QQ_P<@?MH_LW2VG@G]HO1[/]JGP'I?VJ
MPN?^$UU*Z\(?&K1[E;N^=BGQ(CT[6$UG[)<WCK?:?XW\*:]JMS!IUAI5AXB\
M.113RR_V&_L._P#!4/\ 8]_X*"Z3<M\!O']W:>.M*M([WQ'\'OB)ID?A'XH>
M'K>>XU.*"=])%[J>@>*+1K?3&O[O4_A_XE\8:3HUO>Z=;Z]?Z5J=VNGKYF+R
M?,\FJPQ3IJI3H5(588FC>I24H24H.HK*=-723]I&,6WRQE(]K <19'Q%0J8)
M5G2JXFC4HU<%B4J5>4:D)0G&E)N5.L^5R:5*<YQ2YY0A8_.G_@B/_P $D/VF
M/^":OCCXZ^)_C;\4?A-XFT3XK>%/"F@V/A;X2>(O'^LV#:KX7U>_U"Q\0>(%
M\6^!_ EHUYI]IK&M:=I30V.HW-I#JVI"&[MXM0NX9/Z(:**\S&XROC\1/%8A
MQ=6HH*3A%034(J$=%_=BKL]O+<NPV582G@<(IQH4G-P52;J23J3E4G>3[RDW
M9))7T04445RG<%%%<7\2/'FA_"SX=^/?B?XG6^;PU\./!?BGQYXA73+=+O4F
MT/PAH=]XAU9=/M9)K:.YOC8:=<"TMY+B!)I_+C::)6+JTG)J,4VY-));MMV2
M7FWH*4HPC*4FHQBG*3>RBE=M^22NS_-[_P""J7B'Q%^V%_P62^,_@?2XYKZ_
MU?\ :%\'?LO>#])TZ>.5XY_".H>'O@S%8V#HNH>7=ZIXIL=3U2>)XKAX-7U:
M[B:SC*?88O\ 2=\,^'-&\'>&_#_A'PY9_P!G>'O"VB:5X<T'3_M%U=_8=&T.
MPM],TNS^UW\]U?77V6QM8(/M%Y<W%U/L\RXGFF9Y&_RB?V7/VHX/@)^V-\.O
MVN/&_@%OBK=>!OB7J?Q8OO ^F^)K/P"FO^*YQJ^IZ4T7B&[\(^/(-%L=-\5W
MUAK4\4?AF_N;FQT^73+"\T:]N;;7-._IM_XBV?\ K'__ .;5_P#Y-U?H&?9/
MF.)IY;A<%AO:T,%A53<E6H4TZC4*=N6K5A)M1I1?-9KWVN9NY^2\*<0Y/@JN
M<X[,\9]7Q698UU8P>'Q-9JDI5:MU.A0J12E.O*+BY)_NT^5+E;_LDK\2/^#A
M/XK?#[X>?\$O_C;X4\:7L(UKXR:K\/\ X?\ P\T8Q6MU<ZOXLL/'?AWQ\TR6
MUQ-&T=KH>C>#-3UFYU*-9#83VMB(Q]LN;-)/Q6\??\'9'Q/U'3;>+X7?L7>
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M=?"_7?AM\ ?#=W=P/H>B^%/AYX6\<:MH]A;Y MKS7_B?I7BRVUB[O1SJ-Z-
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M-8##XR>/JXN-.5'#X7XJJO3I5*C<HU9:Q_API3;5TN5RNT>SQGFV,R^GE5#
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MQ+X<E-MX6BU'PV+K1VL-=TN[O8O$U_8+%<:M':+>K=:9J!_)G_@M'^U7J/\
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MGQWNCV]SH.I-J_@;PM?F>ZM('N?&?B+1/LL-CF[FGT?3?$-^=.O+'2M06/\
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M>YABO?L.DZUHEW+H8NY=3G3P_?:5!=ZSJ.I0:@\?]C'_  3F^)>M_%W]AO\
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M^11@O^OK_P#<YWY5_P EIGG_ &"+_P!*P!^DM%%%>,?<A1110 4444 %%%%
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M6,GB+Q[XK@L+B%]<TNUU2=_#&A>'+V==-N+[2_$MSX@TK4+0Z&Q\E_X.<O\
MD_3X2?\ 9HG@+_U<OQ]K^G;_ ((XZ5IVC_\ !,O]D2TTNTALK:;X=:AJLL,
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M_LURQM=>$VBW6EZK:6.H>O? K_@Z&\<Z9:Z3I/[2/[,OA[Q9*KK#JWC?X/\
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MMI)+K6O'4NES>$/#6CVB7<)N;F:]U#5YW,\.C:!J\]AJ<5E_.U_Q"Z_M_?\
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M -AR]_\ 26PKL?\ R+*G_84O_2("C_&C_@E^:/8J***\LZ0HHK'\0ZW:>&M
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MJOBO6O$.B:1=65_X@U][NXT*VU<Z5!?PMI<+:9:Z?9'37N+&XU75/D+_ (B
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M84E032I/%35*,G)))MJ?UE*[>M-/39?<=?R;_MK?\%W?VP/A=_P4@\1_L/\
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MWQ!U.W:!H60:%K7QE^(^L^%T8P1Q()H_#-_I$=PK*9DN$E6XDFG$DK_SP_\
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MSC\4H^VI.\KSC)U(2G-1A(_0FBBBOF3[8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB\TVUFW26NN_%'Q=/H)_M18XQ&+A-'^%^G3Z?!/-)<VMIJ,]REO:V^JI-?\
M]:W_  3]^&EI\'_V'?V2OAQ:7"7?_",_L^?"J&^O(HHX(;W6=1\'Z5K&OWL$
M44,&RWO-;U#4+FW$R/=>3*AO9[J[,]S-_#K^V]*G[;O_  <$:C\.?M<J>'+[
M]JSX0?L^RBUNI]5.C>'OA9<>$? /Q!ELGMK*PGCF&I>'?&GB"6R95BTO4KVZ
MLIM7DM+1M6/E9/-8GB',<QJ?P\-'&8A2WM'F]C36NMU0E*VGV7HM$>[Q%3E@
MN$LHRBE;VV-GEN#<=N:?*L15EII9XF$+J^\T[NS9_;W_ ,$[_@!:?LN_L/\
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M</V6_P!H/X[S7$5M/\*?A!X]\9Z1YT:3)=>)=(\.7\WA73%BE22"2;6/$O\
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MPIX+L];^).J7T\(L[B/4;'3_ !/X7\$6\ED]Q8NE]J>G:C'-,NGR6L_XF?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHSNRJI(_SK?^"37A.X_;P_X+8:=\8?%ZZAJ]C8?%GXL_MA>))]/L[F6.WOM
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MC"DI-<TE&,H4HRA9M2C)33<9(****\@^@"BBB@ HHHH **** "BBB@ HHHH
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M_P &TO\ S>G_ -VY?^]XK^IBOY9_^#:7_F]/_NW+_P![Q7]3%<N:_P"_U_\
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MYX_^#EO_ ),4^$__ &=IX$_]4[\>*\>_X-B?^2)?M2?]E3\#_P#J)7]>P_\
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M>4WC_1;SXKS/Y[WKO]IN/BEJ'C*XO=IOYQ#]LEG^S)'91V_E)IVGK:_SB_\
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M[9L_X1/^S/\ A*OM6>?L/]C?;=OS_9]GS5_*S_P6[_X*;?#']MWQ#\.?A/\
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M?3YC_P B#*O\<?\ TW5/SW(O^2UXB_Z\U/\ T_A3](:_BM_X.BO^3A?V8?\
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M?Z$W[,?P3TW]F_\ 9W^"GP'TJ>"\M_A/\-/"'@BYU.VCDAAUO5]$T:UMM?\
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MK_3UKZ[BC^%D_P#V"S_])PY^?<#?Q^(?^P^'_I>*"O\ ,*_X*[?\I+OVS/\
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M)=Z3K6IZ5>:=J%Y^='_!0+_@X6_9B^"?@#Q%X3_9'\4V'Q^^.NL:9>:=X?\
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M:+5T%%%%>.?1!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:OJ^K3?FY\#_ /@U._:"OO&%N?VDOVCO@YX7\ V\UM+=I\#_ /A-O'?C#5X
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MK^WN(&G\W^S_ (N:Q\--<M9K)@EGJ,$NF,BWS$:;<:KIZ_VB?]&>BO/RW/\
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ME61\\\%2G*O4CR3Q->:JUW"]^1-1A"G%M)R5*G#G:CS\W+&WPS_P4B_8[?\
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M]HHKQ\;C\5F%;V^+JNI-+EBK*,(1O?EA!6C%7U=E=O63;U/H<LRK Y1A_JV
MH*C3<N>;;<ZE6;5G.K4DW*<K*RN[17NQ45H?GE_P4C_X)Q_"'_@I+\$H/A?\
M1-3OO!?C'PI?7FO?"?XJZ18C5M4^'WB.^@@MK^6?09-1TJU\4>&]<M;6VM/$
M?AJZU+3CJ$-M9W-AJNCZQI^FZK9_Q/\ Q3_X-Q?^"H_@+Q1<Z'X,^%G@'XWZ
M''\]KXS^'GQ?^'6@Z-<1/'#*B2Z;\7M?^&7B:VO$\UK>ZB&ASVD=W;7*VU_>
M6GV2]N_]&VBN[+<_S#+*;HT)4JM%MRC2Q$)3A"4G>3@X3ISCS/5QY^3F;ER\
MTI-^7G/"F4YW5CB,3&O1Q*BHRKX6I"G4JQBK1C552G6ISY5I&7(IJ-H\[C&*
M7\)_[&W_  ;#?M&^-?%^CZY^VAXGT#X,?#>PN-%O]9\$>!?$6C>-OB9XFM)[
M2XNM3T"VUS1WU3P7X2N+*Y6RTR\UH7GBN-FFOI=*LKR&WMKRY_MP^%?PK^'?
MP0^'?A#X2_"7PAHW@/X<^ ]&M] \)^$] MS;Z;I.FVY>0JID>6ZO+V\NI;C4
M=6U;4;B[U;6]6N[[6-8OK[5+Z[NYO0**PS'-\;FDHO%5%R0UA1IQY*4&U9R4
M;R<I-?:G*4DFU%J+L=63\/Y9D<)QP-*7M*J2JXBM)5,14BG=0<U&,8P3L^2G
M"$6TI23DDS^2OX?_ /!!_P#;%O/^"I&F_MU_&SXC_LWZO\/Q^UEJ_P"TEJ/A
MKPUX]^,>L>-;.VM/'.H^/? F@:/:ZQ\*_#^G2?\ ",ZC#X9TVVL+SQ?'I5GI
M.E+99U/3[==-O/ZU***RQN88G,'1>(<+4*2HTHPBH1C".VB;N]DWU22Z'1EN
M4X/*HXF.$C43Q>(EB:\JM1U)2JR23=VE:.C:71RD^NGY]?\ !4;]FCXV_MB?
ML4_%;]FOX!^(O ?A/QM\4KKP3IM]X@^(GB#Q;X:T*Q\*:%XUT'Q=XAMH]1\&
M>&?%NK276MV_A^+P]/I\VC2Z;J&CZMJUM?2QI(JO\=_\$1/^"6_Q0_X)H> _
MCY9_&GQ#\,?%'Q#^,GB[P5<KJOPJ\2>,]?T%/!G@+1M;B\/Z??1^,/!7@:6R
MU>WUSQAXON97L--NX[NSO;);B^9K6*"#]R:*4,PQ%/ U<NBX+#5JJK5%R^_*
M<73:O.]^5.E!J-K75]PJ93@ZN:4,XG&I+&X:A+#T9<[]G"G)54[4[6YFJU1<
MU[VDUM9'S?\ M<?LO?#?]LS]GKXD_LY?%6.[3PE\1=(BLSJVEI9'7/#&MZ;>
MVVK>'?%.@27]M=VT.KZ#K-E9W]OYL#PW,<<UA=*]G>7,;_PB_&[_ (-L_P#@
MI1\./%%[IOPL\)> ?VAO"PO&32O%'@[XC>!_ MW/8-%YL5SK'AWXK^(_!DNE
MW8/[BYLM.U/Q!#%< _9[^\ML71_T2J*ZLLSO'94IPPSISI5)<\J5:$IPY[)<
M\>6=.<9-))VFDTE=.RMPYUPSEF>RIU,9&M3KTH^SCB,-.-.JZ=W)4Y<].K3G
M%2;<>:#<7*7*US._\('[(7_!L!^T]\0->T/7OVP_&?ACX!_#V+4(F\0>"/!7
MB#2/'_QEU.P@^S3W-EIVI:/!KGPM\,_VA'+-96GB*7Q#XUFTR\MYKFY\&:C:
M+;"^^H/VZO\ @V=^(?Q$^,ND:I^PUJ?[.WPD^!FD?#CPGX;B\+_$WQQ\4XO&
M%SXNTN75F\1>(-2O-'^%?CU]8?6_M-C=/J>J^);O4&N//LH;;3='LM)T^V_L
M?HKJEQ/F\L0L1[:G'EC*,:,:=J"4FFWR.3<I:64IRE**<E%I2=^*'!'#\,(\
M+]7JSYIPG/$SJWQ4G!-*/M%&,80?,W.%*%.,VHN2;C&W,Z"GBNU\':,FO_V3
MJ7CBW\,Z<FM&WOIH-#O_ !7#I<(U'R-2CT.VGATFZU=9O+OH_#4$T=G(LZZ'
M$X%@O\LO_!-C_@@_^UE^S3^WUX5_;'_:F^*OP"\?VWAJX^)_C*XM_ASXB\<:
M]XB\1_$WX@^'O$'A\:MJVF^+/@YX+T2"PMY?%VM^)3=:=JEK?6/B"QT66PM3
M LRQ_P!8%%>9ALPQ&$I8NC0<(PQM/V5>\$Y>SM./+"3U@FJDD[;Z7U2M[>-R
MC!YA7R_$8E59U,LK>WPR51QA[7FI34ZL5I4:E1@U?1>\MI,*_)O_ (+(?L5?
MM%?M^?LK:'^SU^SQXO\ ACX*OKWXL^&/&/Q O_BEK_B?0]&UGP9X7T7Q.UKX
M;M/^$5^'OC^_N+R?QE?^%O$'F-%I$=NOAH1FZN4NY+8_K)16&&Q%3"UZ6)I<
MOM*,U4ASQYHJ4?A;CI>SU7FDSJQF$I8["U\'7Y_8XBFZ57V<G";A*W-%26JY
ME[K[IM=3\F_^"-__  3V\9_\$X?V5M<^$'Q.\0>"/%7Q-\:?%GQ/\2_%FM?#
M^\U75/#,4-]HOACPKX>T72M6\0>$O!GB"ZL['1?"EOJ4]OJ6D!;/7-;UP6,\
MMI,C'XP_X+;_ /!)K]KG_@I7\3_@=K7P7^(WP*\,?#GX2> _$FE_V'\5O%'Q
M$T/5AXU\8>(8+OQ'JNF6OA'X9>.M-ETZ^T+P]X-M&GGO;&^:YTJ6.2U>".VE
M;^C.BNJGFF+I8^691E!XJ4IR<I03BG4BX2M'9>XW%6V6AP5LCP%;*H9+*-58
M&G&E!0A5E&<E1FJD>:>\KU(J<M-9:Z:6^7OV*?V>$_9._9,_9]_9T:YTZ^U+
MX4?##PUX:\2ZEH[SR:/JWC4V@U+QWK.D/=V6G7ATG6/&=_KNIZ;]MLK:^%C=
MP"\B%T)2?F/_ (*9_P#!+#X'_P#!2_X>Z)H_C74[OX;_ !;\"_:_^%:_&G0-
M(M]:U7P_:ZBZ/J?ASQ)X>GO](A\9>#;^:.*^;1)=8T;4--U6!+[0M>TA;W7+
M?6?T]HKGAB\32Q7URE5E3Q/M)U?:1LGSS;<VTTXM2YFI1:<9)M---HZZN7X.
MO@5EU:A"K@U1IT/83OR^SI1C&FDTU*,H*,7"<7&<))2C)229_G2?$_\ X-M_
M^"GW@75M1LO!W@7X8?&C3;695L-:\ _%OPCH4&J6\B6<BRQV7Q8N_AO?VDT(
MNYH;R"ZA1([G3=06SN+^U;3+O4]SX+_\&U7_  4A^(6O:+:_%#0OAM\ ?#=W
M=SIKFM>*_B'X6\<:MH]A;X)N;/0/AAJOBRVUB[O1QIUD=?TV%W&-3U#24Q)7
M^A_17T#XOS9PY.7"*5K>U5&?.G:U[.LZ=^NM-J_2VA\DO#W(55]HYY@X7O[!
MXBE[)J]^6ZPZK6Z:5E*WVKZGY\?\$Y/^"<GP9_X)N?!F^^&/PQOM4\6^)_%N
MJ0>(/B?\3_$$$=EK?CO6[*.YM]*_XE5O<W5CH&@:!8W4]EH.@V4]PEHEQ>WM
M[>ZEJVI:CJ-U^('_  4C_P""$G[7_P"WI^W[XR_:+3XI?L^^&O@9XDOOA=X>
MTW1;_P 6^/H?BAH7PZ\)^%_#&@^*?LUA8?!&^\,S^)=0U.U\6>(M$MM1\3:C
M:13ZM8Z9>:RMA:HMM_6-17D8?-L=AL76QT*JGBJ\)0J5:L5-VG*$FXK2,6O9
MQC&R2C%<L4HZ'T.,R#+,;@,/EE2C*G@<+4A4I4*$W2BI4XSBE)J\II^TG*?,
MVYSE[23<_>*]I:6EA:VUA86UO96-E;PVEG9VD,=M:VEI;1K#;VUM;PJD,%O!
M"B10PQ(D<4:*B*JJ /S;_P""M'[)/QM_;C_8Q\6_LU_ GQ#\//#/B7QQXQ\
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M-#^"?"'C:\U?46\9V7@N^M=)U71X]'"6$^KM?0ZKI.E13\Q_P1J_X)]>/O\
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M_@V<T77?A)^SSX _84U;X<^&/%O@"_\ B/>_&OXE?M!>,/&-KXH^+-QXLM_
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M)K;,,NP>:86>#QM%5J$VI6;<90G&_+4ISBU*%2-W:47JG*,DX2E%_P";-/\
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MBB:SFM);'1_'?CJ73=%M-)T.ZECO$UW3/!G]JW]_IIMX=/\ %VC7=W<2:?\
MV<45[>(XKS:O2=)/#T.9.+J4*<XU6FK.TJE2HHO^]!1DMXM/4^7PG 60X6M&
MM)8O%\DE*-+%5J<J*<7=<T*5&BZD;[PJ2G"2TE%IM&9HFB:-X:T;2/#GAS2-
M,T#P]H&F6&B:#H.B6%KI6C:)HVE6L5CI>D:1I=A%!8Z;IFFV,$%G86%G!#:V
M=K#%;V\4<,:(NG117S3;;;;NWJV]V^[/M$DDDDDDK)+1)+9)=$@HHHH&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC0:SX9UJ),P-J&CWMI+=6,MUI=_]KTJ^OK&Y_"+X@_\ !MY\(=5U*^N/A?\
MM*_$'P1ID\JR6.F^,_ WA_XC2V"%;4RP/J&D:Y\-FO(A*M]]E+VT4T-O/917
M$U[-97%UJ7])M%=-'%XG#JU&M*$;WY=)1N]WRR4HINVKM<\S'9-EF924\;@Z
M5::7*JEYTZO*MHNK1E3J.*N[1<FDVVDFS^;?X8?\&X'P>T+6(+WXN_M'^/?B
M-I-O=1W']B>"_ ^B_"X7D,6U_L6H:CJ7B+XEW36UQ(I2[?3ETR\:U=XK.[LK
MKR[V/]V/V?\ ]F_X*_LN^ ++X:_ WP#HO@7PQ;N+F]^P1-/K7B+4RNV76_%?
MB&[:?6?$VM2IB!=0UB]NY;6QBM=+L/LFE6-C8VWN%%%;%XG$*U:K*:7V=(QN
MNO+!1C?SM<,#DV69;)RP6#I49M.+J7G4J\KWBJM:52HHNRO%22=M@KR;XV?
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M !7X?_\ #@O]CS_A?/\ PT/_ ,+)_:5_X37_ (6Y_P +G_LO_A,?A=_PB_\
MPE'_  F7_"<?8/L7_"G/[6_L#^UO]'^R_P!M_P!H_P!G?NO[5^T_Z77[@45O
M1Q-?#\_L*LJ?M(\L^6WO15]'=/35_>SBQF78+'^R^N8:GB/82<Z/M$W[.;Y;
MRC9K5\L?N04445@=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<)J/_ "-VF_\ 7WI7_I1'7=UPFH_\C=IO_7WI7_I1'6U#XI_]
M>Y_D9U?A7^*/YGN=%%%<)H%%%% 'Y@?MZ?\ !)O]G3_@HAXR\">./C5XT^-7
MA?5OA[X9O_"FBV_PN\1^!=%TZZT[4-5?5YIM4B\6?#CQM<S7JW+E(I+2[LH%
M@PKVSR9E/T;^Q;^QQ\,?V%?@E:_ 7X2:[X\\1>$+3Q-X@\5QZE\1M3\/ZOXD
M;4?$<EM)?0O>>&?"_A#2S91-:QBTC71UG0,_G7,Y*E?K*BNB6+Q$Z$<-*K-X
M>#O"D[<L6G)W6E[WE+KU9Q0R[ T\94S"GAJ<<95BXU,0D_:3BU%-2=[6M""V
M^R@HHHKG.T**** /R@_;K_X(\?LS?\%!OBYX=^,WQF\<_'7PSXH\,_#G2/AC
M86'PQ\3> -%T";0-&\3>+_%5K=W=KXJ^&/C349-7DU'QIJD-Q<0ZI;V3V5OI
M\<>GQ3Q7%Q=?>?[./P&\(?LP? _X;_ +P#J7B35_!WPO\/KX;T#4O%]YI=_X
MFO+%;R[O1+K%YHNC^']+N+OS;R53)9:-I\/EK&/(#!G;VRBMYXK$5*-/#SJS
ME1I.].FVN6#LUHK=FU\SCI9?@J&*K8VCAJ=/%8A.->O%/GJ)N,FI.]M7"+T2
MV05^8'[>G_!)O]G3_@HAXR\">./C5XT^-7A?5OA[X9O_  IHMO\ "[Q'X%T7
M3KK3M0U5]7FFU2+Q9\./&US->K<N4BDM+NR@6#"O;/)F4_I_14T:]7#U%5H5
M)4ZD4TIQM=*2L[73W3:9>*PF&QU&6'Q=&%>A-Q<J4[N,G"2E%M)K:236NZ/G
M/]DO]F+P%^QM^S[X _9N^&.K^+]=\#_#G_A*O[#U7QY?Z-JGBNZ_X2_QMXD\
M>:E_:M]X?T#POI$_D:OXHU"VL?LFA6/E:;#9PW'VFZCGO+C)_:P_8U_9Z_;6
M^'B_#?\ :"\!V/BO3+*X-YX<U^V*:9XU\&7TEQ87%W>>#O%<,+:IH#ZH--L[
M76K>TD^PZW8P1V6K6E[;QQQI]144>WK*L\0JDU6<W5=5-J?M)-RE*ZMJVVW;
MNQO"89X58*5"E+"1I0H+#S@ITO8PBHPIN$KIQC&,4KWM9/=7/Y0_&?\ P:S>
M +[4(I?A[^V1XP\+Z4(L367C/X,:+X\U"2?"?O(M3T3XB?#FVABW"0^2^D3O
MAT7S\QLTOT1^SY_P;5_L@_#/Q-;^)OC9\0?B)^T5#89:T\&WL<'PR\#7<SQZ
MA&9O$%KX5U*]\8:G]E:;3+O3[:P\;Z)8_;-/N$UJTUW2]2?2[;^C2BN^>=9I
M.#A+&5%%JUXQIPG9_P#3R$(SOY\U_,\6GPGP[2JJM'*Z+FGS)5*F(JTKK_IS
M5K3HM?W73Y?(^$?VN_\ @G/^S7^V3\!?!G[.7CC1=5^&WPZ^'/B31O$WP_A^
M"4?A+P)>>"YM$TC5]!@T?PY:77A+Q!X9T[PW<Z1K=[9W>A1^'38MLL;FW2WO
M-.L;B#/_ &"/^"='P?\ ^"=OASXB^$O@QX]^,?B[PY\2=;T+Q'J6E?%;7/ ^
MMP:)K>BV-]IDNH>'7\(?#WP+/;RZY8W-A;:TNJ2ZO%(F@Z.=.CTUUU%M1^_J
M*X_K6)]A+#>VFZ$I<\J;=XN7,I<VMVGS)-V>KN^KOZO]FX%8N&/6%I+&0I^R
MA7C%QFJ:@Z:A[K47%0;BDT[*R6RMS/C3P7X3^(WA/Q%X#\>>'=(\7>#/%VD7
MV@>)O#.OV,&I:-KFC:E ]M?:=J-C<H\-Q;W$+LK*RY4[71DD567^=SX]?\&S
M_P"RG\0_$/B/Q'\%/BS\2?@(=;E6ZL/",NG:7\3O ?AFY*.MQ#HUAJ][X=\8
MOI4SB&YCL-3\=W\]K.UY';7\>GRV-AIG])-%5AL;BL&V\-7G2YK<R5G&36S<
M)*4&U:UW&]KK9M&>/RG+LTC&./PE+$\EU"4E*-2">ZA5IRA5BGNU&:3:3M=)
MK^3/P]_P:Q>%;:Z9_%?[:OB#6K,[=EOX>^ VF^&+I<1SAMUWJ7Q:\71/F5K9
MUQ9)MCBGB.YKB.:V_<?]BC_@F+^R/^P5;7UW\$_!-YJGCW5K<V.K?%WXC7>G
M^*OB==Z822^D6>MV^D:/IGAG2+EBCZGI?@[1/#MEK<MM83ZY#J4^FZ=):?H+
M16V(S3,,5!TZ^)G.#WA%0IQEY2C2C!26E[235]=SFP/#N2Y=55;!Y?2IUH_#
M5G*K7J0?>G+$5*KINUUS0<79M7LV@KS?XM_!_P"%WQX\ >(/A;\8_ GAOXC_
M  _\46K6FL^%_%.FPZCI\_RM]GOK5G N=*UG396%YHNOZ3<6.MZ%J45OJFC:
MA8ZC;6]U%Z117!&4HM2BW&46G&46TTUJFFM4T]4UJCV)PA4C*%2,9PG%QG"<
M5*,HM6<91DFI1:T::::T9_,?\8/^#8;]F[Q3K=_J?P7_ &@/BC\(M.O4>6'P
MYXG\/:'\5]*TF\=[XB/3+HZEX#UYM'A6334ALM8UC5]5_P!$O6GUZX.H0?V9
MYUX"_P"#6CX;Z=K4<_Q0_;#\;^,/#H:$RZ5X"^$.@_#?6G17)N%CU_Q#XZ^*
MMC$TL>U87;PW,('!=TN%(C7^K6BO46=YJH\BQD[6M=PI2E;_ !RIN=_/FOYG
MSTN$>')5/:O+*2E?FM&MB84[_P#7F-=4K?W>3EZ6L?(O[)'["_[,?[$'A._\
M*_L\_#;3_"\VMRK/XH\9:E*^O?$#Q:\;;K6#Q#XQU$2:M=:7IYW-I7A^VEL_
M#NE3SWMYIVDVM[J6IW-Y]=445YM2I4JSE4JSE4G)WE.<G*4GYR;;?;TT/>HT
M*.&I0HX>E3H4::M"E2A&G"*WM&,4DKN[>FK;;U84445!J?G9^W[_ ,$S?@9_
MP4:@^%5K\;?&GQC\*6WPAF\:W'AZV^%/B/P?H4&J3^.D\*1ZE/XBA\6^ O'$
M=[-IT?A&SCT62Q73'LTU'65G:\6\B%M^</\ Q#&_L%_]%;_:[_\ "]^#7_S@
MJ_HQHKMHYECL/3C2HXFI3IPORPBU9<TG)VTZR;;\V>3BLAR?&UYXG%8"A7KU
M.7GJS4G*7)"-.-[22]V$8Q6FR1_.=_Q#&_L%_P#16_VN_P#PO?@U_P#."H_X
MAC?V"_\ HK?[7?\ X7OP:_\ G!5_1C16O]L9G_T&UOO7^1S_ .J_#_\ T*L+
M_P" R_\ DC\-/V>/^#?_ /8W_9I^-OPU^/7@3XE_M,ZMXO\ A;XFM/%?A_3?
M%OC+X67_ (;O-1LXYHXH=9L]'^#.@ZI<63+,YDCLM8T^<D+MN5 (/[ET45R8
MC%8C%2C/$59591CRQE.UU&[=E9+2[;^9Z6"R_!9=3G2P.'IX:G4G[2<*::4I
M\JCS.[>O+%+T2"BBBL#L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O,OA7_R-VK?]@J__P#3GIU>FUYE\*_^1NU;_L%7_P#Z<].K:/\
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MU_XCT33=2U?P[XZT7P["/#EOJ5[I.O:5XATC2O">@W;^%+719=:G_FT\-?\
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ML!7Q1X9^)&L:#X:TS4+20RB1=#\<^([2[M(X+V*:WN[F72+'E?@O_P &U/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5?\ PH%_^AK7_P $A_\ EO1_PH%_^AK7_P $A_\ EO1_Q#C$?]!53_P7A_\
MYI#_ %OSO_HGJ7_AQI>7]W^ODS_54_X:3_9T_P"B^_!7_P .GX&_^7M'_#2?
M[.G_ $7WX*_^'3\#?_+VO\JO_A0+_P#0UK_X)#_\MZ/^% O_ -#6O_@D/_RW
MH_XAQB/^@JI_X+P__P TA_K?G?\ T3U+_P .-+R_N_U\F?ZJG_#2?[.G_1??
M@K_X=/P-_P#+VC_AI/\ 9T_Z+[\%?_#I^!O_ )>U_E5_\*!?_H:U_P#!(?\
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M2SL[3XF^ ;:UM+2VC6&WMK:WAUM(8+>"%$BAAB1(XHT5$554 6/^&D_V=/\
MHOOP5_\ #I^!O_E[7^57_P *!?\ Z&M?_!(?_EO1_P *!?\ Z&M?_!(?_EO7
M)_Q#C$?]!53_ ,%X?_YI/07%^=Z?\8]2Z?\ ,QI+M_=T_3Y,_P!53_AI/]G3
M_HOOP5_\.GX&_P#E[1_PTG^SI_T7WX*_^'3\#?\ R]K_ "J_^% O_P!#6O\
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M_P"(<8C_ *"JG_@O#_\ S2'^M^=_]$]2_P##C2\O[O\ 7R9_JJ?\-)_LZ?\
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M/^B^_!7_ ,.GX&_^7M?Y5?\ PH%_^AK7_P $A_\ EO1_PH%_^AK7_P $A_\
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M^% O_P!#6O\ X)#_ /+>C_A0+_\ 0UK_ ."0_P#RWH_XAQB/^@JI_P""\/\
M_-(?ZWYW_P!$]2_\.-+R_N_U\F?ZJG_#2?[.G_1??@K_ .'3\#?_ "]H_P"&
MD_V=/^B^_!7_ ,.GX&_^7M?Y5?\ PH%_^AK7_P $A_\ EO1_PH%_^AK7_P $
MA_\ EO1_Q#C$?]!53_P7A_\ YI#_ %OSO_HGJ7_AQI>7]W^ODS_54_X:3_9T
M_P"B^_!7_P .GX&_^7M'_#2?[.G_ $7WX*_^'3\#?_+VO\JO_A0+_P#0UK_X
M)#_\MZ/^% O_ -#6O_@D/_RWH_XAQB/^@JI_X+P__P TA_K?G?\ T3U+_P .
M-+R_N_U\F?ZJG_#2?[.G_1??@K_X=/P-_P#+VC_AI/\ 9T_Z+[\%?_#I^!O_
M )>U_E5_\*!?_H:U_P#!(?\ Y;T?\*!?_H:U_P#!(?\ Y;T?\0XQ'_054_\
M!>'_ /FD/];\[_Z)ZE_X<:7E_=_KY,_U5/\ AI/]G3_HOOP5_P##I^!O_E[1
M_P -)_LZ?]%]^"O_ (=/P-_\O:_RJ_\ A0+_ /0UK_X)#_\ +>C_ (4"_P#T
M-:_^"0__ "WH_P"(<8C_ *"JG_@O#_\ S2'^M^=_]$]2_P##C2\O[O\ 7R9_
MJJ?\-)_LZ?\ 1??@K_X=/P-_\O:/^&D_V=/^B^_!7_PZ?@;_ .7M?Y5?_"@7
M_P"AK7_P2'_Y;T?\*!?_ *&M?_!(?_EO1_Q#C$?]!53_ ,%X?_YI#_6_._\
MHGJ7_AQI>7]W^ODS_54_X:3_ &=/^B^_!7_PZ?@;_P"7M'_#2?[.G_1??@K_
M .'3\#?_ "]K_*K_ .% O_T-:_\ @D/_ ,MZ/^% O_T-:_\ @D/_ ,MZ/^(<
M8C_H*J?^"\/_ /-(?ZWYW_T3U+_PXTO+^[_7R9_JJ?\ #2?[.G_1??@K_P"'
M3\#?_+VC_AI/]G3_ *+[\%?_  Z?@;_Y>U_E5_\ "@7_ .AK7_P2'_Y;T?\
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M_P#T-:_^"0__ "WH_P"(<8C_ *"JG_@O#_\ S2'^M^=_]$]2_P##C2\O[O\
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M7E_=_KY,_P!53_AI/]G3_HOOP5_\.GX&_P#E[1_PTG^SI_T7WX*_^'3\#?\
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M_P#0UK_X)#_\MZ/^% O_ -#6O_@D/_RWH_XAQB/^@JI_X+P__P TA_K?G?\
MT3U+_P .-+R_N_U\F?ZJG_#2?[.G_1??@K_X=/P-_P#+VC_AI/\ 9T_Z+[\%
M?_#I^!O_ )>U_E5_\*!?_H:U_P#!(?\ Y;T?\*!?_H:U_P#!(?\ Y;T?\0XQ
M'_054_\ !>'_ /FD/];\[_Z)ZE_X<:7E_=_KY,_U5/\ AI/]G3_HOOP5_P##
MI^!O_E[1_P -)_LZ?]%]^"O_ (=/P-_\O:_RJ_\ A0+_ /0UK_X)#_\ +>C_
M (4"_P#T-:_^"0__ "WH_P"(<8C_ *"JG_@O#_\ S2'^M^=_]$]2_P##C2\O
M[O\ 7R9_JJ?\-)_LZ?\ 1??@K_X=/P-_\O:/^&D_V=/^B^_!7_PZ?@;_ .7M
M?Y5?_"@7_P"AK7_P2'_Y;T?\*!?_ *&M?_!(?_EO1_Q#C$?]!53_ ,%X?_YI
M#_6_._\ HGJ7_AQI>7]W^ODS_54_X:3_ &=/^B^_!7_PZ?@;_P"7M'_#2?[.
MG_1??@K_ .'3\#?_ "]K_*K_ .% O_T-:_\ @D/_ ,MZ/^% O_T-:_\ @D/_
M ,MZ/^(<8C_H*J?^"\/_ /-(?ZWYW_T3U+_PXTO+^[_7R9_JJ?\ #2?[.G_1
M??@K_P"'3\#?_+VC_AI/]G3_ *+[\%?_  Z?@;_Y>U_E5_\ "@7_ .AK7_P2
M'_Y;T?\ "@7_ .AK7_P2'_Y;T?\ $.,1_P!!53_P7A__ )I#_6_._P#HGJ7_
M (<:7E_=_KY,_P!53_AI/]G3_HOOP5_\.GX&_P#E[1_PTG^SI_T7WX*_^'3\
M#?\ R]K_ "J_^% O_P!#6O\ X)#_ /+>C_A0+_\ 0UK_ ."0_P#RWH_XAQB/
M^@JI_P""\/\ _-(?ZWYW_P!$]2_\.-+R_N_U\F?ZJG_#2?[.G_1??@K_ .'3
M\#?_ "]H_P"&D_V=/^B^_!7_ ,.GX&_^7M?Y5?\ PH%_^AK7_P $A_\ EO1_
MPH%_^AK7_P $A_\ EO1_Q#C$?]!53_P7A_\ YI#_ %OSO_HGJ7_AQI>7]W^O
MDS_54_X:3_9T_P"B^_!7_P .GX&_^7M'_#2?[.G_ $7WX*_^'3\#?_+VO\JO
M_A0+_P#0UK_X)#_\MZ/^% O_ -#6O_@D/_RWH_XAQB/^@JI_X+P__P TA_K?
MG?\ T3U+_P .-+R_N_U\F?ZJG_#2?[.G_1??@K_X=/P-_P#+VC_AI/\ 9T_Z
M+[\%?_#I^!O_ )>U_E5_\*!?_H:U_P#!(?\ Y;T?\*!?_H:U_P#!(?\ Y;T?
M\0XQ'_054_\ !>'_ /FD/];\[_Z)ZE_X<:7E_=_KY,_U5/\ AI/]G3_HOOP5
M_P##I^!O_E[1_P -)_LZ?]%]^"O_ (=/P-_\O:_RJ_\ A0+_ /0UK_X)#_\
M+>C_ (4"_P#T-:_^"0__ "WH_P"(<8C_ *"JG_@O#_\ S2'^M^=_]$]2_P##
MC2\O[O\ 7R9_JJ?\-)_LZ?\ 1??@K_X=/P-_\O:/^&D_V=/^B^_!7_PZ?@;_
M .7M?Y5?_"@7_P"AK7_P2'_Y;T?\*!?_ *&M?_!(?_EO1_Q#C$?]!53_ ,%X
M?_YI#_6_._\ HGJ7_AQI>7]W^ODS_54_X:3_ &=/^B^_!7_PZ?@;_P"7M'_#
M2?[.G_1??@K_ .'3\#?_ "]K_*K_ .% O_T-:_\ @D/_ ,MZ/^% O_T-:_\
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M .'3\#?_ "]H_P"&D_V=/^B^_!7_ ,.GX&_^7M?Y5?\ PH%_^AK7_P $A_\
MEO1_PH%_^AK7_P $A_\ EO1_Q#C$?]!53_P7A_\ YI#_ %OSO_HGJ7_AQI>7
M]W^ODS_54_X:3_9T_P"B^_!7_P .GX&_^7M'_#2?[.G_ $7WX*_^'3\#?_+V
MO\JO_A0+_P#0UK_X)#_\MZ/^% O_ -#6O_@D/_RWH_XAQB/^@JI_X+P__P T
MA_K?G?\ T3U+_P .-+R_N_U\F?ZJG_#2?[.G_1??@K_X=/P-_P#+VC_AI/\
M9T_Z+[\%?_#I^!O_ )>U_E5_\*!?_H:U_P#!(?\ Y;T?\*!?_H:U_P#!(?\
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M:_\ @D/_ ,MZ/^(<8C_H*J?^"\/_ /-(?ZWYW_T3U+_PXTO+^[_7R9_JJ?\
M#2?[.G_1??@K_P"'3\#?_+VC_AI/]G3_ *+[\%?_  Z?@;_Y>U_E5_\ "@7_
M .AK7_P2'_Y;T?\ "@7_ .AK7_P2'_Y;T?\ $.,1_P!!53_P7A__ )I#_6_.
M_P#HGJ7_ (<:7E_=_KY,_P!53_AI/]G3_HOOP5_\.GX&_P#E[1_PTG^SI_T7
MWX*_^'3\#?\ R]K_ "J_^% O_P!#6O\ X)#_ /+>C_A0+_\ 0UK_ ."0_P#R
MWH_XAQB/^@JI_P""\/\ _-(?ZWYW_P!$]2_\.-+R_N_U\F?ZJG_#2?[.G_1?
M?@K_ .'3\#?_ "]H_P"&D_V=/^B^_!7_ ,.GX&_^7M?Y5?\ PH%_^AK7_P $
MA_\ EO1_PH%_^AK7_P $A_\ EO1_Q#C$?]!53_P7A_\ YI#_ %OSO_HGJ7_A
MQI>7]W^ODS_54_X:3_9T_P"B^_!7_P .GX&_^7M'_#2?[.G_ $7WX*_^'3\#
M?_+VO\JO_A0+_P#0UK_X)#_\MZ/^% O_ -#6O_@D/_RWH_XAQB/^@JI_X+P_
M_P TA_K?G?\ T3U+_P .-+R_N_U\F?ZJG_#2?[.G_1??@K_X=/P-_P#+VC_A
MI/\ 9T_Z+[\%?_#I^!O_ )>U_E5_\*!?_H:U_P#!(?\ Y;T?\*!?_H:U_P#!
M(?\ Y;T?\0XQ'_054_\ !>'_ /FD/];\[_Z)ZE_X<:7E_=_KY,_U5/\ AI/]
MG3_HOOP5_P##I^!O_E[1_P -)_LZ?]%]^"O_ (=/P-_\O:_RJ_\ A0+_ /0U
MK_X)#_\ +>C_ (4"_P#T-:_^"0__ "WH_P"(<8C_ *"JG_@O#_\ S2'^M^=_
M]$]2_P##C2\O[O\ 7R9_JJ?\-)_LZ?\ 1??@K_X=/P-_\O:/^&D_V=/^B^_!
M7_PZ?@;_ .7M?Y5?_"@7_P"AK7_P2'_Y;T?\*!?_ *&M?_!(?_EO1_Q#C$?]
M!53_ ,%X?_YI#_6_._\ HGJ7_AQI>7]W^ODS_54_X:3_ &=/^B^_!7_PZ?@;
M_P"7M'_#2?[.G_1??@K_ .'3\#?_ "]K_*K_ .% O_T-:_\ @D/_ ,MZ/^%
MO_T-:_\ @D/_ ,MZ/^(<8C_H*J?^"\/_ /-(?ZWYW_T3U+_PXTO+^[_7R9_J
MJ?\ #2?[.G_1??@K_P"'3\#?_+VC_AI/]G3_ *+[\%?_  Z?@;_Y>U_E5_\
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M_P#!(?\ Y;T?\0XQ'_054_\ !>'_ /FD/];\[_Z)ZE_X<:7E_=_KY,_U5/\
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M5/\ AI/]G3_HOOP5_P##I^!O_E[1_P -)_LZ?]%]^"O_ (=/P-_\O:_RJ_\
MA0+_ /0UK_X)#_\ +>C_ (4"_P#T-:_^"0__ "WH_P"(<8C_ *"JG_@O#_\
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M[1_PTG^SI_T7WX*_^'3\#?\ R]K_ "J_^% O_P!#6O\ X)#_ /+>C_A0+_\
M0UK_ ."0_P#RWH_XAQB/^@JI_P""\/\ _-(?ZWYW_P!$]2_\.-+R_N_U\F?Z
MJG_#2?[.G_1??@K_ .'3\#?_ "]H_P"&D_V=/^B^_!7_ ,.GX&_^7M?Y5?\
MPH%_^AK7_P $A_\ EO1_PH%_^AK7_P $A_\ EO1_Q#C$?]!53_P7A_\ YI#_
M %OSO_HGJ7_AQI>7]W^ODS_54_X:3_9T_P"B^_!7_P .GX&_^7M?&/\ P4:^
M/_P'US_@G_\ ML:-HOQL^$>KZQJO[*WQZT[2]*TOXD>#=0U+4M0O/AEXEM[2
MQL+&TUF:ZO+RZGDC@MK:WBDGGF=(XD9V53_F\_\ "@7_ .AK7_P2'_Y;T?\
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M4?\ "^?@;_T6;X4?^'$\(?\ RXK_ #L/^% O_P!#6O\ X)#_ /+>C_A0+_\
M0UK_ ."0_P#RWK#_ %1Q7\TO_*'_ ,O.[_63._\ H14O_"^E_EY_GV9_HG_\
M+Y^!O_19OA1_X<3PA_\ +BC_ (7S\#?^BS?"C_PXGA#_ .7%?YV'_"@7_P"A
MK7_P2'_Y;T?\*!?_ *&M?_!(?_EO1_JCBOYI?^4/_EX?ZR9W_P!"*E_X7TO\
MO/\ /LS_ $3_ /A?/P-_Z+-\*/\ PXGA#_Y<4?\ "^?@;_T6;X4?^'$\(?\
MRXK_ #L/^% O_P!#6O\ X)#_ /+>C_A0+_\ 0UK_ ."0_P#RWH_U1Q7\TO\
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MS2_\H?\ R\/]9,[_ .A%2_\ "^E_EY_GV9_HG_\ "^?@;_T6;X4?^'$\(?\
MRXH_X7S\#?\ HLWPH_\ #B>$/_EQ7^=A_P *!?\ Z&M?_!(?_EO1_P *!?\
MZ&M?_!(?_EO1_JCBOYI?^4/_ )>'^LF=_P#0BI?^%]+_ "\_S[,_T3_^%\_
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M/_X7S\#?^BS?"C_PXGA#_P"7%'_"^?@;_P!%F^%'_AQ/"'_RXK_.P_X4"_\
MT-:_^"0__+>C_A0+_P#0UK_X)#_\MZ/]4<5_-+_RA_\ +P_UDSO_ *$5+_PO
MI?Y>?Y]F?Z)__"^?@;_T6;X4?^'$\(?_ "XH_P"%\_ W_HLWPH_\.)X0_P#E
MQ7^=A_PH%_\ H:U_\$A_^6]'_"@7_P"AK7_P2'_Y;T?ZHXK^:7_E#_Y>'^LF
M=_\ 0BI?^%]+_+S_ #[,_P!$_P#X7S\#?^BS?"C_ ,.)X0_^7%'_  OGX&_]
M%F^%'_AQ/"'_ ,N*_P [#_A0+_\ 0UK_ ."0_P#RWH_X4"__ $-:_P#@D/\
M\MZ/]4<5_-+_ ,H?_+P_UDSO_H14O_"^E_EY_GV9_HG_ /"^?@;_ -%F^%'_
M (<3PA_\N*/^%\_ W_HLWPH_\.)X0_\ EQ7^=A_PH%_^AK7_ ,$A_P#EO1_P
MH%_^AK7_ ,$A_P#EO1_JCBOYI?\ E#_Y>'^LF=_]"*E_X7TO\O/\^S/]$_\
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M_A0+_P#0UK_X)#_\MZ/^% O_ -#6O_@D/_RWH_U1Q7\TO_*'_P O#_63._\
MH14O_"^E_EY_GV9_HG_\+Y^!O_19OA1_X<3PA_\ +BC_ (7S\#?^BS?"C_PX
MGA#_ .7%?YV'_"@7_P"AK7_P2'_Y;T?\*!?_ *&M?_!(?_EO1_JCBOYI?^4/
M_EX?ZR9W_P!"*E_X7TO\O/\ /LS_ $3_ /A?/P-_Z+-\*/\ PXGA#_Y<4?\
M"^?@;_T6;X4?^'$\(?\ RXK_ #L/^% O_P!#6O\ X)#_ /+>C_A0+_\ 0UK_
M ."0_P#RWH_U1Q7\TO\ RA_\O#_63._^A%2_\+Z7^7G^?9G^B?\ \+Y^!O\
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M -%P^$'_ (<OP9_\NJ/^&A/@'_T7#X0?^'+\&?\ RZK_ #2/^% O_P!#6O\
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M>7]W^ODS_2W_ .&A/@'_ -%P^$'_ (<OP9_\NJ/^&A/@'_T7#X0?^'+\&?\
MRZK_ #2/^% O_P!#6O\ X)#_ /+>C_A0+_\ 0UK_ ."0_P#RWH_U&Q/_ #]G
M_P" T/\ Y>'^M>=_]""E_P"'&EY?W?Z^3/\ 2W_X:$^ ?_1</A!_X<OP9_\
M+JC_ (:$^ ?_ $7#X0?^'+\&?_+JO\TC_A0+_P#0UK_X)#_\MZ/^% O_ -#6
MO_@D/_RWH_U&Q/\ S]G_ . T/_EX?ZUYW_T(*7_AQI>7]W^ODS_2W_X:$^ ?
M_1</A!_X<OP9_P#+JC_AH3X!_P#1</A!_P"'+\&?_+JO\TC_ (4"_P#T-:_^
M"0__ "WH_P"% O\ ]#6O_@D/_P MZ/\ 4;$_\_9_^ T/_EX?ZUYW_P!""E_X
M<:7E_=_KY,_TM_\ AH3X!_\ 1</A!_X<OP9_\NJ/^&A/@'_T7#X0?^'+\&?_
M "ZK_-(_X4"__0UK_P""0_\ RWH_X4"__0UK_P""0_\ RWH_U&Q/_/V?_@-#
M_P"7A_K7G?\ T(*7_AQI>7]W^ODS_2W_ .&A/@'_ -%P^$'_ (<OP9_\NJ/^
M&A/@'_T7#X0?^'+\&?\ RZK_ #2/^% O_P!#6O\ X)#_ /+>C_A0+_\ 0UK_
M ."0_P#RWH_U&Q/_ #]G_P" T/\ Y>'^M>=_]""E_P"'&EY?W?Z^3/\ 2W_X
M:$^ ?_1</A!_X<OP9_\ +JC_ (:$^ ?_ $7#X0?^'+\&?_+JO\TC_A0+_P#0
MUK_X)#_\MZ/^% O_ -#6O_@D/_RWH_U&Q/\ S]G_ . T/_EX?ZUYW_T(*7_A
MQI>7]W^ODS_2W_X:$^ ?_1</A!_X<OP9_P#+JC_AH3X!_P#1</A!_P"'+\&?
M_+JO\TC_ (4"_P#T-:_^"0__ "WH_P"% O\ ]#6O_@D/_P MZ/\ 4;$_\_9_
M^ T/_EX?ZUYW_P!""E_X<:7E_=_KY,_TM_\ AH3X!_\ 1</A!_X<OP9_\NJ/
M^&A/@'_T7#X0?^'+\&?_ "ZK_-(_X4"__0UK_P""0_\ RWH_X4"__0UK_P""
M0_\ RWH_U&Q/_/V?_@-#_P"7A_K7G?\ T(*7_AQI>7]W^ODS_2W_ .&A/@'_
M -%P^$'_ (<OP9_\NJ/^&A/@'_T7#X0?^'+\&?\ RZK_ #2/^% O_P!#6O\
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M>7]W^ODS_2W_ .&A/@'_ -%P^$'_ (<OP9_\NJ/^&A/@'_T7#X0?^'+\&?\
MRZK_ #2/^% O_P!#6O\ X)#_ /+>C_A0+_\ 0UK_ ."0_P#RWH_U&Q/_ #]G
M_P" T/\ Y>'^M>=_]""E_P"'&EY?W?Z^3/\ 2W_X:$^ ?_1</A!_X<OP9_\
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M2_\ #C2\O[O]?)G^G5_PT7^SY_T7;X-_^'/\$_\ R\H_X:+_ &?/^B[?!O\
M\.?X)_\ EY7^8K_PH%_^AK7_ ,$A_P#EO1_PH%_^AK7_ ,$A_P#EO1_J%B/^
M?U3_ ,!H?_+_ %_I:G^M>=_]""E_X<:7E_=_KY,_TZO^&B_V?/\ HNWP;_\
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M ."0_P#RWH_U"Q'_ #^J?^ T/_E_K_2U/]:\[_Z$%+_PXTO+^[_7R9_IU?\
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M]W^ODS_3J_X:+_9\_P"B[?!O_P .?X)_^7E'_#1?[/G_ $7;X-_^'/\ !/\
M\O*_S%?^% O_ -#6O_@D/_RWH_X4"_\ T-:_^"0__+>C_4+$?\_JG_@-#_Y?
MZ_TM3_6O._\ H04O_#C2\O[O]?)G^G5_PT7^SY_T7;X-_P#AS_!/_P O*/\
MAHO]GS_HNWP;_P##G^"?_EY7^8K_ ,*!?_H:U_\ !(?_ );T?\*!?_H:U_\
M!(?_ );T?ZA8C_G]4_\  :'_ ,O]?Z6I_K7G?_0@I?\ AQI>7]W^ODS_ $ZO
M^&B_V?/^B[?!O_PY_@G_ .7E'_#1?[/G_1=O@W_X<_P3_P#+RO\ ,5_X4"__
M $-:_P#@D/\ \MZ/^% O_P!#6O\ X)#_ /+>C_4+$?\ /ZI_X#0_^7^O]+4_
MUKSO_H04O_#C2\O[O]?)G^G5_P -%_L^?]%V^#?_ (<_P3_\O*/^&B_V?/\
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MX)_^7E'_  T7^SY_T7;X-_\ AS_!/_R\K_,5_P"% O\ ]#6O_@D/_P MZ/\
MA0+_ /0UK_X)#_\ +>C_ %"Q'_/ZI_X#0_\ E_K_ $M3_6O._P#H04O_  XT
MO+^[_7R9_IU?\-%_L^?]%V^#?_AS_!/_ ,O*/^&B_P!GS_HNWP;_ /#G^"?_
M )>5_F*_\*!?_H:U_P#!(?\ Y;T?\*!?_H:U_P#!(?\ Y;T?ZA8C_G]4_P#
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M%V^#?_AS_!/_ ,O*_P Q7_A0+_\ 0UK_ ."0_P#RWH_X4"__ $-:_P#@D/\
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M_P"7^O\ 2U/]:\[_ .A!2_\ #C2\O[O]?)G^G5_PT7^SY_T7;X-_^'/\$_\
MR\KSCX8_M!? 2W\5:I+/\;OA#!$^EWJI)-\2O!D2,S:EI[ *[ZTJL2H+  DD
M D< U_FN?\*!?_H:U_\ !(?_ );TYO@!@+M\6Y)'S!M!VA3QPI&M,6&<\D)T
M!QS@4N!<2J=6G[:?[V*BWRT-+:W2]OJ2^*<[DXR_L"E[KV_M"EK>WEI_5]F?
MZCO_  T?^SQ_T7GX,?\ AT? _P#\O*/^&C_V>/\ HO/P8_\ #H^!_P#Y>5_E
MP?\ "@7_ .AK7_P2'_Y;T?\ "@7_ .AK7_P2'_Y;UR_\0[Q'_014_P# ,/\
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M7_AQI>7]W^ODS_4?_P"&C_V>/^B\_!C_ ,.CX'_^7E'_  T?^SQ_T7GX,?\
MAT? _P#\O*_RX/\ A0+_ /0UK_X)#_\ +>C_ (4"_P#T-:_^"0__ "WH_P"(
M=XC_ *"*G_@&'_\ F@/]:\[_ .A!2_\ #C2\O[O]?)G^H_\ \-'_ +/'_1>?
M@Q_X='P/_P#+RC_AH_\ 9X_Z+S\&/_#H^!__ )>5_EP?\*!?_H:U_P#!(?\
MY;T?\*!?_H:U_P#!(?\ Y;T?\0[Q'_014_\  ,/_ /- ?ZUYW_T(*7_AQI>7
M]W^ODS_4?_X:/_9X_P"B\_!C_P .CX'_ /EY1_PT?^SQ_P!%Y^#'_AT? _\
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M8_\ #H^!_P#Y>5_EP?\ "@7_ .AK7_P2'_Y;T?\ "@7_ .AK7_P2'_Y;T?\
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M\*!?_H:U_P#!(?\ Y;T?\*!?_H:U_P#!(?\ Y;T?\0[Q'_014_\  ,/_ /-
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M0+_]#6O_ ()#_P#+>C_A0+_]#6O_ ()#_P#+>C_B'>(_Z"*G_@&'_P#F@/\
M6O._^A!2_P##C2\O[O\ 7R9_J/\ _#1_[/'_ $7GX,?^'1\#_P#R\H_X:/\
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M\%X?_P":0_UOSO\ Z)ZE_P"'&EY?W?Z^3/\ 54_X:3_9T_Z+[\%?_#I^!O\
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MGX&_^7M?Y5?_  H%_P#H:U_\$A_^6]'_  H%_P#H:U_\$A_^6]'_ !#C$?\
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MI_T7WX*_^'3\#?\ R]H_X:3_ &=/^B^_!7_PZ?@;_P"7M?Y5?_"@7_Z&M?\
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M_P"'3\#?_+VO\JO_ (4"_P#T-:_^"0__ "WH_P"% O\ ]#6O_@D/_P MZ/\
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M ."0_P#RWH_X4"__ $-:_P#@D/\ \MZ/^(<8C_H*J?\ @O#_ /S2'^M^=_\
M1/4O_#C2\O[O]?)G^JI_PTG^SI_T7WX*_P#AT_ W_P O:/\ AI/]G3_HOOP5
M_P##I^!O_E[7^57_ ,*!?_H:U_\ !(?_ );T?\*!?_H:U_\ !(?_ );T?\0X
MQ'_054_\%X?_ .:0_P!;\[_Z)ZE_X<:7E_=_KY,_U5/^&D_V=/\ HOOP5_\
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M:3_9T_Z+[\%?_#I^!O\ Y>T?\-)_LZ?]%]^"O_AT_ W_ ,O:_P JO_A0+_\
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M:U_\$A_^6]'_ !#C$?\ 054_\%X?_P":0_UOSO\ Z)ZE_P"'&EY?W?Z^3/\
M54_X:3_9T_Z+[\%?_#I^!O\ Y>T?\-)_LZ?]%]^"O_AT_ W_ ,O:_P JO_A0
M+_\ 0UK_ ."0_P#RWH_X4"__ $-:_P#@D/\ \MZ/^(<8C_H*J?\ @O#_ /S2
M'^M^=_\ 1/4O_#C2\O[O]?)G^JI_PTG^SI_T7WX*_P#AT_ W_P O:/\ AI/]
MG3_HOOP5_P##I^!O_E[7^57_ ,*!?_H:U_\ !(?_ );T?\*!?_H:U_\ !(?_
M );T?\0XQ'_054_\%X?_ .:0_P!;\[_Z)ZE_X<:7E_=_KY,_U5/^&D_V=/\
MHOOP5_\ #I^!O_E[1_PTG^SI_P!%]^"O_AT_ W_R]K_*K_X4"_\ T-:_^"0_
M_+>C_A0+_P#0UK_X)#_\MZ/^(<8C_H*J?^"\/_\ -(?ZWYW_ -$]2_\ #C2\
MO[O]?)G^JI_PTG^SI_T7WX*_^'3\#?\ R]H_X:3_ &=/^B^_!7_PZ?@;_P"7
MM?Y5?_"@7_Z&M?\ P2'_ .6]'_"@7_Z&M?\ P2'_ .6]'_$.,1_T%5/_  7A
M_P#YI#_6_._^B>I?^'&EY?W?Z^3/]53_ (:3_9T_Z+[\%?\ PZ?@;_Y>T?\
M#2?[.G_1??@K_P"'3\#?_+VO\JO_ (4"_P#T-:_^"0__ "WH_P"% O\ ]#6O
M_@D/_P MZ/\ B'&(_P"@JI_X+P__ ,TA_K?G?_1/4O\ PXTO+^[_ %\F?ZJG
M_#2?[.G_ $7WX*_^'3\#?_+VC_AI/]G3_HOOP5_\.GX&_P#E[7^57_PH%_\
MH:U_\$A_^6]'_"@7_P"AK7_P2'_Y;T?\0XQ'_054_P#!>'_^:0_UOSO_ *)Z
ME_X<:7E_=_KY,_U5/^&D_P!G3_HOOP5_\.GX&_\ E[1_PTG^SI_T7WX*_P#A
MT_ W_P O:_RJ_P#A0+_]#6O_ ()#_P#+>C_A0+_]#6O_ ()#_P#+>C_B'&(_
MZ"JG_@O#_P#S2'^M^=_]$]2_\.-+R_N_U\F?ZJG_  TG^SI_T7WX*_\ AT_
MW_R]H_X:3_9T_P"B^_!7_P .GX&_^7M?Y5?_  H%_P#H:U_\$A_^6]'_  H%
M_P#H:U_\$A_^6]'_ !#C$?\ 054_\%X?_P":0_UOSO\ Z)ZE_P"'&EY?W?Z^
M3/\ 54_X:3_9T_Z+[\%?_#I^!O\ Y>T?\-)_LZ?]%]^"O_AT_ W_ ,O:_P J
MO_A0+_\ 0UK_ ."0_P#RWH_X4"__ $-:_P#@D/\ \MZ/^(<8C_H*J?\ @O#_
M /S2'^M^=_\ 1/4O_#C2\O[O]?)G^JI_PTG^SI_T7WX*_P#AT_ W_P O:/\
MAI/]G3_HOOP5_P##I^!O_E[7^57_ ,*!?_H:U_\ !(?_ );T?\*!?_H:U_\
M!(?_ );T?\0XQ'_054_\%X?_ .:0_P!;\[_Z)ZE_X<:7E_=_KY,_U5/^&D_V
M=/\ HOOP5_\ #I^!O_E[1_PTG^SI_P!%]^"O_AT_ W_R]K_*K_X4"_\ T-:_
M^"0__+>C_A0+_P#0UK_X)#_\MZ/^(<8C_H*J?^"\/_\ -(?ZWYW_ -$]2_\
M#C2\O[O]?)G^JI_PTG^SI_T7WX*_^'3\#?\ R]H_X:3_ &=/^B^_!7_PZ?@;
M_P"7M?Y5?_"@7_Z&M?\ P2'_ .6]'_"@7_Z&M?\ P2'_ .6]'_$.,1_T%5/_
M  7A_P#YI#_6_._^B>I?^'&EY?W?Z^3/]53_ (:3_9T_Z+[\%?\ PZ?@;_Y>
MT?\ #2?[.G_1??@K_P"'3\#?_+VO\JO_ (4"_P#T-:_^"0__ "WH_P"% O\
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M'&(_Z"JG_@O#_P#S2'^M^=_]$]2_\.-+R_N_U\F?ZJG_  TG^SI_T7WX*_\
MAT_ W_R]H_X:3_9T_P"B^_!7_P .GX&_^7M?Y5?_  H%_P#H:U_\$A_^6]'_
M  H%_P#H:U_\$A_^6]'_ !#C$?\ 054_\%X?_P":0_UOSO\ Z)ZE_P"'&EY?
MW?Z^3/\ 54_X:3_9T_Z+[\%?_#I^!O\ Y>T?\-)_LZ?]%]^"O_AT_ W_ ,O:
M_P JO_A0+_\ 0UK_ ."0_P#RWH_X4"__ $-:_P#@D/\ \MZ/^(<8C_H*J?\
M@O#_ /S2'^M^=_\ 1/4O_#C2\O[O]?)G^JI_PTG^SI_T7WX*_P#AT_ W_P O
M:/\ AI/]G3_HOOP5_P##I^!O_E[7^57_ ,*!?_H:U_\ !(?_ );T?\*!?_H:
MU_\ !(?_ );T?\0XQ'_054_\%X?_ .:0_P!;\[_Z)ZE_X<:7E_=_KY,_U5/^
M&D_V=/\ HOOP5_\ #I^!O_E[1_PTG^SI_P!%]^"O_AT_ W_R]K_*K_X4"_\
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M,1_T%5/_  7A_P#YI#_6_._^B>I?^'&EY?W?Z^3/]53_ (:3_9T_Z+[\%?\
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MF[L-5L/M^E7]W:_;=,OK+4+7S?/LKNWN8XYD_MH_X<J_\$S/^C:O_,R?'_\
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M2E",W&4KU')1M'?6,9N_;0_FBHK^R#_@H#_P2I_8)^"/[&WQ_P#BM\,/@/\
M\(QX^\$^"AJ_AC7O^%H?&;6O[,U#^VM)M/M']E^(?B)JVBWO^CW,\?E:AIUW
M!\^_RMZHR_QOUAD>?8//\/6Q.#IXFE3HUG0DL3"E";FJ<*EXJE6K1<>6:5W)
M.Z>EK-WC<#5P-2%.M*G*4X<Z=-R:2NXZ\T(.]UT35NH4445[9QA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'G?VE]J^WQ?8_L]U^,'_ !$M?]66?^;&_P#XAZ^IO^#BS_DR;X7?]G3>"?\
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M'EFE=-.\9Q=[2A+9Q=GYIIII232**_KK_P""8'_!,#]AG]HC]AGX'_&+XQ?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /[/O^#=/_DR;XH_]G3>-O\ U4OP0K]\
MJ_ W_@W3_P"3)OBC_P!G3>-O_52_!"OWRK^<.+/^2CS?_L+E_P"D0/T'*_\
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M-I^//_9<X?\ U ?"]?IO'W_)-8K_ *_X3_U(@?.9%_R,*?\ U[J_^D,_7_\
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MW,%MX>\5ZE\4K+Q;9:G?V=NUNUYK.B>'?#%OJ]U$-1T^PT_3+M-/'H_['?\
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MZOYFO^#:7_F]/_NW+_WO%?TR_$?_ ))YX\_[$SQ1_P"F.^KYOC/_ )*['_\
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MFAN(-2O%^'*_;G_@@!X'T;Q9^WPVO:I8O=WWPQ^"7Q&\<>'+A+R>V73-9O\
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M%M9V7V>TA_LF_P""2_PN\'_"W]@#]G>V\):<EK+XZ\'P?%'Q;J+V]A'J.O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=6EU#%<VMU;2QSV]S;SHLL%Q;SQ,\4T,T3+)%+&S1R(RNC%2"?P\_P""MO\
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M/*@7R=0UOXH?%:SU.X\]8A<R?:;;P_I$?E2S200_9-]O%%)/<M-_997\8/\
MP<6?\GL_"[_LUGP3_P"K:^-]?AGA\D^(Z3:3:PN*:NMGR)779V;5UT;6S/L\
M];_L^>N]6DGYKFO9_-)^J/P-K]O_ /@W[\7:?X;_ &];K1KV^MK2Y^('P,^(
MGA'2()Y4CEU/4++5_!OCV6QLT:-VGN8]*\$:GJ3Q1M"XL]/NIC(8X7AE_$"O
M9/V>?C1X@_9U^./PK^.'AB 7NL?#'QKH?BM-+:Y^Q1:[8:?=I_;7ANYO?LUX
M]G9^)=%DU#0+V[BM9I[:TU&:>W0SQQD?M&<X*68Y5F&"@TJF)PM:G3;LE[5P
M;I7;T4?:*/,^USY#"5EA\30K/X:=6$I6WY4US6\^6]C_ $S*_P X[_@H!\-]
M8^$W[;'[4/@G6X$MKBW^,_C?Q#IZ(9R'\-^.M6F\=>$+D_:!YP>\\*>)-&NY
M%9YE5YV6.YNHPES+_H2?!GXO^ OC[\+/ _QC^&.M0Z_X&^(.@VVO:#J$;P--
M&DC26]_I6IQ6\]S'8Z]H&J6]]H/B+2FF>XT?7M-U'2KK;=6<R+^5_P#P5(_X
M)/:-^W =/^+?POUK2_ G[0OAO1/[#FN-7CG'A/XF^'M/COKG1]#\3-9I)/H_
MB'2[ZY\C1O&<%K?2#2)I="UZPU.QM/#EUX8_%^#,XHY#FV(I9CS8>CB:;PM:
M4XROA\12JIP=:*3E&*:J4I^ZW"4E*5HQDU]AF^$GCL+3EA[5)TY>T@DU:I3G
M'7D=[-M<LHZV:32NVC^&ROW6_P"#?'P3?>(/VW?$/BQ=+OI])\ ?!+QC?7&L
M1VUT=,TW5_$.M^%O#NE6-W?1O':0WVJZ?>>()=.L;EIIKVWTO5+FUM'73;F[
ML?,]!_X(2_\ !1'6/%__  C6H?#_ , ^%=&V1M_PL'7OBGX1N/"&72V9H_L7
MAB\\1^/=\+3RQR'_ (0C87LKDQ/+&]F]W_5S^P!^P;\._P!@CX17G@+PMJ7_
M  F'C;Q;J4&N_$OXE7>CVNCZEXMU.R@EMM'TZVLXI[^YTWPKX;MKB]3P_H=S
MJVIBRO-6U_5!<?;-=O\ =]SQ=Q3E*R?$X/!XRAC<3CJ7L(1PM6-:-.G-KVM2
MK4IN4(6IMQC3;524Y)<O*IN/B95EF*>+IU:U&=&G0ESMU(N#E*-^6,(R2<KR
MLW)+E23UNXI_=M?YR_\ P4,\>M\2_P!N+]JCQ9Y?EQ2_&OQQX?LL36\XETSP
M5JTW@K2KGS;6&" _:]-\/VMUL03&+SO*>\OY$:^N/[7?^"E?[;?AC]B7]G/Q
M#XG_ +8M(_B]X[T[6_"WP0\-D)<W^I^+C9117'B9]/\ ,1W\-^ TU&QUKQ!>
MR&.S6>;1=":=-2\1:5!<_P">U7E>&N6U8+'9K4@XTZL(83#2::]HHS]IB)1;
M:O",X4H72:E-3BI)TY)]7$6(@W0PT6G*#=6HD_AO'EII^;3E*VC2Y79J2/\
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MZR?^K_\ BK6/_P %O/\ E&S\=/\ L,?"+_U<'@:MC_@BK_RC,_9I_P"ZR?\
MJ_\ XJUC_P#!;S_E&S\=/^PQ\(O_ %<'@:ODU_R77_=UR_\ 5NSTW_R)/^Z9
M'_U%1_!G7]0'_!M9_P A_P#; _[ _P #O_2WXKU_+_7]0'_!M9_R'_VP/^P/
M\#O_ $M^*]?K'&__ "2^:>F#_P#5AA#Y?)O^1EAO6K_Z9J']3'B'_D :Y_V!
M]3_](IZ_RYZ_U&/$/_( US_L#ZG_ .D4]?Y<]?*>&'P9W_BR_P#+&GJ\2?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI?ZK?_8-*L+NZ^Q:98WNH77E>196EQ<R1PO_ &T?\/JO^"9G_1RO_F&_C_\
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MV&/@'X?NKO2/BEIWQT\7,;N#2/!?P5NK+Q<;RZM_.A$^I>,8KB/P3HNC+>+
MEQ>2:Y>:K/93G4- T'Q!%#)'7YA?L*?\%I/!GB3XX?M+_%/]MKXJI\+- \4Z
M5\--%^!_P]TCPO\ $;Q?X4\):'H5_P"/+C7M.TJ#P;X7\22_VU<C4]"O/%/B
MK7H;"_\ %-\]M':K;Z)HFCZ!X?\ Y7Z*6'X!R2A@L3A92Q56KBHPA/&2G26(
MI0A6IUN7#)T9T:*G*G&-23ISJ2@Y1YU&5D5,\QDZU.JE3C&DVXTDI^SDW%QO
M4M-2G92;BN:,4[.UU<_MH_:M_P""NG_!//XE?LN?M)_#GP5^T'_;7C+Q_P#
M+XQ>"O"6C_\ "J/C?IW]K>)O%7P\\1:%H.F?VAJWPUL-*L/M^JW]I:_;=3OK
M+3[7S?/O;NWMHY)D_B7HHKVLBX?P7#]*O1P57%58XBI&K-XJ=*<E*,>1*+I4
M:*2MNFI._5;''C<?6Q\X3K1IQ=.+BO9J233=W?FG-WOV:/ZQ?^"47_!2_P#8
ME_9J_8N\"?";XV?&K_A"_B!HWB;X@:AJ6@?\*X^+7B/[-9ZYXMU/4]+F_M7P
MEX#U[1)OM5C<0S^7;ZE++!O\JX2&96C7IO\ @I__ ,%/_P!AG]HC]AGXX?!W
MX._'#_A,/B/XP_X5I_PCGAS_ (5I\7_#_P#:/_"/_%_P!XIU?_B;^*?A_HFA
M6GV30M$U2^_T[5+7[1]E^RVOG7DUO;R_R*45YDN"<JEFW]LO$9A]:^OQS'V:
MJX;ZO[>-=8A1Y?JGM/9<Z2<?:\_+ISI^\=*SG%+"_5/9T/9^P>'YN6IS\CI^
MSO?VO+S<NM^6U_LVT"BBBOL#R3U#X.?&GXI?L^_$+0_BI\&_&>J^ _'OAQYF
MTO7]*6SG98KF(PW=CJ&FZG;7VCZSI5["QBOM'UG3]0TN]CPEW9S*J@?U9?LJ
M?\'"/P4\7:+IN@?M:>$]8^$OC:';!?>._ VC:GXO^&&K1H( =3FT2REU+Q_X
M6NY'FE4Z'9Z7XXM?)LY+T>((I;N#2(/X_:*\/.>'<JSV,?KU!^V@N6GBJ$E2
MQ,(WOR^TY9*<$VVH585(1;<HQ4FV^W"9ABL$W[&?N2=Y4YKFIM]^6Z<7LG*+
MBVDDVTD?Z.NB_M__ +#>OZ=;ZI8_M>_LW06UT@>.+6OC+X!\-:BH958"XT?Q
M%KNE:O:/A@#'=V,+JP9&4.C*/&OC1_P5L_8!^">DS7VH_M!^$_B+JK6&JWFE
M>%_@O,/BIJVMW&DF!7TN'5/"SW7@S0K^^>XC32I/&?BOPOINH@3S6^HM;VMW
M-!_GWT5\G3\-,KC44JF/QU2DG?V<50IR:Z)U/9STVYFH)M7LXMIKU)<18EQ:
MC0HQE;XFYR2[OEYE\KO3K?9_LA_P4-_X+#_&#]LJWU/X8?#RPOO@U^SU.]U:
MZAX5BU"UOO&'Q+MX=3\[2]0\?ZY:VD7]F6/V2VL[C_A ?#MU/HMK?W-_%K>N
M^-TMM$O--_&^BBON\OR[!97AH83 X>&'H1;?+&[E.;LG4JSDW.I4DDDYSE*5
ME&*:C&*7B5\16Q-1U:]1U)O2[T22VC&*M&,5O:*2NV]VV_WR_P"#=/\ Y/9^
M*/\ V:SXV_\ 5M?!"O[/J_C!_P"#=/\ Y/9^*/\ V:SXV_\ 5M?!"O[/J_$_
M$'_DHZO_ &"87_TB1]CD/_(OC_U]J_FC^<+X,_\ !<'0?A?^T%\=/V>_VO;>
M_B\*>#/CS\8?"O@7XV>'](NM5FT/PEHGCOQ3;:'H/Q"\+Z):W.L:K'HMG9VF
MAZ5XE\+:;J.KW=F-.CU[1+R]@U3Q1>_L/IG[?/[#VK6JWEK^U_\ LTQ0L[QA
M-3^-OPZT6ZW1G#%K'6/$-A>JA/W)&MQ'(.8V8<U_ G^V+_R=U^U/_P!G'?'#
M_P!6;XGKYQK[6OP!E&8T\-BJ-6O@)U</1G6IT%"="<Y4X-SC3FKTY2;;E&$E
M3VY81=^;QJ>>XJ@YTIQA7C&<E"4[J:2DTDY1?O)+9M<W>3Z?W&_M8_\ !<#]
MDCX%^'K^P^#_ (BM_P!H;XG7FE7$F@:;X)9Y_ .E7\]M<?V;=>+_ !H[VEDU
M@EU&AO=*\+OK.NF/$-Q#I2W$=]'_ !E_'#XX?$W]HOXF^)_B[\7?$]YXK\;^
M*[PW-_?W)\NULK6/*6&BZ+8(?L^D:#I%OML]*TJS5+:SMD"J&E:663R:BOH\
MBX9RW((S>$C.KB*L5&KBJ[C*M*"=_9PY8QA3I\R3<813DU%SE-QBUP8W,<1C
MG%57&-.+O&E334$]N9W;<I6T3;TN^5*[N5_31_P3X_X+OQ?#_P (:'\'OVT(
M/%7BBT\/P0Z5X9^.>B6[>(?$AT:VA<6=E\3=)DN$U/Q#>:?''%8P>,='^W:]
MJMO]E/B'2=3U9-3\3:C_ #+T5VYMDV7YWAEAL?1]I&+<J52#Y*U";5G*E42;
MC=64HM2ISLN>$N56QPN,KX.I[2A/E;5I1:O":3O:4>MNC34E=V:N[_Z+7@[_
M (*/_L&>.=-M=5T7]K;X$V5K=V<-]%%XQ\?Z)\.]22&<D(EUHWQ N/#.KV5X
MI'[[3KVQM]0MQ@SVT8()W=4_;\_8<TB$3W?[7W[-DJ'/RZ7\:/A]K<W#QIS;
M:+K]_<#F52,Q#*"20?)%*R?YQ%%?$/PSR[FO',L:H7^%PH.5NW.H15_/D^1[
M*XCQ%M</1OU:E-*_I=M>EWZG]@7[7_\ P<!_!3PIX8U3PQ^R!IFL?%3Q[JNF
MS06'Q)\2Z#J?A'X>^#I;M+V"/4[?0?%&GV7B[Q?KNFR06]S'H=]X?\/>'GCO
MK2[F\0:BUG?^'YOY(_&GC3Q9\1?%GB#QUXZ\0:KXK\8>*]5N];\1>(M;NY+[
M5-7U2^E,MS>7ES*2SN[':B+MB@B6."".."..->9HK[#)N'\LR&G.&!I2]I5M
M[7$UI*IB*J7PQE-1A&,%NH4X0A?WG%RU/)QF/Q&.DG6DN6-^2G!<M.-]VDVV
MV^\I2=M$[:!7H/PG^)OBKX+_ !.\ ?%OP/<PVGB[X;^+_#_C3P])=+<26,FI
M^'=3M]3M[/4X+6YLYKS2-0-N;'6-/6Z@74-,N;NQDD6*X>O0/AE^RE^TC\:?
M!.K_ !#^#_P5^(/Q2\)Z#KK^&M8O/A[X?N_&&H:?K<=MI%X;*?P[H"W_ (D&
MZTUS3[F*Y72&M)H#>RPSNFE:J;+]4O\ @G1_P1V_:!^*OQA\"?$#]I/X4^)/
MA5\"?"NL0>)M:TCXAZ18Z-XH\>W'A_49GM/!<WP]\2Q-X@LM"UK4M.C@\1W7
MB3P[96M_X6N9?[':Z_M2TOH-<RS;*L%A<5/&8K#<E*%2%7#NM3E5J2<'_LZH
M\SG*I4B[*GRW:E=I1NU.'PN*K5:2I4JB<I1E&IR248JZ_>.=K*,7KS7Z66MD
M?V<^#/$7_"7^#_"GBS^SKO1_^$H\-:%XB_LB_&+[2_[;TNUU+^SKT;$Q=V/V
MG[-<C8F)HG^1>@_,'_@M#^TA'^S[^PQ\0M*LH7N?%/Q\=_@1X?7R%GM+/3_&
M>DZK-XZU34U&I:;<16L7@#3?$FF:=<6GV]X?%&L>'#>:9=:2VHM%^K\<<<,<
M<44:111(L<44:JD<<:*%2.-% 5$10%55 55     K^+W_@X(_:$L_B=^U5X.
M^"VAWUI?:)^SUX*GM-7\NTU&&[L_B-\1Y[#7/$]A+=71CL;VTM_"FC?#HV[:
M;;NEO?R:M;W6HW-PALM+_#N$<MCFG$&$@X/ZOAYRQU:.LE&GAVI4H2>EXRKN
MC2DV]5)O79_:9KB'AL#5DI?O*B5&#T3<JFDFO-0YY*W5?,_!2BBBOZ'/@3N/
MAK\2O'GP=\>>%_B=\,?%&J^"_'O@O58=9\->)=&F6*^TZ^B5XG!25)K6^L+Z
MTFN-.U;2=1M[O2=:TF[O=(U>RO=,O;NTF_KT_9(_X+\_L]?$?2= \+_M16&H
M_ _XBKIT<6K^,]/T;4?$'P@US5TNK&QC^P2:1)K?C'PG-JQNI=2^R:[HMYX;
MT.TLKY=1\<EDM/M?\:=%>%G7#N69]"$<;3FJM)-4L30DJ>(IQ>K@I.,XSA?W
ME"I"<5)MQ47)M]N#S#$X&3=&2<96<J<TY4Y-=;)IJ5M.:+3:T=[*W^C]8?MZ
M_L/ZC;I=6_[8'[,L<3[2%O\ XX_#72[@;D20;[/4_$EG=QX610P>!2L@>)L2
MQR(OC_Q7_P""KW_!/_X1Z7<:CJO[2/@7QG=1S/:VVB?"F[D^*&J:A<I&)3';
MOX-35=(M83'N*:EJVJZ;I#R*;9=0-TT<#_Y\-%?)T_#3+(S3J9ACJE---PC&
MA3DUV<W"=D]G:*?9IGJ2XBQ+BU&A1C+HVYR2\^6\?EK]Y^JG_!1__@J5\2OV
M\-8M/"ND:7??#'X!>&[Y[O0OAXNKB_U'Q1JD$TR6?B[Q]>VD%I:WFJ"U9&TS
MP[;K=:/X6::XAM;_ %J]:77+O\JZ**^^P. PF6X:G@\%1C0P])/EA&[;;^*<
MY2;E.<GK*<VY2>[T1X=>O5Q%256M-SJ2W;Z);))648KHDDD?V@_L2_\ !63_
M ()_?"+]DC]G?X8_$/X^_P#"/>.? OPI\)>&O%6A_P#"J_C5JW]EZWIFG1V]
M]9?VEH?PXU/2+[R)5*?:=.U"\M)<;H9Y%PU?%O\ P6A_X*%?L?\ [67[+G@+
MX<_L_P#Q=_X3_P 9:+\??"WC74]'_P"$!^)_A7[-X9T[X>?%/0KW4_[0\:^"
MO#FE3>3JOB/1;7[%;WTNH2?;//BM)+:WNYH/YD**^:PW!.587-(YM3Q&82Q,
M,3/%J$ZN&=#VE24Y2BXQPD:G(G-V7M%*UKR>M_1J9QBJF&>$E3H*FZ4:7,HU
M.?EBDD[NJX\UDKOEMY!7Z[?\$7OVH/@9^R;^U'X]^(W[0'CC_A /!NM? +Q3
MX*TS6/\ A&O&'BK[3XFU'XA_"S7;+3/[/\%>'_$>JP^=I7AS6KK[;<6,6GQ_
M8_(ENX[FXM(9_P B:*^DS# TLRP6)P%>52%'%4W2J2I.,:BBVG>#G"I%/3>4
M)+R//H5IX>M3KP47.G+FBIIN+>NZ3B[:]&C^^3_A]5_P3,_Z.5_\PW\?_P#Y
MU5?PX_'CQ+HGC/XX_&;QAX:O?[2\.>*_BM\1/$N@:C]FN[/[?HFN^+]8U32K
MW[)?P6M]:_:K&Z@G^S7MK;7<'F>5<P0S*\:^4T5X^1<+Y?P]4Q%3!5L95EB8
M4X5%BJE":2IRE*+A[+#T&FW)WYG)6M9(ZL;F5?'QIQK0I15-R<?9QG%MR23O
MS5)]E:UC]\O^"'G[:O[,W['W_#3_ /PT7\2_^%=_\+$_X4K_ ,(=_P 4;\0/
M%O\ ;'_")?\ "VO^$A_Y$7PKXF_L_P#L_P#X2;0_^0I]A^U_;O\ 0?M/V:\^
MS_N9XU_X+,_\$V-7\&^+=*T_]I#[1?ZGX9U[3[&W_P"%/_'J+S[R]TJ[MK:'
MS9_A=%#%YLTJ)YDTD<2;MTCH@+#^$&BN/,^"<JS7,:V9XC$9A#$5I493A1JX
M:-%.A1I48<L9X2I-)QI1<KU'>3DU9-);8;.<5A:$,/3IT)0ASV<XU'-\\Y3=
MW&K%;R=K16EKW>H5_0E_P2H_X+%:1^S+X3TS]G/]IE/$.I?"'3+G49? /Q&T
MJW_MS4_AM;7]S;79\*ZMX?LK)-9UGP:+V?7-5MM3LKK6_$.AW%Y;Z'8:)>:!
M]D30/Y[:*][-<JP6<X26#QU-SI-J<)1?+5HU(IJ-6E.SY9Q3:U4HRBW&<91;
M3X<+BJV#JJM0DE)+E::O&<6TW&2TO%M+9III---)G^C=H/\ P4'_ &%_$=F+
M[3_VO/V=;>$K"X37OBYX)\+7F)XEF0'3_$^L:1?AE1@)D-L'MY0T%PL4RM&/
MF7]HC_@LW^PM\"-(U'^Q/BC8_''QK%I=MJ.D>#?@^9/$]IJC7EXUE!#=>/[>
M%_A_I#6YCGO-3M;CQ!-KEEIT'VA-#NI[S2[74/X*Z*^+H^&N4PK*=7&XZM2B
MT_8_N:?-9I\LZD:;ERO52Y%3E9^[.+U/8GQ%BG%J%&C"35N;WY6\U%R2NNE[
MKNF?U+_L._\ !<RR\0_'SX^Z_P#MJ>.(/AK\+O&6@>&K[X0:)HWA?Q;XJ\,_
M#FZ\*ZG?V,WA&Q@\':!K_B;4-7\7:5XC_MSQ!XJUK36M=1U#PL\<<_AVQ.@>
M&U^ZOVA?^"I?_!+;X_\ P,^+7P5UO]IA(;#XF^ ?$WA 7C_!O]H#_B5ZAJ^E
MW$&CZW%_Q::<"XT/5S8ZQ:EH+A!<V,1DMYT#0O\ P_45Z6)X$R6OC(8VE/&X
M&=/ZNZ=+!5,/3HTY8:,(TYQC4PM:?._9QE.3FW.=YRO*4F^:GG>,A2=&2HUX
MRY^:5:-24Y*HVY1;C5@N7WFHI)<L;16B25F\@BM;R[MH+RVU&&WN9X(=0LTO
M$L[^*&5XX[RU34+6POTMKI%$\"7UC9WBQ.HN;6WF#PI_3G_P2)_X*]_#/X7?
M#/PY^RK^U/K3^#M)\'.^F_";XO7@US6='ET?6=<N+J'P5X_E3^U;OP\GAZ[U
M4VWA?Q,D4'@[3?!T$&CZV/"UMX6MM3\0_P P=%>_G&38/.\$\%C5-P4HU*=6
MFU&M1JQ3BJD&XN%^64HRC*$H2C)KEORM<6$Q=;!5E6HM7LXRC)7C.#:;C)73
MM=)IIIIK?=/_ $@8_P!O']B&2U-VO[8/[,0B"22%)/CM\,8KK;$6# 64OB=+
MPN=A\N,6YDF!4Q*X="W\_G_!=/\ ;3_93_:"^!WPR^%WP7^+_ASXF^/_  Y\
M7M*\:ZE!X2L=4U31=/\ ";>"/'&CW4[>,Q8)X;DO'U;4=&B?0].U2]U$*3<W
M]M9QVUNUQ_,#17S.5<!8#*\?A\?''8NM4PT_:4H.-&$'+E<?WEH2E*-I/2+@
MV[:VNGZ.*SROB:$Z#HTH1J+EE).;=KI^[JDG==>;T/Z2/^"*?[?7[)?[)'P.
M^+?@_P#:$^+'_"O_ !'XG^*T7B70]._X03XE^*_MVB+X0T'2S>_:_!'@WQ)8
MVV+ZRN8/LUY=6]V?*\T0>2\<C_I!^U;_ ,%=/^">?Q*_9<_:3^'/@K]H/^VO
M&7C_ . 7QB\%>$M'_P"%4?&_3O[6\3>*OAYXBT+0=,_M#5OAK8:58?;]5O[2
MU^VZG?66GVOF^?>W=O;1R3)_$O177C."<JQV9SS:KB,PCB*E>EB'"G5PRHJ=
M)044HRPDZG*_9KF3J-N[M):6RI9SBJ.&CA8TZ#IQA*FG*-1SY97NVU54;ZNW
MNV\@HHHK[ \D*_67_@B9\6M6^%O_  4'^%>FV,"7.E_%S1O%_P )?$T:VEY=
MW::3J^DGQ5IL]D+.51;O:^+_  =X7N=0N[N"[LX-$BU1IHK=O+U&Q^2+?]A3
M]LO4/"G@KQSH7[,/QN\6^$OB'X?M?%7A#7O WP\\1^.['5- OHH9[#49F\'6
M.N2:2E_;W$-S8PZU'IUS>VKBYMH98 9!_1O_ ,$8_P#@EA\2/@/XV?\ :J_:
M0T(^$/&]EI&N>'OA7\--06UN-?\ #PUVV_LK6_'7B&:UN)XM(U&[T.;5?#FC
M:&'>]&EZUK%WJR6<DEA WRO$^;Y51R3,H5<5AJTJ^&Q&%I4*=:G.K4Q$XRIQ
MBHPE*2]E4M*I)JU+D;EJDGZ>6X7%2QF'E"E4@H5*=6<Y0E&,:::DVVTD^>-U
M%7]Z^FEVOZ2Z_E1_X../C\MUK'P&_9ATJ]1X]*MM2^-GC:T1I) M_J']H^"_
MA\KE"MM!<VEC#\09[BWE\Z[-KK&F7 6SMIXWU#^JBYN;>SM[B\O+B&UM+6&6
MYNKJYEC@M[:W@1I9[BXGE9(H888E:2661ECC16=V"@D?YQG[=?[1[_M8?M7?
M&/XX0->+X>\3^)!I_@FUO7E\RS\">%[&U\->$E^RR1PC3IK[1M*MM8U&PCA0
M1:QJ>HR3/<74MQ=S_FWA[EKQ>=2QLXMT<MHRJ<WV?K%=2I48OSY/;U%VE33[
M'T.?8A4L&J*?OXB:C;K[.#4YO_P+DB^ZDSY(HHHK]S/BPHHHH *_MH_92_X*
MZ?\ !//X:_LN?LV_#GQK^T'_ &+XR\ ? +X.^"O%NC_\*H^-^H_V3XF\*_#S
MP[H6O:9_:&D_#6_TJ_\ L&JV%W:_;=,OKW3[KRO/LKNXMI(YG_B7HKPL]X?P
M7$%*A1QM7%4HX>I*K!X6=*$G*4>1J3JT:R:MLDHN_5[';@L?6P$YSHQIR=2*
MB_:*322=U;EG!WOW;/Z;_P#@M#_P4*_8_P#VLOV7/ 7PY_9_^+O_  G_ (RT
M7X^^%O&NIZ/_ ,(#\3_"OV;PSIWP\^*>A7NI_P!H>-?!7AS2IO)U7Q'HMK]B
MM[Z74)/MGGQ6DEM;W<T'\R%%%=&3Y1ALDP4<!A)UZE&-2I54L1*G.IS5&G)-
MTZ5*-E;1<E^[9GB\74QE9UZL81FXQC:FI*-H[:2E-W[ZA1117JG,%>K? ?Q+
MHG@SXX_!KQAXEO?[-\.>%/BM\._$NOZC]FN[S[!HFA>+]'U35;W[)8075]=?
M9;&UGG^S65K<W<_E^5;033,D;>4T5%2"J4YTY74:D)0;5KI23B[735[/2Z:O
MT8XR<91DK7C)25]KIW5]M#^^3_A]5_P3,_Z.5_\ ,-_'_P#^=57\R/\ P6A_
M:@^!G[67[4?@+XC?L_\ CC_A/_!NB_ +PMX*U/6/^$:\8>%?LWB;3OB'\4]=
MO=,_L_QKX?\ #FJS>3I7B/1;K[;;V,NGR?;/(BNY+FWNX8/R)HKY7)^#,KR3
M&QQ^$KX^I6C3J4E'$5</.GRU$E)M4\+2E=6T?/;NF>IB\WQ.,HNA5A0C!RC*
M].-12O';656:MWT"BBBOK3RC])?V#?\ @I_\?OV$]1.B>'6MOB/\%M2OYM0\
M0_!SQ->-9:<;ZY>U-SK?@WQ+%97^I>"O$,T-L;>6:"UU;PY?I<S7.M^%M7U"
MWTR]T[^J;X"_\%JOV"_C=#;6NJ?$F\^"/B:6'S)O#_QHTP>&+1&C?RK@P^-=
M/N=9\!-")"CVJWWB73M2NK65)O[+ADBO8+/^#2BOE<YX/R?.JDL15IU,+BY?
M'B<+*,)57T=:G*,Z51]'/EC5:LG4LHI>G@\VQ>#BJ<91JTEM3JIR45VA)-2B
MNRNXK=1NW?\ TA+C]NW]B.VA>>3]L+]E]D3;N6W^/7PMNYCN94&RWM?%,T\F
M"P+>7&VQ=SMA%9A^</[3W_!>G]D?X0Z;J6E? X:Q^TA\08I;^PMX="M=3\'_
M  WTO4-.U2WT^Y?6_'/B/2H;O5;22V>\U/0[OP#X=\8:-X@2Q2W;Q!HMKJ5K
MK"_Q,T5XV$\.,GHU8U,3B<9C(1:?L6X4*<_*HZ4?:N+_ .G=2F_/H=E7B'%S
MBXTZ=*DW=<ZYIR7G%2?*FO[T9+R/HO\ :=_:L^-_[7WQ(NOB?\<?%K^(M:V7
M%EH.D65M'I?A;P9H,EY-=V_AOPGH=N6BT[2K,S"+[1=2W^N:J8DOO$.LZSJS
MSZA-\Z445]]1HT</2IT*%*%&C2BH4Z5.*A3A%;1C&*22]%OKN>%.<ZDI3G*4
MYR=Y2DW*4GW;>K/<_P!G+]HWXL_LJ?%GP[\9?@UXB?0/%N@.T%S;3K+<Z!XI
MT"YE@DU;PCXNTF.>V76O#&M+;0B]LC-;W5M=6]CK.C7VE>(-*TC5[#^L3]G7
M_@X(_9<\<^'+6#]H?0_%7P.\<6MHIU6XTO0]7\?> =4NA/=QAO#][X<MM0\6
M6OFVT-I=366L^'(H[&:]:QAUC5DM&U";VK_@GW^RK^PW^T!^P]^S7X^U+]FK
MX!^+M8O_ (6Z#X?\6>);OX5>&(?$.J>-/!,DWA/QE=:UJLN@:=K5_K$GBG0M
M5-]JUU)/)JP/VN+4-4TVZMKVYZ?]I3_@CQ^QA\4?A?\ $2U^&7P!\!> _C#/
MX'\5V_PO\1Z+K/C/P9X?T?QY<:(T7A>]US2/"VL1Z'>Z5%K%GIOV[^T?#6NK
M;6LNHW5OIMS=75S'=?DV=Y[POF^-EA<WRS,,-B<-B)X.6.P\Z$*U)4JLJ;53
MFDE*E&7-)QJ4ZDJ<>9TUS-I_4X+!9EA**JX7$4*E.I3C65"HJCA+F@I+ELKJ
M36EXRBI-)2=K-4?&/_!<O_@G'X9T6ZU71?BWXJ^(=];PRR1>&_!WPG^)%EK5
M\\:[DM[6?X@>'/ WAU)IS\D37NOV< ;F>>%/GK\L?@]_P5"^+?[??_!2K]DW
MPE8:--\,?@CX:\<>*=6TOX:V6N'4KCQ#J.G> /'-TGBOQQJBVVF0:KJ5GI<9
M.F:+#;'2]"?[3]A.H:A</J$_XW>*/^";?[>W@_Q4O@[5OV2OCC=ZN\UO;B\\
M+^!M5\<>%1)=7+6L;-XZ\%1^(/!"0K*A>XN7\0K;VEL5O+N6&S=)V_;/_@CU
M_P $I?VA/A3^T#H'[47[1GABY^%FG_#K2]>?X>>"=1O] U#Q+XLU[Q=X:UKP
MA<:AKNF:==:M+X;T30-'UO5;F.TU5](\1W'B#^QKB"T72[:Z>[[<1DW".0Y9
MF&,H8VEC,54P.*IX*>(QF&Q-3VM>A.E3^K4L/&G&3E*:O55.<J<.:?/"*DS&
MGC,UQN)P]*=&5*E&O2E65.C4IQY:=2,Y>TG4<FK*+]WF2D[+E;LC^J*OX!O^
M"R%X;_\ X*3_ +3<YG2X*:K\.;/S(S&54:=\'/AWIZP$Q +OMEM1;2@_O!)$
MXF)E#D_W[221PQR2RR)%%$C22RR,J1QQHI9Y)'8A41%!9F8A54$D@ FO\W?]
MMSXN6_QV_:Z_:+^*VGWMIJ6A^+/BSXPD\+:A8Q1Q6]]X+TC5)O#_ ()O (I[
MF*2:Y\):5HTUU<13R175T\US&0DJJ/(\-*,Y9KC\0E^[IY?[&4NTZ^)H3@OG
M'#S>_0ZN(II8:A"_O2K\Z7=0IS3?R=2/WGZ3_P#!$;]L3]G']D/QE^T#JO[1
M'Q%_X5[8>-_#/@+3_"]Q_P (CX[\6?VG>:+JOB6YU.'RO _ACQ+-9?9H=0M'
M\S4([2*;SMMN\KQRJG]#'_#ZK_@F9_T<K_YAOX__ /SJJ_@;HK[C-N"<JSG'
MULPQ6(S"G6KJDIQH5<-&DE2I0HQY8U,)5FKQ@G*\W>3;5E9+QL+G&*PE"-"E
M3H2A!R:<XU'+WI.3NXU8K=NWNK3N%%%%?8'DGZ4?\$U_^"BGB[]@7XF:K?3Z
M7J7C7X-?$#^R;/XD> K*\LK6[22PO8UM/&_AB2^MI(_^$JT#2KG6+>VTEK_1
M=*\3Q7D6GZ[J-K]BTG5-'_L.^%__  5#_8)^*^@:7KVD_M.?"WPFVI02RR:'
M\4/$^F?#'7]+FMR%N+/5+'QK<Z/%%/&Y*12VUS=6-^ 9=+O+ZW(F/^>317R6
M>\&Y9GE?ZW.5;"8MJ,:E;#\C591BHQ]M3G%J4X12C&<7"7*E&3DE'E]7!9OB
M<%#V45"K23;C"I>\&W=\DDTTF[MQ=U=MJS;O_H;?%'_@J+^P'\)=(75]>_:B
M^%OB19;M+&WT[X7Z]%\6]7GNI+66\4-I_P -E\3R6-IY,+J^JZH;#2(KHQ6,
MU_'?7%O;2_A1J/\ P7QUWQU^V;\$-:M;'5/A+^QWX5\3W6G^.]#O+1=;\7>+
M=)\4Z/?^&KCQKX]CT!-3N?L/@1]3A\4Z/X*\&MJ4HNM+GNKF7QCJ3Z)I^F?S
M045R9?P#DF"C6]M[?'5:U&K1]IB'34:,:L)4Y3H4HPY8U5&3<*E3VKIR2E3Y
M9*YI7SS&5G#DY*,83C/EAS-S<)*24Y-W<+K6,>7F3:E=']\G_#ZK_@F9_P!'
M*_\ F&_C_P#_ #JJ_BZ_;.D^"]]^T]\9?$'[/?C2S\=?"#QCXUUGQMX.U2ST
M/Q9X=&F6GBZ\EUZ[\,2Z3XS\-^%]9MCX9U&^N]'M6-A<V\VFVMC,FI7TSSR+
M\P45Z61\*X#A^O6KX+$X^H\125*I3Q-7#SI-1DIQGRTL-1ESP?,HOG:49S7*
M[IKGQN9U\?"$*U.A'DDY1E3C44E=6:O*I-6>C:M>Z6I_77_P3 _X*?\ [#/[
M._[#/P/^#OQB^.'_  A_Q'\'_P#"R_\ A(_#G_"M/B_X@_L[_A(/B_X_\4Z1
M_P 3?PM\/];T*[^UZ%K>EWW^@ZI=?9_M7V6Z\F\AN+>+-_X*F_\ !3?]A[]H
M[]B/XK_"'X,?&W_A,OB)XEU+X<W&B>'O^%;?%WP]]MAT'XD>%=?U9_[6\5^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 445/:VMU?75M965M/>7MY/#:VEI:PR7%U=75Q(L-O;6UO"KRSSSRND4,
M,2-)+(RHBLS $VW @HKT!/A-\5)06C^&GQ D4'!9/!OB-P#@'!*Z:1G!!QUP
M1ZT__A47Q8_Z)A\0_P#PBO$G_P K*S]M2_Y^T_\ P./^92C)ZJ,FNZ3_ ,CS
MRBO0_P#A47Q8_P"B8?$/_P (KQ)_\K*/^%1?%C_HF'Q#_P#"*\2?_*RCVU+_
M )^T_P#P./\ F')/^67_ ("_\CSRBO0_^%1?%C_HF'Q#_P#"*\2?_*RC_A47
MQ8_Z)A\0_P#PBO$G_P K*/;4O^?M/_P./^8<D_Y9?^ O_(\\HKT/_A47Q8_Z
M)A\0_P#PBO$G_P K*/\ A47Q8_Z)A\0__"*\2?\ RLH]M2_Y^T__  ./^8<D
M_P"67_@+_P CSRBO0_\ A47Q8_Z)A\0__"*\2?\ RLH_X5%\6/\ HF'Q#_\
M"*\2?_*RCVU+_G[3_P# X_YAR3_EE_X"_P#(\\HKT/\ X5%\6/\ HF'Q#_\
M"*\2?_*RC_A47Q8_Z)A\0_\ PBO$G_RLH]M2_P"?M/\ \#C_ )AR3_EE_P"
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M%1?%C_HF'Q#_ /"*\2?_ "LH_P"%1?%C_HF'Q#_\(KQ)_P#*RCVU+_G[3_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?V??\&Z?_)D
MWQ1_[.F\;?\ JI?@A7[Y5^!O_!NG_P F3?%'_LZ;QM_ZJ7X(5^^5?SAQ9_R4
M>;_]A<O_ $B!^@Y7_P B_"?]>E^;"BBBOGCO"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX"/R8O\ GE'_ -\+_A1Y,7_/*/\ [X7_  J2BB[[O^O^&7W 1^3%_P \H_\
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M_P"&7W 1^3%_SRC_ .^%_P */)B_YY1_]\+_ (5)11=]W_7_  R^X"/R8O\
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M(U";NM>J_-?Y+[B9_"_E^:.]T?\ Y!=A_P!>L7_H(K2K-T?_ )!5A_UZP_\
MH(K2K@G\<O\ %+\V=$/@C_AC^2"BBBI*"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N%U
M D>+M,P2,7>E8YZ?Z3&?Y\_6NZKA-1_Y&[3?^OO2O_2B.MJ'Q3_Z]S_(SJ_"
MO\4?S/<Z***X30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,_A62?%NK DD?V5
M?'&3C/\ :>G<X]:],KS+X5_\C=JW_8*O_P#TYZ=6T?\ =\7_ ->X_FS*?QTO
M67Z'T+1117DFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <9\0B1X.UH@D'R[3D'
M!_Y"%H/Y<5;^"))\&S9)/_$[OAR2>/L]CQS5/XA_\B;K7_7.T_\ 3A:5;^"'
M_(FS?]AN^_\ 2:QKL?\ R+:G_84O_2("C_&C_@E^:/8:***\LZ0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#Y?\,LW_"[M2&3C^U/$HQDXP(+
MT@?0$#BOJ"OE[PQ_R6_4O^PKXE_])[ZOJ&N_,/CP_P#V"4/_ &XY\-\$_P#K
MY+\HA1117 = 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\1?\%+O^4=O[<__ &:5^T%_ZJSQ17V[7Q%_P4N_Y1V_MS_]FE?M!?\ JK/%
M%=."_P!\PG_830_].P.3'_[CC?\ L$Q/_IF9_-!_P;2?\D,_:7_[*QX3_P#4
M/>OZ7*_FC_X-I/\ DAG[2_\ V5CPG_ZA[U_2Y7V^:_\ (PQ/^*'_ *;@?,\*
M?\D]EG_7JK_ZD5@HHHKSSZ$**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R-8_U$7_ %U_
M]D:M>LC6/]1%_P!=?_9&IQW7JOS)G\+^7YH[W1_^058?]>L/_H(K2K-T?_D%
M6'_7K#_Z"*TJX)_'+_%+\V=$/@C_ (8_D@HHHJ2@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KA-1_P"1NTW_ *^]*_\ 2B.N[KA-1_Y&[3?^OO2O_2B.MJ'Q3_Z]S_(S
MJ_"O\4?S/<Z***X30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,OA7_P C=JW_
M &"K_P#].>G5Z;7F7PK_ .1NU;_L%7__ *<].K:/^[XO_KW'\V93^.EZR_0^
MA:***\DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M76HTJKBM5%U(1FTF]6DW9!11169L%%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?_!M)_R0S]I?_LK'A/\ ]0]Z_I<K[?-?^1AB?\4/_3<#YGA3_DGLL_Z]5?\
MU(K!1117GGT(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5D:Q_J(O^NO_ +(U:]9&L?ZB
M+_KK_P"R-3CNO5?F3/X7\OS1WNC_ /(*L/\ KUA_]!%:59NC_P#(*L/^O6'_
M -!%:5<$_CE_BE^;.B'P1_PQ_)!1114E!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7":
MC_R-VF_]?>E?^E$==W7":C_R-VF_]?>E?^E$=;4/BG_U[G^1G5^%?XH_F>YT
M445PF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %>9?"O_D;M6_[!5__ .G/3J]-
MKS+X5_\ (W:M_P!@J_\ _3GIU;1_W?%_]>X_FS*?QTO67Z'T+1117DFH4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ3K.DV?CKPGJ=E#+XI^),4-NUMXHT3Q(L_A'1(]2U'PM=^&]8O[%M<?^;_\
MX(>? ;PW^T+_ ,%,_P!G+PIXUT>SU[P5X3U#Q7\4_$FD7RV$]K??\*Y\'ZWX
MB\+6UU8:G97]GJNGS>/;?PE%J^F2VQ^UZ,^HHDMNX6>/_3AKW.+,VQ&&E2P&
M&J2I.I2]M7J0?+-PE*4(4XR7O1NX2E-QLVN57Y7)/YC@+(,+C(5\UQM*%=4:
MWU?"T:L5*FJD(0J5*\H/W9M*I"%/F3C&2J2MS*#CRW@[P-X*^'>AV_ACX?\
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M5_:W@WQ_INJ)%$-3FT+Q;X!U8WTZ3);6R:I)HOB/0XIUM(X=1:T%MY4YYO\
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M1DM[FVN([G3-7T?5],N6CF@GAD6"\T_4=/O(&CDCD6&YM+F%E98Y8R!_5O\
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M,;0?^RV_%O\ ]+-%K]#XN_Y%/_<U1_\ 2:A^1>'G_(^G_P!B_$?^G<.?K_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *^(O^"EW_*.W]N?_LTK]H+_ -59XHK[=KXB_P""EW_*
M.W]N?_LTK]H+_P!59XHKIP7^^83_ +":'_IV!R8__<<;_P!@F)_],S/YH/\
M@VD_Y(9^TO\ ]E8\)_\ J'O7]+E?S1_\&TG_ "0S]I?_ +*QX3_]0]Z_I<K[
M?-?^1AB?\4/_ $W ^9X4_P"2>RS_ *]5?_4BL%%%%>>?0A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !61K'^HB_ZZ_P#LC5KUD:Q_J(O^NO\ [(U..Z]5^9,_A?R_-'>Z
M/_R"K#_KUA_]!%:59NC_ /(*L/\ KUA_]!%:5<$_CE_BE^;.B'P1_P ,?R04
M445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5PFH_\ (W:;_P!?>E?^E$==W7":C_R-
MVF_]?>E?^E$=;4/BG_U[G^1G5^%?XH_F>YT445PF@4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %>9?"O_D;M6_[!5_\ ^G/3J]-KS+X5_P#(W:M_V"K_ /\ 3GIU
M;1_W?%_]>X_FS*?QTO67Z'T+1117DFH4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY0'_  \7_P""@_\ T?9^V3_XD]\;?_FXH_X>+_\ !0?_ */L_;)_\2>^-O\
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M/UC6;>9A>:Q>^#-;U.22ST^WBU"TTO\ M&QU'_1W_8V_;2^ G[=WP9TOXW?
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MV6WO+FVO?$E]:+K.LWS#_,:K_8XTG2K#0]*TS1-*@^RZ9H^GV6E:=;>;-/\
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M4Q6(K1ITZ52G*$71I1<G5BN?K5;@Y-=*<5>S9_I=_MS_ +%?PA_;P_9]\7?
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M?&X.M@:U*#P]6C*CR<L5&$>7E@Z:M:$J3M*FXI.$HQ<;-(_QOZ_N _X-0/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7Q%_P %+O\ E';^W/\ ]FE?M!?^JL\4
M5]NU\1?\%+O^4=O[<_\ V:5^T%_ZJSQ173@O]\PG_830_P#3L#DQ_P#N.-_[
M!,3_ .F9G\T'_!M)_P D,_:7_P"RL>$__4/>OZ7*_FC_ .#:3_DAG[2__96/
M"?\ ZA[U_2Y7V^:_\C#$_P"*'_IN!\SPI_R3V6?]>JO_ *D5@HHHKSSZ$***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *R-8_U$7_77_P!D:M>LC6/]1%_UU_\ 9&IQW7JO
MS)G\+^7YH[W1_P#D%6'_ %ZP_P#H(K2K-T?_ )!5A_UZP_\ H(K2K@G\<O\
M%+\V=$/@C_AC^2"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N$U'_D;M-_Z^]*_
M]*(Z[NN$U'_D;M-_Z^]*_P#2B.MJ'Q3_ .O<_P C.K\*_P 4?S/<Z***X30*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O,OA7_R-VK?]@J__P#3GIU>FUYE\*_^
M1NU;_L%7_P#Z<].K:/\ N^+_ .O<?S9E/XZ7K+]#Z%HHHKR34**** "BBB@
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M;YN?>_M5:W9WW/\ 6'HK_* _X>+_ /!0?_H^S]LG_P 2>^-O_P W%'_#Q?\
MX*#_ /1]G[9/_B3WQM_^;BOG/]2\5_T&X?\ \%U/Z[_T]/L/^(DX'_H68O\
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M%X#\>:KJGB::\UF_LKO2=0?P>)Y-5U=;>^\'W"M+IUO=:=IEO^ZU?Y WP?\
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M<ZGJVL:MJ=S%9:;I>EZ;913WFH:CJ%Y/#:6-C:0S7-W<S100122R(A_T5_\
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MW5M%ANO\O:OJ#]J[]LO]I']MGXBM\3?VD?B;K/C_ %VW6XMO#VE2+;Z3X/\
M!6EW M4DT?P3X/TJ*TT#PU8RQV-C_:$MA9)J6OW5I'JOB34-9UJ2XU*?[@_X
M)'_\$J_B3_P4.^-OA[4?$WAKQ3X<_9.\':R]W\7/BHEE<Z=I^MC284O#\+_
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M-I O8Y;-M<N;-9K/0DNX9[9]8N+%9[>>(O"_]5G_  =)_L9>-/%=O\&?VW?
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M:?9;/4IQX3\?^$_ 5]JFED)=6UQJ'@2[BO;M/,UR#5TDFCE_,3XG?$7]M?\
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MK7_!/3]K#PUX\U'4)E^"7Q#FTOP)\?M'2PGU0R> [G44DC\6Z=86BO>2>(?
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M+F3LU"M&HD]+IRI\\4U>S5]&FG9IV_I5HK\B_P!FO_@N3_P3>_:@\6Z'\/\
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M5LYRFAAZ>+JYC@UAJLI0I5HXBG4IU9P=IQIRIRE[1P>DU"_)]JQ^\5%?F_\
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MM]%\%^ ]%O5O[AM!\%>%M.2+3='L0L5I!=WTBW?B'7A86=YXHUO7=4B:_?\
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M+C&K452JY3]R/*I7DN5:JQ^GM%%%?%'Z6%%%% !1110 4444 %%%% !1110
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M4<'0G2GC,OPWMY3J*HHXV&%E*7*O=O#V\E%;/E5^M_\ 2VHHHKY4^["BBB@
MHHHH **** "BBB@ HHHH QO$?B/P]X/\/:]XN\7:]HWA;PIX6T;5/$?B?Q/X
MCU2QT3P]X<\/:)8SZGK6O:]K6ISVNFZ1HVD:;:W.H:IJFH7-O8Z?8V\]W=SP
MP0R2+\G_ /#Q?_@GQ_T?9^QM_P")/?!+_P";BC_@HO\ \H^/V[/^S-OVGO\
MU27CBO\ * KZ;(LAHYO1KU:F(J471JQII0C&2DG'FNW+9]#XKBGBG$</U\)1
MHX6CB%B*,ZDG5G.#BX34;+DT::?7J?ZO_P#P\7_X)\?]'V?L;?\ B3WP2_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(UC_41?\
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MOC<#0Q-90C352JI.2A%N48*TDE%.4G:V\GW9\F_L5_L8_!K]@OX$Z/\ L^_
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MT(8BCSQJ>SJ7Y>>*:C)I-7MS.R>FNVQ_.I\/?^#8S_@GKX \=^#_ !R_CO\
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M_@GO_P $U?@7_P $V?"7Q%\&_ SQ7\6?%>E_$WQ'H_B?7I_BQKO@_7;^TO\
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M7\$Z+JDMPT@FTBVU[7?#WBV/21$QC.CWGC*]='"M::C:6RK:#^G6BHP>88W
M2E+"8BI1<[<RCRRA*VSE3FI0DUK9N+:NTFKLTS#*,MS6$89AA*6)4+\DI<T:
MD%+XE"K3E"K!2LFU&:3:3:NE;^2KX6_\&G_P<T3Q#8WOQD_:^^(GQ%\-033R
MWF@_#[X6>'_A-J-_'Y"_8K?^W]=\9?%Q+6%+Q6DU%HM&-Q>V+FSLI])N@NI#
M^B3]G+]A_P#9@_92^#>I_ GX)_"K0O"_@/Q+I+Z5XZWB:^\1?$4W.COH>H:E
MX[\33O\ VQK^HW^GS743O+<Q6FGI>7-OHEGI5DR6L?UC16N+S;,<<E'%8NI4
MC%J2@E"E#F3NI.%*,(.2>JDTVNC1AE^09/E<I3P. HT9R3BZC=2M5Y9)*455
MKSJU(PDE[T8R47U3/YI/^(5[_@GQ_P!%B_;)_P##@_!+_P"AYK]COV%_V(OA
M[^P#\%W^ OPI^(/Q9\<_#^'Q/J_BG1+?XMZIX&UG4_#-SKQBGUC3=%O_  5\
M/_ (.D7VHQS:N]OJ\&K7,.HWMXUK>06TPM4^S:*G$YIF&+I^QQ.*JUJ?,I<D
MW%KFCM):)IK573V;75WO!Y'E.7UOK&"P-'#5N25/VE+F4G"5N:+]YIQ;C%V:
M:NE+=7.6\;^"/!_Q*\'^)?A_\0/#6C>,?!/C'1K_ ,/>*?"WB&PM]3T37M$U
M.W>UO]-U*PNDD@N;:Y@D9&5URIVR1LDB(Z_RX?&[_@U0^ GB[Q1>ZQ\!_P!I
MWQ]\%O#U[>-<IX0\8_#[3_C-::5"\6&T_1]83QM\-=:%I'/E[9];NM>OTM\0
M7-[>3#[6?ZN**6"S+'9>Y/!XB='GMSQ2A.$FMFZ=2,X.2V4N6Z6E[%9EDV69
MO&$<QPE/$^RO[.3E4IU(*5FXQJT9TZBBVDW'GY6U=JY_)M\,/^#4+X&Z+JVG
M77Q@_:U^)_Q#TBWF:74=)\ _#KPS\*I]214O#!;QZGK?B+XL-8PF9].^V,EI
M-<3VUMJ$-K/83ZA:WFE?U5^%O#UCX1\,>'/">F37UQIOAC0=(\/:?/J=T]_J
M4UCHNGV^FVDVH7T@$EY?206T;W=U( ]Q.TDS ,Y%;U%&-S+'9@X/&8B5;V?-
MR)QIPC'FMS-1IPA&[LKNU]%V#+<FRS*%46782&&]KR^T:G5J3FH7Y5*=:I4F
MU'FE9<UDVVMV?@%^VI_P;K_L6?M5>,M1^)OP\U#Q+^R_\0M?OKK4?%9^&UAI
MFK_#GQ/J%Y#<&?6+KX<:L]K:Z#K,E[]AN+B3P5K?A;1;Y(]4GU'0;S7M8F\0
M6_P!X=_X-,O!5MXA6Y\6?MP>*-;\*":9GT7P[\ ])\+^(6@:4&"-?$^I?%GQ
M?IJS1P9CFG/A%TGE(F2WMT!@/]?E%=5'/\XH4E1IXZHJ<5RQ4X4JLE'HE.K3
MG422TC[WNJR5DDCAQ'"G#V*K2Q%;+*+JRESR=.I7H0E)N[E*E0JTZ3<GK*\'
MS-MRNVV_SX_8>_X)@?L@_P#!/S2KZ+X#> KBZ\9:ND$6N?%GXA75CXL^*&JP
M0626;6:>(DTO2[30-,N\2W5]HOA'2?#NBWM[<23W&GR>7:I;_!'Q]_X-POV%
MOVA_C9\5/COXJ^(G[3_AGQ3\7_'7B/XB>)]%\$>-/A/IWA6U\2>+-2GUG7I=
M&LM<^"?B+5K>WO\ 5KN\U"1+[6]1F-S=3L;@JRHO[_45S4\TS"E6J8F&+KJO
M52C4JN;E.<4TXQ;E?2-ERI626BLM#MJY)E-?#4<)5R_#2PV'DYT:*IJ,*<FK
M2E%0Y?>DOB;NY/65WJ?F)_P3U_X)3_ [_@FIJ7Q,N?@/\4_C]XGT?XLV7AR#
MQ9X3^*_B#X9^(/#W]I>$Y]4DT#Q%I)\*_"?P3KNFZS96NN:YILPBUQM)U.QU
M,_VMI5]>:7H-WI/Z=T45S5\16Q565?$5'5JSY>:I*W-+EBHQYFDKM125WK9)
M=#LPN$P^!H0PV$I1H4*?-[.E"_)#GDYRY4V[*4Y2DTM.:3>[84445B= 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO_@UA^/G_"7_ ++GQS_9ZU37HKS5O@S\5;3QCX=T6:W\B[TSP-\5M'#".SN
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M\*8"<<)BZE\0^6\JM?$\\7))IU'A^6A1NFI+VD8>ZU+X6F?GM#.N/<TI3S#
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M55)'X(?\&UGC&[\3?\$PO"VBW$EP\/P[^,OQ=\'6"S/(T<-I?:MI_P 0'CM
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M_AFXF\/?$'0K:R;5M:OK'1D\2Z=?:CX176+]M8U#P5J/AK6KZ*&35 @\#/\
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M"?Q_XHU>\L/#WAB.6TFMMNEVD^O>+5DO;&:3PQ'IDLVI6WX\G_@[2T'^VKB
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MWJ5]JFN7]E8:K?P:9I>F6%[J%X--TK5-3FAMF@TW3-0OY;>TF_J3T[_@TO\
M$\OAZ.YU?]NG0;'Q6;&>2;1=._9WU#5/#T>I*)?LUI'XFN?C1H^I2V,K"$3Z
M@WA*&>W$DK1Z9<F%%G^OK93PQE2I4LQG*=:<>92J3Q7-)7LY>SPEE"',FH\R
M[KFDU<_/,/GW&^>RK5\GI0IX>G4<'&E3P"A!V4E3=7'W=2HH2BY<C6ZER132
M/O+]G?\ X.>/V*?BIXDT_P *_&/P!\4?V=KC5;C3;2T\5:Q_8_CWX>VEQ>S6
MMI.NNZYX>DL?$>CV]M<7+3#47\&7.EKIEK=WVI7NE.D5I-_1[HFMZ-XET;2/
M$?AS5],U_P /:_IEAK>@Z]HE_:ZKHVMZ-JMK%?:7J^D:I82SV.I:9J5C/!>6
M%_9SS6MY:S17%O+)#(CM_E0?MX_L'?&W_@GO\;;CX,?&>WTZ^>^TYO$7@CQO
MX=74)/"GCOPI)J%Y86VKZ1<W]G:217L4EH8];T2027FA7DD=O<R3136MU=?T
ML_\ !KU^W-XIUFX^)?["/Q"U_4];TC0M D^+/P%^W'4=0_X1G3K74HM/^)O@
MF&]EFN8-/T">\UCP]XK\-Z3'#I]C8ZK-XYN3-=7>O6UO#P9QP_@X8'^TLJG*
M5&,8U)T^=U83I-I.I2G*\TX-WG&;:Y5)^ZX\LO5X=XMS&IFG]BY[3C'$3G*E
M3K>S5"I#$13DJ->G"U-JHE:E.G&/ON*M.-12A_7AXY\7:;X \%>,/'FLP7US
MI'@GPMX@\7:K;:9'!-J5QIOAO2;O6;Z#3X;JYLK66^EM;*6.TCN;RT@DG:-9
MKF",M*G\YO\ Q%0_\$^/^B._MD_^&^^"7_T0U?O=^TO_ ,FX?M ?]D2^*W_J
M":]7^1)7/PUD^"S2GBY8N-23HSHQAR5'#2:FY7LG?X5Z:G7QGQ#F61UL!# 2
MHQCB*=>53VM)5+NG.DHV;:MI*5^]_(_UN_V7OVF_!/[7'[.?@#]IGX7>'O&E
MEX,^)6BZWK7AKPWXNL_#FD^-BFAZ]K?AR:QO[33O$^L^&K2^O-2T*Z^Q8\4R
MV)@GM9;R]LRTZ6_X>ZA_P=(_L#Z3?WVE:K\$/VU=,U33+RYT_4M-U#X:_!BR
MO]/O[*9[:\L;ZSN?V@X[BTO+2XCD@N;:>..:":-XI41T91]V?\$,_P#E%+^Q
M[_V*'CC_ -6[\0J_B^_X+W?LD6?[*?\ P4-^(]UX8TZ\LOA[^T+9I^T#X362
M#_0+'5O&VK:M%\1M"L;R+%H8K#XA:=XAU2RT>&*TD\/^&]?\-Z<;0V:V&H:C
M.4Y9EN*S7,,OQ,:EJ52LL+RU'%\M"M.$H2>O-)P<9)VVA-[V*S[.LYP.0Y/F
MV#G1O7H89X]3HQFN?%8:E5A4@FUR0515(-)O6K!+:Y_>_P#L,_MP_!G_ (*"
M_ U/C[\#[7Q?I?A:/Q?X@\#:IH'CZR\.Z9XPT#Q)X<33KJZL-<T[POXG\7Z3
M9R7FDZQHNNZ>D>N3S3:/K&G74\-LUQY*_8M?Q _\&K7[2[>&_C+\?_V3];OI
M%TSXF^$-.^+_ (&MY8HOLT'B[X?7,>@^+;&VFC9;C[?XD\*^(M+U*2.>*>T%
MGX D:*>PN&:'5?[?J\G.< LMS&OAH<WLERU*+D[MTJD5)7>E^67-!NVK@V>_
MPYFLLXRC"XVIR^W:G2Q*BDDJ]*3C)J*;45./)54>BFD?F5_P4,_X*O\ [,__
M  34NOA=IGQST;XH^+];^+-OXIOM!\/_  BT?P3XAUK2=*\)R:);W>L>)K/Q
M;\0/ O\ 9>EZI=ZXEEH%S#)>_P!K7>EZ[%"B_P!D7;)\Q?LH?\' '[)G[9GQ
M^^'W[.'P9^"G[6$WC[XBWNHP:?>>)?!_P7T?PQH>FZ)HVH>(O$'B+Q)JMO\
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M-Q\#M+L9KQU$9DL7\200QLSJNH2B-6D_9']A+_@MI^Q3^WAK^G_#KPGK^O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6^)_#/C3Q1?6GCY7CM;6R2Z\::'JVG:SKEE8QQVMAXEDUJWL[:UTP:?%7?\
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M-V]_$$MKFTT#P_IMK)906UB8?L=K;01>$_$/QOKGQ,\?^.?B/XGOK[4_$OQ
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M;JZG98UO]5U*:"RM9KFXD(F>*UMI9I&6&%F7N/V>?"/@CQ_\?O@=X#^)FO\
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MSV:2:/SGQ!Q%*OGT*=*492PN!H8>KRV?+5=7$5G!M=8PK0NMU)M/70_T]O\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\;?^#@/_E$7^UK_P!T&_\
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M1C/*,!A\'@Y.4:=2C1HTJ?*I-2<:F-J2A/EDI*4J--6DFDE)6/Y!O&'B>_\
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ML.Y*+UY6I-6E%O\ T(O^#8>WGA_X)N:S)-!-%'=_M*?%"XM9)8WC2Y@7PO\
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MKXFM9?WK0QRZ3K_COP1=6(D:TMXDN(?^$5@O)K:.>^:.'4;2XDN(_MB6EO\
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MN/\ 8O\ 9_U-XBM_']G[7VMX*IS7UV4>6_V?D?SI?\%N/^"C/[-O_!2+XC_
MKXD_ 3PI\9?"FI^ /!'BOP/XUM_BWX5\!>'_ +783:]8:]X2F\/WG@SXA^/;
MC4MEQJ/BR/5;;5AI,.F_\2V73#?OJ>I?8O1/^#:7XA:OX/\ ^"F.B>%;&YF3
M3?BO\&?BIX-UNU6-);>X@T73]/\ B192RB25!;S6U_X&@6"]ACFN42XN+%52
MUU"\D7]Z?^(5[_@GQ_T6+]LG_P .#\$O_H>:^G?V.?\ @@=^R%^Q#^T1X#_:
M7^$OQ0_:=UKQS\/H?%EOIFB^//&WPQU'P;JMOXP\&^(/!.I0:_IOAKX.>$]7
MOH;:P\0W&I:=%;Z]9)#K=CI=Y.MU#:O:3X5L[R2.45\MPLL0T\-6I4%5I2;Y
MYJ4X*4V]E4DK.WNI>2OU8?AKB6?$&%SG&PP:DL;A:V*E1K0C>G3=*G5<::6\
MJ,97BG[TN:VZ1\=?\'0'[)?B[XO_ +./P?\ VDO F@W^O7?[->O^,K+X@VFC
M:>UY?6_PS^(]IX>FO?%FHK::?<7TVC^"=>\%Z6;J9[R"QT+3O%&MZO=0M:I>
M7EE_$'\(OC%\4_@'\0O#GQ6^#'CWQ/\ #3XB^$[O[9H/BWPEJEQI6JV;.IBN
MK.9X6\G4=(U2U>73];T/4X;S1==TJXN])UFPOM-N[FTE_P!<SQOXQ^'GA+2I
M/^%C^*O!GAG1-4M[JTF_X3?7-#T;2M1M)/)L[VVD_MZZMK2[MW^WV]K=0MYD
M;?;88)5/VF-7_G@^.'_!%3_@D!^VQ\0-=LOV<?BQX#^$7Q?LH;_Q5XQ\'_LP
M?%/X?^+-+CTN2Y?16U34O@J=5\0Z?X(T*QUZ6PL$'@NQ\$>'XKI)=,>T&H7P
MN(>;(<^HX7!O!8ZA5EAH.IRUX4G5IQIU).4Z=:%OAYY2M)<]^=1<$ES/MXJX
M5Q&/S)9GEF*H0QE14O:8:I7]A6E5HPC"E5PU2]N?V<(7C)T^7V?/&<I2Y5^'
M_P "/^#G+_@H!\-TAT_XPZ-\(/VC--\UY+K5/$?A*/X<>-G1KB65;>TU;X8M
MX>\&6L*0S"U!N/AU?W#1VUI(TYG%Y)>_J5\(/^"_W_!+[]I[QOHVM?ME_L?Z
M)\*/B6+/3/#VG?$WQEX \!_M&^']%T/2_$&IWNA:3/\ $(>#-(^)6F:?IE[X
M@U+Q%9V5K\/I=%TB]U/Q)<I=P74PN-7_ #R^-?\ P:T_MF>#)Y;GX)_&#X*_
M&W15NO(A@UF77_A-XQE@=R(KU]$U*U\5^%(H8XUW7D0^($MS"[QQVD-^IDDB
M_ W]I']E;]H3]D+X@?\ "KOVD/A;XA^%?C:33H]8LM,UI],O['6-'EN;FR35
M_#OB+P_?ZOX:\2:4;VSN[(ZEH&L:E9+>6MQ:M.L\,D:^U# <-YHY/!3I4ZTH
MMWP=66&K1CU:P[Y8J.U^:@TM$[7/FZN:\99'&*S*G7K8:,TK9E0AC</*:^%/
M%KFFY;\O+B4WJU=JZ_U>_@]JWPA\2?#OPSXK^!-SX#U#X7>*].MM=\*ZO\-8
M]$3P?K.GS6\5I!?:8_A^./390D%G%82;%$UJ;(6$Z1269@B_)'_@X!_9+\7?
MM6_\$^_$*_#G0;_Q+\0_@7XZT#XWZ#X?T33VU#Q!XCTG1-)\1>%O&6@Z5;6V
MGW^I7T@\,>+;_P 3+H^G&VN-5O\ POIL2-<31065Q_/G_P &Q/[77Q"\&?M5
MZ_\ LA:GXBU/4?A#\9/!/B_Q;X?\)7,TUSI_AKXK>"[.QUYO$FC))YT6D1Z[
MX)TOQ)I?B2"T6U37;NS\*W%[-)+H5G#+_=1XC\4^&/!^FOK/BWQ'H/A;2(V9
M)-5\1ZOI^B::CI!/=,CWVIW%K:JRVMK<W+*TH(@MYYB!'%(R_&8S#5\AS>GR
M3]O*E.GB*,FFG5IR;7+-*[3?+.G.S=[.2M=)?HV7XS"\5</UO:0^K0KTZV#Q
M,(M-4*T8Q]ZG)I)Q2E3K4U)*UU&5[-O_ !]/"OBOQ3X%\2:'XR\$>)=?\'>+
M_#&IV>M^&O%7A76-1\/>)/#VLZ?,MQ8:OH>N:1<V>J:3J=C<(D]G?V%U;W5M
M,BRPRHZAA^\GP'_X.4/^"D'PH>*T^(VL_##]HS1 88FB^)7@+3O#GB&TL8;>
MU@2#3/$?PJ;P&LEUFV:634_%.D^++RXEO+V2[>XD:U>T_HV_:F_X):?\$<OV
MZ_B9/I?A/XD?"+X6?M->-;N\UN0?LW_%_P"'-KXO\9-IL(U[Q+?WWP6AU36O
M#6LWDVFSW>N>)/$NC^#=.\274MY_PD'B'7;^-6\W\;/CY_P:M_M*^%Y]6U+]
MG/X^_"SXLZ)#-+<:;H'Q#L-<^%GC22SD?,&G0SV$'C?PEJ>HVBNL,U_?:SX4
ML;](9;Y+;3I)8M*7[%YQD.91IPS&C&C5<;QAC:#3BI.S=+$*+482:TESTW+E
MUBFK+\[7#O%62SJU<GQ,L314[3J99BDU-Q5XJOA)23G449)N'LZRAS:2::;^
MJ/ '_!QA^P-^TKJOABR_;P_8=T_1;[P[%JNG^&?&MYX=\"?M->&_#46N6VA7
M'B.ZBMO%7A'POXR\':?XEU#P_IRZAI?A72/&$]P^C>&3J5Q?+:?:]*_IT_9D
M\>_LR?%;X8:9\2OV4=1^%^M_"[Q(TD-MK7PMTG2=&TN6\T^::2XTS5M-T[3]
M+O-*UG3+B_N'O-%URPL=6TZ:^E:ZLH'NV,G^7Y^US^P9^U9^PSXETOPW^TO\
M)M6\!+XBFU2/PCXFAO\ 2/$G@OQC%I#V_P!LF\.>*_#E_J>D74T-O>6%Y<Z1
M=7%EXATRVU"S.L:/IT\WD+]\_P#! O\ :Z^(7[.?_!0'X1_#C3/$6IK\)OVD
M?$=M\*?B3X*$TTVCZQJNMV&I6?PZ\21V)\VVM-?\,^-+G2?*UM+?[8GAN_\
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MCL-2RO"XM8C'2QRKN>+JXB<XM4,12I\L>6T;0OKJV?KU_P +H^%/_0^^&_\
MP8)_A1_PNCX4_P#0^^&__!@G^%?D+17YY_Q'C/\ _H2Y/_X%C?\ YH/DO^)M
MN,/^B8X:_P# LT_^;/7^EK^O7_"Z/A3_ -#[X;_\&"?X4?\ "Z/A3_T/OAO_
M ,&"?X5^0M%'_$>,_P#^A+D__@6-_P#F@/\ B;;C#_HF.&O_  +-/_FSU_I:
M_KU_PNCX4_\ 0^^&_P#P8)_A1_PNCX4_]#[X;_\ !@G^%?D+11_Q'C/_ /H2
MY/\ ^!8W_P": _XFVXP_Z)CAK_P+-/\ YL]?Z6OZ]?\ "Z/A3_T/OAO_ ,&"
M?X4?\+H^%/\ T/OAO_P8)_A7Y"T4?\1XS_\ Z$N3_P#@6-_^: _XFVXP_P"B
M8X:_\"S3_P";/7^EK^O7_"Z/A3_T/OAO_P &"?X4?\+H^%/_ $/OAO\ \&"?
MX5^0M%'_ !'C/_\ H2Y/_P"!8W_YH#_B;;C#_HF.&O\ P+-/_FSU_I:_KU_P
MNCX4_P#0^^&__!@G^%'_  NCX4_]#[X;_P#!@G^%?D+11_Q'C/\ _H2Y/_X%
MC?\ YH#_ (FVXP_Z)CAK_P "S3_YL]?Z6OZ]?\+H^%/_ $/OAO\ \&"?X4?\
M+H^%/_0^^&__  8)_A7Y"T4?\1XS_P#Z$N3_ /@6-_\ F@/^)MN,/^B8X:_\
M"S3_ .;/7^EK^O7_  NCX4_]#[X;_P#!@G^%'_"Z/A3_ -#[X;_\&"?X5^0M
M%'_$>,__ .A+D_\ X%C?_F@/^)MN,/\ HF.&O_ LT_\ FSU_I:_KU_PNCX4_
M]#[X;_\ !@G^%'_"Z/A3_P!#[X;_ /!@G^%?D+11_P 1XS__ *$N3_\ @6-_
M^: _XFVXP_Z)CAK_ ,"S3_YL]?Z6OZ]?\+H^%/\ T/OAO_P8)_A1_P +H^%/
M_0^^&_\ P8)_A7Y"T4?\1XS_ /Z$N3_^!8W_ .: _P")MN,/^B8X:_\  LT_
M^;/7^EK^O7_"Z/A3_P!#[X;_ /!@G^%'_"Z/A3_T/OAO_P &"?X5^0M%'_$>
M,_\ ^A+D_P#X%C?_ )H#_B;;C#_HF.&O_ LT_P#FSU_I:_KU_P +H^%/_0^^
M&_\ P8)_A1_PNCX4_P#0^^&__!@G^%?D+11_Q'C/_P#H2Y/_ .!8W_YH#_B;
M;C#_ *)CAK_P+-/_ )L]?Z6OZ]?\+H^%/_0^^&__  8)_A1_PNCX4_\ 0^^&
M_P#P8)_A7Y"T4?\ $>,__P"A+D__ (%C?_F@/^)MN,/^B8X:_P# LT_^;/7^
MEK^O7_"Z/A3_ -#[X;_\&"?X4?\ "Z/A3_T/OAO_ ,&"?X5^0M%'_$>,_P#^
MA+D__@6-_P#F@/\ B;;C#_HF.&O_  +-/_FSU_I:_KU_PNCX4_\ 0^^&_P#P
M8)_A1_PNCX4_]#[X;_\ !@G^%?D+11_Q'C/_ /H2Y/\ ^!8W_P": _XFVXP_
MZ)CAK_P+-/\ YL]?Z6OZ]?\ "Z/A3_T/OAO_ ,&"?X4?\+H^%/\ T/OAO_P8
M)_A7Y"T4?\1XS_\ Z$N3_P#@6-_^: _XFVXP_P"B8X:_\"S3_P";/7^EK^O7
M_"Z/A3_T/OAO_P &"?X4?\+H^%/_ $/OAO\ \&"?X5^0M%'_ !'C/_\ H2Y/
M_P"!8W_YH#_B;;C#_HF.&O\ P+-/_FSU_I:_KU_PNCX4_P#0^^&__!@G^%'_
M  NCX4_]#[X;_P#!@G^%?D+11_Q'C/\ _H2Y/_X%C?\ YH#_ (FVXP_Z)CAK
M_P "S3_YL]?Z6OZ]?\+H^%/_ $/OAO\ \&"?X4?\+H^%/_0^^&__  8)_A7Y
M"T4?\1XS_P#Z$N3_ /@6-_\ F@/^)MN,/^B8X:_\"S3_ .;/7^EK^O7_  NC
MX4_]#[X;_P#!@G^%'_"Z/A3_ -#[X;_\&"?X5^0M%'_$>,__ .A+D_\ X%C?
M_F@/^)MN,/\ HF.&O_ LT_\ FSU_I:_KU_PNCX4_]#[X;_\ !@G^%'_"Z/A3
M_P!#[X;_ /!@G^%?D+11_P 1XS__ *$N3_\ @6-_^: _XFVXP_Z)CAK_ ,"S
M3_YL]?Z6OZ]?\+H^%/\ T/OAO_P8)_A1_P +H^%/_0^^&_\ P8)_A7Y"T4?\
M1XS_ /Z$N3_^!8W_ .: _P")MN,/^B8X:_\  LT_^;/7^EK^O7_"Z/A3_P!#
M[X;_ /!@G^%'_"Z/A3_T/OAO_P &"?X5^0M%'_$>,_\ ^A+D_P#X%C?_ )H#
M_B;;C#_HF.&O_ LT_P#FSU_I:_KU_P +H^%/_0^^&_\ P8)_A1_PNCX4_P#0
M^^&__!@G^%?D+11_Q'C/_P#H2Y/_ .!8W_YH#_B;;C#_ *)CAK_P+-/_ )L]
M?Z6OZ]?\+H^%/_0^^&__  8)_A1_PNCX4_\ 0^^&_P#P8)_A7Y"T4?\ $>,_
M_P"A+D__ (%C?_F@/^)MN,/^B8X:_P# LT_^;/7^EK^O7_"Z/A3_ -#[X;_\
M&"?X4?\ "Z/A3_T/OAO_ ,&"?X5^0M%'_$>,_P#^A+D__@6-_P#F@/\ B;;C
M#_HF.&O_  +-/_FSU_I:_KU_PNCX4_\ 0^^&_P#P8)_A1_PNCX4_]#[X;_\
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MC_B.6>_]";*?_ L9_P#+P_XFZXP_Z)?AK_P+-/\ YL/VG_X7M\'O^BB>&/\
MP8+_ /$T?\+V^#W_ $43PQ_X,%_^)K\6**/^(Y9[_P!";*?_  +&?_+P_P")
MNN,/^B7X:_\  LT_^;#]I_\ A>WP>_Z*)X8_\&"__$T?\+V^#W_11/#'_@P7
M_P")K\6**/\ B.6>_P#0FRG_ ,"QG_R\/^)NN,/^B7X:_P# LT_^;#]I_P#A
M>WP>_P"BB>&/_!@O_P 31_PO;X/?]%$\,?\ @P7_ .)K\6**/^(Y9[_T)LI_
M\"QG_P O#_B;KC#_ *)?AK_P+-/_ )L/VG_X7M\'O^BB>&/_  8+_P#$T?\
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M'_B-V>_]"C*?OQG_ ,T#_P")N>,?^B8X9_\  LT_^;?7^EK^ZO\ PT'\$_\
MHIGA3_P8K_\ $T?\-!_!/_HIGA3_ ,&*_P#Q-?A511_Q&[/?^A1E/WXS_P":
M _XFYXQ_Z)CAG_P+-/\ YM]?Z6O[J_\ #0?P3_Z*9X4_\&*__$T?\-!_!/\
MZ*9X4_\ !BO_ ,37X544?\1NSW_H493]^,_^: _XFYXQ_P"B8X9_\"S3_P";
M?7^EK^ZO_#0?P3_Z*9X4_P#!BO\ \31_PT'\$_\ HIGA3_P8K_\ $U^%5%'_
M !&[/?\ H493]^,_^: _XFYXQ_Z)CAG_ ,"S3_YM]?Z6O[J_\-!_!/\ Z*9X
M4_\ !BO_ ,31_P -!_!/_HIGA3_P8K_\37X544?\1NSW_H493]^,_P#F@/\
MB;GC'_HF.&?_  +-/_FWU_I:_NK_ ,-!_!/_ **9X4_\&*__ !-'_#0?P3_Z
M*9X4_P#!BO\ \37X544?\1NSW_H493]^,_\ F@/^)N>,?^B8X9_\"S3_ .;?
M7^EK^ZO_  T'\$_^BF>%/_!BO_Q-'_#0?P3_ .BF>%/_  8K_P#$U^%5%'_$
M;L]_Z%&4_?C/_F@/^)N>,?\ HF.&?_ LT_\ FWU_I:_NK_PT'\$_^BF>%/\
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MZ)CAG_P+-/\ YM]?Z6O[J_\ #0?P3_Z*9X4_\&*__$T?\-!_!/\ Z*9X4_\
M!BO_ ,37X544?\1NSW_H493]^,_^: _XFYXQ_P"B8X9_\"S3_P";?7^EK^ZO
M_#0?P3_Z*9X4_P#!BO\ \31_PT'\$_\ HIGA3_P8K_\ $U^%5%'_ !&[/?\
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M * ,A_\ "7,/_GH'_$VOB/\ ]"7@G_PVY[_]$A^ZG_#9'[-__11O_+0\>?\
MS+T?\-D?LW_]%&_\M#QY_P#,O7X5T4?\1EXG_P"@#(?_  ES#_YZ!_Q-KXC_
M /0EX)_\-N>__1(?NI_PV1^S?_T4;_RT/'G_ ,R]'_#9'[-__11O_+0\>?\
MS+U^%=%'_$9>)_\ H R'_P )<P_^>@?\3:^(_P#T)>"?_#;GO_T2'[J?\-D?
MLW_]%&_\M#QY_P#,O1_PV1^S?_T4;_RT/'G_ ,R]?A711_Q&7B?_ * ,A_\
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MNI_PV1^S?_T4;_RT/'G_ ,R]'_#9'[-__11O_+0\>?\ S+U^%=%'_$9>)_\
MH R'_P )<P_^>@?\3:^(_P#T)>"?_#;GO_T2'[J?\-D?LW_]%&_\M#QY_P#,
MO1_PV1^S?_T4;_RT/'G_ ,R]?A711_Q&7B?_ * ,A_\ "7,/_GH'_$VOB/\
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M* "BBB@ HHHH XOXA_\ (FZU_P!<[3_TX6E6_@A_R)LW_8;OO_2:QJI\0_\
MD3=:_P"N=I_Z<+2K?P0_Y$V;_L-WW_I-8UV/_D65/^PI?^D0%'^-'_!+\T>P
MT445Y9TA1110 4444 %%?S)_\%BO^"\7@+]G/PWXG_9V_8T\;:!X^_:2U![_
M ,-^,/B-X?EM]?\ !_P'C6%(M2^QZJB7&@>*?BC#)/+IUGH]C/J>F>!]8M-1
M;QD(]<T=?"M]X_\ \&I7PND@^#?[7/Q_U 27M_X^^+'@SX71:I>7-I=W?F?#
M?PM=>-=;$9>W.K6\FI3?%_2;C5;FXOYK35Y++3=EO%<Z3<37'LO)<13RNKF>
M(D\/%2I1P]"=-^TQ"J3C%S=Y1]E!)\\&XS=11DTHQ<92^<7$F%K9Y0R3!Q6+
MFX5YXO$TZJ]EA'2IN<::Y835>HY+V=1*=.-&4HIRG/GA#^LRBBBO&/HPKGO%
M?B[PIX$\/:GXM\<>)_#W@WPIHL,=QK/B;Q7K6F^'?#VDP2SQ6L4^IZUJ]S9Z
M;80RW5Q!;1R75S$CSS10JQDD16_E\_X*T?\ !PO8_L]>)_$_[-_[$@\-^,_B
MWX;OETCQ]\;-6@MO$O@+P'JD U"#6?"G@[2/-6P\6^-]&O$L(]3UC46U#P?H
M-TFH:%/I6OZO%?)H?\O?@#]GK_@I9_P59\?7'C;1/#7QJ_:7UP3+I%_\3_'6
MNO!X(\/I!!+.VE-X]\<:GI'@G08;6VLY98_#FF:C!<22+';V&DW%_=VMO<?3
M8'AJM7H+%X[$4\NPK2DI5DO:2@[-2<93IPIQDOAE.?-U]FU9OXK-.-,-A<4\
MORO"5LXQT92A*&'<O90J+1P4H4ZTZTX/XXTZ?*K./M5)-+_1QG_;^_8/M=37
M1;G]MC]DBWUAIK>W729_VD/@Y%J;7%V(FM(%L)/&:W1FNEFA:WB$1>831&-6
M$B9^E/"WC'PCXYTH:[X)\5>'/&.B-<36BZSX6US3/$&E&[M]GVBV&H:3=7=H
M;B#>GG0B;S(MZ;U7<,_P'V__  :]_P#!1N;PU!KLGB[]ERTU26&.23P9<?$S
MQXWB6V>2Y6!K>>ZM?A+<^#VFAB)O9&MO%=Q ;962&>6\VVC?G?\ $;X*?\%)
M/^"1'Q5TS6M:M/BS^S9XCO[Q3X<^(G@?Q!]M^''C]=/;45@LX/%/AJ\U3P)X
MNVV4EW>W?@?Q*T^M:;I>IQOXC\+::FI+%+U1X=RS%-TL!G5*KB$G:G.,'SM+
M7EY9J?+U<H1J)+H]SAGQ?G6 4:V:\-5Z&$;BI5J<ZB]FI6MS.=.5/F=[*%2=
M%MZ7331_J1T5_/?_ ,$9/^"V%C_P4 GO?@%\=]+\/>!OVGO#?AY]=T:ZT1O[
M.\)_&?PYHMM8PZ]JF@:?>W4DFE^/-+EDFUKQ!X.L9+FVN-!^V^)?#D<>CZ+X
MAL?#O]"%?,XS!XC 8B>&Q,.2K"ST=XRB]8SA):2C);/=-.,DI)I?:Y=F.$S7
M"T\9@JJJT:EU>SC.$XVYJ=2#UA4C=7B]&FI1<H2C)E%8GB;Q)H/@WPWX@\7^
M*=4M-#\,>%-$U7Q)XCUO4)/)L-'T'0["XU35]4O9<'RK33]/M;B[N9,'9#"[
M8.,5_ 3_ ,%/O^"^7[0?[4WCSQ+\)/V/_&'C+X,?LWI>0>']*U7PB;WPQ\7O
MB]+;WLB2:YJ'B'3?(\6>$O#OB&5HK;3? VAWFG7NHZ*!#XR:\EU>\\.:7U97
ME.*S6K*%!1A3IV=:O4NJ=-/9:)N4Y)-Q@M[-MQBG)<.>9_@<AH1JXIRJ5:K:
MP^%I<KK5G'=^\TH4XMI3J2T5THJ4FHO_ $$:*_S%/#7_  2&_P""L_QDT-_C
M;9_LP_%_61/I-GXJ3Q%XY\7^$?"_Q!U*RL;.0Z7=V'A[XA^-]#^(^KZC%8Z1
M$NCZ?8:+=ZQ);KI$>FV;I?Z0MST/P _X*5_\%,?^"87Q3M/AWXN\0?%FUT[P
M7]EM/$7[,?[2D/C&?0+?P_JEQ::X;?1O#GBYXM9\!_VS;-_:>B>(?![:;!<1
MZG)JL2:OIVJ7<-_[<N%8U(SC@LVPF+Q%-7G02C!IK=.4*]9Q=[)<\(IMZN)\
MU'CN5&=*69Y#F&7X2LTJ>*DYS4DWI)0J8;#*<>6\I>SJ5)63Y8S/],JBOE/]
MBC]KOX:?MR?LW?#K]HWX7SQ0:9XQTXV_B;PJ^HQ:CJ_P\\>:7LMO%O@'Q!(M
MO8S#4= U(G['>7&FZ:OB'P_=:)XLTVS71/$&ES3?5E?)U*=2C4G2JQ<*E.<H
M3A+1QG%M2B_---=NQ]Y1K4L11I5Z$XU*-:G"K2J1=XSISBI1DO)IIZV?=)A1
M7XL_\%<O^"PWP]_X)O>$+3P9X/T_0_B9^U-XVTB74?!/P]U"Y>?PSX-TKSXK
M>'QM\5HM*U73=>M=!NG-VOAW0=-N;#5?&%WIU];6VJ:)86MYK5I_%(WB/_@J
MW_P5Q\>:H--N_P!H;]IF>UU5+2^TO0[B^T?X+?#RZ\7A[6"QN;>*?P]\&_AC
M:ZW:64D+RZG+H"ZIINE7%SJ%U=V^FW=S#[N6\/XC'4'BZ]>E@<'K:O7WFD[<
MT8N5./)?3GG4@F_AYK.WR^<\783+,4LOPV&KYIF+MS87#.RIMI-0G.,*LO:N
M/O*G3I5&E\?)=7_U :*_RY_'GP!_X*B?\$I/$/ASQQXBT+XX?LO75UJ\%YI'
MB_P1XWLM3\#ZMJMBMC<#3-:U_P"&OB;Q-\/]:^TP3V]M?>%_$MW>6VM6)O=*
MO]*OK./4;1/[:?\ @BG_ ,%3C_P49^"6NZ%\35T;2/VF?@HNBZ=\2K32T2PL
M?'_AW58)8?#_ ,5M$TA8+>UTYM6O;#4=*\8Z%HS76G>'O$-M:WT4>AZ-XO\
M#.AVKS+A^I@L,L;A\51Q^$NE.M127)S/E4FHU*L)0<FHN4:C:DTG%)W#)N+*
M698UY;C,!B,IS#E<J>'Q+;]HHQ<W%.=*A4C44$ZBA.BE*$9.,FU9_M?1117S
MQ]:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME]TKY_'XB&*QN+Q--2C3KXBK5@II*:C.;DE)1E)*23U2DU?9L^LRK"U,#EN
MP=64)5<+A,/AZDJ;DZ<ITJ482<'*,).+<6XN48MK>*>A^8O_  5K_8%T[_@H
M3^R'XL^%^E66F+\9/!EP/B%\"->U"Y734L/'VDVL]O+X?O=4VGR= \<Z)<ZA
MX9U2"\9M)@OKK1/$EW ]YX:TRXM?\PCQ!H&M>%->UOPOXDTR[T7Q#X;U?4M
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M_#W_ (-C?^";'@O7(]6\27_[1OQ;L$:%F\,?$+XI:!INAS")RSI)<?"GX?\
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M3HP2;JTJ,N9.G*ZY+6:LWJE1U/3--UK3=0T;6=/L=6TC5K&[TS5=*U.T@O\
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M>(P_NTI5Z3PR6)IQ:Y/:XJ4H3<-(N3J>SJ32;K\SYC\H_P#@CC^Q!XD_;?\
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M6:]+\//V\?AUH5]K6C^&?#4/PL^/PM9[FYD\-Z7;ZR)_ACXT73BLR1:-/?\
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M^:8K.*^+RK!JOA\7&%>HU7PM%4\3*\:T>6M6I2DYRBJ\IJ+3E6DKW32^[/\
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MH;K6;ZZU75+B&"34Y[=?V9_XA6_V]_M_E_\ "Z_V0O[+^V;/MG_":?&;[?\
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M#+/_ %&1_EKXY?\ ):4/^Q!E?_I6)"BBBOQ@_' HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OV@_8P^"Q^'?@3_A,M<M#%XL\<P07>R9'6?3/#N?.TVR*NJ&.6
M]!74;I2I/SVT98^217P%^R?\&&^+7Q&MKG5+9I/!_A%[?6-?=T?R;V='+:9H
MV\,@+7UQ'YER@8L+&"?*?.N?W+1$C54151$541$4*J(H 554 !54 !5
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M2ZFJ3S(5<_Q4_P#!:+XB:M^T%_P59_:=BT*5_$$VC_$K1/@;X4TRR0+Y=_\
M#G1M"^&]YH5FDEQ-FXE\:Z7KC7)>=5EU6]O)4BLX9$M+?_23^#'P[L/A!\'O
MA1\)M*BMX-+^%_PU\"_#O38+1VDM(;#P3X7TOPU9Q6LCV]H\EO';Z9&D#O:V
MS/$JLUO"28U]GBC&5*F597"JE"KBW'%5(1NE'DHQ?)JV[1>(2UW<+Z6/F^!\
MOHT<]SRI0E.I0P$98"E4J<KE4]IB&O:7BE"\EA'*T=HU$M;W/2J_ C_@X _X
M*,W_ .Q?^S+9?"+X6>('TC]H+]I2WUKP_H&I6$=A=WO@;X9:8;&T^('BV1;A
MIGTO4]:M]5A\(>#[V2R$S7=]XAUO0[RWU7P<9H/WWK_,R_X+I?M"ZU^T#_P4
MN_:)^TZI<77ACX-^(T^!7@S23J]WJMAH5K\,[>/0O%D-BL\5M!82:K\0H?%V
MMZC8V=I%':7^H36<EQJ<MJVJ7GA\-9?#'YE'VL5*CAH/$5(M7C.491C2@UU3
MG)2DFFI1A*+T9]-QIFU3*\FFJ$G#$XVHL)2G%M2IPE&4JU6+5FI*G%PC)-2C
M.I":^$[O_@BW_P $H;S_ (*,_%G5_%OQ)N-1T+]F#X.ZCI?_  L6^TR8V>L?
M$#Q)=A;_ $WX7>';Y)$N-,%]IZ-J/B[Q#:"2[T+0Y+2TL39ZQXBTC4[#_1C\
M ^ /!'PK\&>'/AW\-O"F@>!O OA#2X-&\,>$_"^F6FC:#H>F6VXQ6FGZ=91Q
M6\$9=Y)IF5/,N+F6:YN'EN)I97^+_P#@EU^RU8?L>?L*_L^_!E=)_LSQ3'X-
MM?&_Q)>Z\.P^&]?N_B1\02?%GBB'Q3:+/=W=QK?AF;4[?P.MSJ5Y<WD6C>%=
M(TU/LECI]EIUE]_UGGV:U,RQM1*;^JT)RIX:FF^1QBW%UFM+SJV<KM7C%J&R
MUWX6R*CDV6T6Z:^O8JE"KC*LDO:*4TIK#IZ\M.A=0Y4[2FI5'K+0KQSX_? '
MX2_M/_"7QA\$?C=X/T[QQ\.?'&G-8:SHU^I2:"9")=/UG1M0B*WFB^(=%O%B
MU'0]<TZ6#4-+U""&ZM9D=.?8Z*\6$Y4Y1G"4H3A)2A.+<91E%WC*,E9III--
M.Z>J/I*E.%6$Z=2$:E.I%PG"<5*$X25I1E&2:E&2;33336C/\K']I7X/?%O_
M ();_M]>)_!.A:SJEAXQ_9[^*.E>,OA/XU=[BRD\4^#OM-KXI^''B>XET:YL
M5DC\1^%KK3[;Q?I6E7_V>SU.3Q)X3FNC-87BK_IK_LO_ !RT3]IC]G7X)_'_
M ,/HL&F_%WX:>$?')L54HVD:EKFCVMSK>@3*9KD+<^'];.H:)=A+J[B%SI\O
MDWEW%LN)?XD?^#IOPK8:3^WC\(?$]G^[N/%O[+OA4:K#^^;S+_0/B7\4["._
M\R6XD1//TR;3K'[+;6]M#%_9GVEO.N+V=Q_1_P#\&^'BV_\ %7_!*/\ 9S@U
M)[RXN/"6J_&#PE'>WVH3:A-=6%C\8?'&HZ4B&= ]G9Z3I>K6>@:?IZRSPVEA
MI%LEL\-N8K.V^US]_7<CRK,YI>W;A2J222YO:4YNH[=O:T;Q6O+SNVC;/S?A
M1?V9Q-GV2TI2^J1C4Q%&$FY<CI5J*IJ_\WL<3RRD]9>SC?5)'B7_  <I_M!^
M(OA!_P $^C\-_"4VJ6FI_M#_ !&T'P#XBU'2KYK";3_ASH<<_B[Q9Y\UL3?O
M8:]J>F>%?!NJVJ"WT[4=(\4:CI6K7AM[]-(UG\@_^#8[]@WPI\6/B!\0OVV_
MB5I-MKFE_ SQ)8> ?@UH^HZ=;:AI)^*MSH\'B+Q)XRN5O[26&/6?A]H6J^$I
M?"3VDDES9ZQXJ?7MVFW^@Z)<77]Q]<YX9\'>$?!5K>V'@[PKX<\)6.I:G<ZW
MJ-GX9T/3-!M=0UF\CMX;S5[VWTJUM8;K4[J&TM8KF_G22ZGCMK=)976&,+XE
M#.7ALHKY91H.G4KSE*IBHU=91FXJ<?9\BY;TH*E=3=XN3LF[GTN*X<CC.(,-
MG6)Q*K4<+2C"C@94?=ISIJ<J=3VOM6I\M:<JW*Z4;244Y24;'1U_.#_P<O\
M[*O@7XF?L,W?[3B:#X>LOBI^SAXM\!-_PFC02P>)=6^&'CSQ?:_#W4_A_P#:
MK:%X]4TY/&7CKPUXOL;75RJ:+)I.N3Z)>64NNZU9:[_1]7\<'_!S=_P4,\'Z
MKH7A[_@GS\,-636/$5AXIT3XB_M#ZK83V\FG^'X](L)[KP)\+96V7!N]9O[S
M5+?QYXF2)K"3P\FB>"[-+G49==UVPT:>'Z6(J9O@_J_,G3JJI6DKVCAXM>VY
MVM%&<&Z:OHY3C'=HKBVMA*/#^8K&<K56A*CAX2LY2Q<U_L[@GJY4ZJC5=M8P
MIRD[)-DW_!IW\4O$D]C^V+\%+JXN+CPAIEW\+/BEH=HUY-]ETGQ)KD/BKPGX
MJN(=/8/;FX\0Z9X>\&QW-Y$;>98_#%I!.+Q&MC8?U2_M-?'[P9^RS\ ?BS^T
M)\0)-OA;X4^#=4\4WML'N8Y-7OH52TT#P[;S6EAJ<UO=^)O$-WI7AZSNOL%S
M#:W6IPW%S']FBE9?P,_X-COV/_$7P5_97^(?[2WCC2GTG7/VI=?T%_ ]C?V+
M0:G'\)/AN->L="\0%[DI=V5OXW\3^(?%-_:6@M(+?5O#>B^$?%$%YJFGZSI;
M67#_ /!TU^TI?>"/V;?@G^S%X=\1+8WGQT\>:AXT\?:/8W:&^U'X??"F/3KG
M2-,URS21GAT'5OB#KOA_7M.DN(8_M^M_#[-A<.-'U2&N_'8>EF?%%3#TFG3J
M8BE"K*+MI0HP^M--7M)>SJ13V<U?K<\K*\77R3@>EC,0FJU'"5JF'C/5WQ.(
MJ?45).S<7[:C)K=4W9:*R_F.^ OPR^-7_!8__@H\MAXQ\0:H?%/QY\=:MX\^
M*WC.)3J@^'OPRT.&*74VTN.^D6&+3/!_A.RTCP)X TJXDCL89(_"?AZ-8[8Q
M1K_I6_ 'X _"7]F#X2^#_@C\$?!^G>!_ASX'TY;#1M&L%+S3S.3+J&LZSJ$I
M:\UKQ#K5XTNHZYKFHRSZAJFH3S75U,[OQ_G,?\$\O^"CWA#_ ()O?!#XX^+_
M (4^ O\ A,_VU?C1J?\ PKOPQXJ\4QSQ?#WX-?![1M.T+7#XE:SBOY!X]\3^
M+O&5Y>0VWA*2PT:QT9O!&D:]J_B+4M.N7\(:UL^-?VD/^"\'Q@TFX^-]SXI_
MX*06G@'4WU;7H/%_PMT#X^_#OX3Q6-_K%Q]I?3;KX:Z5X>\%KHUCJ1ETNP D
MEMM*2!=)M9(8X1 OOYSE>,S*M3HQK4,!EV%4*.'A6ERJM5Y4G.%.-O=@FJ--
M3::4)NG'EG>7RG#N>9?DN'JXF6'Q.:YQCG/$8RIAX*;PU"52\:=6M+[=25Z]
M;D4HN4X0JR4Z?+'_ $*?VM?V?_#O[5/[,_QP_9Y\46&F7^G?%?X<^(_"]B=7
M"BSTGQ1+9M>>"?%"S-IVL?8[_P '^,K/0?%6DZBNDZI)INJZ-9:A%I]Y+;);
MR?SX?\$=O^"*G[9G_!.K]K>\^./Q/^)'[-WB#X?>(/A+XS^&/B?2?AUXG^)&
MN^*[J#7=6\*^)=)-C:^*OA%X.TN"&#Q%X.T:XOKH:W%<K9Q300P7"W$B5^1O
M[ '_  <8_M2? CQQIOAW]KG6M8_:3^"6LZHR:[JVH+IL'Q;\$1ZE=:1%/KWA
MS6X[6VM_%5AH=E:ZC<Q^"-=^QG4[B_>*T\4Z&D42U_?1X1\6>&O'OA3PQXZ\
M%ZWIWB;P=XT\/:+XL\)^)-'N4O-)\0>&O$>FVVL:%K>EW<9,=UIVK:7>6M_8
MW,9*3VUQ%*A*L*^:QE+-<AH5\!4=*>$QZE[\5[2G-J*C)P<E&5.HERWO%-VB
MXN2C=?9Y?7R+BK$X;-:*KPQ^5N%J4Y>RJTU*;G#VBBY0K4G)347&;2YIJ2BY
M6.AHHHKYP^Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^7O#'_ "6_4O\
ML*^)?_2>^KZAKY>\,?\ );]2_P"PKXE_])[ZOJ&N_,/CP_\ V"4/_;CGPWP3
M_P"ODORB%%%%<!T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XE^
MTO\ \FX?M ?]D2^*W_J":]7^1)7^P_XY\(Z;X_\ !7C#P'K,]];:1XV\+>(/
M".JW.F200ZE;Z;XDTF[T:^GT^:ZMKVUBOHK6]EDM)+FSNX(YUC::VGC#1/\
MSF_\0KW_  3X_P"BQ?MD_P#AP?@E_P#0\U]9PUG&"RNGBXXN52+K3HRAR4W/
M2"FI7LU;XEZZGP/&?#V99Y6P$\!&C*.'IUXU/:U53LZDZ3C9-.^D97[6\SS_
M /X-3/\ DTS]I3_LXFU_]5KX2K^INO@7_@GY_P $Z/@E_P $WOAYXX^&GP.\
M4_%/Q5H7C[QG'XYUB[^*VM^$M<U:VU:/0].T!;?3)_"'@?P+9PZ<;/3()3#=
M6%Y<_:7F<78B9(8_OJO$S;$TL9F.*Q-%R=*M-2@Y+EE94X1U735,^FR#!5\O
MR? 8+$J*KX>BX5%"2G%2=2<M)+1JTEJ%%%%><>P%%%% !1110 4444 %%%%
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M=I-[?-J.H0:+I]]J6MZQ<7.I7ABDU#5=>UW6M8NXK33[26_:RTZPM[?]2O\
M@V5^"FJ_$'_@H9=?%==-MYO#WP!^$7C;Q#>:O<C=]@\2>/[0?#CP_I]@$D$J
M:IJFC:]XQN$F>%[1=*TC6(99(KJXL5F_23P[_P &F7@JV\0K<^+/VX/%&M^%
M!-,SZ+X=^ >D^%_$+0-*#!&OB?4OBSXOTU9HX,QS3GPBZ3RD3);VZ P'^E/]
MC[]C'X _L,?"&R^"_P"SWX3;P_X;COKC6-=UK5;B+5/&/C7Q#= )<>(O&?B%
M;:TDUG5# D-E:A;>UT_2]-MK72](L+#3K:&V3[#-.(,KCEE3 99[_M:3H1C"
MC4HTJ-.=_:-JI"#E*47))133E)RE+2TOSO(^$L\J9U2S3._W?L*\<5*53$4L
M37Q-:FTZ*3HU*D8QC*,6W.2Y8P4(0LTX_5-%%%? 'ZP%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_&W_P=L_\ ./\ _P"[
MJ_\ WVZOPM_X(C_\I4?V./\ LH'B#_U7/C2O[R?^"B/_  2N_9\_X*8_\*?_
M .%[^,?C+X3_ .%*?\+ _P"$5_X5)XA\$Z#_ &A_PLC_ (0G^W/^$@_X3'X>
M>/?M7V7_ (0+1_[*_L[^RO(^TZE]L^W>=:_8_E#]EK_@WK_8P_9'^/WPU_:-
M^&_Q-_:?UOQO\+-8O-;\/Z5XW\:?"G4O"MY=WNBZIH4L>LV.@_!7PUJ]Q;K9
MZM<R1I9:YIT@N4@=I7B62&3[; 9[@,/D+R^I*JL3]7QM.RI-PYJ]2O*G[][6
M:J1N^FO;7\US3A?-<7Q7'-Z,*#P:QN6UW*5:,:GL\+3PD:K]G:]TZ,^57]Y)
M=T?NY1117Q)^E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-+:,9S<82_1__@KK_P '"^C>!H?%G[-/[ OB"S\0>.6^V:!X[_::TR=;G0?
MUS:7]UI^L^'/A+;W>FRV/BSQ'.ENT;?$R"ZG\+Z)9S";P9_PD6L7EKXB\*?G
MM_P1^_X(E_$3]M+QAH_[6G[9EAXDT[]G#4[YO'>DZ9XCU6['CS]IS6]0U2[O
M)KR^NY+Q_$NE?#_4;^.;5?$OC'4I+/7/'-K>V\/@VXFM]9N_&.A??G_!(W_@
MWEL_!5QX1_:5_;ZT&QUCQ3"FE^)? '[--Z8KW2/"VH07EQ<V6J_&A(S/8>(M
M56.'2]1LOA]#<3Z%I_G2V7CJ/5KPWGAO2_ZY+2TM+"UMK"PMK>RL;*WAM+.S
MM(8[:UM+2VC6&WMK:WA5(8+>"%$BAAB1(XHT5$554 >UB\TP>4T)Y=DGO5)>
M[BLQ=G.;V:HS5KM:I3BE3IJ[I*4Y>U7S67Y'F.?XJGG'$UXT86G@<G2<:5.-
MTXRQ%.5VHO1RIS;K56HJNXTXJ@ZFB:)HWAK1M(\.>'-(TS0/#V@:98:)H.@Z
M)86NE:-HFC:5:Q6.EZ1I&EV$4%CINF:;8P06=A86<$-K9VL,5O;Q1PQHB_Y]
MO_!S?\1K[Q?_ ,%'++P=*;%=/^$_P&^'/A>RBM'22=KCQ#>^)OB!?76IGF6&
M^E7Q9:6T=JS+"NFV6GW<4*27MQ+<?Z$M?YOW_!Q;;SP_\%5_C9)-!-%'=^"O
M@K<6LDL;QI<P+\*O"UJT]NS*%FA6ZMKFV:2,L@GMYX2WF12*N?"$5/-JDI:R
MC@ZTXM[\SJ48-^KC.7WLW\0I.&04X0TC/'X:G)+1<BI8BHE;LI4X66FJ1^OW
M_!O#_P $E?AIJWPTT']OK]I#P78^-/$GB;6=5;]G3P'XNTJQU/PMX;\/>'=0
M&F+\8-2T/4HIEU'QAJ/B73M8A\ C4[);+PUI&DV'CW1CJ.K>(?#6K>%_[ Z^
M</V./#=IX._9$_97\(V#;['PK^SA\#O#=D^)5W6FA_#'POIELVV:>ZF7=#:H
M<2W-Q*,XDGF?,C?1]>-FN.K8_&UZU6;:52<*4+OEI4HR:A"*V6B3DTES2;DU
M=GT60Y9A\JRS"X>A3C&3HTJF(J))3K5YP4JE2<E=R]YM03;4(*,(OEBC^'#_
M (.9_P!@'X;?!/Q/\)OVPO@QX)T;P)HOQ>\0:U\.OC/H?A?2[;1/#%S\3TLK
MOQ=X4\;6FDZ=8Q6%KXE\=Z)9^-4\9S13646K7WA'3?$']GWGB#6?%NLWO[#?
M\&T_QLUOXJ_\$WK;P;X@O5N[KX _&?Q]\*=$,^IB_P!4?P?>Z?X8^)^B37<4
MB+=V=C:7_P 0]=\-Z)#-)<V\>F^&XK2PN([6S33M/^8_^#K'XI>&]/\ V6?V
M</@K)<V[^+_%_P ?W^*5G:+>P_:[?PW\.?AUXV\)ZE<S:> UQ]GO-4^*6E16
MUZQCA\VQNX$$[[S;^N_\&NO@&[\,?\$^_'_C+4-/^S3?$K]I?QQJNCWWG7#?
MVEX7\-^"/AQX3M6\AV%M%]D\4Z5XSM_,MX_,F^[<3R"&&&V^BQ%2=?A&A/$M
MSG3Q2AAYS=Y.,:E2"U;N^6#J4U_=@NUSY'!T:>%\0<93P:C3IU<!*IBJ=-)0
MC.I2H5)>ZE://5]E5?\ ?J-W][E/Z2****^,/T8**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#Y>\,?\EOU+_L*^)?\ TGOJ^H:^7O#'_);]2_["OB7_ -)[
MZOJ&N_,/CP__ &"4/_;CGPWP3_Z^2_*(4445P'0%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_JK/%%?;M?$7_!2[_E';^W/_ -FE?M!?^JL\45TX+_?,)_V$T/\ T[ Y,?\
M[CC?^P3$_P#IF9_'K_P1C_Y-!^/?_9R/@'_U6'BFOT_K\P/^",?_ ":#\>_^
MSD? /_JL/%-?I_7\Z^/G_)Q\Q_[ ,L_]1D?Y:^.7_):4/^Q!E?\ Z5B0HHHK
M\8/QP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM?%XJA".'H8Y1JSP[A!<E)U72IRHU7%))U%B:*<4G42ES2?S5^V#^T9\=O\
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M@Z=?>?;-]HU7PY9^']0UFU^S),UY%]CL_%.@S>?/;Q6UQ]N\NUFGEM;Q+?\
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M)H[FUN[2YC6:WN;:XA9X9[>>%TEAFB=XY8W5T9E8$V*_GZ_X-N/VD]=^.?\
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MW4VA^$M)\0^(1:74>DR02?P0ZA_P<&?\%;;V_OKRV_:EL])M[N\N;F#2M/\
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MI4EB,.YUL,Z\I.KRQERXC#R<WS<U*;52$7>7+*JM(4DE^IM%%%?%'Z4%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7XV_P#!P'_RB+_:U_[H-_ZT
MU\&*_9*OQM_X. _^41?[6O\ W0;_ -::^#%=^5?\C3+?^P_!_P#J13/*SW_D
M1YS_ -BK,?\ U$K'^:3117^M=^Q3_P F;?LE?]FR_ ;_ -59X4K].SK.?['I
MT*GU;ZQ[><X6]M['EY(J5[^RJ\U[VM96[L_$>&N'?]8:V*I?7/J?U:E3J<WU
M?ZQS\\G&UO;T.6UKWO*^UD?Y*->U_ G]H_X[_LQ^,X/B!\ ?BKXR^%7BR' D
MU+PGJTMG!J,:VU[:);ZWI,HGT;Q!:1P:C?+#9ZYI^H6L+W,DT4*3$2#_ %F?
M'WP@^$WQ5LY].^*/PO\ AW\2-/NK&73+FQ\?>"?#7C"SN--FBO()M/GMO$.F
M:C!+8RP:CJ$,MI(C6\D5]>1O&4NIP_\ $1_P7Y_X(]_#?]DW3M*_:\_9:T"X
M\+?![Q3XJM_#'Q4^%EE]IO?#_P -?%6NK=7&B^*_"5S>7MS>Z5X*\57\4NDW
M/AB1&TKPEXBGTRR\.3VN@:YI7AOP[Y^7<383-*RP6(POL)5TX0C4G&O1JR?_
M "ZDW3A9S6D5*#C)^[=2<4_7S?@K,,DP\LRPF.6*CA6JE25*G/"8FC%?\OH*
M-6K=0?QN-13A'WTG%2<?WK_X(V?\%B_#_P#P46\*ZI\,OBK8Z!X$_:L\ :6=
M6U[0M$\RS\*_$[PBERMM_P )OX%L;^^O]0L+S2)9[.Q\:^&)[N]73KF[T_7-
M'O9]*U>XTKPS^Z%?Y''[*G[1/C+]DO\ :-^#G[1W@(S2^(_A)XXTGQ2NF1:@
M^E)XFT)&>P\7>"[W4H[:\ELM)\<^$K[7/!^LW$-K<31Z3KEZT43R;17^L]X&
M\8Z'\1/!7@_X@>&+AKOPUXZ\+>'_ !CX>NG5%>YT/Q/I-IK>DW#K')-&K36%
M];R,L<LJ L0LCKAC\OQ+E-/+<53JX>/+AL4I2C#=4JL&O:4XWNU!J49P3VO*
M*T@C[C@O/ZN<X*K0QD^?&X%PC.I:SKT*BE[*K*R2=1.$Z=1K?EA.7O5&?P=_
M\'4/_*0?X._]F;?#[_U=O[0U>?\ _!LA_P I*;G_ +-V^*?_ *>? E?U:?M^
M?\%I?V6_^"<OQC\-?!'XW> OC]XI\5^*?AIHWQ4T_4/A7X6^'>M^'H?#VM^*
M?&7A&TL[R[\7?%3P/J4>LQZEX'U:>XMX-)N+%+&XTZ2/499YKFVM,?\ 85_X
M+@?LH?\ !07XX/\  /X,_#[]H;PSXQC\&:_XY;4OB=X3^&^C>&CI/ARZTFTO
MK<7GA7XL^--4_M&636;5K6$Z,+9TCG,UW RQK+Z,<PQ_]@/"K**KPWU.5/Z[
M[=<GLW>]7V?L;V5_A]ITW/)GE.5/BQ8UY_06-_M&G5_LSZK+VGM4H6H>V^L6
MYI:6E[+K\+LS]D:**_%/]N7_ (+Q?L3?L2>,O$'PGN[KQ;\</C)X:F6QU_P1
M\)H-&O-)\*:P'NDNM&\:>-]7U:PT31]6TQK5K?6=&TB/Q)XAT:_N+6QU31;2
M7[:UC\CAL)B<94]EA:-2O4M=Q@KV5[<TGI&,;M+FDTKM*Y]_C<?@\NHO$8[$
MTL-2ORJ=62CS2LWRPCK*I-I-J$(RDTF[63/VLHK^.S5_^#M32(=2O(M!_8-U
M'4M'28KI]]J_[2]MHFI7,&T8DO-*L_@-X@M;&8MN!@@UG44"@,+@EBJ_4_P"
M_P"#HO\ 8Z^(OB&R\._&SX3?%?X KJ=]IME:^+$N-&^)W@G31>7TUK=WGB6]
MT=/#WBO3+&P@:PO6FTKP9XA>6)]35XK9M/M#JWI5.'<ZIP<Y8&HXI7:A4H5)
MV_Z]TZLYM^2C?RT9XM+C#ANM45.&:4E)NR=6CBJ$+[:U:U"G22\W-+S/Z;**
MY;P1XW\'_$KP?X:^('P_\2Z-XQ\$^,=&L/$/A;Q3X>O[?4]$U[1-3MTNK#4M
M-O[5Y(+FVN8)%=61LJ=T<BI(CHO4UXS33::::;335FFM&FGJFGHT]CZ1-22E
M%J49).,DTTTU=--:--:IK1H**\]^*?Q9^&?P0\#:[\2_B]XZ\,?#GP%X:LYK
MW6O%/BW5K31]*M(H899_)2:ZD1KS4+E(9$T_2K%+G4]3N=EIIUI=74D<+_SA
M_M _\'2O[(W@#59='_9^^#?Q1_:&^R7&J0S^)M7OK3X+>#+^.W^32;O0+C7-
M(\6>-[NWU.5'DN5U_P  >%[K3;)[:86M]>27.GV?9A,NQV/;6$PU2LHNTII*
M-.+WM*I-QIIVULY)^1YN89QEF5)/,,;1PSDKQA)RG6DKVYHT:49UI13=G*,&
MEU9_3]17\A/@_P#X.S/ =[?R1^/_ -B/Q=X9TP?9_*O/!_QUT;QQ?ONF"W7F
M:=K7PN^'EO'Y-OF6WVZI+]IF @D^R(3<K^_G[$W_  4R_9 _;\\/+J/P$^)4
M(\86L)E\0?![QU%:>%/BYX:*1"XD:]\*/?WT&N:=# \;S>)/!&K>*_"<<KO8
MMKPU*UO;.VVQ>39G@H.IB<'4ITU\52+A5A&^SE*C.I&*=[7DTKZ7OH88#B+)
M,SJ>QP684:M9_#2G&K0J3MNH0Q%.E*HUNU!2=M;6U/OJBBOST_X*$?\ !2KX
M%_\ !-GPE\.O&7QS\*?%GQ7I?Q-\1ZQX8T&#X3Z%X/UV_M+_ $73(-5NIM7B
M\8>._ EO;V<EO.B6\EG=7\SS!EDMXD D/#0H5<35A0H0E4JU&U"$;<TFDY-*
M[2T2;WZ'IXG$T,'0J8G%584:%))U*LW:,%*2@FVD]Y2BEINT?H717X9_LD_\
M' G[&'[9'[0/@3]G+X<_#_\ :/\ "?B_Q_;^-+O3O$?Q,\*?"G0? VDVG@3P
M#XI^(VN7/B#5]"^,_BC5+"W_ + \(ZI';30:'>Q_;Y+1+QK.R>XOK;Y%_:I_
MX.A?V=?@[\1]4\!_L^?!#7/VG=)\/WEUI>L?$1OB1:_"OP9J&I6-Y?6EVW@F
MX/@3XB:AXKT0?9[:2R\02V.B6&JQW,EQI?VO3X[2^U#T(9)FM2N\/'!5?;*G
M&JXR<()4Y2E&,I3G.-./-*$U%.2;<963LSR:G$V14L,L9/,J'U=U94(S@JM2
M4JL(4YSA&G3ISJR<(5:<IN,'&"G'F:N?U#45^-W_  3#_P""SGP6_P""F'B'
MQ1\-_#GPN^(GPD^+G@GP/#\0/$7AW7I=.\5^";C01JVC^']1;PW\0=)33I+Z
MZTW6]<TZ!K+Q'X4\(WVHV-W%J.CVNH)9Z]#HGZ>?&OXX_"3]G+X;^(/B[\</
M'N@?#;X<>%TMFUKQ3XCN)(;*WDO;F.SL+*VM[:*YU#4]3U"\FBM=.TG2K.]U
M/4+F18+.TGE(6N.O@\5AL1]5K4)PQ%XI4K<\I.=N10Y')3YKI1Y'*[T6NAZ&
M%S' XW"?7L-B:53"6FW7;=.$%3OS^T]HH.GR6O)5%%Q6KLCU6BOY0?C/_P '
M6GP'\+>);_2?@5^RU\1/B_H%CJ-U8Q^*O''Q#T?X-V^L6MJ\D*ZQHND6?@_X
MI:J=.U!XUN-.BUV'0-6.GS12ZII>E:@)M+A]?_96_P"#G;]DCXS^,]*\#_'S
MX9^,_P!EVXU^[L=/TOQMJ'B+3_B9\+K"]N;:;S(_&'B73=%\)^(_#%G)J?V/
M3;'6O^$)U3088[I]7\5ZIX1T>RO+R+T)</YS&DZSP%7D4>9I2I2J6_Z\QJ.M
M?^[[/F\CRH<6\.U*ZPT<TH>T<N1.4*\*+DW9?[1.E'#V;^U[7E\S^=?_ (.*
M/^4K7QT_[%#X)_\ JHO"%?>W_!J)_P G'_M5?]D2\*?^IW#7Y[?\'!NMZ-XE
M_P""H/Q=\1^'-7TS7_#VO_#WX":WH.O:)?VNJZ-K>C:K\&/!5]I>KZ1JEA+/
M8ZEIFI6,\%Y87]G/-:WEK-%<6\LD,B.WZ$_\&HG_ "<?^U5_V1+PI_ZG<-?:
MXQ-<)135FLMP*:>Z?^SZ,_,\O:?'\VFFGG.9--:II_6K-/JF?W(T45^5/[?_
M /P6*_8[_P"">L\O@_XC>(-9^(GQMDL8+VT^"/PPMK+5_%FGV^HZ;<WVD:GX
MXU;4;W3?#7@31KQETUFCU;5)O%]QI>L66O>'O!GB+2Q/-'^<8?#5\75C1PU*
M=:K+50IQ;=EO)](Q5U>4FHKJT?LN+QF%P-&6(QE>EAJ$+)U*LE&-W>T8WUE.
M5GRPBG*5M$S]5J*_CRO_ /@[2T&/6I8-,_81U>\\.B\C2#5+_P#:0LM.UJ2P
M+();F70;?X':I8PWB*9#'8IXDGAD945M0B$C-'^G'[&7_!P9^PU^UKXNTSX:
MZ[<^*OV=OB1X@U33=&\*:+\68]-/AKQ=JVJ-96EII6B>.=!NK[1;75+C5;I[
M"RLO%$?AMM19;4:>]S>7GV"#T*^0YOAZ;JU<#44(KFDX2I5G&/5RC1J3FDMV
MW%65V[),\?"\5\/8RM&A0S.BZLI*,8U:=?#J4GHHQGB*5*$FWI%*3<FTE=M)
M_NK117A?[3/[07@S]E7X#?$W]H?XAZ9XGUGP5\*?#C^)_$6E^#++2M1\47M@
ME[:6)AT6RUS6O#NDW%YYU[$PCOM;TZ'RUD)N P5'\J$)5)PIPBY3J2C"$5O*
M4FHQBO-MI(]ZI4A1IU*M22A3I0E4J3>T80BY3D_*,4V_)'NE%?S2?\14/_!/
MC_HCO[9/_AOO@E_]$-7TM_P4@_X+M?LU_L >+KCX0Z3X9U3]H/X\Z;'97/B3
MX?\ A7Q)8^%_#O@BWO[2ZN;:T\:>/)=*\3)I/B.94L+A?#&G^&]9U2VTS48-
M2U1=.CFT^+4?2_L7-?:TJ#P595:RG*G%J*O&GR<\G)R481BZD$Y3E&*<HJ]W
M8\;_ %DR)X>OBEF>&E0P[IQK3BYR<95N?V45",'4J3FJ=1QA3C*5H3=K1;7[
MBT5_-+^Q-_P<I?!;]J;XU?#WX#_$3]F[XB?!?QA\6/'&B_#_ ,!:MX9\8:=\
M9/";Z]XDN;/3M!7Q7=IX8^'/B+P_:W^K7)TZ:]TWPOXEL=*#VFIZQ=6&C'5=
M1T;^EJN;&8#%Y?4C2QE&5&<H\T4Y0DI1O:\9TY3@[-6=I-KKNCLR[-,!FU&5
M?+\3'$TH3Y)M1J4Y0G9/EE3JPIU(W337-%)K9NS"BBBN0] **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .194_["E_Z1 4?XT?\ !+\T>PT445Y9TA1110 4444 %%%% !1110 4444
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MDYR;E)N4I2E*4I2DVVVVV%%%%8'4%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/#=S'\,O#.C7Y");1M'=^#?$7B2VB@>Z>.#Q6$N[F.Z633M/_H(KY#_X)_\
MP_L_A9^PU^R#X!L[2&R;P[^S=\&H-2C@ 5)_$-WX!T+4O$^H,JW5[&LVJ^([
MS5-3N%AN[B!9[R46\K0B,U]>5\5F5=XG'XRNW?VF(JN/E!3<::Z_#!1C\C])
MR;"QP64Y=A8JWLL'04NEZDJ<9U96[RJ2G)^;/\Z7_@Y,_P"4H7C7_LD?P?\
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M;X??^KM_:&K\;?\ @G1_RD'_ &$_^SR?V8?_ %=O@>OV2_X.H?\ E(/\'?\
MLS;X??\ J[?VAJ_G6^'/Q \7?";XA>!/BI\/]7_L#Q[\,_&7A?X@>"->^P:9
MJO\ 8GB[P9K=CXC\-:O_ &7K=EJ6C:E_9NLZ;97GV#5].O\ 3+SR?L]_975K
M)+!)]+E$'4R+"4XV4JF#E!-WLG)3BKV3=KO6R;MT9\;Q#5C1XJQU::;C1S&G
M5DHI.3C3=*;44VDVTG9-I7W:W/\ 86HK_-)_XB _^"N?_1VO_F!OV9?_ )S%
M9^J_\%\/^"M>L6$^G7?[7.H0V]SY7F2:5\'/V>M#OU\F:.=/(U71/A+I^IVN
M7B59?LUY#Y\)DMIO,MYI8G^.7!N9WUQ& MUM4Q#=O3ZJK^EUZGZ$_$;)+.V$
MS6_2]'")7\W]>=O6S]#^[S_@JU\9?AO\$?\ @GG^UIK_ ,3;^SATOQC\#_B5
M\)O#^BS:K9Z7?^,/&7Q2\%Z[X,\.^%M&-S>6=Q=7EW<:K)J&H)I/VO5;#PYI
MFNZ[;6-TFD31U_E@U]&_M!_M>?M/?M6ZEIFI_M&?'3XD?%Z30YKZXT#3_&'B
M2]O/#WARXU,0+J4_AOPM"UOX:\.S:BEI9QW\NBZ3827L5E917+2QVELL4O[*
MW[)'Q[_;0^*^E_!W]GSP)J'C3Q5>?9;O6+Q5DMO#?@OP]-J=CI5UXO\ &VN>
M5+;Z!X8TNXU"V^V7LJ37,S21V>EV6HZG<6MA<?6Y-ED<DP=;ZQB*<I3G[:M4
MNX4:<8QY4DYVT2NY3DHW;M:T5?X'B/.Y\3YAAEA,)5C&G#ZOAJ-E4Q%:=2?-
M)N-.ZNWRQC"+G91<N:\FE_8K_P &IO@_7M._99_:6\<7EIY'A[Q5\=](T#0[
MIVVR7M_X.\!Z5=ZX\<+ ,;.!?%NDP17:EH9[M;^U1O.L+A5_JAKY3_8F_9'^
M'W[#G[-'PT_9L^'%Q-JND^!=.NY=:\57UC;6&K>-_&.NW]QK/BOQ?JT%L\YB
MFU;6+RX&FV$U[J3Z#X?M]&\-0:C=V6BVDI^K*_-<UQ<,=F.+Q5._LZM5^SNF
MFZ<(JG"33U3E&"DT]F['[/D6!J99E& P-6WM:%!*JDU)1JU)2JU(J2TDH3G*
M*DM&DGU.+^)/Q \,?"?X=^/OBGXVO6TWP9\-/!?BGX@>+M12(SOI_ACP;H=_
MXCU^]2%2K3-:Z5IMW.L08&0QA 03FO\ )9_:5^-NN?M)?M!_&CX^>)(EMM7^
M+_Q+\8^/Y[",.(-(M_$FN7FHZ=H5HLEQ=RK9:#ILUGHUBDMW=S)9V,"RW5S(
M&GD_NH_X.7?VL;CX'?L1:+\!- \E?%?[6?BR7PO>7,T;E]/^&'PWFT/Q;X]N
MM,EBOX&CU6_UV\^'WA>1+G3]2L)?#7B7Q,'-CJ:Z3<U_GWV]O<7=Q!:6D$UU
M=74T5O;6UO$\UQ<7$SK'#!!#&K22S32,L<44:L\CLJ(I8@'[7@[!>SPM?'35
MI8B?LJ;>WL:+]Z2_Q5>:+_Z](_-/$3,O;8[#973=X8.G[>NE?7$8B*<(M=Z=
M!1G%K_G_ "70_J8_X-]/^":/A[]J;X+_ +:/Q;^*(6R\)?$KX:>-/V0/A_J3
MZ/9:EJ&@^(/%>D^'?%'C#XD>'OM>H126^L^"=_@F'1IC81VFK2:CK^CMJQM8
M==TV;^9?XE_#_P 2?";XC>/_ (5^,K:.S\7_  T\;>*OA_XJLXC,8K7Q)X-U
MV_\ #FN6T9N8+6X,<&IZ;=1(9[:WF*J#+!"^Z-?]1/\ X);_ +,G_#(O[!7[
M-WP7OM+_ ++\7V7@&R\8_$B"?2?[(U5/B1\199O''C'3M;BE)O;K4/#&J:Z_
M@V&\U$I>-I7AO3;8VNG6]M;Z99?QE?\ !R3^RC>? K]O&7XVZ98_9_ ?[5WA
MV'QMILJ2;K>'XA>"-/T'PI\2]+BC:".2.21I/"OC&[+SWBO=^-IO)FAA5+"S
MK)\Y>+SS,:$IWHUVWA%=6_V7W/=ZWJTE*K+5_ R.(>'%@.&,GQ4*3CB,*E]?
M=O>_V^U1NH]K4,1RX>%K?Q$M=S]&_P#@U?\ VN5EM/C=^Q#XBNI#-:R7G[0?
MPTDO-1ED7[),?"W@WXA^&]-M9K0Q6\=O='PMXEM[&WU,&>6_\3ZG;Z2#'K.H
M-_8S7^3S^P)^T[JW['G[8'P&^/\ 8ZI?:;HO@SX@:"GQ ALIM20:Q\+]8OX-
M*^(FC7%OI;?:+];OPI=:E+96LEOJ$"ZO;Z;>/IM^]I';2?ZO&F:GINM:;I^L
MZ-J%CJVD:M8VFIZ5JNF7<%_INIZ;?P1W5CJ&GWUK)+:WMC>VLL5S:7=M+)!<
M021S0R/&ZL?"XMP/U;,%B8*U/&PYW;;VU.T:J^:<)ONY29]5P#F?US*)8.I*
M];+:GLDG:[PU7FG0?>T9*K27:-..I>HHHKY4^Z"BBB@#\;?^#@/_ )1%_M:_
M]T&_]::^#%?YN?@;P+XS^)OB_P /> /AWX5U_P ;^-_%NJ6^B^&?"?A?2KS6
M]?UW5;MBMO8Z7I>GPSW=W</AG*11-Y<2232%(HW=?]6;]NK]D[2?VX_V7/B-
M^R[K_C/4? &A?$W4?AK+K7BK1](MM;U:RTGP+\5O _Q(U*QTNRO;VQLXM1UZ
MS\'S>'['5+M[RVT*YU2+6Y]'UZ+3GT34//?V)O\ @F;^R!^P'X>73O@)\-83
MXPNH3%X@^,/CJ6T\5_%SQ*7B%O(M[XK>PL8-#TZ:!(TF\-^"-)\*>$Y)4>^;
M03J5U>WES];DN?8?*<LK4G"=;%3Q=2I3I)<L%&5'#PC.I4>BCS0DN6"E-\NJ
MBFI'P'$G"F+S_.\-B%5IX? TL!1HU:S?/5<XXG%5)TZ5):N7)5@^>HX07-HY
MN+B?PJ?MR_\ !(WQ=_P3[_8B^"?QH^.NKO%^T5\7_C(WAK6_AYHVJ:1JOA7X
M9>#H/!7B+6K?0+O6-):^L_$WC:YU"QMKK7=7TC5KCPSIZ+'H^B/JJ0W&OZG^
M+E?W6_\ !UG_ ,FF?LU_]G$W7_JM?%M?PI5]ED.,KX_+H8K$24JM2M7ORKEC
M&*J-1A%=(QBDE=N32O*4I-M_G7%>7X7*\WJ8'"0<*%'#X5+FES3G*5&,IU*D
MM+SG)N4FE&*;M&,8I17^P1\)O^25_#3_ +)_X-_]1S3:] KS_P"$W_)*_AI_
MV3_P;_ZCFFUZ!7Y%/XY?XI?FS^@:?\.G_@C_ .DH*_D*_P"#D;_@I^_AO1+G
M_@GM\#_$=HVK^*].TS5_VE?%/A[6X)KW1/#S74UUIGP4G6T@DGTS4?$AMM,\
M2>-D34;*];PFVE^&;ZUO-$\8Z[:-^Y/_  55_P""@_A+_@G;^RSXE^)DUUIU
M[\8/&D.J>"?@#X-N?*NY==^(MUI-S+;>(=3TD3PW5QX'\!*UOX@\970>UM94
M_LGPL-2L=;\6Z +C_,^MX/C#^U'\;8+:-O$/Q7^.7QU^(<<$;7%Q'=^(_''Q
M"\=ZVL:M/=74EO:I=:KK&H RW%S-::=91NTDTEI8P,T7UW"V4JO4>9XF*6'P
MTFZ*GI&=:&KJMO3DH6O?;VEM?W<D?GW'/$$L+162X&4GC,9%+$NGK.EAZFD:
M*4;OVN*3Y>5>\J+>G[V#/;OV-/V,?B#^V)XA^+2>&&DTCP1\!?@G\1/CO\5?
M&$UG--9:5X;\!^'=0U;3O#=G/M%F?%?CO5[2'0?#UG-*TT-H-=\4"PU/3?"F
MK6I^-J_TD_@=^P+X5_X)Y?\ !(W]HOX1V8M-4^)?B+]F7XY>-?C7XPCM;*.X
MU_XA:I\'O$8O-+MKRV5IKCPQX-A4>'/"\<UQ*K6EK<ZQY<%]KFH*W^;97U^5
M9HLSK8^5/_=\/5I4J#MK-<LW.J]+_O):Q3V@HZ*7,?G^?9&\DP^4PK7^N8NA
M6Q&*5]*4N:FH4$DVKTHMJ<E?FJ.=FX*%O]$G_@VF_P"48V@_]EM^+?\ Z6:+
M7[G?$3QA!\/?A_XZ\?W5E-J5KX'\'>)_&%SIUO*D$]_!X9T2^UJ:R@GD5XX9
MKJ.R:".61&2-Y%=E900?PQ_X-IO^48V@_P#9;?BW_P"EFBU^H7_!0>_N]*_8
M(_;?U2PE\B^TW]D+]I6_LI_+BE\F[L_@SXTN+:7RIDDAD\N:-'\N6.2)]NV1
M&0E3^<9G!5,\Q=-[5,PG!^DZW*]M>I^QY'4=+AC+ZJWI953J+UA0<EOINNI_
ME%^(->U7Q3KVM^)]>NOMVN>(]7U+7M9OO(MK7[9JNKWLVH:C=?9K.&WL[?[1
M>7$TWD6MO!;1;_+@ABB5$7^U7_@T_P#A_I5G\(?VN_BG]FMWUSQ#\2/AY\/_
M +8Q\R[M]*\'>&-7\1BVA#P#[);W=YXZ,MT8+EO[0DLK074"?V99R/\ Q)U_
M?;_P:O?\H^/C%_V>3\0?_5)?L\U][Q5)PR6M&.BG4P\&EHE%58S2LNEX+0_*
MN!(*IQ'AYSUE3H8NJF]7SNC*FW=];5).^]S^ENO\GS_@H7\-]&^$/[=?[7WP
MW\-:;_8WACPK^T7\7+'POHXANH8])\+S^-=8O_#>EV_VZXN[N>TT_1+NPM+.
M]N+F:34+6&&^9S]HP/\ 6#K_ "W/^"P?_*3G]M/_ ++;KW_I'IU?.\%R:QF,
MA=\LL-&35]&X58I.W=*<K/I=]SZ[Q)A%Y?EU1I<\<9.$7;51J4)2DD]TFZ<&
MUULK[(_7#_@U2^)=UHO[6O[17PE?4OLNE?$+]G^U\:MITDT44.J:_P##'Q_X
M=TO2A$LES&]QJ%EHWQ,\4W%O!#:W,@L#JMR9;:&VE$_]V=?YU?\ P;7W$\/_
M  4_\(QPSS11W?P=^+UO=1QR/&ES NBV=TL%PJL%FA6ZMK:Y6.0,@GMX)@OF
M11LO^BI7%Q;",<WE);U,/0G+SDE*G\_=IQ7RL>EP!5E4X?C!WM0QF)I1OTB_
M9UM.RYJTGZW?4_SLO^#D?]GX?!W_ (*.:Y\0=/2Y.A?M'_#CP;\4XWDF>>VL
M_$VDP7'PV\4Z5;/*BS(QD\%:9XFN(&ENH8&\51QVDT-J(M-T_P!S_P"#7[]I
M[7OAY^V!XZ_9BN[VSD\#_M$^ =0UZQTZ]O?)N[3XE_"6RO\ Q#I=YH$-Q>+!
M)_:/@6[\<P^(["PL9=3U.+2O#VIS7,6G>%)XY/N#_@[$^'=A<>"?V.?BS''>
M)JFD^*OBK\.[N5$F>PN+#Q!I/A3Q+IT=R[.UO:WEE<>&=4:Q2*..:^AO]0,[
MSIIUL+?^7'_@GY\5;_X(_MP_LG_$_3Y-G_"+_'OX9MJ:[YH_M/AO6/%&GZ!X
MLL?,MX;F>/\ M#PQJNKV/F16MVT?VC>+2ZV_9Y?JL''^U.%XTI+FG]4J48\R
MVJ864HT'YV=*F[W]>J/ALQE_8G',J]-N%-9A0Q$[.UZ..A3GBHKR:KUH6V73
M2Q_K$4445^7G[>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7XV_
M\' ?_*(O]K7_ +H-_P"M-?!BOV2K\;?^#@/_ )1%_M:_]T&_]::^#%=^5?\
M(TRW_L/P?_J13/*SW_D1YS_V*LQ_]1*Q_FDU_K7?L4_\F;?LE?\ 9LOP&_\
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M:5X?UGQ79>(?%WA34?"=IJ5A9^)_%7@W23"FFZQJUC?2RZTDL=G?3>1;7$C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?$7_!2[_E';^W/_ -FE?M!?^JL\
M45]NU\1?\%+O^4=O[<__ &:5^T%_ZJSQ173@O]\PG_830_\ 3L#DQ_\ N.-_
M[!,3_P"F9G\>O_!&/_DT'X]_]G(^ ?\ U6'BFOT_K\P/^",?_)H/Q[_[.1\
M_P#JL/%-?I_7\Z^/G_)Q\Q_[ ,L_]1D?Y:^.7_):4/\ L097_P"E8D****_&
M#\<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***[+X?>!]9^(_C'0O!F@Q&34-;O8[82;&>*SMAF2\
MO[C;]VWL[99)Y68J"$"!@SKG6A0JXFM2P]"G*K7KU(4:-*"O.I5J24*<(KK*
M4FHI=V=.#P>*S#%X7 8*A4Q.,QN(HX7"X>E%RJU\1B*D:5&C3BM93J5)QA%=
M6T?:7[#'P6/B/Q%/\5]>M"VC>%[@VOAF.9'"7WB+9F:^3*A)(M&B=2C!R/M\
M\?R[K9L?K97)^!O!NC?#[PGH7@_0(1#IFA6$-G"=N)+B11NN;VX.6+7-Y<-)
M<SLS,3)(0&V@8ZRO[$X1X=I<,Y)ALNBHRQ,E]8Q]:/\ R^QE6,?:M/K3I)1H
MTMOW=.,FE*4F_P#6#PKX!PWAUP=EV0P5.>8S7U[.\5!)_6LVQ$(?6'&=DY4,
M-&,,'AM%>A0A-Q52=1LHHHKZ<_1PHHHH **** "BBB@ HHHH **** "BBB@
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M_P"Q0^-G_JHO%]=;_P ')G_*4+QK_P!DC^#_ /ZCLU<E_P &Z_\ RE:^!?\
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M6Z<7M[.,%:Z;?^G+_P $,_\ E%+^Q[_V*'CC_P!6[\0JY#_@X#_Y1%_M:_\
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M_?XIBZF2UY1]Y0GAZC:U]WVL8W]/?3OVUV/D^!:D:/$>&A-\KJT<515]/?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<?Z/9Z)X-U"\NQY:YM()QY]KG[3#_"E_P1M_9+\:_M:_M_? /1]"TN\?P/\
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M/ -OJ\0%MJ5MX'T1GBO+BQ,^ER>*]7\57&CWVI:3<V6H7/Y4?\'7_P#R0?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R]X8_Y+?J7_ &%?
M$O\ Z3WU?4-?+WAC_DM^I?\ 85\2_P#I/?5]0UWYA\>'_P"P2A_[<<^&^"?_
M %\E^40HHHK@.@**** /S6_X+!?!D_'?_@FM^USX(MM%N==U?3OA;??$;P]8
MZ?:I=ZLVN_"?4=/^)=BND1;DN'OKH>%I=/-O8%[_ %"SO;O2[6WO9+[[#<_Y
M<%?[(%W:6E_:W-A?VUO>V-[;S6EY9W<,=S:W=I<QM#<6US;S*\,]O/"[Q30R
MH\<L;LCJRL0?\G;]O+]G*?\ 9(_;&_:)_9W>%H--^&WQ+UNR\)K(]Y)--\/M
M<\CQ5\-[RX>_+W;7-]X!UWPW>W)EGNQ]HN)/+O\ 4(ME[<??<%XI.&,P3>JE
M'%4UW4E&E5?_ &ZXT?\ P+[_ ,H\2<"U4R[,HKW90G@JK[2@Y5Z"\^92Q'IR
M+>^G^EU_P3=^)UQ\8OV!_P!D#XB7J0IJ6N?L_?#2VUC[.KI;R:[X=\-6/AG7
M9X(I+>V,$-SJ^C7MQ%;(DD5LDJP075[#''>3_:]?SD?\&QGQQ3XB?L :W\(K
MB"ZAU+]GOXO^+-!MWDN)[JSNO#'Q$=?B/I=S:^=B.PF'B/6_&5I=:7:J8$%I
M;ZLTK76LW,</]&]?(9IAWA<QQM!JRAB*O*MOW<I.=-VN[7IRB[7TN?H61XI8
MW)\MQ*?,ZN#H<[_Z>PIJG66J5^6K":OUM<_SI?\ @Y,_Y2A>-?\ LD?P?_\
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M['/[1'Q1_9Q^)JPR^*/AIXA?2QJ]G;W5OI?B?0KRW@U3PSXMT9+M$G&D^)M
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M0^%)8)4I_6GP\\*J%ES_ %AY;[+V5KVY_:>Y:]K]3_*RK_4Y_P""2UO!;?\
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M<]&_=JU)15F[WH7LKJY1117R!^@G\47_  =0?LEC0O'7P-_;6T#<MAXZL4^
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M^)?P3^&OCOQ/)INGW6D+8:?)K_BGPSJNJO8V2RR+:6C79@MA(XAC0.V?Z7/
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M-_E7FN>)OC!X?OWQ-,J>9IMA\&?$UO'NMU@E?;JLNR:2: >8D*7-Q[S\$/\
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MLO\ [7/BO7_BU\&?$ES^R_\ %WQ+<ZGK7BJ30= ;Q9\,O''B74+F"[GUK6/
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MX!_]5AXIK]/Z_,#_ ((Q_P#)H/Q[_P"SD? /_JL/%-?I_7\Z^/G_ "<?,?\
ML RS_P!1D?Y:^.7_ "6E#_L097_Z5B0HHHK\8/QP**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7DGQ\^,OA3]G?X)?%?XZ^.)EB\*?"3X?^*O'^LQ&ZMK
M.?4;?PSH]WJD6BZ=+=ND+ZSKUU;P:)H=I\\U_K&H6-C;137-S%"_K=?A3_P7
MD^"'[<O[57[.7@[]FC]COX+WWQ&T+QOXPMO%/QL\0)\2?A?X#L[30O!$]IJ?
M@_P:]GX^^(?@^YUU=:\5R6GBFZ:#3]1T_39_!>D.9DO;F(V_7@:%/$8O#T:U
M6G0HSJ1]K5JU(TX0I+WJC<YN,5)Q34$VKS<4M6<&9XFM@\OQ>)P]"KB<13HR
M="A0I3K5*E:7N4DJ=.,YN*G*,JC46HTU*3T3/\^CXF^//'7[2/QR\=?$G74F
MUSXC?''XGZ_XLO[:V$.^_P#%?Q"\37.I'3K"**.TM883J.JK8Z=:6\%I9VMN
MMO;6UO;6T4<4?^GI_P $ROV-M-_83_8U^$_P'6&'_A,H=./C/XL:A"[.-4^*
M?BV"UO/%3935M9LFAT00V'A*QN-,O!I]]IOAVRU"&"*2[F!_G0_X(J?\$+OV
MA_@K^U)#^TA^W#\,K/X?:?\ !BSAUCX->"_^$[^'?C6Y\3_%"^=X-/\ %VI-
M\/O$?C/3K70_A_IR7^H6=EJ&H:-JMSXROO"NK6)N-/T#5;6\_LHKZ7BG-:.(
M=#+\'4A4PU!1J5)T9QG2G/EY:5.$H-QE&E!N]FUS3MI*F?%<#9%B,(L5FV8T
M:M+&8ERHT:>(A.G7A2Y^>M5J0J)3C.O424>:*ER4W)7C5"BBBOCS]$"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_#]U*@DNKJ0);QZ_P".-?CM[6?Q;XMGM8)]2G@MM.TZVTKPYI6B:+IWK/\
MP5T_X*C^,O\ @H_\<))M!N/$_A;]FCX>W<UI\'OAGJUW;1M/.D<EE??$KQ98
M:<BVK^,O$\+.T%I<76L+X.T6?_A'=)U.X,VM:EK/P-^S/^S5\7OVN?C3X+^
MGP.\--XF\?\ C:^>"TBEE-GH^B:7:1FYUGQ1XFU4QRQZ/X:\/V"2W^JW[QS3
M>5&EII]IJ&JW=AIUWRY#DE/*J+QV-Y%BG3<Y.;2A@Z7*W*/,]%4<;^UJ7M%+
MD@^7GE4[^*N):V>XF.5Y9[26!C65.$::E[3,:[DHPDX+WG24_P#=Z5KRDU5F
MN?V<:6S^R1^RM\5_VT/CWX$_9[^#NE_;/%7C34%6\UB[M=3F\/>"_#=M)%_;
MGC;Q?=:78ZA<:7X8T"WE26]O/LTC37,UEI=G'<:GJ-A:W'^FE^P%^P%\#_\
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MYX'TX>-+.*,PG0_B7H ?P[\2= :%[6Q=8=*\:Z7K=OIMU]AL[?5M'&G:WI\
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MF.R:%H6;Q'9^&H/$+W#F!!=W;ZHUW?JTR7\URMS<"7^+3_@DQ_P7E\5?L!^
MM/\ V=/C1\.M4^+_ .SOI^OW>H^$KOPEJ>E:/\1/A+9^(=6U37_&%MH.FZG:
MV^B_$'2]6U_4[K7;/P_K?B+P?<Z?J^I:Q.OBR2PNK72K+^LOX%_\%OO^"8WQ
M[DN+/1OVHO!WPYU:U2*6?3/CHEY\&(Q'+:-<AH/$GCV'2/!=^Z-%<6DMMIWB
M:[NX[N!5:#R;[2YK_P C/</G\<;7JR>,JX9U9RP\\-*K*C3H\UZ:Y*3_ ',H
MQY8SYXQ<IIR4IIJ;^AX7QG"D\MPF'@LOHXQ4:<,73QD*,,16Q*@O:R52NO\
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MM_*SY;BW.?[&RV_U;ZS]>=7!?QO8^R]KAZK]K_"J\_+;X/<O_.C\VJ_T2?\
M@VF_Y1C:#_V6WXM_^EFBU_G;45^C9OEO]JX3ZK[;V'[V%7VGL_:_ I+EY?:4
M]^;?FTMLS\=X>SK^P<?+'?5OK?-AZE#V7MO86]I*G+GY_95MO9VY>36]^96U
M_P!DBBOPM_X-R?\ E%=\(_\ LH'QG_\ 5C:W7OG_  55_P""I?PO_P"":WPA
MAU*ZM['QS^T!\0;'4H/@S\*'GF2"]N+0+;W7C?QS/:2176D_#_P]=3PBY6":
MVUCQ;J07P[X>DML:YXA\,_E53+ZRS&KEN'3Q%6&(J4(.,>3G]G)IS<7*2A%)
M.4FY-0BFW*RN?NU+-L-_9%#.,6XX3#U<)1Q=12G[3V:K0C-4XR48.K-RDH04
M8*5232C"[2/U(U/4]-T73=0UG6=0L=)TC2;&[U/5=5U.[@L--TS3;""2ZOM0
MU"^NI(K6RL;*UBEN;N[N98X+>".2::1(T9A\MZY^WO\ L+^&;^32O$G[:/[)
MOA_5(M_FZ;KG[1GP?TF_C\N::V?S+._\8V]PFRXMYX'W1C;-#-$</&ZK_F7?
MM:_M]?M9?MN^++SQ1^T1\8O$_BVQ>[N+C1/A_8WDV@_"[PA;RSQR0V/A7X?Z
M7)!X>L/L\5O8VLNLW5K?>*=9CTZPNO$NOZWJ4'V]_CJOK</P7>">*QKC4:3E
M"A23C%]4JDY)S]?9Q^9\!B_$FU64<#EBE13M&IBJSC.:[NE2BU3OT7M:G=VV
M/]A+P/\ $SX<?$VPFU3X;?$#P1\0=,MOLWVC4? _BO0?%EA!]MA-S9^=>:#?
MW]O%]KMP9[;?(OGP@RQ;T^:NVK_'S^&_Q2^)/P=\6:?X[^$_C[QA\-O&>EM&
MUAXH\#^(M5\,:Y;".ZMKP0KJ6CW5I<O;-=6=K/-:22/:SO;Q&>&0(H']I_\
MP1O_ ."_&H?'OQ=X+_9-_;3N=(L?BCXB_L?PG\)/CA:6ZZ;:?%#Q9=7;6&G>
M#_B#IUN$TS1_'/B!Y]/L?#&MZ1;6.B^*=6SH]W8:=XAOM,;7O.S/A7$X*E+$
M8:K];I4TY5(\G)6A%*[DHJ4E4BM7+E:DEKRM)M>QDG'>"S*O#"8R@\OKU9*%
M&;JJKAZLV[1@YN%.5*<GI!24H2>GM%)QB_ZO:**_C;_X.V?^<?\ _P!W5_\
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MU44)2J)4OWF!Q$N6#BVOWEKR=HK6_P#L+?#GX?\ A'X3?#WP)\*_A_I']@>
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M8^%? _Q-\,>)O$-Y;:=9I+>7]Q;:1I=Y-#96L4ES=2(L$"/+(JG[T_X*7_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\1?\%+O^4=O[<_\
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MQC&*M&,8I)1C%))))))62L%%%%,H**** "BBB@ HHHH **** "BBB@ HHHH
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MVMU%"UO)_J]Z#KFD^)]#T;Q+H%]#J>A>(=)T[7-%U*WWB#4-)U:SAO\ 3KZ
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MPF84ERQQ-)3<+WY*D92IU:=^OLZL)POI?EO97LBOXV_^#MG_ )Q__P#=U?\
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MW><=+[NR?]"U%?YI/_$0'_P5S_Z.U_\ ,#?LR_\ SF*/^(@/_@KG_P!':_\
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M/6BT'6/%H-HD-HS>,;>*P\5WB6EM:6MGJ6LWNG6UK##9HM?@)_P=L_\ ./\
M_P"[J_\ WVZO>_\ @U(\07=S^R_^U!X6=K@V.C?'O1/$%NC7<CVJW?B7X>Z-
MIUXT-@5$-M</#X3L!<W:,9+V-+2&556PA+^"?\';/_./_P#[NK_]]NKQ<#AX
M87B]4*:4:<*V*E"*T48U,%6JQBDND5-17DD?39KBZF.\/7BJK<JM3"X"-2;=
MW.I2S'#49S;:7O3E3<WYMVNM3^-NO]&/_@CA_P $B_@?^R;\ /A]\7/B;X"\
M-^/?VF_BQX$\.>+?%OB#QEX>T[6)?AE:^*=)_MF/X=>$;/4YM:L=$O=$L=:.
M@>,?$6BR07'BR^LI=\@T>*RLT_SY_@OI&FZ_\8OA/H.LV<.HZ/K?Q+\":1JN
MGW +6]]INI>*=*L[ZSG52K-#<VLTL$H#*2CL 0>:_P!?VO3XQQM>C1PF%I3E
M3AB'6G6<6XN<:7LU"#:UY6YN4ELVHWO8\/PZR[#8C$8_'5Z<*M3"+#T\,IQ4
ME3G6]M*I52::4U&G&,);Q4IVM?7Y+_:P_8<_9@_;7\$ZGX+_ &A/A3X:\737
M6C7.D:)XZBTVPL?B5X(:2+4!9:CX+\;K:2ZQHUSI-YJ5UJ=G8O)>>'[J^=AK
M.B:K93W5G<?Y>7[67[./B[]D7]I#XP_LW>.;C[=XA^$OC*^\-MK"Z==Z1#XC
MT:2&WU7PKXLL],O6DN;+3_%WA;4=&\3:= \]TJV.JVYBO+R$QW4W^N#7^=A_
MP<J>'+71/^"GGB;4[=MTWC#X,?"/Q'?#$@V75KIFI^$47+SS*V;'PM9OF&.U
MC^?:8&F66YN//X.QE98NM@I5)2H3H2JPA)MJ%2G."O!/2"E"<N9*RDU&^J1Z
M_B)EN'> H9E"E"&)I8J%&I4C%1E5HUJ=1VJ-6<W"I3AR.5W%2FE929]*?\&M
M_P"TOJG@G]J;XJ_LOZG?(/"'QQ^'-WXUT&S>.)ID^)GPOFM[F%;61F22&WU/
MP!JOC&?4PAF::;P[HH$*I'-/'_7E_P %%_\ E'Q^W9_V9M^T]_ZI+QQ7^?Q_
MP0=\2W'A;_@J_P#LDW<*33QZGK7Q+\-7=M%=O9I/;^)O@O\ $?1%>X*1S+<0
MZ?=7MMJRVDD92XN-/@026TGEW4/^@/\ \%%_^4?'[=G_ &9M^T]_ZI+QQ4<2
M48TL_P )4BK?6(X2I-]YQKRI-_\ @%.'K]YKP9B9UN%,=2G)M86ICZ%-.[Y:
M4L-#$):]/:5JEDMETV/\H"O]$G_@VF_Y1C:#_P!EM^+?_I9HM?YVU?Z)/_!M
M-_RC&T'_ ++;\6__ $LT6O?XN_Y%/_<U1_\ 2:A\IX>?\CZ?_8OQ'_IW#A_P
M<L_\HQM>_P"RV_"3_P!+-:K_ #MJ_P!$G_@Y9_Y1C:]_V6WX2?\ I9K5?YVU
M+A#_ )%,O^PNM_Z12%XA?\C^/_8!AO\ TY7/]7__ ()T?\H^/V$_^S-OV8?_
M %27@>OP _X.O_\ D@_[(_\ V5SQ_P#^H;IU?O\ _P#!.C_E'Q^PG_V9M^S#
M_P"J2\#U^ '_  =?_P#)!_V1_P#LKGC_ /\ 4-TZODLF_P"2CH_]A6*_]-US
M[_B'_DC*_P#V+\#_ .G,*?P_U_HF?\$5?^"2_P #_P!E_P#9Q^'7QR^)7@OP
MY\1?VC_C?X%\,^/]:\0>,- T[6E^%V@>,="AUG2?AWX*L]6L[A-!O+#1M7CM
M/'6LVF=1\0:ZVH6?]H3>&[+1[.'_ #LZ_P!C#P]HEIX:T#0_#EA)<2V/A_1]
M,T2SENWCDNY;32K*"PMY+EX8H(7N'A@1IGB@AC:0L4BC4A%^DXQQ=:AA\)AZ
M525..)G6E5Y6XN<:*I6@VM>5RJ\S5[-Q5[I'QOAU@,-B<9C\77I0JSP5/#1H
M<\5)4YXAU^:I%.ZYU&ARQE:\5*5FFS\]_P#@IU^P/\(?VZ/V9/BCX9\3^ -.
MU;XPZ!X#\1:U\$O'FEV%M!X\\/?$'P[HNNZEX+TBUUN&UDU+4/">L:[>2Z;X
MA\'7,DVEZM8ZQ?3VL-AXBBTC7=+_ ,M>O]DBO\;>L^"Z]6=''4)3E*G1GAYT
MHMMJ#K*NIJ-]HOV47965[O=LV\2<+0IXC*\5"G&%;$PQ=.M.,4G46'>&=)SL
MDY2C[>:YG=\O+&]HH_NG_P"#4WQAKVH_LL_M+>![R[\_P]X5^.^D:_H=JZ[I
M+*_\8^ ]*M-<2.9B6%G.OA+29XK10L,%VU_=(OG7]PS?0O\ P<I?M2ZO\"OV
M#K3X0^%;J&T\2_M3>.+?X>:I<E[F*^L_AAX8M/\ A+O'TVDS6U[;A;K5;^V\
M'>#=2AO;6_L+KPMXM\1V[Q07LEA<Q_*?_!J!_P D'_:X_P"RN> /_4-U&OG/
M_@[+U6_F\?\ [$NB23[M,T_P?\<]5L[;RH1Y-_K&M?#&TU&?SEC%Q)]IM]#T
MJ/RI97AA^R[X(XGGN6FXOJ\*_&4H2BN2-=5VNCE2PD:T7;K>K&,G??6_GZGU
MNKAO#F-6$I>TEA/JRE?50KX]X::3W5J,Y1C;;2UK:?R.:/I&I>(-7TO0=&LY
MM1UC6]1L=(TK3[<*9[[4M2N8K.QLX S*IFN;J:*&,,RJ7=06 YK_ %"?^"=7
M_!,/]GS]@/X2>!-'T+P)X%\1?'RRT"#_ (63\>3X>CN?%WB7Q5?6]ZNN'P_K
M6LB[UCPWX5A34[S0])T72)=)MKC0XH9=6LIM3NK^>;_,"\+^)-8\&^)?#OB_
MP[<PV?B#PKKND>)-"O+BPT_5(+76-#U"WU33+F?3-6M;[2M1A@O;6"66PU.R
MO-/O$1K>]M;BVDEA?]=?^(@/_@KG_P!':_\ F!OV9?\ YS%?1Y_EN8YG3HT,
M'7HT:*<Y8B-6I5I^U;Y533]G2J<T(KG;C)I.33:;BFOC>%,YRC)*V)Q.8X7$
MXC$R5*.%G0I4*JH13FZLE[:O1Y*DW[-*<4Y*,9)2BI24O[:O^"EO_!+3X _M
M^_!;Q5I-YX+\/>$_CSI.G:MK?PL^+_AS0]%TSQ;:>+8XKZ_M-#\3:FL=C)XE
M\&>)=4N98/$&BZU??9XY;^;7M.N=,UVVM]4B_P P[4-/O])O[[2M5L;S3-4T
MR\N=/U+3=0MIK*_T^_LIGMKRQOK.Y2.XM+RTN(Y(+FVGCCF@FC>*5$=&4?L/
M_P 1 ?\ P5S_ .CM?_,#?LR__.8K\A/$&O:KXIU[6_$^O77V[7/$>KZEKVLW
MWD6UK]LU75[V;4-1NOLUG#;V=O\ :+RXFF\BUMX+:+?Y<$,42HBF09=F.64J
MU#&5Z-:BW"6'C2J59ND_>55?O*5/EA+W&HQNE)2=DY.ZXKSC*,ZK8;$Y=A<3
MAL1&-2&+E7I4*2KQ]QT9?N:];FG"U12E)1;C**O)127^D7_P0(_:AE_:6_X)
MQ?"RTUS5_P"U?'?P#U#5O@+XO>:XNYKUK7P>EGJ'P_NIEOWENGCD^&NN>$M/
M:^2>YLKS4]*U9;66WDMKG2]._::OY(?^#3K6[^?X2?MD^')),Z9I7Q&^$VMV
M<6^8[+_7_#/C&QU&38TK6Z^;;^&M+7?%!',_E8GEF2.V2#^MZOSW/:$,-F^.
MI05H^V]HET7MH0K-+LDZC27161^N\+XJ>,R#*Z]1\T_JRHRD[WE]6J3PRDV]
M7*2I)R?63;ZA1117DGO'^??_ ,'-7[2&L_$[]O2T^ 4%UJ=MX0_9H^'/A+27
MT:74+N72KSQ]\3-%L/B9KGBBVTYDALK:XN?"'B3P%X>DDCCNKA_^$>D>34"D
MR6%A^/?["_[*7B']MO\ :M^#O[,WAW4IM!?XD^(;F'7?$T-C!J3>%?!_A_2-
M1\3^,?$GV&[U#2K6\FTGPUHVIW-C83:E9G5-2%EI=M(]Y>VT$ON__!8JXGN?
M^"GG[:4ES/-<2+\9]7MUDGD>5U@M-,TJUM8%:1F80VUK##;6\8.R&"*.&-5C
MC51^C7_!K?H>DZM_P42^(E_J-C#=WGAC]DSXCZYH%Q)OWZ9JUQ\4?@EX:FOK
M?:ZJ9I-"\0ZUIK>8)$\C4)R$$@C=/UJ$_P"S>'(5*"2G1RZ%2#237MJE)2=1
MIZ-.M4<VG>ZNC\!J4UG/&%2CB6W3Q.<3HU%=I_5J-=TU24E9I_5Z2IJ2M9VD
M?VW?LR_L??LV_L>>!=.^'W[.WPD\)?#G1[*U:WOM5T[3HKGQCXGFEE2XN=1\
M9>-KX7/BCQ9J-S-%"3<ZYJMZ+6VM;#3-.CL])TS3;"S_ !T_X+:_\$C_ (#?
M'S]FKXK?M$?!SX6^'O /[2WP=\):O\1X]3^'?A^PT#_A;/AWPI:-JOBWPQXT
MT/0[&*'Q9XA?PO97\_A#61:2>+3K6FZ+X>BU&?1;F33&_H@K/U;2K#7-*U/1
M-5@^U:9K&GWNE:C;>;-!]IL-0MI;2\@\ZVDAN(?.MYI(_-@EBFCW;XI$<*P_
M,L-F&*PV+AC(UJKJJI&=23G*3K1YDYPJ-N\XS5TU)O>^CLS]LQN4X'&9?4RZ
M>&H1P[I2ITH1I0C'#RY7&G4HJ,4J<J;M*+@DU:VJNC_''K^X#_@U _Y(/^UQ
M_P!E<\ ?^H;J-?P_U_<!_P &H'_)!_VN/^RN> /_ %#=1K]*XI_Y$N)_QX?_
M -2*9^,<"_\ )28/_KUB_P#U%JGZT?\ !7#_ ()V?$C_ (*4?!GX<?!OP;\=
MM'^#7A[PE\1F^(/BFPUCP+<^+(?&-]9^'M4T+PT?[0L/$.AWVEQ^'5UO796T
MPPWUAK4VK6U]<M:7?AW3OM'\[WA'_@U4^/UA\3/AS+XV_:#^"WB3X0Q^,_"\
MWQ6M]!F\>^&/'LW@&+5TE\867@<77@CQ%HC^)[K1(GM- N-9O;'3H-0O/M5Z
M##8""_\ [)OCG\>/A#^S3\,/$_QF^.GCO1OAQ\-/!]M'<Z]XGUO[9-%";B9+
M:SL=/TS2[6_UK7=9U*ZDCM-)T'0=-U+6]6O)([33=/NKF1(F_D&_:C_X.I_'
M.HW&M>'/V/OV??#WAC35FUO3].^)WQMU*\\3ZY>V4LAM='UW2_AQX9FT+2/#
M>JVUNKZE';ZYXM\<Z<]Y<6MM?:7-:Z?<PZM\CDE?B"I0>&RQ16&A*:E4G3HQ
MITYU+RDW6E%3G-73M%U)Q3A[JARH^_XFPO"5+$K&YW*;QE2,'&E2K8BI5JTZ
M5HQ7U>$I4Z=)J+7-)4J<W[3WG/F9_7_\'O@;\'OV?O!FD_#[X*_#?PA\-/"&
MC:7I6D6FD>$]&M--\^TT6S6PT^76+]$;4_$&II;J3<ZWKU[J6LZA<RW-[J%_
M=7MU<W$O\X__  <L_LQ_LR6O['>C_&RP\&?"_P !_'WPE\1/"EEX9UW0K3PY
MX1\;>//!.HSMH'BGPI<VEA9P7OCO1=!FUO0O$<<-Q'//X0FM6N]-U'2[+6M=
MT[Q#_,/\8/\ @M#_ ,%//C6Z#Q)^U]\3_"EK"L"6]E\'[G2_@FD0@(?+WWPI
MT[PCK%ZTTV^6=]2U.]>02&V#+91P6L7YIZYX@U[Q-?R:KXDUO5_$&J2[_-U+
M7-2O=6OY/,FFN7\R\OYKBX??<7$\[[I#NFFFE.7D=F]O+.&<;A<72QN(S"*J
M0J*I4A2]K4=9:\T*E6HZ;M):2O"=TWY,^;SOC;+<=E]?+<)E,W2JT94J53$>
MPHQPSLN2I2H4E65Z;7-!*I3LXQ?=+(K_ %E/V2Y](^-7["G[,]SX\TJQ\:Z#
M\6OV2_@S/XRT3QGI6FZUIOBW2/'GP>\-R>(M*\5Z)>QWNCZM8Z]9ZK>6FNZ5
M=PW>FW\%W=6D\=Q:RNK_ .377^LO^P3I7]@_L+_L7:']H^U?V-^R;^SGI7VK
MRO(^T_V=\'_!UG]H\CS)O)\[R?,\KSI?+W;/,?&XKC32A@)+22KU>5K1KW(M
MV?351?JEV#PVN\7FD7K"6%H<T7K%M59I73T>DIK5/1M==?Y4?^#G+]FO]G3X
M!^"?V0+OX%? +X*_!:Z\3>*?C+;^)+GX3?"OP+\.;CQ!;Z7I/PYDTR#6YO!^
MA:-)JT.G27U[)817[7"6CWET]NL;7$I?^1:O[4_^#LS_ )$']B3_ +&_XZ?^
MF7X7U_%97K\,SG4R;"RG*4Y.6(O*<G*3MB*J5VVV[))+71*Q\]QI3ITN(\?"
ME"%.$8X3EA3C&$5?!8=NT8I)7;;=EJVV?ZPMO_P3P_8 M+B"[M/V&?V/+6ZM
M9HKBVN;?]F;X*PW%O<0NLD,\$T?@E9(IH9%62*6-E>-U5T8, 1/^WC^S=XR_
M:\_9/^,/[-_@?XHVOP=UCXKZ%9^'KKQS=^$G\:);Z%'K.G:GKN@_V.GB#PYY
M,/B[3;"?PKJ&JB[NYM*TG6-0O++3;O4([3R_KRLS6];T;PUHVK^(_$>KZ9H'
MA[0-,O\ 6]>U[6[^UTK1M$T;2K66^U35]7U2_E@L=-TS3;&">\O[^\GAM;.U
MAEN+B6.&-W7\MCB<0JM&K[6<ZE&I&=)U&ZO+.,HRC:-3GB_>C&\6FI62::T/
MW2>"PCH8BA["E2HXBE.E75%+#\].4)0DG.C[.<;0E)*2DI1NW%IZG\-7B3_@
MU+_:LM?._P"$/_:8_9[UW;]N^S_\))I_Q'\*>;Y>/[-\[^R_#/C+[/\ :^?M
MWE_:?[/P/L_]IY./ZSOV'_V#?@)^PS\$_ GPN^&'@;PY#XBT+3+:Z\8_$6;3
M;.^\9^-?'-YIJ6OB?Q1J?B>XL;?5I1J$TEW:Z;91BSL-(T%K?1=.T^RT^%;4
M?@+^V3_P='> ? GB3Q)X%_8Q^#VG_&$:5+/9:?\ &KXEZIKWA_X?ZC=K86[1
MW>B?#JQT_1O&GB#2(]3GN+::YU7Q+X%N)X]+9["WN;35;;4;3\"?C+_P7>_X
M*A_&?^T;6Z_:4U3X::'J-G>6/]A_!KPYX:^''V"&^V">33O%6D:8_P 0K:\5
M8XUL]0/C*2_TW:[Z=<VDMQ=R3_93P'$V=4*4,;4I8:@FI\M2U*<^9))SHT(R
M=XJ]H553<6W=(_.:>;<%<-XJM4RVC7QF)<?9.5"]>G3Y7=JEB,54BN6;2<JE
M"552LK-I6/[;?^"OO[,/[,/QF_8C_:7\3?&+PG\,=+\<^&/@_P".?%?PV^*N
MOP^&_#7B[1OB1X)\'ZOXB\!V-CX[NK/^VOL>J:MHMIHNJ^'K>ZG_ +>\/W&H
M:1':.TL30_YBE=Y\0OBG\3OBWKDGB?XK?$;QY\3?$LS3/-XA^(7B_P 0>--<
ME>X<27#R:MXDU'4K]VGD59)F:X)E<!G+, :X.OILERNIE6'G0J8J6)YYJ<5R
M.$*7NJ+C!.<VT[)W]U:?"CXOB7/*.?8NGB:6!C@_9TW3E+GC4J5_>YHSJN-.
MFDXW:2O-V?Q6LE_H]_\ !NAXPO\ Q1_P2R^$6G7]W>7G_"#>._B_X/LS=K#_
M */8?\)]JWBFVM+::,M/<6=O_P )0Z0->'SK?YK" +I]G9(O[FU^"_\ P;<:
M7_9__!+KP%=^?YW]N?%?XPZIY?E>7]E\GQ2=$\C?YC^?N_L?[3YNV''VCR?+
M/D^;+^]%?F.<J*S7,5'1?6Z[[:NHW+_R:Y^V\/.3R+)W+5_V=@UKKHJ$%'_R
M5(****\T]@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /E[PQ_P EOU+_ +"OB7_TGOJ^H:^7O#'_ "6_
M4O\ L*^)?_2>^KZAKOS#X\/_ -@E#_VXY\-\$_\ KY+\HA1117 = 4444 %?
MGE_P59_:6\7_ +(O[ ?[1'QW^'/B.Q\*_$CPOX?\/Z3\/=:O;'2=6-EXN\9>
M-/#?@_3;NRT77--UG2=9OM.37+C58=/U'2=0T]TL)9]2MQIMO>31?H;7\O/_
M  =0_&*U\+?LA? GX*1.$UGXN_'";Q61]IDC,OA;X2^%+]=:B%K&R"X_XJ'X
M@^"I?,G,MO;^3S;-<S6MS:>CE&'6*S/!4)14X3Q$)5(22E&5.F_:U(R3T<73
MA)-/I?1['C\08R6 R7,\5";IU*>$J1I3C)QE"M62HT91DM5*-6I!Q::?,E9K
M<^:_^"%/_!2O_@H]^W-^VM??#[XZ_M"KXY^#_@3X.^-_B/XO\.2_"GX,>$DU
M6X@U+PSX-\-6D.N^!OA/HVMQWT&O^,;+6HK%-?T6&\L=%U*26XO(K632=0_L
M:K^/O_@T^^#3VWA7]KS]H._TYFCUCQ!\.O@UX5U8M?1I"_AO3=9\;>/].5%N
M%TV[:Z7Q7\-;EVFM);[3A:(+:X@@U2ZCN/ZQ/BI\5/AW\$/AWXO^+7Q:\7Z-
MX#^'/@/1KC7_ !9XLU^X-OINDZ;;E(PS"-);J\O;RZEM].TG2=.M[O5M;U:[
ML='T>QOM4OK2TF[N(H45F]7#X2A3IQI1HT8T\/2A!3J2A&;M"E%<TW*IR/1R
M;BEK9'F<'U,3_J_0Q>88NM6G7GB<3*MC*]2K*G1A.5./-4KRDX4E"C[5>\H)
M3<M&Y'2^)/$WAOP;H.J^*?%_B#1/"GAC0[234-;\1^)-5L-#T'1["''FWNJZ
MOJEQ:Z?I]I%D>9<W=Q#"F1N<9%?Q!?\ !27_ (.0_CMK_P 8;KP3_P $\_&=
MG\-/@]X&O+G3I/BOJ/@+P=XL\4?&'4XFE@N]7L=&^)?AGQ-I?A;P"CA/^$8M
M1H5IXNU2.(ZWK=]IL>I)X5T?X8_X*T_\%E?BG_P4;\3-\(_AII^L_#O]EG0_
M$OF>&/ <,LK>+OBSJ5I>+%H'BGXFK82RP33K(D6H>&_ .G&[TGP[?W2S7=]X
MFURQTS6++]8_^"*W_!!339--\(_M<_MU^#9KF\N9M+\4?!S]G3Q);&*SMK.(
MI?Z5XU^,NBW,0DO;B]D%K?:%\--0"6-O9(LWCRRU&349?#&E>OA,JP62X7^T
M,[C"K6FFJ& :A47,UM*$FX5*EM^;]U16K<IN/+\]F&>YEQ)C?[(X9G4H8:G)
M2Q6:1E4HOEB]XU(VJ4:-_A4;5\1)6BHTE/G^_O\ @CW<?\%B_P!H&/PY^TE^
MW%^T?J>@_ #6M BUWX<_!X_!W]GWPSXQ^+$.K+=1:?XA\5W6A_"72?$_@CP*
MEFL.M:'%8ZAI?B3QC'>Z3JMI=:=X9V2^(OZ'J*_-/_@JI_P4*\(_\$Z?V7M<
M^)]P=.UGXM>,IKCP3\#/ MQ>Q0W/B'QM=VCR3^(;NU^S7T[>$_ %@Q\2>);I
M[-=/N9UT/PC+J6F:KXQT263YFK.IFF.C'#X6A1G7G&G1PV%I0I4X)MV3Y(Q4
MFE>52K/HG)\L(J,?MJ,*.199.>+QV*Q%/#4Y5L3C,;7JXBM4DDN9Q]I.;BI-
M*-&A3=KN,5SU)2E/&_X*-_\ !6?]F;_@G#X;LX?'EZ_Q(^,VOHLOA;X$>"-9
MT9?&<EA)#-)#XH\9RW4\H\!^"9IH?L5IKVIV%Y?:U>-/%X7T+7UTK7I-(_C3
M_:"_X."_^"F?[1FM:IHWPY\>VGP%\*:Y:)8VW@3X&^$]-/B#R[,Q7[WL'Q"U
MS3?$'Q-M=7/V-Y;R[\*^(/#5J]E]HMVTY+1[A)?CG]EK]F#]JG_@K?\ M<:M
MI%IXAU3Q9X[\::I+X[^.'QM\:O+?:9X,\.S7EO::AXIUYH3;)/)&C6^B^#/!
M6C_8EO)(M/T'1X-%\.Z;=WVC?Z'?[$'_  32_9._8&\(:9H_P5^'6EW'CQ-+
M2Q\3_&KQ596.L?%7Q?<.LGVV:\\1O;*^AZ9=/*ZKX:\,1:/X?B@2!9+&XNDE
MO)_J:E+)N&Z=.%>A#,\SG%3E&:BZ=/JG:<9QI1NO<E[.=:=N9\L6K?"T:_$7
M&56K4PN*J9+DM.<J<)TW)5JUM&G*G*G.O.S_ 'D55IX:%^1.<TW+^#$?$G_@
MO-J>FV_Q)@\3_P#!5N?PS/\ 8K^U\36$O[5T?@BXCCN(;&UEB>RC3PG<6<]V
MD5I)&L;VE_=N\5PEQ/<2K)[1^S?_ ,'"'_!1_P#9N\6S:7\6_%L?[0WA;3M4
MOK;Q%\/OC+HMCI/BK3[^!+ZROK.S\<Z1HVG^,=%O[743;M<V&OCQ#864FFFR
MM]'L7N+YY?\ 1BK\M_\ @I+_ ,$HOV<O^"BW@/5&\4:!I/@;]H'2]#FLOAQ\
M?=$TQ(_$^CW,!2XTW1?&B6<EF?'O@?[1$UL^@Z])=3Z%:ZCK%WX-O?#VJZC=
MWEQA2XARW%35',<HPL,/-\OM:48RG13LE*RIQG9=94IQG%+W(R=HOJK\(9S@
M:;Q.3\08ZIBZ:Y_85YRA3Q#C9N-W5G2N[>["O3J4Y.RG.*3D>G?L!_\ !1_]
MF[_@HG\-I/&?P4\036/C#P[:Z</B=\(_$B_8_'7PXU34!,L,5_#M6SU_P]?R
M6T[Z'XP\/37VB:E$#:74FE>(K36/#^E??5?Y8O[)G[0GQP_X)1_MUZ=XPU71
M=;T/Q1\)?&6I_#3X[_#29KBPD\9?#]]8M;3Q_P""KB.:2SM[G[=;Z?:^(O!>
MI7JW&D6WBC2O!_BY;:_MM/MXYO\ 43\$^,_"_P 1_!GA'XA^!]:L_$G@KQYX
M8T#QGX0\1:>9#8:]X7\4:5::YX?UJQ,T<4QL]4TF^M+ZV,L44AAG0O&C94>7
MGV41RRO3GAY.>"Q47.A-OF<6K.5-S2M))2C*G)ZR@[-RE&4G[?"O$$\[PM:G
MBX1I9C@IJGBH*+@IQ=U"LH/6$G*$X58+2%2-THQG"*Z>O\\/]J;_ (+]?\%'
MK']I;X_:=\"_VF6\-_!C2_C%\1M)^%6BO\'/V>M=>Q^'^E>+-5T[PFKZMKGP
MHU;6+YIM%MK.Y:74M5U2\!F,<^I7[H;N;^[7]KGXO?\ "@?V6/VC/C8FI6^D
MWOPL^"?Q-\<:+>7$NE1;O$?A[P?J^H>&+&T&N)+I-SJFJ^(8=,TO1]/OH+F'
M4]5O+/3C:7;72VTO^<#_ ,$7O@^_QK_X*>?L@^&RZPVOA3XGVWQ@O;AYS (D
M^">EZC\5K%!L/G3->ZQX1TS34@B202/>J;D1V2W4\7H\,X;"O#YIC\9AZ.(I
M8:DN2-:G"I&\(5*U7E52,E&7+&FDTF_>:\GY'&N-QRQF1Y7E^,Q.#K8W$252
MIAJU2C*U6K1P]#F=*I3<H*4ZLG&34;Q3NM6O3_\ B(#_ ."N?_1VO_F!OV9?
M_G,4?\1 ?_!7/_H[7_S W[,O_P YBO\ 2VHJ?]8LK_Z)K ??A_\ Y@+_ -4,
M[_Z+/-?NQ?\ \]3_ #<?"?\ P<1_\%7O#NI1WVL?'WPOX\M4FAD;1O%GP1^#
M5GILR1"8/;R2^!O!'@S5Q#<&1&F:'58IU-O#]GG@5IUG_HD_X)+_ /!P):_M
MD?$GP?\ LP?M.>!O#WP\^./BZ'5[;P1\1/!4]U9?#;X@ZQI5G<:K;>&K[P_K
M=[J6H^"_%NI:-97AL)!X@U;0O%.NVITS2H/#^HZOH7AVY_H2^*WP'^"7QUT*
M]\,_&CX1_#?XJZ%J%K%976F?$#P7X>\66[06\TUS:"'^VM/O)+6:PNYY;W3;
MFU>&YTV_<WUC-;W8$P_RZ/VT_A3!^Q5^WK\<?AG\)==OK6S^!'QROKOX7ZU+
M/9ZCJVA6.E:M:>*_ R7=V9=1M=1UGPQ:SZ58WUW=HKWVI:;//J&EZ=/+<:5:
M^A@UE'$4,3AH9;2R[%4Z7M*=2AR67V%)NE3HJ2C.4>>G*#4HNZ:DDX^3F,N(
M>#ZN"QE3.J^;X&M7]E6I8GVCDTDJDH)5ZV(<)3IQG[.K3JIPE&THN,G&7^K?
M17/^$]=_X2CPKX9\3?9?L/\ PD7A_1M=^Q>?]J^Q_P!KZ=;:A]E^T^3;_:/L
M_P!H\GS_ +/!YNSS/)BW;%Z"O@VFFT]T[/U1^J)II-:II-/R>J"BBBD,*_G_
M /\ @O1_P5,\6_L$_"7P/\,/V?/%$/AS]J+XPZC;:YI/B!M \->)D^'7PL\-
M:F&U_P 32Z1XMT_7?#]UJWC#5[6'P3X?M-7\-ZK93:2_CK5H+C2M<\/:)-<?
MN9\1_B+X)^$7@'QE\4?B1XBL?"7@'X?>&]8\7>,/$NI"=K/1?#V@V,VHZI?R
MPVD-S>W30VL$A@LK"UNM0OIS%9V%K=7D\$$G^9-X^\:?&3_@LI_P4PL)K;3)
MK+Q)^T;\4],\)^$- A,-S'\,OA!HS2BT2_O+#38QJ%K\,OAAI6H>)/%^OPZ2
M;C5I-'U[7ETLS7:Z>/H^',MIXS$U,5BHQ^I8&#K5O:).G.:3E&$E+W90C&,J
ME5.ZY8QC)6J(^.XQSFME^#I8' SFLSS2HL/A_92:K4J;E&,ZL'%J4*DY2A1H
MR3C+FG*=.7-2=OOO]B+_ (+Q?\%&?&'[8'[-'@OX[_M(S>+?@_XW^-7P]\$?
M$#0(/@U\!-%>]\/^,?$=AX9N)6U/PK\)],\26T.GRZI#J5P=#O[;5)K>SE@L
MW,TJ(W^@E7^7G_P5(^%]A^QW_P %+_B_\.OAQ($TGX)ZY\$;SX?C4&AU$VFE
M:=\(/A;XI\(6NH^3I^D6US)86-QIUK?00V-O;&2":"%IH0MQ+_IP^ _%=KX\
M\#>#/'-C%Y%CXS\*>'?%=G!ODE\FU\1:19ZQ;Q>;-;6<TGEPWB)OEM+61]NY
M[:!B8EZ>)\/A8PRO&8/#TL/2Q>'E+EHTH4D[JE5@Y1IQBG)QJM7:NU&VR1Q<
M$8S'3J9WEV88O$8O$8#%PASXBO5KR5I5Z%2,)59SDH*=!/E32O.^[9U=%%%?
M)GWP445X]\5OVA_@!\"(M.F^.'QR^#WP:AU>18M)E^*WQ,\%?#R+5)66Y=8]
M.D\7:WHZ7LC)9WC*EL96*VERP&()2E1A.<E&$93D]HQBY2?HDFW]Q,YPIQ<Z
MDXTX+><Y*,5=V5Y2:2N]-7N>PT5YE\,_C7\&OC587NJ_!OXM_#+XM:7IOV'^
MT=2^&?CWPKX\L-/_ +4AEN=,^VWGA;5=5M[7^T;>&:>Q\^2/[7#%++;^8D;,
M/3:)1E"3C.,HR6\9)QDNNJ=FM.X0G"I%3ISC.$M8SA)2BU>UU*+:>J:T>Y1U
M/4]-T73=0UG6=0L=)TC2;&[U/5=5U.[@L--TS3;""2ZOM0U"^NI(K6RL;*UB
MEN;N[N98X+>".2::1(T9A_-[_P /Y-/_ &HOV[_V=OV,?V$?"=QK_A#QA\8=
M%LOBG\=_&&E/!)KWP^\&7>H>,OB+8_"3P?<">XM-'U3P-X7U%;KQYXVL[/5X
M](N]=M]&\'>']3AT+Q[:?J7_ ,%6OC&_P%_X)R_MA_$>W$HU"'X*^)?!.BW%
MO?V^FSZ;XA^+#6OPH\.:S!<W,,\3S:'KWC;3M8BL?+,NIO8KIMN\4]W%*G\>
M7_!L/\)4\<_\%"?$/Q&NI)8K7X)_ GQOXCLC''<,EQXA\9:EH'P\LK.XD0+;
M1PMH'B/Q5> 3RO*]Q80"WM956>YLOHLIR_#3RW,\SQ,/:?583IX:$G^[]O[*
MZE.*UGRRJ4N5-\FKNF[./Q^?YMC:6=9)DF"J*C]>JTZV,G&/[[ZJJ]G"G.5X
MTU.G1Q'-**]I[L;2BK\W^@E1117S9]D%%> ?$K]K']ECX,ZS/X<^,'[2W[/_
M ,*?$-M]C^TZ%\2OC)\.O NLV_\ :-H;_3_/TOQ1XCTN^B^W6(-Y9^9 OVFT
M!N(-\(WU;^&'[4/[,_QNOYM+^"_[1/P+^+NIV_F>?IWPP^+?@#Q]?P>5";F7
MSK3PIX@U:XC\NW!GDWQKLA!E;"?-6OL:RA[1T:OL[7Y_9SY+=^:W+;5:WMJ8
M?6<,ZGLEB*'M;N/LO:T_:<RWCR<W-==5:Y[I11161N%%%>"_%']JG]E_X'ZM
M:Z!\:OVD/@+\(-=OH7N++1?BC\8/A[\/]6O((TMI))[73O%GB+2;RXACCO+2
M1Y(871$NK9F8+/$6J$)U)<M.$IR>T81<I/Y139%2I3I1YZM2%.":3G4G&$4V
M[)<TFE=O1*^K/>J*XOP'\2/AW\4]#;Q/\,?'O@OXC^&EOKC3&\0^ _%.A^+]
M#74K1(9+K3VU;P]?:C8"^MH[FWDN+0W'GPI/"TD:K*A;M*33BW&2<9)V::::
M?9IZI^HXRC.*E"491DKQE%J46GLTU=-/NF%%%%(H**\J^)7QV^"'P8B@F^,/
MQD^%7PHANK>6\MI?B5\0_"/@6*XM(%G>>Z@D\4:QI22V\*6URTL\9:*-;>=G
M8"*0KP_P]_;$_9&^+>N1^&/A3^U-^SE\3?$LS0I#X>^'OQO^&7C37)7N',=N
MD>D^&_$^I7[M/(K1PJMN3*X*H&8$5HJ-:4'45*HX)-N:A)P26[<DK6774Q>(
MP\:BI2KT8U6TE3=6"J-NUDH.7,V[JVG5'T;11169L%%%% !17B?Q6_:6_9R^
M!%UIUC\</C_\$_@U>ZO;K=Z39_%;XJ^!/AY=:I:M)<PK<Z=;^+M>T>:]MVFL
M[R)9K9)8S):7*!MT$H3JOAS\7/A3\8M&/B/X1_$[X>_%/P\/)SKWPY\:>&_&
M^C#[2KO;YU3PSJ6IV(\](I&AS/\ O5C=DW!&(MTJB@JCIS5-Z*HX24&^RE;E
M?R9DJU%U'15:DZL=94E4@ZB6CNX)\RT:>JZKN>A5\E_MX_'B?]F/]C/]ICX[
MZ?J3:1K_ ,.?@[XUU;P;J*6^FW9MOB!>Z3-HOP\8VNL6M_I4ZOXXU/P_$\6H
MZ?J5FZ.RSZ;J,9:RG^M**=*485:<YP]I"%2$IT[\OM(QDG*',XR2YDG&[C*U
M[\KV"O"=2C6ITJGL:E2E4A3J\KE[*<H.,*G*I0<N234N53@W:W-&]U_&O_P0
MT_X*7_\ !2K]N+]MZ+X=_&SX_?\ "??!GP7\*O'?Q#^(&@/\)?@AX5BNX[;^
MR?"?A>--?\&?#CPSK]K>1>+O%FBZE%:V6K(U[::;?K/;7%A%>F/^RBBBNO,L
M91QN(]M0P=' TU3C!4*"ARWBY-S;A2HQ<I.5F^1.RBKNR//R;+\1EF#>'Q68
MXC-*SK3JO%8EU'.TE",:<55KXB4804+I*I;FE*22<F%%>%_$_P#:A_9G^"-_
M#I?QH_:)^!?PBU.X\OR-.^)_Q;\ > ;^?S81<Q>3:>*_$&DW$GF6Y$\>R-M\
M)$JY3YJJ?#;]K']ECXS:S!X<^#_[2W[/_P 5O$-S]L^S:%\-OC)\.O'6LW']
MG6@O]0\C2_"_B/5+Z7[#8D7EYY<#?9K0BXGV0G?7+[&MR>T]C5]G9OG]G/DL
MMWS6Y;+J[V._ZSAU4]B\1156_+[+VM/VG,[67)S<UW=:6OJNY[_11161L?FW
M_P %%_\ @J+^SE_P3:\$Z3JWQ7DUGQ?\2?&MEK$_PU^#W@P6C^)_%#Z7$(CJ
MNLZA?31:;X.\%PZK/9:?J/B;4?M=Z1+>MX8\.^+-0TF_TJ+*_P""2W[67QK_
M &XOV6-1_:?^,_A_0/"*?$KXP_$/_A57A3PQ;3)HWASX4^$6T;P1I>F0ZE>I
M_:?B*_7Q=X;\:76N^(=2GE;4?$%SJATRT\/Z!%I'A30?Y#_^#FGXQO\ $+_@
MHU'\.(!+!I_P#^"OP]\$SVYO[>\@N?$/C!=3^*^HZS';10QRZ5-=:#XZ\*:/
M/8W4D\LJ>'[?4D=(-0BB3^SO_@F%\)4^"'_!/;]C_P"'/F2R75A\"? _B/5Q
M-'<1/!XA^(.FK\0_$MFL=T%N4AL=?\4ZE9VXGBMY?L\$1>UM&)MHOI,;E^&P
M618&OR<V-Q\X5)5)N_)0Y)U%&E%>[&ZE1<F[S=Y)OE]U?&Y;FV-S/BC-,(JB
MCEN54JE&-*G'E]IBO:4Z3G7D[RFXRCB5"*<::Y8R47).4ONZBBBOFS[(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0I]%3A+$3IP2M90M9)(****^1/T **** "BBB@ HHHH **** "BBB@ HHHH
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MH?\ 8@RO_P!*Q(4445^,'XX%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI>]A\!34,)0M[LO9SKJ,9UZERBBBOK3]1"BBB@ HHHH **** "BBB@ HHHH
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MJ>+:ND[-86K9J^S71K5']9%?R#_\'-?_  3P&O:!HG_!0GX8Z8QU?PM;:+X
M_:+TZW624ZCX<DNK/1_AO\188(+,^7<Z!>77_"%>*[NZO91=:1?>!FM+6RA\
M/ZM<WO\ 7Q7%_$?X=>"?B[X!\9?"[XD>';'Q;X!^(/AO6/"/C#PUJ1G6SUKP
M]KUC-IVJ6$LUI-;7MJTUK/((+VPNK74+&<17EA=6MY!!/'^;99CZF6XVCBH7
M:A+EJP7_ "\HR:52&Z5VM8WT4XQET/V7.\JI9SEN)P-3E4JD>:A4DOX.(@FZ
M-72[LI>[-+65.4X?:/\ 'KK_ $)_^#>C_@I!=_M<?LZW/[.?Q4U?[9\=_P!F
M/1-"T:QU">*-+GQ[\#[>UL=!\&>);JY$YFU+Q/X3NH/^$/\ &-W+:1RW=N?!
MGB'4-1UC7_$^N36W\6'_  4*_8N\9_L#_M4_$7]GCQ4=4U'2-'N(O$/PS\8:
MEI_]GK\0/A=KTMTWA3Q;:K&6M)I&^R7_ (?U[^SY9K.Q\7:!XCT=)/,TR5$\
MT_9)_:;^('['/[1'PN_:.^&30R^*/AIXA35#I%Y<75OI?B?0KRWGTOQ-X2UE
M[1TG&D^)M O=1T>\>+,MLEVMY;@75M R_I^:8&CG>6KV4HRG*$<1@ZW3F<5*
M*;T:C5B^2:?PW4G%R@D?B.19GB>&<Y?UB,X4XU)83,</UY%/EG))74JE"2]I
M3:^-)P4E&HV?ZW=?P%_\'-O[)NH?"7]LKPY^TSH>B+!X!_:<\'V U?5+19/(
MA^+WPUL;'PSXDLKVW1I+?36U;P2G@/6[&<BS/B+4CXMN8K6XO-)UF_N/[@/V
M9OVA?A[^U;\!?A?^T-\++_\ M#P1\4O#$&OZ9N+FYTR_AN;G2?$GAO4-\4.-
M7\)^)].UGPQK(2,0KJND7@@>2$1R/YG^W1^Q=\*_V]_V<_&'[//Q6C:SM-7:
M+7O!7C&TLXK[6/AQ\1=)M+^W\,^.M$MY9K5;BYTQ=2O]/U/3OMEBNO>&M6UW
MP[+?6=OJ\US%^=9/CI91F<:E:,HP3GAL5"SYXP<DI^[OS4JD(S<;7?(XK5W7
M[!Q%E<.(<EG1PTX3J25+&8"K=>SG447*G:6RA7HSG34[I+VBF[J+3_RP/@Y\
M6?&_P&^*_P .OC3\-M4_L;Q[\+?&7A[QUX4U!D::VCUGPWJ5OJ=I!J-HLD2Z
MCI%\UN;'6=*G?[+JVE7-YIMXDEK=31M_J5?L$?MQ?"3]OG]GKPC\:OAGK6F'
M6IM,TZR^*'@*.]MW\0?#/QZ+=DUGPWKFFBYGOK2SEOK:]N_"VIW:I%XC\.FR
MU>T)$TT4'^:!^V=^Q5\=_P!A+XTZY\%?CMX8FTS4;2:XN?"?B^PANYO!/Q)\
M,+*%LO%W@;6Y[>WCU72KJ.2$7EJR0ZMX?U!IM$\0V&F:S:75C%YC\"OVA_C?
M^S+XZM/B7\ _B=XM^%GC:SAFMEUOPKJ36AO+.XAE@FL-7TZ99]*US3G29V.G
M:S8W]B)O+N!;BXBBE3[_ #?*:&>X:C6H5H1JPBY8?$)<].I3FKN$W'5P;2<9
M*[IOFM%\TD_RCA[/\5POC,1A\5AJLJ$YJ&+PLOW=:C5INWM::G[OM%&\90ER
MQJQY??CRQD?Z\59FMZWHWAK1M7\1^(]7TS0/#V@:9?ZWKVO:W?VNE:-HFC:5
M:RWVJ:OJ^J7\L%CINF:;8P3WE_?WD\-K9VL,MQ<2QPQNZ_P!>%O^#H7_ (*-
M>']*&GZMX._99\<W8N)ICKOBGX:>/[356CEV;+0P^"?B[X.T3[/;[3Y++HPN
MVWO]HN9\)L_/#]KW_@KE^WI^VUHLW@[XR_&O4+#X:W'GB\^%?PUL+;X>> M8
MCGNM/OA;^*]/T#RM4\=V=I>:5IMYI5EX\UCQ/::+>V@OM'@L;VXO+BY^3H\'
MYE.JHUJF'I4D_>J1G*I)QZNG!0C=]E-P7GT?WF)\0\FIT)3PU'&8BNXODHRI
M1HP4K:>UJ.<N6/=TXU7=6M9W/I?_ (+G_P#!2W1?^"@?[1VAZ#\)=5N[[]F_
MX"6FM^'_ (;7MUI2Z3)XU\4Z_<6(\=_$?R9E&K-I&N?V%H.E>$;36?L]Q9Z!
MHR:K_9&A:IXEUZQ;\FO@-\%?'7[1GQE^&WP,^&FE3:SXX^*'BW2O">@64/D@
M)/J,X%UJ-U)<3VMM!IVCZ>EWJ^J75S=6UM::;8W5U<7$,,+R+Y?I^GW^K7]C
MI6E6-YJ>J:G>6VGZ;INGVTU[?ZA?WLR6UG8V-G;))<7=Y=W$D<%M;01R33S2
M)%$CNZJ?[WO^""'_  2 U[]D#1;C]K+]I;P_:6/[1'Q#\,)I?P]\ ZG8^;K/
MP-\#:RHGU>XUIKAWATSXG>-[465GJME;6L6K^!_"\=[X6O-32_\ %GC3P[IO
MU^,Q6$X>RN-.E92ITW3PE&33G6JO5SDE:ZYY.K6G:*U:5I2BG^>Y=@<PXNSN
M=:LI.-6M&MC\1%-4\/05DJ<&V[2]G%4<-3O*6B;O"%2:_HE^%_P[\-_"#X9_
M#OX3>#8KB#PA\+_ OA'X=^%8+MX9+J'PWX)T#3_#6AQ7,EM;VEO)<1Z9IEJD
MSP6MM"\BLT5O"A6-?X;?^#H/]JN\^(O[6'@+]E31KQAX4_9T\%Z?XB\4VC0V
M\;S_ !4^*NGV?B)R\L4TTMQ9:9\-F\"R::;@6DL-[K_B%/LKP-;7EQ_<5\6O
MB?X1^"?PO^(7Q?\ 'U__ &9X*^&7@WQ'XY\3W@>T2:/1O#.E76K7T=H+ZZL;
M2;4+F&U:VTZUFN[9;N_FM[43(TRFO\DCXU_%OQA\>_B_\3/C7X_U";4_&?Q4
M\<>)?'?B*ZFD$@&I>)=6NM4EL[54C@AM].TY;A-.TNQM;>UL=.TVUM+"PM+6
MSMH+>+Y7A#!O$8ZOCZGO+#1:C*5VY5\1S)R3V;C353FZWJ19]WX@YA'"99A<
MJH^[+&34IQB[*.%PO*U!I:I3K.ER=&J,T0_![X0?$CX^_$[P5\&OA!X6N_&O
MQ+^(>MV_AWP?X7LKK3;";5M5N$DE$;ZCK-[INCZ9:6]O#/>:AJFKZC8:5IEA
M;W-_J-[:V5O//'^I/_$/Y_P5S_Z-*_\ ,\_LR_\ SYZ_1;_@UC_9HC\9_M$_
M'#]J77+&WGTOX)>!;'X>^"Y+B6ZCFC\>_%::Y?4]8TU(%%O/)H?@7PUK>B:B
ME_.(HX?'UG+;65W< 7>E?W05ZF><2XG+\=+"82EAJBI4X.K*O"K)JK-<_+'V
M=:FE%4Y0;NF^9M:6/$X9X+P>;Y7',,?6QE*5:K55"&&G1A%T*;]GSS]KAZS<
MI58U$K.*Y(Q=G>Y_FD_\0_G_  5S_P"C2O\ S//[,O\ \^>O-_B__P $5_\
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MV&#[/YD_Y:?\%Y_^"P^I?LD:%<?LE?LT>(VT[]I/QIHT-U\0_'-A'.M[\$_
M>NV FL%\/7I6.WM_B7XQL[A)]&U&W>ZNO!GA_P S7H8K'7]5\)ZM8?OE^TK\
M=/#7[,G[/_QC_:"\7VTVH>'_ (/_  \\4>/+S2+:X2TO-?GT'2[B[TSPU874
ML4T-MJ/B755LM TZXN(VMH+[4;>6YVP)(P_R=?C5\8?'_P"T%\6OB)\;?BEK
M<WB'X@_%#Q;K/C+Q3JDC2B%M2UF[DN38Z;;RS3C3="TBW:#2/#VC6\@L=#T*
MQT[1]/CAL;&WAC]'A[ 2S?'5\QQ]JT*4U.2E&$8U\3+WDI0C%0Y*<5SS@HQ3
ME*FFG%RB_'XOS:/#V687)\KOAZE>DZ<'&<Y3PN"I^ZW"I.4JBJ59-TZ=1RE*
M,8U9)QFJ<EC>!O!'CKXP_$+PM\/? VC:IXT^(OQ(\5:7X8\,Z):R+-JOB/Q5
MXFU**PT^T%S>SQ0BXO\ 4;N,3WM_=0VT.^2[OKJ&".:=/]&G_@D)_P $A/A]
M_P $Z/A\GC7QJFC>.OVL/'6C10>/?'L$0NM+\#:7="*YF^&WPVFN8HY[;1+>
M>.+_ (2+Q%Y5MJ7C34K:.YN8[/1K/1M&T[_-@HK[+-\MQ&9T8X>GCOJ=!ZUH
M1H>UE6M;EC*?MZ5J:W<$FI.SDVDDOSGA_.<)DF(EC*V6?VAB5IAZD\4J$<.F
MFIRA3^K5^:K*]E4<DX1NHI.4F_\ 9(HK_&WK][O^#;/_ )2A>"O^R1_&#_U'
M8:^1QG"/U3"8C%?VA[3ZO1J5>3ZIR<_LXN7+S?69<M[6ORRMO9GZ#EOB!_:&
M/P>!_LCV/UO$4J'M?K_M/9^TDH\_)]2AS\M[\O/&^W,C_1:HHHKXP_1PKX6_
MX*>:%_PD7_!.?]N33_M7V/[/^RM\<M=\[R/M&_\ X1?X>:]XF^R^7YT&W[=_
M9'V+S][?9?M'VGR;CROL\OW37S-^VIX(USXF?L<?M9_#CPQ8WVI^)?B!^S-\
M>/!'A[3=,LWU'4M0USQ7\+/%6@Z38Z?I\;Q27]]=W]_;P6EG')&]U/)' KHS
MAAT862ABL--M)1Q%&3;V2C4BVWY*USEQL'/!8N"3DYX7$045O)RI35E;6[O9
M6/\ )0K_ $2?^#:;_E&-H/\ V6WXM_\ I9HM?YVU?OQ_P3+_ ."\7C;_ ()U
M?L]^(?V>I_V=_#WQHT*3Q9K'C+P-KI^(U]\.M2\,ZEXCM(TUJR\0V\?@OQK!
MXOTI]0LM.O\ 38K-_">H6*G5K2YU/48K[3GT3]3XBP6)Q^7.AA::J557I5.1
MSA"\8\RE:5248W7,G9R5TG:[LG^%\'9I@LIS=XG'U71H2PE>C[14ZE7EG*5*
M<;QI1G4M+V;C>,)6DU>T;R7^@-\9O /_  M7X/\ Q7^%WG6]O_PLCX:^.O /
MVB[-RMK!_P )AX7U3P]YURUFRW8MXO[1WS&U9;D1JQ@82[37^0]XH\-:[X+\
M2^(O!WBC3IM'\2^$]=U?PUXBTFX>&2?2]=T+4+C2]7TZ=[>2:W>:RU"UN+:5
MX)I86>)C%(Z%6/\ I^_\$G/VX?%W_!0;]DBR_:#\>>'?"'A/Q7+\2OB'X-U+
MP[X(34UT32;3P]JL,_AZV9]9US7=2N=4_P"$8U719=6OIY-,BU"_DGOK'1-+
MT^XM+>OY4_\ @XO_ .":.M_ GXZ:M^VQ\*/#EY>?!'X^ZY/JGQ632K6:XM?A
MA\;-1FMQK&IZR8[;_0/#OQ@U"Y?Q)I^JW5U>(?B%<>+]*O)=(AU/P7IVH_-\
M+XC^S\PQF5XIQIU*DE&&J<?K%!RC*FI+1NI&5X])."BO>DD_LN.,(LVRG+L\
MP*E5HT(2G.T6I_5,4J<HU90:YDJ,X)36\%4E*2Y82<?T)_X-5?VD= U?X.?M
M"?LFZEJ%C;^,?!7CN#XY^%M.FDM8=2UOP5XUTCP_X,\4RZ? D_VF]L?!OB7P
MOX>.L7<MHHLI_B'H5M]MN4NH+:P_K1K_ "%/@1\=_BO^S1\5_!WQL^"?C'4_
M OQ(\"ZFFIZ#KVF.AX*-!?:7JEC.LECK6@:U8R3Z7KV@ZI!=:5K.E75UI^H6
ML]K/)&W]0'@3_@[!^*VD^$;?3?B+^QYX(\:^-8-#LK.3Q7X:^+^L> ]&O->@
MM)HKS6KKPE>?#SQM,+.^N_LUW_8UEXFLOLRI=6T6I%;B"2RO/N&\;B,=4Q>!
MA"M#$.,JE+VD*<Z=1149M.K*,91G;GNI<RDY+ELDWEPMQEEN$RRCE^:5)X:I
MA%*G2K*E5K4ZU%RE*":HPJ3A4II^SLX<CC&$E.[DE_3E_P %0?VBO!/[,'[!
MW[2_Q)\9ZQ#IDVH?"SQ?\/? MD);(:EXC^)?Q%\/ZEX3\$:%I%G>ECJ$QUC4
MH]7UA;:UU&72O"FD>(?$EQI]SINB7X7_ "L*_1;_ (*"?\%/_P!I[_@HWXNT
M_4_C/K6EZ!\//"U_<WOP_P#@UX'@NM-\!>$IKBUCL)-6F2\NKW5_%/BNZLXW
M%YXE\1ZA>S6TE]JUMX9L_#6A:@^AQXW_  3>_8#^)?\ P41_:1\-?!KP?%J.
MB>!;":#7?C+\3X]/ENM)^&W@.#SYKF[FF,3VLOBCQ(UI-H'@71)3G5_$-Q'/
M=BU\.Z7XAUC2?;R7+UD67UZN-JPC.;]OB))MTZ4(1M""=DYR5W?E3YIRY(<U
MDY?-<29M+BG-L+0RVC5G3IKZMA(RCRU*U2K.]2JXW:ITWRQMS-<E.FZE3DO*
M,/[+_P#@V:^#.I?#;_@G3/X^UG2IK"Z^/'QJ\=^/=&N9[P2OJ/A#P]9Z#\-=
M*F6P1@-,A&O>"_%DENES"M]?P7$>I^=/I5WHXB_/?_@[9_YQ_P#_ '=7_P"^
MW5_71\+?AIX.^#/PV\"?";X>Z1#H7@;X;^$]!\%>%-)@5 MEH7AS3;?2]/CE
M>-(Q/=/!;)+>W;H);V\DGNYRTTTC'^1?_@[9_P"<?_\ W=7_ .^W5\GE&*>-
MXHIXJS2KUL9.,7O&#PF(4(O5ZQ@HIVTNM++0^\XAP2R[@>M@;J3PV'RZE.2T
M4JBQV$=625E92J.4DGK9J[;NW_'EX?UR_P##.O:)XDTJ3RM4\/ZOINN:;+OF
MC\N_TF]AO[.3?;36]PFRXMXVWP3PS+C,4T;A77_7+_9U^-WA3]I/X$?"/X]^
M"+BQF\-?%OX?^&/'-A!8:K;:VFCSZYI=O=:KX:O-0M8X8WUGPIJ[7_AG7[:6
MVL[S3]<TG4=/U"QL+ZUN;.#_ "([>WN+NX@M+2":ZNKJ:*WMK:WB>:XN+B9U
MCA@@AC5I)9II&6.**-6>1V5$4L0#^O'_  3D_P""QW[3W_!-:T\1?#GP_HNB
M?%#X/ZKJ]UJE]\(?B#+J>F#POXKDEM(-6UCPEKM@O]K>&-0OX; 6FL:3=6NJ
M:#/<AM0?1(M7,][-]7Q'D]7-:%&6'<?K.&E-QA.7*JE.KRJ<5)Z1DG",HN6F
MDE=7/@^#N(:&1XK$0QBFL'C(TU.I"+FZ-6BYNG-P2<I0<:E2,U"\KN#49*-C
M_3*K_,[_ ."\/QL\,?'+_@IU^T!K'@R^T[5O#7@5?!GPILM:TN]M[^VU74O
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MG_@Y9_Y1C:]_V6WX2?\ I9K5?YVU+A#_ )%,O^PNM_Z12%XA?\C^/_8!AO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA%G=7<]IIDM]IGAJ/Q7\3OB)XGU*6:::/4]9UG5K72K>"UL]/]MC]BSX_?\
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MDZ:@[ZZ\O<_-,@Y8\=<0QHV]DZ&*<TOA558K!\^VG,JLJJMI:\NQR'_!Q/\
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M^L2Z7_8M_P $PO\ @C_\!/\ @F[X?D\1Z?<_\+3_ &BO$FAC1_&WQFUC3([
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M6%PD_J^64I[1E%6@[7:O0I2]I42T>)Q'/"7[MH_@ _X.<O +^$_^"D.G^*!
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M4Z[H^ZVN6\H\\92T<U1@Y*3C=?Y_W_!2O_@EE^TO_P $^_\ A#?B)^T7X_\
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M>++WQ/8K?7H\5V6A>(M/N=!DP/\ @VD_8G\,?M _M0^-?VC_ (D>'6UWP?\
MLKV/A75O EO?6I_L>;XX^)-4N;SP=KAEE;R-2N?A]I'AK6_$,%A##++I/B74
M/!7B&:YL9+/3H=4_OTKHS+,8Y"XY7E$:=*K3A"6+Q<J<*E6I5E%22]]2BVXM
M3ES1E&/,H4XP47?CR7)Y<5J>>\03JUZ-:I5A@,!"K4I8>E1A-PDU[.4)J*G%
MTX\DX2FZ<JE6524UR_Y]?Q@_8[_X*"?\&^/QA\(_M1_"7X@:9\3_ (,:CK\'
MA?6_%V@V6K:7X+\8V$]WJ$EG\.?CO\-)M4NKC2$\1Z9;37FCZC8ZSKMAH6M2
MQR>&O&ECXLL]-FD^6O\ @M7^WIX4_P""@?[0'P5^*O@!Y;#PAHW[,_P\TNX\
M(33B\F\%?$#7-4\3>*OB#X=O=158$U;4M'U'5[#0)M7AL-)M]2LM#TVYBTJV
M+O)<?Z"G[;WP9\/?M"?L@?M)_!OQ/#%+IOCKX.>.M/MIIGG1-+\066A7>L>$
MO$"FV82--X;\5:=HOB"WB99K>:XTV*&ZMKJU>:VE_P RK_@G5\)V^.'[=W[(
M_P ,'5GL/$GQ^^&DNOK'+<V\Y\*>'_$MCXF\7_9+BTL[Z6"^'A;1M7-A.]O]
MFAO!!)>SVEFL]W!Z>1XVGF,*N9XNG#Z]EM.I"I7A%0]MAYTW.,II+EYX^SJ1
M5DE%-V24W$\;B?+*V45:&29?6J?V7G5:C4I86K.55X?%TJT:<XTI2?-[.;K4
M9OF;E.22DVZ<9/\ T]OV2_@W_P ,\_LO?L]_ QUQ=_"?X-_#KP)JK_:?M?VG
M7?#OA72]/\07OVA998G^W:W#J%YBV<6<?G^791Q6B01)_.#_ ,%O_P#@N;XL
M_9^\8:U^R!^QGK^G6/Q-T>&>Q^-'QJLI-'U[_A!+N^L9[:7X>>!$66_M;/Q_
MI;3B;Q7K]_"MWX)U""'1-.M!XD74+SP]^[G_  4F_:QC_8F_8K^.?[0MJ]BW
MBKPQX:@T3X=V-Y>65L^H?$7QGJ=EX3\(FTMKZRU*+5VT34M77Q3J&DC3KQ;K
M0] U9[I;?3X;R]M?X<O^"''[$C_\%!_VXM7^(GQH@OO&7PP^#%S'\9OC!=:G
M<WV?&WCWQ%K6H7G@?P]K5]%I]W;WC>*O%=EJWB/7M.O;O36UWP_X:\2VT5PY
M:6,^!DF#H588W.\RBJF&PLIR5-I-5\3*TY7BVE*SG",(R]V=2I%/2+3^JXES
M#%4)Y;PSDTY4<9CH4X.M%M2PV#C>G%QG%7@W&E4E.<??ITJ,G%)SC)>E_L@?
M\$)_VZ_^"B-@?VA_VA?B?J_P>\-^-Y=,UG2_'WQPC\4_$SXN_$G2-?A;6F\9
M:9X<U+7=/U:]TBZAOH[ZRU+Q?XK\/R^()-0^VZ:+JQDDU$^@?M??\&RG[3?P
M"^''B+XE_ SXN>%OVG+'PC97>M:_X/B\)2_"GX@/X>TZPCOM4U3PYI&J>+_%
M_A_Q#<Z9''J4\^@Q^*[/7-0L[.W3PY8Z[KFH0Z#'_?114OBS-%752FZ%/#IK
MEPBI0=-06T74Y56O;1RC.*OJHQ5DM(\!9%]5=&JL35Q4HOFQ\L1559U'JYJD
MI/#V4G=1G2F[:2G*5Y/^)+_@A'_P6H^*T/Q>\#_L5?M9^-=9^(_A'XIZS9>$
M_@M\5_&6LW.J^+O _C>ZLQ8^&/AYX@UB_>XU+Q-X6\;:E;V'AKPK+=S76L^'
M_%VJZ;8R3W/AO5)'\,_VVU_F$?\ !6OP-!^RS_P5<_:9T[X4I:^#9/"7Q?\
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M/6/"_BO0+];G2[VXL8_$?@;Q \K11Z%XT\.W4%C_ *?5?YF__!>7XFV7Q/\
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M_5.'LLIM6E4P_P!9EW;Q<Y8A7\U"I&/>T4GJ%%%%>.?1!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %?$7_  4N_P"4=O[<_P#V:5^T%_ZJSQ17V[7Q%_P4N_Y1V_MS_P#9
MI7[07_JK/%%=."_WS"?]A-#_ -.P.3'_ .XXW_L$Q/\ Z9F?QZ_\$8_^30?C
MW_V<CX!_]5AXIK]/Z_,#_@C'_P F@_'O_LY'P#_ZK#Q37Z?U_.OCY_R<?,?^
MP#+/_49'^6OCE_R6E#_L097_ .E8D****_&#\<"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSR3*\X]B\QPJQ#P_M/8OVV(HN"J\G.KT*M)R3]G'2?,E;W;7=_P0_P""6_\
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M3?\ 60#_ ,U4_P#RD:/^(2;_ *R ?^:J?_E(U_9)177_ *SYY_T'?^6V#_\
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M:46G%V::=FD[--/JCZ6I"-2$Z<US0J0E"<;M7C-.,E=--73:NFFNC3/XV_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9I)A1117BGT@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<8[B[#U\%E.98R@\BRR*K87 8K$4G*,L2I152E2G!RBVE)*5TVDT<-17<_\
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M[_Y1YK[SAJ*[G_A6'Q+_ .B>>.?_  DM?_\ E?1_PK#XE_\ 1//'/_A):_\
M_*^C^Q\W_P"A5F7_ (0XK_Y5YK[P_P!6N(_^A!G?_AJQW_RCS7WG#45W/_"L
M/B7_ -$\\<_^$EK_ /\ *^C_ (5A\2_^B>>.?_"2U_\ ^5]']CYO_P!"K,O_
M  AQ7_RKS7WA_JUQ'_T(,[_\-6._^4>:^\X:BNY_X5A\2_\ HGGCG_PDM?\
M_E?1_P *P^)?_1//'/\ X26O_P#ROH_L?-_^A5F7_A#BO_E7FOO#_5KB/_H0
M9W_X:L=_\H\U]YPU%=S_ ,*P^)?_ $3SQS_X26O_ /ROH_X5A\2_^B>>.?\
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M+_Z)YXY_\)+7_P#Y7T?\*P^)?_1//'/_ (26O_\ ROH_L?-_^A5F7_A#BO\
MY5YK[P_U:XC_ .A!G?\ X:L=_P#*/-?><-17<_\ "L/B7_T3SQS_ .$EK_\
M\KZ/^%8?$O\ Z)YXY_\ "2U__P"5]']CYO\ ]"K,O_"'%?\ RKS7WA_JUQ'_
M -"#._\ PU8[_P"4>:^\X:BNY_X5A\2_^B>>.?\ PDM?_P#E?1_PK#XE_P#1
M//'/_A):_P#_ "OH_L?-_P#H59E_X0XK_P"5>:^\/]6N(_\ H09W_P"&K'?_
M "CS7WG#45W/_"L/B7_T3SQS_P"$EK__ ,KZ/^%8?$O_ *)YXY_\)+7_ /Y7
MT?V/F_\ T*LR_P#"'%?_ "KS7WA_JUQ'_P!"#.__  U8[_Y1YK[SAJ*[G_A6
M'Q+_ .B>>.?_  DM?_\ E?1_PK#XE_\ 1//'/_A):_\ _*^C^Q\W_P"A5F7_
M (0XK_Y5YK[P_P!6N(_^A!G?_AJQW_RCS7WG#45W/_"L/B7_ -$\\<_^$EK_
M /\ *^F/\-/B/& 9/A_XVC!. 7\*:ZH)ZX!:P )QVH_L?-_^A5F7_A#BO_E7
MFOO#_5KB/_H09U_X:L=_\H\U]YQ-%=\GPI^*,B+)'\-O'TB. R.G@[Q"R,IZ
M,K+IQ# ]B"0:=_PJ;XJ?]$T^('_A&^(__E;1_9&;?]"O,?\ PBQ/_P J\U]X
M_P#5KB/_ *)_._\ PU8__P"4'G]%>@?\*F^*G_1-/B!_X1OB/_Y6T?\ "IOB
MI_T33X@?^$;XC_\ E;2_LC-O^A9F/_A%B?\ Y5YK[P_U9XC_ .B?SO\ \-6/
M_P#F<\_HKT#_ (5-\5/^B:?$#_PC?$?_ ,K:/^%3?%3_ *)I\0/_  C?$?\
M\K:/[(S;_H69C_X18G_Y5YK[P_U9XC_Z)_.__#5C_P#YG//Z*] _X5-\5/\
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M^B:?$#_PC?$?_P K:/\ A4WQ4_Z)I\0/_"-\1_\ RMH_LC-O^A9F/_A%B?\
MY5YK[P_U9XC_ .B?SO\ \-6/_P#F<\_HKT#_ (5-\5/^B:?$#_PC?$?_ ,K:
M/^%3?%3_ *)I\0/_  C?$?\ \K:/[(S;_H69C_X18G_Y5YK[P_U9XC_Z)_._
M_#5C_P#YG//Z*] _X5-\5/\ HFGQ _\ "-\1_P#RMH_X5-\5/^B:?$#_ ,(W
MQ'_\K:/[(S;_ *%F8_\ A%B?_E7FOO#_ %9XC_Z)_.__  U8_P#^9SS^BO0/
M^%3?%3_HFGQ _P#"-\1__*VC_A4WQ4_Z)I\0/_"-\1__ "MH_LC-O^A9F/\
MX18G_P"5>:^\/]6>(_\ HG\[_P##5C__ )G//Z*] _X5-\5/^B:?$#_PC?$?
M_P K:/\ A4WQ4_Z)I\0/_"-\1_\ RMH_LC-O^A9F/_A%B?\ Y5YK[P_U9XC_
M .B?SO\ \-6/_P#F<\_HKT#_ (5-\5/^B:?$#_PC?$?_ ,K:/^%3?%3_ *)I
M\0/_  C?$?\ \K:/[(S;_H69C_X18G_Y5YK[P_U9XC_Z)_.__#5C_P#YG//Z
M*] _X5-\5/\ HFGQ _\ "-\1_P#RMH_X5-\5/^B:?$#_ ,(WQ'_\K:/[(S;_
M *%F8_\ A%B?_E7FOO#_ %9XC_Z)_.__  U8_P#^9SS^BO0/^%3?%3_HFGQ
M_P#"-\1__*VC_A4WQ4_Z)I\0/_"-\1__ "MH_LC-O^A9F/\ X18G_P"5>:^\
M/]6>(_\ HG\[_P##5C__ )G//Z*] _X5-\5/^B:?$#_PC?$?_P K:/\ A4WQ
M4_Z)I\0/_"-\1_\ RMH_LC-O^A9F/_A%B?\ Y5YK[P_U9XC_ .B?SO\ \-6/
M_P#F<\_HKT#_ (5-\5/^B:?$#_PC?$?_ ,K:/^%3?%3_ *)I\0/_  C?$?\
M\K:/[(S;_H69C_X18G_Y5YK[P_U9XC_Z)_.__#5C_P#YG//Z*] _X5-\5/\
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MNC_A3GQ=_P"B5_$?_P (?Q-_\JZ/[)S7_H69A_X18G_Y6'^K/$?_ $3^=_\
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M6/\ _F<\XHKT?_A3GQ=_Z)7\1_\ PA_$W_RKH_X4Y\7?^B5_$?\ \(?Q-_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZB+_ *Z_^R-6O61K'^HB_P"NO_LC4X[KU7YDS^%_+\T=[H__ ""K#_KUA_\
M016E6;H__(*L/^O6'_T$5I5P3^.7^*7YLZ(?!'_#'\D%%%%24%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %<)J/\ R-VF_P#7WI7_ *41UW=<)J/_ "-VF_\ 7WI7_I1'
M6U#XI_\ 7N?Y&=7X5_BC^9[G1117":!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-C&4EAL5&*=117-+V<HMWE"/O2A.,)\MY14HQDX_I[1117A'U 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'R]X8_Y+?J7_ &%?$O\ Z3WU?4-?+WAC_DM^
MI?\ 85\2_P#I/?5]0UWYA\>'_P"P2A_[<<^&^"?_ %\E^40HHHK@.@**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_(W_@JU_P26^%
M_P#P4R\$^&;R?Q"OPP^._P ,['6[;X>?$VVTB#4K;4=,U2(W3>!/']I$UM?Z
MOX/?6X;?4]-N(+I]2\'7MSK6H:#!,FO^(=+UO]<J*WPV)KX2M#$8>HZ5:FVX
MS5G:Z:::::E&2;4HM---IHY<9@\-F&&JX3&4HUL/624Z<KJ]FI1DI1:E&49)
M2C*+4HR2::9_ #!_P0X_X+;_ +)_B#Q$?V7O&=\\5ZHLY_$W[-?[4<GP?D\4
M:;,VE77E7L7BGQ)\(-498Y5A%[9:FC0+>Z%.;2:_@BT>]U"(_P#!$/\ X+@?
MM3ZE;6O[3'BO6;73[;6M/N/[4_:-_:HB^+:0.T5OI4NO:?9^$_%_Q=N7N=-T
MB26$>:+"^ELK62PMF*/!'+_H!T5[_P#K7F/Q>PR_VMK>W^K2]MLE?F]KRWT_
MEMV5K)?)_P"H>4?!]:S;ZO=OZI]<A]7U=[<OU?GM>SO[2^B;;9^/'_!+G_@C
ME\#_ /@FUIVI>+X]9D^+W[0_BC2VT?Q!\7-5TDZ+;Z)H%TNG3WO@_P !>'/[
M0U.'0]$GU&P2ZU#5KFYN_$6N,(X[R\M=-BMM(MOV'HHKP,3BJ^,K3Q&)JRJU
M9_%.5MEM&*248Q72,4HKHCZS!8+"Y=AZ>$P=&%"A33Y:<+[O>4I2;E.<GK*<
MY2E)[MA1116!U!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2K@G\<O\4OS9T0^"/^&/Y(****DH**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X34?^1N
MTW_K[TK_ -*(Z[NN$U'_ )&[3?\ K[TK_P!*(ZVH?%/_ *]S_(SJ_"O\4?S/
M<Z***X30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT1?#&IZEXG\17/A;Q+H#:'I>E75QXNTBY\0_^#B__@J?XQ\0WNK>%/C+X/\
MA/H\]]J=Q9^%O!GP<^%&M:;8V=Y?2W-CIYU#XD^$/'6NW2Z1:O'IUM<R:FD]
MS!"L^H&ZO'>X;W\WRS,LSG'!8)4\+EN#A"G%5ISI4Z]2,5K&,(5)SITH\L(-
MP4.=3<9-[?)\/YUDV2TYYGF<JV.SG,:E2M-X>G3KU<-0G)V4YU*M*G3JUY<]
M6I&-3VGLY4HRC%)*7]TO_!0?]D;P5^VK^R;\9?@EXE\+:9K_ (EUGP+XBNOA
M7JMQ:Z>=9\)?%+3K$ZMX$UO0-5OKO2VTIQXITW1K?6H4US1;+7] DU+P[KE^
MFAZIJ"M_.7_P0?\ ^";/_!1O]AG]LGQ%XY^/?P$D\!?!OQ[\%_%O@+Q/K+_%
M_P"#_BBTM-:&N^%/%7A2^7PUX"^)?B35+[5%O?#EUHMI?3:-<0:;IVOZR3<6
MHNG9^(_8 _X.</%EQXXTWX??M_>'M ?PAXBU1K6T^.7PW\/OI=UX,FU&ZTBU
ML#XV\$VUU+;ZAX0TQ#J][JVN^&$E\1V=N;5+?PUKKQRN?[.+2[M+^UMK^PN;
M>]L;VWAN[.\M)H[FUN[2YC6:WN;:XA9X9[>>%TEAFB=XY8W5T9E8$_-8B6:Y
M'AL1E>(HT98?&J3C.7M*D-E&<L/.-2$8R3Y'*,X-J2@W&SU^SPD,BXGQN$SS
M!XBO'&9:XJ5.'LJ-2S<I0AC*<Z52<H->TC"5*I&+4JD8S;C[MBBBBOG3[ **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#Y>\,?\ );]2_P"PKXE_])[ZOJ&O
ME[PQ_P EOU+_ +"OB7_TGOJ^H:[\P^/#_P#8)0_]N.?#?!/_ *^2_*(4445P
M'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?$7_!2[_E
M';^W/_V:5^T%_P"JL\45]NU\1?\ !2[_ )1V_MS_ /9I7[07_JK/%%=."_WS
M"?\ 830_].P.3'_[CC?^P3$_^F9G\T'_  ;2?\D,_:7_ .RL>$__ %#WK^ER
MOYH_^#:3_DAG[2__ &5CPG_ZA[U_2Y7V^:_\C#$_XH?^FX'S/"G_ "3V6?\
M7JK_ .I%8****\\^A"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\R^%?_(W:M_V"K_\
M].>G5Z;7F7PK_P"1NU;_ +!5_P#^G/3JVC_N^+_Z]Q_-F4_CI>LOT/H6BBBO
M)-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK>:[O+R[FCMK6TM+:-IKBYN;B9DA@MX(4>6::5TCBC1G=E521_&#_P %=/\
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M@'4KT*=HTJ4ITZ-9I06D4ZJC.*2CR*LXPY8-1/Z8J***^+/T@**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#Y>\,?\EOU+_L*^)?_2>^KZAKY>\,?\EOU+_L
M*^)?_2>^KZAKOS#X\/\ ]@E#_P!N.?#?!/\ Z^2_*(4445P'0%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1#X(_P"&/Y(****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X34?\ D;M-_P"OO2O_
M $HCKNZX34?^1NTW_K[TK_THCK:A\4_^O<_R,ZOPK_%'\SW.BBBN$T"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KS+X5_\ (W:M_P!@J_\ _3GIU>FUYE\*_P#D
M;M6_[!5__P"G/3JVC_N^+_Z]Q_-F4_CI>LOT/H6BBBO)-0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH XOXA_\B;K7_7.T_\ 3A:5;^"'_(FS?]AN^_\ 2:QJI\0_
M^1-UK_KG:?\ IPM*M_!#_D39O^PW??\ I-8UV/\ Y%E3_L*7_I$!1_C1_P $
MOS1[#1117EG2%5[N[M+"UN;^_N;>RL;*WFN[R\NYH[:UM+2VC::XN;FXF9(8
M+>"%'EFFE=(XHT9W954D6*^!?^"H/@W]HWXE?L(_M"_#+]E#PM=>+_CC\2_"
M^F> ?#FDVOB3POX1(\/>*O$VB:3\1KE_$'B[Q9X,TG3S'\-KCQ;%9N=9:>34
MI[&)+"^B>>$ZT*:K5J-*52%*-6K3IRJU&HPIQG)1=2<FTE&";E)MI))ZF&)K
M2P^'Q%>-*I7E1HU:L:-*,IU:TJ<)2C2IQBI2E.HTH148MN35DS^%/_@JC_P4
M.^*?_!57]J_1?AW\(D\4ZC\$]+\=V/P[_9I^$MG)*DOCCQ1KFK)X3TGQ_?Z/
M+8Z1/)XT^)%Y>VT>BZ;K<<UWX.T?4X/#-M<1W$VO7FJ_U^_\$A/^"0GP^_X)
MT?#Y/&OC5-&\=?M8>.M&B@\>^/8(A=:7X&TNZ$5S-\-OAM-<Q1SVVB6\\<7_
M  D7B+RK;4O&FI6T=S<QV>C6>C:-IW\>7_$/Y_P5S_Z-*_\ ,\_LR_\ SYZ/
M^(?S_@KG_P!&E?\ F>?V9?\ Y\]?HV.HY;B,%1R[!YY@,!A*<;5*<:N'JRKV
MLU[2:Q5)V;O.:L_:3?-)Z)'X[EF(SG"9EB<WS#A?-LTS"M+FI59T<70AA;II
MJE2>!KI-1M3IOF7LJ<>2"5VW_I;45_FD_P#$/Y_P5S_Z-*_\SS^S+_\ /GK]
MCO\ @AI_P1Y_;/\ V6_VWH?C[^U=\%;/X8^$_ 7PJ\=Q>!]3F\>?!WQ]=ZC\
M0O%@TKPC%8V5KX$\<>+M4T/;X*UKQK/<ZX\%DIC0:+Y\D.L7,5?-8K(\NP^'
MK5J>?X/$3I4Y3A0IQHN=627NPCRXV<KR=E=0E97=FD?:8'B?.,7C,-AJO"F8
MX2E6K0IU,36GB52H4Y/WZLW/+:<6H1NU%U(*32CS)NY_917\0/\ P<]_L->)
M/#OQ?\)_MW>"=%N-0\#?$70- ^'?QGGTS19I/^$6\?\ A.%-&\&^+/$NK6D9
MA32_&?A,Z%X-TV?44B^PZKX+M=/;4;EO$&BZ=:?V_5RWC?P1X/\ B5X/\2_#
M_P"('AK1O&/@GQCHU_X>\4^%O$-A;ZGHFO:)J=N]K?Z;J5A=))!<VUS!(R,K
MKE3MDC9)$1U\O*LQGE>-IXJ$>>*3IUJ=[>TI3MS1O9V::C.+VYHQOI=/W<]R
MBEG>6UL#4E[.<G&K0K6YO95Z=^2;C=<T6G*G-;\DY<MI6:_CS_X(._\ !;#P
M-X(\&>#/V&?VN/$.E^"](\,Q_P!A_ /XU:W=M:>'UTV\U&:>T^&?Q'U.[D:T
MT :7-?/;^"O%UU+9^'HM$A@\,ZU)I,NEZ5?:U_6)^T%X;^)'Q0_9\^*7A'X"
M^/\ 1_ ?Q(^(7PYUWP]\._B?/-JMQ8>$;_Q5I4FG6GC;2;WPS>6^I+J>C6-]
M+K7A;4]-N72VUNWTJ_:.[M(I+>;^1_\ ;:_X-=?&EGXAU;QE^P?\1M&UGPE>
MW-O<Q?!KXRZY-IOB?0C?7UPM_9^%?B%:Z1)I&O:-I*3VCZ99>,(=(UN'1;6\
M2^\4^*-=@MVUG\F;/]DC_@NM^R/83^"/A[\/O^"@?PVT%=4N+:;0?V</%7Q6
MU[PK)?QO/>37:Q_L_P#B37O#UQ;R37EU-'K$;R6%U<W-SY%[+/+*&^FKY=E.
M:UUC\MS'#X:M.<:U7"XE12=3F4I2=*<HR5Y?Q(J-2E.3?+)1>OQ.%S?B#(<*
M\KSC)\7CL/3INA1QV"E-R5'E]G"'MJ<)PERQ:5*<IT:\$HJ4925UR'CKX*_\
M%%/^"('[2GA7X@7=KJ'@/6-,UQH?"OQ(\+3ZIXC^!'QHTVT@6?5/#4][+;:-
M%XDT34=.NY8M5\)^)].\/^+=,BE_M2#3M$U*VT[5;?WO_@JG_P %POB5_P %
M%/A]X$^"_A3P0?@S\';'3O#/B7XG^&SJ5OKNK>/_ (IV-M'<W(DUE+:![;X>
M>$]5>?\ X1#1TC@OM9N43Q/XIS>QZ'HOAGR;0?\ @E9_P6'_ &P_&,6K>._@
M?^T+K6NWD,]_>^._VH?$NJ>%)[2WG>QDN9[[5?C+K=GXCNKN:6^M6ETS3K/4
M=;G=+R3^SI%TK5)++SGX[?LT?M$?\$;?VU?AA>_$SP;\/_B-J/@#6?"GQ1^'
M6O:WX:O?$_P1^+MII\&FW^J6VGQZ_I^F7ES+X9UB[F\/ZNCVVD^)_"^OV5AX
MDTAK);CPKKUY])%8#$8C#SK5,!C<WPU&I*G[":AS.*5KQ]I5LXMIP=3F=-N=
M2G"*4K?&U)9MA<)BZ6'I9KEW#N,Q-*%7ZS3E4]G&;UM-TZ/,I)-5%2Y%54:=
M&M4DY+F_I$_X-S_^"5>I?";1[+]OWX^: UCX_P#''ANYLOV<O!VKZ=<6FK>!
MO!.OQ:AINO\ Q-U>UU.PANK/Q!\0]"D33?!+V$L4=O\ #;6-8U"XFU2+QY:0
M:#_6-7P+^P!_P4:_9X_X*(?"NT\<_"'7H=,\<:1I.EW'Q2^#FL7L4GC;X8:Q
M?R7=J;3456&VCUSP]>7FGWC>'?%VF0+I^M:>+=[JVT76?[0T#3?O*[FDMK6Y
MN(;2XOYH+>::*PM&M$N[V2*-G2TMGO[FRL4N+EE$,+7EY:6BR.IN+F"$/*GY
MKFV(Q>)Q]>IC82I5U+D]C+3V,(_!3C>R<4G=36E1R=1-\]W^SY!A,OP6586E
MEM6%?#.'M?K,+-XFK-+VE:=FVIRDN5TW[U)15%I>SLOXQ_\ @X^_X*E>(O\
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M0<E-PERMQC*HXTU[)-^QITJ<&U)SC$HHHKYH^S"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ^7O#'_);]2_["OB7_TGOJ^H:^7O#'_);]2_["OB7_TGOJ^H
M:[\P^/#_ /8)0_\ ;CGPWP3_ .ODORB%%%%<!T!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7Q%_P4N_Y1V_MS_\ 9I7[07_JK/%%?;M?
M$7_!2[_E';^W/_V:5^T%_P"JL\45TX+_ 'S"?]A-#_T[ Y,?_N.-_P"P3$_^
MF9G\T'_!M)_R0S]I?_LK'A/_ -0]Z_I<K^:/_@VD_P"2&?M+_P#96/"?_J'O
M7]+E?;YK_P C#$_XH?\ IN!\SPI_R3V6?]>JO_J16"BBBO//H0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K(UC_41?\ 77_V1JUZR-8_U$7_ %U_]D:G'=>J_,F?POY?
MFCO='_Y!5A_UZP_^@BM*LW1_^058?]>L/_H(K2K@G\<O\4OS9T0^"/\ AC^2
M"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N$U'_ )&[3?\ K[TK_P!*(Z[NN$U'
M_D;M-_Z^]*_]*(ZVH?%/_KW/\C.K\*_Q1_,]SHHHKA- HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *\R^%?_ "-VK?\ 8*O_ /TYZ=7IM>9?"O\ Y&[5O^P5?_\
MISTZMH_[OB_^O<?S9E/XZ7K+]#Z%HHHKR34**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^7O#'_);]2_["OB7_P!)[ZOJ&OE[PQ_R6_4O^PKXE_\
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M /"F_'G_ $,6E_\ @SUG_P"5U'_"F_'G_0Q:7_X,]9_^5U?4%%']IXKO3_\
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M_P %Q#ZO#O/_ ,"?]?\ #ORM\O\ _"F_'G_0Q:7_ .#/6?\ Y74?\*;\>?\
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M*;\>?]#%I?\ X,]9_P#E=1_PIOQY_P!#%I?_ (,]9_\ E=7U!11_:>*[T_\
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M?\*;\>?]#%I?_@SUG_Y75]044?VGBN]/_P %Q#ZO#O/_ ,"?]?\ #ORM\O\
M_"F_'G_0Q:7_ .#/6?\ Y74?\*;\>?\ 0Q:7_P"#/6?_ )75]044?VGBN]/_
M ,%Q#ZO#O/\ \"?]?\._*WR__P *;\>?]#%I?_@SUG_Y74?\*;\>?]#%I?\
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M75]044?VGBN]/_P7$/J\.\__  )_U_P[\K?+_P#PIOQY_P!#%I?_ (,]9_\
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M_'G_ $,6E_\ @SUG_P"5U?4%%']IXKO3_P#!<0^KP[S_ / G_7_#ORM\O_\
M"F_'G_0Q:7_X,]9_^5U'_"F_'G_0Q:7_ .#/6?\ Y75]044?VGBN]/\ \%Q#
MZO#O/_P)_P!?\._*WR__ ,*;\>?]#%I?_@SUG_Y74?\ "F_'G_0Q:7_X,]9_
M^5U?4%%']IXKO3_\%Q#ZO#O/_P "?]?\._*WR_\ \*;\>?\ 0Q:7_P"#/6?_
M )74?\*;\>?]#%I?_@SUG_Y75]044?VGBN]/_P %Q#ZO#O/_ ,"?]?\ #ORM
M\O\ _"F_'G_0Q:7_ .#/6?\ Y74?\*;\>?\ 0Q:7_P"#/6?_ )75]044?VGB
MN]/_ ,%Q#ZO#O/\ \"?]?\._*WR__P *;\>?]#%I?_@SUG_Y74?\*;\>?]#%
MI?\ X,]9_P#E=7U!11_:>*[T_P#P7$/J\.\__ G_ %_P[\K?+_\ PIOQY_T,
M6E_^#/6?_E=1_P *;\>?]#%I?_@SUG_Y75]044?VGBN]/_P7$/J\.\__  )_
MU_P[\K?+_P#PIOQY_P!#%I?_ (,]9_\ E=1_PIOQY_T,6E_^#/6?_E=7U!11
M_:>*[T__  7$/J\.\_\ P)_U_P ._*WR_P#\*;\>?]#%I?\ X,]9_P#E=1_P
MIOQY_P!#%I?_ (,]9_\ E=7U!11_:>*[T_\ P7$/J\.\_P#P)_U_P[\K?+__
M  IOQY_T,6E_^#/6?_E=1_PIOQY_T,6E_P#@SUG_ .5U?4%%']IXKO3_ /!<
M0^KP[S_\"?\ 7_#ORM\O_P#"F_'G_0Q:7_X,]9_^5U'_  IOQY_T,6E_^#/6
M?_E=7U!11_:>*[T__!<0^KP[S_\  G_7_#ORM\O_ /"F_'G_ $,6E_\ @SUG
M_P"5U'_"F_'G_0Q:7_X,]9_^5U?4%%']IXKO3_\ !<0^KP[S_P# G_7_  [\
MK?+_ /PIOQY_T,6E_P#@SUG_ .5U'_"F_'G_ $,6E_\ @SUG_P"5U?4%%']I
MXKO3_P#!<0^KP[S_ / G_7_#ORM\O_\ "F_'G_0Q:7_X,]9_^5U'_"F_'G_0
MQ:7_ .#/6?\ Y75]044?VGBN]/\ \%Q#ZO#O/_P)_P!?\._*WR__ ,*;\>?]
M#%I?_@SUG_Y74?\ "F_'G_0Q:7_X,]9_^5U?4%%']IXKO3_\%Q#ZO#O/_P "
M?]?\._*WR_\ \*;\>?\ 0Q:7_P"#/6?_ )74?\*;\>?]#%I?_@SUG_Y75]04
M4?VGBN]/_P %Q#ZO#O/_ ,"?]?\ #ORM\O\ _"F_'G_0Q:7_ .#/6?\ Y74?
M\*;\>?\ 0Q:7_P"#/6?_ )75]044?VGBN]/_ ,%Q#ZO#O/\ \"?]?\._*WR_
M_P *;\>?]#%I?_@SUG_Y74?\*;\>?]#%I?\ X,]9_P#E=7U!11_:>*[T_P#P
M7$/J\.\__ G_ %_P[\K?+_\ PIOQY_T,6E_^#/6?_E=1_P *;\>?]#%I?_@S
MUG_Y75]044?VGBN]/_P7$/J\.\__  )_U_P[\K?+_P#PIOQY_P!#%I?_ (,]
M9_\ E=1_PIOQY_T,6E_^#/6?_E=7U!11_:>*[T__  7$/J\.\_\ P)_U_P .
M_*WR_P#\*;\>?]#%I?\ X,]9_P#E=1_PIOQY_P!#%I?_ (,]9_\ E=7U!11_
M:>*[T_\ P7$/J\.\_P#P)_U_P[\K?+__  IOQY_T,6E_^#/6?_E=1_PIOQY_
MT,6E_P#@SUG_ .5U?4%%']IXKO3_ /!<0^KP[S_\"?\ 7_#ORM\O_P#"F_'G
M_0Q:7_X,]9_^5U'_  IOQY_T,6E_^#/6?_E=7U!11_:>*[T__!<0^KP[S_\
M G_7_#ORM\O_ /"F_'G_ $,6E_\ @SUG_P"5U'_"F_'G_0Q:7_X,]9_^5U?4
M%%']IXKO3_\ !<0^KP[S_P# G_7_  [\K?+_ /PIOQY_T,6E_P#@SUG_ .5U
M'_"F_'G_ $,6E_\ @SUG_P"5U?4%%']IXKO3_P#!<0^KP[S_ / G_7_#ORM\
MO_\ "F_'G_0Q:7_X,]9_^5U'_"F_'G_0Q:7_ .#/6?\ Y75]044?VGBN]/\
M\%Q#ZO#O/_P)_P!?\._*WR__ ,*;\>?]#%I?_@SUG_Y74?\ "F_'G_0Q:7_X
M,]9_^5U?4%%']IXKO3_\%Q#ZO#O/_P "?]?\._*WR_\ \*;\>?\ 0Q:7_P"#
M/6?_ )74?\*;\>?]#%I?_@SUG_Y75]044?VGBN]/_P %Q#ZO#O/_ ,"?]?\
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M^#/6?_E=7U!11_:>*[T__!<0^KP[S_\  G_7_#ORM\O_ /"F_'G_ $,6E_\
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M5]044?VGBN]/_P %Q#ZO#O/_ ,"?]?\ #ORM\O\ _"F_'G_0Q:7_ .#/6?\
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MABZ<:6%Q-6#ESTL/6J1NVUS0IRDKK9JZU75-KM;\VO\ @G]^V)\"OVUO!WQ
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MM'_Y!5A_UZP_^@BM*N25>HI25UI)KX5T?IY+[C:-*+C%ZW:3W?9?\#[D>?\
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M .,5Z!11]8J=X_\ @*_R\E]P>RA_>^]_UT7W'G__  B^L?\ /];_ /?^Z_\
MC%'_  B^L?\ /];_ /?^Z_\ C%>@44?6*G>/_@*_R\E]P>RA_>^]_P!=%]QY
M_P#\(OK'_/\ 6_\ W_NO_C%'_"+ZQ_S_ %O_ -_[K_XQ7H%%'UBIWC_X"O\
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M?<>?_P#"+ZQ_S_6__?\ NO\ XQ1_PB^L?\_UO_W_ +K_ .,5Z!11]8J=X_\
M@*_R\E]P>RA_>^]_UT7W'G__  B^L?\ /];_ /?^Z_\ C%'_  B^L?\ /];_
M /?^Z_\ C%>@44?6*G>/_@*_R\E]P>RA_>^]_P!=%]QY_P#\(OK'_/\ 6_\
MW_NO_C%'_"+ZQ_S_ %O_ -_[K_XQ7H%%'UBIWC_X"O\ +R7W![*'][[W_71?
M<>?_ /"+ZQ_S_6__ '_NO_C%'_"+ZQ_S_6__ '_NO_C%>@44?6*G>/\ X"O\
MO)?<'LH?WOO?]=%]QY__ ,(OK'_/];_]_P"Z_P#C%'_"+ZQ_S_6__?\ NO\
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M_P"$#\2_]!2S_P# R_\ _D6O8**/K=;O'_P%>7^7]65CV4/[WWO^NB^X\?\
M^$#\2_\ 04L__ R__P#D6C_A _$O_04L_P#P,O\ _P"1:]@HH^MUN\?_  %>
M7^7]65CV4/[WWO\ KHON/'_^$#\2_P#04L__  ,O_P#Y%H_X0/Q+_P!!2S_\
M#+__ .1:]@HH^MUN\?\ P%>7^7]65CV4/[WWO^NB^X\?_P"$#\2_]!2S_P#
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M_ R__P#D6O8**/K=;O'_ ,!7E_E_5E8]E#^]][_KHON/'_\ A _$O_04L_\
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M5CV4/[WWO^NB^X\?_P"$#\2_]!2S_P# R_\ _D6C_A _$O\ T%+/_P #+_\
M^1:]@HH^MUN\?_ 5Y?Y?U96/90_O?>_ZZ+[CQ_\ X0/Q+_T%+/\ \#+_ /\
MD6C_ (0/Q+_T%+/_ ,#+_P#^1:]@HH^MUN\?_ 5Y?Y?U96/90_O?>_ZZ+[CQ
M_P#X0/Q+_P!!2S_\#+__ .1:/^$#\2_]!2S_ / R_P#_ )%KV"BCZW6[Q_\
M 5Y?Y?U96/90_O?>_P"NB^X\?_X0/Q+_ -!2S_\  R__ /D6C_A _$O_ $%+
M/_P,O_\ Y%KV"BCZW6[Q_P# 5Y?Y?U96/90_O?>_ZZ+[CQ__ (0/Q+_T%+/_
M ,#+_P#^1:/^$#\2_P#04L__  ,O_P#Y%KV"BCZW6[Q_\!7E_E_5E8]E#^]]
M[_KHON/'_P#A _$O_04L_P#P,O\ _P"1:/\ A _$O_04L_\ P,O_ /Y%KV"B
MCZW6[Q_\!7E_E_5E8]E#^]][_KHON/'_ /A _$O_ $%+/_P,O_\ Y%H_X0/Q
M+_T%+/\ \#+_ /\ D6O8**/K=;O'_P !7E_E_5E8]E#^]][_ *Z+[CQ__A _
M$O\ T%+/_P #+_\ ^1:/^$#\2_\ 04L__ R__P#D6O8**/K=;O'_ ,!7E_E_
M5E8]E#^]][_KHON/'_\ A _$O_04L_\ P,O_ /Y%H_X0/Q+_ -!2S_\  R__
M /D6O8**/K=;O'_P%>7^7]65CV4/[WWO^NB^X\?_ .$#\2_]!2S_ / R_P#_
M )%H_P"$#\2_]!2S_P# R_\ _D6O8**/K=;O'_P%>7^7]65CV4/[WWO^NB^X
M\?\ ^$#\2_\ 04L__ R__P#D6C_A _$O_04L_P#P,O\ _P"1:]@HH^MUN\?_
M  %>7^7]65CV4/[WWO\ KHON/'_^$#\2_P#04L__  ,O_P#Y%H_X0/Q+_P!!
M2S_\#+__ .1:]@HH^MUN\?\ P%>7^7]65CV4/[WWO^NB^X\?_P"$#\2_]!2S
M_P# R_\ _D6N>\-^']4U[4[G3M-NX+6ZM[::XEEFGN(8WCBN(('57MX99&9I
M)D8!D"E58DA@ ?H&O,OA7_R-VK?]@J__ /3GIU:1Q-5T:\VXWIPC*/NJU[VU
M77;^M+1*$5.FE>S;O=OI:WH2?\*O\8?]!K3O_!AJG_R!1_PJ_P 8?]!K3O\
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M%'_"K_&'_0:T[_P8:I_\@5] T4?VAB/^G?\ X+0>RAV?_@3\O/R_JRM\_?\
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M ."T'LH=G_X$_+S\OZLK?/W_  J_QA_T&M._\&&J?_(%'_"K_&'_ $&M._\
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M?[3Q7_3K_P %K^O^'?E;;ZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\
M*VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\
MGY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/
M%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_
M (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[
MCY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\
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MH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\
M*VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\
MGY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/
M%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_
M (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[
MCY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\
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MH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\
M*VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\
MGY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/
M%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_
M (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[
MCY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\
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MH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\
M*VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\
MGY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/
M%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_
M (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[
MCY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\
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MH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\
M*VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\
MGY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/
M%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_
M (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[
MCY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\
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MH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\
M*VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\
MGY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/
M%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_
M (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[
MCY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\
M3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4W
MX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_
MX4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P
M6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z
M&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX
M]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_
MX=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O
M_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&
M'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5
MCZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_  ::S_\ *VC_ (4WX]_Z&'2O_!IK
M/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3[2_\"?\ GY+[CY>_X4WX]_Z&'2O_
M  ::S_\ *VC_ (4WX]_Z&'2O_!IK/_RMKZAHH_M/%?\ 3K_P6OZ_X=^5CZO3
M[2_\"?\ GY+[CY#^'6G7>F?%2VTZ[ECFNM/N-<M[N:.222.66'3K^&1XWE1)
M)%:0A@TB(Q'S, W%?7E?+WAC_DM^I?\ 85\2_P#I/?5]0T9E)RJT).UY86E)
MVTU;FWITWV0L-\$U_P!/)?E$****\XZ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=;Z?/\,\3_ZQ2QD?J/U/ZI&@[_6?K'M/;NLK?[O0Y.7V7][FYNEM?0****\
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M_P!0]Z_I<K[?-?\ D88G_%#_ --P/F>%/^2>RS_KU5_]2*P4445YY]"%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %9&L?ZB+_ *Z_^R-6O61K'^HB_P"NO_LC4X[KU7YD
MS^%_+\T=[H__ ""K#_KUA_\ 016E6;H__(*L/^O6'_T$5I5P3^.7^*7YLZ(?
M!'_#'\D%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<)J/\ R-VF_P#7WI7_ *41
MUW=<)J/_ "-VF_\ 7WI7_I1'6U#XI_\ 7N?Y&=7X5_BC^9[G1117":!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5YE\*_\ D;M6_P"P5?\ _ISTZO3:\R^%?_(W
M:M_V"K__ -.>G5M'_=\7_P!>X_FS*?QTO67Z'T+1117DFH4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M7O#'_);]2_["OB7_ -)[ZOJ&OE[PQ_R6_4O^PKXE_P#2>^KZAKOS#X\/_P!@
ME#_VXY\-\$_^ODORB%%%%<!T!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKA[:\M)O*>6WGC#IYEK>V<]S8:A:207VGW5U97$%Q)_>]_P;5?M=?$+]H?\
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M"OX<6@N-,U?XB"UG=XKCQ3?ZNT>A_#^TO;.YTEKRS\2:]J+2_P#"+VVB:_\
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MO:A]GNKO[#HVAV%QJ>J7GV2P@NKZZ^RV-K//]GL[:XNI]GEV\$TS)&W\M?\
MP;V?\%<?$_Q_1?V'OVF/%+:[\5?"WAMK_P" 7Q!UJZ$NO_$GPEX:L;JY\1>
MO$]]=7(NM:\;^"]"M8]=T'58XKO4?$O@O3?$ESXAFBU'PB^J>)OZ0OVE_P#D
MW#]H#_LB7Q6_]037J^-QF7UL!C7@\0O>4X6G'X:E.;M&I!M;-7W5XR4HM7BT
M?HN79OALURU9C@W>+IU'*G/XZ-:G%N=&JD_BB[/1VG"49Q?+*+/S:_XB _\
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MA7XX44?\1ZS?_H09;_X4XK_+U_I:G_$W/$?_ $2&2?\ A=CO_D?7^EK^Q_\
MPL_X:?\ 10_ W_A6Z!_\L*/^%G_#3_HH?@;_ ,*W0/\ Y85^.%%'_$>LW_Z$
M&6_^%.*_R]?Z6I_Q-SQ'_P!$ADG_ (78[_Y'U_I:_L?_ ,+/^&G_ $4/P-_X
M5N@?_+"C_A9_PT_Z*'X&_P#"MT#_ .6%?CA11_Q'K-_^A!EO_A3BO\O7^EJ?
M\3<\1_\ 1(9)_P"%V._^1]?Z6O['_P#"S_AI_P!%#\#?^%;H'_RPH_X6?\-/
M^BA^!O\ PK= _P#EA7XX44?\1ZS?_H09;_X4XK_+U_I:G_$W/$?_ $2&2?\
MA=CO_D?7^EK^Q_\ PL_X:?\ 10_ W_A6Z!_\L*/^%G_#3_HH?@;_ ,*W0/\
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M_H09;_X4XK_+U_I:G_$W/$?_ $2&2?\ A=CO_D?7^EK^Q_\ PL_X:?\ 10_
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M"R[5M_[SB>K]/7\.VMKZ7?$:27^J&2:)+_?L?T_[=/W _P"%L_"O_HI?P_\
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M_P 1SS;_ *$67?\ A3B?\O7^EJ?\3><1_P#1'Y)_X78__P"1/W _X6S\*_\
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M1NU;_L%7_P#Z<].K:/\ N^+_ .O<?S9E/XZ7K+]#Z%HHHKR34**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** .+^(?_ ")NM?\ 7.T_].%I5OX(?\B;-_V&[[_TFL:J
M?$/_ )$W6O\ KG:?^G"TJW\$/^1-F_[#=]_Z36-=C_Y%E3_L*7_I$!1_C1_P
M2_-'L-%%%>6=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\O>
M&/\ DM^I?]A7Q+_Z3WU?4-?+WAC_ )+?J7_85\2_^D]]7U#7?F'QX?\ [!*'
M_MQSX;X)_P#7R7Y1"BBBN Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNNHXAMV=[RBG.2ZIQYEK&Y_5[7\&'_!T?^SWX6^&_P"UG\&?CCX6\/VF@O\
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M^1S@_P#L$P__ *E8D\K@'_DG,Q_[#\9_Z@8,_P B2O\ 3E_X(9_\HI?V/?\
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M5^J7PF_Y)7\-/^R?^#?_ %'--K\K?^#@/_E$7^UK_P!T&_\ 6FO@Q7PN6_\
M(VP'_8QPO_J33/U'.?\ D09K_P!B?'?^H54_S2:_V"/A-_R2OX:?]D_\&_\
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MY;9)VO(8;V\\'Z_#!//;16UR]A<1VD]Q+:WL=KZ&<-T>&(QH/E@\-@:=X_\
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M]_\ 9R/@'_U6'BFOT_K\P/\ @C'_ ,F@_'O_ +.1\ _^JP\4U^G]?SKX^?\
M)Q\Q_P"P#+/_ %&1_EKXY?\ ):4/^Q!E?_I6)"BBBOQ@_' HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZJ_96^% \<>,
M/^$IU:V$GAOPA/#<%)55HM0ULCS;"T*LK!X[0A;ZY7:!\MO&6'FXKYKT'1-2
M\2ZSIF@:/;M=:GJUY!8V4"@G?-.X4%BJL5CC&9)7"G9$CN00IK]K_AMX$T[X
M<>#='\)Z<%<6, >^N@,-?ZG. ]]>OD*?WTV1&"H*0)%'@;*_4_"KA+_6#.UF
M6+I\V5Y-.G7J*2O#$XV_-A<-KI*,&OK%=:KEA3IS7+73/Z(^CIX;?ZZ<6+/,
MSH<_#W"U6ABZT:D+TL?FU_:9?@'S+EJ4Z4H?7<7'WH^SI4:%6/+BXL[NBBBO
MZU/]* HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MX34?^1NTW_K[TK_THCKNZX34?^1NTW_K[TK_ -*(ZVH?%/\ Z]S_ ",ZOPK_
M !1_,]SHHHKA- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\R^%?_(W:M_V"K__
M -.>G5Z;7F7PK_Y&[5O^P5?_ /ISTZMH_P"[XO\ Z]Q_-F4_CI>LOT/H6BBB
MO)-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH XOXA_\ (FZU_P!<[3_TX6E6_@A_
MR)LW_8;OO_2:QJI\0_\ D3=:_P"N=I_Z<+2K?P0_Y$V;_L-WW_I-8UV/_D65
M/^PI?^D0%'^-'_!+\T>PT445Y9TA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'R]X8_P"2WZE_V%?$O_I/?5]0U\O>&/\ DM^I?]A7Q+_Z3WU?
M4-=^8?'A_P#L$H?^W'/AO@G_ -?)?E$****X#H"BBB@#XV_X*+_\H^/V[/\
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MJ-S$HA2RT[XB> ]&LOL:VT-RK>)_!7B[4M9O8;SQ+I4%U^)W_!/;]OKXM?\
M!.SX^6GQM^&%G8^)[*^T:]\+>/?AUKNHZII_AKQWX8OBLJV>H2Z9*LEIJNCZ
MA%;ZOX<UDVU\=*U& ^997VGW>HZ?>_ZC_P 5/A7\._C?\._%_P )?BUX0T;Q
MY\.?'FC7&@>+/">OVYN--U;3;@I(%8QO%=6=[9W45OJ.DZMIUQ::MHFK6ECK
M&CWUCJEC:7</\@/[3'_!JIXKN/%>O:U^R)^T/X.MO"5_,UYH?@/X\6GB/3[W
MP^UQJ0,FCOX_\%:)XJDUC3K'3))'T^_N?!EOJ4LUO!8:@)VGGUM,\FS[ U<
MLLS9J,84_81G4C*5*M0VA"<H)NG.G&T5)\JY8QDIJ:9MQ'PKFE'-7G60Q<Y5
M*OUF=.E*$*^'Q-[U*D(U'&-6G6E><HKFESSG&5-TVCZ+\9_\'6O[-=O\.S>_
M#S]F7XXZO\6989$'AKQGJ?@+P[\.[&X>WO?*N#XXT/Q'XH\2ZK#!=+IYDLQ\
M/=&>[MYKT+?64EK UW_''^TK^T+\7_VL?C)XW_:*^-NL/K_CGXD:R\]_J-O8
MG3M"LXM)L=/L--\+^'+-"\%CHWA70AHVEZ?IXGNKR"P6SN-3N[W4+R?4+O\
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M?^'!^-O_ -#S7]A__!-_]FKQU^Q]^Q/\!OV;OB7JWA/7/'/PNT+Q'I?B#5?
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MX]+UWP!X-TEW/GWU[X7O+_1_B)XA:SBEM])LM.T"QU::T?Q;HRWG]XG[2_\
MR;A^T!_V1+XK?^H)KU;'P4^!WPD_9R^&_A_X1? _P%H'PV^''A=+E=%\+>'+
M>2&RMY+VYDO+^]N;BYEN=0U/4]0O)I;K4=6U6\O=3U"YD>>\NYY26K1^+_A'
M4O'_ ,)OBAX#T:>QMM7\;?#OQMX1TJYU.2>'3;?4O$GAK4]&L9]0FM;:]NHK
M&*ZO8I+N2VL[N>.!9&AMIY L3_(YIFLLTS".)DG3H4Y0A0A)ZPI1GS.4[-KG
MFVY3M=+2*<E%-_H&1Y%#(\HJ8.$E6Q-:-6KB:L595*\Z?(H4[I2]E!*,*:E9
MM\TVHN;BO\?NO]1+_@C1_P HO?V,?^R1P?\ J1:]7\I'_$*]_P %!_\ HL7[
M&W_AP?C;_P#0\U_97^P#^S[XS_95_8V_9^_9X^(>I^&-9\:_"GP+'X8\1:IX
M,O=5U'PO>WZ:KJ=\9M%O=<T7P[JUQ9^3>Q*)+[1-.F\Q9 ;<*%=_H>*LRP.-
MP>&AA<32KSAB>>48-MJ/LJBYG=+2[2]6?(<"Y-FF6YEBZV.P5;#4IX&5.$ZJ
MBE*;KT)J*M)N_+&3VZ/J?07Q9_Y)7\2_^R?^,O\ U'-2K_'WK_8@\<:)=^)?
M!?B_PY826\5]X@\+Z_HEG+=O)':Q7>JZ3=V%O)<O#%/,ENDTZ-,\4$TBQABD
M4C (W\'7_$*]_P %!_\ HL7[&W_AP?C;_P#0\UAPGF&"P4,<L7B*=!U)8=P4
MVUS**JJ5K)[<ROZG7Q[E.8YG/*W@,)5Q2HQQBJNDD^1U)8;DYKM?%RRM_A?8
M_I;_ .#?S_E$7^R5_P!UY_\ 6FOC/7[)5\"?\$O?V5_B%^Q/^PO\#OV8_BIK
M/@W7_'OPS_X69_;VK_#_ %#6]5\(W?\ PF?Q@^('Q TO^R+_ ,1^'?"FLS^1
MHWBO3K:_^V:!8>5J<-[#;_:K6."]N?ONOF,QJ0JYACJM.2G3JXS%5*<UM*$Z
M]249+RE%IKR9]MD]*I0RG*Z%:#IU:.78&E5IRTE"I3PU*$X2\XR3B_-!1117
M&>B?Y0'_  47_P"4@_[=G_9Y/[3W_J[?'%?UR?\ !J9_R:9^TI_V<3:_^JU\
M)5\5_M7?\&V7[<WQU_:D_:4^-WA'XK?LGZ=X4^,?Q^^,?Q4\,:?XC\<_%^T\
M0V/A[XA?$3Q'XNT6SUZTTSX%:OIMKK-KINKVT&J6^GZMJEC#?)/'::C>P+'<
MR_N=_P $3_\ @G1\;?\ @F]\#_B[\-/CCXI^%GBK7?'WQ6A\<Z/=_"G6_%NN
M:3;:3'X1T/0&M]3G\7^!_ MY#J)O-,GE$-K87EM]F>%S=B5GAC^_SK,\!B,B
MCAJ.*I5*ZCA$Z46W*]/V?/TM[MG?7HS\GX:R3-<'Q//&8G UZ.&<L?:M-1Y'
M[3G]GJI/XKJVG4\A_P"#EG_E&-KW_9;?A)_Z6:U7\"7[/_\ R7CX)_\ 97/A
MO_ZF6BU_I6_\%>/V*?BI^WY^QYJ?[/GP=U_X?^&O&=[\1/ WBZ+4_B7JOB/1
M_#"Z;X9GU"6_@DO?"WA3QEJHOIENXQ:1KHKP2,KB:YMP%+?S%_"__@V$_;X\
M%?$OX=^,M5^+G[(-QI?A+QUX2\3ZE!I_C[XSRW\]AH.OZ?JMY#8Q7/P!M+>2
M\DM[21+:.>ZMH7F9%EN(4+2*N',SP&$RJI1Q.*I4:KKUY*$V^9QE3IJ+T3T;
M32]'V*XPR7-<?GU'$X/ U\10CA\+"56FHN*E"K4<T[R3O%23>FS]3^[.OPM_
MX.-O^45WQ<_[*!\&/_5C:)7[I5^;G_!6+]CSXF?MV_L6>.OV<OA'KG@7P[XW
M\3^*/A]K=AJOQ'U/Q!I'A6&T\*>+-.UW48[R^\,^&/%^KQW$UG:2QV20Z'<1
MR7+(D\MM$6F7X_+*D*.8X&K5DH4Z>+H3G.6T81JQ<I/R23;/T+.Z-7$9/F="
MA"52M6P&*I4J<?BG4G1G&$5>RO*326I_EM5_LD5_ E_Q"O?\%!_^BQ?L;?\
MAP?C;_\ 0\U_?;7T?%F/P>._L_ZIB*=?V7UKVG(V^3G^K<E[I?%RRM_A?8^/
MX!RK,<L_M;Z_A*N%]O\ 4/9>U27M/9_7/:<MF_A]I"_^)>84445\<?H@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?$7_!2
M[_E';^W/_P!FE?M!?^JL\45]NU\1?\%+O^4=O[<__9I7[07_ *JSQ173@O\
M?,)_V$T/_3L#DQ_^XXW_ +!,3_Z9F?QZ_P#!&/\ Y-!^/?\ V<CX!_\ 58>*
M:_3^OS _X(Q_\F@_'O\ [.1\ _\ JL/%-?I_7\Z^/G_)Q\Q_[ ,L_P#49'^6
MOCE_R6E#_L097_Z5B0HHHK\8/QP**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<KI2<9U%[.A&5Y4L+2H4;M4TPHHHKZ$^V"BBB@ HHHH **** "BBB@ HHHH
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M;KX2^*O&/[$^O^//"/Q:\+:3JVNZ1\-_&WB%_&7@_P"(0LR+\^%;#4;C3?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML[QPDFM>FJW/A<5"-3C:5.23C4XBI0DFKIQGCX1::ZIIZKJ?DKXX\(ZM\/\
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M%OI[H;F2:_\ $'Q"\*W3:I!*L5A;Z5/87$,K:U!)!_*A_P $GO@7_P -%_\
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M!_V1+XK?^H)KU?Y$E>3P5_"S#_KYA_\ TFJ?0>)?^\93_P!><7_Z70/[@/\
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M\X3J/Y,^$\0L3['(X4$US8O&T:;CU=.E&I7E+M93ITD_\2^5?_@C-\2O@/\
M _\ ;]^%OQY_:2\:>&_ WPH^"OA[XB^-]5U?Q)9W6M"36[OP5J_@GPE#H7A;
M2M&\0>(_%7B2S\3^+]*UW2=-\+:1>:[IKZ/+XJA$%EX=OKF'^KSQ%_P=%?\
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MY3=.K-)\DHS<*DO<482<5+^IBO\ (>^.&GW^K?M#_%_2M*L;S4]4U/XT>/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5\1?\%+O^4=O[<__ &:5^T%_ZJSQ17V[7Q%_P4N_Y1V_MS_]FE?M
M!?\ JK/%%=."_P!\PG_830_].P.3'_[CC?\ L$Q/_IF9_'K_ ,$8_P#DT'X]
M_P#9R/@'_P!5AXIK]/Z_,#_@C'_R:#\>_P#LY'P#_P"JP\4U^G]?SKX^?\G'
MS'_L RS_ -1D?Y:^.7_):4/^Q!E?_I6)"BBBOQ@_' HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF7PK_P"1NU;_ +!5_P#^G/3JVC_N^+_Z]Q_-F4_CI>LOT/H6BBBO)-0HHHH
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MK1G-KX%*$%*32<HIW7\\O_!%;_@N-\5_A=\5_ 7[+?[8'Q'N/''P"\<7&B^
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MF? V.RC RS*ACXXBKA(JM7ITJ4\/.C&&LJM"M[63J>R^-MQHR4(RE&\DHO\
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ME>(=+FT7PQXE^&NOZ8?"?@_0_#>F>&_#OAI;[0]?U:UOY= TK1]/TU[^+3;
M^(9DN_$=_%9:GJ%U:-W_ /P2H_X-\[']D;XM>-_B_P#MAR?!GX^:[I5CHNG_
M  *TCPZ_B'Q%X0\/3W]KK$7CGQ1XR\*>-_!6@Z??^)8XY=(TSP1B77=-TBW?
M7=;EMXO$$GA^ZT'3*\QR/*,M52E5A7QKI1G7C&$HUZM6?+>C&=2$;4J3=M'R
MJ,95.64V[Y9YD_$_$&<NE7HU,+EBKSIX64ZM.>&H4*?-;$3IT:LVZ]>,>;WE
MS.<XT>>-.*<?X+ZZ7P?XS\8?#SQ/HOC;P!XK\2^!O&?AJ^CU/PYXN\'Z[JGA
MGQ/H&I1!EBU#1=?T6ZLM5TJ^B5W6.[L;N"= [!9 &.?]?W6/!?@[Q#H<'AC7
M_"?AG7/#5M#%;VWA[6-!TO4]#MX(;.73X8(-)O;6>PBABL)YK&*..W5([.:6
MV51#(Z'_ #6_^"YWP,^!?P _X*(_%#PG^SQI_@WP[\/]<T'PIXNN?!'@&\TR
M7PMX!\9W]M=Z1XU\*:=H^E(MIX/\GQ#H=[J\W@N-OLWAN76&L-,M-'T9=-T'
M2O3R?B&GF]>IA9825"2I2J)NJJU.<5*,7&7[NGRMJ=TFFFE)7O9/Q.(.$*W#
M^%I8Z.80Q,77A2:5&6&JTYRC*<)PM6K*2BX--\T)1;@TG=\O]07_  07_P""
MOOC+]MW3O$O[,_[2>H6FJ?M$?#;PP_C'PQ\08K2VTN3XN?#VUU.TTK5VUS3M
M-L++0[/QOX)O-7T."YFTW[*WB[0-3CU4:,E_X:\4ZUJGY;?\'7?_ "<?^RK_
M -D2\5_^IW-7P1_P;K^*KKP]_P %6O@5I%O<WD$/CKPC\;/"M]%;"(PWEK9_
M"+QAXW2VU R.K"S6]\'6=XAA$DOV^UL04$)E=/\ 06^*_P"S#^S5\>=2TK6?
MCE^SS\#?C/J^@V,NF:'JOQ7^$O@'XBZEHVFSSFZGT_2K[Q?X?UBZTZQFNB;F
M6TLY88))R9GC:0[J\#'2PW#_ !##$4Z#]A4PSK>PI.,5&5;VM*7LTU:,>:#E
MR[*[4;12BOK,JCC>+.$*N#K8E?6:>,CAOK-=2G*4,-+#XF+J.+YIS]G45/G=
MI2Y5*;E)RE+_ "*:*]X_:FT?2?#W[3O[1N@:!I>G:'H6A_'CXO:/HNBZ/8VV
MF:3H^DZ9\0?$-EINEZ7IME%!9Z?IVGV<$-I8V-I##;6EM#%!!%'%&B#]Z/\
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MP4Z=#!8=8JE&$;RI5%AZ5-/:%./LIMN*WCRP2NDF];?&9?P%FF90JXG,\7+
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MD^5M_P"JC1117Y,?O@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^-O$XS T,PRFK&4(5JM-8BA.Z=+$X2K=22Z2LITYVTFG%MODB?JE_P $1_\
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M%%?D9_0!\R_MK?\ )FW[6O\ V;+\>?\ U5GBNO\ )1K_ %KOVUO^3-OVM?\
MLV7X\_\ JK/%=?Y*-?H7!7^[X[_K]1_](F?D?B5_O>5?]@^)_P#3E,_T'/\
M@V#_ .4;_B'_ +.:^)W_ *B'PPK^BROYT_\ @V#_ .4;_B'_ +.:^)W_ *B'
MPPK^BRODL\_Y&^8?]A-3]#[_ (8_Y)_*/^P*C^3"BBBO*/=/\D#]K[_D[/\
M:A_[.)^-G_JRO$U?TM_\&G'_ "53]L[_ +)_\'__ %(_'%?S2?M??\G9_M0_
M]G$_&S_U97B:OZ6_^#3C_DJG[9W_ &3_ .#_ /ZD?CBOU?/?^2>Q'_7C"_\
MI[#GX+PM_P E=@_^PK'?^H^*/[9****_*#]Z"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %>9?"O_ )&[5O\ L%7_ /Z<].KTVO,OA7_R-VK?]@J__P#3GIU;1_W?%_\
M7N/YLRG\=+UE^A]"T445Y)J%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%_$/_D3
M=:_ZYVG_ *<+2K?P0_Y$V;_L-WW_ *36-5/B'_R)NM?]<[3_ -.%I5OX(?\
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MVYJDY.52I*VG-4E*5DE>R2/S)_X++_\ *+W]L[_LD<__ *D6@U_EVU_J)?\
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M,KGYD_\ !9?_ )1>_MG?]DCG_P#4BT&O\NVO]1+_ (++_P#*+W]L[_LD<_\
MZD6@U_EVU]1P9_R+\5_V&/\ ],43XCQ(_P"1K@?^Q>O_ %)KG^F-_P $$=(T
M72?^"3O[)_\ 8OV>1-3T_P"*VKZG=0_9'DNM:O?CC\2SJ7VN>TBC$]QI\T?]
MC+]H\R[M+73+;3KB5WLN/V"K^=C_ (-FOV@?#WQ+_P""?3_!*'689O&/[-?Q
M(\6Z)JWAYK6*WO-,\(?%'7M:^)7A+6S+#)+]NT[7M?U7X@:?9W=T8+Y;[PUJ
M]BUHMC9:=>7W]$]?$YQ3G2S7,(S34GBZ\U>Z;C5J2J0EJE\4)QDNC3NKJS/T
MSAZK3K9%E$Z;3BLNPE-V::4Z-&%&K'2^L*D)Q?5--.SNC^8;_@ZI\.:;=?L/
M_ ;Q;*C'5]$_:KT'PY8R!8"BZ;XI^$7Q=U/549F@:Z#/=>#]&9%AN8H&$;FY
M@N)$M9+7^#"O[6/^#KCX]:;:_#O]ES]E^RO8I]8UWQIXA^/7B73EMSY^F:;X
M4T/4OA[X(O9;J2$+Y6NW7C/X@P06]I<2'?X=N)-0AA']F//_ !H^!/!7B3XE
M>./!OPZ\&Z;<:SXO\?>*_#W@KPKH]I%-<76J^)/%6KV>A:'IMM!;13W$UQ?:
MG?VMK#%!#--))*J112.RH?T/A:,J>2T95/=C*I7J1OI:G[22N[VLG*,I)[--
M.]F?D''$H5N),3"E[\XTL)2FHJ[=7V,'RJU[R2G"+6ZDN7='^MY^SO?76J?L
M_P#P,U.^E\^^U'X._#*^O)]D<7G75WX*T2XN)?+A2.&/S)I'?9%&D:9VHBJ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)_\ 9O\ A%-.>P^W_P#"1?\ "Y/!7G?;]_F_9?["B^RX\O[1<YWC)_X)U_\
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M>787ZQ&A2Q$:K]OAJ/(ZDZ3@K5ZU)RNHRUBFE;6UT>N?\&H'_)!_VN/^RN>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K^-W_@ZG_:JL9[?]GW]C7PQKT-Q=6NHZE\=/BSI-G/IL
MIL)XK"?PK\*-/U%K>:;5+6ZFM-6^(.M76CWR6%K):3>%=96+4VEL9],_L4U/
M4]-T73=0UG6=0L=)TC2;&[U/5=5U.[@L--TS3;""2ZOM0U"^NI(K6RL;*UBE
MN;N[N98X+>".2::1(T9A_E%?\% /VI;_ /;0_;#^._[1]R+R#2_B!XRE7P;I
M]\(4N=)^'OAFQL_"G@#3)X;>"VMX;NV\(Z)HYU+RX%>XU62^O+J6ZO;FYNY_
MJN$L%]8S%XF2O3P4.?R=:JI0I)^D?:336TH1[GPO'^9+"9/'!0E:MF554VD[
M-8:BXU:TDU_-+V-)IZ2A4GV/CJO],G_@AI^UO9_M:?\ !/+X0W5[J-Y>?$+X
M%6<'[/WQ*74I_M-_-JWP]TG2XO"NNO>2[+O58O$OP]OO"6J7>L747F3^)'\1
MZ=+=ZE>:3>:A<?YOOBGX2_$'P7X#^%OQ-\2>'+W3/ WQGL?%NH?#?Q!<(8[/
MQ/!X$\477@[Q8;#>$DF71M?M'L+FXC1[,SL;>*YDN[6_MK/^@C_@V8_:ZN?@
MY^V/XB_9K\2>(K>P^'O[3WA6>#1M/U*;RK6+XS> (+K7/",]C=S[K73[C7_"
M<GC?PY/9J;.3Q1K,W@ZP-Q=:AINB:=<_5\2X...RNK4IVG4P<I5XN+OI2<H8
MB%U?X8J;E'?GI).UF?!<%YC++,]HT:W-3HYC"&&FIKE]ZLHU<'42=M)S<(QE
MLZ==R5[H_OYHHHK\J/W<_@2_X.H?^4@_P=_[,V^'W_J[?VAJ\_\ ^#9#_E)3
M<_\ 9NWQ3_\ 3SX$KT#_ (.H?^4@_P '?^S-OA]_ZNW]H:O/_P#@V0_Y24W/
M_9NWQ3_]//@2OTZ/_)(O_L6S_*1^)U?^3@K_ +'%'\H'^A;17RQ^U;^VM^S+
M^Q%X2\->.?VH/B7_ ,*Q\+>,/$3^$_#NJ?\ "&_$#QI_:/B!-,N]8:P^P_#W
MPIXLU&TQIUC=7'VJ^M+6R/E>2+DSO'$_PI_Q$!_\$C/^CM?_ # W[37_ ,YB
MOSRE@,=7@JE#!8NM3;:52EAZU2#:=FE.$)1;3T:3T>C/UVOFN686HZ.*S+ 8
M:M%)RI5\9AZ-1*2O%NG4J1DE):IM6:U6A^R5%?C;_P 1 ?\ P2,_Z.U_\P-^
MTU_\YBC_ (B _P#@D9_T=K_Y@;]IK_YS%:?V5FG_ $+<?_X1XC_Y68_V[DG_
M $.<J_\ #CA/_EQ^R5?QM_\ !VS_ ,X__P#NZO\ ]]NK^DO]DW_@HM^QM^W)
MJOC/1/V6_C%_PM#4_A[I^CZKXPMO^%??%/P5_9%AK]S?6FDS^=\1/!'A*WU#
M[7<:;>Q^5I<M[-!Y.^YCA22)I/YM/^#MG_G'_P#]W5_^^W5Z?#M&K0S_  =*
MO2J4:D?K'-3JPE3G'FP5>2O":4E=--76J::T9XG%^(H8KA3,:^&KT<11G]44
M:U"I"M2DXYEA8R4:E.4H2Y9)QE9NTDT]4S\;?^#?S_E+I^R5_P!UY_\ 69?C
M/7^EM7^:3_P;^?\ *73]DK_NO/\ ZS+\9Z_MF_;"_P""S7[ G[%'B2X\ _$W
MXL7'C+XH:?<10:U\,?@]I ^('BKPSNFO;>Y7Q;>07NG>#O">IZ?+9K]M\+>(
MO%6F>,DMK[3M0@\.3Z;>1WE>CQ7AL1BLWP]+#4:E>I_9])\E*$IM+ZQBDY/E
M3Y8KK)V2ZL\?@/&83 \/XNMC,31PU)9M67M*]2-.+D\'@;1BY-<TG;2,;R?1
M'ZH45_/!\/?^#G+_ ()L>--<CTGQ)8?M&_"2P=H5;Q/\0OA;H&I:'")7*N\E
MO\*?B!\3?$I6W4"280^'I79& MTGDW1C]Z_AU\1_ /Q=\$^'?B1\+O&7AOX@
M^ ?%MB=2\->,/".L6.O>'M:LUGFM)I;#5-.FGM9FM;VVNK"]@$@GL=0M;JPO
M(H+RUG@C^7Q6 QN"Y?K6&K4%/2,JD&H2=KV4]8N26KBG==4?<8+-<MS+F^HX
MW#XIP5YPI5(RJ0BW92E3TG&+>BDXJ+>B=SM***YCQGXV\&?#CPOK7CCXA^+O
M#'@/P5X;LSJ'B+Q?XSU_2O"_A?0; 21PF^UKQ!KEW8Z3I=F)I8HC<WUW!"))
M8T+[G4'E2;:23;;222NVWHDDM6V]$EN=[:BG*348Q3<I-I))*[;;T22U;>B1
MT]%?S\_%/_@Y<_X)H_#K6;G2/#=]\=/C5%:W@LWUKX6?#"RMM&EQ:PSRW5M-
M\5_%WPMO;FSAN9)=-,\-@_VBZMIKBR6ZTF2TU.ZZCX+?\'&W_!,[XOZMI6B:
MQXR^)GP/U#6-1_LVV;XU> 8=)TFV=DG:&[U7Q)X%\0?$#PSHVG3/#'#]NU76
M+."V>Z@DOFM+=;J>V])Y-FJI^T>7XKEM?^#-R2[N"7.OG%'C+B/(95?8K-L"
MYWY5_M$.1N]K*JW[)W;LK3=^ES]WJ*Q/#?B;PWXRT'2_%/A#Q!HGBOPQKEI'
MJ&B>(_#>JV&N:#K%A-GRKW2]7TNXNM/U"TEP?+N;2XFA?!VN<&MNO-::;333
M3LT]&FMTUT:/9332::::333NFGJFFM&FM4UN?Y;G_!8/_E)S^VG_ -EMU[_T
MCTZOZ+O^#3/_ )$']MO_ +&_X%_^F7XH5^A'[2/[8/\ P;\>!OCK\3_"/[3/
MA+]EN]^/>@>*;O3_ (IW?C#]AOQ+\0_$\_BN*.%KR36O&UI^S]XFMO$M\8G@
M\S4X=?U5)0%47;["%^T?^">?QO\ ^":GQITCXI7/_!.71?A!HVC^']2\*0?%
M9?A-^SYJOP#M[C4]1M=>D\(MK=IJGPU^'+>)IH[6S\0"PN(8=6&EH]U&\MH;
MY4N/M<QS6M6R)8265X^C3]A@X?6ZM*<</:E.@XSYW!+EJN-H/FU<HVO<_-<G
MR+#8;B=X^&>97B:OUG,)_4*%>G+%WK4\0I0]FJCES4>>3JKEO%4Y72UM^CE%
M?/\ ^TM^U)\"?V/OAC<?&3]HOQU_PKOX;VNMZ1X<G\1_\(SXQ\6[-9UUYX]*
ML_['\"^'O$VO-]J>WF'VA-+:U@V9N9X0R%OBOX5_\%M/^"8OQK^)'@?X1_#+
M]IG_ (2;XA_$CQ/I'@[P7X?_ .%,_M!:-_;/B37KR*PTK3O[6\0?"C2M#T[[
M5=S1Q?;-5U*QL(-WF7-U#$&<?)4\'BZU.5:CA<35HQYN:K3H59TX\JO+FG&+
MBN5-.5WHM79'W];,<OP]:.'Q&.P=#$3Y>2A6Q5"E6GSOEARTISC.7/).,;1?
M,U979^JE%?GI^V=_P5*_8H_8.VZ5\>?BY9I\0KBT%]I_P@\"64OC?XH7=L_V
M"2&>_P##VE/]D\'V=[:7ZWVD:G\0-5\(Z5K]O::@F@WVIWEE-:K^:_AW_@Z!
M_P""<6M^(5T74O"O[4/A#36FFC/B[Q%\,O ]SX>1(Y1&EPUMX3^*WBCQ68;A
M"9X53PPTZQ B>""?$)WHY5F6(I>VH8+$5*35XSC3ERR2ZPO;G72\.;6ZW3.7
M$Y[DV#K/#XG,L'1KII2IRK1YH-[*I9M4WJG:HXM)J3T=S^C.BO*O@I\<?A)^
MT;\-_#_Q=^!_CW0/B3\./%"7+:+XI\.7$DUE<265S)9W]E<V]S%;:AIFIZ?>
M0RVNHZ3JMG9:GI]S&\%Y:02@K7YX?M>_\%L/^"??[&6O:YX'\>_%34/B'\4O
M#>H2Z7K_ ,*_@KH8\=^*M$O[7[2E_8:YJ]Q?Z%\/= U?3+NW73]2\/:]XWTS
MQ'97EQ$D^D+%%>S6G/2PF*KUI4*.'K5*T6U.E&G-S@T^67/&UX<KTDYV47H[
M'7B,PP.%P\<5B,7AZ.&FHN%:I6A&G44ES1]G+FM4YHZQ4.9R6L4T?K)17\_W
MP>_X.5O^":GQ2\2IX<\1W_QO^!4=Q-9VUEXC^,/PXTK_ (1JZN;UYHDB>_\
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MG_@LO_RB]_;._P"R1S_^I%H-=F7?\C# _P#89A?_ $_ \_-O^15F?_8OQO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'H?PL^'^H?$SQK
MI'A:R#)#<R_:-5NU VV&DVQ#WMRQ8@;_ "\0P+R7N)8D"D$X_:O1M(T_0-)T
M[1-)MH[33=*LX+&RMHE5$BM[>-8XUPBJI8A=TC;07D9G;+,37SG^R]\*/^$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML&D77Q8T3Q%<,QD34)&>36_"\:*L5Q9PB-R\EG-/&M]^B/\ P4L_X-_O#?\
MP4$_:=U#]I;0_P!I&/X$:IXC\$^$?#OC+PZGP1A^(K>)/$GA*"\T:U\7RZ]%
M\5?A\\,DWA"#PKX:&FW.E:C-;Q>&([A=8DM[N#3M,K_\$W?^"#7B[_@G-^TQ
MIO[0GA?]L^S^(EC-X1\1^ ?&O@*\_9TN_"B^*_"/B*33=1EL(/$=K\?]<&D7
MEEXAT#P[KEK=76@:[:>=I*Q2::[RQW-MGF6?99F635J#Q'L<56HTY^P='$2Y
M:U.=.LZ2JJC[-IRAR*?,HV:D[:I;9-PKG>3<1X;%1PCQ& P^)K4UBEB,'!SP
MU:E5H>W=&6(=5.,*JJ2IJ#G>+C!2?*WSG_!Q=_P3>\7?M6_!WP=^TS\$O#FJ
M>*?C%^SUIFM:7XH\'Z%:M?:SXZ^#VI3KK5X^EV9NA->ZU\.M5AU'6],T;1[*
M;4]=TSQ+XGACBU#4++0[$_P,:/K&K>'M6TO7] U34=#UW0]1L=8T76M'OKG3
M-6T?5M,N8KW3=4TO4K*6"\T_4=/O((;NQOK2:&YM+F&*>"6.6-''^QO7X!?M
MW_\ !O%^R-^U_P"*]5^*/PVU[6?V7/BQX@O;W4O%&I^"/#^F^*/ASXLU74[F
M^U#4O$&O?#6\U#P_)!XDO-0NHYI]0\*^+O"^GWB+=R:GH^H:I>C5;;S^'^(Z
M6"HK X_F]A%R=&O&+G[.,FY2IU(1O*4.9MP<5*4;N+BXV<?6XLX.KYCB7FF5
M.'UJ:C]9PTIQI*M*$5&%:C4DXPA5Y8Q4XSE",N534E/FY_Q4_9W_ .#IS]H7
MX<^"-#\)_'S]G?P;^T!K.@Z'9Z./'NB_$+4?A'XH\17%DL4*:YXMB/@SXBZ!
MJ&KW=O&QU*30]&\-6EU>N;R*TM5+V\GAG[;O_!Q[^TO^UA\(?'OP*\ _"+X?
M_ 'X?_%#P_KW@_QUJ%MKFL?$;X@:EX-U\-8ZGX9T[Q'?V/A;P[I5CKGAV>^\
M/>)KG_A";O4M1L[^>71KWPW(<'U'Q)_P:J?MLVMTJ>$/C[^RSKEB=V^X\2:S
M\6O"MTN(X"NVSTSX4^,H7S,URC9ODVQPP2C<UQ)#:])\/?\ @U*_:JU*]CC^
M*W[37[/O@O3C?0QS77P]TWXC?$V]CTUD)N+N/3_$GASX202WT4F$AT]M2AMY
MT)D?4[=@(SZ\9<'TJJQ47A54C)5%9XF24DTTXX?6":=FDJ6CV6A\_*'B'6HO
M SCCG2E!T976#A*4&E%J6+?+4::=G*5>[5[RW/Y@O!O@WQ9\1/%GASP)X$\.
M:SXO\9^+]9T_P[X7\+^'=/N=6US7]<U:YCL]-TK2M-LXY;F\O;RZECA@@AC9
MW=AQC)'^I#_P2[_9$OOV'OV(/@I\ /$,=B/'VCZ5J?BGXGW&GWR:G:S_ !#\
M:ZO>>(_$%K!J$,%K;WMMX?%]:>%+"ZMH%BGTW0+*7SKV1Y+^Z\5_X)[?\$9O
MV1_^">6JCQ_X(LM?^)WQQDTO4-'?XP_$:6SN=6T;3M5S'J5EX'\.Z=!;:!X/
MCO[+&G7FIVT%]XHN=.FU#2YO$;Z/JE_ILWZV5\_Q%GT,S]GAL*I+"TI^TE.:
MY95JB4HQ:C>\:<8R;2E[TG*[C'E5_K.$.%:N2.KC<=*#QU>G[&-*G+GAAZ+E
M&<E*=K3JSE"/,X7A",;1E/GE;^6#_@Y5_P""=OC;X\>!/!7[9_P=\.ZSXO\
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MGSTZG*JF)K5(>_2G4IN\)1>DG:]G9II?F3_P67_Y1>_MG?\ 9(Y__4BT&O\
M+MK_ %K?VS/V<O\ AKC]E[XS_LV_\)C_ ,*^_P"%O>$7\*_\)G_PCW_"5_\
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M;&..TT[3K2-5"K)=W<EWJ-W>WMS^Z/\ P;D_\$^_%/Q\_:DTG]KKQEHUQ9?
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M)I/=72?=)Z'[3%N48MQ<&XIN#<6XMJ[BW%RBW%Z-QDXMK1M:A1112*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ^7O#'_);]2_["OB7_TGOJ^H:^7O#'_);]2_["OB
M7_TGOJ^H:[\P^/#_ /8)0_\ ;CGPWP3_ .ODORB%%%%<!T!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU=V>MX=YI6KT,7EE><JD<(J=?"N3;<*51RA5I)O:G":A*"Z.I-:+E2_S>?\
M@L'_ ,I.?VT_^RVZ]_Z1Z=7]%W_!IG_R(/[;?_8W_ O_ -,OQ0K^='_@L'_R
MDY_;3_[+;KW_ *1Z=7]%W_!IG_R(/[;?_8W_  +_ /3+\4*]C./^257_ &"Y
M;_Z<PI\[PY_R7,O^PW./_36-/O;_ (.6?^48VO?]EM^$G_I9K5?P ?!SXL^,
M_@1\4_ 7QE^'5Y9Z=X]^&?B?2_&/@[4;^PM]5M--\2:).MYI&HRZ9>+)97_V
M"]CAO([._AN+"XEA2*^M;JU::WE_O_\ ^#EG_E&-KW_9;?A)_P"EFM5_GD:-
MI=QK>KZ5HMH\,=UJ^I6.EVTEPSI;I<:A=16D+SO''+(L*R3*TK1Q2NJ!BD;L
M I.$E&63U(R2E&6*KJ46KIQ=.DFFGHTU=-=4''TIPXBI3IRE&I#!864)1;4H
MSC5K.,HM:J2:336J:N?L5^RC_P $>?\ @HC_ ,%-=-\2?M)V<_AK0O#OCO6=
M<UX?&K]H_P :>)-+?XM>)Y=69/$=]H2:%X9\>^.-?8:C-=&Z\57_ (>LO"EY
M>VFJ:9I_B*\U?2[_ $ZU^-?VY/V!?VB_^">WQ5LOA3^T)H6C17.OZ-_PD7@G
MQOX-U2?Q!\/O'NAQW+V%[?>&=:NM/TC4H[G2=2B>QUC0/$>B>'_$^EB33M2O
M-$BT37_#NJ:O_J>?"_X=^&_A!\,_AW\)O!L5Q!X0^%_@7PC\._"L%V\,EU#X
M;\$Z!I_AK0XKF2VM[2WDN(],TRU29X+6VA>16:*WA0K&O\K7_!V-HEA/\)/V
M-O$<D>=4TKXB_%K1+.;9"=EAX@\,^#K_ %*/S&B:X7S;CPSI3;(IXX7\G=/%
M,\=L]OP97Q+BL;FU/"NG1A@ZTJD*4(P:G3C"G.5)\W-JWR)35E'WGRJ-DEZF
M><&8'+<@K8Y5L14S'#QH5*]6=12IUIU:U.G6CR<ONP3JRE3?,YWC'GE*[/Y=
M/V4/^"B7[6/[%/@_XS^!OV>_B7>^$/#_ ,;_  L_A[7[=Q<W;^%=8>ZTW'Q'
M^'O^EPP>%?B7'H5E>^$X?%<,%U)%H>LSW"6H\2:'X+\0>%ON+]F;_@@#_P %
M$OVL/A3;_'2QTSX;?"[P]XLT^+Q/X,MOCIXR\0Z!XS^).D:I#<WUMXAT?1/#
MG@_QO?:9::N\:2Z?=_$*7P=+K5OJ.GZ]IRWOA[4(-9?\X/V)/A/H?QV_;$_9
M<^#?BE&D\*?$OX^_"?P=XLACE2">?PGK7C;1;3Q/;VDLMGJ$*7UQH+ZA!8FX
ML[BV^V20"YC-N9"/]9^TM+2PM;:PL+:WLK&RMX;2SL[2&.VM;2TMHUAM[:VM
MX52&"W@A1(H88D2.*-%1%55 '9Q#FL\GJ4U@J-".)QG[W$5ITU*4H4N6G33L
MX\S>JO)ODC%J*O+F7G\(Y##B&E5EF6)Q4\%E[]AA,-3K.,8U*]ZM5KF4E""]
MV34%%SG).4N6'++_ ",OVD/V;_C#^R9\8?%OP*^.OA*X\'?$/P=<0)?V#SP7
MVG:EIU] EWI'B#P_J]H\ECK6@:U8R1W>G:C:2,I5I+2[CM-1M+VRMOZ@?^#6
MC]K[Q5%X_P#C!^Q3XIUO5]3\':AX-N?C+\*;"]EO+[3O">MZ#KFG:5X]T32"
M]U+%HUGXKMO%&G>)'LHK*'39-3T#5KYKFWU;5WCU;P'_ (.I=%TJR_;=^!NM
M6EA;VVJ:W^S#HL>KWD*>7)J/]E?$_P")D.GR784B.:XMK>X>V6Z=#<M:QVUK
M)*]O9VD4'S[_ ,&U]Q/#_P %/_",<,\T4=W\'?B];W4<<CQI<P+HMG=+!<*K
M!9H5NK:VN5CD#()[>"8+YD4;+T8RHLSX9J8FO"*G/!O$6BM(UJ+;YH7;<4Y0
M=M6^23BV[LY,NHRR/C2C@\-5G*G3S".#O)^]4P^)M'DJ\O+&34*D6WRJ/M(*
M:BFDE_?_ /'+XS^ OV=?A!\1?CC\4-2N-*\ ?"[PKJGB_P 47EG9RZA?C3M+
MA,GV73;"$K)>ZGJ%PT&GZ9:!XEN+^ZMX7FA1VE3_ "UOVYOVY/C;^WS\<_$?
MQF^,&NZC]BN-1U!/A[\.(M9O[_P;\*/"EP;6&T\+^$;"X,-G;%K/3M.?Q'K5
MMI]A>>+=;MYM>U:+[7<".'^T'_@Y^^+>L^!?^"??A7X<Z-++##\;OCWX+\->
M*LHQMKGPCX.T7Q+\16LFDCO(&2\;QKX9\#7UNLMI?6CVVGW^];>[2RF'\+G[
M-\_PMM?VB/@+=?'*XCM/@G;?&CX6S_&&ZETV]UF*V^%L/CC0I/B#<2:/INF:
MUJ.JQP^$EU>1]-L-'U:]OE4VMKIE_/+':R^?PE@J=+!ULRE3]I7G*I"E9<TH
MTJ27,J:M=3JU.:+M=M1@E:\D_7X_S*M7S'#9-"JJ6&IPHU:_-+DISKUY/DE6
M=[>SH4N6<6](N=233M%K]2OV3_\ @@%_P4&_:S^'6F?%32-"^''P6\%^(K&V
MU;PC>_'OQ'XH\)ZEXNT6^M-/O]-US1?#WA3P/XZU^+1M5L]02ZTK4=;TW1[;
M4K6"6ZLWFM9;*:[_ #^_:^_8B_:4_86^(5A\-OVDOA[<>#-8US2WUOPMJ]GJ
M%AX@\)>+M(BF%M=7OAKQ-H\]UIE_)I]PT<.K:8\MOK.CO<61U73;*/4+![G^
M_P!M/^"_'_!(&PM;:PL/VK+>RL;*WAM+.SM/@!^TM;6MI:6T:PV]M;6\/P62
M&"W@A1(H88D2.*-%1%55 'X^?\%Q?^"E7_!,_P#;A_8EO_ WP3^.^A^/_CCX
M)^(7@KQG\/=+O_@M\<O#VLSVKZFOA_QG8:#XL\7_  N\/Z%HGG>&]7N-9U2#
M4]=L++5[3P\EK''>:TFB6YTP.<9[5Q].&*RNO3P=:HJ=_J>)@\.I.T)RJRCR
MN,6U[5S2CRWDN2QAFG#O"]#*JM7 YYA:V88:BZMO[1P518N4$I5*<:$)<RE)
M*2H1IMRYG&,O:-W%_P"#;_\ X*B>/?&'C*3]@/X_^--<\9_:_#&J:]^S7XJ\
M6:QJ&MZWIJ^"=*COM<^"T-Q+IU]?76B6O@NQUGQ?X0GUK7+73_">C^#-6\)Z
M:'M+[PSI.G_U7_M+_P#)N'[0'_9$OBM_Z@FO5_E:_L=?%74O@?\ M8?LW?%W
M29EANOA[\;OAGXGE$OGF"ZTW3O%VDOK.FW8M4DNVL=5T<WVF7RVB-=-9W<ZV
MV)S&1_JE?M+_ /)N'[0'_9$OBM_Z@FO5XW$^ IX3,\-7HP4(8RTI0BDH^VIU
M(JI))62YXSIR:2UFY2>LCZ/@G-*V/R3&X7$5)5:F7J5.G.3;E]6K49RHPDW=
MOV<J=6,6WI34())05_\ (DKWK7_%/Q\_:S\;?#W0FT[QA\7O'/AOX<?#+X(_
M#CPGX,\*WNO:W;^!/A?X:TGP)X#\*^'_  SX6TVXO+MK:PL[59FMK*>^UC7=
M0O=4OI+K5=5N)IO!:_T#?^#9;]FOPQ\-/V#[G]H5M#L?^$^_:3^('BZ[F\4F
M0SZE)\._AEKVH?#SPYX85!.\.GV.G^,-"\?ZTZ1V]M?:C<:VDNHS7EG8Z$EC
M]IG&8T\KPGUR5)5JJFJ-&+:C>=6\I+GM)QCR4Y2DDFY<BCI?F7YMP[E%7/<?
M_9\<1+#T72EB<3-)SM3HM1BU3YHQG/VE6,(N32ASREK;EE_*3_P3A_8-^*/Q
M1_X*/?LS_ +XW?"3QU\/+'_A-Q\1O'WACXI^$/%O@*[O_A]\)7O/%OBW2[FQ
MUC2].UI(/$$_AM_ ?G6<,+P:SK4-M+?:8R37UG_I0_&SPMX\\;_"'XE>$?A=
MX\OOA?\ $CQ#X+\0Z7X$^(&GPZ3<7'A/Q;<Z;<)H&KR1:WX?\4:>UE#J?V9=
M3)T*^O4TU[N32C:ZJME>V_I#6EH]W#?O;6[WUM;W-I;WC0QM=P6E[):37EM#
M<%3-%;W<UA82W,*.L<\EE:/*KM;0E+%?FV;9S5S6OAZTJ4:2P\%&-+F]K!S<
MW.<VI12:FE"+A)--02;:9^SY!PY0R+"XO#0KSKO%U7.5?E]A55)4E3A34H3D
MTZ;=6<:D91:=1M*+5W_(A_P3G_X-[?BS;_'#3/VL?^"D7CC_ (2KQUX>^(>G
M_$;3OA:GBD_$W4_'WC"PN%UZ+Q/\:?B%?76H1:W%'XF%K?7GANSN=?3Q7)93
MQ^)=;?2+JZTC5/ZS/&/BG2O WA'Q5XVUTW"Z)X.\.:YXIUEK2'[1=C2O#^F7
M6K:@;:WWIY]P+2TF,,.]/-DVIO7=D='7GOQ;^']K\6?A3\3?A9?7G]G6/Q+^
M'OC3X?WFH?9Y+O[!:^,O#>I>'+B\^R0WNFS77V6'4GG^SQ:C823[/*2]M683
MQ\V,S'$9E7IU,9-<D.6$84X\E.C2NN94X*]M-6VY2=DFVE%+MRW*,)DN$JT,
MNI-SGSU)U*T^>MB*_*^65:H^5/6R2BH0BG)J*<I-_P"5Q^W)^V=\6OV[?VA_
M&OQV^*NN:C>)J>HW]A\/O"<]P&T?X;?#J'4;N?PQX&\/V4 2SM;72K.X5]3O
M(8ENM?UV;4_$.K37FK:G>7<WZ)?LT?\ !O'_ ,%"OVF/AEX1^+>GP?!GX2>$
MO'GAZQ\6>$%^,/CK7M,UO6?#>L6FGZAH.K'0_ 7@GXA7^E1:[IVH+?Z?:Z[%
MI>H):V\KZA9V+36"7OXR?$KX=^+_ (1_$+QO\+?'^CW&@>-_AWXJU[P7XLT6
MZ5EFTW7_  WJ5SI.J6I+*GF1QW=K+Y$ZCR[B QSQ%HI$8_NM^QG_ ,'&O[97
M[+/@'X?_  >\;>#_ (:?M"_"_P"'UMIF@Z0WBR/7/"?Q4M?!&C66E:5I'@S3
M?B!X?OI_#_V'1M+TZ2WTG5_$_P .?%OB&.6[W:GJFK65G9Z?#^HXV./I8.C#
M)(87W%%*%31>Q4/<5'6-.[TNYM)IW3O=GX;EE3*J^88FIQ-4QS=24I2J4KN7
MUAU/WCQ*495DDKV5.+::::LDCXJ_;S_X)(?MB?\ !.[3-&\5?&_0?!_B/X;:
M_K,'AO3/BG\+/$-[XG\$GQ%<:7_:L.B:BNM:'X6\5Z%>SP1:A%9-K_A?3+/5
M+C2-472;J_BMEED]Q_X(A_\ !1;Q=^Q)^U=X,\$^(O%MQ;_LU?'/Q5I'@_XK
M>&M4U!HO#/A_6-=D@T/P[\5K=7LM0_LG5/"UY+8KK]W8I:#6_"L=QI^KSLNG
MZ/=Z3^\3?\'#?_!,_P#;/^&'B#]GO]MO]G_XO^!/A]\3+JSTCQGI\ZK\0?AS
M%H>FZWH>N:)K.H^*_AWKGA3XM6&HZ9KFG6^N(OA'P!=:EI4VBVMWI6IWE_)%
M:Q_I/^R-^Q3_ ,$2?C7X7M?B-^RC\$OV7?B_HFAZII]Q/J4$4_Q#UGPSK%M>
MW=_IMKXJT3X@7^L^)_"]_/+#-=VVD>*],TZ;4M,CM9EL[K2%LF'@XG-Z\,OJ
MX;/LJQ//44J;JT:=/ZM)-+V<_:.I*$*\9^\E%M*48SC:_+'ZK \/X6IF]#&\
M+9[@W3HN%:-#$5JOUV+3;JTG05&$ZF&G3M&3FHNTYTYI\O/+]EZ***_/#]>"
MOS)_X++_ /*+W]L[_LD<_P#ZD6@U^FU?F3_P67_Y1>_MG?\ 9(Y__4BT&NS+
MO^1A@?\ L,PO_I^!Y^;?\BK,_P#L7XW_ -1JI_EVU_J?_P#!)W_E&M^Q)_V;
MM\.O_3-%7^6!7^I__P $G?\ E&M^Q)_V;M\.O_3-%7W7&G^Y83_L*?\ Z9F?
MEOAO_P C+,/^P&/_ *D4S]":^'_^"EWPZTKXJ_\ !/G]LSP7J\4<L5U^SA\5
M]=TX2R>5##XD\%>$=3\:^$KNX<6]TZV]EXI\/:/>7'E023&&"00;)BCK]P5X
M/^U/?6NE_LQ?M':G?2^18Z=\!_B_?7D^R27R;6T^'WB&XN)?+A22:3RX8W?9
M%&\CXVHC,0I^ PTI0Q.'G&_-"O2E&V_-&I%JWG=*Q^LXV$:F#Q=.:3A4PU>$
MT]4XRI3C)._1IN_D?Y%]?Z9W_!!_X@/\0_\ @E5^RK>W-W-=ZEX7T?Q[\/\
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M:V]HHT^=I?\ +N.C/\S3_@I/^WA\1/\ @H#^TYXU^+/B?7=9D^'.E:SK>A?
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MJ$EE;Z98^(+;Q+X<\&>*-*;5+R]%AI]W/X<.FW-];SVZWH=[/[54_P""2/\
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M*_&#\<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]9IM^E@ # & . !T ]****_KL_TR"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA-1_Y&[3?^OO2O_2B.N[K
MA-1_Y&[3?^OO2O\ THCK:A\4_P#KW/\ (SJ_"O\ %'\SW.BBBN$T"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KS+X5_\C=JW_8*O_\ TYZ=7IM>9?"O_D;M6_[!
M5_\ ^G/3JVC_ +OB_P#KW'\V93^.EZR_0^A:***\DU"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#B_B'_P B;K7_ %SM/_3A:5;^"'_(FS?]AN^_])K&JGQ#_P"1
M-UK_ *YVG_IPM*M_!#_D39O^PW??^DUC78_^194_["E_Z1 4?XT?\$OS1[#1
M117EG2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?+WAC_ )+?
MJ7_85\2_^D]]7U#7R]X8_P"2WZE_V%?$O_I/?5]0UWYA\>'_ .P2A_[<<^&^
M"?\ U\E^40HHHK@.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTGPY=:3:7UN+SPK\6?&FJ?VC+)K-JUK"=&%LZ1SF:[@98UE_&S_@[9_YQ_\
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M\"?A]\+OVV=5\3_";XK?#CPQI'@[4/B79>"_$OCCP%\1],\.:1#INC^*9H/
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MRY\94BYU4Y<D72;M"<DUR-K[VHHHKXP_1PHHHH **** "BBB@ KXB_X*7?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>9?"O_
M )&[5O\ L%7_ /Z<].KTVO,OA7_R-VK?]@J__P#3GIU;1_W?%_\ 7N/YLRG\
M=+UE^A]"T445Y)J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%_$/_D3=:_ZYVG_
M *<+2K?P0_Y$V;_L-WW_ *36-5/B'_R)NM?]<[3_ -.%I5OX(?\ (FS?]AN^
M_P#2:QKL?_(LJ?\ 84O_ $B H_QH_P""7YH]AHHHKRSI"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3X(P:O%+>VCW<4BVGCOXFVVGW*ZIX9^'EA(CRP&0V.K>.;VWET#PK+$D&O\
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M[!XJ45>4<-B:-=Q7=JE.32\V=U117RC^W9\7O^%"?L8?M2_&"+4KC2-3\!_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"OR+_P""G?\ P1\^ '_!2/1K7Q-JU[>?"O\ :%\*Z'=:5X,^+_ARQL;E=3M
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M*V_9I\(&["Z]JGB'QAH/Q/\ %]MIRR>6\_ASPG\+]8US0-=U!@5G@L-9\?\
MA"TD@$GG:M;7"QVTO^A)17T$N,,VE!P4,'"5K>UC1J.HG;XDIUITK]=:;C?[
M-M#Y.'AYD,*JJ2J9A5@G=T9XBDJ37\K=/#TZUNFE92_O7U/B?]A']@7X ?\
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M9K=C3/$Z7UY:W^E?UST5C5XHSFK%P^L1I)JS=*C3C*WE-J4HOSBXM=&CHP_
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M.K&#'E>(_"OQO^"5GHUYEG4_9H/&_C[P=XA7 4.?MF@VORR(!EPZIZQ\'O\
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MVU>72!<RC39-5MK+X W=G;ZC)9^2U]!:75S;17)EC@N)HE21OZ_O^"<GP/\
MCO\ LT_L:_!7]G[]HSQ!X'\6?$?X/Z%>^!HO$WP]\3>*?%'AS5?!.DZO?_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]5OV5OA0? _@\^*-7
MMO+\2>+X8;DI(K++I^A\2V%H5=5,<EUD7MRNW.6@C+'RJ^,OV;?A2_Q)\<P7
M>HV[/X6\,26^I:RSH_DWDZN7T_2MX9 3=31^9<*&+"TBE!7]XM?KLJJJJJJ%
M50%55 "JH& J@8      P!P*_H#P:X2YYU.*\=2]VFZF%RB,UO4LX8K&I-:J
M"<L-1DM.9XAV3A!G]H_19\-O:U:_B-FV'_=T77R_AJG5CI.M9TLPS6*:U5*+
MG@,--77M)8UV4Z5.0M%%%?T0?V^%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PFH_\C=IO_7WI7_I1
M'7=UPFH_\C=IO_7WI7_I1'6U#XI_]>Y_D9U?A7^*/YGN=%%%<)H%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7F7PK_Y&[5O^P5?_P#ISTZO3:\R^%?_ "-VK?\
M8*O_ /TYZ=6T?]WQ?_7N/YLRG\=+UE^A]"T445Y)J%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>)Y<*S7+[;>WGEC_ %!^'?Q1^&?Q?\-Q>,OA-\1/ OQ0\(3W#VD'BKX=^+M
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M@>%[;4FFF@%SXB^'WQE\(>'@\$HA=F\7>+/AQHGA1(6<@PW#ZTL%Q%F>"22
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /E[PQ_R6_4O^PKXE_P#2>^KZAKY>\,?\EOU+_L*^)?\ TGOJ^H:[\P^/
M#_\ 8)0_]N.?#?!/_KY+\HA1117 = 4444 %?A3_ ,'&GPIG^)7_  2]^)6N
MV=@NHWGP:^(GPL^*T,"65Y>WT4">(_\ A7.KW^GI9I)Y#:9H/Q&U74-4O;E1
M9V?AZUUF>=XPBR)^ZU?)G[>7PF_X7I^Q9^U1\)8V2.^\;_ ?XF:7HLLJVS0P
M>)(O"NI:AX8N)Q=QO"+>W\0V>F37# PS)#&[VUU9W*PW</9EU;ZOC\'7O94\
M31E)_P!Q5(\Z]'&Z?DSSLWPWUS*LQPJ5Y5\%B807_3QTI>S:\U446O-'\D?_
M  :D?%:QT+]H;]J?X+W-XMO=?$KX2>"_B!IUO*;:-+^?X2>*]1T6>""26+[3
M+?0V?Q;N+N.SM;E/-L;?4;N>UN$L!/9?W'U_F@?\$%/BK?\ PK_X*D_LW&WD
MQIGQ&N?&?PJ\06^^9/M=AXQ\%ZXNE1[H(;@_Z+XOL/#.I;)(3#+]A\F6:R20
MW]K_ *7]>YQ=0]EFSJI:8G#T:C?]Z'-0:^4:4?O^[YCP_P 3[?(%1;UP>+Q%
M%+M&HXXE/T<J\UZI^K^$?^"DW[9FA?L'_L@?%/X^W[PR^*K/3F\)?"C2)[>:
MXAU[XL>)[2]M_!MC<I';SQ#3K">WNO$>M&Z,$+Z'H6IPQS?;);6&;^#S_@C]
M^QIXA_X*4_M[KK7QADO?'7P^\'ZS>_'O]I+Q!XJ>]U>7Q[=7_B)M1C\-:_J'
M]H65Y?:S\4_%UW<#5KB2]:ZFT>'Q5JK1W;V4EO-] ?\ !P[^W>W[6O[7]K^S
M[\--477/A!^RY<ZEX(TR70YKF]MO''QGUQM/B^).M10K8V4EVOAN_L;#X9:'
M;%-7MTOO#7BC7_#FKW.E>-_+']9'_!&']@BW_8)_8Q\*>&/$FGPI\;?B[-;_
M !7^-=_+IZ6NI6&NZUIUM'X;^'IDNM*T[78-.^'7AI+/2[C1M6FO(;/QU?\
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M06NB:!:?\(VOQ%O=*M+&R@M].M)M.O\ Q_-I4T%FL@LK?3;/1Y'A;2A86/\
MHUU_EN?\G^_\%9>U[H?[3O[<'MXFMM,^&WC+XO\ _<NG7M(\*_#R3_J#2ZEI
M6D_\N4LW[O['AK$XG&8[&8_&UZE=83"2]ZH[QINK)2;A%6C#]W2J*T(I--GY
MWQG@\'E^69=E&686CAI9ACX+EI1M*K&A#D2JU'>=1^UKT'S5)R=TG<_T6O\
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MV9TL93BHX'%J4_8^SJR=25&-6;AR5(4XJI%04O:.$^?FCR_Z<OP^\:Z-\2O
M7@CXC>'/M'_"/>/_  AX:\:Z#]K^R_:_[&\5:-9:[I?VK[!=W]C]H^PW\'G?
M8[Z]M?,W?9[NXAV3/^''_!R7\8T^&G_!,[Q5X*AO+6WU+X\_%/X9?#*"%C<'
M4I--T?6)?BOJ\^G_ &:^M7@A\KX;V^F:I>74&H:>UCJ[Z3/;)=:Q8W4'[1_
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M&_BGIGQ,_P""HWQCL='N?MEE\+/"OPV^%C72B,0OJ>C^%+3Q%K]M!MABF/\
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MSA<;CJ7/F$*>$IX>;J58*EB,5[">*_=0G&G-RIT:BM4A/EM>-K,\R_X)@_\
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M@>:"Q=;VF.Q48\T<!EM!J>-QD_L_NJ7NT8R<55Q-2A0NI54?8GP<^&]I\+O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUI>:)X$\2W5A)++-X,3P5XNOM)BO=/\ ^$@U+1O$%GK/A*R_</Q?_P $#O\
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MO,O(;EIK![3P_P#X.N/C1#K7QE_96^ %AJT4G_" ?#WQO\4O$>DV=W?G;?\
MQ*U[2_#?AY]:ME/]D->6.G_#C6)=&4E]8L;/7]2FGCMM/UNPDO?W0_X-^?@U
M_P *?_X)>? RZNM.L].USXO:IXZ^,NN?9K/[--??\)5XEN](\*ZCJ$Y<MJ-Y
M=?#WPUX-*7C1P>58)9:<B2Q6$=W<^U4_V+A"G%KEGF.*4FNK7M'-2]'2PM/7
MM)+=GS5+_A1\0:T[\U/)\#RQ:?NJ7LHPE'3K&MCJWNOK"3Z'F'_!R7\8T^&G
M_!,[Q5X*AO+6WU+X\_%/X9?#*"%C<'4I--T?6)?BOJ\^G_9KZU>"'ROAO;Z9
MJEY=0:AI[6.KOI,]LEUK%C=0?RB?\$MOVN?VG?@]X/\ BU^RM^P7X!UG6?VO
MOVQO'?PWT:R^(446EZC9?#_X=_#?2_%T\EYHNF:Q%=:)I^LM<>-/$EWXB\<^
M*XHO#?@?PC9W6K.L^IO9:KX9_6?_ (.POBTEUXP_9!^!5M'*DFB>&OB3\6M:
ME:2X\BY3Q3JFA>#O#$<40*6IEL3X/\7-/)(+BX":A;K";.,S_;OLG_@V._8N
MTCX8?LS^)?VR?$VBPGXB_M$:CK'A3P/JEU;VQOM&^#'@GQ ^F7EOI\RS2WEE
M#XU^(6@ZAJ&L6UQ#:#4K/P=X,U&**>T2RO)^O"3P^7<*JMB*4*SQ6(=6%"I_
M#JUE52HJHD_?IQCAHUI0>DXP<'N<&/IXO...I8;"8B>&6!P<:%7%4?XM##.@
MY8ET9-/V=:<\9/#0J)-TYU.=:Q/*/@K_ ,&OFB^.8KGXD?MW_M9?%WQ[\7/'
M5O-XB\;6?PKNM(BU"Q\;ZM=17FI7.N?%KXI:7\2=6^)=PX:[.IZM<>#_  O=
M7VIW0F6ZG@LC/JOXM?\ !93_ ()(6W_!,3Q5\*O&OPH^)'B/QU\&OBI>:[8>
M';SQ=+I5K\2/ OC/PG]@U%M+UF]T"QT/3-=M-2TN_M]2T'Q+H>C:1)#>Z9K5
MAJNDZ4T&AWVO_P"CY7\4O_!V'\5K"_\ B/\ L>? ^UDVZGX3\$_%#XK:[#OA
M?S;#X@Z[X:\(^%)/+,/VBW\BX^&7C)=ZW'DWGVG:\/F6,;US9#G&:8W-J%&K
M7YZ$XUO:453IQI0IPI3E%0C&*Y>62A&+3N[I2<DV=G%/#N1Y;P_B:]#"*GBJ
M4L/['$.K5E7J5:F(IPFZDYSE[3FA*I.46N56;@H-1M^\?_!#S]KKQG^V1_P3
MY^'/CCXF^(KCQ=\4_AUXC\4_!GXA^*;V;S]3\0:KX-DL-3\.:MK4K;I[C7[W
MX>^)?!<NOZC=RSWFMZR;[7KJ7SM4>./Z#_X*/?MZ?#W_ ()W?LS^)?CKXQM(
MO$GB>XN[;PG\*/ATMZUC>_$+XA:K'-)8:3]L2"Y_LS1-(T^VU#Q+XIUB6+;9
M:#I%Y;V*WOB"_P!#TC4_S^_X-L?AGJW@#_@F/X9\0:I:0VD?Q@^,?Q4^)FDJ
ML"6]S<:3;W6C?#&"[O@#YLLUQ<_#6[DM)[A4>;2#IK0A[/[+-+_-K_P<=_M;
MZK\>OV\-7^">EZA>'X;_ ++.D67@+3+ 3ZK#IVH_$+7-/T_Q'\1?$3:7?&&"
M+4+6]O=/\#->P62K?6O@V*\M+R^TZ[M)VYJ&54<?Q'B\-"*6#H8BO5K1@[15
M.G42E2BXVY5*K)4[1:<8<W+9QNNW%9[B,JX/R_&SES9AB<'A:&'E4]^3JU:/
M-'$34N;GE"A%UFYWC.IRJ=^>S\L_9S_9Y_;=_P""^G[6OBOQO\2/B1=CP[X;
MFTZ^^)/Q+\0C5[CP+\'_  5K&MRR:=\-OA'X2CDN;"UU&6U.MWWA'P/;WFDV
M.I2Z=K/B#Q9XC34;O4M;U']Z_%'_  :F_LN2_#NZLO!?[2/Q]L?BRNG77V+Q
M+XHA^'>J_#N?5A;W7V(W7@?2?!NC>);73FNFL1="'XA7EREO%=&)I))X5M_V
M/_X)1_LB:1^Q9^PQ\$?A0FA-H?CO7_#6E_%'XSK<65YI^J77Q>\>:'H]]XJ@
MUBUOKB>>.^\*VUMI'@")BED9--\(:?))IMA.TUK'^C%3F'$6,6*E2RZJL+@L
M-+V6'ITH4^6<:;Y5.5XM.,VFXPTBH-)Q<KMUD_!^7O PKYQ0>/S+&P5?%U<1
M4JN5.=9<_LHVG%QG3349U+N<JBDU)1Y8K_,V\1_M&_M?_P#!.GX0_ML?\$I?
MCCIUW=:-XWTW1M#T;0[O68=5\/?#?6KWQEX0\9:KXY\ 74MC++J7@SXK?#N/
M4FBTRVN-'B@US6])\53V&G>(+7Q+IFH_IK_P:F_"&YUO]HW]IGXY3Z9;S:9\
M._@]X?\ AO9ZE=0[I+77?BCXN@UX?V6TD@C%PFC_  OU&#4)X(9+FUM-1@MG
MN+6WU5X;^+_@ZT\!>'](_:3_ &8/B/8V5O;^(?&_P9\4>&-?N88Y8Y-0M/ /
MC%+W0YKLBX-M/<0KXXU&T6X%G%>FU@MK:YO+NUM=.M]/_5G_ (-@?A#_ ,(/
M_P $_P#Q9\3KW3;BWU/XV_'CQAK%AJ<T.JVT>I>#? VD>'O ND06B7<@TR]M
M]/\ %^E?$$-JVD0#SKNZN=(O[J>XT-;>Q]S,,93EPS4QD*<*-;-)4E7Y%:,\
M0Y1IUY)7T4Z>'GWWO*\G*3^8RG+JM/C6EEU2O4Q&'R2%:6&]H^:5/"\DJV&I
MN22NZ=7&4[MV6G+%1@H1C_2!1117YV?KX5_F'_\ !1S2K?\ 99_X*_?M :MI
MFCS:=:^ _P!JC2_C78:/:PI R0>)=7\._&NUBTRWO[."T@M;F/Q DFDVYM7T
MJ&SFM8K5KK35AFF_T\*_ST_^#FWX<Q^#/^"DEOXL@L;>"/XN? #X9>-;N]MK
M98OM^J:)J'BWX9S?;[E+&U6ZU2UTOP%HT3^9<ZE<0:4VC1M=Q6YM;"S^LX0J
M)9C7H2^&O@ZD6NCE"=-JZ_P.I]_J?!>(5%O*,+BH:5,)F%&:E;6,:E.K%V?3
M]XJ3\[(_T)+2[M+^UMK^PN;>]L;VWAN[.\M)H[FUN[2YC6:WN;:XA9X9[>>%
MTEAFB=XY8W5T9E8$PZGJ>FZ+INH:SK.H6.DZ1I-C=ZGJNJZG=P6&FZ9IMA!)
M=7VH:A?74D5K96-E:Q2W-W=W,L<%O!')--(D:,P^8OV%?B+_ ,+;_8L_9-^)
M3R>9=^,_V=/@WK>JC?>2^3KUSX T$>(+3S]01+NZ^Q:VFH6GVR8-]M\C[5'+
M/%,DTGX\?\'''[?3_LT?LLV/[-7P[U^;3OC-^U-%J&E:E=Z/J<%OJ_@SX(Z+
M<6B^.-4N%M=075=.F^(EU-;_  ZT0W6F-IFN^'Y_B>UGJ5KJWAB.-_!PN JX
MK'PP$$_:2KRI2=O@C"3]I.2[0C&4FMW:RU:/J<;FN'P.55,UJN]*.&A7A%;U
M)58Q]C2CYU9SA!/9<UVTDV?R_?MW_';XC?\ !8K_ (*?6'AGX4G^U=!\1>,M
M(_9Z_9SL?LL5M9Z?\-M)\0:HX\9ZN( LKP:M=:CXG^)OB+4;^2>]TS0[P:4U
MR-+\/:=;6O\ H"_"7X>_ _\ X)Y_L?\ AKP1_:^E^"/@G^S7\+KR^\3>*KRW
MO8+06FC6]]XF\>^-[^QCGUK47U/Q3XANM>\5WVF6,FJ7MUK.LS6.EQ7<\UK!
M)_.'_P &QG_!/[_A&/"GBK]O_P")>A6DFL^.K/4?AW^SO%J%H9+W1?"EGJ5U
M8_$KX@6J7MH\=K=^*=4L+7P7X=U?3;BWU&WT'2?'5C*\^C^,-DGH?_!TK^U3
M?^!/V?/@Y^R9X9U::TO/CSXHO/'?Q(M;:&WD6[^'7PLN]+NO#^AZE+<;G@M=
M=^(U_HWB*R;3XOM3WGPW>.XO;.S>2SUCZ;,E',<RP/#^#?)@\$U2J2CK[\(-
MUYO2SG1IQG!.6]:512=I7/BLF=3*,FS3BW,8JIF&8QE7I1G=/V56HEA:2UYH
MT\16E3FU%OEPT*+2]RR_"O\ ;$_;_P#VU?\ @M-^TK8?L_? W2?'%A\*?&7B
M&ST3X5?LU^'-5:VTW4;#1;N74H/'OQCNK6XBT74M5L8XF\4>(-8URZ;P;\/=
M/T^,Z?,B:1=^(M5_9;]G+_@U3^$Z>"]+U']K#]HGXGZCX\U32;*\U/PO\"+?
MP=X1T#P?JUQ;6<E[H@\4^./#?Q'N?&T.G7(OH!K<'A[P:E\'@>/3($MF>^\@
M_P"#<&+]AS]G+X:_$K]I[]H#]IS]EWP#\=_B/KEQ\/\ P1X6^)7QH^%OA#QK
M\/?A=X:,<FKWZZ3XH\3:3K>DWGQ+\33O]M2;3VCF\.^"_"][IM^8-<U2UK^G
MO_AXO_P3X_Z/L_8V_P#$GO@E_P#-Q5YMF&-P57^S<FH5,-A<*HPE4HX=RG6J
MI+G?M)0DVHNT937OU)J4I3E&2(R'*,NS*C_;/$6*H8['XUNI"CB,5&,,/0;?
MLX^RC4BE*2?-&F_W=*G*$(TX34F_XL_^"JO_  0D\<_\$^/",?[3?[.?Q'\5
M_%'X)^&-?M9O%$VM06&B_%/X,O=:Y:6O@SQ%=:QX=?3K#Q7I9U.ZT[3;WQ/H
M.B^%K_0]=?3[W^P$TN\GOM'_ 'T_X-_O^"H/B[]MGX1^*?@5\>_$7_"1_M"_
M ?3]-O+7Q5<P7?\ ;/Q+^$DYL](T[Q/XFOMLEGJ/C+PUK<D>@>)M6>2TO?$%
MKJ/AO6;V#4==N/$>L77W%^U)^W3_ ,$^_B!^S+^T7X#C_;8_9#UR3QM\"?B[
MX131=,_:1^">IZEK#^)/A_XAT9=+T_35\77K:A>Z@UZ+2TL19W9NYYHX!;3F
M3RG_ (X?^#;;Q=JOAO\ X*A^!=&T^>XAM/B!\)OC!X1UV.&X\F.ZTJR\,KX\
MA@NX_*D^UVZZWX)T:Z6WWP;;NVMKKS3]F\F:E+$9OD..>94I?6LN3K8?$SI^
MSJ2BH.I*+7+%.\82A)I)23IMKGASN)0PG#W%.5K)Z\?J&<26&Q6#I5O;485)
M3C2A-6J3<??JTZE/FNX-58PE[*;IQ_T//%WBSPUX"\*>)_'7C36].\,^#O!?
MA[6O%GBSQ)K%REGI/A_PUX<TVYUC7=;U2[D(CM=.TG2[.ZO[ZYD(2"VMY97(
M537^<G^WE_P4#_:G_P""Q/[5VD? CX+MXRB^#GBKXAVO@3]G_P" &DZC=:/I
MOB9#K,D6A?$7XM:?!?MHEWXKFM$/B76]6UZXNO#?PHT&/48=/U&WTW3_ !#X
MEUO_ $/?C5\'? ?[07PG\?\ P4^)^G7VK_#[XF>&M0\)^+=-TW6M6\/7UYH^
MI($N(;?6-#O+#4[-B54MY%RL4Z!K6\BN;*:XMIORX_9C_P""2O\ P3Y_X)M_
M&X?M*>"/&7BKP=XDG\$^)/ ^EVGQ@^*OA1_!FGVGB"]\+#5-:TC^UM#T/6/[
M?A33TT>*XE\276G16?BS5K:XTR:XNM$FTOQLDQV!R]8G$5:,Z^8<CC@HNFIT
MHRY79W4N:,Y2LFU&\:::C+WY6^CXFRS-,WE@\)0Q-/#92YJ69R55TZ]2'.ER
MJ+AR2IQ@FXQ<[2JR3G!JG&_Y<_L^_P#!J9\(K3PK:7/[57[2GQ'\0^-[RQ@F
MOM%_9]M?#/@[PKX<U)XK7[3I]IXF^(WA+QUJ_C2QMYUO1!K$WA+P%/>13VK2
M:%8O:RK>?+O_  42_P"#:>S^ ?P6^)7Q^_9,^,WC#Q]I'PK\-7OC;Q'\(OBS
MIWAR;QA=>"O#6BSZKXVUOP]\0_"]OX6T;6-9T6UL;S6K+PA/X TN?5])6YT_
M3-;O?$5EINF>)OZNM:_X*(?L!^'?MZ:U^VY^R587.FV[W-YI\G[17PCDU6.-
M+8786/2(?%TNJ7-Q-;LDEK:6UI-=WGF1):PS/+$K_FM_P4$_X+.?\$[[']E/
M]H_X>^ ?VFO 'Q'^*GQ"^!7Q9\%?#[POX/T[QSXNTW5_$_B?P1>Z#IEOJ/B;
MPGX4U?PSHL*W'B"VN%;7M=T.UOS:WMC'J5I+:WUQ8=F$S7B2KC*4U]:JQG5@
MIT_JG[GV<I1YDXQI)0BH[S3C*,;RY]6WY^/R+@VCE]>F_J-"5.A4=.M]>2Q/
MM8P?))2E7;J3<[6IRC.$I-15-JT3\G/^#:W_ (*-?%[6OB]JO[#/Q>\:^)?B
M!X)\0>#]9\6?!.X\37YUS5/ 6N>#K2.^U_PI8:WK&K)JL7@O5O"\%W?V/ANV
MAUBVT76-'%QH]EHUGJOB.ZN/[4:_SQO^#9WX?WGB[_@I7:>*8;.::S^%GP.^
M*/B^\O%!%O9/K(T'X=VJRR&YMT,UTWC:9(+?R[Z65([B=+(1VL]_8?WX_&/X
MD:;\&_A#\5/B]K,4-QH_PJ^&_CCXD:K!<7ITVWFTWP-X8U3Q/?13ZBMI?M80
MR6NERI+>BPO3:HS3BTN3'Y+X\44*4,XY,/",95J-&<X122=>I*<;VT2<XJ#>
MUY-R>K;.C@;%5ZO#RJ8NK*<,/B,13I5*CE)QPU.%.:3D[MQISE5C'5J,(Q@K
M**2_S8O^"D/[0'A_Q]_P5[^/OQA\=QWGC;P)X!_:7M/#MUI'AB]TZ&7Q%X(^
M FIZ1X#@\/Z!J6JZ??Z+I_\ PD6F^!OLO]NRZ-KNF07>J77B%M*\4(SVVJ?K
MS^SM_P $TOVL/^"Y/Q O_P!O#]OKXD>)?@]\&/%C0VOPA\&>$].CA\1ZE\/;
M;4EGM-(^%>D>)H]2TCX?_#2*SN-0&B^,M<T[Q/K/C/7I+KQ=>:-X@AU27Q'J
M_P"$W_!.7]EV_P#^"@/[>'PB^#'BS4KN;0_'?C+5O'7QBUTS36]_<>!O#,%_
MXX^((BOK.-I;#6_%MI87'AC1-32"2'3_ !)XCTN]N(OL<,^W_4RT31-&\-:-
MI'ASPYI&F:!X>T#3+#1-!T'1+"UTK1M$T;2K6*QTO2-(TNPB@L=-TS3;&""S
ML+"S@AM;.UABM[>*.&-$7W,_S#^R(8+!X-0CC(82-)8AQ4I8?#+EA:DI)QC.
MO*E[SLVHTUI=QE'Y?A3*?]8*F99AF+J2RZKF$Z[PBFX0Q>-ES57+$.'+*=/#
M0K^Y&ZBYUI;)3C/\#?V&/^"!WPF_81_;8L/VFO!7Q3\4?$;P5X8^'GB[2OA[
MX<\?0:7'XW\'_$#Q66\-WFM7FL^&](TC0/$VE2_#G5?$FAJR:1X<N;34M3EN
M/L-]!/$=-_H%HHKX?%XW$XZI&MBJKK5(TXTE.2BGR0;<5:*2WDVW:[;;=VVS
M]/P&78++*,L/@:$</1G5G6E3BY->TFHQE*\G*6JA%)7M%)1C:*21117QO_P4
M&_:=/[&W[&/[07[24%O#=ZO\-_ Y;PI;7,4T]G-XZ\6ZSI7@7P E_#!;73R:
M<?&OB?0/[15HA#]B%P;B>UMQ+=0XTJ4ZU6G1IKFJ5JD*5./>=22A%?.32.BO
M6IX:A6Q%:7+2P]*I6JRWY:=*$JDY?*,6S^;3_@O+_P %KO&W@KQCXH_8?_9
M\7OX9O=#MM0\/_M%?%_0O-C\2VNM7D-_IFJ?"#P3?W5B@T"72+.6*Z\7^-=
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M LQU'Q?8Z]=V5M96\<;17L(1;JX>:]N_+X2P_M,V=62TPN'K5+]%.?+12?\
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M3P-H&OB:R@U$ZUX#ATGQ=IFI:UJ=[?ZCXCLM2T$ZHRZKHM[?:I_J;5_EI_\
M!7?P%X?^&O\ P4N_;*\*^%[*WT[1C\9M9\3P6-I'+#:VMWX\L-,\=ZK#;027
M%R+>W35O$E\(;>W>*RMX]L.GV>GV*6]C;]/#.8U<RK2H8]K$5<(GBL+7G%>U
MI\R]A5BY1MS)JK%Q35[W<F^6')P\:Y/A\EPT,3E7-@Z&826!Q^%ISDZ-90:Q
M-":A)RY91E0DI.+LU914>:K[3^RK_@VJ^$-S\./^":ND>,[_ $RWLKSXY_&'
MXD_$BUNO)V:C>Z%I$VE?"[2_MKR2/.+=;KX>ZM=Z9 5M[8VFH?VC;6[?VG+>
MWO\ 0%7RC^PG\(?^%"?L8?LM?!^73;C2-3\!_ ?X8Z/XEL;N'5;6[C\9-X3T
MR^\;SW5CK<DFIZ9<7OB^[UN]FTFY$/\ 9,EPVFPVMG;VL5I#]75\9F5?ZUC\
M9B-U5Q%64?\ !SM4UN]H**WMVT/TC)\+]2RK+L*U:5'!X>$U_P!/?9Q=5_.H
MY/YA1117$>D?'?C[_@GO^PW\3O&#_$/QK^R?\!M5^(,WB1O&-[X]M?AOX:T+
MQMJGBMM4M-:?Q'K7BSP]8Z5X@US67U2R@O)-0U?4;VY>5KD/(R7UZMQ]B45Y
ME\8?C/\ "C]G[X>>(OBQ\:_'_ACX9_#KPI:->:WXK\6:G#IFG0?*WV:PM%<M
M=:MK>IS*MEH?A[2+>_U[7]3FMM*T33M0U*ZMK275SKUW3IN=6LT^2E3<IU&G
M)I<M.#;LY-17+%:M)6=D8*GAL*JU90H8=27M*]51ITE)03?/6FE%-13D^:;]
MU-NZ39UGB[Q9X:\!>%/$_CKQIK>G>&?!W@OP]K7BSQ9XDUBY2STGP_X:\.:;
M<ZQKNMZI=R$1VNG:3I=G=7]]<R$)!;6\LKD*IK_,8_;6^+WBW_@JQ_P4S\5:
MY\&M*O-4E^.?Q-\'?"3X%:)J-M-I#1^%=-ATCP'X-O\ 6X9)]3?0(-0MK-_&
MOC"ZN9WL]"DU/7;^=;'3K1K>U^U?^"HG_!9GXZ_\%+/%[?LP_LN^&O'WA[]G
M7Q/K?A[1M!^&VBZ%/J'QB^/7B:"Z=]/C\3:7X4EUJ^N=,O=9GM&\/?#'0[C5
M;>ZO=+TG6M7?4M:6PLM"_?G_ ((?_P#!&"/]BG2M._:?_:+M$O/VJO%6@7-M
MX?\ "<=TMQI7P*\+>(+,PZAH[R6LKV>L?$;6]/F:S\5:JCW&G:#9RS^&- DF
M1]9UG6_L\#1APUA*N88YQ_M#$TG2PF$3O*,7RR?M+;>^H.JT[4XQ4$W4GR'Y
MSFF)J<:9A0RG+%/^R,%7C7Q^/:<83E'FA:DW\5J<IJA%KFJSFZCC&E3YW^]'
M@KP[X7^ /P4\)>$YM6^S^"_@I\+=!\.RZYJ"R+Y'A?X<>$[339-6O41KJ8>5
MI.C&\N55[F0;7 :9L%O\Q+_BL/\ @J+_ ,%+_P#F)0ZG^UK^TO\ ].%K?^#O
MA[K_ (F_[?[18_AM\+[3_J+W$MIX;_YC5Z_^F?W]?\%IOBW)\&?^"7W[8/B6
MVDMQ?>)?AD/A):6\SV@EO(_C7XAT3X3:O':0W; 7%Q:^'O&.L:HZ6ZO=P6EA
M=7MNH>U\Q/Y$/^#:'X)6OQ._X*+K\0=6T:+4=+^ 7P?\<>/[&]NI)!:Z=XO\
M03:3\.- (MTCEAO=0;2_&'B>^TZ&\$<%I)I<FL03QZII>G+)'#K^JY;G&;RU
MJQC.E3D[?'&"J];?Q*M6CS=^563>A?%Z6.SGAWA^"M0E4IUZU.-[>RG5]BNC
MLZ5"AB>7LIZV6I_H,^&?#>@^#?#?A_PAX6TNTT/PQX4T32O#?AS1-/C\FPT?
M0=#L+?2](TNRBR?*M-/T^UM[2VCR=D,*+DXS6W117Q;;;;;;;=VWJVWNV^K9
M^DI)))))))))622T226B26B2V/X=/^#KSQ"ES^T/^RAX3#0F31?@QXR\0NBQ
M3K.J>)_'"Z;&TD['[+)"[>$9!!%"!/"Z7#W),<]J!_1=_P $.K>>V_X)4?L=
MQW,$UO(W@KQA<+'/&\3M!=_%7Q[=6LZK(JL8;FUFAN;>0#9-!+'-&S1R*Q_C
MC_X.+?BW%\3_ /@J#\3]$MI+B:Q^#'@+X9?"2UFG>Z\IY;;P]_PL'5X[."[;
M-M;VGB'XA:Q8LEO%!:W-W:W6H0+.EY]MNO[M?^">OPRN/@Y^PK^R'\-;ZS:P
MUCPO^SM\)8/$=DXA!M?%=_X,TC5_%L(\FULU9$\2ZAJHC>2 7+IM>\DN+MIK
MB7[#-XJCPWDE"6DYRC72V?+*E5J/3R^L1OZZ[GYYP_+ZUQGQ+BHZTZ5.6$;5
MVN:%:A16NVOU.;7=7:ND=3\9_P!BW]D7]HFZU#4_CC^S1\#_ (HZ_J=I%8W7
MBSQ?\-/">J>-Q:P1VL$$5GXXDTM?%^F^3;V5I:Q/IVM6LB6EO%:JXMU$5>Z>
M"?!GA?X<>#/"/P\\#Z+9^&_!7@/PQH'@SPAX=T\2"PT'POX7TJTT/P_HMB)I
M)9A9Z7I-C:6-L)999!# @>1VRQZ>LS6];T;PUHVK^(_$>KZ9H'A[0-,O];U[
M7M;O[72M&T31M*M9;[5-7U?5+^6"QTW3--L8)[R_O[R>&UL[6&6XN)8X8W=?
MDG5JSC&DZE2<(OW*;G*48MJWNP;:3:LM%>VA]]&C0ISJ5XT:-.I-?O:T:<(S
MG%/F_>5$E*23N_>;2>IIU_G=?\'$_P"W'X/_ &L_VQ-#^&GPLU^'Q/\ "[]E
MOP]K7@*'Q#92&?1=?^*GB+5;>]^*6I^'+M;AH+[0]/71/"'@M=0CLX$U'6?!
MVM:CIU[K'AR[T#4)/N;_ (+ ?\'!]UXXB\4_LQ?L#^(M0TCPBW]M>%_BA^T?
M9K%:ZGXOB9GT^[T/X(7MO>37&E>%)[<W,5[\2)(;+7]<DE!\%1Z-H]G;>*/%
M.Y_P0U_X(:Z[=:[X/_;2_;2\'ZOX:L/#6KV/B;X$? CQ-8WFC:[JVNZ->1WF
MC_$WXFZ/>1VVH:5H&E:A;0W_ (+\%W\,%YXHO(+?Q#XAMXO"$6G:=XT^PRG!
M0R.D\YS3]W4]G*."PETJTY5(M-N+UC.4'RJ/_+N$YRJJ+LE^>9_F53B>O'AS
M(_WU'VL)YECTF\-3A2FI**FG:5.%1<\I?\O:E.G"@YW;?]$7_!(_]F3Q%^R/
M_P $]OV<O@YXWTZ;2/B#%X7U'QU\0-)NGN?MVB^+/B7X@U7QW>^&]2@N$C2S
MU7PC::]8>$M6M;2,6<>I:%=-%/?L\FI7GY@_\'0_Q_M/A]^Q/\.O@-:W>H0^
M(?VB/BS9W,]K;W<EK8WG@+X/06OBCQ&-12&[B?4?L_C36?AA+::==6=WIWG$
MZI++:ZCI6E>?_2_7\RO_  6@_P""//[8O_!23]HWP%\2/A'XV_9S\'_#?X=_
M";3O >E6'Q)\=_%*Q\4ZEKTWB;Q)XD\0ZW/I'AGX/>*]!TNSE35M)TBSBMM9
MOKVZCT4W]]<1BZMM,TSR,JQ%&KG4,;CZL*,/;5<7.4FU'VK<ITXQW:2JRBTM
M;1C;;5?0Y]A,30X:J9;E6'J8BI]6P^7TH05YJ@E"E5G+9-NA&:DVTN:=[O9_
MS6_\$XO^"M.N?\$S/@O\9M$^#OPD\+>.?C=\:?'GA6_U/Q/\1AJA\"Z!X%\!
M^'=9MO#M@=-\,^(=$\1>)=9N?$7B[Q'=/;'4?#6GZ'I\6^.^UZZU]XO#?1S_
M /!PU_P5DE\0KK4?[1NA6NFC4;>^/A&#X'? MO#S6T,L4DFCM<W/PZN/%8TZ
M[2-X+B5?$ZZLL4TIM-4M9A#-#_7A_P $YO\ @B)^RC^Q1\/O#^H_$/P#X%^/
MG[25]I;OXY^*GC708_%&A:3?ZC"JWGAWX6>&/%$-UI/AG0-*A>YTF'Q0FC67
MCGQ5;76ISZY?V6D:G:^$=#_53XP? OX-?M!>$;[P%\;_ (7>!?BMX0O[>YMY
M="\=>&=*\1VD'VI8P]UIC:C;3W&CZG%)!;W-EJ^DS66JZ?>VMG?V%Y;7MI;3
MQ>UBL^R3ZY6J+*88[VLU[;%5_9RE)0BJ<94:56G52BH12BN:BVDG))MV^;P/
M"O$JR[#4GG]3+'0IMT,!A55C3INI*564<17H5J+E4=24I5'R8B,92DH2E&R/
MYP_^"6?_  <4Z/\ M->/] _9[_;*\->!_A)\2_%,T.E_#_XM>$[S4-(^&GC?
MQ#/+';:=X/\ $>@>(+S5[CP/XHU8[1I.M#Q1?^&O$^LW#:-!IOA*\;1;'6_Z
MD:_S$/\ @L'^PEI?_!.O]M/5OAI\.;W6A\+/&'AO0_B_\'+K4+^:\UK0O#NM
M:GJ^EW/ANYUI1'/<WWA#Q;X;URPTV[GEDUF3P\GAW4M5N+C4;Z2\N/\ 0:_X
M)R?'K5?VG/V%_P!ESXX>(;FXOO%/C7X1>&D\9ZE=#;-JWCGPO'+X.\;ZR5\J
M()'K'BSP]K.IPQJK+'#=QHDLZJ)Y.#/\NP=*CA,SRY<F%QJ2=+6T)RASQY4V
MW'F2FIPNU"<+1T=EZG"><9C7Q.89)G$E4Q^6MM5].:K2C45.?.THJ?+*5*5.
MKRJ52G43G[RYI?:M%%%?+GW 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?+W
MAC_DM^I?]A7Q+_Z3WU?4-?+WAC_DM^I?]A7Q+_Z3WU?4-=^8?'A_^P2A_P"W
M'/AO@G_U\E^40HHHK@.@**** "BBB@#_ "G/&%E=_L3?\%(]:C:!=$?]EO\
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MZ0UPR6HUWQEXHU#1?">A?;);>Q_MC6;'[;<VMIYUQ%[U7X/_ /!R#::_<_\
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M-3@N"EM#-K-[INH&*33KC^P?_@X0_P""EW@/]GK]G'QI^R%\/O$6D>(?C_\
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MXH6RL/A7X,_L_P#_  6 ^"%KJ]_^SS\$O^"DWPAL?'-OH=WKUY\&?AM^T_X
MM?&-II4>H3>&[G5[CP1HNDP^(;?38=<U670YKQ[N.SCUC4'L&C74+DS?4/\
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ME4J0]E4J4J<YT^9S]G.45*4.9Q@Y<DFX\SA!NU^6-[(HHHJ#4**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "OB+_@I=_RCM_;G_[-*_:"_P#56>**^W:^(O\
M@I=_RCM_;G_[-*_:"_\ 56>**Z<%_OF$_P"PFA_Z=@<F/_W'&_\ 8)B?_3,S
M^/7_ ((Q_P#)H/Q[_P"SD? /_JL/%-?I_7Y@?\$8_P#DT'X]_P#9R/@'_P!5
MAXIK]/Z_G7Q\_P"3CYC_ -@&6?\ J,C_ "U\<O\ DM*'_8@RO_TK$A1117XP
M?C@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(<+^^QV98BAS48-.4:4*D94U-+6+JUU3]G>R<:=23:25_P"Z'_@@_P#"^_\
MA9_P2Q_9?L=6DCDU3QII/C/XH7"P72W5I#8?$+Q_XF\1>&8[=Q:VKPR?\(A=
M>'Y-2M9OM+6VM2:G#'=2VZ0!/XL?^"U'Q&U']I/_ (*P_M&:?X4']JOHOQ"\
M+?L_>#]+\[2[?;K/P]T;0?ASK&E_V@Z:=;_Z9\2++Q/<_:-7N6;3_P"T/L4]
M^MC80^3_ *5/A'PGX:\!>%/#'@7P7HFG>&?!W@OP]HOA/PGX;T>V2STGP_X:
M\.:;;:/H6B:7:1@1VNG:3I=G:V%C;1@)!;6\42 *HK_+[_8BU#3/C%_P5B_9
MP\1_$65=(C\>_MO>"?&>M6NJ:7;PK<>(=4^+MMXIL?#&HZ//]IMX%\0>)FLO
M#-WI[F:. :E);AGV!CU<.5?;8[.LU<?>C2JU%!ZM+$5:E>VG5*@HZ=&TMSBX
MQH/#Y9PSD,9^[4KT*$JBT3^J4:.%4FW9)-XIS?-I=)O8_P!-7X(?#33?@O\
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M[ XN.7JI]8PM&I*:QN.UJ.G'VJ:CBE%2C44XSBDE&<91LK67\;?_ !"3?]9
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MA=X>\(VD5VT=P98;*\\0^)O&TT]O!*]K''<SV-M)=1VMQ*UI9M?1PZ=\4?\
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M(T_\//\ P'\7/&__  T?_P */_X59XNT#PK_ &9_PJ#_ (67_;O]N:-<ZO\
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M@*_8;\':K^VU_P %0_@38^+].E\3S?&;]J.#XI?$S3-0O-5U637/#=IXJO\
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M^R])T/4[[^UK1-7CN/[>^QH^E-97(U7[D_X(@?L9?$[]A[]A+0OAC\:_#_\
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MVL?%'Q#<7VE7>OZ%\/-&LK?4HE;0!96WSUI?PY\ _M&_\%5?A'^SG\)KM?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?$7_!2[_E';^W/_ -FE?M!?
M^JL\45]NU\1?\%+O^4=O[<__ &:5^T%_ZJSQ173@O]\PG_830_\ 3L#DQ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *X34?\ D;M-_P"OO2O_ $HCKNZX34?^1NTW_K[TK_THCK:A\4_^O<_R
M,ZOPK_%'\SW.BBBN$T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8;_@G+\5%\?? _P+\6];U*U;4M$T#XO?L@WVN>/)M=T:>6R-Y9:EX6\'PO\
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M%?@[X<)XUUWPMX::Z;2KT>(-:\8_$"[MM4U.Q\-R:1X5L/#D^J7>D>(?MO\
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M&RM8HK:TM+:*."W@CCAAC2-%4?C?_P $.?\ @GS=?L'_ +(=G+\0/#\>C?M
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MYQDN!SO#+#8V$GR-RHUJ;4:U";5G*G)J2M)64H3C*$K+FBW&+7^9%;_L_?\
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M@/\ P5B/_FH^'_XASDG_ $%9K_X/PG_S"?YI/_$/Y_P5S_Z-*_\ ,\_LR_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ^7O#'_);]2_["OB7_TGOJ^H:^7O#'_);]2_["OB7_TGOJ^H
M:[\P^/#_ /8)0_\ ;CGPWP3_ .ODORB%%%%<!T!1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=_\ */-?><-17<_\*P^)?_1//'/_ (26O_\ ROH_X5A\2_\ HGGCG_PDM?\
M_E?1_8^;_P#0JS+_ ,(<5_\ *O-?>'^K7$?_ $(,[_\ #5CO_E'FOO.&HKN?
M^%8?$O\ Z)YXY_\ "2U__P"5]'_"L/B7_P!$\\<_^$EK_P#\KZ/['S?_ *%6
M9?\ A#BO_E7FOO#_ %:XC_Z$&=_^&K'?_*/-?><-17<_\*P^)?\ T3SQS_X2
M6O\ _P KZ/\ A6'Q+_Z)YXY_\)+7_P#Y7T?V/F__ $*LR_\ "'%?_*O-?>'^
MK7$?_0@SO_PU8[_Y1YK[SAJ*[G_A6'Q+_P"B>>.?_"2U_P#^5]'_  K#XE_]
M$\\<_P#A):__ /*^C^Q\W_Z%69?^$.*_^5>:^\/]6N(_^A!G?_AJQW_RCS7W
MG#45W/\ PK#XE_\ 1//'/_A):_\ _*^C_A6'Q+_Z)YXY_P#"2U__ .5]']CY
MO_T*LR_\(<5_\J\U]X?ZM<1_]"#._P#PU8[_ .4>:^\X:BNY_P"%8?$O_HGG
MCG_PDM?_ /E?1_PK#XE_]$\\<_\ A):__P#*^C^Q\W_Z%69?^$.*_P#E7FOO
M#_5KB/\ Z$&=_P#AJQW_ ,H\U]YPU%=S_P *P^)?_1//'/\ X26O_P#ROH_X
M5A\2_P#HGGCG_P )+7__ )7T?V/F_P#T*LR_\(<5_P#*O-?>'^K7$?\ T(,[
M_P##5CO_ )1YK[SAJ*[G_A6'Q+_Z)YXY_P#"2U__ .5]'_"L/B7_ -$\\<_^
M$EK_ /\ *^C^Q\W_ .A5F7_A#BO_ )5YK[P_U:XC_P"A!G?_ (:L=_\ */-?
M><-17<_\*P^)?_1//'/_ (26O_\ ROH_X5A\2_\ HGGCG_PDM?\ _E?1_8^;
M_P#0JS+_ ,(<5_\ *O-?>'^K7$?_ $(,[_\ #5CO_E'FOO.&HKN?^%8?$O\
MZ)YXY_\ "2U__P"5]'_"L/B7_P!$\\<_^$EK_P#\KZ/['S?_ *%69?\ A#BO
M_E7FOO#_ %:XC_Z$&=_^&K'?_*/-?><-17<_\*P^)?\ T3SQS_X26O\ _P K
MZ/\ A6'Q+_Z)YXY_\)+7_P#Y7T?V/F__ $*LR_\ "'%?_*O-?>'^K7$?_0@S
MO_PU8[_Y1YK[SAJ*[G_A6'Q+_P"B>>.?_"2U_P#^5]'_  K#XE_]$\\<_P#A
M):__ /*^C^Q\W_Z%69?^$.*_^5>:^\/]6N(_^A!G?_AJQW_RCS7WG#45W/\
MPK#XE_\ 1//'/_A):_\ _*^C_A6'Q+_Z)YXY_P#"2U__ .5]']CYO_T*LR_\
M(<5_\J\U]X?ZM<1_]"#._P#PU8[_ .4>:^\X:BNY_P"%8?$O_HGGCG_PDM?_
M /E?1_PK#XE_]$\\<_\ A):__P#*^C^Q\W_Z%69?^$.*_P#E7FOO#_5KB/\
MZ$&=_P#AJQW_ ,H\U]YPU%=S_P *P^)?_1//'/\ X26O_P#ROH_X5A\2_P#H
MGGCG_P )+7__ )7T?V/F_P#T*LR_\(<5_P#*O-?>'^K7$?\ T(,[_P##5CO_
M )1YK[SAJ*[G_A6'Q+_Z)YXY_P#"2U__ .5]'_"L/B7_ -$\\<_^$EK_ /\
M*^C^Q\W_ .A5F7_A#BO_ )5YK[P_U:XC_P"A!G?_ (:L=_\ */-?><-17<_\
M*P^)?_1//'/_ (26O_\ ROH_X5A\2_\ HGGCG_PDM?\ _E?1_8^;_P#0JS+_
M ,(<5_\ *O-?>'^K7$?_ $(,[_\ #5CO_E'FOO.&HKN?^%8?$O\ Z)YXY_\
M"2U__P"5]'_"L/B7_P!$\\<_^$EK_P#\KZ/['S?_ *%69?\ A#BO_E7FOO#_
M %:XC_Z$&=_^&K'?_*/-?><-17<_\*P^)?\ T3SQS_X26O\ _P KZ/\ A6'Q
M+_Z)YXY_\)+7_P#Y7T?V/F__ $*LR_\ "'%?_*O-?>'^K7$?_0@SO_PU8[_Y
M1YK[SAJ*[G_A6'Q+_P"B>>.?_"2U_P#^5]'_  K#XE_]$\\<_P#A):__ /*^
MC^Q\W_Z%69?^$.*_^5>:^\/]6N(_^A!G?_AJQW_RCS7WG#45W/\ PK#XE_\
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M8_\ ^4'G]%>@?\*F^*G_ $33X@?^$;XC_P#E;1_PJ;XJ?]$T^('_ (1OB/\
M^5M+^R,V_P"A9F/_ (18G_Y5YK[P_P!6>(_^B?SO_P -6/\ _F<\_HKT#_A4
MWQ4_Z)I\0/\ PC?$?_RMH_X5-\5/^B:?$#_PC?$?_P K:/[(S;_H69C_ .$6
M)_\ E7FOO#_5GB/_ *)_._\ PU8__P"9SS^BO0/^%3?%3_HFGQ _\(WQ'_\
M*VC_ (5-\5/^B:?$#_PC?$?_ ,K:/[(S;_H69C_X18G_ .5>:^\/]6>(_P#H
MG\[_ /#5C_\ YG//Z*] _P"%3?%3_HFGQ _\(WQ'_P#*VC_A4WQ4_P"B:?$#
M_P (WQ'_ /*VC^R,V_Z%F8_^$6)_^5>:^\/]6>(_^B?SO_PU8_\ ^9SS^BO0
M/^%3?%3_ *)I\0/_  C?$?\ \K:/^%3?%3_HFGQ _P#"-\1__*VC^R,V_P"A
M9F/_ (18G_Y5YK[P_P!6>(_^B?SO_P -6/\ _F<\_HKT#_A4WQ4_Z)I\0/\
MPC?$?_RMH_X5-\5/^B:?$#_PC?$?_P K:/[(S;_H69C_ .$6)_\ E7FOO#_5
MGB/_ *)_._\ PU8__P"9SS^BO0/^%3?%3_HFGQ _\(WQ'_\ *VC_ (5-\5/^
MB:?$#_PC?$?_ ,K:/[(S;_H69C_X18G_ .5>:^\/]6>(_P#HG\[_ /#5C_\
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M-=)_5Z%.4ESRFV4445]4?HH4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<)J/_(W:;_U
M]Z5_Z41UW=<)J/\ R-VF_P#7WI7_ *41UM0^*?\ U[G^1G5^%?XH_F>YT445
MPF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^7O#
M'_);]2_["OB7_P!)[ZOJ&OE[PQ_R6_4O^PKXE_\ 2>^KZAKOS#X\/_V"4/\
MVXY\-\$_^ODORB%%%%<!T!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW1_^058?]>L/_H(K2K@G\<O\4OS9T0^"/^&/Y(****DH**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *X34?^1NTW_K[TK_ -*(Z[NN$U'_ )&[3?\ K[TK_P!*(ZVH?%/_
M *]S_(SJ_"O\4?S/<Z***X30**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7WAS1_FC]Z_KJOO.DHKF_P#A,O"/_0T^'?\ P=:;_P#)-'_"9>$?^AI\._\
M@ZTW_P"2:/95?^?=3_P"7^7FOO#FC_-'[U_75?>=)17-_P#"9>$?^AI\._\
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MZ2BN;_X3+PC_ -#3X=_\'6F__)-'_"9>$?\ H:?#O_@ZTW_Y)H]E5_Y]U/\
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M>:^\.:/\T?O7]=5]YTE%<W_PF7A'_H:?#O\ X.M-_P#DFC_A,O"/_0T^'?\
MP=:;_P#)-'LJO_/NI_X!+_+S7WAS1_FC]Z_KJOO.DHKF_P#A,O"/_0T^'?\
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M?^ 2_P O-?>'-'^:/WK^NJ^\Z2BN;_X3+PC_ -#3X=_\'6F__)-'_"9>$?\
MH:?#O_@ZTW_Y)H]E5_Y]U/\ P"7^7FOO#FC_ #1^]?UU7WG245S?_"9>$?\
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MO-?>'-'^:/WK^NJ^\Z2BN;_X3+PC_P!#3X=_\'6F_P#R31_PF7A'_H:?#O\
MX.M-_P#DFCV57_GW4_\  )?Y>:^\.:/\T?O7]=5]YTE%<W_PF7A'_H:?#O\
MX.M-_P#DFC_A,O"/_0T^'?\ P=:;_P#)-'LJO_/NI_X!+_+S7WAS1_FC]Z_K
MJOO.DHKF_P#A,O"/_0T^'?\ P=:;_P#)-'_"9>$?^AI\._\ @ZTW_P"2:/95
M?^?=3_P"7^7FOO#FC_-'[U_75?>=)17-_P#"9>$?^AI\._\ @ZTW_P"2:/\
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M[SI**YO_ (3+PC_T-/AW_P '6F__ "31_P )EX1_Z&GP[_X.M-_^2:/95?\
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M)17-_P#"9>$?^AI\._\ @ZTW_P"2:/\ A,O"/_0T^'?_  =:;_\ )-'LJO\
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MN;_X3+PC_P!#3X=_\'6F_P#R31_PF7A'_H:?#O\ X.M-_P#DFCV57_GW4_\
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M_P!_$_QH^UVO_/Q#_P!_$_QHL^S_ *_X=?>%UW7]?\.OO+%%5_M=K_S\0_\
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M(V/_ (%V_P#\<HY9?RR^Y_UU7WAS1_FC]Z_KJOO+U%4?[3TW_H(V/_@7;_\
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MWM#_ .@QI?\ X'VO_P =HY)_RR_\!?\ D%UW7WHUJ*R?[>T/_H,:7_X'VO\
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M )!==U]Z-:BLG^WM#_Z#&E_^!]K_ /':/[>T/_H,:7_X'VO_ ,=HY)_RR_\
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MO_QVC^WM#_Z#&E_^!]K_ /':.2?\LO\ P%_Y!==U]Z-:BLG^WM#_ .@QI?\
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M?>C6HK)_M[0_^@QI?_@?:_\ QVC^WM#_ .@QI?\ X'VO_P =HY)_RR_\!?\
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MN?\ X#+_ ""Z[K[T8_Q#_P"1-UK_ *YVG_IPM*M_!#_D39O^PW??^DUC7/\
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M_P T?O7]=5]YTE%<W_PF7A'_ *&GP[_X.M-_^2:/^$R\(_\ 0T^'?_!UIO\
M\DT>RJ_\^ZG_ (!+_+S7WAS1_FC]Z_KJOO.DHKF_^$R\(_\ 0T^'?_!UIO\
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MPF7A'_H:?#O_ (.M-_\ DFCV57_GW4_\ E_EYK[PYH_S1^]?UU7WG245S?\
MPF7A'_H:?#O_ (.M-_\ DFC_ (3+PC_T-/AW_P '6F__ "31[*K_ ,^ZG_@$
MO\O-?>'-'^:/WK^NJ^\Z2BN;_P"$R\(_]#3X=_\ !UIO_P DT?\ "9>$?^AI
M\._^#K3?_DFCV57_ )]U/_ )?Y>:^\.:/\T?O7]=5]YTE%<W_P )EX1_Z&GP
M[_X.M-_^2:/^$R\(_P#0T^'?_!UIO_R31[*K_P ^ZG_@$O\ +S7WAS1_FC]Z
M_KJOO.DHKF_^$R\(_P#0T^'?_!UIO_R31_PF7A'_ *&GP[_X.M-_^2:/95?^
M?=3_ , E_EYK[PYH_P T?O7]=5]YTE%<W_PF7A'_ *&GP[_X.M-_^2:/^$R\
M(_\ 0T^'?_!UIO\ \DT>RJ_\^ZG_ (!+_+S7WAS1_FC]Z_KJOO.DHKF_^$R\
M(_\ 0T^'?_!UIO\ \DT?\)EX1_Z&GP[_ .#K3?\ Y)H]E5_Y]U/_  "7^7FO
MO#FC_-'[U_75?>=)17-_\)EX1_Z&GP[_ .#K3?\ Y)H_X3+PC_T-/AW_ ,'6
MF_\ R31[*K_S[J?^ 2_R\U]X<T?YH_>OZZK[SI**YO\ X3+PC_T-/AW_ ,'6
MF_\ R31_PF7A'_H:?#O_ (.M-_\ DFCV57_GW4_\ E_EYK[PYH_S1^]?UU7W
MG245S?\ PF7A'_H:?#O_ (.M-_\ DFC_ (3+PC_T-/AW_P '6F__ "31[*K_
M ,^ZG_@$O\O-?>'-'^:/WK^NJ^\Z2BN;_P"$R\(_]#3X=_\ !UIO_P DT?\
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MX3+PC_T-/AW_ ,'6F_\ R31[*K_S[J?^ 2_R\U]X<T?YH_>OZZK[SI**YO\
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MH_>OZZK[SI**YO\ X3+PC_T-/AW_ ,'6F_\ R31_PF7A'_H:?#O_ (.M-_\
MDFCV57_GW4_\ E_EYK[PYH_S1^]?UU7WG245S?\ PF7A'_H:?#O_ (.M-_\
MDFC_ (3+PC_T-/AW_P '6F__ "31[*K_ ,^ZG_@$O\O-?>'-'^:/WK^NJ^\Z
M2BN;_P"$R\(_]#3X=_\ !UIO_P DT?\ "9>$?^AI\._^#K3?_DFCV57_ )]U
M/_ )?Y>:^\.:/\T?O7]=5]YTE%<W_P )EX1_Z&GP[_X.M-_^2:/^$R\(_P#0
MT^'?_!UIO_R31[*K_P ^ZG_@$O\ +S7WAS1_FC]Z_KJOO.DHKF_^$R\(_P#0
MT^'?_!UIO_R31_PF7A'_ *&GP[_X.M-_^2:/95?^?=3_ , E_EYK[PYH_P T
M?O7]=5]YTE%<W_PF7A'_ *&GP[_X.M-_^2:/^$R\(_\ 0T^'?_!UIO\ \DT>
MRJ_\^ZG_ (!+_+S7WAS1_FC]Z_KJOO.DHKF_^$R\(_\ 0T^'?_!UIO\ \DT?
M\)EX1_Z&GP[_ .#K3?\ Y)H]E5_Y]U/_  "7^7FOO#FC_-'[U_75?>=)17-_
M\)EX1_Z&GP[_ .#K3?\ Y)H_X3+PC_T-/AW_ ,'6F_\ R31[*K_S[J?^ 2_R
M\U]X<T?YH_>OZZK[SI**YO\ X3+PC_T-/AW_ ,'6F_\ R31_PF7A'_H:?#O_
M (.M-_\ DFCV57_GW4_\ E_EYK[PYH_S1^]?UU7WG245S?\ PF7A'_H:?#O_
M (.M-_\ DFC_ (3+PC_T-/AW_P '6F__ "31[*K_ ,^ZG_@$O\O-?>'-'^:/
MWK^NJ^\Z2BN;_P"$R\(_]#3X=_\ !UIO_P DT?\ "9>$?^AI\._^#K3?_DFC
MV57_ )]U/_ )?Y>:^\.:/\T?O7]=5]YTE%<W_P )EX1_Z&GP[_X.M-_^2:/^
M$R\(_P#0T^'?_!UIO_R31[*K_P ^ZG_@$O\ +S7WAS1_FC]Z_KJOO.DHKF_^
M$R\(_P#0T^'?_!UIO_R31_PF7A'_ *&GP[_X.M-_^2:/95?^?=3_ , E_EYK
M[PYH_P T?O7]=5]YTE%<W_PF7A'_ *&GP[_X.M-_^2:/^$R\(_\ 0T^'?_!U
MIO\ \DT>RJ_\^ZG_ (!+_+S7WAS1_FC]Z_KJOO.DHKF_^$R\(_\ 0T^'?_!U
MIO\ \DT?\)EX1_Z&GP[_ .#K3?\ Y)H]E5_Y]U/_  "7^7FOO#FC_-'[U_75
M?>=)17-_\)EX1_Z&GP[_ .#K3?\ Y)H_X3+PC_T-/AW_ ,'6F_\ R31[*K_S
M[J?^ 2_R\U]X<T?YH_>OZZK[SI**YO\ X3+PC_T-/AW_ ,'6F_\ R31_PF7A
M'_H:?#O_ (.M-_\ DFCV57_GW4_\ E_EYK[PYH_S1^]?UU7WG245S?\ PF7A
M'_H:?#O_ (.M-_\ DFC_ (3+PC_T-/AW_P '6F__ "31[*K_ ,^ZG_@$O\O-
M?>'-'^:/WK^NJ^\Z2BN;_P"$R\(_]#3X=_\ !UIO_P DT?\ "9>$?^AI\._^
M#K3?_DFCV57_ )]U/_ )?Y>:^\.:/\T?O7]=5]YTE%<W_P )EX1_Z&GP[_X.
MM-_^2:/^$R\(_P#0T^'?_!UIO_R31[*K_P ^ZG_@$O\ +S7WAS1_FC]Z_KJO
MO.DHKF_^$R\(_P#0T^'?_!UIO_R31_PF7A'_ *&GP[_X.M-_^2:/95?^?=3_
M , E_EYK[PYH_P T?O7]=5]YTE%<W_PF7A'_ *&GP[_X.M-_^2:/^$R\(_\
M0T^'?_!UIO\ \DT>RJ_\^ZG_ (!+_+S7WAS1_FC]Z_KJOO.DHKF_^$R\(_\
M0T^'?_!UIO\ \DT?\)EX1_Z&GP[_ .#K3?\ Y)H]E5_Y]U/_  "7^7FOO#FC
M_-'[U_75?>=)17-_\)EX1_Z&GP[_ .#K3?\ Y)H_X3+PC_T-/AW_ ,'6F_\
MR31[*K_S[J?^ 2_R\U]X<T?YH_>OZZK[SI**YO\ X3+PC_T-/AW_ ,'6F_\
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M (4)I7_0P:A_X"6W_P 71_PH32O^A@U#_P !+;_XNO?**/[0QG_/^7_@,/\
MY'R_/NP]A2_D7WR_S\OS[L\#_P"%":5_T,&H?^ EM_\ %T?\*$TK_H8-0_\
M 2V_^+KWRBC^T,9_S_E_X##_ .1\OS[L/84OY%]\O\_+\^[/ _\ A0FE?]#!
MJ'_@);?_ !='_"A-*_Z&#4/_  $MO_BZ]\HH_M#&?\_Y?^ P_P#D?+\^[#V%
M+^1??+_/R_/NSP/_ (4)I7_0P:A_X"6W_P 71_PH32O^A@U#_P !+;_XNO?*
M*/[0QG_/^7_@,/\ Y'R_/NP]A2_D7WR_S\OS[L\#_P"%":5_T,&H?^ EM_\
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M_H8-0_\  2V_^+KWRBC^T,9_S_E_X##_ .1\OS[L/84OY%]\O\_+\^[/ _\
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M (4)I7_0P:A_X"6W_P 71_PH32O^A@U#_P !+;_XNO?**/[0QG_/^7_@,/\
MY'R_/NP]A2_D7WR_S\OS[L\#_P"%":5_T,&H?^ EM_\ %T?\*$TK_H8-0_\
M 2V_^+KWRBC^T,9_S_E_X##_ .1\OS[L/84OY%]\O\_+\^[/ _\ A0FE?]#!
MJ'_@);?_ !='_"A-*_Z&#4/_  $MO_BZ]\HH_M#&?\_Y?^ P_P#D?+\^[#V%
M+^1??+_/R_/NSP/_ (4)I7_0P:A_X"6W_P 71_PH32O^A@U#_P !+;_XNO?*
M*/[0QG_/^7_@,/\ Y'R_/NP]A2_D7WR_S\OS[L\#_P"%":5_T,&H?^ EM_\
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M_H8-0_\  2V_^+KWRBC^T,9_S_E_X##_ .1\OS[L/84OY%]\O\_+\^[/ _\
MA0FE?]#!J'_@);?_ !='_"A-*_Z&#4/_  $MO_BZ]\HH_M#&?\_Y?^ P_P#D
M?+\^[#V%+^1??+_/R_/NSP/_ (4)I7_0P:A_X"6W_P 71_PH32O^A@U#_P !
M+;_XNO?**/[0QG_/^7_@,/\ Y'R_/NP]A2_D7WR_S\OS[L\#_P"%":5_T,&H
M?^ EM_\ %T?\*$TK_H8-0_\  2V_^+KWRBC^T,9_S_E_X##_ .1\OS[L/84O
MY%]\O\_+\^[/ _\ A0FE?]#!J'_@);?_ !='_"A-*_Z&#4/_  $MO_BZ]\HH
M_M#&?\_Y?^ P_P#D?+\^[#V%+^1??+_/R_/NSP/_ (4)I7_0P:A_X"6W_P 7
M1_PH32O^A@U#_P !+;_XNO?**/[0QG_/^7_@,/\ Y'R_/NP]A2_D7WR_S\OS
M[L\#_P"%":5_T,&H?^ EM_\ %T?\*$TK_H8-0_\  2V_^+KWRBC^T,9_S_E_
MX##_ .1\OS[L/84OY%]\O\_+\^[/ _\ A0FE?]#!J'_@);?_ !='_"A-*_Z&
M#4/_  $MO_BZ]\HH_M#&?\_Y?^ P_P#D?+\^[#V%+^1??+_/R_/NSP/_ (4)
MI7_0P:A_X"6W_P 71_PH32O^A@U#_P !+;_XNO?**/[0QG_/^7_@,/\ Y'R_
M/NP]A2_D7WR_S\OS[L\#_P"%":5_T,&H?^ EM_\ %T?\*$TK_H8-0_\  2V_
M^+KWRBC^T,9_S_E_X##_ .1\OS[L/84OY%]\O\_+\^[/ _\ A0FE?]#!J'_@
M);?_ !=>"?M4:+%^SW^S/^T!\>-)GD\1ZI\&O@U\2?B?IWA_456SL-;O? WA
M'5O$EKI5[=VWF7%M:W\VG);7$\$;S112L\:EU K[WKXB_P""EW_*.W]N?_LT
MK]H+_P!59XHK;"X[%5,3AZ<ZSE"=>C"2Y8*\95(QDKJ*:NM+II[ZZG/C*<*>
M$Q52$>6=/#5YPE=MQE"E*47JVG9I/5-/K>[O^2G_  2P_;P\4?\ !0CX?_%3
MQEXL\ :!\.;GX>^,='\,6EEX=U;4=9@U*#4]$.JO=7$NI06\D,L4@\I8X@R,
MGS$AN*_4_P#L:/\ Y[O_ -\K_C7\WG_!M)_R0S]I?_LK'A/_ -0]Z_I<KZS,
M(QHXRO3II0A"45&*U23A%O5W>[;U9X7#U>MC,FP.)Q,W5KU:=252HU%.35:I
M%-J*C%6C%+1):>;OC?V-'_SW?_OE?\:/[&C_ .>[_P#?*_XULT5Q<\N_X+_(
M]GECV7]?\-^?=F-_8T?_ #W?_OE?\:/[&C_Y[O\ ]\K_ (ULT4<\N_X+_(.6
M/9?U_P -^?=F-_8T?_/=_P#OE?\ &C^QH_\ GN__ 'RO^-;-%'/+O^"_R#EC
MV7]?\-^?=F-_8T?_ #W?_OE?\:/[&C_Y[O\ ]\K_ (ULT4<\N_X+_(.6/9?U
M_P -^?=F-_8T?_/=_P#OE?\ &C^QH_\ GN__ 'RO^-;-%'/+O^"_R#ECV7]?
M\-^?=F-_8T?_ #W?_OE?\:/[&C_Y[O\ ]\K_ (ULT4<\N_X+_(.6/9?U_P -
M^?=F-_8T?_/=_P#OE?\ &C^QH_\ GN__ 'RO^-;-%'/+O^"_R#ECV7]?\-^?
M=F-_8T?_ #W?_OE?\:/[&C_Y[O\ ]\K_ (ULT4<\N_X+_(.6/9?U_P -^?=F
M-_8T?_/=_P#OE?\ &C^QH_\ GN__ 'RO^-;-%'/+O^"_R#ECV7]?\-^?=F-_
M8T?_ #W?_OE?\:/[&C_Y[O\ ]\K_ (ULT4<\N_X+_(.6/9?U_P -^?=F-_8T
M?_/=_P#OE?\ &C^QH_\ GN__ 'RO^-;-%'/+O^"_R#ECV7]?\-^?=F-_8T?_
M #W?_OE?\:/[&C_Y[O\ ]\K_ (ULT4<\N_X+_(.6/9?U_P -^?=F-_8T?_/=
M_P#OE?\ &C^QH_\ GN__ 'RO^-;-%'/+O^"_R#ECV7]?\-^?=F-_8T?_ #W?
M_OE?\:/[&C_Y[O\ ]\K_ (ULT4<\N_X+_(.6/9?U_P -^?=F-_8T?_/=_P#O
ME?\ &C^QH_\ GN__ 'RO^-;-%'/+O^"_R#ECV7]?\-^?=F-_8T?_ #W?_OE?
M\:/[&C_Y[O\ ]\K_ (ULT4<\N_X+_(.6/9?U_P -^?=F-_8T?_/=_P#OE?\
M&C^QH_\ GN__ 'RO^-;-%'/+O^"_R#ECV7]?\-^?=F-_8T?_ #W?_OE?\:/[
M&C_Y[O\ ]\K_ (ULT4<\N_X+_(.6/9?U_P -^?=F-_8T?_/=_P#OE?\ &C^Q
MH_\ GN__ 'RO^-;-%'/+O^"_R#ECV7]?\-^?=F-_8T?_ #W?_OE?\:/[&C_Y
M[O\ ]\K_ (ULT4<\N_X+_(.6/9?U_P -^?=F-_8T?_/=_P#OE?\ &C^QH_\
MGN__ 'RO^-;-%'/+O^"_R#ECV7]?\-^?=F-_8T?_ #W?_OE?\:/[&C_Y[O\
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M_,7^-'_"MK+_ *"=U_WYB_QKTJBCZS7_ .?C^Z/^0>RA_*OO?^?E^?=GFO\
MPK:R_P"@G=?]^8O\:/\ A6UE_P!!.Z_[\Q?XUZ511]9K_P#/Q_='_(/90_E7
MWO\ S\OS[L\U_P"%;67_ $$[K_OS%_C1_P *VLO^@G=?]^8O\:]*HH^LU_\
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M@S>_^ T'_P 57L=%'U[%_P#/Y_\ @,/_ )$/94_Y?QE_F>.?\*=T[_H,WO\
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MPH32O^A@U#_P$MO_ (NC_A0FE?\ 0P:A_P" EM_\77OE%<']H8S_ )_R_P#
M8?\ R/E^?=F_L*7\B^^7^?E^?=G@?_"A-*_Z&#4/_ 2V_P#BZ/\ A0FE?]#!
MJ'_@);?_ !=>^44?VAC/^?\ +_P&'_R/E^?=A["E_(OOE_GY?GW9X'_PH32O
M^A@U#_P$MO\ XNC_ (4)I7_0P:A_X"6W_P 77OE%']H8S_G_ "_\!A_\CY?G
MW8>PI?R+[Y?Y^7Y]V>!_\*$TK_H8-0_\!+;_ .+H_P"%":5_T,&H?^ EM_\
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M^44?VAC/^?\ +_P&'_R/E^?=A["E_(OOE_GY?GW9X'_PH32O^A@U#_P$MO\
MXNC_ (4)I7_0P:A_X"6W_P 77OE%']H8S_G_ "_\!A_\CY?GW8>PI?R+[Y?Y
M^7Y]V>!_\*$TK_H8-0_\!+;_ .+H_P"%":5_T,&H?^ EM_\ %U[Y11_:&,_Y
M_P O_ 8?_(^7Y]V'L*7\B^^7^?E^?=G@?_"A-*_Z&#4/_ 2V_P#BZ/\ A0FE
M?]#!J'_@);?_ !=>^44?VAC/^?\ +_P&'_R/E^?=A["E_(OOE_GY?GW9X'_P
MH32O^A@U#_P$MO\ XNC_ (4)I7_0P:A_X"6W_P 77OE%']H8S_G_ "_\!A_\
MCY?GW8>PI?R+[Y?Y^7Y]V>!_\*$TK_H8-0_\!+;_ .+H_P"%":5_T,&H?^ E
MM_\ %U[Y11_:&,_Y_P O_ 8?_(^7Y]V'L*7\B^^7^?E^?=G@?_"A-*_Z&#4/
M_ 2V_P#BZ/\ A0FE?]#!J'_@);?_ !=>^44?VAC/^?\ +_P&'_R/E^?=A["E
M_(OOE_GY?GW9X'_PH32O^A@U#_P$MO\ XNC_ (4)I7_0P:A_X"6W_P 77OE%
M']H8S_G_ "_\!A_\CY?GW8>PI?R+[Y?Y^7Y]V>!_\*$TK_H8-0_\!+;_ .+H
M_P"%":5_T,&H?^ EM_\ %U[Y11_:&,_Y_P O_ 8?_(^7Y]V'L*7\B^^7^?E^
M?=G@?_"A-*_Z&#4/_ 2V_P#BZ/\ A0FE?]#!J'_@);?_ !=>^44?VAC/^?\
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M&,_Y_P O_ 8?_(^7Y]V'L*7\B^^7^?E^?=G@?_"A-*_Z&#4/_ 2V_P#BZ/\
MA0FE?]#!J'_@);?_ !=>^44?VAC/^?\ +_P&'_R/E^?=A["E_(OOE_GY?GW9
MX'_PH32O^A@U#_P$MO\ XNC_ (4)I7_0P:A_X"6W_P 77OE%']H8S_G_ "_\
M!A_\CY?GW8>PI?R+[Y?Y^7Y]V>!_\*$TK_H8-0_\!+;_ .+H_P"%":5_T,&H
M?^ EM_\ %U[Y11_:&,_Y_P O_ 8?_(^7Y]V'L*7\B^^7^?E^?=G@?_"A-*_Z
M&#4/_ 2V_P#BZ/\ A0FE?]#!J'_@);?_ !=>^44?VAC/^?\ +_P&'_R/E^?=
MA["E_(OOE_GY?GW9X'_PH32O^A@U#_P$MO\ XNC_ (4)I7_0P:A_X"6W_P 7
M7OE%']H8S_G_ "_\!A_\CY?GW8>PI?R+[Y?Y^7Y]V>!_\*$TK_H8-0_\!+;_
M .+H_P"%":5_T,&H?^ EM_\ %U[Y11_:&,_Y_P O_ 8?_(^7Y]V'L*7\B^^7
M^?E^?=G@?_"A-*_Z&#4/_ 2V_P#BZ/\ A0FE?]#!J'_@);?_ !=>^44?VAC/
M^?\ +_P&'_R/E^?=A["E_(OOE_GY?GW9X'_PH32O^A@U#_P$MO\ XNC_ (4)
MI7_0P:A_X"6W_P 77OE%']H8S_G_ "_\!A_\CY?GW8>PI?R+[Y?Y^7Y]V>!_
M\*$TK_H8-0_\!+;_ .+H_P"%":5_T,&H?^ EM_\ %U[Y11_:&,_Y_P O_ 8?
M_(^7Y]V'L*7\B^^7^?E^?=G@?_"A-*_Z&#4/_ 2V_P#BZ/\ A0FE?]#!J'_@
M);?_ !=>^44?VAC/^?\ +_P&'_R/E^?=A["E_(OOE_GY?GW9X'_PH32O^A@U
M#_P$MO\ XNC_ (4)I7_0P:A_X"6W_P 77OE%']H8S_G_ "_\!A_\CY?GW8>P
MI?R+[Y?Y^7Y]V>!_\*$TK_H8-0_\!+;_ .+H_P"%":5_T,&H?^ EM_\ %U[Y
M11_:&,_Y_P O_ 8?_(^7Y]V'L*7\B^^7^?E^?=G@?_"A-*_Z&#4/_ 2V_P#B
MZ/\ A0FE?]#!J'_@);?_ !=>^44?VAC/^?\ +_P&'_R/E^?=A["E_(OOE_GY
M?GW9X'_PH32O^A@U#_P$MO\ XNC_ (4)I7_0P:A_X"6W_P 77OE%']H8S_G_
M "_\!A_\CY?GW8>PI?R+[Y?Y^7Y]V>!_\*$TK_H8-0_\!+;_ .+H_P"%":5_
MT,&H?^ EM_\ %U[Y11_:&,_Y_P O_ 8?_(^7Y]V'L*7\B^^7^?E^?=G@?_"A
M-*_Z&#4/_ 2V_P#BZ/\ A0FE?]#!J'_@);?_ !=>^44?VAC/^?\ +_P&'_R/
ME^?=A["E_(OOE_GY?GW9X'_PH32O^A@U#_P$MO\ XNC_ (4)I7_0P:A_X"6W
M_P 77OE%']H8S_G_ "_\!A_\CY?GW8>PI?R+[Y?Y^7Y]V>!_\*$TK_H8-0_\
M!+;_ .+H_P"%":5_T,&H?^ EM_\ %U[Y11_:&,_Y_P O_ 8?_(^7Y]V'L*7\
MB^^7^?E^?=G@?_"A-*_Z&#4/_ 2V_P#BZ/\ A0FE?]#!J'_@);?_ !=>^44?
MVAC/^?\ +_P&'_R/E^?=A["E_(OOE_GY?GW9X'_PH32O^A@U#_P$MO\ XNC_
M (4)I7_0P:A_X"6W_P 77OE%']H8S_G_ "_\!A_\CY?GW8>PI?R+[Y?Y^7Y]
MV>!_\*$TK_H8-0_\!+;_ .+H_P"%":5_T,&H?^ EM_\ %U[Y11_:&,_Y_P O
M_ 8?_(^7Y]V'L*7\B^^7^?E^?=G@?_"A-*_Z&#4/_ 2V_P#BZ/\ A0FE?]#!
MJ'_@);?_ !=>^44?VAC/^?\ +_P&'_R/E^?=A["E_(OOE_GY?GW9X'_PH32O
M^A@U#_P$MO\ XNC_ (4)I7_0P:A_X"6W_P 77OE%']H8S_G_ "_\!A_\CY?G
MW8>PI?R+[Y?Y^7Y]V>!_\*$TK_H8-0_\!+;_ .+H_P"%":5_T,&H?^ EM_\
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M^44?VAC/^?\ +_P&'_R/E^?=A["E_(OOE_GY?GW9X'_PH32O^A@U#_P$MO\
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M?=G@?_"A-*_Z&#4/_ 2V_P#BZ/\ A0FE?]#!J'_@);?_ !=>^44?VAC/^?\
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M&,_Y_P O_ 8?_(^7Y]V'L*7\B^^7^?E^?=G@?_"A-*_Z&#4/_ 2V_P#BZ/\
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M*?\ )/99_P!>JO\ ZD5@HHHKSSZ$**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R-8_P!1
M%_UU_P#9&K7K(UC_ %$7_77_ -D:G'=>J_,F?POY?FCO='_Y!5A_UZP_^@BM
M*LW1_P#D%6'_ %ZP_P#H(K2K@G\<O\4OS9T0^"/^&/Y(****DH**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *X34?^1NTW_K[TK_THCKNZX34?^1NTW_K[TK_THCK:A\4_
M^O<_R,ZOPK_%'\SW.BBBN$T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS+X5_\
MC=JW_8*O_P#TYZ=7IM>9?"O_ )&[5O\ L%7_ /Z<].K:/^[XO_KW'\V93^.E
MZR_0^A:***\DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_B'_ ,B;K7_7.T_]
M.%I5OX(?\B;-_P!AN^_])K&JGQ#_ .1-UK_KG:?^G"TJW\$/^1-F_P"PW??^
MDUC78_\ D65/^PI?^D0%'^-'_!+\T>PT445Y9TA117D'[0FIZEHOP"^.&LZ-
MJ%]I.KZ3\(/B7J>E:KIEW/8:EIFI6'@O6KJQU#3[ZUDBNK*^LKJ**YM+NVEC
MGMYXXYH9$D16%0BYSA!.SG*,4WLG)I7?WDSER0G-J_)&4K=^5-V^=CU^BO\
M* _X>+_\%!_^C[/VR?\ Q)[XV_\ S<4?\/%_^"@__1]G[9/_ (D]\;?_ )N*
M^S_U+Q7_ $&X?_P74_KO_3T_-_\ B).!_P"A9B__  =1_P O7^GI_J_T5_E
M?\/%_P#@H/\ ]'V?MD_^)/?&W_YN*Z[0?^"IW_!2#PX+4:?^W!^TW<?8_/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.,RAE&78C,:E*=:&']CS4X-1G+VU>E05G+1<KJJ3ONDUNS^K^BO\H#_AXO\
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MXRA@:ZQ#P/L57JT_>H.5=UE&-*JG:JX^PDY2A>GK'EG)\RB4445PGIA1110
M4444 %%%% !1110 4444 %%%% !1110!\O>&/^2WZE_V%?$O_I/?5]0U\O>&
M/^2WZE_V%?$O_I/?5]0UWYA\>'_[!*'_ +<<^&^"?_7R7Y1"BBBN Z HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXB_X*7?\H[?VY_\
MLTK]H+_U5GBBOMVOB+_@I=_RCM_;G_[-*_:"_P#56>**Z<%_OF$_[":'_IV!
MR8__ ''&_P#8)B?_ $S,_F@_X-I/^2&?M+_]E8\)_P#J'O7]+E?S1_\ !M)_
MR0S]I?\ [*QX3_\ 4/>OZ7*^WS7_ )&&)_Q0_P#3<#YGA3_DGLL_Z]5?_4BL
M%%%%>>?0A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !61K'^HB_P"NO_LC5KUD:Q_J(O\
MKK_[(U..Z]5^9,_A?R_-'>Z/_P @JP_Z]8?_ $$5I5FZ/_R"K#_KUA_]!%:5
M<$_CE_BE^;.B'P1_PQ_)!1114E!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7":C_ ,C=
MIO\ U]Z5_P"E$==W7":C_P C=IO_ %]Z5_Z41UM0^*?_ %[G^1G5^%?XH_F>
MYT445PF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>9?"O_ )&[5O\ L%7_ /Z<
M].KTVO,OA7_R-VK?]@J__P#3GIU;1_W?%_\ 7N/YLRG\=+UE^A]"T445Y)J%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '%_$/_D3=:_ZYVG_ *<+2K?P0_Y$V;_L
M-WW_ *36-5/B'_R)NM?]<[3_ -.%I5OX(?\ (FS?]AN^_P#2:QKL?_(LJ?\
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M:+[$=[:I<Z_?^"=8TO32UW9RW6H^*+Z(:?<-<'4_X_\ XT:MX4U[XQ?%C7/
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M3HJR4IN,ZB?,THODNDM+?JU_P;^?\I=/V2O^Z\_^LR_&>O\ 2VK_ !Z?A_\
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M\1]8EB*%?"0H4'63G.G4G6G[2G3C0HTXV<JLG4<E=J,80E.;C%2E'^Z&BO\
M(7^+_P"T'\=?V@=>N/$WQP^,/Q)^+.MW%Y+??;?B!XSU_P 4"UGEWC9IEKJU
M]<V>D6D$3FVLM/TJWL[#3[(1V-C;6]G%' GIG[.O[<7[6W[*&NV>M_ /X_?$
MOX?QVU[H][=^&;#Q1J=WX$UXZ"ZG3+3Q-X#U&XN_"7B*QMH!)8QVVK:1=)%I
M]S=V4!B@NIT?KEP565.\<?2=6WP.A*-._;VJJ2E;S]E\CSX^)6&=;EGE5>.'
MO;VL<53E6Y>_L'1A"_\ =^L6_O'^LY17XI_\$>/^"NWA/_@I%X%U3P3XTTS3
MO _[47PP\/6&J^/_  GI\X_L/QQX<6:QT>X^)_@6WF8WEIHYUR\LK'Q+X>N&
MO'\(ZEK6AVO]J:E::SI]PW[65\ABL+7P5>IAL1!TZM-VE%ZIIJ\91DM)1DFG
M&2T:?>Z/T+ X["YEA:6,P=55:%97C))IIIVE"<79PG"2<91:NFNUFRBOAO\
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MRY(3FU?DC*5N_*F[?.QZ_17^4!_P\7_X*#_]'V?MD_\ B3WQM_\ FXK^V_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5W/!8?!5*#A7HQE!*5?,,-4YDE[R=))/9L_FO,/'K@_P^6!X<SK+>)<5CJ6
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MTE\:?^AS_P#+=\)__**C_B.O"/\ T+N(_P#PDRS_ .>X?\39>'7_ $)>-?\
MPW9%_P#1&?JM17Y4_P##27QI_P"AS_\ +=\)_P#RBH_X:2^-/_0Y_P#EN^$_
M_E%1_P 1UX1_Z%W$?_A)EG_SW#_B;+PZ_P"A+QK_ .&[(O\ Z(S]5J*_*G_A
MI+XT_P#0Y_\ EN^$_P#Y14?\-)?&G_H<_P#RW?"?_P HJ/\ B.O"/_0NXC_\
M),L_^>X?\39>'7_0EXU_\-V1?_1&?JM17Y4_\-)?&G_H<_\ RW?"?_RBH_X:
M2^-/_0Y_^6[X3_\ E%1_Q'7A'_H7<1_^$F6?_/</^)LO#K_H2\:_^&[(O_HC
M/U6HK\J?^&DOC3_T.?\ Y;OA/_Y14?\ #27QI_Z'/_RW?"?_ ,HJ/^(Z\(_]
M"[B/_P ),L_^>X?\39>'7_0EXU_\-V1?_1&?JM17Y4_\-)?&G_H<_P#RW?"?
M_P HJ/\ AI+XT_\ 0Y_^6[X3_P#E%1_Q'7A'_H7<1_\ A)EG_P ]P_XFR\.O
M^A+QK_X;LB_^B,_5:BORI_X:2^-/_0Y_^6[X3_\ E%1_PTE\:?\ H<__ "W?
M"?\ \HJ/^(Z\(_\ 0NXC_P#"3+/_ )[A_P 39>'7_0EXU_\ #=D7_P!$9^JU
M%?E3_P -)?&G_H<__+=\)_\ RBH_X:2^-/\ T.?_ );OA/\ ^45'_$=>$?\
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MI5P3^.7^*7YLZ(?!'_#'\D%%%%24%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<)J/_(W
M:;_U]Z5_Z41UW=<)J/\ R-VF_P#7WI7_ *41UM0^*?\ U[G^1G5^%?XH_F>Y
MT445PF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>9?"O\ Y&[5O^P5?_\ ISTZ
MO3:\R^%?_(W:M_V"K_\ ].>G5M'_ '?%_P#7N/YLRG\=+UE^A]"T445Y)J%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% '%_$/_D3=:_ZYVG_IPM*M_!#_ )$V;_L-
MWW_I-8U4^(?_ ")NM?\ 7.T_].%I5OX(?\B;-_V&[[_TFL:['_R+*G_84O\
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MJ:WC3Y8MMIM_Z[?[-'_)N'[/_P#V1+X4_P#J":#7\/\ _P '4/\ RD'^#O\
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M?KVJ64]V-+\+>!_#MTUEJ(M=5\6:TSRWE]-;PPV/A30_%%Q:W]OKRZ';WO\
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MR.L5G<7W]0O_  0T_84_:Y_X)_?!GXS_  A_:5UGX9WOA;Q%\1M(\>_"_2O
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M;_P\=1U.ZDT72]3N-)UW4[29='AFM_\ ,Z^(_P -_'OP@\<^)OAG\4?"&O\
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MP'XAT_Q1H,>N6NAZQH&K76F+JVEV<EY:V.M:;-<PHT'VJ-)&S_05_P 14/\
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MJE3"8:O6QV%I8G$5:U&G5E-8F"JQIMU(RM3IPG&"@O=NG)IRDV_\T+_@L_\
M\$R;/_@FW^T%X:TSP#K&L^(/@/\ &K1M;\4_"J]\0F*;7?#]YX=O[*S\8_#[
M5=2A6&/7)_"QUGPYJ%EK8M+.6ZT3Q-I-M?13ZG97U_>?CI7]Y_\ P=4^'--N
MOV'_ (#>+948ZOHG[5>@^'+&0+ 473?%/PB^+NIZJC,T#709[KP?HS(L-S%
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M_P $[OV.OV&O"/[+>J?LM?!__A5U]\1O$?Q7L/&<_P#PL#XH^-O[9M/#6F>
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M9+^"ZL;K[+?6L$_V>\MKBUGV>7<030L\;?YS?_$0'_P5S_Z.U_\ ,#?LR_\
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M[1M1\0L@JS49QQ^&3=G4K8:G*"\VL/7KSMZ0;\C^^*BOS]_X)^_\%)OV<O\
M@HQ\.K_Q?\%]5OM(\7>%%TR#XD?"GQ5]DM?&W@?4-1M(YHII+>WGFAUSPM>7
M0O+/1?%VF$Z=J<MA=6\\.FZI;7FEVOZ!5\W6H5</5G1KTY4JM-VG":M*+M=>
MJ::<6KJ2::;33/LL-B</C*%/$X6K"O0JQYJ=6G+FC);/7=---2BTI1DG&24D
MTBBBBLC<**_D+_X+Q?\ !9']IG]EK]J;PE^SA^QQ\8K'X=W7P^^']IKGQON8
M/AUX"\8WMQXU\?&TUWPOX6OIOBAX,\56=NOA_P  Q>'_ !3:2^$X+."YC^(D
MEOK.HZG>Z=#I^@?A[_Q$!_\ !7/_ *.U_P#,#?LR_P#SF*^EPG"V8XS#4<5"
MIA*<*\%4A"M.M&IR-OEE)1P\XI3C:<;2=XR3T;LOC,PXZR?+L9B,#5HX^M4P
MU1TJE3#TL-.DZD4N>,93Q=.3=.3=.:<(VG&2U2N_]+:BOS'_ ."0?[:.N?MV
M_L+?"[XR^.=0T[4OBUH=UK?PO^,=UID&FV<-Y\0?!$\$3:[<Z9I$-GINCZCX
MS\):AX4\=ZEH^GZ9I&EZ;>^*)[31-,M=#BTP/^G%>!B*%3#5ZV'JI*I1J3I3
M2U7-"3BW%V5XNUXNVJ:?4^KPF*I8W"X?%T&W1Q-&G7IMI*7)4BI)22;49QOR
MSC=\LDU?0****Q.@**** "BBOX)?^"D7_!:7_@IA\ _VZOVGO@W\)OVE/^$3
M^&_P[^*6K^'/!WAS_A3GP!UW^Q]&M;:RD@L_[8\2_"O6=>U#8\LA^T:IJE]=
M-NP\[ *!Z6695B,VJU*.'G1A*G3]K)UI3C%QYHPLG3IU'>\EHTE:^O0\7.\]
MPF0T*.(QE/$U(5JWL8+#0I3FI\DIWDJM:BE&T6KJ3=[:6U7][5%?YI/_ !$!
M_P#!7/\ Z.U_\P-^S+_\YBOZ)?\ @WR_X*H_M-?ML_$?]H/X+_M7?$JS^)WB
MGP[X(\-?$_X:ZLG@SX?^![_3O#^G:\?"GC[3KFS^'WA;PKIVK6;:CXG\!W-E
M<W=D][I\TNH1275S!?VL-CZ.-X8S# X6KBZM3"5*=%1E.-&I6E4Y7*,;I3H4
MXM1YN:5Y*T4VKVL>1EO&^49IC:& HT<?2JXB4HTYXBEAXTN:,)3492IXJK-.
M?+RQM!IS<4VD[K^I&BBJ.IZGINBZ;J&LZSJ%CI.D:38W>IZKJNIW<%AINF:;
M80275]J&H7UU)%:V5C96L4MS=W=S+'!;P1R332)&C,/G-]C[%M)-MV2U;>R7
M=EZBO\W/QW_P<,_\%3]>\<>,M<\&_M'6_@CP?K/BOQ#JOA3P9:?!3]GS4[7P
MCX;U'5[R\T+PQ;:EXA^%VO:_J%OH&ES6NE0WVN:YK6KW<=HL^I:MJ-[)/>3<
MK_Q$!_\ !7/_ *.U_P#,#?LR_P#SF*^L7!N:-)NM@8MI.SJU[JZV=L,U=;.S
M:OLVCX%^(V1IM+#9I))M*2H86TK.UU?&IV>ZND[;I/0_TMJ*_#O_ ((#?M@_
MM%_ML?L=?$GXJ?M-_$3_ (69X]T#]I?QC\/](U[_ (1+P+X,^R>$=*^%OP:\
M1V&D?V7\/_#/A31I_(UGQ7K]Y]ON=.FU.7[?]GFO9+6ULH+;]Q*^<Q>%J8+$
MUL+5<)5*$^2<J;DX-V3]URC"36O6*?D?98#&TLQP>'QU"-2%+$TU5IQJJ,:B
MBVTE-0G.*>FT9R7F%%%%<QV!17\J_P#P5D_X.$/'?[(/[2EQ^SA^R5X-^#?Q
M"U+X:6<MG\;?%WQ1L?%7BO18?'.HP:9?V7@GP;%X"^(7@A;6\\%V,EQ:^.[O
M5;[5YO\ A*-0E\*C3/#^H^#-8?6O-?\ @E[_ ,%^?VQ?VV/VZ/@=^S'\5/AM
M^S1H'@+XF?\ "S/[>U?X?^#OBEI7B^T_X0SX/_$#X@:7_9%_XC^,GBO1H//U
MGPIIUM?_ &S0+_S=,FO8;?[+=207MM[:X?S)X)X]TZ<:"H3Q+4ZB53V,(.IS
M<FKO*"YHJ]VFKV;L?,RXMR6.9+*E6JSQ3Q5/!+V=&4J7UBI4C2Y/:72M&I+D
MG*UDXRM=)-_UY445^'?_  7Y_;!_:+_8G_8Z^&WQ4_9D^(G_  K/Q[K_ .TO
MX.^'^KZ]_P (EX%\9_:_".J_"WXR^([_ $C^R_B!X9\5Z-!Y^L^%- O/M]MI
MT.IQ?8/L\-[':W5[!<^9A,-4QF)HX6DX1J5YJ$'4<E!-WUDXQE)+3I%OR/:S
M#&TLMP6(QU>-2='#4W4J1I*,JCBFE:"G.G%N[7Q3BO,_<2BO\TG_ (B _P#@
MKG_T=K_Y@;]F7_YS%'_$0'_P5S_Z.U_\P-^S+_\ .8KZ7_4W-/\ G_@/_!N(
M_P#F4^,_XB-DG_0+FO\ X(PG_P W'^EM17^:3_Q$!_\ !7/_ *.U_P#,#?LR
M_P#SF*ZGP[_P<1_\%7=$=6U/X^^%O%ZK-+*8_$7P1^#5LCI);B%+=CX2\$>%
MY!#!(#=1,CI<-<$K//-:XM@GP;FB5U6P+\E5KW_'#)?B->(V1MI/#9I%=W0P
MMEZ\N-D_N3/](VBOXIOV2?\ @Z;^(5IXCTKPY^VE\%_">M^$K[4?LUW\3/@E
M!JOA_P 1>'+&[N;?9?ZKX$U_6-?TWQ3#IB/>&X71-9\,7CV"6HM[#4=2MYCJ
MO]C/PK^*GP[^-_P[\(?%KX2^+]&\>?#GQYHUOK_A/Q9H%P;C3=6TVX+QEE$B
M175G>V=U%<:=JVDZC;VFK:)JUI?:/K%C8ZI8W=I#XF895CLLE%8JCRPFVH58
M-3I3:ULIK:5KOEFHRLFU&RN?393GV69U&;P&(YYTTG5H5(NG7IIZ*3IR^*%V
MDYTW."DU%RNTCT"BBBO./8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\0/"/Q9^'O@3XJ?#_5_[?\!?$SP;X7^('@C7OL&IZ5_;?A'QGHECXC\-:O\
MV7K=EINLZ;_:6C:E97GV#5].L-3L_.^SW]E:W4<L$?95SM.+<9)J2;333333
MLTT]4T]&GJF=<91G&,X24HR2E&46I1E&2NI1:NFFFFFFTT[H****0PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **^?_ -I;]J3X$_L??#&X^,G[1?CK
M_A7?PWM=;TCPY/XC_P"$9\8^+=FLZZ\\>E6?]C^!?#WB;7F^U/;S#[0FEM:P
M;,W,\(9"WY\Z?_P7T_X)+:K?V.EV'[6'GWVI7EM864'_  HK]I6+SKN\F2WM
MHO-F^#<<,?F32(GF2R1Q)NW2.J L.JC@<;B(>TP^#Q5>FFXN='#U:L%)6;CS
M0A*-TFFU>ZNK[G#B,SRW"5%1Q688'#57%25+$8NA1J.,FU&2A4J1ERR::3M9
MM-)Z,_8:BBBN4[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^(O
M^"EW_*.W]N?_ +-*_:"_]59XHK[=KXB_X*7?\H[?VY_^S2OV@O\ U5GBBNG!
M?[YA/^PFA_Z=@<F/_P!QQO\ V"8G_P!,S/X]?^",?_)H/Q[_ .SD? /_ *K#
MQ37Z?U^8'_!&/_DT'X]_]G(^ ?\ U6'BFOT_K^=?'S_DX^8_]@&6?^HR/\M?
M'+_DM*'_ &(,K_\ 2L2%%%%?C!^.!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !116QX?T+4/$VMZ9H&E0F?4-
M6O(K.VC'0/*WS2.?X8H8P\TK?PQ1NW:M*5*I7JTZ%&$JM:M4A2I4X)RG4J5)
M*$(0BM92G)J,4M6VDC;#X>OB\10PN&I5*^)Q-:EA\/0I1<ZM:O6G&G2I4X*[
MG4J5)1A"*3<I-):L^BOV8_AC_P )9XG/BW5K82:#X7FCDMTE5&BO]<XDM8MK
MD^9%8@"[F^0IYGV="P)85^DU<CX$\'Z=X#\*Z3X8TU1Y6GVZBXGPH>]OI 'O
M;V4JJ9>XG+.,KE8]D?1!775_<' 7"M+A+A_#8!QB\?72Q>:58V?/C*D5S4XR
MZTL-!1H4[:2Y)5;*561_JGX1^']#PZX.P.4RA3>;XM1S#/L1"TO:YE6A'FH1
MFOBH8&FH82A:T9*G.NHQG7G<HHHK[0_3PK(UC_41?]=?_9&K7K(UC_41?]=?
M_9&IQW7JOS)G\+^7YH[W1_\ D%6'_7K#_P"@BM*LW1_^058?]>L/_H(K2K@G
M\<O\4OS9T0^"/^&/Y(****DH**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#2:QJI\0_^1-UK_KG:?^G"TJW\$/\ D39O^PW??^DUC78_^194_P"PI?\
MI$!1_C1_P2_-'L-%%%>6=(5XE^TO_P FX?M ?]D2^*W_ *@FO5[;7B7[2_\
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MH#_LB7Q6_P#4$UZO\B2O]=O]I?\ Y-P_: _[(E\5O_4$UZO\B2NC@K^!C_\
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M3RC'SRK'.5/"XJM[-JII]4QJ?L^:2?P1J-*E6O\ #*-.;<8PFW_H'U_G$_\
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M]DO^#K__ )(/^R/_ -E<\?\ _J&Z=7XV_P#!MG_RE"\%?]DC^,'_ *CL-?Z
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M *I+QQ7\A7_!JC_R>3^T/_V;+=?^K3^'5?UZ_P#!1?\ Y1\?MV?]F;?M/?\
MJDO'%8<0?\E'3_Q8'\X'7PA_R2%7TS+\IG^4!7]ZW_!K3\:-%\7_ +&/Q?\
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M6=W#'<VMW:7,;0W%M<V\RO#/;SPN\4T,J/'+&[(ZLK$'_+'_ ."GG[#?B?\
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M2O9SDI5&KOEYN2[Y3_7;_9H_Y-P_9_\ ^R)?"G_U!-!KVVO$OV:/^3</V?\
M_LB7PI_]030:]MK\?K?Q:O\ U\G_ .E,_H;#_P"[T/\ KS2_](B%%%%9FQ_G
M2_\ !R9_RE"\:_\ 9(_@_P#^H[-7D?\ P;^?\I=/V2O^Z\_^LR_&>O7/^#DS
M_E*%XU_[)'\'_P#U'9J\C_X-_/\ E+I^R5_W7G_UF7XSU^KT_P#DEG_V)*G_
M *AR/P:M_P EU'_LI:'_ *L*9_I;5_EN?\%@_P#E)S^VG_V6W7O_ $CTZO\
M4CK_ "W/^"P?_*3G]M/_ ++;KW_I'IU?,\&?[]B_^P3_ -S4C[3Q(_Y%> _[
M#_\ W7K'Z;?\&KW_ "D'^,7_ &9M\0?_ %=O[/-?WVU_ E_P:O?\I!_C%_V9
MM\0?_5V_L\U_?;7'Q9_R.*G_ %XH?^DL]#@#_DGJ?_87BO\ TJ)_-)_P=0_\
MH^/@[_V>3\/O_5)?M#5_ E7]]O\ P=0_\H^/@[_V>3\/O_5)?M#5_ E7UO"7
M_(GA_P!A%?\ .)\!Q]_R457_ +!<+_Z0S_7;_9H_Y-P_9_\ ^R)?"G_U!-!K
M^8C_ (.Q],GE^%?[&.LJ\(M;#X@?&#3)HV9Q.T^K>'/ ]U;/&HC,9A2/1;I9
MV:5'5Y+<1QR*\C1?T[_LT?\ )N'[/_\ V1+X4_\ J":#7\WO_!UQH.I7'[,W
M[+?B>*!FTC1_CKXBT&^N1%.4BU+Q'X U'4-*@:986M8VN+7PKK,B137$4\HM
MG:VAGCANGM_C,B=L_P *_P#I_B%K_>I5DOO;LO,_2>*(\W">-5F[83"2T_N5
M\-._HN6[\DS^&:O]DBO\;>O[EH_^#K+]F\?#OPE<K^S3\9KKXOW<.B0^-O#U
M[K'@S0OA7HUY/ R^(+S0/']EJGB_QGK.G6-X(WTV"\^%6F7U[8R2F86UU;1P
MWOU7%>78W'_V?]3H2K^R>)53EE"/+[3ZOR7<Y123]G/796U:NK_"<!YOEN5?
MVM_:&*AAO;1P4J7/&I+G5%XM5%%0A-N4?;4_=2YFFW%.SM[)_P '1'PGU+QG
M^P1X!^)6D:5=7\GP:_:!\*ZEXDO8(!+!HG@GQOX:\5^#+O4+V5+.::VBN/'-
M]\/-)BD>\L[&2YU*&&=;F\DTU(_X!:_USOVHOV?/!_[5G[//Q@_9U\=R36OA
MKXN>!]8\)7.J6T9GO/#^I740N/#WBJPM_M%M'=:CX3\16VE>)=.L[F86-W?:
M5;VU^DUE+<0R?Y4O[2O[._Q,_91^.'Q$^ /Q=T.XT+QQ\.M?N-(O4EB9+36-
M.8+=:%XGT:4EDO- \3Z-/8Z[HMY&[K/I]] 7V3++&D\'XV%3!U<$Y)5L/4E4
MC'K*C5L^9=^6KS*=M(\T+_$5XB9;5I9C0S.,6\/BZ,*,YI:0Q-!22C)K;GH\
MCA?63A4MI'3_ %-_V+/CCI/[2?[)?[.WQST?4'U*/XC_  D\%ZWJLTLEY-<6
MWBN/1[;3?&NDW=Q?[KJZOM"\86.N:)?7;RW"7=YI\]S!=WD$L5U-].U_FP_\
M$I/^"SWQ9_X)NSZM\/==\.S?&/\ 9N\3:C<ZYJ'PWDU9=(U_P=XGN+80S>)/
MAYKMQ!>VM@-4:&S_ .$D\.:C:3Z3JQM8[RQET/5I;[4;_P#??XA?\'67[+EG
MX.GN/A3^S=\??$7Q!?296MM)^(4WP[\%^#K;762U6&*?Q%X;\9>/=;OM)ADD
MO9)9X_"^G7EREI:PI;VC:C+<:7\]C^&<RI8NI#"X=U\/.I*5&I"=-)0DVXPJ
M<\HN$H)J,FTHRM>+L[+Z_*N-<FKY?1J8W%QPN*I4H1Q-*I"HY2J0BHRJ4?9P
MFJD*C3E&,;SBGRRBFKNG_P '5_QFT/2?V;_V<?@!#K=JOBOQQ\9KOXK76@V\
MDSZE_P (G\._!GB/PNM[J*P7(BM-)O=>^(EJMA%J5JPUG4-&N9M*EW^&]55/
MX==/T^_U:_L=*TJQO-3U34[RVT_3=-T^VFO;_4+^]F2VL[&QL[9)+B[O+NXD
MC@MK:".2:>:1(HD=W53]'_M>_M<?&;]M[XZ>*?V@_CKJNEW_ (U\2QV>GVVF
M^'M/DTCPKX3\-Z4DD6B>$O">E3W>H7=EH&C12RBV_M'4]5UB^N9[O5-;U?5=
M9O[_ %&Y_93_ (-[?^":FM_M1_M$:3^U3\2=$:']GG]G+Q):ZQI3ZC8K/:?$
MWXTZ0;/4O#'A6QCN-L$VC>"I+BS\:^+;_%W&MU:^&/#)L+B+Q+J%]HGVF$IT
M^'LE7UF<7*C"=6KRO2=>HVU1IWUDW)QI1=M;<[48W2_-\?5J\7<2/ZG2G&&)
MJ4J-'F7O4L+1BHSQ%:S:BE%3K32;Y>94X\\K<W]WO[/WP[_X5#\!?@C\)O+\
MG_A5_P (OAM\._)V6<?E?\(5X,T7PUY?EZ<\FGIL_LS;LL)'LUQMM7: (Q]=
MHHK\GG)SE*<G>4Y.4GW<FVW][/WJG"-.$*<%:%.$817:,4HQ7R204445)844
M44 %%%% !1110!\O>&/^2WZE_P!A7Q+_ .D]]7U#7R]X8_Y+?J7_ &%?$O\
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MG_@/XN>-_P#AH_\ X4?_ ,*L\7:!X5_LS_A4'_"R_P"W?[<T:YU?[?\ ;?\
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M?O,#4=2BGUPV(DY-+>_LZ_M')Z)*K!6ZOU"BBBOCS]$"BBB@ K_+<_X+!_\
M*3G]M/\ [+;KW_I'IU?ZD=?Y;G_!8/\ Y2<_MI_]EMU[_P!(].K['@S_ '[%
M_P#8)_[FI'YUXD?\BO ?]A__ +KUC\VJ_5__ ((B_'ZT_9W_ ."F?[,_B36M
M8?2/"7CSQ'JGP7\6-NCBM;RT^+&B7_A'PQ%J=S):W1M-,T_XBWW@K7[V[!M(
MX(]&WWM]9Z=]MF7PG]AOX(R?'\?M=^![.RU?4-9TC]BWXL_$[P_9Z$JS:K=:
MU\(?%OPS^)EM8VMF^X:A_:D7A:XTJ?3XH;B^N[:^FBTB!M9;3BOQGX7\2Z[X
M+\2^'?&/A?49M'\2^$]=TCQ+X=U:W2&2?2]=T+4+?5-(U&!+B.:W>:RU"UM[
MF-)X986>)1+&Z%E/WE>-/&4L9@I:.5%TIZ[1KTFHSV=K/FL[.SA==E^682=7
M+Z^79E%-J&(C7IM=986O%U*;U5[KDYE=)QJ<KZG^Q77Y6?\ !:WX]I^SW_P3
M0_:@\1V]]-9>(/'O@O\ X4KX7%O!/)<3ZE\7KN+P3JOD7$4,D6FS:=X/U/Q/
MK<>HW,UF('TH)8W/]L2Z;;S_ 'M^S_\ %C2OCO\  OX._&K1+G3[K2_BO\,?
M _Q"M9-*:Y-@G_"6^&].UN:U@2]6._@^PW%Y+92VFHQ0ZE9S6\EIJ$$%[#/$
MG\MG_!UK\?H+#X?_ ++_ .S#I>N3#4/$OBCQ-\;O&6@6\2)''I'A?3I/!7@*
M^U&Y>T$TL.I:EXC\>+86-G?FV-QH%S=ZQ8M<6_AZYC_*,GPDJ^;X3#SB_<Q"
ME5BUM'#MU*D9::)^S<'?J[;M'[SQ%F$<)P_C\93FOWF$Y*$DU=RQ?+1I3AJK
MN/M545KV46[-)G\66GZ??ZM?V.E:58WFIZIJ=Y;:?INFZ?;37M_J%_>S);6=
MC8V=LDEQ=WEW<21P6UM!')-/-(D42.[JIJ5^@O\ P3%^!_\ PO3]J_2+"ZMQ
M-H?PQ^&/QJ^.&N2F+S_L?_"J?A;XH\2^%;CRR54&3XA0^#;+S6=/LWVO[2@E
MEACMYOSZK]=C5C*M4HKXJ5.C4EY>UE627K^Z;MV:[G\^RH3AAZ.)>D*U7$4H
M>?L(X>4I+NFZZC?O%KHS^^W_ (-7O^4?'QB_[/)^(/\ ZI+]GFOZ6Z_FD_X-
M7O\ E'Q\8O\ L\GX@_\ JDOV>:_I;K\CS[_D<9A_U_?_ *3$_H+A;_DGLI_[
M!(?^E2"OQG_X+6?\%++/_@GO^S0]GX&O[&?]I/XW+JGA/X/Z5,D]P?#.FPP1
MQ^,?BMJ4=O<V?DVO@ZSOK6T\-I)=-+?^.-9\/,-+U;0=+\4_8/TW_:!^.GP]
M_9F^"OQ*^/GQ5U"XTWP!\*_"NH^*_$4UE##<ZG=06:K'9:-HMI<7-E;WNO\
MB#4YK+0M L9[RSAO=9U&QM);NV29IX_\M?\ ;I_;*^)_[>'[2/CC]H/XGWTQ
MFUB;^P_ OA@2NVF?#[X;:3>W\WA/P/HL)DDC@M=-CU"\U#5)82HUCQ/JVO\
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M??\ JDOVAJ_+LB_Y'&7_ /81'\F?M_%7_).YM_V"O_TN!_ E7]8'[.G_  ;
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MY2_EW^RQ_P '-'_#2_[2'P/_ &?/^&)_^$*_X7+\3?"/PY_X2[_AI'_A)/\
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M_9FW[3W_ *I+QQ7^4!7^K_\ \%%_^4?'[=G_ &9M^T]_ZI+QQ7^4!7VG!?\
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MI\[J1M[T5=7_ +T**_GC_P""9'_!P+\'/VWO'FE? ;XT>"+7]GCXY^(IFM/
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M9)5EALCA4C[N)SGE3JXQ)JTJ>64II4Y6:>-K0G"2J8.2+-%%%?U$?WJ%%%%
M!61K'^HB_P"NO_LC5KUD:Q_J(O\ KK_[(U..Z]5^9,_A?R_-'>Z/_P @JP_Z
M]8?_ $$5I5FZ/_R"K#_KUA_]!%:5<$_CE_BE^;.B'P1_PQ_)!1114E!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7":C_ ,C=IO\ U]Z5_P"E$==W7":C_P C=IO_ %]Z
M5_Z41UM0^*?_ %[G^1G5^%?XH_F>YT445PF@4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ**^?QN.Q685?;8NM*K-+EC=*,81O?EA"*48KO97D]9-N[/K,NRO Y3A_JV
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MGFXKE3=DM$M%L>E@L'1P&%H8/#J2HX>FJ=-3ES244VUS2=KO7<_GD_X*=?\
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M7L_9^R]C:^O)R<EK]^7KWU/X$O\ B%>_X*#_ /18OV-O_#@_&W_Z'FOZDO\
M@CC^PM\6_P#@GK^R7JOP&^-'B+X<^)_%]]\8/&/Q!BU+X7ZOXFUKPVNC>(=!
M\':796TEYXK\(^"M4&IQ7'AZ]>ZA71WM4AEM6BO9W>6.#]6Z*]7'9]F&8T/J
M^)E2=+GC.T*2A+FC>VJ>VKT\_0\'*^%<IR?%?7,%"O&M[.=*]2O*I'DGR\WN
MM)7]U6?34*_BM_;1_P"#<;]M[]HS]K3]HSX\^"/BG^RKI?A#XO?&#QU\0?#6
MF^*O&_Q<L?$ECHWB?7KS5+"VURSTCX':YI=MJ<-O<(EY#8:QJ=K',&6&]N$
MD;^U*BN;+\SQ665*E3"N"E4@H2YX*:Y5)2T3:L[K?L=N;Y)@<[I4J..C4E"C
M4=6'LJCIM2<>5W:3NK/8_FH_X(I?\$;OVG?^"<'Q^^*GQ4^.'CKX#^*O#WCC
MX/S?#[2;/X4^)_B#KFLV^LR>-/"GB-;G4;?Q=\+_  -8PZ8+'0KN(S6VHW=U
M]JDMD%D87EGA_8[_ (*+_P#*/C]NS_LS;]I[_P!4EXXK[)KXV_X*+_\ */C]
MNS_LS;]I[_U27CBKGC:^89EA\3B7%U95L-%N$5"-H3@EHNMMS.EEF%RG)\5@
ML&IQH0H8N:52;J2YJE.<I-R=NNRMH?Y0%?UU_P#!*'_@EA^SK_P4E_X)67ME
M\28KSP/\6/"'[1_Q4L_A[\;?"EE:S^*O#MA<>&/AC>3^'=;L+B2WM/&7@V>[
M>6[_ .$>U6X@FTN\N;Z]\-:MH%YJFK3W_P#(I7^@Y_P;!_\ *-_Q#_V<U\3O
M_40^&%?HG$V(K87+8U\/4E2JT\50<)P=FM)II[IQ:TE&2<9)M233:/R#@G"8
M;'9S/"XNC"O0JX'$J=*HKQ=I4FFMG&479QG%J49)2BTTF?SH?%O_ (-NO^"G
M7@#Q#J&F^ O /P[^.NA0ZC);Z9XD\"?%;P-X82^TUH([FVU&[TCXLZS\/;_3
MIL2_8;ZPC_M!K;5(+J.SN=3TI;36;WT[]F__ (-E?V[OB5XDTC_AH*]\ _LV
M>"&WSZ_=7/B?P_\ %+QS!##?O;?8='\._#_6=3\,7>H7EK']O@GOO'%C86MI
M/ 9Y)-02?2H_] VBOD)<7YM*G[-+"QE:WMHT9>TO:W-:565*_7^%:_2VA^@P
M\/L@C6]JWCIPYK_5YXF'L;7OR\T*,,1R]/X_-9_%?4^2/V*_V*_@?^P=\#]!
M^!WP.T'['IMGLU+Q;XMU)+>7Q?\ $;Q=+;Q0ZEXP\8:E#%%]LU*\\I8;.SA6
M+3-"TR*TT71;2STVS@@7ZWHHKYJK5J5JDZM6<JE2I)SG.;;E*3=VVW_2V6A]
MG1HTL/2IT*%.%*C2A&%.G"*C"$(JRC%+9)??N]6>9?&'X,?"C]H'X>>(OA/\
M:_ 'ACXF?#KQ7:-9ZWX4\6:9#J>G3_*WV:_M&<+=:3K>F3,M[H?B'2+BPU[0
M-3AMM5T34=/U*UMKN+^2?]KK_@U?N+G6/$7BW]B?XZ:98:3=O-?Z5\&_CI!J
M(_LEWG^T7&E:-\6O#=IJES?6"Q236GAVR\2>!OM]JEK8V_B'QKJTUW>Z];?V
M2T5W8#-<=ELF\)7<(2=YTI)3I3>FKA)-*322<X<L[:<UCS<TR+*\YBEC\+&I
M.":IUX.5*O36ND:L&I.*;;5.?/3OJX-G^:UJ_P#P;W?\%:M-U*\L;/\ 9BT[
MQ!:VTQC@UG2/CI^SY#INHH%!%Q9Q:]\4M$UA(225"ZAI5C/N5LP!=K-]D?LX
M_P#!KO\ ME_$'5+.]_:+^(WPN_9X\("XOX=1L=)OI/B[\3&^R1VTMC+8:#X=
METOP -,UAY9K4:C<_$Y=5TEK>2ZF\+WT9@@N?[W:*]BIQ?FU2#C&.$HMJWM*
M=&;FO-*K5JPOUU@U?H?.T?#W(*513G+'XB*=_8UL135-ZWLW0H4*MNFE5.W6
M^I\3?L2?\$^/V8?^"?WP]D\"?L]^"/L>H:IL?QE\3O%1TS6OBO\ $&:%RUJ?
M%_B^TTK2?/T_3\L=*\-Z-I^B>$M(FFO;W2] L]0U35KN^^V:**^:JUJM>I.M
M6J3JU9N\YSDY2D_-OLM$MDDDDDDC[.AAZ&%HPP^&I4Z%&E'EITJ45"$5Y1BD
MKMW;>\FVVVVV<+\3OAGX"^,WP^\8?"KXH^%]+\:_#WQ]H&H>&/%WA?6(Y'L-
M8T74X6AN;=W@D@N[2X3*W%CJ6GW-IJ>EW\-MJ6F7EGJ%K;7,7\2G[97_  :_
M_M#>#/%E_P"(/V*_&OAKXR_#;4[X/8> OB%KNG^!?BKX12[N;YEL)-:U&.V\
M ^-=&TJS@LC-XE;5_!NNW-S?BSA\$7$5C/K%S_=+17?EV;XW*Y2>%J1Y)M.I
M1J1YZ4VM$W&\91DEIS0E&35DVTDCR\XR#+<\A"..I2]I235+$49>SKTU+5Q4
M[2C*+>O)4A."=Y**DVS_ #<?"/\ P;N?\%7O$FK#3=9^ 7A?X?V9A$IU_P 7
M?&[X-7NDAS<VT'V<P^ O&_C?7?.$4\MZ6&BFW^S65R@G-X]G:7?]-O\ P2V_
MX( _"C]B3Q-H/QW^/WB;0_CY^T7HOV+4_"<.GZ1=VGPJ^$.NK:1BXU#PG;:P
MRZGXZ\3Z??-<RZ#X\\2:/X<_LI38ZAHO@G0?$>GP:X?Z(:*[<;Q-FF.I2H2E
M2H4YIQJ1PT)0<XO>,ISJ5)J+^THRCS)N,KQ;1YF6<%9)EE>&)A"OBZU.2E2E
MC:D*D:4T[J<:=*E1IN<7K&4X3<))2C:24E_!?XI_X-<OV_\ 6_$_B/6K3XO_
M +'D=KJ^NZOJEM'<?$#XU)<);ZAJ%Q=PI.D?[/LL:S+',JRK'+*BN&"2.H#'
M^E?_ ((M?L!_&/\ X)R_LM^/?@C\;O$OPT\4^*_%/Q^\4_%33]0^%>L^*=;\
M/0^'M;^'?PK\(VEG>7?B[P;X'U*/68]2\#ZM/<6\&DW%BEC<:=)'J,L\US;6
MGZ\T5AC<^S#'X=X7$2I.DY0E:%)1E>'P^]=OU[G5EG"N4Y3BUC<'"O&NH5(7
MJ5Y5(\M2W-[K25]-'T/CW]O[]GWQG^U5^QM^T#^SQ\/-3\,:-XU^*W@63PQX
M=U3QG>ZKIWA>ROWU73+X3:U>Z'HOB+5K>S\FRE4R6.B:C-YC1@6Y4LZ?QJ?\
M0KW_  4'_P"BQ?L;?^'!^-O_ -#S7]]M%3E^=X[+*4Z.%E24*E3VDE.FIOFY
M8QT;:LK12MZFF;<-97G=>EB,="M*I2I>QA[.LZ:Y.>4]4D[OFE+7L[=#X$_X
M)>_LK_$+]B?]A?X'?LQ_%36?!NO^/?AG_P +,_M[5_A_J&MZKX1N_P#A,_C!
M\0/B!I?]D7_B/P[X4UF?R-&\5Z=;7_VS0+#RM3AO8;?[5:QP7MS]]T45YM:M
M/$5JU>HTZE>K4K5&E9.=2;G)I=%S2=ET6A[&&P]/"8;#X6BFJ6&H4L/24GS2
M5.C3C3@I2ZOEBKOJ]3^0W_@J%_P0&_;%_;8_;H^./[3GPK^)/[-&@> OB9_P
MK/\ L'2/B!XQ^*6E>+[3_A#/@_\ #_X?ZI_:]AX<^#?BO1H//UGPIJ-S8?8]
M?O\ S=,FLIKC[+=23V5MW7_!)#_@A;^UM^P3^V3X>_:'^,'Q$_9T\2>"M)\"
M^//#%SI?PV\6_$O6/%#W_BC2H['3YH++Q1\(O!VDM9PS*6O))-;CFCCP8+>X
M;Y!_5Q17K/B#,7@OJ#E1^K_5EA;>R7/[*--4DN:]^;E7Q=VWVMX$>$LGCF3S
M50Q'UMXR6.YO;R]G[>=5UF^2UN7G;:C>UG;L%?%G[<_[!/[/O_!07X0R?"?X
M[>'YI)M+FO-4^'_Q!T%H++QU\-?$=W;+;2ZQX7U66&>-K6^CBMHM>\.:G!>^
M'O$,-I8MJ6GR7VEZ/?Z;]IT5Y%*K5H5(5J,Y4JM.7-"<&XRBUU37=736S3::
M:;1]!7H4<51J8?$4H5J%6+A4I5(J4)Q>MFGIHTFGO&24DTTF?Y[?[07_  ;-
M_P#!0CX9:_J47P4_X5M^TMX0%V5T'5/#WC#0?AAXON=.:3RTG\1^$_BAK&AZ
M!H6H* T\]AHWC_Q?:1P&/R=6N;AI+:+'^!__  ;4?\%(/B1XAM;+XJ:+\,_V
M=O#2JMQJFO>,OB'X9\=:FD OEM9;71/#_P )M2\:Q:IK/V9CJ5M:ZKK?AO1Y
M;5&BG\06E^4LV_T/**^D7%^;*E[.V%<K6]LZ,O:W_FLJBHW_ .X7+_=/C7X?
M9 ZWM;XY0O?ZLL3'V-OY>9T7B+?]Q^;^\?SG?%'_ (((>"?!G_!-WXB?L??L
MDZIX3D^.'Q1\3?"_Q+\0/CK\<+O4-'N/&MSX(\2Z;KM[8W%YX,\)>+-0\,>$
M[%8-0'@OP5IFDZE:Z:]V9-;UK6=;N=4\3ZA^(?\ Q"O?\%!_^BQ?L;?^'!^-
MO_T/-?WVT5R8;B/-<-&HHUH5'5JRK5)UH*I.4Y1A%ZMJT5&$8QBDHQ6D4E9+
MOQG!V18V5&53#U*4</AX8:E3P]5TJ<:4)SFDXI-RFY5)RG.3<YN3E)N6IYW\
M(/".I> /A-\+_ >LSV-SJ_@GX=^"?".JW.F23S:;<:EX;\-:9HU]/I\UU;65
MU+8RW5E+):27-G:3R0-&TUM!(6B3T2BBO#E)RE*3WDW)^K=W^)]/"*A&,(_#
M",8J^KM%)*[]$%%%%(H_E'_X*W_\$+?VMOV]OVR?$/[0_P '_B)^SIX;\%:M
MX%\!^&+;2_B5XM^)>C^*$O\ POI4ECJ$T]EX7^$7C'25LYIF#6<D>MR321Y,
M]O;M\AX7_@E[_P $!OVQ?V)_VZ/@=^TY\5/B3^S1K_@+X9_\+,_M[2/A_P",
M?BEJOB^[_P"$S^#_ ,0/A_I?]D6'B/X-^%-&G\C6?%>G7-_]LU^P\K3(;V:W
M^U74<%E<_P!>5%>VN(,Q6"^H*5+ZO]7>%M[)<_LI4_9-<U[\W(W[UKW=^Q\S
M+A+)Y9E_:KAB/K:QD<=S>WE[/V\*L:R?):W+SQ7NWVNO0K^,G]O+_@W8_;7_
M &HOVP_VA/V@_ 'Q0_9;T?P9\6/B)J?B[PYIGC#QM\6=/\3V6FWL%I%%!K5E
MHOP1\0:5;7RM YDCL=:U*  J5N7)(']FU%<>7YEBLLJSJX5P4ZD/9RYX*:Y>
M:,M$VK.\5KV/0S?)<#G=&E0QT:DJ=&K[:"IU'3?/RRAJTG=<LFK?,_F+_P""
M+7_!%K]J3_@G+^U)X]^-WQN\>_ 'Q3X4\4_ 'Q3\*]/T_P"%?BGXB:WXAA\0
MZW\1/A7XNM+R\M/%WPK\#Z;'HT>F^!]6@N+B#5KB^2^N-.CCTZ6":YN;3^G2
MBBHQV.KYA7>)Q+BZKC&#<(\BM!66BNK]S7*\KPF4858/!QG&C&<ZB52;J2YI
MM.3YFEIHK+H?D-_P6E_8#^,?_!1K]EOP%\$?@CXE^&GA;Q7X6^/WA;XJ:AJ'
MQ4UGQ3HGAZ;P]HGP[^*GA&[L[.[\(^#?'&I2:S)J7CC29[>WGTFWL7L;?49)
M-1BGAMK:[_F+_P"(5[_@H/\ ]%B_8V_\.#\;?_H>:_OMHKNP.?9AEU!8;#2I
M*DIRG:=)3ES3:;U;VTV/,S/A3*,WQ;QF,A7E7E"%-NG7E3CRTU:/NI-7MHWU
M/._A!X1U+P!\)OA?X#UF>QN=7\$_#OP3X1U6YTR2>;3;C4O#?AK3-&OI]/FN
MK:RNI;&6ZLI9+22YL[2>2!HVFMH)"T2>0?MD_LC?"C]N']G[QI^SO\8H-4'A
M?Q7';7NGZSH5X]CKWA/Q5I+O<^'/%FBR_-;37^B7S"<6&I07>E:G;-<:=J=G
M<V5U-&?J.BO)C6J0JQKPFX58U%5C.+LXS4N92CV:>J/>GAZ-3#RPM6G&I0G2
M=&=.:YHSI./(XR3W3CHS_.U^-W_!MG_P4H^''BB]TWX6>$O /[0WA87C)I7B
MCP=\1O _@6[GL&B\V*YUCP[\5_$?@R72[L']Q<V6G:GX@ABN ?L]_>6V+HYW
MPP_X-M_^"GWCK5M.LO&/@7X8?!?3;J9EO]:\??%OPCKL&EV\:7DC2R67PGN_
MB1?W<TPM(8;."UA=)+G4M/6\N+"U74[O3/\ 1;HKZ9<89LH<G)@W*UO:NC4]
MHW;XK*LJ5^NE-1O]FVA\6_#W(75=3GS!0<K^P6(I>R2O\*;P[K\O2[K.5OM7
MU.1\ :'J7ACP'X)\-:S<6-YJ_A[PCX;T/5;O3(YX=-NM2TG1K*POKC3XKIY+
MJ*QGNK>66TCN7>=(&C69VD#$_%W[>/\ P32_98_X*&^#%T/XX^#?L?CK1]/%
MEX%^-'A#[+H_Q0\#K'<7%W%966MO;7%OKWAA[B]U!KOP;XJL]9\-O)J5[J=A
M8:;XC%AKUA]_T5\W2KUJ%6->C4G2JQES1G3;C)-N[VZ/9Q=XM7333:/LJ^%P
M^*P\L+B:-.OAYP4)TJL5.,DE973^TM'&2M*,DI1::3/X)_VC_P#@UV_;#^'M
MY/?_ +.7Q*^&G[1'AI[ZWM[32]7G/P@^(D-O<P>;+=7>E>(;W5O DUEILZR6
M4]U!\1(M2O@UG>VOA^-;F[M-+^,M(_X-[O\ @K5J6I6=C>?LQ:=X?M;F81SZ
MSJ_QT_9\FTW3D*L3<7D6@_%+6]8>$$!2NGZ5?3[F&("NYE_TI:*^CI\7YM3@
MH2CA*TDK>TJT9J;\VJ56E3OZ01\=6\/L@JU'4A+'X>+=_8T<13=-:WLG7H5Z
MMNG\6]NM]3^.#]C;_@UGEL=;T_Q=^W/\8]&UC2+5!/\ \*<^!-QK(CU2:06\
MUO'XH^*GB#2]#OK*VM@+FSU;0_"GA)I[R22.?2O'UE%:_P"G_P!=?PZ^''@'
MX1>"?#OPW^%W@WPW\/O /A*Q.F^&O!_A'1['0?#VBV;3S7<T5AI>G0P6L+75
M[<W5_>SB,SWVH75U?WDL]Y=3SR=I17C8_-,;F4U+%UG.,6W"E%*%*%]+QA&R
MO;3FES3:T<K'T>59'EF30E# 8:-.4TE4K3;J5ZJ3NE.K)M\J>JA'EIIZJ-]0
MHHHKSSU@HHHH **** "BBB@ HHHH ^7O#'_);]2_["OB7_TGOJ^H:^7O#'_)
M;]2_["OB7_TGOJ^H:[\P^/#_ /8)0_\ ;CGPWP3_ .ODORB%%%%<!T!1110!
M\;?\%%_^4?'[=G_9FW[3W_JDO'%?Y0%?ZO\ _P %%_\ E'Q^W9_V9M^T]_ZI
M+QQ7^4!7Z)P7_NF-_P"PB'_IL_(?$G_?<L_[!:W_ *>1_3OX%_X)N0_MB_\
M!!KX7?'3X9>&?[1_:/\ V<O$OQWU[2OL+7\FK>.OA'IGQ!\7:WXT^'EII=HM
MPNLZY:M)+XK\%V<=G-JMSJ]GJ'AW1V\_Q7+#-_,17^CM_P &Y/\ RBN^$?\
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MP-?^GZQ]+X<?\B?&_P#8RG_ZBX4_SI?^#DS_ )2A>-?^R1_!_P#]1V:O$_\
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MXE^!+>WLY+>=WN([RUOYGF"M'<1(#&?T+_XBH?\ @H/_ -$=_8V_\-]\;?\
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M.K:*JU.24HQC&+A!R<N:4U%P****^-/T<**** "BBB@ HHHH **** "BBB@
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MX/R:ID%"6(PWM<7B\#3Q,\5*I4C5IU:]%5HJGRRY81HN2BDHM346ZBGS-/\
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MQOXS\4:D!DX%YJVN:_KFK7BQ001+<7E[>7$<$$;R.B'^O/\ 9"_X-:/#>O\
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M&D7US>:/^3G["G[:?Q7_ &#?VBO!GQY^%NJ7B1Z;>0:7\0/!_P!IF31/B/\
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M5GNTACNIO#?C;0-/\2Z'+<QVUQ=V\=Q)IFIVKS)!=7,*2,RQ7$R!9&_S@_\
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M/A>XGL(;FVN-8T!9K3X>:?#I,&H_:YM#L+:Q?6[N9;O4/UEK\1?^#A[QS?\
M@S_@E;\<;'3;^33KCQ]XH^$G@:2>![^&[EL+OXD>'O$.JV%O<6,T(ACU+2_#
M=YI^I)?>987VC7.IZ7-#(]]$*^)J9MC<]K8/+\5[*-*KC:+;HPE"24I>S:=Y
MRO&$9R:NKWU;=E;]*I9!EG"V'S#-\#[>=>AEF(26(JPJ1DX159-6IPY9U*E.
M$96?+;2,(W?-_G_?M9_M/?$O]L;]H+XE_M#_ !6U&:Z\3?$'Q#>ZA9Z2+J6Z
MTOP9X82>2/POX#\.^:D;1>'O"&B_9-%TS?&MU>):R:IJDEWK%_J%[<_T>_\
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M%QI>KZ=.]O)-;O-9:A:W%M*\$TL+/$QBD="K'^__ /X-E/C9XA^)W_!/[7_
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M$_\ IF9_'K_P1C_Y-!^/?_9R/@'_ -5AXIK]/Z_,#_@C'_R:#\>_^SD? /\
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MJS='_P"058?]>L/_ *"*TJX)_'+_ !2_-G1#X(_X8_D@HHHJ2@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KA-1_Y&[3?^OO2O_2B.N[KA-1_Y&[3?^OO2O\ THCK:A\4
M_P#KW/\ (SJ_"O\ %'\SW.BBBN$T"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS
M+X5_\C=JW_8*O_\ TYZ=7IM>9?"O_D;M6_[!5_\ ^G/3JVC_ +OB_P#KW'\V
M93^.EZR_0^A:***\DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:=NJ,ZM.-:E4HR;4:M.=.3C9249Q<6XMII-)NUTU?=/8_P TG_B'\_X*Y_\
M1I7_ )GG]F7_ .?/7]BO_!"+]DW]H#]C/]B?6?A'^TGX _X5O\0[OXZ>._&-
MOX?_ .$J\%>,/,\-ZSX<\"6&FZC_ &MX"\1^*=#3[3=Z-J47V-]26_A^S>9<
M6L44UN\O[0T5[>8\18W,\-]5KTL+"GSQJ7HPK1GS0O97G7J1MJ[^[?LT?,Y/
MPAEF28SZ[A*^.J5?93H\N(JX>=/EJ<O,[4\-2ES+E5GSVWNF%%%%>"?5!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA?!7Q]HWAB&RWFXE\8PZ#=ZEX,011@R7,+>*['1Q<V<>U[VV\ZT62-IA(O\
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MJNO^!+@P^,O#=F\:2:A?:3)H*WNGVNN7MTO^G]IGC?PAK'@K3_B1I_B71IO
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MK<V'E4G3Y:DJ*2O4I4I<RY7=<EMK-]/X$J_U?_\ @G1_RCX_83_[,V_9A_\
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M *ANG5_+O_P2Q_Y20?L/_P#9S7PB_P#4OTROZB/^#K__ )(/^R/_ -E<\?\
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M .;O7E<)Y13J_P#"G7M-4YN&&IO5*I&W-6FMKQNE2725YM74&>]Q[Q#5H?\
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M1?\ Y1\?MV?]F;?M/?\ JDO'%?Y0%<?!?^Z8W_L(A_Z;/2\2?]]RS_L%K?\
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M3UNHM#3QYXUN[;0;;7=$\/K<F^TO0--\)>'],D\0;/$&KPZK?Z7X6/AOR?\
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M*C6I5ZLY8R4%'FA*=\'&BJSO3<$ZJI)7IRJ-QE^!]?ZO_P#P3H_Y1\?L)_\
M9FW[,/\ ZI+P/7^4-<6]Q:7$]I=P36MU:S2V]S;7$3PW%O<0NT<T$\,BK)%-
M#(K1RQ2*KQNK(ZA@0/\ 5"_X)4>.]&^(W_!-O]B+Q!H-Q9W5CI_[-OPM\"3R
MV-ZM_"NL_"WPU9?#'Q';O.L,(2\L_$/A#5+34+(HS:=?P7.GO-</:M/)AQHF
M\)@I)>ZL1--]+RIMQ7S49->C.CPVDEF&8P;2D\'"2CU:C7BI.W9.<4_\2/T
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M]\)3P;BTZE2+****_;#^I HHHH **** "LC6/]1%_P!=?_9&K7K(UC_41?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KS+X5_\ (W:M_P!@J_\ _3GIU>FU
MYE\*_P#D;M6_[!5__P"G/3JVC_N^+_Z]Q_-F4_CI>LOT/H6BBBO)-0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH XOXA_\B;K7_7.T_\ 3A:5;^"'_(FS?]AN^_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI_P;N_\ !/W]KK]A;_AL#_AJCX2?\*M_X6E_PS__ ,()_P 5Y\,O&_\ ;O\
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MSO(L)GU"CA\94Q-.%&M[:#PTZ4)N?)*%I.K1K)QM)NRBG>VMM'_)C_P;^?\
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M#A_)LUFJN.P%*M5LDZJE4HU9):)3JX>=*I-):)3E)):))'\I_P %_P#@U/\
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M+PC:6=Y=^+O!OCC39-&DTWQQJT]Q;P:3;WSWUOITD>HQ00W-M=_D-_Q"O?\
M!/C_ *+%^V3_ .'!^"7_ -#S7]+=%/#YIF&$IJCAL75HTE)R4(-*/-)IMZIZ
MNR)QF191CZSQ&,P%#$5W&,'4J1DY.,?A3M):):+38_FD_P"(5[_@GQ_T6+]L
MG_PX/P2_^AYH_P"(5[_@GQ_T6+]LG_PX/P2_^AYK^ENBM_[>SC_H88C[X_\
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MC4:E.+7-:TI13M:UTFK,****X3TPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^(O^"E
MW_*.W]N?_LTK]H+_ -59XHK[=KXB_P""EW_*.W]N?_LTK]H+_P!59XHKIP7^
M^83_ +":'_IV!R8__<<;_P!@F)_],S/X]?\ @C'_ ,F@_'O_ +.1\ _^JP\4
MU^G]?F!_P1C_ .30?CW_ -G(^ ?_ %6'BFOT_K^=?'S_ )./F/\ V 99_P"H
MR/\ +7QR_P"2TH?]B#*__2L2%%%%?C!^.!1110 4444 %%%% !1110 4444
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M4?S/<Z***X30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,OA7_ ,C=JW_8*O\
M_P!.>G5Z;7F7PK_Y&[5O^P5?_P#ISTZMH_[OB_\ KW'\V93^.EZR_0^A:***
M\DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#B_B'_R)NM?]<[3_ -.%I5OX(?\
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M E_P=0_\I!_@[_V9M\/O_5V_M#5_5!_P2F_X*7?\/.?A+\2OBC_PI7_A2/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'R]X8_Y+?J7_85\2_^D]]7U#7R]X8_Y+?J
M7_85\2_^D]]7U#7?F'QX?_L$H?\ MQSX;X)_]?)?E$****X#H"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-+]H'_ ((^_P#!.C]J7XN^
M+?CO\=_V=_\ A.OBMXZ_L'_A*O%7_"V_CGX8_M3_ (1CPSHO@[0_^)'X.^)O
MA[PW8_8?#?A[1]._XEVCV?VG[']LO/M%_<75U/\ I;16U'$5\--SP]>M0FXN
M#G1J3I3<&TW%RA*+<6XQ;BW9N*=KI'/B<)A<9!4L9AL/BJ49JI&GB:-.O",T
MI14U"K&45-1E**DE=*4DG9N_Q-^R;_P3I_8V_8;U7QGK?[+?P=_X5?J?Q"T_
M1]*\87/_  L'XI^-?[7L- N;Z[TF#R?B)XW\6V^G_9+C4KV3S=+BLII_.V7,
MDR1Q+']LT45-6M5KS=6O5J5JDK<U2K.52<N5**O.;<G9))7>B22T15##T,+2
MC0PU"CAZ,.9QHT*<*-*+E)RDXTZ<8PCS2;E*R5Y-MZMA11169L%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7Q%_P4N_Y1V_MS_]FE?M!?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:%X/\,^+=<N[FV^)T'@^]26WTC%DEK)?&]L9+>.X3^['_B(#_P""1G_1VO\
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M)<D+ZQ/6\0\SJU<PHY9&<EA\+1A6J03LIXBM>2E-)Z^SH\BAS:Q<ZC6DKO\
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M** "BBB@ HHHH **** /E[PQ_P EOU+_ +"OB7_TGOJ^H:^7O#'_ "6_4O\
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M,,+]:QM2O2C5G)8:%&5.#E"G=3J2]I2J^ZY)QC91MRMMM3B?GG$_&6)RG'K
MY;1PM>=&G&6,GB(5JD85*MG2HP]E7HVDH-2G=SNZD8KE<)G^N#\&?C'\-_V@
MOA?X+^,_PA\1_P#"7?#7XA:0NO>#_$G]D:]H']KZ4US<6BW7]C^)]+T77]/S
M<6L\?D:II5E<C9O,.QD9O3:\J^!/PUB^#'P0^#?P>AGM[J'X4?"KX>?#6*YL
MXE@M+B+P+X1T?PO'/:P)!;)#;RII0D@B6VMUCB946"( 1KZK7R51052HJ3DZ
M:G)4W)IR<.9\CDTHIRY;7:C%-]%L??475=&DZZBJSI4W64$XP55Q7M%"+E-J
M*G?E3G)I63E)ZLHHHJ#4**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKA-1_P"1NTW_ *^]*_\ 2B.N[KA-1_Y&[3?^OO2O_2B.MJ'Q3_Z]S_(SJ_"O
M\4?S/<Z***X30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8W_$*]_P4'_Z+%^QM_X<'XV__0\T?\0KW_!0?_HL7[&W_AP?C;_]#S7[M?\
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MZ^(7A2SU_4O!/Q3^(>E7'A7P#X:NAK'B[Q3 NC>)]),7_"&>#K'6]6TQ5O;
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M%S9^%/#=SK>DMI3ZG-X;\*-9: ]^EM9Q78AN9H;*S@NFM4_JO_X-?]"_:/\
MB$W[1'[0_P 5/B_\9O%7PKTS2O#GP3^'GA;QGX]\9^)/!6L>)Q=6WBSQ9KEC
MH^MZ_<Z/!JO@'2++PIH>DZA!I,]Q#9>//$.G66H:=$-3M-1]K'\,SR_ 2QM7
M&P;A"DY471:E[6HXQ=*,U5FI.,I-<W*DXQ<FDKV^;RGC:GF^:0RVAEM51J5*
MRAB5B%*/L*2G-5ZE.5&FX*<(I\G,W&4XP4I2:O\ UTT445\L?<A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTE*5:,'9*,%5J_O)4(1_5K_@T]^$WDZ%^V!\=;ID;^T-6^&?PFT-%6V,D/\
M9%GX@\8>*FF9HWNU2Y_MSP<+98I;>V9K2[,\=Y*ELUC_ &'5^)'_  ;S_"(?
M"K_@ES\%]3N+2&RUCXP^)?B1\7=9BB@TU'D.K^+;WPEX;N[B[TV6;^TIK[P-
MX+\*7JSW\G]I6-O/!HEU%;#28[:']MZ^2SZO]9S?'5$[J-9T8VVMAXQH77DW
M3;OUO<^_X5POU/A_*Z5K.>&CB97WYL7*6)L_.*JJ-MU:SV"BBBO(/H#$\3>(
M]&\'>&_$'B[Q'>?V=X>\+:)JWB/7M0^SW5W]AT;0["XU/5+S[)8075]=?9;&
MUGG^SV=M<74^SR[>":9DC;_*)^$_AOQ!^V3^UIK']N6UUK7B+XNZ[\;/BMXD
M2ZO]7U&XFO+/PIX]^+OB34-2U<74>M7,-H-)U#4M6U>6XGOC;6]UJ%S%?2"2
MVG_T8/\ @L;\9)/@9_P3-_:^\8VEQI\&IZY\*K[X5Z2+ZXN[>5[OXSZEIWPH
MGFTDV$T-ZVN:7IGC#4-;TIH&:.UN]+2_OT.F6E\1_'K_ ,&V?P%M?C)^WOXH
M\1:PEQ#H?PI_9W^*FK-J5O:13S0:U\1(-,^#]O965Y-.L>DZI<^&/'GC'4+2
M_FL-7@>'1[VPEL!]M6[M?M>&VL%E6;YD]'&*I4WVG2IN22Z^].O2OZ*VS/S3
MC./]HY[P]DRU4INM6BO^?=>M"$F[Z>[2PM9I;V;O=-'T+_P:I_$*WT?]KG]H
MCX97$JPMXZ_9]@\5V9EFLXDN;WX>?$#PU8?88$F O+B^>P\?ZA?Q06;E!8Z;
MJ5S=1.MO%+!_=M7^<C_P;V>*[OX3_P#!63X:>"O$=O)H^H^-/#/QJ^$^K6][
M+96_]FZUIO@O6_%@T^]>Y+?Z1+K?@&'1K>"RE6ZN-5NK.VB:6*66&;_1NKAX
MMIJ&;.:6E?#4*MUJI6YZ5T_2DE\K]3U/#^LZF0*FV[X;&XFC9Z.-U3KVMZUV
M_5L*_GU_X.'_ -O*/]EO]D*Z^!/@G6/LOQD_:GM-6\%VS6%_:QZEX6^$\(@@
M^(GB&XMX[^+5;7_A)+&Z_P"$&T6Z6R>TN#JOB"XAO(;S0UCD_>GQ=XK\/>!/
M"GB?QQXMU.'1?"G@WP]K7BOQ-K-Q'/+!I/A[P[IMSJ^M:G/%:Q7%U+#8:;9W
M-U)';033ND3+#%)(51O\W+XB^(_BM_P71_X*P6-AH/\ :^D>'?B?XRT_P;X2
M1?.U*W^#7[,WP_-Q<:CXB%CKFK6]E;WEAX6@\1?$76=!CU32=/\ $OQ2\4:K
MI6A16E_XHTZP./#N AB<5+%XFT<'ET?K-:<O@<X7E3@^Z7*ZDEJN6'*U[Z.G
MC#-*F#P$,OP=Y9CF\_J>&IP?[Q0J-0JU(]G+GC1@[Q:G5YXO]V[?GIXU^#<7
MPX_9T^$7Q&\4VYA\9?'_ ,1^*O$?@*P>74X+S3/@[\.Y[GP;<>)[NQEM+?2Y
M]/\ B/\ $6[U_2M!NH[O4;^ ?"/696@TJPU>SFUW_13_ ."''PC7X._\$N_V
M5M,GTA]*U?QSX3UCXN:R\I<W&K-\4?%&M>+_  YJ\VZ*%0ESX'U'PK#9".)4
M&FVUD#+=2>9>7/\ $%_P5K\0P?%[_@I#XX^"7PQL;72/ /P&OOAY^Q-\"O"
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M8X7$U\3@Z\<+0HT+5*N.Q+<U*G0II<T8TG3G[:I*\8)*RE*<(2_M[HK^%?\
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M++\IRS$XW/IT_8UY4*DL9BI3KU?W,>2<VJ3E42=J4$HT::DU%0C%WL_NROX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7A88>,FDJF(JZSQ&+K<MDZ^+Q$JF(K-:>TJ244HI)%%%%>J?0A1110 4444
M%%%% !1110 5D:Q_J(O^NO\ [(U:]9&L?ZB+_KK_ .R-3CNO5?F3/X7\OS1W
MNC_\@JP_Z]8?_016E6;H_P#R"K#_ *]8?_016E7!/XY?XI?FSHA\$?\ #'\D
M%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %<)J/_ "-VF_\ 7WI7_I1'7=UPFH_\
MC=IO_7WI7_I1'6U#XI_]>Y_D9U?A7^*/YGN=%%%<)H%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7F7PK_Y&[5O^P5?_ /ISTZO3:\R^%?\ R-VK?]@J_P#_ $YZ
M=6T?]WQ?_7N/YLRG\=+UE^A]"T445Y)J%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '%_$/\ Y$W6O^N=I_Z<+2K?P0_Y$V;_ +#=]_Z36-5/B'_R)NM?]<[3_P!.
M%I5OX(?\B;-_V&[[_P!)K&NQ_P#(LJ?]A2_](@*/\:/^"7YH]AHHHKRSI"BB
MB@#_ # /^"L'_!.[XM_L$_M,^/+/7O#.IS_ [XB^-O%?B7X%?$F%KC5M!UWP
MCJVLZAJNE^%=7U\6-C;V_P 1O"FF30Z;XMT.ZMK&ZEN+4Z_I=M=>&M5TG4[O
M\MJ_V)_%?A'PIX[\/:GX2\<>&/#WC+PIK4,=OK/AGQ7HNF^(O#VK013Q744&
MIZ+J]M>:;?PQ75O!<QQW5M*B3PQ3*HDC1E^;K#]@C]A?2]:B\2:9^Q=^R;IW
MB*"\DU"#7K#]G/X/V>M0W\K.TM]%JEOX.COH[R1I)&DN4G$SM(Y9R68G[K"<
M9>SP\*>*PDJE:$5%U*52,8U.5)*4HRBW"3^U9R3=VDD^5?EV/\.75Q=6K@<?
M3HX>K-S5&M1E*5'FE>4(3A)*<(W?)>,)*-H2<FG.7\Z7_!IUK6IS_"3]LGP[
M+'>#1M+^(OPEUJPF>UU%+!]3U[PSXQL=6CMKV4?V3<7D5KX;T5KZULB=1LX9
MM/EU0"VOM()_/'_@ZA_Y2#_!W_LS;X??^KM_:&K^]?0]!T/PQI-CH'AK1M)\
M/:%ID/V?3=%T/3K/2=)T^ N\A@L=.L(;>SM(3)(\GEV\,:;W=MNYB3K5XU//
ME3SJMFRPEU5@X?5_;\MKTJ=/F=7V+NVX<[7L]Y6N[7?T=;A9UN&\/P_+'\KH
M3C-XOZMS*5J]2MRJA[>-DE4Y$_:O2/-;7E7^6Y_P1\_Y2<_L6?\ 9;=!_P#2
M/4:_U(Z**Y\ZS?\ M>O1K?5_J_LJ3I<OM?;<UYRGS7]E2MO:UGM>_0[.&\@_
MU>PE?"_6_K?M\0Z_/[#ZORWITZ?)R^VK\WP7YN9;VY=+O\R?^"R__*+W]L[_
M +)'/_ZD6@U_EVU_LD45UY+Q#_9&'JT/J?UCVE9U>?ZQ[+EO"$.7E]A5O\%[
MW6]K:7?G\2<)?ZPXNABO[0^J>PPZH<GU3ZQS6J5*G/S?6:'+\=N7E>U^;6R_
M&W_@W\_Y1%_LE?\ =>?_ %IKXSU^C'[3?[-?PE_:[^"'CK]G[XVZ#+KWP^\?
M:=%::@EC=G3M:T;4K&ZAU+0O$WAS5%CF.F^(?#NKVMGJVE7,D%W927%L+/5M
M/U31[K4-,O/>J*\6OBIU<;6QM/FHSJXJIBH*,VY4I3JRJQ49I1;<&U:2C&[5
M[+8^DPN!IT,MPV6U>7$TJ&"HX*HYTTH5X4J$:$G*DY32C4C%MP<II*7+S2W?
M^87_ ,%#O^"17[5/[ 'C/Q3<ZYX-U_XC_L^VFIN?!_[0/A31I;SPM?Z'<_OM
M.'C>TT^74+CX=^(X8V^P:IIGB,V^G3:K;71\-ZOK^E&TU*Y_*NO]DBOE[Q9^
MQ!^Q;X\U*36?'/[(7[+WC/5YIIKB;5?%GP!^%'B+4I9[@0K<3R7VL>$[RZ>:
M=;>!9I&E+RB"$.S"--OU^$XSG"G&&,PGM:D4DZU&HH<]M+RI2BTI/>3C-1;>
MD(K0_/L?X<4ZE:=3+L?["E.3:P^)I2J^R3=W&%>$U*4(WM",Z;FDES59MN1_
MDTZ/H^K>(=6TO0- TO4=<UW7-1L='T71='L;G4]6UC5M3N8K+3=+TO3;**>\
MU#4=0O)X;2QL;2&:YN[F:*""*261$/\ 8;_P1'_X(1^,="\8^%_VP/VY/ ]]
MX3D\)WVG^(?@G^S[XJLH8=?NM?AAAOM+^(7Q8T.Y$EUX<A\.74D5QX9^'NK0
MV/B=O$]B-3\7V.C:?HUKH_BG^L?X:?LZ_L^_!=$B^#OP*^#GPGBCFEN$C^&G
MPQ\$^!$2>XBG@GG1/"VB:4JS30W5U#+( 'DBN9XW9DFD#>QURYGQ97Q=&>'P
ME!X6%1.-2K*ISUG!Z.,.6,8T^974I7G*S]UQ>IW9)P#ALOQ-/&8_$K'5*,E.
ME0C2]GAXU(ZQG4YI3G6Y)6E&+5./,ESQFM HHHKY _00HHHH _&3_@L'_P $
ME_"/_!2+X967B3PI>VG@[]J#X7Z)?6WPM\7WTT\?A_Q/I#SSZG-\-/',<2S>
M7H.IZA+/<Z-XAMK:74?">LW<M_''?:5>ZUI&I?Y[/[2/[)_[17[(GCFX^'G[
M17PD\9?"_7Q>:I:Z1<^(-'NHO#?B^'1IK>"_U7P)XLBCD\.>-]#@>[M!)K'A
MC4]4L(GNH(;B:&X8PK_K@U@^(_"WACQAIKZ-XM\.:#XITB1F>32O$>D:?K>F
MN[P3VK.]CJ=O=6K,UK=7-LS-$28+B>$DQRR*WTF4<28G+*:P]2FL5A4VX0E-
MPJ4KZM4YVDN1N\G"46KM\LHW=_C>(.#<%G=5XNE5>!QLDE4JQIJI2KJ-DI5J
M7-3;J**Y54C.+:24XSY8V_QU:];^"OP&^,O[1GCK2OAI\#/AMXM^*'CC69O*
MLM \)Z5/J,Z 0SW$EUJ-T FGZ/IT%M:W5S=:IJ]W8Z;:6UM<7%U=0PPR.O\
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M7B\-\)?ZO8NOBO[0^M^WP[H<GU3ZORWJ4ZG/S?6:_-\%N7E6]^;2S*_RW/\
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MH6LIO](NO\WS_@M]9:M\ O\ @LG\7OB'IBM<2+XI^!?QM\+B74"EQ-/:^ _
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M/QO\":19?V==QSC1/#BZ_I6GZ3";Z/5XM(L;2'4+I-62YE'^HA7^8;_P6?\
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M_P ,+9+>"&WGUG7=%\47?A2%8+6.]OK>";4=0ME$<":C=PQO,L:WMPBB=_\
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MHM#M)(+@VTEKIT+VL5M;F*VB_P Q_P#X9]_MC]L#_AE;X=>)O^%CC5/VD_\
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M(IO]/D@^&7AJP\-Z'+=1QQEDTN:Z^)^JO''<S10WE_IL<UO!=S:3)+8>X?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHR/\M?'+_DM*'_8@RO\ ]*Q(4445^,'XX%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!>TW3KW5]0LM+TZ"2ZO\ 4+J&SM+>-2SRSW$BQQH
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MZP_^@BM*LW1_^058?]>L/_H(K2K@G\<O\4OS9T0^"/\ AC^2"BBBI*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "N$U'_ )&[3?\ K[TK_P!*(Z[NN$U'_D;M-_Z^]*_]
M*(ZVH?%/_KW/\C.K\*_Q1_,]SHHHKA- HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\R^%?_ "-VK?\ 8*O_ /TYZ=7IM>9?"O\ Y&[5O^P5?_\ ISTZMH_[OB_^
MO<?S9E/XZ7K+]#Z%HHHKR34**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .+^(?_(F
MZU_USM/_ $X6E6_@A_R)LW_8;OO_ $FL:J?$/_D3=:_ZYVG_ *<+2K?P0_Y$
MV;_L-WW_ *36-=C_ .194_["E_Z1 4?XT?\ !+\T>PT445Y9TA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>ZMVOY;_ ,"^"_$6O>';DOJ5KJ O9)O'O_",'40$2_:PEO[FSO;*^BAO8/\
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MV]90D_5L^@X3POU3A[+*=K2J4/K,G:S;Q4Y8B-_2%2,5Y104445XQ]$%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"TY*U!26U7%SM0A9\T8RJ54FJ4D?JG@]X>UO$7C'!Y94A-9+@.3,<^KQNE'
M4:D;82,TURU\PJ\N%I6?/"$JV(BI1P\T?0>BZ/I_A_2=/T32H%MM.TNTAL[2
M%<?)#"H4%B H9W.7D; WR,S$ FM.BBO[>ITZ=&G3I4H1ITJ4(TZ=.$5&%.G"
M*C"$(JRC&,4HQBDDDDEH?ZGT:-+#4:6'P].%&A0I4Z-&C2BH4Z5*E%0ITZ<(
MI1A"$(QC",4E&*222044459J%%%% !1110 4444 %%%% !1110 5D:Q_J(O^
MNO\ [(U:]9&L?ZB+_KK_ .R-3CNO5?F3/X7\OS1WNC_\@JP_Z]8?_016E6;H
M_P#R"K#_ *]8?_016E7!/XY?XI?FSHA\$?\ #'\D%%%%24%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<)J/_ "-VF_\ 7WI7_I1'7=UPFH_\C=IO_7WI7_I1'6U#XI_]
M>Y_D9U?A7^*/YGN=%%%<)H%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F7PK_Y&
M[5O^P5?_ /ISTZO3:\R^%?\ R-VK?]@J_P#_ $YZ=6T?]WQ?_7N/YLRG\=+U
ME^A]"T445Y)J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%_$/\ Y$W6O^N=I_Z<
M+2K?P0_Y$V;_ +#=]_Z36-5/B'_R)NM?]<[3_P!.%I5OX(?\B;-_V&[[_P!)
MK&NQ_P#(LJ?]A2_](@*/\:/^"7YH]AHHHKRSI"BBB@ HHHH **** "BBB@ H
MHHH **_+;_@H5_P5T_9B_P"";'B3X:>$?CAX:^,OC#Q#\4-$\0>(])T_X2>%
MO">M_P!C:-H%_IVF+>>(+OQIX\\ 6,?]LWUY=P:5;Z+<ZW=)_8NI2:Q!I,,V
MCR:M]2_L9_M9^!?VX/V>_!W[2WPQ\*?$#PC\/O'M]XJM/"]G\2[+PEIOB>_@
M\'^*-6\&ZMJ<FG>#O&7CC3[*Q;Q'H.LV%I'>ZM!J4PT][M]/ALKFQN+KIG@\
M53PU/%SH3AAJLN2G6DDH3E[VD;N[;Y)M::J+:T5SBIYC@:N,JY?3Q-.>-H0]
MI6P\6W4IPM3?-.RLE^]IK?>:6^A]24445S':%%%?EI_P4)_X*Y_LU?\ !-?Q
M/\-O"7QR\(_&?Q;J_P 4-!UWQ'H<?PET#P#KR:;IN@:A9:9.^O+XO^)7@2ZL
MVOKJ]*Z8UG;:A!<BROP\\,EOY;[8?#U\55C0P]*56K)-QA!7DU%.4GK9623;
MNSFQ>+PV!H3Q.+K0H4(.*G5J-J,7.2A%.R;]Z4DEIU['ZET5\L?L8_M<?#W]
MN3]GSPC^TG\*_#/Q"\*^ O&VH>*=/T&P^)NC:)H?B:?_ (1'Q+JGA/5+TVOA
MSQ+XMT:73Y-9T;4;>TN;/7;O>UM-%<);74,]M%]3U%2G.E4G2J1<*E.<H3@]
MXSBW&47YIII^9K1K4\12I5Z,U4HUJ<*M*I&_+.G4BI0G&]G:46FM-F%%%%0:
M!117XT_M._\ !>K_ ()P?LO^*-7\"ZG\5-;^,GC7P_\ :(]<T#X!>'X/']KI
ME_!'8R+I$OC6]U?PY\-[O5W-W/;76GZ9XSOIM"U'2M4TKQ.-#U2WBL[CHP^%
MQ.+FZ>&H5:\TKM4H2GRKO)I6BKZ7DTKZ7N<F+QV"P%-5<;BJ&%IM\L95ZD:?
M/+?E@I-.<K:N,$VE=VLFS]EJ*_G@^'O_  <Y?\$V/&FN1Z3XDL/VC?A)8.T*
MMXG^(7PMT#4M#A$KE7>2W^%/Q ^)OB4K;J!),(?#TKLC 6Z3R;HQ^Y7P8^.7
MP@_:*\!:;\4/@=\1?"OQ1\ :K<7EG9^*/"&J0ZIIQO\ 3Y1#?Z;=>65N-/U.
MRD9!=Z9J$%K?VZRPO-;HDT3/IB<OQN#2>*PM>A&324YTY*#;5^53LX.5M>7F
MNNJ,L%FV69BW' X[#8F<5>5.E5BZL8Z+F=)M5%&[2YG'EOI>YZK1117&>@%%
M?-G[3/[8/[,_[''A"Q\<?M+_ !A\*_"?0-7N+JTT)=:;4=2U_P 27-@ML^H0
M^%O!_ARPUGQ?XHDTV.\LY-37P_H6I?V;'>6DE]]G2Z@:3\5)_P#@Z*_X)TQ>
M(5T6/P+^U9=::=1M[$^+H/AM\.%\/+;32Q1R:PUM<_&2W\5G3K1)'GN(E\,-
MJS10RBTTNZF,,,W=ALMQ^+@ZF&PE>M36G/"F^1M.S49.T9-/=1;:ZI'F8S.<
MJR^HJ6,S#"X>J[/V52K'VB3LU*5-7G"+3NI22BU=INS/Z/J*^2_V4/VZ/V4_
MVW/#%[XH_9H^,?AKXB+HZP'Q+X907V@>//"9N&:.%O$_@/Q)::5XKTBQN;F.
MYM-.UN?2CX>UN>SO?[!U;5(K:65?K2N2I2J49RIUJ<Z52#M*G4C*$XO>THR2
MDM-=5MJ=U&O1Q%*%;#U:=>C45X5:4XU*<UWC.#<6NFCWT"BBOS6_:^_X*W_L
M(?L1Z[;^#?C1\9;:\^(DS2>?\-_AQI5[\0?&.C0PO''/-XIM=!672_!S*9HG
MM[#Q9JVBZMJD1EGT;3]1AM+V2VNAAZ^)J*EAZ-2M4>JA2A*<K+=M13LEU;LE
MU:(Q.+PN#I.MB\11PU%-)U*]2%*%WHES3:3DWLE=OHC]*:*_F[T/_@Z/_P""
M=FK7\=G?_#W]K+PS;OLW:KKGPW^&-Q81;IH8CYD?AOXU^(-4/EI(]R_E:;)F
M&WF5-]PT$$W[1_LR?MI_LL_MD^'M0\3?LT?&GPE\5-/TB98=9LM,_M31?$^B
MEXK::*76O!?BK3M!\8:/:SK=PI;WFI:%:VEQ.)[6">2YM;J*'HQ.69AA(\^)
MPE>E3_GE3?(F[)*4U>,6V[)2:;Z''@\ZRG,)^RP>886O5M?V4*L55:M=N-.7
M+.22^)QBU'K:Z/J&BBBN$]0**_-?]H7_ (*^?\$[/V5/BUXE^!GQZ_:)A\#?
M%3P?#H4_B7PI%\+/C9XM?2$\2Z!IGBC1%N-8\$?#?Q+H#37V@:SI>IK;P:K+
M<06]] +F*&5C&/%?^(@/_@D9_P!':_\ F!OVFO\ YS%=L,MS&I"-2G@,;.$X
MJ4)PPM>4)QDKQE&4:;4HR3333::=T['FU,YR>E4G2JYMEM*K3G*G4IU,=A85
M*<X-QG"<)55*,XR3C*,DG%III-'[)45^-O\ Q$!_\$C/^CM?_,#?M-?_ #F*
M^VOV3OVZ_P!E?]N/2/&6O?LN?$^;XGZ/\/\ 4=)TCQ;J#> OB9X(@TS4M<MK
MR\TVSC/Q%\&^$6U2:6UL+B:<:0M^MBGV<W[6QO+,3S5P&.H0=6O@L71IQMS5
M*N&K4X1YFHJ\YP45=M)7>K:2U9=#-<KQ56-'#9E@,16DI.-*AC,/6JR44Y2<
M:=.I*;48IRE9.R3;T1]<4445R'>%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%% !1110 5\1?\%+O^4=O[<__9I7[07_ *JSQ17V[7Q%_P %+O\ E';^W/\
M]FE?M!?^JL\45TX+_?,)_P!A-#_T[ Y,?_N.-_[!,3_Z9F?QZ_\ !&/_ )-!
M^/?_ &<CX!_]5AXIK]/Z_,#_ ((Q_P#)H/Q[_P"SD? /_JL/%-?I_7\Z^/G_
M "<?,?\ L RS_P!1D?Y:^.7_ "6E#_L097_Z5B0HHHK\8/QP**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ***M6-E=:E>VNGV,$ES>WMQ#:VMO$-TDUQ/(
ML<4:#U=V YP!G)( )JHQE.480BY3G)1C&*;E*4G:,8I:MMM)):MNR*ITYU9P
MI4X2J5*DXTZ=.$7*<YS:C"$(Q3E*4I-1C%)MMI)-L]P_9]^&;?$'QG#<W\#/
MX;\./#J.JLROY5U.K[K'3-X* FYE3S)U#;A:Q2Y7YUS^IJJJJJJH55 554 *
MJ@8"J!@     # ' KS?X4?#^T^&_@W3M!B6-M0=%O=;NT5<W6JSHGV@[P6+0
MV^%MK<%F BB##!=J])K^V/#GA*/"7#U&A6A%9KC^7&9I/1RC5E']UA.9;PPE
M-^SM=Q=:5>I'2I8_U'\%?#N'AYP=AL+BJ48Y_F_L\RSZI9.<,1.G^XR_GZT\
MNHR]C9-P>)GBJT':L%%%%??'Z^%%%% !1110 4444 %%%% !1110 4444 %9
M&L?ZB+_KK_[(U:]9&L?ZB+_KK_[(U..Z]5^9,_A?R_-'>Z/_ ,@JP_Z]8?\
MT$5I5FZ/_P @JP_Z]8?_ $$5I5P3^.7^*7YLZ(?!'_#'\D%%%%24%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<)J/_(W:;_U]Z5_Z41UW=<)J/\ R-VF_P#7WI7_ *41
MUM0^*?\ U[G^1G5^%?XH_F>YT445PF@4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>9?"O\ Y&[5O^P5?_\ ISTZO3:\R^%?_(W:M_V"K_\ ].>G5M'_ '?%_P#7
MN/YLRG\=+UE^A]"T445Y)J%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%_$/_D3=
M:_ZYVG_IPM*M_!#_ )$V;_L-WW_I-8U4^(?_ ")NM?\ 7.T_].%I5OX(?\B;
M-_V&[[_TFL:['_R+*G_84O\ TB H_P :/^"7YH]AHHHKRSI"BBB@ HK^:7_@
MM1_P6M^./_!.WX]_#+X'_L_>#_@AXQU#7/A8GQ&\?3?%30?''B*XTE];\3ZW
MH7A?3=,/@SXC^!8M.F>U\,:MJ.H6NIQZC=2VU]H]U#]DMID:\ZGQ)_P72_X9
MX_X)S? ']I+]I;PU\//$7[7?[2/AS7/&'PX_9U^%/]O>$-$/@U_&.O:1X7\;
M^);GQ+X@^(6O>&_!K^&--T_5)]8N9[FX\4^)+V;PUX5TUK;3->UW0?6CDN83
MH83$0HJ<<;-4\/",TZDFU.7-*+LH04:<I.<FHQC9R:31X,^)<HI8K'X2KB)4
MIY;2=7%U)TY*C!*5*/)&:NZE64ZT80I0C*<YJ481;6O]&-%?Y^WQ:_X+*_\
M!>=+67XVWWASQM\"OA"M[:V;/I/['MA:?!Z&\>.;6H[ ^-OBW\/_ !QKBW%[
MI#JY@D^(37+:1;1WMKY4IN+^;]E/^",7_!=K6OVQ?&*_LQ?M9V?A+P]\:O\
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MD>']#@\)^';&\\1V45Q?-H]E?Z_")I-0K]]?^(2;_K(!_P":J?\ Y2-> _\
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MBBO)/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E
M[PQ_R6_4O^PKXE_])[ZOJ&OE[PQ_R6_4O^PKXE_])[ZOJ&N_,/CP_P#V"4/_
M &XY\-\$_P#KY+\HA1117 = 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>X_FS*?QTO67Z'T+1117DFH4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^(O^"E
MW_*.W]N?_LTK]H+_ -59XHK[=KXB_P""EW_*.W]N?_LTK]H+_P!59XHKIP7^
M^83_ +":'_IV!R8__<<;_P!@F)_],S/Y=?\ @W4\$>%_'O[//[2&C^+-,_M;
M3K;XS>#]2AM_MNH6.R]A\$7EK'-YVFW=G.VV"\N8_+>5H3YFYHRZ1LO]"O\
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M-OP6_P"A,_\ +B\6?_+VO<J*/]3N$?\ HEN'/_#'EG_S*'_$-?#K_H@>"O\
MQ%<B_P#F \-_X9M^"W_0F?\ EQ>+/_E[1_PS;\%O^A,_\N+Q9_\ +VO<J*/]
M3N$?^B6X<_\ #'EG_P RA_Q#7PZ_Z('@K_Q%<B_^8#PW_AFWX+?]"9_Y<7BS
M_P"7M'_#-OP6_P"A,_\ +B\6?_+VO<J*/]3N$?\ HEN'/_#'EG_S*'_$-?#K
M_H@>"O\ Q%<B_P#F \-_X9M^"W_0F?\ EQ>+/_E[1_PS;\%O^A,_\N+Q9_\
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MA_Q#7PZ_Z('@K_Q%<B_^8#PW_AFWX+?]"9_Y<7BS_P"7M'_#-OP6_P"A,_\
M+B\6?_+VO<J*/]3N$?\ HEN'/_#'EG_S*'_$-?#K_H@>"O\ Q%<B_P#F \-_
MX9M^"W_0F?\ EQ>+/_E[1_PS;\%O^A,_\N+Q9_\ +VO<J*/]3N$?^B6X<_\
M#'EG_P RA_Q#7PZ_Z('@K_Q%<B_^8#PW_AFWX+?]"9_Y<7BS_P"7M'_#-OP6
M_P"A,_\ +B\6?_+VO<J*/]3N$?\ HEN'/_#'EG_S*'_$-?#K_H@>"O\ Q%<B
M_P#F \-_X9M^"W_0F?\ EQ>+/_E[1_PS;\%O^A,_\N+Q9_\ +VO<J*/]3N$?
M^B6X<_\ #'EG_P RA_Q#7PZ_Z('@K_Q%<B_^8#PW_AFWX+?]"9_Y<7BS_P"7
MM'_#-OP6_P"A,_\ +B\6?_+VO<J*/]3N$?\ HEN'/_#'EG_S*'_$-?#K_H@>
M"O\ Q%<B_P#F \-_X9M^"W_0F?\ EQ>+/_E[1_PS;\%O^A,_\N+Q9_\ +VO<
MJ*/]3N$?^B6X<_\ #'EG_P RA_Q#7PZ_Z('@K_Q%<B_^8#SWP=\*O /@&[N[
M_P )^'X]*O+V!;:XN&U#5M0D:!'\P1QG5+^]\A6?#2>0(C+M02%PB!?0J**]
MG!X'!9=0CA<OP>%P&%@Y2AAL'AZ.%H1E.3E.4:-"$*<7.3<I-13E)MN[9]-E
MF597DN$A@,GRW 93@*<ISIX++,'A\!A*<ZLG.K.&&PM.E1C*I-N<Y1@G.3<I
M-MMA11174=X4444 %%%% !1110 4444 %%%% !1110 4444 %9&L?ZB+_KK_
M .R-6O61K'^HB_ZZ_P#LC4X[KU7YDS^%_+\T=[H__(*L/^O6'_T$5I5FZ/\
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M#*G.IA*%L)B90BVZ24ZLDWJES3IXFLZ:T4I4G%M71_I[5\3_ /!0W]LGPO\
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M"^M]4T_1[\C1M/L=7UE=2AT+\8+_ .)]W\0/C5+\8?CU'KGQ<N/%GQ)C\?\
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M(UW!?(OC5=%MKWQN+:ZM9;BUDL?^$MO-9.GBVN+F".Q^SQ0W5S&BSR?R4?\
M!O\ _P#!'WQMXM^(O@;]O']I'PM-X:^''@#5H_$OP$\!>)=/OK/Q#X[\<Z/<
M"70/BA=V,DMG/HWA/P7J\$6K^$)+V"2X\4^([&SU>WMHO#NFVMWX@_N KJXE
MQ>'C#!Y1@Y*='+XVJS333K**IJ-UHYP7/*JU=<]1Q=I1DCAX-P&,E/,.(,QA
M*GB<VGS4:<DXN.&<O:N?*U>-.HW3C1B[/V5*,K.,XL****^4/O HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y>\,?\EOU+_L*^)?_
M $GOJ^H:^7O#'_);]2_["OB7_P!)[ZOJ&N_,/CP__8)0_P#;CGPWP3_Z^2_*
M(4445P'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGQ:7I%G;Z'X-^)?AWPY80VMG"JL+#2+5KF=Y[V[:>]N;BXE^\/ /@7PI\+_
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MC%_W[3_"CR(/^>,7_?M/\*/K."_Z %_X43\O[O\ 7S8>SK?\_O\ R1>7]?\
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MC%_W[3_"CR(/^>,7_?M/\*/K."_Z %_X43\O[O\ 7S8>SK?\_O\ R1>7]?\
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MC%_W[3_"CR(/^>,7_?M/\*/K."_Z %_X43\O[O\ 7S8>SK?\_O\ R1>7]?\
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MC%_W[3_"CR(/^>,7_?M/\*/K."_Z %_X43\O[O\ 7S8>SK?\_O\ R1>7]?\
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MC%_W[3_"CR(/^>,7_?M/\*/K."_Z %_X43\O[O\ 7S8>SK?\_O\ R1>7]?\
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MC%_W[3_"CR(/^>,7_?M/\*/K."_Z %_X43\O[O\ 7S8>SK?\_O\ R1>7]?\
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MC%_W[3_"CR(/^>,7_?M/\*/K."_Z %_X43\O[O\ 7S8>SK?\_O\ R1>7]?\
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MC%_W[3_"CR(/^>,7_?M/\*/K."_Z %_X43\O[O\ 7S8>SK?\_O\ R1>7]?\
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MC%_W[3_"CR(/^>,7_?M/\*/K."_Z %_X43\O[O\ 7S8>SK?\_O\ R1>7]?\
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MC%_W[3_"CR(/^>,7_?M/\*/K."_Z %_X43\O[O\ 7S8>SK?\_O\ R1>7]?\
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M'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\
MP9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W
M]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.
M2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_
M .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?
MU_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y
M<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_
MY\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7
M_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-
M'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\
MP9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W
M]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.
M2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_
M .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?
MU_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y
M<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_
MY\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7
M_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-
M'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\
MP9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W
M]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.
M2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_
M .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?
MU_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y
M<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_
MY\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7
M_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-
M'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\
MP9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W
M]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.
M2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_
M .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?
MU_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y
M<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_
MY\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7
M_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-
M'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\
MP9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W
M]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.
M2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_
M .>:?]\K_A1Y<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?
MU_P[.$_X3&X_Y\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y
M<?\ SS3_ +Y7_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_
MY\H?^_K_ /Q-'_"8W'_/E#_W]?\ ^)KN_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7
M_"CVE+_GPO\ P9+_ "\OS[L.2I_S\_\ )5Y?U_P[.$_X3&X_Y\H?^_K_ /Q-
M8L^KR3ZI;ZH845[>6VE6(,Q5C;2+(H+$9 8K@D#@'BO5?+C_ .>:?]\K_A7#
M:@JCQ;IH  'VO2^  !S<1YXZ<UI2G3;ERTN5J$G?G;NDE=6:Z]_\R)QFDKSN
MKKIZ6?GK_GU9K_\ "RKS_H%VW_?^7_XBC_A95Y_T"[;_ +_R_P#Q%>M[$_NK
M_P!\C_"C8G]U?^^1_A7+[6A_T#+_ ,&2_P#D2^2I_P _/_)5Y?U_P[/)/^%E
M7G_0+MO^_P#+_P#$4?\ "RKS_H%VW_?^7_XBO6]B?W5_[Y'^%&Q/[J_]\C_"
MCVM#_H&7_@R7_P B')4_Y^?^2KR_K_AV>2?\+*O/^@7;?]_Y?_B*/^%E7G_0
M+MO^_P#+_P#$5ZWL3^ZO_?(_PHV)_=7_ +Y'^%'M:'_0,O\ P9+_ .1#DJ?\
M_/\ R5>7]?\ #L\D_P"%E7G_ $"[;_O_ "__ !%'_"RKS_H%VW_?^7_XBO6]
MB?W5_P"^1_A1L3^ZO_?(_P */:T/^@9?^#)?_(AR5/\ GY_Y*O+^O^'9Y)_P
MLJ\_Z!=M_P!_Y?\ XBC_ (65>?\ 0+MO^_\ +_\ $5ZWL3^ZO_?(_P *-B?W
M5_[Y'^%'M:'_ $#+_P &2_\ D0Y*G_/S_P E7E_7_#L\D_X65>?] NV_[_R_
M_$4?\+*O/^@7;?\ ?^7_ .(KUO8G]U?^^1_A1L3^ZO\ WR/\*/:T/^@9?^#)
M?_(AR5/^?G_DJ\OZ_P"'9Y)_PLJ\_P"@7;?]_P"7_P"(H_X65>?] NV_[_R_
M_$5ZWL3^ZO\ WR/\*-B?W5_[Y'^%'M:'_0,O_!DO_D0Y*G_/S_R5>7]?\.SR
M3_A95Y_T"[;_ +_R_P#Q%'_"RKS_ *!=M_W_ )?_ (BO6]B?W5_[Y'^%&Q/[
MJ_\ ?(_PH]K0_P"@9?\ @R7_ ,B')4_Y^?\ DJ\OZ_X=GDG_  LJ\_Z!=M_W
M_E_^(H_X65>?] NV_P"_\O\ \17K>Q/[J_\ ?(_PHV)_=7_OD?X4>UH?] R_
M\&2_^1#DJ?\ /S_R5>7]?\.SR3_A95Y_T"[;_O\ R_\ Q%'_  LJ\_Z!=M_W
M_E_^(KUO8G]U?^^1_A1L3^ZO_?(_PH]K0_Z!E_X,E_\ (AR5/^?G_DJ\OZ_X
M=GDG_"RKS_H%VW_?^7_XBC_A95Y_T"[;_O\ R_\ Q%>M[$_NK_WR/\*-B?W5
M_P"^1_A1[6A_T#+_ ,&2_P#D0Y*G_/S_ ,E7E_7_  [/)/\ A95Y_P! NV_[
M_P O_P 11_PLJ\_Z!=M_W_E_^(KUO8G]U?\ OD?X4;$_NK_WR/\ "CVM#_H&
M7_@R7_R(<E3_ )^?^2KR_K_AV>2?\+*O/^@7;?\ ?^7_ .(H_P"%E7G_ $"[
M;_O_ "__ !%>M[$_NK_WR/\ "C8G]U?^^1_A1[6A_P! R_\ !DO_ )$.2I_S
M\_\ )5Y?U_P[/)/^%E7G_0+MO^_\O_Q%'_"RKS_H%VW_ '_E_P#B*];V)_=7
M_OD?X4;$_NK_ -\C_"CVM#_H&7_@R7_R(<E3_GY_Y*O+^O\ AV>2?\+*O/\
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MHBS7$%P6#*I)*F * 0 0Q)Y KWW8G]U?^^1_A7F7PL56\6ZJ&56 TJ^(# $
M_P!IZ>,X(QTK2-2BZ->7L$HQA%RC[23YU?:]M+?CL1*,U*"<[MMV=EIHK^O]
M/JRW_P +BU#_ * MG_X%3_\ QNC_ (7%J'_0%L__  *G_P#C=>\>3%_SRC_[
MX7_"CR8O^>4?_?"_X5P?6,)_T!+_ ,'2\O[O]?-E\D_^?K_\!7^?E^?=G@__
M  N+4/\ H"V?_@5/_P#&Z/\ A<6H?] 6S_\  J?_ .-U[QY,7_/*/_OA?\*/
M)B_YY1_]\+_A1]8PG_0$O_!TO+^[_7S8<D_^?K_\!7^?E^?=G@__  N+4/\
MH"V?_@5/_P#&Z/\ A<6H?] 6S_\  J?_ .-U[QY,7_/*/_OA?\*/)B_YY1_]
M\+_A1]8PG_0$O_!TO+^[_7S8<D_^?K_\!7^?E^?=G@__  N+4/\ H"V?_@5/
M_P#&Z/\ A<6H?] 6S_\  J?_ .-U[QY,7_/*/_OA?\*/)B_YY1_]\+_A1]8P
MG_0$O_!TO+^[_7S8<D_^?K_\!7^?E^?=G@__  N+4/\ H"V?_@5/_P#&Z/\
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M_7S8<D_^?K_\!7^?E^?=G@__  N+4/\ H"V?_@5/_P#&Z/\ A<6H?] 6S_\
M J?_ .-U[QY,7_/*/_OA?\*/)B_YY1_]\+_A1]8PG_0$O_!TO+^[_7S8<D_^
M?K_\!7^?E^?=G@__  N+4/\ H"V?_@5/_P#&Z/\ A<6H?] 6S_\  J?_ .-U
M[QY,7_/*/_OA?\*/)B_YY1_]\+_A1]8PG_0$O_!TO+^[_7S8<D_^?K_\!7^?
ME^?=G@__  N+4/\ H"V?_@5/_P#&Z/\ A<6H?] 6S_\  J?_ .-U[QY,7_/*
M/_OA?\*/)B_YY1_]\+_A1]8PG_0$O_!TO+^[_7S8<D_^?K_\!7^?E^?=G@__
M  N+4/\ H"V?_@5/_P#&Z/\ A<6H?] 6S_\  J?_ .-U[QY,7_/*/_OA?\*/
M)B_YY1_]\+_A1]8PG_0$O_!TO+^[_7S8<D_^?K_\!7^?E^?=G@__  N+4/\
MH"V?_@5/_P#&Z/\ A<6H?] 6S_\  J?_ .-U[QY,7_/*/_OA?\*/)B_YY1_]
M\+_A1]8PG_0$O_!TO+^[_7S8<D_^?K_\!7^?E^?=G@__  N+4/\ H"V?_@5/
M_P#&Z/\ A<6H?] 6S_\  J?_ .-U[QY,7_/*/_OA?\*/)B_YY1_]\+_A1]8P
MG_0$O_!TO+^[_7S8<D_^?K_\!7^?E^?=G@__  N+4/\ H"V?_@5/_P#&Z/\
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M_7S8<D_^?K_\!7^?E^?=G@__  N+4/\ H"V?_@5/_P#&Z/\ A<6H?] 6S_\
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M:?X4>1!_SQB_[]I_A1]9P7_0 O\ PHGY?W?Z^;#V=;_G]_Y(O+^O^'9\T_\
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M:?X4>1!_SQB_[]I_A1]9P7_0 O\ PHGY?W?Z^;#V=;_G]_Y(O+^O^'9\T_\
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M:?X4>1!_SQB_[]I_A1]9P7_0 O\ PHGY?W?Z^;#V=;_G]_Y(O+^O^'9\T_\
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M:?X4>1!_SQB_[]I_A1]9P7_0 O\ PHGY?W?Z^;#V=;_G]_Y(O+^O^'9\T_\
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M:?X4>1!_SQB_[]I_A1]9P7_0 O\ PHGY?W?Z^;#V=;_G]_Y(O+^O^'9\T_\
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M:?X4>1!_SQB_[]I_A1]9P7_0 O\ PHGY?W?Z^;#V=;_G]_Y(O+^O^'9\T_\
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M:?X4>1!_SQB_[]I_A1]9P7_0 O\ PHGY?W?Z^;#V=;_G]_Y(O+^O^'9\T_\
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M:?X4>1!_SQB_[]I_A1]9P7_0 O\ PHGY?W?Z^;#V=;_G]_Y(O+^O^'9\T_\
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M:?X4>1!_SQB_[]I_A1]9P7_0 O\ PHGY?W?Z^;#V=;_G]_Y(O+^O^'9\T_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ=6T?]WQ?_7N/YLRG\=+UE^A]"T445Y)J%%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E[PQ_R6_4O^PKXE_]
M)[ZOJ&OE[PQ_R6_4O^PKXE_])[ZOJ&N_,/CP_P#V"4/_ &XY\-\$_P#KY+\H
MA1117 = 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\1?
M\%+O^4=O[<__ &:5^T%_ZJSQ17V[7Q%_P4N_Y1V_MS_]FE?M!?\ JK/%%=."
M_P!\PG_830_].P.3'_[CC?\ L$Q/_IF9_%Y_P1S_ .2&?$__ +*Q+_ZA_ABO
MUXK\A_\ @CG_ ,D,^)__ &5B7_U#_#%?KQ7\R>-__)T.*/\ %D__ *H,J/\
M)OQ=_P"3A9[_ ->LC_\ 6>RH****_*3\V"BBB@ HHHH **** "BBB@ HHHH
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M#P\US1>)J8F2Y:N%BQ]%%%?TN?W(%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9&L?ZB+_KK_
M .R-6O61K'^HB_ZZ_P#LC4X[KU7YDS^%_+\T=[H__(*L/^O6'_T$5I5FZ/\
M\@JP_P"O6'_T$5I5P3^.7^*7YLZ(?!'_  Q_)!1114E!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7":C_P C=IO_ %]Z5_Z41UW=<)J/_(W:;_U]Z5_Z41UM0^*?_7N?
MY&=7X5_BC^9[G1117":!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YE\*_^1NU;
M_L%7_P#Z<].KTVO,OA7_ ,C=JW_8*O\ _P!.>G5M'_=\7_U[C^;,I_'2]9?H
M?0M%%%>2:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!Q?Q#_ .1-UK_KG:?^G"TJ
MW\$/^1-F_P"PW??^DUC53XA_\B;K7_7.T_\ 3A:5;^"'_(FS?]AN^_\ 2:QK
ML?\ R+*G_84O_2("C_&C_@E^:/8:***\LZ0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#Y>\,?\EOU+_L*^)?_ $GOJ^H:^7O#'_);]2_["OB7
M_P!)[ZOJ&N_,/CP__8)0_P#;CGPWP3_Z^2_*(4445P'0%%%% 'QM_P %%_\
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M(]:@>5SIL^KC2F\=>"Y;BU^=&U&7Q1X.L?#VE7J1&YM3XDN[830:?J.I%_\
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MNOC\-]+U:;P_\,;*<"]U&*+^ROA[I'AG2HK:VO;BRM8;*.VL7%G% J_Z4/\
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MFR:6UN;=);:#QOX]\9>'G>VFGBOH1>:#=QM=6=NEQ'/8M=V=U_$K_P %4O\
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M?XL_\$S_ !7H>MG79OBM^SMX^U$Z3X%^+T.BKH=QI_B=K.]U.3X=^/-&BO\
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MK*X0&-OWN_X*P?\ !+S_ (>?^ _A'X(_X7C_ ,*/_P"%6>+M?\5?VG_PK/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5D:Q_J(O^NO_ +(U:]9&L?ZB+_KK_P"R-3CNO5?F3/X7\OS1WNC_ /(*L/\
MKUA_]!%:59NC_P#(*L/^O6'_ -!%:5<$_CE_BE^;.B'P1_PQ_)!1114E!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7":C_R-VF_]?>E?^E$==W7":C_R-VF_]?>E?^E$
M=;4/BG_U[G^1G5^%?XH_F>YT445PF@4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>9?"O_D;M6_[!5__ .G/3J]-KS+X5_\ (W:M_P!@J_\ _3GIU;1_W?%_]>X_
MFS*?QTO67Z'T+1117DFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <7\0_\ D3=:
M_P"N=I_Z<+2K?P0_Y$V;_L-WW_I-8U4^(?\ R)NM?]<[3_TX6E6_@A_R)LW_
M &&[[_TFL:['_P BRI_V%+_TB H_QH_X)?FCV&BBBO+.D**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV\WEQ>+OACX@E@76( HBF?\ M?PW?0:;XS\-/#Y+OK_AVPL+J9M'O]5M+O\
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MS"?^"(__ "E1_8X_[*!X@_\ 5<^-*_T]JCC/_D887_L#7_I^L:^''_(GQO\
MV,I_^HN%/\Z7_@Y,_P"4H7C7_LD?P?\ _4=FKXL_X))^!-&^*7_!0G]GGX8^
M([>SO/#WQ&N?B7X$UZTU"R74;"ZT;Q?\&_B'X?U2WOM/>:W2_LY['4)XKFR:
M>%;J%G@::,.77[3_ .#DS_E*%XU_[)'\'_\ U'9J\C_X-_/^4NG[)7_=>?\
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MC;EPV)RS#IK9JC0PE._1N_+=MJ[;N]3_ %?Z_P Z7_@Y,_Y2A>-?^R1_!_\
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MZYK<E]:V5A<:<^L?"_2'U(:Q-9+IVF?QT^!/!7B3XE>./!OPZ\&Z;<:SXO\
M'WBOP]X*\*Z/:137%UJOB3Q5J]GH6AZ;;06T4]Q-<7VIW]K:PQ00S3222JD4
M4CLJ'_6X_9U^"/A3]FSX$?"/X">"+>QA\-?"3X?^&/ UA/8:5;:(FL3Z'I=O
M:ZKXEO-/M9)HTUGQ7JZW_B;7[F6YO+S4-<U;4=0U"^O[ZZN;R?[KBS'O"8/#
MX:B^2I7JQFN73DIX64*BLDM/WOLN796A)6:O;\MX!RJ./S#%XW$1]I0PN'G2
M?/=^TK8V%2E*[;]ZU#VZGNTZD&[-IG^1UXH\-:[X+\2^(O!WBC3IM'\2^$]=
MU?PUXBTFX>&2?2]=T+4+C2]7TZ=[>2:W>:RU"UN+:5X)I86>)C%(Z%6/]DO_
M  :P?M=V][X?^./[$WBS7[QM4T6\3XZ_!_3=0NKNZMV\/Z@=/\-?%70]':>(
MVND0:1K1\&>)K;0;6\)U6[\5^,=?M=,A>Q\0ZA=?E]_P<A_LT-\$/^"A6J?%
M#2;&2W\(?M.>"="^)MK,LL36</C?0XD\$>/]+MXRJ74=Q)<:)H?C&_,QN('N
M?&Q^QW817T[3/S4_X)V_M6ZA^Q5^V5\"_P!H>"6;^P?"'BQ--\?V,<EYY6J?
M#;Q;:7'A;QW:S6UE#<R7TMKX=U:]UC2+=K*^\GQ#I>CW\-K)=V5L5[\73CGN
M1.5.*YZ^'C7HQ33Y,137-[--W_Y>1E1D^SEL]O)R^K4X7XH4*LFJ>%Q<\+B)
M-653!U7R>U:73V4H8F"_FC#H?ZN5%5[2[M+^UMK^PN;>]L;VWAN[.\M)H[FU
MN[2YC6:WN;:XA9X9[>>%TEAFB=XY8W5T9E8$V*_)3]_WV"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#\1/#<ESX.^):6UOIN+**RA^('A[Q+#8+!#: V4=NSV&G2%[&W_@(_X. _\
ME+I^UK_W0;_UF7X,5\_PKAU'-\70Q%.$I4<)7A*$XJ:C4IXK#0=E);IIJ]D]
MSZ[CO&2GP_E^+PE:I3AB,?A*M.I3G*G*5*K@L95A=PDG9KEE:[5TGT3/=?V4
M/^"[G[17[,/[)?QO\/:K\4_B7\?_ -I_XD_$?2++X<>(?CQXS\;?%'1_@_\
M#ZW\#:Q;:UXRTZY\::QK$%YKJ^*[K0_^$<\&KYV@W\]KJNL>+(&L].L-'\3?
MC9\=/VG/VAOVF_$C>+/V@?C/\1OBYK8DD>SE\;^*=4UFPT:.2:YN#9^'-#FN
M!H?AC3$FO;R6#2?#VG:9IEL]W<FWM(O/EW?HI_P1"_8(\*?M\?MG6/A;XIVD
MM_\ !+X1>$[_ .*_Q0T6*[O-.?QE!8ZCINA>%? *ZG8C[58P^(?$NL6>H:ZT
M,EG<W?@[P_XIT_3=4TG6+O3+^#_1V\-_!CX/>#O 1^%7A'X4?#7PK\+S')$?
MAOX;\"^%]#\!&*:2.::,^#],TNU\/&.6:**61/[.VO)'&[ LBD>UF.:9;D6-
MG&A@(UL76Y*M><7"E[*+BHPA"7LYM>[!2]G&,8^\I2DY2=OFLGR/.>*,MISQ
M.:SPV PW/A\+2E&I7]O.$N>I4G3]M2BUSS</;3G4FG!PC",(*_\ EK_LK_\
M!1']LG]C3Q+HNO? CX[>.-!T?29;?[3\-];UF_\ %'PGU_3XG7SM*USX<ZW<
MW7AJ2&XM?/L8M5TZSTWQ+HT%W<S^&M=T346COH_]%?\ X)E_\%'/AG_P4D^
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MI%=74-O+J6GZ3K@N!HFL&&'^V=!FTO56M[26\DM(/\N']I#X4Q? C]HCX]?
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ML,T;-'+%(K)(C,CJ5)!_M7_X.6?^48VO?]EM^$G_ *6:U7^?+\/O^1^\$?\
M8W^&O_3U95?"E"C4RF<JE&E.7UFLN:=.$G90I-*\DW9/6QEQWBL31S^G"EB*
M]*'U/#/EIU:D(W=6M=\L9)7=E=VN[+L?[#-?S:?\%S/^"S_BC]AVZT;]F?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_B'_ ,B;K7_7.T_]
M.%I5OX(?\B;-_P!AN^_])K&JGQ#_ .1-UK_KG:?^G"TJW\$/^1-F_P"PW??^
MDUC78_\ D65/^PI?^D0%'^-'_!+\T>PT445Y9TA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'R]X8_Y+?J7_85\2_^D]]7U#7R]X8_Y+?J7_85
M\2_^D]]7U#7?F'QX?_L$H?\ MQSX;X)_]?)?E$****X#H"BBB@#XV_X*+_\
M*/C]NS_LS;]I[_U27CBO\H"O]7__ (*+_P#*/C]NS_LS;]I[_P!4EXXK_* K
M]$X+_P!TQO\ V$0_]-GY#XD_[[EG_8+6_P#3R/\ 1V_X-R?^45WPC_[*!\9_
M_5C:W7XF_P#!S!_P3MF\ ?$33?V^_A;X>6/P1\4;[1_"'Q\M=*CN'30OBBEC
M+9^&O'US8V\#6NEZ-XYT72K70];U)3:V+>.M/LKK4'G\1^/UDO?VR_X-R?\
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MDEQ?@TM$JV9)+R6"QJ1_5O\ M+_\FX?M ?\ 9$OBM_Z@FO5_D25_KM_M+_\
M)N'[0'_9$OBM_P"H)KU?Y$E>5P5_"S#_ *^8?_TFJ>]XE_[QE/\ UYQ?_I=
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MMVNJ38U'QO?Z!<Z?87_AR[:Z^)?^#?S]G:_^/G_!2[X0:LUM<2>%O@%8:_\
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MOA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8QBDHQBE91BE9)))))*R6B"BBBF,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LC6/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB\7U_2U_P4F_X(#?\/"OVH=;_:2_X:Q_X5#_ &QX1\'^%?\ A#/^%$?\)_\
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MQ?\ A,?$NI^(O[)_M/\ X:%T[^T?[._M'[']O_L^P^V>3]H^QVOF>0GZF_\
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MU&OZR*_)O_@D_P#\$O/^'8'@/XN>"/\ A>/_  O#_A:?B[0/%7]I_P#"L_\
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MU/V]O9IKF]I];H_%>]N16[L_QMZ*_P!DBBO3_P!=O^I9_P"7O_WH>+_Q#/\
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MOG;H?2QPW+@XX3GORX58;VG+:]J7LN?DYO\ M[EYO+FZG^-O7^HE_P $:/\
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MQE7!W]F9T\X_M'V]ZF*G]7^I^S_WF-16]M]:J?![2]_9>];:-]/P _X.6?\
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M].P.3'_[CC?^P3$_^F9G\7G_  1S_P"2&?$__LK$O_J'^&*_7BOR'_X(Y_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#B_B'_P B;K7_ %SM/_3A:5;^"'_(FS?]AN^_])K&
MJGQ#_P"1-UK_ *YVG_IPM*M_!#_D39O^PW??^DUC78_^194_["E_Z1 4?XT?
M\$OS1[#1117EG2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?+
MWAC_ )+?J7_85\2_^D]]7U#7R]X8_P"2WZE_V%?$O_I/?5]0UWYA\>'_ .P2
MA_[<<^&^"?\ U\E^40HHHK@.@**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *X34?^1NTW_K[TK_ -*(Z[NN$U'_ )&[3?\ K[TK
M_P!*(ZVH?%/_ *]S_(SJ_"O\4?S/<Z***X30**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU'%7JXBLU92KXFM*IB*\[+GK59RLKV11117I'N!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !61K'^HB_ZZ_\ LC5KUD:Q_J(O^NO_ +(U..Z]5^9,_A?R
M_-'>Z/\ \@JP_P"O6'_T$5I5FZ/_ ,@JP_Z]8?\ T$5I5P3^.7^*7YLZ(?!'
M_#'\D%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %<)J/_(W:;_U]Z5_Z41UW=<)J
M/_(W:;_U]Z5_Z41UM0^*?_7N?Y&=7X5_BC^9[G1117":!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5YE\*_^1NU;_L%7_\ Z<].KTVO,OA7_P C=JW_ &"K_P#]
M.>G5M'_=\7_U[C^;,I_'2]9?H?0M%%%>2:A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXN98M6CN=-\+^"?BEX?MKZYM6DU+PWXH\/:#I^E:\VCJ+Z\M_#WB[3)VU@W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK(UC_41?]=?_ &1JUZR-8_U$7_77_P!D:G'=>J_,F?POY?FCO='_ .058?\
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MXO\ Z]Q_-F4_CI>LOT/H6BBBO)-0HHHH **** "BBB@ HHHH **** "BBB@
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M7J2QFYNY;X(%%^(KT7$,?YF?\'"W[?G_  RA^R/>? [P)JUO!\9OVJ=,\0^
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M%_\ SW?\%$/B#J/[8?\ P5 _:)UW0;^;7Y/B1^T:_P +? U];Z*-.N-2\/\
MA?5-*^#7P[,&C2#3IC+)X;\-Z!'$NHBPU2_<+<:PMIJ=S>+'^B8.5&6:0P&'
MLL'D>%E=Z6EC*J]DY3=K.5.E*NI2NI>UG5NGJ?D.80Q$<DJ9KC+RS+BC'048
MM-.&74)>W4::YKJ-6O#".$6I15"GA[-.U_[V/^")WPA_X4Q_P2^_9'T"?3;>
MPU/Q?\/9_B]JEQ'%I2W>K_\ "X_$.L?$G0M2U&YTEY4O;@>$?$OAS3;.6^F?
M5;71M.TK2M12TN-.:QM?ST_X.C?B[:>#_P!ACX:_">&\N(=;^,?QXT.9[.*6
M..&\\(_#GP[KVO:Y)=!E>6=+7Q-J/@,QV\:Q+YTR7,ETGV9+:\_HR\#>#M#^
M'?@KP?\ #_PQ;M:>&O OA;P_X.\/6KLC/;:'X8TFTT32;=VCCAC9H;"QMXV:
M.*)"5)6-%PH_B(_X.K/C7)XC_:8_9R^ 5GJ-O<Z9\+?@]K'Q%U.TL[RTF%GX
MH^+/BJYTA[#5X+>5KBWU2U\.?#+0=4M;74HXY(-*\26]]9(+?6)))_D<E3S#
MB&%>2NGB,1C9WZ6YZD--=JDJ:MT^1^@<2-93PA5PL6E*.$P>70_O7]E1J;6U
M=&-65^KW6K/9?^#3WX0VL^O?M@?'N]%P+W2](^&?PA\-F*]C%J]KK][XA\9^
M-A?Z<8#,UQ%-X;^'_P#9%ZMU'&D<NMP-!,TB20?V=U^"7_!MO\)Y_AO_ ,$P
M_!_B>Y18I/CC\6_BM\6%A,MXUQ'!::II_P (K1[JWN[.U2S:[M/A1!?6L5E+
M?6=SIMU8ZFMX)[^XM+7][:Y.(*_UC.,=-.ZA5]A'6Z7L(QI22\G.$GZMG?PE
MA5A.'LLA:TJM#ZU)VLV\5.6(BWWM"I"*?\L4%>1_M >'-)\8? ;XV^$=?M(;
M_0O%/PC^)/AS6K&X@MKJWO=)UOP;K6F:E:3VU[!=6=S#<V=U-#+!=VUQ;3([
M1SP31,\;>N5\N?MO_$&T^%'[&O[5GQ'N]1M]+_X0[]G?XQ:W975Q=Q6._6;7
MP!K_ /8-A:3RWNG;M4U76VT_2]'M8;ZUNK[5;RSL;*9;NX@KRZ$92KT8QOS2
MJTXQMOS.:2M;K>Q[N)E"&'Q$YVY(T:LIWM;DC"3E>^EK)WOH?YM'_!);6[_0
M/^"EG[$U_ITGE7$_[0G@'1)&WS)FP\2ZD/#FJ1Y@EA<^;IFJWD6QG:&3?LN8
MI[=I8)/]3JO\O+_@C+\/=7^)?_!3[]CC1-(MIIY-$^*]K\0K]XI$A2UTCX8Z
M-J_Q!U*YN)Y8I8HX1;>&W@6-PCWMQ/!IUM+'>7ELP_U#:^LXS<?KV$2MS+"7
MEWY76J<M_FI6^9\!X;J2RO'R:?(\?:+Z.4</1Y[>=I0O\BO=W=I86MS?W]S;
MV5C96\UW>7EW-';6MI:6T;37%S<W$S)#!;P0H\LTTKI'%&C.[*JDC_,O_P""
MI?[8WCK_ (*@_MYR1_#--9\7>"K/Q+IGP'_9;\#Z?;/;3:U9:EXD72M-U&ST
M@ZE=VDOBGXH>+]16]?4F>WO[[2Y/"FBWRP6_A_3[.R_J0_X.0/V_F_9U_9F@
M_90\!7_D_%3]JK1-5TWQ/>V=[)!?^$/@?:7UM9>+97ACC9)?^%GL+_X=QPW)
M^SW/AM_'6T)>6UG*GY5?\&S'[ ,OQ)^,/B#]N?XE>'_.\"?!?[=X4^"D&K:?
M=BU\0?%[5[06^L^,M.EE=-/U"S^&WABYOM.A2:TOHX_%_BS2M8TZZT_7/!(:
MKR&C3RO+\3GV*BG)PE2P4);R;?)S+JG5J?N[I)QIPJ3UA*Y'%6(JYWFV"X6P
M4VH*I"OF52#=H)+G49='["C>LU*\9UJE&&DX6/ZK_P#@FS^QCX>_8._9 ^%G
MP#TVTTX>+;73E\7_ !=US3XHE/BKXN>)[2RF\8:O<7,;,=0BTXVNG^$="O)6
M:7_A%/#'A^U.%M45?\\+X^2K^R!_P5C^)>MZ<UQI]C\ /V[]6\>>'IKNVEU:
MZMO#_@OXWGQKX7NKJVNK>T.K7 T*UTRXGC\E;?4I2WD/+;3Q32?ZE=?YJW_!
MP+\/[/P%_P %5?VBY--M(;'3?'-E\+OB!;VT  0WFN_"_P )6OB*[8_:KF1I
MM4\5Z7KVJW!E2T(GOI4AM5M5MYICA3$3Q.99A&O)SEC,-.K5;^U)5HJ2MZ5I
M62T25MD@X\P<,'D^43PL%3AEV,I4**6].#H3<7=)?:P\.9W3E)IN[=U_I4T5
M\J?L+_$NP^,7[&'[*WQ,T^__ +23Q?\ L_\ PHU*^N6\XRIKJ>"]'L_$EE<F
MXGNIC>:;XAM=3TV]+W=YF[M)BMY=H5N)?JNOCJM.5*I4I2^*G.=.6EO>A)Q>
MG35;'Z'1JQKT:-:'PUJ5.K&SNN6I!35GUT:UZA1114&I_*)_P=8_&8Z#^S]^
MS+\!K'6KFVNOB1\4O$_Q&UK2+*Z2-+[0OAAX;AT6S76X8E^T/8R:W\1K>[TR
MWN)4L+O4-&ENQ;W5[HEO/IWP=_P2N_9CO_%7_!#[_@K1\1(;".'4OB;I&MV.
ME?;]/UBXEUS2OV6_A^OQ8M7TNT=)-/O?M.M>+_$.AZ#J&DV[7*>*+.\M]1N6
M.E6D=GY5_P '0'QE_P"$Z_;W\'?"BRU&SN=+^!GP/\+Z;?Z?;7GVJ?3/&?Q"
MU/5O&^K_ -H0A(UTZ[O?"%Y\/IDLB)I&L%LM1:X:/4(K:U_IJ_X)%?LQZ9H7
M_!';X*_!_6"EJWQ\^"_COQ9XKU1=(D22ZM?VAY/$FMZ9>3Z7JDLD-\^E^ _$
MWAO1HI28M.UNUT>VOHHTMKX$_=3J_P!F<-99TGB,90Q$K+>,:TL7&6VMHTJ*
MZN]K76WY?3H_VSQKG?VZ6$R[$X2#;5HU)8:& G!.^C<ZV*?1+WD[/?\  _\
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MYIJ7<?\ PB_C3Q%"_B2VUVZGDM=*^'&G:)J6H0Z<]KJBK_0;_P %5? OA/\
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M9\,?#^A6U_':P2WUM"=%T^T@U&6RBO;Z+;>7=LEY--$/]4/X=^#--^''P_\
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M5[1248I122****Y3N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY?%?PX\5RZ?=6%CXR\&WU_:W4=CK%C'=2I)')%)9ZC9R36%_#-;S$+_F^_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW=<)J/\ R-VF_P#7WI7_ *41UM0^*?\ U[G^1G5^%?XH_F>YT445PF@4444
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M/2OAI\#/&OQ<F2>SO]+O(KC5Q\3=*\%R6US;:]9WFC^)]:BOC!%)8V\?[O\
M_!MC^P#_ ,*'_9YU+]L+XC>&;C3?BU^TEI:6G@%M4MKFTU'0OV?/M.FZOHT]
MO;RR)LM_BGK>FV/C1+A[<IJ?A?2? >J6$YMKQS-Z4HQR66=9M-15?$8O$8;+
MH-)J]2I*<ZB5_A4M9)6LJ,H?;2/&A.?$D>&N'Z<I_5<)E^$QF;S3:]VE2A3I
M47)+2<J=N5NZ<L3"HTW29^V_C^Z\!_L)_L4^/-2^&^A^'O#?@;]EW]GKQ?K/
M@OP_?H;;1&C^&_@?4M4T6PU3^S!9W=]=>(-4T^!-4FL]NLZ]JVIW,\;3:MJ
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M(;I%1GMM#\,:3=ZWJUPBR20QLT-A8W$BK)+$A*@-(BY8?Y87[*7A?4OVQ_\
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MX^)&JP7%Z=-MYM-\#>&-4\3WT4^HK:7[6$,EKI<J2WHL+TVJ,TXM+DQ^2_\
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MK>-_&.NW]OHWA3PAI,]RDYBFU;6+RW.I7\-EJ3Z#X?M]9\2SZ==V6BW<1_@
MB\4_\%*/^"]7[3&I>!['Q1<:W8QW&I^+O^$4OM=U3PG^SK\!/!]W>:98PSW-
MC9PZL\%G ]IHVG6]PNE>+/B#XHO+1M0,6MWT>IW<?]-O_!T5;Z[-_P $Z? T
MFD032Z?:?M6?#:X\421QPR);:$WPX^,EK;SW#2J7AA;Q-<^';99+<K,9[B"%
MF^SRSJWRA_P:@>,/AT/AO^UMX BUJQB^+,GC?P%XPOO#D\EI!J5_\.H=!O\
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M&:-?2:%H4VH16&K?$'QJ]A>3^%OASX55XKF2Z\2^+=0M/L%GY=K<0:7:"_\
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M8M/ET#P]'XF\4Z5:1WFR9[>P\>>,/%D;7*6]O:W=V;JZL/MEC-;ZE??W=_\
M!.'X0?\ "AOV#/V2/A7-;7%GJGASX#_#V\\2V=R;8R6OC/Q3H5MXO\;VR&UL
MM/0V\'B_7M;BM#+;?;#:)"=0N+V_^TWMQ_FZ:!_:O[>?_!2+3);S^SX+W]K#
M]L6*^O@/M,FC:5I_Q:^+OVV^2WAUS[5>-H>A:1K,R6>GWT=W=_V78PV'V:YG
MVVTG^K!7H<3_ .RX#)LN6]*CSU%UYJ=.G2BVEI>4I5FWW3[GD\$?[=FG$6<R
MO:OB/9T7TY*U:K7G%-MM*$(8=)=FNP4445\6?I(4444 %%%% !1110 4444
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MBONS]9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R-8_U$
M7_77_P!D:M>LC6/]1%_UU_\ 9&IQW7JOS)G\+^7YH[W1_P#D%6'_ %ZP_P#H
M(K2K-T?_ )!5A_UZP_\ H(K2K@G\<O\ %+\V=$/@C_AC^2"BBBI*"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N$U'_D;M-_Z^]*_]*(Z[NN$U'_D;M-_Z^]*_P#2B.MJ
M'Q3_ .O<_P C.K\*_P 4?S/<Z***X30**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M</#?_"6_&;XB_"K7_AYX/T!=>\.^&);V/QWY'A/Q-);:_P"*]4T70-*O-/\
M".L:]J5G=7VK:>RW=I"MG<QW[6IK^!;_ (A_/^"N?_1I7_F>?V9?_GSU_I;4
M5OEF>XO*:52CAJ6%FJM3VDI5H593ORQBHIPK4URI*Z3BW>4M;-)<N=\+8#/J
M]&OC,1CJ<J%+V-.&&JT(4[.<IRFU5PU:7/)R2DU))QA!<MTV_P#-)_XA_/\
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M;;U;>[/;C&,(QA"*C"$5&,8JT8QBK1BDM$DDDDMD%?E?_P %G/V2?'W[:/[
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M0QVUK:6EM&L-O;6UO"J0P6\$*)%##$B1Q1HJ(JJH \L^/'P,^&'[2WPA\=_
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MA:$ITZ6:YO3R^I-SJ9?3Q3IT:E[7A4=-1YH.RBVX>T<$E[3F]\_D"_X*)_\
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M@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D:Q_J
M(O\ KK_[(U:]9&L?ZB+_ *Z_^R-3CNO5?F3/X7\OS1WNC_\ (*L/^O6'_P!!
M%:59NC_\@JP_Z]8?_016E7!/XY?XI?FSHA\$?\,?R04445)04444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5PFH_P#(W:;_ -?>E?\ I1'7=UPFH_\ (W:;_P!?>E?^E$=;
M4/BG_P!>Y_D9U?A7^*/YGN=%%%<)H%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW_8;OO\ TFL:['_R+*G_ &%+_P!(@*/\:/\ @E^:/8:***\LZ0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#Y>\,?\EOU+_L*^)?\ TGOJ^H:^
M7O#'_);]2_["OB7_ -)[ZOJ&N_,/CP__ &"4/_;CGPWP3_Z^2_*(4445P'0%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6>_]>LC_ /6>RH****_*3\V"BBB@ HHHH **** "BBO>OV?/AFWQ \9PW-_
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M@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KA-1_Y&[3?^OO2O\ THCKNZX34?\
MD;M-_P"OO2O_ $HCK:A\4_\ KW/\C.K\*_Q1_,]SHHHKA- HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R]X8_Y+?J7_
M &%?$O\ Z3WU?4-?+WAC_DM^I?\ 85\2_P#I/?5]0UWYA\>'_P"P2A_[<<^&
M^"?_ %\E^40HKX%3]L#1+A%N(?B-\-$AG59HDDU[P\)$BE >-7 UAP'5& 8!
MV&X'#-U+O^&NM)_Z*1\,?_!]X?\ _EM73_868_\ /FWRJ?\ RLCZ[A_YU]\?
M_DO-?>??%%? _P#PUUI/_12/AC_X/O#_ /\ +:C_ (:ZTG_HI'PQ_P#!]X?_
M /EM1_868_\ /K\*G_RL/KN'_G7WQ_\ DO-?>??%%? __#76D_\ 12/AC_X/
MO#__ ,MJ/^&NM)_Z*1\,?_!]X?\ _EM1_868_P#/K\*G_P K#Z[A_P"=??'_
M .2\U]Y]\45\#_\ #76D_P#12/AC_P"#[P__ /+:C_AKK2?^BD?#'_P?>'__
M );4?V%F/_/K\*G_ ,K#Z[A_YU]\?_DO-?>??%%? _\ PUUI/_12/AC_ .#[
MP_\ _+:C_AKK2?\ HI'PQ_\ !]X?_P#EM1_868_\^OPJ?_*P^NX?^=??'_Y+
MS7WGWQ17P/\ \-=:3_T4CX8_^#[P_P#_ "VH_P"&NM)_Z*1\,?\ P?>'_P#Y
M;4?V%F/_ #Z_"I_\K#Z[A_YU]\?_ )+S7WGWQ17P/_PUUI/_ $4CX8_^#[P_
M_P#+:C_AKK2?^BD?#'_P?>'_ /Y;4?V%F/\ SZ_"I_\ *P^NX?\ G7WQ_P#D
MO-?>??%%? __  UUI/\ T4CX8_\ @^\/_P#RVH_X:ZTG_HI'PQ_\'WA__P"6
MU']A9C_SZ_"I_P#*P^NX?^=??'_Y+S7WGWQ17P/_ ,-=:3_T4CX8_P#@^\/_
M /RVH_X:ZTG_ **1\,?_  ?>'_\ Y;4?V%F/_/K\*G_RL/KN'_G7WQ_^2\U]
MY]\45\#_ /#76D_]%(^&/_@^\/\ _P MJ/\ AKK2?^BD?#'_ ,'WA_\ ^6U'
M]A9C_P ^OPJ?_*P^NX?^=??'_P"2\U]Y]\45\#_\-=:3_P!%(^&/_@^\/_\
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M*1\,?_!]X?\ _EM1_868_P#/K\*G_P K#Z[A_P"=??'_ .2\U]Y]\45\#_\
M#76D_P#12/AC_P"#[P__ /+:C_AKK2?^BD?#'_P?>'__ );4?V%F/_/K\*G_
M ,K#Z[A_YU]\?_DO-?>??%%? _\ PUUI/_12/AC_ .#[P_\ _+:C_AKK2?\
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MYU]\?_DO-?>??%%? _\ PUUI/_12/AC_ .#[P_\ _+:C_AKK2?\ HI'PQ_\
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M /\ +:C_ (:ZTG_HI'PQ_P#!]X?_ /EM1_868_\ /K\*G_RL/KN'_G7WQ_\
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M ,^OPJ?_ "L/KN'_ )U]\?\ Y+S7WGWQ17P/_P -=:3_ -%(^&/_ (/O#_\
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M2\U]Y]\45\#_ /#76D_]%(^&/_@^\/\ _P MJ/\ AKK2?^BD?#'_ ,'WA_\
M^6U']A9C_P ^OPJ?_*P^NX?^=??'_P"2\U]Y]\45\#_\-=:3_P!%(^&/_@^\
M/_\ RVH_X:ZTG_HI'PQ_\'WA_P#^6U']A9C_ ,^OPJ?_ "L/KN'_ )U]\?\
MY+S7WGWQ17P/_P -=:3_ -%(^&/_ (/O#_\ \MJ/^&NM)_Z*1\,?_!]X?_\
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M _\ A5^'_P#Y8T?5<1_SYJ_^"Y__ "/]6?E<]O2_GC_X%'_/S7WGL%%>/_\
M"YOA]_T47P#_ .%7X?\ _EC1_P +F^'W_11? /\ X5?A_P#^6-'U7$?\^:O_
M (+G_P#(_P!6?E<]O2_GC_X%'_/S7WGL%%>/_P#"YOA]_P!%%\ _^%7X?_\
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M'_\ Y8T?\+F^'W_11? /_A5^'_\ Y8T?5<1_SYJ_^"Y__(_U9^5SV]+^>/\
MX%'_ #\U]Y[!17C_ /PN;X??]%%\ _\ A5^'_P#Y8T?\+F^'W_11? /_ (5?
MA_\ ^6-'U7$?\^:O_@N?_P C_5GY7/;TOYX_^!1_S\U]Y[!17C__  N;X??]
M%%\ _P#A5^'_ /Y8T?\ "YOA]_T47P#_ .%7X?\ _EC1]5Q'_/FK_P""Y_\
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MGC_X%'_/S7WGL%%>/_\ "YOA]_T47P#_ .%7X?\ _EC1_P +F^'W_11? /\
MX5?A_P#^6-'U7$?\^:O_ (+G_P#(_P!6?E<]O2_GC_X%'_/S7WGL%%>/_P#"
MYOA]_P!%%\ _^%7X?_\ EC1_PN;X??\ 11? /_A5^'__ )8T?5<1_P ^:O\
MX+G_ /(_U9^5SV]+^>/_ (%'_/S7WGL%%>/_ /"YOA]_T47P#_X5?A__ .6-
M'_"YOA]_T47P#_X5?A__ .6-'U7$?\^:O_@N?_R/]6?E<]O2_GC_ .!1_P _
M-?>>P45X_P#\+F^'W_11? /_ (5?A_\ ^6-'_"YOA]_T47P#_P"%7X?_ /EC
M1]5Q'_/FK_X+G_\ (_U9^5SV]+^>/_@4?\_-?>>P45X__P +F^'W_11? /\
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MS\U]Y[!17C__  N;X??]%%\ _P#A5^'_ /Y8T?\ "YOA]_T47P#_ .%7X?\
M_EC1]5Q'_/FK_P""Y_\ R/\ 5GY7/;TOYX_^!1_S\U]Y[!17C_\ PN;X??\
M11? /_A5^'__ )8T?\+F^'W_ $47P#_X5?A__P"6-'U7$?\ /FK_ ."Y_P#R
M/]6?E<]O2_GC_P"!1_S\U]Y[!17C_P#PN;X??]%%\ _^%7X?_P#EC1_PN;X?
M?]%%\ _^%7X?_P#EC1]5Q'_/FK_X+G_\C_5GY7/;TOYX_P#@4?\ /S7WGL%%
M>/\ _"YOA]_T47P#_P"%7X?_ /EC1_PN;X??]%%\ _\ A5^'_P#Y8T?5<1_S
MYJ_^"Y__ "/]6?E<]O2_GC_X%'_/S7WGL%%>/_\ "YOA]_T47P#_ .%7X?\
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MA]:H_P Z^^/EY^?]75_H:BOGG_A??@G_ **-\/?_  I_#_\ \LJ/^%]^"?\
MHHWP]_\ "G\/_P#RRH_L_%_\^9_^ 3_^1#ZU1_G7WQ\O/S_JZO\ 0U%?//\
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M *NK_0U%?//_  OOP3_T4;X>_P#A3^'_ /Y94?\ "^_!/_11OA[_ .%/X?\
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M )$/K5'^=??'R\_/^KJ_T-17SS_POOP3_P!%&^'O_A3^'_\ Y94?\+[\$_\
M11OA[_X4_A__ .65']GXO_GS/_P"?_R(?6J/\Z^^/EY^?]75_H:BOGG_ (7W
MX)_Z*-\/?_"G\/\ _P LJ/\ A??@G_HHWP]_\*?P_P#_ "RH_L_%_P#/F?\
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M_5U?Z&HKYY_X7WX)_P"BC?#W_P *?P__ /+*C_A??@G_ **-\/?_  I_#_\
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M^%]^"?\ HHWP]_\ "G\/_P#RRH_L_%_\^9_^ 3_^1#ZU1_G7WQ\O/S_JZO\
M0U<)J/\ R-VF_P#7WI7_ *41UYI_POOP3_T4;X>_^%/X?_\ EE5!_B]X#N;R
M/5?^%@>!GEMI(I!(GB?0C"C6I65=^-0*X7 9P6'RG)P#6E/ XJ#DY49V<)17
MN3W>B^R1/$4I))26Z>\=E9]_/^M#[-HKY3_X:0\)_P#11_AS_P"%)X?_ /EG
M1_PTAX3_ .BC_#G_ ,*3P_\ _+.N;^R\9_SZE_X#4_\ D"_K5'^=??'R\_/^
MKJ_U917RG_PTAX3_ .BC_#G_ ,*3P_\ _+.C_AI#PG_T4?X<_P#A2>'_ /Y9
MT?V7C/\ GU+_ ,!J?_(!]:H_SK[X^7GY_P!75_JRBOE/_AI#PG_T4?X<_P#A
M2>'_ /Y9T?\ #2'A/_HH_P .?_"D\/\ _P LZ/[+QG_/J7_@-3_Y /K5'^=?
M?'R\_/\ JZO]645\I_\ #2'A/_HH_P .?_"D\/\ _P LZ/\ AI#PG_T4?X<_
M^%)X?_\ EG1_9>,_Y]2_\!J?_(!]:H_SK[X^7GY_U=7^K**^4_\ AI#PG_T4
M?X<_^%)X?_\ EG1_PTAX3_Z*/\.?_"D\/_\ RSH_LO&?\^I?^ U/_D ^M4?Y
MU]\?+S\_ZNK_ %917RG_ ,-(>$_^BC_#G_PI/#__ ,LZ/^&D/"?_ $4?X<_^
M%)X?_P#EG1_9>,_Y]2_\!J?_ " ?6J/\Z^^/EY^?]75_JRBOE/\ X:0\)_\
M11_AS_X4GA__ .6='_#2'A/_ **/\.?_  I/#_\ \LZ/[+QG_/J7_@-3_P"0
M#ZU1_G7WQ\O/S_JZO]645\I_\-(>$_\ HH_PY_\ "D\/_P#RSH_X:0\)_P#1
M1_AS_P"%)X?_ /EG1_9>,_Y]2_\  :G_ ,@'UJC_ #K[X^7GY_U=7^K**^4_
M^&D/"?\ T4?X<_\ A2>'_P#Y9T?\-(>$_P#HH_PY_P#"D\/_ /RSH_LO&?\
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M[X^7GY_U=7^K**^4_P#AI#PG_P!%'^'/_A2>'_\ Y9T?\-(>$_\ HH_PY_\
M"D\/_P#RSH_LO&?\^I?^ U/_ ) /K5'^=??'R\_/^KJ_U917RG_PTAX3_P"B
MC_#G_P *3P__ /+.C_AI#PG_ -%'^'/_ (4GA_\ ^6=']EXS_GU+_P !J?\
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M/^KJ_P!645\I_P##2'A/_HH_PY_\*3P__P#+.C_AI#PG_P!%'^'/_A2>'_\
MY9T?V7C/^?4O_ :G_P @'UJC_.OOCY>?G_5U?ZLHKY3_ .&D/"?_ $4?X<_^
M%)X?_P#EG1_PTAX3_P"BC_#G_P *3P__ /+.C^R\9_SZE_X#4_\ D ^M4?YU
M]\?+S\_ZNK_5E%?*?_#2'A/_ **/\.?_  I/#_\ \LZ/^&D/"?\ T4?X<_\
MA2>'_P#Y9T?V7C/^?4O_  &I_P#(!]:H_P Z^^/EY^?]75_JRBOE/_AI#PG_
M -%'^'/_ (4GA_\ ^6='_#2'A/\ Z*/\.?\ PI/#_P#\LZ/[+QG_ #ZE_P"
MU/\ Y /K5'^=??'R\_/^KJ_U917RG_PTAX3_ .BC_#G_ ,*3P_\ _+.C_AI#
MPG_T4?X<_P#A2>'_ /Y9T?V7C/\ GU+_ ,!J?_(!]:H_SK[X^7GY_P!75_JR
MBOE/_AI#PG_T4?X<_P#A2>'_ /Y9T?\ #2'A/_HH_P .?_"D\/\ _P LZ/[+
MQG_/J7_@-3_Y /K5'^=??'R\_/\ JZO]645\I_\ #2'A/_HH_P .?_"D\/\
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MX_\ Y]/_ ,!J?_*_ZL_*Y]:H_P Z^^/EY^?]75_M*BOBW_AJ7P]_T4?X:_\
MA0^'_P#Y:T?\-2^'O^BC_#7_ ,*'P_\ _+6C^Q<?_P ^G_X#4_\ E?\ 5GY7
M/K5'^=??'R\_/^KJ_P!I45\6_P##4OA[_HH_PU_\*'P__P#+6C_AJ7P]_P!%
M'^&O_A0^'_\ Y:T?V+C_ /GT_P#P&I_\K_JS\KGUJC_.OOCY>?G_ %=7^TJ*
M^+?^&I?#W_11_AK_ .%#X?\ _EK1_P -2^'O^BC_  U_\*'P_P#_ "UH_L7'
M_P#/I_\ @-3_ .5_U9^5SZU1_G7WQ\O/S_JZO]I45\6_\-2^'O\ HH_PU_\
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MT4?X:_\ A0^'_P#Y:T?\-2^'O^BC_#7_ ,*'P_\ _+6C^Q<?_P ^G_X#4_\
ME?\ 5GY7/K5'^=??'R\_/^KJ_P!I45\6_P##4OA[_HH_PU_\*'P__P#+6C_A
MJ7P]_P!%'^&O_A0^'_\ Y:T?V+C_ /GT_P#P&I_\K_JS\KGUJC_.OOCY>?G_
M %=7^TJ*^+?^&I?#W_11_AK_ .%#X?\ _EK1_P -2^'O^BC_  U_\*'P_P#_
M "UH_L7'_P#/I_\ @-3_ .5_U9^5SZU1_G7WQ\O/S_JZO]I45\6_\-2^'O\
MHH_PU_\ "A\/_P#RUH_X:E\/?]%'^&O_ (4/A_\ ^6M']BX__GT__ :G_P K
M_JS\KGUJC_.OOCY>?G_5U?[2HKXM_P"&I?#W_11_AK_X4/A__P"6M'_#4OA[
M_HH_PU_\*'P__P#+6C^Q<?\ \^G_ . U/_E?]6?E<^M4?YU]\?+S\_ZNK_:5
M%?%O_#4OA[_HH_PU_P#"A\/_ /RUH_X:E\/?]%'^&O\ X4/A_P#^6M']BX__
M )]/_P !J?\ RO\ JS\KGUJC_.OOCY>?G_5U?[2HKXM_X:E\/?\ 11_AK_X4
M/A__ .6M'_#4OA[_ **/\-?_  H?#_\ \M:/[%Q__/I_^ U/_E?]6?E<^M4?
MYU]\?+S\_P"KJ_VE17Q;_P -2^'O^BC_  U_\*'P_P#_ "UH_P"&I?#W_11_
MAK_X4/A__P"6M']BX_\ Y]/_ ,!J?_*_ZL_*Y]:H_P Z^^/EY^?]75_M*BOB
MW_AJ7P]_T4?X:_\ A0^'_P#Y:T?\-2^'O^BC_#7_ ,*'P_\ _+6C^Q<?_P ^
MG_X#4_\ E?\ 5GY7/K5'^=??'R\_/^KJ_P!I45\6_P##4OA[_HH_PU_\*'P_
M_P#+6C_AJ7P]_P!%'^&O_A0^'_\ Y:T?V+C_ /GT_P#P&I_\K_JS\KGUJC_.
MOOCY>?G_ %=7^TJ*^+?^&I?#W_11_AK_ .%#X?\ _EK1_P -2^'O^BC_  U_
M\*'P_P#_ "UH_L7'_P#/I_\ @-3_ .5_U9^5SZU1_G7WQ\O/S_JZO]I45\6_
M\-2^'O\ HH_PU_\ "A\/_P#RUH_X:E\/?]%'^&O_ (4/A_\ ^6M']BX__GT_
M_ :G_P K_JS\KGUJC_.OOCY>?G_5U?[2HKXM_P"&I?#W_11_AK_X4/A__P"6
MM'_#4OA[_HH_PU_\*'P__P#+6C^Q<?\ \^G_ . U/_E?]6?E<^M4?YU]\?+S
M\_ZNK_:5%?%O_#4OA[_HH_PU_P#"A\/_ /RUH_X:E\/?]%'^&O\ X4/A_P#^
M6M']BX__ )]/_P !J?\ RO\ JS\KGUJC_.OOCY>?G_5U?[2HKXM_X:E\/?\
M11_AK_X4/A__ .6M'_#4OA[_ **/\-?_  H?#_\ \M:/[%Q__/I_^ U/_E?]
M6?E<^M4?YU]\?+S\_P"KJ_VE17Q;_P -2^'O^BC_  U_\*'P_P#_ "UH_P"&
MI?#W_11_AK_X4/A__P"6M']BX_\ Y]/_ ,!J?_*_ZL_*Y]:H_P Z^^/EY^?]
M75_M*BOBW_AJ7P]_T4?X:_\ A0^'_P#Y:T?\-2^'O^BC_#7_ ,*'P_\ _+6C
M^Q<?_P ^G_X#4_\ E?\ 5GY7/K5'^=??'R\_/^KJ_P!I45\6_P##4OA[_HH_
MPU_\*'P__P#+6C_AJ7P]_P!%'^&O_A0^'_\ Y:T?V+C_ /GT_P#P&I_\K_JS
M\KGUJC_.OOCY>?G_ %=7^TJ*^+?^&I?#W_11_AK_ .%#X?\ _EK1_P -2^'O
M^BC_  U_\*'P_P#_ "UH_L7'_P#/I_\ @-3_ .5_U9^5SZU1_G7WQ\O/S_JZ
MO]/?$/\ Y$W6O^N=I_Z<+2K?P0_Y$V;_ +#=]_Z36-?(VJ?M(>%M<L)]*N_B
M+\.GM[SRD=8?$>@)*Q2:.5 C#4V.3)&@P%)(R!UJ7P]^TEX9\(V+Z3IOQ$^'
M44!N9+ITN_$6@23"6:.)6R6U-"%*11E5V^^3FMWE6-^IRP_LI>TE651>[4Y>
M51BGKR7O==OF*.)HJHI\ZLHM;QW=FNO]=#]%:*^!_P#AKK2?^BD?#'_P?>'_
M /Y;4?\ #76D_P#12/AC_P"#[P__ /+:N+^PLQ_Y]?A4_P#E9M]=P_\ .OOC
M_P#)>:^\^^**^!_^&NM)_P"BD?#'_P 'WA__ .6U'_#76D_]%(^&/_@^\/\
M_P MJ/["S'_GU^%3_P"5A]=P_P#.OOC_ /)>:^\^^**^!_\ AKK2?^BD?#'_
M ,'WA_\ ^6U'_#76D_\ 12/AC_X/O#__ ,MJ/["S'_GU^%3_ .5A]=P_\Z^^
M/_R7FOO/OBBO@?\ X:ZTG_HI'PQ_\'WA_P#^6U'_  UUI/\ T4CX8_\ @^\/
M_P#RVH_L+,?^?7X5/_E8?7</_.OOC_\ )>:^\^^**^!_^&NM)_Z*1\,?_!]X
M?_\ EM1_PUUI/_12/AC_ .#[P_\ _+:C^PLQ_P"?7X5/_E8?7</_ #K[X_\
MR7FOO/OBBO@?_AKK2?\ HI'PQ_\ !]X?_P#EM1_PUUI/_12/AC_X/O#_ /\
M+:C^PLQ_Y]?A4_\ E8?7</\ SK[X_P#R7FOO/OBBO@?_ (:ZTG_HI'PQ_P#!
M]X?_ /EM1_PUUI/_ $4CX8_^#[P__P#+:C^PLQ_Y]?A4_P#E8?7</_.OOC_\
MEYK[S[XHKX'_ .&NM)_Z*1\,?_!]X?\ _EM1_P -=:3_ -%(^&/_ (/O#_\
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MS'_GU^%3_P"5A]=P_P#.OOC_ /)>:^\^^**^!_\ AKK2?^BD?#'_ ,'WA_\
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MD_\ 12/AC_X/O#__ ,MJ/["S'_GU^%3_ .5A]=P_\Z^^/_R7FOO/OBBO@?\
MX:ZTG_HI'PQ_\'WA_P#^6U'_  UUI/\ T4CX8_\ @^\/_P#RVH_L+,?^?7X5
M/_E8?7</_.OOC_\ )>:^\^^**^!_^&NM)_Z*1\,?_!]X?_\ EM1_PUUI/_12
M/AC_ .#[P_\ _+:C^PLQ_P"?7X5/_E8?7</_ #K[X_\ R7FOO/OBBO@?_AKK
M2?\ HI'PQ_\ !]X?_P#EM1_PUUI/_12/AC_X/O#_ /\ +:C^PLQ_Y]?A4_\
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M=P_\Z^^/_P EYK[S[XHKX'_X:ZTG_HI'PQ_\'WA__P"6U'_#76D_]%(^&/\
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MQ_\ !]X?_P#EM1_PUUI/_12/AC_X/O#_ /\ +:C^PLQ_Y]?A4_\ E8?7</\
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M_P#^6U'_  UUI/\ T4CX8_\ @^\/_P#RVH_L+,?^?7X5/_E8?7</_.OOC_\
M)>:^\^^**^!_^&NM)_Z*1\,?_!]X?_\ EM1_PUUI/_12/AC_ .#[P_\ _+:C
M^PLQ_P"?7X5/_E8?7</_ #K[X_\ R7FOO/OBBO@?_AKK2?\ HI'PQ_\ !]X?
M_P#EM1_PUUI/_12/AC_X/O#_ /\ +:C^PLQ_Y]?A4_\ E8?7</\ SK[X_P#R
M7FOO/OBBO@?_ (:ZTG_HI'PQ_P#!]X?_ /EM1_PUUI/_ $4CX8_^#[P__P#+
M:C^PLQ_Y]?A4_P#E8?7</_.OOC_\EYK[S[XHKX'_ .&NM)_Z*1\,?_!]X?\
M_EM1_P -=:3_ -%(^&/_ (/O#_\ \MJ/["S'_GU^%3_Y6'UW#_SK[X__ "7F
MOO/OBBO@?_AKK2?^BD?#'_P?>'__ );4?\-=:3_T4CX8_P#@^\/_ /RVH_L+
M,?\ GU^%3_Y6'UW#_P Z^^/_ ,EYK[S[XHKX'_X:ZTG_ **1\,?_  ?>'_\
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M%(^&/_@^\/\ _P MJ/["S'_GU^%3_P"5A]=P_P#.OOC_ /)>:^\^^**^!_\
MAKK2?^BD?#'_ ,'WA_\ ^6U'_#76D_\ 12/AC_X/O#__ ,MJ/["S'_GU^%3_
M .5A]=P_\Z^^/_R7FOO/OBBO@?\ X:ZTG_HI'PQ_\'WA_P#^6U'_  UUI/\
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MPQ_\'WA__P"6U'_#76D_]%(^&/\ X/O#_P#\MJ/["S'_ )]?A4_^5A]=P_\
M.OOC_P#)>:^\^^**^!_^&NM)_P"BD?#'_P 'WA__ .6U'_#76D_]%(^&/_@^
M\/\ _P MJ/["S'_GU^%3_P"5A]=P_P#.OOC_ /)>:^\^^**^!_\ AKK2?^BD
M?#'_ ,'WA_\ ^6U'_#76D_\ 12/AC_X/O#__ ,MJ/["S'_GU^%3_ .5A]=P_
M\Z^^/_R7FOO/OBBO@?\ X:ZTG_HI'PQ_\'WA_P#^6U'_  UUI/\ T4CX8_\
M@^\/_P#RVH_L+,?^?7X5/_E8?7</_.OOC_\ )>:^\]7\,?\ );]2_P"PKXE_
M])[ZOJ&OC3X->((_'/CJ'Q?HUY8^(--GOM;34]9T&6+4M'MM0DTR>>6UDOK"
M2XL[:=6N[0_9Y)Q(JW5OE?W\1;[+K#,X.G7I4Y:3IX>E":ZJ4>9--.S7>S2=
MFM"L*TZ<FM4YMI]TU&S7<_B_HHHK^CSX **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=^PG_P ,P_#O1O'W_"T_^$W_ +7\::=X0_LG_A"/^$:^S_;]#\1ZU_:/V_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^"6O_"OOAWX]\??\+T_M?_A"/!?BGQ?_ &3_ ,*R^P?VI_PC6AWVM?V=]O\
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MW>R1^2'PL_X)1>$Y/#%I=_&3QUXL7Q9>1Q7-QI/@&YT'3]+T3S;>W9M,FO\
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MB_Y"-OY'VC[3^^\GR)?TX_X=#?\ 5PG_ )B;_P#&77Q?_P $]/\ D\#X0_\
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M_F!X)_X)+>#X+*)_B/\ %;Q)J>HO(KS6W@G3-+T*RMXMN&MHKW78/$4]Y(7
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MRC^PG_PT]\.]9\??\+3_ .$(_LCQIJ/A#^R?^$(_X27[1]@T/PYK7]H_;_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMC]I#_DW?X]?]D7^*7_J#Z[7\D]>1X<_[EF7_852_P#3+.KB#^+A_P#KW/\
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MHUFO/"/@GQ)KVGPN!LFU+3M*NI]-AE)CE"Q37ZV\<KM%*L<;,[1NJE3\&?\
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M=,E&C^$Y'M;[QHEW;R?\(UI^E+)!<1PRQ.&1K>W*^1'XO_P[T_; _P"B0_\
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M_P 9_P#IQT"OD_\ X)Z?\G@?"'_N?_\ U5_C6OK#_@KA_P C5\%/^Q?\9_\
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MZ<;-_;A4C&]N=[OZ-91AJ48SQN+G*W\U2-*FGUBG-RD_E*+=KV6Q\O?LR_\
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M00R2VGBGP9);7#0JXB>XMQ)/%#+(CM%#=721[?/<G^@ROYZ/^"5W_)R&O?\
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MH _H9K^>C_@JC_R<AH/_ &2;PS_ZDOC2OR?@+_D?K_L#Q/\ [C/J,[_W%_\
M7VG^I]0_\$G/B'H,O@;XD?"F2YAM_$MAXN'CZUM9Y[6.;5=&UO1=%T"[ETZV
M-P;RY71+SPW;#5I%M%@M/[=T@&>1[ORX?U+\;^!_"7Q(\+:QX*\<:%9>(_"^
MO6WV35-)OQ((IXPZRQ2PSV\D-W97MI/'%=6&HV-Q;:AI]Y#!>6-S;W4,4R?R
M-> _B!XR^&/B>P\9> O$-_X9\2Z9YHM-4T]HBXCN(S%<6]Q;W$<]G>VEQ&Q2
M>SO;>XM9ACS87VKC]B?A#_P5<T.[@M-,^.'@2[TK43/!;R^*_A^HOM%DCN+N
MX1[R_P##.KWZZKI4&FV9LVNFTW6/$UUJ+B^N+/3;,BUTV7V>*>%LSEF57-LJ
MC*NJTX5ITZ,^3%8>O",4ZE--Q<XN454BZ4G5A-M<BC%2.3+<SPRP\<+B6H."
ME!2G&].I!WM&3U2=FXM22BTEJV['=?$3_@E1\(M?EO;WX=>-/%?P^N;AH7M]
M,U"*W\9^';(1I&DD-M#=S:5XAV7/EO*TM[XEU!X+B>22-6MDBLD^5-7_ ."=
MO[6/PBU#5=?^#?CBRUB7^SEL8[OP/XPU7X?>,=4TZ\DL&U+39X+N;2M/2V6Y
MC-U)9MXJN8+^UTZ&<)_:+V^F+^M7@3]KK]FSXC^4GACXP^#Q>3WT&F6^E^(K
MV7P9K%YJ-S]F6WM-/TGQA!H=_JDD\MW#;P/IEO>07%T9+:WEEFAF1/HJ*6*>
M-989(YHFSMDB=9(VVL5;:Z$J<,"IP3A@0>0:\*/$_$V6M4,<ZE6%K/#YKA&W
M-+ENI2G&EB)W22?-5?Q.7Q/F.UY;EV(]^CRQ>ZJ8:K:U[[).5-;Z6CV6VA_)
M)\2M4^/'AO6;_P )?%?7/B?8:Q$M[#>:/XQU[Q)*US;7$]Q8WD\*ZC>S6^IZ
M7J$UI<0B_M'NM-U-(7:&XN8ANKQZOZZ/C-\%O 7QW\$:CX%\?Z4M[872M+IN
MIVXBBUOPWJJH5MM;T"_DBE:RU"V8X8%);2^MFFT[4[6]TVZNK2;^4[XE^!M2
M^&7Q!\:?#[5_/>_\'>)=8\/R7%Q92Z>VH0Z;>S6]IJL5I+)*T5IJ]FEOJEB5
MGN(I;*[MYH+FX@DCGD_1>%^(L-G5*K2CAH8/%X=1G5HT[.E4IR]U5J348M+F
M]V5.2;A>/OS4KKP,RP%3!RC)U)5J51M1G+XXR6O+)7=]-5):.ST5M>(HHHKZ
ML\L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_!0O_DS_ .+W_<@?^K0\%5S_ /P3;_Y-0\'?]C!XV_\ 4FU"N@_X*%_\F?\
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M77BGQ-/;H2+71-'$BSS*\YAM9M3N3:Z-ITUQ =4U&RBE60S0XZS?$X:& P^
MA6S*I!4:>*IN4Y2ERJ/M5A%3:=71SE+VGL5+WG24$X,GDN%IU)5ZE=QP\7SR
MIR2BDKWY75YDU"[44N7FMIS<SN>OZ?86>E6%EI>GVZ6EAIMI;6%C:Q9\NVL[
M.%+>VMX]Q9MD,,:1IN8G:HR2>:_-+_@JY_R;OX,_[+1X=_\ 4'^(M?6G[+OQ
M>UCX[?!K0OBCK>G66CW?B76/%_D:1I[R36VF:9I?BS6='TFR-U,$EO;F'3;"
MV%]?M%;K>WQN+J&SL()8K*W^2_\ @JY_R;OX,_[+1X=_]0?XBU\_D-"KA>*,
M#AJZ2KT,PE1K)24DJM/VD9KF5U*TDUS)M/=-K4[L=.-3+:U2'P3H1G#2WNRY
M91TZ:-:=-C\MOV%?BI#\)_VD_ VHZA>0V.@>+6N? 'B&XN)##!'8^)S!'ILL
M\Y816]M:>)[70+V[N+D&VAM+6>29H%7[5!_4#7\7]?N[^QS_ ,%"/#'B+0M/
M^'?Q]\1Z=X8\6Z5%#8Z)XZU=UL- \46,$+"-/$.I%$T[0=<M(8=LVHZE-9:5
MJZB-OM$.JR>1>_9\=9!B<7*EFN"I2K2I4O8XNE3BY573A)RI5XPBG*IR\\X5
M;7E&"IR2<(S</(R7'4Z2EA:TE!2ESTI2=H\S24H-O2-[)QOHWS*]VD_DG]N7
M]CSXA>"OB?XK^)?@7PIJGB;X<>-]8N_$DDGANPN]6N?">L:JSWVN66M:?90R
MW%AI<NJ/>7>EZBD T>"UN[32GG@NXXH)OC?X.? [XC?''Q7I'AGP/X:UC4+>
M^U2WL-5\1PZ;<R^'_#5JQ26^U/7-5(BT^RAL+-C="WGO(;J_D-O8:?'<:A>V
M=M/_ %NPS17$44\$L<\$\:30S0NLD4T4BAXY8I$+))'(C!T=&*NI#*2"#4E>
M)A./L?A<!#"3PE&OB*-*-&CBY59QLH1Y(2K4>27M9I)7:JTE)J\DVVSLJY'0
MJ5W556<*<Y.<Z2BG>[NU"=URIZVO&5KZ/0^&9?\ @G)^R9-;VT0^'VI6TT,,
M,<]U:^-_&X>[EC0K)/+'>>(+V&)IW/F.END4:%56)43<'_)3]O'X%_!CX >-
M/!?A#X6W?B,ZS>^'[[6?%^F:WJ7]J6UC:SWL-OX9N+*X.EVC)=7YM]>%_!]O
MO%6"TTR1;2P,K3:C^QW[37[9GPP_9ZT;5=/CU?2_%GQ26&2#2? &FWHNKJRO
MGM[6>"Y\8261E_X1O3H[>_M+]+?4'M-4UFUD T:WGC%S>6?\UOCGQKXD^(_B
M_P 1>.O%VHS:KXC\4:K<ZMJMY*[L#/</^[MK6.1Y/LNG6%NL-AI=A$PMM.TV
MVM;"U2.VMH8U]K@REG^*K_VCF&.S!X"$)*C2Q-:K..+J5(N*E&%63;HTE)S5
M1)*510C!R49J/)F\L#2A["A1H*NVN>5.$(NE&+3:;BE[\FK<KU4;MI<RO]]?
M\$P_BM!X(^.>I>!=3O([72?BKH(TNV$AD1)/%GAZ6;4O#RLXS"#-I]QXCT^!
M)55IKV_M(H9ED<07/]#=?QD65[>:=>6FH:?=W-A?V%S!>V-]93RVMY97EK*D
M]M=VES \<UO<V\R)-!/"Z2PRHDD;JZ@C^A']EG_@H5\/?B=I.C^$/BOJ5IX$
M^)5O;V=C)J>I/%9^$?%]RTR64%QIFIRW#C3-6NF:*2^TO5%M;?SIC)I=[>1&
M:WL<..>'\35Q"S?!49UXRIQIXVG2CS5(2I)1IU^6-YS@Z:C3G:+]FJ<9-\LF
MXWDN.IPIO"5I*#4G*C*3M&2D[N%WHI*5VKM*7,TM5K\(?M1?\$]_BIX)\8^(
M/$WPA\+77COX<:M>ZCK%AIGAJ**?Q#X3CN)GNO\ A'I/#B2#4]4MK3S)+;1[
MG0K?4GFL[:.._AL[QH4NN-^ /_!/GXV_%'Q)HLWQ \+:]\+OATTDUSKNM>(8
M+;2O$\MK97/D2Z3H_A74V&NVVK:FZ.EEJ.LZ-!H]G9B35V;40NGZ7J_]'%CJ
MNEZG9)J6FZE8:AITB&6/4+&\M[NR>,*',B75O)) R!"'+K(5"D-G!S7RM^T)
M^V?\&O@'I>IV]UX@T[Q?\08K:X&E_#[P[?Q7NI-J*PVLEO%XEO;-;NU\(V3+
M?VEV\VL&+4+K3C/<Z)I>L2V[V]>=@N+^),50AEF$PM/$XUQ5&.)C1JRQ$8VY
M/:5(\_L8U(-J4J]2*I12YJL'[TCHK95E]*;Q-6K*G1OSNFY15-N]^6+MSN+U
M]R+<G>T6M$?4^CZ1IGA_2=+T'1+&VTO1M$TZRTC2-,LHE@L].TS3;:*SL+&T
MA0!8;:TM88K>")0%CBC1 , 5\0?\%)/^34/&/_8P>"?_ %)M/KUW]D3XD^*?
MB_\ L^>!OB1XTN;:Y\2>*;WQU=W[65JEE8V\5K\1/%FFZ;I]C;*7:.RTO2[*
MRTVT,\US>26UI%)?7EY>//=3>*_\%+KS[+^ROK\'E[_[1\7>#;/=OV^3LU3^
MT/,V[6\S/V'R=F4QYOF;CLV/\_E6'JX;B;!86LU*MALXI4:LHR<HRJ4<6H5)
M*4DG).4)--I-K5J[L=V*J0J9=6J1NH5,)*4$U9J,Z5XII72=FE9:+O8_'O\
M85^*D/PG_:3\#:CJ%Y#8Z!XM:Y\ >(;BXD,,$=CXG,$>FRSSEA%;VUIXGM=
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M1110 5_6Q^S?_P F[_ 7_LB_PM_]0?0J_DGK^MC]F_\ Y-W^ O\ V1?X6_\
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MEN6L_$FL/87.I6NF67A^XE2\T6S$T6M3>(;.WU"==.L=,@CU[]HJ_+K]K/\
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M?*_L[=OWMO\ .V[4\O+_ "Y_P3T_Y/ ^$/\ W/\ _P"JO\:U^B98FN JJ?\
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ME3E"ZDKQE%N2E]/C\OAF"I259T^1/EE%*I"49\KNES16ME:2>J>J:M;\2O\
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M 5J:/KFM^'KP:AH&L:IH=^JA%OM'U"[TR\""6*<(+FRF@F"B:"&8*'P)88I
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M]YQ<M$DEKHDET+52I%<L:DU'LI22U=WHG;5Z^H4445L0%%%% !1110 4444
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M1C%648I))+9)*R279";;;;;;>K;=VWW;>X5^IW['G[#_ ,(OVD?@Y=>.M?\
M%WC_ $GQ/8>,-;\,7UOH-WH,6C6QL+#2=1LQ]DU3PQ=W<T[VFL6=S/-#JSV[
M+)Y"+#.DHB_+&OT&_8%_:KL?@%XTU'PCXYNVM_AAX[EMVO+Y8!*?"_BB,P6U
MCX@G9/WQT>>R$MAKD4<<TL:KI^HPA4T^Y@O/#XCAF4LJK3RFI4IXRC*%:*I6
M=2K3@W[6G%.,N:3@W*,$KRE!1C=M)]F7O#K$P6*C&5*:<&Y?#&3MRR;NK)-6
M;>B3;>BNOL;6O^"27@:>%U\._&+Q9I=P4B$4NM>&M'UZ%)!,&F=X+&^\-O(D
MEOF**-;B)HIB)VEF0?9C^*GBWPMK7@CQ/K_A#Q'9R6&N^&M6OM&U2UDCFC,=
MY87#V\K1K/%#*T$I036TK1)Y]O)%,J[)%K^P[2-8TGQ!IECK>@ZIIVMZ-JEM
M%>Z9J^D7MMJ6F:C9SKOAN[&_LY9K6[MIE(:*>WEDBD4Y1R.:YCQ5\,OAMXZ>
M.7QO\/O _C*2+RO*D\5>$]!\0O'Y"SK#Y;ZO87C)Y*W-RL6TCRUN)PF!+)N_
M.,HXYS'!5*T,U]KF%.22@G[*C6H5(MJ5FJ2<U):2A4?NN*<6KS4OH,5DN'K1
MB\-RT)+5OWIPG%VMO-\K6Z<5K>SOHU_+)^SG\./$WQ3^-'P^\+>%])O-4F'B
M?0]6UJ6U 2'1?#6EZO83ZWKNHW<B/!8V.GVA)\Z97:XO);33K."\U*^LK*Y_
MK3K%T'PWX=\*Z?#I'A?0-%\-Z5;1I%;Z9H.E6.CZ?!%$NV..&RT^"WMHHXU^
M5$2)51>% '%>1?'O]HGX;_L\^%+GQ#XVU:W;59K.YF\-^#[6Y@'B+Q3=0M%"
M(--M'8R):1SSP+J&JRQ_8M.A<R2M)*8K>;S<]SG$<4X["4\-@IP=-3HX>A";
MK5:DZLDY3DU&$8IJ$-$N6"C*4JC6L>C!82GEE"K*I63YFIU)M<D(J*LDM6WJ
MWK>\FTE%/?\ %W_@J9XB@U?]HW2-&MKX7"^%/AGX=TR^LH[Q+B.PU;4=7\1Z
M]*);6.1A87MUI&J:)-+',D5S/9C3[A@]J]HY_-BNV^(_Q \2?%3QUXG^(?BZ
MXAN/$/BO5)M4U VT;PV=OO5(;6PL(999Y8=.TRRAMM.T^&:XN)HK*U@CFN)Y
M%:5^)K]ERG!2R_+,#@I-2GA\-3IU''6+J\MZKB[)N/M'+E;2;5FU<^2Q598C
M$UJR32J5).*>_+M&_GRI7\PHHHKT3G"BBB@#J/#/CCQKX*DNIO!OB_Q1X2EO
M?)^VR^&?$&K:#)=_9EN%M_M3Z5=VC7'V=;NZ6'S2_E+<W CVB:0-TVO?&SXS
M>*M/FTCQ1\6_B=XDTJYC>*XTS7O'OBK6-/GBE7;)'-9:AJUQ;2QR+\KH\3*Z
M\,".*\QHK&6'H3FJLZ%&51--5)4X2FFK)-3<7)-)))WTLNQ:J32Y5.:B[IQ4
MFE9[JR=M>H4445L0%%%% !1110 4444 %%%% !1110 59LKV\TZ\M-0T^[N;
M"_L+F"]L;ZRGEM;RRO+65)[:[M+F!XYK>YMYD2:">%TEAE1)(W5U!%:BAI--
M-73T:>S79AML>P6W[0WQ^LHE@L_CC\8+2!<;8;;XF>-((EVJJ#;'%K:(,(BH
M,*,*JJ.% '.>)OBI\3_&EM)9^,?B/X]\66DQA:6U\3>,/$.O6TK6S;[=I(-4
MU&ZB<P/\\)928F^9-IYK@J*YXX3"PDIPPV'C-.ZG&C3C)-;-244T_.Y;JU6F
MG4J-/=.<FG?>Z;MJ%%%%=! 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!_01_P2C_Y-W\9_P#9:/$7_J#_  ZK].*_,?\ X)1_\F[^,_\
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M1_P[T_; _P"B0_\ E_\ PO\ _FUK^G"BC_B(>=?] N5_^",7_P#-H?V#@_\
MGYB?_ Z7_P I/YC_ /AWI^V!_P!$A_\ +_\ A?\ _-K1_P .]/VP/^B0_P#E
M_P#PO_\ FUK^G"BC_B(>=?\ 0+E?_@C%_P#S:']@X/\ Y^8G_P #I?\ RD_F
M/_X=Z?M@?]$A_P#+_P#A?_\ -K1_P[T_; _Z)#_Y?_PO_P#FUK^G"BC_ (B'
MG7_0+E?_ ((Q?_S:']@X/_GYB?\ P.E_\I/YC_\ AWI^V!_T2'_R_P#X7_\
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M'_1(?_+_ /A?_P#-K1_P[T_; _Z)#_Y?_P +_P#YM:_IPHH_XB'G7_0+E?\
MX(Q?_P VA_8.#_Y^8G_P.E_\I/YC_P#AWI^V!_T2'_R__A?_ /-K1_P[T_;
M_P"B0_\ E_\ PO\ _FUK^G"BC_B(>=?] N5_^",7_P#-H?V#@_\ GYB?_ Z7
M_P I/YC_ /AWI^V!_P!$A_\ +_\ A?\ _-K1_P .]/VP/^B0_P#E_P#PO_\
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MC+"95*,DU*,L/BI1DGNFGC6FGU35AK(L(FFJN*36J:G233[IJCH?B9IND?\
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MT2'_ ,O_ .%__P VM'_#O3]L#_HD/_E__"__ .;6OZ<**O\ XB'G7_0+E?\
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MV!_T2'_R_P#X7_\ S:U_3A11_P 1#SK_ *!<K_\ !&+_ /FT/[!P?_/S$_\
M@=+_ .4G\Q__  [T_; _Z)#_ .7_ /"__P";6C_AWI^V!_T2'_R__A?_ /-K
M7].%%'_$0\Z_Z!<K_P#!&+_^;0_L'!_\_,3_ .!TO_E)_,?_ ,.]/VP/^B0_
M^7_\+_\ YM:/^'>G[8'_ $2'_P O_P"%_P#\VM?TX44?\1#SK_H%RO\ \$8O
M_P";0_L'!_\ /S$_^!TO_E)_,?\ \.]/VP/^B0_^7_\ "_\ ^;6C_AWI^V!_
MT2'_ ,O_ .%__P VM?TX44?\1#SK_H%RO_P1B_\ YM#^P<'_ ,_,3_X'2_\
ME)_,?_P[T_; _P"B0_\ E_\ PO\ _FUH_P"'>G[8'_1(?_+_ /A?_P#-K7].
M%%'_ !$/.O\ H%RO_P $8O\ ^;0_L'!_\_,3_P"!TO\ Y2?S'_\ #O3]L#_H
MD/\ Y?\ \+__ )M:/^'>G[8'_1(?_+_^%_\ \VM?TX44?\1#SK_H%RO_ ,$8
MO_YM#^P<'_S\Q/\ X'2_^4G\Q_\ P[T_; _Z)#_Y?_PO_P#FUH_X=Z?M@?\
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M (*PO_RCU_IZ']BX7^5?^!5?_D_ZN_*W\\/_  P1J'_13K/_ ,)*?_YH:/\
MA@C4/^BG6?\ X24__P T-?T/?\(WX=_Z &B_^"NQ_P#C%'_"-^'?^@!HO_@K
ML?\ XQ1_KWFG\\O_  5A?_E'K_3T/[%PO\J_\"J__)_U=^5OYX?^&"-0_P"B
MG6?_ (24_P#\T-'_  P1J'_13K/_ ,)*?_YH:_H>_P"$;\._] #1?_!78_\
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MJ_\  JO_ ,G_ %=^5OYX?^&"-0_Z*=9_^$E/_P#-#1_PP1J'_13K/_PDI_\
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M>7_@K"__ "CU_IZ']BX7^5?^!5?_ )/^KORM_/#_ ,,$:A_T4ZS_ /"2G_\
MFAH_X8(U#_HIUG_X24__ ,T-?T/?\(WX=_Z &B_^"NQ_^,4?\(WX=_Z &B_^
M"NQ_^,4?Z]YI_/+_ ,%87_Y1Z_T]#^Q<+_*O_ JO_P G_5WY6_GA_P"&"-0_
MZ*=9_P#A)3__ #0T?\,$:A_T4ZS_ /"2G_\ FAK^A[_A&_#O_0 T7_P5V/\
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M  C?AW_H :+_ ."NQ_\ C%'^O>:?SR_\%87_ .4>O]/0_L7"_P J_P# JO\
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M8H_X1OP[_P! #1?_  5V/_QBC_7O-/YY?^"L+_\ */7^GH?V+A?Y5_X%5_\
MD_ZN_*W\\/\ PP1J'_13K/\ \)*?_P":&C_A@C4/^BG6?_A)3_\ S0U_0]_P
MC?AW_H :+_X*['_XQ1_PC?AW_H :+_X*['_XQ1_KWFG\\O\ P5A?_E'K_3T/
M[%PO\J_\"J__ "?]7?E;^>'_ (8(U#_HIUG_ .$E/_\ -#1_PP1J'_13K/\
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M_P!>\T_GE_X*PO\ \H]?Z>A_8N%_E7_@57_Y/^KORM_/#_PP1J'_ $4ZS_\
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M:&C_ (8(U#_HIUG_ .$E/_\ -#7]#W_"-^'?^@!HO_@KL?\ XQ1_PC?AW_H
M:+_X*['_ .,4?Z]YI_/+_P %87_Y1Z_T]#^Q<+_*O_ JO_R?]7?E;^>'_A@C
M4/\ HIUG_P"$E/\ _-#1_P ,$:A_T4ZS_P#"2G_^:&OZ'O\ A&_#O_0 T7_P
M5V/_ ,8H_P"$;\._] #1?_!78_\ QBC_ %[S3^>7_@K"_P#RCU_IZ']BX7^5
M?^!5?_D_ZN_*W\\/_#!&H?\ 13K/_P )*?\ ^:&C_A@C4/\ HIUG_P"$E/\
M_-#7]#W_  C?AW_H :+_ ."NQ_\ C%'_  C?AW_H :+_ ."NQ_\ C%'^O>:?
MSR_\%87_ .4>O]/0_L7"_P J_P# JO\ \G_5WY6_GA_X8(U#_HIUG_X24_\
M\T-'_#!&H?\ 13K/_P )*?\ ^:&OZ'O^$;\._P#0 T7_ ,%=C_\ &*/^$;\.
M_P#0 T7_ ,%=C_\ &*/]>\T_GE_X*PO_ ,H]?Z>A_8N%_E7_ (%5_P#D_P"K
MORM_/#_PP1J'_13K/_PDI_\ YH:/^&"-0_Z*=9_^$E/_ /-#7]#W_"-^'?\
MH :+_P""NQ_^,4?\(WX=_P"@!HO_ (*['_XQ1_KWFG\\O_!6%_\ E'K_ $]#
M^Q<+_*O_  *K_P#)_P!7?E;^>'_A@C4/^BG6?_A)3_\ S0T?\,$:A_T4ZS_\
M)*?_ .:&OZ'O^$;\._\ 0 T7_P %=C_\8H_X1OP[_P! #1?_  5V/_QBC_7O
M-/YY?^"L+_\ */7^GH?V+A?Y5_X%5_\ D_ZN_*W\\/\ PP1J'_13K/\ \)*?
M_P":&C_A@C4/^BG6?_A)3_\ S0U_0]_PC?AW_H :+_X*['_XQ1_PC?AW_H :
M+_X*['_XQ1_KWFG\\O\ P5A?_E'K_3T/[%PO\J_\"J__ "?]7?E;^>'_ (8(
MU#_HIUG_ .$E/_\ -#1_PP1J'_13K/\ \)*?_P":&OZ'O^$;\._] #1?_!78
M_P#QBC_A&_#O_0 T7_P5V/\ \8H_U[S3^>7_ (*PO_RCU_IZ']BX7^5?^!5?
M_D_ZN_*W\\/_  P1J'_13K/_ ,)*?_YH:/\ A@C4/^BG6?\ X24__P T-?T/
M?\(WX=_Z &B_^"NQ_P#C%'_"-^'?^@!HO_@KL?\ XQ1_KWFG\\O_  5A?_E'
MK_3T/[%PO\J_\"J__)_U=^5OYX?^&"-0_P"BG6?_ (24_P#\T-'_  P1J'_1
M3K/_ ,)*?_YH:_H>_P"$;\._] #1?_!78_\ QBC_ (1OP[_T -%_\%=C_P#&
M*/\ 7O-/YY?^"L+_ /*/7^GH?V+A?Y5_X%5_^3_J[\K?SP_\,$:A_P!%.L__
M  DI_P#YH::W[!.I!6*?$VQ9PI**WA2=%9L':&<:^Y52< L$<J,D*Q&#_1!_
MPC?AW_H :+_X*['_ .,5\;_\%$H(/"_[ _[:/B3PU#%X=\1:#^RW\=M8T+7M
M"C32-:T75M.^&GB2[T_5-)U33Q;WVG:C87445S9WUG/#<VMQ%'-!*DB*PTH\
M;YK6JTJ2J.+JU(4TW2PK2<Y1C=KV&J5[^=O/3*OE.%H4*U9PYE1I5*KBIU$Y
M*G!S:3<VDWRVO;2^VQ^*GB?]CCXL:?KS:+X/M;3QVMOI&GZIJ%[:7VC>'DL6
MU.\U>TMK5H/$&M6DEPSC1YY?-MFE10P201L$,F)_PQY^T9_T3O\ \N[P+_\
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M_P!$[_\ +N\"_P#S3T?\,>?M&?\ 1.__ "[O O\ \T]?N111_K?F7_/C _\
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M[1G_ $3O_P N[P+_ /-/7[D44?ZWYE_SXP/_ (*Q'_S2']CX;^>O_P"!4_\
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M1_PQY^T9_P!$[_\ +N\"_P#S3U^Y%%'^M^9?\^,#_P""L1_\TA_8^&_GK_\
M@5/_ .5'X;_\,>?M&?\ 1.__ "[O O\ \T]'_#'G[1G_ $3O_P N[P+_ /-/
M7[D44?ZWYE_SXP/_ (*Q'_S2']CX;^>O_P"!4_\ Y4?AO_PQY^T9_P!$[_\
M+N\"_P#S3T?\,>?M&?\ 1.__ "[O O\ \T]?N111_K?F7_/C _\ @K$?_-(?
MV/AOYZ__ (%3_P#E1^&__#'G[1G_ $3O_P N[P+_ /-/1_PQY^T9_P!$[_\
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M3_R\OA__ /-57[Y44?Z[9K_T#Y?_ ."L3_\ -8?V)A/^?F(_\#I__*C\#?\
MABK]IG_HFG_EY?#_ /\ FJH_X8J_:9_Z)I_Y>7P__P#FJK]\J*/]=LU_Z!\O
M_P#!6)_^:P_L3"?\_,1_X'3_ /E1^!O_  Q5^TS_ -$T_P#+R^'_ /\ -51_
MPQ5^TS_T33_R\OA__P#-57[Y44?Z[9K_ - ^7_\ @K$__-8?V)A/^?F(_P#
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MYB/_  .G_P#*C\#?^&*OVF?^B:?^7E\/_P#YJJ/^&*OVF?\ HFG_ )>7P_\
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M -$T_P#+R^'_ /\ -51_PQ5^TS_T33_R\OA__P#-57[Y44?Z[9K_ - ^7_\
M@K$__-8?V)A/^?F(_P# Z?\ \J/P-_X8J_:9_P"B:?\ EY?#_P#^:JJS?L;_
M +1Z74=F_P /(DNI3&L<+>-?A\K,TKA(UR?%84,[$  D'!SC;S7[]UPFH_\
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M1_X'3_\ E1_/'_PPQ^U-_P!$N_\ +V^'7_S74?\ ##'[4W_1+O\ R]OAU_\
M-=7]#E%'^O.;?] ^7?\ @G$__-8?V)A/^?F(_P# Z?\ \J/YX_\ AAC]J;_H
MEW_E[?#K_P":ZC_AAC]J;_HEW_E[?#K_ .:ZOZ'**/\ 7G-O^@?+O_!.)_\
MFL/[$PG_ #\Q'_@=/_Y4?SQ_\,,?M3?]$N_\O;X=?_-=1_PPQ^U-_P!$N_\
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M *!\N_\ !.)_^:P_L3"?\_,1_P"!T_\ Y4?SQ_\ ##'[4W_1+O\ R]OAU_\
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M$N_\O;X=?_-=1_PPQ^U-_P!$N_\ +V^'7_S75_0Y11_KSFW_ $#Y=_X)Q/\
M\UA_8F$_Y^8C_P #I_\ RH_GC_X88_:F_P"B7?\ E[?#K_YKJ/\ AAC]J;_H
MEW_E[?#K_P":ZOZ'**/]><V_Z!\N_P#!.)_^:P_L3"?\_,1_X'3_ /E1_/'_
M ,,,?M3?]$N_\O;X=?\ S74?\,,?M3?]$N_\O;X=?_-=7]#E%'^O.;?] ^7?
M^"<3_P#-8?V)A/\ GYB/_ Z?_P J/YX_^&&/VIO^B7?^7M\.O_FNH_X88_:F
M_P"B7?\ E[?#K_YKJ_H<HH_UYS;_ *!\N_\ !.)_^:P_L3"?\_,1_P"!T_\
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M$>26&/QU\.-Z1QR)$[G=XO4%5DD1<J2"6&,C-?T45YE\*_\ D;M6_P"P5?\
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M_P"!TO\ Y2?S'_\ #O3]L#_HD/\ Y?\ \+__ )M:/^'>G[8'_1(?_+_^%_\
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M/^B0_P#E_P#PO_\ FUH_X=Z?M@?]$A_\O_X7_P#S:U_3A11_Q$/.O^@7*_\
MP1B__FT/[!P?_/S$_P#@=+_Y2?S'_P##O3]L#_HD/_E__"__ .;6C_AWI^V!
M_P!$A_\ +_\ A?\ _-K7].%%'_$0\Z_Z!<K_ /!&+_\ FT/[!P?_ #\Q/_@=
M+_Y2?S'_ /#O3]L#_HD/_E__  O_ /FUH_X=Z?M@?]$A_P#+_P#A?_\ -K7]
M.%%'_$0\Z_Z!<K_\$8O_ .;0_L'!_P#/S$_^!TO_ )2?S'_\.]/VP/\ HD/_
M )?_ ,+_ /YM:/\ AWI^V!_T2'_R_P#X7_\ S:U_3A11_P 1#SK_ *!<K_\
M!&+_ /FT/[!P?_/S$_\ @=+_ .4G\Q__  [T_; _Z)#_ .7_ /"__P";6C_A
MWI^V!_T2'_R__A?_ /-K7].%%'_$0\Z_Z!<K_P#!&+_^;0_L'!_\_,3_ .!T
MO_E)_,?_ ,.]/VP/^B0_^7_\+_\ YM:/^'>G[8'_ $2'_P O_P"%_P#\VM?T
MX44?\1#SK_H%RO\ \$8O_P";0_L'!_\ /S$_^!TO_E)_,?\ \.]/VP/^B0_^
M7_\ "_\ ^;6C_AWI^V!_T2'_ ,O_ .%__P VM?TX44?\1#SK_H%RO_P1B_\
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M\1#SK_H%RO\ \$8O_P";0_L'!_\ /S$_^!TO_E)_,?\ \.]/VP/^B0_^7_\
M"_\ ^;6C_AWI^V!_T2'_ ,O_ .%__P VM?TX44?\1#SK_H%RO_P1B_\ YM#^
MP<'_ ,_,3_X'2_\ E)_,?_P[T_; _P"B0_\ E_\ PO\ _FUH_P"'>G[8'_1(
M?_+_ /A?_P#-K7].%%'_ !$/.O\ H%RO_P $8O\ ^;0_L'!_\_,3_P"!TO\
MY2?S'_\ #O3]L#_HD/\ Y?\ \+__ )M:/^'>G[8'_1(?_+_^%_\ \VM?TX44
M?\1#SK_H%RO_ ,$8O_YM#^P<'_S\Q/\ X'2_^4G\Q_\ P[T_; _Z)#_Y?_PO
M_P#FUH_X=Z?M@?\ 1(?_ "__ (7_ /S:U_3A11_Q$/.O^@7*_P#P1B__ )M#
M^P<'_P _,3_X'2_^4G\Q_P#P[T_; _Z)#_Y?_P +_P#YM:/^'>G[8'_1(?\
MR_\ X7__ #:U_3A11_Q$/.O^@7*__!&+_P#FT/[!P?\ S\Q/_@=+_P"4G\Q_
M_#O3]L#_ *)#_P"7_P#"_P#^;6C_ (=Z?M@?]$A_\O\ ^%__ ,VM?TX44?\
M$0\Z_P"@7*__  1B_P#YM#^P<'_S\Q/_ ('2_P#E)_,?_P .]/VP/^B0_P#E
M_P#PO_\ FUH_X=Z?M@?]$A_\O_X7_P#S:U_3A11_Q$/.O^@7*_\ P1B__FT/
M[!P?_/S$_P#@=+_Y2?S'_P##O3]L#_HD/_E__"__ .;6C_AWI^V!_P!$A_\
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MK_H%RO\ \$8O_P";0_L'!_\ /S$_^!TO_E)_,?\ \.]/VP/^B0_^7_\ "_\
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M_P _,3_X'2_^4G\Q_P#P[T_; _Z)#_Y?_P +_P#YM:/^'>G[8'_1(?\ R_\
MX7__ #:U_3A11_Q$/.O^@7*__!&+_P#FT/[!P?\ S\Q/_@=+_P"4G\Q__#O3
M]L#_ *)#_P"7_P#"_P#^;6C_ (=Z?M@?]$A_\O\ ^%__ ,VM?TX44?\ $0\Z
M_P"@7*__  1B_P#YM#^P<'_S\Q/_ ('2_P#E)_,?_P .]/VP/^B0_P#E_P#P
MO_\ FUH_X=Z?M@?]$A_\O_X7_P#S:U_3A11_Q$/.O^@7*_\ P1B__FT/[!P?
M_/S$_P#@=+_Y2?S'_P##O3]L#_HD/_E__"__ .;6C_AWI^V!_P!$A_\ +_\
MA?\ _-K7].%%'_$0\Z_Z!<K_ /!&+_\ FT/[!P?_ #\Q/_@=+_Y2?S'_ /#O
M3]L#_HD/_E__  O_ /FUH_X=Z?M@?]$A_P#+_P#A?_\ -K7].%%'_$0\Z_Z!
M<K_\$8O_ .;0_L'!_P#/S$_^!TO_ )2?S'_\.]/VP/\ HD/_ )?_ ,+_ /YM
M:/\ AWI^V!_T2'_R_P#X7_\ S:U_3A11_P 1#SK_ *!<K_\ !&+_ /FT/[!P
M?_/S$_\ @=+_ .4G\Q__  [T_; _Z)#_ .7_ /"__P";6C_AWI^V!_T2'_R_
M_A?_ /-K7].%%'_$0\Z_Z!<K_P#!&+_^;0_L'!_\_,3_ .!TO_E)_,?_ ,.]
M/VP/^B0_^7_\+_\ YM:/^'>G[8'_ $2'_P O_P"%_P#\VM?TX44?\1#SK_H%
MRO\ \$8O_P";0_L'!_\ /S$_^!TO_E)_,?\ \.]/VP/^B0_^7_\ "_\ ^;6C
M_AWI^V!_T2'_ ,O_ .%__P VM?TX44?\1#SK_H%RO_P1B_\ YM#^P<'_ ,_,
M3_X'2_\ E)_,?_P[T_; _P"B0_\ E_\ PO\ _FUH_P"'>G[8'_1(?_+_ /A?
M_P#-K7].%%'_ !$/.O\ H%RO_P $8O\ ^;0_L'!_\_,3_P"!TO\ Y2?S'_\
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M7*__  1B_P#YM#^P<'_S\Q/_ ('2_P#E)_,?_P .]/VP/^B0_P#E_P#PO_\
MFUH_X=Z?M@?]$A_\O_X7_P#S:U_3A11_Q$/.O^@7*_\ P1B__FT/[!P?_/S$
M_P#@=+_Y2?S'_P##O3]L#_HD/_E__"__ .;6C_AWI^V!_P!$A_\ +_\ A?\
M_-K7].%%'_$0\Z_Z!<K_ /!&+_\ FT/[!P?_ #\Q/_@=+_Y2?S'_ /#O3]L#
M_HD/_E__  O_ /FUH_X=Z?M@?]$A_P#+_P#A?_\ -K7].%%'_$0\Z_Z!<K_\
M$8O_ .;0_L'!_P#/S$_^!TO_ )2?S'_\.]/VP/\ HD/_ )?_ ,+_ /YM:/\
MAWI^V!_T2'_R_P#X7_\ S:U_3A11_P 1#SK_ *!<K_\ !&+_ /FT/[!P?_/S
M$_\ @=+_ .4G\Q__  [T_; _Z)#_ .7_ /"__P";6C_AWI^V!_T2'_R__A?_
M /-K7].%%'_$0\Z_Z!<K_P#!&+_^;0_L'!_\_,3_ .!TO_E)_,?_ ,.]/VP/
M^B0_^7_\+_\ YM:/^'>G[8'_ $2'_P O_P"%_P#\VM?TX44?\1#SK_H%RO\
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MV!_T2'_R_P#X7_\ S:U_3A11_P 1#SK_ *!<K_\ !&+_ /FT/[!P?_/S$_\
M@=+_ .4G\Q__  [T_; _Z)#_ .7_ /"__P";6C_AWI^V!_T2'_R__A?_ /-K
M7].%%'_$0\Z_Z!<K_P#!&+_^;0_L'!_\_,3_ .!TO_E)_,?_ ,.]/VP/^B0_
M^7_\+_\ YM:/^'>G[8'_ $2'_P O_P"%_P#\VM?TX44?\1#SK_H%RO\ \$8O
M_P";0_L'!_\ /S$_^!TO_E)_,?\ \.]/VP/^B0_^7_\ "_\ ^;6C_AWI^V!_
MT2'_ ,O_ .%__P VM?TX44?\1#SK_H%RO_P1B_\ YM#^P<'_ ,_,3_X'2_\
ME)_,?_P[T_; _P"B0_\ E_\ PO\ _FUH_P"'>G[8'_1(?_+_ /A?_P#-K7].
M%%'_ !$/.O\ H%RO_P $8O\ ^;0_L'!_\_,3_P"!TO\ Y2?S'_\ #O3]L#_H
MD/\ Y?\ \+__ )M:/^'>G[8'_1(?_+_^%_\ \VM?TX44?\1#SK_H%RO_ ,$8
MO_YM#^P<'_S\Q/\ X'2_^4G\Q_\ P[T_; _Z)#_Y?_PO_P#FUH_X=Z?M@?\
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M !$/.O\ H%RO_P $8O\ ^;0_L'!_\_,3_P"!TO\ Y2?S'_\ #O3]L#_HD/\
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M-TXN33DTDFG)I)7UZ)+R"BBBO+.H**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOYH_^#:3_DAG[2__ &5CPG_ZA[U_2Y7V^:_\C#$_XH?^FX'S/"G_ "3V6?\
M7JK_ .I%8****\\^A"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\R^%?_(W:M_V"K_\
M].>G5Z;7F7PK_P"1NU;_ +!5_P#^G/3JVC_N^+_Z]Q_-F4_CI>LOT/H6BBBO
M)-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH XOXA_P#(FZU_USM/_3A:5;^"'_(F
MS?\ 8;OO_2:QJI\0_P#D3=:_ZYVG_IPM*M_!#_D39O\ L-WW_I-8UV/_ )%E
M3_L*7_I$!1_C1_P2_-'L-%%%>6=(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!\O>&/^2WZE_V%?$O_I/?5]0U\O>&/^2WZE_V%?$O_I/?5]0U
MWYA\>'_[!*'_ +<<^&^"?_7R7Y1"BBBN Z HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\-K&=MW=7_Q@U*S\ ZH+"0C$%WIWA/6_$>NI<AX9K:/2)9[.47T=LK?Q1_\
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MB_"C7_$DVL_$S]E/5E^%FMVNH.9-5C^&FH?;=5^#&H%E>2(Z%:>'+?5/ASH
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M<_\ H[7_ ,P-^S+_ /.8H_XB _\ @KG_ -':_P#F!OV9?_G,57^IN:?\_P#
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M %=O[0U'_!J]_P I!_C%_P!F;?$'_P!7;^SS1_P=0_\ *0?X._\ 9FWP^_\
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M/'9W'QN\7:Y9:H?#OB7X9&[-Y)I7@S4I-%O;GX@W^H17T/PI<1V=V==N-?\
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M)5%&I@,;3IMVYXNA4DEIJX>TAHM6[2;LM$WH?Z=-%?EI_P $L?\ @J+\+_\
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M?_10_'/_ (5NO_\ RPH_X6?\2_\ HH?CG_PK=?\ _EA1_P 1ZRC_ *$&9?\
MA3A?\O7^GH?\3<\.?]$AG?\ X78'_P"1]?Z>G['T5^.'_"S_ (E_]%#\<_\
MA6Z__P#+"C_A9_Q+_P"BA^.?_"MU_P#^6%'_ !'K*/\ H09E_P"%.%_R]?Z>
MA_Q-SPY_T2&=_P#A=@?_ )'U_IZ?L?17XX?\+/\ B7_T4/QS_P"%;K__ ,L*
M/^%G_$O_ **'XY_\*W7_ /Y84?\ $>LH_P"A!F7_ (4X7_+U_IZ'_$W/#G_1
M(9W_ .%V!_\ D?7^GI^Q]%?CA_PL_P")?_10_'/_ (5NO_\ RPH_X6?\2_\
MHH?CG_PK=?\ _EA1_P 1ZRC_ *$&9?\ A3A?\O7^GH?\3<\.?]$AG?\ X78'
M_P"1]?Z>G['T5^.'_"S_ (E_]%#\<_\ A6Z__P#+"C_A9_Q+_P"BA^.?_"MU
M_P#^6%'_ !'K*/\ H09E_P"%.%_R]?Z>A_Q-SPY_T2&=_P#A=@?_ )'U_IZ?
ML?17XX?\+/\ B7_T4/QS_P"%;K__ ,L*/^%G_$O_ **'XY_\*W7_ /Y84?\
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M_P#].>G5M'_=\7_U[C^;,I_'2]9?H?0M%%%>2:A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!Q?Q#_P"1-UK_ *YVG_IPM*M_!#_D39O^PW??^DUC53XA_P#(FZU_
MUSM/_3A:5;^"'_(FS?\ 8;OO_2:QKL?_ "+*G_84O_2("C_&C_@E^:/8:***
M\LZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y>\,?\EOU+_L
M*^)?_2>^KZAKY>\,?\EOU+_L*^)?_2>^KZAKOS#X\/\ ]@E#_P!N.?#?!/\
MZ^2_*(4445P'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&MVZE",5&<O.I2=.HWUE*5MC^&[_ (.N_P#DX_\ 95_[(EXK_P#4[FK\FO\
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MQ;W%I<3VEW!-:W5K-+;W-M<1/#<6]Q"[1S03PR*LD4T,BM'+%(JO&ZLCJ&!
M_P!<K5/VI_V8M$U.PT76OVCO@-I&LZKJ]OX?TO2=4^+_ ,/K#4]2UZ[U&UTB
MUT2PL+OQ#%=7FKW.K7UEI=OIMO%)>3:C>6ME'"US<0Q/YQ^T?^P%^QC^UPD[
M_M#_ +.7PT^(VKW+6YF\83Z/)X;^(A2TL?[-M[9/B7X.N?#WQ!ALHK(0P+80
M^)8[(BTL':W,FG6+V_VN7<55\'1I4,PPU2M",5&G7A[E9P@DDI1J6C6<5ISJ
M<'MS<S;D?FN<<"87,*]?%9/C:-"K.3G6PM3]YAU4J-R;A4I.53#QD[M4W2JK
M?DY(I07^5U\-/B]\6/@OXA7Q;\'?BA\1/A/XK2&6W3Q-\-/&OB7P)XA6">"X
MM9X%UKPMJ>E:DL,UK=75M+&+D))!<W$+J8YI%;]KOV3O^#C#_@H!^SYJ.A:7
M\5_$.D?M4_#73]UM?^&_BA!:Z5X^?3I;H7DS:/\ %[0=-_X2/^V_,\V"VU;Q
M[IWQ'M;:RN9K0:/(EOI9TW]R_C?_ ,&K_P"R=XP>TNO@3\=_B_\ !2Z6&YBU
M"R\5:;H7QC\/3R>0B:?<6%D\_P /?$%A-'<^;/JBW7BK5;?4(FAM["#16BDG
MG_E8_P""A7_!,/\ :4_X)O>,]#T3XS6>@>)/!'C6341\/OBQX$NKZ_\ !GBA
MM-\J6[TBZ34[#3-7\.>*["SNK2XU'0-7L4B?S)Y?#^J>(M-LY]3'T-+'9#GK
M]A*-*K6E%VI8BBZ=>R3O[.I9/F44W^YJN48W>BN?(5\KXJX7B\5">(P^'A-<
MU?"8A5<+>3BDZU%-I0E)QA_M-!0G.T?>;C?_ $,/^"?O_!2;]G+_ (*,?#J_
M\7_!?5;[2/%WA1=,@^)'PI\5?9+7QMX'U#4;2.:*:2WMYYH=<\+7ET+RST7Q
M=IA.G:G+875O/#INJ6UYI=K^@5?Y>7_!'O\ :K\1_LE_\% ?V??%]CK\VD^"
M/B!XXT+X._%FQEGN5T35?A_\2M5L_#-Y=ZY;6TT+W,/@[5K[2O'FG,IDDM]6
M\,V<GV>]@-SIU[_I_P"IZGINBZ;J&LZSJ%CI.D:38W>IZKJNIW<%AINF:;80
M275]J&H7UU)%:V5C96L4MS=W=S+'!;P1R332)&C,/AL_RF.5XR,*+E+#UX>T
MH\SYI1:?+.DW9<W*[.+M?EG%-N2;?ZAPGGT\]RZ=7$J$,7A:GL<2X+EA-.*G
M3KJ-WR*HN92C\*G";BE%J*_SN/\ @Y$^.?\ PMK_ (*3^)_!5E>Z)?:'^S[\
M-O 7PJLIM$D^T[]6OK&X^)/B==7O \L4FMZ;K?CR?PY?VEI*MMI?]@Q:?<6U
MOKD&M"3^K_\ X(&? S_A2'_!,+X"O=V>MV&O_&*3Q/\ '/7[?6XOL^[_ (3O
M5W@\(7FD6A0/!HFI_#70_!&J6$KRW']I_;9=:B>&WU.&RM?\_'XM^*/$_P"V
M9^V=X_\ %.B6<VJ>*OVFOVC=<NO#6EZ#HLXGNM1^*OQ#FA\,Z1HV@/=37LDV
M=9T[3M.TRXU"XU"=UA@N]0N;R26[D_U</AOX#T/X6?#OP%\,/##7S>&OAQX+
M\+> _#S:G<)=ZDVA^$-#L?#VDMJ%U'#;1W-\;#3K<W=Q';P)-/YDBPQ*P1?;
MXD?U+*,IRU:/EC.HEHVZ%*,9.2Z<]6M*5NLHOL?,\&)YGQ!GV=R5X<TZ=%OH
ML57<X*+ZNG0P\8-](S5_B.TK^$;_ (.B/VL;?XC_ +2WPR_9,T$S1Z;^S?X>
MG\4>.'>.-!?_ ! ^+NB>&->TRUWI?W/G6OA_P#!H%U8O)8Z9<QW?B[7(Y?MU
MK]@FB_M_^*/Q$\-_"#X9_$3XL^,I;B#PA\+_  +XN^(GBJ>T2&2ZA\-^"= U
M#Q+KDMM'<W%I;R7$>F:9=/"D]U;0O(JK+<0H6D7_ "3/CU\9O&'[1/QI^*/Q
MT\?30S>,/BOXX\1>.=>%LBQV=K=Z_J,]ZNFV$:J@CT[2K>2'3-.CV@QV5I;H
MQ+*6/-P?@O;8VKC9J\,)#EIWZUJRE%-='R4E4NNCG!G;XAYE]7RVAET':ICZ
MO/5MTPV&<9M/JG.NZ/*^L:=1=3]6/^" 7[*EY^TK_P %%OA;XDOK-I? G[-C
M?\+]\6W2S6\+IK/A&XB7X86=L;B&X66YE^)EQX9U6>W2#S9=#T/6S!<V5RD%
MW%_7Y_P7E_9-U#]JS_@G;\3X_"FB+K?Q'^!5]8?'SP1:Q+(-0NH/!%KJ%O\
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M)_[FI'U/B1_R*\!_V'_^Z]8_HN_X-,_^1!_;;_[&_P"!?_IE^*%?T#?M6?\
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MM<)0ERR5!)[59-*5=[IJ-):0E*?\"7_!U#_RD'^#O_9FWP^_]7;^T-7X^?\
M!._]CS5?V[_VO/A'^S99:Q)X;T7Q=J>H:MX[\40C-SX=^'OA+2[OQ)XPOM-W
M66HPG7[S2M.ET/PJMY93::_BK5M$CU9K?2FO;J#]@_\ @ZA_Y2#_  =_[,V^
M'W_J[?VAJP?^#77PYINM_P#!1?QSJ=\C-=>#_P!E3XE>(]&95@(CU*Z^(WP<
M\)2NYF@ED13I'BG58PUK):SEW16G:U:YMKCZS#8B>%X7IXBF[5*67RE3=K\L
MWS1A*ST=I-/6ZTU31\#C\)3QW'-7"5ES4:^:THU8W:YJ24)5(76JYH1<;JS5
M]&F?UU?#S_@D-_P38^''PZL?AKI_['7P.\3Z;:PV:W7B?XA^!-!\>_$75KRU
MM]/AEU&^^(/B:RO_ !7!-?R:='=7EAI&IZ7H8N+G4%L])M+74+NVE_A5_P""
MW/[#'PO_ &!/VUY?A?\ !9]1M?A;\0_AAX:^,W@[PQJNJ7^NWG@:R\2>)O&W
MA*^\'KKFJM+JNK:=INM>!=3NM$NM7O-3UA-#O]-M-8UC5]4M;O4KK_3+K^$'
M_@ZN_P"3R?V>/^S9;7_U:?Q%KYKA;'8NIFOLZN(K585J5:52-2K.:E.*4HSM
M)M<RM9-6=FU>VA]GQSEF7T<A]M0P>&H5,-7P\:,Z-&G2E&$Y>SE3O",6X---
MQ=XWC%VNDUQO_!K?\0M=\/?MY_$SX?V\\S^&OB-^SGXIN-7TY9(8H!KO@OQI
MX&U+P[K<@:UFN+B;3M/U+Q1I$%M%<VD)3Q)<74[3O9V\1_JC_P""S'[7>L_L
M8?\ !/\ ^+_Q,\%Z_+X;^*7BV71/A+\)=5M;JTM-1L?&OCNZDBNM6TF6[BN<
MZOX8\$:=XQ\7Z:MO:7%P;KP]&RFSB674K+^/W_@VKOKJT_X*>>&;>WE\N'5/
M@Q\7+&^39&_GVL>F:9J:1;G1FBQ?:=9S[X6CD/D^67,,DL;_ +3?\'6_B"[M
MOV7_ -E_PLC7 L=9^/>M^(+A%NY$M6N_#7P]UG3K-IK *8;FX2'Q9?BVNW82
M64;W<,2LM_,4[,UPU/$<5X*E.*<*L</4J1:NIJE[23C)/1J4:2A)=8Z'G9%C
MJN$X#S.O3G*-2A4Q=&C)-ITI5_81C*FUJG">(<XOI.[V/XEOAI\/_$GQ9^(W
M@#X5^#;:.\\7_$OQMX5^'_A6SE,PBNO$GC+7;#PYH=M(;:"ZN!'/J>I6L3F"
MVN)@K$Q03/MC;_28_9$_X(E?L"?LR?##0O"_B;]G_P"&'Q\^(,VDV#^.OB'\
M</!GAOXIW&L>)'T_34UJ7PWI/C'1K[1?"OA[^TK.:30]-TG2;6]M+&=X]0O]
M1O+B^N[K_-C^'/Q \7?";XA>!/BI\/\ 5_[ \>_#/QEX7^('@C7OL&F:K_8G
MB[P9K=CXC\-:O_9>MV6I:-J7]FZSIME>?8-7TZ_TR\\G[/?V5U:R2P2?K!_Q
M$!_\%<_^CM?_ # W[,O_ ,YBO>SW+\TS!4:>!Q5+#T8*3K*56M2E4FVN36E2
MJ-PBD]&TN9W:=DU\MPOFV1Y0\36S3 U\9B9N$</*G0PU>%&FD^=I8BO2Y:DY
M-)RC&3Y(V4DG)/\ 27_@OW_P1\^!_P"RQX \.?M=?LM:/9_#?P--XGTGP#\4
M/A)'J6K7VCVVKZ^E[+X;\:>"#J]QJ-UIT=Q-97&D^)_#QU'^SD:71M2T&RLE
M36UG_+W_ ((=_M6:M^RK_P %%O@?>?V@MMX&^.&LVG[/7Q)LKB2T@L[K0_B=
MJNF:=X9U&XO;VTO$TI?"_P 1[?P7XHN=2MQ9W+:1I.K:-+J=AI6LZI(?+_VA
M_P#@KO\ \%#/VKOA-XB^!WQ_^/UO\0?A?XKN-#N];\-3?![X#^'9)[OPWKFG
M^(]&N;37_"/PPT#Q-I-Q::MI=I*TVD:S827=J+G2[UKC2[^_LKGX(^'VO#PM
MX]\$>)S=?81X<\7^&M>-]Y'VK[&-(UFRU#[5]F\FX^T?9_L_G>1]GG\W9Y?D
MR[MC;8/ 8S^RJN S.K3Q-2<*U)5(3J5+TIP7L^:=2G3FZE.3E9V;2C!J3:TY
MLPS3+_[=P^:Y)AZN"HTZF'KRHU*=*BHUZ<_WJA3HU:M.-&K!1YH\T4W*HG!1
M>O\ L-5_D)_M ?\ )>/C9_V5SXD?^IEK5?Z]E?Y"?[0'_)>/C9_V5SXD?^IE
MK5?,\%?Q<P_Z]X?_ -*JGVGB7_"R?_KYC?\ TG"G]X'_  ;!_P#*-_Q#_P!G
M-?$[_P!1#X85\Q_\'7__ "0?]D?_ +*YX_\ _4-TZOIS_@V#_P"4;_B'_LYK
MXG?^HA\,*^8_^#K_ /Y(/^R/_P!E<\?_ /J&Z=7-1_Y+&7_8;7_],U#MQ?\
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M2"E!XO%Q]Z/L*,*-1)8J#.[HHHK^PS_2<**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R-8_U$
M7_77_P!D:M>LC6/]1%_UU_\ 9&IQW7JOS)G\+^7YH[W1_P#D%6'_ %ZP_P#H
M(K2K-T?_ )!5A_UZP_\ H(K2K@G\<O\ %+\V=$/@C_AC^2"BBBI*"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N$U'_D;M-_Z^]*_]*(Z[NN$U'_D;M-_Z^]*_P#2B.MJ
M'Q3_ .O<_P C.K\*_P 4?S/<Z***X30**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGLZ56T9U%&2Y*T*D'=:7<6UT:9^H?[$?_!Q__P -C_M4?!S]F;_AC7_A7/\
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MQC__ ,*+_P"%%_\ "J?^:K?\+._X2G_A9W_"R?\ JFWP]_L3^Q/^%>_]1?\
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MBCXV^.9WU74[4^8FF37G@/P):QV>A7";8;J_MH/B-XBCE\R2PM[N'R5U&?\
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ML<,;NO\ )O\ &+_@ZR^'O@OXI^/?"/PI_9%N_B]\.O#/B?5-"\)?%&\^/;>
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MKF@ZS:1WNG:A:2E4<1SV\J,T,T<5S;R;[>YAAN(I8D_S$/\ @H]_P3!^/_\
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MKV5_D)_M ?\ )>/C9_V5SXD?^IEK5/@K^+F'_7O#_P#I54CQ+_A9/_U\QO\
MZ3A3^\#_ (-@_P#E&_XA_P"SFOB=_P"HA\,*^8_^#K__ )(/^R/_ -E<\?\
M_J&Z=7TY_P &P?\ RC?\0_\ 9S7Q._\ 40^&%?,?_!U__P D'_9'_P"RN>/_
M /U#=.KFH_\ )8R_[#:__IFH=N+_ .3=0_[%V"_]2J!_+O\ \$L?^4D'[#__
M &<U\(O_ %+],K_50K_*O_X)8_\ *2#]A_\ [.:^$7_J7Z97^JA6G&G^^8/_
M +!I?^G9&?AM_P B[,?^PV'_ *8@?PW?\'7?_)Q_[*O_ &1+Q7_ZG<U?!/\
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M%_P4N_Y1V_MS_P#9I7[07_JK/%%=."_WS"?]A-#_ -.P.3'_ .XXW_L$Q/\
MZ9F?QZ_\$8_^30?CW_V<CX!_]5AXIK]/Z_,#_@C'_P F@_'O_LY'P#_ZK#Q3
M7Z?U_.OCY_R<?,?^P#+/_49'^6OCE_R6E#_L097_ .E8D****_&#\<"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUUC.I%JZZ26THO6,DXNS3/S'_P""(_\ RE1_8X_[*!X@_P#5<^-*_P!/:O\
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MXK_8WK_+R_X) _L=ZQ^VC^W9\&O AT6+5OAWX \0Z/\ %[XRO?/?6^EK\-?
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M26"P]KW]I74E.2:UBZ=!5JD9;*<8K=H_F[K]5_\ @H1_P3KU?]C'X"_\$_\
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MH/FA2=*FZ<9:ZQ@X\L7[TM4D_>?=GQM_P[H_X)\?]&)_L;?^(P_!+_YAZ/\
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M>L/_ *"*TJS='_Y!5A_UZP_^@BM*N"?QR_Q2_-G1#X(_X8_D@HHHJ2@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KA-1_Y&[3?^OO2O\ THCKNZX34?\ D;M-_P"OO2O_
M $HCK:A\4_\ KW/\C.K\*_Q1_,]SHHHKA- HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKM_M+_\ )N'[0'_9$OBM_P"H)KU?Y$E>3P5_"S#_ *^8?_TFJ>_XE_[QE/\
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ME"<).+C-.T9Q?F?9/_$0'_P2,_Z.U_\ ,#?M-?\ SF*/^(@/_@D9_P!':_\
MF!OVFO\ YS%?YI-%?=?ZFY7_ ,_\?_X-P_\ \RGY?_Q$;._^@7*O_!&+_P#F
MX_UH?V4OVUOV9?VW?"7B7QS^R_\ $O\ X6=X6\'^(D\)^(M4_P"$-^('@O\
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M5\<:+:W4D[+I/BC19+74H8DN[T6%Q)=:5/=RWFGW.WZ7_P""4?\ P4!\2_\
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M=G^U#_V<3\;/_5E>)J_I;_X-./\ DJG[9W_9/_@__P"I'XXK^:3]K[_D[/\
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M,^2\-*M1PS>BVW1A+!U8KI&I46(A-KSG&E33\H(ZBBBBOA3]2"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7":C_ ,C=IO\ U]Z5
M_P"E$==W7":C_P C=IO_ %]Z5_Z41UM0^*?_ %[G^1G5^%?XH_F>YT445PF@
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %>9?"O_ )&[5O\ L%7_ /Z<].KTVO,O
MA7_R-VK?]@J__P#3GIU;1_W?%_\ 7N/YLRG\=+UE^A]"T445Y)J%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '%_$/_D3=:_ZYVG_ *<+2K?P0_Y$V;_L-WW_ *36
M-5/B'_R)NM?]<[3_ -.%I5OX(?\ (FS?]AN^_P#2:QKL?_(LJ?\ 84O_ $B
MH_QH_P""7YH]AHHHKRSI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /E[PQ_R6_4O^PKXE_P#2>^KZAKY>\,?\EOU+_L*^)?\ TGOJ^H:[\P^/
M#_\ 8)0_]N.?#?!/_KY+\HA1117 = 4444 ?&W_!1?\ Y1\?MV?]F;?M/?\
MJDO'%?Y0%?ZO_P#P47_Y1\?MV?\ 9FW[3W_JDO'%?Y0%?HG!?^Z8W_L(A_Z;
M/R'Q)_WW+/\ L%K?^GD?Z.W_  ;D_P#**[X1_P#90/C/_P"K&UNOW2K\+?\
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MB,'B\16KRG!5J$J]2=62</=JP4IRE*THRC-1ORKDFU9MW_/N/LBPN&PN$S'
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M&[L[B&XC\Q$?9(NY%;('F<6X'ZMF"Q,(VIXV'.[;*M3M&JO^WDX3?=RDSW.
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M/W\&IZ3J5NES%/:S-:WMM#(UM=V]Q9W2!K>[MY[:66%_]23_ ()O?MV>"/\
M@H5^RYX,^._AN+3]#\7_ +[PQ\6_A_:WRW=QX ^(VCGRM6TQ@99;C^Q-;MS:
M^*?"%U<N]Q=>%M:TL7YAUB#5+*S\[BO*?JU?^T*$;4,3*U=16E+$/7F?:-;5
M[6512NUSQ1[' >?_ %S"_P!D8J=\5@X)X64FKUL)&T537>>&TC:]W1E!I/V<
MY'WI1117QY^AG^2!^U]_R=G^U#_V<3\;/_5E>)J_I;_X-./^2J?MG?\ 9/\
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MOBC5KQKW5O'?PDLY3_Q-;/7;NXNM1\2?#^*9=0TS57EO/!4&HZ7J:^&_#/\
M'QXE\+^)?!>NZCX7\8^'==\)^)='F2WU;P[XETC4-"UW2YY(8[A(-1TC5+>U
MU"RF>WFAG2.YMXG:&6.4*4=6/Z;6IY=Q3@:<H5?9U:?O1Y7%UL-.22J0J4VU
MS0E9)O2,^6,H35C\4P];..!LSK1G056A6M3GS*4<-C:4'*5*K1K)/DJQ4I-+
MWI4N><*E-G^NM\8/CI\&OV??"-]X]^-_Q1\"_"GPA86]S<2Z[XZ\3:5X<M)_
MLJQE[73%U&Y@N-8U.62>WMK+2-)AO=5U"]NK.PL+.YO;NV@E_P ZO_@M/_P5
M#3_@H]\=_#]K\/+34='_ &=/@?%XBT3X4VVK6T5GK'C#5?$%W8_\)7\3=9M#
M;0W^FCQ+;Z'H%AX=\.:G<74N@Z%I$=Y)#I6M^(_$>GI^,%?8O[)7[ O[67[;
MOBRS\+_L[_!WQ/XML7N[>WUOX@7UG-H/PN\(6\L\D<U]XJ^(&J1P>'K#[/%;
MWUU%HUK=7WBG68].O[7PUH&MZE!]@?/+<@P62SEC<1BE5J4XR4:U6,</1H1D
MG&4DG4G[[BW'FE4MRMI13=S7.N+,RXEIPRS"8&5"E6G%SP]"<\77Q,H-2A!R
MC2I?NXS2J<D:5^:,92E:-CW#_@D-^R#JO[9G[=_P2\ /HG]K_#SP5XGTGXL?
M&%[F+55TB/X<> M6L-8U71]4O]*M9Y+#_A,[R*P\%V#R3Z=YU]KT,4.I64NV
MYB_U$Z_,C_@EE_P32\ ?\$TO@1?> =(UF'QS\5_B'J.G>)?C-\3%TR+3$\0Z
MQIEI/:Z%X9T"V(>_MO _@N"^U2/P[;:I=W=[<:GK?B;Q%*NFMXA;1=,_3>OC
M>(<UCFF-3HMO#8>+I4&[KG;=ZE7E:3CSM))/7DA%R2;<5^C<(Y%/),M<<0DL
M;BYJOB4N5^R2CRTL/SQ;4_9)RE)I\OM*DU%N*4I%%%%>"?5!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %?&W_!0+]K;_AA7]D7XM_M4?\ "O\ _A:7_"K?^$#_
M .*$_P"$K_X0C^W?^$W^)O@SX<_\C1_PC?B[^S/[,_X2_P#MG_D7=0^V_P!G
M_P!G_P"B?:_MUM]DU^-O_!P'_P HB_VM?^Z#?^M-?!BNO+Z5.OC\%1JQYJ5;
M%X:E4C=QYJ=2M"$X\T6I*\6U>+35[IIZGGYM7JX;*LSQ-"7)6P^7XRO1GRQE
MR5:6'J5*<N6:E"7+.*?+*,HNUI)JZ/QM_P"(MG_K'_\ ^;5__DW4?\1;/_6/
M_P#\VK__ ";J_C;K^B'X7_\ !L]^W=\6?AG\._BIX<^+/[)-EX>^)G@7PE\0
M=!L];\=_&*VUFTT;QGH&G^(]+MM7M[#X#:E8P:G!8ZE!%?PV>HW]K%=)*EO>
MW4*I/)^BXK)N&<$H2Q5"%"-1N,'/%8Q*35FTK5WLFFS\?P/$?&V92J0P&)JX
MJ5*,95(TL%ES<(R=HMWPJT;31^A]A_P=JV$EW$FJ?L$7EG8MYGGW-A^T[#J5
MW'B)S%Y5E<?L_:5#-OF$<<F^_@\N)GE7S6C6&3]!?V7_ /@Y+_8+^.^O6_A+
MXG6_CK]F37[RXECLM6^)L.CZG\-[F-;:[N8O.\=>'+^Y?1K@BT,,_P#PDGA[
M1-,2YN[""TU:^DGG%K_/#X^_X-E/^"EG@^SGN?#S_L]?%6>*QENX].\ _%34
M].O+JXCBO)$TR!_BCX)^&^GK?3/:P0127-];Z:)=1LS-J$4":A-8_AC\7?@[
M\4_@'\0O$?PI^,_@+Q/\-/B+X3N_L>O>$O%NEW&E:K9LZB6UO(4F7R=1TC5+
M5XM0T37-,FO-%UW2KBTU;1K^^TV[MKN7"&2<,YA&4,%.*J*-V\/BZDZD$WI*
M5.M.KI?1W@EK:Z=F=-7B;C3*)TZF9TYNE*5E'%X"C2HU'NX1K8:E1]_E3:2J
M-K=Q:5C_ %][2[M+^UMK^PN;>]L;VWAN[.\M)H[FUN[2YC6:WN;:XA9X9[>>
M%TEAFB=XY8W5T9E8$V*_A,_X-Y/^"K'BKX2_%;P=^P;\;?$=WK'P6^+&MC0/
M@;JVL77GO\*/BAK4UQ-I?@ZQGF+78\&_%'6YX]$L=%A-Q;Z-\0M4TF^TZTT^
MS\1^+=0/]V=?$9IEE;*L5+#U6IQ:YZ-5*T:M-MI2M=\LDTXSA=\LEHW%QE+]
M.R+.L/GN!CC*"=.:DZ6(H2DI2H5HI-QYDESPDFI4ZEESQ>L8S4X1_ G_ (*H
M_P#!<?\ X=G?M!^#O@1_PR__ ,+K_P"$L^#7A[XM_P#"5?\ "Z_^%;_V?_;W
MC;XA^#O^$?\ [#_X5)X]^U?9?^$"_M'^U?[8MO/_ +5^Q_V;#]A^U7G/_P#!
M,C_@O)_P\:_:5E_9X_X95_X4YY?PZ\5>/O\ A+_^%Y?\+"S_ ,(S>Z%9_P!D
M_P#"/_\ "G_ ^/MO]M^9]O\ [;/V;[-L^QW'G;HO(?\ @M+_ ,$6OVI/^"C7
M[4G@+XW?!'Q[\ ?"WA3PM\ ?"WPKU#3_ (J>*?B)HGB&;Q#HGQ$^*GBZ[O+.
MT\(_"OQQILFC2:;XXTF"WN)]6M[Y[ZWU&.33HH(;:YN^7_X(]?\ !#_]J_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?$7_!2[_E';^W/_P!FE?M!?^JL\45]NU\1?\%+O^4=O[<__9I7[07_
M *JSQ173@O\ ?,)_V$T/_3L#DQ_^XXW_ +!,3_Z9F?QZ_P#!&/\ Y-!^/?\
MV<CX!_\ 58>*:_3^OS _X(Q_\F@_'O\ [.1\ _\ JL/%-?I_7\Z^/G_)Q\Q_
M[ ,L_P#49'^6OCE_R6E#_L097_Z5B0HHHK\8/QP**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#M?A[X*O_B#XLTKPQ8;D-Y+YE[= 9%CIT.'O+ML
M@C]U&=L8*L&F>)"#NK]@-%T?3_#^DZ?HFE0+;:=I=I#9VD*X^2&%0H+$!0SN
M<O(V!OD9F(!-?/G[-/PR/@SPG_PD>J0>7X@\50Q7#*X82V.CY\RQM"&5=KW
MVWLZX."\*;CY>!]+5_8'A+PA_J[D2S+&4N7-LZA3KU%.-JF%P-N;"X776,II
M_6*\?=?/.%.:O03/](_H[^&_^I?"BSO,J')Q#Q12H8NO&I&U7 95;VF P&OO
M0J5(S^N8N/NR]K5I4*L>;"184445^L']"A1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ$$W^]5KJ%Y2C*"GR_T0?\$T?^"C7PK_ ."D7P'7XF^"K.;PIX_\(S:;X?\
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MA7X9>&M=M;G0-0'A35$$>I^,O$5AK.CZKK-E<Z=HV@WFAVL>OZ[_ #0>,/\
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M(IM^D*JJJJJA54!550 JJ!@*H&      , <"EHHK^R3_ $PVV"BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH XOXA_P#(FZU_USM/_3A:5;^"'_(FS?\ 8;OO_2:QJI\0
M_P#D3=:_ZYVG_IPM*M_!#_D39O\ L-WW_I-8UV/_ )%E3_L*7_I$!1_C1_P2
M_-'L-%%%>6=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\O>&
M/^2WZE_V%?$O_I/?5]0U\O>&/^2WZE_V%?$O_I/?5]0UWYA\>'_[!*'_ +<<
M^&^"?_7R7Y1"BBBN Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQM_X. _\ E$7^
MUK_W0;_UIKX,5^R5?C;_ ,' ?_*(O]K7_N@W_K37P8KORK_D:9;_ -A^#_\
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MK4<-2YH^UJ5JU.5.FXT[\SC"4E.<DK1A&3O>R?\ );7^H?\ \$9/".J^"?\
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M_P#*0?X._P#9FWP^_P#5V_M#5Y__ ,&R'_*2FY_[-V^*?_IY\"5W1_Y)%_\
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MB#5?$&MZ3!:7NJP76[0=/MXKJ74H-,U^Y:2U32=MU^27P@_X.=/@5\;OCO\
M"?X)Z_\ LTZG\/?AO\6/$]AX#\7_ !1^(_Q8T!=&\%?\)/*VCZ?=ZOX9M_ M
M]I>J>&+B^NK.S\0:CK'BOPWINBZ9=7FJ:D[:=8W+-\_P_6SK!4*E;"X'ZW@*
MCG5G%U(4WS4KQJ2HR<N;G:ARN/LZCDXQ48MVO]7Q;AN&\RQ5'#8[,UE^:TE"
MA3G&C5K+DK-3I0Q$5#D]FI5>>,_;4E#GFYSY>;E_A9L-0O\ 2KN*_P!+OKS3
M;Z#S/(O;"YFL[N'S8GAE\JYMWCFC\R&22*38Z[XI'C;*LP/Z._L__P#!7_\
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M"P+C'%8FE*I4Q4H*?LZ<&H+V5.?/!U*D^9N4^=4XQLE*4U*'] 'Q?_X.6/\
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ML>)_A9K6OZABXNIY//U35;VY._89MBHJ^G?\1 ?_  5S_P"CM?\ S W[,O\
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M*:_3^OS _P"",?\ R:#\>_\ LY'P#_ZK#Q37Z?U_.OCY_P G'S'_ + ,L_\
M49'^6OCE_P EI0_[$&5_^E8D****_&#\<"BBB@ HHHH **** "BBB@ HHHH
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M *1 4?XT?\$OS1[#1117EG2%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%>(?2A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?C;_P<!_\ *(O]K7_N@W_K37P8K]DJXWX@?#GX>_%GPCJ_P_\
MBIX$\&_$SP%K_P!@_M[P1\0/"^B>,_".M_V5J=EK>E_VOX:\1V.I:-J7]FZS
MING:O8?;+*;['J=A97]OY=U:P2Q].#KK#8O"XF47*.'Q-"O**LG)4JL:CBF]
M$VHV5]+LX\PPTL;@,=@XR4)8O!XG#1G)-QA*O1G24I):M1<TVEJTM#_'IHK_
M %?_ /AW1_P3X_Z,3_8V_P#$8?@E_P#,/1_P[H_X)\?]&)_L;?\ B,/P2_\
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M?!'$M>$,+B\\I2P4>5*D\7F&(A",?AY,-5I4Z7NV7+'GBE;1H_ED_P"#>_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\1?\%+O^4=O[<_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#]./X7O^"P?_  4@_P""@_Q?_;3_ &@_V#_V4O$7Q.7X6>$-5T;P:G@3X">
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MM.M]1;4M"^#7A_X>?!KP_(RWT0MDT'PO:>*/%>G);W]O;20KI_Q&\9>-;4M
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M 4444 %%%% !1110 5\1?\%+O^4=O[<__9I7[07_ *JSQ17V[7Q%_P %+O\
ME';^W/\ ]FE?M!?^JL\45TX+_?,)_P!A-#_T[ Y,?_N.-_[!,3_Z9F?QZ_\
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MJN(E1H)J56)]7_!_X>6_PV\%V&B[(VU:Y U#7KE0A:?4YT7?$)% +PV:!;6
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *X34?^1NTW_K[TK_ -*(Z[NN$U'_ )&[3?\ K[TK_P!*
M(ZVH?%/_ *]S_(SJ_"O\4?S/<Z***X30**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "O,OA7_ ,C=JW_8*O\ _P!.>G5Z;7F7PK_Y&[5O^P5?_P#ISTZMH_[OB_\
MKW'\V93^.EZR_0^A:***\DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_B'_R)
MNM?]<[3_ -.%I5OX(?\ (FS?]AN^_P#2:QJI\0_^1-UK_KG:?^G"TJW\$/\
MD39O^PW??^DUC78_^194_P"PI?\ I$!1_C1_P2_-'L-%%%>6=(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME-T-2LEO&^+NL1:?''926.J&PU-IKJ&?2((I_P"M*O\ /?\ ^#FWXQ3>/O\
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M_;'P]T.]EEEN;NTT_P '?#V_T'2[?03<165CK]QXJUM-,TS5_$NN12?QR_\
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M;#1AJ&NZ)IMS9>'/&30Z=::9?>)-&U^*QCGT>6VFG_U+*_S[/^#H2W\-0_\
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M\5?%T_A^..[D@NWNGU2#2?A79W*V>H65NNGZ=JUM=Z?/.NN7BQ?W*U_F4_\
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MKUW;W"BBBLCH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;-4\*_M!:9XQUF#YD ^S:#J_P>\"V-UE"['S?$=GAE11D.7C_?K]A[_@I_\
ML@_\% ]*OI?@-X]N+7QEI"02ZY\)OB%:V/A/XH:5!/9)>->)X=35-4M-?TRT
MS+:WVM>$=6\1:+97MO)!<:A'YEJ]QTXO)LSP,/:XG"5*=-;U(RIU81OHN>5&
M=103>EY-*^AQ8#B/),SJJC@LPHU:S^&E.-7#U)M*[5.&(ITI5&E=M04FDF]D
MS]!Z***\P]L**_#/]K;_ (.!_P!B7]CK]H'X@?LX>/?!W[0?CGQK\-+C1K'Q
M/K?PJ\+_  N\0>#(M5U?P_I7B*31[35O$'QA\)ZC/JFB0ZO!I?B"VDT:#^R]
M=MM1TF1WN;"X"?.'_$5#_P $^/\ HCO[9/\ X;[X)?\ T0U>I3R7-:L(5*>!
MKRA4C&<)**M*$TI1DKM.S337EZ,\.KQ+D5"K4HU<TPL*M*I.E4@Y2O"I"3C.
M+M%J\9)IV>Z?9G]+=%?S2?\ $5#_ ,$^/^B._MD_^&^^"7_T0U?JA_P3W_X*
M3_!7_@I+X2^(OC?X'^!?C)X0\/?#7Q'H_A75KSXM^'_!6A?VOK.K:9/J[6WA
M\>#OB!X\2Z_LJQ2SEU4Z@^F-#_:NFBV2[$LYML\1E68X6E*OB,)5I4HN*E.:
M2BG)J,5NW=MI;?D[:X3/LGQU>.&P>84,17FI.-*FY.34(N<GK%*RBFW=K:V^
MA^A=%4=3U/3=%TW4-9UG4+'2=(TFQN]3U75=3NX+#3=,TVP@DNK[4-0OKJ2*
MULK&RM8I;F[N[F6."W@CDFFD2-&8?RK_ +//_!S???M%_M#_  <^ /AG]AA=
M(NOC'\5_!?PTTWQ+J?[3B.FBV_C#Q-8:$?$FH:1%\ %$ZZ/97DFKW>DVNK--
M<BUDL+.\EGDAD>,)EV,QT*\\+1]K##14JTG4I4U",E.2?[V<.;2$VU'F:MJE
M=7TQ^<9=EE3"TL=B/8U,9.4,-!4:]5U91E3BU^XI5.7WJM-)SY4W+1NTK?U;
M4445Q'IA17Y&_P#!3?\ X+#_ +/O_!-?3=*\.ZYI%]\8OCWXHL8]5\-?!7PO
MKVGZ%-9Z&;I8CXE^(?BJXL];/@7P_>1QWT.@2Q^&_$FM^(=4MC;Z?H)TFWUG
M7M%_/O\ 8R_X.#/CA^W7\</#WP+^!?\ P3?_ +2UO4MNH^)O$VH_M57$'A'X
M=^$8+B"'5?&GC358?V9Y_P"S=$TWSXHHHHHI]3UK4Y['0=!L=2UO4K"PN/3H
MY/F-?#/&4\-;"J,I.M4JT*,>6/Q37MJM-N"U]Y)Q;32;:/%Q'$63X;&K+JN,
MOC92A!8>CA\5B9\\_AIOZM0JQC4=TW!R4XIIR233/Z=J***\P]H**_G2_; _
MX. ],^ G[9M]^Q;\ ?V3M<_:M\=Z5K?ASX?7VHZ/\78_A_+??&'7+LV]W\._
M#.AP_"[XA/K7]A/=Z/I>I:Y=ZIHQB\4-X@T632(;+P_'K>K_ -#^F2:E+ING
MRZS:6-AJ\EC:2:K8Z9J$^K:;9:D\$;7UII^JW6F:+=:G8V]T98;34+G1M)GO
M8$CN9M,L))&M8NO$8'%82GAZN(I>RABH>TH7G3<IPM%\SIQG*I!-2C;VD8WN
M[7:=N#!YG@<?5Q='"5_;5,#5]CB>6E6C"G5O)<BJSIQI59)PE?V4Y\MDW9.-
M[U%?G-^W/_P52_8Y_P""?%M86?QT\=7NK?$+5[87^D?!OX:6>G>+?BI>:62%
M36;W0KG6-%TKPMHUTQD32]5\::]X:L=>EM=0@T"?5)]+U.*T_!'4_P#@[1\,
MQ:ND.C?L+:[?Z"9E634M3_:)T_2-72 W,B/(FB6GP6UNSDF6S$4ZP-X@C1[E
MY+0W"11+>R].%R7-,;357#8.I.D_AG*5.E&2[P=:=-372\+J^FYQ8_B3(\MK
M.AC,PI4JRTE2A"M7G!Z.U2.'IU73;332J<K:=TK']@]%?D;_ ,$\O^"SO[)7
M_!1#6)_A[X*E\2_"KXWVEC?:FOPC^)<>F6^I>)=+TR"&ZU/5?A_XATB^OM$\
M76VG6TSS7VEM)H_B^VM;#5]7D\*CP[ILVMM^N5<6)PV(PE5T<32G1JQ2;A-6
M=GM*+U4HNSM*+<79V>AZ6#QN$S"A'$X+$4\30DVE4I2NE)6O&2TE":NKPFHR
M5U=*Z"BOC_\ ;T_:ZT+]A;]E/XJ?M/:]X:7QM'\.K;PZFE^"/^$B3PK/XOUW
MQ3XLT/PEI.B6NN-HWB)[!FNM;6^NKF'0=6>UTVQOKQ[0V]O-+%_,W_Q%L_\
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M;G"K/+L2\0L.Z:JOV&)HJ+J\[@DZ]&DIMJ$FU#FY;+FMS1N4445P'J!1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61K'^HB_ZZ_\ LC5K
MUD:Q_J(O^NO_ +(U..Z]5^9,_A?R_-'>Z/\ \@JP_P"O6'_T$5I5FZ/_ ,@J
MP_Z]8?\ T$5I5P3^.7^*7YLZ(?!'_#'\D%%%%24%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<)J/_(W:;_U]Z5_Z41UW=<)J/_(W:;_U]Z5_Z41UM0^*?_7N?Y&=7X5_
MBC^9[G1117":!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YE\*_^1NU;_L%7_\
MZ<].KTVO,OA7_P C=JW_ &"K_P#].>G5M'_=\7_U[C^;,I_'2]9?H?0M%%%>
M2:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Q?Q#_P"1-UK_ *YVG_IPM*M_!#_D
M39O^PW??^DUC53XA_P#(FZU_USM/_3A:5;^"'_(FS?\ 8;OO_2:QKL?_ "+*
MG_84O_2("C_&C_@E^:/8:***\LZ0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M35U=QDGI.$I0;7-=?YI'_!,W_@M-^T3_ ,$X;#4/A[9:!IGQO^ >JZFVM/\
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MM;:PL+:WLK&RMX;2SL[2&.VM;2TMHUAM[:VMX52&"W@A1(H88D2.*-%1%55
M%BO(KU95ZU:M+XJU6I5E_BJ3<W^+/H<+0CA<-A\+#X,-0HT(?X:-.-./X105
M_FS_ /!=G_@G^W[#W[8=_KW@[2K33_@1^T?_ &_\2OA5'IJ20V'AS5[74+5/
MB/\ #I8+J_O+L2^%-6UC2-;M'B2+24\-^-/#ECI^R>PU"QT__28KYF_:F_8Z
M_9L_;5\"Z1\-OVG/AA8_%#P=H'B2V\7:+I\^O^+O"E]I7B&UL-0TN._L?$'@
M;Q!X8\1VRR6&IWMM=V46K+I]^DD9OK6X>VM6A]3(\U>4XSVLE.>'JQ=/$4X6
M<I15W"<%*48N<)V:YFKQE.-US77A\39#'/LO^KP=.GBZ,U5PE:JY*$)MJ-2%
M1PC.?LZM.Z?+&34XTYVER6?P7_P1%_;_ %_;O_8[T67QEXA;6/C[\#6TOX<_
M&D:A?VUWK^MR_8IG\&?$J_CM[2Q9+;X@:5I]^&NI+<_:?$_ASQ; +B[>QEN)
M/V-KX/\ V5/^"9O[$W[$?C/Q%X__ &7_ (-WGPO\4^+/##^#O$5XGQ5^,WC"
MPU;0&U73=:2VN?#_ (_^(?BKP]]LMM1TJUEL=8BTJ/6M/ADU"RL=0M['5]6M
MKW[PKBQ]3"5<76JX*%6GAJD^>%.K&$)4W+6<$J<ZD>12OR6EI"T6M+OTLJI8
M^AE^&H9E4HU<91IJE4K4)U*D*JA[M.HY5:5*?M)04?:7C9SYI)M2LBO\N/\
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MC_@K7\<(?#$]SXBG^+'[4VE_!#P1<6<5I;SZUIF@:[H'P*\"OIJV>G+'LO\
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M<J?\$R_^%M?\+S_X9I_XNG_PL7_A;'_"4?\ "Y/V@/\ D?\ _A)?^$P_M_\
ML3_A:O\ PCO_ ",7_$Q_LK^R/[%_Y=/[-^P_Z+7%D>:X?+<5B<7BXXBM5JT9
M0@X*$VYU*D:E2=252I!WDX1O)<TG>5]]?2XHR+%YS@<%E^ GA<-0H8B%2K&K
M*I32I4J4J5*%&-*C434(U)VA+D@G&%GII]^_!#X::;\%_@O\(?@[HT:Q:/\
M"?X7^ /AII427=UJ"1Z;X$\*:3X6L8TO[Y(KV]5+72HE6[O(X[JY $UPB3.Z
MC^%;_@Z1F\4R_P#!03X:IK%I);>';;]EKP+#X0F1I6M+^U;XC_%JXUF[8?:9
MX$U1-9GN+"\5(K*X.G66BO/;/"]I>7?]_-?$G[:O_!//]EG]OWP?IWA;]HGP
M$VKZCX>6X7P=\0?#=[_PC_Q%\$B]NK&ZU*+P[XC2WNXQ8ZF=/@BU#1]8L-7T
M6Y'^D-IHOHK:[@QR7,J>7YC'%XB,ZD)1JPJ.%G.+JZNHDVE)IKWE=/E<K7=D
M^GB/)JN;9-/+L'.G2J0E0G1C4;C3DJ&BI2<8R<4X_"U%I24;VC=K\-_^"5G_
M  6>_P"">'P&_8)_9W^ 7C'QQXI\+_&7P!I5SX+N_A/HWP@\<:IJWBSQ9KOC
M+4=3;4O#&L>&-!O_ (?W*^+-6\22W_VK7_%N@ZM=ZE)J-SK-E:W=Q&]W_4W=
MVEI?VMS87]M;WMC>V\UI>6=W#'<VMW:7,;0W%M<V\RO#/;SPN\4T,J/'+&[(
MZLK$'^?_ .$?_!MA_P $_O@_\6/!?Q<TOQ=^TSXIU+P%XPT/QOH'A?Q;\1/
MC>$UUCPYKEEK^C1W8\+_  I\+>*+FQM+RP@B,!\4)+<6V]+F>:5A,/Z"*G-Z
MF6U<1[;+I8F;K3K5L0\1RI*I4FI*-)*,9**;FVY.3U2YG8KAZCG.'P:PV;PP
M4%AJ6'PV$CA'*4I4J--PE.O*4Y1<Y)4XI0C"*Y9/E]Y'^:3^WK^R;\?_ /@C
MS^WKI7Q+^']A<:1X(L?BC>_%G]E/XDOI\&K>&-4T#3M<&L6/@O6L00:?-XC\
M&6=[;>%/''AVYMM-DU"R:+7+&P@\/>(]&N9?ZE?V:?\ @Y5_8!^)O@+1K_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHUT_5I8UAUF&.TD\/'Q5X.\9^']1LM0L+=;NPU706\.ZYJ.EZ=;>*?[!M/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(UC_41?]=?_
M &1JUZR-8_U$7_77_P!D:G'=>J_,F?POY?FCO='_ .058?\ 7K#_ .@BM*LW
M1_\ D%6'_7K#_P"@BM*N"?QR_P 4OS9T0^"/^&/Y(****DH**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *X34?^1NTW_K[TK_THCKNZX34?^1NTW_K[TK_ -*(ZVH?%/\
MZ]S_ ",ZOPK_ !1_,]SHHHKA- HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\R^%
M?_(W:M_V"K__ -.>G5Z;7F7PK_Y&[5O^P5?_ /ISTZMH_P"[XO\ Z]Q_-F4_
MCI>LOT/H6BBBO)-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XOXA_\ (FZU_P!<
M[3_TX6E6_@A_R)LW_8;OO_2:QJI\0_\ D3=:_P"N=I_Z<+2K?P0_Y$V;_L-W
MW_I-8UV/_D65/^PI?^D0%'^-'_!+\T>PT445Y9TA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'R]X8_P"2WZE_V%?$O_I/?5]0U\O>&/\ DM^I
M?]A7Q+_Z3WU?4-=^8?'A_P#L$H?^W'/AO@G_ -?)?E$****X#H"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIO??'GX];-&O]2M;_P ,10^';[5O[6T*_FBU[X4_##PMKD%K;ZE=W-H/[O\
MX$?!7P%^SC\&OAG\"?A?IG]E> OA3X-T/P5X<@DBT^._N[31;..WGUO7)=*L
M-+LM0\3^([T77B#Q5K,>GVLNN^)-3U76;J+[5?SLWU>)_P"$;)*>#7NX[-DJ
M^*Z3I85?PZ3ZKG3Y6GU>(CT3/@\'_P 9'Q+6S!VGE>02EAL#UA6Q[LZM>/1^
MS:4U)=(82:W9E?M+_%R/X _LZ_';XX.=),GPC^$/Q%^(UI#KCW":3>ZCX/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]R<$<+T>$N'\)ED5"6+DOK.95XZ^WQU6,?:M2LFZ5%*-"CHOW5.,FN:4F_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KA-1_P"1NTW_ *^]*_\ 2B.N[KA-1_Y&[3?^OO2O
M_2B.MJ'Q3_Z]S_(SJ_"O\4?S/<Z***X30**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O,OA7_P C=JW_ &"K_P#].>G5Z;7F7PK_ .1NU;_L%7__ *<].K:/^[XO
M_KW'\V93^.EZR_0^A:***\DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_B'_R
M)NM?]<[3_P!.%I5OX(?\B;-_V&[[_P!)K&JGQ#_Y$W6O^N=I_P"G"TJW\$/^
M1-F_[#=]_P"DUC78_P#D65/^PI?^D0%'^-'_  2_-'L-%%%>6=(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!\O>&/^2WZE_V%?$O_ *3WU?4-
M?+WAC_DM^I?]A7Q+_P"D]]7U#7?F'QX?_L$H?^W'/AO@G_U\E^40HHHK@.@*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6OA%])MO&/\ +K\+/B7<_##XK^!_BW/X3\&_$W4? _C/1_'*^$OBGI^J^(_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MA-1_Y&[3?^OO2O\ THCKNZX34?\ D;M-_P"OO2O_ $HCK:A\4_\ KW/\C.K\
M*_Q1_,]SHHHKA- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\R^%?\ R-VK?]@J
M_P#_ $YZ=7IM>9?"O_D;M6_[!5__ .G/3JVC_N^+_P"O<?S9E/XZ7K+]#Z%H
MHHKR34**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .+^(?_(FZU_USM/\ TX6E6_@A
M_P B;-_V&[[_ -)K&JGQ#_Y$W6O^N=I_Z<+2K?P0_P"1-F_[#=]_Z36-=C_Y
M%E3_ +"E_P"D0%'^-'_!+\T>PT445Y9TA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^(O^"EW_*.W]N?_LTK
M]H+_ -59XHK[=KXB_P""EW_*.W]N?_LTK]H+_P!59XHKIP7^^83_ +":'_IV
M!R8__<<;_P!@F)_],S/YH/\ @VD_Y(9^TO\ ]E8\)_\ J'O7]+E?S1_\&TG_
M "0S]I?_ +*QX3_]0]Z_I<K[?-?^1AB?\4/_ $W ^9X4_P"2>RS_ *]5?_4B
ML%%%%>>?0A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !61K'^HB_ZZ_P#LC5KUD:Q_J(O^
MNO\ [(U..Z]5^9,_A?R_-'>Z/_R"K#_KUA_]!%:59NC_ /(*L/\ KUA_]!%:
M5<$_CE_BE^;.B'P1_P ,?R04445)04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PFH_\
M(W:;_P!?>E?^E$==W7":C_R-VF_]?>E?^E$=;4/BG_U[G^1G5^%?XH_F>YT4
M45PF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %>9?"O_D;M6_[!5_\ ^G/3J]-K
MS+X5_P#(W:M_V"K_ /\ 3GIU;1_W?%_]>X_FS*?QTO67Z'T+1117DFH4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 <7\0_P#D3=:_ZYVG_IPM*M_!#_D39O\ L-WW
M_I-8U4^(?_(FZU_USM/_ $X6E6_@A_R)LW_8;OO_ $FL:['_ ,BRI_V%+_TB
M H_QH_X)?FCV&BBBO+.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?_T+\7_@@U3_ .2*^H:*/KF'_P"@"C_X$_\ Y$/93_Y_3_KYGR]_PM#XG_\
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M+0^)_P#T+\7_ ((-4_\ DBOJ&BCZYA_^@"C_ .!/_P"1#V4_^?T_Z^9\O?\
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M0:I_\D4?\+0^)_\ T+\7_@@U3_Y(KZAHH^N8?_H H_\ @3_^1#V4_P#G]/\
MKYGR]_PM#XG_ /0OQ?\ @@U3_P"2*/\ A:'Q/_Z%^+_P0:I_\D5]0T4?7,/_
M - %'_P)_P#R(>RG_P _I_U\SY>_X6A\3_\ H7XO_!!JG_R11_PM#XG_ /0O
MQ?\ @@U3_P"2*^H:*/KF'_Z */\ X$__ )$/93_Y_3_KYGR]_P +0^)__0OQ
M?^"#5/\ Y(H_X6A\3_\ H7XO_!!JG_R17U#11]<P_P#T 4?_  )__(A[*?\
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M"C_X$_\ Y$/93_Y_3_KYGR]_PM#XG_\ 0OQ?^"#5/_DBC_A:'Q/_ .A?B_\
M!!JG_P D5]0T4?7,/_T 4?\ P)__ "(>RG_S^G_7S/E[_A:'Q/\ ^A?B_P#!
M!JG_ ,D4?\+0^)__ $+\7_@@U3_Y(KZAHH^N8?\ Z */_@3_ /D0]E/_ )_3
M_KYGR]_PM#XG_P#0OQ?^"#5/_DBC_A:'Q/\ ^A?B_P#!!JG_ ,D5]0T4?7,/
M_P! %'_P)_\ R(>RG_S^G_7S/E[_ (6A\3_^A?B_\$&J?_)%'_"T/B?_ -"_
M%_X(-4_^2*^H:*/KF'_Z */_ ($__D0]E/\ Y_3_ *^9\O?\+0^)_P#T+\7_
M ((-4_\ DBC_ (6A\3_^A?B_\$&J?_)%?4-%'US#_P#0!1_\"?\ \B'LI_\
M/Z?]?,^7O^%H?$__ *%^+_P0:I_\D4?\+0^)_P#T+\7_ ((-4_\ DBOJ&BCZ
MYA_^@"C_ .!/_P"1#V4_^?T_Z^9\O?\ "T/B?_T+\7_@@U3_ .2*/^%H?$__
M *%^+_P0:I_\D5]0T4?7,/\ ] %'_P "?_R(>RG_ ,_I_P!?,^7O^%H?$_\
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MX6A\3_\ H7XO_!!JG_R11_PM#XG_ /0OQ?\ @@U3_P"2*^H:*/KF'_Z */\
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MUS#_ /0!1_\  G_\B'LI_P#/Z?\ 7S/E[_A:'Q/_ .A?B_\ !!JG_P D4?\
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M_P#DBC_A:'Q/_P"A?B_\$&J?_)%?4-%'US#_ /0!1_\  G_\B'LI_P#/Z?\
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M "17U#11]<P__0!1_P# G_\ (A[*?_/Z?]?,^7O^%H?$_P#Z%^+_ ,$&J?\
MR11_PM#XG_\ 0OQ?^"#5/_DBOJ&BCZYA_P#H H_^!/\ ^1#V4_\ G]/^OF?+
MW_"T/B?_ -"_%_X(-4_^2*/^%H?$_P#Z%^+_ ,$&J?\ R17U#11]<P__ $ 4
M?_ G_P#(A[*?_/Z?]?,^7O\ A:'Q/_Z%^+_P0:I_\D4?\+0^)_\ T+\7_@@U
M3_Y(KZAHH^N8?_H H_\ @3_^1#V4_P#G]/\ KYGR]_PM#XG_ /0OQ?\ @@U3
M_P"2*/\ A:'Q/_Z%^+_P0:I_\D5]0T4?7,/_ - %'_P)_P#R(>RG_P _I_U\
MSY>_X6A\3_\ H7XO_!!JG_R11_PM#XG_ /0OQ?\ @@U3_P"2*^H:*/KF'_Z
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M_P!"_%_X(-4_^2*^H:*/KF'_ .@"C_X$_P#Y$/93_P"?T_Z^9\O?\+0^)_\
MT+\7_@@U3_Y(H_X6A\3_ /H7XO\ P0:I_P#)%?4-%'US#_\ 0!1_\"?_ ,B'
MLI_\_I_U\SY>_P"%H?$__H7XO_!!JG_R11_PM#XG_P#0OQ?^"#5/_DBOJ&BC
MZYA_^@"C_P"!/_Y$/93_ .?T_P"OF?+W_"T/B?\ ]"_%_P""#5/_ )(H_P"%
MH?$__H7XO_!!JG_R17U#11]<P_\ T 4?_ G_ /(A[*?_ #^G_7S/E[_A:'Q/
M_P"A?B_\$&J?_)%'_"T/B?\ ]"_%_P""#5/_ )(KZAHH^N8?_H H_P#@3_\
MD0]E/_G]/^OF?+W_  M#XG_]"_%_X(-4_P#DBC_A:'Q/_P"A?B_\$&J?_)%?
M4-%'US#_ /0!1_\  G_\B'LI_P#/Z?\ 7S/E[_A:'Q/_ .A?B_\ !!JG_P D
M4?\ "T/B?_T+\7_@@U3_ .2*^H:*/KF'_P"@"C_X$_\ Y$/93_Y_3_KYGR]_
MPM#XG_\ 0OQ?^"#5/_DBC_A:'Q/_ .A?B_\ !!JG_P D5]0T4?7,/_T 4?\
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M_P *;3__ )%KU.BCV-3_ *":W_@-#_Y5Y?GW8<R_DC]\_P#Y(\L_X2_XA?\
M1,9?_"FT_P#^1:/^$O\ B%_T3&7_ ,*;3_\ Y%KU.BCV-3_H)K?^ T/_ )5Y
M?GW8<R_DC]\__DCRS_A+_B%_T3&7_P *;3__ )%H_P"$O^(7_1,9?_"FT_\
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M *":W_@-#_Y5Y?GW8<R_DC]\_P#Y(\L_X2_XA?\ 1,9?_"FT_P#^1:/^$O\
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M .U]?Z6KY)_\_)?<O\_7^EKY[_PD.O\ _/HO_@'/_P#%4?\ "0Z__P ^B_\
M@'/_ /%5Z%11[6G_ ,^(??\ _:^O]+4Y)_\ /R7W+_/U_I:^>_\ "0Z__P ^
MB_\ @'/_ /%4?\)#K_\ SZ+_ . <_P#\57H5%'M:?_/B'W__ &OK_2U.2?\
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M??\ _:^O]+4Y)_\ /R7W+_/U_I:^>_\ "0Z__P ^B_\ @'/_ /%4?\)#K_\
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M/5[!11[:G_T#T_O?]=_Z6I[.7_/R7]6\_+\?6_C_ /PF/B__ *!<?_@MO?\
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M!<?_ (+;W_X]7L%%'MJ?_0/3^]_UW_I:GLY?\_)?U;S\OQ];^/\ _"8^+_\
MH%Q_^"V]_P#CU'_"8^+_ /H%Q_\ @MO?_CU>P44>VI_] ]/[W_7?^EJ>SE_S
M\E_5O/R_'UOX_P#\)CXO_P"@7'_X+;W_ ./4?\)CXO\ ^@7'_P""V]_^/5[!
M11[:G_T#T_O?]=_Z6I[.7_/R7]6\_+\?6_C_ /PF/B__ *!<?_@MO?\ X]1_
MPF/B_P#Z!<?_ (+;W_X]7L%%'MJ?_0/3^]_UW_I:GLY?\_)?U;S\OQ];^/\
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M_P# GY?W?+\?6YR2_P"?DOP/G[_A87C[_H#1?^"?4?\ X_1_PL+Q]_T!HO\
MP3ZC_P#'Z^@:*/K5#_H"I?\ @3\O[OE^/K<Y)?\ /R7X'S]_PL+Q]_T!HO\
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MR_N^7X^MSDE_S\E^!\_?\+"\??\ 0&B_\$^H_P#Q^C_A87C[_H#1?^"?4?\
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M_P"A?B_\$&J?_)%'_"T/B?\ ]"_%_P""#5/_ )(KZAHH^N8?_H H_P#@3_\
MD0]E/_G]/^OF?+W_  M#XG_]"_%_X(-4_P#DBC_A:'Q/_P"A?B_\$&J?_)%?
M4-%'US#_ /0!1_\  G_\B'LI_P#/Z?\ 7S/E[_A:'Q/_ .A?B_\ !!JG_P D
M4?\ "T/B?_T+\7_@@U3_ .2*^H:*/KF'_P"@"C_X$_\ Y$/93_Y_3_KYGR]_
MPM#XG_\ 0OQ?^"#5/_DBC_A:'Q/_ .A?B_\ !!JG_P D5]0T4?7,/_T 4?\
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MZ^9\O?\ "T/B?_T+\7_@@U3_ .2*/^%H?$__ *%^+_P0:I_\D5]0T4?7,/\
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MC_X$_P#Y$/93_P"?T_Z^9\O?\+0^)_\ T+\7_@@U3_Y(H_X6A\3_ /H7XO\
MP0:I_P#)%?4-%'US#_\ 0!1_\"?_ ,B'LI_\_I_U\SY>_P"%H?$__H7XO_!!
MJG_R11_PM#XG_P#0OQ?^"#5/_DBOJ&BCZYA_^@"C_P"!/_Y$/93_ .?T_P"O
MF?+W_"T/B?\ ]"_%_P""#5/_ )(H_P"%H?$__H7XO_!!JG_R17U#11]<P_\
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M .A?B_\ !!JG_P D5]0T4?7,/_T 4?\ P)__ "(>RG_S^G_7S/E[_A:'Q/\
M^A?B_P#!!JG_ ,D4?\+0^)__ $+\7_@@U3_Y(KZAHH^N8?\ Z */_@3_ /D0
M]E/_ )_3_KYGR]_PM#XG_P#0OQ?^"#5/_DBC_A:'Q/\ ^A?B_P#!!JG_ ,D5
M]0T4?7,/_P! %'_P)_\ R(>RG_S^G_7S/E[_ (6A\3_^A?B_\$&J?_)%'_"T
M/B?_ -"_%_X(-4_^2*^H:*/KF'_Z */_ ($__D0]E/\ Y_3_ *^9\O?\+0^)
M_P#T+\7_ ((-4_\ DBC_ (6A\3_^A?B_\$&J?_)%?4-%'US#_P#0!1_\"?\
M\B'LI_\ /Z?]?,^7O^%H?$__ *%^+_P0:I_\D4?\+0^)_P#T+\7_ ((-4_\
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M_@@U3_Y(KZAHH^N8?_H H_\ @3_^1#V4_P#G]/\ KYGR]_PM#XG_ /0OQ?\
M@@U3_P"2*/\ A:'Q/_Z%^+_P0:I_\D5]0T4?7,/_ - %'_P)_P#R(>RG_P _
MI_U\SY>_X6A\3_\ H7XO_!!JG_R11_PM#XG_ /0OQ?\ @@U3_P"2*^H:*/KF
M'_Z */\ X$__ )$/93_Y_3_KYGR]_P +0^)__0OQ?^"#5/\ Y(H_X6A\3_\
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MGR]_PM#XG_\ 0OQ?^"#5/_DBC_A:'Q/_ .A?B_\ !!JG_P D5]0T4?7,/_T
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M_P!"_%_X(-4_^2*/^%H?$_\ Z%^+_P $&J?_ "17U#11]<P__0!1_P# G_\
M(A[*?_/Z?]?,^7O^%H?$_P#Z%^+_ ,$&J?\ R11_PM#XG_\ 0OQ?^"#5/_DB
MOJ&BCZYA_P#H H_^!/\ ^1#V4_\ G]/^OF?+W_"T/B?_ -"_%_X(-4_^2*/^
M%H?$_P#Z%^+_ ,$&J?\ R17U#11]<P__ $ 4?_ G_P#(A[*?_/Z?]?,^7O\
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MP_\ T 4?_ G_ /(A[*?_ #^G_7S/E[_A:'Q/_P"A?B_\$&J?_)%'_"T/B?\
M]"_%_P""#5/_ )(KZAHH^N8?_H H_P#@3_\ D0]E/_G]/^OF?+W_  M#XG_]
M"_%_X(-4_P#DBC_A:'Q/_P"A?B_\$&J?_)%?4-%'US#_ /0!1_\  G_\B'LI
M_P#/Z?\ 7S/E[_A:'Q/_ .A?B_\ !!JG_P D4?\ "T/B?_T+\7_@@U3_ .2*
M^H:*/KF'_P"@"C_X$_\ Y$/93_Y_3_KYGR]_PM#XG_\ 0OQ?^"#5/_DBC_A:
M'Q/_ .A?B_\ !!JG_P D5]0T4?7,/_T 4?\ P)__ "(>RG_S^G_7S/E[_A:'
MQ/\ ^A?B_P#!!JG_ ,D4?\+0^)__ $+\7_@@U3_Y(KZAHH^N8?\ Z */_@3_
M /D0]E/_ )_3_KYGR]_PM#XG_P#0OQ?^"#5/_DBC_A:'Q/\ ^A?B_P#!!JG_
M ,D5]0T4?7,/_P! %'_P)_\ R(>RG_S^G_7S/E[_ (6A\3_^A?B_\$&J?_)%
M'_"T/B?_ -"_%_X(-4_^2*^H:*/KF'_Z */_ ($__D0]E/\ Y_3_ *^9\O?\
M+0^)_P#T+\7_ ((-4_\ DBC_ (6A\3_^A?B_\$&J?_)%?4-%'US#_P#0!1_\
M"?\ \B'LI_\ /Z?]?,^7O^%H?$__ *%^+_P0:I_\D4?\+0^)_P#T+\7_ ((-
M4_\ DBOJ&BCZYA_^@"C_ .!/_P"1#V4_^?T_Z^9\O?\ "T/B?_T+\7_@@U3_
M .2*/^%H?$__ *%^+_P0:I_\D5]0T4?7,/\ ] %'_P "?_R(>RG_ ,_I_P!?
M,^7O^%H?$_\ Z%^+_P $&J?_ "11_P +0^)__0OQ?^"#5/\ Y(KZAHH^N8?_
M * */_@3_P#D0]E/_G]/^OF?+W_"T/B?_P!"_%_X(-4_^2*/^%H?$_\ Z%^+
M_P $&J?_ "17U#11]<P__0!1_P# G_\ (A[*?_/Z?]?,^7O^%H?$_P#Z%^+_
M ,$&J?\ R11_PM#XG_\ 0OQ?^"#5/_DBOJ&BCZYA_P#H H_^!/\ ^1#V4_\
MG]/^OF?(?PZO;W4/BG;7U_"(;V]GUN>]B$4D(AFETZ^DE412,SQ;9<+LD)*Y
MVD[L&OKROE[PQ_R6_4O^PKXE_P#2>^KZAIYDU*K1:2BGA:345M%-S:2\EL+#
M?!/_ *^2_*(4445YQT!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7Q%_P4N_Y1V_MS_\ 9I7[07_JK/%%?;M?$7_!2[_E';^W/_V:5^T%
M_P"JL\45TX+_ 'S"?]A-#_T[ Y,?_N.-_P"P3$_^F9G\T'_!M)_R0S]I?_LK
M'A/_ -0]Z_I<K^7C_@W4\;^%_ 7[//[2&L>+-3_LG3KGXS>#]-AN/L6H7V^]
MF\$7EU'#Y.FVEY.NZ"SN9/,>)81Y>UI [QJW]"O_  TE\%O^AS_\MWQ9_P#*
M*O?XBXBX?RW-\5A<QSS)\!B5[*;P^-S/!86NH3I0<)NC7KTZBC):QDXVDM4V
M?FF4<9\'Y)E.78#.N*^&LHQT<.ZLL'FF>Y7@,7&G4KUG3J2P^+Q5*LH5$FX3
M<.623<6T>Y45X;_PTE\%O^AS_P#+=\6?_**C_AI+X+?]#G_Y;OBS_P"45>)_
MKCPC_P!%3PY_X?,L_P#FH]'_ (B5X=?]%]P5_P")5D7_ ,WGN5%>&_\ #27P
M6_Z'/_RW?%G_ ,HJ/^&DO@M_T.?_ );OBS_Y14?ZX\(_]%3PY_X?,L_^:@_X
MB5X=?]%]P5_XE61?_-Y[E17AO_#27P6_Z'/_ ,MWQ9_\HJ/^&DO@M_T.?_EN
M^+/_ )14?ZX\(_\ 14\.?^'S+/\ YJ#_ (B5X=?]%]P5_P")5D7_ ,WGN5%>
M&_\ #27P6_Z'/_RW?%G_ ,HJ/^&DO@M_T.?_ );OBS_Y14?ZX\(_]%3PY_X?
M,L_^:@_XB5X=?]%]P5_XE61?_-Y[E17AO_#27P6_Z'/_ ,MWQ9_\HJ/^&DO@
MM_T.?_EN^+/_ )14?ZX\(_\ 14\.?^'S+/\ YJ#_ (B5X=?]%]P5_P")5D7_
M ,WGN5%>&_\ #27P6_Z'/_RW?%G_ ,HJ/^&DO@M_T.?_ );OBS_Y14?ZX\(_
M]%3PY_X?,L_^:@_XB5X=?]%]P5_XE61?_-Y[E17AO_#27P6_Z'/_ ,MWQ9_\
MHJ/^&DO@M_T.?_EN^+/_ )14?ZX\(_\ 14\.?^'S+/\ YJ#_ (B5X=?]%]P5
M_P")5D7_ ,WGN5%>&_\ #27P6_Z'/_RW?%G_ ,HJ/^&DO@M_T.?_ );OBS_Y
M14?ZX\(_]%3PY_X?,L_^:@_XB5X=?]%]P5_XE61?_-Y[E17AO_#27P6_Z'/_
M ,MWQ9_\HJ/^&DO@M_T.?_EN^+/_ )14?ZX\(_\ 14\.?^'S+/\ YJ#_ (B5
MX=?]%]P5_P")5D7_ ,WGN5%>&_\ #27P6_Z'/_RW?%G_ ,HJ/^&DO@M_T.?_
M );OBS_Y14?ZX\(_]%3PY_X?,L_^:@_XB5X=?]%]P5_XE61?_-Y[E17AO_#2
M7P6_Z'/_ ,MWQ9_\HJ/^&DO@M_T.?_EN^+/_ )14?ZX\(_\ 14\.?^'S+/\
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M***\DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_B'_P B;K7_ %SM/_3A:5;^
M"'_(FS?]AN^_])K&JGQ#_P"1-UK_ *YVG_IPM*M_!#_D39O^PW??^DUC78_^
M194_["E_Z1 4?XT?\$OS1[#1117EG2%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?+WAC_ )+?J7_85\2_^D]]7U#7R]X8_P"2WZE_V%?$O_I/
M?5]0UWYA\>'_ .P2A_[<<^&^"?\ U\E^40HHHK@.@**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_(W:;_U]Z5_Z41UM0^*?_7N?Y&=7X5_BC^9[G1117":!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5YE\*_^1NU;_L%7_\ Z<].KTVO,OA7_P C=JW_ &"K_P#]
M.>G5M'_=\7_U[C^;,I_'2]9?H?0M%%%>2:A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3A*5*4XJ2C*+Y6[V:=K-!117DWQS^.7PM_9L^%'C'XW_ !J\4?\ "%_"_P
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M6E4A5I5(QG3J4Y1G3J0DKQG"<6XRC)-.,HMIIW3L%%%%26%%%?C;_P 1 ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]Q_-F4_CI>LOT/H6BBBO)-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XOXA_P#(
MFZU_USM/_3A:5;^"'_(FS?\ 8;OO_2:QJI\0_P#D3=:_ZYVG_IPM*M_!#_D3
M9O\ L-WW_I-8UV/_ )%E3_L*7_I$!1_C1_P2_-'L-%%%>6=(4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!\O>&/^2WZE_V%?$O_I/?5]0U\O>&
M/^2WZE_V%?$O_I/?5]0UWYA\>'_[!*'_ +<<^&^"?_7R7Y1"BBBN Z HHHH
M^-O^"B__ "CX_;L_[,V_:>_]4EXXK_* K_5__P""B_\ RCX_;L_[,V_:>_\
M5)>.*_R@*_1."_\ =,;_ -A$/_39^0^)/^^Y9_V"UO\ T\C]1O\ @D=_P4&U
MK_@GI^UAX:\>:CJ$R_!+XAS:7X$^/VCI83ZH9/ =SJ*21^+=.L+17O)/$/@&
M\E;Q#I@L(Y;V^L5UGP_#%(FNS(?]/33-3TW6M-T_6=&U"QU;2-6L;34]*U73
M+N"_TW4]-OX([JQU#3[ZUDEM;VQO;66*YM+NVED@N()(YH9'C=6/^.+7]V7_
M  ;5?\%#U^+_ ,'=0_89^)6H^9\1O@/I%WX@^$>I7,D2-XF^"LE_90S>&F,U
MR]Q>:Y\.-?U5[>!HHXH7\$:OX>L;:T0>%M2O;M<6Y5[2DLSHQ_>4DH8I):SI
M;0JNV[I/W9/5N$DVU&GJ^ ,]]C6EDN)G^ZQ$I5<#*3=H5[7J4%?11K17M(+1
M*K&22<JQ_4M7\(/_  =7?\GD_L\?]FRVO_JT_B+7]WU?P@_\'5W_ ">3^SQ_
MV;+:_P#JT_B+7@<*?\CFE_UYK_\ IMGU?'G_ "3F(_[",)_Z>1^8_P#P1'_Y
M2H_L<?\ 90/$'_JN?&E?Z>U?YA/_  1'_P"4J/[''_90/$'_ *KGQI7^GM79
MQG_R,,+_ -@:_P#3]8\_PX_Y$^-_[&4__47"G^=+_P ')G_*4+QK_P!DC^#_
M /ZCLU?@C7[W?\')G_*4+QK_ -DC^#__ *CLU?BM\+/AOK/Q8\7-X,\/1WEQ
MK+^$?B-XHL++3]/;5+_4Y?A]\.O%7Q!?2+&PCN+::YO-8A\+R:7;);-/=K-=
MI):6.I7*1:?=?:Y1)1RC 2DTHQP5"4F]DE23;?DDKGYKQ!"4^(<UA!.4YYEB
M(1BMY2E6:BEYMM)'Z4?\$-?CNGP#_P""G7[,VIWTTL>A?$_Q+>? C6X84N'>
M\?XP6$OA'PA"1;Q3LL4/Q'O/!=_</)"UNEO9RFXELX@U];?Z;=?XZGA?Q+KO
M@OQ+X=\8^%]1FT?Q+X3UW2/$OAW5K=(9)]+UW0M0M]4TC48$N(YK=YK+4+6W
MN8TGAEA9XE$L;H64_P"NG\!_BMH7QU^"7PC^-'AF]M=0T+XJ_#?P7\0-,NK*
M*:W@:W\6>'M/UKR1:7,L]W836LEX]K<Z;>RO?:;<PS6-\1=V\P'R'&F&Y:^#
MQ:6E2G.A-]%*E+GA?2UY*K-+6[4/(_0/#?&\^%S#+Y/6C6IXJFFU=QKP]E42
MUO:$J,&]+)U+[L]"U[7-)\,:'K7B77[Z'3-"\/:3J.N:UJ5QO,&GZ3I-G-?Z
MC?3B-))##:6=O-<2^6COLC;:C-@'_(P_:(^+VI?M ?'SXV?'35[5;#4?C'\5
M_B#\3KK38WG>#27\<>*]5\2)H]H;J[OITL=(BU%--L89+VZ-O9VL$ GE6,.?
M](W_ (+9_';_ (4!_P $S?VGO$%GJMYI/B'QYX1M_@SX8DL+;SKNZO\ XL:E
M:^#]9MXKA[.\MM-\GP7J'BG49-2G:QFMHK!QH^H6WB&31RW^9CX/\*ZSXZ\6
M^%O!'ARV^V>(?&/B/1/"N@V>6'VK6?$.IVND:7;91)''GWUY!%E4=ANRJ,<
M]7!F'4*&-QDM.><:$6[JT:4?:5'V:;J03?1P:TU.'Q'Q;J8K+<NA=NG2J8F<
M8ZWGB)JE132UYHJC4:6C:J)ZW1SM?V2?\&DW_.0#_NU3_P!^1K^13XH>&+#P
M5\2_B)X-TJ:\N-+\)>.O%OAC39]0DAEOY[#0=?U#2K.:^EMK>TMY+R2WM(WN
M9(+6VA>9G:*WA0K&O]=?_!I-_P Y /\ NU3_ -^1KV>)9*618R2VDL+)>CQ>
M':_ ^<X+BX\49;%[Q>.B_58#%IG]6_[2_P#R;A^T!_V1+XK?^H)KU?Y$E?Z[
M?[2__)N'[0'_ &1+XK?^H)KU?Y$E>-P5_"S#_KYA_P#TFJ?1^)?^\93_ -><
M7_Z70"BO[@/^#4#_ )(/^UQ_V5SP!_ZANHU_6175F7%7]GXVO@_J'MO82BO:
M?6O9\W-3A._)]7GRVYK?$[VOULN+)^!/[6RW"YA_:OU?ZS"<O8_4?:\G)5G3
MM[3ZY3YK\G-?DC:]K.UW_C;T5_L2^*O!WA'QWHUSX<\;^%?#GC+P]>I-%>:#
MXJT/3/$.C7<=S:W-C<1W.EZO:WEC.D]C>7=G,DL#K+:W5S;N&AGE1O\ .\_X
M. _V!_A=^Q'^UEX4U?X%:!9^#?A!\?\ P1<^-M+\"6-Y<SZ=X+\<^']7?1_'
M>D>'+.\:XN=-\(Z@MUX<\3Z38-?SVFEZGK^OZ#H-EHWA?1=!TFUZ,HXEI9IB
M?JLL-+#590E.F_:JM"?(KRBW[.DXRY;R7NM-1E=IV4N3B#@O$9'@_KT,;#&T
M(5(0K+V$L/4I^T?+":C[6O&4'-J$GSQDI2C:,DY./Z/?\&^W_!7WXD:I\3M%
M_8<_:B\?:YXYT3QE9PZ9^SKXV\2_;-<\2>'O$VD6$:P_##6O$,MQ)=W/A35-
M#TZ9O"5QJ<5W<Z+K=JNB&_\ [+U>P@TC^TBO\?/X6?$+7/A)\3OAS\5O#$C0
M^)?AEX\\(?$+P],DSV[Q:YX+\0:=XDTF1+B,-) R7^FV[+-&I>(@.H+*!7^P
M97S7%N HX7%T,11C&G'&0J.<(I1BJM%P4YI*R7/&I!R26LU*3UDS[/@#-<1C
M\!BL)B:DZL\OJ453JS;E/V&(C4]G3E)MN7LI4*BBV](2A!:10445^?7_  5-
M_:CM_P!C[]@W]HGXR6VM0Z+XS7P/?^!OA;(NMIHFL3?$_P"(:GPEX0NO#K*?
MM^H:KX6NM3E\=SZ?I2B__L/PIK-_]ITVSL;S5;#Y>A1GB*U*A35ZE:I"E!?W
MJDE%7\KO5]%J?<8K$4\)AJ^*K/EI8>C4KU'VA2@YRMW=HNRW;LEJ?P5_\%O/
MVL[_ /:U_P""A_QIU:UU>WU+X>?!C4YO@%\+8["XL;W3$\.?#?4M1LO$&KV.
MIZ=:VL&M6_BWXAW7C+Q79:O*;Z9M%UC2-(@U34-(T?2I1^2%37%Q<7=Q/=W<
M\UU=74TMQ<W-Q*\UQ<7$SM)-//-(S22S32,TDLLC,\CLSNQ8DGZ>_:#_ &3/
MB7^SC\/OV7/B)XZM98='_:G^"O\ PNGP@LEA+8'3M-E\9>)-$LM'E^TSFYU"
M:\\'6G@?XAPZHEG9Z?/H_P 1-(M;%KXV5Q>S?M.'A1P5'"X.,HQY8*C1CLZC
MI4W*;2ZMQC*<V^MVVV]?YLQ57$YEB,=F$XRFY5)8G$3WC2C6K1A!-O:*G4A2
MIQ6RLDE&.G]B'_!KK^UH/B'^S9\3/V1->W)KO[._B4^-/!$[3NT.H_#;XL:K
MJ^JZEIMM;,TQBN?"WQ#@\0:CJ=P&M;:YM_'VAQ6UFUU9ZI>7']2E?Y>/_!'O
M]KG_ (8R_;]^"/Q*UCQ)#X9^&OC#5C\'_C+>WKV,&C+\-/B+=6.GW>I^(+V^
M>'^S]"\&>*;7PI\1=0OK:Y@N+=/!JLRWUH;K2[__ %#J_-N*<#]4S.=:*M2Q
ML?;QM>RJWY:\;]9.=JK[>U1^S\#9G]?R2G0G+FKY=+ZK).UW0MS865EM%4[T
M8WLW["5[[LHHHKYH^S"BBB@ K_-)_P"#@/\ Y2Z?M:_]T&_]9E^#%?Z6U?YI
M/_!P'_RET_:U_P"Z#?\ K,OP8KZW@W_D:5_^P"K_ .I&%/@/$;_D1X7_ +&M
M#_U$QQ^0GA_7]:\*:]HGBCPWJ=WHOB'PWJ^FZ_H.L:?*T%_I.M:/>PZCI>IV
M4Z_-#=V%];075M*OS1S1(XY6O]/?_@DI^WUIW_!0G]D/PG\4-5O=,7XR>#+@
M_#WX[Z#I]LNFI8>/M)M8+B+Q!9:7N/DZ!XYT2YT_Q-I<]FK:3!?76M^&[2=[
MSPUJ=O:_Y>-?J_\ \$<O^"@ES_P3Y_:\\/\ C'Q'<7$OP.^*-O!\./CCID*^
M9);>&[ZZ\W0/'%BCSQ0IJ?P_\0O;:U,[QW$UWX5E\6:%9QPWFMP7MI]9Q%E?
M]I8*3IQOBL-S5:%DN::M^\HW_P"GD4G%?\_(PU2;O\%PAGKR;,XQK3M@<;RT
M<4FWRTI7_=8FW>E)M3?_ #ZG4T<E&W^G37Y.?\%S/^44O[87_8H>!_\ U;OP
M]K]6[2[M+^UMK^PN;>]L;VWAN[.\M)H[FUN[2YC6:WN;:XA9X9[>>%TEAFB=
MXY8W5T9E8$_E)_P7,_Y12_MA?]BAX'_]6[\/:_-,L_Y&67_]AV$_]2*9^TYU
MKDV;-;?V9C__ %%JG^8U7^I__P $G?\ E&M^Q)_V;M\.O_3-%7^6!7^I_P#\
M$G?^4:W[$G_9NWPZ_P#3-%7W'&G^Y83_ +"G_P"F9GYAX;_\C+,/^P&/_J13
M/G;_ (. _P#E$7^UK_W0;_UIKX,5_FDU_I;?\' ?_*(O]K7_ +H-_P"M-?!B
MO\TFM>#?^177_P"P^K_ZCX4P\1O^1YA?^Q50_P#4O''^CM_P;D_\HKOA'_V4
M#XS_ /JQM;K]TJ_"W_@W)_Y17?"/_LH'QG_]6-K=?NE7PV<?\C7,?^PS$?\
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MS3KRYM_M5A=VM[;^9YUK<P3I'*O^B?7\Z_PX_P"#9?\ 8/\ A?\ $/P'\2]
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M)\=OVP?V%=)^,G[1?CK_ (6)\2+KXI?$3PY/XC_X1GP=X2WZ-H5SID>E6?\
M8_@7P]X9T%?LJ7$P^T)I:W4^_-S/,50K_)U_P5Q_X(P:1_P3G^%FB_'FZ_:D
MF^+>L?%/XS/X/TGP!%\#7\"I9P:OHWBSQAJFMW'BT_%KQE"\.BKH]GIBV/\
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MQM;Z;!?32:DOAK7O!LUEX:M;Z\L+EK=6U[P9KT"2V&F2Q);'^U#J?[ >*?\
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M_P#].>G5M'_=\7_U[C^;,I_'2]9?H?0M%%%>2:A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!Q?Q#_P"1-UK_ *YVG_IPM*M_!#_D39O^PW??^DUC53XA_P#(FZU_
MUSM/_3A:5;^"'_(FS?\ 8;OO_2:QKL?_ "+*G_84O_2("C_&C_@E^:/8:***
M\LZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y>\,?\EOU+_L
M*^)?_2>^KZAKY>\,?\EOU+_L*^)?_2>^KZAKOS#X\/\ ]@E#_P!N.?#?!/\
MZ^2_*(4445P'0%%%% 'QM_P47_Y1\?MV?]F;?M/?^J2\<5_E 5_J_P#_  47
M_P"4?'[=G_9FW[3W_JDO'%?Y0%?HG!?^Z8W_ +"(?^FS\A\2?]]RS_L%K?\
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M_*5']CC_ +*!X@_]5SXTK_3VKFXS_P"1AA?^P-?^GZQW>''_ ")\;_V,I_\
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M/VM?^Z#?^LR_!BO]+:O\TG_@X#_Y2Z?M:_\ =!O_ %F7X,5];P;_ ,C2O_V
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MD[RKX-86K&G.[=W*B[4:FFD?8R;<IRM_G.5_J?\ _!)W_E&M^Q)_V;M\.O\
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MMG1_[5_L[[3_ &=_:NF_;/)^W6OF_P!7_P#P\7_X)\?]'V?L;?\ B3WP2_\
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MGZA/<:%+J"+>W'A;Q/HNJZ3XET"2274#IR:C=^%[K6-6UCPWJUX_Y*?M$_\
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MO!\D_P"GZ1?_ /+YIFJ:9>?]-K*_T^_LIO\ ME<6EY:7$7_3.:":/^"1./\
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MK'^O[_@EQ_P<+_LK?L_?LR?!G]E[]H7X4_$/X=WWPITA?!5A\0_AGHNB^,/
M&MZ- U]JG_"7^*M&75="\9>'?$6J7]W+#KECX?T#Q\NL:U-<>)Y-1T]-6N=+
MTG](K1J9/E]*&4X!8OE<5.,)*,I)Q;E7ERISK3G))-1N_>37N127XWAYT>(<
MWKU<_P UE@%-2<)5(.4(R4U&.%@Y-4\-"G%M\TUROD?-[\W(_DS^*/P2^,_P
M/U:UT#XU?"+XG_"#7;Z%[BRT7XH^ ?%?P_U:\@C2VDDGM=.\6:3I-Y<0QQWE
MI(\D,+HB75LS,%GB+?T;?\$,O^"SWQ5^%7QA\ _L@_M,^,]7^(?P0^+/B?3O
M!GP\\9^,-3OM7\4_![Q[XFOFL_#EJ->NTO=0U3X>^*_$%[8Z%JNFZW=BR\%W
M%]:>)]-U/1M#T_Q'I^K_ -!O[0?QG_X)5_\ !7W]G7Q3^SQ8?M;_  /?Q!XR
MLY&^%NK:YK%KX0^)W@GX@PVLVI>'?%'AOX=?$>Y^'GC?Q!%IMUIR3^*/"]E'
MIRZ_X?BOM%U'4-)^V0:C:_GWX&_X-2O@)HVI6E]XU_:X^-6NQVE]!=1GP-X.
M\&?#_4HD@N+29#::EJUQ\05M;Y%BN_(OELY!!<36EP+5A9217OC5\ZR['8*K
MAL[P]7!8A\RC3E0K2G&7*N2O1DZ2<)*3LXR:^%QDY0DT_HL+PWF^5YG0QO#6
M,H9GA%R2J5H8K#4Z<X\S]IA<3"-:2J0G!7C."E;F4XJ%2"D?U=45GZ3I_P#9
M.E:9I7VW4-3_ +,T^RT_^T=6N?MFJZA]CMH[;[;J=YLC^UZA=^7Y][<^7'Y]
MS)++L3?M&A7YV?KRO975G;5;V?:X5XE^TO\ \FX?M ?]D2^*W_J":]7MM>)?
MM+_\FX?M ?\ 9$OBM_Z@FO5I1_BTO^OD/_2D98C_ '>O_P!>:O\ Z1(_R)*_
MT=O^#<G_ )17?"/_ +*!\9__ %8VMU_G$U_H[?\ !N3_ ,HKOA'_ -E ^,__
M *L;6Z_2N,/^15#_ +#*/_INN?C/AW_R/:W_ &+<1_ZD80_=*O"?VG_@5X:_
M:;_9Y^,GP!\6V=C>:+\5?A_XB\)'^T1-]FT_5KZQD?PYKNZW#7$5SX<\10Z5
MK]C/ KS6][IMO/$CO&JGW:BOS.$Y4YPJ0;C.$HSA):.,HM2BT^Z:31^TU*<*
MU.I2J14Z=6$J=2#U4H3BXRBUU4HMI^3/\;VXM[BTN)[2[@FM;JUFEM[FVN(G
MAN+>XA=HYH)X9%62*:&16CEBD57C=61U# @?Z)'_  ;6?%/4_B)_P3*T'PWJ
M5U]J7X*_&GXI?"S36<2F:'3+EO#_ ,5[>UFEEAC,WV:7XI3PVI26ZBM[!;2R
MCFC6U%G:_P  7QPL;72_C5\7],L8O(L=.^*/Q L;.#?)+Y-K:>+-6M[>+S)G
MDFD\N&-$WRR/(^-SNS$L?[7/^#4S_DTS]I3_ +.)M?\ U6OA*OT[BJ,:N2^T
M:UA6P]6/DY7@_P#R6I)'XEP'.5'B/V2>E3"XNC/7>,.6JO7WZ47T/G;_ (.V
M?^<?_P#W=7_[[=7X6_\ !$?_ )2H_L<?]E \0?\ JN?&E?NE_P ';/\ SC__
M .[J_P#WVZOPM_X(C_\ *5']CC_LH'B#_P!5SXTJ<I_Y)-_]@>9_^G<6:9[_
M ,E]'_L99)_Z9R\_TV_$WB30?!OAOQ!XO\4ZI::'X8\*:)JOB3Q'K>H2>38:
M/H.AV%QJFKZI>RX/E6FGZ?:W%W<R8.R&%VP<8K_-(_X*@?\ !7'X]_\ !07X
MF>(]-LO$FO\ P^_9ETG5)K/X>_!S1=7O+/3-4TVP;4+.T\8_$(0?9#XE\7:[
M9WUQ//;WT3:5X=LKJ/0]*M&>#4-6UC_06_X*!>$?%?C[]A7]L;P5X&\Y_%OB
MK]F/XXZ%H-E;VUG=3ZS?:E\-_$=LOAV!+^:WM(9O$T<DGA^.^EGB_LU]2748
MW$MJE?Y.=>5P;@\/4^M8NI&%2O1G3ITE)*7LHRBY.I%/12FURJ?Q)0DHM*4K
M^YXBYAC**P. I3G2PN(IU:M?D;C[>4)PC&E*2=W"FGSRA\,G.#DFXQM] _#+
M]DS]JGXUZ$_BCX-?LS_M _%OPU',UN_B+X9?!GXC>/="2=)KBW>!]7\*^&]5
MT]9EN+2Z@:,W =9K:XB*AX9%7S_QAX$^*OP0\9Q:%X_\&_$'X0_$/0+BUU6'
M1O&'A[Q'X \9Z+=VE[)]BU*+3]:L])US3;BUU"QE^RWB0PR0WMG)Y4BSV[;/
M[<?V+?\ @Y7_ &)Y/AE\*OAA\?\ P!\0_P!G?Q)X1\&Z%X0U36/#/A:#Q[\%
M+"V\*V&F>'M.GT)O"5P_Q&TVTU"PMAJ</AJ+X9:A;>&;6*30X?$6OO:VE_J7
MUI^V!X,_X)I?\%O/A+X:^%WP_P#VO/@K;_%_2?$.D^(/AGXL\/:QX?U+XM:%
M9VVIZ?!XIT6X^$OB#Q!X)\<ZSX>\2:)JMUH\5M?PV=CI'BF^T;7XDO[K2)]%
MU/U99]CL-BN3,,IJX?!N<HRQ$/:5XTX:KGE*%-TZD5O)0:ERN\5)I*7A0X4R
MO&X'VF49_0QF8JG&<,'4]CAI59V3=*-.K5C6HS;?+"51.'.E&3BFY1_-O_@W
M]_X+'?$;XE^.?#W[!W[4OB:\\:ZKJ^D:G_PSW\6=?NKB[\53W7AG1Y=7N_A3
MXUU22&4Z]'-X>TO5M6\&^*]<O8]9BO-,F\'WU[K\NM^%+;1_[!J_F4_9N_X-
ME/@9\!_BK\-OB_J7[57QT\1>*?A?XV\.>/-!;P;HW@_X;QRZSX5U<:UI<,]S
M/%XXU&&PFNK;3H-3CL[VVNKJPCU*WM[RRDU""XTW^@+]I#XPV'[/?[/GQP^.
MVIP17EG\'?A-\0?B6^G2RPQ?VM-X+\*ZKX@M-%A-Q=V$4EYK5W80:58VYO;5
MKJ\O(+:*>.65&'QN=2R[%8^%3*KM8A152FJ4J4/K$I<J<(S4;*HG&Z44E-2E
M?WG;]&X:AG&!RJ=+/DHRPKE*C5E7A7J?5(TU)QJRIRG=T6IJ,G.3=-QBE:"<
MOY@?^"[7_!;;XA?!;Q[K_P"Q5^Q[XG3PMXRT"PM(/CI\:=':9O$OA36]2BTK
M6K'P!\,]7@NDLM*UJRT>79XZ\1K;:E?:7=:N/#>C7'A_Q-H.MSP?QR^%_!GQ
M=^/7CJ[TSP5X4^(_QG^)GBB^OM=O]/\ "^A>)OB+XZ\1:EJ6H+)J>L7=II-K
MK'B#5[Z_U34$DOM0FCN)[K4+Y6N)I+BY!?E?%'B77?&GB7Q%XQ\4:C-K'B7Q
M9KNK^)?$6K7"0QSZIKNNZA<:IJ^HSI;QPVZ37NH75Q<RI!#%"KRL(HT0*H_T
ML?\ @B5^R)\,/V9/V!/V?_$WA?0M)F^(/Q\^&'@SXX?$/QT]AI[^)-8N/BGX
M;T;QCI/AN76DTVSU+_A'O"NBWVDZ3INAR33V-I>VM_J$;W%YJ-W?77V=>IA>
M%<MHJC0C6Q%64:<I:0=:JHN52I4G:4E3C]B"ORIQBK>](_-\+2QW'6<XAXC%
M2P^$H1E5C#^)'#T'44*5&C2YHP=6:?[RJ[<SC*<K^Y!_YP'COX8_&?X ^,+/
M1_B;\/?B?\%/'VDS6.L6&E>._"?BOX;^,--N(1::GINJ6=CX@T_1M:LYHEFL
M=0L;Z&*-T$MI=V\H#PR'^K#_ ((B?\%T?BUK7Q4^'G[&7[9?BZ7XAZ+\0=5M
M/!WP>^./BB?7=8^)MIX_U^^M=/\ "G@#Q[K:C5)_&VE>*]7N(='\/^*=:BA\
M1Z)KNHQ1>)?$6L>'KJT?PM_2]_P4<_8[^&O[;/[)_P 4_A/X\\)-XCUZQ\+>
M(/%?PIU/2[:V?Q;X6^)^B:+?7?A74?"EY-%))!<ZC?QQ:'JUA&\4.O:'J.H:
M+=NL5YYL7^51;W%Q:7$%W:3S6MU:S17%M<V\KPW%O<0NLD,\$T;+)%-#(JR1
M2QLKQNJNC!@"#"8C"<4X"O2Q&'C2KT;0<DU-TIU(R=.M1FU&44Y1E>F]'RN,
MG.+'C\)C^!<TPE;"8N=?#8E.?*TZ4<1"C.*K8;$4U*<)-1G#EJQUBYJ<8PDC
M_9"K^1W_ (.#?^"O_P 4O@;XY7]A_P#94\;ZG\/?&=EH&B^(OCY\5/"MUJ&C
M^.?#<GB>PBUOPI\-/!NO1I9WGAG4+GPQ>:/XV\1^*_#D[ZFUAXA\,:-HNO:3
M/!XNL+G^CG]AWXZ7G[3/['W[-GQXU5VDU_XF_!WP/XB\6.UI!8HWC5M%MK+Q
MN;:UM8K>UCL?^$ML]9&GFVM[:"2Q^SRPVMM&ZP1_B]^U=_P;:? _]IWXY_%O
MX^/^T[\:?"WBOXO^-/%'CS6;#5= \$>+])TC5O$ER;V+2]'%M9>$;U?#>@S2
M/8:1I][=W>I)H-OINGW6M7-]:7.L7_QF3O+\'F,Y9L_=PW/&$/9RJP>(C/DO
M.,8RO&"4Y)..LN5_9L_T?B%9MF&3TXY!K/&^RG.HJT*%18.I3]I:E.4X)3J-
MTU)J:M3YXJ_,FOX4/ GPQ^,_Q^\87FC_  R^'OQ/^-?C[5IK[6+_ $KP)X3\
M5_$CQAJ5Q,+O4]2U2\L?#^GZSK5Y-*L-]J%]?312.XBN[NXE(2:0:/Q/_9Z^
M/OP1\G_A='P.^,'PB^T7D>GP?\+/^&GC3P#Y]_+9C48K&'_A*]$TGS+R33R+
M^.V3=,]F1=*A@^>O]-W_ ()K?\$\/AO_ ,$WOV?H_@[X0UBT\>>,M;UN_P#$
MGQ,^+K^$;+PAK?Q"U:2[O!H,5WID.K>([O3]$\*:)/%I&@Z)<>)=8M[*9]9U
M:WDAN_$&I*_SA_P6._:,_8@?]AK]J3X,_&3XW?!J7QYKWPO^(>G_  Z^&Y\4
M^'?$GQ D^-?A;1-9U+X>0V?@_2_[<\1:->:=\1=#TO3+[7;O2].L-!NY&LM3
MUG1YKE)*^IAQ6ZV/CAL+@G7PKJQI1JQ=3VLH.2BZRIJG[L4KRC"24N5+F<'=
M+X6IP''#93/&8[,X87&QH3K2HU%2^KPJ*#G'#RK.K[\V_<E4@W'GE[D:D8J4
M_P"(S_@FY_P5+_:"_P"">'Q4\/ZKX;\1Z[XQ^!-[J-I:?$WX&:KJ<]WX8UWP
MU-?7%QJ=YX1M+V9K7P?XXLFO[[5=$U_2/L4=UJQ2V\2Q:QH=UJ&G7/\ I[Z#
MKFD^)]#T;Q+H%]#J>A>(=)T[7-%U*WWB#4-)U:SAO].OH!(D<@AN[.XAN(_,
M1'V2+N16R!_CFU_K%_\ !/F_N]5_8(_8AU2_E\^^U+]D+]FJ_O9_+BB\Z[O/
M@SX+N+F7RH4CAC\R:1W\N*..)-VV-%0!1R<982C!X3%PA&%6K*I2JRBDO:J,
M8RA*=MY1]Y<S]YII-M1BEW^'./Q-3Z_E]6K.IAZ-.C7P\9R<E1;G*%2-.^L8
M3O"7(O=C*+E%)SFY?RM_\%]O^"QOQ6B^+7C/]AK]F'QE?> ?!_@!G\/_ !S^
M(_A#5KFS\5>-O%&H:08M=^&>G:K:I;SZ!X6\,1:A+I'BT:=<G4M?\1Q7FDSW
M5EI.D75KKG\MOPV^#7QO^/FO:CI?P@^%/Q5^-/B>+=J&K:=\-O WB[XC:]']
MK^U7+7VHVGAC2]9U!/M/V6]G:YN8QYWV>ZE+MY,S+] _\%(O"/BOP/\ \% ?
MVTM \;>=)XC_ .&G/C5KMU?3VUG9/K-CXM\?Z[XLT/Q$MC833VEC#XET+6]-
M\06]C#*?L4&I1VKI%)$\2?MO_P $:O\ @NA\ /V%?V?$_9B^/OP>\=Q:39^.
MM8\4Z+\5?A)9>'-?N-6D\::A;'59/B/X7UO6/"=]"_A>VMK>*V\1^']4\5ZG
MJN@6^GZ'%X4LYM M[G6O>HTY95E%"65X*.,JRIT9S49J$JKJ04IUY2:<JFK7
M+3C9J,DHVC"Q\KB*\,^X@Q,<\S*67T(5<13IRG!SA05&HX4\+"-U"C[J?-5D
MFI3BW/FG-,_G:^*W[-_[1'P(BTZ;XX? 7XT?!J'5Y%BTF7XK?"WQQ\/(M4E9
M;EUCTZ3Q=H6CI>R,EG>,J6QE8K:7+ 8@E*?JY_P22_X+)_%_]A#XF>&O 'Q2
M\5:_\0/V1_$^IZ5HGC+P?KU[J>N7?PIL)6LM+C\?_#)C%J6J:<?"MA#'/J?@
M73(GT3Q5HUO<Z=;Z;9^(CHVNZ9_8!J?[?W_!(O\ X*-?![Q5\#/$W[3/P?U+
MPO\ $_0W\.7_ (2^)NM/\&/&-MJ>M*NEV)\*1_%2Q\+7+>-]+U&^C.@WGAD:
MO*=0C6XTYM1L"[3?E%X)_P"#4;X)R6]C?^*OVSOB'XOTZ\L;.ZANO!/PR\)>
M%;>_2>S>3[=8W>H^*_'\#6-Y)+:W=F$%R%LU>+[5=-<1WD'G2SS!8K"UL-GV
M#JX*;]V-*="O+G37\2BW2YJ52F];MJWNN,I7<5[,.&,RP..PV-X5S&CF5-6E
M*O3Q.&@J335Z6(BJ[C6HU5>ZBG=*<9PBU&4OZV;2[M+^UMK^PN;>]L;VWAN[
M.\M)H[FUN[2YC6:WN;:XA9X9[>>%TEAFB=XY8W5T9E8$_C3_ ,%F/^"JME_P
M3;^#WAW3O %EH'BG]I7XOOJ$/PR\.Z_#<ZAX?\,>'M$GL(_$WQ"\8:?I]]IU
MW)86GVZ#1_"NF/?V'_"0>(KB:XB-_I7A?Q+:I^I/P,^$>C? /X-_#+X)^'/$
M/B_Q5X>^%7@GP_X#T'Q!X^U:UUSQCJ>C>&=.@TK2YO$&K6&FZ-8WM^EC;00-
M)9Z3IUJL<4<5O9V\,:1K_FI?\%G?VAK[]I+_ (*2_M/^*7NC/X?\ ^/+_P"!
M_@R%&LY;.W\.?!N:7P--<Z;<V4]U'=Z=XC\3:7XB\8VMU)=3/.OB1F5;.#R-
M/L_FN'LLHYCF,HU+U,+AHRJR37+[:TU&E"2O>*FWSRCK>,)0;UN?:<79WB,H
MR>$Z-J..QLHX>#C)3^KMTW.O4A*R4G32]G"5E:=2%1+W;/X?^+OQI^.G[4WQ
M.D\>_&+QWXX^,WQ2\3S6.B6VIZ_>7NOZW="2[D72/#7A[38$:+3].2]OYH]&
M\,^'[&TTVWN+R2+3=.B>X97L?$C]F?\ :0^#>A:/XH^+W[/WQN^%7AGQ$N_P
M_P"(OB1\*?'G@;0M=39:2;]'U?Q/H.EZ?J:^7J%@^ZRN)QLO;1L[;F$O_6=_
MP:U?LB?##7/ 7QH_;,\5:%I/B7X@Z1\3Y_@?\/GUFPT_4AX&M_#OA3P/X]\0
M^)-!CO=-EDTOQ#KDGC71=,CURROUOK?3=)O["!+2WU&]:_\ ZX_&_@CP?\2O
M!_B7X?\ Q \-:-XQ\$^,=&O_  ]XI\+>(;"WU/1->T34[=[6_P!-U*PNDD@N
M;:Y@D9&5URIVR1LDB(Z_39AQ13RW&O T<'&='#.-.HU-4K>ZFX481@XI0325
M]&TTE%6D_BLHX(JYSEJS/$YC.EB,8IU:$94_;W7,TJF(J2J*<G5:;M'6$6I-
MSDW!?YPO_!,C_@M/^TI^P7XJ\,^"?%'B35_C#^RY<WFDZ-X@^%GC35]7UB?X
M>^'1>(+G6?@OJ,]W/-X,U#2H9;F[/A2"&Y\%^($EOH+O0K37+NP\4:-_H[^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M$U'_ )&[3?\ K[TK_P!*(Z[NN$U'_D;M-_Z^]*_]*(ZVH?%/_KW/\C.K\*_Q
M1_,]SHHHKA- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\R^%?_ "-VK?\ 8*O_
M /TYZ=7IM>9?"O\ Y&[5O^P5?_\ ISTZMH_[OB_^O<?S9E/XZ7K+]#Z%HHHK
MR34**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .+^(?_(FZU_USM/_ $X6E6_@A_R)
MLW_8;OO_ $FL:J?$/_D3=:_ZYVG_ *<+2K?P0_Y$V;_L-WW_ *36-=C_ .19
M4_["E_Z1 4?XT?\ !+\T>PT445Y9TA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/MPIGOM2U*YBL[&S@#,JF:YNIHH8PS*I=U!8#FO]<[]F_P"$EI\!/V?/@?\
M!&RBT^*'X2_";X??#MO[*DEFL)[KPAX5TO0KZ^@N9[/3[F]_M"]LKB_EU"\L
M;2]U":YDOKVWBN[B91S\8UU2P.$PD/=56LY<J_Y]X>%N7TYJD&O..^]^KPZP
MTJ^:8_'U+R]AAE3YG>[K8NKS.=^LN2C533O\=][,_P I[]JZQM=+_:D_:4TR
MQB\BQT[X_?&.QLX-\DODVMI\1/$=O;Q>9,\DTGEPQHF^61Y'QN=V8EC_ %3?
M\&DW_.0#_NU3_P!^1K^63]K[_D[/]J'_ +.)^-G_ *LKQ-7]3?\ P:3?\Y /
M^[5/_?D:]#B#_DG<1_UZP7_J3ACR>$DEQAA$E9*OF226R7U+&Z']6_[2_P#R
M;A^T!_V1+XK?^H)KU?Y$E?Z[?[2__)N'[0'_ &1+XK?^H)KU?Y$E>5P5_"S#
M_KYA_P#TFJ>[XE_[QE/_ %YQ?_I= _L0_P"#9C]F3]FWX]?!;]J'5?CG^SW\
M#_C/JGA_XH^"-/T'4OBQ\)_ 7Q%O]$L+OPG?W-U8Z1>>,- UBXTVSN;A$GN+
M:SDAAFF199$9U##]BOVQO^"#7[ _[2OPW\4:7\-_@WX)_9O^+\MAJ$_@3XE_
M"C2)_"VD:'KT]RFH11>(?AWH%[IG@KQ'X;O+F%+"^LYM%BU72M'GN8?">J:#
M,4>OSE_X-0/^2#_M<?\ 97/ '_J&ZC7]9%>)G>.QF%SS%RP^)K4G3J4I14*D
ME#2A2=G"_)*+?Q1E%QDFU)--H^GX9RS+\;PQE\,7@L-756C74W.C!S=\167,
MJG*JD9I)<LXR4XM)QDFDU_D2_M&_L\_%3]E3XT^/?@'\:/#[>'/B%\/-9DTK
M5K9&EFTW4K62-+K2/$7A^^E@MFU3PUXDTJ>TUK0-3^SP&\TR]MI9;>VN/.MH
M?U*_X).?\%F_C#_P3\\9Z)\/OB%J6O\ Q._9'UK4VC\5_#F:2#4->^'[:C]A
MMI?&GPKOM09+BQO-)CLX[B[\"2ZC;>$?$ML^I1"WT7Q%?VWBC3_Z7/\ @X._
MX)E#]J_X&?\ #3?P>\,I=?M"? '1KRZU?2?#OAE]2\4?&'X8-<63ZCX:>33,
M:EJ&L^ HAJ'BGPG"UKJDTMI)XDT&RMEN=9M)(/\ /KK[7 8G"<0Y9;$4X3E;
MV>)I6UIUDM*E-OWH<R]^E.+O&[CS.49'YIFN"Q_".=<V$K5:<;^VP6(3TK8=
MRUI5DO<J<C7LJ].2M*T9\BC.!_L/^"/&_@_XE>#_  U\0/A_XET;QCX)\8Z-
M8>(?"WBGP]?V^IZ)KVB:G;I=6&I:;?VKR07-M<P2*ZLC94[HY%21'1>IK^*[
M_@VA_P""D-YH?B&?_@GA\6-9:7PYX@;6O%?[,]_=O;PP^'O$(;6O%7Q$^&TD
M\TZ-)9>*FEN_&GA6WBB5K7Q%!XOMY)+V?Q1ID%A_:C7YMFF7U,LQE3"U'S17
MOT:EK>UHR;Y)VZ/1QFME.,DFTDW^SY'F]'.\NHXZDE"4KT\12O=T<1!+VE._
M6/O1G3D]94YPDTFW%?@+_P '&W[6.H_L[_L"W_PS\):[_9'CK]J;Q.OPD MU
MNEU,?"V#3;C6OBU<VEQ&4LH[/4]+CT7X>ZY#=FXENM&^(=Y%9V9?S-1TO_.Q
MK]W_ /@XE_:GB_:(_P""AWBWP)X?URWU;P%^S%H%C\%=(&G2W1TYO'%I-+KO
MQ9N98;F5U77],\::E<?#[6YK>"T@E'P]T^%(K@6HU&]_-_\ 80_8^\8?MW?M
M1?#7]FGP=K4/A6;QM=:E=^(?&=SIBZU;>"O!_A_3+G6?$GB:713JFB'69K&P
MM&AT[1UU?3&U;5KK3]._M"Q6Z:[A_1LAP]/+,FA5KM4_:0EC<1.2:<(RBI14
ME9R]RC&-XVOS<R2N[/\ '.*\95SKB.KA\,G65*K#+<'3C)-3J0GR3Y6VH?O,
M3*=IW2<.1N7+&YZ%^RW_ ,%2?VZ_V+?AUJ'PG_9F^.$/PR\ ZMXLU+QUJ6A1
M?"OX+^+'O?%>KZ7HFBZAK%QK'CKX=>)]=DFGTKPYHEBL!U/['!;Z= EO;Q9D
M+_2/_$0'_P %<_\ H[7_ ,P-^S+_ /.8K]DO^(2;_K(!_P":J?\ Y2-'_$)-
M_P!9 /\ S53_ /*1KFJ9MPG5G*I56#J5)N\ZE3+*LYR?>4I81RD_-ML[:60\
M>T*<*-!YC1I4XJ-.E2SJA3IPBMHPA#,%&,5T44D?RE_M%?M'?&/]K#XKZ[\<
M/CYXJL_''Q2\3V>B6/B'Q9;>$?!/@R;68?#FD6?A_17U#3/ 7ASPOHES>6&B
M:=I^E)J$FF&_EL+"QMI[F6*TMUCQ/@9\7_%O[/WQF^%GQQ\"7'V?Q?\ ";Q]
MX5^(&@;IIH;>[O\ POK-IJRZ9J'D,CSZ1J\=M)I6LV3%H;_2KR\L;F.6WN)8
MG_IR^/O_  :S>,_A3\%?B?\ $SX>_M<_\+>\8^ O!NM^+-#^&8_9^MO!$GC2
M?0[1]0N-$M_%-Y\>M>MM(N[BQ@NFLYIM(ODGNHX;3RU-P)8_Y.*]G XS+LPH
M3A@9TZE"DE1G2C2G2C"$HVC!4ITZ;4'&\8\L>2R<4_=:7SF9Y=G&4XJE5S.G
M5HXJO*6)IUIUZ>(G4J1J*4ZKK4JM92JJHU*?-/VEY1E)6DF_]?CX)?%CPQ\>
M/@[\+?C7X+G6X\*?%CX?^$OB%H#+(97ATWQ;H5CK=O9W)>&WECOK!;W[#J%O
M<6UK=6M];W%M=VMM<PRP1_SZ?\'4/_*/CX._]GD_#[_U27[0U<[_ ,&P/[64
M'Q)_99\>_LK^(];:[\9_L^^,+WQ%X0T^=M2DE'PA^($D.H6\4,URLUD5T7X@
M'Q;')#9W<(MK/7-'A.F0!#>WW[S?M4?L??LZ?ML?#W1_A7^TW\._^%F> M \
M9:?\0-(T'_A+?'7@S[)XNTK1/$7ARPU?^U/A_P")O"FLS^1HWBO7[/[!<ZC-
MIDOV_P"T364EU:V4]M^9J,<DSQ*M&I*E@\3SKD2=2=%IRIRBI2A%N4)1;O)*
M]U?0_:93GQ-PN_JTZ4:^88)0;J2DJ5/$1E&->,W3A4DHQJPFE:#=K/E29_DG
M45_I;?\ $/Y_P2,_Z-*_\SS^TU_\^>C_ (A_/^"1G_1I7_F>?VFO_GSU]A_K
MEE?_ #XQ_P#X*P__ ,U'Y[_Q#G._^@K*O_!^+_\ F$_/;_@U,_Y-,_:4_P"S
MB;7_ -5KX2K^>3_@X#_Y2Z?M:_\ =!O_ %F7X,5_H'_LI?L4_LR_L1>$O$O@
M;]E_X:?\*Q\+>,/$2>+/$6E_\)E\0/&G]H^($TRTT=;_ .W?$+Q7XLU&TQIU
MC:V_V6QN[6R/E><;8SO)*_\ GX?\' ?_ "ET_:U_[H-_ZS+\&*X<AQ=/'<1Y
MCBZ49QIUL'4E"-114TE5P<?>493BG>+VD]+'J\5X&MEG!V48"O*G.MALPHPG
M*BY2IMO#YC*\'.%.35I+>$7>^G4^B?\ @V0_Y24W/_9NWQ3_ /3SX$K^YC]K
M_P#9<^'_ .V=^SG\3_V</B7YUMX<^(VA"RM]<L[:UNM5\)^(M/NH-5\,>+M'
MCNQY3:CX=UVRL=1CA9X4OX(;C3+B9+2]N,_PS_\ !LA_RDIN?^S=OBG_ .GG
MP)7^A;7F\5U)TLZA5IR<*E/#X><)K>,X3G*,EYII-'L<"4J=?ANK0K0C4I5L
M7BZ56G+6,Z<Z=*,XORE%M/U/\AG]H+X#_$G]F+XT_$?X!_%[1&T#XB?"_P 2
M77AOQ%8@7)L[DI'#>:5KNC3W=K93W_AOQ1HEWIOB7POJS6ENFL>'=6TO588D
MAO(Q7V)^S;^WOK_PK_8C_;0_8=\72WFJ?#3]H3PWX;\2_#O<TLR^!/BSX:\:
M^#M5U=K6&&WD<:1\0O"N@I9:P9YC;V&L^%_#=U9I9IJ'B"XN_P"HS_@Y5_X)
MX+\7_@[I_P"W-\-=.\SXC? ?2+3P_P#%S3;:.)&\3?!62_O9H?$JB&V>XO-<
M^'&OZJEQ.LLD4+^"-7\0WUS=H/"VFV5W_";7VF6XNAG>7T:U2,7.G4I2JP7_
M "ZQ6'G"K&4>J3DHU(ZZPER2;]Y'YMG& Q7#.;8C#TIR5*K1KQP]5[5\#C*=
M2C*$^DI1C*=*>BM5A[2*7N,*_P!3_P#X)._\HUOV)/\ LW;X=?\ IFBK_+ K
M_4__ ."3O_*-;]B3_LW;X=?^F:*O&XT_W+"?]A3_ /3,SZ/PW_Y&68?]@,?_
M %(IGSM_P<!_\HB_VM?^Z#?^M-?!BO\ -)K_ $MO^#@/_E$7^UK_ -T&_P#6
MFO@Q7^:36O!O_(KK_P#8?5_]1\*8>(W_ "/,+_V*J'_J7CC_ $=O^#<G_E%=
M\(_^R@?&?_U8VMU^Z5?A;_P;D_\ **[X1_\ 90/C/_ZL;6Z_=*OALX_Y&N8_
M]AF(_P#3DC]1X>_Y$63_ /8MP?\ ZCTPHHHKS3V K_&WK_9(K_&WK[S@G_F9
M_P#<E_[MGY7XF?\ ,D_[J7_N@?U@?\&P7[.G[/GQ^_X;@_X7O\"?@U\:_P#A
M$_\ AFG_ (17_A;?PP\$_$C_ (1G^WO^%_\ ]N?\(_\ \)CH>L_V-_;/]C:/
M_:O]G?9O[1_LK3?MGG?8;7ROZ ?VG_\ @A=_P3N_:*\!>)?#OA_X%^#OV?\
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M?\$ _P#@F!\%=5L]?/P*O/BYK>G7%A<V5W\;?%^M^.M*CDL?+=EO/!*2Z/\
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MS_#]/"LGBR1?#%S=#Q+IUCIR^-O#0M]3U;2;#3=8>_FCT2[U&32]66Q^_?\
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M?BS#RQ?&&+PL'&,\37RW#PE*_+&5;!X*G%RLF^5.2;LF[7LCY>^+W[.'QM^
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MO!7_ &2/XP?^H[#4X;_DD)?]@&*_&=:X\;_R<&'_ &-\O_".&L?Z+5?Q-_\
M!V/_ ,E4_8Q_[)_\8/\ U(_ ]?VR5_$W_P '8_\ R53]C'_LG_Q@_P#4C\#U
M\KPM_P CK#?X,1_ZCU#[[CC_ ))K'_X\'_ZF4#\K?^#?S_E+I^R5_P!UY_\
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M4/#C^'T^R6MPWP_O+Y[V;X>>([+3K58]%O=&C.A^=%;Q:[H&MV$?V0?VW_\
M!5KX9_\ !-:']F[XR^*_VO/!7P(L?$\7P_\ &OB#P?KEU:^%?#/QRU/QG?:5
M/::')\/-=T^V3QYJ'B#6/$MKH]OY=JFJZ1?W5E;/XIT^_P!&TZZ2+_,QKV<O
MQN&XAPE95\#*%)-0E"M:I3DY)N]&JE%N4+:R482@W%IWV^<S;+,9PCF&'>&S
M.$Z\HNK"IAW*E5IJ,DN7$47*<5"I]F$I5(5%&:E&RL_]@#X._%;P;\=?A/\
M#;XT?#R]FU#P-\5? _ACX@>%+JZB2WOFT+Q9H]IK6GPZE:)+.+#5K6WO$M=6
MTUY7FTW4H;JQG(FMY /2*_,;_@C-X9\4>$/^"8'['6B>,;'5-.UP?#*ZU;[%
MK%MJ-G?PZ-XC\8^)_$?AC?;ZI;VUY';R>&=5TB6Q_=?97L'MGT^2?3VM9Y/T
MYK\LQ5*-'$XBC!\T*5>M2A)ZN4:=248MM::I)G[K@:\\3@<'B:D>2IB,+AZ]
M2"NE"=6C"I*-GJN64FM== KQ+]I?_DW#]H#_ +(E\5O_ %!->KVVO$OVE_\
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MS\K<H12BWR35V[)_RV_\0_G_  5S_P"C2O\ S//[,O\ \^>C_B'\_P""N?\
MT:5_YGG]F7_Y\]?W%?\ !3#_ (*2_"'_ ()^?L^_$'QC=^,? 6K_ !^;0I].
M^#/P7U#5[;4O$?BGQUJT$<&@ZEKG@[3-;TCQ(/AYX;DO+;Q+XYU87V@Q'P]:
MMI&E:Y#XHU_PS9ZC_,IX>_X.N?VEK9U/BS]EGX&:U&)I6=?#WB3Q]X8=H&@"
MP1K)J5]XN5)H[K,TLYC=)H"+9+>"0&Z/C8+-N)<PHO$8; Y?*FI."<XUJ7.T
MDVX>TQ<>:*NES)VO=7NG;Z/,L@X*RG$QPF,S3-HUG!3E&G/#UU33;257V6 F
MX2=G)0:YN6TK6E&_]0/_  28^"?Q=_9S_P"">O[./P3^._@K_A7GQ6^'^C^.
MM*\5>$?^$C\,>+?[-^T_%7QUJVAW']O^#M5USPW>?VQX;U#1];\K3M5O?[/_
M +1_LV\D6_L[J-/P@_X*W_\ !P[XR^$OQ,\5_LT_L%W7AA-:\#W>I>%_B=^T
M#K_AVV\42:5XYTC5K>+4O#GPDT'73<>$[V/P[-I^HZ!XD\5^,?#OBO1]:N[V
M_MO"NC6T&D:;XPUC^I'1/%?Q+\0_ *S\;Z_X&;X;_%G6?A6?$][\.=-U8^.[
MGP5XVOO"[ZG'X2BU:;PWH(\3:EH>JR1:9.__  C-I!?:A;RPPV,T#(9?\B&X
MN+B[N)[N[GFNKJZFEN+FYN)7FN+BXF=I)IYYI&:26::1FDEED9GD=F=V+$D^
M=P[@*&:8[,,;CJ=*I*E6Y_8)\U!U<14K3E)IRFITX.#5-2G.,D[R<N5-^OQA
MFF*R/*\HR[+*U:C"OAW2^M2O#%+#X.EAZ=.*DH4W2JU%4C*K*-.E.#CRQ4.9
MI?4GQ-_:W_;,_:DO['P]\3_C[\?/C1<7PO\ 3]*\(:MXX\8^)+"<:M-'=ZC8
MZ5X.MKV72_\ 3WM+4W5M8Z2//@T^P@=&M].LX[?H?#__  3P_;D\2> /$_Q6
ML_V5_C5IOPS\'>!_&GQ(\0^/_%O@G5/ GA"S\$_#[PYJ'BOQ9KL'B#QM%X?T
MS4X;#1-*U":SM=*N;[4-<OK9]&T"TU/6BFGM_9G_ ,&V/BS]C:X_8S\/^'/A
MHGP_TG]K#3M9\<V_Q_@O#IZ?%K7)M3\6ZMJGA6]MKS4(;;6]4^'\W@'2/"0T
M^Q\.JWA;2M3T+5(KV.?Q1::]JVH?1O\ P6E_X*-_LR_LZ?LA_M$? S4_'_AC
MQA\>OC?\'_B3\'?"WP@\,:_;ZAXJTIOB)H%[\/\ 5_%GC&/2K;6%\%Z1X3LO
M$&H:];0^*TT:3QC>:!>>&O#TSWJ:C=Z3ZU3/J]+,7E6!RI1<,0J3;3C>'/RR
MK*C3A",:3C^\C4=1Q=.TY-)Z>%1X5PE;*%GN:9ZYJIA?K%HRC)QJ.FI0P\L1
M6G4G4KJ5J,Z4:2FJO[N*DTK_ .;I7^K_ /\ !.C_ )1\?L)_]F;?LP_^J2\#
MU_E 5_JW_P#!/[^U?^'<G[$W]A?V?_;?_#$W[-W]C?VM]I_LK^U?^%%>#/[/
M_M/['_I?]G_:_)^V_9?])^S>;Y'[W;6/&G^[8'_K_4_]-HV\-O\ ?LR_[!*7
M_IX_-O\ X*Z_\$-_"G_!0O7(OCK\(/&FC?"/]IFQT:UT35[SQ1::K>_#SXL:
M7I5M'9>'['QC-I O=6\(ZSH-LBVMEXST/0?$DUQH\$>AZKX:U)8=(U+0OXWO
MVBO^"0?_  42_9B?6[OQ_P#LS>/-?\*:)J)L)?'OPML6^)_A"X@-NES%K)NO
M!XU/5M'T.>.2.)=1\3Z/H*0WSKI=XEMJA%G7Z!?&_P#X.&_^"L/@_P"(WQ$^
M&^O:E\%_A5XO\!>,_$_@7Q/X?\+?";3M0B\-^)O"/B;4-(U[2[:7QQJOC2XF
M^P7]C<Z,7OKB]9K2V24L;]I+Z3^AW_@BU_P6!\&?MB_ ^Q^'/[2OQ?\ #&G_
M +7W@2[UV/Q5)XM?P9\/E^+7ANZU;5=8\/>+_!.DZ18^&O#,\NA^'I;?PYXI
MT+0+%;_3KGP^WB6^LH-.U^UE$49\09%@85*D<-CL'3<(QIQG4J5J-*2NI1J1
MA%*BM()R=3DYHJ,536F^(I<)<49I4HT98[+,QJJI*5:=.C1P^(KP:C*$J-2I
M-O$2NYM15!U.2;G)U7[W^=Y<6]Q:7$]I=P36MU:S2V]S;7$3PW%O<0NT<T$\
M,BK)%-#(K1RQ2*KQNK(ZA@0/N_\ 8J_X*4?M:_L'>,-&USX*?$S69?!5G?)/
MKWP9\5:CJ>M_";Q78O<7-Q>V.H>$WO8H-*N;J2]O)EU_PU)HWB"UNIWN(=2Q
M)/%-_H]?ME_#']@+7_A[XBU_]N#P=^SO)X-ETR[N]1\4_%W3_"NFZZ(= TR=
M7G\,>*KA;/QI#K^FZ9<SVFF-X.U*/Q)''?'3])S)?BWG_P KCQPWA-O&OC!O
M 4>HP^!F\4>(&\%PZO/]IU:+PF=6NSX=CU2Y^SVGVC48]'^QK>S_ &6V\VY$
MLGV>'=Y:^SEF9T,_H5X5L#*%."BIQJ\M:A4Y^;2$W&-YQY6VN1.-XM.[T^;S
MO),3PIBL+5P^:1J5:CJ2ISH<V'Q-+V;@[U*:G42A/G25ZC4[2BXM+7_5Z_8J
M_:P\#?MN_LR_"S]ICX?6-YHNB_$72+Q]0\,:E<PWFI^$?%6@:M?^'/%OA:^N
M88K<7?\ 8_B'2M0@T[5&LM/_ +=T8Z9K\-A9VVJ00)_EG_M/_P!J_P##2W[0
M_P#;O_(;_P"%Y_%K^V/^/;_D*_\ "?>(/[0_X\_]$_X^_._X]?\ 1O\ GA^Z
MVU_>I_P;3>&?%'A[_@F?IEYXCL=4LK'Q9\</BAXF\(?VE;:C;1W?A=[?PMH2
MWVE?;K>"&XTNX\0:%X@\NYTMKG3I;I;O%P;U;V&'^2C_ (+B?LWZS^SC_P %
M*/VC(;FUU,^&/C/XOO?V@/!FMWVGW=E;:W:_%N>7Q9XLCTZ:X>>"]M_#OQ#O
MO%WA@SV=U-$W]CI))#I\LK:=:>-P[&AA,ZS? TW[J<E1N[ODH5FG"[OS2BJB
M3=[OD;MH[?1<82Q.8<-\/9I5B^=QB\3RJT?:8K#PDJO*DE&,Y49.-ERQ]I&-
M]5?Q?]F#_@E=^WG^V9\-[CXN?LV? G_A9'P\M/$^J>#KCQ!_PL_X->#_ "_$
MFC6>EW^I:=_9/CWXA^%M<?[-::SILOVQ--:PF^T^7;W4LL-PD7T7_P 0_G_!
M7/\ Z-*_\SS^S+_\^>OT._X-P?\ @IC\*/V:]0^(/['_ ,??%.D?#WP5\6?&
M:_$OX9_$+Q)?:;HWA'2/B1-X?T;PQXD\->*]<NX(%TB/Q=H/AGPP^@:MK.K0
M:#9ZGX>FTG;;:CXDMWNO[/\ XJ_M&_ 7X'_#>3XO?%OXO_#WP%\-1HC^(K/Q
MAX@\4Z5;:5KFE?8X;^WD\+,ES+<>+KO4[>ZLQH>E^%X-7U77[F_TZRT2RO[W
M4;*WGO-<^SC+\?/"T\)AITY27U63H8B<JT))-).&(BIS4KPDHQ3YD]+--YY#
MPKP[FV54L=5S#&TZT(26.A'$X.G##U(-J3DJF%G*G3E'EG"4YM.$E>5[I?YV
M7_$/Y_P5S_Z-*_\ ,\_LR_\ SYZ_IS_X-X_V$_VNOV&] _:MT/\ :H^#O_"J
M_P#A8.L?!K5? EU_PL'X9>./^$C_ +!LOB99^*+?R/ASXO\ %O\ 9']A_P!H
M^'9/-UF:R_M/^V]FGQS?V;?,GY9ZS_P=9?M%P^-/%[>'_P!F[X*:E\.V\2^)
MSX!AUF7QUHGC2+P>^O7;^#5\7W%EXS\0:'<>);;PO]AMO$[Z+:VNEWVO"[OM
M*33].:'3U_IZ_P""7O[:?Q&_;]_9=TS]I#QY\%=)^"MAXC\6>*="\%66E>.;
MSQI#XQT+PKJ<NAZCXJC2[\)^&WT&UB\2VFM>%H[%KS7);N]\.:EJ+3V,%S:V
M2<F>8K/_ .SIT\PPN!I86O*E!SHRE[534XUH1C&6*F[MTWS+V<K14GI;F7H<
M,8'A19O3JY1C\TKXW#4Z]2-/$0C["5.5.6'J3G*&!II12K+D;JPO-P7O7Y7^
MBM%%%?#GZ<%%%% !1110 4444 %?$7_!2[_E';^W/_V:5^T%_P"JL\45]NU\
M1?\ !2[_ )1V_MS_ /9I7[07_JK/%%=."_WS"?\ 830_].P.3'_[CC?^P3$_
M^F9G\>O_  1C_P"30?CW_P!G(^ ?_58>*:_3^OS _P"",?\ R:#\>_\ LY'P
M#_ZK#Q37Z?U_.OCY_P G'S'_ + ,L_\ 49'^6OCE_P EI0_[$&5_^E8D****
M_&#\<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_3[]G'X9#P-
MX/76-2@V>(_%$<-Y=[P!)9:;M#V&G_=#*VUC=7 +-F655X\H"ODC]G3X9'QW
MXP35=1@W^'/#$D%]>[U8QWM_O#V&G9 VLK,C7-P-RD0Q!<'S17Z@].E?T7X)
M\(7]KQ=CJ6WM,)DT)QZZPQ>.C==-<+0DO^HJZ^!G]I_1<\-]:_B-FU#;V^7\
M,TZL.OO4<QS6-_+GR_"R7?'-K2E(****_HT_M4**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ K(UC_41?]=?_9&K7K(UC_41?]=?_9&IQW7JOS)G\+^7YH[W1_\
MD%6'_7K#_P"@BM*LW1_^058?]>L/_H(K2K@G\<O\4OS9T0^"/^&/Y(****DH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *X34?^1NTW_K[TK_ -*(Z[NN$U'_ )&[3?\
MK[TK_P!*(ZVH?%/_ *]S_(SJ_"O\4?S/<Z***X30**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O,OA7_ ,C=JW_8*O\ _P!.>G5Z;7F7PK_Y&[5O^P5?_P#ISTZM
MH_[OB_\ KW'\V93^.EZR_0^A:***\DU"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#B_B'_R)NM?]<[3_ -.%I5OX(?\ (FS?]AN^_P#2:QJI\0_^1-UK_KG:?^G"
MTJW\$/\ D39O^PW??^DUC78_^194_P"PI?\ I$!1_C1_P2_-'L-%%%>6=(44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)26&IUX5%B:E:#;JRIN/)[+#UDTE!WYG'I9/6WYD_P#!J!_R0?\ :X_[*YX
M_P#4-U&OZR*^3?V3_P!AO]EK]A[0?%WAC]EWX7_\*PT/QWJ^GZ]XJL?^$V^(
MGC7^U=5TNSDT^PNOM/Q#\6^+;RQ\BSFDA\C3;BSMI=WF30R2A7'UE7D9MBZ>
M/S#$XNC&<:=:4'&-114THTH0?,HRG%:Q;5I/2W70^AR'+ZV5Y1@L!B)4IUL-
M"I&<J,IRI-RK5*BY)3A3DURS2=X1UONK-E?YTO\ P7J_X)H?\,2?M$_\+?\
MA=H?V+]FS]H75]3U;PQ!;W/VF'P#\22C:KXQ\ 21&..2QTBY>:;Q'X(C<R1?
MV)-?Z);2R'PO<2-_HM5XG^T+^SE\$_VK/A;KGP6_:!\ :7\2?AIXBN--O-2\
M.ZE=ZOI4BW^CWL6H:9J6E:[X<U'1O$>@:I:7$6V/4]!U?3;\VLUW8/<-8WU[
M;3[9+FL\JQ:K6E.A47)B*46KSANI13:BZE-OFA=JZ<H<T5-M<W$F14\^R^6'
MO"GBJ3=7!UYWY:=6UI0FXQE)4:L?=J<JDTU"HHRE3C%_Y)'@SQAXG^'GC#PI
MX_\ !.M7WAKQGX&\2Z%XP\(^(],D$6I:!XG\,ZI:ZUH&M:?*RNL=]I6JV5I?
M6DC(X2>"-BK 8/\ HV_ W_@L1\/_ (D_\$I?B%^WSJUK:6/CGX(>#;SPQ\3O
M!,WEW5NGQZMX-$\/^%M/2TL+O3[B/PI\2?%_B?PE>Z,XGL9++2O$4NGM=?;=
M&O)EZ3_B'\_X)&?]&E?^9Y_::_\ GSUVVC_\$0_^"8N@>!O&OPST;]G#4].\
M!?$;4_!^M>./"UO\?OVEUTKQ+JO@!]>D\&7^IQ-\8V>2X\.OXH\0G3722/RO
M[7O P<28'NYMG>2YK'#^TH8^,Z%:$N;V6'O*@YQ]O1;6*TYX*\7KRS2V3E?Y
M?(.&N)<BEB_8XK*YT\5AJM/V;Q&+Y88E4Y?5<0D\#9NG4:4XW7/2E):RC"W^
M9)K&KZEX@U?5=>UF\FU'6-;U&^U?5=0N"IGOM2U*YEO+Z\G*JJF:YNII9I"J
MJI=V(4#BO[(_^#4[]FB2WT_]I7]L#6;&XB_M&32?V>/A_>F2T2&>TM7TCXA_
M%,-;LKZA+&UY_P *IBL;V,VNG&>RUJTSJ5Y;RKI'[!?\0_G_  2,_P"C2O\
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MC+JN"Q$/9XJC2K8IS?+>5*K34\'"+J4Y-JTIQ3ISJ*Z;BU_.;_P=L_\ ./\
M_P"[J_\ WVZOXVZ_U?\ ]K;_ ()^_LB_MT_\*_\ ^&J/A)_PM+_A5O\ PE?_
M  @G_%>?$WP1_87_  F__"-_\)1_R3GQGX1_M/\ M/\ X1#P[_R&?[0^Q?V?
M_P 2_P"R?:[[[3\;?\0_G_!(S_HTK_S//[37_P ^>NC)^)L!E^78?!UJ.+E5
MH^VYI4J=&5-^TKU:L>5SQ$).T9I.\5[R:5U9ODXBX*S7-\XQF88;$9?"CB/J
M_)&O5Q,:J]EA:%"7-&GA*L%>=*3C:<KQ:;L[I?LE1117PY^GA1110 5_*1_P
M<(_\$B_&/Q^GN?VY/V:O#D.O_$CPQX3L].^.OPVT/3';Q3\1/#GA>V-OI/Q#
M\/"V9Y/$7B_PEX<@M/#^J:!]F?5=9\'Z+HT>ARW%_P"'K;1=6_JWHKMR_'U\
MMQ4,5AVN:-XRA+X*E.5N>G-+[,K)IK6,E&2UBCS<VRO"YQ@JN!Q:?).TH3CI
M.C5C?V=6FWIS1NTT[J47*$DXR9_C>W%O<6EQ/:7<$UK=6LTMO<VUQ$\-Q;W$
M+M'-!/#(JR130R*T<L4BJ\;JR.H8$#Z,OOVR_P!K_5/!$OPSU/\ :L_:3U'X
M<3VB:?/\/[[XY_$^[\$36$5VE_'92^%+CQ1)H,EI'?1QWB6SV!A2[1+A4$RJ
MX_T?/VL?^"//_!/W]LKQ)-X[^+'P.L-'^)%[</<ZM\1OA?J=]\-_%7B.:>8S
MW=SXO_X1UX-"\9ZG=MY<<GB#Q9H>L^)(;:&*TLM8M;13"WYX0?\ !K9_P3OB
MU-K^3XD_M;W5J9KB4:+/\1OA2NF*DPE$=NLMM\#K?6##:&1&MV;5FN&,,7VN
M>Z4S+-][3XLRFM"$L31K4ZD+2Y)485E&?>G-2Z-*TG&F_)'Y35X"S_#5:D,'
MB</5HU/=]I#$5,-*=/M6I.-EN[P4ZL=[-MV/X"]/T^_U:_L=*TJQO-3U34[R
MVT_3=-T^VFO;_4+^]F2VL[&QL[9)+B[O+NXDC@MK:".2:>:1(HD=W53_ 'O?
M\$$/^"0&O?L@:+<?M9?M+>'[2Q_:(^(?AA-+^'O@'4['S=9^!O@;65$^KW&M
M-<.\.F?$[QO:BRL]5LK:UBU?P/X7CO?"UYJ:7_BSQIX=TW]6OV1/^"6W[#7[
M$%\/$7P$^!NA:=\0#"(7^*GC&[U'Q]\28E:SU+3KH:'XG\5W.I2^"H=3TS5K
MS3M<L? -OX5TW7[,P1ZW9:@UM Z?H+7AYWQ.\?2EA,'3G1P\]*M2HTJM6*=_
M9J,7)4Z;:][WY2FO=?+'FC+Z?AK@B.5XB&/S*K2Q&+I:X>C14G0H3Z593G&$
MJM6*?N+V<84I7G%U)J$X%%%%?(GZ"%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^3_ /P7#^'/Q"^+
M/_!+K]I[X?\ PK\">,OB9X]U_P#X4K_8/@CX?^%];\9^+];_ +*_:'^$NMZI
M_9'AKPY8ZEK.I?V;HVFZCJ]_]CLIOL>F6%[?W'EVMK/+'^L%%;X:N\-B</B8
MQ4I8>O2KJ+;2DZ52-11;6J3<;-K5)G-C<-'&X/%X.<G".+PU?#2G%)RA&O2G
M2<HIZ-Q4VTGHVM3_ "@/^'='_!0?_HQ/]LG_ ,1A^-O_ ,P]?Z?'[(FB:SX:
M_9/_ &8?#GB/2-3T#Q#H'[/'P5T37M!UNPNM*UG1-9TKX;>&K'5-(U?2[^*"
M^TW4]-OH)[._L+R"&ZL[J&6WN(HYHW1?H>BO6S?/:N;TZ,*E"G15&<YIPE*7
M,YQ46GS;6M?3N?/\/\+8?A^KB:M'%5L0\33A3DJL(045"3E=<FK;;Z] HHHK
MPCZD*^)/^"AG[%'@O]O[]EGQY^SOXMN;'1=4U5K+Q+\./&UWI?\ :\OP^^).
M@"X/A[Q7:6BW%I.RM:WFJ^'-;CM;JVN;SPMXAU_38IH_MQ-?;=%:4:M2A5IU
MJ4G"K2G&I3FK7C*+33L[IZK5---:---HQQ%"CBJ%7#8B"JT*].=*K3E>TX33
MC)7336CT::E%V<6FDS_*-_:H_P""=W[9/[&GB76M!^._P)\<:#H^DRW'V;XD
M:)HU_P"*/A/K^GQ.WDZKH?Q&T2VNO#4D-Q:^1?2Z5J-YIOB71H+NV@\2Z%HF
MHM)8Q_/WPF^!?QF^//BC2_!?P6^%GC[XI>*=9O'L=/T;P+X5UGQ)=23PQQSW
M;SG3+2XAL;33K65+[5=0OI;:PTG3M^HZE<VMC')<+_KYT5]E#C6NJ2C/ 4IU
MK6]I&O*%-RMO[)TYRM?5I5?)-'YS4\-<+*NY4LTKT\/S7]C/#0J55&^L575:
MG&]M%)X=V>KB]C_/S^)?_!N[^TC\'/V _%?QX\4:)XG\>_M8P^-_AU=:3^SM
M\%[&;XEW_AWX:ZO<2Z!XIL-4M_">GZS=^-_'L&M^(-%U74HO 4FJ>&_"?ASP
MMJVIQZYXEL-1O[OP_P#'?["W[-7_  4#_95_;"_9T_:"NOV#_P!L.31_AG\4
M_#.L>*8YOV6/CK=E_!-[=?V)XZ6UAM? DMS_ &B?!VJ:X-+EAM[N2WU+[)<+
M97IB^R3?Z:%%<D.+,:Z->EB:%'$JNZBDVY4U"E4@H.E",;VC%*5FVY-RO)MJ
M[]&IP#EL<1A<1@L5B<'+"*BXI*%9SKT:KJK$3E/E?/)\JDHJ,%RKDC&-HKY/
M_;T\.>(?&'[#/[9_A'PCH.L^*?%?BG]D_P#:*\.>&/#'AS2[[6_$/B/Q#K?P
M@\8Z9HN@Z#HNF076I:OK.KZE=6VGZ7I>GVUQ?:A?7$%I:033S1QM_F8?\.Z/
M^"@__1B?[9/_ (C#\;?_ )AZ_P!7^BN+*,^K912K4J>'IUE6J1J-SE*+3C'E
MLN7I;OU/2X@X6P_$%;#UJV*K8=X>G.G&-*$)*2G-3;;GLU:VGJ?"_P#P3)\(
M^*_ 7_!/O]D#P7XZ\,>(?!?C'PS\!_ 6C^)/"?BS1=2\.>)?#^K6>DQ1W>EZ
MWH6L6UGJFDZC:R QW-C?VMO<P."DL2L,5]T445XM:HZU:K6:475J3J-+5)SD
MY-*^MDW9'T>&HK#8>AAXR<HT*-*BI-).2I0C!2:6B;4;M+2Y_*!_P<_?LZ?M
M!_'[_AA__A1'P)^,OQK_ .$3_P"&EO\ A*O^%2?##QM\2/\ A&?[>_X4!_8?
M_"0?\(=H>L_V-_;/]C:Q_97]H_9O[1_LK4OL?G?8;KROQG_X(_?L1_MG_#/_
M (*3_LH^.OB1^R)^T_\ #[P1X=\<:Y=^(/&7C?X!?%;PIX5T*TF\ ^+K.*YU
MGQ#KWA.PTC2[>6\N;:UCFO;R"-[FX@@5C++&K?Z*]%>]AN(J^%RS^S(X:E*'
MLL12]K*4U.V(E5DWRK2\?:M+O97ZW^6QO"&&QN=K.YXRO"JL1@\1["-.FZ=\
M'"A",>9^]::H)R>Z<G;;4K_/X_X+5_\ !(?XX_#O]L[Q/X^_9+_9R^+_ ,4_
M@[\>8;SXGKIWP9^%_CCXBV'PZ\>:GJ,__"?^%;^#P=H.KQ^&].O]<E/BOPMI
M\RV>FV^DZ^^@:!"EEX:DM[7_ $!Z*X,JS2OE.(E7HQC44X.G4I3;4)JZ<6[;
M2A)7B[.R<EM)GJ9[D6%S["0PV(E*E*E556C7IQBZE-_#.*YM'"I!VE&]KJ$M
M7!'\2O\ P;XW7[>7['/[0^M? [XP?L<_M9>'/V=_VAO(74?$GB;]GOXK^'O#
MWPQ^*.AVS_\ ".^-]6U[7_#.G:/H_AC6]&2_\*>+9)Y(Y);E_!VJ-=PVOAVX
MM+_]6O\ @Y-^"WQC^.O[#/PI\(_!'X3?$OXQ^*]._:P\#>(]0\,?"OP)XI^(
M7B&Q\/6GP@^.NF7>O7FB^$=*U?4K71K74M7TG3[C5)[9+&&^U33K22=9[VVC
ME_H0HK>MG,JN:4<U6%I4ZM-PE.G&<N2K."<5*3:NFX\L7;=176[?+A^'(T,C
MQ&12QU>MAZRG&G5G""J4*=249RIP2]V4544IQYM5SR5[**7^7Q^RS^P!^WAX
M>_:=_9RU_7_V)_VN-#T+0_CQ\(=8UK6M8_9N^,FF:3H^DZ9\0?#U[J6J:IJ5
M[X,@L]/T[3[.":[OKZ[FAMK2VAEGGECBC=Q_J#T45.;YQ5S>="=2C3HNA&<4
MH2E+FYW%MOFVLXZ6[FG#_#U'A^EB:5'$U<0L3.G4DZL(0<73C*-ER;I\U]=C
M_. _X*I_L-_MK_$/_@HE^USXV\ ?L??M2>.?!GB7XOZWJ?ASQ=X/_9^^+/B;
MPQK^FRVM@L6H:+K^B^$KW2M5L961UCN[&[G@=D8+(2IQ_0A_P;,? /XZ? 7X
M+?M0Z5\<_@M\6?@QJGB#XH^"-0T'3?BQ\.?&'PZO];L+3PG?VUU?:19^,-&T
M>XU*SMKAT@N+FSCFAAF=8I'5V"G^F^BNG%\0UL7EL<MEAZ4(1IT*?M(SFYVH
M.FT[/2\N37M?38XLOX1PV7YS/.(8RO4JSJ8JHZ,J=-03Q2J*2YE[UH>T=N]E
M?J%?YU'_  6!_8C_ &S_ (F?\%)_VKO'7PW_ &1/VG_B#X(\1>.-#N_#_C+P
M1\ OBMXK\*Z[:0^ ?"-G+<Z-XAT'PG?Z1JEO%>6US:R365Y/&ES;SP,PEBD5
M?]%>BN/*<UJ93B*E>G2A6=2BZ+C.4HI)SA.Z<=;^Y;MK<]'/\BI9_A:.%K5Z
MF'C1Q$<0ITHQE)RC3J4^5J6B5JC=][I=+G\H'_!L%^SI^T'\ ?\ AN#_ (7O
M\"?C+\%/^$L_X9I_X17_ (6W\,/&WPW_ .$F_L'_ (7_ /VY_P (_P#\)CH>
MC?VS_8W]LZ/_ &K_ &=]I_L[^U=-^V>3]NM?-_>S]O;]ACX0_P#!07]GWQ!\
M"?BQ'-I<TDRZ]\/OB!I=G;7?B/X:^.K*":+2O%&CQ7+11WUJT<\^F>(]!EN;
M2'Q#X>O=0TU;[2[Z2PUC3?M.BL\9F5?%9C+,H?[/7<J4X^S;:A*C2ITXM.6]
MU33:::=W%IHUR_)<+@<HIY-4;Q>%C"O3G[:*3JPQ%:K6DI*+LK.JU%Q:DN6,
MDU)7/\PC]KG_ ((S_M^_LAZ_XD'B'X&>+?B?\-=(U%X=)^+_ ,'])NO'_A+6
M-&<.]IKFIZ;X>74?%/@:%MAL[Z#QMHNB)::H%M;>[U"TO=(U'5/RZ_L^_P#M
M_P#97V&\_M3[9_9_]F_9IOM_V_SOLWV'['L^T?;/M'^C_9O+\[SOW6S?\M?[
M'E%?2T.-,1""CB,%2K5$DO:4ZTJ"=EO*#IUE=[OE<8WVBEHOC,5X;82I5<L)
MF=;#4FV_95L/'%.-W?EC4C6PSY5LN:,Y6MS2D[M_Y2O[.'_!-S]N3]K*\@B^
M!G[-?Q+\3Z1-?7&G2^-=7T;_ (0CX=V=Y90?:K^VN_B#XWE\/>#UO;&U*33Z
M7#K$VK,9[.VM[">\U"PMKK^_C_@D?_P2N\'_ /!-'X0Z[8ZOJN@_$+]H+XE7
MR7OQ.^)^E:?=6UE!H]D$70/AWX-.I)%J$'@_1)%N-6NKNYM;'5/$WB'4KK4=
M6ACL=/\ #.CZ!^N5%>5FO$>,S2G]7Y(8;#-J4J=-RE.HT[Q52H[<T8M)J,80
M5]9<S4;>[D/!V7Y)66+]I4QF,47&%:K&,*=%234I4:,>;DG--Q<YU*DE%N,'
M%.?,5_)-_P %;O\ @WCUSXT>//%_[37["A\/6GC?QCJ-WXD^(_[/>NZEIOA7
M1_$7B.] ?4O$/PI\17D=GX>T36-?U(MJFN^%_&>I:-X>FU"]U?6=-\5Z2OV3
MPS/_ %LT5YF S'%9;7]OA9J,FN6<)+FIU(7ORU(W5U=733C*+^&2NSV\URC
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MJ>&+O2[O5]9_BB^.W[(O[3_[,>JW.D?'[X#?%'X52V[PHNH^+/"&K6?AN_\
M/VB&31?%T5O/X5UZW>5OLXNM$UG4+87D<UDTHN[>>&/_ %OJ*WRSBC&8"C##
MU*4,70IJU-3G*G5A%6M!54IIPBOA4J<I13LI<JC%<F=<#9=FN(J8NA6J9?B:
MSYJSITXUJ%2;^*I*BY4W&I/>;A5C&3O-P<Y2E+_'4T+POXF\43FU\,^'==\1
M70FMK<VVA:1J&KSB>]=X[. PZ?;W$@FNY(Y([:,KOG='6)796 _<W]A+_@WX
M_;3_ &GO&>C:E\=O ?BK]EGX'6]Q!=>)/$WQ'TR#0OB1K-I;7FDMJ'AOP?\
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M[!,3_P"F9G\>O_!&/_DT'X]_]G(^ ?\ U6'BFOT_K\P/^",?_)H/Q[_[.1\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?+WAC_DM^I?]A7Q+_Z3
MWU?4-?+WAC_DM^I?]A7Q+_Z3WU?4-=^8?'A_^P2A_P"W'/AO@G_U\E^40HHH
MK@.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*TJS='_Y!5A_UZP_^@BM*N"?QR_Q2_-G1#X(_P"&/Y(****DH**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *X34?\ D;M-_P"OO2O_ $HCKNZX34?^1NTW_K[TK_THCK:A
M\4_^O<_R,ZOPK_%'\SW.BBBN$T"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS+X
M5_\ (W:M_P!@J_\ _3GIU>FUYE\*_P#D;M6_[!5__P"G/3JVC_N^+_Z]Q_-F
M4_CI>LOT/H6BBBO)-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XOXA_\B;K7_7.
MT_\ 3A:5;^"'_(FS?]AN^_\ 2:QJI\0_^1-UK_KG:?\ IPM*M_!#_D39O^PW
M??\ I-8UV/\ Y%E3_L*7_I$!1_C1_P $OS1[#1117EG2%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M')C_ /<<;_V"8G_TS,_CU_X(Q_\ )H/Q[_[.1\ _^JP\4U^G]?F!_P $8_\
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MZ=6T?]WQ?_7N/YLRG\=+UE^A]"T445Y)J%%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?I^BZ!>ZMI\WBZU=_#-C?:O,?$WABWU7PA+'"(8X+7Q!<W\_VZ*R;1]2CB7
MX:AG%&,'##TL7"E5K-*T*4IU9TZE7E2^%J'M&HJ[ESV5WKKP7F>,Q/#V(G5C
M4Q=;+ZM>AAU>]2O"GAZ5:C0YY/6:E4]E&4FE&#IINR;7\3?_  5:_P""U_QY
M_;@^)NJ_L\_LJ:SXV\"_LV_V_'X-T70O! N(/B)^T/KDE_)H]KJ6MW?AY9?$
M,GAGQ!=W0M/"?PRT>]:RUJ"XL=2\5V6KZ]+I.F^&.)^#G_!MY_P4N^+'@EO&
MFL^'?A)\$VN-)L-9T;PA\8_B!?Z=XVUNVU*RFO[>V71/ ?A7X@1>&=6CC2V@
MO]%\>WWA'5M*O;Z&QU2SL[JTU:+3?VF_X(W?\$*_C1^Q?^UGXC^/?[5MM\(O
M%<7@'P3?:9\$;OP/XKUOQ+;1>/\ Q'J3:7J/C:WL=3\.>&+FWDT;P79ZSIMA
M_P )!8)Y?_"<V]]9Z:-<TK[5H/\ 5K79C,^HY4J>!R.&&=&G"$JF):]HZM1V
M;U3BI2M;VDY\SO)PC&'(K^=EW"N(SUULTXHJ8R.)JU:D*."4E1C1HQ=EI*,W
M"'-?V5.GR+EBJDY574=O\M;XV_LT_M^_\$AOCCX4\2:^_C'X(>-UFGE^'?QB
M^&7B.ZE\'^-(+*/2K[6]*T;Q18+;V7B#3HUO+"S\7>"/$U@B7MI,+/Q#X=NM
M'OHQ=_WA?\$>_P#@I39_\%)?V;K_ ,6^)--T;PQ\<_A/K.G>"OC+X6T>\B>Q
MNKR^TF._\.?$;0],,\^H:/X4\?);ZW#IMAJ3-+8^(?"_B[1[6YU*QTBVU2]\
M]_X.#_#/P]\0?\$J_P!H'4/'=KIDNH>$-8^%7B;X<7U['#)J.D?$)_B;X7\-
M65UX>\R*>6/4]0\,^(_%/AV_DM8O.7PMKGB(22VMFUU=P?@9_P &I%YK*?M.
M_M0Z? /^*>NO@/H-YJC><RXUFQ^(.DP:"/LXN%67-CJ/B,^<;29H-NQ;BU%P
M\=W>+JPSSA^MF->C3I8W U?9JK37*JB3HN2U;?)*%9>Y*4N6K&\6E)Q>6 H5
M.%^+,/D^%Q-6OEN:4?;.A5:E*DY+$*$G:*7M(3P[_>1C#GHRY9W<%)?W.444
M5\,?J 5X!^U9\8K?]GO]F;X_?'&XFF@/PI^$'Q!\<V36]@FJ7#ZMX>\,:E?Z
M+;P:?,\5M=S7>KQ6-K%#>SVM@SS*=0N[2R$]S%[_ %^&G_!Q3\6W^%__  2]
M^*>C6NHIINI?&7QS\,_A)I\FTM<7:7OB-?'>NZ=:MYT:QO?^%/ /B"VNF>*[
M#::]]$D,<LL=Y:]> H?6L;A,.U=5L11IRZ^Y*<5-^BA=OR1P9KBOJ.68_%IV
MEA\)B*L-;7J1IR=-7[RGRI>;/XM/^".7P9/QT_X*6_LD>$9]%N=;T?0?BA8_
M%#Q!#%:I=6-OI/PDL;WXCB?6_/9+./1KC4_#6FZ9=I>/Y-^^HP:3%#>WFHVM
MA=?ZBU?P??\ !J[\'QXI_:]^._QGO+%KNP^$?P-B\,6,[6;O!IGBOXK^+=-&
MFWRZ@MY$MK?2>%_ ?C?3;>RDLKM+^SU'4IQ-:2:;&MU_>#7O\7XCVN:1HIZ8
M;#TXM=IU&ZLGOUA*GT6WH?)^'N%]CDD\0U[V,QE6:?>G14*$5Z*I"M\VPHK\
M/_V9O^"^G['W[6O[3?@S]E3X/?#3]I._\>^/-?\ %&B:!XCUCPO\(],\ RVO
M@_0/$/BK7/$LVL1_&R\UD:!%X;\,:MK-J;;P[<ZS?6\<%M::-+J-S%9-Z3^W
MG_P6N_8N_8'U^Y^'7C'7-?\ BS\9H-,O+NZ^%OP@70-?U'PK?B-#I&F_$G7-
M0UW2]'\"W&JO+'=-IEQ+JGBRRT/;KS>%+BRO]"&L>*\JS%8B&%>$K?6*E-58
MTN6\O9MN/M'9VC#F3CS2<4FFF[GTJSW*'A:F-688;ZI2J^PG7Y[0]LHQG[*+
M:3G4Y91ER04I6:=K'Z[T5_('X=_X.S?!5SXA6V\6?L/^*-$\*&:97UKP[\?-
M)\4>(5@64""1?#&I?";PAIK3209DF@/BY$@E A2XN$)G']/O[,?[3_P3_;!^
M#WAOXY_ +QG9^-/ 7B/SK8S(CV>L^'==LEB_M;PIXLT2?%]X?\3Z,\\/V[2[
MU!YMK<V.KZ;-?Z'JFE:G?/&93F&7QC/%X:=*$WRQGS4ZD.:U^5RI3G&,FKM*
M33=G9.SLLNS[*,VG.GE^-IXBI3CS2IN%:C4Y;I.<85Z=*<XIM*4H*48MQ4FN
M97]_K_/X_P"#GOXU/X^_;Z\+?":TN87TKX#?!7PMI-W9Q7L%W);^,/B'=W_C
MW6+BX@@D9],FN_"FH^ 8UL+N..[>WLX-3W/9:E8[?] >O\NW]NO7-4_;4_X*
MQ_'2Q\.7UUJ=U\7OVLQ\%? ^I6N_Q!<:AI.F^+]+^"7@"^TVUD31)+N&[T/1
M-#N-)T622T>WMI+71VOW: W\GM\(45+,*V(G;DPN%G+F>T9U)1BGY?NU5^5S
MYGQ"Q$HY3AL'3NZF.QU*'(MYTZ,93:_\'.@?WT_\$??@R?@1_P $UOV1_!%S
MHMSH6KZC\+;'XC>(;'4+5+35EUWXL:CJ'Q+OEU>+<]PE]:CQ3%IXM[\I?Z?9
MV5II=U;V4EC]AMOTIK\K_P!M_P#X*H_L6_\ !,70?#'P\^(&IZSK?CR#PMI4
M?@?X#?"S38-=\86OA&P@_L;1-1UBYU;4M*\.>$?#<(LHK2VN/$GB&WUK5;6W
MO+GPUHOB1M,U&.W_ !.L_P#@[/\ "3Z]=6]_^PUXCMO#"7<Z66L6?[06F7VO
M7%@MZJ6US=>')O@]I^GV=W+IY>ZGLHO%5]#;WJK81ZA<P.=13S8Y5FN:3K8Z
MA@ZDX8BK5K*<I4Z2E[2<I-P]M4@YI-M7AS*Z:OHSV)9[D.1T\-EF)S&C3JX3
M#T,.Z<(5J\H*C2A!*I]7I5%3DTD[5.25FG:S/[ :*^5OV/OVSO@#^W/\(;+X
MT?L]^+&\0>&Y+ZXT?7=%U6WBTOQCX*\0VH#W'AWQGX>6YNY-&U00/#>VI6XN
MM/U33;FUU32+^_TZYAN7^J:\BI3J4:DZ56$J=2G)QG":<91DMTT]4SZ&C6I8
MBE3KT*D*M&K%3IU*<E*$X25U*,E=-/\ X&Y_/-_P6[_X)9?M=?\ !2WQ=\!(
MO@GX_P#@/X3^&_P>\.>-'N]-^*?BKX@Z#K.H>-_'&IZ*NIWUO9^#_A9XXL;O
M3+30?"F@06%S?:I!=P75SK,4&GV\,TEQ????_!*3]B37O^"?_P"QAX%_9]\:
MZKX5U_XD0>(_''C/XCZ[X'N]5OO"6J^)/$_B.[?3GT.[UW0O#6LSV^G^"['P
MGHMQ+J.CV<TM_IEW+%&MJ]NB?&'QE_X.)OV*/@O^T'\0/V:]1^%_[4GC;X@_
M#OXEZM\)-2NO '@KX3:EX<UCQMHNN-X:U#3M O->^-WAO5+E8?$$<VD;M0T;
M3)?MD$J-"J!7;][:];&5LTHY=A,!BJ7L,&Y.OATX*,JEKS<G)-N2O7YFFE[T
MEUC9>!E^'R3$9OC\UP-?ZSF"BL-BY*K*<*-U"$81@XJ,)6PO(G%OW8S5[2/X
MP?\ @Z^^-3S>(OV2OV=;*YA6/3M%\>?&KQ-9K>P27$SZU?67@;P/<RZ<DGVJ
MSAM5T'XA107MS$8-2>[N(+*19-*U!6_5K_@W$^"\/PM_X)E>!/%\VDQ:;KGQ
MX^(7Q(^*6IRRVE_;:K=6%GX@D^&WAM[XZ@ QL[C0_ -KK&AKIPCT>;2M9@U6
MUC>[U74;N[_E9_X.'?C /BM_P5$^,&E6M\VH:1\&O"?PV^#^D7'VQ[J",Z5X
M7MO&?B6QM8)+.U;35TSQQXY\5:;=68DO4DU*TOM1CO#'?K;VW]*FN_\ !6[]
MBO\ X)*_LT_LZ_LD:PWB?XN_'SX1_ _X9^$O'?PN^%6F:?$W@_QK9>$-+?Q7
M+\2_$>N:V/#WA#6]7\3_ -NW^J>$](U+QAXMT'4;M(]6\/V&F7EAJ$WT&,PN
M(?#V3Y=A:-2K6Q36*G"FKOD<95I.H]%&,9XBBFYM)-1C=.R/DLOQ^#7%W$.;
MX[$4J.&P4'@J=2K))*JIT\-!4DKRG*5/"8AJ-.,G)2G))J[/Z-J*_D7^'7_!
MV+\-=7\3Z98?%3]C+QAX$\)7-];0:IXC\%?&K2?B5K&F6,HF%Q?1>&-7^&7P
MT@U!K606Q^R)XBMGGMY+F2.03VT-K>_TW?LU_M-_!#]KOX2Z#\;?V?O'6G>/
MOA]KTMW8IJ%I%=6.I:-K6G&-=4\.>)M"U*&UU?P[XATTS027.E:M9VUQ)97>
MGZM9BZT?5-,U"\^6QF59AEZC+%X6=*$G93YH5*?-NHNI2G."DTFU%R3:3:6C
M/N<NS[*,VE.&7XVGB*D$Y2I.-6C5Y4TG-4J].E4E!-I.<8N*;2;3:/>J_"7_
M (+?_P#!-#]I7_@I1X9_9V\)? /QG\%?"6C_  OUWXD^(O'"?%W6_&NAW&HZ
MEX@T_P &:9X.;PU/X.^'OCQIH;*ULO&(UR+4!I0#WFBO:F]*W M/W:K\)?VJ
M/^#A7]B3]DG]H#XE?LY^.O ?[2/C#QC\*]6L-#\2:]\./!WPPU7P;/JUWH6E
M:W=V.E7_ (G^,7A'6[B;1)-5.B:O]K\/V*1ZWIVHPV3WUC';:A=UE4<>L9"M
MEU%UL1AXRJ*/(IJ,9+V3E*+:6GM++6Z;36Q.>RRIY?4P^<8B.&P>*G3I.3J.
MG*<X35>,(RBG)7=&\K*W*FFU<]^_X(X_L#_$'_@G3^R7JOP/^*FN^!?$?CWQ
M'\8?&/Q0U[5/AQK7B37?"LO]NZ#X-\+Z7'9W7BKPIX,U2&XAT7P9IT=[:_V*
M+9;D//#=3F>39\]?\%Y_^"E'Q>_X)\? WX5Z=\ )_#6C?%SX\>)?%>D:1XQU
M[3[/Q!>>"_#7@;3M%O/$6M^'/"NKV%[X<U?66O\ Q/X;T^.[\2P:GH^F07<P
ME\/:M<7UM<Z5^@/[9G[?'PD_84_9TT']I7XW^$/BL_A;7]?\'^%X?!WA+P_X
M9U'XAZ?K_C+2=1UFUTO5M*UOQCX=\/6=QH]KI.HQZX1XHECMKJU>WLI-0=XC
M)_"!_P %LO\ @IG\.?\ @I3\9?@YXG^#.D?%GPU\+_A7\,M0T&'P[\6+/PSH
M]_%X]\2^*M1U#Q9K6D:)X2\7^-])AL]4\/:7X"L;C59-:AU'49M$6TN-+MK;
M2+*[U#V,GP.)S;-(X_&4/:X6=6M/$3<5[&=2$'RT^6[37M'3]VSBXIQU5T?.
M\19I@\AR*>59=BW0QT,/AZ6$IQF_K-.A.I'GJ\UDXR=%5;3O&:DU*-I)-?TG
M_P#!L_H_CCQ?^S9^TC^U)\4_&GBKQ]\2OV@OVA&T[7?$_C#5=7U[6]:TSX7>
M#-#M-,U.^UK6)YKB_N&U3Q?XCTM1$TMO9V&CZ?8Q7 6W^P:?_2A7\='_  2/
M_P""V_[&W[.7[,_[+7[$'_"GOVG/$7Q?F\0OX.O;SP'\//AKJGA[Q+\1?BQ\
M4=7O[)].GN_C-9^+-:#WOBO3=)BD?PTFJ316<-GINCK##8Z>G]B]>?G]'$0S
M+$U:]"5&%:K-8?F22G0H\M*FX);15.,+*RLFET9Z_"F)P=7)L'0PV)AB*N'P
M])XSE<I2IXK$J6(K1J2EO-U9U.9W=VFW:]@HK\@_VXO^"V_[#_[#FLZSX!\3
M>+M3^+'QFT&XAM=7^$WPGMH-;U?0+EKJPCNK3Q5XDO)[+PAX:U.SLKN:_DT.
M_P!:.NJ+-[>?3+>2XMVD_&Z__P"#M+08]:E@TS]A'5[SPZ+R-(-4O_VD++3M
M:DL"R"6YET&W^!VJ6,-XBF0QV*>))X9&5%;4(A(S1YX;(\VQ=-5:&"J2IR5X
MRG*G14EHU*'MITW.+35I133Z-V9MC.*,AP%5T,5F5&-6+<9PI0K8EPDM'&I]
M6I5E"2>CC-QDGND?V&T5^)7[!'_!>/\ 8T_;B\2:+\+;J37_ -G[XZ:]<6NG
MZ#\._B=+I\VA>-M7O)KQ(=)^'?Q$TM_[%UO4]D6GP1:+XHL/ _B36=5U6'3?
M"FA>(S;W5S'^VM<.)PF)P=5T<51G1J)7Y9JW,OYHR5XSC?3F@Y1NFKW3/2P6
M/P68T%B,#B:6)HMV<J<KN,K)\E2#M.G-)IN%2,9I--JS045@^*?$>F^#_#'B
M/Q;K+M'I'A;0=7\1ZK(C0(Z:;HFGW&IWSHUU/:VJLMK:RLK7-S;P*0#-/%&&
MD7\A_P!A_P#X+B?LI_M]_&34/@K\'?AM^T7X9US1? /B7XE^(?%'Q.\*_"_0
M?!'AWPCX5N-(LM2U+6]7\._&#Q;J%C$VH:[I&GV\S:.]I]JOH%NKFUB)E!2P
MF)KTJU:E1G4I8=*5:<;<M-.[3DVUORNR5V[#KX_!X:OAL-7Q%.E7Q<I1PU*3
M?/6E%Q4E!)/9SC>]EK?9.W[+45_,Q^UE_P '.W[*_P $_&^I>!_V>OAAK_[5
MAT1UM-2\<:?XQ'PL^'-QJ<-W<6VI67AS7=5\%^+=<\26]AY ,6O67A>/PWK1
MD2?P_K&J:5)#JDWZ#_\ !+#_ (*BQ?\ !3GPE\2?%VF_L]>*_@QIGPUO_#NA
M:AJ^I^./#_C?PWK'BG6+6_U'4?#VC7]MIGA;7Y+C1-,31M0FO+OPI:V5S#K4
M<9FM;BW2&ZZJV49EA\+]<KX6=+#^[>=25.,ESM1C>DYJLFW)*SIWZO1.W#A^
M(<FQ>-_L[#8ZG7Q?OVITJ=:<'[.+E-QKQI/#R45%MM56M+)W:/U@HHHKS3V0
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH X7XB?%'X9_"#PW+XR^+/Q$\"_"_PA!<):3^
M*OB)XNT#P3X;ANI(;BYCMI=<\2ZAIFF1W$EO:74Z0O=+(\-M<2JI2&1E_E2_
MX*%?\'-7@K0-,UOX:_\ !/O2;CQ9XO:X^Q3?M!>._#QM?!6D012RI=7'@+P-
MK<<>K>*+^4+$++5_&.GZ-HMH2\H\/>(H)(G3[E_X+B?\$\_VI_\ @I!JG[+'
MPI^ ]MX)\.^ O >H?$_QA\3OB3\2/$-II/AS2M5UFS\)Z9X.TO2]/T)/$?C_
M %74UL=,\7F]@M?!J:"TVK>&Q-X@A"ZI)I'C7[&__!LI^RY\%[^P\7_M1>-M
M3_:A\3P6]E<1^#8])N?A]\*--U&2POHM3MKW3K+7-3\3>-+>UN[NUDTJ]OM9
M\-VMP^E1W6H^&?*OY=+M?I,MIY%AL/3QN95I8G$2YI0R^G'G2Y*DHQ]JE:+<
ME%34*M2G#DE:49W/C,YK<4XW&5LMR?#0P6$AR0J9M6ER.?M*4*D_8<R<U&#G
M*DYT*5:?/%N-2FXL_A4^(GCGXA?%#Q?K'Q(^*7BGQ5XY\;^-KAM:UKQGXTU3
M4M<U_P 2S*S:8+^ZUG5I;B[U".W_ +..EP/Y\D%I'IXTZ 1162P1?Z3?_!";
MX0_\*>_X)<?LPV5UIMQIVM_$'1/$WQ>UR2YAU6UDU/\ X61XPUSQ!X5U);/5
M9&^SV\OP]E\'6]I-IT-MI6K6EK#KMG'/_:LE[=_P]?\ !6WQ''\9/^"HG[17
MACP5H>AZ#I/A;XG>'OV</ 7A;PWI]I8Z#H>G_!W1O#WP4TG1M+TS0H)H[2TC
MO_"\K1Z996SMIOG'2K.QM8;.WTVV_P!,#X6> =-^%/PP^''PNT:XFN](^&W@
M/PAX!TJZN%*SW.F^#O#VG>';&XG5I9V6::UTZ*256FF(=F!ED(WGV>*\5SY;
ME=-0]C]9:Q+I)W5.-.C%*G=))J#Q"6B2;C=)65OG. \![/.L[K.J\0L$I8)8
MB2LZTZV)DW62E*4DYK"2D[RE)*I:4G=W[ROQ;_X.!OBQ!\+?^"6GQ\M59DUC
MXJ:E\._A/H),5G-;F?Q#XWT;6?$"W275Y:RJK^!_#?BQ+66PBO[R#4FL9S9K
M9QW=[9_M)7\A_P#P=??&9[+X=_LE?L]66JQ-'XD\:>._C-XET1;.W>>%_!6A
MV7@CP1JLNH2*+JVBN1X_^(-I!9VC/;WSVMQ/J"QR:?IAE^8R*A]8S? 4[74:
M\:TNW+03K._D_9V[-M+J?;\48KZGP_FE6]G+"RP\;6OS8J4<,FM5K'VO-IJD
MFUL?RI?"SX,3^+_V5/VL/C4MA#/;?!CQ#^SIH,M^UK:W5QI\_P 6/$?CRSMU
MB9XS>:?#>1^#KJ.?4K>9+8/%;Z7=PS2ZM926_P#;!_P:_?$7_A*_^">GB_P5
M<28N_A9^T7X[T2V@WWDN-!\2^%_ OC2RN]TZ?9(/M&MZYXFMOL=E*WE_8?MM
MS%%+J DG_$K]E7]G&.__ .#<K_@H+\45LXY_%/C3XX^!?$>E22W\$-I;^$/@
M;XQ^#[2WFR"VANCJBPZ_\6+;[!J5Y?V-Q')I$VGV5A?2RW=Q]V?\&F_Q%^T>
M&/VS_A-<2;/[)U[X._$72(M]X_VG_A(-/\=^&O$<GE[#I]K]B_X1GPLN_P R
M.\O_ +?MV30:=N@^QSZJL9E>;M:K YE1A%=5RTL)3F_/WZU5>2OVN?G?"M!Y
M=GN0IZ/-,FQ%63Z2<ZV.K05^_LL-0TUU:[I']@U%%?F!_P %<_V\[?\ X)_?
ML=^,_B9H-_8Q_&7QHTGP[^!NGW T>\E3QWK5E<L?%TVB:M/MU71O 6FQ7'B+
M4(AI^JV,VHQ:'H^JVGV/6C(OY]AZ%7%5Z6'HQYJM:<:<%TO)VNWK:,5>4G;2
M*;Z'ZUB\51P.%KXS$2Y*&'I2JU);OEBKVBKJ\Y.T81O>4FHK5G\JW_!PK^V7
MXA_;%_;)\'_L3_!".]\9^&O@1XP_X5[;:!X52]U34/B#^TMXKU"S\+ZWHMKI
M2:?;3WFL^$=3:+X::/IUL=18>(9/%7V.Z<:L+>'\H?'W[,UE)^W5\-/V'/!4
M%AK/B#PU\1?A=^S)XQUBSM$LE\1_%^]\4V6D_&*^OY['5+IY],\,_$GQ#XM\
M(:7KLNJV\TG@;PAH>H7*>'Q&VEZ5^AW_  0]_9YM].NOVE/^"I/Q>MM*N/AC
M^P[\-_B'XI\ 77C14U#1_&?[2P\%WFM:)'<6E_"4\0S>"])U"WU465IKGA_Q
M:GQ&\:_"74?"NH3ZC'<"#RW_ (($_#C4OCO_ ,%7OA%XK\1PWWB2/X?6WQ2^
M.OC&\:+4V=]2L?#.K:9H>O:E>Z0UNNGK#\3/&'A._:?4)(])U"^-OH=W%<C5
MXK&Y_4*4Z66X7%4,.[T<GP+YY6_C8VK"59WZ<\4HMJ]E+$\MER*WX?7I5\XQ
MV Q>,BUB.(LTBJ4&W_L^6T:M/#P4=+^SFY2C&3C?DP?.N;VLK_Z05I:6EA:V
MUA86UO96-E;PVEG9VD,=M:VEI;1K#;VUM;PJD,%O!"B10PQ(D<4:*B*JJ +%
M%%?E)^\[;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?$7_!2[_E';
M^W/_ -FE?M!?^JL\45]NU\1?\%+O^4=O[<__ &:5^T%_ZJSQ173@O]\PG_83
M0_\ 3L#DQ_\ N.-_[!,3_P"F9G\>O_!&/_DT'X]_]G(^ ?\ U6'BFOT_K\P/
M^",?_)H/Q[_[.1\ _P#JL/%-?I_7\Z^/G_)Q\Q_[ ,L_]1D?Y:^.7_):4/\
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M7$1@\76O9-TJ;C##8922<<+0HJ7O\S91117U)]\%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !61K'^HB_P"NO_LC5KUD:Q_J(O\ KK_[(U..Z]5^
M9,_A?R_-'>Z/_P @JP_Z]8?_ $$5I5FZ/_R"K#_KUA_]!%:5<$_CE_BE^;.B
M'P1_PQ_)!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7":C_ ,C=IO\ U]Z5_P"E
M$==W7":C_P C=IO_ %]Z5_Z41UM0^*?_ %[G^1G5^%?XH_F>YT445PF@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>9?"O_ )&[5O\ L%7_ /Z<].KTVO,OA7_R
M-VK?]@J__P#3GIU;1_W?%_\ 7N/YLRG\=+UE^A]"T445Y)J%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/E[PQ_R6_4O^PKXE_P#2>^KZAKY>\,?\EOU+_L*^)?\ TGOJ^H:[\P^/#_\
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M\\#Z)XIM3 TMLB02SW;2S"U^Q77\Y7_!KY^RWI?Q3_:P^*'[2/B?3(=1T?\
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M,Z1</I*16VO?9D\7MH-N=-2YU_Q'JLUS=2:EJ-]JMSPY#0GFV8>VS&M5Q-'
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M<J-.=.C"-2-.3BY1]HESRYW"+FY2<IR7-)MMME%%%<IW!1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OB+_@I=_P H[?VY_P#LTK]H+_U5GBBOMVOB+_@I=_RCM_;G_P"S2OV@
MO_56>**Z<%_OF$_[":'_ *=@<F/_ -QQO_8)B?\ TS,_CU_X(Q_\F@_'O_LY
M'P#_ .JP\4U^G]?F!_P1C_Y-!^/?_9R/@'_U6'BFOT_K^=?'S_DX^8_]@&6?
M^HR/\M?'+_DM*'_8@RO_ -*Q(4445^,'XX%%%% !1110 4444 %%%% !1110
M 5^E?[,OPR_X1#PL?%.JVQCU_P 50PS1K*CK-8Z)_K;.#8^TQR7F5O)P4#;3
M;HS'9@?(_P  OAHWQ#\:0/?0EO#F@-%J.LLRDQW+*Q-GIH.Y 6NYU!F +%;6
M.8E"&%?JFJJBJB*J(BA410%554 *JJ  JJ        ,5_0O@IPA[6K5XMQU+
M]W1=3"Y/&<=)5K.&*QL4^E*+EA:,MG.6(>DJ46?V5]%SPW]O7K^(N;8>]+#2
MKX#AJG5AI/$.+I9AFD5):QH0E/ 8::NG5GC'I.A3D.HHHK^DS^W@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "LC6/]1%_UU_\ 9&K7K(UC
M_41?]=?_ &1J<=UZK\R9_"_E^:.]T?\ Y!5A_P!>L/\ Z"*TJS='_P"058?]
M>L/_ *"*TJX)_'+_ !2_-G1#X(_X8_D@HHHJ2@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KA-1_Y&[3?^OO2O_2B.N[KA-1_Y&[3?^OO2O\ THCK:A\4_P#KW/\ (SJ_
M"O\ %'\SW.BBBN$T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS+X5_\C=JW_8*
MO_\ TYZ=7IM>9?"O_D;M6_[!5_\ ^G/3JVC_ +OB_P#KW'\V93^.EZR_0^A:
M***\DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMJ3^#8%T^[5K.^FOO%3:/86]G>A;&YN+F*&]>.U>61?\\?\ X(1?"&U^,/\
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MM%^&?@G4=5UCXF?%IK&72=+FACOB/%GC%SJ%D^IS:7:^'O#LU_=Q:?I44/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KXB_X*7?\H[?VY_^S2OV@O\ U5GBBOMVOB+_ (*7?\H[?VY_^S2O
MV@O_ %5GBBNG!?[YA/\ L)H?^G8')C_]QQO_ &"8G_TS,_CU_P"",?\ R:#\
M>_\ LY'P#_ZK#Q37Z?U^8'_!&/\ Y-!^/?\ V<CX!_\ 58>*:_3^OYU\?/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#=]_Z36-=C_Y%E3_ +"E_P"D0%'^-'_!+\T>PT445Y9TA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[IFN76K7LN@_V/JUA8:<%\4ZE<Q_%?\ P3K_ .#>NP_8*_:M\"_M07G[5O\
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M[5]@M+"Q^T?8;"#SOL=C96OF;OL]I;P[(4_GZ_X*0_\ ! O5O^"AW[4GB/\
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MT2!YFN]"^!.@^(O&FJZI'\R00VWBOX@:5X"M-!<[DN9KF7P;XC4>4UBEH?M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?%/_ *]S_(SJ_"O\4?S/<Z***X30**** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^%>6?_.@\_\ XE-\.O\ H=<:_P#AQR+_ .AP_*G_ (9M^-/_ $)G_EQ>$_\
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MJ.*C6ITZ]*4X.4>=)L9'&D2)%$B1Q1HL<<<:A$C1 %1$10%5%4!550 H
MI]%%?L*22LE9+1);)=C^D4DDDDDDDDDK)):))+1)+9!1110,**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R-8_P!1%_UU_P#9&K7K
M(UC_ %$7_77_ -D:G'=>J_,F?POY?FCO='_Y!5A_UZP_^@BM*LW1_P#D%6'_
M %ZP_P#H(K2K@G\<O\4OS9T0^"/^&/Y(****DH**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *X34?^1NTW_K[TK_THCKNZX34?^1NTW_K[TK_THCK:A\4_^O<_R,ZOPK_%
M'\SW.BBBN$T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS+X5_\C=JW_8*O_P#T
MYZ=7IM>9?"O_ )&[5O\ L%7_ /Z<].K:/^[XO_KW'\V93^.EZR_0^A:***\D
MU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#B_B'_ ,B;K7_7.T_].%I5OX(?\B;-
M_P!AN^_])K&JGQ#_ .1-UK_KG:?^G"TJW\$/^1-F_P"PW??^DUC78_\ D65/
M^PI?^D0%'^-'_!+\T>PT445Y9TA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'R]X8_Y+?J7_85\2_^D]]7U#7R]X8_Y+?J7_85\2_^D]]7U#7?
MF'QX?_L$H?\ MQSX;X)_]?)?E$****X#H"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OB+_@I=_RCM_;G_P"S2OV@O_56>**^W:^(O^"E
MW_*.W]N?_LTK]H+_ -59XHKIP7^^83_L)H?^G8')C_\ <<;_ -@F)_\ 3,S^
M:#_@VD_Y(9^TO_V5CPG_ .H>]?TN5_-'_P &TG_)#/VE_P#LK'A/_P!0]Z_I
M<K[?-?\ D88G_%#_ --P/F>%/^2>RS_KU5_]2*P4445YY]"%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %9&L?ZB+_ *Z_^R-6O61K'^HB_P"NO_LC4X[KU7YDS^%_+\T=
M[H__ ""K#_KUA_\ 016E6;H__(*L/^O6'_T$5I5P3^.7^*7YLZ(?!'_#'\D%
M%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<)J/\ R-VF_P#7WI7_ *41UW=<)J/_
M "-VF_\ 7WI7_I1'6U#XI_\ 7N?Y&=7X5_BC^9[G1117":!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5YE\*_\ D;M6_P"P5?\ _ISTZO3:\R^%?_(W:M_V"K__
M -.>G5M'_=\7_P!>X_FS*?QTO67Z'T+1117DFH4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 <7\0_^1-UK_KG:?\ IPM*M_!#_D39O^PW??\ I-8U4^(?_(FZU_US
MM/\ TX6E6_@A_P B;-_V&[[_ -)K&NQ_\BRI_P!A2_\ 2("C_&C_ ()?FCV&
MBBBO+.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTJ?\^9?^!+_+U_IZ?4%%?+__  HOQ%_T'M+_ /)[_P",T?\ "B_$7_0>TO\
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M  HOQ%_T'M+_ /)[_P",T?\ "B_$7_0>TO\ \GO_ (S1]5PG_0?#_P $3_\
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M /)[_P",T?\ "B_$7_0>TO\ \GO_ (S1]5PG_0?#_P $3_\ DO7^GH>TJ?\
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M\O7^GI]045\O_P#"B_$7_0>TO_R>_P#C-'_"B_$7_0>TO_R>_P#C-'U7"?\
M0?#_ ,$3_P#DO7^GH>TJ?\^9?^!+_+U_IZ?4%%?+_P#PHOQ%_P!![2__ ">_
M^,T?\*+\1?\ 0>TO_P GO_C-'U7"?]!\/_!$_P#Y+U_IZ'M*G_/F7_@2_P O
M7^GI]045\O\ _"B_$7_0>TO_ ,GO_C-'_"B_$7_0>TO_ ,GO_C-'U7"?]!\/
M_!$__DO7^GH>TJ?\^9?^!+_+U_IZ?4%%?+__  HOQ%_T'M+_ /)[_P",T?\
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MO7^GH>TJ?\^9?^!+_+U_IZ?4%%?+_P#PHOQ%_P!![2__ ">_^,T?\*+\1?\
M0>TO_P GO_C-'U7"?]!\/_!$_P#Y+U_IZ'M*G_/F7_@2_P O7^GI]045\O\
M_"B_$7_0>TO_ ,GO_C-'_"B_$7_0>TO_ ,GO_C-'U7"?]!\/_!$__DO7^GH>
MTJ?\^9?^!+_+U_IZ?4%%?+__  HOQ%_T'M+_ /)[_P",T?\ "B_$7_0>TO\
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M  HOQ%_T'M+_ /)[_P",T?\ "B_$7_0>TO\ \GO_ (S1]5PG_0?#_P $3_\
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M /)[_P",T?\ "B_$7_0>TO\ \GO_ (S1]5PG_0?#_P $3_\ DO7^GH>TJ?\
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M%%<__9%Q_P ]H_S?_P")H_LBX_Y[1_F__P 319?S+[G_ )>O]/0YI?RO[_\
M@>?Y]F=!17/_ -D7'_/:/\W_ /B:/[(N/^>T?YO_ /$T67\R^Y_Y>O\ 3T.:
M7\K^_P#X'G^?9G045S_]D7'_ #VC_-__ (FC^R+C_GM'^;__ !-%E_,ON?\
MEZ_T]#FE_*_O_P"!Y_GV9T%%<_\ V1<?\]H_S?\ ^)H_LBX_Y[1_F_\ \319
M?S+[G_EZ_P!/0YI?RO[_ /@>?Y]F=!17/_V1<?\ /:/\W_\ B:/[(N/^>T?Y
MO_\ $T67\R^Y_P"7K_3T.:7\K^__ ('G^?9G045S_P#9%Q_SVC_-_P#XFC^R
M+C_GM'^;_P#Q-%E_,ON?^7K_ $]#FE_*_O\ ^!Y_GV9T%%<__9%Q_P ]H_S?
M_P")H_LBX_Y[1_F__P 319?S+[G_ )>O]/0YI?RO[_\ @>?Y]F=!17/_ -D7
M'_/:/\W_ /B:/[(N/^>T?YO_ /$T67\R^Y_Y>O\ 3T.:7\K^_P#X'G^?9G04
M5S_]D7'_ #VC_-__ (FC^R+C_GM'^;__ !-%E_,ON?\ EZ_T]#FE_*_O_P"!
MY_GV9T%%<_\ V1<?\]H_S?\ ^)H_LBX_Y[1_F_\ \319?S+[G_EZ_P!/0YI?
MRO[_ /@>?Y]F=!17/_V1<?\ /:/\W_\ B:/[(N/^>T?YO_\ $T67\R^Y_P"7
MK_3T.:7\K^__ ('G^?9G045S_P#9%Q_SVC_-_P#XFC^R+C_GM'^;_P#Q-%E_
M,ON?^7K_ $]#FE_*_O\ ^!Y_GV9T%%<__9%Q_P ]H_S?_P")H_LBX_Y[1_F_
M_P 319?S+[G_ )>O]/0YI?RO[_\ @>?Y]F=!17/_ -D7'_/:/\W_ /B:/[(N
M/^>T?YO_ /$T67\R^Y_Y>O\ 3T.:7\K^_P#X'G^?9G045S_]D7'_ #VC_-__
M (FC^R+C_GM'^;__ !-%E_,ON?\ EZ_T]#FE_*_O_P"!Y_GV9T%%<_\ V1<?
M\]H_S?\ ^)H_LBX_Y[1_F_\ \319?S+[G_EZ_P!/0YI?RO[_ /@>?Y]F=!17
M/_V1<?\ /:/\W_\ B:/[(N/^>T?YO_\ $T67\R^Y_P"7K_3T.:7\K^__ ('G
M^?9G045S_P#9%Q_SVC_-_P#XFC^R+C_GM'^;_P#Q-%E_,ON?^7K_ $]#FE_*
M_O\ ^!Y_GV9T%%<__9%Q_P ]H_S?_P")H_LBX_Y[1_F__P 319?S+[G_ )>O
M]/0YI?RO[_\ @>?Y]F=!17/_ -D7'_/:/\W_ /B:/[(N/^>T?YO_ /$T67\R
M^Y_Y>O\ 3T.:7\K^_P#X'G^?9G045S_]D7'_ #VC_-__ (FC^R+C_GM'^;__
M !-%E_,ON?\ EZ_T]#FE_*_O_P"!Y_GV9T%%<_\ V1<?\]H_S?\ ^)H_LBX_
MY[1_F_\ \319?S+[G_EZ_P!/0YI?RO[_ /@>?Y]F=!17/_V1<?\ /:/\W_\
MB:/[(N/^>T?YO_\ $T67\R^Y_P"7K_3T.:7\K^__ ('G^?9G05D:Q_J(O^NO
M_LC56_LBX_Y[1_F__P 35:YLI;5%=Y58,VT!-Q.<$\YQQQ0DKKWENNC\O+U_
MIZ*3;3O&WG?T\OZ^3/3]'_Y!5A_UZP_^@BM*O.+7PQ=W5M#<I=0*L\:R*K>;
MN 89 .%(SCK@D>]3_P#"(7O_ #^6_P"4O_Q-<LJ=)R;=9)MMM<C=G?;=;&\9
M248I4VU9:W6NBU_'^M;>@45Y_P#\(A>_\_EO^4O_ ,31_P (A>_\_EO^4O\
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M%>?_ /"(7O\ S^6_Y2__ !-'_"(7O_/Y;_E+_P#$T>SI?\_U_P" /_,.>?\
MS[?_ ($O+_/\/6WH%%>?_P#"(7O_ #^6_P"4O_Q-'_"(7O\ S^6_Y2__ !-'
MLZ7_ #_7_@#_ ,PYY_\ /M_^!+R_S_#UMZ!17G__  B%[_S^6_Y2_P#Q-'_"
M(7O_ #^6_P"4O_Q-'LZ7_/\ 7_@#_P PYY_\^W_X$O+_ #_#UMZ!17G_ /PB
M%[_S^6_Y2_\ Q-'_  B%[_S^6_Y2_P#Q-'LZ7_/]?^ /_,.>?_/M_P#@2\O\
M_P /6WH%%>?_ /"(7O\ S^6_Y2__ !-'_"(7O_/Y;_E+_P#$T>SI?\_U_P"
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M_P#"(7O_ #^6_P"4O_Q-'_"(7O\ S^6_Y2__ !-'LZ7_ #_7_@#_ ,PYY_\
M/M_^!+R_S_#UMZ!7":C_ ,C=IO\ U]Z5_P"E$=1?\(A>_P#/Y;_E+_\ $UCS
M:5-!J=OIC3H9;B6VB61=_EJ;EU12V<-A2V6P"<#C)K2E"FG+EJJ3Y))KE:LG
MN]W>W;KY$3E)I7@UJNJ\M/G?^M4OI"BO'_\ A7.J_P#02L__ "9_^-T?\*YU
M7_H)6?\ Y,__ !NN7V5'_H)C_P""Y?Y^O]/1\]3_ )]/_P "_P#M?7^GI[!1
M7C__  KG5?\ H)6?_DS_ /&Z/^%<ZK_T$K/_ ,F?_C='LJ/_ $$Q_P#!<O\
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M_P#)G_XW1[*C_P!!,?\ P7+_ #]?Z>ASU/\ GT__  +_ .U]?Z>GL%%>/_\
M"N=5_P"@E9_^3/\ \;H_X5SJO_02L_\ R9_^-T>RH_\ 03'_ ,%R_P _7^GH
M<]3_ )]/_P "_P#M?7^GI[!17C__  KG5?\ H)6?_DS_ /&Z/^%<ZK_T$K/_
M ,F?_C='LJ/_ $$Q_P#!<O\ /U_IZ'/4_P"?3_\  O\ [7U_IZ>P45X__P *
MYU7_ *"5G_Y,_P#QNC_A7.J_]!*S_P#)G_XW1[*C_P!!,?\ P7+_ #]?Z>AS
MU/\ GT__  +_ .U]?Z>GL%%>/_\ "N=5_P"@E9_^3/\ \;H_X5SJO_02L_\
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M *"5G_Y,_P#QNC_A7.J_]!*S_P#)G_XW1[*C_P!!,?\ P7+_ #]?Z>ASU/\
MGT__  +_ .U]?Z>GL%%>/_\ "N=5_P"@E9_^3/\ \;H_X5SJO_02L_\ R9_^
M-T>RH_\ 03'_ ,%R_P _7^GH<]3_ )]/_P "_P#M?7^GI[!17C__  KG5?\
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M_DS_ /&Z/^%<ZK_T$K/_ ,F?_C='LJ/_ $$Q_P#!<O\ /U_IZ'/4_P"?3_\
M O\ [7U_IZ>P45X__P *YU7_ *"5G_Y,_P#QNC_A7.J_]!*S_P#)G_XW1[*C
M_P!!,?\ P7+_ #]?Z>ASU/\ GT__  +_ .U]?Z>GL%%>/_\ "N=5_P"@E9_^
M3/\ \;H_X5SJO_02L_\ R9_^-T>RH_\ 03'_ ,%R_P _7^GH<]3_ )]/_P "
M_P#M?7^GI[!17C__  KG5?\ H)6?_DS_ /&Z/^%<ZK_T$K/_ ,F?_C='LJ/_
M $$Q_P#!<O\ /U_IZ'/4_P"?3_\  O\ [7U_IZ>P5YE\*_\ D;M6_P"P5?\
M_ISTZLS_ (5SJO\ T$K/_P F?_C=<_X;\-7?B/5+G3+6[BMIK:VFN7EF\W8R
M0W%O;LB^6&;+-.K#( PISS@5I&G2]C7C[=.,H)2ER2]Q7WM?WNNEUMYZ1*4W
M*#<+--V7-OM?6RM8^N**\ _X5'K?_09L/_)O_P"-T?\ "H];_P"@S8?^3?\
M\;K@^K8;_H-A_P""I?\ R7K_ $]-.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\
M09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?
M_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMA
MO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T
M?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_
MHKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7
MK_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A
M_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\
M09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?
M_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMA
MO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T
M?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_
MHKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7
MK_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A
M_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\
M09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?
M_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMA
MO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T
M?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_
MHKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7
MK_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A
M_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\
M09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?
M_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMA
MO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T
M?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_
MHKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7
MK_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A
M_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\
M09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?
M_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMA
MO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T
M?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_
MHKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A_P"3?_QNCZMAO^@V'_@J7_R7
MK_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\ 09L/_)O_ .-T?\*CUO\ Z#-A
M_P"3?_QNCZMAO^@V'_@J7_R7K_3T.>?_ #Z?_@2_R\_S[,]_HKP#_A4>M_\
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M_?\ /\/6Q[2K_P ^'_X&O\CZ@HKY?_X49XE_Z#VE_P#?5_\ _&*/^%&>)?\
MH/:7_P!]7_\ \8H^JX3_ *&$/_!,O+^_Y_AZV/:5?^?#_P# U_D?4%%?+_\
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MUL>TJ_\ /A_^!K_(^H**^7_^%&>)?^@]I?\ WU?_ /QBC_A1GB7_ *#VE_\
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M^JX3_H80_P#!,O+^_P"?X>MCVE7_ )\/_P #7^1]045\O_\ "C/$O_0>TO\
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MX3_H80_\$R\O[_G^'K8]I5_Y\/\ \#7^1]045\O_ /"C/$O_ $'M+_[ZO_\
MXQ1_PHSQ+_T'M+_[ZO\ _P",4?5<)_T,(?\ @F7E_?\ /\/6Q[2K_P ^'_X&
MO\CZ@HKY?_X49XE_Z#VE_P#?5_\ _&*/^%&>)?\ H/:7_P!]7_\ \8H^JX3_
M *&$/_!,O+^_Y_AZV/:5?^?#_P# U_D?4%%?+_\ PHSQ+_T'M+_[ZO\ _P",
M4?\ "C/$O_0>TO\ [ZO_ /XQ1]5PG_0PA_X)EY?W_/\ #UL>TJ_\^'_X&O\
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MI5_Y\/\ \#7^1]045\O_ /"C/$O_ $'M+_[ZO_\ XQ1_PHSQ+_T'M+_[ZO\
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M /QBC_A1GB7_ *#VE_\ ?5__ /&*/JN$_P"AA#_P3+R_O^?X>MCVE7_GP_\
MP-?Y'U!17R__ ,*,\2_]![2_^^K_ /\ C%'_  HSQ+_T'M+_ .^K_P#^,4?5
M<)_T,(?^"9>7]_S_  ];'M*O_/A_^!K_ "/J"BOE_P#X49XE_P"@]I?_ 'U?
M_P#QBC_A1GB7_H/:7_WU?_\ QBCZKA/^AA#_ ,$R\O[_ )_AZV/:5?\ GP__
M  -?Y'U!17R__P *,\2_]![2_P#OJ_\ _C%'_"C/$O\ T'M+_P"^K_\ ^,4?
M5<)_T,(?^"9>7]_S_#UL>TJ_\^'_ .!K_(^H**^7_P#A1GB7_H/:7_WU?_\
MQBC_ (49XE_Z#VE_]]7_ /\ &*/JN$_Z&$/_  3+R_O^?X>MCVE7_GP__ U_
MD?4%%?+_ /PHSQ+_ -![2_\ OJ__ /C%'_"C/$O_ $'M+_[ZO_\ XQ1]5PG_
M $,(?^"9>7]_S_#UL>TJ_P#/A_\ @:_R/J"BOE__ (49XE_Z#VE_]]7_ /\
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M_?\ /\/6Q[2K_P ^'_X&O\CZ@HKY?_X49XE_Z#VE_P#?5_\ _&*/^%&>)?\
MH/:7_P!]7_\ \8H^JX3_ *&$/_!,O+^_Y_AZV/:5?^?#_P# U_D?4%%?+_\
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MUL>TJ_\ /A_^!K_(^H**^7_^%&>)?^@]I?\ WU?_ /QBC_A1GB7_ *#VE_\
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M** "BBB@ KXB_P""EW_*.W]N?_LTK]H+_P!59XHK[=KXB_X*7?\ *.W]N?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7":C_R-VF_]?>E?^E$==W7":C_R-VF_]?>E?^E$=;4/
MBG_U[G^1G5^%?XH_F>YT445PF@4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>9?"
MO_D;M6_[!5__ .G/3J]-KS+X5_\ (W:M_P!@J_\ _3GIU;1_W?%_]>X_FS*?
MQTO67Z'T+1117DFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <7\0_\ D3=:_P"N
M=I_Z<+2K?P0_Y$V;_L-WW_I-8U4^(?\ R)NM?]<[3_TX6E6_@A_R)LW_ &&[
M[_TFL:['_P BRI_V%+_TB H_QH_X)?FCV&BBBO+.D**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ^7O#'_);]2_["OB7_TGOJ^H:^7O#'_);]2_
M["OB7_TGOJ^H:[\P^/#_ /8)0_\ ;CGPWP3_ .ODORB%%%%<!T!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q%_P4N_Y1V_MS_\ 9I7[
M07_JK/%%?;M?$7_!2[_E';^W/_V:5^T%_P"JL\45TX+_ 'S"?]A-#_T[ Y,?
M_N.-_P"P3$_^F9G\FO\ P0;^)&N?"_\ 9=_:&U_0+72KR\O/CYX(T>6+6(+R
MXMEMKCX>:W>O)&EE?:?*)Q+I\*JS3-&(VE!B9F1T_:K_ (:_^)?_ $ _ W_@
MLU__ .::OP5_X(Q_\F@_'O\ [.1\ _\ JL/%-?I_7XSXT<8<39+Q[C\#E><X
MS!82.#R^I&A1E!4U.IAXN<K2A)WDTF]?U/\ .SQ4\2..N&.),-E60<39EE>7
M0R7+ZT<)A9TXTHU:T\1*K-*5.3YIM)RU_ ^J_P#AK_XE_P#0#\#?^"S7_P#Y
MIJ/^&O\ XE_] /P-_P""S7__ )IJ^5**_*/^(B\;_P#129E_X'3_ /E?E^?=
MGYI_Q&GQ4_Z+?.__  ;1_P#E/E^?=GU7_P -?_$O_H!^!O\ P6:__P#--1_P
MU_\ $O\ Z ?@;_P6:_\ _--7RI11_P 1%XW_ .BDS+_P.G_\K\OS[L/^(T^*
MG_1;YW_X-H__ "GR_/NSZK_X:_\ B7_T _ W_@LU_P#^::C_ (:_^)?_ $ _
M W_@LU__ .::OE2BC_B(O&__ $4F9?\ @=/_ .5^7Y]V'_$:?%3_ *+?._\
MP;1_^4^7Y]V?5?\ PU_\2_\ H!^!O_!9K_\ \TU'_#7_ ,2_^@'X&_\ !9K_
M /\ --7RI11_Q$7C?_HI,R_\#I__ "OR_/NP_P"(T^*G_1;YW_X-H_\ RGR_
M/NSZK_X:_P#B7_T _ W_ (+-?_\ FFH_X:_^)?\ T _ W_@LU_\ ^::OE2BC
M_B(O&_\ T4F9?^!T_P#Y7Y?GW8?\1I\5/^BWSO\ \&T?_E/E^?=GU7_PU_\
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M#_B-/BI_T6^=_P#@VC_\I\OS[L^J_P#AK_XE_P#0#\#?^"S7_P#YIJ/^&O\
MXE_] /P-_P""S7__ )IJ^5**/^(B\;_]%)F7_@=/_P"5^7Y]V'_$:?%3_HM\
M[_\ !M'_ .4^7Y]V?5?_  U_\2_^@'X&_P#!9K__ ,TU'_#7_P 2_P#H!^!O
M_!9K_P#\TU?*E%'_ !$7C?\ Z*3,O_ Z?_ROR_/NP_XC3XJ?]%OG?_@VC_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH XOXA_P#(FZU_USM/_3A:5;^"'_(FS?\ 8;OO_2:Q
MJI\0_P#D3=:_ZYVG_IPM*M_!#_D39O\ L-WW_I-8UV/_ )%E3_L*7_I$!1_C
M1_P2_-'L-%%%>6=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M\O>&/^2WZE_V%?$O_I/?5]0U\O>&/^2WZE_V%?$O_I/?5]0UWYA\>'_[!*'_
M +<<^&^"?_7R7Y1"BBBN Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KXB_X*7?\H[?VY_\ LTK]H+_U5GBBOMVOB+_@I=_RCM_;G_[-
M*_:"_P#56>**Z<%_OF$_[":'_IV!R8__ ''&_P#8)B?_ $S,_CU_X(Q_\F@_
M'O\ [.1\ _\ JL/%-?I_7Y@?\$8_^30?CW_V<CX!_P#58>*:_3^OYU\?/^3C
MYC_V 99_ZC(_RU\<O^2TH?\ 8@RO_P!*Q(4445^,'XX%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% #D1Y'5$5G=V5$1%+.[L0%55
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D:Q_J(O\
MKK_[(U:]9&L?ZB+_ *Z_^R-3CNO5?F3/X7\OS1WNC_\ (*L/^O6'_P!!%:59
MNC_\@JP_Z]8?_016E7!/XY?XI?FSHA\$?\,?R04445)04444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#Y>\,?\EOU+_L*^)?\ TGOJ^H:^7O#'
M_);]2_["OB7_ -)[ZOJ&N_,/CP__ &"4/_;CGPWP3_Z^2_*(4445P'0%%%%
M'C?[1?Q;_P"% _L^?';X[_\ "/\ _"6?\*4^#7Q/^+?_  BO]J_V#_PDW_"M
M_!.N>,?^$?\ [<_LW6?[&_MG^QO[._M7^Q]5_L[[3]L_LV^\G[++_)__ ,1;
M/_6/_P#\VK__ ";J_I;_ ."B_P#RCX_;L_[,V_:>_P#5)>.*_P H"OL^&,IR
M_,</BIXS#^VE3K1A!^UKT[1<+M6I5()ZZW:;\S\XXWS[-LGQ6!IY=B_J\*V'
MJSJ1]AAJW-*-113O7HU6K+2T6D^JN?Z7_P#P2D_X+ ?#K_@IY9_$[14^&[?
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MGP5_96JZI9R:A86OV;XA^.?"5Y?>?9PR3>?IMO>6T6WRYIHY2J'ZR_XA_/\
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M>'_AEX'MFB;6/B'\1;^TN)-"\/6$#W-HR:; T,FK^*=4$RKHWAJPU*]B2[U
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M(^-<=''5,LR1*#HU7AZF)]E&O6K8B,G3E3P].2G#D4[P4G3G.I-7I\L;.?\
M13KG_!U1^W1<7\DGAOX%_LFZ3I9W^59ZYX9^,'B"_3,TS)YFI6'QF\,V\FVW
M:")]NE1;YHYIQY:3);6_HGPP_P"#K?\ :0T[5M.;XS_LO_!'QCH0F9=7B^&&
MN>//AMJSV[I>(DNG7'BO6/BM9QS6TDFGSM!<VTJ7R6=Y:"XT]M2@O=)^;? G
M_!L3_P %)/%^C6^J>(-6_9M^%M]/9V5S+X<\=_%'Q+J&LV<UTLS3Z?<3_#'X
M<_$;P\UYIQC1+U[37KJPD:XA.GWU^BSM#\7_ +9O_!&;]N_]AOPMJ7Q$^*GP
M\T3Q=\*=&N!!K'Q3^$OB ^,O".BI+>VFG65[KUM=:?H7B_PYI>HWM]:6MEJG
MB#PMI=@]U<0V<MQ#>2QV[^G#"\*8B?U>FL#*I)\L8PK2C*3=DE3FJB<Y/IR2
M;;VUN>+5QW'N$IO&5I9I3I07/.=3#PE"$59N56E*E)0@DO>=2$8QU3M=G]NO
M["7_  6X_8I_;P\2:7\-?"6M>)_A/\:-5M+5M/\ A=\6;'2])O?$^IK87M[K
M-AX"\1:-JVLZ#XJ_LI-/N9XX)[C0_$6H::T%_%X:A*ZA:Z=^O]?XY&CZQJWA
M[5M+U_0-4U'0]=T/4;'6-%UK1[ZYTS5M'U;3+F*]TW5-+U*RE@O-/U'3[R"&
M[L;ZTFAN;2YABG@ECEC1Q_I&_P#!#'_@HCK_ .WY^R;>#XJZM8:G^T)\!M?M
M/ /Q2O;<Q0WOB_0]4L9-1^'?Q/O]+M;*VL=(N/%EC::[X<U*"UFGBU#Q3X#\
M3Z]!;Z18:O8:/8_.\0<.PRZFL9@Y3EAN90JTZCYI492=H2C*RYJ<G:+4KRC-
MQUDI>Y]APEQ?/.*KR[,8TXXWDE4H5J<>2&)C!<TX2IW:C6A'FJ>Y:$Z<9/E@
MX>_^U5?R$_$#_@ZO_P"$%\>>-O!'_#!W]J?\(=XN\2>%?[3_ .&H?L/]H_\
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M?_-Q7^4!17W?^I>%_P"@W$?^"Z?]=_Z6OY9_Q$G'?]"S"?\ @ZM_EZ_TM?\
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M)]U>W9VL]:/B5B%./M\KHRIW][V.(G":7>//3G%M:OE=K[<T?B/]ABBOY/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N$U'_D;M-_Z^]*_]*(Z[NN$U'_D;M-_Z^]*_P#2B.MJ'Q3_ .O<_P C
M.K\*_P 4?S/<Z***X30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&M^-=>AT;2WUOPG?3SZ1<BZU*\NCI5K9ZKJ.HW4DE]=I^A/_  20_P"",_\
MP4Q_9._;6^"O[0_Q \->#_A7X$\-3^(K'XE:7+\7O#6L:OKO@OQ%X3U#2]1\
M.3:3X"?QII>O,VHW]A?6>GWUVFFQZ]X?LM5CU/2[FPTC6XO[8:*^EJ\4YA6P
MCPDZ>&E&=!T*M6<*DZM12AR2FVZB@IM7;?(_>=SXS#\"Y3A\>LPIUL9&=/%+
M%4*-.I2IT*,HU?:PII*BZDJ<6E%+VD?<7*[[A7^>[_P<G_M9:Q\:_P!N63]G
MVRFFC\ ?LKZ'8^';.WV7UO%JGC_Q[H7AWQ=XTUEX)[Z2WN!9VL_A[PO:W2Z;
MI\N_0]1:*2^T^ZM+R;_0BK_)8_;=\<W_ ,3/VROVK?'^I7\FI7'BS]HKXS:S
M'<N]^T:V%U\0O$#:59V2:G-/?VNEZ;I8L].TFPN)6;3M,M;2P4)';(B]7!V'
MC4Q]?$22;PU#W+_9G6ER\R\U3C4CZ39P^(N,G1RK"X2$G%8S%7JV?QTL-#G<
M&NJ]K.C/U@NY6_8W_9H\3_MB?M/?!K]FKPC>0Z9J_P 5?%J:1/J\\<\T6B>'
MM+TZ_P#$GC#7FAMK>ZEF.A>$M%UO5TA\H12R62QW$UM;M+<Q?ZIOP!^ /PE_
M9@^$O@_X(_!'P?IW@?X<^!].6PT;1K!2\T\SDRZAK.LZA*6O-:\0ZU>-+J.N
M:YJ,L^H:IJ$\UU=3.[\?PH?\&OW@M/$G_!1;Q7XBF698_AY^S/\ $;Q';S+;
MW$ENVI:MXQ^&G@N&SEN(YX8+>:?3?%&KW4 N4NQ,FGW"Q6HD47EG_H)4^,<7
M4GC:6#4FJ-"C&HX)NTJU5RO*2T3<::BHWORWG9KF:)\.\!1IY;B,Q<$\1B<1
M.@JC2;CAZ,86A%[Q4JKG*=FE/EIW3Y(L*^'O^"AG[$/P]_;]_9A\?_ CQE::
M7:^)KO2[S6?A)XYO+2&2\^'7Q1T^UEE\+>([:[^PWU];Z/<7RQZ-XTLM-2.\
MUSP9J&N:/;W%K=7=M>VOW#17R=&M4H5:=:E)PJTIQG"2WC*+NGYKNGHU=---
MGWV(P]'%4*V&KP52C7ISI582VE":<9+R=GHU9IV:::3/\OWX?_\ !%?_ (*B
M?$B\L[31?V//B9HBW<PB-Y\0)O#'PTL[1,W/F7%Y)X^U_P .R10PI9SR%5AD
MN)@;9+2"XGU#3HKO^R__ ((4?L5_ME?L(_!;XP?!S]J.7P9%X2U;QQH?COX2
M:/X7\8IXOO-"U+6-.U/2/B19W\L6EVT&EZ=>?\(_X'U?2K&RU34;&6^U#7[W
M[)INI7.IOJ'[IT5[N9<1XS,Z$L-5HX:G1DXR]R$W44H24DU.=223TY6U%7C*
M2ZGR^3<'9?DN+AC:&)QM7$0C4A^\J4HT91J0<)*5.G2C*2UYDI5))3C&5KQ0
M51U/4]-T73=0UG6=0L=)TC2;&[U/5=5U.[@L--TS3;""2ZOM0U"^NI(K6RL;
M*UBEN;N[N98X+>".2::1(T9A>K\5O^"^/[7,G[*O_!/?XAZ9H-U;Q>/?VC;B
M?]GSPPBZC:V^IZ?HWC7P]KDOQ!\26EC+:7MS=6^G>"K#5-$:^M5L6T;6?$_A
M^[BU:QU%M,2Z\;"8:>+Q5##4_BKU84T_Y5)^])^4(WD_),^BS#&4\OP6*QM9
M_N\-1G5:ZR<5[D%_>J3Y81_O26J/X+?^"A?[4<G[9O[9O[0'[1D,NJ-X=\?>
M.KN/P#;ZS:VNGZG8?#/PQ:VOA/X<66H:;8R366G:G'X+T/1)-9MK:XNU.LRZ
MC//J&IW<]QJ-W]%?L&_\$Z]7_:^_9<_X*%?'.SM;RXU']FCX-Z'K?PSL[,W\
MMWK/C^#7HOB!XH@L-*L3"NO3P_"3P!XT\,IIMS<N\>L_$'PWJ&FZ1K6HV<$5
MI^5%?Z:__!%']D-/V5/^"<?PB\$^*;6QO/%?QHL;SX\?$W3V1;S3?[3^+>D:
M1+I/AZ[M+O3K1FN=$^&>G^"?"WBBSN1J5J_B+2]<%CJ%[HTE@5_3\[QT<FR[
M#PP_NS53#T:$+_\ +J@X3FGI9Q=.FJ4O^OJT/Q'AG*Y<1YQBYXR\Z;HXO$XJ
MI:]Z^*4Z=-K6ZFJU5UX:_P#+EZK<_P RBO\ 2#_X-]/VL[;]I?\ X)Y> /!V
MIR7'_">_LOW"_ 7Q.EQ_J[SPWX?L;>^^%NL::#=7D@TP?#^\T?PHXN9+>8Z]
MX/U][>PM-)?2_-_A7_X*,_LHW/[%'[9OQR_9W47DOAWPCXGBU3P%J%U:W-NN
MI_#WQ?IMEXK\'36\US>ZF^H?V?HVL6^@W]\-1NW?6=(U2"[:"_M[NTM_TN_X
M-OOVL;CX!?MZVGP<UO7?[-^'7[5GAR7X>:G9W"VBZ:WQ,\,Q:CXC^$VJW%Q(
M8[V/4)+J3Q3X!T6"U>>"[O\ XC+%=V$C"UU#2YS_  \,SR9XBC[[IPACJ$M;
MRIJ'--65W[U&4FHV^.,4[6NKX3QE3).(XX7$_NU6JU,LQ46U:%5U.2F[NR]S
M$PA%STM3E-K1V?\ H?T445^5'[N?Y+'[;]MK-E^VE^U[9^(VN'\0VG[4/Q_M
MM>>[NUO[M]9@^*_BR+5&N;])KE;VX:^2<S7:W$ZW,A:832AP[?MU_P &PWQL
M^!_PL_;"^*/@_P")FL:!X8^(?QJ^&ND> _@UKVNL;3^UM9@\56VMZY\.=-U1
MX#:6NI^-/L.@W^FV-[>62Z]JOA33]%TX7VNW>DZ?<YO_  <=?\$_?$/P$_:A
MOOVN? ^@WUS\$OVE[U-3\4:A9VM[<6'@3XXQ6JQ>*-'U:Z,=Q#8VOQ%@M4\>
M>'KB]OTEU37;KQ]I6GZ?9Z9X:LA/_-M7Z_"-'.LEA3C4<(8G#0A*4+<U*I3Y
M>:+C?7DJ0Y9PNN:-TI)24C^>JL\3PWQ)4K5*,:E7!8VK5C"I=1KT:O/RSC*S
M:]K1J<].=FZ<VFXN47$_V2*Y[Q=X4\/>._"GB?P/XMTR'6O"GC+P]K7A3Q-H
MUQ)/%!JWA[Q%IMSI&M:9/+:RV]U%#?Z;>7-K));3PSHDK-#+'(%=?\P7]G/_
M (+ ?\%%?V7-,T?PW\,/VEO%]YX*T.W6QT_P+\1+31/B=X7M=,23SDTO3H/'
M.FZWJ6@6$<F##'X9U/19+>/=;V\L5K)+#)^XWP"_X.N/B!:3S6?[4G[+G@[Q
M#;3RQ-;^(O@%XAUKP=/ID"O/Y\4W@SXB:EXYCUR6:-[;RIT\>^'DMWMIP]O=
M+?1G3_B<3PGFN';EAW2Q48N\72J>RJJS5FX5>1*75*%2=K:.]K_I>#X^R+%I
M4\7'$8&4ERS5>E[:@^9.\54H>TE*+^%NI1IIWU25[?FU\4_^#>O_ (*>Z1\3
MOB-I/PT_9I7Q7\.-+\>>+].^'_BE/C;^S]IR>)?!-EX@U&V\*:^FG^(_BQI7
MB&Q76="BL-16SUW3--UFV%R(-4L+.^2>WC_;'_@W[_X)T?M]?L-_M(?&G6_V
ME_@E-\,OA7\0O@BVE6VL+\4O@]XQ@OOB!H/CSPG=^&]-DT/X?^._%FMI,WAS
M4O'%U!JMQ:VFE6:6UQ9W$[7>IV$9_9+]CO\ X*_?L&_MN/HNA_"KXOP^%OB9
MK,+NOP<^+5DO@+XBV]S_ &M#I%KIEHMQ=W_@WQ9JNHR7>GW5C8> /&/B^>6U
MOXUD$-[::I9V'Z;T9CG^;3H5<NQV$H4?:04)\]#$0K-1DFIQ<Z[@VY134U!Q
M>\=+#R?A3A^GBL/F^5YABL1[&JZM/V>*PM7#IRC).E-4\,JD4HS<73E4C4BM
M).]PK_(3_: _Y+Q\;/\ LKGQ(_\ 4RUJO]>RO\A/]H#_ )+Q\;/^RN?$C_U,
MM:KOX*_BYA_U[P__ *55/(\2_P"%D_\ U\QO_I.%/Z6_^#43_DX_]JK_ +(E
MX4_]3N&O[D:_RO/^"?/_  4C^.7_  3;\;?$#QY\#?"OPH\5ZO\ $?PMI_A'
M7+;XKZ'XOUS3;73=-U9=9@GTJ'PAXZ\"W4%\]T@CEDO+R^@:#*I;1R?O1^JW
M_$5#_P %!_\ HCO[&W_AOOC;_P#1#5KGO#^8X_,JV)P\:3I3A1C%SJJ,KPIQ
MC*\6FUJG;NEZ&/"_%F3Y3D]#!8R>(C7IU,1*2IT)3C:I6E.-I)I/W9*_:S7:
M_P#?;17\"7_$5#_P4'_Z([^QM_X;[XV__1#4?\14/_!0?_HCO[&W_AOOC;_]
M$-7D?ZIYQ_)A_P#P?'_+^K/RO]#_ *_</?\ /S%_^$LO_DOZL_*_]]M%?F!_
MP2'_ &UOBI^WY^QYIG[0?QBT#X?^&O&=[\1/'/A&73/AII7B/1_#"Z;X9GT^
M*PGCLO%/BOQEJHOIENY#=R-K3P2,J&&VMP&#?I_7S^(H5,-7JX>JDJE&<J<U
M%\R4HNSLUNK]3ZS"8JECL+0Q=!R='$TH5J3E'EDX35X\T=;.VZZ!1116)TA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7XV_\' ?_ "B+_:U_[H-_ZTU\&*_9*OQM_P"#@/\ Y1%_M:_]T&_]::^#
M%=^5?\C3+?\ L/P?_J13/*SW_D1YS_V*LQ_]1*Q_FDU_K7?L4_\ )FW[)7_9
MLOP&_P#56>%*_P E&O\ 3X_9$_;\_81\-?LG_LP^'/$?[:W[).@>(= _9X^"
MNB:]H.M_M'_!W2M9T36=*^&WAJQU32-7TN_\907VFZGIM]!/9W]A>00W5G=0
MRV]Q%'-&Z+]MQC2J5:&"5.G.HU6JMJ$)3:3A!)M13M=Z:]3\R\.JU&CB\S=:
MM2I*6'H*+JU(4U)^UGHG-J[\D?H)\2?@O\(?C'I.H:%\5_ACX#^(NE:KI-WH
M5]:>,_"FB>(5FTB^MK^SN;%)=3LKB>WADMM4U&)?LTL+Q"^NFA>-YY&;_.%_
MX+??L*^ OV"OVVK_ ,"?",7=I\(_BIX!T3XS^ ?#MU]MNQX#M=?U_P 4^&-<
M\!0ZW>R2RZU::+XA\(:EJ>B2SR2:AIWA77O#NDZM<ZIJ5C<ZWJO]U?Q/_P""
MNG_!-7X3:-?ZUK_[9OP(\1)8Z>^H+IGPP\=:1\7-9O\ "W1BLK#3?AI/XIFE
MU"XDM'B2VE,'DM+:RWCVMM=03R?P$_\ !6K]OR/_ (**_M<ZW\9= TC6?#OP
MP\*^&M,^&7PDT'7Y+(ZQ#X*T#4=8U3^W-8M].ACM;/6?%FNZ[K'B&\L&N=7N
M-'M[VQ\/-KNJVNBV=P.#A*AF-/&3E*G7I8)T9*HJL9PI3FW'V?LXS24IIW?-
M%>[#F4FN9*7K\?8K)JV74XPJX2OF7UBFZ+H3IU*T*24O;.K.FVXTI1LE&;M.
MIR.,7R.4/I?_ (-S?B%KG@O_ (*I_!WPWI,C)8?%OP'\:/A[XG59GB$VAZ;\
M,_$'Q6MXW105N%'B7X9>'IA#(517B2X!\R"-3_H]5_GA_P#!M1\#_$/Q(_X*
M0:+\5+*U5?#7[.WPS^(?C+7M4N%OA FI^.O#6I?";P_HEK+:JUM_;.IQ>-=;
MU6VMM2*6LNC^&_$$\3&_M+-&_N*_;J_::M/V./V0_C[^TK/9V>HWOPM\ WVI
M>&-,U**2;2M5\>ZW=V7A3X<Z3K*0:AI5T=$U7Q[KWAS3]::QU"WU&/2KF[DT
MXR7RV\,G-Q7!5\ZHT:*4JL\/AJ+BMW6J5:O)%^;A.E\FCLX#J/"\-XK$XEN&
M'IXS&8B,Y;1P]+#T'4E'^[&I3K7M]I2ZGS-^WG_P6$_8Q_X)]7DWA#XI>+-9
M\<?&46-EJ$'P3^%NG6_B'QM:V>J0>?IVH>*KZ_OM(\)>"K&>&2SOA;>(_$5G
MXEOM&O;?6/#WAO7K-@6_#W7/^#M+0;>_DC\-_L(ZOJVEC?Y5YKG[2%EX?OWQ
M-,J>9IMA\#O$UO'NMU@E?;JLNR:2: >8D*7-Q_(+K6M?$CX[_%&_US7+_7_B
M-\6?BWXV>ZOKZZ=]2\2>,_'/C/60,DX#7.IZUK-^L4,,:HAFGC@@CCC"(O\
M4=\*_P#@U(^,/B7X;Z9XA^+/[6/A#X6_$K4=+AOY_AQH/PGN_B7I6AW=SI5I
M=QZ)K?CV/XF>#[=M3L=3FNM(UF;P_P"'/$&C0?8_M^C:MK]O<1JOJRR7A[*:
M-'^U:KJ5:J^*4\0E*22Y_9TL+::IQ;7O3YK77-+5)>##B7B_/\37_L&A&CAZ
M+^"%/!R<(2;]G[;$8Z].5:23?+3Y+I/E@TG(^P?A-_P=:_L]^(=3TJR^-'[+
M?Q5^%]E>WCVVHZQX&\;^&OBW::/#)+'%::A/;:GHWPLU*\LT#M/JJ6-G-?V=
MO$_]FV.MW)CM7_I$_9Q_:4^"?[6?PHT#XT_ +QYI'Q \ >(-\$>HZ:[Q7^C:
MO;PV\^H>&O$^C7*Q:GX;\3Z4EW:MJ.A:Q;6M_!#=6EXL4EC?65U<?YGW_!2/
M_@FY\7O^":WQ>T#X;?$G7_#WCGP[XY\/2^)_AY\0_#$5S8Z?XDT^QN4T_6[&
M^T34'DU#0M<T+4)($O[!Y[^SDL[_ $N]LM4NOM4\%G^CO_!LQ^T'XJ^'7[?L
MGP-BUJ[_ .$$_:'^&WC73=2\+R7OEZ5-XS^'>BW/Q"\-^*(K%YHQ-KFE:!X?
M\8Z)!)"DT@TKQ'JK30.D$=S98YGP_EE3+9YCE4G&-.E*NDJDZM*K2A=U%^]<
MJD)Q2EO+247"<$VW'IR7BW.J6<TLGSV$9SJUX864G2IT<10KU>546_8*-&I3
MG*44[05XU%4A4<4HR_O-^-/Q4\/? KX._%GXW>+K/6=1\*?!SX:>._BIXGT_
MPY;V-WXAOO#WP]\+:KXNUJST&TU/4=(TVZUFZTW2+F#2[?4-6TNQFOG@CN]1
MLH&DN8OY[_\ B*A_X)\?]$=_;)_\-]\$O_HAJ_9+_@HO_P H^/V[/^S-OVGO
M_5)>.*_R@*XN&\FP69T,34Q4:CE2K1A#DJ."Y7#F=TD[N_7L>GQEQ'F>28G!
M4L#*C&%>A4J5%5HJHW*-115FVK*VC1_I'_MY_P#!=;]ES]B7PWX$M[70=?\
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M(GXI@L+F2WCUSPX?%GQF\*>)6T;45C^TZ>^N>&]$U)[:2-[G3;61C$OYN?\
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M2:%K.P7OAW5]8TJ>UOY_JZO\C;]F+]IWXS?L@?&;PG\=_@1XLN/"GCOPI<$
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MQ>:)X?U7QOX+^%.F^%;.[LM%U3799-9OM!^-7B75[>W:STFYCC>RT/49#<O
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MRC,88#B>@G"HX<U9TZ-*K1A.7*J\)8;_ &:O034N=0BWHW&I>#A+_4RKQ/\
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MC?8-]CTGX3_#^[^)'C+3M!C61-.1A>ZW=HK8M=+@=3.=XP%FN"5MK<%E+2R
M@_(V/UTL;*UTVSM=/L8([:SLK>*UM;>(;8X8($6.*-!Z(B@9)).,DDDFO#_V
M??AD/A]X-BN=0@5/$GB-(=0U5F5?-M("I:QTP,"Q MXI#)<*& -U+(&7]VN/
M>J_LGPLX0_U9R"&)Q=+DS?.(T\5C.96J8>A9O"X)WUBZ<).K6CHU7JSA*ZI0
MM_IAX ^'"X%X0IX[,*'L^(^)(4,?F//&U7!X3E<LORQW]Z$J-*I*OBH636+K
MU*4^94*;11117Z>?O 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9&L?ZB+_ *Z_^R-6
MO61K'^HB_P"NO_LC4X[KU7YDS^%_+\T=[H__ ""K#_KUA_\ 016E6;H__(*L
M/^O6'_T$5I5P3^.7^*7YLZ(?!'_#'\D%%%%24%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<)J/\ R-VF_P#7WI7_ *41UW=<)J/_ "-VF_\ 7WI7_I1'6U#XI_\ 7N?Y
M&=7X5_BC^9[G1117":!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YE\*_\ D;M6
M_P"P5?\ _ISTZO3:\R^%?_(W:M_V"K__ -.>G5M'_=\7_P!>X_FS*?QTO67Z
M'T+1117DFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 <7\0_^1-UK_KG:?\ IPM*
MM_!#_D39O^PW??\ I-8U4^(?_(FZU_USM/\ TX6E6_@A_P B;-_V&[[_ -)K
M&NQ_\BRI_P!A2_\ 2("C_&C_ ()?FCV&BBBO+.D**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ()??LSV5QI":7XA^)NB:[\;/$MPJW<<FMR?$_Q#J.O>#]7GBN9YEC<_# ^
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MO[3N@RWD*:QJ7P!TC5['3V)^T7.FZ)\1-!L]5O(EQM,-C=:_HT$Y+ J^HVX
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ME77QHTB[9I'COK3XU6=K\3-0>!I@)-EAXB\2ZYHDJE5CBN]*N8K<O:QPRO\
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M&]!*C[M%TXVIKE5K*]KG]]O_  47_P"4?'[=G_9FW[3W_JDO'%?Y0%?ZO_\
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M3_@ZA_Y1\?!W_L\GX??^J2_:&KX+(O\ D<9?_P!A$?R9^J<5?\D[FW_8*_\
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MCZ?96UIIRV?[%^!O^#H'X:?%+0!\./VW?V%?#_C;P%JTNG77BJ7P-K.@>/M
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MA%OV<,QPD85'!./M'AL7&G&3D[13FY5XI\O-%Z'^QY7^3O\ \%!/B5JOQ?\
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M"7@SQ'X;UR?1O$_PO\<Z_%_:\^O:[81:G<:C:6%_<Z#J%K860?2[R>;]>_\
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M32^'V\H-*_NI7Z*_Z44445\.?IX4444 %%%% !1110 5\1?\%+O^4=O[<_\
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MV7[7_8WA71K+0M+^U?8+2PL?M'V&P@\[['8V5KYF[[/:6\.R%/\ -S_X()_
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MYX%\#^$_V?O^"@/]N+8>#M)T/PEX#_:-\,:!JOBJ\;PUHFESVMNGQQT:RO\
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M@N]"GTG4/"/\''[2/[$O[5W[(^LW6D?M"_ CXC?#>VAU/4-)LO%6K>'-0F\
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M>+B\7B(S5:,*::7M%.JU*I**]E&FI1OS.,7^AM?Y"?[0'_)>/C9_V5SXD?\
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M )@;]IK_ .<Q7^:317%_J;E?_/\ Q_\ X-P__P RGI?\1&SO_H%RK_P1B_\
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M\.P/ ?Q<\$?\+Q_X7A_PM/Q=H'BK^T_^%9_\*T_L+^P]&N=(^P?8O^%@>/\
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M5J<,<[Z-XDT;1-9-GJ$>GOI]U_7]H'_!U;^QC<^&_M7BG]GO]I[1O%_V3?\
MV'H%A\*O$OAO[?\ 8(9/LW_"5:C\2O"FI_9/[3:XL_MO_"'>=]@BAU'^S_M$
M[Z5;9/[7/_!KQ\ _B=K_ (D\<?LJ_%_7?@#JFMZB^K+\,_%>AQ^/?A78RSAQ
M=:5X6N[2[T3QEX/TF2=DOH$U"]\>I82"ZT[3[.UTN?3[?1?RZ_XA6_V]_M_E
M_P#"Z_V0O[+^V;/MG_":?&;[?]@\[;]I_LW_ (43]G^V?9_WOV'^U?)\[_1_
M[0V?Z37OXC%<+YQR8C%5?95HQC&7.ZM"JH[J$^5.G4Y6VN:+FTKI22L?)X/
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M]?$02]BY0H-TZ-*DXQER-J7N1I^S46Y+FOVHOV>_!?[5W[//Q@_9T^(,</\
MPB_Q;\#ZQX3GOY-.MM5F\.:M<1+=>%_&6FV%XRVL^N^!_%%IHWC#P\9G1(==
MT/3IRZ&(,/\ *?\ VC?V>?BI^RI\:?'OP#^-'A]O#GQ"^'FLR:5JULC2S:;J
M5K)&EUI'B+P_?2P6S:IX:\2:5/::UH&I_9X#>:9>VTLMO;7'G6T/^NU7PG^W
M#_P3@_92_P""@_A*Q\/?M"^!;BX\0Z!;W%OX+^*?@V_C\-?%#P.MTSO/%H7B
M(V>H6.H:9*TLTK^&?%VC>)_"3WLHU1M ;5K>SOK;R.'\\_LFI4I5XRJ82NU*
M2A9SI5$N7VL8MI24HVC4C=-J,7%WCRR^BXLX8>?4J5;#3A2Q^%C*,'4NJ=>C
M)\SHSE%-P<9WE2G9Q3E.,E:?/#^1[_@F%_P<5ZY^R9\)?"'[./[47PS\2_%W
MX7_#K2K'P]\.?B%X#U:U?XH^%O"=E=7 M/".LZ%XOU2S\/\ C+1M TN>UT?P
M4UMXD\%/X7T#0M/\.2PZU926=WH?N?[>O_!SL?B9\+?$/PO_ &'/AO\ $GX4
MZYXOLVTO4OCC\3+OPSI'C?PEHUS;K'JL/@+PEX0UCQCI^F^)]0\V:TL/&UUX
MR:Z\,VL4E]HVBKXBO--UKPQSOQ;_ .#47XYZ?>:A+\"/VJ?A/XNL'U&1M*L/
MBWX6\7_#J\MM)D:-XHM0U;P=;?%*&]U&T5YK:2>VT6PMM1:WCO5M]+%XUA8<
M[\+?^#4O]I_4O$-C%\:_VE_@+X,\*>=.VI7WPML?B%\3?$/V>*!9+6.QTOQ9
MX7^$FF^=>W6^TGGGUC9I<!74([?5Y =,/T,GPA4KO'RJTG-R=65-_6%"52ZD
MY2PW)JV]7!1Y).]X2;9\?"/B%1PJRJ%"NJ:@J$*J>#=2%&W(H1QJJ6C%1TC4
M<_:0C\-2*BK?S/?!WX1?$+X^?%/P%\&/A3X<N_%GQ%^)?B?2_"7A+0;/:C7F
MJZK<+"DUY=2E+72](TZ'SM3US6]0EM]*T+1;._UG5KNTTVQN[F+_ %'_ /@G
M1^QGH/[!?[(_PM_9VTV?3-4\1Z'83>(/B=XGTE;D67BWXH>)#'>^+];M9+V&
MUO9],@N5M] \.RWMI9W@\+Z'HD5U:6]Q%)$OG/\ P3__ ."5O[*W_!.WP_>#
MX2>'KOQ3\3?$%IID/B[XR^.Q8ZKXWU-K+3A:7-AX?>*UAM/!/AB\NYM0OY-
MT!(Y+MKR*'7]4U_^R]*EL_TFKP>(,^6:.&'PRE#!TI<]YJTZ]1)I3<?LPBFU
M"+;;NY2L[1C]5PEPJ\CC4Q>,E"IF%>'L^6#YJ>&HMJ3IQG9<]2;C%U)I**45
M"#:YI3_AN_X.N_\ DX_]E7_LB7BO_P!3N:OC;_@VS_Y2A>"O^R1_&#_U'8:_
MJ2_X*N_\$8?^'GOQ'^%7Q!_X:1_X4A_PK+P1JO@[^R/^%/?\+*_MO^T]>?6_
M[1^W_P#"TO ']F^1O^S?8_L5_P";CSOM4>?*'C7_  39_P"" W_#O7]J'1/V
MDO\ AK'_ (6]_8_A'QAX5_X0S_A1'_" ?:?^$KTY+#[?_P )%_PN3QKY/V#9
MYOV7^PI?M6?+^T6V-Y]*CG&70X<E@)8FV+>$KTE2]C7?[R<ZCC'VBI.EJI+7
MGLKZM:GBXKAW.:G&,<UA@^; +,<)7=?ZQA5^ZI1H*I/V3KJM[KA+W?9\SM[L
M7=7_ *+:_B;_ .#L?_DJG[&/_9/_ (P?^I'X'K^V2OQ-_P""LG_!';_AZ%XJ
M^#'B;_AHK_A1W_"HO#_C#0OL7_"H_P#A9G_"0_\ "5ZCH>H?:OM/_"SOA_\
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M*:_3^OS _P"",?\ R:#\>_\ LY'P#_ZK#Q37Z?U_.OCY_P G'S'_ + ,L_\
M49'^6OCE_P EI0_[$&5_^E8D****_&#\<"BBB@ HHHH **** "BBB@ HHHH
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M^S3"BBBOHS[8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?+WAC_DM^I?]A7Q+_Z3WU?4-?+WAC_DM^I?]A7Q+_Z3WU?4
M-=^8?'A_^P2A_P"W'/AO@G_U\E^40HHHK@.@**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "LG7-!T/Q/I-]H'B71M)\0Z%J</V?4M%US3K/5M)U"
M.D@@OM.OX;BSNX1)&DGEW$,B;T1MNY01K44)M.Z=FM4UNGW$TFFFDTU9IZII
M[IKJF?)NN?L$?L+^)K^35?$G[%W[)OB#5)=_FZEKG[.?P?U:_D\R::Y?S+R_
M\'7%P^^XN)YWW2'=---*<O([-Z5\._V;OV=OA#?QZI\)O@)\%OA?J<-FFGPZ
MC\._A;X&\%7\5A'"]M'8QW?AK0M,N$LTMY)($MED$*PN\2H$9E/M%%:RQ%>4
M>25:K*.W+*I-QMVY7)K\#".%PL)\\,-AX33NIQHTXS3[\RBG?SN%%%%9'0%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 51U/3--UK3=0T;6=/L=
M6TC5K&[TS5=*U.T@O]-U/3;^"2UOM/U"QNHY;6]L;VUEEMKNTN8I(+B"22&:
M-XW93>HHVV!I---73T:>S79GRGKO["/[#WBB<77B;]C7]E/Q%=":YN!<Z[^S
MQ\(M7G$]ZZ27DXFU#PA<2":[DCCDN9 V^=T1I6=E4C=\%?L<?LA_#:Z-]\.O
MV5OV;_ -Z?/S>>"O@=\,?"MT?M4<4-SFXT+PO83?Z1#!#%/\_P"^CABCDW+&
M@'T?16SQ&(:Y77K./\KJSM]W-8YU@\(I<ZPN'4[WYU0I*5]->91O?1=>B"BB
MBL3H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK^BS^T@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?+WAC_DM^I?]A7Q+_Z3WU?4-?+WAC_DM^I?]A7Q+_Z3WU?4
M-=^8?'A_^P2A_P"W'/AO@G_U\E^40HHHK@.@**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7Q%_P %+O\ E';^W/\ ]FE?M!?^JL\45]NU\1?\%+O^
M4=O[<_\ V:5^T%_ZJSQ173@O]\PG_830_P#3L#DQ_P#N.-_[!,3_ .F9G\>O
M_!&/_DT'X]_]G(^ ?_58>*:_3^OS _X(Q_\ )H/Q[_[.1\ _^JP\4U^G]?SK
MX^?\G'S'_L RS_U&1_EKXY?\EI0_[$&5_P#I6)"BBBOQ@_' HHHH **** "B
MBB@ HHHH **** "BBB@ K1TG2K_7-4L-'TRW>ZU#4[N"RL[>-69I)[B18XQA
M0Q"@MN=\81 SMA5)&=7W)^RC\,0?M'Q(UBWZ>;8>&8Y8^A^:._U10Q^EI:OL
M_P"?ET?[M?2\(\-XGBK/L%E%#FC3J3]KC:\5=8;!4FGB*SOIS<K5.DGI*O4I
M0>DKGW/ASP3C?$#BW+.',(IPHUJGUC,\7%76!RK#RC+&8EMIQ4^5QH8>,O=J
M8JM0IMI3;7U3\-O UC\//"&E>&K,*\MO%Y^I70!W7NIW #WERQ))V[_W4*\!
M+>*) HP:[NBBO[JP6#PV7X3#8'!THT,+A*%+#X>E#X:=*C!0A%=6U%*\G=R=
MY2;;;/\ 6'+,MP63Y=@<JRVA#"X#+L+0P6#P]-6A1P^'IQI4H+JVH17-)WE.
M5Y2;DVV4445TG<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9&L?ZB+_K
MK_[(U:]9&L?ZB+_KK_[(U..Z]5^9,_A?R_-'>Z/_ ,@JP_Z]8?\ T$5I5FZ/
M_P @JP_Z]8?_ $$5I5P3^.7^*7YLZ(?!'_#'\D%%%%24%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %<)J/_(W:;_U]Z5_Z41UW=<)J/\ R-VF_P#7WI7_ *41UM0^*?\
MU[G^1G5^%?XH_F>YT445PF@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>9?"O\
MY&[5O^P5?_\ ISTZO3:\R^%?_(W:M_V"K_\ ].>G5M'_ '?%_P#7N/YLRG\=
M+UE^A]"T445Y)J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%_$/_D3=:_ZYVG_I
MPM*M_!#_ )$V;_L-WW_I-8U4^(?_ ")NM?\ 7.T_].%I5OX(?\B;-_V&[[_T
MFL:['_R+*G_84O\ TB H_P :/^"7YH]AHHHKRSI"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /E[PQ_P EOU+_ +"OB7_TGOJ^H:^7O#'_ "6_
M4O\ L*^)?_2>^KZAKOS#X\/_ -@E#_VXY\-\$_\ KY+\HA1117 = 4444 %%
M%<7\1_B+X)^$7@'QE\4?B1XBL?"7@'X?>&]8\7>,/$NI"=K/1?#V@V,VHZI?
MRPVD-S>W30VL$A@LK"UNM0OIS%9V%K=7D\$$C2<FHQ3E*32C%)MMMV226K;>
MB2U;%*481E.<E&,4Y2E)J,8QBKN4F[)))-MMI)*[.AUO6]&\-:-J_B/Q'J^F
M:!X>T#3+_6]>U[6[^UTK1M$T;2K66^U35]7U2_E@L=-TS3;&">\O[^\GAM;.
MUAEN+B6.&-W7\$/VE_\ @Y%_X)[? Z[OM ^&FH>.OVF_%-G)' Y^%VB)I/@*
MWNDU!K>^M[KQ]XUET.#4(X+"*2_L]2\%:)XST;499]/M(M2B6:_N]+_E0_X*
M??\ !5W]H#_@IA\6+SX:>#I?$FD?LWVOQ GT_P""?P3\-V%VFN^.7GU"UTCP
MCX@^(&E:1+>W/C#Q_KDD-O?:-X;#:II_@[4-:N-"\,+>WDE[KFM?JU^PY_P:
M]ZUXQ\-^'?B%^W/\3M?^';ZO;PZDWP,^%!T23QEIEM-#<O;V7C+XAZM:^(/#
MVD:GYOV&74=%\.>'O$'EV;7-DOB;3]4<OIWV%+(LNR[#T\3GV)E&=57IX.BW
MS.R3<9.*=2<DFE-P=.%.3LZDKIGYY6XHS?.,75P7"V#A.E1?+5S'$I<BN[*<
M%-QI4XMJ3@JGMJM6*<HT8M-'?W__  =JV$=W*FE_L$7EY8KY?D7-_P#M.PZ;
M=R9B0R^;96_[/VJPP[)C)''LOY_,B5)6\II&AC^R/V=_^#GC]BGXJ>)-/\*_
M&/P!\4?V=KC5;C3;2T\5:Q_8_CWX>VEQ>S6MI.NNZYX>DL?$>CV]M<7+3#47
M\&7.EKIEK=WVI7NE.D5I-]0:=_P;R?\ !)RQ\/1Z+<_LYZ]K&I1V,]HWBW4?
MCC\<XO$,T\HE$>IR6VD?$32_"@OK8R(T$</AF+36,$7VG3[A3,LWXR?\%)O^
M#:K2?AY\/O$?QK_80\2^*M=B\$^&[WQ!XO\ @3\0]5L];UW5[#1H8)=1U#X7
M^*H-.TAY[^WTN"^UBZ\'^)A?7VKW,-W#X:UUKRYT?PH[I/A'&36'C0Q>"G-\
MD*]2I44>9NT7>6(Q$(W?6I3C!7]YKI-=>(.74WC)XK 9E3IKVE3"TJ-)SY$K
MR7+#"8.I.RO=4:LYNWNJ3W_L<\ ^/_!'Q4\&>'/B)\-O%>@>.? OB_2X-9\,
M>+/"^IVFLZ#KFF7.X17>GZC922V\\8=)(9E5_,M[F*:VN$BN(98DZ^O\X#_@
MAU_P4O\ 'G[%W[3?@?X2>*O$&LZS^S-\=O&&B^!?&/A"^U;5+K1?A_XG\7ZE
M8Z+HOQ9\*Z/+JL&C:-J5AJKZ/#X^O+>PN;O7O MO>P?9-0UG2/#1L_\ 1_KQ
M,XRFIE.)5&4O:4JD7.A5MRN44[.,E=I3@[*5G9IQDK<UE]-P[GU'/\$\1"'L
M:]&:I8JAS<RA-QYHSA*R;I5%=P;5TXR@[N/,RLS6];T;PUHVK^(_$>KZ9H'A
M[0-,O];U[7M;O[72M&T31M*M9;[5-7U?5+^6"QTW3--L8)[R_O[R>&UL[6&6
MXN)8X8W=<GQOXW\'_#7P?XE^('Q \2Z-X.\$^#M&O_$/BGQ3XAO[?3-$T'1-
M,MWNK_4M2O[IXX+:VMH(V=F=LL=L<:O(Z(W^<Q_P5K_X*_\ Q;_X*)_$;5?A
ME\.+[7_!O[)NA:_'8> _AKIYN+;5/BC=Z=J)&E^/OB3!;HEWJVL:M=I;:AX<
M\%R^=HW@V---AMK6^\3P:CXDU,RC)\1FU9Q@U2H4[.O7DKQ@GM&*NN>I))M1
MNDDFY22M<X@XAPF08:-2K%U\56YEAL+"2C*HX_%.<K/V=&+:4I\LI-M1A&3N
MX_T\?M,_\'*7[!'P0UNZ\*_"ZU^('[3.NV-\]I?:K\.+'3M#^'5N(%A-RT'C
M;Q9=6,^ML7F:.QN/#/AS7-%OFM;M_P"V[>'[%+??G_\ \1:MA]O\O_A@B\_L
MO[9L^V?\-.P_;_L'G;?M/]F_\,_?9_MGV?\ >_8?[5\GSO\ 1_[0V?Z37FO_
M  3U_P"#935?B%X1\-_%K]O+QEXJ^'-OX@M[#7='_9^^'K6>F^/;32IUBN[6
M#XJ^*M=TG4K?PGJE\@*:GX(\/:1>Z[I>G7,46H>+?#7BI-0T31/VRT[_ (-Y
M/^"3ECX>CT6Y_9SU[6-2CL9[1O%NH_''XYQ>(9IY1*(]3DMM(^(FE^%!?6QD
M1H(X?#,6FL8(OM.GW"F99O:J+A'!2="=+%YA.#Y9UJ=2?+S+>THU\+3DD^M.
M,X]F]6?-47X@9G%8JG7P&4TJBYZ>'K4J:GR.W+S1J87&UH-K6U25.6]XQT1X
M7^S!_P '+'["?QPUO2O"/Q:TGX@?LQ>(]3;RDUKQ[#I7B7X6)<NJ""TE\>^&
MKDZIIK2RF57U#Q)X)\/Z!:Q+%-=ZS")'2#^A'1-;T;Q+HVD>(_#FKZ9K_A[7
M],L-;T'7M$O[75=&UO1M5M8K[2]7TC5+"6>QU+3-2L9X+RPO[.>:UO+6:*XM
MY9(9$=OX=O\ @JS_ ,&[L'[-WPQ\5?M(_L:>(O&7CGP#X(M#K7Q$^#7BN%_$
MGCCP[X;B:TAU'Q5X)UW0M*@D\2:)H*27.L^)]+UO3;2_T#PW9W^NC7M6M[*Y
MMK>I_P &Z?\ P5#\<_#KXP^%?V"OC#XK_M?X*?$R35++X(W&O2S3WOPU^*%P
MSZI9>$-%U*21C!X-^(4JZE9P^')HYK:S\>WFD7>AG2VU_P 2C5HQF2Y?B\#4
MS+)*M24**DZ^%JMN4(PCS3Y>9<ZG"/O.,I3C4C=TYW24M<OXDS; 9I2R;B:C
M2A4Q/+'"XZBHQIU)3ER4^?D:I2IU)IPYX1IRI5+1J4U%N4/[IZ***^1/T **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKY _;P_:\\$_L-_LL
M_%/]HKQI=61F\*:,VG^!?#]TT4EQXT^)6O;M.\$>%+'3SJ6EWFJ+>:Q)'J&O
M1:9=K>Z9X0TSQ)XB;R[+1;RXATI4IUJM.C2BYU*LXTX16\I3:C%+U;,J]:EA
MJ-7$5IJG1H4YU:LY.RC"G%RE)^B3]=D?#W[;W_!=C]C/]@WX\:C^SK\3O#GQ
MR\>_$'0?#7ASQ#XH;X1>%_A_KFB>%9_%-K+JND^&=<NO&/Q0\":A%XE?PY)H
MWBB6VL]+O=-30O$^@S)JLE[/?6.G_1__  3V_P""F7P#_P""E/AGXD^*/@5X
M:^*?A:U^%FNZ#H'B33_BMHW@S1-6FN/$FGWVHZ9>:9:>#_'OCN.33I(]-O8#
M<7]QISO<V\T=O#.L,KQ_YS'P^^%GQ=_;<\6?M:_'SQ-=:IXDN_AU\,OBM^T[
M\9O%0OM.M;B;5KJXGETX%M5F8R1ZGXRUFS>32]/@NKP^'[#5+73UL_)CO;/]
MV_\ @U,^)=IHO[3'[3GPFN-3^RS?$+X+>&_&MAITDLL4.J77PQ\9KI;^4IN8
M[:XU"QLOB9>3P0&UN+T6#:K<VTMM:6VHB?[3,.'<#A,KQ%2E*I4QV$I4)5I*
M;<.>4J;J_N_LKV;E.*>JBXMM[GYKE'%^:8_/,)1KPI4LKS"OBH8:#I*-3V<(
M5%1_?7]^4:L80FUI*?/%)627]SM%%%?#GZ>%%%% !1110 5\Y?M._M;?L[_L
M<_#J[^*'[1GQ1\-?#?PU&LZ:3;:G=BX\3^+]0MS;J^B^!O"5D+CQ'XQUE3=V
MTMS8>']-OI--LGDU;5FL-'M;S4+;Z-K_ ##?%WC;Q-_P4L_X*S:)9:WXG\2>
M+O!GQM_;'M/"W@VU\0:QK'C>P\&_!+Q!\6UBM-.T>PU;68(X_#?ASX?,U_+H
M>D7>B:9+;64\6G0Z9#)#'![>2Y5#,ZF(E6JRHX;"4U5KRA%.<HOF:A%O2#:A
M-\SC-)1?NL^:XDSZ>2TL)3P]"&(QN85GA\+"I)QIQDG!.I44;2G&,JM./)&4
M&W)>_$_TW-!U9-?T/1M=CL-6TJ/6M)T[5H],U[3I](US34U*SAO%L-:TFZ"W
M6EZM9K,+?4=.N56>RO(YK:8"2)A7S'^VO^V7\)/V#/@%KW[1/QHL_&6K>$-$
MUOPSX<BT+X?Z-IVM^+]<UGQ3JT.F65GI%IK>M^&= C^R6[7NLW]QK?B/1K5-
M,TJ]BM)[S6)M,TG4?K*OB/\ ;X_8+^$G_!1/X,Z%\#?C1XL^*/A'PAH/Q&T7
MXF17GPFUWPSH&O:AK.@^'O%?ARRTS5+CQ7X.\;Z7=: UOXOO=0GLETB&Z.JZ
M?H]W%?PI:2P7/F87ZL\31^M.<<+[2+K<EW/V:=Y*-M;M>[=:J]T>UC?KBP>(
M^HJG+&^QDL/[7W:7MFK1E/IRI^]9Z.UGHSR#_@GE_P %6_@'_P %+M2^*MC\
M!OAW\<O#%K\'+'P?=^,-9^*^A?#?0--,_CN?Q)#X:TS2HO"?Q3\<:O>WUY'X
M1\174LCZ5;:;:0:<5N=0BNKNPMKK].Z_.[_@GM_P3-^ ?_!-;PS\2?"_P*\2
M_%/Q3:_%/7=!U_Q)J'Q6UGP9K>K0W'AO3[[3M,L],N_!_@+P)''IT<>I7LYM
M[^WU%TN;B:2WF@6:5)/T1J\<\&\55^H*HL)[BI>UNZC_ '<>=ROU=3GMT4;>
MIEE:S!8&A_:KI/'M5'B/8J*I)^UG[-0Y=-*7)S/6\^9Z*R11117(>@%%%% !
M1110 4444 %<QXS\;>#/AQX7UKQQ\0_%WACP'X*\-V9U#Q%XO\9Z_I7A?POH
M-@)(X3?:UX@UR[L=)TNS$TL41N;Z[@A$DL:%]SJ#T]?P&?\ !S=^TKXF\;_M
MPV/[/.D>+O$D/@#X+_"CP#;^)O!$/B;6#X4N_B3XL.K?$%_$5YX62\30%UE/
M!7BKP38PZA)ISZM]FME\S4)+1K.UL_4RC+99KC(X55/914)5:E11YW&G!Q3M
M&\5>4I1BFW9-W:=K/Q.(,YAD673QTJ7MYNI"A1I.?LU.K44Y*\N6348QA.<D
ME=J+2:;NO[=_V;/VE_A/^UI\,8?C+\#]5UCQ)\,=1\2>*/#?ASQ=J7AK7/#-
MAXN;PAK%QX?UC7/#$'B"RT_4-3\-C7+'4M*M=7-G!%<7^EZE;"-9+251[Y7P
M!_P2L^$'_"B_^"='['?PZD@^RWT'P/\ "7C'6K(V/]GR:?XD^*4,WQ2\3Z=<
M6XO;\/>:=XA\9:G8WMXMP$U&[MYM02UL5NA8V_W_ %Q8J%*GB<13HN3HTZU6
M%)S:<I4X3E&$I-**YI12;LDKO1(]' U*];!82MB8QCB*N&H5:\8)QA&K4I1G
M4C%.4FHQFW%7E)V6K;"BBBL#J"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K$\2>)O#?@W0=5\4^+_$&B>%/#&AVDFH:WXC\2:K8:'H.CV$./-O=
M5U?5+BUT_3[2+(\RYN[B&%,C<XR*_,__ (*G?\%0O!__  3$^&OP[\9:Y\+=
M9^+_ (E^*7B76_#WA3PGIOBS2_!5BJ>'-)AU+5]2UCQ!>:7XDO[6V@DU#2+.
M,:;X5U@%[YGNI;-H[6*__AX_:$_;G_X*4?\ !8/Q[;_"JWL_%_CG0[S5/[5\
M._LY_ OPSJ=MX$TR33X[^_M-1UFPM)+[4->N-*LX;VYC\0^/M<U,:>(+F>PF
MTV$-$GO97D&)S&"Q,YT\+@4WS8FI*.JA)QGR0YD[Q::<JCIP6ZE*S1\KGG%F
M!RBI+!TZ=7'9FU%0P=&$URRJ1C*E[6IRM6G&2<84E5J/1.$5)2/U,_X+)?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%JI&U7 Y;R\^7Y?9KFIS<)O%XN+Y9>WK1HU$WA8,****_53^@0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *R-8_U$7_ %U_]D:M>LC6/]1%_P!=
M?_9&IQW7JOS)G\+^7YH[W1_^058?]>L/_H(K2K-T?_D%6'_7K#_Z"*TJX)_'
M+_%+\V=$/@C_ (8_D@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA-1_P"1NTW_
M *^]*_\ 2B.N[KA-1_Y&[3?^OO2O_2B.MJ'Q3_Z]S_(SJ_"O\4?S/<Z***X3
M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O,OA7_P C=JW_ &"K_P#].>G5Z;7F
M7PK_ .1NU;_L%7__ *<].K:/^[XO_KW'\V93^.EZR_0^A:***\DU"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#B_B'_R)NM?]<[3_P!.%I5OX(?\B;-_V&[[_P!)
MK&JGQ#_Y$W6O^N=I_P"G"TJW\$/^1-F_[#=]_P"DUC78_P#D65/^PI?^D0%'
M^-'_  2_-'L-%%%>6=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO4A!-1LG*%2/>"3T]@_X)Z?\%'_@!_P4A^%NK_$#X,2:YH/B+P5>:7I'Q/\
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MRD\-VLMU8_##PM=0R7-A<V(L[_Q#XX\-WMIJ#R>%M7TZ7^FW_@L4_P"UW?\
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M,MI/=S0Q:%:Z+X2M[Z32+B:YBTG5_AY:K>7,FFR1:GI=G]H%U_95^QQ^V/\
M _\ ;K^!^B?'SX!ZWJ&I>$=2U"\T#6=&U^SM]+\7^!_%VEV]C=ZMX,\9Z3:7
MVJ6FF^(M-M-4TN^DCL=4U33+[3-4TO6-'U34M(U*QOKC\??^#F#X/_"OQ3_P
M3]N?B]XD\,Z--\4OA;\1/ 5A\./&+K%:^(=/L_&7B&VTCQ3X;@O$*7&H:-JN
ME-+J=WH<K36HOM'LM96!+C3%F7\_?^#3+7O&$MS^W!X8%S<W/@&Q@^ FO-9S
MZA</9Z-XPU63XL:>ESI>E/?"UMKGQ+HNCR1:]J%MIDEQ>Q>%/#EM>WT,>GV%
MO/.,PV7YCDM7.,+A(X"OAZT:56E3DO8U+SI0?+%*,5I6C*+C"#34H-3TD7EV
M-S;*.):/#V-Q\\UPN+P\JU"O6A_M-&U*O57/-RG.6N'G":G4J)Q<*L?9WE _
M0S_@MS_P6(^,?_!-SQK\"/AO\ _!/PH\7>*_B%X6\6^-_'$WQ<T7Q3KFFZ9X
M>M-6TW0?!T7AVV\&?$7P/J45]J&I6GC!]8GU=)[$6]AI4>EO<3R:H+'^%']J
M']H[XA?M<?'WXE_M&_%1=(B\>_%/6[?6]>M?#XUM/#^G?8=)T[0=+TC08/$>
MN>)=9L]$T?1M)T[2](L+S7-1_L_3[.VL;>5+6W@AC_U1OVN?B]_PH']EC]HS
MXV)J5OI-[\+/@G\3?'&BWEQ+I46[Q'X>\'ZOJ'ABQM!KB2Z3<ZIJOB&'3-+T
M?3[Z"YAU/5;RSTXVEVUTMM+_ )]?_!OC\(?^%K_\%2/@;>W6FW&IZ)\(]$^(
MGQ>UR.&'53':?\(_X/U+P_X5U*[O-*DA_LZWL/B%XJ\'7"S:C,FE7]VEMH5Y
M'=_VO'97/?PWB,-0RW&XQ8*,*F!HS53$*JW4Q;?/7=-ITTJ23C1A'6I>\6[6
MU\CC/!XW%9SEN7RS*=6CFF)INCA'14:67J]+"JJFJLI5W+GKU)WC2M:25^=\
MO[I?\$@/^"U?[9G[=G[7/@G]FOQ1\(/V8_!WP=T/X=^,O%'BR7X2_#7XJZ-K
M'AGPIX.\/)I'A:UT.YU#XN^*/"_AC28_&&J^#-%9]2\.S:;_ &?<_P!@Z<+/
M5-2TJ>'^F;X_?'[X2_LP?"7QA\;OC=XPT[P/\.? ^G-?ZSK-^Q>:>9R(M/T;
M1M/B#7FM>(=:O&BT[0]#TZ*?4-4U">&UM87=^/8Z_P [C_@O3^WIXQ_;;_;+
MNOV;OABVM:Q\'OV=/&VJ?"OP)X4T""XU"Y^)7QJ.H1>&/''BZ/2=+MY;C7[^
M3Q);R^ /AW;PR:RCZ%ITNM^&_L5Q\0M=L9O%PN$I9_F26'PL<NPE*E&6)5.?
MM+1C)WDIRA!.K5<E&-XVBHN;4E!I_38W'XCA/)I2QF.GG&/KXB4,&ZM+V/-.
M4(*,'3A4J-4:$82J2<9ISG-4TX.HI+ZV_:K_ .#GC]I+Q_XXU'P3^Q%\+_#'
MP_\ !USKAT?PAXM\<>&9_'WQA\5_:&M['2)[/PK'J,_@OP_=ZI?2SO%X>?2/
M&][*TVEVT6IQS17<%[\\:]_P5:_X.%_@UH%O\3/BU:_'#0OATXL]GB+XJ_L1
M>#?!7@*Z^UQ_VI:'_A*8O@?X/B;[?IUG=20>1KZ"?3C=W5O\T,=U;_U"_P#!
M(O\ X).?#/\ X)[_  =\+^)O%WAG0/$/[7GBS0+N3XJ_$P,NIR^&X]?GM;U_
MAAX%N6:2VT[PSX=MK+3-/U?4]/!NO&.OVFJ:Y<7BZ+=:)H6B?L7=VEI?VMS8
M7]M;WMC>V\UI>6=W#'<VMW:7,;0W%M<V\RO#/;SPN\4T,J/'+&[(ZLK$'HK9
MODV$J/#X/)L)BL/2ER/$8A1G5K<KM*<)3IU)1C*S<9.3NFGR17NG'A^'^(\?
M16+S'B3'X'%UHJI'"8-SIT<-S+FC3JTZ5:C"<HIJ,X1C'EDFO:U/B/YBO^"8
M_P#P<7^$_P!J3XBZ'\!_VN/!_@OX(_$OQC?#3O 7Q#\(WVJ6/PE\3Z[<"P@T
MSP;J=AXIU77-8\&^(-9O'O4T&^O_ !+JNB:O=/9:$UQIVKSZ>FL?T^U_G.?\
M%_OV&/"G[$O[96@^+_@OH#>"OA%^T'X;N/B1X3T;0M'MO#?A?P-\0?#^N/IW
MCSP9X$AT:VLM-L-&T5;CP?XML-.T]+8^'5\:P:3;6EKIEGI,EQ_:5_P25_:1
M\3_M8_\ !/+]F?XT>.M376/'VI>#]3\'^.M4DN5N-2U?Q/\ #'Q5KWPXOO$6
MNG[3<O'KOBZ'PM:^,-3#FW$\^OF\M[*RL[JVM8L<[R_!QPN#S;+HNGA<9:$Z
M+;?LJKC.5HW;:5Z=2$XW<8SA[NDK+HX9S?,9X[,,@SB2K8[+TZE/$I)>WPZG
M3C>=E%-VK4:E.7*I3IU&JBYH-RU/^"HO[8NN?L(_L4_%;]HSP=:>$]5^('AJ
MZ\%:'\/M!\;Z=K&J^&M>\3>*_&NA:)+8ZE8:#K_A;5)X;3P[=:_K;_9?$&F/
M$FD/,KW;1KI]Y^,'[(G_  <)^+-3_9(_:%_:K_;<\,?"+0H?"GC;0/A?^SC\
M-O@CX=\<^%O$GQG^)$7AJ]\2^-] .H>.?'OQ#L9-,\.6.N?#J]\1>(=/AL[;
MX?Z/K!N];M=<U7Q7X'T'5(?^#K'XP/X=_9I_9F^!L**LGQ5^,7B?XA7-P8#(
MYTSX-^$X='FL5F8-% MSJ7Q?T>\?:$NI3IJ)#*MM]MBF_(__ ((&?\$P-)_;
MG^(FM_&_]H/3[[Q!^S%^SSK-KI6B>"]0NKPZ!\2OBYJ L_$4OA.XMC#-9S>#
M_"^D2Z=XC^(>D1W6FS:U=>(_ ^FW$6K:'JGB.WA[,NR[+ED$\?F$-)8B53VD
M5^_E2IU(4UAZ+NDG5JTY0<MU&<W>/Q1\_-\XSB7%D,JRFKK'"1I.C-_[-"O6
MHSK2Q>(CRR<EAZ%:%2,5I*=.E'EFVX3Z7XN_\%OO^"U?Q2TKQ'\?OA#X+\7?
M []G)-0V:?KW@G]FK3?B#\./#EMIVDBZN+'5?B[\2?AIXOTO4+^6RD37-8NI
M+[2HUW)<V&G:1I3?9#_7S_P3%^(G[3OQB_8N^$/QC_:WU#1;GXL_%FPOO'\.
MEZ'X,A\$P^'? 6NW;M\/].O+*WU&]CU*_P!5\,06/B^;4OLNC200^)X-"GTR
M2;19-6U3[FM]!T.TT.#PQ:Z-I-MX:MM)CT&V\/6^G6<.AV^APV:Z?#HT&DQP
MK81:3%8*MC'IT=NMG'9JMLL(A 2K&F:9INBZ;I^C:-I]CI.D:38VFF:5I6F6
MD%AINF:;801VMCI^GV-K'%:V5C96L45M:6EM%'!;P1QPPQI&BJ/%Q^983%T(
M4,/E>%P+A44E5I*,JLZ2BXJG.HZ<9R=[2E)R;DTMKRYOI,JR7'X#%U,5C,\Q
MV9JI0<'0KRG"A"O*<92JTZ*JSIQCRIPIP4(J"D_B]WDO4445XY]$%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?!O[77_!.#]F+]NGQU\(?&/[3NA^*?B'I'P3LO&-OX-^&\?B
MBY\+^!9K[QT^@R:_K.O/X4M]%\<:M>S-X5\,"&Q?QK#X>C31((WT26._UM-4
M^D?@S^SY\"_V=?#8\(_ CX0_#GX1>'6M].M[O3OA_P"$=$\,?VM_94,L%C=:
M_=:79V][XBU.-;BZDEU?7;G4=5NKF\O;N[O)[J\NIIO8:^>/VN?B]_PH']EC
M]HSXV)J5OI-[\+/@G\3?'&BWEQ+I46[Q'X>\'ZOJ'ABQM!KB2Z3<ZIJOB&'3
M-+T?3[Z"YAU/5;RSTXVEVUTMM+TQJXFO&CA%6J2IJ2IT:#G+V495*E]*:?*G
M*I)R<N7F;=VV<4L/@L-/$Y@\/1C7<)5:^)5.'UB<*5)1M*JUSN,:4%&,>914
M59)*Y_FS_M$W5S^W3_P5A^)%AX4>XURW_:#_ &S9_ 7@Z6[EWM<^%=:^)=OX
M#\)7%U-:26PM+"#PK!IDT[1W:1Z7IT+;]3=+5M0;_47M+2TL+6VL+"VM[*QL
MK>&TL[.TACMK6TM+:-8;>VMK>%4A@MX(42*&&)$CBC141550!_FV?\&^/PA_
MX6O_ ,%2/@;>W6FW&IZ)\(]$^(GQ>UR.&'53':?\(_X/U+P_X5U*[O-*DA_L
MZWL/B%XJ\'7"S:C,FE7]VEMH5Y'=_P!KQV5S_I-U]-Q=.,*^ P,/@PF$37DZ
MC5-)^:A0@_)2WW/BO#ZE*IA<US.HOWF/S!J6^JI1=5M7Z.IBJBO=MN+NM$V5
M_$E_P=??%F;4/C!^R7\"HUMTM_"/PU\<_%F\96A:[NIOB-XHM?!^FK.ID>X@
MM[&/X6ZL;5EBMX;J74;P/)=R6<:V7]MM?YH?_!>SXPP?&'_@J)^T5+I\E\^D
M?#2;PE\'M-6^FLY3#/X!\+Z;9>*([5+*6XBM[$^.+GQ3-:PRW,MXR2_:+Z+3
M[R>?2K#GX2H>US95&M,-0JU;].::5%+UM5DU_A?5'7Q_BO89!*BG[V-Q6'H6
MZ\M-RQ,GMLG0@G:VLDMFT_V5_92_9GG?_@V _:=DN;.::3XOO\6/VF%M+:;5
M3>0P?!SQUX.M;2\O(/[-5K.%;7]G:#6C#:&\TJZT)[?4KK4K6/4+]=/XG_@T
MY\?/9?$K]LKX7/.K1>)/ WPD\?6UM)*2\3^"M?\ &7AZ^GM(3>(L:W"^/].C
MU"6/3YS,;73$FO+00P07O]+?PH_9FL_!'_!,+PQ^RE<^'+J!U_8SG^%GBCPU
M<IJ&N7UUXF\4_":ZTWQS:3VDKPWM[=:KXHUG7))=+M18Q":[;3M,M--M$M;2
MW_C;_P"#8WQ\_A/_ (*0ZAX7,ZK;_%']GKXF>$OLTLI"2WFCZQX+^(-O/!";
MRV22^M[7P7J$<4OV?4)8K&ZU)$MHHYI[VU]&G7_M#*^*%>Z^MO&0U3M#FC*%
MO2&%BK];:'CUL+_9.=\#R:Y9?4(Y?4>UZBIN%1:I/6ICI.S7VNY_H35_+S_P
M<N_M]_\ "F/@=X>_8I\ :M=VOQ(_:)TC_A*/B5/8D0MH7P+L=6N]*@TRYEN=
M-D6;_A:/BG2=5TE#H^I0W=MHW@KQ18ZRD5AK]A'J/]'/QI^+W@;X _"3XC_&
MSXEZI_8_@+X6>#=?\<>*;Y!"]W_97A[3I]0FL]+MIY[9=0UO4VA33-!TF.9+
MG6-9O+#2[0/=7D*-_G.? +X<_%7_ (+@_P#!4^\UKQ\-9A\,_$7QK<?$+XQ:
MQHB74=M\-/@+X.2WMK3PSI5Y.=<CT*YGT"PT'X8^"[NZ&JP1>+-<TK4M1AO[
M9=3F/E\.8*G4KU<RQ7NX/+8NO*36DJT4Y4XK^;DM[1Q3NY*G&S4SW.,<RK4<
M+0R? WEF.<S6&IJ+M*GAY24*LF_L^UYO8J3LE!UI\R=.Y^DO_!.[]GN?]@C_
M ()"?MN?\%+_ (A>&)?^%I?'7X*ZE\)/@A:W<[C^POA/\2]>\.?#O0/%-Q9P
M-/%)#XY^*GB30/$M]IFJZ<TLWA3X<>%[S2M5TJR\6ZI-7S/_ ,&R/P@_X3__
M (*+WGQ%N8,6/P)^!_Q!\8VEZ]C]JC7Q)XOFT7X6Z?IT=P+VV.F7E[X>\:^+
M[Z*\^SZBDMII%_IYM8FODOK3]?/^#GWQ_P"'OA'^Q-^S+^S'X/TG3M!TCQI\
M3[:XT/2;&[GM(-(\ ? ;P3_9$.@Z;I$47E7.G6E[XZ\&(LUU>^5IB:;:0II]
MY<7T-]I/-_\ !J-\(;G1_@A^U5\=;S3+>.+Q[\3?!7PQT/4Y8?\ 3Y(/AEX:
MO_$FN16LDDA9-+FNOB?I22R6T,4-Y?Z;)#<3W<VDQQ6'MSQE2ID&;9G4]VIF
M5>5*E&_PX=2AA84HZM/D@J[;27,W-VN[GS-/+J5+BO(<DH^]1R7#0Q%>26LL
M8X3QU6O)V3_>U'A8Q3<E"*A%.RY5_671117P!^LA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %?$7_!2[_E';^W/_V:5^T%_P"JL\45]NU\1?\ !2[_
M )1V_MS_ /9I7[07_JK/%%=."_WS"?\ 830_].P.3'_[CC?^P3$_^F9G\>O_
M  1C_P"30?CW_P!G(^ ?_58>*:_3^OS _P"",?\ R:#\>_\ LY'P#_ZK#Q37
MZ?U_.OCY_P G'S'_ + ,L_\ 49'^6OCE_P EI0_[$&5_^E8D****_&#\<"BB
MB@ HHHH **** "BBB@ HHHH *^A/V=?AD?'GC%-2U*W+^&_##P7U_O5O*O;X
M/OL--W ;6#NAN+E=P(MX2I!$JY\(TW3KW5]0LM+TZ"2ZOM0N8;2TMXU+/+//
M(L<:  ' +,-S'A5!9B%!(_7CX7> K/X<^#M,\.VX1[M8Q=:O=JH!O-5N%5KJ
M4G+$QQL!;VX+$+!%&  217ZEX4\(?ZRY]'&XNES91DTJ>)Q*DKPQ.*NY83!Z
MZ2C*<76KJS7L:3IRM[:+/WSZ/OAO_KQQ=#,\QP_M.'>&9T<=CE4C>EC<?S.>
M7Y:[IQJ0G4@\3BX6<7AJ#HU.7ZS3;]#  & , < #H!Z4445_8Q_I8%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5D:Q_J(O^NO_ +(U:]9&
ML?ZB+_KK_P"R-3CNO5?F3/X7\OS1WNC_ /(*L/\ KUA_]!%:59NC_P#(*L/^
MO6'_ -!%:5<$_CE_BE^;.B'P1_PQ_)!1114E!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7":C_R-VF_]?>E?^E$==W7":C_R-VF_]?>E?^E$=;4/BG_U[G^1G5^%?XH_
MF>YT445PF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>9?"O_D;M6_[!5__ .G/
M3J]-KS+X5_\ (W:M_P!@J_\ _3GIU;1_W?%_]>X_FS*?QTO67Z'T+1117DFH
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 <7\0_\ D3=:_P"N=I_Z<+2K?P0_Y$V;
M_L-WW_I-8U4^(?\ R)NM?]<[3_TX6E6_@A_R)LW_ &&[[_TFL:['_P BRI_V
M%+_TB H_QH_X)?FCV&BBBO+.D**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC+XR^-[XWVNV2/-#I-]+X!\'Z=9#0&=4@OKJT?Q[K4CI,]@LEI)!]ME^ /\
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MAF67Q<I58**5:$:BIS<XP;I\\93IN,Z5J=6$TU&-KS_S2?V[?B[??'G]L_\
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MXN^*GCC39-&DTWQQJT]Q;P:3;WSWUOITD>HQ00W-M=_Z9]?C+^T'_P %X_V
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MKZ_B</*W)B,'433^U*$Z=E_X!*H='B#2E_96#QE._M,'F-*:DOLQJ4ZJYO\
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M[7C+,)2QF)S".5X>K2CB\74=:M*M^[PTX\[LHP4IXI4XI.,8)13DW[1_+?\
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M"FXTZ**2YO;-+-+.]ELWEM[R[DM;3?<:==3W,-M,W^D-7^=+^V'K&C?LR?\
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M %5GBBOMVOB+_@I=_P H[?VY_P#LTK]H+_U5GBBNG!?[YA/^PFA_Z=@<F/\
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M"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N$U'_ )&[3?\ K[TK_P!*(Z[NN$U'
M_D;M-_Z^]*_]*(ZVH?%/_KW/\C.K\*_Q1_,]SHHHKA- HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *\R^%?_ "-VK?\ 8*O_ /TYZ=7IM>9?"O\ Y&[5O^P5?_\
MISTZMH_[OB_^O<?S9E/XZ7K+]#Z%HHHKR34**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** .+^(?_(FZU_USM/_ $X6E6_@A_R)LW_8;OO_ $FL:J?$/_D3=:_ZYVG_
M *<+2K?P0_Y$V;_L-WW_ *36-=C_ .194_["E_Z1 4?XT?\ !+\T>PT445Y9
MTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/]M?#KQ?!=006?B5(;"2'53H]G8^(]&N[G2].FT[^E'P)_P=8?L@:AHUO/\
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M2GF$W4Q6#QCDHNI.3J3?N\JE'VLIU(RC5I5(>TE32G%MORS]K_\ X.;OV8?
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M5+/6M/MKW6/ 7B+POX@>QBU2PLKN;3UU5;&\>VB2]M[B)?+KY$_9U_X)%?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ^7O#'_);]2_["OB7_P!)[ZOJ&OE[PQ_R6_4O
M^PKXE_\ 2>^KZAKOS#X\/_V"4/\ VXY\-\$_^ODORB%%%%<!T!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 4444 %?$7_!2[_E';^W/_V:5^T%_P"JL\45]NU\1?\
M!2[_ )1V_MS_ /9I7[07_JK/%%=."_WS"?\ 830_].P.3'_[CC?^P3$_^F9G
M\T'_  ;2?\D,_:7_ .RL>$__ %#WK^EROYH_^#:3_DAG[2__ &5CPG_ZA[U_
M2Y7V^:_\C#$_XH?^FX'S/"G_ "3V6?\ 7JK_ .I%8****\\^A"BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH XOXA_P#(FZU_USM/_3A:5;^"'_(FS?\ 8;OO_2:QJI\0_P#D3=:_ZYVG
M_IPM*M_!#_D39O\ L-WW_I-8UV/_ )%E3_L*7_I$!1_C1_P2_-'L-%%%>6=(
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\O>&/^2WZE_V%?$O
M_I/?5]0U\O>&/^2WZE_V%?$O_I/?5]0UWYA\>'_[!*'_ +<<^&^"?_7R7Y1"
MBOP)U3_@Y-_X)H:1J>HZ5<ZQ\;GN-,O[O3[AX/A/,T+S65Q);2M"TFO1NT32
M1,8V>.-RA!9%)*BA_P 1+W_!,K_H*_'/_P --)_\T-:?V+FSVR_%:_\ 3J76
MWEY_U9GF?ZR9 O\ F;X#_P **?\ F?T"T5_/U_Q$O?\ !,K_ *"OQS_\--)_
M\T-'_$2]_P $RO\ H*_'/_PTTG_S0T_[%S;_ *%^+_\ !,O\O/\ /LP_UDR#
M_H;X#_PHI_YG] M%?S]?\1+W_!,K_H*_'/\ \--)_P#-#1_Q$O?\$RO^@K\<
M_P#PTTG_ ,T-']BYM_T+\7_X)E_EY_GV8?ZR9!_T-\!_X44_\S^@6BOY^O\
MB)>_X)E?]!7XY_\ AII/_FAH_P"(E[_@F5_T%?CG_P"&FD_^:&C^Q<V_Z%^+
M_P#!,O\ +S_/LP_UDR#_ *&^ _\ "BG_ )G] M%?S]?\1+W_  3*_P"@K\<_
M_#32?_-#1_Q$O?\ !,K_ *"OQS_\--)_\T-']BYM_P!"_%_^"9?Y>?Y]F'^L
MF0?]#? ?^%%/_,_H%HK^?K_B)>_X)E?]!7XY_P#AII/_ )H:/^(E[_@F5_T%
M?CG_ .&FD_\ FAH_L7-O^A?B_P#P3+_+S_/LP_UDR#_H;X#_ ,**?^9_0+17
M\_7_ !$O?\$RO^@K\<__  TTG_S0T?\ $2]_P3*_Z"OQS_\ #32?_-#1_8N;
M?]"_%_\ @F7^7G^?9A_K)D'_ $-\!_X44_\ ,_H%HK^?K_B)>_X)E?\ 05^.
M?_AII/\ YH:/^(E[_@F5_P!!7XY_^&FD_P#FAH_L7-O^A?B__!,O\O/\^S#_
M %DR#_H;X#_PHI_YG] M%?S]?\1+W_!,K_H*_'/_ ,--)_\ -#1_Q$O?\$RO
M^@K\<_\ PTTG_P T-']BYM_T+\7_ ."9?Y>?Y]F'^LF0?]#? ?\ A13_ ,S^
M@6BOY^O^(E[_ ()E?]!7XY_^&FD_^:&C_B)>_P""97_05^.?_AII/_FAH_L7
M-O\ H7XO_P $R_R\_P ^S#_63(/^AO@/_"BG_F?T"T5_/U_Q$O?\$RO^@K\<
M_P#PTTG_ ,T-'_$2]_P3*_Z"OQS_ /#32?\ S0T?V+FW_0OQ?_@F7^7G^?9A
M_K)D'_0WP'_A13_S/Z!:*_GZ_P"(E[_@F5_T%?CG_P"&FD_^:&C_ (B7O^"9
M7_05^.?_ (::3_YH:/[%S;_H7XO_ ,$R_P O/\^S#_63(/\ H;X#_P **?\
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M #0T?V+FW_0OQ?\ X)E_EY_GV8?ZR9!_T-\!_P"%%/\ S/Z!:*_GZ_XB7O\
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M&C_B)>_X)E?]!7XY_P#AII/_ )H:/[%S;_H7XO\ \$R_R\_S[,/]9,@_Z&^
M_P#"BG_F?T"T5_/U_P 1+W_!,K_H*_'/_P --)_\T-'_ !$O?\$RO^@K\<__
M  TTG_S0T?V+FW_0OQ?_ ()E_EY_GV8?ZR9!_P!#? ?^%%/_ #/Z!:*_GZ_X
MB7O^"97_ $%?CG_X::3_ .:&C_B)>_X)E?\ 05^.?_AII/\ YH:/[%S;_H7X
MO_P3+_+S_/LP_P!9,@_Z&^ _\**?^9_0+17\_7_$2]_P3*_Z"OQS_P##32?_
M #0T?\1+W_!,K_H*_'/_ ,--)_\ -#1_8N;?]"_%_P#@F7^7G^?9A_K)D'_0
MWP'_ (44_P#,_H%HK^?K_B)>_P""97_05^.?_AII/_FAH_XB7O\ @F5_T%?C
MG_X::3_YH:/[%S;_ *%^+_\ !,O\O/\ /LP_UDR#_H;X#_PHI_YG] M%?S]?
M\1+W_!,K_H*_'/\ \--)_P#-#1_Q$O?\$RO^@K\<_P#PTTG_ ,T-']BYM_T+
M\7_X)E_EY_GV8?ZR9!_T-\!_X44_\S^@6BOY^O\ B)>_X)E?]!7XY_\ AII/
M_FAH_P"(E[_@F5_T%?CG_P"&FD_^:&C^Q<V_Z%^+_P#!,O\ +S_/LP_UDR#_
M *&^ _\ "BG_ )G] M%?S]?\1+W_  3*_P"@K\<__#32?_-#1_Q$O?\ !,K_
M *"OQS_\--)_\T-']BYM_P!"_%_^"9?Y>?Y]F'^LF0?]#? ?^%%/_,_H%HK^
M?K_B)>_X)E?]!7XY_P#AII/_ )H:/^(E[_@F5_T%?CG_ .&FD_\ FAH_L7-O
M^A?B_P#P3+_+S_/LP_UDR#_H;X#_ ,**?^9_0+17\_7_ !$O?\$RO^@K\<__
M  TTG_S0T?\ $2]_P3*_Z"OQS_\ #32?_-#1_8N;?]"_%_\ @F7^7G^?9A_K
M)D'_ $-\!_X44_\ ,_H%HK^?K_B)>_X)E?\ 05^.?_AII/\ YH:/^(E[_@F5
M_P!!7XY_^&FD_P#FAH_L7-O^A?B__!,O\O/\^S#_ %DR#_H;X#_PHI_YG] M
M%?S]?\1+W_!,K_H*_'/_ ,--)_\ -#1_Q$O?\$RO^@K\<_\ PTTG_P T-']B
MYM_T+\7_ ."9?Y>?Y]F'^LF0?]#? ?\ A13_ ,S^@6BOY^O^(E[_ ()E?]!7
MXY_^&FD_^:&C_B)>_P""97_05^.?_AII/_FAH_L7-O\ H7XO_P $R_R\_P ^
MS#_63(/^AO@/_"BG_F?T"T5_/U_Q$O?\$RO^@K\<_P#PTTG_ ,T-'_$2]_P3
M*_Z"OQS_ /#32?\ S0T?V+FW_0OQ?_@F7^7G^?9A_K)D'_0WP'_A13_S/Z!:
M*_GZ_P"(E[_@F5_T%?CG_P"&FD_^:&C_ (B7O^"97_05^.?_ (::3_YH:/[%
MS;_H7XO_ ,$R_P O/\^S#_63(/\ H;X#_P **?\ F?T"T5_/U_Q$O?\ !,K_
M *"OQS_\--)_\T-'_$2]_P $RO\ H*_'/_PTTG_S0T?V+FW_ $+\7_X)E_EY
M_GV8?ZR9!_T-\!_X44_\S^@6BOY^O^(E[_@F5_T%?CG_ .&FD_\ FAH_XB7O
M^"97_05^.?\ X::3_P":&C^Q<V_Z%^+_ /!,O\O/\^S#_63(/^AO@/\ PHI_
MYG] M%?S]?\ $2]_P3*_Z"OQS_\ #32?_-#1_P 1+W_!,K_H*_'/_P --)_\
MT-']BYM_T+\7_P""9?Y>?Y]F'^LF0?\ 0WP'_A13_P S^@6BOY^O^(E[_@F5
M_P!!7XY_^&FD_P#FAH_XB7O^"97_ $%?CG_X::3_ .:&C^Q<V_Z%^+_\$R_R
M\_S[,/\ 63(/^AO@/_"BG_F?T"T5_/U_Q$O?\$RO^@K\<_\ PTTG_P T-'_$
M2]_P3*_Z"OQS_P##32?_ #0T?V+FW_0OQ?\ X)E_EY_GV8?ZR9!_T-\!_P"%
M%/\ S/Z!:*_GZ_XB7O\ @F5_T%?CG_X::3_YH:/^(E[_ ()E?]!7XY_^&FD_
M^:&C^Q<V_P"A?B__  3+_+S_ #[,/]9,@_Z&^ _\**?^9_0+17\_7_$2]_P3
M*_Z"OQS_ /#32?\ S0T?\1+W_!,K_H*_'/\ \--)_P#-#1_8N;?]"_%_^"9?
MY>?Y]F'^LF0?]#? ?^%%/_,_H%HK^?K_ (B7O^"97_05^.?_ (::3_YH:/\
MB)>_X)E?]!7XY_\ AII/_FAH_L7-O^A?B_\ P3+_ "\_S[,/]9,@_P"AO@/_
M  HI_P"9_0+17\_7_$2]_P $RO\ H*_'/_PTTG_S0T?\1+W_  3*_P"@K\<_
M_#32?_-#1_8N;?\ 0OQ?_@F7^7G^?9A_K)D'_0WP'_A13_S/Z!:*_GZ_XB7O
M^"97_05^.?\ X::3_P":&C_B)>_X)E?]!7XY_P#AII/_ )H:/[%S;_H7XO\
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M_P#PTTG_ ,T-']BYM_T+\7_X)E_EY_GV8?ZR9!_T-\!_X44_\S^@6BOY^O\
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M7_05^.?_ (::3_YH:/[%S;_H7XO_ ,$R_P O/\^S#_63(/\ H;X#_P **?\
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M_P#+RC_B()_X)Z_]!+XQ_P#ALG_^7E'U#&_] M?_ ,%R_P O/\^S#_6'(_\
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M?#_/S_/LS]O:*_$+_B()_P"">O\ T$OC'_X;)_\ Y>4?\1!/_!/7_H)?&/\
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M_P -?+_\O*/^(A[_ ()U?]!7XS?^&OE_^7E']F9A_P! >(_\%2_R#_6/(O\
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M1?\ 0VP/_@^'^9^YU%?AC_Q$/?\ !.K_ *"OQF_\-?+_ /+RC_B(>_X)U?\
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M (B'O^"=7_05^,W_ (:^7_Y>4?V9F'_0'B/_  5+_(/]8\B_Z&V!_P#!\/\
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M_P#E_1_969?] 6)_\%2_R\_S[,/]8\B_Z&V!_P#!\/\ ,_>&BOP>_P"(C/\
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M )?T?V5F7_0%B?\ P5+_ "\_S[,/]8\B_P"AM@?_  ?#_,_>&BOP>_XB,_\
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M_P 1&?\ P3?_ .@I\:__  UC_P#R_H_LK,O^@+$_^"I?Y>?Y]F'^L>1?]#;
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M_P"(DG_@FK_T$_CA_P"&I;_YH:/[&S7_ * ,5_X*E_77\^S#_6+(O^AM@/\
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MQ$O?\$RO^@K\<_\ PTTG_P T-']BYM_T+\7_ ."9?Y>?Y]F'^LF0?]#? ?\
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M_-#1_P 1+W_!,K_H*_'/_P --)_\T-']BYM_T+\7_P""9?Y>?Y]F'^LF0?\
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MS_/LP_UDR#_H;X#_ ,**?^9_0+17\_7_ !$O?\$RO^@K\<__  TTG_S0T?\
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M\!_X44_\S^@6BOY^O^(E[_@F5_T%?CG_ .&FD_\ FAH_XB7O^"97_05^.?\
MX::3_P":&C^Q<V_Z%^+_ /!,O\O/\^S#_63(/^AO@/\ PHI_YG] M%?S]?\
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M;?\ 0OQ?_@F7^7G^?9A_K)D'_0WP'_A13_S/Z!:*_GZ_XB7O^"97_05^.?\
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MA_K)D'_0WP'_ (44_P#,_H%HK^?K_B)>_P""97_05^.?_AII/_FAH_XB7O\
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M_,_H%HK^?K_B)>_X)E?]!7XY_P#AII/_ )H:/^(E[_@F5_T%?CG_ .&FD_\
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M7_X)E_EY_GV8?ZR9!_T-\!_X44_\S^@6BOY^O^(E[_@F5_T%?CG_ .&FD_\
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M5^.?_AII/_FAH_XB7O\ @F5_T%?CG_X::3_YH:/[%S;_ *%^+_\ !,O\O/\
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MQ$O?\$RO^@K\<_\ PTTG_P T-']BYM_T+\7_ ."9?Y>?Y]F'^LF0?]#? ?\
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M_-#1_P 1+W_!,K_H*_'/_P --)_\T-']BYM_T+\7_P""9?Y>?Y]F'^LF0?\
M0WP'_A13_P S^@6BOY^O^(E[_@F5_P!!7XY_^&FD_P#FAH_XB7O^"97_ $%?
MCG_X::3_ .:&C^Q<V_Z%^+_\$R_R\_S[,/\ 63(/^AO@/_"BG_F?T"T5_/U_
MQ$O?\$RO^@K\<_\ PTTG_P T-'_$2]_P3*_Z"OQS_P##32?_ #0T?V+FW_0O
MQ?\ X)E_EY_GV8?ZR9!_T-\!_P"%%/\ S/Z!:*_GZ_XB7O\ @F5_T%?CG_X:
M:3_YH:/^(E[_ ()E?]!7XY_^&FD_^:&C^Q<V_P"A?B__  3+_+S_ #[,/]9,
M@_Z&^ _\**?^9^LGAC_DM^I?]A7Q+_Z3WU?4-?@[^QG_ ,%>?V/?VP?VNM&^
M$WP>U#XC2>+_ !F/'FLZ%%XF\#RZ'I\UIHGAS6?$-\L]\-2O5MIUTNQN9HDE
M0)))'Y(D$CQJW[Q49K1JT*U"G6IRI36$HMQFK26LUL_-->J9UY;B\+C:%2MA
M*]+$4E6G!U*,U.*FHPDXMQ;5TI1;79I]3\=;[_@@/_P26U*]O-1O/V46FO+^
MZN+VZE_X7K^TI'YMS=2O//)Y<7QB2)-\LCMLC1$7.U%50 *O_$/U_P $C?\
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M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
MT::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$
M?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2
M-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#
M_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<
MT_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__
M )\E'_$/U_P2-_Z--;_P_'[2_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-
ME7_ANPG_ ,I#_B'Z_P""1O\ T::W_A^/VE__ )\E'_$/U_P2-_Z--;_P_'[2
M_P#\^2BBC^U<T_Z&6/\ _"S$?_+ _L+)/^A-E7_ANPG_ ,I#_B'Z_P""1O\
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3&+FX4HQBY-1BG)J[48INR1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>nmra-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-12T16:28:14.0195+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.neumoratx.com/20250331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:nmra="http://www.neumoratx.com/20250331" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage" id="DocumentCoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited" id="StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited">
        <link:definition>100040 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementStockholdersEquityDeficitUnauditedParenthetical" id="StatementCondensedConsolidatedStatementStockholdersEquityDeficitUnauditedParenthetical">
        <link:definition>100050 - Statement - Condensed Consolidated Statement Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidity" id="DisclosureOrganizationAndLiquidity">
        <link:definition>995455 - Disclosure - Organization and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1" id="DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1" id="DisclosureCashEquivalentsAndMarketableSecurities1">
        <link:definition>995475 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995485 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>995495 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssets" id="DisclosureAcquisitionsOfAssets">
        <link:definition>995505 - Disclosure - Acquisitions of Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995515 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreements" id="DisclosureStrategicLicenseAndResearchAndCollaborationAgreements">
        <link:definition>995525 - Disclosure - Strategic License and Research and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquity1" id="DisclosureStockholdersEquity1">
        <link:definition>995535 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosurePreferredStockWarrants" id="DisclosurePreferredStockWarrants">
        <link:definition>995545 - Disclosure - Preferred Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensation" id="DisclosureStockbasedCompensation">
        <link:definition>995555 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995565 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995575 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>995585 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEvent" id="DisclosureSubsequentEvent">
        <link:definition>995595 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies">
        <link:definition>995605 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" id="DisclosureCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>995615 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>995625 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>995635 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995645 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>995655 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>995665 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>995675 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>995685 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995695 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails" id="DisclosureOrganizationAndLiquidityAdditionalInformationDetails">
        <link:definition>995705 - Disclosure - Organization and Liquidity - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme" id="DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme">
        <link:definition>995715 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails" id="DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails">
        <link:definition>995725 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Marketable Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995735 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995745 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" id="DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails">
        <link:definition>995755 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails" id="DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails">
        <link:definition>995765 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails" id="DisclosureAcquisitionsOfAssetsAdditionalInformationDetails">
        <link:definition>995775 - Disclosure - Acquisitions of Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails" id="DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>995785 - Disclosure - Strategic License and Research and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>995795 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" id="DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>995805 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" id="DisclosureStockbasedCompensationAdditionalInformationDetail">
        <link:definition>995815 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails" id="DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails">
        <link:definition>995825 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail" id="DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail">
        <link:definition>995835 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail">
        <link:definition>995845 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails" id="DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails">
        <link:definition>995855 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" id="DisclosureSegmentReportingAdditionalInformationDetails">
        <link:definition>995865 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails" id="DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails">
        <link:definition>995875 - Disclosure - Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>995885 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar" id="DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar">
        <link:definition>995895 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>995905 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" id="DisclosureSubsequentEventAdditionalInformationDetails">
        <link:definition>995915 - Disclosure - Subsequent Event - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage" xlink:href="nmra-20250331.xsd#DocumentCoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="nmra-20250331.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="nmra-20250331.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="nmra-20250331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited" xlink:href="nmra-20250331.xsd#StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementStockholdersEquityDeficitUnauditedParenthetical" xlink:href="nmra-20250331.xsd#StatementCondensedConsolidatedStatementStockholdersEquityDeficitUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="nmra-20250331.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidity" xlink:href="nmra-20250331.xsd#DisclosureOrganizationAndLiquidity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1" xlink:href="nmra-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1" xlink:href="nmra-20250331.xsd#DisclosureCashEquivalentsAndMarketableSecurities1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="nmra-20250331.xsd#DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="nmra-20250331.xsd#DisclosureBalanceSheetComponents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssets" xlink:href="nmra-20250331.xsd#DisclosureAcquisitionsOfAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="nmra-20250331.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreements" xlink:href="nmra-20250331.xsd#DisclosureStrategicLicenseAndResearchAndCollaborationAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquity1" xlink:href="nmra-20250331.xsd#DisclosureStockholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosurePreferredStockWarrants" xlink:href="nmra-20250331.xsd#DisclosurePreferredStockWarrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensation" xlink:href="nmra-20250331.xsd#DisclosureStockbasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReporting" xlink:href="nmra-20250331.xsd#DisclosureSegmentReporting" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShare" xlink:href="nmra-20250331.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="nmra-20250331.xsd#DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEvent" xlink:href="nmra-20250331.xsd#DisclosureSubsequentEvent" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" xlink:href="nmra-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:href="nmra-20250331.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="nmra-20250331.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="nmra-20250331.xsd#DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="nmra-20250331.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="nmra-20250331.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="nmra-20250331.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingTables" xlink:href="nmra-20250331.xsd#DisclosureSegmentReportingTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="nmra-20250331.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="nmra-20250331.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails" xlink:href="nmra-20250331.xsd#DisclosureOrganizationAndLiquidityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme" xlink:href="nmra-20250331.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails" xlink:href="nmra-20250331.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="nmra-20250331.xsd#DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="nmra-20250331.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" xlink:href="nmra-20250331.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails" xlink:href="nmra-20250331.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails" xlink:href="nmra-20250331.xsd#DisclosureAcquisitionsOfAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails" xlink:href="nmra-20250331.xsd#DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="nmra-20250331.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:href="nmra-20250331.xsd#DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" xlink:href="nmra-20250331.xsd#DisclosureStockbasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails" xlink:href="nmra-20250331.xsd#DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="nmra-20250331.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail" xlink:href="nmra-20250331.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails" xlink:href="nmra-20250331.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:href="nmra-20250331.xsd#DisclosureSegmentReportingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails" xlink:href="nmra-20250331.xsd#DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="nmra-20250331.xsd#DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar" xlink:href="nmra-20250331.xsd#DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="nmra-20250331.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="nmra-20250331.xsd#DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TradingArrangementThreeMember" xlink:label="nmra_TradingArrangementThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EarlyExerciseLiabilityCurrentPortion" xlink:label="nmra_EarlyExerciseLiabilityCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" xlink:label="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities" xlink:label="nmra_OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RelatedPartyTransactionObligationWithRelatedParty" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CollaborationAgreementNonRefundableQuarterlyPayments" xlink:label="nmra_CollaborationAgreementNonRefundableQuarterlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesReservedForIssuanceUnderThePlansMember" xlink:label="nmra_SharesReservedForIssuanceUnderThePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ContingentConsiderationMilestonePaymentSettledInCash" xlink:label="nmra_ContingentConsiderationMilestonePaymentSettledInCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AdvisorsMember" xlink:label="nmra_AdvisorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NavacaprantNMRA-511ProgramExpenses" xlink:label="nmra_NavacaprantNMRA-511ProgramExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" xlink:label="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DaljitBillSinghAuroraMember" xlink:label="nmra_DaljitBillSinghAuroraMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DevelopmentMilestonesMember" xlink:label="nmra_DevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_LiquidityMember" xlink:label="nmra_LiquidityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" xlink:label="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SecondVanderbiltSponsoredResearchAgreementMember" xlink:label="nmra_SecondVanderbiltSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AlairionCarveoutPlanMember" xlink:label="nmra_AlairionCarveoutPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NetCashProceedsFromFinancingActivities" xlink:label="nmra_NetCashProceedsFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NumberOfLicenseAgreements" xlink:label="nmra_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SeriesA1ConvertiblePreferredStockMember" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MaximumFutureCapitalStockOfferingsInvestment" xlink:label="nmra_MaximumFutureCapitalStockOfferingsInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAgreementExpiryDate" xlink:label="nmra_ResearchAgreementExpiryDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SeriesA2ConvertiblePreferredStockMember" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="nmra_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_OrganizationAndLiquidityLineItems" xlink:label="nmra_OrganizationAndLiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SummaryOfFairValueOfStockOptionsTableTextBlock" xlink:label="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CollaborationAgreementTerm" xlink:label="nmra_CollaborationAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AccruedClinicalTrialAndPreclinicalCosts" xlink:label="nmra_AccruedClinicalTrialAndPreclinicalCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_BlackthornTherapeuticsIncMember" xlink:label="nmra_BlackthornTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RestrictedCommonStockMember" xlink:label="nmra_RestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrancheTwoMember" xlink:label="nmra_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" xlink:label="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MarketableSecuritiesMember" xlink:label="nmra_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" xlink:label="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPayments" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NavacaprantNMRA-140ProgramExpenses" xlink:label="nmra_NavacaprantNMRA-140ProgramExpenses"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrdArrModifiedDate" xlink:label="nmra_TrdArrModifiedDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetAssetValuePerShare" xlink:label="us-gaap_NetAssetValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PrepaymentPenalty" xlink:label="nmra_PrepaymentPenalty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TermLoansMember" xlink:label="nmra_TermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EarlyExerciseLiabilityNetOfCurrentPortion" xlink:label="nmra_EarlyExerciseLiabilityNetOfCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MilestonePaymentDueDescription" xlink:label="nmra_MilestonePaymentDueDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AlairionMergerAgreementMember" xlink:label="nmra_AlairionMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AcquiredInProcessResearchAndDevelopment" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_K2HealthVenturesLLCMember" xlink:label="nmra_K2HealthVenturesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo" xlink:label="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesIssuedUponAchievementOfMilestone" xlink:label="nmra_SharesIssuedUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" xlink:label="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod" xlink:label="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NoncashOperatingLeaseExpense" xlink:label="nmra_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndDevelopmentPersonnelRelatedCosts" xlink:label="nmra_ResearchAndDevelopmentPersonnelRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NavacaprantMember" xlink:label="nmra_NavacaprantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AwardsWithPerformanceConditionsMember" xlink:label="nmra_AwardsWithPerformanceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SeriesBConvertiblePreferredStockMember" xlink:label="nmra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:label="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_OfferingExpenses" xlink:label="nmra_OfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DeferredOfferingCostsPolicyTextBlock" xlink:label="nmra_DeferredOfferingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MilestonePayments" xlink:label="nmra_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:label="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember" xlink:label="nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne" xlink:label="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AwardModificationMember" xlink:label="nmra_AwardModificationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CaseTwoMember" xlink:label="nmra_CaseTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenIncLicensesMember" xlink:label="nmra_AmgenIncLicensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AchievementOfSpecifiedCommercializationEventsMember" xlink:label="nmra_AchievementOfSpecifiedCommercializationEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PerformanceRestrictedStockMember" xlink:label="nmra_PerformanceRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CaseOneMember" xlink:label="nmra_CaseOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ServiceConditionsMember" xlink:label="nmra_ServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" xlink:label="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_M4PAMProgramsExpenses" xlink:label="nmra_M4PAMProgramsExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ServicesAgreementMember" xlink:label="nmra_ServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NonRule10B51ArrModifiedFlag" xlink:label="nmra_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CollaborationAgreementTerminationDescription" xlink:label="nmra_CollaborationAgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease" xlink:label="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenIncMember" xlink:label="nmra_AmgenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TradingArrangementOneMember" xlink:label="nmra_TradingArrangementOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="nmra_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" xlink:label="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TradingArrangementTwoMember" xlink:label="nmra_TradingArrangementTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrancheOneMember" xlink:label="nmra_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AdditionalSharesOfCapitalStockMember" xlink:label="nmra_AdditionalSharesOfCapitalStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" xlink:label="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RepurchaseOfUnvestedEarlyExercisedShares" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AcquisitionDateFairValueOfSharesTransferred" xlink:label="nmra_AcquisitionDateFairValueOfSharesTransferred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_UpfrontCashPayment" xlink:label="nmra_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock" xlink:label="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PaymentsForExecutionOfAgreement" xlink:label="nmra_PaymentsForExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CommercialMilestonePayments" xlink:label="nmra_CommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrancheThreeMember" xlink:label="nmra_TrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ForfeitureOfUnvestedRestrictedCommonStockShares" xlink:label="nmra_ForfeitureOfUnvestedRestrictedCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FundsReceivedUponExecutionOfAgreement" xlink:label="nmra_FundsReceivedUponExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EarlyExerciseOfEmployeeStockOptionsMember" xlink:label="nmra_EarlyExerciseOfEmployeeStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SalesBasedMilestonesMember" xlink:label="nmra_SalesBasedMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_VanderbiltSponsoredResearchAgreementMember" xlink:label="nmra_VanderbiltSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_BlackthornCarveoutPlanMember" xlink:label="nmra_BlackthornCarveoutPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ParkinsonsResearchVenturesFundingAgreementMember" xlink:label="nmra_ParkinsonsResearchVenturesFundingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:label="nmra_ScheduleOfOrganizationAndLiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FirstVanderbiltSponsoredResearchAgreementMember" xlink:label="nmra_FirstVanderbiltSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="nmra_CashEquivalentsAndMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" xlink:label="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="nmra_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="nmra_OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_OtherSegmentItems" xlink:label="nmra_OtherSegmentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_Rule10B51ArrModifiedFlag" xlink:label="nmra_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesReservedForFutureIssuanceUnderThePlansMember" xlink:label="nmra_SharesReservedForFutureIssuanceUnderThePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CommercialMilestonePaymentMember" xlink:label="nmra_CommercialMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" xlink:label="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_VanderbiltLicenseMember" xlink:label="nmra_VanderbiltLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SyllableMergerAgreementMember" xlink:label="nmra_SyllableMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ContingentConsiderationMilestonePayment" xlink:label="nmra_ContingentConsiderationMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AchievementOfSpecifiedDevelopmentEventsMember" xlink:label="nmra_AchievementOfSpecifiedDevelopmentEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_StockPurchaseRightMember" xlink:label="nmra_StockPurchaseRightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MilestonesAchieved" xlink:label="nmra_MilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty" xlink:label="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AccruedResearchAndDevelopmentServices" xlink:label="nmra_AccruedResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MaximumAdditionalFinancingInEquitySecurities" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndCollaborationAgreementPayments" xlink:label="nmra_ResearchAndCollaborationAgreementPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_VanderbiltIprDAssetsMember" xlink:label="nmra_VanderbiltIprDAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationAwardTrancheFourMember" xlink:label="nmra_ShareBasedCompensationAwardTrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone" xlink:label="nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_UpfrontConsiderationTransferredShares" xlink:label="nmra_UpfrontConsiderationTransferredShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_LoanAndSecurityAgreementMember" xlink:label="nmra_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:label="nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_Nmra511Member" xlink:label="nmra_Nmra511Member"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PreclinicalProgramsExpenses" xlink:label="nmra_PreclinicalProgramsExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NumberOfMilestoneAchieved" xlink:label="nmra_NumberOfMilestoneAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" xlink:label="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NumberOfTranches" xlink:label="nmra_NumberOfTranches"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MichaelMilliganMember" xlink:label="nmra_MichaelMilliganMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RisksAndUncertaintiesPolicyTextBlock" xlink:label="nmra_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrancheFourMember" xlink:label="nmra_TrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_UnderwritingDiscountsAndCommissions" xlink:label="nmra_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AcquiredInProcessResearchAndDevelopedExpense" xlink:label="nmra_AcquiredInProcessResearchAndDevelopedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase" xlink:label="nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_BlackthornMergerAgreementMember" xlink:label="nmra_BlackthornMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DevelopmentAndRegulatoryMilestonePayments" xlink:label="nmra_DevelopmentAndRegulatoryMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ProceedsFromMaturitiesOfMarketableSecurities" xlink:label="nmra_ProceedsFromMaturitiesOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MaximumRepaymentAmountAgreedToPay" xlink:label="nmra_MaximumRepaymentAmountAgreedToPay"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MarketAwardMember" xlink:label="nmra_MarketAwardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" xlink:label="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock upon completion of initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TradingArrangementThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Trading arrangement three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TradingArrangementThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Arrangement Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TradingArrangementThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Arrangement Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseLiabilityCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercise liability, current portion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseLiabilityCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercise Liability Current Portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseLiabilityCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Early exercise liability, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCovenantDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt instrument, covenant description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance stock options (with performance conditions to be established) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance stock options (with performance conditions to be established).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Stock Options (With Performance Conditions to Be Established)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs in connection with at-the-market offering included in accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering costs in connection with at-the-market offering included in accrued liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Costs Connection With At The Market Offering Included In Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at Beginning (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at Ending (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Amortization of Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net accretion of investments in marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction obligation with related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Obligation with Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction obligation with related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementNonRefundableQuarterlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement non-refundable quarterly payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementNonRefundableQuarterlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Non-refundable Quarterly Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementNonRefundableQuarterlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement non-refundable quarterly payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForIssuanceUnderThePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for issuance under the plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForIssuanceUnderThePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved for Issuance under the Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForIssuanceUnderThePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Reserved for Issuance Under the Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ContingentConsiderationMilestonePaymentSettledInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration, milestone payment settled in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ContingentConsiderationMilestonePaymentSettledInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration, Milestone Payment Settled in Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ContingentConsiderationMilestonePaymentSettledInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, milestone payment settled in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lender Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canceled and forfeited, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options, cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Canceled and forfeited, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AdvisorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advisors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AdvisorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advisors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AdvisorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advisors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NavacaprantNMRA-511ProgramExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Navacaprant (NMRA-511) program expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NavacaprantNMRA-511ProgramExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Navacaprant (NMRA-511) program expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NavacaprantNMRA-511ProgramExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">NMRA-511 program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities by Contractual Maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued based on volume weighted average price per share prior to date milestone was met</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Based on Volume Weighted Average Price Per Share Prior to Date Milestone Was Met</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued based on volume weighted average price per share prior to date milestone was met.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DaljitBillSinghAuroraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Daljit (Bill) Singh Aurora.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DaljitBillSinghAuroraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Daljit (Bill) Singh Aurora [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DaljitBillSinghAuroraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Daljit (Bill) Singh Aurora</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_LiquidityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_LiquidityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_LiquidityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funds provided for pre-clinical research and development activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funds Provided For Pre-clinical Research And Development Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funds provided for preclinical research and development activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SecondVanderbiltSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Vanderbilt Research Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SecondVanderbiltSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Vanderbilt sponsored research agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SecondVanderbiltSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second vanderbilt sponsored research agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionCarveoutPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alairion Carveout Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionCarveoutPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alairion Carveout Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionCarveoutPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alairion Carveout Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NetCashProceedsFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash proceeds from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NetCashProceedsFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Proceeds from Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NetCashProceedsFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net cash proceeds from financing activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares reserved for potential future issuances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A-1 convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A-1 Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award Options Vested in Period Incremental Expense Resulted in Modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total incremental expense resulted in modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested in period incremental expense resulted in modification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumFutureCapitalStockOfferingsInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Future Capital Stock Offerings Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumFutureCapitalStockOfferingsInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum future capital stock offerings investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumFutureCapitalStockOfferingsInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum future capital stock offerings investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited and expired, Weighted Average Grant Date Fair Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated other comprehensive (gain) loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research agreement expiry date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Expiry Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement expiry date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amgen research and collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amgen Research And Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amgen Research and Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized gain (loss) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-2 Convertible Preferred Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A-2 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2 Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A-2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and Liquidity [Line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization and Liquidity [Line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Fair Value of Stock Options [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of fair value of stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of the agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Computation of Basic and Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedClinicalTrialAndPreclinicalCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trial and preclinical costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedClinicalTrialAndPreclinicalCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial and Preclinical Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedClinicalTrialAndPreclinicalCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial and preclinical costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested shares repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BlackThorn Therapeutics, Inc. member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BlackThorn Therapeutics, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BlackThorn Therapeutics, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares or restricted stock remained outstanding and unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding and unvested, Shares at beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding and unvested, Shares at ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price to public, per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock option and and restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option and and Restricted Stock Units Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Options and Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercised, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercised stock options subject to future vesting.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early exercised stock options subject to future vesting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early Exercised Stock Options Subject to Future Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">General and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research And Collaboration Agreement Quarterly Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Collaboration Agreement Quarterly Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and collaboration agreement quarterly payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, term of plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NavacaprantNMRA-140ProgramExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Navacaprant (NMRA-140) program expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NavacaprantNMRA-140ProgramExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Navacaprant (NMRA-140) program expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NavacaprantNMRA-140ProgramExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Navacaprant (NMRA-140) program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and collaboration agreement quarterly payments for first two years.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Collaboration Agreement Quarterly Payments For First Two Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and collaboration agreement quarterly payments for first two year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock warrants, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of unvested stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrdArrModifiedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Trd arrangement modified date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrdArrModifiedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trd Arr Modified Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrdArrModifiedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Modified Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetAssetValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Net Asset Value Per Share, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetAssetValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Net Asset Value Per Share, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetAssetValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Asset Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetAssetValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net asset value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PrepaymentPenalty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment penalty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PrepaymentPenalty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment penalty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term Loans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Canceled and forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic License and Research and Collaboration Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseLiabilityNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercise liability, net of current portion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseLiabilityNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercise Liability Net Of Current Portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseLiabilityNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Early exercise liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonePaymentDueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment due description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonePaymentDueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Due Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonePaymentDueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment due description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Current Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount funded on closing date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alairion Merger Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alairion Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AlairionMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alairion Merger Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from equity financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_K2HealthVenturesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">K2 HealthVentures LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_K2HealthVenturesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">K2 HealthVentures LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_K2HealthVenturesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">K2HV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, Weighted Average Grant Date Fair Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum liquidity covenant percentage of outstanding obligations two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum liquidity covenant percentage of outstanding obligations two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturity of the Company's Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesIssuedUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued upon achievement of milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesIssuedUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares issued upon achievement of milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesIssuedUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued upon achievement of milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Weighted Average Grant Date Fair Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining service period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and fifteen TSRI license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Fifteen TSRI License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 TSRI License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based compensation arrangement by share-based payment award, per share of purchase price of offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, per share of purchase price of offering period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Per share of purchase price of offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-cash operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash operating lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndDevelopmentPersonnelRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Personnel Related Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndDevelopmentPersonnelRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development personnel related costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndDevelopmentPersonnelRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development personnel-related costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of cash and restricted cash:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NavacaprantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Navacaprant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NavacaprantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Navacaprant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NavacaprantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">navacaprant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments for offering costs in connection with at-the-market offering and initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Series B convertible preferred stock, issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AwardsWithPerformanceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Awards with performance conditions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AwardsWithPerformanceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Awards with Performance Conditions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AwardsWithPerformanceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Awards with Performance Conditions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited and expired, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award milestones achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Milestones Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based payment, milestones achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series b convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrant Liability [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock warrant liability policy text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expired, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Expired, Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt maturities after one through two years fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Two Years Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After one year through [two] years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">After one year through two years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award Options Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unaudited interim condensed consolidated financial statements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unaudited Interim Condensed Consolidated Financial Statements [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unaudited Interim Condensed Consolidated Financial Statements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved For Future Issuance Under The Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for future issuance under the employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Reserved for Future Issuance Under the Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, outstanding stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash and cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash and cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum liquidity covenant percentage of outstanding obligations one</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum liquidity covenant percentage of outstanding obligations one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AwardModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Award modification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AwardModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Modification [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AwardModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of NOL and Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Tax Credit Carryforwards [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CaseTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Case two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CaseTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Case Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CaseTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Case Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenIncLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amgen Inc. Licenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenIncLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amgen Inc. Licenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenIncLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amgen Inc. Licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available-for-Sale Securities, Debt Maturities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AchievementOfSpecifiedCommercializationEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Achievement of specified commercialization events.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AchievementOfSpecifiedCommercializationEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Achievement of Specified Commercialization Events [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AchievementOfSpecifiedCommercializationEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement of Specified Commercialization Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Federal Income Tax Rate and Effective Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for acquisition of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination and Asset Acquisition [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance restricted stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CaseOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Case one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CaseOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Case One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CaseOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Case One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ServiceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Service conditions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ServiceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Conditions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ServiceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Conditions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liabilities, Convertible Preferred Stock, and Stockholders' Equity (Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition compensation recognized and paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt conversion amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted, exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance restricted stock (with performance conditions to be established).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance restricted stock (with performance conditions to be established) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Restricted Stock (With Performance Conditions to Be Established)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at Beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at Ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration payable in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_M4PAMProgramsExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M4 PAM Programs Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_M4PAMProgramsExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">M4 PAM programs expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_M4PAMProgramsExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">M4 PAM programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock sold in initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Services agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Services Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and collaboration agreement quarterly payments for third year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Collaboration Agreement Quarterly Payments For Third Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and collaboration agreement quarterly payments for third year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-Rule 10b5-1 arr modified.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-Rule 10b5-1 Arr Modified [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Rule 10b5-1 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement termination description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Termination Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement termination description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award Percentage of Anuual Increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award percentage of anuual increase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase of outstanding shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amgen Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amgen Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AmgenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amgen Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TradingArrangementOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Trading arrangement one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TradingArrangementOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Arrangement One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TradingArrangementOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Arrangement One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Interest Rate Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for options and restricted stock unitsissued underthe plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved For Options And Restricted Stock UnitsIssued UnderThe Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Reserved for Options and Restricted Stock Units Issued Under the Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation granted under plan vested period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share based compensation forfeited under unvested plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TradingArrangementTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Trading arrangement two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TradingArrangementTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Arrangement Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TradingArrangementTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Arrangement Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AdditionalSharesOfCapitalStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional shares of capital stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AdditionalSharesOfCapitalStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Shares of Capital Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AdditionalSharesOfCapitalStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Shares of Capital Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Organization and Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of clinical and preclinical neuroscience programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Clinical And Preclinical Neuroscience Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of clinical and preclinical neuroscience programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate grant-date fair value of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase of unvested early exercised shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Of Unvested Early Exercised Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of unvested early exercised shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquisitionDateFairValueOfSharesTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition date fair value of shares transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquisitionDateFairValueOfSharesTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Date Fair Value of Shares Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquisitionDateFairValueOfSharesTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition date fair value of shares transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront cash payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Information on the Company's Operating Leases [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental information on the company's operating leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Information on the Company's Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PaymentsForExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for execution of agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PaymentsForExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Execution Of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PaymentsForExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for execution of agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Income (Expense), Nonoperating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Outstanding (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ForfeitureOfUnvestedRestrictedCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forfeiture of Unvested Restricted Common Stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ForfeitureOfUnvestedRestrictedCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Forfeiture of unvested restricted common stock, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ForfeitureOfUnvestedRestrictedCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeiture of unvested restricted common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock, policy policy text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundsReceivedUponExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funds received upon execution of agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundsReceivedUponExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funds Received Upon Execution Of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundsReceivedUponExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funds received upon execution of agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseOfEmployeeStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercise of employee stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseOfEmployeeStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercise of Employee Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EarlyExerciseOfEmployeeStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early Exercise of Employee Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SalesBasedMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales-based milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SalesBasedMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Based Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SalesBasedMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales-based Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vanderbilt sponsored research agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vanderbilt Sponsored Research Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vanderbilt Research Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornCarveoutPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BlackThorn Carveout Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornCarveoutPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BlackThorn Carveout Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornCarveoutPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BlackThorn Carveout Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stockholders' equity (deficit):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ParkinsonsResearchVenturesFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Parkinsons research ventures funding agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ParkinsonsResearchVenturesFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Parkinsons Research Ventures Funding Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ParkinsonsResearchVenturesFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Parkinson's Research Ventures Funding Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ScheduleOfOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of organization and liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ScheduleOfOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Organization And Liquidity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FirstVanderbiltSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Vanderbilt Research Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FirstVanderbiltSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Vanderbilt sponsored research agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FirstVanderbiltSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Vanderbilt sponsored research agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents and Marketable Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash and cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three employee share purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Employee Share Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Employee Share Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Income (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_LineOfCreditFacilityAdditionalBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Additional Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_LineOfCreditFacilityAdditionalBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility, additional borrowing capacity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_LineOfCreditFacilityAdditionalBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional borrowing capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs related to initial public offering included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering costs related to initial public offering included in accounts payable and accrued liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Costs Related To Initial Public Offering Included In Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OtherSegmentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Segment Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OtherSegmentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other segment items.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_OtherSegmentItems_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificates of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule 10b5-1 arr modified.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule 10b5-1 Arr Modified [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10b5-1 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Acquisition, Contingent Consideration, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration deemed due or payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents and restricted cash at beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Lender [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForFutureIssuanceUnderThePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Reserved for Future Issuance Under the Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForFutureIssuanceUnderThePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares reserved for future issuance under the plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SharesReservedForFutureIssuanceUnderThePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for future issuance under the plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CommercialMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CommercialMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_CommercialMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory approval milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Approval Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Regulatory Approval Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vanderbilt License.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vanderbilt License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vanderbilt License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SyllableMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Syllable Merger Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SyllableMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Syllable Merger Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_SyllableMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Syllable Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ContingentConsiderationMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration, milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ContingentConsiderationMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration, Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ContingentConsiderationMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Amortized Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Operating lease liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AchievementOfSpecifiedDevelopmentEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Achievement of specified development events.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AchievementOfSpecifiedDevelopmentEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Achievement of Specified Development Events [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AchievementOfSpecifiedDevelopmentEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement of Specified Development Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_StockPurchaseRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase right.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_StockPurchaseRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Right [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_StockPurchaseRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Converted shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of convertible preferred stock automatically converted into shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestones achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestones Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestones achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development services due to related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research and Development Services Due to Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development services due to related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research and Development Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AccruedResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants vest percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum additional financing in equity securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum additional financing in equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and collaboration agreement payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Collaboration Agreement Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ResearchAndCollaborationAgreementPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and collaboration agreement payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltIprDAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vanderbilt IPR&amp;D Assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltIprDAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vanderbilt IPR&amp;D Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_VanderbiltIprDAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vanderbilt IPR&amp;D Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of common stock reserved for future issuance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Frequency of Payment and Payment Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationAwardTrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Based Tranches</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationAwardTrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationAwardTrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Award Tranche Four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fund Received Upon Completion Of Certain Development Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fund received upon completion of certain development milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fund received upon completion of certain development milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UpfrontConsiderationTransferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront consideration transferred shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UpfrontConsiderationTransferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Consideration Transferred Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UpfrontConsiderationTransferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront consideration transferred shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Short-Term Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S Government and Agency Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares vesting of restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares, Vesting Of Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Nmra511Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NMRA-511.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Nmra511Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NMRA-511 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_Nmra511Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NMRA-511</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PreclinicalProgramsExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Preclinical programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PreclinicalProgramsExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preclinical programs expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_PreclinicalProgramsExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preclinical programs expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of milestone achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Milestone Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of milestone achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fund eligible to receive upon completion of certain development milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fund Eligible To Receive Upon Completion Of Certain Development Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fund eligible to receive upon completion of certain development milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of tranches</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_NumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of tranches.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MichaelMilliganMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Michael Milligan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MichaelMilliganMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Michael Milligan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MichaelMilliganMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Michael Milligan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commitments and contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Segment Loss Including Significant Segment Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, outstanding stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and uncertainties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks and Uncertainties [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_TrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fourth Tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split conversion ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeiture of restricted stock subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forfeiture of restricted stock subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeiture of restricted stock subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting of restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquiredInProcessResearchAndDevelopedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and developed expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquiredInProcessResearchAndDevelopedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired in-process Research and Developed Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_AcquiredInProcessResearchAndDevelopedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired in-process research and developed expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Vesting Of Common Stock Subject To Repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value vesting of common stock subject to repurchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of common stock subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BlackThorn Merger Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BlackThorn Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_BlackthornMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BlackThorn Merger Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Regulatory Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_DevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price Per Share, Outstanding, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price Per Share, Outstanding, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled, Weighted Average Grant Date Fair Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average. Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ProceedsFromMaturitiesOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ProceedsFromMaturitiesOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturities Of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_ProceedsFromMaturitiesOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from maturities of marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at Beginning (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at Ending (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumRepaymentAmountAgreedToPay_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum repayment amount agreed to pay.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumRepaymentAmountAgreedToPay_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Repayment Amount Agreed To Pay</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MaximumRepaymentAmountAgreedToPay_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum repayment amount agreed to pay.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MarketAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MarketAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Award [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_MarketAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated fair value of available for sale debt securities fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Fair Value Of Available For Sale Debt Securities Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TradingArrangementThreeMember" xlink:to="nmra_TradingArrangementThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EarlyExerciseLiabilityCurrentPortion" xlink:to="nmra_EarlyExerciseLiabilityCurrentPortion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantDescription" xlink:to="us-gaap_DebtInstrumentCovenantDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" xlink:to="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities" xlink:to="nmra_OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_RelatedPartyTransactionObligationWithRelatedParty" xlink:to="nmra_RelatedPartyTransactionObligationWithRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CollaborationAgreementNonRefundableQuarterlyPayments" xlink:to="nmra_CollaborationAgreementNonRefundableQuarterlyPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SharesReservedForIssuanceUnderThePlansMember" xlink:to="nmra_SharesReservedForIssuanceUnderThePlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ContingentConsiderationMilestonePaymentSettledInCash" xlink:to="nmra_ContingentConsiderationMilestonePaymentSettledInCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AdvisorsMember" xlink:to="nmra_AdvisorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NavacaprantNMRA-511ProgramExpenses" xlink:to="nmra_NavacaprantNMRA-511ProgramExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" xlink:to="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DaljitBillSinghAuroraMember" xlink:to="nmra_DaljitBillSinghAuroraMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DevelopmentMilestonesMember" xlink:to="nmra_DevelopmentMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_LiquidityMember" xlink:to="nmra_LiquidityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" xlink:to="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SecondVanderbiltSponsoredResearchAgreementMember" xlink:to="nmra_SecondVanderbiltSponsoredResearchAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AlairionCarveoutPlanMember" xlink:to="nmra_AlairionCarveoutPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NetCashProceedsFromFinancingActivities" xlink:to="nmra_NetCashProceedsFromFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NumberOfLicenseAgreements" xlink:to="nmra_NumberOfLicenseAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SeriesA1ConvertiblePreferredStockMember" xlink:to="nmra_SeriesA1ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MaximumFutureCapitalStockOfferingsInvestment" xlink:to="nmra_MaximumFutureCapitalStockOfferingsInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ResearchAgreementExpiryDate" xlink:to="nmra_ResearchAgreementExpiryDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AmgenResearchAndCollaborationAgreementMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SeriesA2ConvertiblePreferredStockMember" xlink:to="nmra_SeriesA2ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="nmra_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_OrganizationAndLiquidityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock" xlink:to="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CollaborationAgreementTerm" xlink:to="nmra_CollaborationAgreementTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AccruedClinicalTrialAndPreclinicalCosts" xlink:to="nmra_AccruedClinicalTrialAndPreclinicalCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_BlackthornTherapeuticsIncMember" xlink:to="nmra_BlackthornTherapeuticsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_RestrictedCommonStockMember" xlink:to="nmra_RestrictedCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TrancheTwoMember" xlink:to="nmra_TrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" xlink:to="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MarketableSecuritiesMember" xlink:to="nmra_MarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" xlink:to="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ResearchAndCollaborationAgreementQuarterlyPayments" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NavacaprantNMRA-140ProgramExpenses" xlink:to="nmra_NavacaprantNMRA-140ProgramExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TrdArrModifiedDate" xlink:to="nmra_TrdArrModifiedDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetAssetValuePerShare" xlink:to="us-gaap_NetAssetValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PrepaymentPenalty" xlink:to="nmra_PrepaymentPenalty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TermLoansMember" xlink:to="nmra_TermLoansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EarlyExerciseLiabilityNetOfCurrentPortion" xlink:to="nmra_EarlyExerciseLiabilityNetOfCurrentPortion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MilestonePaymentDueDescription" xlink:to="nmra_MilestonePaymentDueDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AlairionMergerAgreementMember" xlink:to="nmra_AlairionMergerAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AcquiredInProcessResearchAndDevelopment" xlink:to="nmra_AcquiredInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_K2HealthVenturesLLCMember" xlink:to="nmra_K2HealthVenturesLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo" xlink:to="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SharesIssuedUponAchievementOfMilestone" xlink:to="nmra_SharesIssuedUponAchievementOfMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" xlink:to="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod" xlink:to="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NoncashOperatingLeaseExpense" xlink:to="nmra_NoncashOperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ResearchAndDevelopmentPersonnelRelatedCosts" xlink:to="nmra_ResearchAndDevelopmentPersonnelRelatedCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NavacaprantMember" xlink:to="nmra_NavacaprantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AwardsWithPerformanceConditionsMember" xlink:to="nmra_AwardsWithPerformanceConditionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SeriesBConvertiblePreferredStockMember" xlink:to="nmra_SeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:to="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_OfferingExpenses" xlink:to="nmra_OfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DeferredOfferingCostsPolicyTextBlock" xlink:to="nmra_DeferredOfferingCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MilestonePayments" xlink:to="nmra_MilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:to="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember" xlink:to="nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne" xlink:to="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AwardModificationMember" xlink:to="nmra_AwardModificationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CaseTwoMember" xlink:to="nmra_CaseTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AmgenIncLicensesMember" xlink:to="nmra_AmgenIncLicensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AchievementOfSpecifiedCommercializationEventsMember" xlink:to="nmra_AchievementOfSpecifiedCommercializationEventsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PerformanceRestrictedStockMember" xlink:to="nmra_PerformanceRestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CaseOneMember" xlink:to="nmra_CaseOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ServiceConditionsMember" xlink:to="nmra_ServiceConditionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" xlink:to="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_M4PAMProgramsExpenses" xlink:to="nmra_M4PAMProgramsExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ServicesAgreementMember" xlink:to="nmra_ServicesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NonRule10B51ArrModifiedFlag" xlink:to="nmra_NonRule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CollaborationAgreementTerminationDescription" xlink:to="nmra_CollaborationAgreementTerminationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease" xlink:to="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AmgenIncMember" xlink:to="nmra_AmgenIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TradingArrangementOneMember" xlink:to="nmra_TradingArrangementOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="nmra_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" xlink:to="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TradingArrangementTwoMember" xlink:to="nmra_TradingArrangementTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TrancheOneMember" xlink:to="nmra_TrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AdditionalSharesOfCapitalStockMember" xlink:to="nmra_AdditionalSharesOfCapitalStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" xlink:to="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_RepurchaseOfUnvestedEarlyExercisedShares" xlink:to="nmra_RepurchaseOfUnvestedEarlyExercisedShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AcquisitionDateFairValueOfSharesTransferred" xlink:to="nmra_AcquisitionDateFairValueOfSharesTransferred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_UpfrontCashPayment" xlink:to="nmra_UpfrontCashPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock" xlink:to="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PaymentsForExecutionOfAgreement" xlink:to="nmra_PaymentsForExecutionOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CommercialMilestonePayments" xlink:to="nmra_CommercialMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TrancheThreeMember" xlink:to="nmra_TrancheThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ForfeitureOfUnvestedRestrictedCommonStockShares" xlink:to="nmra_ForfeitureOfUnvestedRestrictedCommonStockShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:to="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_FundsReceivedUponExecutionOfAgreement" xlink:to="nmra_FundsReceivedUponExecutionOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EarlyExerciseOfEmployeeStockOptionsMember" xlink:to="nmra_EarlyExerciseOfEmployeeStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SalesBasedMilestonesMember" xlink:to="nmra_SalesBasedMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_VanderbiltSponsoredResearchAgreementMember" xlink:to="nmra_VanderbiltSponsoredResearchAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_BlackthornCarveoutPlanMember" xlink:to="nmra_BlackthornCarveoutPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ParkinsonsResearchVenturesFundingAgreementMember" xlink:to="nmra_ParkinsonsResearchVenturesFundingAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:to="nmra_ScheduleOfOrganizationAndLiquidityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_FirstVanderbiltSponsoredResearchAgreementMember" xlink:to="nmra_FirstVanderbiltSponsoredResearchAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="nmra_CashEquivalentsAndMarketableSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" xlink:to="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="nmra_LineOfCreditFacilityAdditionalBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="nmra_OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_OtherSegmentItems" xlink:to="nmra_OtherSegmentItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_Rule10B51ArrModifiedFlag" xlink:to="nmra_Rule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SharesReservedForFutureIssuanceUnderThePlansMember" xlink:to="nmra_SharesReservedForFutureIssuanceUnderThePlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_CommercialMilestonePaymentMember" xlink:to="nmra_CommercialMilestonePaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" xlink:to="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_VanderbiltLicenseMember" xlink:to="nmra_VanderbiltLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_SyllableMergerAgreementMember" xlink:to="nmra_SyllableMergerAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ContingentConsiderationMilestonePayment" xlink:to="nmra_ContingentConsiderationMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AchievementOfSpecifiedDevelopmentEventsMember" xlink:to="nmra_AchievementOfSpecifiedDevelopmentEventsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_StockPurchaseRightMember" xlink:to="nmra_StockPurchaseRightMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MilestonesAchieved" xlink:to="nmra_MilestonesAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty" xlink:to="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AccruedResearchAndDevelopmentServices" xlink:to="nmra_AccruedResearchAndDevelopmentServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MaximumAdditionalFinancingInEquitySecurities" xlink:to="nmra_MaximumAdditionalFinancingInEquitySecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ResearchAndCollaborationAgreementPayments" xlink:to="nmra_ResearchAndCollaborationAgreementPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_VanderbiltIprDAssetsMember" xlink:to="nmra_VanderbiltIprDAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ShareBasedCompensationAwardTrancheFourMember" xlink:to="nmra_ShareBasedCompensationAwardTrancheFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone" xlink:to="nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_UpfrontConsiderationTransferredShares" xlink:to="nmra_UpfrontConsiderationTransferredShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_LoanAndSecurityAgreementMember" xlink:to="nmra_LoanAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:to="nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_Nmra511Member" xlink:to="nmra_Nmra511Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_PreclinicalProgramsExpenses" xlink:to="nmra_PreclinicalProgramsExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NumberOfMilestoneAchieved" xlink:to="nmra_NumberOfMilestoneAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" xlink:to="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_NumberOfTranches" xlink:to="nmra_NumberOfTranches_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MichaelMilliganMember" xlink:to="nmra_MichaelMilliganMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_RisksAndUncertaintiesPolicyTextBlock" xlink:to="nmra_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_TrancheFourMember" xlink:to="nmra_TrancheFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_UnderwritingDiscountsAndCommissions" xlink:to="nmra_UnderwritingDiscountsAndCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_AcquiredInProcessResearchAndDevelopedExpense" xlink:to="nmra_AcquiredInProcessResearchAndDevelopedExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase" xlink:to="nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_BlackthornMergerAgreementMember" xlink:to="nmra_BlackthornMergerAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_DevelopmentAndRegulatoryMilestonePayments" xlink:to="nmra_DevelopmentAndRegulatoryMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_ProceedsFromMaturitiesOfMarketableSecurities" xlink:to="nmra_ProceedsFromMaturitiesOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MaximumRepaymentAmountAgreedToPay" xlink:to="nmra_MaximumRepaymentAmountAgreedToPay_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_MarketAwardMember" xlink:to="nmra_MarketAwardMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" xlink:to="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EarlyExerciseLiabilityCurrentPortion" xlink:label="nmra_EarlyExerciseLiabilityCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EarlyExerciseLiabilityNetOfCurrentPortion" xlink:label="nmra_EarlyExerciseLiabilityNetOfCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="nmra_EarlyExerciseLiabilityCurrentPortion" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nmra_EarlyExerciseLiabilityNetOfCurrentPortion" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AcquiredInProcessResearchAndDevelopment" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="nmra_AcquiredInProcessResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ForfeitureOfUnvestedRestrictedCommonStockShares" xlink:label="nmra_ForfeitureOfUnvestedRestrictedCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:label="nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase" xlink:label="nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_12"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nmra_ForfeitureOfUnvestedRestrictedCommonStockShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementStockholdersEquityDeficitUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities" xlink:label="nmra_OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NoncashOperatingLeaseExpense" xlink:label="nmra_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ProceedsFromMaturitiesOfMarketableSecurities" xlink:label="nmra_ProceedsFromMaturitiesOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="nmra_OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RepurchaseOfUnvestedEarlyExercisedShares" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nmra_OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nmra_NoncashOperatingLeaseExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="nmra_ProceedsFromMaturitiesOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nmra_OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nmra_RepurchaseOfUnvestedEarlyExercisedShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TradingArrangementOneMember" xlink:label="nmra_TradingArrangementOneMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TradingArrangementTwoMember" xlink:label="nmra_TradingArrangementTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DaljitBillSinghAuroraMember" xlink:label="nmra_DaljitBillSinghAuroraMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TradingArrangementThreeMember" xlink:label="nmra_TradingArrangementThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MichaelMilliganMember" xlink:label="nmra_MichaelMilliganMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_Rule10B51ArrModifiedFlag" xlink:label="nmra_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NonRule10B51ArrModifiedFlag" xlink:label="nmra_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrdArrModifiedDate" xlink:label="nmra_TrdArrModifiedDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="nmra_TradingArrangementOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="nmra_TradingArrangementTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="nmra_DaljitBillSinghAuroraMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="nmra_TradingArrangementThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="nmra_MichaelMilliganMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="nmra_Rule10B51ArrModifiedFlag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="nmra_NonRule10B51ArrModifiedFlag" order="15.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="nmra_TrdArrModifiedDate" order="16.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="nmra_CashEquivalentsAndMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosurePreferredStockWarrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReporting" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEvent" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:label="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RisksAndUncertaintiesPolicyTextBlock" xlink:label="nmra_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DeferredOfferingCostsPolicyTextBlock" xlink:label="nmra_DeferredOfferingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:label="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="nmra_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmra_RisksAndUncertaintiesPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmra_DeferredOfferingCostsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmra_EmergingGrowthCompanyStatusPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="nmra_CashEquivalentsAndMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock" xlink:label="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SummaryOfFairValueOfStockOptionsTableTextBlock" xlink:label="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_OrganizationAndLiquidityLineItems" xlink:label="nmra_OrganizationAndLiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" xlink:label="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:label="nmra_ScheduleOfOrganizationAndLiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_LiquidityMember" xlink:label="nmra_LiquidityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_UnderwritingDiscountsAndCommissions" xlink:label="nmra_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_OfferingExpenses" xlink:label="nmra_OfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nmra_ScheduleOfOrganizationAndLiquidityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nmra_LiquidityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nmra_OrganizationAndLiquidityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_UnderwritingDiscountsAndCommissions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_OfferingExpenses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MarketableSecuritiesMember" xlink:label="nmra_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nmra_MarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" xlink:label="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MarketableSecuritiesMember" xlink:label="nmra_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nmra_MarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetAssetValuePerShare" xlink:label="us-gaap_NetAssetValuePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_NetAssetValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AccruedClinicalTrialAndPreclinicalCosts" xlink:label="nmra_AccruedClinicalTrialAndPreclinicalCosts"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AccruedResearchAndDevelopmentServices" xlink:label="nmra_AccruedResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nmra_AccruedClinicalTrialAndPreclinicalCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nmra_AccruedResearchAndDevelopmentServices" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty" xlink:label="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_BlackthornMergerAgreementMember" xlink:label="nmra_BlackthornMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CaseOneMember" xlink:label="nmra_CaseOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SeriesA2ConvertiblePreferredStockMember" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_BlackthornTherapeuticsIncMember" xlink:label="nmra_BlackthornTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" xlink:label="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_BlackthornCarveoutPlanMember" xlink:label="nmra_BlackthornCarveoutPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CaseTwoMember" xlink:label="nmra_CaseTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ContingentConsiderationMilestonePayment" xlink:label="nmra_ContingentConsiderationMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NavacaprantMember" xlink:label="nmra_NavacaprantMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DevelopmentMilestonesMember" xlink:label="nmra_DevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SyllableMergerAgreementMember" xlink:label="nmra_SyllableMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MilestonePaymentDueDescription" xlink:label="nmra_MilestonePaymentDueDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_Nmra511Member" xlink:label="nmra_Nmra511Member"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SalesBasedMilestonesMember" xlink:label="nmra_SalesBasedMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AlairionMergerAgreementMember" xlink:label="nmra_AlairionMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ContingentConsiderationMilestonePaymentSettledInCash" xlink:label="nmra_ContingentConsiderationMilestonePaymentSettledInCash"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenIncMember" xlink:label="nmra_AmgenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AchievementOfSpecifiedDevelopmentEventsMember" xlink:label="nmra_AchievementOfSpecifiedDevelopmentEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AlairionCarveoutPlanMember" xlink:label="nmra_AlairionCarveoutPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NumberOfMilestoneAchieved" xlink:label="nmra_NumberOfMilestoneAchieved"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_VanderbiltIprDAssetsMember" xlink:label="nmra_VanderbiltIprDAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AchievementOfSpecifiedCommercializationEventsMember" xlink:label="nmra_AchievementOfSpecifiedCommercializationEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenIncLicensesMember" xlink:label="nmra_AmgenIncLicensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CommercialMilestonePaymentMember" xlink:label="nmra_CommercialMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_VanderbiltLicenseMember" xlink:label="nmra_VanderbiltLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NumberOfLicenseAgreements" xlink:label="nmra_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_UpfrontConsiderationTransferredShares" xlink:label="nmra_UpfrontConsiderationTransferredShares"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AcquisitionDateFairValueOfSharesTransferred" xlink:label="nmra_AcquisitionDateFairValueOfSharesTransferred"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_UpfrontCashPayment" xlink:label="nmra_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AcquiredInProcessResearchAndDevelopment" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" xlink:label="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AcquiredInProcessResearchAndDevelopedExpense" xlink:label="nmra_AcquiredInProcessResearchAndDevelopedExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_BlackthornMergerAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nmra_CaseOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmra_SeriesA2ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_BlackthornTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_BlackthornCarveoutPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nmra_CaseTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_ContingentConsiderationMilestonePayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_NavacaprantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_DevelopmentMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_SyllableMergerAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_MilestonePaymentDueDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_Nmra511Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_SalesBasedMilestonesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AlairionMergerAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_ContingentConsiderationMilestonePaymentSettledInCash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_AmgenIncMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_AchievementOfSpecifiedDevelopmentEventsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AlairionCarveoutPlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_NumberOfMilestoneAchieved" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_VanderbiltIprDAssetsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_AchievementOfSpecifiedCommercializationEventsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenIncLicensesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_CommercialMilestonePaymentMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_VanderbiltLicenseMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_NumberOfLicenseAgreements" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_UpfrontConsiderationTransferredShares" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_AcquisitionDateFairValueOfSharesTransferred" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_UpfrontCashPayment" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_AcquiredInProcessResearchAndDevelopment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_AcquiredInProcessResearchAndDevelopedExpense" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" xlink:label="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DevelopmentAndRegulatoryMilestonePayments" xlink:label="nmra_DevelopmentAndRegulatoryMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CommercialMilestonePayments" xlink:label="nmra_CommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_VanderbiltSponsoredResearchAgreementMember" xlink:label="nmra_VanderbiltSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MilestonesAchieved" xlink:label="nmra_MilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FirstVanderbiltSponsoredResearchAgreementMember" xlink:label="nmra_FirstVanderbiltSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MilestonePayments" xlink:label="nmra_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SecondVanderbiltSponsoredResearchAgreementMember" xlink:label="nmra_SecondVanderbiltSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ParkinsonsResearchVenturesFundingAgreementMember" xlink:label="nmra_ParkinsonsResearchVenturesFundingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CollaborationAgreementTerm" xlink:label="nmra_CollaborationAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CollaborationAgreementTerminationDescription" xlink:label="nmra_CollaborationAgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RelatedPartyTransactionObligationWithRelatedParty" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CollaborationAgreementNonRefundableQuarterlyPayments" xlink:label="nmra_CollaborationAgreementNonRefundableQuarterlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPayments" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndCollaborationAgreementPayments" xlink:label="nmra_ResearchAndCollaborationAgreementPayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAgreementExpiryDate" xlink:label="nmra_ResearchAgreementExpiryDate"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" xlink:label="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FundsReceivedUponExecutionOfAgreement" xlink:label="nmra_FundsReceivedUponExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PaymentsForExecutionOfAgreement" xlink:label="nmra_PaymentsForExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone" xlink:label="nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" xlink:label="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MaximumRepaymentAmountAgreedToPay" xlink:label="nmra_MaximumRepaymentAmountAgreedToPay"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_DevelopmentAndRegulatoryMilestonePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CommercialMilestonePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_VanderbiltSponsoredResearchAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_MilestonesAchieved" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_FirstVanderbiltSponsoredResearchAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_MilestonePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_SecondVanderbiltSponsoredResearchAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_ParkinsonsResearchVenturesFundingAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CollaborationAgreementTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CollaborationAgreementTerminationDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_RelatedPartyTransactionObligationWithRelatedParty" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CollaborationAgreementNonRefundableQuarterlyPayments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPayments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementPayments" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAgreementExpiryDate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundsReceivedUponExecutionOfAgreement" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_PaymentsForExecutionOfAgreement" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_MaximumRepaymentAmountAgreedToPay" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ServiceConditionsMember" xlink:label="nmra_ServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_BlackthornMergerAgreementMember" xlink:label="nmra_BlackthornMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AdditionalSharesOfCapitalStockMember" xlink:label="nmra_AdditionalSharesOfCapitalStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MaximumAdditionalFinancingInEquitySecurities" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesIssuedUponAchievementOfMilestone" xlink:label="nmra_SharesIssuedUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MilestonesAchieved" xlink:label="nmra_MilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="nmra_ServiceConditionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_BlackthornMergerAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nmra_AdditionalSharesOfCapitalStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nmra_MaximumAdditionalFinancingInEquitySecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nmra_SharesIssuedUponAchievementOfMilestone" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nmra_MilestonesAchieved" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" xlink:label="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesReservedForIssuanceUnderThePlansMember" xlink:label="nmra_SharesReservedForIssuanceUnderThePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesReservedForFutureIssuanceUnderThePlansMember" xlink:label="nmra_SharesReservedForFutureIssuanceUnderThePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember" xlink:label="nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForIssuanceUnderThePlansMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForFutureIssuanceUnderThePlansMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="nmra_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RestrictedCommonStockMember" xlink:label="nmra_RestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AdvisorsMember" xlink:label="nmra_AdvisorsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" xlink:label="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease" xlink:label="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EarlyExerciseOfEmployeeStockOptionsMember" xlink:label="nmra_EarlyExerciseOfEmployeeStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationAwardTrancheFourMember" xlink:label="nmra_ShareBasedCompensationAwardTrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MarketAwardMember" xlink:label="nmra_MarketAwardMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod" xlink:label="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AwardsWithPerformanceConditionsMember" xlink:label="nmra_AwardsWithPerformanceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AwardModificationMember" xlink:label="nmra_AwardModificationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_StockPurchaseRightMember" xlink:label="nmra_StockPurchaseRightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ServicesAgreementMember" xlink:label="nmra_ServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PerformanceRestrictedStockMember" xlink:label="nmra_PerformanceRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmra_TwoThousandTwentyEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nmra_RestrictedCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nmra_AdvisorsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_EarlyExerciseOfEmployeeStockOptionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="nmra_ShareBasedCompensationAwardTrancheFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_MarketAwardMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_AwardsWithPerformanceConditionsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_AwardModificationMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_StockPurchaseRightMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_ServicesAgreementMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="9.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_PerformanceRestrictedStockMember" order="10.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="11.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="12.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NavacaprantNMRA-140ProgramExpenses" xlink:label="nmra_NavacaprantNMRA-140ProgramExpenses"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_M4PAMProgramsExpenses" xlink:label="nmra_M4PAMProgramsExpenses"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NavacaprantNMRA-511ProgramExpenses" xlink:label="nmra_NavacaprantNMRA-511ProgramExpenses"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PreclinicalProgramsExpenses" xlink:label="nmra_PreclinicalProgramsExpenses"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndDevelopmentPersonnelRelatedCosts" xlink:label="nmra_ResearchAndDevelopmentPersonnelRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_OtherSegmentItems" xlink:label="nmra_OtherSegmentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="nmra_NavacaprantNMRA-140ProgramExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="nmra_M4PAMProgramsExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="nmra_NavacaprantNMRA-511ProgramExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="nmra_PreclinicalProgramsExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="nmra_ResearchAndDevelopmentPersonnelRelatedCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="nmra_OtherSegmentItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" xlink:label="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" xlink:label="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" xlink:label="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" xlink:label="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RelatedPartyTransactionObligationWithRelatedParty" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SeriesBConvertiblePreferredStockMember" xlink:label="nmra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SeriesA1ConvertiblePreferredStockMember" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MaximumAdditionalFinancingInEquitySecurities" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_RelatedPartyTransactionObligationWithRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmra_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmra_SeriesA1ConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_MaximumAdditionalFinancingInEquitySecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrancheOneMember" xlink:label="nmra_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TermLoansMember" xlink:label="nmra_TermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_LoanAndSecurityAgreementMember" xlink:label="nmra_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_K2HealthVenturesLLCMember" xlink:label="nmra_K2HealthVenturesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrancheTwoMember" xlink:label="nmra_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NumberOfTranches" xlink:label="nmra_NumberOfTranches"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrancheThreeMember" xlink:label="nmra_TrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrancheFourMember" xlink:label="nmra_TrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="nmra_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NetCashProceedsFromFinancingActivities" xlink:label="nmra_NetCashProceedsFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne" xlink:label="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo" xlink:label="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PrepaymentPenalty" xlink:label="nmra_PrepaymentPenalty"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MaximumFutureCapitalStockOfferingsInvestment" xlink:label="nmra_MaximumFutureCapitalStockOfferingsInvestment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="nmra_TrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nmra_TermLoansMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="nmra_LoanAndSecurityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="nmra_K2HealthVenturesLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="nmra_TrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_NumberOfTranches" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="nmra_TrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="nmra_TrancheFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_LineOfCreditFacilityAdditionalBorrowingCapacity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_NetCashProceedsFromFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentCovenantDescription" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_PrepaymentPenalty" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_MaximumFutureCapitalStockOfferingsInvestment" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ForfeitureOfUnvestedRestrictedCommonStockShares" xlink:label="nmra_ForfeitureOfUnvestedRestrictedCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:label="nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase" xlink:label="nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmra_ForfeitureOfUnvestedRestrictedCommonStockShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementStockholdersEquityDeficitUnauditedParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TradingArrangementOneMember" xlink:label="nmra_TradingArrangementOneMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TradingArrangementTwoMember" xlink:label="nmra_TradingArrangementTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TradingArrangementThreeMember" xlink:label="nmra_TradingArrangementThreeMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="nmra_TradingArrangementOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="nmra_TradingArrangementTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="nmra_TradingArrangementThreeMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DaljitBillSinghAuroraMember" xlink:label="nmra_DaljitBillSinghAuroraMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MichaelMilliganMember" xlink:label="nmra_MichaelMilliganMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="nmra_DaljitBillSinghAuroraMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="nmra_MichaelMilliganMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:label="nmra_ScheduleOfOrganizationAndLiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_OrganizationAndLiquidityLineItems" xlink:label="nmra_OrganizationAndLiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" xlink:label="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_LiquidityMember" xlink:label="nmra_LiquidityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_UnderwritingDiscountsAndCommissions" xlink:label="nmra_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_OfferingExpenses" xlink:label="nmra_OfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nmra_ScheduleOfOrganizationAndLiquidityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nmra_LiquidityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmra_ScheduleOfOrganizationAndLiquidityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nmra_OrganizationAndLiquidityLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_UnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="nmra_OfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmra_OrganizationAndLiquidityLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MarketableSecuritiesMember" xlink:label="nmra_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nmra_MarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MarketableSecuritiesMember" xlink:label="nmra_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nmra_MarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_BlackthornMergerAgreementMember" xlink:label="nmra_BlackthornMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CaseOneMember" xlink:label="nmra_CaseOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SeriesA2ConvertiblePreferredStockMember" xlink:label="nmra_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_BlackthornTherapeuticsIncMember" xlink:label="nmra_BlackthornTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" xlink:label="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_BlackthornCarveoutPlanMember" xlink:label="nmra_BlackthornCarveoutPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CaseTwoMember" xlink:label="nmra_CaseTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ContingentConsiderationMilestonePayment" xlink:label="nmra_ContingentConsiderationMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NavacaprantMember" xlink:label="nmra_NavacaprantMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DevelopmentMilestonesMember" xlink:label="nmra_DevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SyllableMergerAgreementMember" xlink:label="nmra_SyllableMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MilestonePaymentDueDescription" xlink:label="nmra_MilestonePaymentDueDescription"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_Nmra511Member" xlink:label="nmra_Nmra511Member"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SalesBasedMilestonesMember" xlink:label="nmra_SalesBasedMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AlairionMergerAgreementMember" xlink:label="nmra_AlairionMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ContingentConsiderationMilestonePaymentSettledInCash" xlink:label="nmra_ContingentConsiderationMilestonePaymentSettledInCash"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenIncMember" xlink:label="nmra_AmgenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AchievementOfSpecifiedDevelopmentEventsMember" xlink:label="nmra_AchievementOfSpecifiedDevelopmentEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AlairionCarveoutPlanMember" xlink:label="nmra_AlairionCarveoutPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NumberOfMilestoneAchieved" xlink:label="nmra_NumberOfMilestoneAchieved"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_VanderbiltIprDAssetsMember" xlink:label="nmra_VanderbiltIprDAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AchievementOfSpecifiedCommercializationEventsMember" xlink:label="nmra_AchievementOfSpecifiedCommercializationEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenIncLicensesMember" xlink:label="nmra_AmgenIncLicensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CommercialMilestonePaymentMember" xlink:label="nmra_CommercialMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_VanderbiltLicenseMember" xlink:label="nmra_VanderbiltLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NumberOfLicenseAgreements" xlink:label="nmra_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_UpfrontConsiderationTransferredShares" xlink:label="nmra_UpfrontConsiderationTransferredShares"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AcquisitionDateFairValueOfSharesTransferred" xlink:label="nmra_AcquisitionDateFairValueOfSharesTransferred"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_UpfrontCashPayment" xlink:label="nmra_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AcquiredInProcessResearchAndDevelopment" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" xlink:label="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AcquiredInProcessResearchAndDevelopedExpense" xlink:label="nmra_AcquiredInProcessResearchAndDevelopedExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_BlackthornMergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nmra_CaseOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmra_SeriesA2ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_BlackthornTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_BlackthornCarveoutPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nmra_CaseTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_ContingentConsiderationMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_NavacaprantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_DevelopmentMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_SyllableMergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_MilestonePaymentDueDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_Nmra511Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_SalesBasedMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AlairionMergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_ContingentConsiderationMilestonePaymentSettledInCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_AmgenIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_AchievementOfSpecifiedDevelopmentEventsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AlairionCarveoutPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_NumberOfMilestoneAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nmra_VanderbiltIprDAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_AchievementOfSpecifiedCommercializationEventsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenIncLicensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nmra_CommercialMilestonePaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_VanderbiltLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_NumberOfLicenseAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_UpfrontConsiderationTransferredShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_AcquisitionDateFairValueOfSharesTransferred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_UpfrontCashPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_AcquiredInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nmra_AcquiredInProcessResearchAndDevelopedExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" xlink:label="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_DevelopmentAndRegulatoryMilestonePayments" xlink:label="nmra_DevelopmentAndRegulatoryMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CommercialMilestonePayments" xlink:label="nmra_CommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_VanderbiltSponsoredResearchAgreementMember" xlink:label="nmra_VanderbiltSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MilestonesAchieved" xlink:label="nmra_MilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FirstVanderbiltSponsoredResearchAgreementMember" xlink:label="nmra_FirstVanderbiltSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MilestonePayments" xlink:label="nmra_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SecondVanderbiltSponsoredResearchAgreementMember" xlink:label="nmra_SecondVanderbiltSponsoredResearchAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ParkinsonsResearchVenturesFundingAgreementMember" xlink:label="nmra_ParkinsonsResearchVenturesFundingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CollaborationAgreementTerm" xlink:label="nmra_CollaborationAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CollaborationAgreementTerminationDescription" xlink:label="nmra_CollaborationAgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RelatedPartyTransactionObligationWithRelatedParty" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_CollaborationAgreementNonRefundableQuarterlyPayments" xlink:label="nmra_CollaborationAgreementNonRefundableQuarterlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndCollaborationAgreementQuarterlyPayments" xlink:label="nmra_ResearchAndCollaborationAgreementQuarterlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAndCollaborationAgreementPayments" xlink:label="nmra_ResearchAndCollaborationAgreementPayments"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ResearchAgreementExpiryDate" xlink:label="nmra_ResearchAgreementExpiryDate"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" xlink:label="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FundsReceivedUponExecutionOfAgreement" xlink:label="nmra_FundsReceivedUponExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PaymentsForExecutionOfAgreement" xlink:label="nmra_PaymentsForExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone" xlink:label="nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" xlink:label="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MaximumRepaymentAmountAgreedToPay" xlink:label="nmra_MaximumRepaymentAmountAgreedToPay"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_DevelopmentAndRegulatoryMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CommercialMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_VanderbiltSponsoredResearchAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_MilestonesAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_FirstVanderbiltSponsoredResearchAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_SecondVanderbiltSponsoredResearchAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_ParkinsonsResearchVenturesFundingAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CollaborationAgreementTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CollaborationAgreementTerminationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_RelatedPartyTransactionObligationWithRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_CollaborationAgreementNonRefundableQuarterlyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementQuarterlyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAndCollaborationAgreementPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_ResearchAgreementExpiryDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundsReceivedUponExecutionOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_PaymentsForExecutionOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nmra_MaximumRepaymentAmountAgreedToPay" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ServiceConditionsMember" xlink:label="nmra_ServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_BlackthornMergerAgreementMember" xlink:label="nmra_BlackthornMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AdditionalSharesOfCapitalStockMember" xlink:label="nmra_AdditionalSharesOfCapitalStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MaximumAdditionalFinancingInEquitySecurities" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesIssuedUponAchievementOfMilestone" xlink:label="nmra_SharesIssuedUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MilestonesAchieved" xlink:label="nmra_MilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="nmra_ServiceConditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_BlackthornMergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nmra_AdditionalSharesOfCapitalStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nmra_MaximumAdditionalFinancingInEquitySecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nmra_SharesIssuedUponAchievementOfMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nmra_MilestonesAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" xlink:label="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesReservedForIssuanceUnderThePlansMember" xlink:label="nmra_SharesReservedForIssuanceUnderThePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesReservedForFutureIssuanceUnderThePlansMember" xlink:label="nmra_SharesReservedForFutureIssuanceUnderThePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember" xlink:label="nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForIssuanceUnderThePlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForFutureIssuanceUnderThePlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EarlyExerciseOfEmployeeStockOptionsMember" xlink:label="nmra_EarlyExerciseOfEmployeeStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="nmra_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RestrictedCommonStockMember" xlink:label="nmra_RestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MarketAwardMember" xlink:label="nmra_MarketAwardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AdvisorsMember" xlink:label="nmra_AdvisorsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" xlink:label="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AwardsWithPerformanceConditionsMember" xlink:label="nmra_AwardsWithPerformanceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease" xlink:label="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AwardModificationMember" xlink:label="nmra_AwardModificationMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationAwardTrancheFourMember" xlink:label="nmra_ShareBasedCompensationAwardTrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_StockPurchaseRightMember" xlink:label="nmra_StockPurchaseRightMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod" xlink:label="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ServicesAgreementMember" xlink:label="nmra_ServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PerformanceRestrictedStockMember" xlink:label="nmra_PerformanceRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_EarlyExerciseOfEmployeeStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmra_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nmra_RestrictedCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_MarketAwardMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nmra_AdvisorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_AwardsWithPerformanceConditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_AwardModificationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="nmra_ShareBasedCompensationAwardTrancheFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_StockPurchaseRightMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_ServicesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nmra_PerformanceRestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" xlink:label="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" xlink:label="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" xlink:label="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" xlink:label="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AmgenResearchAndCollaborationAgreementMember" xlink:label="nmra_AmgenResearchAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RelatedPartyTransactionObligationWithRelatedParty" xlink:label="nmra_RelatedPartyTransactionObligationWithRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SeriesBConvertiblePreferredStockMember" xlink:label="nmra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_SeriesA1ConvertiblePreferredStockMember" xlink:label="nmra_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MaximumAdditionalFinancingInEquitySecurities" xlink:label="nmra_MaximumAdditionalFinancingInEquitySecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nmra_AmgenResearchAndCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_RelatedPartyTransactionObligationWithRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmra_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmra_SeriesA1ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nmra_MaximumAdditionalFinancingInEquitySecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrancheOneMember" xlink:label="nmra_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TermLoansMember" xlink:label="nmra_TermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_LoanAndSecurityAgreementMember" xlink:label="nmra_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_K2HealthVenturesLLCMember" xlink:label="nmra_K2HealthVenturesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrancheTwoMember" xlink:label="nmra_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NumberOfTranches" xlink:label="nmra_NumberOfTranches"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrancheThreeMember" xlink:label="nmra_TrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_TrancheFourMember" xlink:label="nmra_TrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="nmra_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NetCashProceedsFromFinancingActivities" xlink:label="nmra_NetCashProceedsFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne" xlink:label="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo" xlink:label="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_PrepaymentPenalty" xlink:label="nmra_PrepaymentPenalty"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_MaximumFutureCapitalStockOfferingsInvestment" xlink:label="nmra_MaximumFutureCapitalStockOfferingsInvestment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="nmra_TrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nmra_TermLoansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="nmra_LoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="nmra_K2HealthVenturesLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="nmra_TrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_NumberOfTranches" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="nmra_TrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="nmra_TrancheFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_LineOfCreditFacilityAdditionalBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_NetCashProceedsFromFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentCovenantDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_PrepaymentPenalty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nmra_MaximumFutureCapitalStockOfferingsInvestment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="nmra_EarlyExerciseLiabilityNetOfCurrentPortion" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="nmra_EarlyExerciseLiabilityCurrentPortion" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EarlyExerciseLiabilityNetOfCurrentPortion" xlink:label="nmra_EarlyExerciseLiabilityNetOfCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EarlyExerciseLiabilityCurrentPortion" xlink:label="nmra_EarlyExerciseLiabilityCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="nmra_AcquiredInProcessResearchAndDevelopment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AcquiredInProcessResearchAndDevelopment" xlink:label="nmra_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nmra_NoncashOperatingLeaseExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="nmra_ProceedsFromMaturitiesOfMarketableSecurities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nmra_RepurchaseOfUnvestedEarlyExercisedShares" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="14" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_NoncashOperatingLeaseExpense" xlink:label="nmra_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_ProceedsFromMaturitiesOfMarketableSecurities" xlink:label="nmra_ProceedsFromMaturitiesOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_RepurchaseOfUnvestedEarlyExercisedShares" xlink:label="nmra_RepurchaseOfUnvestedEarlyExercisedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" xlink:to="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" xlink:label="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="nmra_AccruedClinicalTrialAndPreclinicalCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="nmra_AccruedResearchAndDevelopmentServices" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AccruedClinicalTrialAndPreclinicalCosts" xlink:label="nmra_AccruedClinicalTrialAndPreclinicalCosts"/>
          <link:loc xlink:type="locator" xlink:href="nmra-20250331.xsd#nmra_AccruedResearchAndDevelopmentServices" xlink:label="nmra_AccruedResearchAndDevelopmentServices"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="nmra_OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities" name="OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_NumberOfMilestoneAchieved" name="NumberOfMilestoneAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_RepurchaseOfUnvestedEarlyExercisedShares" name="RepurchaseOfUnvestedEarlyExercisedShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_AwardsWithPerformanceConditionsMember" name="AwardsWithPerformanceConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_NavacaprantNMRA-511ProgramExpenses" name="NavacaprantNMRA-511ProgramExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase" name="StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember" name="EmployeeStockOptionAndAndRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_CashEquivalentsAndMarketableSecuritiesAbstract" name="CashEquivalentsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_CollaborationAgreementTerminationDescription" name="CollaborationAgreementTerminationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_PreclinicalProgramsExpenses" name="PreclinicalProgramsExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_PaymentsForExecutionOfAgreement" name="PaymentsForExecutionOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_MaximumFutureCapitalStockOfferingsInvestment" name="MaximumFutureCapitalStockOfferingsInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_TwoThousandTwentyThreeEquityIncentivePlanMember" name="TwoThousandTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne" name="MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_ProceedsFromMaturitiesOfMarketableSecurities" name="ProceedsFromMaturitiesOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_DevelopmentAndRegulatoryMilestonePayments" name="DevelopmentAndRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_BlackthornMergerAgreementMember" name="BlackthornMergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_FundsReceivedUponExecutionOfAgreement" name="FundsReceivedUponExecutionOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_TrancheThreeMember" name="TrancheThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AmgenIncLicensesMember" name="AmgenIncLicensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_CaseTwoMember" name="CaseTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_NavacaprantMember" name="NavacaprantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_SalesBasedMilestonesMember" name="SalesBasedMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease" name="Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_UpfrontCashPayment" name="UpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_AdvisorsMember" name="AdvisorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_PerformanceRestrictedStockMember" name="PerformanceRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_Rule10B51ArrModifiedFlag" name="Rule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_OfferingExpenses" name="OfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_SeriesA2ConvertiblePreferredStockMember" name="SeriesA2ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_DevelopmentAndRegulatoryApprovalMilestonesMember" name="DevelopmentAndRegulatoryApprovalMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_MaximumRepaymentAmountAgreedToPay" name="MaximumRepaymentAmountAgreedToPay" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_LineOfCreditFacilityAdditionalBorrowingCapacity" name="LineOfCreditFacilityAdditionalBorrowingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_AchievementOfSpecifiedCommercializationEventsMember" name="AchievementOfSpecifiedCommercializationEventsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_SecondVanderbiltSponsoredResearchAgreementMember" name="SecondVanderbiltSponsoredResearchAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_EarlyExerciseLiabilityNetOfCurrentPortion" name="EarlyExerciseLiabilityNetOfCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" name="ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_CaseOneMember" name="CaseOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" name="PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AlairionCarveoutPlanMember" name="AlairionCarveoutPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_NetCashProceedsFromFinancingActivities" name="NetCashProceedsFromFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_RelatedPartyTransactionObligationWithRelatedParty" name="RelatedPartyTransactionObligationWithRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_MichaelMilliganMember" name="MichaelMilliganMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" name="StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_NavacaprantNMRA-140ProgramExpenses" name="NavacaprantNMRA-140ProgramExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_TrancheFourMember" name="TrancheFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_NonRule10B51ArrModifiedFlag" name="NonRule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_AmgenResearchAndCollaborationAgreementMember" name="AmgenResearchAndCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ServiceConditionsMember" name="ServiceConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ResearchAgreementExpiryDate" name="ResearchAgreementExpiryDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" name="SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_Nmra511Member" name="Nmra511Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_TrdArrModifiedDate" name="TrdArrModifiedDate" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" name="PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms" name="NumberOfClinicalAndPreclinicalNeurosciencePrograms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nmra_AlairionMergerAgreementMember" name="AlairionMergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_OtherSegmentItems" name="OtherSegmentItems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember" name="SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_UpfrontConsiderationTransferredShares" name="UpfrontConsiderationTransferredShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock" name="SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_LiquidityMember" name="LiquidityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ScheduleOfOrganizationAndLiquidityTable" name="ScheduleOfOrganizationAndLiquidityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AcquisitionDateFairValueOfSharesTransferred" name="AcquisitionDateFairValueOfSharesTransferred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_M4PAMProgramsExpenses" name="M4PAMProgramsExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_VanderbiltLicenseMember" name="VanderbiltLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_AccruedResearchAndDevelopmentServices" name="AccruedResearchAndDevelopmentServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_SeriesA1ConvertiblePreferredStockMember" name="SeriesA1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AcquiredInProcessResearchAndDevelopedExpense" name="AcquiredInProcessResearchAndDevelopedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_MaximumAdditionalFinancingInEquitySecurities" name="MaximumAdditionalFinancingInEquitySecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_RestrictedCommonStockMember" name="RestrictedCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ResearchAndDevelopmentPersonnelRelatedCosts" name="ResearchAndDevelopmentPersonnelRelatedCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_VanderbiltIprDAssetsMember" name="VanderbiltIprDAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_TradingArrangementOneMember" name="TradingArrangementOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities" name="FundsProvidedForPreClinicalResearchAndDevelopmentActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_SharesIssuedUponAchievementOfMilestone" name="SharesIssuedUponAchievementOfMilestone" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_ContingentConsiderationMilestonePayment" name="ContingentConsiderationMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_ContingentConsiderationMilestonePaymentSettledInCash" name="ContingentConsiderationMilestonePaymentSettledInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_EarlyExerciseLiabilityCurrentPortion" name="EarlyExerciseLiabilityCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_TrancheTwoMember" name="TrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_MarketAwardMember" name="MarketAwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ConvertiblePreferredStockPolicyPolicyTextBlock" name="ConvertiblePreferredStockPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_MilestonesAchieved" name="MilestonesAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_TradingArrangementThreeMember" name="TradingArrangementThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_SummaryOfFairValueOfStockOptionsTableTextBlock" name="SummaryOfFairValueOfStockOptionsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" name="ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" name="EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone" name="FundReceivedUponCompletionOfCertainDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_AwardModificationMember" name="AwardModificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod" name="Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_AdditionalSharesOfCapitalStockMember" name="AdditionalSharesOfCapitalStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" name="TwoThousandTwentyThreeEmployeeSharePurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_K2HealthVenturesLLCMember" name="K2HealthVenturesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember" name="EarlyExercisedStockOptionsSubjectToFutureVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_FirstVanderbiltSponsoredResearchAgreementMember" name="FirstVanderbiltSponsoredResearchAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo" name="MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_SyllableMergerAgreementMember" name="SyllableMergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_TwoThousandAndFifteenTsriLicenseAgreementMember" name="TwoThousandAndFifteenTsriLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_BlackthornCarveoutPlanMember" name="BlackthornCarveoutPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty" name="AccruedResearchAndDevelopmentServicesDueToRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_CommercialMilestonePaymentMember" name="CommercialMilestonePaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AmgenIncMember" name="AmgenIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ParkinsonsResearchVenturesFundingAgreementMember" name="ParkinsonsResearchVenturesFundingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_BlackthornTherapeuticsIncMember" name="BlackthornTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" name="UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_AcquiredInProcessResearchAndDevelopment" name="AcquiredInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_VanderbiltSponsoredResearchAgreementMember" name="VanderbiltSponsoredResearchAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_TradingArrangementTwoMember" name="TradingArrangementTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_NumberOfTranches" name="NumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_StockPurchaseRightMember" name="StockPurchaseRightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_CommercialMilestonePayments" name="CommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" name="SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_SharesReservedForFutureIssuanceUnderThePlansMember" name="SharesReservedForFutureIssuanceUnderThePlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ShareBasedCompensationAwardTrancheFourMember" name="ShareBasedCompensationAwardTrancheFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_NoncashOperatingLeaseExpense" name="NoncashOperatingLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_MilestonePaymentDueDescription" name="MilestonePaymentDueDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_MarketableSecuritiesMember" name="MarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ServicesAgreementMember" name="ServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" name="FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_EarlyExerciseOfEmployeeStockOptionsMember" name="EarlyExerciseOfEmployeeStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ResearchAndCollaborationAgreementQuarterlyPayments" name="ResearchAndCollaborationAgreementQuarterlyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_ForfeitureOfUnvestedRestrictedCommonStockShares" name="ForfeitureOfUnvestedRestrictedCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_AchievementOfSpecifiedDevelopmentEventsMember" name="AchievementOfSpecifiedDevelopmentEventsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_AccruedClinicalTrialAndPreclinicalCosts" name="AccruedClinicalTrialAndPreclinicalCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_OrganizationAndLiquidityLineItems" name="OrganizationAndLiquidityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_CollaborationAgreementTerm" name="CollaborationAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities" name="OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_TrancheOneMember" name="TrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_SharesReservedForIssuanceUnderThePlansMember" name="SharesReservedForIssuanceUnderThePlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_TermLoansMember" name="TermLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_CollaborationAgreementNonRefundableQuarterlyPayments" name="CollaborationAgreementNonRefundableQuarterlyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_DaljitBillSinghAuroraMember" name="DaljitBillSinghAuroraMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_PrepaymentPenalty" name="PrepaymentPenalty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_NumberOfLicenseAgreements" name="NumberOfLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nmra_ResearchAndCollaborationAgreementPayments" name="ResearchAndCollaborationAgreementPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nmra_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" name="ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001885522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUMORA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-41802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-4367680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">490 Arsenal Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">760-0900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NMRA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,747,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 126,860<span></span>
</td>
<td class="nump">$ 142,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">122,493<span></span>
</td>
<td class="nump">165,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">5,264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">254,866<span></span>
</td>
<td class="nump">314,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">982<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">256,748<span></span>
</td>
<td class="nump">316,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,052<span></span>
</td>
<td class="nump">3,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">26,272<span></span>
</td>
<td class="nump">24,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_EarlyExerciseLiabilityCurrentPortion', window );">Early exercise liability, current portion</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">28,384<span></span>
</td>
<td class="nump">29,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_EarlyExerciseLiabilityNetOfCurrentPortion', window );">Early exercise liability, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">28,384<span></span>
</td>
<td class="nump">29,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,243,564<span></span>
</td>
<td class="nump">1,234,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (gain) loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,015,213)<span></span>
</td>
<td class="num">(947,221)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">228,364<span></span>
</td>
<td class="nump">287,064<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 256,748<span></span>
</td>
<td class="nump">$ 316,972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_EarlyExerciseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early exercise liability, current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_EarlyExerciseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_EarlyExerciseLiabilityNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early exercise liability, net of current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_EarlyExerciseLiabilityNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 52,151<span></span>
</td>
<td class="nump">$ 45,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,785<span></span>
</td>
<td class="nump">14,317<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">70,936<span></span>
</td>
<td class="nump">60,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(70,936)<span></span>
</td>
<td class="num">(60,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">3,074<span></span>
</td>
<td class="nump">6,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">3,049<span></span>
</td>
<td class="nump">6,353<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(67,887)<span></span>
</td>
<td class="num">(53,721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(67,992)<span></span>
</td>
<td class="num">(53,721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (68,057)<span></span>
</td>
<td class="num">$ (53,793)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">161,451<span></span>
</td>
<td class="nump">157,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted</a></td>
<td class="nump">161,451<span></span>
</td>
<td class="nump">157,943<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Beginning at Dec. 31, 2023</a></td>
<td class="nump">$ 469,076<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 1,172,570<span></span>
</td>
<td class="num">$ (76)<span></span>
</td>
<td class="num">$ (703,434)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Beginning (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable debt securities</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">7,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(53,721)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,721)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Ending at Mar. 31, 2024</a></td>
<td class="nump">424,542<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">1,181,829<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="num">(757,155)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Ending (in Shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Beginning at Dec. 31, 2024</a></td>
<td class="nump">287,064<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">1,234,207<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="num">(947,221)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Beginning (in Shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ForfeitureOfUnvestedRestrictedCommonStockShares', window );">Forfeiture of unvested restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits', window );">Vesting of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase', window );">Vesting of common stock subject to repurchase</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable debt securities</a></td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">9,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(67,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,992)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Ending at Mar. 31, 2025</a></td>
<td class="nump">$ 228,364<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 1,243,564<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (1,015,213)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Ending (in Shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ForfeitureOfUnvestedRestrictedCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forfeiture of unvested restricted common stock, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ForfeitureOfUnvestedRestrictedCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares vesting of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value vesting of common stock subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (67,992)<span></span>
</td>
<td class="num">$ (53,721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,324<span></span>
</td>
<td class="nump">7,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfDiscount', window );">Net accretion of investments in marketable securities</a></td>
<td class="num">(1,289)<span></span>
</td>
<td class="num">(1,147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">966<span></span>
</td>
<td class="nump">7,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,255)<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">1,679<span></span>
</td>
<td class="num">(4,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(915)<span></span>
</td>
<td class="num">(802)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(59,448)<span></span>
</td>
<td class="num">(42,955)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(44,385)<span></span>
</td>
<td class="num">(185,804)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Cash paid for acquisition of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(775)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ProceedsFromMaturitiesOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">88,545<span></span>
</td>
<td class="nump">36,578<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">44,160<span></span>
</td>
<td class="num">(150,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents and restricted cash</a></td>
<td class="num">(15,288)<span></span>
</td>
<td class="num">(191,111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">143,361<span></span>
</td>
<td class="nump">375,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">128,073<span></span>
</td>
<td class="nump">184,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Components of cash and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">126,860<span></span>
</td>
<td class="nump">182,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash and cash equivalents and restricted cash</a></td>
<td class="nump">$ 128,073<span></span>
</td>
<td class="nump">$ 184,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ProceedsFromMaturitiesOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturities of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ProceedsFromMaturitiesOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of purchase discount on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (67,992)<span></span>
</td>
<td class="num">$ (53,721)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this Quarterly Report on Form 10-Q.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Liquidity</a></td>
<td class="text"><p id="organization_and_liquidity" style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization and Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neumora Therapeutics, Inc. (the Company), was originally incorporated in the State of Delaware in November 2019, and is headquartered in Watertown, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. The Company&#8217;s therapeutic pipeline currently consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">seven</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The Company&#8217;s most advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of major depressive disorder (MDD), which the Company believes has the potential to provide significant advantages relative to the standard of care, if approved. Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company&#8217;s next most advanced product candidate is NMRA-511, a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer&#8217;s disease (AD). The Company is advancing a Phase 1b signal-seeking study investigating NMRA-511 initially in healthy elderly adult participants and then people with agitation associated with dementia due to AD. The Company&#8217;s M4 positive allosteric modular (PAM) franchise comprises multiple novel compounds that each have different chemical composition and what the Company believes are optimal pharmacological properties, which have demonstrated robust activity in preclinical efficacy models and high selectivity for the M4 receptor subtype.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company has devoted a significant portion of its financial resources and efforts to building its organization, acquiring technologies and companies, executing clinical and preclinical studies, conducting research and development, identifying and developing potential product candidates, building its precision neuroscience tools, organizing and staffing the Company, business planning, establishing, maintaining and protecting its intellectual property portfolio, raising capital and providing general and administrative support for these operations. The Company has not generated revenue from the sale of products.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred net losses and negative cash flows from operations since inception and as of March 31, 2025, had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,015.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of March 31, 2025, the Company had cash, cash equivalents and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which are available to fund future operations. The Company believes that its existing cash, cash equivalents and marketable securities as of March 31, 2025 will be sufficient to support operations for at least the next 12 months from the date these condensed consolidated financial statements are issued.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects to incur additional losses in the future as it continues its research and development efforts, advances its product candidates through preclinical and clinical development, enhances its precision</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neuroscience approach and programs, expands its product pipeline, potentially seeks regulatory approval, prepares for potential commercialization, as well as hires additional personnel, protects its intellectual property and potentially grows its business. The Company will need to raise additional capital to support its continuing operations and pursue its long-term business plan, including to complete the development and commercialization of its product candidates, if approved. Such activities are subject to significant risks and uncertainties, including clinical failure which can impact the Company&#8217;s ability to secure additional funding. The Company expects to finance its cash needs through a combination of public or private equity offerings or debt financings or other capital sources, which may include strategic collaborations or other arrangements with third parties, or other sources of financing. However, there is no guarantee that any of these financing or opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies and Basis of Presentation</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	Summary of Significant Accounting Policies and Basis of Presentation</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unaudited Interim Condensed Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The condensed consolidated balance sheet as of March 31, 2025, condensed consolidated statements of operations and comprehensive loss, statement of stockholders&#8217; equity (deficit) for the three months ended March 31, 2025 and 2024, and the condensed consolidated statements of cash flows for the three months ended March 31, 2025 and 2024, and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s consolidated financial position, results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2024 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 3, 2025.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management&#8217;s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, the fair value of the Company&#8217;s common stock, stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company&#8217;s estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the Company's ability to successfully develop, manufacture, and market any approved products; the Company's ability to obtain regulatory approval from the U.S. Food and Drug Administration or foreign regulatory agencies prior to any commercial sales; new technological innovations; dependence on key personnel, protection of intellectual property; compliance with governmental regulations; uncertainty of market acceptance of any approved products; product liability; and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests its excess cash in marketable debt securities with high credit ratings including but not limited to money market funds, securities issued by the U.S. government and its agencies, commercial paper and corporate debt securities that are accounted for as available-for-sale and carried at fair value. Marketable securities are classified as short-term or long-term based on the maturity date and their availability to meet current operating requirements. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income in the consolidated statements of operations and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">comprehensive loss. Realized gains and losses on marketable securities, if any, are included in other income (expense), net. The cost of securities sold is determined based on the trade date using the specific identification method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company periodically assesses its available-for-sale debt securities for impairment. For debt securities in an unrealized loss position, this assessment first considers the Company&#8217;s intent to sell, or whether it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#8217;s amortized cost basis is written down to fair value within other income (expense), net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security is considered, among other factors. If this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded in other income (expense), net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as provision for (or reversal of) credit loss expense. Losses are charged against the allowance when management believes the un-collectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. These changes are recorded in other income (expense), net.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company measures fair value by maximizing the use of observable inputs, where available, and minimizing the use of unobservable inputs when measuring fair value. Financial assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized in the fair value hierarchy based upon the lowest level of input that is significant to the fair value as follows:</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses primarily consist of internal research and development expense, including personnel-related expenses (such as salaries, benefits and noncash stock-based compensation) and other expenses, including laboratory supplies and other non-capital equipment utilized for in-house research, research and consulting expenses, software development costs, license fees and allocated expenses, including facilities costs and depreciation and amortization; external research and development expenses incurred under arrangements with service providers conducting research and development services on its behalf, such as contract research organizations (CROs), preclinical testing organizations and contract manufacturing organizations (CMOs). Payments made prior to the receipt of goods or services to be used in research and development are capitalized, evaluated for current or long-term classification, and included in prepaid expenses and other current assets or other assets in the consolidated balance sheets based on when the goods are received or the services are expected to be received or consumed, and recognized in research and development expenses when they are realized.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to estimate expenses resulting from its obligations under contracts with service providers in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in cash flows that do not match the periods over which materials or services are provided. The Company estimates and records</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accrued expenses for the related research and development activities based on the level of services performed but not yet invoiced pursuant to agreements established with its service providers, according to the progress of preclinical studies, clinical trials or related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and services.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the course of a clinical trial, the rate of expense recognition is adjusted if actual results differ from the Company&#8217;s estimates. The Company estimates accrued expenses as of each balance sheet date in its consolidated financial statements based on the facts and circumstances known at that time. The clinical trial accrual is dependent in part upon the timely and accurate reporting of CROs, CMOs and other service providers. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its estimate may vary from the actual results. To date, the Company has not experienced material differences between its accrued expenses and actual expenses.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity (deficit) that are excluded from net loss, such as unrealized losses on the Company&#8217;s available-for-sale marketable securities.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company was an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) until December 31, 2024. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has evaluated whether any accounting standards which it previously delayed adopting would have a material impact to the consolidated financial statements or disclosures and concluded that there is no such material impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the Financial Accounting Standards Board, or FASB, issued ASU 2024-04, Induced Conversions of Convertible Debt Instruments, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard is effective for annual reporting periods beginning after December 15, 2025, and interim periods within those annual periods. We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which is intended to improve disclosures by requiring additional information about specific expense categories in the notes to the financial statements on an annual and interim basis. The standard will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The standard updates may be applied on either a prospective or retrospective basis. We are currently evaluating the disclosure requirements related to this new standard.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ASU 2023-09), which requires issuers to make additional disclosures on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, and disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 will be effective for the Company as of January 1, 2025 for annual periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	Cash Equivalents and Marketable Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the amortized cost and fair value of the Company&#8217;s cash equivalents and marketable securities by major investment category for the periods indicated:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,347</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,347</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,347</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,347</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,630</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,627</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">607</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">607</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,969</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,970</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,290</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,289</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,496</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,493</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198,843</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198,840</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,411</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,411</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,875</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,881</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,286</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,292</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,374</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,383</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,918</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,918</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,411</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,444</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,671</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,685</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165,374</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165,430</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290,660</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290,722</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company has not realized any material gains or losses on its marketable securities, including any impairment charges on its securities related to expected credit losses. As of March 31, 2025, the aggregate difference between the amortized cost and fair value of each security in an unrealized loss position was de minimis. Since any provision for expected credit losses for a security held is limited to the amount the fair value is less than its amortized cost, no allowance for expected credit loss was deemed necessary at March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (see Note 4).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amounts of the Company&#8217;s financial instruments, including prepaid expenses and other current assets, accounts payable, accrued liabilities and the current portion of operating lease liabilities approximate fair value due to the short-term nature of those instruments.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company&#8217;s assets and liabilities measured at fair value on a recurring basis by level within the valuation hierarchy:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,347</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,347</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,627</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,627</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">607</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">607</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,970</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,970</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,289</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,289</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,317</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,523</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198,840</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,411</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,411</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,881</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,881</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,383</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,383</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,918</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,918</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,444</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,444</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,685</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,685</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168,855</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,867</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290,722</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are highly liquid and actively traded marketable securities that generally transact at a stable $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> net asset value representing its estimated fair value. The Company estimates the fair value of its commercial paper, certificates of deposit, U.S. government and agency debt securities, and corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data, and other observable inputs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	Balance Sheet Components</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:63.473%;box-sizing:content-box;"></td>
          <td style="width:1.86%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.943%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.7%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:15.023%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial and preclinical costs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,482</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,606</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development services ($</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;million and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;<br/>&#160;&#160;&#160;&#160;&#160;million due to related party in 2025 and 2024, respectively)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,250</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation and benefits</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,159</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,975</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,972</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,686</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">409</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">326</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued liabilities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,272</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,593</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions of Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions of Assets</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.	Acquisitions of Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BlackThorn Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2020, the Company entered into an agreement and plan of merger (BlackThorn Merger Agreement) to acquire all of the equity interests of BlackThorn Therapeutics, Inc. (BlackThorn), which became effective in September 2020. The Company acquired BlackThorn for its in-process research and development programs, including an antagonist of the kappa opioid receptor (navacaprant (NMRA-140)) for the treatment of MDD and an antagonist of the vasopressin 1a receptor (NMRA-511) for the treatment of agitation in AD. The Company also gained access to a cloud-based computational psychiatry and data platform that was being developed to support drug target identification, patient stratification and objective clinical trial endpoints. Both navacaprant and NMRA-511 were exclusively licensed to BlackThorn by The Scripps Research Institute (TSRI). The acquisition was accounted for as an acquisition of assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The BlackThorn Merger Agreement requires the Company to pay the former stockholders of BlackThorn contingent consideration (i) with respect to navacaprant, in the form of development and regulatory approval milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">365.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which includes a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant,</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and sales-based milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and (ii) with respect to NMRA-511, in the form of development and regulatory approval milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and sales-based milestones of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (BlackThorn Milestones). At the Company&#8217;s sole discretion, the BlackThorn Milestone payments may be settled in cash or shares of the Company, or a combination of both, subject to the provisions of the BlackThorn Merger Agreement, other than one development milestone in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which must be settled in cash. None of the BlackThorn Milestones were subject to liability classification and/or derivative accounting and any such contingent consideration will be recognized when the contingency is resolved, and the consideration becomes payable. The Company settled the Phase 3 navacaprant dosing milestone in December 2023 by issuing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,072,445</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock based on the volume weighted average price per share prior to the date the milestone was met and paying cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the former stockholders of BlackThorn and participants in the carveout plan (discussed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">below). As a result, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in acquired in-process research and developed expenses in the fourth quarter of 2023 related to the BlackThorn Milestones. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of the other Blackthorn Milestones have been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were deemed due or payable as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BlackThorn Carveout Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The BlackThorn Merger Agreement required that the Company establish a carveout plan (the BlackThorn Carveout Plan), pursuant to which each BlackThorn stock option holder as of immediately prior to the closing date was allocated a certain number of units (the BlackThorn Carveout Units) based on the number of shares underlying the outstanding options held by each participant at that time. Each BlackThorn Carveout Unit represents a right to receive a portion of the BlackThorn Milestone payment (the BlackThorn Carveout Payments) upon the later of (i) the achievement of a BlackThorn Milestone and (ii) the vesting of the BlackThorn Carveout Unit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The BlackThorn Carveout Units vest based on time-based schedules that mirror the vesting schedules for the original option awards held by each participant. As of the closing date in September 2020, a portion of the BlackThorn Carveout Units corresponding to the pre-acquisition service periods were fully vested (Vested Carveout Units). The remainder of the BlackThorn Carveout Units had vesting subject to the continued service of the participants, the last of which became fully vested in May 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vested Carveout Units represent contingent consideration for the acquisition as they are attributable to pre-acquisition services rendered by the participants and continuing service is not required for the participants to receive future payments upon a BlackThorn Milestone being achieved. The Company recognizes the contingent consideration obligation for the Vested Carveout Units when the contingency is resolved, and the consideration becomes payable. The BlackThorn Carveout Units that were unvested as of the closing date are dependent on the continued service of participants and were deemed to be a compensation arrangement. The Company recognizes compensation starting from the time payment becomes probable over each participant&#8217;s service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company settled the Phase 3 navacaprant dosing milestone in December 2023. The Company recognized contingent consideration related to Vested Carveout Units, which was included in acquired in-process research and developed expenses in the fourth quarter of 2023 related to the BlackThorn Milestones as described above. In addition, the Company recognized and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in compensation related to the BlackThorn Carveout Units that were a compensatory arrangement in 2023. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of the other BlackThorn Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were deemed due or payable as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amgen Inc. Licenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, the Company entered into two license agreements with Amgen Inc. (Amgen) pursuant to which it obtained exclusive, worldwide licenses to develop, manufacture, use, commercialize and distribute products containing compounds that are directed to, in one case, CK1&#948;, and in the other case, glucocerebrosidase (GCase), both for the treatment of neurodegenerative diseases (the Amgen License Agreements) and related know-how and clinical material (collectively, the Amgen IPR&amp;D Assets). The Company accounted for these transactions as acquisitions of assets. Concurrently, the Company also executed a research collaboration agreement as well as a stock purchase agreement with Amgen. Both agreements were deemed to be separate transactions and not accounted for as part of the acquisition of assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total upfront consideration transferred to Amgen of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of the Company&#8217;s Series A-2 convertible preferred stock, with an acquisition date fair value of $1</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the Amgen IPR&amp;D Assets and expensed in 2021.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under these </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> license agreements, Amgen is eligible to receive contingent consideration up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">360.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in commercial milestone payments per product payable in cash with a compound directed to CK1&#948; and up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">360.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in commercial milestone payments per product payable in cash with a compound directed to GCase, in each case, upon the achievement of certain sales thresholds and single digit royalties on potential future net sales, related to CK1&#948; or GCase (the Amgen Milestones). Such contingent consideration was not subject to liability classification and/or derivative accounting and will be recognized when the contingency is resolved, and the consideration becomes payable. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of the Amgen Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were deemed due or payable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, until a specified period of time following the achievement of the first successful Phase 2 clinical trial for any licensed product, if the Company chooses to sell, transfer, sublicense or divest rights to a licensed product in certain major markets, Amgen has a period of time to enter into an agreement with the Company for such rights. The Company determined that these rights of first negotiation were not freestanding instruments from the Amgen License Agreements and did not meet the definition of a derivative.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vanderbilt License</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2022, the Company and Vanderbilt University (Vanderbilt) entered into a license agreement (Vanderbilt License Agreement). Pursuant to the Vanderbilt License Agreement, as amended, the Company obtained an exclusive, worldwide royalty-bearing, sublicensable (subject to certain restrictions) license under certain patent rights and a non-exclusive, worldwide, royalty-bearing, sublicensable (subject to certain restrictions) license under certain know-how covering small molecule positive allosteric modulators (PAMs) predominantly of the muscarinic acetylcholine receptor subtype 4 (M4) to develop, manufacture, and commercialize products, processes and services covered by such patent rights or that incorporate or use such know-how, for any and uses (the Vanderbilt IPR&amp;D Assets). Concurrently, the Company also executed a sponsored research agreement (see Note 8) with Vanderbilt. The sponsored research agreement was deemed to be a separate transaction and not accounted for as part of the acquisition of assets. The acquisition of Vanderbilt IPR&amp;D Assets became effective in February 2022. In May 2024, the Company and Vanderbilt entered into a second sponsored research agreement with Vanderbilt and concurrently entered into an amendment to the Vanderbilt License Agreement (Second Amendment to the Vanderbilt License Agreement), to extend the rights granted to the Company under the Vanderbilt License Agreement to the data and patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research pursuant to the second sponsored research agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensed patent rights are subject to Vanderbilt&#8217;s right to use the patent rights for research, internal non-commercial use, and educational purposes. The Company intends to develop the PAMs for the treatment of schizophrenia and other neuropsychiatric disorders. The Company has agreed to use commercially reasonable efforts to develop and commercialize licensed products, and to achieve certain development milestones.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid Vanderbilt a non-refundable, non-creditable upfront cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the Vanderbilt IPR&amp;D Assets, which was immediately recognized as acquired in-process research and development expense in the condensed consolidated statement of operations and comprehensive loss as it was determined to have no alternative future use as of the acquisition date. Under the Vanderbilt License Agreement, Vanderbilt is eligible to receive contingent consideration payable in cash up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specified development milestones and up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">380.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of commercial milestone events as well as tiered royalties at mid-single digit percentages on potential future net sales, subject to specified reductions for the lack of patent coverage, generic entry and payment obligations for third-party licenses (the Vanderbilt Milestones). Such contingent consideration was not subject to liability classification and/or derivative accounting and will be recognized when the contingency is resolved, and the consideration becomes payable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In October 2023, a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million Vanderbilt Milestone was achieved and settled in cash in November 2023 and was recognized in acquired in-process research and developed expenses in the fourth quarter</span><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of the other Vanderbilt Milestones had been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were deemed due or payable as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company also had an exclusive option, exercisable for a specified period of time, to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research pursuant to the sponsored research agreements between the Company and Vanderbilt, the first of which was entered into at the same time as the Vanderbilt License Agreement and the second of which was executed in May 2024. The Company determined that the right to negotiate was not a freestanding instrument from the Vanderbilt License Agreement and did not meet the definition of a derivative. The Company exercised the above disclosed exclusive option under the first sponsored research agreement and the parties executed an agreement in December 2023 pursuant to which the Company licensed certain patent rights in return for a payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.	Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware law. The Company currently has directors&#8217; and officers&#8217; insurance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Commitments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has various manufacturing, clinical, research and other contracts with vendors in the conduct of the normal course of its business. Such contracts are generally terminable with advanced written notice and payment for any products or services received by the Company through the effective time of termination and any non-cancelable and non-refundable obligations incurred by the vendor at the effective time of the termination. In the case of terminating a clinical trial agreement at a particular site, the Company would also be obligated to provide continued support for appropriate medical procedures at that site until completion or termination.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic License and Research and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Strategic License and Research and Collaboration Agreements</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.	Strategic License and Research and Collaboration Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2015 TSRI License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the acquisition of BlackThorn (see Note 6), the Company gained certain exclusive rights to intellectual property related to Kappa Opioid Receptor and V1aR Receptor Antagonist programs as well as an oxytocin receptors positive allosteric modulator program (collectively, the TSRI Programs) under a license agreement between BlackThorn and TSRI originally entered into in November 2015 (as amended, the 2015 TSRI License Agreement). The technology licensed under the 2015 TSRI License Agreement is used in the Company&#8217;s navacaprant and NMRA-511 research and development programs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the 2015 TSRI License Agreement, the Company is obligated, among other things, to pay TSRI (i) a nominal annual license fee due and payable on the first day of each calendar year and after the fourth anniversary creditable against any royalties due for such calendar year, (ii) development and regulatory milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate for the first product from each TSRI Program, which are contingent upon achieving specific development and regulatory milestone events, (iii) commercial milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate for each occurrence, which are contingent upon achieving specified commercialization milestone events, (iv) tiered low-single digit royalties on future net sales of each royalty-bearing product and (v) a percentage in the mid-single digits of any sublicensing revenues the Company receives. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the Phase 3 navacaprant dosing milestone was met and the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to TSRI, which was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of the other milestones have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> been achieved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> royalties were due under the 2015 TSRI License Agreement as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Collaboration Agreement with Amgen</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, and concurrently with the Amgen License Agreements (see Note 6), the Company entered into a research collaboration agreement with Amgen (Amgen Collaboration Agreement) to collectively discover drug targets, biomarkers, and other insights associated with central nervous system (CNS) diseases utilizing Amgen&#8217;s deCODE genetics and human data research capabilities. The Company received exclusive rights under intellectual property generated in the collaboration to exploit therapeutic compounds and diagnostics for use with therapeutics in the CNS field and Amgen received exclusive rights to exploit therapeutic compounds and diagnostics for use with therapeutics outside of the CNS field.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In return for Amgen performing research and development activities under the agreement, the Company committed to making non-refundable, non-creditable quarterly payments over the first two years totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and for the third year $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025 and December 31, 2024, the Company was obligated to pay Amgen $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and nil, respectively, under the Amgen Collaboration Agreement, which was recorded within current liabilities on the condensed consolidated balance sheets. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and nil of research and development expenses during the three months ended March 31, 2025 and 2024, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> On May 1, 2025 the Company made a final payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Amgen under the Amgen Collaboration Agreement for research and development activities. The parties agree that this is the final amount due under the agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sponsored Research Agreement with Vanderbilt</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2022, concurrently with the Vanderbilt License Agreement (see Note 6), the Company entered into a sponsored research agreement with Vanderbilt (First Vanderbilt Research Agreement), pursuant to which Vanderbilt agreed to provide the Company research services to develop a M4 PAM back-up program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In return for Vanderbilt performing research and development activities under the agreement, the Company agreed to make quarterly payments for research up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on an annual basis. The term of the agreement ended in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, the Company also had an exclusive option to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research (see Note 6).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, concurrently with the Second Amendment to the Vanderbilt License Agreement (see Note 6), the Company entered into a second sponsored research agreement with Vanderbilt (Second Vanderbilt Research Agreement), pursuant to which Vanderbilt agreed to provide the Company additional research and development activities on the M4 PAM back-up program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In return for Vanderbilt performing research and development activities under the agreement, the Company agreed to make payments for research up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The term of the agreement ended in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, the Company also has an exclusive option to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored r</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">esearch (see Note 6).</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Parkinson&#8217;s Research Ventures Funding Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Company entered into a research funding agreement with Parkinson&#8217;s Research Ventures Limited (PRV), pursuant to which PRV agreed to provide the Company funding up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in two tranches to carry out preclinical research and development activities related to the Company&#8217;s NLPR3 program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The first tranche was due upon execution of the agreement and was received in March 2024, for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company notified PVB of a successful drug candidate nomination, the trigger for the second tranche of funding, in December 2024 and received payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in January 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded the funding arrangement was an obligation to perform services and the funding received is recognized as a contra-R&amp;D expense as project costs are incurred. $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and nil of costs were incurred during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon achievement of certain development, regulatory or commercial trigger events, the Company agreed to pay PRV in aggregate an amount equal to no more than four times the funding provided by PRV, i.e., a maximum repayment amount of up to &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The trigger event payments meet the derivative scope exception under ASC 815 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and therefore do not need to be bifurcated and separately accounted for.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.	Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's board of directors has the authority to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock in one or more series with rights, preferences and privileges to be determined. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock issued and outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025.</span></p><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock outstanding in the condensed consolidated balance sheet and condensed consolidated statement of stockholders&#8217; equity as of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136,920</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of restricted stock that vest based on service conditions and are subject to the Company&#8217;s right of repurchase upon termination of services. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:75.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:78.02%;box-sizing:content-box;"></td>
          <td style="width:1.7%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:18.28%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for options and restricted stock units issued under the equity plans</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,187</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future issuance under the equity plans</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,389</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future issuance under the employee stock purchase plan</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,681</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,257</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company may be required to issue additional shares of its capital stock if certain milestone conditions are met pursuant to the contingent consideration associated with the Company&#8217;s acquisitions of assets (see Note 6). In December 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,072,445</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were issued related to BlackThorn Merger Agreement upon achievement of the Phase 3 navacaprant dosing milestone that was met in October 2023. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been reserved for potential future issuances as no other BlackThorn Milestones have been achieved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.	Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the Company adopted the 2023 Equity Incentive Plan (2023 Plan). The 2023 Plan provides for the grant of stock options, restricted stock awards, restricted stock unit awards, and other stock-based awards to employees, directors, and non-employee service providers of the Company. The 2023 Plan replaced the Company&#8217;s 2020 Equity Incentive Plan (&#8220;2020 Plan&#8221; and together with the 2023 Plan, Plans). The Company no longer grants stock options or other awards under its 2020 Plan, but any stock options outstanding under the 2020 Plan remain outstanding and effective in accordance with their terms. Awards granted under the 2023 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant. The price of stock options shall not be less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the estimated fair value on the date of grant and typically vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period although may be granted with different vesting terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2023 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s outstanding shares of common stock as of the last day of the prior year. On January 1, 2025, the number of shares of common stock available for issuance under the 2023 Plan increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,085,495</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares as a result of the automatic increase provision of the 2023 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Employee Share Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the Company adopted the 2023 Employee Share Purchase Plan (ESPP). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may hold one or more offering periods each year during which employees will be able to purchase shares under the ESPP through payroll deductions made over the term of the offering. The per-share purchase price at the end of each offering period is equal to the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the closing price of the Company's common stock at the beginning or end of the offering period. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2025, the number of shares of common stock available for issuance under the ESPP increas</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ed by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,617,099</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares as a result of the automatic increase provision of the ESPP. No shares were issued under the ESPP during the year the three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option Activity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:41.7%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.88%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.42%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.06%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:11.36%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.58%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding<br/>Stock Options</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic <br/>Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except per share amounts and years)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,927</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.20</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,953</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,995</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.68</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Canceled and forfeited</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,166</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.16</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.58</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,635</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.51</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.9</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable as of March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,490</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.54</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The stock option activity table above excludes options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">446,068</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock that were originally granted with market conditions to one of the Company&#8217;s executives.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Activity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Plans allow for the grant of restricted common stock and restricted stock units to certain employees, executives, non-employee scientific advisors, and third-party service providers. The restrictions lapse over time primarily according to service-based vesting conditions of each award. In the event of a voluntary or involuntary termination of the holder&#8217;s continuous provision of services to the Company, any unvested portion of the restricted stock award is automatically forfeited.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s restricted stock activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:45.46%;box-sizing:content-box;"></td>
          <td style="width:1.06%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.74%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.28%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:11.64%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.86%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.8%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares of<br/>Restricted<br/>Common<br/>Stock</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares of<br/>Restricted<br/>Stock<br/>Units</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average Grant<br/>Date Fair<br/>Value Per<br/>Share</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except per share amounts)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding and unvested as of December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">371</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.82</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,441</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.32</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.50</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.07</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited and expired</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">231</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.87</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.07</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding and unvested as of March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.67</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,106</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.08</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes total stock-based compensation included in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.434%;box-sizing:content-box;"></td>
          <td style="width:1.163%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.911000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.465%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:14.027000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,748</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,812</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,576</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,561</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,324</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,373</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation related to stock options and restricted stock outstanding, respectively, including stock options and restricted common stock for which achievement of milestones was not probable, which were expected to be recognized over a weighted-average remaining service period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Segment Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment related to the development of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5ef6507a-991a-417b-a92b-153ec2aede3b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (CEO) serves as the CODM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CEO manages and allocates resources to the operations of the Company on a consolidated basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#8217;s strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, cash forecasting, allocating resources and setting incentive targets. The CEO bases this assessment on the Company&#8217;s consolidated net loss. Through this analysis, the CEO assesses performance by comparing budget to actual results, and then decides how to allocate resources to invest in the Company&#8217;s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below is a summary of the segment loss, including significant segment expenses (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Program expenses</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Navacaprant (NMRA-140) program</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,493</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,319</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;M4 PAM programs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,882</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,524</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;NMRA-511 program</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,580</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,887</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Preclinical programs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,002</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,409</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development personnel-related costs</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,326</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,875</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,785</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,317</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,074</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,365</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,998</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,755</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,992</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,721</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Includes other research and development costs, provision for income taxes, and other income (expense).</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.	Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58.42%;box-sizing:content-box;"></td>
          <td style="width:1.94%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.279999999999998%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.94%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.419999999999998%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except per share amounts)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,992</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,721</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161,451</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,943</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.42</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.34</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options and restricted stock units</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,187</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,084</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Early exercised stock options subject to future vesting</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">650</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Performance restricted stock (with performance conditions to be established)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,596</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,044</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.	Related Party Transactions</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025 and December 31, 2024, the Company was obligated to pay Amgen $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, under the Amgen Collaboration Agreement, which was recorded within current liabilities on the condensed consolidated balance sheets. During the three months ended March 31, 2025 and 2024, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, of research and development expenses with Amgen.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.	Subsequent Event</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 9, 2025 (the &#8220;Closing Date&#8221;) the Company, entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with K2 HealthVentures LLC (&#8220;K2HV&#8221;) that provides up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million principal in term loans (the &#8220;Term Loans&#8221;) over </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> tranches. The first tranche consists of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million with $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million funded on the Closing Date and an option for an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at the Company&#8217;s request through December 31, 2025. The second tranche commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is available to be drawn at the Company&#8217;s option through September 30, 2026, subject to the achievement of certain clinical and regulatory milestones and receipt of not less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net cash proceeds from certain financing activities, with at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from an equity financing. A third tranche commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is available to be drawn at the Company&#8217;s option from December 1, 2027 through December 31, 2027, subject to certain regulatory approvals. A fourth and final tranche commitment of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is available subject to K2HV&#8217;s review of certain information from the Company and discretionary approval by the Lenders.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loan matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c244de65-f8a1-4f33-b839-be154c63280c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 1, 2029</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company is obligated to make interest only payments for the first 36 months, or 48 months if the second tranche is funded, and then interest and principal payments for the next 12 months.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loan bears a variable interest rate equal to the greater of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and (ii) the sum of (A) the prime rate as quoted in The Wall Street Journal and (B) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our obligations under the Loan Agreement are secured by a security interest in substantially all of our assets, other than certain intellectual property assets. The Loan Agreement includes customary affirmative and negative covenants, as well as standard events of default, including an event of default based on the occurrence of a material adverse event. The negative covenants include, among others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying cash dividends or making other distributions, making investments, creating liens, selling assets and making any payment on subordinated debt, in each case subject to certain exceptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beginning January 1, 2026, the Company is subject to a minimum liquidity covenant. Depending on the Company&#8217;s achievement of milestones and/or exceeding a specified market capitalization, the minimum liquidity amount will be one of the following: (i) four months cash runway, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding obligations under the Loan Agreement, (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding obligations under the Loan Agreement or (iv) waived (i.e., zero).</span></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may prepay, at its option, all, but not less than all, of the Term Loan then outstanding plus the accrued and unpaid interest on the portion of principal so repaid, subject to a prepayment premium and end of term fee. K2HV may elect prior to the full repayment of the term loans to convert up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of outstanding principal of the term loans into shares of the Company&#8217;s common stock, at a conversion price of the lesser of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8774</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and the lowest effective price per share of the Company&#8217;s next equity financing. There will be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> prepayment penalty for any principal amount converted into common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company granted K2HV the right, prior to repayment of the term loans, to invest up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate in future offerings of the Company&#8217;s capital stock subject to certain exceptions and conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock', window );">Unaudited Interim Condensed Consolidated Financial Statements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unaudited Interim Condensed Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The condensed consolidated balance sheet as of March 31, 2025, condensed consolidated statements of operations and comprehensive loss, statement of stockholders&#8217; equity (deficit) for the three months ended March 31, 2025 and 2024, and the condensed consolidated statements of cash flows for the three months ended March 31, 2025 and 2024, and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s consolidated financial position, results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2024 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 3, 2025.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management&#8217;s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, the fair value of the Company&#8217;s common stock, stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company&#8217;s estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the Company's ability to successfully develop, manufacture, and market any approved products; the Company's ability to obtain regulatory approval from the U.S. Food and Drug Administration or foreign regulatory agencies prior to any commercial sales; new technological innovations; dependence on key personnel, protection of intellectual property; compliance with governmental regulations; uncertainty of market acceptance of any approved products; product liability; and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All highly liquid investments, including money market funds, with original maturities of three months or less at the time of purchase are considered to be cash equivalents. All of the Company&#8217;s cash equivalents have liquid markets and high credit ratings. The Company maintains its cash in bank deposits and other accounts.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash consists of a facility lease agreement collateralized by a letter of credit pursuant to certain banking and lease agreements. Restricted cash, which is unavailable for a period of less than one year from the consolidated balance sheet date, is classified as a current asset.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests its excess cash in marketable debt securities with high credit ratings including but not limited to money market funds, securities issued by the U.S. government and its agencies, commercial paper and corporate debt securities that are accounted for as available-for-sale and carried at fair value. Marketable securities are classified as short-term or long-term based on the maturity date and their availability to meet current operating requirements. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income in the consolidated statements of operations and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">comprehensive loss. Realized gains and losses on marketable securities, if any, are included in other income (expense), net. The cost of securities sold is determined based on the trade date using the specific identification method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company periodically assesses its available-for-sale debt securities for impairment. For debt securities in an unrealized loss position, this assessment first considers the Company&#8217;s intent to sell, or whether it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#8217;s amortized cost basis is written down to fair value within other income (expense), net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security is considered, among other factors. If this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded in other income (expense), net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as provision for (or reversal of) credit loss expense. Losses are charged against the allowance when management believes the un-collectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. These changes are recorded in other income (expense), net.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company measures fair value by maximizing the use of observable inputs, where available, and minimizing the use of unobservable inputs when measuring fair value. Financial assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized in the fair value hierarchy based upon the lowest level of input that is significant to the fair value as follows:</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p><p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses primarily consist of internal research and development expense, including personnel-related expenses (such as salaries, benefits and noncash stock-based compensation) and other expenses, including laboratory supplies and other non-capital equipment utilized for in-house research, research and consulting expenses, software development costs, license fees and allocated expenses, including facilities costs and depreciation and amortization; external research and development expenses incurred under arrangements with service providers conducting research and development services on its behalf, such as contract research organizations (CROs), preclinical testing organizations and contract manufacturing organizations (CMOs). Payments made prior to the receipt of goods or services to be used in research and development are capitalized, evaluated for current or long-term classification, and included in prepaid expenses and other current assets or other assets in the consolidated balance sheets based on when the goods are received or the services are expected to be received or consumed, and recognized in research and development expenses when they are realized.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to estimate expenses resulting from its obligations under contracts with service providers in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in cash flows that do not match the periods over which materials or services are provided. The Company estimates and records</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accrued expenses for the related research and development activities based on the level of services performed but not yet invoiced pursuant to agreements established with its service providers, according to the progress of preclinical studies, clinical trials or related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and services.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the course of a clinical trial, the rate of expense recognition is adjusted if actual results differ from the Company&#8217;s estimates. The Company estimates accrued expenses as of each balance sheet date in its consolidated financial statements based on the facts and circumstances known at that time. The clinical trial accrual is dependent in part upon the timely and accurate reporting of CROs, CMOs and other service providers. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its estimate may vary from the actual results. To date, the Company has not experienced material differences between its accrued expenses and actual expenses.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity (deficit) that are excluded from net loss, such as unrealized losses on the Company&#8217;s available-for-sale marketable securities.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company was an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) until December 31, 2024. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has evaluated whether any accounting standards which it previously delayed adopting would have a material impact to the consolidated financial statements or disclosures and concluded that there is no such material impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the Financial Accounting Standards Board, or FASB, issued ASU 2024-04, Induced Conversions of Convertible Debt Instruments, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard is effective for annual reporting periods beginning after December 15, 2025, and interim periods within those annual periods. We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which is intended to improve disclosures by requiring additional information about specific expense categories in the notes to the financial statements on an annual and interim basis. The standard will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The standard updates may be applied on either a prospective or retrospective basis. We are currently evaluating the disclosure requirements related to this new standard.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ASU 2023-09), which requires issuers to make additional disclosures on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, and disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 will be effective for the Company as of January 1, 2025 for annual periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim condensed consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the amortized cost and fair value of the Company&#8217;s cash equivalents and marketable securities by major investment category for the periods indicated:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,347</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,347</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,347</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,347</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,630</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,627</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">607</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">607</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,969</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,970</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,290</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,289</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,496</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,493</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198,843</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198,840</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,411</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,411</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,875</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,881</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,286</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,292</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,374</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,383</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,918</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,918</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,411</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,444</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,671</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,685</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165,374</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165,430</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290,660</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290,722</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company&#8217;s assets and liabilities measured at fair value on a recurring basis by level within the valuation hierarchy:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,347</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,347</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,627</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,627</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">607</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">607</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,970</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,970</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,289</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,289</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,317</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,523</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198,840</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.22%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,411</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,411</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,881</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,881</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,383</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,383</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,918</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,918</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,444</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,444</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,685</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,685</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168,855</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,867</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290,722</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:63.473%;box-sizing:content-box;"></td>
          <td style="width:1.86%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.943%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.7%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:15.023%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial and preclinical costs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,482</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,606</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development services ($</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;million and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;<br/>&#160;&#160;&#160;&#160;&#160;million due to related party in 2025 and 2024, respectively)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,250</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation and benefits</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,159</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,975</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,972</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,686</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">409</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">326</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued liabilities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,272</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,593</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:75.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:78.02%;box-sizing:content-box;"></td>
          <td style="width:1.7%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:18.28%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for options and restricted stock units issued under the equity plans</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,187</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future issuance under the equity plans</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,389</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future issuance under the employee stock purchase plan</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,681</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,257</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option Activity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:41.7%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.88%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.42%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.06%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:11.36%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.58%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding<br/>Stock Options</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic <br/>Value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except per share amounts and years)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,927</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.20</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,953</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,995</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.68</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Canceled and forfeited</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,166</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.16</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.58</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,635</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.51</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.9</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable as of March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,490</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.54</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s restricted stock activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:45.46%;box-sizing:content-box;"></td>
          <td style="width:1.06%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.74%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.28%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:11.64%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.86%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.8%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares of<br/>Restricted<br/>Common<br/>Stock</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares of<br/>Restricted<br/>Stock<br/>Units</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average Grant<br/>Date Fair<br/>Value Per<br/>Share</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except per share amounts)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding and unvested as of December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">371</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.82</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,441</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.32</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.50</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.07</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited and expired</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">231</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.87</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.07</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding and unvested as of March 31, 2025</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.67</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,106</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.08</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense Recognized</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes total stock-based compensation included in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.434%;box-sizing:content-box;"></td>
          <td style="width:1.163%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.911000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.465%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:14.027000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,748</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,812</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,576</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,561</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,324</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,373</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Loss Including Significant Segment Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below is a summary of the segment loss, including significant segment expenses (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Program expenses</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Navacaprant (NMRA-140) program</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,493</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,319</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;M4 PAM programs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,882</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,524</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;NMRA-511 program</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,580</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,887</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Preclinical programs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,002</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,409</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development personnel-related costs</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,326</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,875</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,785</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,317</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,074</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,365</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,998</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,755</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,992</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,721</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Includes other research and development costs, provision for income taxes, and other income (expense).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58.42%;box-sizing:content-box;"></td>
          <td style="width:1.94%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.279999999999998%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.94%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.419999999999998%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except per share amounts)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,992</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,721</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161,451</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,943</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.42</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.34</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options and restricted stock units</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,187</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,084</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Early exercised stock options subject to future vesting</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock awards</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">650</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Performance restricted stock (with performance conditions to be established)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,596</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,044</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Liquidity - Additional information (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_OrganizationAndLiquidityLineItems', window );"><strong>Organization and Liquidity [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms', window );">Number of clinical and preclinical neuroscience programs | Program</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (1,015,213)<span></span>
</td>
<td class="num">$ (947,221)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nmra_LiquidityMember', window );">Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_OrganizationAndLiquidityLineItems', window );"><strong>Organization and Liquidity [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">1,015,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="nump">$ 249,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of clinical and preclinical neuroscience programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_OrganizationAndLiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and Liquidity [Line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_OrganizationAndLiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nmra_LiquidityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nmra_LiquidityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 198,843<span></span>
</td>
<td class="nump">$ 290,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">198,840<span></span>
</td>
<td class="nump">290,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">76,347<span></span>
</td>
<td class="nump">125,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">76,347<span></span>
</td>
<td class="nump">125,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">76,347<span></span>
</td>
<td class="nump">94,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">76,347<span></span>
</td>
<td class="nump">94,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">122,496<span></span>
</td>
<td class="nump">165,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">122,493<span></span>
</td>
<td class="nump">165,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember', window );">Marketable Securities | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">80,630<span></span>
</td>
<td class="nump">61,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">80,627<span></span>
</td>
<td class="nump">61,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember', window );">Marketable Securities | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">1,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">1,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember', window );">Marketable Securities | U.S. Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">26,969<span></span>
</td>
<td class="nump">74,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">26,970<span></span>
</td>
<td class="nump">74,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember', window );">Marketable Securities | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">14,290<span></span>
</td>
<td class="nump">27,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 14,289<span></span>
</td>
<td class="nump">$ 27,685<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 198,840<span></span>
</td>
<td class="nump">$ 290,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">103,317<span></span>
</td>
<td class="nump">168,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">95,523<span></span>
</td>
<td class="nump">121,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">76,347<span></span>
</td>
<td class="nump">94,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 1 | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">76,347<span></span>
</td>
<td class="nump">94,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 2 | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 3 | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">80,627<span></span>
</td>
<td class="nump">61,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 1 | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 1 | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 2 | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 2 | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">80,627<span></span>
</td>
<td class="nump">61,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 3 | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 3 | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of Deposit | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">1,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of Deposit | Level 1 | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of Deposit | Level 2 | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">1,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of Deposit | Level 3 | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Securities | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">26,970<span></span>
</td>
<td class="nump">74,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Securities | Level 1 | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">26,970<span></span>
</td>
<td class="nump">74,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Securities | Level 2 | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Securities | Level 3 | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">14,289<span></span>
</td>
<td class="nump">27,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities | Level 1 | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities | Level 2 | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">14,289<span></span>
</td>
<td class="nump">27,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities | Level 3 | Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nmra_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetAssetValuePerShare', window );">Net asset value per share</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAssetValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478494/946-205-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478494/946-205-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAssetValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AccruedClinicalTrialAndPreclinicalCosts', window );">Accrued clinical trial and preclinical costs</a></td>
<td class="nump">$ 11,482<span></span>
</td>
<td class="nump">$ 11,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AccruedResearchAndDevelopmentServices', window );">Accrued research and development services</a></td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">6,159<span></span>
</td>
<td class="nump">9,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">2,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 26,272<span></span>
</td>
<td class="nump">$ 24,593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AccruedClinicalTrialAndPreclinicalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial and preclinical costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AccruedClinicalTrialAndPreclinicalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AccruedResearchAndDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AccruedResearchAndDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Liabilities (Parenthetical) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty', window );">Accrued research and development services due to related party</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services due to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions of Assets - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>Agreements </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>Milestones</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=nmra_AmgenIncMember', window );">Amgen Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfLicenseAgreements', window );">Number of license agreements | Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=nmra_VanderbiltIprDAssetsMember', window );">Vanderbilt IPR&amp;D Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration deemed due or payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ContingentConsiderationMilestonePaymentSettledInCash', window );">Contingent consideration, milestone payment settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfMilestoneAchieved', window );">Number of milestone achieved | Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | BlackThorn Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration deemed due or payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Contingent consideration payable in cash</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AcquiredInProcessResearchAndDevelopedExpense', window );">Acquired in-process research and developed expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | BlackThorn Therapeutics, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet', window );">Shares issued based on volume weighted average price per share prior to date milestone was met | shares</a></td>
<td class="nump">6,072,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | navacaprant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_MilestonePaymentDueDescription', window );">Milestone payment due description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | navacaprant | Maximum | Development and Regulatory Approval Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | navacaprant | Maximum | Sales-based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | NMRA-511 | Maximum | Development and Regulatory Approval Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember', window );">BlackThorn Merger Agreement | NMRA-511 | Maximum | Sales-based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornCarveoutPlanMember', window );">BlackThorn Carveout Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfMilestoneAchieved', window );">Number of milestone achieved | Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration deemed due or payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Asset acquisition compensation recognized and paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember', window );">Amgen Inc. Licenses | Amgen Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfMilestoneAchieved', window );">Number of milestone achieved | Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration deemed due or payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember', window );">Amgen Inc. Licenses | Amgen Inc. | Series A-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_UpfrontConsiderationTransferredShares', window );">Upfront consideration transferred shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AcquisitionDateFairValueOfSharesTransferred', window );">Acquisition date fair value of shares transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember', window );">Amgen Inc. Licenses | Amgen Inc. | Maximum | Case One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Contingent consideration payable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember', window );">Amgen Inc. Licenses | Amgen Inc. | Maximum | Commercial Milestone Payment | Case Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Contingent consideration payable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember', window );">Vanderbilt License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ContingentConsiderationMilestonePaymentSettledInCash', window );">Contingent consideration, milestone payment settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfMilestoneAchieved', window );">Number of milestone achieved | Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember', window );">Vanderbilt License | Maximum | Achievement of Specified Development Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Contingent consideration payable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember', window );">Vanderbilt License | Maximum | Achievement of Specified Commercialization Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Contingent consideration payable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember', window );">Vanderbilt License | Vanderbilt IPR&amp;D Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AcquiredInProcessResearchAndDevelopedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in-process research and developed expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AcquiredInProcessResearchAndDevelopedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in-process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_AcquisitionDateFairValueOfSharesTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition date fair value of shares transferred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_AcquisitionDateFairValueOfSharesTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ContingentConsiderationMilestonePaymentSettledInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration, milestone payment settled in cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ContingentConsiderationMilestonePaymentSettledInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_MilestonePaymentDueDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment due description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_MilestonePaymentDueDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_NumberOfMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestone achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_NumberOfMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued based on volume weighted average price per share prior to date milestone was met.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_UpfrontConsiderationTransferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront consideration transferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_UpfrontConsiderationTransferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nmra_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nmra_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nmra_VanderbiltIprDAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nmra_VanderbiltIprDAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nmra_BlackthornTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nmra_BlackthornTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nmra_NavacaprantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nmra_NavacaprantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nmra_DevelopmentAndRegulatoryApprovalMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nmra_DevelopmentAndRegulatoryApprovalMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nmra_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nmra_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nmra_Nmra511Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nmra_Nmra511Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornCarveoutPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_BlackthornCarveoutPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nmra_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nmra_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nmra_CaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nmra_CaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nmra_CommercialMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nmra_CommercialMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nmra_CaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nmra_CaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nmra_AchievementOfSpecifiedDevelopmentEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nmra_AchievementOfSpecifiedDevelopmentEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nmra_AchievementOfSpecifiedCommercializationEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nmra_AchievementOfSpecifiedCommercializationEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic License and Research and Collaboration Agreements - Additional Information (Details)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,757,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone', window );">Fund received upon completion of certain development milestone</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_TwoThousandAndFifteenTsriLicenseAgreementMember', window );">2015 TSRI License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_MilestonesAchieved', window );">Milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_TwoThousandAndFifteenTsriLicenseAgreementMember', window );">2015 TSRI License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_DevelopmentAndRegulatoryMilestonePayments', window );">Development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember', window );">Amgen Research and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_CollaborationAgreementTerminationDescription', window );">Collaboration agreement termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024.<span></span>
</td>
<td class="text">The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears', window );">Research and collaboration agreement quarterly payments for first two year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_RelatedPartyTransactionObligationWithRelatedParty', window );">Related party transaction obligation with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember', window );">Amgen Research and Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear', window );">Research and collaboration agreement quarterly payments for third year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltSponsoredResearchAgreementMember', window );">Vanderbilt Research Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ResearchAgreementExpiryDate', window );">Research agreement expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-09<span></span>
</td>
<td class="text">2023-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_FirstVanderbiltSponsoredResearchAgreementMember', window );">First Vanderbilt Research Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ResearchAndCollaborationAgreementQuarterlyPayments', window );">Research and collaboration agreement quarterly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_SecondVanderbiltSponsoredResearchAgreementMember', window );">Second Vanderbilt Research Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ResearchAgreementExpiryDate', window );">Research agreement expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-03<span></span>
</td>
<td class="text">2025-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_SecondVanderbiltSponsoredResearchAgreementMember', window );">Second Vanderbilt Research Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ResearchAndCollaborationAgreementPayments', window );">Research and collaboration agreement payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_ParkinsonsResearchVenturesFundingAgreementMember', window );">Parkinson's Research Ventures Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_PaymentsForExecutionOfAgreement', window );">Payments for execution of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_MaximumRepaymentAmountAgreedToPay', window );">Maximum repayment amount agreed to pay. | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_ParkinsonsResearchVenturesFundingAgreementMember', window );">Parkinson's Research Ventures Funding Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities', window );">Funds provided for preclinical research and development activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_CollaborationAgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_CollaborationAgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_CommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_CommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_DevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_DevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fund received upon completion of certain development milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds provided for pre-clinical research and development activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_MaximumRepaymentAmountAgreedToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum repayment amount agreed to pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_MaximumRepaymentAmountAgreedToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_MilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_MilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_PaymentsForExecutionOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for execution of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_PaymentsForExecutionOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_RelatedPartyTransactionObligationWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction obligation with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_RelatedPartyTransactionObligationWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ResearchAgreementExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research agreement expiry date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ResearchAgreementExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ResearchAndCollaborationAgreementPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and collaboration agreement payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ResearchAndCollaborationAgreementPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ResearchAndCollaborationAgreementQuarterlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Collaboration Agreement Quarterly Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ResearchAndCollaborationAgreementQuarterlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and collaboration agreement quarterly payments for first two years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and collaboration agreement quarterly payments for third year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_TwoThousandAndFifteenTsriLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_TwoThousandAndFifteenTsriLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_VanderbiltSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_VanderbiltSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_FirstVanderbiltSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_FirstVanderbiltSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_SecondVanderbiltSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_SecondVanderbiltSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_ParkinsonsResearchVenturesFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_ParkinsonsResearchVenturesFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for potential future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,257,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | BlackThorn Merger Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_SharesIssuedUponAchievementOfMilestone', window );">Shares issued upon achievement of milestone</a></td>
<td class="nump">6,072,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Service Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=nmra_AdditionalSharesOfCapitalStockMember', window );">Additional Shares of Capital Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for potential future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_SharesIssuedUponAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_SharesIssuedUponAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=nmra_ServiceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=nmra_ServiceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=nmra_AdditionalSharesOfCapitalStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=nmra_AdditionalSharesOfCapitalStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">48,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember', window );">Shares Reserved for Options and Restricted Stock Units Issued Under the Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">25,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_SharesReservedForFutureIssuanceUnderThePlansMember', window );">Shares Reserved for Future Issuance Under the Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">18,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember', window );">Shares Reserved for Future Issuance Under the Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">4,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nmra_SharesReservedForFutureIssuanceUnderThePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nmra_SharesReservedForFutureIssuanceUnderThePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">48,257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation recognized</a></td>
<td class="nump">$ 9,324<span></span>
</td>
<td class="nump">$ 7,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Stock options granted to purchase</a></td>
<td class="nump">446,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation</a></td>
<td class="nump">$ 73,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining service period</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested shares repurchased</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares or restricted stock remained outstanding and unvested</a></td>
<td class="nump">111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation</a></td>
<td class="nump">$ 18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining service period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEquityIncentivePlanMember', window );">2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation, term of plan</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation granted under plan vested period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock available for issuance</a></td>
<td class="nump">8,085,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEquityIncentivePlanMember', window );">2023 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Grants vest percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease', window );">Percentage of annual increase of outstanding shares of common stock</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember', window );">2023 Employee Share Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock available for issuance</a></td>
<td class="nump">1,617,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember', window );">2023 Employee Share Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod', window );">Per share of purchase price of offering period</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, per share of purchase price of offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award percentage of anuual increase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Detail) - Employee Stock Option - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance, Outstanding Stock Options</a></td>
<td class="nump">13,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, outstanding stock options</a></td>
<td class="nump">11,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, Outstanding Stock Options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled and forfeited, Outstanding Stock Options</a></td>
<td class="num">(2,166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, Outstanding Stock Options</a></td>
<td class="num">(121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance, Outstanding Stock Options</a></td>
<td class="nump">23,635<span></span>
</td>
<td class="nump">13,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Outstanding Stock Options</a></td>
<td class="nump">6,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding, beginning of period</a></td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Granted</a></td>
<td class="nump">1.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Canceled and forfeited</a></td>
<td class="nump">8.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Expired</a></td>
<td class="nump">3.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding, end of period</a></td>
<td class="nump">5.51<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable</a></td>
<td class="nump">$ 7.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term, Outstanding (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Vested</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested, Shares at beginning balance | shares</a></td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, Shares | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, Shares | shares</a></td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled, Shares | shares</a></td>
<td class="num">(231)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested, Shares at ending balance | shares</a></td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at beginning balance | $ / shares</a></td>
<td class="nump">$ 10.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted Average Grant Date Fair Value Per Share | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted Average Grant Date Fair Value Per Share | $ / shares</a></td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue', window );">Cancelled, Weighted Average Grant Date Fair Value Per Share | $ / shares</a></td>
<td class="nump">8.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at ending balance | $ / shares</a></td>
<td class="nump">$ 14.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested, Shares at beginning balance | shares</a></td>
<td class="nump">1,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, Shares | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, Shares | shares</a></td>
<td class="num">(269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled, Shares | shares</a></td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested, Shares at ending balance | shares</a></td>
<td class="nump">1,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at beginning balance | $ / shares</a></td>
<td class="nump">$ 17.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted Average Grant Date Fair Value Per Share | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted Average Grant Date Fair Value Per Share | $ / shares</a></td>
<td class="nump">18.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue', window );">Cancelled, Weighted Average Grant Date Fair Value Per Share | $ / shares</a></td>
<td class="nump">18.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at ending balance | $ / shares</a></td>
<td class="nump">$ 17.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average. Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 9,324<span></span>
</td>
<td class="nump">$ 7,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">3,748<span></span>
</td>
<td class="nump">2,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 5,576<span></span>
</td>
<td class="nump">$ 4,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">The CEO manages and allocates resources to the operations of the Company on a consolidated basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#8217;s strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, cash forecasting, allocating resources and setting incentive targets. The CEO bases this assessment on the Company&#8217;s consolidated net loss. Through this analysis, the CEO assesses performance by comparing budget to actual results, and then decides how to allocate resources to invest in the Company&#8217;s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NavacaprantNMRA-140ProgramExpenses', window );">Navacaprant (NMRA-140) program</a></td>
<td class="num">$ (24,493)<span></span>
</td>
<td class="num">$ (24,319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_M4PAMProgramsExpenses', window );">M4 PAM programs</a></td>
<td class="num">(2,882)<span></span>
</td>
<td class="num">(3,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NavacaprantNMRA-511ProgramExpenses', window );">NMRA-511 program</a></td>
<td class="num">(2,580)<span></span>
</td>
<td class="num">(1,887)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_PreclinicalProgramsExpenses', window );">Preclinical programs</a></td>
<td class="num">(1,002)<span></span>
</td>
<td class="num">(2,409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_ResearchAndDevelopmentPersonnelRelatedCosts', window );">Research and development personnel-related costs</a></td>
<td class="num">(12,326)<span></span>
</td>
<td class="num">(10,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="num">(18,785)<span></span>
</td>
<td class="num">(14,317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">3,074<span></span>
</td>
<td class="nump">6,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_OtherSegmentItems', window );">Other segment items</a></td>
<td class="num">(8,998)<span></span>
</td>
<td class="num">(2,755)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (67,992)<span></span>
</td>
<td class="num">$ (53,721)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_M4PAMProgramsExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>M4 PAM programs expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_M4PAMProgramsExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_NavacaprantNMRA-140ProgramExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Navacaprant (NMRA-140) program expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_NavacaprantNMRA-140ProgramExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_NavacaprantNMRA-511ProgramExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Navacaprant (NMRA-511) program expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_NavacaprantNMRA-511ProgramExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_OtherSegmentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other segment items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_OtherSegmentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_PreclinicalProgramsExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preclinical programs expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_PreclinicalProgramsExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_ResearchAndDevelopmentPersonnelRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development personnel related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_ResearchAndDevelopmentPersonnelRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (67,992)<span></span>
</td>
<td class="num">$ (53,721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">161,451<span></span>
</td>
<td class="nump">157,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">161,451<span></span>
</td>
<td class="nump">157,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">25,596<span></span>
</td>
<td class="nump">18,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember', window );">Common Stock Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">25,187<span></span>
</td>
<td class="nump">17,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember', window );">Early Exercised Stock Options Subject to Future Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember', window );">Performance Restricted Stock (With Performance Conditions to Be Established)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 52,151<span></span>
</td>
<td class="nump">$ 45,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember', window );">Amgen Research and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_RelatedPartyTransactionObligationWithRelatedParty', window );">Related party transaction obligation with related party</a></td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_RelatedPartyTransactionObligationWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction obligation with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_RelatedPartyTransactionObligationWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 09, 2025 </div>
<div>USD ($) </div>
<div>Tranche </div>
<div>$ / shares</div>
</th>
<th class="th"><div>May 01, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantDescription', window );">Debt instrument, covenant description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Beginning January 1, 2026, the Company is subject to a minimum liquidity covenant. Depending on the Company&#8217;s achievement of milestones and/or exceeding a specified market capitalization, the minimum liquidity amount will be one of the following: (i) four months cash runway, (ii) 50% of the outstanding obligations under the Loan Agreement, (iii) 105% of the outstanding obligations under the Loan Agreement or (iv) waived (i.e., zero).<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=nmra_LoanAndSecurityAgreementMember', window );">Loan Agreement | K2HV | Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Company is obligated to make interest only payments for the first 36 months, or 48 months if the second tranche is funded, and then interest and principal payments for the next 12 months.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDescription', window );">Interest rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Term Loan bears a variable interest rate equal to the greater of (i) 10.45%, and (ii) the sum of (A) the prime rate as quoted in The Wall Street Journal and (B) 2.95%.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne', window );">Minimum liquidity covenant percentage of outstanding obligations one</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo', window );">Minimum liquidity covenant percentage of outstanding obligations two</a></td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Loan Agreement | K2HV | Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Principal amount</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NumberOfTranches', window );">Number of tranches | Tranche</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">May 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_PrepaymentPenalty', window );">Prepayment penalty</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_MaximumFutureCapitalStockOfferingsInvestment', window );">Maximum future capital stock offerings investment</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Loan Agreement | K2HV | Term Loans | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion amount</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="nump">$ 0.8774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Loan Agreement | K2HV | First Tranche | Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Principal amount</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Amount funded on closing date</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Additional borrowing capacity</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Loan Agreement | K2HV | Second Tranche | Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Principal amount</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Loan Agreement | K2HV | Second Tranche | Term Loans | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nmra_NetCashProceedsFromFinancingActivities', window );">Net cash proceeds from financing activities</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity financing</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Loan Agreement | K2HV | Third Tranche | Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Principal amount</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Loan Agreement | K2HV | Fourth Tranche | Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Principal amount</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility, additional borrowing capacity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_MaximumFutureCapitalStockOfferingsInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum future capital stock offerings investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_MaximumFutureCapitalStockOfferingsInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum liquidity covenant percentage of outstanding obligations one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum liquidity covenant percentage of outstanding obligations two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_NetCashProceedsFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash proceeds from financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_NetCashProceedsFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of tranches.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmra_PrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment penalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmra_PrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=nmra_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=nmra_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=nmra_K2HealthVenturesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=nmra_K2HealthVenturesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nmra_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nmra_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=nmra_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=nmra_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=nmra_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=nmra_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=nmra_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=nmra_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=nmra_TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=nmra_TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #2$K%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( #2$K%H8XY6&\P   "L"   1
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MJ)M-4_&VY>WM^^SZP^\B; =MMN9_&5_7WXS/@J*#7W<A/@%02P,$%     @
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M3@H\W/[O#;#"Q([A[8N_ 5!+ P04    "  TA*Q::(O+!?8%  #('P  &
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M,JK[SQE :"IDFZ6#](?FM#_L2O&9C3H;/*/J_ZR8@=&8H2FT-B6'$P#X_X\
MH$;U>OYLUI&91@\!C*(%1M'"US/2_OOR< Z OO,<P-7^>]G5]PA-[8X,TMAU
M_[_4V"#'=E6P0&,X5IXMH<X&6M!%T#Z1J<,Q #)X#*#/FM%C *0Y!I B2#T8
M61F-&AA%"TVA[2F='+WK4;[[(PF1>I6#E*PEO/7.E[EB^]=I]@U!M]7K'P]4
M")I5EQN"8\)* _G[FE+QK5&^4=*\U+3X#U!+ P04    "  TA*Q::62F5@L&
M  #N&0  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;*U96V_;-A3^*X17
M#"TPUR(E67*6&$C<%>U#UZ!IMV=&HF,NDNB2="[[]3N49,L6*3K!G(=8EW..
MOG/]2.G\4<A[M6),HZ>RJ-3%:*7U^FPR4=F*E52]%VM6P9VED"75<"KO)FHM
M&<UKI;*8D""83DK*J]'\O+YV+>?G8J,+7K%KB=2F+*E\OF*%>+P8X='VPC=^
MM]+FPF1^OJ9W[(;I'^MK"6>3G96<EZQ27%1(LN7%Z!*?+<+ *-02?W'VJ/:.
MD7'E5HA[<_(YOQ@%!A$K6*:-"0H_#VS!BL)8 AP_6Z.CW3.-XO[QUOK'VGEP
MYI8JMA#%WSS7JXM1.D(Y6])-H;^)QT^L=2@V]C)1J/H_>FQE@Q'*-DJ+LE4&
M!"6OFE_ZU 9B3P'LN!5(JT#Z"M& 0M@JA+6C#;+:K0]4T_FY%(](&FFP9@[J
MV-3:X VO3!IOM(2['/3T?"&J')+"<@1'2A0\IQI.;C3\0+:T0F*)%E2MT$?(
MN$)O?U1TDW.0>8?&Z,?-!_3VS3OT!O$*?5^)C:)5KLXG&I 9^Y.L17'5H" #
M*$+T151ZI= ?@"8_U)^ 1SNWR-:M*^(U^(7*]RC$OR$2D-B!9_%R]<@#)]Q%
M.:SMA0/VOJZ9I)I7=TW9<LV9.G.%J3$3N<V8ECY3:YJQBQ'TK&+R@8WFO_Z"
MI\'O+A]/9.S XVCG<>2S/O\3)E AE+,6&LUIK6G&S,-\/$UF,W(^>=B'[Q"+
MPX3@G=@!L'@'+/:FXC+_![JJ*6TM8!)EHLIXP5#5(C97S7%FBGYC.@-J6[PT
M@?$I$W@B8P=QFN[B-/4F\$:+['YL)F2.,E$";2AJ!J_+Z<92O)>I66CZYB"=
MME 2)J$[F<D.9.*O,E&-ZSQU^2D80$;LR0!F+K")A2--DAY66R:9#=1=NH.:
M>J%^8)"DC-.&O*H<T5)(S?\=#&IJ8<!Q'Z=+)G7CG.UPSHXV+LTRR6J@,/QY
M]<"V#0.= &1_SS2]A8Y1+-O(NA5<^&<6MC$FZ:SG@4L*1XG;!QQTK!9XNWRQ
MHM4=4[W658J!$R;X!:>WO!ANX];\B?KX5-8.@[%'\=B;TFO)UI3GVZ9H(B#T
MBDE884@)F6U#XXP$MIM[.NUET2&4A/% QV#2 2=>X)=9)C:F[M;TV52<$Q^Q
M*XB0..XCM,4PWI,Z1-CQ.O:2J$$H-^R@GIP@0_OI0'E]C+;4.,)X8$;BCHJQ
MGXN_]H;C,;"1#6.&K8 ZI-* #&#MV!E[2:T>/T>9UXDZMO'$LRA*^[@=<A&9
M#99"QY=XZATYG^LY^8(E O82[ZMGRXFL'7K=$3#V,_#U1F8K:H8*4,6+N0';
M!#N.HC"UBLPAA],X#:*!;'5LC/UT7&]IZJD(6V'(V,\-5WQ+>9YI:#-NT,=L
MBXR39*B\.EK&?EZ^EB)C+%=H*44)D=9M>%\7=YMNTS2.K+#;8N$T3@96%J1C
M9>(ENJZYUU(\<-CIH=MG]+;M]'?M2N-XJ[=/V8<715#1/2\<8F,<!T$PP$ND
M(U2"O:W^D5<4-@W'6YUXB?FUK7XJ:X=>=VQ,_&Q\6('LB<F, YM _2FS5X!)
M;?K'G3&;?:UL.0@ZC0;:AG0$3?P$[2RYI2-_3M@V(5NP'<P^#+NC;')\^YS5
M:UC#@;4#9M%6'S"850^TJ!?DYB+D6DN>F=<VYK[3$0=9XYBD?7)TRLTP_ TX
MU/$Z\?/ZXC4N(*K1+;OC565R! 7VS*AT^F63.8["<(K[?MER81*3H14JZ4B?
M^'?)KW:+F:7W$L&BAHO<Z9*]3X9M4["W4VY=<LBE$8Z" 9<Z1B>)?^L$FWU1
M;5_][4JOYXM[W'G7"J\>=R>R=AB';H5 7K!"<*76Z;EC)TZFJ<U)#KF4S,C
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MQUQO41 F0-]O.%=[PR3H]W+R&U!+ P04    "  TA*Q:BF4;_]L"   @"
M&    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;)V6;6_:,!#'O\HIDZ96&B1
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MJ'U)>\U4[U'5<3HOWX"E=O2BE,V4GG TWH#F$ZW=KN,7J/\43/X!4$L#!!0
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MM7-X#6>Q<VE-K.6)KT()_P8U,"I1=H]-P$O<0;#0[:"UE12M,(WZ*1HH+.3
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M,M\A_?_G9N8'1S#ZWT,*RWQ/#L\'U_K)KU6CGY^L83EWIT]>_/$/C[Z_>OJ
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M%?^YU(H8(%Z@YW-+(2]\P +IY^ O_@]02P,$%     @ -(2L6K/0H)G !
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M8,H*X/U:(ICMQ&[0?:$M_P502P,$%     @ -(2L6CHT*4WL @  7P8  !D
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MHFHXHJ@*5!0R.SG]F3X^&D91OSG&78-.TA:;MB!C'U12,80.K,.>JL@I=EG
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MAYU+_J#*N@36)C:2^/8NDMX:3=ZQ-X.C1\3>56)=($IZ TQ'@S[5/0]O%YP
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M]U&<G:9EU?2Y;</0LW,+H=SSA52/&%P?E+>(% \F0TH1D!$>%8<A03=\Z7H
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M0WAF /A88&.?<8#5JI76G ;7;8V:6:5GP?7>W"]P N/)X.PLA5._R4>#29K
M:? 1I:)RZ>2_^=K$\E?V0! ;[U!-OG@+!JA7&4OFR?_!$>>2<3+(\@22G"QE
MHV?K/<EC6HY-/,SVQ.+A**/ERV ?&(9&6926,R&>.@QJ5CU/JXI[P.\M?V""
MI QLD4)#L1*MB^M:J_I8HEY/#Y'07H-.N"KIQCT3Z8176+#6('#IT/V;H$%
MS;45)50409) :J=$=L]S%OQG9D^#RT-?5.,X&A\QLFPU+YSM[K*5G%Q,\T$R
MG4 R&<33+* 2IL#@(^J"FUYR#V/:U3_4YL$J6+>V)?\>"-1Q3\>0Y\%7Z?9X
MQ!;;,DWN)TD"XSP.J"S\H),%_BQ[LN6V<A'K10I%R>LHD.D5I<2X N+4C\M3
M>/]NFB;I!_(D#Z[J1J@G*H@.JFDI7C1,H!%,0CI)]\+!G;),..?SLS$DTT&<
M97"LJT0'/9\*8^,GFR%&5"U=^^]/^^%YWLV,9_%N\E+R-IQ<$+@FU7@XR4/0
MW33K-E8U?H*LE*5YY)<5?0"@=@)TOU;T>'<;9Z#_I%C^ %!+ P04    "  T
MA*Q:D'3!><$"  !F!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6R5
M5<MNVS 0_)6%6O1D6++DI$%J"["3%NVA@)'T<2AZH*2U1(0/E:2B^.^[I&S5
M11VCN5@DM3.<6>^N%KTV#[9!=/ DA;++J'&NO8YC6S8HF9WJ%A6]V6HCF:.M
MJ6/;&F15 $D1ITER&4O&590OPMG&Y O=.<$5;@S83DIF=FL4NE]&L^AP<,?K
MQOF#.%^TK,9[=%_;C:%=/+)47**R7"LPN%U&J]GU>N[C0\ WCKT]6H-W4FC]
MX#>?JF64>$$HL'2>@='C$6]0"$]$,G[M.:/Q2@\\7A_8/P3OY*5@%F^T^,XK
MURRCJP@JW+).N#O=?\2]GPO/5VIAPR_T0VQ&P65GG99[,"F07 U/]K3/PQ'@
M*GD&D.X!:= ]7!14WC+'\H71/1@?36Q^$:P&-(GCRO\I]\[06TXXE]^A8 XK
MV##C=O#%,&59R)==Q([X?51<[KG6 U?Z#%<&G[5RC87WJL+J;WQ,ND9QZ4'<
M.CU+^)F9*62S":1)>G&&+QO-9H$O>[%9^+$JK#.T^WG*]T [/TWK^^;:MJS$
M942-8=$\8I2_>36[3-Z=$3T?1<_/L;_P'SK/-<NF<"8)*PMZ"Y3ULAG3#DQ5
M<(LER@+-X70^ =<@W&C9,K6#GA&P$+P.Q$Y#RW:PDC4J> V7TXP*5XC0@\2E
MN( )];-M,72DV$V@HX(Q@7) 48\)5FC#0N>N:H-(@\!-H&\X:?/W&2RUH3*C
M?G$-5]0KQE (",X*+KCC2)I4X"PUT2M+L;2R6O JZ"R88*I$",UCIW#;&:[J
M@' -W0ARJ&;TU7PJ*_\F8A3U?[8IV;Y> K./J9#.=>NM CZU7K,-_H:T3$]5
M4WS4^Q)-'2:<):>=<L,8&$_'(;H:9L>?\&$"D\6:4QD(W!(TF;Z]B, ,4VW8
M.-V&25)H1W,I+!OZ$*#Q ?1^J[4[;/P%XZ<E_PU02P,$%     @ -(2L6F:7
M" RL!P  $!,  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULI5AK;]O&
M$OTK"S4M'$#0RW;L)+8!VVV1VR9HT+3IAXO[844.I;TF=YG=I13UU]\SLR1%
M^86@]XLM[F/FS.O,D!=;Y^_"FBBJKU5IP^5H'6/]9CH-V9HJ'2:N)HN=POE*
M1SSZU334GG0NEZIRNIC-7DTK;>SHZD+6/OJK"]?$TECZZ%5HJDK[W0V5;GLY
MFH^ZA=_-:AUY87IU4>L5?:+X9_W1XVG:2\E-13889Y6GXG)T/7]S<\+GY<!G
M0]LP^*W8DJ5S=_SPK_QR-&- 5%(668+&OPW=4EFR(,#XTLH<]2KYXO!W)_UG
ML1VV+'6@6U?^9?*XOAR=CU1.A6[*^+O;OJ/6GE.6E[DRR%^U36<7KT<J:T)T
M57L9""ICTW_]M?7#X,+Y[(D+B_;"0G G18+R1QWUU85W6^7Y-*3Q#S%5;@.<
ML1R43]%CU^!>O/K4+ -]:<A&]=,&?R^F$5)Y;YJU$FZ2A,43$H[5!V?C.JB?
M;$[YX?TIT/20%AVDF\6S C]H/U''\[%:S!:GS\@[[DT\%GG'WVAB4/^^7H;H
MD1#_><S<).WD<6E<)&]"K3.Z'*$* OD-C:Y^^&[^:O;V&:PG/=:3YZ1_4SB>
ME? XOOG)1-T7K7ZSZH/>J=?)T>HHKDG]\-WY8C%[>UNZ8.Q*(:5(EN9O7RK>
MOW55K>UNK"" /.7*V.B45J73J#";JT!9XTW<*;WR1!7K&0I^S^>NNZU>]-;$
MM?IUH=Z1+N/Z,[8:8%?OW]^JH_;FKXMWGP=0=%2U=QN3XUA3*X!XH>:+T\D,
M15*67.^U-S8SM2Z!40%L)2## 9P_>)DQA5ZTVY!7A6N\0H98<&"8J#]PHS ^
MQ&Y-90ZT%)!*KNC5G\P&VL6B%_!LOU(T7!\*O\21 P^+X^ 75PM1@6GY2>>Y
MX6<8<" 'E@\BP;CG9V\#"!*Q981K[YK56OU(&55+V-)54C(#\7'0MK>CJDR4
M,,$2UC.PP02E-]J4>ED2F[@DE7N]?1)"B[]#\(GJV$*8"8178W#_\K_@8Y;&
M$G2V-K2A3G]&/J*/J Q);3(8SH[QM&I*'9W?,3"8Z"QBGG8R,K7<M"XJ[ 7.
M#,NI<#9,!8BTZ&^9#FO.FHPH#ZKPKNHU%L;"(1P0:1-P/(5Q"J)FR1J>A=33
MH7M$ +3!\9SPO8B)N@8,XY_V\OST__>R:.^#G&)\]F3TSPY<WUD]<*VNN9QT
M&1@]IS];#A^S5>43AG2)?_J$,0.-7?6VJ;KA=CT(N+%IO.@-&Q@N,'(3,D]2
M#@.P:KF3D^\)I>7;0NUK&FTRT8A+1)<\\5J-1>)0 U"[96E6J,6<T5;ZCIC9
MP'"(N[/E3M5Z5TGOX.J,/1\<OU*5=+^QPOK)>?ND3"&'[E4;]"06Z"'8O1I>
MV7/6 WV6OD8P7*O@OJE+TAZN5QOMC?B^%^N98)"B',54=&!?K'GV_Y%YJ>:S
MR<FI^CY!.C(F$3V&-#EPG1X!K*(D2P?UI7%1N%]0_*7+4J$%\0CY"S+'MH5[
M=/-2+2:O(7NB?@.?MBY&#$'9'+ 4NX..H+2GU$,@']'5^X;26P2UR*P0M8T&
MJG$(^H&5.5N'0)&# =$^D<$^QR)F/^0CNP+Y4V-]UUY([KP'!:$H&^XO:0R3
MQ"L0=L[332)M2ZOTD*%MH/Q9-?RSA2+^SQAS#2*@-'< 9#LPCEOIPC@V[0^V
M9=#L>X7+X )/-B,^HCFO"6&&BAS-*E"ZGFQXB*BS \B0.ZOD&N!D7WJ3I7A
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M1.N6GVO2X P^@/W"88)I'UA!_Q'LZG]02P,$%     @ -(2L6DX":;PT%@
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M:\^24"T8 V8+0GY2&L">6-M*6-"IAV(E:>%U2<M3U=[!=N'ZLI!/1WSCZ1!
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MEZ]++=ZQ3J.E4O.L*XA0^8XK1$S&+^""HPOH**K4N"B.Z4YR[4Z6/0D&ZT^
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MZ;:':0\FN1"KCIW:E]+^]SL[(:,3(.V%^./N]V'[CME&FR=; "![+:6R\Z!
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M3%!7OA.L-%)?\<."&CD8%T#[N=:XG3B"[J\A^0-02P,$%     @ -(2L6K&
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MJUYN2+PB16D@OE]3RI_>E ]H+F'/_P=02P,$%     @ -(2L6ER##7]E"
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M]4W7D$I-]P8@(N]7\963\B25FNZ\6OW53@&6% NW:AWHB0/K<9SUT!SI?*7
M.S&>IXWS/PY R?M5U.6D)$JEICL/2)1;*>SR9LFV\2T%S$0?+: ?Q]'O8/1W
M/2_"]8W7SL:I'P=6Y/TJ_G)2OJ12TYT'?,FM%(!Q56,?-"O%R"Y" /\)G/_0
M/.E\E< [,?[>CXWS00%P*?I54Q:D+$JEICL/6%18J2F+9L&X;3_18H;L)P1
MH, A\& 6=#UBQ?6-U]#&*:&H?;VO7S5F0?NM01N,*8 QA94:,ZYJ[(-F*?H
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MO0/=[XQQ1\/WV?B7R/X"4$L#!!0    ( #2$K%JOAM;Z^P(  *<(   9
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M/55^IO@G =($X'@BA'YNF,NJ^3>9_0%02P,$%     @ -(2L6JIY479B @
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M%J(T-9]-:8GY7FG)=QW;;,TAM+0$JME0S8%JU-RM?#".6XX7NM!N/:CF0[4
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MM-60-@V5=?LP[8.;',2J$Z>V ^V_W]E)4]H"VCKX0OQVCY^[>\S=<"7DM<H
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M+3;K]F/E;I^QT$%8+X3.?VG5WE4+E0[4+47;;3F=*M//D$.XT$-8+X@.<)]
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M6YQFS;(SG+)Y=A1V2[E:C@+%L%)=O<Y Y95GITO9@V1;<Z*S9%*RQ-QN@(;
M=0/U?<68/#YH@.*,;_H?4$L#!!0    ( #2$K%I90B^2* ,  +@+   9
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MPK[-#&-LK4'H 'P^YUP]3_0&9;,>_ -02P,$%     @ -(2L6G.M0K]"!
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MIR+-"5Y3^!P<\)VKFX-9@Y"<,2CO!)140492+I41/S'@>[X7#?A-9DX2A^8
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M^\;>&OQDL%$[8V*4O CQ:B9?XY'3-@Y!"I$V#!3_UC"%-#5$Z,:OBM.I/VF
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MGF1[AP]<*1YEAP%0'X0>@/?7G*O]B9Z@W'Z>_0=02P,$%     @ -(2L6B
M[UL: P  C@L  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N>&ULM59M;YLP
M$/XK%JNF5MH*X26)LB124C:MTBI%?=D^3/O@P"6@ F:VD[3_?F=#:$@H:Z;L
M"]CFGL=WS]G'#3>,/XH(0)*G-,G$R(BDS >F*8((4BHN60X9?EDPGE*)4[XT
M1<Z!AAJ4)J9M65TSI7%FC(=Z;<;'0[:229S!C!.Q2E/*GZ>0L,W(Z!C;A=MX
M&4FU8(Z'.5W"'<B'?,9Q9E8L89Q")F*6$0Z+D3'I#/R^LM<&WV/8B)TQ49',
M&7M4D^MP9%C*(4@@D(J!XFL-5Y DB@C=^%UR&M66"K@[WK)_T;%C+',JX(HE
M/^)01B.C;Y 0%G25R%NV^0IE/)[B"U@B])-L2EO+(,%*2):68/0@C;/B39]*
M'78 R-,,L$N O0]P7P$X)<!Y*\ M :Y6I@A%Z^!32<=#SC:$*VMD4P,MID9C
M^'&FTGXG.7Z-$2?'MY!0"2&942Z?R3VGF: Z(X)\)),PC-68)N0Z*XZ8RM6Y
M#Y+&B;A DX<[GYR?79 S$F?D/F(K0;-0#$V)OJD=S*#T8UKX8;_BAT-N6"8C
M03YG(81UO(DQ58'9V\"F=BOA#>67Q.E\(+9E>PW^7+T=[C; _7:X#\%K\%HT
M3I4F1_,YQZ:)_/R&IN1:0BI^-<E>\+K-O*JH#$1. Q@96#4$\#48X_?O.EWK
M4Y-FIR3S3T16T].M]'3;V%%/ 90'$<'3BF5BC>4OQV(F"3QA0170>((+RJZF
M5.5T/?;LCM<9FNM=C0ZM7*_G]>I6?JM[_QB\5P7OM08_29>0D9H$6#83.F>\
MN."3)0=0<C2IT,I][($Z)9E_(K*:IMU*T^Y_NJ#=4^IY2C+_1&0U/7N5GKV_
M7-!"SUSK*7?T9/,D7A;G=!/+"'N/'<LF@8N-O)T+V74L:^_6MGISK'"]@Q+P
MLEU-C7ZE1O_TY:I_X$5#W(=&>Q9^JV?'G@)SIU-)@2]UQR=(P%:9+/[MU6K1
M5$X[@RO=?.VM8[,YT3V6^4)3=*KXYU[&V+XDL$!*Z[*'F>=%]U=,),MU/S1G
M$KLK/8RP80:N#/#[@C&YG:@-JA9\_ =02P,$%     @ -(2L6CB%"22!"
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MZ\I#$K7"V\T!_0,\H2Y$8*'9^XAJ51&X5<7.GJZQD++8*F&R:!KS9H%1X9W
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  TA*Q:<OREYE8$  #S(   #P
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ML^Y_Z_034$L! A0#%     @ -(2L6D;'34B5    S0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  TA*Q:&..5AO,
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ -(2L6HV,HB>G!
M!!(  !@              ("!KA,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( #2$K%I?(CA[[@4  . D   8              " @8L8
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  TA*Q::62F
M5@L&  #N&0  &               @(&O'@  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ -(2L6H(C8%Q- @  HP4  !@
M ("!\"0  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( #2$
MK%J*91O_VP(  " (   8              " @7,G  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    "  TA*Q:';I(HV0)  !>%@  &
M        @(&$*@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
M  @ -(2L6K.^=[6)%   &CX  !@              ("!'C0  'AL+W=O<FMS
M:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( #2$K%JST*"9P 0  'P,   9
M              " @=U(  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L!
M A0#%     @ -(2L6J#Q'*B%!0  K0T  !D              ("!U$T  'AL
M+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  TA*Q:.C0I3>P"
M  !?!@  &0              @(&04P  >&PO=V]R:W-H965T<R]S:&5E=#$R
M+GAM;%!+ 0(4 Q0    ( #2$K%IL.2 H]0\  '(U   9              "
M@;-6  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ -(2L
M6@J9XAOQ!   T L  !D              ("!WV8  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    "  TA*Q:]+E3&Z *  !6'P  &0
M        @($';   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( #2$K%K9MN16E 0  ,@*   9              " @=YV  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ -(2L6ORD6TJP"   @A8
M !D              ("!J7L  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    "  TA*Q:^'W/ .D%  "##0  &0              @(&0A
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( #2$K%H@:<O%
MR@,  %X(   9              " @;"*  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ -(2L6I!TP7G! @  9@8  !D
M ("!L8X  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  T
MA*Q:9I<(#*P'   0$P  &0              @(&ID0  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #2$K%I. FF\-!8  "!'   9
M          " @8R9  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#
M%     @ -(2L6OX?X G[ P  <@H  !D              ("!]Z\  'AL+W=O
M<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  TA*Q:6;Z4[[$#  !'
M"0  &0              @($IM   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;%!+ 0(4 Q0    ( #2$K%J\2. H] (  %,&   9              " @1&X
M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ -(2L6A )
MJ!FO @  )@8  !D              ("!/+L  'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6Q02P$"% ,4    "  TA*Q:L8!QZ%\$   !"P  &0
M    @($BO@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M #2$K%KGQ3V0<@,  &0'   9              " @;C"  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ -(2L6@N/YX8%!   <0D  !D
M             ("!8<8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    "  TA*Q:S/\PZ_$"  #-"0  &0              @(&=R@  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( #2$K%JF16O$S08
M ) M   9              " @<7-  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ -(2L6ER##7]E"   "%<  !D              ("!
MR=0  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  TA*Q:
MR\5&I L"   Q!   &0              @(%EW0  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( #2$K%JOAM;Z^P(  *<(   9
M      " @:??  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ -(2L6JIY479B @  9 4  !D              ("!V>(  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  TA*Q:4#RFY2$.  ";P0
M&0              @(%RY0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( #2$K%JJR6"=50L  (:5   9              " @<KS  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ -(2L6CQ_@-[(
M P  *!$  !D              ("!5O\  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    "  TA*Q:\.TJ ^X"  "E"@  &0
M@(%5 P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( #2$
MK%KF"CW<> 8  )<L   9              " @7H& 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ -(2L6IDKQF\)!0  (Q@  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( #2$K%J^!WSM$0,  +()   9
M  " @9,B 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M-(2L6GU@ )-8!   BA8  !D              ("!VR4! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    "  TA*Q:( #O6QH#  "."P  &0
M            @(%J*@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( #2$K%HXA0DD@0@  *4Z   9              " @;LM 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ -(2L6GX66CU< P
MS!4   T              ( !<S8! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  TA*Q:EXJ[',     3 @  "P              @ 'Z.0$ 7W)E;',O+G)E
M;'-02P$"% ,4    "  TA*Q:<OREYE8$  #S(   #P              @ 'C
M.@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ -(2L6HYA./J] 0  >AT
M !H              ( !9C\! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ -(2L6IPKTP^] 0  =QT  !,              ( !6T$!
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #D .0"&#P  24,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>208</ContextCount>
  <ElementCount>250</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidity</Role>
      <ShortName>Organization and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1</Role>
      <ShortName>Summary of Significant Accounting Policies and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Acquisitions of Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssets</Role>
      <ShortName>Acquisitions of Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Strategic License and Research and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreements</Role>
      <ShortName>Strategic License and Research and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquity1</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquity1</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReporting</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Organization and Liquidity - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails</Role>
      <ShortName>Organization and Liquidity - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Liabilities (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Acquisitions of Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails</Role>
      <ShortName>Acquisitions of Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Strategic License and Research and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>Strategic License and Research and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails</Role>
      <ShortName>Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar</Role>
      <ShortName>Net Loss Per Share - Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nmra-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Subsequent Event - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails</Role>
      <ShortName>Subsequent Event - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="nmra-20250331.htm">nmra-20250331.htm</File>
    <File>nmra-20250331.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img236770017_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="441">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nmra-20250331.htm": {
   "nsprefix": "nmra",
   "nsuri": "http://www.neumoratx.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "nmra-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "nmra-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 192,
   "keyCustom": 58,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 25,
   "memberCustom": 42,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 4
   },
   "contextCount": 208,
   "entityCount": 1,
   "segmentCount": 74,
   "elementCount": 657,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 441,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_907c9317-d7f8-46fd-952b-f6aa7821fdb9",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
     "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited",
     "longName": "100040 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited)",
     "shortName": "Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_807f1ef6-efe1-47cd-a1ac-f6eebc286522",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_807f1ef6-efe1-47cd-a1ac-f6eebc286522",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidity",
     "longName": "995455 - Disclosure - Organization and Liquidity",
     "shortName": "Organization and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation",
     "shortName": "Summary of Significant Accounting Policies and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1",
     "longName": "995475 - Disclosure - Cash Equivalents and Marketable Securities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurements",
     "longName": "995485 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponents",
     "longName": "995495 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssets",
     "longName": "995505 - Disclosure - Acquisitions of Assets",
     "shortName": "Acquisitions of Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "longName": "995515 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreements",
     "longName": "995525 - Disclosure - Strategic License and Research and Collaboration Agreements",
     "shortName": "Strategic License and Research and Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquity1",
     "longName": "995535 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensation",
     "longName": "995555 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReporting",
     "longName": "995565 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "995575 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactions",
     "longName": "995585 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEvent",
     "longName": "995595 - Disclosure - Subsequent Event",
     "shortName": "Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies",
     "longName": "995605 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies)",
     "shortName": "Summary of Significant Accounting Policies and Basis of Presentation (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables",
     "longName": "995615 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "995625 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "longName": "995635 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables",
     "longName": "995655 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "nmra:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "nmra:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables",
     "longName": "995665 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingTables",
     "longName": "995675 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995695 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
     "longName": "995705 - Disclosure - Organization and Liquidity - Additional information (Details)",
     "shortName": "Organization and Liquidity - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "nmra:NumberOfClinicalAndPreclinicalNeurosciencePrograms",
      "unitRef": "U_Program",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "nmra:NumberOfClinicalAndPreclinicalNeurosciencePrograms",
      "unitRef": "U_Program",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
     "longName": "995715 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995735 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_27e8bd25-1d8a-462a-a5a8-60599bc36dcb",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_27e8bd25-1d8a-462a-a5a8-60599bc36dcb",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995745 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "us-gaap:NetAssetValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "us-gaap:NetAssetValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails",
     "longName": "995755 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)",
     "shortName": "Balance Sheet Components - Schedule of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "nmra:AccruedClinicalTrialAndPreclinicalCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "nmra:AccruedClinicalTrialAndPreclinicalCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails",
     "longName": "995765 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Parenthetical) (Details)",
     "shortName": "Balance Sheet Components - Schedule of Accrued Liabilities (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
     "longName": "995775 - Disclosure - Acquisitions of Assets - Additional Information (Details)",
     "shortName": "Acquisitions of Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_eba48cde-044c-4cf6-83fc-6f6426dd681f",
      "name": "nmra:NumberOfLicenseAgreements",
      "unitRef": "U_Agreements",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eba48cde-044c-4cf6-83fc-6f6426dd681f",
      "name": "nmra:NumberOfLicenseAgreements",
      "unitRef": "U_Agreements",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails",
     "longName": "995785 - Disclosure - Strategic License and Research and Collaboration Agreements - Additional Information (Details)",
     "shortName": "Strategic License and Research and Collaboration Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9725a19f-6026-4597-becd-68b62f258eb7",
      "name": "nmra:FundReceivedUponCompletionOfCertainDevelopmentMilestone",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "995795 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
     "longName": "995805 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "shortName": "Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ee1bf88c-a716-432c-9927-f73c12f7dabe",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
     "longName": "995815 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_e2a1d014-20d2-44f9-b860-5500f8f6d49e",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e64685c-4df1-4cfc-8090-786dde3ed56d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
     "longName": "995835 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_504593b3-57d4-4b02-8b18-4bdd29a7ac8f",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3dcb2394-89b3-4597-ac19-7d6a28943660",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail",
     "longName": "995845 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_097e4542-80e5-445f-9968-c8d2e3c75940",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bc0aae18-ce73-4dfb-b51a-da049eec95c8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails",
     "longName": "995855 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3b83541b-7d35-4924-a941-cdc46db3b104",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
     "longName": "995865 - Disclosure - Segment Reporting - Additional Information (Details)",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails",
     "longName": "995875 - Disclosure - Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details)",
     "shortName": "Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "nmra:NavacaprantNMRA-140ProgramExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "nmra:NavacaprantNMRA-140ProgramExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "995885 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar",
     "longName": "995895 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "995905 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
     "longName": "995915 - Disclosure - Subsequent Event - Additional Information (Details)",
     "shortName": "Subsequent Event - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:DebtInstrumentCovenantDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_444ace39-c318-4dbb-a4fe-64b15e36d5b1",
      "name": "us-gaap:DebtInstrumentCovenantDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r710"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts payable",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "nmra_AccruedClinicalTrialAndPreclinicalCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AccruedClinicalTrialAndPreclinicalCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial and preclinical costs.",
        "label": "Accrued Clinical Trial and Preclinical Costs",
        "terseLabel": "Accrued clinical trial and preclinical costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "nmra_AccruedResearchAndDevelopmentServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AccruedResearchAndDevelopmentServices",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development services.",
        "label": "Accrued Research and Development Services",
        "terseLabel": "Accrued research and development services"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AccruedResearchAndDevelopmentServicesDueToRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AccruedResearchAndDevelopmentServicesDueToRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development services due to related party",
        "label": "Accrued Research and Development Services Due to Related Party",
        "documentation": "Accrued research and development services due to related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties",
        "terseLabel": "Royalties due",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive (gain) loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r74",
      "r144",
      "r512",
      "r541",
      "r542"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r17",
      "r418",
      "r421",
      "r459",
      "r537",
      "r538",
      "r836",
      "r837",
      "r838",
      "r845",
      "r846",
      "r847",
      "r848"
     ]
    },
    "nmra_AchievementOfSpecifiedCommercializationEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AchievementOfSpecifiedCommercializationEventsMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified commercialization events.",
        "label": "Achievement of Specified Commercialization Events [Member]",
        "terseLabel": "Achievement of Specified Commercialization Events"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AchievementOfSpecifiedDevelopmentEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AchievementOfSpecifiedDevelopmentEventsMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified development events.",
        "label": "Achievement of Specified Development Events [Member]",
        "terseLabel": "Achievement of Specified Development Events"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AcquiredInProcessResearchAndDevelopedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AcquiredInProcessResearchAndDevelopedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and developed expense",
        "label": "Acquired in-process Research and Developed Expense",
        "documentation": "Acquired in-process research and developed expense."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired in-process research and development",
        "label": "Acquired in-process research and development",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AcquisitionDateFairValueOfSharesTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AcquisitionDateFairValueOfSharesTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition date fair value of shares transferred",
        "label": "Acquisition Date Fair Value of Shares Transferred",
        "terseLabel": "Acquisition date fair value of shares transferred"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r845",
      "r846",
      "r847",
      "r848",
      "r917",
      "r977"
     ]
    },
    "nmra_AdditionalSharesOfCapitalStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AdditionalSharesOfCapitalStockMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares of capital stock member.",
        "label": "Additional Shares of Capital Stock [Member]",
        "terseLabel": "Additional Shares of Capital Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AdvisorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AdvisorsMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advisors.",
        "label": "Advisors [Member]",
        "terseLabel": "Advisors"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r751",
      "r761",
      "r794"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r764",
      "r797"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "nmra_AlairionCarveoutPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AlairionCarveoutPlanMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alairion Carveout Plan.",
        "label": "Alairion Carveout Plan [Member]",
        "terseLabel": "Alairion Carveout Plan"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AlairionMergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AlairionMergerAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alairion Merger Agreement.",
        "label": "Alairion Merger Agreement [Member]",
        "terseLabel": "Alairion Merger Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r755",
      "r765",
      "r789",
      "r798",
      "r802",
      "r810"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share based compensation recognized",
        "verboseLabel": "Total stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r380"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AmgenIncLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AmgenIncLicensesMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen Inc. Licenses.",
        "label": "Amgen Inc. Licenses [Member]",
        "terseLabel": "Amgen Inc. Licenses"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AmgenIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AmgenIncMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen Inc.",
        "label": "Amgen Inc [Member]",
        "terseLabel": "Amgen Inc."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AmgenResearchAndCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AmgenResearchAndCollaborationAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen research and collaboration agreement.",
        "label": "Amgen Research And Collaboration Agreement [Member]",
        "terseLabel": "Amgen Research and Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r913"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Contingent consideration",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r915",
      "r916"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition compensation recognized and paid",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r915",
      "r916"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Asset Acquisition, Contingent Consideration, Liability, Total",
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration deemed due or payable",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r913"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r118",
      "r139",
      "r163",
      "r193",
      "r202",
      "r215",
      "r218",
      "r258",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r411",
      "r415",
      "r445",
      "r508",
      "r596",
      "r671",
      "r672",
      "r710",
      "r728",
      "r878",
      "r879",
      "r931"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r145",
      "r163",
      "r258",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r411",
      "r415",
      "r445",
      "r710",
      "r878",
      "r879",
      "r931"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets measured at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r699"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r735",
      "r747"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r735",
      "r747"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r735",
      "r747"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r266",
      "r507"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "terseLabel": "Gross Unrealized Gain",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "negatedLabel": "Gross Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-Sale Securities, Debt Maturities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails": {
       "parentTag": "nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt maturities after one through two years fair value",
        "label": "Available For Sale Securities Debt Maturities After One Through Two Years Fair Value",
        "terseLabel": "After one year through [two] years",
        "verboseLabel": "After one year through two years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails": {
       "parentTag": "nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r505"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Total marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r266",
      "r429",
      "r501",
      "r699",
      "r702",
      "r859",
      "r921",
      "r922",
      "r923"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "nmra_AwardModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AwardModificationMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award modification.",
        "label": "Award Modification [Member]",
        "terseLabel": "Award Modification"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "nmra_AwardsWithPerformanceConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "AwardsWithPerformanceConditionsMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Awards with performance conditions.",
        "label": "Awards with Performance Conditions [Member]",
        "terseLabel": "Awards with Performance Conditions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r944",
      "r945"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r277",
      "r944",
      "r945"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies and Basis of Presentation",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "nmra_BlackthornCarveoutPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "BlackthornCarveoutPlanMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BlackThorn Carveout Plan.",
        "label": "BlackThorn Carveout Plan [Member]",
        "terseLabel": "BlackThorn Carveout Plan"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_BlackthornMergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "BlackthornMergerAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BlackThorn Merger Agreement.",
        "label": "BlackThorn Merger Agreement [Member]",
        "terseLabel": "BlackThorn Merger Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_BlackthornTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "BlackthornTherapeuticsIncMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BlackThorn Therapeutics, Inc. member.",
        "label": "BlackThorn Therapeutics, Inc. [Member]",
        "terseLabel": "BlackThorn Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions of Assets",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r405"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "nmra_CaseOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "CaseOneMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Case one.",
        "label": "Case One [Member]",
        "terseLabel": "Case One"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_CaseTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "CaseTwoMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Case two.",
        "label": "Case Two [Member]",
        "terseLabel": "Case Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r137",
      "r661"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r108"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and marketable securities",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of year",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r83",
      "r161"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r83"
     ]
    },
    "nmra_CashEquivalentsAndMarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "CashEquivalentsAndMarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities.",
        "label": "Cash Equivalents and Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r722",
      "r723",
      "r724",
      "r725"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r141",
      "r142",
      "r143",
      "r163",
      "r182",
      "r183",
      "r185",
      "r187",
      "r195",
      "r196",
      "r258",
      "r286",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r313",
      "r314",
      "r317",
      "r320",
      "r328",
      "r445",
      "r548",
      "r549",
      "r550",
      "r551",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r584",
      "r605",
      "r627",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r822",
      "r842",
      "r849"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r195",
      "r313",
      "r314",
      "r315",
      "r317",
      "r320",
      "r326",
      "r328",
      "r548",
      "r549",
      "r550",
      "r551",
      "r686",
      "r822",
      "r842"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "nmra_CollaborationAgreementNonRefundableQuarterlyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "CollaborationAgreementNonRefundableQuarterlyPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement non-refundable quarterly payments.",
        "label": "Collaboration Agreement Non-refundable Quarterly Payments",
        "terseLabel": "Collaboration agreement non-refundable quarterly payments"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_CollaborationAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "CollaborationAgreementTerm",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement term.",
        "label": "Collaboration Agreement Term",
        "terseLabel": "Term of the agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_CollaborationAgreementTerminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "CollaborationAgreementTerminationDescription",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement termination description.",
        "label": "Collaboration Agreement Termination Description",
        "terseLabel": "Collaboration agreement termination description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Strategic License and Research and Collaboration Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r123",
      "r131"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "nmra_CommercialMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "CommercialMilestonePaymentMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payment.",
        "label": "Commercial Milestone Payment [Member]",
        "terseLabel": "Commercial Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_CommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "CommercialMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payments.",
        "label": "Commercial Milestone Payments",
        "terseLabel": "Commercial milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper",
        "verboseLabel": "Commercial Paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r285",
      "r722",
      "r723",
      "r724",
      "r725"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r113",
      "r509",
      "r583"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r279",
      "r280",
      "r656",
      "r868",
      "r873"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance",
        "verboseLabel": "Shares reserved for potential future issuances",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementStockholdersEquityDeficitUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r722",
      "r723",
      "r724",
      "r725",
      "r845",
      "r846",
      "r848",
      "r917",
      "r976",
      "r977"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r584"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r584",
      "r602",
      "r977",
      "r978"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r511",
      "r710"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r149",
      "r151",
      "r156",
      "r502",
      "r522",
      "r523"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r125"
     ]
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ContingentConsiderationMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ContingentConsiderationMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration, milestone payment.",
        "label": "Contingent Consideration, Milestone Payment",
        "terseLabel": "Contingent consideration, milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ContingentConsiderationMilestonePaymentSettledInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ContingentConsiderationMilestonePaymentSettledInCash",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration, milestone payment settled in cash",
        "label": "Contingent Consideration, Milestone Payment Settled in Cash",
        "terseLabel": "Contingent consideration, milestone payment settled in cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of preferred stock into common stock upon completion of initial public offering",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "nmra_ConvertiblePreferredStockPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ConvertiblePreferredStockPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock, Policy [Policy Text Block]",
        "documentation": "Convertible preferred stock, policy policy text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "verboseLabel": "Converted shares",
        "terseLabel": "Number of convertible preferred stock automatically converted into shares of common stock",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r39",
      "r67",
      "r95",
      "r323"
     ]
    },
    "nmra_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock Warrant Liability",
        "label": "Convertible Preferred Stock Warrant Liability [Policy Text Block]",
        "documentation": "Convertible preferred stock warrant liability policy text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r690",
      "r699",
      "r711",
      "r716",
      "r973"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r876"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r876",
      "r877"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_DaljitBillSinghAuroraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "DaljitBillSinghAuroraMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Daljit (Bill) Singh Aurora.",
        "label": "Daljit (Bill) Singh Aurora [Member]",
        "terseLabel": "Daljit (Bill) Singh Aurora"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r26"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r57",
      "r58",
      "r110",
      "r112",
      "r164",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r709",
      "r843",
      "r869",
      "r870",
      "r871",
      "r927",
      "r928"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable interest rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r297"
     ]
    },
    "us-gaap_DebtInstrumentCovenantDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCovenantDescription",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, covenant description",
        "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r52"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r296"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r681",
      "r922",
      "r923"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r164",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r709",
      "r843",
      "r869",
      "r870",
      "r871",
      "r927",
      "r928"
     ]
    },
    "nmra_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs.",
        "label": "Deferred Offering Costs [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization expense",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r193",
      "r203",
      "r218",
      "r671",
      "r672"
     ]
    },
    "nmra_DevelopmentAndRegulatoryApprovalMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "DevelopmentAndRegulatoryApprovalMilestonesMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and regulatory approval milestones.",
        "label": "Development and Regulatory Approval Milestones [Member]",
        "terseLabel": "Development and Regulatory Approval Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_DevelopmentAndRegulatoryMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "DevelopmentAndRegulatoryMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and regulatory milestone payments.",
        "label": "Development And Regulatory Milestone Payments",
        "terseLabel": "Development and regulatory milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_DevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "DevelopmentMilestonesMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones.",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r341",
      "r372",
      "r373",
      "r375",
      "r692"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r735",
      "r747"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r735",
      "r747",
      "r790"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "nmra_EarlyExerciseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "EarlyExerciseLiabilityCurrentPortion",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early exercise liability, current portion.",
        "label": "Early Exercise Liability Current Portion",
        "verboseLabel": "Early exercise liability, current portion"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_EarlyExerciseLiabilityNetOfCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "EarlyExerciseLiabilityNetOfCurrentPortion",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early exercise liability, net of current portion.",
        "label": "Early Exercise Liability Net Of Current Portion",
        "verboseLabel": "Early exercise liability, net of current portion"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_EarlyExerciseOfEmployeeStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "EarlyExerciseOfEmployeeStockOptionsMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early exercise of employee stock options.",
        "label": "Early Exercise of Employee Stock Options [Member]",
        "terseLabel": "Early Exercise of Employee Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_EarlyExercisedStockOptionsSubjectToFutureVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "EarlyExercisedStockOptionsSubjectToFutureVestingMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early exercised stock options subject to future vesting.",
        "label": "Early exercised stock options subject to future vesting [Member]",
        "terseLabel": "Early Exercised Stock Options Subject to Future Vesting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r180",
      "r182",
      "r185",
      "r186",
      "r187",
      "r192",
      "r402",
      "r408",
      "r426",
      "r427",
      "r503",
      "r524",
      "r662"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r182",
      "r185",
      "r186",
      "r187",
      "r192",
      "r402",
      "r408",
      "r426",
      "r427",
      "r503",
      "r524",
      "r662"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r189"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r188",
      "r190",
      "r191"
     ]
    },
    "nmra_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status.",
        "label": "Emerging Growth Company Status [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average remaining service period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_EmployeeStockOptionAndAndRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "EmployeeStockOptionAndAndRestrictedStockUnitsMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock option and and restricted stock units.",
        "label": "Employee Stock Option and and Restricted Stock Units Member",
        "terseLabel": "Common Stock Options and Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Common Stock Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementStockholdersEquityDeficitUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r133",
      "r153",
      "r154",
      "r155",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r194",
      "r259",
      "r260",
      "r275",
      "r329",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r403",
      "r407",
      "r408",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r459",
      "r520",
      "r537",
      "r538",
      "r539",
      "r557",
      "r627"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r751",
      "r761",
      "r794"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r748",
      "r758",
      "r791"
     ]
    },
    "nmra_EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of available for sale debt securities fair value.",
        "label": "Estimated Fair Value Of Available For Sale Debt Securities Fair Value",
        "totalLabel": "Total marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executives"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r441",
      "r699"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r441",
      "r699"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r700"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r700"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r440",
      "r441",
      "r443",
      "r471",
      "r472",
      "r473",
      "r682",
      "r683",
      "r688",
      "r689",
      "r690",
      "r699",
      "r702"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r433",
      "r699",
      "r922",
      "r925"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r331",
      "r336",
      "r430",
      "r441",
      "r471",
      "r688",
      "r689",
      "r690",
      "r699"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r331",
      "r336",
      "r430",
      "r431",
      "r441",
      "r472",
      "r682",
      "r683",
      "r688",
      "r689",
      "r690",
      "r699"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r430",
      "r431",
      "r432",
      "r433",
      "r441",
      "r473",
      "r682",
      "r683",
      "r688",
      "r689",
      "r690",
      "r699",
      "r702"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r433",
      "r699",
      "r922",
      "r925"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r440",
      "r441",
      "r443",
      "r471",
      "r472",
      "r473",
      "r682",
      "r683",
      "r688",
      "r689",
      "r690",
      "r699",
      "r702"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r925"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r311",
      "r326",
      "r423",
      "r444",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r521",
      "r680",
      "r699",
      "r700",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r711",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r863",
      "r864",
      "r865",
      "r866",
      "r918",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "nmra_FirstVanderbiltSponsoredResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "FirstVanderbiltSponsoredResearchAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Vanderbilt Research Agreement",
        "label": "First Vanderbilt sponsored research agreement [Member]",
        "documentation": "First Vanderbilt sponsored research agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ForfeitureOfUnvestedRestrictedCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ForfeitureOfUnvestedRestrictedCommonStockShares",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeiture of Unvested Restricted Common Stock, Shares",
        "documentation": "Forfeiture of unvested restricted common stock, shares.",
        "terseLabel": "Forfeiture of unvested restricted common stock, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r755",
      "r765",
      "r798"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r755",
      "r765",
      "r798"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r755",
      "r765",
      "r798"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r755",
      "r765",
      "r798"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r755",
      "r765",
      "r798"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund eligible to receive upon completion of certain development milestone.",
        "label": "Fund Eligible To Receive Upon Completion Of Certain Development Milestone",
        "terseLabel": "Fund eligible to receive upon completion of certain development milestone"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "FundReceivedUponCompletionOfCertainDevelopmentMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fund Received Upon Completion Of Certain Development Milestone",
        "documentation": "Fund received upon completion of certain development milestone.",
        "verboseLabel": "Fund received upon completion of certain development milestone"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "FundsProvidedForPreClinicalResearchAndDevelopmentActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds provided for pre-clinical research and development activities.",
        "label": "Funds Provided For Pre-clinical Research And Development Activities",
        "terseLabel": "Funds provided for preclinical research and development activities"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_FundsReceivedUponExecutionOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "FundsReceivedUponExecutionOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds received upon execution of agreement.",
        "label": "Funds Received Upon Execution Of Agreement",
        "terseLabel": "Funds received upon execution of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "negatedLabel": "General and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r607"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r88"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r115",
      "r117",
      "r504",
      "r517",
      "r664",
      "r671",
      "r851",
      "r853",
      "r854",
      "r855",
      "r856"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r435",
      "r439",
      "r442",
      "r534",
      "r536",
      "r612",
      "r659",
      "r701",
      "r946"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r435",
      "r439",
      "r442",
      "r534",
      "r536",
      "r612",
      "r659",
      "r701",
      "r946"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Provision for income taxes",
        "negatedLabel": "Provision for income taxes",
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r130",
      "r177",
      "r178",
      "r193",
      "r204",
      "r218",
      "r386",
      "r387",
      "r398",
      "r525",
      "r696"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r384",
      "r385",
      "r390",
      "r391",
      "r392",
      "r395",
      "r547"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Taxes Paid, Net, Total",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r160",
      "r393",
      "r394"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r840"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r755",
      "r765",
      "r789",
      "r798",
      "r802",
      "r810"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r814"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r814"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r814"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income (Expense), Nonoperating",
        "totalLabel": "Interest Income (Expense), Nonoperating, Total",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r839",
      "r853"
     ]
    },
    "us-gaap_InvestmentIncomeAmortizationOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeAmortizationOfDiscount",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Amortization of Discount",
        "negatedLabel": "Net accretion of investments in marketable securities",
        "documentation": "Amount of accretion of purchase discount on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Net",
        "terseLabel": "Interest income",
        "totalLabel": "Investment Income, Net, Total",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r81"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r634",
      "r636",
      "r638",
      "r641",
      "r642",
      "r643",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r720"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r634",
      "r636",
      "r638",
      "r641",
      "r642",
      "r643",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r720"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Marketable Securities by Contractual Maturity",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_K2HealthVenturesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "K2HealthVenturesLLCMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "K2 HealthVentures LLC [Member]",
        "documentation": "K2 HealthVentures LLC.",
        "terseLabel": "K2HV"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Maturity of the Company's Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r57",
      "r58",
      "r59",
      "r62",
      "r63",
      "r64",
      "r65",
      "r163",
      "r258",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r412",
      "r415",
      "r416",
      "r445",
      "r582",
      "r663",
      "r728",
      "r878",
      "r931",
      "r932"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r114",
      "r514",
      "r710",
      "r844",
      "r867",
      "r926"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities, Convertible Preferred Stock, and Stockholders' Equity (Deficit)",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r136",
      "r163",
      "r258",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r412",
      "r415",
      "r416",
      "r445",
      "r710",
      "r878",
      "r931",
      "r932"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Additional Borrowing Capacity",
        "documentation": "Line of credit facility, additional borrowing capacity.",
        "terseLabel": "Additional borrowing capacity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r61",
      "r843",
      "r876",
      "r877"
     ]
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Amount funded on closing date",
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r61"
     ]
    },
    "us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment terms",
        "label": "Line of Credit Facility, Frequency of Payment and Payment Terms",
        "documentation": "Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r61"
     ]
    },
    "us-gaap_LineOfCreditFacilityInterestRateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityInterestRateDescription",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Interest Rate Description",
        "terseLabel": "Interest rate description",
        "documentation": "Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r61"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r61",
      "r843",
      "r876"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r61"
     ]
    },
    "nmra_LiquidityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "LiquidityMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity [Member]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan and Security Agreement [Member]",
        "documentation": "Loan and security agreement.",
        "terseLabel": "Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r869",
      "r870",
      "r871"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r35",
      "r869",
      "r870",
      "r871"
     ]
    },
    "nmra_M4PAMProgramsExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "M4PAMProgramsExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "M4 PAM Programs Expenses",
        "documentation": "M4 PAM programs expenses.",
        "negatedLabel": "M4 PAM programs"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_MarketAwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "MarketAwardMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market award.",
        "label": "Market Award [Member]",
        "terseLabel": "Market Award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "verboseLabel": "Short-term marketable securities",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "nmra_MarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "MarketableSecuritiesMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities.",
        "label": "Marketable securities [Member]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Noncurrent",
        "verboseLabel": "Long-term marketable securities",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "nmra_MaximumAdditionalFinancingInEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "MaximumAdditionalFinancingInEquitySecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum additional financing in equity securities.",
        "label": "Maximum additional financing in equity securities"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_MaximumFutureCapitalStockOfferingsInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "MaximumFutureCapitalStockOfferingsInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Future Capital Stock Offerings Investment",
        "documentation": "Maximum future capital stock offerings investment.",
        "terseLabel": "Maximum future capital stock offerings investment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r337",
      "r381",
      "r433",
      "r499",
      "r533",
      "r535",
      "r543",
      "r574",
      "r575",
      "r635",
      "r637",
      "r639",
      "r640",
      "r644",
      "r657",
      "r658",
      "r679",
      "r686",
      "r691",
      "r702",
      "r703",
      "r707",
      "r708",
      "r713",
      "r880",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "nmra_MaximumRepaymentAmountAgreedToPay": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "MaximumRepaymentAmountAgreedToPay",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum repayment amount agreed to pay.",
        "label": "Maximum Repayment Amount Agreed To Pay",
        "terseLabel": "Maximum repayment amount agreed to pay."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "nmra_MichaelMilliganMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "MichaelMilliganMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Michael Milligan.",
        "label": "Michael Milligan [Member]",
        "terseLabel": "Michael Milligan"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_MilestonePaymentDueDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "MilestonePaymentDueDescription",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment due description.",
        "label": "Milestone Payment Due Description",
        "terseLabel": "Milestone payment due description"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_MilestonesAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "MilestonesAchieved",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones achieved.",
        "label": "Milestones Achieved",
        "terseLabel": "Milestones achieved"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum liquidity covenant percentage of outstanding obligations one",
        "documentation": "Minimum liquidity covenant percentage of outstanding obligations one."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum liquidity covenant percentage of outstanding obligations two",
        "documentation": "Minimum liquidity covenant percentage of outstanding obligations two."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r337",
      "r381",
      "r433",
      "r499",
      "r533",
      "r535",
      "r543",
      "r574",
      "r575",
      "r635",
      "r637",
      "r639",
      "r640",
      "r644",
      "r657",
      "r658",
      "r679",
      "r686",
      "r691",
      "r702",
      "r703",
      "r707",
      "r713",
      "r880",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "nmra_NavacaprantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "NavacaprantMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Navacaprant.",
        "label": "Navacaprant [Member]",
        "terseLabel": "navacaprant"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_NavacaprantNMRA-140ProgramExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "NavacaprantNMRA-140ProgramExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Navacaprant (NMRA-140) program expenses",
        "documentation": "Navacaprant (NMRA-140) program expenses.",
        "negatedLabel": "Navacaprant (NMRA-140) program"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_NavacaprantNMRA-511ProgramExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "NavacaprantNMRA-511ProgramExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Navacaprant (NMRA-511) program expenses",
        "documentation": "Navacaprant (NMRA-511) program expenses.",
        "negatedLabel": "NMRA-511 program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetAssetValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetAssetValuePerShare",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Net Asset Value Per Share, Beginning Balance",
        "periodEndLabel": "Net Asset Value Per Share, Ending Balance",
        "label": "Net Asset Value Per Share",
        "terseLabel": "Net asset value per share",
        "documentation": "Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r567",
      "r568",
      "r586",
      "r602",
      "r650",
      "r728"
     ]
    },
    "nmra_NetCashProceedsFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "NetCashProceedsFromFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash proceeds from financing activities",
        "label": "Net Cash Proceeds from Financing Activities",
        "documentation": "Net cash proceeds from financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r85",
      "r116",
      "r134",
      "r148",
      "r150",
      "r155",
      "r163",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r184",
      "r258",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r402",
      "r408",
      "r427",
      "r445",
      "r519",
      "r604",
      "r625",
      "r626",
      "r726",
      "r878"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_Nmra511Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "Nmra511Member",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NMRA-511.",
        "label": "NMRA-511 [Member]",
        "terseLabel": "NMRA-511"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r755",
      "r765",
      "r789",
      "r798"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "nmra_NonRule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "NonRule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Rule 10b5-1 arr modified.",
        "label": "Non-Rule 10b5-1 Arr Modified [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "nmra_NoncashOperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "NoncashOperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash operating lease expense",
        "documentation": "Noncash operating lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_NumberOfClinicalAndPreclinicalNeurosciencePrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "NumberOfClinicalAndPreclinicalNeurosciencePrograms",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of clinical and preclinical neuroscience programs",
        "label": "Number Of Clinical And Preclinical Neuroscience Programs",
        "terseLabel": "Number of clinical and preclinical neuroscience programs"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_NumberOfLicenseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "NumberOfLicenseAgreements",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of license agreements.",
        "label": "Number of License Agreements",
        "terseLabel": "Number of license agreements"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_NumberOfMilestoneAchieved": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "NumberOfMilestoneAchieved",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestone achieved.",
        "label": "Number of Milestone Achieved",
        "terseLabel": "Number of milestone achieved"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r852"
     ]
    },
    "nmra_NumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "NumberOfTranches",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of tranches",
        "documentation": "Number of tranches."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs in connection with at-the-market offering included in accrued liabilities",
        "documentation": "Offering costs in connection with at-the-market offering included in accrued liabilities.",
        "label": "Offering Costs Connection With At The Market Offering Included In Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs related to initial public offering included in accounts payable and accrued liabilities",
        "documentation": "Offering costs related to initial public offering included in accounts payable and accrued liabilities.",
        "label": "Offering Costs Related To Initial Public Offering Included In Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_OfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "OfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering expenses.",
        "label": "Offering Expenses",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating Income (Loss), Total",
        "terseLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r664",
      "r851",
      "r853",
      "r854",
      "r855",
      "r856"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Operating lease liabilities, current portion",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease right-of-use assets",
        "terseLabel": "Right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "nmra_OrganizationAndLiquidityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "OrganizationAndLiquidityLineItems",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and Liquidity [Line items]",
        "label": "Organization and Liquidity [Line items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies and Basis of Presentation",
        "verboseLabel": "Organization and Liquidity",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r106",
      "r544",
      "r545"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other assets",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gain (loss) on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "verboseLabel": "Unrealized loss on marketable debt securities",
        "terseLabel": "Unrealized loss on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r257"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "nmra_OtherSegmentItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "OtherSegmentItems",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Segment Items",
        "documentation": "Other segment items.",
        "negatedLabel": "Other segment items"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r753",
      "r763",
      "r796"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r756",
      "r766",
      "r799"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r756",
      "r766",
      "r799"
     ]
    },
    "nmra_ParkinsonsResearchVenturesFundingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ParkinsonsResearchVenturesFundingAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Parkinsons research ventures funding agreement.",
        "label": "Parkinsons Research Ventures Funding Agreement [Member]",
        "terseLabel": "Parkinson's Research Ventures Funding Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "nmra_PaymentsForExecutionOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "PaymentsForExecutionOfAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for execution of agreement.",
        "label": "Payments For Execution Of Agreement",
        "terseLabel": "Payments for execution of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementStockholdersEquityDeficitUnauditedParenthetical",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs",
        "negatedLabel": "Payments for offering costs in connection with at-the-market offering and initial public offering",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Issuance of Series B convertible preferred stock, issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Contingent consideration payable in cash",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r406"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire in Process Research and Development",
        "negatedLabel": "Cash paid for acquisition of assets",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "nmra_PerformanceRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "PerformanceRestrictedStockMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance restricted stock.",
        "label": "Performance Restricted Stock [Member]",
        "terseLabel": "Performance Restricted Stock"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance restricted stock (with performance conditions to be established).",
        "label": "Performance restricted stock (with performance conditions to be established) [Member]",
        "terseLabel": "Performance Restricted Stock (With Performance Conditions to Be Established)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Stock Options",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "PerformanceStockOptionsWithPerformanceConditionsToBeEstablishedMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance stock options (with performance conditions to be established) [Member]",
        "documentation": "Performance stock options (with performance conditions to be established).",
        "terseLabel": "Performance Stock Options (With Performance Conditions to Be Established)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "nmra_PreclinicalProgramsExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "PreclinicalProgramsExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Preclinical programs",
        "label": "Preclinical programs expenses",
        "documentation": "Preclinical programs expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r313"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r584"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued",
        "verboseLabel": "Preferred stock warrants, issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r313"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r584",
      "r602",
      "r977",
      "r978"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosurePreferredStockWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Preferred Stock Warrants",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid research and development costs",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "nmra_PrepaymentPenalty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "PrepaymentPenalty",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment penalty",
        "documentation": "Prepayment penalty."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering",
        "verboseLabel": "Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "verboseLabel": "Proceeds from equity financing",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r548"
     ]
    },
    "nmra_ProceedsFromMaturitiesOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ProceedsFromMaturitiesOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds From Maturities Of Marketable Securities",
        "documentation": "Proceeds from maturities of marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r500",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r660",
      "r687",
      "r712",
      "r713",
      "r714",
      "r715",
      "r717",
      "r874",
      "r875",
      "r881",
      "r943",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r974",
      "r975"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r500",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r660",
      "r687",
      "r712",
      "r713",
      "r714",
      "r715",
      "r717",
      "r874",
      "r875",
      "r881",
      "r943",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r974",
      "r975"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r148",
      "r150",
      "r158",
      "r163",
      "r168",
      "r174",
      "r177",
      "r178",
      "r258",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r402",
      "r408",
      "r410",
      "r413",
      "r414",
      "r427",
      "r445",
      "r504",
      "r518",
      "r556",
      "r604",
      "r625",
      "r626",
      "r697",
      "r698",
      "r727",
      "r838",
      "r878"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r458",
      "r506",
      "r516",
      "r710"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r126",
      "r129",
      "r515"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r330",
      "r337",
      "r367",
      "r368",
      "r369",
      "r381",
      "r433",
      "r474",
      "r483",
      "r499",
      "r533",
      "r535",
      "r543",
      "r574",
      "r575",
      "r635",
      "r637",
      "r639",
      "r640",
      "r644",
      "r657",
      "r658",
      "r679",
      "r686",
      "r691",
      "r702",
      "r703",
      "r707",
      "r708",
      "r713",
      "r720",
      "r872",
      "r880",
      "r922",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r330",
      "r337",
      "r367",
      "r368",
      "r369",
      "r381",
      "r433",
      "r474",
      "r483",
      "r499",
      "r533",
      "r535",
      "r543",
      "r574",
      "r575",
      "r635",
      "r637",
      "r639",
      "r640",
      "r644",
      "r657",
      "r658",
      "r679",
      "r686",
      "r691",
      "r702",
      "r703",
      "r707",
      "r708",
      "r713",
      "r720",
      "r872",
      "r880",
      "r922",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r748",
      "r758",
      "r791"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r608",
      "r609",
      "r612"
     ]
    },
    "nmra_RelatedPartyTransactionObligationWithRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "RelatedPartyTransactionObligationWithRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction obligation with related party.",
        "label": "Related Party Transaction Obligation with Related Party",
        "terseLabel": "Related party transaction obligation with related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r553",
      "r554",
      "r555",
      "r610",
      "r611",
      "r612",
      "r631",
      "r633"
     ]
    },
    "nmra_RepurchaseOfUnvestedEarlyExercisedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "RepurchaseOfUnvestedEarlyExercisedShares",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase of unvested early exercised shares",
        "label": "Repurchase Of Unvested Early Exercised Shares",
        "negatedLabel": "Repurchase of unvested early exercised shares"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ResearchAgreementExpiryDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ResearchAgreementExpiryDate",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research agreement expiry date",
        "label": "Research Agreement Expiry Date",
        "documentation": "Research agreement expiry date."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ResearchAndCollaborationAgreementPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ResearchAndCollaborationAgreementPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and collaboration agreement payments",
        "label": "Research And Collaboration Agreement Payments",
        "documentation": "Research and collaboration agreement payments."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ResearchAndCollaborationAgreementQuarterlyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ResearchAndCollaborationAgreementQuarterlyPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Collaboration Agreement Quarterly Payments",
        "label": "Research And Collaboration Agreement Quarterly Payments",
        "terseLabel": "Research and collaboration agreement quarterly payments"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and collaboration agreement quarterly payments for first two years.",
        "label": "Research And Collaboration Agreement Quarterly Payments For First Two Years",
        "terseLabel": "Research and collaboration agreement quarterly payments for first two year"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and collaboration agreement quarterly payments for third year.",
        "label": "Research And Collaboration Agreement Quarterly Payments For Third Year",
        "terseLabel": "Research and collaboration agreement quarterly payments for third year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r659",
      "r671",
      "r939"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "nmra_ResearchAndDevelopmentPersonnelRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ResearchAndDevelopmentPersonnelRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Personnel Related Costs",
        "documentation": "Research and development personnel related costs.",
        "negatedLabel": "Research and development personnel-related costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r759",
      "r792"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r750",
      "r760",
      "r793"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r757",
      "r767",
      "r800"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r841",
      "r940",
      "r942"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Total cash and cash equivalents and restricted cash",
        "totalLabel": "Total cash and cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r108",
      "r137",
      "r161",
      "r510"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of cash and restricted cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r841"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r833",
      "r841"
     ]
    },
    "nmra_RestrictedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "RestrictedCommonStockMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted common stock.",
        "label": "Restricted Common Stock [Member]",
        "terseLabel": "Restricted Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "verboseLabel": "Restricted Common Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested Restricted Stock Awards",
        "verboseLabel": "Restricted Stock Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r97",
      "r513",
      "r540",
      "r542",
      "r552",
      "r585",
      "r710"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r259",
      "r260",
      "r275",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r403",
      "r407",
      "r408",
      "r417",
      "r419",
      "r420",
      "r422",
      "r425",
      "r453",
      "r454",
      "r537",
      "r539",
      "r557",
      "r977"
     ]
    },
    "nmra_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and uncertainties.",
        "label": "Risks and Uncertainties [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_Rule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "Rule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rule 10b5-1 arr modified.",
        "label": "Rule 10b5-1 Arr Modified [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Common stock sold in initial public offering",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price to public, per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SalesBasedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SalesBasedMilestonesMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestones.",
        "label": "Sales Based Milestones [Member]",
        "terseLabel": "Sales-based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShar"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Outstanding Potentially Dilutive Common Stock Equivalents were Excluded from Computation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Amortized Cost and Fair Value of Cash Equivalents and Marketable Securities by Major Investment Category",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r404"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "nmra_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock reserved for future issuance.",
        "label": "Schedule of common stock reserved for future issuance [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Computation of Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reconciliation of Federal Income Tax Rate and Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r696",
      "r910"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense Recognized",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r919",
      "r920"
     ]
    },
    "nmra_ScheduleOfOrganizationAndLiquidityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ScheduleOfOrganizationAndLiquidityTable",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of organization and liquidity.",
        "label": "Schedule Of Organization And Liquidity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other assets",
        "label": "Schedule of Other Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r608",
      "r609",
      "r612"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Loss Including Significant Segment Expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r99"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r92",
      "r94",
      "r96",
      "r97",
      "r141",
      "r142",
      "r143",
      "r195",
      "r313",
      "r314",
      "r315",
      "r317",
      "r320",
      "r326",
      "r328",
      "r548",
      "r549",
      "r550",
      "r551",
      "r686",
      "r822",
      "r842"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reconciliation of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r695"
     ]
    },
    "nmra_SecondVanderbiltSponsoredResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SecondVanderbiltSponsoredResearchAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Vanderbilt Research Agreement",
        "label": "Second Vanderbilt sponsored research agreement [Member]",
        "documentation": "Second vanderbilt sponsored research agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r670",
      "r678"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r667",
      "r675"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r193",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r205",
      "r206",
      "r207",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r225",
      "r665",
      "r668",
      "r669",
      "r671",
      "r673",
      "r676",
      "r677"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r221",
      "r224",
      "r666",
      "r667",
      "r674"
     ]
    },
    "nmra_SeriesA1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SeriesA1ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 convertible preferred stock.",
        "label": "Series A-1 convertible preferred stock [Member]",
        "terseLabel": "Series A-1",
        "verboseLabel": "Series A-1 Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SeriesA2ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SeriesA2ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 Convertible Preferred Stock.",
        "label": "Series A-2 Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-2 Convertible Preferred Stock",
        "verboseLabel": "Series A-2"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series b convertible preferred stock.",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock",
        "verboseLabel": "Series B"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ServiceConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ServiceConditionsMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service conditions.",
        "label": "Service Conditions [Member]",
        "terseLabel": "Service Conditions"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ServicesAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services agreement.",
        "label": "Services Agreement [Member]",
        "terseLabel": "Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation arrangement by share-based payment award, per share of purchase price of offering period",
        "documentation": "Share-based compensation arrangement by share-based payment award, per share of purchase price of offering period.",
        "terseLabel": "Per share of purchase price of offering period"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award Percentage of Anuual Increase",
        "documentation": "Share-based compensation arrangement by share-based payment award percentage of anuual increase.",
        "terseLabel": "Percentage of annual increase of outstanding shares of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share based compensation granted under plan vested period",
        "verboseLabel": "Share based compensation forfeited under unvested plan",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled, Shares",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled, Weighted Average Grant Date Fair Value Per Share",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period Weighted Average Grant Date Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average. Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited and expired, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Share based compensation forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited and expired, Weighted Average Grant Date Fair Value Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Unvested shares repurchased",
        "verboseLabel": "Granted, Shares",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, Weighted Average Grant Date Fair Value Per Share",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Shares or restricted stock remained outstanding and unvested",
        "periodStartLabel": "Outstanding and unvested, Shares at beginning balance",
        "periodEndLabel": "Outstanding and unvested, Shares at ending balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at beginning balance",
        "periodEndLabel": "Outstanding and unvested, Weighted Average Grant Date Fair Value Per Share at ending balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested, Shares",
        "negatedLabel": "Vested, Shares",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, Weighted Average Grant Date Fair Value Per Share",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Stock options granted, exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMilestonesAchieved",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award milestones achieved.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Milestones Achieved",
        "terseLabel": "Share based payment, milestones achieved"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares of common stock available for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable, Outstanding Stock Options",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Expired, Outstanding Stock Options",
        "negatedLabel": "Expired, Outstanding Stock Options",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Canceled and forfeited, Outstanding Stock Options",
        "verboseLabel": "Stock options, cancelled",
        "negatedLabel": "Canceled and forfeited, Outstanding Stock Options",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Options Grant Date Fair Value",
        "terseLabel": "Grant date fair value",
        "documentation": "Share based compensation arrangement by share based payment award options grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted, outstanding stock options",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Beginning balance, Outstanding Stock Options",
        "periodEndLabel": "Ending balance, Outstanding Stock Options",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted-Average Exercise Price Per Share, Outstanding, beginning of period",
        "periodEndLabel": "Weighted-Average Exercise Price Per Share, Outstanding, end of period",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested, outstanding stock options",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Vested",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "nmra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodIncrementalExpenseResultedInModification",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Options Vested in Period Incremental Expense Resulted in Modification",
        "terseLabel": "Total incremental expense resulted in modification",
        "documentation": "Share based compensation arrangement by share based payment award options vested in period incremental expense resulted in modification."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "terseLabel": "Stock options granted to purchase",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Canceled and forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "nmra_ShareBasedCompensationAwardTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "ShareBasedCompensationAwardTrancheFourMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Based Tranches",
        "label": "Share Based Compensation Award Tranche Four [Member]",
        "documentation": "Share Based Compensation Award Tranche Four."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche Three",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r345",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share based compensation, term of plan",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of unvested stock awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding (Years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Vested",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate grant-date fair value of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Number of options vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Grants vest percentage",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued based on volume weighted average price per share prior to date milestone was met",
        "label": "Shares Issued Based on Volume Weighted Average Price Per Share Prior to Date Milestone Was Met",
        "documentation": "Shares issued based on volume weighted average price per share prior to date milestone was met."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SharesIssuedUponAchievementOfMilestone": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SharesIssuedUponAchievementOfMilestone",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued upon achievement of milestone",
        "label": "Shares issued upon achievement of milestone",
        "documentation": "Shares issued upon achievement of milestone."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodStartLabel": "Balance at Beginning (in Shares)",
        "periodEndLabel": "Balance at Ending (in Shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Reserved For Future Issuance Under The Employee Stock Purchase Plan [Member]",
        "documentation": "Shares reserved for future issuance under the employee stock purchase plan.",
        "terseLabel": "Shares Reserved for Future Issuance Under the Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SharesReservedForFutureIssuanceUnderThePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SharesReservedForFutureIssuanceUnderThePlansMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Reserved for Future Issuance Under the Plans",
        "label": "Shares reserved for future issuance under the plans [Member]",
        "documentation": "Shares reserved for future issuance under the plans."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SharesReservedForIssuanceUnderThePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SharesReservedForIssuanceUnderThePlansMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares reserved for issuance under the plans.",
        "label": "Shares Reserved for Issuance under the Plans [Member]",
        "terseLabel": "Shares Reserved for Issuance Under the Plans"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares reserved for options and restricted stock unitsissued underthe plans.",
        "label": "Shares Reserved For Options And Restricted Stock UnitsIssued UnderThe Plans [Member]",
        "terseLabel": "Shares Reserved for Options and Restricted Stock Units Issued Under the Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r141",
      "r142",
      "r143",
      "r163",
      "r182",
      "r183",
      "r185",
      "r187",
      "r195",
      "r196",
      "r258",
      "r286",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r313",
      "r314",
      "r317",
      "r320",
      "r328",
      "r445",
      "r548",
      "r549",
      "r550",
      "r551",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r584",
      "r605",
      "r627",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r822",
      "r842",
      "r849"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementStockholdersEquityDeficitUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r71",
      "r72",
      "r133",
      "r153",
      "r154",
      "r155",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r194",
      "r259",
      "r260",
      "r275",
      "r329",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r403",
      "r407",
      "r408",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r459",
      "r520",
      "r537",
      "r538",
      "r539",
      "r557",
      "r627"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementStockholdersEquityDeficitUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r194",
      "r454",
      "r500",
      "r546",
      "r568",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r606",
      "r607",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r627",
      "r721"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementStockholdersEquityDeficitUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r194",
      "r226",
      "r454",
      "r500",
      "r546",
      "r568",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r606",
      "r607",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r627",
      "r721"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r752",
      "r762",
      "r795"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued under ESPP",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r97"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeiture of restricted stock subject to repurchase",
        "label": "Forfeiture of restricted stock subject to repurchase",
        "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total",
        "terseLabel": "Forfeiture of restricted stock subject to repurchase",
        "verboseLabel": "Vesting of restricted stock",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r97"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock upon exercise of stock options, shares",
        "verboseLabel": "Exercised, Outstanding Stock Options",
        "negatedLabel": "Exercised, Outstanding Stock Options",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r97",
      "r351"
     ]
    },
    "nmra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares vesting of restricted stock units.",
        "label": "Stock Issued During Period Shares, Vesting Of Restricted Stock Units",
        "terseLabel": "Vesting of restricted stock units, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted common stock",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r97"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r71",
      "r72",
      "r97"
     ]
    },
    "nmra_StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Vesting Of Common Stock Subject To Repurchase",
        "documentation": "Stock issued during period value vesting of common stock subject to repurchase.",
        "terseLabel": "Vesting of common stock subject to repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "nmra_StockPurchaseRightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "StockPurchaseRightMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase right.",
        "label": "Stock Purchase Right [Member]",
        "terseLabel": "Stock Purchase Right"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementOfStockholdersEquityDeficitUnaudited",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodStartLabel": "Balance at Beginning",
        "periodEndLabel": "Balance at Ending",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r87",
      "r586",
      "r602",
      "r628",
      "r629",
      "r710",
      "r728",
      "r844",
      "r867",
      "r926",
      "r977"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity (deficit):",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r162",
      "r312",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r327",
      "r329",
      "r424",
      "r630",
      "r632",
      "r655"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split conversion ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r466"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r466"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r466"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r466"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r466"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r467"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SummaryOfFairValueOfStockOptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SummaryOfFairValueOfStockOptionsTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value of Stock Options",
        "label": "Summary of Fair Value of Stock Options [Table Text Block]",
        "documentation": "Summary of fair value of stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfTaxCreditCarryforwardsTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of NOL and Tax Credit Carryforwards",
        "label": "Summary of Tax Credit Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SupplementalInformationOnTheCompanysOperatingLeasesTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Information on the Company's Operating Leases [Table Text Block]",
        "documentation": "Supplemental information on the company's operating leases.",
        "terseLabel": "Supplemental Information on the Company's Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_SyllableMergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "SyllableMergerAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syllable Merger Agreement",
        "documentation": "Syllable Merger Agreement.",
        "label": "Syllable Merger Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r36"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "verboseLabel": "Convertible preferred stock, shares authorized",
        "terseLabel": "Convertible preferred stock, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible preferred stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodStartLabel": "Balance at Beginning (in Shares)",
        "periodEndLabel": "Balance at Ending (in Shares)",
        "verboseLabel": "Convertible preferred stock, Shares Outstanding",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Summary of Convertible Preferred Stock",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r36"
     ]
    },
    "nmra_TermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TermLoansMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loans",
        "label": "Term Loans [Member]",
        "documentation": "Term Loans."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r930"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "nmra_TradingArrangementOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TradingArrangementOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading arrangement one.",
        "label": "Trading Arrangement One [Member]",
        "terseLabel": "Trading Arrangement One"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_TradingArrangementThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TradingArrangementThreeMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading arrangement three.",
        "label": "Trading Arrangement Three [Member]",
        "terseLabel": "Trading Arrangement Three"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_TradingArrangementTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TradingArrangementTwoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading arrangement two.",
        "label": "Trading Arrangement Two [Member]",
        "terseLabel": "Trading Arrangement Two"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_TrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TrancheFourMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Four [Member]",
        "documentation": "Tranche four.",
        "terseLabel": "Fourth Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Tranche",
        "label": "Tranche One [Member]",
        "documentation": "Tranche one."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_TrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TrancheThreeMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Tranche",
        "label": "Tranche Three [Member]",
        "documentation": "Tranche three."
       }
      }
     },
     "auth_ref": []
    },
    "nmra_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Two [Member]",
        "documentation": "Tranche two.",
        "terseLabel": "Second Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r311",
      "r326",
      "r423",
      "r444",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r521",
      "r699",
      "r700",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r711",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r863",
      "r864",
      "r865",
      "r866",
      "r918",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "nmra_TrdArrModifiedDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TrdArrModifiedDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trd arrangement modified date.",
        "label": "Trd Arr Modified Date",
        "terseLabel": "Modified Date"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "nmra_TwoThousandAndFifteenTsriLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TwoThousandAndFifteenTsriLicenseAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fifteen TSRI license agreement.",
        "label": "Two Thousand And Fifteen TSRI License Agreement [Member]",
        "terseLabel": "2015 TSRI License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_TwoThousandTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_TwoThousandTwentyThreeEmployeeSharePurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TwoThousandTwentyThreeEmployeeSharePurchasePlanMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty three employee share purchase plan.",
        "label": "Two Thousand Twenty Three Employee Share Purchase Plan [Member]",
        "terseLabel": "2023 Employee Share Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_TwoThousandTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "TwoThousandTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Three Equity Incentive Plan [Member]",
        "label": "Two Thousand Twenty Three Equity Incentive Plan [Member]",
        "terseLabel": "2023 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesShorttermDebtSecuritiesMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Short-Term Debt Securities [Member]",
        "terseLabel": "U.S Government and Agency Debt Securities",
        "verboseLabel": "Amortized Cost",
        "documentation": "Debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae) which have maturities of one year or less. Excludes US Treasury securities and debt issued by Government-sponsored Enterprises (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae)."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723",
      "r724",
      "r725",
      "r941"
     ]
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfAmortizedCostAndFairValueOfCashEquivalentsAndMarketableSecuritiesByMajorInvestme",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Securities",
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "nmra_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited interim condensed consolidated financial statements.",
        "label": "Unaudited Interim Condensed Consolidated Financial Statements [Policy Text Block]",
        "terseLabel": "Unaudited Interim Condensed Consolidated Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_UnderwritingDiscountsAndCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "UnderwritingDiscountsAndCommissions",
     "crdr": "debit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts and commissions.",
        "label": "Underwriting Discounts And Commissions",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "nmra_UpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "UpfrontCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront cash payment.",
        "label": "Upfront Cash Payment",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_UpfrontConsiderationTransferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "UpfrontConsiderationTransferredShares",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront consideration transferred shares.",
        "label": "Upfront Consideration Transferred Shares",
        "terseLabel": "Upfront consideration transferred shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r122",
      "r124",
      "r127",
      "r128"
     ]
    },
    "nmra_VanderbiltIprDAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "VanderbiltIprDAssetsMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vanderbilt IPR&amp;D Assets.",
        "label": "Vanderbilt IPR&amp;D Assets [Member]",
        "terseLabel": "Vanderbilt IPR&amp;D Assets"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_VanderbiltLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "VanderbiltLicenseMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureAcquisitionsOfAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vanderbilt License.",
        "label": "Vanderbilt License [Member]",
        "terseLabel": "Vanderbilt License"
       }
      }
     },
     "auth_ref": []
    },
    "nmra_VanderbiltSponsoredResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neumoratx.com/20250331",
     "localname": "VanderbiltSponsoredResearchAgreementMember",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStrategicLicenseAndResearchAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vanderbilt sponsored research agreement.",
        "label": "Vanderbilt Sponsored Research Agreement [Member]",
        "terseLabel": "Vanderbilt Research Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted",
        "verboseLabel": "Weighted-average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r187"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.neumoratx.com/20250331/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.neumoratx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic",
        "verboseLabel": "Weighted-average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r187"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0000950170-25-069311-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-069311-xbrl.zip
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MJ,S;?9?(/4P%68OGE+G5\#YCONX:#^:!;<3FT?QJ"NDN>FO? @8Z72L 9D=
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M@>0(0YFP&U8K%F7^Y-;J&R,#%._!-0$PF12NVX+:^HKL.08'V;:W?SC?X8,
MX$J+,73;D8]H3',B-8PAU$HY"O72"<EWQ2!KRCLC70AD) :TY"('476@-_BH
M4:F,]YB!V8_!-O9G\XH*?)R2'H/L\^_P$\68Z7<NH1DDFP[EKTRPK0,N+I\)
M@/4(0CV:?V*SD\;W5_]T)U>^,MN])+8DINC**:+:_K.//DPFJ**?Z"W<+*=.
M3H4N?#DG *3=J_=YGCQZZVCXY7)Z7JQ-B7Y@7,+B6&'^2)V?_ID0:I_F_!9E
M$/-QFP 0DQ8 #QX*@$$V?@(%I=)DP:^O*C(03&L,I.*?'2*Y0ED9YKAU:QG=
M;*?P"LB:B_6)<Y=9NMGNY;C&+YWA)Q,\UE8*OQ3MU7)62CHG#<>W-0NS+ALM
M %J"454"8'BX70#$I/Z\E,'@"H P8S;%=V-EV'>!7W77X>L+_AL:$Y,,J6PN
M<V9%U>U8Z$Y9(E7AMUCM0OPQ*)A5/#WL:H%!QQ@'G%W Z]?5UK'FHX-'JL4%
M@-?BJ:7,K7.CBO'6+$14\[5?LE7!YH!WTNS/D*$ V"4,;2O@WH',QN_;M3N
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M0I@;,HN,PAN^1='-!, /$ V&ZCAMRFX<Y3)_E)?'/_0IJX1M$AM^+J)X23^
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M@W4865QNJZ-50HU2YUPUZ/ @4>6\;;N=OU;^>GA9X?OYFX03-EBM#XPL]YQ
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MX3KP=DLEOWG'TO8XE6?_X8U\'+8O$^PY#_J#'"TB%48Z.Z\X]14J%,\7=A4
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MPPNG04@_^>O];SSUQ[.!_ZC$A^FV!7[G/S 9UH4AS2^'S-!D^1.(.H<$.#M
M*H)^+Y:!$88JV%%0 P,A"D5?&3&P*9FD+<C,15= Y#7ST=K>I1 <\B1RQ5_#
MW_U>G'?.X;)^DA##>ZC";E9%V^SIHE;92-.U^%33S7O8<+*S._=RRX_J;_/D
MFB2/.%2:Q:56F)8VUB2(8]5KGU:M5)@/H->+\^/49Y,'_XEG>__E32RS^;0
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M'OE04SVBA=R#\Y\3>M7$/?&-(_ [%R@2E)F\$-JANJES 5JTB?F9U7AN2/Z
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MGPLK4Z4_;-@D[HF[D9CP<"YL*,8]-9L+^YIXBPLKMW;EPCZD)D+R<V><DX&
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M%< /Y"D%EAN^Y0CI#R+%E4I^Y;\123K.AK-4V$X.WL8;+0C!YM,>T_38Q?K
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MSC^A<1=QX<*</W%ABQ>K2M0-N;"_K:(XSR$']2YF@'@5?X[4H=27]0.0!L^
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M#"35.C\8RQ> ^OH)J2PPC_\WXE:/-;,C<:)EXJC+:"_Y[(PG:ERWMKXIOON
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ME6[VBK1IH:=7)(DQ^PBK'!DQ\[7J B?RXLSRT-D9\U^O[DS?T@<M/CC%NDZ
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MOEG58"X+E\F0"["!1B/W!=:HDJKCQ[PO-@\O53?C.\DJC5\"%<9[O6A&"$8
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M@Y)>I)]*VV$U_RJB*OLQ)?HO/.T30I!Z?9$-YT^I"2$D PI?^Q'_&8Z&W#G
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M%3\7VCL5)#C0^(]F3L>#FID$:N9WI3,(0.^2P-X!=!V^(,Z!+MYD)ZD(,;E
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M6*CBOU;](H3D,Y+;STQLPN?Q7U= O]_/CMU0!+]Z9L_2[&8@O@54+B!QUA)
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M(D53UL7]!7\N;#:!T!2$__X4UX_@.&*UA) W\<YKL<B(%WC*340'C*^_XSN
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M57W;JQG8!!.(KK!G!3)UO$,;4TT/#-ME.V-,1"\P@OX8E\'(X3EXWC'#BQ[
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M@-_U]61J4S\=>Z&]5LI&EZ$:TA.+MABT]_@Z&D\RB+/=A/$840M69J>6C,-
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M^/,4ECN2-F]-6P#WB[$Q=D/J99\-=K.N,!<X. #+D4XL+RI +M(/XHQ('>5
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M>FS2T._5Y2:ZG*^()=O:SZJ8U9_IL3,?L$E<V,#!VQPJBTGGWPV?2KB3>A;
M]FC+29]W++)]Q?PHB^IH0)]-S=M_-VU.R;*3\ 6*M$+7P)%1$ [XL#0XYUGS
MU44DW.71F\ L6\>BUM)$YJW!/H:+MH8(3J^ZI4Y!3?FK"1N90._(_+,B 8ET
M6Z8?@!!D1/Z;VP)8#2+%>IS("1FF8#1H73-"JRM$TU O@,C6H#8<I 0173XB
MIU&&^VKK]+O:10]UH/Q.'W[7(LVZ\ <3?NA7PR&?PY<+>N4[-A/VJ7U$-"-8
M=@1 GL"3('+H_%I#W? /F?#5E =2CPV,RI9 60"#"F/7<E!#Y6N@'%;1]#6+
M%/79O_I;BR[=PJL04Y/I!A"<JA\2#V'TYU\^,\7 XM[3/Y. GS)X8F.<I_P4
M" X&/,%79ZS%L$;AT>!/+,*CK@C#?<!M@,K82J3;CC0%J;5[7F!7H?$B30^8
M& ^Y !$LQARY;V(I=/BP0JU0NZSGMD0U@3I:^?&AKKO_KC-O]7QGSY(U,:+*
MY=D&QM)IGNH-CDGR>MUD\[L)IP<KB98]5MU5"YK?;F':CSNMJ<S5;3OON\$P
M=BB+;!_(/;Y'@CO((:/:-(.7VO*O&G?K.%9&!J/@A?CO3,M-^M[(-&2EO1,5
MCYXG;)SK@M+*+8@II,,+!;#K-PD;"CT4UE3DCLC.EP@(XD%IZ[%D>!?B /YZ
M?QSA*,6+\&@(IP\4L=Q=<3:CZR>!7'9(QZPGX,'(\ON99S(H/V1X J!WNFI=
M6PJ'-V9TB83X^!2@>Z9%+7RUO:L;6H:"$<Q=UL,:&UE<62?SEJ8A;<MS7R:O
M#06K&<YC5/B&8,_-^JJ6BJ8:[.>= JA33Q]BGI]^ZJN0*!\[,.",KS!LSETR
M5/RP21+!<,XNATH]N9=M:C1:/9G(%#$R&RF=?SU\VT>SZ>Y>_]7/"K49O??"
MDB^,.;;"%VS8$/^%XL[CYU@[)J4]0(1W$A 3P(0M&)Z)LQJ'QG&ZP!.Z% @#
M_!<Z#??&V-;)28V1X:) "O/^H]+%AF9.PNU/H_<:FY4G;@<C:]QHET92[V]E
MP+VH>A^]3<5BWE54V$7.VJ:YWSJAJ&MY]WUFD6OH%W-E<X,^6EYEM0=%?];S
MV O-HP:>ENE]0T56]H%'<8U[/Z+L"[X5C=Z[,\RG8X[UG".HD<QUT+9.X#QB
M)AM//@?2X!4A;^ TY64_-9[U+/['21KN2NW@B?3W;5U,GRCUSTV*[/W30Y9U
M/@V#J_+L6_'%]$6.U&%WK5#YSW^H2C4DOABE)=)I9!Y$^5M;*)6$M37NH44"
MW% ('"'\0Z-%EJ?)?EKRDN<(A# +PQ5PQ]GI6:C9MV6JO!.S2-%E:>0_006
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M0RWJ/N*;I+T ]AJ"\Z]^M@&UH"S>)]<!&7#ZO:CPFQ!>]8:@A!2E)H2?K">
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MRC>=60=^0O(DB.;LD"@R]"43B+<50SC37/IT/P0UQSCHC.[JJN$U?W7O+[E
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MFI56Y5-'M6O=VA.Y[2P-KB2"?X0T)YK4)("\2Q/#@F$X(8!(8#184'O K H
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M+("P6*;<FQ8"B"-H\W-!$3?/H)0EJB9P'*$""$P V<J"\AVB!)"5-%'<9XH
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M2\8X)?S/L-GYM-.B8LNYN'4UIF*[HZQD2Y/WCXDEB:9QK6B7Z_71W3*KN$,
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M=+:A:2=P*O*HR?D*I:&2'/,PE9'TY',2L97EJ&:D?$L>"-#/>/G6B.[#G11
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MN1FXCS=R*,"Z:ST&_!Z*@S@#U]@K,[<+G3L :Z:6!6SJU<QZ_8NEZ093.=3
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MX"5]W9@WRH'*>[ J_M6H1;8[%;3[ U4VK5-Z7=>94Q<:IUH.!;;1^"V%GV0
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MYM*2<'95'U2%ODF6Q6M)"&7W:C%BKGA"0W7DX,M*O_'(D,4Y2-PEKA$?R[Z
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MTEB9M9S%5(\-7#;+9#CSLJ]V1H56"7!*Y&^O1!80?",W+W4G0/T<:8A.TA$
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ME>9[]D"-FD_-?N/L8Z0@9 AITS9$":8JGA9,'8_2F"OA## <NTT')"8'YF5
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MA8G5KMQ<=BV?*7:']0(/2XS&AA<>MULW]D0V7X249=W\Z%#]2/G?",I56DV
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MG[L##_"X..,U,\ *3@ ?JFYZ-J:OV6'OSN(]J@'B3)<];QH?_&[IC0M/UIU
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M:GGE';"KX6 ;6JQCEY<[/-2AV#9=FZCS#;-UH^3KC&$>4U$;71D4IUUC;!*
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MX^<$AS5W(<)HC^M->@>/,O$>V2_>O9;SR.WO[W_M3QH+\_BYU6#K[]C:,=:
MG)ZU8VUMW=]JK^J7T:!(&IO9749<SY"Q);]!?<KU\GB8T>0YC#!R/3".5\&G
M+=6_OY568;]3^?Q=NG79Q2*<<5%>@8:CKYVD5?-U+>M](96B9M@_*D6)H/_;
MH?ZY4X('^F^V$CNIQ@/Q0':/PQX'162323]E&E"' G >:'70CE#,W>8G(F(P
M>RJ#:^A=RQ$K#"A*W+&]_FO):J>&C\<X'N@C#Q0U4\!"P^L'N=4%,BX'%E@*
M!?L/^, 4-KG/3Q'^"TT\D-X8]SZ6<7/^)W1[.IT[*,QZS0.-C2P&<F)YH.=>
M6-3V@3I?+K>YDGQ'ACT 5^[>FSZ>37\_Y3]10W+X5@CQ*XH:R<D'%X1R15VQ
M"Y:+$4>A>A\60P8WVNL.+:GTPDW.JN7DCG-OI&8.J7ZE@L0^A+[' 6C4QA$>
MR/+CH1P/1/^;?9;/D-3.\YQRTD('F $C3NU_V*=./.6J(;#U6-QLK)P<@&*D
MTM> 0(>-QC0; K+/?C4$;49Q-RGR(M^_?[=C5#=B9E TY6W@C\G 8#>L$9PI
M3/S5D-4<RS+A@<@\T"*,!S+;BPSG/P5TPQ?#MBI+]7MQ5!P-'A=Z6<=^_04;
MPF>Z]I!W'_] H!18[DZ#B9M<V2F*[FC<VA=-^YWAT/?74!6F+\OKK$J5DTZT
MQ:U:V34&&7Y-K7XC;O=H(O/0\&%>_MRV1IN5B<OPZ)>KP^U>&J;78"+V5CW.
M%0JC$/P55D/%2'NX)YO96:VI5$!3ID#X&B#[JR%6TQ_N&J:/2IDVK$R@J0*H
M[//^<Z1^NHTC]B$'FJ"[JHN51I-M#;<=3T\!RK2Y^)#P,)]BT]HTI9>EB$[)
M82TE4L'?C;F<OXQ/T43$:=O1[ L+X!/3#?@XMACMR1&R'+CA83*+JAQ77VDK
M:=WT*/6J[]TX\J<YO<L]IT^75 4TWV)*;H#Y_/KUU__/%O([SXW^VKR5+],Q
M9AQ&MU&/A$ACO)A5C8])W1!QC[^"_)\HALD@U66@8H 7<?,""7X"'?6%8INS
M)6PS<#,P)R6OXX ;[7(T(M?L2J5%OIQHOKBPI-!EA/G'_DQK.]5.UW+RY=CP
M1-LV@ZM$EV>U0BVZ)\SO^=T8^WQYQ*';^DI(LKRDJD7.F[20W#<KAG56JE;E
MU7X"!MA,'/N,/A=VR/K& ]61.678O5" 2JHC 8I@]BE+5@"@R#>LI!XX59^F
M'].I$_65!SIEK%L$K'LDT>\F^/+SA##[<DQW3E ^L00 _X_QJ#:;>R8(27&N
MFU9JH><2C!S'"GK4*_2>57E\?[%:(_9-FU4Q'#H;R15J.;3\[M[SQC#N)0';
M=;WS$L*0\.R#I@ KMYP[+'>QKK,NS[%2ZG[0W:QS__-3E/WWSQ_P-1'OE5.+
M2!K#X+Y<BM5PRF/C/;_C5S_=PMNE)1L4C2S=#_KH_67(;NW[SRB1_DO-[8.&
MO;<1#D0-+<610J$:AUA%]\:+#A7]"HM?,J_VGJX+ML^KVAB,PP9  272QK7#
MO]&06PQ4-VZJG_:D/=L]C).:O@@30!M1\H\#SVA6VQI$S0NC&%TZYXAU_6A0
MV<ARNV%>8W9Y'HSB\CB/D-E;5QA8,ZV@RXT@G1C$D1;R^7[$'B:,J$%G6O(I
MY2Z<F@,YBGS,?19</HF84_G*UEVL,+Y !T UC\8<^.5S$B-]T)M9B;#4GY"3
M80ILO8P4+-#LZ<"6]V!?Q;,E6NF1,$"5N)D4AC0>GW">E]G+34+F1LB=VUR)
MF[=-.[>0H^=V,4=5XD[JC2EO?2>_?SY(4YXAQX@.,M&5!HZ%QMK9"M^^%?W,
M-%"I@&?:Z4JGN1NIXWTK<9<F,0I7/O>)6>2==S*^C:LO/3:2L2@5Z1K27/IY
M]5,:Z[Y+L)V53BYTI)/T+Q10<=EP^;53G-/$=]2FEYA?.@XA[,!A#)AI1&_,
M8_337!(:P,<\ TU/,<!D6:@#[CK#M&Y1Q(8B:;B%6YA5FJ:D$9/8OF$5:\XL
MYU9N,?T,L@5"O8';_PE7^;7;K7%EH^]0'-! 3[.2@.)B0&F.>0<NAKY[;*MA
M7A;=NGF[.:"*?7EA5EIF(.266UF37CKRM#L50%GEN\+AX_6Y%OKJM"4IMH7@
M*0.?!T/=$P0QWS\6#;[H8P:G>D4W&XN^Y83?:DQ<&66*NL0.7'J1:B1C+"<N
MXG1;[:-=IJ%#[9(WU4DB[59&AG1&D.K<<*#*#\C4KV8#AS)1_Y%$,?H+6!#F
M-("ERV)OU-=S9X'*1>)1P+\'+-[N2S#_9AM2M2ZG-J;3EG=]7#7L6-0L'L#>
MR*)0<H1K;"7_KON,4WZ'">$\YX'X49T*_7 PP;<C2:3?3,^ALRW&[^4,A1UK
MER]<-57]6N;8:N/E0N[4'-X(,C:CY=VE;#;=';0?:I"Q>3Z\Q:*::>;M[37T
M+>AWXP##&%;DT#9QDRO.[2=)8B+]4!DUH\;!BV+'V)>E8Y-.3']#>DE/T&/'
M'^%"7RBVUY[3RO_BW]I<T] 2B]AA*S+5N:))G*IVY_U6>!=N:GH!3QD?6VZO
M&59D:DZD=*JCL^ULKQ]!E,GJ>8A8TK@I3^C",A_MEZGT0_(^U6EC5:2C+VXI
M]N.9V:\?FZ,[X"B5,?RM_H)IYV[R:?O[^[7E:^:$C:*6H#N951%.Z/382_5R
MI\4+W9-]-[B$^ ^C%7:W;+*S=HJEM6T#IG.79YLB"Q*Q]6#*-E^XNHRA*"@8
M#?G0>;$YMQM>I]QWHP$5+Z?4W'*WLV/$&%HUA6ZBS>&KK4JJ4X_BR]$/@X3@
MXE.(^=M-J0=/8+"&#(]WUO-K3B5K68;+V67K[IX\4."([A/30<>1:DS%VT/S
MU$*4[&P)U[;[P8S9BL? ^7Q'IKE.9*.-]%4_\+?%0VNV)3#%C%R,QW&5N$/!
M:T/LN\S.0CPZIC?&@Y'9]+3A:-K^]>%<L]?MFOXEWQ]1_4JXYZ1U#GR2_GZ*
MVOVHL2>O..VMN]1W0&2K\D!I7HQI;C=8$+MFA'?!2I"MXQS4JK6)&^_(A!O(
M<Q_-1+_1-XB2^JJ6YB6-+B.?%J1?H*NX><=&\<]8P.,,5:?AT+=KOO+'OA@/
MWRJO*+<H([HJ?MXD_JS$>#+_FF^<9TMX.//][O8B?IAMQ(QA=0UWRB"YRF.*
M\39-#']R2Y3R%"!X8T1CUCW2Y.(@V?1(=/^-$7Q[*S) NM?$##[NV8DG0 ]4
M,8J<%)(?^*FI3!VC@ SCHX$O6#K(JSD:B*@C#'8KX=#0O4]SO(6N>?W3CV[3
MBZ/^J;V]1GD.WF.ZFA:K&E7#]#6GAG\MV?>Q70_XDO=R7HX+COI*XMLN)/8I
M5I1MPS1;@/7D(3V!@L4I8_#=.04FA#PO@Q0N1^?29;<3C;6+)\OJQ)Y"4#[C
M&!>Q%,TJ71'Q_S7EK\.8<96ELTJ9X=5LO\/+V*Y'I(4B;-U?AA9\J1=V'UF,
M?ZJ35V.^0,))>P"32>8U.%N;2-1YZEP 23QHL;XQFFI[98CM'UP\Y>VAL&+5
MG+CBT#AJ=+G9L&5<\(B#>O=(BN$9^>,TD^)87UVI4LG_<IPN?%HHOF6N4K*H
M4+*]O/0Z1?3<@+:AP?+1^O7;P?85,+GRWI)2VR_%81?7/EH[!H:\2W7T-PC1
M/]=KGVAS<,B_:+G8+@62_^"T)+]&C8CQ6,'V(PLD*O8Z8[F%+A8[9\+PC]^%
M' WD*C"?9=P,S,H78C9L%830",K=[OHI=T8DR36!G7H%]O$?:M>;3)6'3YRV
M+)\.Q!: &=<'?VW5. -FG00&%O,B%YMBV;HT;#0/=-943E:Y._]4 U!3B#SX
M$K\X(.,0X\2(3UCYBE$W)=$(SG0R&7(*[;UFXW7/\YI8\I_M]:3FQII1C9(>
MX#@/)&B#.<V4'2O+/+P1]47.&/#B/D6>Z-0"?.@I$'I62DB5PJ.DB(@(&@%I
M!V )0+AY<_;FC^GIU0-<:IBZA(>,JFCQ\DR@'@\T-/]K"[0UYCBG@OV;#].,
M]03(HQ4D<(5(?)%#!&C/F#TI\Y3,A-:Q+6D#SM-V3,@S79]O_ZU8,O5P)6O1
MLG6YET^\_(\K>C%BW.MIY;^]/M/DB4<.57E^MM]'$<[X6R/Q[1F+@I%6>D5$
M(X[WZ6P1?X/2$]-:/3V^[X?:2N.#*=;O7.S0R;KNEPD.L[FE:B]K'Z0EEVS:
M5ONS>CG%H:@I,,L;F#^T1#[*RLF "F$$WR$/[%*P4:U>!<\Q'@^_!G0*,GIZ
MB\P:,J*4F?D5;P',3)?(V"B<>JUJ8_M^K%XZ-C]^P^=0&Q/ G^</W-G6=O@I
M8SC]W!UF9U,UQI53R-6Z5J:Y#J H<8]RD$%JLR]#;>6V7=N"H%U@L?IKT@&=
MLHUI _=T$&P36D5H _<=OU*6L9)P-(I[?(2V*3ULPN*; 2@"%9=_:DQF, >L
MUMM/!HMC(L_G>_ZE.!X&_6-U*$+RMT*X]J::Z5#0;^!/@VQQ0:Y01,6O?8*Z
MI&13A:^F@@"*SFIA^EHS[B;(%1/1)$=&%5=BN%TSG&[$L?C4C3C0JY%E>RNV
MC^N\WH[Z^L*D$KC?_U^XQVOR 1L:1X2I]-+?WTRNV5O^_O7A \_W,;'W\RR*
M6CS?.08ZVS^(#LXL*AADWM<7]GA>.W/4S]EQITKQ*OWRY>1 *[M2<_M'&0@+
M)P6\=&B \IDE ?O*Y,(!)=)7RP7]#=U#1>Z J?![AG(7#_3OO&B[08F;N?0,
M?!9 V4VTVQ"\A#6OD%<<)MBPZFOER)S.XG+S$L0.?##\\:HQZZ-*@E Y.+^
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M*S4C/8<QEPO7O14GM@M'="!B",/4%D*@B\QGZ:CTDJD!;/F\G;R5PB6JV_1
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M@$\=#_.TP-W7IQ]W#7L*YR-F%T,N9[\N'T8R?6E#=>7#R=.$6D1OD>\&1JP
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M%%:(KHC]ZB39^%M0 OX >"$Z>A]@SH?V2$_RA43$=55822D7NF/>,E"#CHH
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M_<,CU&/F\<-K,P58M@P$_\+>>#$A_8]:*RD<^W6*A3T'=/&VBMQ8\%^UKD6
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MT\M!X+=*Y8'8JYI(9%,5HPND$AECV-'L49-I[FKH-GF0T)T29M=/&[>-1J'
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M4J1I^X0_=RG.=OLW_Q#\@4AM,\[R*^SA_SUG08=L'Z*P>8^<0TBAE0_WU5>
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MV.\QH@K*KU7Z(W#!-^!V' ,"))#MK :>^"7>BSF/@XI/"L\#J4@T/^KO^7H
MT3E8+M3[O&@0GG6,DF_7-"+<P;$/M":U/9M)%1_0%5UI5V*YKP:*XZL_4T_?
M0?)KC<Z@PT^DJ[@J'J25/B4X2 ^G!8\T^)WI^5EVFTEB!F9W'MIYHTZO!45N
MVO:TR[UT_?EHUW^XZZ_[SR3W$X[-.A65!PT5G^GV[=-_]LN,C0 .YPL/Y+?3
MW>@%UHNQ;-4^ E)VS89#5!/Z\$:KK_E?3?'^ K XRD_O$/7X+X["R4TE'VQ]
M_>X<?_85.4Q,PLJT'1+^P9WPE07LN<L?*#+"PSLZ)]O9B"3,_L^6\NQWX66)
M4PR[?QI@LL&;MY^K=^7Q\]Y8]H7469J.\4XK))KXSJ=PMVH'/,D[*O^T-KO%
MM=KE=?;/G&^ZI^=/ GOVRC8]:?<[2:@V2^IT?,%8G-2^LC!"_/__G<5/X)R;
ML"TRF9UB&3\\VH_W<%ZE-3VI&Y<*:U1.UJ(M_@S(F!+\R5/<2"%+6]8-X"T]
M#9(#>*=]N8KDVYLT>$*8&_W/-V%F3FTT2]P24KP;S\.*%1!"^5)^%Y"J)H$$
MM,5/8U/1ZJ^F4I<7?QEO%<9R2H0FM!T<"?LIFPO$#EIT61G1#&MJ&!/'2Z.1
M>TLVW'0CD 0)I! !&&^P3_B@.OEMP,*#8U7'D]G$1)9TQ(T\B\PCWRR=7X>V
MG>)99O5?\'Q^!QXO//+&^M"[=]*5WL8=GTY+,=M2M9 R6;/_?%W2Z2C96Y0W
M[[P1&-B"75)@V=UGT;Z>2=>+/G"WQYT</$KX9RR><;ULA/VQP:WQ0$-T]&S(
MI 324"!6PDXO(-3GS9.6G 5&PE/YCL$1F;LPU!9<QF)$5OYO>B3H4]9^LC5;
MY.SHCEQS"W-BLF]GWIF3V[P@JRY+_3DU3&D)$6M3IA=PCS:[B5W$\4!^5B/)
M9DTV^L.4)@ E^/;DS6_>?LNVQVSTEAPDO;]?%6D4FN=[FA?!>'AT@LDT2R*=
M/C%N$[F?,LL.OG#V$[2DKR5RQIXR&Q% +[WK;!?:%-X8AWZ@DL4F!];;5XYV
M]+]V%ZMT.;\/#L^9.+9A8Q!XJ[;-!$!((#NIF$F6$@84PD 5FYH*J[//3VH[
MCE+N0.R+4#V'[,4>)) *[55['N[$<<X9,-V;W@"R53?:J]K]J\XK"DT?IHMJ
MW&U.>$U-7JBR+*;_'[XZ\QDKW <"FC7W(C]']#=&!KV7)]65*1<$;<C\ -X"
M*I9M^+1-':CV'EXCRJ/>7^8^D683MP$#[?M8WIZ3J!F'4;1AP LO5&*<J4RZ
MUP5>,)FV#E@2K#L9L\E8:VS(,I/.=Q*E6AZN1E7/;'0O[T'=WH WO"MTX.[%
M57HLP.0MX9B"RS_?^I6BHMM-\V$,FF_HR7'5,-CU47E;[E<S=[>C;O2(@=#*
MGZ%#78$3YZU5W;=7M8^F>W04FR3<S^&4C6@JD'("%,K*&H*G!%X][5RB]$VC
M_D,YU0[&6A>*;4GE&=?Q#J5/?*[:MQX^ R\PB@]QS)T)_2(&%S5'<1G0AHF4
M#+^ MM@KU\,2)Q6(N['31:QZ.,BM_%E?JJ>U%ID\.4]N[U-T*/=]9\%4(4??
MOSU?A<!*^+F\3CP$Y'=K1GBU/K#Y3 JMMK@1^86P8Y"?7C%HF;=B>X?M[@(=
MR%QL!NW>LI5:(9Z$-=&3Q KB3P7*'4MR[*8N.?7SE9[HLSS$7P2RZTNA-F#&
M'DD#\%V^1KQ/A3%LF$+(?<\?)P>J0Y6)Q#D$L\VD]0VW]W'-VG.35IG.^]@[
MH[U=!XN8^7)//L[[W?HVD)QN:>Z]QM)[D>NE&;CLH*.EW>^8G5;DA!QBZT'E
M5CF\7YIJ$2YGWQ@14I'C8YG&)_H^.]B3!"T/PAV?</"*VI?[NK$[$-R(Y<XS
MEF:"4+0R4!P0*EL#E<<&$BSL1J;.&+BNRQT0PGB]J6$&ZZJI58<( 87B_<1]
MP$4[K]BPS+"=N=N;]L='*V1)(+[2@IOH<X K"!8\+F*)Q+/S> ??UBXX+30
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M<C/VUI9 3(GC@1P"47B *I91U'J*.6L=$\.F/$:H69T6&@//H]G5'@8%V#U
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MG]X)99R\N&_D*[<WTZ\1U]F2F!->UO-\9U/T"R!K_O>KGPO_???,DL7?>DW
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MQ3*NH)D_BLHI/]/!&Y5  %=$*HP;MB',1S+,Q'V&B1+(^JF4$E7Q)8"Z*91
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MNOLFIP7#8BYR^5SV3W$> ,U+VR^@?%B$]1$>II<S5DF?>*D >TPA3O]V3CJ
M['S6F )IR(:/$5T(IU>?S*"]C"91W-'*=:VSKM:/]NR*T]<%!:*R(_1XH'L#
MZ@&GNJ_;3' U(P8HI\BV= 'WL-9J>*]D2.SP2TQ(Q3S\]J.6Y@E.V))*ZFGT
M$)?NM&#Q K+0JOEJSM)?_TZZJ]4W+ A*7.E )>*89CSYCGK8Q7Z67X^Y".07
M<^P (7JX7Z_G& ?+7);V#$:==@VO<%R8=FC,MG+BG&?<]+S\P;?&$8BU>)02
M%B"^_^=!'G2)#&5:+:9PSXQ"L**8!^,1(("^-G:1+AB[*#;VPTS7L/QX=JF[
M3^WJ@F9"!UFNQKL6[CZ'H&J5RW%3*Y#PF>]ST%C-/@\?\HV-P@:^&X_=;6S%
MW:.?F5N1Q ZJY!>O89ML,CP4;U!7FX:NPS+G8+MU0Q>['MGV?IDS,M7H?,#\
M%&^;(G6V:$/9ULRXF 7+4["'B&Q[B>H&EM".9Q3SI!^*' :T^&F?VX58&HG8
M!]N)[EKC9!1^U8%:DLY,I'_>.Q&'@3*D3>:*_P%0-X$7GDB:WO#O \$^Z7VE
M;D#%0*^6@W.7LXM/2U_L3FYN_D,+#L_)O%2.&./J';S!+A6"CVJJZ=E-$A?Y
M,'[ "]KV\T5A_8NR:T*KU"76<N4AZ"0N^LLD,>Y+S/5*M'7O,YXK161//S'H
M33\$"5M@^KS*UIX,'_S-I6*9/(_]*7$)V@46-6*:TFMR6>L,]W):_M-9&CN5
M.?6!8TRSE.JYOAJ@$$LB2*%+-CZA P0%'=>RQ1IUDV,RL57KTU=F79V-BW\;
MU(0/'((X9V/9?[+Z-HWWT1@H4.U?XC['N7J0JV]3S O*2 8_X+XV G29-S5/
MMDL!X>I;\D:!=$M4KY88E9K\??AXYK_KNGD5[A+GL%Y'X-+Z1=>R DIW@V]6
MG.ON2JO:/E72]N6\]2+;O1]F956<DY2?!M?.H06TZ!NE&<7,:U0/")]_X!%5
ML7:WI B6GH13+>7#MK"WA4Y"!#VEAOASK.!C<,Z%YJ5PTQX<TTI%^EG_%)L^
M2\O>%&)V]4EV-[RS5A73#>9&,A9C1MU\8$:(0&E2^MKBV:!6Q966G,[C$RC-
M?<_6L-S$,*G%#SA "T<C;#2SQKZS:P /UOI2[/O%Q 6-T>IV<?3W]U<Y]H#-
M$C8NAT2(68"+ V%]J,)%-*&SA9QCG^]1/KP$:2=:PBZ3FZ>J'S6\F_?%/EF<
M7MG48Y[HA)*T-PY8@>QGK(_I+F@4O>]E<.JI.9^GHV\(F@(FRQ?]?VURX.CR
MDSTZ[V,HPA)HR*1;&HXM>WB&A.%O^D:D.UGH7\/FQ;[DX3\,VR%Q"$*I^%HX
M,3^VF';#HY]53\;4T^8=(93H]BL8Q>F2,!?*QB;L<MO+[<Z"&V-J[=.%R"F5
M<.U8TKH>,MXWO5M&JG7<%ZASTG]JF=*_:L=V_,]R^NUV@(YI3MZT:KJE NQ<
MJ0TA!O)@@6V@+O>R'TA7'5898?\,-D<*)+1![*]DJSG# A(MW6"5DL3T^KQ5
M2Q5JWY[0(:B+3+D/WKM*^<3+B$*Y2XV'H*N:V/_A)(0UO?%K1>\D+_P#,8%,
M]U>$=8K43NJ+=M6F!$72=NRBQ+GUKIRLV/)$N9;6F,5N"Z1V-&1>R=.)]FYR
M _)W6.T%BY#2U9 ?2J6"J;R!L\A\$K+Q@=E("TDQE.'V+6B!)=OUU_?LMF,U
ML1) H-5D=;L41PMG5Y=V"N.ZH#KA&[0/%U_7A;1]#&F7><=\/D5$!$?'!U<_
M&@S:;]-:Z2U].;3FX!AL#3[?'/!A<#KYAD]Z1H7V?_\2(CSE<QK59AWVG&=P
MIVTZ!R36/6V+WPY*C#LB)LLV@ZU$8.R4RME7/>;JG#4E,\(8_!3G%*^--]&X
M[I6NA>. -B_[S[($DXB#SRQ%OD8( Z'[5]86%,;)UB5KXD^O(Q3NC.Z$)=N/
MNX_ONEW;&[(0O&1P:_KN^-8F57'+5_[V(<A,A;--68J!OAM.@3[&SFIW8:4X
M'J5KV93C/ 99%$<<@L3T0QG69ZF+:\XAR8;R7_?:8B@T,"C9*JQLJ)9NX."2
M,]MK>-FB',+OR-$N=B^-*_)BR20C>.I2*'!^X=R-"W>NK)^W%;\Q#BO?5#](
M*B6JKZ@T&RN1O*GJXFT[KM=?6U_ON->KWY#B=FKJ"7[C<7LM'](Y6?G)CX<Z
MYD(A:0&VYE/D!,5"\L-5P2XXH)C-$=M_CV5:@U/@S$)]^+X>QIBU10E9\I7J
MVP/':2Z*H,.ZVJ6F-2W#=]4,.RW,"(]WU8SMP6>_&EX<A2A1ZC];. 659'V"
MZZ>YN$3D<OLHQ*SX?7C$QU_M16@( A$_.NW!HIR+9]K\:;ZW=B%F'.WJF86%
MKQ'R(T638\-6;CX#9BSYS$I'1 MM;"=[:N>K6K"39K*\1>]X-?8L=(EA#2@<
M@N(.0=ZXE^["!Q7M(M[9DHO=V)D^RZD-[A]?G_)K4F/CVD\L_,Q9**IT<HG4
MIJ*X$NM/7-<+.Z?X'9J9??$8KW(WMWGKM]Y[08LI6.9?6$ U-9KR@-_-FOWX
MH/B/UD3V4Y9I/(KLPAOB<3GRZ67KSQ8[*:)K4WOA)>\@U8)F"=_M6"=>0.*(
MGS0\4_\<)Y!-WR(OK2T/WYE6([VAC;47GK<"2Z>-]WCNY-5.>#VV@^@,!=K
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M$.1G';,GL,-+F1@A)HJ1H?4LG)#2?A)]".II@<>2!@PB4$0CS87?R*S?6^Y
MA3!70R#%V?;.J3$]6V^+J>Z(K';5<:*T/7MA"%M'3U*[XS7Q_;&JIXN  _])
MJWOCN'IB*>Q<CEE3KWEEI*_S]<BDYK_IN&6.0')1-M;[;XG5+H&4HI1*V-E*
M.4M[LM)H.9^5I5*_>D).PE30FE)7SM7T5/Y?1>1XW6 ,Y_4L# )_D1T0,09E
M%FL.OW3&=NLA#62Y(CO0<Y2&;>XE5T#+S=1F_QG'' CW+_DIQCTU5MW>I[PV
M,I"J>[PN,$#]$ 3&TL^A]OX[P?4I/01E)&/O+\BRK&/TP27M]?1%H:^&8F.R
MC\P@<*&UO8CXDJ)BX?EK!NQ2?Z1/54-#H[9JM>(E_M#E/TQ%DBC)AZ &+$<\
MD'WLX U'M&864&%8);(.0?08/&TP"'W]SX."7>AIS)UQ-;+Q >XW;P=#659U
M22GT.='MFH&I37U3.R)8[:%M2G^?_;Y&S&[BNL9&(DY#[6/]EKFC:DNP] UM
MB5L%8M&WNPH"\O+6S*.HKF,9>*7^_FT7&79@^I.B2OBU(<1HLD_"M4I8C9ZH
MN9U!_@W8RVAE]&LELUM7HAY:Y2_D:&WQ.L[M!!O^CF6Z.5\2T5=PG&5/8&F;
M3$ 17R..("(,1S!Z@K$DL*CW%0POZT?)[_?E>,5ND>!"SMYB@8@K[NA"T<G@
MQ'T#60MKTKJV_ZR+NR9\_0@"@?! ^GIX^/[O6L$"^/S\XJO_IU;PN]E9%Y?.
M\E^U@N-%KG3'7[ I+%2N> X=TN,*; (.(:PN+M];YGA/P<6FIFD'&C0F0A$3
MQ+I,K7).(814KCWQ3@.@IA/;NS?]5US@5/1W.C@6<SLXW-PB;ALBK:MW?LHE
M'R9/V/D3P-%7F">ZX'$1^BG'FM,[#(^S4(E%#>B/'YYPI48@ I[WT?;+'_!.
MSO^9C%9_>?O/59O (X8^S_3A]K:]]]_ES7TKBH%E5&5#G+]_R1PSDY^4L/@K
M;;FN8:"7^4/0*@O^YM&%A S_&WTG>[=<B5>(/^GI?C"?:P28=GJ G[COU\6?
MP]R)D7E>0/Y%66INO\:TC.8)3_P.-(Y"(L1&G.9'QJ9W-0%>S$;8*%<*2.'*
MOT2H[^2K#W<8GISBF/RP9_756#Y6F 2;IW9K!R*Z#N21G!GLT@OJ8A?/8QVS
M!(P8ULD%D)&@Q$0#%7I)(VTPD'Z\)>L?="0]IFUI$VD\KK8R24K5&OO1W9(
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M9>G?0]".(^4ABG,#*H7=DT'^0J>7%WC!?IM[,F(,5R?8@7JQ\ ?PBB>R[%<
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M%"TGWA'AGZ1%')Y"KW8OVWDXB"KJV):4W[S%)W07EM$NBI]-;]U(FY$=Z _
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MTBH6D3WNHKA[X\+VEM<MR/63FOE>9F/!2#"=0,_F2/TJA_ 7$QR'(N*.<R!
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MM-S2JLH^4S)3 A(N3FY(Y^/D\LS??Q$]<*+#YL]]%6]L_?0&B\=S,89\[6U
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MYLE_+0)G1!B3$OD@2<YQ-@EP(<F$"U^@0::0X*#:#C,,?4P4\32:>T'A#,*
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MN8ET9VB)SMFS#"IAXGO$S,*H!EQ"G5;;;H9YE#1R3BZ1//WF1EV9>I?2L;Q
ML@WU<7QQZL3EH-G!R\U6ESU?6ADIW$Q_>^5=R$&1?*=*=<19K3M.U3?BYU6Q
MCNF,W**N&C2A!/-NKF1Y4_$3E]%=75V=@",F)!"[\S+RN@SRGSSY^TUP$ P6
M+-,/#PZ&'ZNZY-%[3/%NOZABJ$5J<ET=B#,G,) 0.P26186 /[XADUJ@K]&G
M.";,L11DZ)("B!9$+1C8/H5HZU^0,1-G)B6?8T60F]"]"V*LFO*8VA'\UQZY
M("^S'Q:\4;6S/\8B#V]FI [MN9N'?L";Z#]U2T7V3&3<F4JZ\B7+1+%:<KJ
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MAV,Q[4!AN#QC=K)C/DS,-X;L9LDA+9G;Z2%SP1]:)66\7S 3MQF@KLG/R6D
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M#?)4@+E]'>3U-BZ:IPJ0G*:1EDO00X@<FTFD-3-G<$%])B(4NR:S&\^.]!]
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M317Y__S.FU!@/J1M?F>.D"$=R -\4/P1=AY3S/L\<[J\!NCO1YU AE/#.P]
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M<JL6NMV9AAO&?-"A54!I_\"OFB1\4((Q(RLU5DGPX24?=-25HXAB-N^2A(+
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M"(6DHK)G54!&A,C)H5"M7+5(AMT)H.T/R<?$=\_7#"9D(@\<,CQUBMR#X":
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M>7(8/?J4:AVNFL3.)N(DF.K@7EQ-D5=N&.LL7;.MM^D B:^H]7DV1GOWH#?
MVY2'QNSUS;=Q3:I72&[\\V*0KT^2J(G?30STJZKU^WKESC059ZCS\,CXF&G@
M( ?1Z6S:0R9(^%S=% .!)CIQ*;FU':^N/N 4%E-"ZIO^;)$HW9;S*E11??DN
M;OT_][1VP< ^#J(<V; \RC.)CX1VX#QI$ZR3@=_1"<DG6T><RH9PFB^'R?A,
M>+Y)KDK0G!V7I;%IAF/*S+?5I"1!S.NZZ/R,B?E'EAOD'K3FTH*_QTM_&R:
M60JH.LM([TM)P:=O?/X\N%'77;)5B9SG("P80O6%BW6A YLG%@-B5&3+&#[3
MGZ8W_-S=7  \:NG8/ZK$"=3^6LO"W#=(\$< @]ZA1D7RN8I[1&JIT]K:C'(-
M2X3I>B&!)]W$^4,J.B_W7I%[[H4Z D;W?ND]KW(K>?S+9_OC;0F@"GRH?GB2
MUX=.N,ECZ(H_@O9,[5G,O2'U1VW1]2=!WU9U]\I9NWU\*E?!*[YTA(/KPY]T
M6)A\5PV9!(;T<Z?!X_W?85: 3&'A-;>(<B?#80ZBK-I&Y>YLQ\B8G9U">-3X
M\H;5P+"2$KV7QCSJG69![WF: +TL_8$ACZ:8>3F<2,HA?2QB$/,W!^#I;!KF
MW87% W^]QU*LI5DW2:>TC*/H-WK&<4;@6RK?N=[NEO$+U96Q=_J\UI^,V^6Q
M+E(N\EY(5^)O'%2/&QDUE![,#?#,7[#>V$KKGBT2LNZR)MH)6GDO]"?8DJ0[
M+[P=JRI;C-67%LO.$B.(9<?J?:"4?,!)\EZ_JR1W+4-706CNDNUIP^6'<;[Q
M!)GI"^KRZC*CVRM1/\)?$-SMO[=-_R;DBMVZ"I,73.(@])<+Y\6_\:/E=]I:
M*/:3:QS$:#1.O0&UM:G2+AMEPM2%NGWZC-P]Z1.3 W4MM667M 19UV@_F5]2
M-79,/)P9=\,Z^OJ8S<FH 7M)@Y+O!4R!)GVH"[^&#N2%Z]P^FCH'H>+&*B+Q
M/QZR36 SLKRIT[$+UVJKZZKCF+O,WZ7/.Z<[#XOD/<^9.WEG5/RX\OWP H0P
MBO(CF<WG!DOK"@?1\8C)08"A8M&O"I(67+V45NIE&.O:?/1 7V!3=LZ#@[BB
MX( >@^I_YB L34 ,:K@/BEAN0+,T G=S$--+2%HO4)[+%IUX0@:]6'SP\48X
M" 4R> VFZ8HMW!?^QD&LC,=\M1\J%K/%N_U,.+@L9_4B%P)].8B?UE58YWM7
MH.7U%>>M@F^,U(6#"(ECIZ%FZUG"'$13[J0'Y#"T:<E!-#X&ML2'MJ]&<!")
M:\!?=IO/-P/O+4U8HO#N9_C][5;)6[+Y *4U*6D#(,:A!LPA<1.&%P>1R:19
M<Q '\(_)F_YZ+%7\XAP'H;,Q280D43N!%0:YG0@)P?W%^T$R>!+%JLKZR]ZQ
MUA/0DP)@LA9N5E5#MR;2.(B>BX;P 55KR35LW NH /]UM% 4N-MS-ME2(>\"
M:'.@! >11((L =H?:"B$!+L1;'#3=<B_[-(/G$:N"9MS$+LH',1F-FJ0M0R%
MS:/!!X1I]L3"I^YUBV]$JH>#X)-E:@ ] : B!Q%J\F:"54=<@9N$X.\XB#4U
M(K27GX-0FOUZ_]F#9QS$'P5X4 7^0><QJ&H&6#,Q@P\;I:+RA8- RP %N5]'
M*^9KL0 ):):<* >14030K@*;'GI_V;L2J<?>!9]Z Q: ,/SK9$TX)8^2H",8
M/\!W:_,LV_(;P:KX)A$%\/?_(O*_:!Y%/7(+-:N0"^V#2_?5JT#1Y@1;L)],
MFS+L8)*'WN)G8^AXQ@_P7RM![\4_9U"!,&@G.X;$+S _=W1@?8*7I4N;:5)"
M6Z=;DV/=]2S[M<7 OH8AV\1RS7EU/NUJ_U-;S9\UD><V6Y-R]AGS4'*WGY:Z
MQX:69/^T.? @Z,=4NC%?.33B0[@+:8)+ 72']O%5 [_ILD2^$U1\B\KAN8,%
M;^^OW+@D&=Z HX]<7+-6<KSMSD%TC_X;_163WFQ6W%R<2ID:T)1>'+B>9W.W
M6N1L8D<F*4;;IM-O@-$[^:[ DMBYY&3]_?PJ9ME?[U+7UK(_^QT\QW:8C)Q@
MN):0*DM*P!G:N?;6]G$)0TU-D[#Z'96DBHK*J)M5E955H797?ZEZ(G0U(^3D
M56J4L("EQ0[';Y"#GH:_Y86+C5DW-.L0$K+K^=?=(=E_3?3%72V;XWAZC!FL
MG[/BAE4;7FQMKMMPW>;_/VXSG_^-8&7]3Z %[QZ<$N @+EFB: Y(#B+Y"MNC
M"_YU.@$^JCAW'N>2Q26+2Q:7+"Y97+*X9'')XI+%)8M+%I<L+EE<LKAD<<GB
MDL4EBTL6ERPN65RRN&1QR>*2Q26+2Q:7+"Y97+*X9'')XI+U/T466@S.L&X]
MBL4SA)K$<Q"5K5&9K+N@7N&".'&QB+Y@W+M6I$+5>^K-9VC6KZ)]&)LXWMO:
MV-IGDSR_LC+O=^+)R,BXO&RZ\U6JKH\EZO/J-^+/Q/Y34W?=#+2E;LD-$"QO
MN>KWYO.&*PL=NG?(K!RPZ660WA72K7P=@EU5CA*$;1,,C U_R/X8D'WD2%$[
M\=Z=)>^1K;-;9SB(IUCH. Y%LVX 1J2&6ATT:+Y!Q<1 6? 6M6NT>5RV1_7P
ME\F8QBB);O<#A0&8D[1L?(W?<6L=(+[DGN*6) S3*DT=BE!OC&&=3S\(Y[4%
M2,.".V4!X:-;+I% >H$\\*_*W'B@I1+1;)5OLWJI'[,R'D'*S*IY68.^[6=S
MQR-U^M41[=T75!5>:CD)FUT?^>'AYWSYL=85@X^,L:5 !IQG#@)$P_3-EN/D
MX#2&4?BA&Z8<Q+Z920^VB$<P$GR@!1M(1S@'H<G_-T(JX2 L'J [55@9\ NZ
MEM?C8!@SA%58*@3( <#? 3(!E@J<SC6;>B& TDR#!: L]\W1AOX[Y+>RPB$,
M,,T/.2 79&"A7E9 @VA#5BT'H?WN/SJ<F'4]858O!]&.9-6B!G]>AH(LR+3Z
MI$T_*. %%,9!T.JWJ>NY \+'#Q5L1+)>94&BW6\FMDY-\*)H5"R<FR1AR.>O
M1OR7W?EHQ4T8['C4)A9X^6*"O0=F(4!E997%/,L6A&'#;7.<V4G+@EF0#4)M
M/M#[*HB*K,6_>M5?=@>.6*_"LXH<L (3;G.6O"4 >W'C%GIZ9I/AO"4+?[^Y
M[8PZ*10]Z(C)'F"%&O-5%*TW/_R5Y;_L%IPG?DZ"KL'#HD!ESL#:<7A<P6OD
MCN[5Q>XUDV]D&OEU"(FK)7\_N_RWRIK8M[>M40<>W+XY( D_,XR?Q7\CW:BO
MXXB>N?GO;1C*HY*3T9O;:0S=>@O/S._#DR!16! JJ.YR5 _JJV0+ 5^%D=S5
M]._F?[9I"Z!*7H'#I\+/Q86+"Q<7+BY<7+BX<''Y_Q N#W&(MYLLNPK')\D'
M5M//-PQF(1RU/C'$9H[BCH4#KO:HF38]8!-"_=\I.@_CHP*WY&O9O2@7E5\C
M<JX7XNZ!EU]6]NRV A,FWUSBW?&]I-O1IPT\SVU1M/=X!"RK5[BC<(23)KLA
M>^O-;/RO?'$Q(M^=N6\<<NE$Z5&W[[_3N[:W[>?T"OR_#OAA/4]SY00IO8@<
M$@HW6^C.)&%GC#3[L>%/2:Q(C%<9A-X^C2JXTPL">6#I-5%XH"/DW<#*? SH
M8O(KL'9#^R! Z: YPP,O9/7^>Y] SY^3A0*[.8@=VVRU0:098.WHO_2TAL!7
M1\W[QGN3.T_\6]GK-G,0W<.P<E2W\UCD!^=1_K\;S-X)2%QP$LD6Y0]"@@]9
MA^%S*4!1,K1WP/*Y#UZ"ST>E <]Z35R]^O=685J*6F4 (-\_].^PK7_>__Y$
MY3\5-U3_71,6&P_M_*=7#&U[Q9/_X2,.)5B87YU^UM>#Y"!4OV[]_TJ9!"QS
M%'Q:O[[_A]%R<\3-$3='W!QQ<\3-$3='W!QQ<_2_.4?%QSF(J8TW(72KM.,L
M-_"JHUW1#Q5/J:BGX7)VSSH.3=F,?!=]/>[-IZ%-\E^OQ*R#B'.QXTK'-D<*
M_]AMWG;8L2C_1OH!@9(+A[4LFYX\^,&=:5/3TD;)&(+;W2,O'AC[GDQB[)(N
M %9^(/2.VP*&6:@^/"2NPL#!+= 2S0-N@8 GP*:?'DL5O;@)!V-T<@(Z K\9
M+(H5\COK?Y/*ET#_*3T6E/]?DH'(O8/DP5JXIQ/Z[\MI<P,<!)\H4QOH\=E^
MI'THJ@'%JLWZQONC/RO^3:>=<0LULV["VKW="*]#B;E?AUJ#3,G<?BSREO($
MW$729D!9."7Q0),.U(U?LZ^'FSY*-\T$?KDBJP7XFZ3^963]'(3M*GGKX+]<
M_,RU_E;08 V1AU>AB*H&,NL"M!=^_33P._'?MM_!SS@(_ "*)HYDD8>V;/%?
MBW4>%FL$&X^:K<%)P*> G\1##J;?""UQ5?CON;A6BES=ROVG8K=@KLW9;ML?
MD%SZ'Z]8IZ%I/4#Y#%O4XRD >K)@;^AH1WTCO G0+?+?=.,B)R# @H-XXP*L
MP&&;<_V*^;["_XP@L]B7FX'N>?PV\>@%MI+).G&[%]_U/UP"]?Z&&N2^$5OK
MS?"_NP2:=SUFDVW^7WTP&R#D?\,RC8E?BP'Y=6 YB-/HO_7G?0*P/Q< V[8)
M$-=(*"YJ7-2XJ'%1XZ+&18V+&A>U_P-06XT)056(OC$$A%UCN^DUE/T"VDF/
M\D].'*H]?.CL.4)N">]RD4*IPC[$WI/?Z2&&-HO_HL[/X(Y?:W!VL7KO)"Z-
M"-$;GQ>=OIFZ<MF+Y\BDV>0-@UPK?"5^^5;FA!*?4E$O8RL6S-6,BR27R/L3
M/99X;<?A]L=Z&#\/T\.'9&H!/7[@:7C8>F\XB']("L7 PI):I3G"HXAYS$'
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MQJS3:5NS2%>B$.0PIDT<YN#?TG:,'DY/]WS[@O;)_0JTO3!3.A*A07C]LWO
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M'%46]/J*:O>-0>7J<INJ;U',8!U78C/NAQ D.&C-(O7B]EN("2A8<>*99>E
M7R,@CNN):ND2G*'X'S\Y*@39 5&L4<FFR4_L;IW--%NIHY4E0:_5&\<-8@>5
MG'MMZO"_Y^QJ?MTPFF^WDI2V>! )@^T7-X'$$!5I52-UT\$##UO>UFV-N106
MK4Q9FDF.A:'&*^JMI1P(F5Y7R[,*+ZML#$EJ!Y8'>G.E_Z]+X82@JR1 HX57
M.LRI%H+>/H1LG?E<R^/SE!BB5&&']F' #O'Q7(C@./)X( ;,Q4X))C@ZZT4.
M$_9<V!1Z%4G@%ZQ;1$T)1I!?'_S@?6N)3MTD*MI8JWU450OLNYA=,#9U0>O
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MP(?WPXU-U*-;P_7S/9Z\"0HC#Q?03'.671]&ANC%WU95W5"5.]G@9;-<@AC
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ME/GAK*E>L*;XP]/#![_]$^@KT=)!Z,B?\"6POK&//@=S_'=/" P1XP)QM!A
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MS>9)\;Z+ V,F[P>GAB6<OE-+6OVT\W]<<A""/FZ/?MUYX+XU+;KX;VCQI#^
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M@A;YG*4VHMHYIO:9P8=.78N$:%9-N4UUG.UM_@YAJ:/$;:2\\MIDSR)PQ#+
M1>JR:^@S*&= 0;6R30BRJ)P/Z)0$C(\S)V LXAON-<'GF/OE+Z'149@+++4N
MG$20KF.MP^MA(>AXG#X3G!Q25_Z:8OEU2J5M3/&#VBTB9?1'[^C$M?9W+>,7
M2)6DPR@O<O%!UOC?\_2#@6U1B3Q-A@_8@24$)9E!2FD]_N7?VLX]%]FV?RO@
MG']J>I!P?_@^-];UO_:E&YXJS/K!>25JDKW\Q/!.W58^'A*@CL[0P7*PO9*_
MK2RVSQ:@GY<CW"L6E._NX *.[WA@C0-RS@U_0M*0@L,+W',\[<^&P9#Y0ZM8
M@DZW<]YXC..405Q )UTBO-YV?&5TK*'=FHF4]EB.&:^\^V;&%[;\'- A[ZY7
M/CV:H_JD^'?68D.Y'WZOG* YU#+F8O>=-^_R[)ML(;=W&V0SS NRR]>6G1X'
M3=1"0QS4K?/[3X\*!@?OF+A46^'TMG%-G)R @6:[?)=8>NZAB:A%:@!/;I!3
M_)DH*QC0Q0S3,*4D)GA=L@X>.50Y!1M"Q)7RC%F^+16HK.Y\/J,Y_I&685J
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MATG00G9/F?/@URBNR$!W'/@HH\+A-35U6U4]@SJ#0J"9AN!=(Z]5T@$ EG8
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M%GJ'H>. UC#P&9\P@SC/S+ K*67@S_*\$E\I8Y_AGB%=XEET)4H*/_L*U:A
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M9RKRRI_JX]*8MCSIST"C'Y4IC?D\0A.M_\IM6;DRW2ZVVO8J_FI5Y+7_7MR
M,^W+O8Q_@MZ] ?VV^2N)A_B5Q*-)<OJ[J3L7:GE=*ZBE] B94R@9/EIS*S@
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MXF(:Y$LF'%U\,I<S5%FB>BEF5<R2M)Q>]%JE_E;ILE9%7Z'I9KZP+<DBUU#
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M84-[(WH+\M\[__<7($<?)BRL0EC'(?.GDP![](P**T$[IT'@/_#D@"+T:6[
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M^(5Y3=-F^/+=*2%H/P*H9<">PUD.ZS11\RK$N<X*CBDCXSRP\08K*;'G_[.
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M_>AK@ 3W&L^"?>_\]YE3+#=.?2P:\W8Y2?:*2[XE&_GO,-]HT^LY8Q\K;-\
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M,%K-<N3JALB7JP[_6O.99":MBBU9&KMXMC,(_'@..2G#>0=@Z8H6OZ(-^']
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M95CA7*Z"4W3*]T80< H(:]L>6UL#RJ>?*4.: LFW0M K7W\HQS-&)/:6'J3
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ML"X=6E ;><$.J9F4Z]\N<4GZ#&39%H[J/OE[6J,0#\ZY;@O ZZ! +EK/@8W
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M"?(GU0^7I'B>E]5BA#D+;L^HQY*XKD!!EYQ$ J4];B[@8'Z6\_(C?[C4T$H
M.IZ(CK=!K0C?=-?4RL^T'0K,SZ"C)_-QFWLCL<[O;HA9<1?<P J(AT3I6H[P
MSW /M52"/V?BW3(N%WM=GHGW,I]F'GQSZXL!75L M;*+4]H-@Q0U1C-_FB6>
M_??7RW?I;P8#EW>%>LU;!D]_\@[*_.B6+N*<L'BC_;)2P:5N;^V4U?Y<PT<M
M20ZYM7[S$PZI%8J]"UT'%VD21J%5;D8IJ6F,2V;N771W[] E"[JF]HG/N1PJ
M^RB(8DFV067,(&AU9O(?8?&FN%;$$9,+^6 C3:XCL9<P5\-/)+M=+O[ZL?KK
MA!=<M^SPDD*;1<A%VJ.4#YZ4 ,0_F?]C%WT-=&8LF3Z'O<CORE/B9>DME2BS
M<,LD<E< P3JBN"?\22E&!\PM _'M+?(IQ^LI4?P^1C-VO)U_T@--KM$;H!1C
M#/VGQS)<Y2S?@.3_$XZZYDY8WT(791QSY?5>OWEG:KT(")NSP;%YAE?M:Y:Q
M,>VR+W7L#I*3HZATM5O*ESK94??G3[BY$BNHC239-MZ3H.I_P]:MY)?3ZS9\
M.9Q O ?Q"[("<,G-D2^0@A@ZS*-J: :4:T #H>,'/W9^G)*'&1O;TWUF;6M(
M! (%)=9<4]-DIG?M5MWSX]?>1BM=8R9*'76^^<O6&-O6]5*2E!/9+GEX\M[/
MV;,A$8B[Z>\?UU6'MVQ;?7A(/OJ%L>!#\!!S/;I5SQAR/MMFDM<Q$I2-C^ X
MHQZ'3^P*N3U5Y_X-93!WA?9$D5G?N*I :T?LF=88'/_/2VB_0X>:7'D'&8(K
MO.R7J)N;' DP]A)D1_J.X$P89'V+GX<78#LB#P_<2 95R!^HX%F#ERT*:(-9
M?!Q? W2"@;Y,4Y_VG<.[0B);T\(_7+?#=T;>'$P/$R=K)YB(S#9&Q%]:F;&J
M2_H\TG;WKVKKX'-'3_"-!"V)P=<FK\2S_/B'XCGGN5"PA./&%Z3IDB8'R+M"
M;8O\*<"J72)I#Q']& I!''4V&JPA+>#H?#D6)*Y&4]Z1WSL2.FGL6LGQ39OV
M&5K6(*]P&\O<E)-YPDNTKIDJPX-&";=?V344R $DZTOK9S^25$CJ2_=MUNX5
M1IHYO;D%EFFTVQ6).]!,KE36/-R:DRU-RCF_]1.OG*FYV-D3T;9FY?.S<%?H
ME2MUKPZY&_4!GGL)NI^ZHWC_/YU$[7CD$SD1@C!^&WUF+7E7Z,S<SVU!YEG:
M9+HK9)ZCRM^GS;?OV5CMZTF.AE9N_'N+Q2T$?=\,=?G"K,2KG:YVT4A19E<'
M/NII7?LX3EA 1":[0M(5)C(^O*B_+8KN>_\&M+PH0=)KWS),SUA3JO T>-1$
MR&*F#GY%6GH$Q54#Q_FB88+P<V1QL2Z-'!\TOQ7;QWX JM.H8GRY[KF51J^I
M<!K^ -HEB'*'[<,6J%#41$;B]\#**@%2+BPAODL*KF[>PWWT.!L"\IBX!,7]
M &44\BZH$R$]N3CUZ^@FL67H 5\!70!/W/)",(+B?=]O5(1&%.O]4N:-EIMG
MS\^/MGM+):FMZ*F3@JZPE)/>K#[L5!6-Z[A3<N\XL,5RB[U:<^AKW,W2FSD#
M_B0]PXX:E?=^)SI'YXJW;7:%M#M!$ZSP+\_(:2X=C(>7KMF+Q=(8ZJ,$FUS#
M2PU2?G8Y P\3TA8^AU#5<Y4C#((67_!_^X433%SQXT@AS7YC;;<'^'5!*?8?
M$OV\@>WV):H\NM&+%9[,A3'6CH"I[BR9/[A/2A?S5+(VW*GO&@?"A %TGJVK
MJT?$FO"$.HSH,8FD^U)7:W!_&K3N"B4BI*E^:PI(O"16A'N%Y=>V*P1!'ID<
M=T.7M69U3,676?H5FP>L+2MG#0\';B[]L$^/('HK=R32#\A(KS_PC*QA+?%%
M]_W[@5Z1F>(2]%#+1>R0M^HH'P(F?8XT;O>6![9?FIW@ZM>RQ-^$ GHCJ60O
M[D7 ZD6-@M^U1ND%J:GT$F\OY*A+7PC2E)(QFAEL.YK,D*M/"+/YZFEYR,U_
M2\&Z+1]/R9]?T[,['Q]U;</0YF@(X6-6U/)[_$$GIMAA%7>86%+;G;([P)#/
MU5P;Q\(%YAD[$\H</$Q5+JV(62"7DFBT:FN4T?1>QDO0SA)>49,LQT40F5?X
ME[@68%@PLAB4H:7<AX@VZ9''8"%Z=;$K?(6%\S_@^%>W(K)15_6SDJB*%:&C
MT2JU>)NDSGF1U8*_/'M6!< 1&$2;#.G$ \[0%RU* SY^E:#U##01<J3)KD?T
MXZDO6]K1V-]!IZ S#7_6+F)@+ /:E]C"PPGKA'K%NZQ*KGG_9J1'NU%MYM_W
MY;P+*E -\P4^!3\:M))]0DH6Z9VDDHD.WZ*%I][9OL>WLZ(+BKWMQ0B)B84Z
MGI,3O<>/6"J].PW9=!7$\7'!O6AM(;[*SSRN84G.JF1D0"FC7<:11K@3"\'^
M5+K^GB6WR!W+[6@LY.)X_H*@X:\)DQV?2;.P,L,:T: 5JZK^97*%9NB%)Y%+
M?FX)9DXI32=]GPRU\:PD#@[F,!=*G8I'[SL%.J:3/L\JG'P] TQ)RN!9&B&R
MYD,_9JD45MB=+*)=</G20(%,==IB<=MYJD%UPOQJ_ABGU?*XZYS?ZEN$!*[U
M^B;,_@BN58")@2C1;JW3T1)CQK.KM8D/6(71:S3$X288T_BWKSW'/P;,M0R0
MF(W_BE?*(%^TT)"\: ^9T)N!U"33 OQF#9:K.# ,!/@&0;+V2G/M"LVJT@(.
MC:]D9(73]? *&",6)&JS'DK1;JVJV@@*NW:&X_M#/V.\B?/';2L2\.Y&.V-^
M^ES44\='3Y4*'#7K?J1_?G!7X;KBN9P[<^?^\@<<K.M4C9SBXF NXX^M_7&O
M:W#Y]EQYVUTAM<XON.5:KL>NT$"O-/7S.G.*.<",@-6KU#349'GL55;-DX^/
M>.55D"7">.URK2C:\OY<G*5KXO#KH?._8RG\MFD 'C0NPQ?Y"<2W4_>;B;MS
M3[-<_ZB9Q&YWR%D2.Z#"2SM;NT+/:B9=/L%1!E/'6H"NA":Y7L5R +D]"@^/
M\V&9I1_@9Q_>"4M\11V9'<:Y] %2&QK413#0RFE\H 39DZ%U8=[N<Z]7B"JI
M(K6VUA[ 2O96OM?R9Z&G4<N^4:3+#3><TOP,G7(\DG6]\-7! ROZ%:3'U(%D
MIM^S93,5[B7P&3!^,WN9[M<.V8\F?]A)[!I[V\PQC8G7E><=7 ^JFG@=%#[G
M,=VM.D8\+<O^Z9B;-,R_@CLFF.NI#(/V( A7G95.>8S5!I&S05(8*,LYYZJ/
M%#G61+YB&@SQK$V8:$4]]'GA-!B8;V%:T]1Q4_96U/95ZH* .O9?YU5B-?GC
MU"KENDY$DO?I:I95>R,NGBJ).5/A#\<^*T#[M\G;FNT*V8^:0 EN"T;BKPO=
M+/T*T!'M3[W?! C$E+^_P4,ZX3.Y?'KQW9015DXP*]H%H6[=)X< !=3.WN9E
M-0F7H<DPEDK. ':PY3 0G1I2O)AW<KC)N(@^/L:]7]4?ND;Q]$)'.'_12(!(
M*@]2ED*!2?[S/+,1^1LQ[7S-D5!()N.3S<=J#6_7^)S?%WN=$@9YTR-J[Y6E
MSJJUP*M2'1[9K-]())]9O=1S<&,B6_LS<'S1]D;1DDUV''OZ9GOGL;2<W^=S
M?M@=#4GP3+M]KGH^^-D703O+(373T0\VJ4G0*H-X/8ZM07M6YJO467(KS^!&
M@]LWEI']6R1?#BQ[^V/%Q*&3'OW"CT$]B,X:OUS3]+YY2+>G[\02N^&NM/=)
MEK@@\?FZ@DOZ_@+CR^R+P6H WY.X(DQ3OS9%'2"ZF@C&M_'5@-6W(85+60??
M%TYT/2E:;' A^"FYZH?7ACM8Z4K23C<8)07_B8O@BNRYLN!:K4UD&?(X4?^,
MZ>JU=M22EWC/U9C.%F,PB.G""L[Z/(!"K(S'8A18HJU\Q>91K?B.L B][9C
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M#?NA4,X_IQJK6BA9\MFPO^[DB?ADZ 8_V?_6]0R-)G:I+9C@DE:8$IAQZF/
M1X?%H<)2);X:A7T/XW[H+ZQ:QU"G8SK<D1Q#/F'=?0ZT/&1M+KD@\YM-?/#
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MX7[C+HW BH2/'_ Q./]I\"QBV8ES!"33S$1XQ=B+O0"MO>4"L)EW#AB.Q^B
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M^SQYA>>=)4V*.J+Q-^G.BO)';1I>I$_<W.N?;I6!=+)?P%\." WL$*1V>IG
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ML%B"N\75#.>>W?[;2N+*V41U"[66%L7ZSZR!X^N(Z=#@'!^+ZFZU*PK_ 9;
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M#4\1G_A4)M[0$(TJ*_= V!?8: 3><6QUK[SFTAO@IS*HN!B45_FF/_'CPJZ
MMG!2UUCWJ)^Q117Q<F;\@\S45V-^:ITVJ5;E,S4 0 (OC&V?[BEO)8]LDBHI
M*\I/?/:^7.>M?WM);K_H76TV/?Q"Z<WS'S;/_&1YPKI=/DEN:;%%8E7,RDM[
M.V3C^)$'/#L9LX"5F#K _L@2#"M'WYG83(HA,-)H;LMY-$I\5K:S$M:T>LJO
M-ES2@EZ?%-2K-Z%#.+EB+%TU55Q'^C:U,*$RMM?O!S;UJ?SD&)SM"3^Z;'VM
M:!4<+Y)D8).5/G'>[IN+"GQ78QVQ]G+ZC,P_.^2!=F'M8HMJP'<XN$HT*JSY
M>;=]V6J+6Z#=T@L_]Z'"[U- "L^<!CD=7)"8\45@E^9.9""8C353$1>!D1XY
M_4F\#D8.+=,PYA>,E%C/(G.*D<4=8731!ZU1UI&[#[(USOMO;_M[UCNEAK6\
M=5C&C%( %2)+%+H 8XEZ=\)$T#+TZST8"32TF&7%D$NAA8=B$J2WH_9GCRS9
MDO>Q%G6Q][(Z.#_1E=K:<C-W6^;,7B(PUS^)%S;&_9#(B1YU=N2M7B:2L82$
M<MN$)>O<["5TTLV55."AG3MBG"+T9NF\D44/]8.8*@UJZ/!W44G;NX#\'<2\
M%0X'G>MFJ,2@]18U^1SH#0DL\#L4H4MZJ2@[HH$Z<@[N*+T<5>%DE7)CT&%,
MUS(,#WY0FW7B4WU+0[;DQ[G8'XG9,+(&1RB8G1JAC,(Z,_0^IB1@SW)!WC=U
M?9YD"O]<_P;.@'48:)5J=MU3'M.LVPSIFM=,,1>YFKARD'^M+>@9'OZ>[*I.
M%EZ=C$^4\TCZ:&';^4C=)K#A6LKE HVG2]:^#])<9AKK*\=\-TA7!J[-38K$
M>+PJCGM 5"P>DO[3%DA7)Z6K=UCTUTD5D:W*BY%?RZE(EC2&'O@;0RAINQ="
M/J*I=,.$;NOLS/N A=LE4!CJC4*,_)_$1PT<RA3:BQ&@Z6'9 ]>52##5DZS7
M>KJ!&_./7+M[J,C.)?*P^4P4TQ;0*V7Q RKT\CMTXK]8ED7M&8MX&F);!&VB
M9V"X$AI3O$@4M>:"9J4YA1C<4+!H:\-5%_CJRT#D.^=5Q_N956Q/$T3"4,V%
MYS8]C];L$UU2(Q\4GWF\542UN!*5&EJJ0UX9C8']^?C[PV*C,S\F2?7?;$X:
MQT,SS=5,' @&=0K\2MNFUVS"[?[+?1.B)]$#,YU W=XX07?C$34U((KAW0<6
MIC*,";2\<Q3:?.F"G[<=?6BX]1'6B13DRB.N:##]E($)L_ "N65VC>X[=65-
MKR$)\?)D;>>$\= [G&CVD_/-$7VB\>4NV&M9BG,NR\EC+LK9$VZW<MS<MOG>
M+.F'(RM^_Z#S;*))"4*V7;9]EM'TCKV<ZYKHENV[:AD<F,D@1AK),S0Z.$H
MAG&BRT4O$2VZ*"O-&_6\&KWA]5/-_5NB[J.ZAB%U1%*PAF!1JF .XB_%QU[!
M WG5IOV7% @[5$8+1^@!P$_;%G-?E_^!"X)3Y-$2]/W-Q8>X5T:>]",(, 0O
MOL/PJ&7+.T%DT+J3T46!2YM8U^8IPACE[,/Y^?O&DYCR>+7?:RZ_</]*1\6-
M?FLPLGU%5:[WS[LW?,;22\NUN'C#T2O-ZVVKQX4^?HCH!F'CZY)MWCTUY\9>
MO!3I_3NR51\VH^Y%)4:9<AJ\,*[]1[,6'N>&_IV-CU!AW1W37(8'RZI\!)]I
MO4XO"S<7USXMP5@+I;QNOZR;J.Q-:I_NA^MV,R?)KV[43$/>N\S#81.PZ-9;
MGE3YTZC SM#'4U/2R!@=684N,OHPCT19LW-::0YOSX'?* C_Y9P[S/QD+3(D
M^!?A $/SZZ!A$Z2-J=ZUOB=GA*5>9R"]A_[)A7=>76ZX;H,[9;HUL#4U^N)T
M@_+@M6@;K^E['FT$[5K?8%]K7TG>?'PSE,=?%GL-/9Y%O(CX(8*,I?L3-YR/
M'%"#-D .??<!0WN#R!"$M3>/HQTC9)S@V<0NK.B:Y)]S4OL)A%CI&C)YQ>!3
M%M&CL3&MPX427>OZ-<4>:_,9J;OY"'G6E?4#E0+H#'8XSE]TQ4I$S,FI3K)4
ME=]B3>C;'V^I='(N^D@_^#T)#2E%.S,BLFO,?O;,#J1*FB]=>MS0\.OOX*DE
M\0DS\+"JK3U\L4P]X&&57;1ZM<U*^AHI[[?4,>.#YHJ,U'O4[F<XX4?EEB*N
ME]^M#3S<"5J#%O";MS199 C4KNJI5!#X/LT^;_$CCJ1,\SSDCZ-?N* .L$[Y
M2OL)E !MO=>E^;9$$\.;)CZ1DF"LZOOA]N-,OR?YEZRT+6L_ZPRV6@:'OP/,
MS.E;"6%A 8H'TNA\MS)7E@CC@"/4R8XF^F"2L.+&AD Y36433,6*L6",J=><
M2RC>#,V2C$57Y\7K&"H)NFK[>:%NTH,/ 16:ILO\/!?DV-(ZKFBYB;3Y:^Z+
M=>]"N;KV]K[X$$3GDYIC:5R,5C/!076\;'E)OT=G46(I7,%K("/514/S#+E)
MV0XF9,8/U>ZR%(I-RY-6STY4ZR^WL'FP=%#4KKSU=3]C'K>LPA*=XO!#Z(8<
M_M)2]/TF0)@!63R(V\,DW'"_$-63+PH0:,(Q$;_0#YA9K[Y-*'XV,BG""K!4
MZ-8M)>LW')N7FTH^79J2,1_?"+[.QA?#W.&A0O-IAR$FXD,P$5=Q1P>&N*Q+
MS=)RJ4:@9:;ZU66X1IU8QGR]>9#AE<;[QC^_NC)M85-P!ZM74RRX<S??^OF2
M58N:M6V:I35<K\7C_]XD^]]^LO[_Y_7#SD$,^&O#&HPISM#FI%&@X[K_8POE
M+S0*<_13 1?4< % 1F+V=V#I=^)5*T_\?0RA@%F.@#87I JP6\ ;0T3X-MO6
M_29AYU^$?<Q_%B5F_:VQ9RW(!07U<D'3OX'W9KX+QX&WF[S9D9/'$B%'*C3Y
M#03C1*=\U=1'X5D[B^KV2>-S+)>IUD#Z;H_!!X1>0@=6E*6VJ"WA!'?1H?_6
M'R:10</RK=23,S/"=$2[V#4EJ)AA&O.$UANX7FK$$*66KQLVX[F(ZP*3!:FF
M962S%&-)(%,(8X9=VM'&>S4TC>US0<)KJOV_9)DR(+&Z0K N@Z\R@0&%:U.?
MU1S_O,*A$A>2P36P+B1YEW/*$\<9 8OO+;7R2$<2<K$R&;G84-\X@=:HQ'1V
M3'G1OR6U&O@O9LY3NMN%)\<&8:/*V?I^V8>]AF$K6K7?MS95.'(8N/P,%T33
MWJABD&C>&T<,F(6?0A]6D&5I_$?%KR^^2TY6S\[Z9O.]UOD&_=.R$(7KRHYY
M0_,[$S[3.+J/D)K6N&<?YG2Z,]^@W3MKZD'&?2T%$?-.<UU7?O742'_M8#%V
MA@G"F81TQNKF>(D_K[AAF>/Q<-%,)JICRN$2Y8:\O+3.6K^:TM9NW>:J(>6M
M@\5 -GC"DPEE%QO+1$QA01%2G,\4 5WQXQFF"#FM_]AIF8!(@G8V?TNO0J5T
M&%^22+5$(FDPOG5XV-^(9UV*]4/AGDH]B0<N:&96(!=T'D,/#F'E0S9X"^V3
M00075 ZA:3X[KLJ"8XDE(V>Z%L<B_J'PD!I3^%^4VC,$/=;%!NF*R;,^\R!@
M]:6?)Z*0 L$\*PV!%Z'-:L?P1J+!R N[+F:T)O1%].2D1"KBL#A$_C_\!'K2
M-7-$@^;S>6(T[X+)?:,O[#7;J&IDQ2KQ>03<8C+5>$1_N/1;KKB1;6V &..\
MQ<T!W\$T$>D_EU.39NW72LKL-G*BYPHT(CQYL4^$"UI2!U?UL=.%SV+6FAC%
M&%P=YB\(2T2>8UMX= $S\RN#CU..E88>AD'UI+B@?[IX%OW[\5;;I&'K32[H
MC;$>I]>."QI_J,8Z[J^?2+=#RJRV7SLNWXYB24W5"0NNO)"3'0O&DA$/2?XN
M4W8,^_RK8[44$12$^IM=]YNY:=0C>4'W58X*XW7,L@DC$H4U_:PE,6(^6C<(
M/L<%J?#(YAF6'7"PN"E)#>E(^0'%(R[=VB+A=;7(4X"99>/$?LY*[:S:OJ;I
MDB9^_+MC: 06$1@6_O+9J(LSN>/R@:B9M(3\"O7H-J;C%'@ACPNJQ?: 95E/
M@*@%S&LFY2Q'$<C_UC.O/=EZB^'=*S&Z9C"TYXJ<ES6$MD[NL0W&MG[7,HG!
M^ODA?N^7S4^3P!:;2.3G=QS]B.E0)7IA 17>@F'93?PAA_9S X$%K:8/IY4C
MP&*Z2 $@QY&^%4O-&O<'?S"2+UN9%Z2W%Q>MS/\R3J!-L.P\@T-*E>M*?>9E
MLQV3;_'=CZ'@3G;K/W'.Z(TYE^3\J,#Z6FJIU1WQJNM+#NK6SW(IE]WF[&J^
MOH+WX*6IGX"[AL,U_;2:TU:G?O=V"7CU?B+#XB_T!?T\:?M5>YRU^G,+]>?0
ME+K<=7-+IT' =A*\$"U/=V +WXWJUB-6\\7A/C3&J"TVC'(NL2089QI+-7,;
M!FH SU^!M%(@D^QQ6BMU=F[U*D2(F@#)OKG]+88,&=061]GU&)]D*#<M4&0
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MQ%FKU-;29N;HI]9C]6S3;HC8:_;AE/5_JLGQD%?)3.;%Z;6-\:/B@-K2&HW
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M%,5"/=>A[:"+BY[:MK9C^M.3+]M'MI4@WT5J=6N"&0F+PXOR?Q6=_9HVB$/
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M% O]P%E9<DMT8I_)FW"T]JU"1,B"B:-=FNB/AO)M,7?2-4-^Y(CXD(2!3G.
MF['4:FSDIM.S<+I@MTS]-WM4*8)9G-:.YW45VYC&E.S%"WW%AQL!H[OQ102@
M/76N#X+P=K2)%J=P*-',+OSB;<L=K"& 5)VC@I6]JF:N'>U4I,@#IMYO6L[8
M*GKV2UZ.B/XM_3NNGP)<:EO8[NT4@"9%+0"K5ZO/;B$I)'^A/!=#>[H.7T5Q
MUIT8+7^OH\A_H%^M#*^N9?8&B>6EDC(2/!Z]?#9[:];;?;7!0Y>^-67@Z<^F
M  :)"TM<50&H8:D7.K7J//&J?8Q\E.M"8F<D/G2OY::\TWL_)TUZT&EJ^K>C
MN15,R+]LN_-V#C^SC21XK_X-GXG)<AW2?LFE"J>9 (%8+U"F)1GB[[6T2O%7
M@=]82=O5W\Q2KN;3>BGR3:8Q<'@<[83BV]JO+*LXB-QGJM)8;][1$:\"3U.<
M872! $1CN:-TI6'B_7LUAJ?KM+4P^IF<R1B%YLS*RT:O9KK7L(W/E\RXHC"9
M\KVUX!,)O[5Q7;[PB:D>-BLL0A+"J\W=.A@'F3N,%4-"I;A0-JU;QC4O,P"W
M#RL.Q[BP#;:;!@@UKH;$!=Q^C/G0B;"(HW/!>Q%)[9$EGDH7^^^5:!>_&SW]
MD#2B2TCIJMX)XQP%U$]"6==U 2W:NE+%LL@9>FX>2WT>'[N]Z$G*_&0NR8R(
M;8]@JUR/[V+V, QDV(<ZVZ9SHOW;&H-T!KO-;L[9G9R+"]\]J$QIKDY[,N93
M?^$EWI;G*>[A%>%8P^2,&S;GX;+NL#+$$OL#]4?KWU@S\Z,)VQ]=E95D,A.4
M]3QG['?&^WF/!*![&3^-?N4F^?_E=>)YE_45MF"*P%R'<,TQ8";\*5C"S+8$
M;=H!.39$Y%HP\5)  G_NQI"^DN2-ENAJGJTCI14]W]S<_,3PD?_]^NF3@=]-
M5"+GUH;^)RD$%8"F3ORJO%RA%@OO.\154MI# )DX.>Y%7ASW5(VU/T,,^N<0
MUH#KD]S[J27+DZU<'$U$4,3;U:N\>M$)F[:#I'Y3HKS7MZS)OK+;@5&TV.W8
MD)#*;S(I!+[=W_U+SQ?A+JEO531SU%T)Q+7E*W:?7%<XJ4Y#'QS(>5#,@%Y@
MI([M]L]>NHU4@%.)#9<\_NYZC_[\;'/R>!C"L++33FT-/TTA67&5)/=.8?39
M!]L8E,=P$?X9_A"J](XB5$;)LE?(5L.G1W-73.-'PK6C;2:X=_2!N$=EVI:K
M[V_&$&G/7S8'_)$03<NI@<ZO>XKH,.V<.(?;&^M1>K2WKWGE/J-U"UWV=[[7
MU$']US7E6SZJI-OML")#]#Z0D9:O^[A[N Y#ROR_\)-"]"7@CV-L&1D)K0EI
M\R@0%UI?_P[(8'MVR^P8Y:LG$,:O?0<BKHQLI<B?IK!ED\*7]:=_!CV<CJQ9
M6]?GF?#WG,?.A91W5/!',3Y"?W&$G ?@'?G-+2PW3CTKL9LFN]SJ78U#S&?(
M8-3; %L>)<+WWH0)-JD$R(&H":75Z='MZCB3&!)]RT0YS3],F]2:4!MT=\+(
M%0]WTV6<$[O%N!!*/G7VATE.?;#M<[5"ZYLAQ=:DT5H#4;7"; ^H>7$!FX.X
MXI[PNTQG&"S'@>JW<O%+EJ.S3[)3U[@#HG-K!A:E8Q3F" W ^4(!8RA'@5=K
MYL40@!),5H%^#AHH9"(["-^BW+K1#RWF*1*K>?GM"L&)+P%<[ZYR9>2]77*C
MTM>2:4\ ?YWU(C10*[)TR@YW$=$82&F3YANUR.S(Y$G2O3H,:L=JAJ<_3]^^
MROKL^?G*^LE!V*^<D/Y%+:MSCIKMP37IQ8_W\804<3X)_ZL*/0(&J%'65A?@
MBJM&LZ?8M'@240*CP79MJIRQB*D,C  ?Y5I7 G#JQ&[.]_]V\G8).T_N<W4C
MJP--6NOJ*P.S9@,5XEKC6N#T%K[5\2_Z%^G.]6AKV.1H5:5]]E=:GX:E4URQ
MT::Q@8@:X1%>NW33;^ND4O>MFL6F^P=]CJ D;6*[G+J<DLO7?41&RAVE-8CA
MSHZ5\M=&'%(R+C[(T Q=I<R_@K)<P%,_^"*% M 1'%^6$BND\8U\63CWG#AP
M#<=P1$=WF.QP<%PM'' %UP)E_"$ Q?4RP7^3^SE$ /80MT9<VUR'0]?H>=,0
MZA<ZKW$Q8W+O5[]8)>PT^%?ABJD,QJ]W=>%_LC>[:+\*5X3CGBH? SP):,L1
MO@3M=P#//%C)(^(8M-0BK?&_?FRAC@0:CH-]!W6Y,_;(L\&0?N29G>:Y+ &(
M]8C&%6HS_@91 (II_161YV@_;<O7<@2@\*5?^;(%<U3L?RQI("HR[?K8[L<'
M;U;ZJM(L\.+GKI1O>(S;9 >WKL[9W^]-^G';2-:IK]+^28<M.(?QV<]2I[RQ
MFWI(LY_NO1/<9.^&>K3: !VFU__*#8L!1I?',$Y, 4@BH$B*U9.(4"NN!3*Z
M\FL3$E]^XT@L#+P;"X]Q9$[ 1M9/__=#)WCC5/Q%(^/_:EL%("@*,%;A'XEE
MSM&=%N:2!:"[\'AO]3="47AO[K'P?Z[*[+F6H<VA6JPNQHOU]<M"E\)L8UB
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MKW[AZ7LV8_=K=6O/W'V0U:$H_==YW(0X)YYE1^FB_ T_B3WI-=E<B63OFQ>
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M!@CH!:\WK6/;N8E.T5Y&ZPJP)T1]SW_S'$?OA[=5!#T$FC+4A##V$H=$*6+
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M_X[_7/*8OX2SD4!V&$A1,TH\+H'P44BRDOA=WT'WRS*BG[LD$']C^.KBWDN
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M!YX'G##X-5Z=I%^@[^XN[]E"&3E)E"$.Y2)\Y5;Y6\E<)9 0"81>#EP'E@I
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MSV?_JL/.@-R"I(QCZB0ZL/&PNA3"G#1$ $CL5"]&F3"RB9%VG=DYT/C"AA0
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M756U%B%:)]A[\5M9._@-Z.%L<^;K+RB,YK:XNJY%FHG?>5>YJU$4U3%*)%5
MI:$BRK=];8_?BSYJI9!>8E'7]*/"I)B6F9&;YJ_(\L?\IZJ*/TA,/4R' F$6
M2WD+[A;03.+%3\)[3<")<*)N3=9YZ"Z+-W8!NSE8HF&^*JQ1/*<>OP-)X5%^
M]A_I:P^793?G1PH6CB(:<B3ZG1;KK2.>#PV<ZQ>)C7:VX[FS>K].[86GI5-U
MBK9Z=9E8W=UAL<XF/579?M^H[M%7MI4UH? RSWG;D!^*UDDG@JI4M!:L\ZJ;
MU'TJ9\IL1K<&]%U)H8+2+J35T$!9QYH6DJZ[JET=SX58C6Y- 7+U[:1M >G7
M\_5M-6WU66[P%LOGQ4]H_'(Q?C/ZWI#Y4"[HH P[&GT&TP$A^ ]*LJ08Z-Q(
MQ2@$HEY(F"7-J,NB&>GW$@0UMJ6?U[G;CHWLVCKK6IV[L3@C-Z*!N#,:,N Z
M8OKB3DT;21-/&+-NE=B)9V<3?"EDTGL1UCEVD;$HTI+6&R7_HKKJKJ&YKU:
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MDPW9*],8$1@]%+/Z8^Y\NSKZ$[A>/24Q_#52R![PCJ!K=[FN)6=5!/M3L<(
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MF1]=]-^AC/M82I:(<=@MZ"1T:HD00>0>!X4@@8P%)X$#?HHY!1@+C@I!:U#
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M+IV\ M.[%&1.>KW1T./:/9%L<];9?PCL'Z'H>V(R^P9^WSQ!=7R:!15YE*:
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MLQ?X+4(A>-/$[J^="]%%/0*M:;W*X) :$B&2T@I^NEWM_R9SI[/=Z_0PZR-
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MFOH>LW\:TQMAG+R3--YC)&=V;'IGE &102'Z.J58?6GMLH3EN3.LR%23RR5
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M]YW[0$34--$J)Y\8:$@1@C0_+?4RE6*ZF'4/FK7EP;"VMOJ@[$M.S2,Y](O
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M+ENIY]JSXTN9GL9N"6^5'.L]="0"Y6P2TL-]*E;F3K&F" SLVN'.^_PT$X-
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MC]L7U,H+KON).A2ZB;I6EI5=VM ,*I$/K^S)N/D3T5.JF&^-G'[R4VDON$
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M\OZ]:I+SNI&!I5,;6P$["O N'/?$98YF4(YN-^XQK0$<MR5N@1-'?^]PPIP
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MZ*8*5!>Z-!._84N' 5K">41N3SVV"&[H[5WNB9.]?H5!5O !6&)74-JU>C4
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M^>AC)<$ZN7A.A5NO\M%* $K:1!>=Y_=]//?B:7]6Z[4HMX.4^33B4SLQ>]R
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MBHF].0O>@3U!N=.B;1"GNW:KX0G0VRF/BW-J7U;P1NY>K"N>\446R"_AD$.
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MS9XHYFU8$/^("'S@^+9;V^';T1>Q","$IXZ]P8%2)WJO:5D-\$V*OP,.;0%
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M[TS@]D(/;\<XAX60/2#_-@7 BX:ZK> -BS5;[ZK%E"%VK$:[G7Q!TTEQ;I)
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M/F)U.[3[P__77\?+_,?<0*3?6 >2;;VZ:>+/ZA>)U'3>=?QB&>=VT#2%?H'
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M]+X)(=5EV-6:V[SM[%^12^FY#AX475LVUDCD<R9X-QUF_/F'\T%K2=[V)?\
M/\.VFK"22-.TGGO_?EP57_WN15K><DZA7!_Q8=93E/>0ZP!G7'#%COG9\UQ\
MELSE<[;S"C5]8CUI#\A'LQI]7;5'%XKPQHKJHOZZVQSHA3X,*'"GV,08<O+K
M^0F /&U$GNYUY"A_B.]I'@#/ 6NHNO8Q?Q6>G&'#R=I8[$AC!AHVE\UM$"2U
M&N&H0HALC>0+2K56Q 154;VNHG8T*-RL:WHQ]S G,]K?G$2(Q2HPY9A18RX#
MA;GJ\6H_$D^)2,?<@*7@6#E4$R8^(0<;S:-<Q$^7TMF6]/TBIA-QX4.)$ 8[
MB7H7&)DV"'?NI$,,/<(U/NO2M)(BRR1@T3JQ&O.Q)I&XD\XH+BC'D>CLD(_[
MF?N4P.SUU;(>QE[U\(1]FL4Z)"2I'/I<8EPKGW\O'>YI^>9G[7();O%"PMML
MP0\7EX;PGTWE3N%SH1]#@]AV/C^&O:*[K.*+]QO1:GPPZ3*A5@*!64JDJ3*O
M6.W]+UZ52^5<]&8/*#*ETJ+KZX_$'_N-E,:)\*CJ,[TZLXVN@@Y'M\F')#7;
M36L\;5^(J\F,T1:AL 0ZZ[C\Y\:@TCD7C)=;?;+IV"DAY%8N#VZ<XB5RN:O?
MGO&X-T<I#X60/P "%_H5IX )FY:,*QM"?%UN/0:$W&5WIOHL>7D6+,YW-GJF
MU]2^-3KE)(1XTA:,+F1W[L ?K2TLVD2P1"QS^B9H[7:9C8\%%3'43AR$4QL?
MSB ? Q0Z&E<C^*Z,/LN+1PO?8@A4_<+1>/+/QI=F7RKH* 0I?3+QN\^*-.;,
MO<][X"Q5_J%N<#\JC+<7''C%-P1B26?P55JLG64 GDJ1VD,N44Z*90]U1JU<
M,Z!2Y-YES-'F#,1]56B+X=!NTUTTS]92!HI5XWJ?N8;?!3P5Q[]E&A:%)LDN
MR?G4>-HG7)VY;OOF_?V3Z71E(Z]](U;-[ZX8KQN)N=;WP)3:QM?/YQ__\$_/
M$:6;AV$/.):15^Y_J'DP[%!=]K:D_^"/-!^;8G5K2G7RN809V&]\7AS0"^Z7
MXEFAD!7=RX&<I1G6%-FK (ANS_UC[#RHH-R[8*%2RG%VJR"8 (%%B&^+:QJU
MQ80CDPL;6SDISHN'3=XZHN7_&M+9]^AA;>JO<[9$-Y*^]IB.657D%<VU-VGW
M6[GEN FW%D.=_=_B!F<+;Z0MV:;6_DV4O7H-X:SJ:S?.%Y%9&P[O(^)?FCFX
M_S('3:U]EM-)_XOBI?Z<#6VKO2S2IMP3SNV[;9@OB<NGID)5@;>@6G74''=Q
M;LU"W6(PQ>Z#E.9KS\UQWC'L#> R.YE;#$ARG+DO!K!V3/A+V(%6)6_D(4-7
M!F4W$$:=4N?LC:$P)-+YM]]Z2V'PG3A5-CXZ6.,R@F.4D[>0>SK>;HS%RF.S
M1DL#N1H^CAX#.M"L%4U-S175IJ9<=&EI<6%]0T-]^EQ]??UKFBDQ%W6L( -5
M\##%Z<'#T!.O)^.EX8/;J\O=7YV09?:_#$J.@8I&XX-5&I+I]9?(%]8)(7\"
M=)&9^)@<)ZJSI#I!>O'4SRPBUR06>Y7A:FX\3*D*SM&S&M0"N\/TOJT;B$^(
M)VLNCF+R!;FY4,F7'P?;>@I0UI&[H^:?)*I,1"04%$RFF[:BZ Z?O]<,@_ZE
M\9USQPH?=1WQ0DK9'.'D?KH1/&Q=4KC_28+#Y7SX]X*,^'1C?5<EGKT0$O,>
M/TV _C;!/R+P]>B[*%NG2M?T0'$UD3B(%HA\['0!OLHD"J? UP$">&: ,W.>
MNAK[S"0)*\.4A (W&;A4AD=17Y%/+I2#>UY*QX0P-Q*"O4DUUR[;U(YHW,Z-
M/%^)QBD.Y&>L#;:M-J]VT($0D^UDVP3X]K/J#O=M]?'Y&I2]DKP=PR1'V(YA
MBJ%NQS#]\XSS85S3Y"79_/"-QD3$)9L(S+]UPA!]2+LS-'1)JJO5;\>I,\P$
MJCAR;VQ[P]<.FZ#%VYXCIY>7AQ)2!JU2$O*VS/HK.#7X_%6^ IV'D*1Y@&)+
MT\E[EA3R.?W+3>'0C]<>&ZZ>'>:KO479ZT>W"YX,ZJ%R1SNQ4N'NTW,OG*-#
M1O@R96[7=V=DAQ 1M\&GA$-&Q_DW  NF "GJND[X#DPO@Y <)/D![X]18NZ-
M7*?LP5!N@2-#YVM:M'A(JIM2Q9"H%WFB[JQFN5%9&?<$57<IE92Z7QI^;S/@
MW_T!/0-N0S3WB:"ENC^R]2SG#$V/2J"1;\0SKK'>K!C':W6:.P\5\Q6&_95,
MG"Q)@65]Y=BK[-_%)X91H1Q=[_*3<>*Q.AHP/Z6V,IR=O2U+_Y^@"EN7\!7O
M=HUAJP#*I1Q9U2/EA<I0E<#'3SW.DXW>[2<-%<;[[XQ)$$R9VJ;8ODDC]3!B
M$I14EAEBMA1;(63@!N5E?YS(BM)9G&ER+%[*4*$0JR3XVT^;(H99ZFR5&_(:
M-MS)R77>7-8^@;\W6#;7FC$QLU[8G)GB3#/>N'0=[2O^^<N <WND!W+ERW^?
MZY$JBS.#W#Z79R'61?"W[V_*44!T+M6A/X<-PSFYZL!Y'1;^WL@C1FO<Q+3$
M9'/(JXG)KLR+;<&!^^^65[C<??[ /XZQNIR+=>"2/\S.%BZ'M[#Z^HQPSJ%/
M?@75) _64P1__OB(_U. SB9(K1-*GR SAL.387KF/'/G+UO'M?BW;_YW.%*>
M 4\!SVC=KK@!":0%V$EG!_2S6GC&N%%"%>&COP+_O" ]B+(/ZP:T32.CIY2'
MF]6GD^,SC,Y4##3#R4X+(1OZ)^;(G&Z705;-%=^5$\MSE(%U \>Y_4-.+B<O
MUGTF_.<P:3V>++ZMGEZ[L3S/0^"^X!6Q_APXUV[$\!0[>F;O<]Q)(-."34X$
M-9&8%)XQNZO%JP0YX?WT&>4C2]*\87BNKBZH*DH(<1S2>/!/25^8W\M_4V['
M""&V(!DY'FY"X\GG]F<2LFE/C,Q#?SV9^+*QB(TZ+ C?FI(5W:A/F&39/>[W
MJ?[,\; [899H=.\GG%\MY;6@V.JVS.8 3XQ?B6\;Q:^A"%5(P1N+,; 4>72,
M78B<].>?$)&JRFN>CD@F=4SB%VLXOOC]=EMD$9#].RM:$-Z!7QB'O@R@\],P
MA"W.2R%DZ!#LFQ)#CY]"B2)PX7R12'P_E^ULI,LA1(+',9<[Z8?X 20GP+_-
M;2>[BS(#DP7B[UT2E]C;#LH.EJ_W'T([=,G-_N.T\,PB<7+]4YS:@T,?9Y6>
MMK_Q_[],LL%NIQB*A'4:%C=)$&G(Z@VP6.NXPYSV= G3W;0VW8P3@0XB6MVN
M"2LM^-T(\RNV&F@;)AUY4^Q>:*TVU=>>FF+99Z!;4V4Y"?^5)K(]N3AZKJ[H
M=Q0XK*@&U)6:OU] 2@2IE3=KL&T^!OK(CLGC7S;O];P2-P5\^V[FZ]ML-:-2
M&]UA=+&QINYE__L^_Z*H5,N!H/II 4&D C&@#$@E[,77XGUAM"KN&T&ZX0F.
M?5BB>3O^C]9C?'-@GNU%!<\"^$*G[WU$@,Q,JF'@I3$E6H> L$ZWTXTOD!+
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M,*[4)!TL96J 0@B..SO0N+:^L6D$>VX)=D(A;I1Q;[A%'/,GX-5A_G0^,2D
M3/3*1>O<)36=<UP8%NK"^^)K*%QE7*LL[@%9!APGU^U^N@Z].;P!%3 ((5(8
M'9& D^*:L*[%;H<=;L6)$'MAD@HIQ<Z3,\O5-%?,'^-/LF&?9.32[:Q\KF2
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M@N)=O.Z,* YJ;\PE6H^2@IBHKKVHRN*OZ!0&M'T@MN7WIE&B<)'3?L8II<M
MCUE(E!^;HN2;!97X3LLQ=6*TE>4\$M0U=LRMMB,<*A1_JD<C%#IF5\<ZYY0Y
MHE][$E0" Q8QPQ$%5B8ZW1+O>U(S4Q92JDQTEIEDL;\T+ZH=JQ-,J)3Q6PS!
M\:UG<<5M"XFECIY+08K*]Q93X@(2+[I__O8MC[??9:T8+[KC8L:JY!5@50S]
M'M$4PW%>H;#HO4@&?ONV-B(6)X919EP_1POX=L5??=U W+>*)CBH,64;L(
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M0.)O\M+ W["3T(_D+NA$(MVU>G;J0!=9'$9W$&"\_61H;1&4*9!0Q/T-?\H
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M9A?CD=Y43V&W"S'N?ZSCEP,_M?P$: @0YE%O\  ;.4L6XEX#=*+=<F8HX#%
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MSI_8S],2P&C&>,"*8]T+=:PR]P^JFA8U6"9R*C&:N!&-/[:F+;QJW^[G533
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MA9_V&VU:67^_;!Q=A?84UGXE8@P]O572TR(OK^&U5I-;&OI+&BS(R&K>[)Y
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M7KRNDK8Z&JFB]5XE3<7\0]N).%*! LL$ESRZUQ+'ARA!)YM8,^QF#@X<=+W
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M]3"Q$HZOYLX*^YT6NKNWH48\Z^^!*X@G#2L\$<@,"\*U]$(V$Y$1PEY4JYU
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M.Z =T]4>GG[-YSDNQ+#*U:STSSM7!@)T.[AX7'"P3G6?CAC7C3]\6NO'D6&
M802WK)F=V2KUE/I!*GI[I6*]61-!$8%."%56:J3]7*IG +F/^D?=T%)F8[<"
M;Q0SO90X<LGKV^!CQ3DZ^M]O,*2BZS4+NVP0UC=*Q/_EM9?M^L+T GJAA7JD
M4;%X&F&JQ=F)YYO,$P]]X[ZT"0@N UYU0)MRH]^MU'QQ-S-I'Y>CY0@(%9>O
M'1ZV/%_VTNS<AW<"<-1[A%3F2*>3I9V<WDANQCNSGLM-W$9!1?9DU\N\9.#I
MZU[Y;/M>N/ZEN_#.*XG^/ZK<TN6[SU<6+E@./F,6,RTB\E$RZ#V=7H>&^ <J
M@/*V'9K2&PZD91,M GUT=<T_H72>_0C[.P?U=TJ<>KZE%WH-UM&\C_/PY<&&
M9!HB=G"QX9F*#B]!K2&/-@#H)W IN,EJX:$#=+O8^I$OQ+\A?DD&I@<1.'@3
MI3K!AD.>8?I1#P7W!F>=IL44!#"F N85D?JLFH!N)&>_</NX"&3_?OB1C\!%
M##JQD+O@(_RS@BC(_0%YC.[[^ CPY &[+Q ?K>-,65F7+ B7\I1O1Y\QE-3O
M#._/4IJ/K!+^!MCU-:3.W:X;T=2=>[&;OEY,Z[76P^-%($6::54Y.L)E:%NP
MQVDDR"3TQLBCX"0YZ.!&95"?N\4HJ?<U,6C&T7JDHNC9=[N1(-ZG,PU5S:0L
MQ6SKU_=S#WIGZ 0P;Q-N0'K*U2ZU'=N.E_1?Z9%.+=(C<B[Q5+N-_,9>^*+1
M%7K*T=IKV@WIMY1'+UM!+T!/J%QCJ!17UEV 5-S+=MUQ'-O-6T.986)Y^X0C
MX5*L-[RSF$."?))UK4\C9_GI%GW!^FK![SE2#*^_P6W4XT'[HUF//.\--2**
M5D-VD>,3CUC;R%-PVFP>:%A731E'5-NT(BV;$ZQTSRXXI"W;!D1T/GZ5F-E=
MG#+WS04?5V!]S-PJJ'P(#TT;&\([J#Y.W0Q(Q6G3\P"5V*Z<4.X#P3.<'R[)
M2]9]E .+$LH@7)2DFX:)<[>:!HU=%]P3(+^@?=K'=E[N,4;2/4/;=W$O%(Q"
MGRTMZA23:QJJ<WW7Q6BI0OOI)@*HS+6 I86#>>\/L-S9$2V&'K2=1+X]^Y5[
M$SOYJ=^K[D@&6!HP9?1VT@[$;DVPOKY8'"7/N+9E9-F^DDG5J*A/7ZP(+9PD
MS8M Z1K8YRW87B:ZUWTJ\J'I\(^FS \I'^I9 RS"<M^47;>Q)7>.)O\D74C<
M-N!IF,PA68NL-5;Y5S?L@T@YS?A=$>@AA'UC#CBKOT;E9')]V3ZLYSQ7= @L
MT9#2<0=C'\#>H$<OU96OF.YCQ\9@3!B]<Q+0U=PSU>S%I70< R?KMR-4&/-G
M?!C9SIX[> >-<GL?\[TM%4B5;1R&%"#R@(L^?.G*#7//_; )'ZZMM0R%5",]
MA?D7\.!!Q>NU+-GH[/80K,+S=JW'2WOE0E%ENC.[I&Z<;L_T]$%<@AUPOHLO
ME]D!>P_^6ZQC)H<7+-H(C@P1:&T#O[H3GA)5R;]0N@*%M-M%U6#/C))M<)VR
MM"/9I;2I;]2C04WNL)%U\A1$:A5[EAW9GU?.A+:O,KK5-0E!Y5JK6O,POBQ/
M>#")LVZ=8*+(S6>'MN5 1\]F1&HOY'MA3B9::!1XQ#QOSS6)O<GVY!68!< U
M:G(8B(;:]7EG7^-LEB9"!#IGTK;,Z1PO5TXLCPGV43=F#Y6KZGS[[I7UM5 $
M"KS4E:&]G.A1_#:M."M[5TFN\W'AYO1%)0FM@D0G>)N<G?RAW]M=VDNT$!<<
MZD4@W\2E(D-L?Z#]\T0/.(D.7H8));I%H+U0 ,+3PER&32ER;[*Y>/$SC]W%
MQ9-@4GQ?P$[V76@%X-W"G=5JC-2^ 231D3?:#0G]Y()O.Z:7ZP8;SY6CK8R2
M[O=(6G0T@_/:7'+!7X)FS <A:8=$($\1*!Y\N/D0=@RW#V/)[F7(YN5C7 $5
MCMW-F"Z/JB&,)39+_P6I'&D[94^)D)(&M-V&MT]B^\I6,L9_]U-0(B,"]\UD
MO:ZT?QF-1>#:(7GLFP.[.D3^ (0T+@*9AC-[T)6Y<K^6/+26\R(;=%^O.&?[
M)(B@Y#::#AU95GV9:=A@-[-H4_-F>7GZ@.OI%'1%UAVLM*1+VFFK$\K0M!,1
MW59.]VY(0M_";97Z-O$R^/Z11X,L"/NF'>V&FZ ,-Y^35VW182?CH3&>R.*#
M@]FKG:%G:>X^5(Y4:Q/*$8B\2'Y284/*;+XXW&A2#.0+;8PK<[6"R^.0!!)=
M&IX!Q9'R^,<1PH,"GA?F=A,PP/L3\R\1*#J:HV8_I!.Y_WM['IMLJ@O8]0^1
M)$)(0TA<%5^* VZ#[L7]1?$&Y\FF96HO1WX>-E5HSA!DX1Y0GT*J=MI.FDH*
M^W/WB=L)9<^.NX_R+0[$0N@7.2D)(0C#U;:+Y6&"J@7B42#;"T4V:51>VRC3
MK5"\C-Q[YJW^EQ.;Z0'^N?K2<;U,U]96 K0R\_R,0E61 X;Y-D>^X4+^HF/
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M\8UT3"4?5E)(=POT?O\E4\,J:.'J]^L.B16C"\IR031(DCAFK%% ['?A0;%
M,D\7@=XL<[-$H.4!V-(KV-I+K[F3]ZO<4&L;Y?<#3F)QA.^\0Z,J@9L"]\SL
MR1[CZ<:AQ2;69Q:B>JG1^./= *HX,7NTT"]C>WF020%"RN+8V@]APT WZYZI
M+?9FX).I[ Q]JBKEO].A([#GD .FBL(!J@1?CNU-EQ(_\V, @KUST_- BU!1
M.#Y.%B>M)!5_?\VQ<9YW^VXQF<@\65N?:P=Q&D7YVPIBD/'QS=EFF N/_+6E
M3QPVUY*.BWK0=W*,Z%+A5#%^)<FR6^4..8CX<.RSP%HR\P&@TE,L]<NS5MN
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ML=9\5=&%'VBPYL@F[QQK"0E"'?_V';XK_$>+0-#=.QRLYC2B7D%TB7##O8,
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MV5'8^1L#+ZPE<RR>-MK(*"K,N7[9>/_%1J.)!%V*#LT'\-;)GA)>0Y65!@/
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MM2*<+^V;\O>UZ<E"$<KNP'WJ6F(X%^I7[F]^ZI)2N=,3<Z:'<+6F:1V:MJ!
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MFNTUYTY#6W?9WU_?'?^4.]ZV*UCL^VQZ@?1F/7]4#)P^\BT?HE7L]L4'EW7
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MI,719@17PB*0'-<OJ[QS3+6\R/V=;-5/?V:?R.06(-4W[\UR#@KFT8$/6FB
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MZ25*)[)\'@6%7E/*W%B4G%-)YH-<K&?48LXM.FU<9&M\ 7Z8US)KGC)A+ M
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M+)XR@>Y/"!Y+-O-HF,NN;D!7J1(YXMTL4'W3DTT22XJ+40VN]DVFD9<I+%]
M6;BWO4?MG;&!N.E"5OK%PN>.MTK2LA;#G6X>_4V<-P^IBTPEPD9F((NB&Y0%
M=+(V\6 X)GGO)#:AIBTTDJK(?./VS69=+P)7\PWR>94F*A)U"6BU?(OM:HFO
M4-M<'J_/][[3]HX4O'.(;D#$*VNX36W#A?W)Q$2.:>5J[L&$>N$K?)#;-($>
MS)LV'ZNWE#$G9+/M)W=B;'G.*F%S&I:U3Z*'V.P!*J&.$.^6DN0=KQ/.:;CZ
MZGKE33SAU9I-N=1XN$SET-7!*VE%=@7J\ZEPB=RL](!JT3G%)UUZIY+ENK*4
MKB;;E7C86(B.6-W)//_J&UNW;S0S/3T],_B+ZR-LMU,29&&"2'XW_4E@,B"L
M%]R"G3EB,!O".9^+[D$?B>KPA-0AMS:(1X&A#3X(MD*?AY+1=0RC$2XN [.N
MSP)SGZ)^1W5#_N <9K12$QZWZ8HFUJM>(:_W08[[DNYOM?DM0D_/!Y3#:.@3
M@2C%IMK&R1+IV'$/\FJ#38J^\+EKL!A)*])&/> X@?J=-P-AA$7^C3Q,LQ9#
M2+(N X8XCI>T?=U, !\DW2&_EKN;P .OZ<"\@L?FOF%%JL*X,GT%?XZ?FUAI
M:LA=<6"J/PY6Q%CXO6ULKI\,(LA8O\>F$AD>6X 2N ]-EW'#D^WL@8#"->W(
M;,AG]($V72H^ ?Q7//NO DO]7M>;+_B@8]7XD]YI]W?V+5Y4WYZKV0L?+FZ4
M?&C-LGL?HAU^/?,RX:)7F0)NR'8"9W0O/;3H^I7(Y/9"![N0H+ES/W*C&O<_
MF%<BW&Y(0_K*]\_HWFE_%/;3@UR2V&N?O)1G-EARV,'V75V ,V\6O8 GUHEN
M=#/S6.>X)1Q+9DH7^F@8\33@O< '/4,Z,69I-431>(X6C2Y#,WV"!%<"*>\C
MM(WT6^IX9+9<>:5_0ZY:)74]NIP/:FR#A)0%'"?K6X@;\^YFS2.O SBF/FV^
M63&)IXR\R5SIH8A])!G,GP'B:((!(DCN69NGS1Y\#YP_/Q&NO!OPU2'=%_;$
MYX'4T*4#37I[]W.4R[.\5JZ7*CD71)7W/KQZ/:?ES>(?*]JD=Y&[CM@C1NI)
MH8.Z++4"A>P#5R%^EJ3,YD7;$G1TKD;%HE6NE4Z \O ,Q_$=])M M![XAA @
M?B^88:$>ZQK.G5M:X?PYKP\0%]@:$6_YH*+/Z*Z82D0I>9SL/V0=X@?G@PX;
M%PLCD.OHW"Y02TQ^NOIF$$K PIV-TE 6FB.V_MX)A<[G-C.ABR+E2S\]H3-(
M[(E\\0^490BVE0VF&P5_#F%A%(>,K//4MTQ0WJ_*JJ8OVXS%!+?2*\N^$+_#
ML V,'QD?WD6J0ED1PK":Y-@3Z._V3Y(OX#59_SN"</[_"N*'%D 9#EBR6Z_
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ML?>9QBGW0_R>;939"\QX#$8_][22[6(5[(4R;RMU[(G6E@RQ^;/8U@YF.!R
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M&1$*%X+=6"Y5=^/+<JS4LI^XK-\]K604CJFOL:M^D!NB\KZG"[HV;Q[!$YM
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MS+KTPH[#C2V'HAXM/E=Z+R444^TQ.SL(WY.ZY#-HTA@Q>[M?-Z=G:XPAO7\
M\NBB,Z6:\"DUCMKL[*(BJ=<9V3N6ZS*N4FL>H7\(!)N8B0E;!SMSRV'FSB'Z
M&U_-8'KQ<H$</HPD))EI925"&3:8#%F_UAE]S^XNL"C' # OL]'8#S))=F.&
M%*0AK&#\E#(W8.5.S!UA0%,WT(+'#D#$VI 5C!<I_POLXFTJQQ79"?TC*^L
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M*!R -I80?QR JJF=>OLHZ OP_]0/>04*ABPM+D-8O^6CUBY"^J"G*4O$4CX
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M-'>M.1FM4L;\DT@A"-7SM-M%+Z\IKYYPA9<5GN6#A_%$[;/UYF'')3)02?.
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M(0GUW?@ U!3&VTY\0!%'GH6'T?AB*@4CB?#3[% X!4 7H%*(ZTQGUK,3!;>
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MAISZM(>?[-EF9Q:PWK1@AXZI1*O>W,"[6MBD#CMK< O.O[K+MLOJ#30-F#X
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MP3XP<$&1_KE!:&V\REM8061LCWN;3Y;&5/F*-<(QG=+L* L6RL*1X_#&B%M
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M0=O%NZ(&;:9=7I"4^L\[6>++\,*380+7%8@:;?Y)@C@/[.R]T81T^(O^U$"
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M!YA A]$G8]%X22R4UUK*5Y6U?[MIHSF^*6T3T1!NR$2C@P+W%?9MMQ6)AB!
M.+0G;YK.?P $K^G$"*R$UCS%#-A)H0=<%JO(@4B"<#KMB% K,"*X=FXY 9IB
M:#EN",]0?E-1X4TW+"^HM0NN1<JBML6+/CI09;AM%R2P%*"$OHB_:"\4UR[Q
M<F+BWE)$JD)IL)1K+^F28>I[E=OI>!"5S3E _MENC\K*B)Q=I9=G<F0H(?1E
M\G\=K7G1O"^!C2\1:X]AQNJ+_$(Y%^>*LTS/DJ[QQQ4.3JGOGQH.ATR/=TU\
M6$\XX>^5B[V2/80I);P;"W?ZLZ\WIOQ(>E.?E2SYH*O--:+64/RL\V(RZNRN
MA"XT%?Z360"OF)\.0%>9XL)$=\:PN1!&D@I'(9F\'%="3$]F^DQVV2NFG9HR
ME&)6##7,@"@6TH$4I^NO^G+*JEB.</MM>,PEM4=:F]V[$GM'Q)"$H2$1TW;\
MMZ"YP!+WEG"4%BQ6 4F.^50&UB[LQY&]L$L@J1HL$O3+<,I\;($D^E4*]AQ@
MF,>/S6Y &77LC+52GW'MM><&/]*=F>L4W45AY(_+4H]1&(Z@ME;/CL/*]23$
M=="< \^$*QK>&LI.,F\F2+T'+>@)W5/%LHWVI@-JAD#]Y).A4 (+$7#13C=@
M=9TVIMU=KO7F@J<M>_J;UCZ'5NGZWQ[+EL:4V899>71!U".JWK\FYY7.XU1?
M+8ACD?6N(T;#0^8?:"W#OK_L.:_"S3:RI=::-518M?I=&?WGLRR=KU\WGSS+
M.BOQ_^:'\@ ?.C*3S8_=2<;)^6.]=IX(;Y:8%Q#'<;* 0]9V^%/>&:Y#W6V^
M#2P5V.IM8Y4_9&WN-*&,I&MFAQ-)GV&0UJ[D&SS-IHJE$7[/5XA0'BHZ5 >D
MBPZ2 >K<BG/: %=F[:>%TA-LCG7//X:GD9&)/]MK5(JN\+J'.T9B.!OIV_;C
M+M?:?CE6@VGS;"V@SZDZ\2..KI2?$&G!9+%*/VP]OB>>AO*+8.!.\32F,GX9
MU7SN>!)KQU/VG<:> X_-FT?T>7C$XN2 M-RF Q8^>OS&> X\G67)7!']HJ!<
M1*I=MCPUA;6/^';"W6:S-D(UMV;S]];"]\NOJP=;RAXC_4RM2V=C=#>@=QX'
MFWX1YB;UL9W()RDZSWC?)Q*MR@YH70YX7WRQ+-$P_NP<JM@@_H]NHI<+*=C<
MD47C3^RTX>?;V,UM*:+C0C,@]@76,+)^[AWVEYWRKH,Q>*WT9E7M!5>/B)/8
M&Y/!)7K&KI/1PY>7/C$01[&_EABGFAD'!1ML6Y5R2G7*+"/PSQU!=;SPF( S
M)93%]UP"VQA;:FI@H< -,^)@Y'\9?%35$P-+YIBK>1V_#2CV3DVL&JPY,^GE
MMVX,-V#N?G48VV2?0%A(]U<$52&+$AR2B3L^@KWXGBN[$L$04"N/?EEX#/"A
MT\)XN$;2.PN>%G<CXW1;\0#[>(O*B8UP;JEG9ZH[VVY45]]0I;H9(K5T</\C
MHM<!W-L8^P#*)MEBP[9KRC0GP4Y_"+GCH4=:KV;<&3D6C$.5S%YSWFKWN5.Z
MM=RF-73BWY<H3*C%\-<2-N(-.O'-'53T\V+W#\1GV35*@L<\)Y(#O/.IO-RG
MBUEG*8]AKRIJEA/"LZN6E=\T57LNF5@5!,;5+'<TD.+VI956(5N/VL0D5:,4
MIYPMQ>(8A)9K,XZ+NSBPK^O8:X,Q]9#_X$,+?#.F(70F471H%,"[3C4+UL(=
M<^&M5\"!A3(S;X>VDO1T(IA:C0T$,U7_PQVS-V]NP4LC1:?"+)Q&BQT:W_ZA
MJ%SI2'KG:7!_5^))NE >O: B_/%JX!W1._RQM;Z*&^GSE$RL[+/W/NR9I:8E
MZFGP^23MD-F5^IZHJ,,\,Y9:]T*8J6?6P-#%Y8B;'6&=#//WSB2>6(7V_XL]
MZ9@! 6[L6'/]F->*:#]1#X$KC%9[O92M.S9<B#*L#.@=9,TM:=Z=L7LDA'-W
M)>1]6\8_KGNMK7YZWL8LB] :CZ8T<C;XOB33_XSR*S\[%[LY&Q!UD+5=*TZT
M9ZNX& 9[;5H, 8LZ<PX=?5/IUK8Q2XS7I'6J-R;4LFB[>;)V5^*SJ:6<QP#D
M&>&3XZZ$Y!EAH&,F&W!Q5 !AD^L?/SF",D ;A] [OC_Q1#-[3<_"MAVLJX>5
MZ/J)0O1QZE4/:EN?[*]1(U?,(;_>''%D+F0+3'\\DL7^-(93Q/=<A =%W,6=
M>5L8:DC[RSNV<<%1>FYVSE^2"L[L)_(@ R;VWYA*#;\@-R/45HRFBF*_))4Z
MQ!71[<OM3-'(4B$/9H+:@K=^$LJ1N'K]Q=BI8[@Q6JL"D4,[.+N$#YCPAQP1
M_@HVBN&><O<TD_B6K,;T"3.EM['TB,3-PI;QDM'6W,V<S>&9(?AV)=+$+2V=
MB"S1+)2<CAZ&.+X8:UZ),$**A@-(,];(8,FR*/4IV7@CX/]@[\WCV4S?_U$S
MG8Z6JMI;2J:U[ZU:2I%I.V@8#&J+DJHJD9+::I=.;;75U):I+5-$:HG4$EI"
M:A\4)9:*6A)%+2$IXJE$G/C]_CGG^_F>/\XYO]<Y_YS7RRWXXWGNY[FOZ[T\
M[N>Z^D"%IO5#*K/?_MUTSZ(&RT7^WJ \.)F=9.!2:C=9:9U[80CG:D*$QE2;
MQ? ".YH^7&E7&OJ26^;8\ K26+SJ2G#$J9;#/W;A1JN1@>#A=-X)X5H($\T3
MVF8.OJ=F?L[',/_Z%/L8<'AM&YV)C6J.ACWANA*@T+D9^SC1Z4U=(OFG3U"/
MU6V4_T"X^\;&8E-,4_+F_($8*7 1+,R]RO1+YT?8(K2!.?^4)$C+1/7&Z[*D
M_[DO+2N:Q-7%>JZ7_#))R+@\>*EA;*=0KG4]1]+QWPM_#E@RDL KMC3\SS,+
M1MSS!F6 'Z2)]V'L(6JAPI"JDH+[=#U0*QJ58J[,14A#%0K%[WC.OFYH_$B"
M^?DH;3U"TALS-UW.ADMZ^!\*1/%%S0IJ)@B<#/K15)!S-E+3_6T3:ZNO^ADI
M@J4&IV;.%O?F,%V[9),F2EYBU\[,0 *V9[C6K*'R)C:V@O0&;0-$T&>-G"C]
MXXWKSW:&F8X?MA]6.K6X;4BIVT%B)6GJXY4.FXTX ]^&;)LH185S'UYE/^+%
M:/1#EM[E15(2"[W&B+<<RJS38.*.>-MM@\=EZI!IBX;O\^.;[5JHCE#R0O6S
M_!>( M>4=JU(UL.:6:U75[@R!VA3X6!%8<9UZ77'46WBK.#[OR 1$<MK8OYS
MF@"1(&+>Z:_*<L$@8&,8[OEK-8 J^ZC%IE/LE8/\=MG52:IJ,LF7=8RFVW$H
M( ($"?=O+-4#$4P,A,0:;\E]09W!-S5-%JP\C97PK>R+_UA8;-,MMMX]%.=_
M<HZO"Y"' G>E#XI1#^"' @&' @J?HL!2X "\A/4XZ;)OE*^2#.\, (+'A<;0
MU++A2O?1/.D88=%GV;8/S4=":<U,'3HZ?^J%ZC*(*P]G_;T./NJC GKB IWX
MD-_^ P"CH])D-].182FVZ2[ "[H#;4@V[L:<E-QNH:<N;6(COQ^EU. &C_Y8
MT"MWU:"U,ER^C729>_/)('/2[3RVW4+N6\O?_IXCMK*9MRA8Z9W8^NP<9X.5
M??R=AL30.S-G9X:N[(+@ZMR YWI5#CA"YXHE%KIM/:1N*:(*\1@G+U#F$UU%
M*WE3\PH$;6\/-ZUXN=B+3,;VKXQ@@Y[9WM9%W7/4OM#E\D<W ^713Y8+?A#I
MFC4;%S\7*/U!>XOM"TM$,8.,.M7-SZ(Z+IDK ,G+ S;"6YF' N+M:ES/UN82
M,SOAYHSU1[&71K>"M'<5E_H4<+3Y9!-#7$4_MN_TR[@R+WA+[@U$X4QK==;L
MP/<B'GGR2D88I24)YJW0_T>&?VN4\0W'[Y\Y7A*=!TXI]0.!4.=+AP+NZ,>L
MT/P+L*$;Y3YSHY U20>+R)71_^^;5_V?C%@+OCO1.13(?<S[?"C AL,:97A5
M(Y*N,T26#%>RE><PPPD]%)C&QG^$[5>;.GA>U=W[H'J0^/%0@/+&^/*AP.;5
M><Y/?#>X^A+31^"*9?%L!1?G#XJRGJ!VW2(KR/;KV\=X)_H.!5026%N\8:OW
MX/T:4R<8;I>[OKC"+8KMX[W7&SFPM/J.6$1S\W/!&]?S^,=R^XNO+UD)K/?_
M3_7E_S_^UP_"A.XGFX4Z2M@,)L/DH-)C%FJ\,R+8HV?2*.NUI>LP*>5^.VA<
MR:6>^.B.G%N0_"V9']O/ !+,TD.!19EN3U#G&ZVZ5<C%-7.E]DPW_/,4Q$6Y
MICFAJL^>O@\9/X0_*/'U_=>R;XN-KG#S;PE,?H&=L?"M6,W/9QL:_O7:#<\(
MO.=V-U7R\:U12SN;\PWBW3D<W422[N[GAT#Z.3O@3GM0_H]7H"Y]5W$F_09^
MYY64WL&XAP*5YRRV';+!^/;T.3D48D4JDF/0M>T[+>_N77_5.7,Q;?B.1'5&
M6GXV+F^T@!W2 /,DV(5]J;J[G+>O5DHN'=GZO^MSCJ4#*8<"%X.(AP)W&. =
M&MR%=P+U;Z'10?(6>:>@MRKVYJ' "R/HH4#M8\S^H\9JU$_@+[:%O*Z(^7U;
M'\\LGD4>>$,=M7I&$I4)8MIL6[T9M9!:*KYPQ[Y[1!#5V0,$\VECCYW%!G-5
MO4ZP8 ED(J_OX-4!^E#@I'D"JA3E?Y# < $'<41GVBEL<-/T 6[@6_P$DCQD
M1TT+SLDH4VNUUH:8R1=$V VO3M>V"#DX9I0I1_9?)5:U! QYNE?C*$[_I0:J
M >?H+0$,G[^\4%UO3 59H1T@)@E%BT1U4HZ:8!$88, %Q<2#WY#?[""*%3=
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M!>P7UX>,NJ/M_T2VB\S%FN:\+S%N<*D?YUK19MUB?5BS69^XSF5R'KJ2_M^
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M!5&1OQ'N^^3?GWY@+SLZ^*;Z5/5;Z^8MQ$1HV'BNKL9N0+_:]L!HNO6WH*G
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M\)/[>]$V>+SD[*' *S^>US*(.XF20[%.&AW</W8H8,"'A@'++""QD%?_PZ%
M025_THJP:65)5,WWE0-!U%(3WVZ\[#J T++VI5%+F][\=/;;AAQ!(!],(U"T
M)!2"D(@A6G$-!;G:NH SF5F"ZN$+_U-'91I.6+&WCE#W%,F/N<+CG\:S78?W
M@??A4""1S/'C6<S>9)#YMYC_]16#X(0W[S1;2"W[!'^JZ:Q!^&AP NHJ*BWO
MY*Y2BWR-7W\;2[S(4.^?K=AM> S116@/,,]9G*35[X-<RTSJ"6HQT FDRQ\X
M.\=E@F/-!,U:. ]B$3*KV33-!\D+7T$2J(Z;Y/O"AP(S76P[()6C/<UUX*\D
M&,F2^X-I-ER]J O<\ ;^7'*+U.U3 +$^1T=P%<> PH[-0P'D.-< ISNC3;KI
M8T! YWM41Y0,HY8IO O\"ZMY@EJN0GV_-<6&6$1'FB[J#:Y:/Q<5VX!;EU6K
M<<Z;V0P[9-QY5S561,RXB(_1]&\V_;TO)>0AE11LG"RZ+D6SUO<!U]Q;A>;Z
M&O<*Z2,HR=F51O%>#[YL4JWG_P-!R_[CE.'\7_]WRS0LNJN:#/[J?BB ?L>W
MZ :8_P3A-KX8*@0S?T4"$03&S=+X,1AS$LQL)M=Q%1=%A0X%.OD$(J3(.W-4
MM[C3%:><PL=AVD7^G>I?A*ENR)G.\QV-MPV[YCO*OZEW^T!ZU'V2?GY1S!HK
M]&DXVME;(UQQ-U8KZI7^.%K?W])ZE<J"UV;*>;^U2GGS=]K5&G/8QCIMS1*O
M?H"4-[?^*W84K<722ZR98*@-Z%8=E6QAV9<+J94^ >>1 357KIS-PD@63"*<
MG(&IF^H&GX@],6'JS8]0.-"ZL)<>)F_%DWH8C5^WT2$0 !D7)LFU!?,4O[GY
MHR=D(9S96_=/^LQZWT<B2&A5NLD<!"J(E^>'K#,Y2*X8<H^%[,-,V_\V^D&O
M83XR @:TTC,A09*B%Y7'B.!$\S/$R/L/4_U,!DQ_^3%_._LV*EK2E7PSM2%:
MLLS28-'Q4EJ&KTNNJH.%?TXA9&!VY0.G*;9"]>G;&*EG)1<C(90\B/%XDM"N
MNF-N(:D )^.O'G[[G6(U7+7R>Q<_<9H.GE3PT0K)^]# _:$5P*OV'-QT =+I
MH-1H=*I,YQ_ %3L*D@MY!;A:8;H*#'-;>MNB@K&KAP+,#.V!@):*2F5>600J
M CP=U@JNA[O 7D7/I98=L0G7F&ZF^/L4UXRPBMY7:?MG_;%T2VTF_BL57]-D
M4O&B>C6"9>]3"2_(R]B>GO_D==T OU0S-O/90DG/Q+!8:M&5X"H&K;C8^+W:
MN;#2&'MV#EGUAT,&BC&>;9XEDO0JH<NQTWOUF_=7I]N5E)#<[W"LKXS&<\?\
MPG>0YG&>_Z$ @@ 86K$AP&A-9'HON2'K.<F9HPO@H%&$J0XV-0QT)OY43V4_
MF%I[&DT+M.18L?R2&+O&)6NJC6,D9"B-+-IG4 H@.PVA004MVO.+/+XV^;F&
M-W=FS?6%/_@\^'Z<C14D;76/2DZ/O_RU(.^#G*42::R&=P)X.ME[;^;/IR)^
M#K_^<^FM<AIA[YU%S-EXY2$F\_:DLG,:Q&J&DNFN1%Y=M"YOI,SEDFIVS6-D
M.HK,,EZO#1[?4%7YW%[M@CT!:4;1+%H<)OE+=*&]N;Z9-<6YRF>42FA<;:5?
M#6\2U;A3T(1&!L<WPT1Y/T0&[DP;G'"\]F!,5XZ.R7KU+GO8Z"WG=G1OBF@G
MNL3&XAE\3J/Q[4LLD5<%]IN?[EM ;50S1R" &<>,>_6CN0S79+16!QG8*'+"
MZS,DJG*N1CT*CZ NUT541J9T[Q]\<9G,WXL^%$@U"'2%OB/6US46?&?4X.^E
MS*C5:CU&9'UX6!>9>CO1<]%:0W_58B=^6.AR;GZEM;4CA#A4;7:^X<) ?0SI
M9W')*DC(,.ESU53V&(M-O(,]VU^^)!0D.0/Y-OL+81'Y7ZO9LR$P/F3(-QP*
M7#V"[];J0X'YH-HY/G6\6!;D+:-V1<]$D?CDH]3+9]D0V/Z;3M"_KEU;WT$D
ML4,!'U0R>6?7%_;UJ/&\.C_"3_"&8<TJ>#HH??[4[BV4'XIZS:/ UA[*>I#Y
MJK::>2A -ZRLWXQ:8>T]92#U<Y!T^2"V&ZJ1A*)QWA)#EA>=I\)@9^?RDL@C
M8-H>-VONQ*% ';D+MA]=3V"?(U3020]4C\&T"$EX$P/)X-2WTY66@.O@5?W%
MJTTY2]D!J]<\56)=?_ %M$:$BVG!GR+OJ0VXQRP5!/R!UC%0IQ1!BXW+J4Z)
M99J&A <4GO#*_\0&*9;0C$=LU$'N$O/5>" ]," .16>0GUEFCW7K;*&[Q+@7
M6B@>#LD2^OG[[JR0&4^;\W_TUT"51DS!?&!DVH,!(RLVZB#7U)-FGW$H "+Y
MJ#)D6.F=)N70K>2PT#*+TE@%9@G1GU)L=#N]RW7%82+6!P_7*XRSLAG?Y<QH
MZW7=;FYN;V8.!$@;1B>B1H>DML^6* W5W<9:1B:=L T9^41),K;3=L?IO\M&
MP2UZKC7N?.3$ROS\Y:PLJYO2,8!W@]AA)C7&\4(AME<']+]\ETN'] Q?"8ZN
M*/[;-9,WBCH)IJ'B1S#R[3^A.J_S"1K#U2$GP"1XXJA.YX.\HW<]3XQPM;)^
M6B\YS2?I!(XHQ\:2-\WKY8]1W@#OTQBY,7Z(#69H@JXQ'&*4I>@W0G!7AT^/
M)99=;56%6^!D'A0\AE_3IZQE82M/C">N#H7>*%<^V<OPNF*GYVIK$$9MX1/"
ME?_Z_/5 G)]H^GQF00$1J(T^[Z/$ZQSELTX'&R0'-/>"F2]1G1)\9N+S&']:
M%0AU5 .9IL#_L;5WQKR+;49^R/N,(D:]Y&BW?S":WW'%9@PWF,:!O-.[.= [
M+(QJ71=EKRQ<9L@N5QD[AVYH?\VJWSS?7U]SL^?N)91K[>I #F;R<C@JPNB<
MM2FQ>CRY5BQB:=EEM'R6QT^#I_GQG?S%98E./S\48 ?SIU7&GPJ*,6?$1&>@
M:'K\::CRI 6/]LPV3O'#@*\'S0X%3D8\C3AH913&3Q^\Q?A^VV9[9 *P%<1_
M</A9TQ6]]XYAE_[&^$*&G8W-GBO@R$HYL1-P.^AKO*YOH#3M[T=S-@5T:4W0
M4_;NQ-4Q9_.Z="SGK?'5OOS,Z$>C ]!OL_,N&_A%5 .NTQ[X ]RP\A[S)XCY
M%ZJ3+P2$G!:FND03,<P\E"^*KP4[^7) :+[#!)1 IOW"Z^*-3:+JR$W\T8BJ
M)S<9P#:V&@^R.-:<?LYM,H9_T2ZB@/(*U_10X#WJ!)>?Y,)]/$D45V-$!L'3
MX%'XMX(/!,*ZG A.J&73F'D'6Q=P4Q#@#7)T^?'")A#7S.,/!30WF(QMC]WL
MM"]EZ=W>K,L]HY7]SS)6#)RRQ1LKRLN_*Y^[/FL-O3H-^ZT&__7>I;._>PFY
MQU]$-W8,%)LXEC$T.G=6K[ZUHMX(KGIW1[&J(*<)/SO_'Q&4[6 1^/P#:SJK
M?I^!"MR(.L!LOJ8LL8N*^->,L]MC/P(("#BB==OWI8I[#@>U\5EWHKUAXZ!Y
MJT[JW4%6(QO55^V*1E/' 6/DT);7:!WLOS6PEXQ+^(:%[$C8B&M6;3R8D"V:
M&\'D (UKT+DQE @A#NGK<X7O7A<_H>#>\0V[2,0&*NY963^C#=/(.PZ]\WEN
M -,W% 1[/,4/%I6CI_G\6VPS CP6?,+3B53DR61Q=44!:+S.1U/G [Z6%QKA
M2>'8,FR%S-#RN(0-&/.-*>J@DDUHC"MCP! 44F:)Z_3R[#)A75G2U5Q5PD/&
MJT)1# R'5MN%+B4:%]TK;?MD><DEPW%,$]$6-/Q!053D29=C!TV=HV5V7&T,
M-^*(T\C%&KY;&PA7CK*VG\N)GO;/!NORY_4/F0D1G=;D"6D&_OR.Y7IS,E:&
ME64U^CR=ALDDB^K^0C'U]L-U4CY_\F]7IA#P6R3C193(S/P'%<[/K16&1.^
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M;"9:\V-O\&E$9OE7YVXUQ^Q&FJ48EB$Q:P<)?=M6=#OW?J&CK7^4.^K$%_?
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MD.3#$EMBJ78AA1'UW. #;'C;O65(;:P]C1,7%7Z-?&K6U*3D197G43,0U]!
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ML69\+X(_YLH;K2F[.ASZ>V^2H+N5Z$F-3\_&7EF+W8:W^YVS?S&DD;U4GEV
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MX_?54WU.9A\8YPIC:978X_YM>[%O+V/OPN(F7<K\R]\R0YR8=YZB*>>@!)"
MBOEK\"'13O8$OW,I'?A[%$VHE+.O%,:SZ!+2V;FC?LOB5'T., O26,^VP_!.
M=4!A!']TX>); F</H,P2ZO[@(B04_KL:QG!V'\5 U&=2(_-B_XDFVW$GZ),6
MA\JK$:@37WOS86\HKL>$KSG:W#N)M>W]5MEGI$!A:^#MK$7GSM6.*MI6F2#5
MS^8D28Q_FY'J59F3M-_N0@<%^8X3!.3R<2D9TD?6)NI&^)!KTLW-8(Z;L[.3
MLYOCAE:OJZO-_RO'U<IFS,\S[OR1XX;>R78 <US)Z73;ISQ76$U=U> :!<2$
M.^"/9=2^&5?E0[SA4UI0&:!;^7I#W6!T,#$^1$:?Y==:J1TP)61^0%]Y/^&0
MD&R!2?'2A^K^"\.C06P^Q! &**YW%0&G03[!YKZ,/!OZX%VP.U.^1^;$\*&+
M+C\RT;&,P]E4J+XF>M@IO?'ZW6 ^1'2I(7/_0;^Y'?UC44VUM]1N\51)M(GU
M* IZAR=H[C/;,<::X!P"U%GJ/7>_5:JK-/#DZBEM(HX3D\H]YUB?3+U80G8M
MJ&>8*',+@^495/&.R\.&V,-4H?2%T)@!C8AD13_?WXIU)JYLYCG!'U"+ Z)?
M-2X<FM/K1J?'$877S8K#;+]G/W1;T[V<B*J:?+W"B]G\)K_FL0/C0+CU!J++
M< &2-W*/(T B.\#N-G^HNSQQM\6.YG_4Q2<SV[4AL46DNM*ZOP"=:!'#=JA/
M+VBFJ)]7V6Q5MQ_^_(:R )SE"=6Q5MA/N=G8GT&:R(>L]LSZ>= 7$C%Z+ =Z
M*SZQQ;' V\FR+H2 %G)K'MDP?_8YU>E#\,I)J9F=KJT9X5<1=JD63S^_233!
M6<G;Z]XK_!X!4A/J[JFU;6J\(9#M\"$^@U'XVL'=%:M(L<ASO@:2 !:$8HS%
M[*"801EA$O#O"'$[]4$_G( .-&YL?#1E.B(\&,^1+G-+%K((&5N[U=@\^OF7
MQ8?$$ ;]]7OGON4%#>5N(2'K7HU/8V<N)I41-$9L;Q5*)?A]T^[-0=DLLK+&
M?KBS@0X1B\DS]2AMU!E+EH_*E1<<3M8JEE=L[$TL22W)U#/5&HS!^D$!+0EV
M'. >4 XTL[59,WD[UP!)SU'U4T#HK&(0:0_F]H?:C?"I*CW+AA'/;&H[_&A)
M V6-5M\VYE<=*>/K].15\%Y=Q"]MO=\L4-^?[H"I\-L?L;07)*;9>EPF]O!:
M,%02'0@2^!<J;FK<[#9][[8SJ1UZ<WZZTIE(P>5O/F&#49M"B7Y2PT)7L!V9
M3?I?G3K%O%HI)=DSLUQ]Y>_$W2,.>4<XDN-P]U:!69,$C?X]"*"'ADR8$63B
MR# Q4]&'O'-C=S$W)]_SY("(?0Q3T::8++5$PG*^II1?[W1QVHQX4]NK)R/]
MI7W:C>FL?2[!3CKW?*YE:&6<"2@JUPVP.ZOH(VFI^,!"'C5P(8I&U%;4P+2%
M=MA>;#J>M'"VRZ$/15OJ.ZITH4+>S);N8RE:0JU[[*-5-F#G,_*PZ,6!9N(8
M I#W6EMC#O($%7<N+^)E]'\@P*/JGM7I[2X), ,\PRO4&BHXFJRV9]8^&WI5
M[AK],B?#?QJIS:FZU.EV@B5<G>6YOZ)@N?Y=B&?1REC83'01!QR< B<PCCET
M/$=D#T,B=BWCDPL&!:0SF^D7$7J&\U-D;@.\<_IJU9E\(Q$7ER6LL'HM^R;C
M3;:T>5_%&X_HM>@UXAR)(^7NS^A"3F4OMCNT4V 37SZY?.HIVY?9E4&>/9&\
M/U&+NAHJW(9[F(+./]]C'><"&"545;;7XID/Y;MLCT3V8/>JRK8=TR")MBFM
M?#@AE_U[/!U[ #"S^RY932ST8KTV.!=U\^V9>^:II15.@59]/C<8Y6@E[2#O
M6Z?C$OS>=9Q__LI7N"'DG;*-I46#9__#Z9T R5&,PS_LW[\2?R(O$E46E9-@
M92=O(Z*RM]Q8\5S>]6]V:;?2;GU*.Y9DUX@$-+;H2JYH,KL-6 D\5R87#^;.
MU(-!-S/T<&?F]&W*46T76/HIO=><LNXB'G/.O#21?//F8*F+1L? )8$I4FTV
M+Q1T4;@H.).X^S'F+$-X(,=?>*L'FXP_R@E 51RO+<26H@,[DHLX\I15MR_O
MYD8L,TO0L>T&JMD]B+&?1)R0R]FC:WD%-Y=?3E.QAIH+ <)8_UR/VWFSE@7/
M6UJCSIJ!T6U/TM2WNVRTB?"FV\F^4Z/%]DFO+C[TZ5O1E'<2IO+R++,1=U)V
M-Q!(B#AE920*^5^]'.)XP]B3'-C.><Y>H&[GG^BOWAY,4@=VSTJ^>FM#]E+E
M$V*(^]V^ O2#L24__^R3)EU2JTW^L1KUSGH%P:K6HT8M72WU[&70U0E:[(BN
MP)DWX!/A3MQL#5+2.&S/*L8"]'H"P./.2/G8MPUN5W WAUK.EII67Z7GD X[
M ROM1SY-?0)BIJZ.V8,OVK?6U39_6"-8*#G/U;11MLC&2:]$S\;G$&*#?Z[H
M5S3MSKS(3E90-&USGLI0G9D\\7'BEGM49Y^ A7U7=[1#3-'< <7QSY'OS.QD
MCRM\^_I-QU09:<.9Y)WB^(&A\1Y\ZC B$5^'[^ID'LYCA3.T8OD0(67&[7SI
ML1:$%[.'_BE$W,D11VX39D:FAE:L:(&IO%^N+C)&0UC/TG$S/$?ZW*C_VESK
M2%T1;QKN20*4!3A'<.S+@#H=\0OU!Y)W*4:5YB]T;;A/A?0/N(\S\0B:V"EA
M]<_LP22.5R7AK7*H)D@D45^=R7+%9::'SAON%7<RP'D6H[%FPQJ)T$'U_[B
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M\#50%"%*I\$5(-R?N6 .8Y:.@\[JS+9&VSF*O@415@N+QQ]!VO,FVYA\2*Q
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M@&7AH]5G^9 7^T/XD)A*\*;P#1E*MG(=Y"A#X[$;"'U0V*@,$A_2NPVGW\2
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MG6"@K<Z5C+-9Y4_9#S")&9_JD[66@EKNSI0U?$-'GG@1-1@@.0,3L<]]959
MC+)*+-2VOQ ,TQRAI'NK&+8.ET[:/XD#65B7P6^\0WP(K>E&)!7;X+7F$UK
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M!>^$'9E"H\S&<QAR5>6^D\BH( M_>PI' ]9>'V;!*_=X78.:=OYIZ O143.
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M0F6A=-BOF3-60H@X31J,Y$IH3-"F#UDSCM,B]0_C+#GIH]Q8]VO5Y<R .OJ
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MU"0NAOK6'QYPWS=5*>I^\B:*>]5\5RL]9< F9U>MX,+'1FL;^=HE5^D%M (
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MI@F<H[U4AR]U9\NT""%#9B8?]15Y0%E%62\.RB2;NY-P.IR+0.[L:T]9V\K
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MN! 2?5^K\_/G*,W$L@<+5 4LPB90"!G;U]EU'D9)2T0<X!"TWTP'P2)P:9=
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M0<>SFV=YTC;A.<F]X;ASD93-]ZHC)XJZV$F$.X,OLRN=M9>L+*\[NGQHX[2
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MF0_J12,$ZZS]4+)\3SW$<U3761#"(0GP/! [0A+%R%*EYXTW^#FPX^.=?F<
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M8 _Y(H$J0H>E!'LBV(!WA/2P7Y#-KPHZT)&G#"1GF([45W.3KCK43Z_GH8H
M1-&E1&G98Z1%$!JG;>M+J*OX"*FRYO)Z31U#\BEJ#D(/-,O*<>:I;39W''DS
M 5&%[S1'TN\QY'ZO1L3^.*'B%^^,/:8*<8*RL-["/XQ!DC?Y9U<AMAI,$B&,
M>6RI>[HW,8ZT9&L2SLU5M;O+#BMQ'?1S8"]^Y\ 6^8$:(NNS'\N+^$*8YK!>
MIY3[QCWEPND)RJ^Q'<,13U-HEY_6R'^@G+]RV31>O:C_O*G5\BN\NDV5">'
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M0:2[=4X<#+M&0SQGFE,L-\R4S;IT/&+4G?WXO[T'+5N-+0 I=+I+T^?RG%&
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MHGW_F3NR'-@+HK6YX>!05Q<<U!RFVU2!>XS@:2:29I PF?Z<Y)[(A8^V,C/
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M[A*72H1/&4Y^^880"!*ER5+*,[\:%V',,DR"1,,:PVX@2KTY,,4Y4+9NXQ[
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M[/#;/T,&UFTA'69-ZV8<QIR#$H$]=9C= S%'8%=R&+55]Z_36$W_C]N'28K
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M,=TC;H94"2BE<:%TMT1:E4ZJX<"-#"OR]A9:"EEEJ],A(?U[8076Z\;. Y:
M.^3UN^G*?C%.K+_3E6RU<=U8916EU?<%0>+*0ZV^4JI5Y4&]:/4\QQ&?B#_[
MWKNJ<>Z'K]J<Q"?TSN^JF>G(^KH5PGU"DY9SC5>DG,-G3),96+8<@J4SRS;2
M(XA [\/2# E]+^X\%XSO\*\"A8B$$QO!\O-[0V],]3^PK6CII]=>=8>W166\
M0YN,%FW-(SZT3#IYOIT"!A0VU5EF;!BG%G,%16$F@;.UIH1%;*+T, FHG/U8
M:&36D&Q=3][0I@B!H2-"W;XE*'<S:=W<BE5:=,T_%R7>+SJW=XYK*8]K\B#E
M#K]CZ8&POEF"^&JN0I/(IA9]\1>Z2>WDGN'[Y_33 [U<389/^T^/LQ"1+U>+
MSH$)5. GN+Q8WM?K7\M:&":4./;]O$=E2]U:L1%>WE/B"WP2' +;Z*8[,$WK
M.4\QA]$_TOVP3]B'J*0$'D2J[H;*=E0MF.S=R1#YW1)'(T@@PI99O?+*DSY'
M,'/5/JT[N*#:\%1=&6$1V['&805SM9H_[]33>Y:L)_&)KB9ET>-9<*<*>]<H
ML;6R"%5+TTWM[4[K^5-6F454$"^7/3&P\CI-0>B/<&]9/0WI4)Q/DR<*@*NY
M>,'[=2[LKVLO1AYS&0^TMZ610+VO7*=5EB(P%\6#3/J!)-B7S/^055S^WN#/
MT)V9SA;',A$=+*M,SM,2=N@$FJ#^CN5>2!>E^20P8[AWHV2 9LS$\F8^]/Z.
M<?U*U"CPDL*WY2-K/E#0CF'^]K$V4W>&D,HG@;,]AJ[O*R[05YL/<A.-=:J^
M3%Y=$_6<]9FS\!6?V'#R'@SRCS1^>#%5N''G4"+;5"/#HU^\Q4]62>$%LUGY
M-&5A*P8*L72B?D([M1?=27:T?30O)"C6A31G8]8Y!L!"/+"3!/NXQ^T3D076
MYL XV#">;?8]P<7G.B_[6#( M?N[;OOP%?818(L"S$#&U$8,2Y1]F)/?I;@V
M+SIE'$9O-V/(Y]*$W=^VS/174&V'4V$#/JH,DX8O>S/<I]1"'YK8J\G-LX7X
M< V3R1VC9XMIMYR,$MO BBMO%Q]JJU)#7&K>Z[]Y[_@TJ#):>OA%>4YNEGM-
M_<I#3;L\O]9RM6:C0S!AFZ@8&\="ERP_1]HE\DVWS(G^*P!S?0.C"G1/S+BR
M*?6$C6W<P.'-JPZ<\J#&FF&L[JG/E'4%(=.S<ZL?HC1^?I.YJ7L@4:.<+^9P
M'.HW;?S<F#FLQ\"R%-A^9, ?.8-GAH'K. _;J@#845,=M"YC[]E%C>RBG6WB
MO#3C?F[5.I-YK [+N)QI]60W?#F4H<%H@;_,^YD^R/T;VJ*W$4'?8](Y>>@8
MEA[:<KS)062UZV*ZPW@'E#8GH1^L SL,DHA[\"K0O[=Y4D]+KKD*Z1\C.=V4
M*@W'09O#U4><;9\ZC@77+4S4$N(H*7R!3&&+K5,IB3!K,&9!) &K@(9>F(HG
M]0$B7>HHF9X/5OZBO0_LZTO8=R:[9 *;/5,_BXKJ%&5+$'S]PQ!1D(FMWR3<
M<P_HD_ZYM<VHXS[G<N1#"N]-P*L=JVQ>MX=4Z1:/1-EK&@_9#)9N^?9':3[X
M6AW5+' 4)FE_DVAM;*+J7J@&/GI98J@]7JW?=,;.-KMOWKIIB+0ARN0;_Y-1
MS%M*$VP GT!IR'V+?#:OSACHA3X[D&^JA6MI$?$2*%LS<AW:@(H]";;?IG.K
M@,5H$>&YD3IXFW+\=O ];T'[*>V:=$,!O^I/?2=*-!)V^*))T!QUM==0@2TF
M\Y:KV47><B86Z7/RV2>X"I,28_OALS6D$RC"P(%]>TE=L4ZMKNBZH;GNB\I
MSYCLD4_-TK!G:)-(U&^&31T1NQ3V*1Z$>R2,%8T9X4&:D?R -9.YF(TE$IX6
M28+6$30OG#G1&22;,;;3.AP%4[C2X$!W[F/[!-^%=-":?3[HN'EO4,5Z7A&>
M-G=EN4<]OHN^5->BK<8 K/@T" HJ*_0H@*I:W2JFDNQ?Q[<[)!<5CL%\$)2C
M7+55B?-N$Z8*J+2#(QKX)>RU3,<Q'-J1VADZ.3E#[L5(MXTW+E::!_F'W>$'
MMWYL^5HS)D)MW\>JD+H2VVML?^*6O\,I5WN=)?L(9:-!FZSS1RM5QK)*#JF&
MMDX;>&I-X^))*&Q\2/C7XQ<?>J2$)-6=CJUR$))NK"27+DI9=EJ/5ZAE%*+Z
M(V1]WQ5'F^W NK78IQJXQP3X$ LJNV^&*?>E/^.*CZ-MZ;,T0>((C"J9%OSM
M2) R QH;'A/6.W^*\:N\YJA&\&F#B#_*UHI$7CUUHW][G%:D(Z>TL[6CT+QV
MX);NK[6[Q(CDGK#BVT$ 2I3*H21VR:(H P19](.#&U]7%8316G320)%PER'9
MZ]=):>0SMB/C/+%(@C[YO$)F>E(.YOYAB^UMBO5' %'E 0><WL<8;!4/<O7[
M]+"%622H2B"./%YT ($%;#Q%_MO5*+5;J*=4'J3/01!UJ_./>6:+85$F W &
M0R)]'XT>6>RL?Y7I$3^Y6QH_=7/\P:*W&0S!R0(6/F[/*M/<4R[Z<ZIU\$<Q
M(Q3A!W[D+9U_M/&G4&&TA-[-1T<AK6UCQEH5*'/G";1HV<AKU?!ARBG4TS[[
M/ V^L9:5@[[].7]^FG%O>N%$+8BYOGRFH$=V--:EV%ST1&!].E'J@V,A!F'J
MY>RR%+3K#M/+=%N\79WUND#>V=$RXC[57?1IU:!96(MV<5)815Q(VW*GNYMD
M9\MUMA[G%0&^+8.9QC82^B@S")IP6=H+&BQI_D*R"[>/[";@2^43U#;+%U38
M(=!GGC8_;"^= <*Z\T[\05V>K+NX,*XS0):Y-4Y<TYMR@G[[7MA].'NM^>0:
MH:4H\0(KPL3<@?-BU\L(J>:[<BM@#RJ_J2/%7DJ9'6 B4L-LTH=R7/*03<@G
M!DY".0ESA.^S+8//H]W)P/U4(>81[$)%#TZ!JD", :C;O<I@=QV*:,T02:N0
M9IN>I^^EZD!/@NK4@51_1F2RCK>M-Z.V2+EC8C-<)DA3X&\X1KK)[D<9.QDB
M!\H^]95[A,2* +KU>9# 58P&R(/0D!MS-(=8S&4PBI:>0#EM;+ @(L]V'3>V
M"CDT^IHA$KN;JF[&4.Z&":, Y_%PO&2 H5W)2#1-6'K%@<YLH!G4:FGZ>(1[
MPRX2=8;J6\71IO*=QL:=*>>MA(SZ2WWC<$>=*X;J,@M4^JZ%F5S(GLO7';IR
M<>\BK4#WJF1<3=*37I<<91GK,*<"QD=X#R[8?UBI:KQW<#SWW*0HNDI=@8]"
M="^6#,Z*>]2==7=VNF_%3N$/M!9ZM4N?@2ACV]-U*V(T5[W%]B5T<T4WCM_+
M'=ZA6BN%IQ+>F1(^.M,<B#S(<?0M,')Q.ZY(]W60;3?V-%N2ADW@:I(SG 76
MY,\P<A( Z@AF4.GFB) WW#/[DY"*D^\50<CS)*XP-!  =6',>1!.Z_1<9_IA
MNV&-"<3\.7]'OCCW(7%%'4Z@3<'BTH"[:[ID7T99>N]1ML("(OG+QI:$5(3(
M<=3K71VI;ZSU_E'M"V]>D9<^4XW)@G'%SWKNUC@3AUPYG083&7$&5<YQ!E9%
M;K&WO;4YRW5E91N;7T*VK/Y:K->_03P47Y,<>XGBAK./E;-I_*3N4G6TVK'3
MNA\S8_LII35*2UWI!8L'84&![K<4NH.<+S5W8W9ATVK 1SM]43!%6RL!\R-#
MDM@)I>*3S_'7K#Z@IYMG%5_1-,%VQ<W",8+YU_)O/]*5[D^GC<#/CQ7)C'AK
M3TO0CIBT_WNQP,X@2QOH;E>@.^.<:;E/="CR*"TJY:V&0L^\-GV2$$F#RJ(=
MZ'HIFN<:1G40<I[1G9+FH&LUVM*PO$3:RQ ^<Q^OF>P74WG1[2"^N'QU9[#2
M@O,"Z+Y)\ .>P9H'-K08 TQ?T+T6U/N%L=U+ MV CX:$7F%SK[&.\W ^"?/O
M%^%SSY,Z#IO1/,@)5&3?XW?RF%2JG>4,<>/Q(1XDOVK$3WA@.NA>$7/VJ92Y
MRMO[K=XW3FCJ5'%""Q^X=#:JFZ7<22S1GPFGO7SY<J5L1=UL)W+BX,4CY6=7
M;R<;E^3Y?25.1D4\T#TL(N(L["QJL, 06WH<4;Z\HI942-'0-W#9$V],W_=P
M_T_%%: 3#_+,G;#P-P_R[1:!K]'UH3+ @3R"U4<W38RDX@^!YL3<':_A&#YF
M"GV15OS<G'XAY_7<JJ==65QO#DG[Y@WFMO:)#QVOS,];NG0XUJMTRGJD=R_Z
M_G'KAH7A5D&])CJURR?"/&?/%N/A-5J /I1]W^#>5ZOT'K>>Z@_=U?;5MH5D
M5*Z1!R&A2*^S91?ZC 0:4)C2#)$G7",0R5RE^\3%?&_HOZB9RE^! /ON.*[H
M@&-\F0'K]K3#Q[.5:P+GT:03STM0%.I\+G5.P"+9H<7.5"/RK>'X3.F'P")E
MLJ@3^WL'7'^@VYQ[#NC6(P0D RFFXN1@M/\"\E3 E.EIL(E>NV[^*YD=34U,
M;"/?2^,&Z7FTC*%MJ=Y!&A&$$^NCJZ'S;Y-K0-0G\V*P!/9DFP/M4D)?!F,8
M^6]]5$!OAGOW@6!ZESPX99MIQ;"*13M4$*N^S/0]'93]DBM!5IT.@4<>:BXN
MIW@UZAWX5,#]JU9;=-OB"IO>P08HFX5\R&U"I:+-(VDDON?/)T#CFS0L/5;
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M>9#N,SS(YP\8$WXD_@?D(YMK0A+B&Y=P";J0 NP$0.5YD(W/:+XBJ";VZ1P
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M/#/(KM1A= N#N+P%YE[P^1XECVZ;@['%XOD@<L;@YED![/\AP#39_3.1=3E
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M7BOX6I'W_:6#RS_8<P>R*F2:'^3*ZI28YHEF6(QEKMVACR2D1J5E-:>E-FT
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M.1V<:UC%$1P,>Q 88<(04@5PH(E9VT<6\<G:DIFMP9_$>-E_J=@Z:V?@_2Q
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ML;*)9N"_[C(WS,S+AO=F50U4!=W?'R?!V<7.!4N@0Q$?/_>W%(C#JY!PSG-
MJ@8N=6JFL3Y1HI=V*"/RR-K1*_X9NIG38V=:I&95U2Z=;6^ZXY4B(H@%OYJ-
M'YD+1L#RD+]2T'^-)DP5ZFVPZ>9B?8*CP,-%O+P[T@0"#C:!9&Z+O:S[CE=
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M=%I=;5P?NM7ZO,Y4IRB&Y/*Z?.SCN9AV;(>3>%)#A-KF9I_M]6(/5(7IZ-$
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M=LJS]-)-R*\PY[&/1DB5L'2-SOJBCMX7$R'3%[9%#K7P!:! "(T(9MY4$/&
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M23)FR8Q5WSUGS")V@Y.\) #/^<&-. %(TMA,* "6T > IZ6DXIE[2/O>)L/
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MU_/+-/A8>$TO;OD('*&^+!NFH?O,BW\%90V$"[D]%G.\'<%LZM\UZ7LZCTE
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MH[31QI4(ROTRY8X8Q /L!428+9#(T1*8RP*[\@)\OE<7K0\(,]W9+< FG:J
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MP8D*'8WH4RQLG\XIKV@K>Y:)PC%65"9:FM'PXQ#_RC?3:[-FL@ </M_B(.&
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M>^U J-F&]XRTZQ9=T7D/OO./ ^=$^8$0[L\POP.AQ5 2^T3*@="T+C0+#EP
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MEFU<X%[H]=928Z H&+?8B*>5)>>?O3#ZP]_O-Y:O]+05_,:L;U*4%<BL;AU
M(.F/'KX +%J=#3:!,RO90LRQCT7!H6S>&2@B2_YF3R-.J>V?GX-1M&1RAOU;
MNYH'C:!\[PO>0+)D;$.W] FE^;]:2IQ4_VWC._!5/;GP.:*&0QI)YD_6()O
M:@V.&J9@,[DQ4L\I!0,T_8XXWT9@BNPZY^(=7637SE)JK:NVHQN[=TYK0\9T
M8%.^W7$\.6=B\[<OF5)U;A&;'Y'OG3KO];?F!<UYS>$#8AU?[E5RW7)S7+;>
M1A>;#[NH3M<EO@'/(;^TSPRKMB63O6O#G3J),353Z12VB+V8T?P]^(<"KEP
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MJIT^?F$/;5I.?<N0('>ZV#[ AH(:G]1<4VEKME_@&XD="-6_P7[<<C_\O<,
M,$:R*ODBR1Q-A&SVL2FT*+T'S@!]+4)HH^L.?^&9Y8;2DBFI?H_;,B*R3I+9
M12E_9E+'OOHA&N<H4VL\0^0WS36]\ASW\H3*O_K=#X0"$O[=N*H">KO>YVVQ
M1+1K7>[2_6(F]YKE994T>$>F> &<="!T%V]SJ=+-_G*!DM&L?#4T4L7M4BI,
M QOQGSJ43P;\9@'+*2)ZD1Y#$3N %O7SFRQIM.TA_S\J"P3X!>U'3F] Y=>
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M*SX4K0'@F=!A^ ]<#=K.$2XXF<9N"&!Y"A3_Z0C3.PR/K*%2#9:<U_H<_PP
M9Q2=:R'[-5)^5^Z8"=;NG94?D?M%Q,)DV500MG\+W$>*/T=]X;"50]NA@!G"
M PX?I@=*1:;0HHSQDU[K6+%N3Y;.398Y%:BTR1QV*!35D43_RKR?/7?O;35!
M,<<S,Y#1]VB9UGN5Y^7H?68\E/6JN\.F8+9$S;&YJN.[2AQGKV?W/B;@/ !7
MPQ=JTF\TLNK..)RMJK-V9K=T7 $W$SO<?^U&-9;#W^UQ0<)\,3Y@Q;D+= W
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M=%HAA[O/O-T4O?F:I;DL+80(FH;]27BT$TO?ZY8XX4K%-?@VI$E"X7A^L9E
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MX'5:R-FFI2X0*38.PY]P"6P:@!-QJC>E<<'NY);RF74#F\)?(E+ L>64(5A
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MC+Z00/F6.DBG;Z5E.\8AL:':D2[F>?DI QBP"2N?=9P_7K,4#(M;E;A1PNW
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MVU :3.DC[8VI[)PV:A8>5<'6'H\%1EG$I"(GX*-R\'DZ%RF#FMG*_-B*CDI
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MQ0KS.)J6,F?4;=P9DE^]W68VAAYOC,4[/0SMF/A19"4T6M69+OZ/FD($;NQ
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M2(>VM[1-!ZF#5-:*VV\XXCEA^0[D*O0^W\R++SK(H_:1%'#!R(YDB^"<\\T
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M?^Z%POICX97&ZE*RY9_-&$Y.0XC'O:%724V)9!7?UO'7)^)4(O4&+T<W_#%
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M:HSSM$H;RR_'J^<V%#5Y%G_39Q9+?+.0X# 2^">82%VJ):<_SL!>BQ*M/&(
M\/,EP)<^KNAL=)RR:TA6?T>@;NQ (^T"UQ]:'M)UT(>&.L'DII!-4\CIYAKD
MZM32Y+:MS>F,GS^/TP0;M5<V@1F?A"J0V>7AH^7#;,F=L^AK!F?LY6?[4TB7
MO]4[-%:CB_O%*_I&'?I7&BZSF0I[CUW>RVGSNCAP?CCHP(:W*$B;-A=-"<6<
M=E3Z0_;2UHUC2+[WZX>5>MC[&+TPU6G/#S4G:X[?0]Z)7YCYP\A^;_V0DL$#
M+?!<NO"(#M LW[,+ C0E>P12=+O$VNC#:'%F;K>=1V4D7F.^B;/%UU;Q,;N@
M.V5$XQ6= .)J;S9 >_?AAJ9QM))?/^06(]N$;.QL$?EPG<61Z&YR Y@"739Z
M0S/7VS'#J,7V/'0XL7^B-UQX>-00*]=MG@\UO.THM:3X.O7+WUYMR,@!75TZ
M(C&:8IQ42HE0$X.;O#,<G5Q_E^V9[JA7:R5L6XV.H*QO3RAP=35-J>4.-ZW&
MZ0MQ03)N[8A-$^*T=TU9&$3A9[K527E>8MN8(20-TFC]=A>49"JLA,NF3ORG
MH$;WH\K4WMIC]*Z];M$7,NU@\HN=]AW9Y;6.E0BW!M%P=*MF3?_INEHDQ@GX
M:0[ZW1!)<\E7DP"JRV</I^^Q""_0X8Y2XA('NH7RHS@#B.2WII-PM><>BX_L
M4\M3W^1XW#[Z]O&7AX.J18V&':B?LSLU0'K/H\[_FMW1V^R(]*&ML?_;[(X'
MBF@/<Q_7F_]OLSOJ)#*95/1S=L>_I27G@E\X+",LZ,/YLJ4;!2<%[^X]R+I%
M;V[?3[>OT9%EEVR-E%XN6')/5318LH_F$>#=^@4N"X+Y/[/*,MNW\FV6X!,_
MIK%=HM?9#([=!2$@4]*6 )S3"$L0G1(G^Y,E$3Z_)O08.2ML>&-9E4^)T$A&
MDF=Q@BZ-^;+SX\;FB/F)6>+8J<;'ABH!771:::7/LJIR^T=#,8L%D1=XB^WJ
MVO*YD-P+:91?D63I6%[E)&.1:!@K@0V^4^^Y%*V7^&)CIT-R-H[=\65"T3U.
MO=GXO __:H:2#M8KXSI&5C6U='(*7=IK5LRQA $GZMK#Z@ (;U1 ((%K@" *
MQ;,C/;%S+^8@US!U(;5NB;Z:&J&RD,XU9MU+CU!I*BD/5'0K04J(6L*7QQZ6
M+SI+BF'T6)QH3NX^!J>'IUI0-+HL3Y5]+Z!NA5TL*(WI]M:D9E\E3"73]+/
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M\/WZJ(4BFM&C/ZC25#B["SKV3?4WTOBJN20K]29;T8%@[H1EXJ67C25*+U4
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MYV7]%#4+X=14H]<?I!8(4:]2RDJ..QR+N]"KKK<@WXWEW#5>$>-TBP\K\_V
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M BR<<03;Y6J(2OB(P#;=$V'+OKUCG;* NT=C1Y.HI^'3>KQ4$A#%'#ZZ])B
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MH8AB::) T=%LQY;U;LVU@4J2?!5T_THI8GM]R7ABN!KN(T7;D'#DT<@Q/S?
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M16?.I0I>.O[ZS:EZ&!5^VN)80WL'D/C:FV[^;#)HVS@V=,AA9LZ1>[J^&)$
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M]W!A]O:C70AX5J4?)D;YM4V@4Q:DTK6?^8QC](##0XRBI R,2_60T=RW8C$
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M7!H0(2M77!G%MCJB1:CK'/)%"(+:OZ'I?2O./P]U</*RV7SXSU\+*?/ CE#
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MRK:[*+V><K7[5XXRKIW/(]G9DUO#-IB1VBAU=D/@EI41K@?/E>,M,<5Z]H4
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M.+#=B*U4D!Y"*_7QQ<"<I7TA4<Q_02S=2[[/Y"@K(]V'#A%!X\FS[+WB9$)
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M4P.2296$+I5%PDZ'M?U;TWD:;;NT$M^IC-$&1KO2H1O"?$GMD^A9V-,/?'D
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M:@1$0AM%'%9<=T;4WNJ6&RG!P[ZM<.#@ 4"8IKW1!>3]VC00=P2$V@!0,N[
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M_FTVOWDKLP>;Y'T4;%N"G,9H@<]I\Q 94)@NEKB;>00DD]V?%SW:)8@A9J[
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M9B2.NC\BW5"9V'T*_"B3WFQ+K[ZVYNU3?9&I%A'PHM"+[KFY<W#4JJ%Y2ZL
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M(,B2_E$U-[*XP@LAHIPL G"P@%W^3PS%7>$H]D4:^61;J4-H0<^L#",QBG1
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M+#[/CCJ5FYV0DD*D;V34#<E]!W-<^-_8ML,D\M0\_7@+RSKL@\-@%-$L4?2
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MN! ?#0;U,!>R^H4L'2ED[L3SF[F>$.3_I08B=[:0((>WCZ4#A@Q]SAFDRT_
MA$<E,NP<X\'4!HY!IMM&+H93N_(AXZ1UG=E!\Q#=0*'QI^1H4K#R^FGL*?1]
MSC6/:G$!HW0?Y0-C4TJ@EN)" 1W+%GW!^ATY55=$_@7N)1"N<VTHHG?J-EEP
M&RZ!41W+GQGIGY77I[9GP[M0ZHMU*28WC^1/+5JU&FMIU?KBZW W,E(//IB[
MU/%H?7S[->2*2HCY.Z_TWV^6"/JL]V1IW-Q8+S.2J9LV>9?_"[)#0]77=GK^
M:GVGP[7 9:MR_:IB:!]4QU#:ZJVAE'JO>9QY0IIU,BV3ELP636>9K&BFN<VK
MK:LPI-JF;B+L8QUI23G,0W13G%^IR!QGR)/2Y2(&6*(\,'6E7R>+;^R\&_B+
M=U9]X:^.@SMA[ZD,$_AD*H=W8B[/H*/@$!L>6HY^U]GG@_%G>G0GXKW()S%.
M]^)&%?)TJCWP2,97SNGZICKA.@FAX>IJY7A4XZ76AB2654JHON^0K'2/1W"&
MJX![3"?\_I1/NGIW[J6Q["5S(TO#DI'<DM2Q2R/':J,>/RK"U[?1A,>OC! <
M_*MM9+Y^/SN=J$I!]N:Z7LXQ(;TRUX-^R0?^7S20?S3;/#:"^8ZM!)@P;]%O
M^]GU2W5L1H>I,IO_6/'/\5:U9>"C2#>"+XPJ6,^C0D1$W\M_7KUPYM7UW\6-
M-B1B$2J<R?&M&4X/F118727H-./$Z<>*_S@2<#X8WY#O&\F123IS+DH%*9EM
M+^*6I#Z6;^!N;=')-Y)@M3*2T"IB%8$H*4EEBR1=>!S)MY64$BF:&L_9=KU,
M%DK^]@JP9TS0A=?%F3GO0<K7?-25"^$5Z"0GY.N,:,N]FKYJ;(PBG$*3[>.&
M?55$JN=4]VU>>/L%7RZN6KG\ZYJRM^S1_IMSM]R1<E+[?W+>(QBF7,CD'H=W
M@1%M"@0RXCMV-3,3"&O>CG1LM[>C 64.>,XT<$K>JW5:V4^X&5*MU#XN;':5
M4?"L6G%I6/N:Q\6F5AR!NCI[81Q$2 A 3:OC23:8;"WGQO&/IQ\R@IZ%*0,I
M[^];MFZLTI)CV!=67RY%"I_6D6W!](N/(A2&?_XX[#3-A10OA&:>F:\,>:J!
MN42[J>SF4G5_K<+4/]=5!->,[,Y.L_E,\:[LE@_SH\W:1Z.=;+PM3I;'H;-H
MG@-(PV&\:;K,@-4TX.%@G>NA&)^2;8XT]7)Q9T;/];0G3_'0EF):!=DH!D^4
MSF6,)M.YV'XU3(CY,.LX'F_VK7Z2L"[2/H/4G,U2DM^(IHM?H'>X#*FH>Y.<
M!<TI.W*.J ;R1[EY@_!F#Q"E@Y D/ 4=WS$KVC*F&$B>O+7[',RO<X[3JX-K
M!V9=$L=&2,X7>PH$ODQLR!.G0QZD=E,%5,1Y,6:^OZ2K)OI)D,KMNU!ERZ<J
M0!Q3 <5F";"AFUVG"XC@BO7MIB,BN9"'XY=!!DB%8$092Y.*;F3B6+/Y'/8(
MFF<N;=T[!"G6(]]:2"\XZJQ\^4BNP=D^T98VL^MW !V<H6TW;?'SZY3V7IR=
M8;V)6?X)!Y=A?[QLG(G<!UUG5L4T$&V4]D?CP^O9YA_/)R?*0L]EDM+A[A;%
MMD;?K%9OQH<'F:=199V^D?=1#LY3B*EIQ">GZ=E/L],=01[!2.4@U?HGF=>J
MQO=4)T[4=MQH9C09'QO6ZKGB4Y/0^[Y@"P0JSR,YU[J8OAR^Y\QXLS=C/BK.
M8G.;46$PS-D1AQ!4I1WQ>X" @ '=5VC9YL7LHZSU->W@>8'3^A,ROKZHH"<^
M-54ZDVXJK;A0SE^BINFNA<L.#V-QNKO.2@:4-6*UYG1_-K;6#KD[/&7?MN3T
M0:5SUJ3Y6L_BX)5:PWK,6ZT,-XY-TTUJV"R,89&CAI2_74 *6D]3O)R!OAQO
M0MG&QL//B'Z;B^>_/V_=$&TX'&!R7]>WQ'FPPDD/;Z]7*DW.LM# 1\ATW7_S
MJ1%SYI%\#M)!9QSS>3!$QTC0(>#Q9_*)2JL,GBM]M&JG)VI9^O*L@0BHCEY%
ML_,=:[6*V6M/[4"XJ1@.KS7-F:,"%^NCL0^-RS8+XQT.(K5OT<R$NLI>*D__
MW:S+-*"!%H!>U! S)ETTLV,;TV?\[EWKP8:B(#$S+EY[S$%L$#L/VT9HU=(1
M 2TM&B"WI[!WJ:?@#ZDQHF>O'<QDUSRG;T;G7R,US=8%G5)+QWW5G"'\-:&J
M.KA+U30L;:@CDG(.#J'8,_"Y]'%!S@",X90<62!P3Q#IAU;<C0)6&9HK'7=%
MJVKD%WX<%"<0)8='=+WMYJ J0\J]\W\9]:8;>SN,C[ LB-:D;$E[%4.WZYQ+
M>'A2M7"\T9XIIB$N96UCZ8S<SFH=_J1Y$B+G#W>C)U8,X.6]L]4H"XNVD<@]
MRF1O9;VQSR9^_SIZNCM,&/";&Q3&W&)VDSQHY"-H@0Y1+B2!C:#+__;W%678
M40!A]&Y"6[<:<<8MP]4#MZRJ%C1Q61KWUZU#:8G3?-C^CJZFB1^'T"@DLZ$(
M4XJ\XHZ)F %03-]A#$:)>N0XO@%D6*KH8RN:+>LSN):I9=7\AR]H+TF;4-4L
MF2%OC"U3J3-3U6O7@1"75O 5RSD>>-  HWF\QQ[B=+4>GEA\PQQ</Z2LHPJ4
MBT?\)=\?_9YZU,N_ ^<Y4>KH%HP4Z$R.>1J =6\9470-2;Q((R1H:U5=RC:+
M>5#7O%T J&[N'FH\R",_S.%"IM[1)3+YZ[L$IHH-1P(%>!P&CZV6HQ%S>E6#
M6)JNG,E9OQZUSND.GN27]C=F<-1(8=I.W^>N,H5"UX?NF$8=RY@!6<F=9@?T
MH];K#K@0(USV=+:"S[ZZ19R%RX1MO@93^(2K^M/4S-'K>V=]O-7KTG">#<.+
M9H&\W6D.08EW;G^A'T3E^W$A/&+HZ'9X+0];T'B.9RV243=]ET&.TG:>WSP,
M2!D,!?2],S:Y[AM)/M2L=+E:-8^@GZ(75&6D;1-VU@MPY*EO''\T[3A*6 \\
M&B(6:MD#GZ-L1J!0<[Y3F_/]BW\MD 9/8S0! ]K,TYNLBPB^K_L]"<WN)0[2
ML1>IUYB9SQ15?MYRTCB!#%>O%OI]@@S#MHT6B!1T84F9[V'AI[.K;)MLVS;#
MZSGR[RCSM?6)VUAAM@OSSG)EFU_9$<>^<H*V'&/UO2U]X.:NJNI6FTK.0>7=
MT>+D?2@86\+"!-L8]1Q>)./X<GJJ'5!>CKD-O"'\))\[OH@] 5#MAYMUQ@DH
M#Y1L)0#K"!,,*2,LD)N?6Z"^'J%/]B#=/6K.-TOQ6B3D!/I?,2I7G5[,O&%O
M8^F]JN 5(%.N1E8AV?@6\)Z99__6:<0;<JS@E^61..,,B=Y(;:72E*:XR$?6
M'D)5$_)KV<BP$1!^,#V6=?^/HK#_GVZ(D]@V8_*".+D>?I!MNWX$S#FU7=#=
M=8P>%W)$@0M)>\+Y# )P)((HS*D8%+(U/7JPQ<N%N"K#M]>.W\&RDM0X;=?@
M^P\]F*M@[G/C0E)U@3TNQ./B'.S 1D*&0-EGCX%A2O*KYE(,]@$Y>=?AE\2*
MU<P78<,NAYHR* 84@HK6R_54&C[V0DCLN;=1P1:',]#WD5F'49>&S]\;.0>O
MPC*J="1!FJ_-'.2<<N!"N!"Y509,_/%:AR#]LJLM_[/N^S+:QQVA%E&G6^PT
MKFB:R% BBJ:\+Q,"IAHY;L!PRM*9#86.B39WC8SKS_]^^W?%)Z=?Y$X:]E[O
M+->SPAG]\3@>:2CCK)IJP*\7!/_GL;YR(9&N3$5.[%(2EI$RP85\1R"2N!"W
M12YD6_8CF1$-VEYO\\1LF"&GV@]V\*L2F:WB1OYND,T:$(W;P-+L,,9<2%'P
M? '[$HD+X=@.@X"L Z0W@H-GN1":)($+^=::O(:A<B+M,SDGZ.3OMMFLC@,'
M.GS_A <6\.K!?DM6V<M5@8)::'\-9'(AM[=ZX( AB@MA$XHYT.A.\KY4O@;X
M3V,$%[(0"OOTG7S 5ZO(/M^%_490V8O>)W5BM\\-<"&,,7#:"Q*H374ON<9_
M%LJ +2<0B]TVT_;G0B(RR*!0^_ W6]A]Z$,$<"L.[.F"VA380<5P(5]U\\"9
M5XJ#EVA/S/XQ:NO_KT0";&"GP&OST4L@]I3'<B'IV]A_6C38RL1)+F3HN187
MTF$#?J0%$YII935+_T*N?Z$93D\_.()U%I9V7 Z\/]@7/E9SD0LI_ 7$&E%5
MX(?T%B*XP]QY\%_(]L^*.4@&@_10Y75PS+.V7(CL%@*-K70RX$)N'MOD0OCM
M-CGFBZU;447O"OZ5;/^L'!9,#9R+C3LXICJ!8[W8"J93FX9D3H0(E2/ZALHN
M[@]=^N^V.8-='5]P)E5]7,BO?@AV97\H[=_V]F][^[>]_=O>_FUO_S^PMY>@
MAG0N=O^42N-"$HL/SPDS2IM>Y3<<J8)(B9?]MPTE\+\RE,YAYV\8&:#XPI47
M;%7F=LS<=4VT5N>5!'RQG$+NK4.?PG7QV/92H!Q<$@J=AW.R%;S#@C=L4J3^
M@&\+QK[0"<X#7('D?RRFU-8/O8""ZBYMV[[Z5_T8Y:VRV&%EX!DHOR\HYG='
M8]9%57!2#\%N$78%_\5BT,F<6/8_#!!4IX<V)VY; +"B0N%?LS&_@6I0Z\2R
MJT'%J'69[5\N. %G)#)AH EY<O[N)W^U?_GC*'BI_R)S/CAR$?8?S@;G0K(&
MX44MA_ZY)Z@K$Z8E)Q;?*<"^B 'MOW<*_E;)=__T0SB@%_M?-./Q0S,%_]!S
M,A>RZ#_XE?#;O^I)L\18@:,BF8= RZ6"WOZM+GDM89H3F97,.7D?^[^;G_U_
MO6*Y6_MR0_^RWS_+_>\5^T];L6HR/UL *""L3IDFPI\U(XIURUPZ?/TJ5F9%
MQK</M,SJ'W[<L[4->G+-L?/%S9K>2R\PDS_?; P6$I=YD-7O1?Q*Z:WEM:JT
M$%KN64'';)F6I-UKQ)GHN5@8K9<0GHRH=C RA>Z_$;I*5 _2RL.8>%E)=[ 4
MQ22>DO"B ?/]FM<2@O&7&G&2T)"Z],EM@;5GC))5T4[J*5(.9KE)J!I)&TUW
M]!ZOK1<67N'S]MS^^].E1V!<@/E[^'CWAZ78PFD(?F28 &/C!2U/].3QO.+)
M6QZ0-NKY1(,</QG)>#-_F>#%^YW$E&L#5WET$9-.8AU6:-OS[>Y_?<F0)%0]
MA!9S(8I,DAO,^]):#MY$7UEZ1G'&XCDJJY<+6;&-;#X2R5A]_G8M/!NOC2G>
M^;PJ? 1;O?@IYM;J=8NWCXMU]<_<41G!VA::6CA]RW$7,D=8A<7]APL7M'O!
MOZDAR3M[..SR[<"9"=XR+N3OF5(N9&(VG0O!G1P?U9$!OS1R] /#H!QICD?C
ML!ZTW?,_O<#"/[T9WJ+:W$=#L!.GZ@_"01UM+^%MP"05U 5.MH'SJ!<KKF@?
M%CU$--<+OESXGTSW>829 IS;,RA.XQ1VN7VDFGV""WFAZLOBIV*751*M@&@N
MY((/F%:=UN';-*0-YU?LWSEJ!U&;Y.WL[G<P=KPL]I,%%S)R3IH+$87/92XF
MNQ;%R?5IWOR/GL#SI8/#!R[588&#*K*/P+0:W6!=B9$\+[#&A90";CWC83RO
M:QF$SADSND!48,&Q*;02C1S>?.Z^XR O1HTY5EI_4%WC.7M^;,HXFK) 6?=9
MDT_?5&NVD=@#[TGA0IX'MHJ$_5UP2EN2I<L9+CBYKJ/%OL]0+<0#\6 ZC6!K
M%0X6LJ6!$/JZPC<ZO:/+3(=PA7,>B*3?D/!4SG-L=TA?CP[?'CRZLNS_A",V
M$>AHPN,\@L49R4UFA&;U\1SCJRD?BI0>.IA1OUE2?I./[U19IDJCA86?7QK)
MPENU8* C\O'OBRI*AJ[NME"+9B:BM=(")SV1.V-HE2BEH/]].LU-1;V-2#OS
MK2<-7,]NG1CIHCC(O]O_N7T/Z8!]<]Q19/']0&V&FY4KHO_BI\V/.MKP@_"[
M7,AT$D:M#;[_7;'WO)Z0[4]#_ZLKL?Q/"SBI!,^G9K';-U =#@<)FOF1='$I
M\Z&=:M5Y]/.[(X$HC2H5,9&/OF?#Q=YIQ58O?)N!/4@DC;W6)PE=IC0]05F-
M+^\)&OXX+NAA?CF^"57A\=W/\3/;G L)OXEM,\GG0EA'S7,Z$6_WNJN?BBL,
M=LK<R"TXH0-=N64SY+WSNX\W_&W])XP)8$+H"RY=.='CZ[V &C;TOU<N/I -
M'Z;LFAT0N9"'F],(VG@6\^)N")!:C&[J7>F>FG=D-->KCNMH,_0+)4L+ D->
M 93V1#^%PF*OICO9Z=5Y7S[L]I]>";(G>B.L*4NDU@8@A\/W O1@-/#C?4&I
MX>UD0>-*0CML2J#=YCIR]BS04N)Y%06;;A+M\I<D/ \[[]D7C/M 5Q28]A*4
MGTT-%6>+4J-P*5LL6;JC^"W+$9+ %QA=F"T&TJ CE@R7QLNI-/+SUD- _;W$
MZX18C@3;$_ H_>K_:ZZL]A,N!-JLR^CK+/01RCHOB'XJ966A<(I7M3N,7GT'
M'_,:>/HR-U#[W;5"$XM*V<]Q>;^73M<3\Z0'%)PHX8EV SFY:444$X[;S:30
M-J#9^<II>UOU#TQKG$O"5<Z(-=*P)"6L-^]IVN*K0M/B/%Y*17G[W32'--MM
M,!H= 9E(^"S[Z$&ZSDET,0V_-LG4:B.?QGHAQ#PS-0VB8>^?#N3,(_C8YZ,X
M<\M-R?':?@0@R$$T+(?>HF8FFC@8H2TIOKY8U_3-,[LG9OMWC)RR6047HDUE
M^%#7SE>'C<+JH)GK-^8/+FS>!318BEY,-)5UGV.3 H.RL4G&S@:TNLBE4A(>
M)1]$0TUG +78"L>.RD]Z96BSCB:!F'6)P6[SX/PQEB2VC8 E4I.:C7$H&)@R
MDMB2#"U:?VEUO1.CX$_2.KR'+$R:41U;_Y(M#[O[]LUHJQC@(NXB(EE'8>N&
M5J'K6,:-48[Q7,C/L[^]U@L^J/R?L,<]2DHLX\OWT$=DV>J=*AMY=;K?"U3&
M5637MP&Y]%9[(^5B4PNKSS@+RZ6WF39'Y0?0\:H=#R=WQ5;.G#UDV;;PS<0H
M4*A8><G4-T]*O3UPR>9JH+6Z1:+*T0;,,JB7&P"QX#!\+I]:)]#IJV"O4*5S
M&)COR-:-,H[)%SC!UJ4XTI:B"*+&%O4R_$ED>I[JM[DV^6:R1_C=3)L$O8^(
MCAZV6!XCFG,ZF0WEH962=7)\*Y8+#K=*L.\"+>73LWHXIRG'[SH2,'ZBN)&Q
MMTG'![\2X!W=+%I%7M995BS/UFR\.F#&YG#X;/O*/N7'QI3P!L[?6) V^B1_
M^M_8>^^XIK*V;73/6%$1E:8H9"QT 0N((I"Q( ("4B,UHX@T 5%*@,">02E2
M%024%@$A]"A=6J2/(B!=00@)TEM""8$D>Y_M.;_GO#//O._SO>]7YOO.[^2/
MQ2\KK&OM>ZUKK?N^[KVS]Z;8<I/K %8U=?(AY\*8@ 1.T)3A2FF:MVM6DPXI
M4]J"TS,F-'5/7UQLT!1BI+W:B,!57*-'9[ELWI"_4>445U-QW5"X' F%X&C8
M]Q^\16'I^A0)CC\KBL%N06^OL:"APC3WT+%!-8CVWA'1I'E\H%"9*S9DT5]&
M$0<;]&& C]B(^I%B^=4&>X,ER-[$%ME@]N/FRRCS$5I)XA*W&Q5:J/=\MSIL
ML]UY,/S9=$,4I=0S:X>GB6Z_N9F\[MH7;'I?JGWE7&OXDFX$O]GXY^T]A2:"
MCFQ)RU3+YX^URA=Z4X]KG+>R.)/X8$.2M/R&-=-/+IGD''(;+,KT>(43O8+8
M'A2$/\8@AI6YVB[I;[K<7:/$<&D>V<X P_'Z!<Z6D8.WU0()_M3%0\Z!/_6I
MR+\?ZWJDZB,:V^:5>=()!KK4R'%DEKPJ9P^&F<JMA(&[,+ ?ZB;\R/%EGV-A
M&B7.TF-^/>Y5BZ89/@X\-J4I0VA&YF.8],C-W:&<7M% /N2$.1/KZ*?XF[L#
M3L7%/R3\\Y ^\1+3]&WU)+7&_*# X^9&44MEF5OWS!S?=G!JEE(US5R]QKT4
M0+()*?+UV8]W!'[ _!":)B\8]''JEK",U8N>2+D'Y\N3K&?BYY@^4S&_"_P&
M;6>0.:)8")&;-'28IDQW$9+*Z7QAI:%0.$AVHC1\J $L(3;.7VF]0G?_U7Q5
M>?@G6Y? $V&.=2):H8;0U\K*?LXE6G6$DX*ROAMS@,OOV7Y:O\MS&'VEJY0M
M+GVU^ZZK<KN\;H_"3Z][/-O/-&R?O^O)U6SI/UMXM^!NX:WPP>[N09G1BJ"S
MU!#E*&'M<11G[S+$E_[]P8H#W-15<#NKF-U@*\5:8YQODFY"[^>XC%:GNJTU
M5CT2XV\IM!\5V.DHF@0EOG3V41,-+M4W@!A2-70H[H%T&%Z?9K'KE*5&LM*L
M\)!-5F';YTON#_ )RRJIM<,?$\Q+A@ONNE+?UH1T0RYZOG>VQUDWW_0_MK=$
M-R'Q>)!HJT9K3\NMFY=V=+\;=6KE#]:[^N&D[JE\TG)E3O,J<?N9N+O35'QV
MN4U0[N-6J>5K'05OGJ_K=G@\&Y<UR1C$+LWK='A@^2WCCR1'W@*?:W-$Y&DA
M^0SV]W<F66#KQ6O6Q%1;#D#;I[R]^\E?D&C4G!YJR-(6VN7NEJ7DX9/'LIR9
M6#1Z6VWEDE_]MJC0KJ>THO1U"0SH&OZ*WED(;>-L9\G2S;O'W14"]^"/L=SI
M58/S$D[[9BB(JW]8ZL[7>#_66L[Z:DGKJX*\Y8R/U(>Z>>._0IJ:  S4EZ/+
MP1"T,^41>##P'.<:-QYO,JHD@/>DAS:C'P^*!M?X,L+931)'NTH)!RUP%4V6
M!HE;R72]:^4UE7W](_ZG1;)H_!I%1RJ?'NMWE0++6[EO,#Y[[>Z5O5ZW%=AF
M*SQ-E3G;8;K8]C%=]YE(WG1.@QME9,#4%X]*&)NZ55+3=JK1M!'32K.3NY?O
MYJ9C6FB;;^[&N)]OH*&2O7(!D50?"-[_N[70?THO_4][ IXRBNXJS7G2.8B%
M/K0^@H%5 3\H47X=R9T?.J&_A01VPP#37%T:!G+\!U;>8MV3D(2U41"2 :<K
M4:<;"$N&]H35&1+TRGR'3$;-\M3_:-;T7RK%*C&K>\$!+/=IONV_?<YM]9HA
MGW*@DQ,GHM>T8>")62C7KQ$&7H9W%PRCH OFJ-59 2A(7K=2FM'&,>9\Z1((
M0E-CO@6%R^3*_)WB7_Y1+_C-K0><7=1%\L^PV>J_/$NN, =O@E0><")G./(<
M(T[G R25>O3I[\Y2Y#_6"7\_3Y$/?I;[?J[;P,_+S]4WL8&\?K#,G;T%"P/3
MG0:%F= BHGQ('IPOSR UVV*N0+IC1OB2_M^Z(I"R6XF&XCRN&N ^0#1[3W"6
M%>LP#!RY2V$>K$-FV44L]U^=+?!&KXN8PL#K+!AX];,1I S6*[5+-")^(<$S
M^+_SX=>\\I]X0+@2S@[2"T1F_29V'[*:-%8#+F'_G>]LUD-;0Q%Z=%%LC\X0
M%N*5L)+KEV6*[K$:&W1U*\+5U0_H;!9W,=B\Y]X%E-/HPWHA OT%3AL*(>R&
M@=%99&-]2_K&- ,GAPTY/V+')^J6 QUAX!1[8+4O8%)'ZP'XE]9HZBEZ#)=?
M$U&D]?U(CO5>V5^.O+Q A'Y06EK&XMYF<KK^^]$/M-<SUTBS>>R.V/ )1/?\
M<V.PP9Z*VA##GT><<:$J#,0Z_M%V^D3,LO8B=L!L+552N!T&_M(8D;YM#>@5
M9=;W6P8M$4ESK&L.R9HZJPBLS>2V]@!J.VHB9H1<E+^HIBN?_.^T1A1PXB-P
MRHF^".TNI4 ZF5_,8(#@A:;S@8E)[,8D=#NJ%K3!C'@^PZC^I2TDJ+0=!C[U
M4"D<<2<R)TZ[.!\&-&? 481,)96U4&4P">T'59%JIF6*W/_2F"-ENQ<&THF-
M9)9:#[@N%6./@0)Z8>"=)&3KLK@;&9MRX"K7"^O;;61-^4MCUK6:HS!PR3 4
MI'MEP\"2OL0'$H>="P._ZG%J!D8.=4&.W-F-F;KE5QEOR7]IC/H+CQKQV/4U
MQ!,#B>N^I)IS/-)YI/-(YY'.(YU'.H]T'ND\TGFD\TCGD<XCG4<ZCW0>Z3S2
M>:3S2.>1SB/]_P^D_T=WE0Z@_V(3"P:@'0)>+F/NG[69[^D^#]U^83A$X$W8
M)SCWZ3 0@E>BYF8.J%^B*?AC6.ZT\_S26I]67$\6E8E;F?<N$H,Z#7L*%(C5
M-55)\OZXVPF7+W4])!K=HA<V.!W7VCH4&:LWV&@^?[NFP_J!X99(G>P1T3VQ
M^F>&,H_%ZID/.;]W]_H*.2&V#!JN'R:4DKGQ,7PP,".QRE7$+/? P-9UO 2K
M@FXX2IG?EL6YS<(R!*B:Q$*./KTC/=.)L@]_@(;>1''N%X%$7'P7/8<,]TU7
MW5[K?_)U[^8*D:ZV70\"I[^BV["?? ;GP4D:BLTBC&&=7I0=#SS<G"LM8U%H
MPOTJ$N6X^FF]0S0R]]LY3[DKUU.<3(T?]43&X<(+I47B,/H:YNT^QXW,H $7
M&$#O@0%*$PR(:?ZI-EHR!P,DEM=:VNJ %Q=L)-6\T<*P;4@<SB48  4YCG_\
M_(^VP;RFO*:\IKRF_VN;6HBU;H219TG0[WW@O#=YF2' Y1@R"FK-'>U#3AYZ
M\W;?[4=>M[;V'_AIGT?:RK&%TAFR"N2R*)0T[L?D#*QG?BH%U[?<  <*T!O;
M"^7JN\L.;E\9DOE65Q+5/2CIZ?_<J"_HUTOR9^U_6MV\R1(UZ.?.W7P7I"M2
M8" :LVM,T<F?1 M @2SYQ2OT9[YVBTHA&AA[I'\E(U.P=(6RL?TSXOMMR#!P
M*)-MB(2CEU$QT)8A&&!\L"Z&+ (ZD4#,6/Y'5&SK-4/-:ZA"06?0+%%$A;3*
M0#T]X-11.QCXS1L&./>C+<#C=9-(Z/^W2,K#\# \# _#P_P/8OK^?)M@/PPX
M39-7]KY!\JYJ$#IG;;/:7L+*-*S4"Q/;7-5C,6EAE*X5[>EPY]E)+=/K>K'O
M9#:_V:]2N/^]+L:0]6"*K;2,]166%!6^0Z@53PHP],LH!BM*T1N[G$ 6"I'6
MK8[0R"<8F#J9A<2' !(,B!<IZL# <3)=%+J2:#,P$N4L+\WV1X+>RY9$Q&PF
MF>,=,S\O #T4PT+;!I$ ,GA.FE.,&(==WS+@M99I&?[^GWO,_"=\]#\.<,%K
M.&"J_[]I468LV*;$V0(#3VQ\L'XJ.06$/QN _C/\&V&I#09^ +^)\LSGF<\S
MGV?^_R;SEY6"P2559PIS!Z*[>])2;<A,9B@,7(A2@H%-\R!KWG>QT>9B0V.S
M6&KSZGQJ:DV2ZYQ'I\\#_AJEHS-G=N?$7IN*G M;R"O0,;NS"4@:/)G8Q]!+
MP'B.V3OXY'_Q.I5LO;)JU49*7PD61KKE0X>0IVXB]M-=;\+ >R&PP9!*VMCO
MB>8<O $N:?G:=A Y; *T26E)I6JA;L7-Z 9(CV.Y0"'B C"PM1_%>:K-.0:)
MP4!Z*#)G]65(E\>,YF; SK?(;)R"@9]X*!Z*A^*A>*C_+Z'LOI^P>JIJ"0-%
MWH2->Z7YX&;T-_UDJ-&'LJ%O9PT#T:OSNY<;DFK+LDM>#5OKB>=$[PRXTN'[
M2C[ >6Z?3+;#_9R"5N<4N03U'YT[ZQ?W3*EA'XV7]Y;52AM6JC5_R]@Y?Z6C
MWT[PPIW\G\)],^]'&@75#;_*!W2V5GV5YJ:>7=)[08O3BQ_Y^J2_OS98I+;4
M"[NYJFAJ+?P_=;&+I/JGJUT=T;QK3KP+C3S2>:3S2.>1SB.=1SJ/=![I/-)Y
MI/-(YY'.(YU'.H]T'ND\TGFD\TC_3Y-.5_K+2TMC^*RMOG*<:BK+TPY&^$?I
M-=VWZMR5>_QT"[.B(V97V,?8H](?"R+K$R<V1[O,^,U^%#0[,9VO\B@CR9^X
MZ/CQWC]>:IK&K_0N2D[G=AP;O"YA5STV5]YZ\'/YZ1J' RWW3D]?@X%@OBSP
M4WT.."I9 0.BMNM:VLR0TQ!(YFPE)*[AR?G%W&"E;U@\N;-MHUI= !*2BD=6
MQ]9T9/$D4#@V*'JZ,FECOXH 9W,Y#-!F*3)$;GHD,D-+R.*\"0._KP<&?*[]
M1P_+"YV;_OF(VAP9?7DHA/\2#/R@0&95K7V0@3ZU@)WKX.@)9/W@R9IS&CP\
M#\_#\_ \/ _/P_/P/#P/S\/S\#P\#\_#\_ \/ _/P_/P/#P/S\/S\/\5O"T?
MV]3Q36 G6(*>_X$QII-FN'>&L+6.'Z_#(A!QH)%9R>O^13P_5=RJ*:'*;'ZX
MXH6'JPMX)B5A0+#^8+N0<4E+5N\.]DC=$1@(2@0_G ?=0+8R:7 G#)@YA,O?
M53PO;"(82E3KN)[J=R)V/*C&WOAD;%6X\ZQ>=MK&S(,QV88T06'CO>.IZBJ^
M#1C7ENM9LEHS@]Y.&B:&A0N+Z[(PL/DUMT;=" :V;&>!#),6V^/TK;_1)R:I
MBY&>X"Y+"YR/>:_7<Q49%8T],R0O#\6L+35/VH0>?KA!VQ5).'FXDM0+ W..
M,#!9#0,4>4B%,P+6EQ*6+J&=0+:\A" ,]&K,;EB3"CX>%3O[864Z:_M%(Z/P
MOF-4D54?__)5A^#&OEF[4W=W2PNJFM=:>DD:9QH9Z)OG"@V&1YIE"I7J.$TL
M1G&C4)PUD#T.ML3\\4@E6AX/VLBCY-^9OG9?0"R=0O"V ^VT84"# JUC&9EL
M,?3Z @RL?8"!J+M=VNK5T$[.PP2-Q%48X%]?NZ/*5 :7AV%@,?[[:T'?9,)
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M!396O[]&63C+H@K-"2I S_:CN)O-X^\9CB6RLM9+,E";P4;4>Z13X^M_9Q:
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M S6EH"X"71\=3MFE;L40;$9OA@$W@:VL"&I=%A4,1V_W:G>@1G LZ%<94)1
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M_0U=JA06J #UH<H$YL49<=3$H,"=^.N]<YK"G LL!D.I>= PINZGSJQ!)XH
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MWHVLW[ZEM]%6X1]FV;NNV2TJ.GO]-$0T%ZU0/J@SK"%Y0%*FVL:BF5S]?KE
MQ"=XHW^'<:G]>\NHRYF647K2;<:R[RV(N(Y3SXZ1G&Q/7?W^,RV-7S+"H>OH
MT<G%027F0]8F&-B%[)H=1\<J6K!!!'H"V*@'-I@AW\31P*BZ@S#0H,]%LNP=
MF]@"T#X!UJ6R]H-L!S92;D ?H"ZV(=.'693%1$O/#]BZN]D$I=E%9CY\-&9@
M5IM%//;5;F[:(+_*LCI'N69PRO=MB_VN3,6F.RJR!J4GH-:D%+'(\?G\[I<%
MXQGC7J:I:SJ%7[C8+NS$4R337OO^9.' GJIM\YGL\[.44O?Y3K9.)UWI,H-;
M1V)<$0BCE**:%_>QY-RW3U?=R?+-U2+A'A@SKN2[DH9^?YUA-?50K[>HS*J_
M[$W/G)+29'E%W)0 2X;(.23,-H>Z(<T!_&FV$FL24=8EZ+G55\X^"2/",/#H
MR"I'B1':TN]Q14&!HS<6(SZM:NR2AJJL@H%K=:_IA" 5&Y1>]T^]ATOZ%_$V
M>=,B8AS;E4IMB3?7&QL*97L\XW6?AQ#%3!=EM4Q*#$QRUJV,PHO-[WOHJRZ]
M'N/DCCI$Y%ZL5<NK3M?;=L DUY:D<-; S"WEID&D;Z_UQ,*@\]XX?:45U>^+
MW019[&6U-NH7"E@1-GVK4Q-684@>B>E56L5-ZKU0,O;L+5J0K-&)7;)PZ]=Z
MKO:U[1CU45$'> .\J<12P"*3MA\WV2B0C]=G$%K!H#.)$:ZTF(<H(3PF'Y?0
M@A48UG=4V4*7#O-Z7Z:/?6<Y_DIDR=K1,%M?*62TEUA)P-!'2/SS*ZKB9Z-W
M-9EDR5(9SV9[=<CV:HJA*G4?'>:=BQR*)XRBUF(M4\X:[COAY7)E?TU5N4CD
MJ\SY:9J(]%-5AW,]3"'[-O'QWV=TWR\U&+R'@6PSX7'LIL#3K)W,<-8%^NQ8
M3 -7=\R,OJT9M6,Z4(E>.SZ>4A6PWE-V]3+!OK= 2D$R@4C\>GPCD.AH:U9!
M+JL,EGJQUQ[4KZXN?5WVEDQ^6U'\IK@B:6%I:<%QOM!502$3$2MN;E*W0W;B
M#FLG.&5Y1LMTI7XQTT$=E/FP[YFDZ($6@U,1^KJG(DHB#$U[]%6J_%"O+M[+
MW8XXUXZ4L0,-'DXMUV.-(S/ZHY%F*ID&X^'R+"3C#\H"ZYO)0GC[,5>74<K<
M#S074BAJ%^=DSDR28BUC1%Y!:AE918*+Q]TS?K7EH,6"B])%']8(U'70;)0L
MM9 U16KJ5RU?BU97^O%]]C ,*%'VU,ER#%@513HT,)RRM\:7H=I4HMRI&A9X
M&$=NDE >D/0/W6>MGE3Q6$5<ESOH*WS[1=+H"^NM]S_^0"IX1P]1$M15\5"A
M/IRT[LJ>KNHS]O>_NMP=>=!R:?F#+C,VDB1,/T<,.^>]NV;JE]=]IT4-K$L*
M\K4%0EW=Y_+\U7IR,A92:I_=E"+Q&2@@'NVUO3!TA?+]4B]ET($)]KF6$8((
MJ$!%SHFZTHHS5^OX&6N//5WX"@0^5SA5#&J59U09$+/>]'CV!YPV>E/UVJ>G
M=,WE/M.\4)1IA.S: !AX^*L2XK,(AUA6S!O<XKN>4=)C2A%E?,KD$-2!FG/V
MNY]2R6$;P]_J5R@_LDH:_+S"G2 AQMW1MFVAJUPIQQI5F@-;,=3C%0ZT">E>
M;'X^H2X?^:XKWD_E9F26_CG3ZP^)YGMU%P+;/S@;A?=;E]S7L[4U'9QZSUI4
M^,C8TT"3Z6V;[8L-%C5^Y7)SQC2NU(EM+^8F&.<=JG&VP7!XTM@CDIPG)A=-
M)-;G.U6%Q'M)KIA7I4:-$!XHOLB=L53,.B3Z6L=5.2FP)-/FL_.&_I+V495L
M8A;6PME<,&RAP&U^(2,<R>[48( E9Y".B(USR/KP#.S9F&R(TF8N<,M5.H,A
M^8K$%L)F]0#5>4E&^4YW(9;8TLS55]U%KV)H_',G6?GU8F&)C8'2KY-H\NOX
M5/EF:</B+G6+EV6M+YZ-$P;+B!?/)GG*M:C3@Z^^9]\@+BZ=G6[?<H>VZN&#
M,8J+*2,X@)]O^.%R1_-OO5XFE.0:1U)1-U7='>:%$AM-1B+O$.22KL>G4,$5
MVPSR1PKS$&+@>^@S6.(^KT!?ICDT+PZ*CBVV4A[1*6<>,J2I%<WH2/(^?$ &
MEJ5J@W-5";#3ZL8;T31N-?2T2!R,E'I++;QX_L)IV\^I<KY@B8K^%5FPF]"@
M>9P^$(.7I<:(XY2L>FKT1Q?%</Y:#(='')W,KUD3<30!?ER,?GF_LH*[7G7D
M\X72>2N]FC+RF[>1S](&:;+7XV]BDK]]CLSPS#0WRC<HM0J^(979+KK8XVR9
MJW6V+.!85G:>CK8 0T(P3!83O]T@V%J=EG<]7^:#LR F^$;EM(Q.;FN-/<I7
M4J;B4Q?V'9$C4@WM5&6$THCSEWSH1*8J:Y5QE(JM!W]]X**YNY)146_XN$Z!
M?IFR'_HIN7*4$?-8486RQ7E09D!=X.6P$YWE\N[I\8WL>/QQ+\I!)[]"YHLQ
M\5/\IT>QGQ?'L!QA0^8 -Z/N4& ':@?:S7UH"]YP;-[ OJ9_%37H,X;K4D=1
M78]T!U@UVYX<R,(>RFX_W3@HF34\5:8CLF9!%M%$=8TAR6_ F8[)[LR&RA>C
MU$A2>&9PQ*M9 V&[\]W9<?$S*AGXM)7,&O</JP8CBD=C3I@N\XVSK'=+HU1L
MSSJ;R1@D1?D5&84J2"K<KLV\%TEJ.R^KM?3^-/><"^<;.#I&V,L*Q2 TO\*;
M=96Y^EOT*8,[< *CT NJJ[Q1GQ+)D\+O5!73&"/@LA%">'GC:Z="491]0-%,
M4EJ9KQ-1RW5+?V$.9>9TRUJBCZ .=R<,U/O7:#- )K*/@^P#.]10[V!@\"#S
M(7T@@H-F:W-4Z5(5#+^>,4S3E*8":ZG!_2%9O"P@$'L ?TGS>'+S1A\YK$8[
M^\OLFJ4"\^V#C!O6%DYG+,VBTEZD.Y9[HQM4F["/*?L"3^"*8*"5(%)W&#=&
MBXGVNGK7=15]@*/%N%,[YBX\<V;#/D4M,'D+#(35Z.4X^]5^50L(KJV-BL2(
MQDIFI>P9^OE-X[XC&RF2"94=ODGY?-W/Y*DWMVT32S2353$Q[S:.M/2H'5 I
MZNL4C%G.Z24:2L;O>#;;D"UZT#PC]X!Q:4Z_07BQ<7+DC/3'[HAO57IZ@85@
M/9FPE&CX11Z:[81*E%K\8$#/&08D"*$PL+?N,%Z*$?B4L8F*C>;8TSM;J[8-
M(<X3[TZ'@68QRD-U; ;H/)U8)97+?4K#[L8Z574D<[,RG2VCGX+,\Y\#OV1C
M1SY;^R94F#1+KUQ /.4A;C'H0HE$T8T1EVF[B57&-@OL1@OA^?-P5K35%N)H
M9QCY4)TT;J@A*:KE!;VZ62TD60,&0I$<,,KP:G6R(;FBHNY- JU#N[0FZ.!S
ML7,9VK9I4N_SQB35/ZA,-^R_MM.8*/.^([#%;%;3O-3Z SZ/K1+PHKG>6N>2
M8O#Q-)QSF=S8\M5*\\C1W)Z-C_<J'9>UV)WQ/?>]AY43*M!D9YD,\EFTW0[H
M# R,SA/66V& .XR%V%[@[7B.*[)$AM#+,3# KB)SF3-KE7:0]G,4^P4,]*I?
M6*I!_G^LQ0$&[F,W7C>@6OEK:YN'FT02GNA[>7DIFS/[^QGJ Z*B@FJMN_9<
M$BN-;5>.?-,LY-QYM#A#]M8/B@H+"HK2I=5!+E;Y%ED5;\LK'U,K*RJ#!\^]
M3#L@?#O<\;9Y](U79KAA"_%+/VXSH;,A[<7-X&<*E<35L,!\!NFF K]Y(ZK.
MG2,DR"QFH8E3;W ^%S\%*LT.(K&X]'S !96SRN1-^,OA/33#7^=&JRT<GC0*
M/,3;I!\W7XOKS+V1/21N[N0E[Y][<!5C+E<C@X[.DBNS@\1,LOA6ZZ)+S]AX
MN>A!>UXO)XADRX*[X_W.^BZ^FNTA&:>5E[]I[!TF9C^>=5]!YB;('^]CB,34
MH]SGFJK*2:6#B5&!>W#7<0D!;DX+9;(<%VJ^(>NRNH_ZP( /)C$IY32K[><!
M^^(^DIL8V_R-OZLNXW!55<)^B/Q?%SP?%SEB%,8D)-CYN8)&>I>J=Z-7A=]]
M=%N+53)7VJ#2E:DFT A&;%P+_(G.34BQ93K=8F.;E 0XUGUN\YG%Q<46I(0)
MT>J:ZEXQI9Y.UG'5UAP8<#!D24W.VXR%?2-'6# $&A4,J4HADMTC"_Q7>IJP
M!VR50LS5:N-7LYI3DEQ;0V@,C8''8V35>RK5CE_*K:HGREY7<T(/_/KL=/@7
MO' *(R]>TC7=UL/3I[QWYD*M:S^S%WK4]N"&&?6KIJM1KISO Y+-R/O>1N-G
M'CLV!E>=3'6<>[H'/L& RN)@XICKVKPD^RK'F[4."K>7$D0A>=9L*[-<]+<M
M+4]?X>*:,!O1P>EJK1[>X56[(\X0,B]'^'CODQ<R\;I_(<U0O']%'-.8^'IZ
MHYWT>5%1.49@]E/CY)"U>W>-R<OI.NE/;C5M%L3'@</I,QM>:T\Z*LZ0'=DJ
MW\ZL/35T%U+3?)J+>XCI7A$7ZW#5OM&_>E#\J&[/?,.+Q3(%W0GY\P?/;CJ5
MFS0QXY@>>5HNT6O+KQ-D;?(H"=R^0OD57=':U/G;QL]E:F #.IA0C&E\?J?X
MRE4E;#T,O%E[Y[ICTGC+6+A%=I]BP9U>-[>BHU;YU<FY145KUNWRJ/XQ-<^\
M3_7-DG@5BWI005WY=6_A-)N5-3)XM_.=I&[148'PCW*J4F^>R9K&#7IY/&G!
MN".[\,NKX?*)/N<8$K*)A]#KNJ)!Y+FGG%^0;>HM!@-:>8B2P;+.=$+&P:,D
M]C%P/WI5/(3<Y4P^-R:P+M8(O9N"@>D/DW.V$N#O(2#S1!,X77 6TTR@7U<:
MPKQ#O4;-U8XAH0'5*K^;&)!UL>X0RV6TY?]B[\VCFMBZ_L_<ZX"(B,@@@Y*K
M" @(.# H(GD4 0$A,DL"Y"(B!(2(" 0(Y#HP3U=D4*;(&.:($% (R84P7$%$
MF2)!"$D$9$Z0H8 ,O_C^NE=WO\_SZ]5OK^[WK^>/JD6Q*I5S]MFU]^>;.F=7
M:]+'61:XR_;!X!8)/+6 +#3/T';[5M\VRK.-0AZ;7DZ=:I/JI//+\RK[RW1Q
M(1M[FVN_3RI])F*E@737(7TI*3\E'T$S(8 ^P:_+*O'+-<P*T-FHK)[?+N.]
MOB62>GG>NS=S-C>?4P-\ PXT'SG<<R!H0>!+X=QB )H'VT1()L''A]KP?]V\
M^89?*)">#/ \"*@Q<R@[YFE%WG+<IM&84Q[C/0%WGRU@I7,[>NP/W<B1\2.#
MFSZM235Y6.&_3D[>_W;Q1L.-VRE#MV '#<Z>&PFQ$"PI$'W[7?H]#/KV:'K.
M:V[G.^*H)_JFM0)-PM2LLP\>',AVV>0>MM5G7K&R[C<P3CL4D/6^YP>*#>V&
M)E :-;I0*I@ @,A2Q#ASE5G0!)2)+:L_#!X%-R -$PQ/] 1X>4NVI17@;]&[
M4/BY2)]4DCPL* ^)]$8><-G@%F_%1J>R4%^&6&*/(;<AOPKHY+/G_3R/  W<
M[@6F7@?CX,07=VH4*UJ"*I"AA5)D>&9'9"R/[J+VLR3V8328H\0,5J"9_6>2
MA\Y7E[ FV+7MYAZ#[3;%SYE'_2ZL.CPO\3M9).ZP>>Q"6?%&X /]QF2[RZ=C
MQ!/P"4^'Z[7\:]&6,OWVS<;/")'/JM7'GX<Z;B0YC%I;PZV,!.]E[<UC%+ W
M_V-FCMQ_?>8%5H[!<=8#+O3UY)#/<!%_H0"-GH3&E8/ ^6NYME*=D,8V,LZ[
M&GC21>-*+%Q^,,2\IM1?NY%> MP0O]U<S_V!_(%.=FIICO9NI\&.)2$C9ZJ_
M^XS=U=:O^<Y\U39<YE SGJIE'_3^HY51F$"AR_I!@[]A2NYJ2,K*+QE>V:K*
M]GA#MD6L?IDG:; U]8*1G%_YN]F+%H=:'#(>)&'I_7*"JP@9@2GO 4"K]C=>
MZ99*$1V>FM\F]9F68-DKQX"\KN<3)DA?68GCH^N71@Z-FY7/C6Z$?:]$^0;B
MD1NC]69[LFJ";_,@0#,7SC2L#JSC:0-Y7 EF>;/O?=3I]?1X@3Y7XTDH'-[P
M[>[\^$W.3%GY1/O]F+[ EZR7:A#?)SH[+S;XUE.Y^<T1*;)+G)K3^:C =_R6
M,'+.MW'X0U,Y(,>&[G9G_9@V#Z4LYYB]LP.I>CLY<;F6@#=RY#_Z3F"6",3#
MA2 Q>=[O'-].J0.\H_PVW@W3DSQUKD6);]$MWL/6-T.+)J&<EE7!_/4E(DK)
MIAPV1@=H?W&_NE]1>1<1@@(G\2#EB>MY44+0H9[?"U7>"=A+NDMZ2X&$1=W
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MT#ER:65_E"5GN1/$LD8[C-%5([-V9POU+K2[A"0ES]H]3L(>*"5"G"L(O3@
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MMNHE"CLZ)S*"++.R@H.@9F(VNUYP!/(/F=:R52Y4>VK_J+V]71G,H.B@_YL
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M@1P)U?L%H\E):ASLOL.5Z@9+N!>?O"^>P8Q_.I#X[<S <<-Z+8L?-5.-'+.
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M1*\LAZJBQW6R=X?CE!<F3PZNYRF$7KC#V7S*3C8G#A,I"MC]"/$U;:PLQA%
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MEJ!O*_YD6[N!1'.+NF7E&AEQNT$L ";T-Z. ^':_W'0BS#[T(<W*?*O&,4E
M22UF[:VN7^Q(=.ZA^]>PL"T,T5C 7'9+_.P0]5Y=>:E:#94Z1\:,#RM5<"U
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MT('411B-IL4==*9S'PNGY0?7HEKM/\VK//A,B$\M7?C6NO\%<V&,!SFBQ.*
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MU(T4ZG0!?T"3]5@ FG"A)RRUX]INPE958OEYC_I2!:#[/0+0)Q6 15S]R+^
MFTO";?C"% 2@U:_8?0)0>6>WWBX.^1S",(?MZ$)2<:P'I@".3=RDY_!@Q&](
M".SK_"*,]4L6;OD<K!]Y@ORU]K4 ]-=AH@!DU14M:8=,@J0<D+2[^'_VX=P;
MNZEUN8LR^^*5W[476Z*N&YK&OKT7-^H'% MH"<<Z!S1QA^V:'U:IVY=Y5AE)
MWM0@53A&:SC.O238XRW5_CB:,&G_,B?)?J(N3;^3MD)G2IYI\'?2I-_7*[O)
MV%0W&ZSRWR+(!I4Y/&[.L\I4/O:'NH&Z;E;EKB;+B^TE !WRB1]*#$;=5(FB
MA1:ES2@[^A*W!I5(B:CT1;._0,VY7]47(_)$?KV.6-)[8+J?$9DW!Q->,CTV
MYACJ&M&4&,]XO8XN_F4=[:U1EMWPLB:IVOG"L\U+'L&X>_=DA$=IVI#.&R?^
M8FZ-=B]F>OD,)95)#=B>6[$6/2 KN5;<J.S\P>D6KCQ2C(V[W%E]Y/W"N6B#
M7/IXX&&.F(@U9='IM8*_6 Z[](9?Z4TUUY$T@M'RV;S0+P"A60./=;S32]T2
MPTTA><\J//_'Z[+>X&7R.1\&.7LQ9=M" 'KJ%,L+ZQ2 7B6,5LY ^)><(5LK
M8/YC3:L&568_UY[[>03\&$9+_?HX0:U,[;_3K?\_W?[)..[KW3'<RKJ5 #0:
MM])<+6$G #UKMA& B*V:@ ,J5I5B'8!_ KE)RUQ-KAUW*! X\R?#_S<7^:^%
M?FR3VAO:5('[I+%7'&,;%AP6$)K=0=Z1(Z$Y!Y "T-*0;541?ST16.Q][N<,
MOI'G.Q[XM6]APH;-'PEJKW[]O_@X J5#N/%-4[S 6@%H+!KOQCXI )VZ0V7)
MM0%7&25;]K\:G?00MB/M* "]P0M Q1?M^+JX=NB 0B>0+;."HC'9:]!_%0)=
MQ'T69U?MU0&U>DY[*O^71FW.M;!4"W[;&/!U=&\D6XJ\,@'GG;+8$4=L ]!S
M\!6N3XA7#5NMQ@#X=&W&G!R[RY^#S8V#=WX7@$B]O,PA$&Y9KG1JV1VP_2EW
M^-Z(W-UG5[G01[BOQ>T"T%0EDE\X :M,4"LDJ\%"]S(,3 XW-P?;^1.YAA*
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M:LRGP-XA5[MQJ*+(85BM3[L ]&3V9-OH2>:!V"=<[_DJ$1MFG@ 4^^/VI%9
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M@Y8T>>I=:YL^7\6#?QC.S[RX0Q2%/<H5@*:^0/C/XDS^73.##27BUO1_;6?
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MV9)(^CZ1I_%LRBH#KV:I-Z.G7-U<\-T%</ !K$0].U  VO\-GB ^W16,I$@
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M9Z.ZM]M.O^6WCU-0>,;"UTE]A#@WVO;8@%<B!G-ML7C9U3#?5\-S<-<QNW5
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MAZR VW+&5)//"T O8GF#N!^!+$,!Z!\\[E,C;ODLWTJ/'U7 N /A%N&Z8*Q
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MO9$ I#7$/@WA%G]CC0E [Z:)N"6%/*1.>\'Z)S)GOP#T93RU%L@L9A@P!PQ
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M:)F_;4W$9&/^NVQ!</50#] 2#W7H;?0)"""-MB.OHO_#.;>=N-XX"/(MX)R
MP=B]A1IHV9UK"H7Q<_I[:5*$D_Y=_0-BCJE:J&'L_+W9[GF(;!0@U(4L*:!
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M/9#@=P\@[+K]^O-7\##D ?9C^+ X(B#,6(20@5X$'69\6$<%Z]%?=/3J(.
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M*?UE/#2$#.>X^#I>'A\V]Y)0BWBJ77E[*^5PZ&97.*F=<$IGB4&FU %O"M&
M6:>(3XB&R[044M,:2(B<J\2S5Z6NSZ68SD9$>I$BZSV9Q,_^<XE$>.]:R%R$
M@2K:9CPHY7,#8[!K0WARR:+6I\%EH@-^BJL)O,!Z^-[CQ!;P2L5CJK1*MX""
MQK:6^K9LU7,'QUVME%G$&*YE%:#>U2;-2HG9EJ@CG "LW88-+>G3+M._IT:J
MNWTB"T;:7Q_]P_+)0D-8!5G0->+Y<*AG3+[LB9XE9^L95)*AI\J](RZ7;(-(
M54/5YJ\&O7R-?0T,]-P>H3-ORZ/4J[/NV2)?W3GOGN/F&5,M;I<SYOX][86;
MO&1N=2G8';SCS(<=J 38Q-I9[LFK[']8TJU;X^Z_L38>0[QI =QR;3?,.KF"
M%J]B,*W*O]XR.?H,4XN9$1[E6E?VOOK2?^^W2 79I$%V5S.6PH=%X ?YL%-:
MU<E\V"_@,:[/D%H0IU*=0>V$_\J]0DZS\$W[@\C,!/RMQA?(?ZD[&0#&G0%A
MJNGUV8DV*TZ!KN\QKRX?6-7L(O9Y<:5]6;N"PA#+0UR]VEGR/4WH:E>; DNW
M9T/"^Q3KG-G99_1(?>L#H4<XMDT1E[5>K[AD/>&&UI_2"5GX_,5;7#>\.^&6
M*Q"^@/B@@9,I7P!N&#)X'Z]DW"37/5@;+97 %.+[VV?+Z]?@%-:IVV?DA>=9
MZ0O4L.BO!3)C7][@ZC!6DN6-'$=;%[:M7[\<X90+GD@H1W]>=G%,6B"5^81D
MTO Y+Y?9(^ZS*^(_:V7)>4E)>37F 2%A(0$R#UQ=+Y])L]9Z*GI]?>5E"1YZ
MD^T7\5 8=VSQRK<2!,L#=.*8O?24GNIDR:\OU1&K!&89_A10U-4FUOCCO>-!
MZR<V@$Y?OY=U;63UFH)LYNFU!>YN]82'DT:E73Q0:E]DY^X^[ICJ3FWVF\Y>
M)QA_B*;'%3T-OT*^9:(0QCE$_Z:HMMR\HKMQJEGS_Z&B_*YK]4+:?ZXHO^Q'
M/3](_1KPG##Q<^]+'/B8[K\C7T/D[(\#,WZK[B$ JEY<T1K(#FQPM(R(?U6O
M>O&*05VU4CHB:M?AO5$[<R#GJ$CO/#R>EO[HIPX>61U5L5&)-=1)==-J /7&
M<8:=EF-UTNK=B#]XNI",U\<9\5ZT'>%: #LLE$WC"&X?L[JC.26>:Z*=?N'+
M2HB-<UFO9Y%W?9:XCM//9C[LB?:EBCK57WHB^O3\@_-,>X9=6^Z^(*5PR1#9
M$Z>4&80U.N<Z,,^. HB1%W-NYG"$W[:=/M&"(0JW26%T&S9#K=_NJLB9GW\\
M@4RQH8QJF]]6TDXYN4*#[EPE.NLK[L>C7$KCP[P9K:W>LP*QJ<$G79S*65=2
MO*1+4(2'0R,T.<J !@.^BA,>>SU2[Y$47632_3VN"._R/ [KT! C1 T+>SDF
M+_[#O> 5>F7B)ZVJ/#*L="4[[]M 0:F/2\S'B8;=&-[J8&!89&38PQ^WW&;<
MOIC+_-35?"\STG^^3[FEY>)>%>2]CY5JQ/_Z6'D/G;B],\;BP]C^0!I':Q:G
M-H17_'RU$$AA9+43#^ >O&:R?] RH^C63T(D1]M.UD[,]TRI/OIY97B5/+6F
M^(0R9%I]+*6\TZORIH^3SFSAOS]ZEHS\MX^>%7VL?.K5CZ3#WRY%+W_0B.IC
MY=8D4%QNAI>;UODB)8>V/G$3Y$AVF81T^\K#5XH#;[7DGT1:J3)>60Q;.ZR.
M8%;RD^0#>:KE>W7+HEX1H% 3($"A!B= D590_E^1=JS@WY$F_>](B_QWI,56
M]]6H[YSQA!Y+!/Z>V,!"<=.:&GB/J3PU :8L>EQ@=1FR$F^A00/RB,;[N2%\
M6"SDVZ.M07%T>W4L_!0$3V+0.0PXLY>Z'#QE]C@(<1JZ',%K@IP8'V8*3H(]
MT#$ CH&]P]0Z?#][<'4*;K#ZAB"__>]-,E8I.V:]J_)[GT8X%_9&!M,H<N+D
M@M['YMA3H?HS/8Y* YKX@0PK[Y[#)3ZOLYTB[:P_<EL>:R2VZ';/E][3(U1<
M23Z;9Q' 'EOZ,> 8YMIZI"ZG>7@8&VRQN%>7Y'@:8?Q?B$U'!+?8=X% TP6%
M?'DOVR1#-=U97F_5D]L.\ JUA0Y.;TR\S<Z*VH9'XS588NFG+%6[&V)2%[M
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M1O3=3QVT;[36.-4GQEVXKJM2Y:Q7SFFU?U"[<_B/:$GP%_ 3)&GVL>!L;Y9
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M!$TIJ#$RA4[UN0#GZ3REA9WLH(N]D968U\=/DS\<WP?VORJLOO#QC7.>17"
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M-'S[E3XT5KXQ6C1UM-W .DXUMMR8MP-4-M:(;%&.&C])<!C]'B-$O(=6!:9
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MT=6:<JIK6N:R<X"3N&/> P#I5^W4,Q%9W9^G9E3.S'U8E&\Y&)$;492;5U2
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MZPS9WSH_1ZEO$2AL9%+X)R;8]'4AUCBX(D2S6?M=UH^3;[+PO5 )GAIK^ZU
M=[0.9;J@=86A\^?FADB(K^I'8JKLK@L]35\T^P22>+M^_(5JCTM"3^Q<<EMS
MKLID=C6?:#4>I7EE)&,/=!_Q29Q3R4\@NY4CO3A_ :%1#'>4M50.8->WZ[-(
M>6(BRIQL:J36;7E!Q0&\K8Y?=-6W("=2\V3DF\[A:O?WRYHT!<WT*^VX?/)O
M HGL/C,P1FD&F?6SZX9;O1"ZO:)WR]("BYG/]"0?)#@)+Z!_>E"W;%05?;1N
MY[@+$_(GNR"5[G(#)>>'>J-+R4.Z8>YW'[2:J+@O&[NH]^L[A4]WM:B\QXY-
MAEA[6<HO7.H\][7Z\4#@J:13<"N2?&/U=4L;E?,3&?Y'?UAIK^N-OYC+M*0?
MGYL3<BM1ZUNJ^]Q*,PX.1Y;\AUOY)Q\YD^FYSZW<F6GZ0F[E(%4O!%D8*"ML
M@"?IWP=M0'3A)-%4G'QDW(@X+X!?UF1S=J"G\^C$VH8>/X[1TFUZR:%]O):P
MQ;5\#PY@R_9F7HO$2:T8WYP@;QL?3R@#S&BPR.'8C3YC+=S^R3,ERET$H"R#
M9ZU>XU?N@?PI(K.H ';@LQJ%4ZAH[O7/RP(=H(O5V!=K,UE8[07;1A^7>61V
M&$ LF.HNV9(FFZ R@$5W[*..*/S*0^_@D@L4UM>R7UWX_YKZ)US\Q)"TR+,H
M$?VJ:S86DAIL3E30/QMK$U=:CD2HJ%_>*<]QS?#.HUQC'#^9)5)Q>D'V20_S
ME7$8TM O<.5CY:N^@1GCYK0:IQS'#'^YUFOOAK!.#OMBI0!U\\'_[PT1#_*K
M,$$($'H2U[C1AYD>849*6L^/I"M)D%FS_(E7O;O)2=7*'T-*3K$#_VH1X>!]
M6(@T/;YL'U9VYFQKO>#3:"UZ)C0*MN0UM.'L<CT";^B<^#S(UN&Y<E/X<\^\
M>SASK$W,2PTJWK/82M]//N]5=^3*=2MVL5%?_X.<U5,WFZ:<1WXX\.L@]S"9
MN'JW_A$9E#C 8)@Z79W2$W-RRN[I/)M[>YR TF2K=3>WY<_A*E!7 <RK%9F"
M:B)P VKM6O+AQT%9X_A_VCYN#?GH]!K[UE1XQ B_[D8V1@$3-"*!SS [A/($
M4EBYO37ZSZDA='&R3QW2-?ZJN\G_P=M[1C6UM6VCV=MM%U$14!"R58IT"T40
MR*,(" @(2"_9"$B)-&D10]:V $HQ6^H6A(B42 D1"3T0Z5L14*H$(04!Z2L@
M84':"<\99XQWG/.<\7W?*>^/^6,Q2#+76O>\[NN:\R[]P:@*\R(OVOA";)BT
MM)UU\3PX.5?G-!J3E>V4[C;QK5UKJQ'[!?%N8Y'+=4/_"B0@R/YMN+T8%]"W
M6F>8F/A4?<;:ZLJ0O%)=,+(-JS2PK"V$'47K>>J2-/"<E<?K>;(N7+'.WNSQ
ME@]1X0>H?<I+6B)0?XOYC8U"HH!W==U(68S\T'2:/A.T[1C?8ZR,/CW]M""M
MW6KT3A%(3]7>?T_V T4OI[,?5^D4V53G8MH\7<=Q_E$OK_Z>I6*6Y6?]Y0VK
MT-ZK?]R[[$YN>%(&\]-Z6.3T,2'L$@+^"=JOW3J:=5JIK$J[4-G@!J=</*6P
M'%-F'T8P=GQ=*O/VY3J?=E^@S3NX?;0A MIB^#Y*+D)^@2Z2 <$G_:N>784*
MP>7NJZ/$R/+0MYWA_L4H(6QO9<N)A"'E&G+]X04OE4&,Y]VZQOC.)9Y!_C\:
M4X(_$3XX2/\^QQ1:>!.(%><74K0J!!_SS[6X!$^QI8AE(O44 2:L\BA?)'.[
M#+#/BU!>4NZOLC;V"$Z#%#?Y7,Z+X%"*_=SMN@UJ7__27M&S6@!:+8WW B%!
M6 E0_#$0@-P7N&MFWLB'04^N"(E:R%,UZ@\]"^Y.D6@3_<KPY.D3,0;2\>3^
MH]^Z8P?:O8U+_0\-*? 0HSP$">W@-L338Z5*.(/T)Y'N#9%\G\NC/\<GX&X#
MH8S@ZK&@6*]"L9KU^&\:JSW!4;\YF'TS4&$U3F>$<8)M[-LJ##(KY__PEXDH
MF?SVTV=9C5-JR:7U+:XQ\>SHRTZ'NJVDSW@6FU\H-B#/%ZUST$\%'(N@C%+G
M<#>O.06@2OY%Z5SC2"YAP4"WP*<\4*8FM810'-3H]TUZ*X100F^5&WY60*"[
M?= @+J4N551YT#S'K12D#UF<^/P/N[%JLX?SB5_,T^/*"7JH,M1 I*0[O\D:
M<F2,I][JMKKT<"%?=5CK#D6/ 1RD//GGLSD+(8-RVQ6O\=F;<VU]5X/^X4-
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M5QG+\ +=%Z8A5"G2A&'[+%:RR#:Z<:/-]L@DS82E/S7(^O7^A'^;1+O/%/6
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M*6C%OZ-VX22LPV-8>"G>*7"=D!PEV[30;+;@RHYY;/R%@9-<V-#+'N%LW/5
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M6O6HON()C0\-98J0>\AT.914&AFGBR=BD,,ZR&1:7[9^AE^(-M&A6R\VN"/
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MGFPY0$LYA+ZWMPQYV(V1^YH<([C8#R,95^2-YKRYVB&<=6/R3/BS)X)[(8X
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M<G\O+,\]W!,IJ_>QO[7EVZM\;M#AV9)=7JI9D-FD=T7*W-P5+BS*HD4C0#=
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M$9HGV&;EODUC_9492443@WZ>*&&C26,3#<V>N95J=%E&0=ZHX1=;2V7%<*7
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M#.X\FRJUJK#MGO!7JI08*7L]4W6*31B?@&</3BJ#_.F<5*/#Z('!'J0T^"N
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MJ\!70OR=MZ(/S70-D>5>'/??G>&V$Q:^I$]CF?X,TW8Z@1E,1W% P'0<>#U
MQ9GAE$^MP(/H43WSYV*N7FA(&^K3;K-YILZ[T.<5+M^S4A]Q[ZB>:8O$A1X;
MQK.B[ZZUFJ/4E&- V;\H2G<5K7&3HJTNHRF2394^U][W'[?^.$MT&[DQ]RU2
M7S3OSI6:S#/0R[T](E:+ZI<7%[-6S.]6>&@M7[<H,ZTK:+VP8X^O:027)JFP
M@,T".:I"!8I/W6EI8QUE*PU3LO.T6XEJ/T62FTAKKP\Y>J>)B)HS'F_8-.=9
MIA('](LD6V^\4MGG^F$E4&8[@7=8H.L/L/<"MP+!8K[@WSHOL,)^,.'<EWB3
M<(E<"OS(*NF+ #I%,B3M<ZXA1\I9P(%5C&^Z#S5JNRESC7><$9A0/!0:&E7F
MZR$^A8?5NG7@409)E-F9@Q:.57?'E[N"K1W\3*MC7)H537YLEH4KF:IKF+=J
M-1HV_-(O=>RNQU6_J\W6C>:*Q+0+6=^JW@3(GQ) : 0QP/1R5LFU]R2-3'#4
MM^(D^@A&2(6QCR<D*^@MF9L-OC,BOH(Z'+)^T9G[DJ>[+"$0Y07P+ZN/3;,I
MV(/0*QZ'M&QD6;M4 V_PL=5: _RO/ZX3.=>H[N'F#>U)VX[$=?V9JT 4VD8<
MU36!:II8; @&QQC^@APZ>Y;^PW/M,30)!T_VT)B\LU. QJV2S/K@OWZ>\Q)2
MW,1?\XF'>/Z-<I%)+S#(HRGU-ZJ"Y97*!+-)LRPT*+A'UDMVJ7RD^-Y?8B3O
MP]7F"T/^EB)0J765;K=&)<KRQW:,?%L!M2,CRR,C0:_ !=:GA8IT@#"RZ<*\
M8TV3Y%YM%Y]U/;:ZKSFE>G5=6WA$DG."X50)JXP(>[]1;F7'8LGT5]<,4+W3
M;?)(_OXW$'#*M$2TX?*17)6J;BWT2@G3C5O# _"FH<):Z!39AI%> YF!(C'"
M[5<3:@&!%V)[>4<F2>?5!N+PX907<KK8IQQ+[](;NX'5^XUV^RW=?<S0=I]"
MSV@ZX!<'O*3BW;+J;T<:Y<.4ZX,JS9O?!,?ZJ:WZCF2WZRDTZEWY>&XP.)[R
MI*^[[';?H,,EJ=&ZXF:_PAM]'Y57-C$CXB$%F9]VM9,4L5K,?UBTKW@X#760
M Z*C$I'G$+\SU%,7-O:S]$P)#)$DA#U5AAVM^<>G$*LK<]^Q6VH6O&5:#(E$
M.C0]7?AFX$%0];MOJ9P6Y"28'H+I0@-8L>YT^-H+NB6$1=IU7!BCLBH9^]QR
MWQK^,J[0.'[*@QSAT]WD$E9)DSWAFYL78G1&F^W6RHI"-#?;1"ID!GEB>B0:
MYV*&@EI3"AYFR4-R9G_@[UI+\OPR@V+"IG*^6RF,.R]Z.W]TS3+2_* 1\BV8
M/-U-K'0J:WY89JU9*5>8F0N4<W4CFFT%F:#V9_(!7>/DYE@_?[7FMP*G^8+:
M::O X;O@IYT:LW[><W] _1-#?7DZ+J2:L<M_S7P,<;*TE;.4[YB.(\$[P%X;
M+-W\MX;G)[3V7D9/H1H$1J:G);#N7 PJ$740E(R5C$ .>R?9JGVLIF][Q)-[
MVZ+C2I>%S;63J>F2*YHS<Y9?OO$"8M3+EATI"&K6:1Y6NE*EA5AM'6PQ=X[T
M*%KM@)+.&Y_D!!KR#-;6?O?+MVMZIA%)XK Q^,?BE)(#W)4T4:>)6B W>-0-
MV -.)(MT:D8(=_,!8DCQB)[?&=L]9.GEH-6SDHSP>-"AOV\21,H_F9]?E-!3
M5U-?:!W;4I&)B^<#+,?7@5K#%J2I6PVM3<EMV%]ML^[3Y&B*S5*FYI6FYM/E
M1968$AN'GSX3_;8%GE<M-)\6ETF95)K:9N"]I%0P$GFP\C'K56-.P.H_)]+K
MX:(>RM+]#G+^AB+1>(-+?X*WCH[[;P4J"7P1]4N<"!3W1CE2]"UAT^X.'[ Z
M">0#;/W0H^GK)7^/G9) >6)) _\H0H,:()P$>Z<+$+$(1W0O=HI(:.*XT\!Q
MG<KTI7A<^KI5X+;5*(Z\KN9C]Z:!C<16?(;E(,-)P(V  ,\< 4P=B>6=YPC0
MD\!:C):A%B.Y+U [/Z9VE9"C* D^@/([;P1]IE-OK_0-'W#8AZ-D$PL]R5,3
M'*MPJ_?J(![6X:B@]J\6"=#74Q0[F*WCS.OG30O:1]X$;V "U= YQAQ9F]FX
MM/:&#Q#X 0R)$:[GGN>AC17@M;9.FX3JI9"*>Q*.L3WW8&WUH5X>MLDI.UJV
MBWUWOQ>$LKRPCO7;L^[QE"I6BLQ(\!%OH1K?<8>+\4^7I,9"3V:5TI[T35<Z
MJPQ*1^>VLBT%%D^?F\/30PZ07]=ETN',9#J0HT)(E""(=5Z(2$,=0W5;+6Q(
MK(TVSA1>L5+^P?9\VWF>H1U#]K.,3)\><_"OT+ZW>,CR''QJ]S\JR3,*SE*4
M7 _@ XZHL"]P7+E58(K 7^XF"AP\5S[@D"SG%IJ>O9< PFT77(/02_X-<4T@
M!24\48(DREOPU0WE-@@<V.^OF.0U/D#P_=.FD=LVT]MO+)GX8=6^UD*T?ZHO
MZIKMT^*7U>-Y,4_OKU@?OH;+*H2(MV<W&N;^8O]+S/N'6Q60@LU9]5]!,*JR
M46!)MVW)R+K/(6*<&=!+\M*IT9294?N.YTPK<8Z@H[VNX*UT/H!#(O !"BO<
M$2X6M8"5;1!9LZ'K4,)[R2GV?KF$$[PK"!!]+QX_@0\ Z(L8U!%HA4XS4"*.
M76_ *XEH,\RD;!R"M:6RE[?/:C ."9ZWT?[F)($B_HEC4K,,>;S_\=2['VX&
M%F)5"XM5][P41Y\JVU8KM<@ME2EG?K6UNF:!J+=8;U>8,I1)W%1U5[7RDXK3
ML3QXR$;4KDS5]*P6S<Y::ZO7MFQ$:5!=(\X0-NB4E$JRV7)*XIU"*J&Z)M$X
M7AE59ADIA!R6_04A1;'1/3#V *D$11BQ\JFR#7W[S$+EF944L!A";@RQ.E.;
M^_#Z;^D-EG\VH>7[L>>D7VRCIS&\8]BV]DE<H3"SA9L?$JUGWM%2WSS>>8%S
M:'+K?O(?)^:Z#GQ=(Q_AP(+JH-#/UP-4MS=E@,\"*KJ;C(@S5A,*'<YJ>I>Z
M=SXHL6VJC:Q4VA[66CA"HL5:[T_Y#EK]O+F &3A]S:ZY?O?+0D&KITNY-%ZQ
M.>K2!\KPH8Z=*B-12^>K)6SY8KQ@$4+[;!)0,KPS+&/J5#=4\MN\/BN8-BQ-
MAM+1R5K"L4'E*Z2 KH@AQ><7VAHZ&MJ2:-83N$+3^3&G49"_Y;KL[?KZ"=7
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MFJ]5OX./7<'2L+7Y)7';']8GLZ_]J&BUY*;AAFVL)G%S8.?11N$SKC<F:@)
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M L]7<'#VJ:+&:/]F=F95O7W&B#Y.'U>3L)[ 5N4L\U^UJG$-L.<G>!+TA3-
M+YQM7EX:2#T9IA5]DU4B(SC%^D)@Q%A"MEKUZ"390#;<-#XG1#QIYJNSY7EF
MYYEO[M>&0L ;^/^PO3XD\A^VUPHX>ON/SL7#V\AX6"UDXS0#-Z7,^1N <"T
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MFDS41)7B;F3:(E.%$>(NU)@_FD\@/DUV6;3GEDSC>I%IOZ_AQ: 2LV[P"M=
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MJ#[+((ZG&,;U!-"V+&&.Z*0JSF,2$"SBHV"!!,\4&*^>*<UA@'^>FM5^1W_
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MCX_9[J7MQ!917Y* <ZH\F2T/?AWY'Y@/8KHZQC!V-,YF?!>7@#SY(%49/OP
MGS)M$U<Z5(6)LY@P@16U^Y3X@T_LB)_KLV?_W)BP,V#<J726U5-0_D'IY:O
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MKWO<T^?)VFP+"@H5GQN?7K7U;/>[O2W!DU06'-GC6N+:K:$75F!DQ(9J1'4
MO@Z=:!(=RM@"\\S9$W7E<+8D)^%=X_@FQ,29@#FGVXPX,3NSUEP)>07$,;P(
MD24!;K?;QL^S",N)K6;T#>L;M?M8O$;%B['R7%^R&CV 1C!Z\/7-O\OM*K^0
M/K;E$TX;FWVS3R&H6<]C:YXN=+&/1UY/7+'[YYN\8\AXQ031J?KL:+E5ZM$'
M!#8UZ,C@I2_IG"P_N6LG]YQ-5E6H;Y& \H47#+B$0#22>]H5\V:>,6F?1[^\
MRJF9G1KP5O[Q8.("^SAU<>WIXVAW@^AHZI%5-\4Y J.#M:J?T5GF[HETGS.+
M"?F^=  2^1?6-^X]]:U!'$5R.D@KJ)H7"BS1/:'+UY/6[,@QR/=4"=TVOYYI
M_OI*8%'GK9H1GD\0:^0\+<PR7&$#83.NN4%H'G6*1GP=NC&BBQ;WG[9(,+E2
M$I KDE O?KGSQO #Q5,=DU8C]7 %*W)2K_6H;JIVQT7-!W,Z\)K'8L9B8H9G
MR77D>(UH3'&\KID +)PS)'G2:&%#@:N#%8^S;\S[ XA@17>!3T%T9UP;+87S
MLV4_V!<5C+DP3R8_&1'(KM!66 C='/V&W)0]-700^DW)I,#<$DQB'U*?;:W!
M) %39C'/O:+>NKM;/3^YLN3GO<!PQ?G<2[U[&:_+C.OPJ<ESXN3/]TG83N_9
M.'@[N;=%-+_['LDUY(%:QH4<[M_X'^9ETTHQ2HR@&!&FQ'KJ(E_2XX0E2CPS
MRB 54LPF/T9Z;-2.VVTR&4.=KNB=MM_[*E8RKA<'ROXE?IF5E_9U1B!NQ<;-
MX(29S^\]+&CA '1D<D.D%*"N*]SMG:+2#8 0>IOL1O3P <C?8 9'1T8:!V>Z
M$C_I_/7'5MG3;=R4.^>V-1K05V#NMLV_/):;TXW_&1O")Y)-H5\Z-)P;<?&Q
M&@UCO"OE?;K-;]/L_@;L%YWCL?#2!>(GPG/1>JY<?=Y:Q4]\XG8.3SZ:&:D)
MU1-\ HMW-25TX\5BY3%SBY^(_1GTO623JZ^Z(7^C%#,^(!/K+K3'W*V-Y.:.
M[G1EN,0<]G/UKJ6<K6OI]+UGN_[:[,^O^JWXN@J-*B6^.]3Z?*<)R81^85(S
MY+N63?A>V"4)<)+EC(!"9_IN9C^?N"F8JT@&TMBR[; CK;\(>=Z/\B1O.@3$
M@[+F:QA;<I@<.TER83)]XW /RL*!FJUP,Q@=G*O@HO*[JXO;7* L[>_*=:U@
MDNIC46,KP37JXC)ZY@ D.'D D@ L!*)\UH+3 2BQ,?GN#CY1*/'%!2_?9*$,
M.FV]_CD '8]5\"K-JI#A>E%CO$.9),FOT'.TWZ)1,GWT!A(Q>09YZC0*JJ/Y
M'G&Y9Z2C8\7&8]R7NC0GMV87M?*@/G4G-"3-?B=E2Y>0X=.4'V-MY<#LNY87
MSFE*Y-:7KU3EMZW,N-!2ECB(KJ'#I.?4Q<8%EF,R58IW8[OU+&NR._8LA;W<
MU=(>(YZ:T Z;TJ#;]9K.Q1<SUE#'41I68W=Y8#0!4.KME9]X@2X*A$GR'$M6
MH\:B8DI)EZ^F<35+"[@X8=+Q%YR8_P1$OF9)I%(#X#K=T#,L8Z_B]E?87P%)
M']5$GC(+\%BM"ZB<-GA"$>5!1K%*V2PQX\[BE7-]UVA_M0J&:")KZ'4J%^8I
M'.PR;#&>2D9OY##:C&_0J $2TWOTAD0ZY&?H&^5&MNP3@136G3+"$UE,5;CN
M+E3_JR> PB^=/4HJP$SEIQ59^^E5(]_4Q7+RW+GOK2*ZWDMX0&^9+L*[L-"(
M3XM5]YKQ@.:P[!=AB21-R%G]>0\E'>!1]5>E$Z-:U=W=67UYT:0CUNS#COK.
M1F&++77DPXR@7W ^H?OB?W@:TG6PYDHC'4N? GR:M)W]W]00I9VLFSEUG?;)
MU-:R>>UO=WG/LW^NWSX.[F#,OO&N2[FKD]_W,GKSR9K!-<GFVO1BQ&DWVR4/
MTLF^B^0C^(4!*5MD#K[IZ?\7[QW^C_[\]QJIS)#9LCRI%H'M##?T #1%B!U&
M[E>8V'H:0O;Z5?E/A'A!>WOET@%HTW"!^VO7 6CE);Z7Q#N9)H"+,!?X^6D/
M<;LNF%(J8FW[%\&1W@/0A3CVEF#0XCULO]+$'DG<Y:TQEWGYV%[!^\M#?'.+
M[T','%YV)FS]:I9P+)=_%R5IL./8[__'OUZW+\D) ^Y@(YE28V0Y,2"T4^(0
M_WL86IT#0+GB!H;3'1;F34V>[Y^=F[;8<H:66F9ZZZQ/'LK\\_9 8J]SJIQ^
MWM.+6,>@L88W64>MP@)-QW[;B+C#%\C2^_N2F^(TZ+.E^/I>WZ:RVRL-><1K
MA76DI*J^2O_;_N:EY^JSWQ1<<=O\P _A&F(O*XFP'J^Y95&&3@)%AM6;V/>_
M-KC=_FE=]P#4?%1'C>O9D8V>__@L9 D$32DF6FEPJ<H?6"\/VS_Z^/NEI<[%
M,O/,.Z-V%?:N3B2[F7&2DWV%[<: ?E:Z):[JC%JG:\21>QS'SI<.5WZ/])*1
MPWPH>?.7^IJ)N7:C5@8IN<NJ]%R=6[15NJV5FHJMF?0J_MK_M4G&_^Z<\K\[
MI_S/ZISRHQ#T /2[!* API-L82RL2W+_ +X->;$&B;#W6\\H^FQD8NPAK.73
M:CV4B"?K>57EJGQU#MT3B931U^<()6FK6BG\>!YC[OCJ=,^J>[(]:25\TDM^
M_$&!S=:W:>HG?'?L21;Q.<^T'+#N59)C[:6TJE5=5Z34T?'27YO1SUI-*ZY*
ML3W-#A.+5CF3N2C>)4_W]M S$4ZC18AC]NJ)RN;(O$K8GVF?D-831>P++[FR
ML1^:(YZ]:LVX%>?UEI\OD)A:N[7P<7!TP>R-.V!D_'5+)4 E0-LN1*?^N>L'
M7]7-M_D^ZRP6,:G#BN!O9C9&L+N4:N.0GEE\L5$41O93F9NVA#I^#X=UYCC+
M.E6+@&V>*U7.CLN/^:C9?LE:.F)SRNI>ZL)YINC%Z5/W P:1@T(B%585&,I3
MX==BC34CXLQ'!>=XYR<J+T1[FFF"[2=;=9@*BF[&05,6''CW9R>*PHC;_L0_
M!>:#I^N_A_U+BU3_&&?RG[PU*MC=,16YSNK)\'Z%"3(?Q9J^#O@W'P\?>6!J
M-&0Y^@ 0:XT74S3J4(@VOOE'NDFA9^NETKWPF7>)1N-,^Z$LD]6&NV]S'/^D
M[^+0?4&C1,3+<8[V1E,H>7TOJWHC8B>LR76"W@J3Z -__&JC@Z%6A*JYM5G-
MODEH3$UWO"+)(=W<=O=R%+CC619#WRV'UET/0#Z-5P] HZ;FU+'G21IXHX$#
M$'EMI&H75\%5M\F!D#FSD_G$ 9R/U<ST1+07__B@PC^P\?7S6,B$H'%#*#]@
M;_>I6BLTXH>^C8IMK.R7+^XS.=;4?CR@2>45[7$&A>+7 B8H<1/'Y:!PM6;2
MD^EL"8ZY4I5$.=][VBDL4E"S_@Y]Y'I.SB=':GOT'#HH(&*9K2J*JS1LEB-M
M2+R)/F;T^L,NHC+4C6"5SUMP?=W'GLG)VHA%W:4JX!87AK[?0*X+4UG8\@]/
M::9I;$HL#5>'[$!.;RTF/*?Z;:4V'VO>Z]P"!XRX!8IZAS_8"#(?JPQ^/58/
MD<2$.KA\,4(_PQI73$^M3COV_]MSRC+DKN8N"N8PLDD6O[P]7T:2H:B'A9!K
MZK^7#5:KEZH?U0EV(!C55DB?)LC,*CBEIP2/KS= ,\0>$:]K=?J0(T-TR_XL
M6WQSA68E3;=ZXF_Y,2-S-/5F=Z.(6@FA;T!KX?M3(4&[3EU\@20CUG]BPJ1F
MUPK%)P7*@J&&W#R\B& 8*C5":&61!0FAW U#S#P-D7.K"8A@&'JCWP;F^CT;
MH!3H5Z >8 TJUO9MZ\>J<>IK_'2-I2V9V"YP#3I-3TT/?T;P#[)V+V4WLC27
M@7+NQH-BI3#)=MG1CX[.(LYS:NC&?<3<L,9'OB\(D(N/3ZQWZ,[L C8Z^6H]
M<OVJY'*IC"KSH@33^M9R*RTUT\],/9GY?R<-\[A@>K=1%M%>NY=[U#XC2"*1
MH$[Y8! AY_QDC'!D?CAEY5U)CIYKPV=<ADU:\>K\V?'ZME_^-;JK&.HYJ:>@
M"#8;>1"M4(!PFM!#V7S1T#*P'MV9N4AL'=-3O/8-@]*\BSJ;^V7SB_^KQVKG
M7PC1[S:5=0,'G 6G/(#( 4C.>_X[$XD8^A43U1@BD+"(7^<R*B[>GMPD [?C
MN=; 4[;W]7>G/#'WP<<]+:5[XV.55H<_ 06MB+_T8+*?OD['I@85 \3]7B"
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M=.C*JR4Y:*NIP:-@:RD"7#L_<"Q<M;34KRMJM4+JBWN;NO8['1W=OP=U,;2
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M9,%C*4*YN%:3OD3S8X2CFP61&I&#WH89Z]WMD+U-4(#-M9B*YI"W_<J8]N5
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M/BX9ZW&T]4^]73Q>D?R##*OY0:J9^O%CBB!<F_HQU?RKGC;5O$A=B$R8F]Z
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M2K.YEDO5:DCHR=7!2O!+$MO6:I5B7^3:'_E<FT#QV?I.YUGTF3'KA#PA\'2
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M29AZO(#2*K7F[8%O;=B/5\U 1JYI)?E/L>+'#>F/RH:2#2&P-/4Y,""SS9(
M/V+>0=\9@7@5SDAW<L2!2$9A]_X($$8A=!<>G]XX,(LS"*.&>S2^2^\TTJ"G
ME016W0V']#W&+^.7)[)K/2K[*%",?:N19"-].P:E6I_W<W-+*7>G$=.XSQ*Z
ML:$3WF;FR81%D4\C+D,]/2/\?S?X90F2-+*N$Z;.DY"_$=HB%;.H>*'PSCBV
M9GD<6Q^IL^K0/E':EK9JBPE+>/?1U.V%IY(GHEQ%3: ?:N1K;I\U81'D8F'P
MW*]G?DAG/ ,QLPRTZG?YG->!FZE@:>X0#;ME7GF^O[)..(]509FC.?CN.QFA
M@7YC*27">8<@TT) /J'K1-113M<AZ!VJ*ZXA;8S9M7"$(T%X^OKI1P^C*PR>
MA <LV-(+&H?D53K''X$3W719GFB9=R+/RUPQ;7RF^B$'XF5M@H:Z9& =L B6
MO9]5<0N3E/D<O_N K1DGZK%F320YQ/'9K76Z3,8I*)BXECYS">9RX3IMR#,"
M<'63PY>YA(JK(S)_98$8M^?%)@WL*;(3!(2Z$$(QTH>J#^$'WI!YT=KT1I-)
MR!\MD;BD>D6?R;:0H-)'4RX)"7@!?F)%A<OZ04[2#M;X&X'#Z\SE$F> !.9C
M@&]P+QKH9!S]OIBP=0BJ<ML0GN?E]([Z:V\_+11T-&]O&=-VL[R9<*>U<<S@
M B59U7WR:^]"MTM/36M$%1SA.-G@+BKV8'+^ J[Y$(3" ;])TQC,VQPRX3S&
MMQ4E@19C)/S)46>Y-T_Z7X0_=9=-H*K'=8B:1!;[&HF30@0@/4:_C++TV444
MS!&7:42+>V8)D.=(HF'1!KG!8=7)]QHQT[K1Z/,43(+427HZ<?B7M88H<;KC
MGRR-5^%7NJ0D2=W1Q.MT0MQ.%11,/%!]FFON+?S8/=,3X?E -MOYU\N_/9)\
MU[>UL5*OF5_&$S> M,Y6/B.-2,8=X_U48.6DEV1AN?2\;&O]6D^Y39E,CG8Q
MX>KKOZAUW)'0Z L\+GWFY"EA]T'UKO'GZZ0JZ">_S)37ZI3>TWOX(EXSL@-6
M1'Z@A)>;\.I1++$R>@%+I-(/\@Y#.\> 6#%6<HKGYQ$O18!MU.*VB*_4Y0DL
M#2?S;A2<A 93" DB1KP)ULTZER4#,.#P?I4;5M\0F24#[>G?EYA'.5,0"6X5
MRL0T;%T&OM]FJ,=KH<! UR8EAZ9,#[K;,8&MEAU9)B183.TJI\J;1VSJ'X+.
M @9FTHEM%[@$;*,BZH%'C-7+?>,I>1',^BI\A>L:GF/N:/UV;HJJB!KQI[,0
M-.V.%_2.X;Y],;M![;CA;DMX_/SY]+M*([,P[]RXDC]'=X9/&_MF8\&)*B%/
M=_4QM(D)G\*RA#H)*W\#!]>_"=B1EV)!*_GWROBM3@<&)27[N9-R-</R?02I
M8S/)R>\>"!O#?BFXSW Z::_BKX=^OJIK512\89=2Q#M@?I6IYO)7NJK>\U6U
M\$;" 93L1H:39^"?[\[,?YZ?(8;Y/$)HA>DTAN9H5$_NZTR=KB,:MM%;+$^.
MZO>I!-2D#+POC,<LOCD$-6*(.$"^<&N"BDJ+TG*%(KOK!@PTZ(64G<8PAS#(
M&:.+"V0W-T0NW]STYPU-1*Y]04'65SQ5TB\B!/]V+'B=DN:LC9R3ZV62#T'W
M\R1]+-G/#T'>T"O=@6Z=5$G]O0A PQ-WO5S?$G.J#D%?(H8>%#N^T_\PYM87
M*;'^D':I[J-D<JUL.CV2.[IB45/["_72M)EJELC([J.:J/.<@8-@^*GZ3<N(
M=DLFE^=3K4K\?:I9L,D%:(LO]M5$\)![!#RAT?'R].LFV*^\KUO;WC4U/&=Q
M++/Z+G_D8'66$UZMVK05<5E(D+4UU)]V?TE26C/Y^9MM<1R6:O#-V=1\=P!A
M+))D5T[QT(ZRF*AH'GB8[,(\H3@P=K?&[W1N?34G$+A 5_\IFQ']-6HZ2HLA
M7+<DJ;;9;3,S#210P[H+!?L?(1;!,00PI%X6/\+2IL!..>.7*8TQD?-YBY"C
MB%]AU7Z6D95 LFMM',MYR1*^?KR/(P!C_W6)?M-!K) FSC2?8YD)IV4"-=VL
MRZ2V,[(_6L/25M03]J6.36BO^9_M[@O8@S$T'Q6W.K:YW5!P>W");<&]&B-.
MMQAJ2YUY#JU%UREY0_1@A%%/%7@Q($L!KW5>/L!7&/A3DQ50O]%KBJ=TLELR
MC.G[IMF#79?7]W^7;2CRJ-XX8_SK0?LB9OSQUX] LLCNBSN#?M5J_"<GE,X4
MG5 +L9Q;]>]AII;U'_-]^/"[R<#6=TTK\/M(JZO5*S%]WDZ?F>C;#"&E1@M[
M;CC<S\C'/!*<PE=NZ]H6F%H(F_U(9WD"CDPG3"<_!"4M4/!+GS4D&:U=YLO1
MH">D&5PY7E0&Z"_Q=-$>TQ8GVB UO@?5FJJ]615N"+'T! -'RN8P379,&ZMI
M"#,GY*X,_F.JBBV-\<&ESH/9Q1P>M!*PNWA>#L6+=J(;/5ERDQ+_J^L[#.K=
M>^WK3@3=,YDCIR=[""+71YK=.]$QYQGX)2?9L_';$^X$\P'";MFSX]N<ZHBG
M6J]$C;R4S)TN#@HL7Q<F+GXM01G<:1])NQJ,'*PJ7\W@O_C=J#V@,<SBK?/-
M0U!-(1WEF+3[OW1V\%D+J:KX9V>'GFT^1([MT/_:V4%D ='0>,YM=O:?G1V"
M4W7$ __9V0'1(+SW(;OURXQ>QD=-@T:="M%JVPH5;42ODM&8XF0JV=PM:&0E
MR<68#)6I&5NA-!D4)7ZOD2ZZ-GA$['(O9?V35=3 PS1A=*U_0UY9TEY0YGYE
MA%@ M#[OYZ+5%J;3$K_]F7\OA NJXCC@3>'<,)HD8V_;=83%4PXM.P0A&I^T
MB;]V(>-2.1=-!&/7Z9N/'Y G8XH (U7W:[0:?*K-JD,R; *+5J]R46?\^-G<
MDON[]C]%"*(KT?]@+"0M,_KI9D0P/[(BB %?"DOV;&5$M58#Q.XPY:HYW\?"
M+P(KR!ON:HS>*F30(ZH W&9"V]+PBE72K6WM(:<-O8[T,B[*'9UB"1,X)S:9
M#S"=UR&^D>I+F,X%";1X,UW]28?0FOM1>AD1?CY\JB>7)TGLZ[#C!'XN[,X8
M]G> 2VP&(X90M@R!KKNS?AU*#4V%5B/UKP,K;B5Z%",@#00Z]! T[2#]F;"G
M"!QC0F81C]U?4'^*-,KU.0*O@AOCORIO)W%45*GPI[;]53>_-31+YB1J*\^!
M+2;N9V5 ?[DU2GOPYAU)5268:0Q^X?$P):UP7,GZI4]RX?:R[T#)KS^*\XMD
M*TM..=U0VV%7KQJ&)&L\TM%]>C6W<0\K86*0>03&SLY[&*=B>?>9W[F4K *_
M_%TE*S5MPU2]8)(+-$H2('($S-G9*+1H@]$1=ID1!/"AGF[RQ@B&$\V!D*7T
MX]H53._/CN\?JSVA[[NZ/B' YAY&73+PWT-^=%&?><7YQ+G;\5LX_QX7&4?K
M1,VX^)?TL/N>1%UFJ8[O# L#EMVYJE_+YX\#>/K758>"!R&B[F-+YDT,QZYM
M:;GD<M^H2W3V=^=/[J2[](9V9"GRP(2-33]XX<@0X<:$QP):/W/);"NR%/%L
M!IRL4\C/D5L()]_/QR^Q],?1CI1!3!QCV'^OT0G[AJ&6PXC$R@OK]%*=<9ZZ
M86\F/-[.)-3EA^J*[YY\P&E,Z"95%E?> $\WD9[/!&@XEFD57#.]._ M05VM
M<87Z56)0<ZN.Z:A:_([ESM<@V3E:8:-46>!KFV3]O,1O?%G60?O"H+SH<,'P
MW#*G'>,%)Y_C8D5\V-8RW6<OA1[2N!>5P A[KR>2? BJ=?D*O0$70.J&<J.1
M 8D-"#FOHD6@*0_S +DS3O3VKR6G"I&(\KGU*^[3)GOFB][[DC!;4K";[IW)
MD((;?>9C6GGB[3#[B1#])A6MN2O0M]&6533C.QTM&<JNRN+*3B7-K:W-V5=5
M%]/,2Y]=,O4 Z@Y!QQGK'1=(A,7GA:!3K4([.HV<B\!01;B?\O3@$\IF8?+\
M%:?E=PT(MZT' ?AP?/*'WWUI/8.SEI4]@G_Y:;C=W2?0W<!DN4/07B#7C;Z<
M$;&&N*! 'VIA4H.8SWO,*3=7]I^1A1SA@NY<2'))6'N6=_1-(!"<"HV;S$&%
M59+]"+\WXUV/)?G[W/[1TB2D0BZ%7V?BI U4K\'SLHWF2,F9F_V2]UDO]H*O
MZ$I$IZ$2W;\-5"Q5R30_*J778F4%L0&/6J^KKYC16^D1E/14PB*.0+=5M23J
M&BGA ?\:SOB"($>%93S!LH<D;*.AI2P(G?8RG;K]]!O9^%5GU?0PYM0S"OL4
MF!<([?W>'6I]%ZZ3[H7!=<EEWL$MP('8/,Z[(X>@W(I#T/(E]U^XPS40+DT!
M$Q>$HDCP!ER?]%.( )?E(+FPK4V#;MEE=!%X054_"3@:OYTRNF@9L006VG@6
MGM[C4OJB;.TQ]N631?\KEN\RY'1SN1<A+>@J.X']V8JN'&/"=45G.&8Q,Y1S
M 7[2G.F^!JW0*4*5)/]M)((.;J'3FUNR%3RSVMS\Z1UP/K5\G*9XJ@?^=3'Y
MINS+KP>B'KFW.*U7/P8E75V-[:<\/>@X&R=F?\F81^*FO9D4)LE.J:G$PF[I
M_IB5NN4LZZ=$;)14M]>SCU>32D4V'\7+GW%)J;T62P_*DM6&W3(6N@X=J%<:
M7UE^Z!?(-"BC)K!N<%.1,^@0-&1W"/KV#+>  V1QK'-E/RNV+QK$@'3JPQ(=
M#D$BNS!AM/4D1]:/8PCG?KVKK;6%,T9?C4-?\W@-+6I,885^<UV;G#^/P)9!
M Y2],VU;PW<&D8D!7U$=5,"6D4R!],&/3Z.- 76&/+<*"*$%RJ&J6%P21QHH
M-&-XQTY-KI^;6Z_S$U.=6VZOP?XNGZBM*K=.&:^?SK\>B41=U4B_A<OJ7;U6
MHYG_MFGV9AD4>FTLBT\P-U_\74Y=B16B9UN8%CDQ9K2I2IE-5L.>#'6-3=6K
MR2_B8_3<J^HAE6?-VM\U<?$WET7(1KA_&IK]V8?;D/ZO[AK^_U+[97G[)*8?
M-4[84J;"V?(=N'+D?WR'<!G@%NP]7N-#4, U^L]N;IM?" IQ@M9W>?[Q/[F+
M_[_M_X(Y=L/I-ML_S%"T82ZSR6)>QVQ4,TPB6__S/4E2]"$(W87Y# 6S]7_)
ME.8LI1Z"WMZ&<5Z\8#WFYBW10]"7D2A#+ESY / <@NP3DI [',)ER&(*YILO
M1.H0M/4%S<V=E<0>[0,,_%.'$::_[R-FZQ>50]#X?4QVQS5,/\*8TWT>SLE*
MY%-X0Q"%2/Q/:VS/--ZS >ZKX\J U*J9E2FK1P_:KDDDE7@1.M.^6X,J9!^,
MYI*/'X.19;+B;U_L@-.E8_#24D"5.;TW]T3FG29X_:R_MZ7RB:<1,],Z5135
MQ9.#61>^:/1-]$2]7Q.3*J1@16Z/!)>;=!26N)CX($]OOM/XKO_RF\7R<A8A
MR2QT&XX/U^4"'/*/^J8$2<L\]?Y*LXW:?-1)*X27GC_<W/@8C]@WFKL3TDVQ
MZ"!F;91"..CKOK*D,I:@ R7:4]^>KA G]:[.UE:85%59O'2VLN[Y1*ZVORV$
M$[*1:Q>TAD_T'9S^/]RX^O>)@7^-_?O$0+'"F[I=?P>B\1C>$&5?N-7BG5XV
MO]&2.IREQ<TP;TFTDM:VPOZ&-&1B6U[X_<R!:$7OS( /16%*Q>:-]VOF$U5G
MM@2*\P+Z_6:FU;8.05H$0%V]9R8]F4"W0Y&MK$,$/CVCSS.[,"?J11<+OMH,
M++R/.CNZQ;KN-]9VAXH"K-30SB&!1V]6( P_9D>[UAUI;^;D81:3"NGFAN#W
M&+"11!19&C]9B&28[?W)V">"?S&CEW6Y7QFKWI4$+YIUZ6-X$2Z.?P8#6I;,
MT ;(Z6V#<_[%:A61$5[']F/]Y3.);SN/MZLG[4(]?XBS<]'*(<Q'F$Z8D:23
M7VCV.6.F2=2D+N2T@:<'-3O3MCZOB[R:'B*=& 6IFSB+6,ET;LKI>KLY$IE&
MI6/\W>M#P\1B+]*V+QV";/4M+2WY79'\_,@(+D(/]U?9HEU((T^.C9&UX^?)
MY'FA6[\W1@O>>ATO<XN:*G3&WN[(/MHLJ2)G\2&K,K;@FH&*T"/3@8"LJUVY
MT1F32MA;_>/+B,%G)HWGS2&#X?I'S'2'KJ"9Y\#(8VD5*BKR85#'JFN3>S7J
MYE9Q2G^EJMV?@/A^R<B(2>=A1*(%%W@[%-2[L=KXP@15^G;OX!+[@G!8I&.G
M&='E;X9#;B(R$!%,BWP=V3'A0-X@AVH^$>C6%'J&Z;^T.$P\!#V%"T<I N(4
M>%>5O\WWOD/0V5TF/($C63=F5:JF5LKX"W,*[NI6<)&_BO$&5K+A.!J>TN<?
M>(+.]//^QEO=,2J.*5E@"6.H ^B?'7=^YWR.DF'>((90X7%U++EWL6:>ACV;
M+,1D<&&<2,->P]240\45L^)PH@V7W4PO=Y!V9O1I+I\F-R(-?\=\,>,(O )$
M>'K @$(,RWPB.,+-S(Q=&'46Z.O3R7$,>YI8!@SV@#WIV\3T4R]>R$RH$=ZA
M8=36&8=<\%M$T/KHAG^8?[6K;Z";F8!=N$29[D>I2E73TYG[;A9:^6^P(0&/
MIF)E)K$R6>1;I)2UOBO#0(1B>NNU"BOL+59@T5/<B?XYY.-@.MY'< ?:&)SG
ML\<MBK\N<N_*@\4%1-%A:(6Q-GV*)-B8 >^%.GSJ^DX-ZVVE2?(D&L"H,J1C
MJ5^DI//NY%B/&R@OSF!T]@SEB7J1!S-*\^[S\,BR.^/J<A@Q[L^P^BE7(5S>
M5K^[D*3%EK=^.1<EW$?1'O?7FFD=A C[P458O$5.&V(GQBW:.[ ^97XNU9EN
MZ]4M61T)['IZXF_,VS91'QR__<Q-/'?0;E+"[#0.#UJBOC5^P09H9'P.3_IV
MO!"*Y/)27I8*/0TG5X$4BANW\5,]&:7 :'RR[3,1W/"GDV%)1T$$Y%F-;/OP
MDVS8F?1/='NE\0(+4L\8]EK_7--8#C[#3=#NM_%[&2F>OCTR&48X_7@1)4K^
M0!:?UAIE?7GW[4Y%KZ*)15L4[CB7:%F5. W89#[,QRGJRDW_X,*,X^77J<)L
M;CWR;<WS3N"<N47PKOAM,JM&UC6&*IZ>9'0DDR@@5/[7=2WETIGP)EB@C*;E
M YJ_A.;-G*#JA<^KM"I&8-11S@=X_7"O]L3"#0(01M>EHA*U)*U^HP7R)-$,
M9"O58R_6\ZJ<1.$,K-6>>=T3Z'D7^8X*UMP@&Y+Z6!1,9WDAC__.(2AF >]#
M.Z)U17LJ.4HVW&SQ:\$?4VN3=%>6 ;TE?,HE7E5-R_Q2[@8L28Q_&/-(=L J
M.W3OP,]9NZ.:G#"/H3\$]S )<3^;;Z#.AS_\,%.\(,%18FD __@VY"7[Y1F9
M?\B16@+4A[R\JJ*FIF(D/#N-I\V*U&*Q0T/M]:?]='7T4M/+\GJO?E5(DY2A
M;BZN0?>34G7M.[XJ#D#V:.DB":LJN&CYY$P_)/_?]]9+R?4E>I71,-/F+Z]E
M2/-AMSF.D,5Y]5@DPY;#ETC'V+:,23N.&8'#8518SY"S)G4!YB_?M6]TFCZ/
M"UGNWK*U8O2EHI6URS5GY/=R/M_.&!2-T,?1E#E\WYGATH#\ZI;G$CQI7KRE
M%IX2I=E1#WC0-7L/YM0]I$\;F*,>!<HGUE0OUXYOK=321>)V:)A>;\E[_?6J
M<(?1>A2?G^W[>5G\ G".Z]X"EGRT&WRO!U@.KU9[H+401^!EZ3$&O3^,^.V[
M*S P*9-?>>HB@&F948/CP3]^)S36_6U4FA,:%G3=2SOG+TSGQ"%(;-<0N9?*
MYB($G\%(4U/Z/G$[AES88\DV(G^[XCNO !10:7"B=4T%\M>2M(J2-8B RE<M
M1KG)BC-B7B[7S:#O5%UX@*%$I.A*OKTEOW70G2Z;,MJ]A58%4DSW@*H?]MI$
MG")Y*G47>NG#0*V0IM&OW9X5NB>M]-I];KA:G,,Z7%7XI!Z\3GJMM[,=\C$3
M_^);(>MT#H=W4(0E*+V7P_AO[+UW7)/;MN_]K.6RHJ)2!2$VBH1BH8-DJ0L0
M$"*]DX6($"(@ M("4:1)78+ DI8E54J(]$XD- $1Z1*$D"#2):$^0,J-^YR[
MS]G[['/?>_=[[K[[O6_^F!\@A-_SG6.,.><8/$_F3.B$DT1&=CNP/[(.+:1,
M2M(_:T%9GX9Y.P@Q+-DLSAK0KPDM0:D\[*B?B<M]XP#.4E&?W6PRETF0P_X8
MAX%2G[XH4S=E[)Q+/C+-(R9_?D<YKN#3O+I.DA,R'VEC\1*Y-R(]'UE]3!?E
M5#"_J5S6CG)V<D;Q6XRDI/3K[FT\WGGX4JYK$>PT;"H4NV>='(J@W8*,K;>@
MW(\VT ,53J ?T-TGRFU?#VTHB*.N%$3*Y[N:::8J8X_Z8/;,532]K_B\?Z"Q
MZ6/+*>5'Y+*JM<_7$K)4+N/%798N5F2)ARLRWQ7!$[WUD(%),:E*^)XNP>6]
MGCB*;%&*;9+CO3^:J^+SX">CBT97)&3HYF>,3$*VY$0>QJIY]O0M2Z8J?B'3
M5SBSCVH(D<S+N$J!_1A"1AQ>#X+L9_R21-V71%N;5NJ(%)B);592[TCV\YN"
MGYK A6'N5-,5(DH;5;2>!N-OWE^I2K^*N%Y3WUB7?GWP#.PYA.;1US(.BX'0
M3%?"2<UYKELDSQ;/G] Z8+N7^Q>X7%WCP+IKXW'*>$/A:1W!PCRPN#--$(?2
M7&W9LV AJ%RZ6M5M8\<&C#DC-J+0L8!3WES4M$4&[,T=%9GM4 A3=TB5>/^F
M4PG'4!_^5G-^)]! M''+/=]U)ZZB_?['][+R"O>01QJOM"M\Y66(!-&B*1LP
MTN[T\$P)%+4WH=4SS$&LV56L5+*VH784[3RM8?4-/11_P#VGG'9J\.<SM4$%
M]:$WY++'PIMV3@FJE_@;"*DG)27#4$]S)%<47,P'"H0+F@IWD=+X"N$\T?.X
M5;5XZ^LAIYW7YP9CG<QOOT=U7*J\BMMK4_*%BA,=VJE2,R0-%BK/!.A;LMZ_
MQK=Z@C(K#,&<[X\CW&'<!,UI';R/-S%BC3?H0BTB^/@-@U_ -L(13\:9'-O%
M 7_,M=JZP<Y62!3OZS$P9=>(?LI"!:?U>UDOI??ZWH@OQ8VP%UBZ8!_3Z?L*
MHHQG UWUS2C>W[Y^JE>D"Z.EKHH4=F=,H!75$CWD5H=P)W&F5=32*DO#*\N7
M,LQ_^_62T@/_QL"\J#^&W :M[CL;6>M?2K-;?[.63Y9-WKZWM"*$E$S=U-/&
M2"!^(DS-Q=E.1W9@PA![?7@_28J*^5'90!L; !CR_9X>,+>P1)ZKMM3]T>O8
M@_.CIIU22RLNIWX;GW3[V"NCY^<6']4]>O'"9?Q&L5WMYP;15/T,KQ?!L46%
M^CRD_M>D&#W"A!E6'J<0.#HR6E'SR#;#>:Q-9JBGC/?XH<NQ,@:?J-*ONY'=
M%X("S>HRDSQ3TT@.HY:<&C4-#D(3&$+D%FQY;-9I)A9V%XH_PC!DYIA,BL+Y
MT#?2-& G&'*@EI*H 5YK<FQI0ZF&7M N)JE<5O_TAG\I0Y32,_[:LKU\,3 B
MM00\<;/E5R^U<'\*K?+SUXTD$O^T3\:"?J_.H9TFVT!M?4.I@!1D:/>#@?;I
M8AFSZ=P[)0OFF>EF<\3Y#Q[CT//X"[7M:@HUL*EB+,TBX2F9!N<-SY*@L9)+
MD>)RS&*&(>79?B(V7'"I9F N-7"FN< EFZ$'/CMT.3]]RGW?9K?M=%Z/EV<)
M^&%AY,A^75L#C5YX6_W^[T/SIR3FTV8HIN4VX?XLV$4O'V_3N@Q"*0I13E2_
M90A=JOT8L[Z5JA)]=\BT_08EN'VYO?WYL"\BRJ_D-__\(Z<;)T_1W#>^OCH]
MF-=(6_*;@#'X8E@'-78-.:/*2@OJ!JF46A:@KD2E";W%P=LDMZCP3H20FZ5(
M*L>Y,2+A39G53!Y*<E_T<I5W"2+X!9)TMUEY1'8%+4HQ^.FB]3@88]P_2C1A
M Q@"$ (P))B_:YT 85,)+9#]\Y/[0>^I8+7[BNXB+0:]FA]N_>FHY1,IC2.-
M-W .BO7Q=:5NE_M>NZ6%K=G;W_K&"#9$Z_!%7JQZH"H3<SSMSKF>Z'9=2FNQ
M4@^/N_2D4:9&G0Z<9!YX/1U$R_-!.H27M) OC5-XSQ'AV#VAR=MT=STE]6<D
M6IJQN<SJZVZ>L=N&^GFFGM.0MCB5*3(1$HT5JOK]56T_2P"M0N]LB[/@B1G,
M'^_-!T5;10J>K61CC6T--M]$&-C+FZ6L6SFDF]W+L+'[G9'*!BYS%MN:UH03
M(9\1--.$)R+P!%D/K=-DM#'SCW'J;,>9X->]GIP,;5]XSJ)-9#LA>K2^H]CK
M@4=88'5R[F+V3//GM-("[\"T1]A I?1=-=ZM3#:PET WRSKZ_688ZU-]HR7L
M+JKO1]"6F&]GGTD'%ZE^3QJ/RU7+OI1D X8Q;0HNJ9(? [8)EF5"!\C=G0P1
M.JV[IYU<LQ7/""ZTKJ1SK)[9Z%3LFBISB@<B #:TAQRD^9;$?QVQ>@2GR)EV
MC+"LZZKJ_)Z+[ZT-A;;?B"01[[[\X"@F8V/F*.=Y\GKT@XKZFI5+QSU& N7L
MD^-EX9"V1I47/38R#]J&$O2NYY\=ED]#5AD<5!*_._ UL=S(DL4&YK*CP8KU
MIV#(GW9J.XM!,@*9B5I\ 2_90!B4(I00<C9 8^E#'V@C?F60H?0UP/7I;80*
M2^#HQ):)4OJVQOWC4@G&2%@08>IQUL'4%@1-'S&6NHQP%9J4@_$WNON>&@\S
M;L<S[.@M_:QWB38VMU+6_ -'=>LQ5Y:A$A/M0YLUWE8]J!KP(\>"BPS72I#)
M,:D.\Q6VE;=P(="E-=.IE?##>E" A=HWHRI:GUXE;3369UE]X-V''@\M"0P1
M(1!'2/?R\[&S-Q3+:Q^?K\;,>>V>1?/5,#-@SH2QM:E?E.FV<%H!9?_CQI/%
MVY?/=_E2[<^UIAP#BTV1=P).)[H[M1%(];C6\9JQ+.JJ1;79XXZ83>MN*P>Q
MKC>>$X46!B>F48I-&0N&2A-P 7[&($R-,J:)$?:2=(($)@MKGG()RA^V,4.J
M-A>9T:YXL187Z];-^2VG"Q@"*BP>/AJ,=;"+$H0],"97T*Y >MH6*#;<^81U
M8KXF90W)$DZD3BH/--K3HQ?&;U</:5ZA"*Z-K!@-R XW&D_KA%G-]2/3S-*P
M,96\+UH=4=/0&[P1!3)5]]9C+7I*<B>?Q_J]R!TRF< &Q'50'C*4;CE<KI2^
MG8N_T/N-W'I V\$T(^MYF.F+K&=7EF#CWIN+3"SF5T28"D$P1 /,%Q6JCS2I
MI@D]]NDZ74<?Y4P1QS_9ZJHPSDT>[;?13IS*354^OB@R,U9-VXIX1:AH&-V
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M.UQEW$]TS=(4"3/]9#OV'G(KR*"G[H^FB)Z=)? 2[5LK97_+2CCD8.5KW-0
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MINH<#_D7T<+N5!O'WLOA;SC_?"OY(3J[26\$GSPS7#24E*Q?]4#5+5E*JK%
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M7IBP#[*2J7R1;AP[Q.?>*\7"KENN*NVJ85J&L0?)+8$.F;M6(1_(?.LKXLA
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M3AJM&EDB;5_B:EI88TDL?RGF.IFBN_D>N]8"6\GGV'/R[3KDMYP]'T.NUZY
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M[?2Q^LJOB&IZ9W%B[N\T1>L?"Q_M)5@_KH_X<YH'2CR+:K]E'%%;X'7:/GI
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M500ABO&S4I)P7#>SD]BE.Q5N&ZG_=5\BX1GV6Q[H4,8H4&$A(\48S.UOY9_
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MA%PFI3W90.Y2K%)0F?W>?0DNOVT5:)!>&\X>U5(Y8O%:[ES=_$.W1V8M?W[
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M23*@+=TUGK@:LWJ.IM<'MK!!.\64<JXBKS:?;Y+>/JTQJ!.@-*T0OB;9NFA
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MTLZ9 27B#P!PFN+C-A,A"=YO#)!=ZA<#S5VY]/::^8ZBP(-UU&DTZ>:0SL7
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M:8:YE_:MBMCZ\ -#<<XG*:S_Q,!QGT@&B4@NX$.2C$57'B&1DZNY.03Z[;7
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M0^*Z]]@S<R=1-:S?F(T #L]A]G,0PZ7O<U:;661[Z>0. 68P*_Q32V,\7(.
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M)1G),"U@J1(SL!'M?D7'H5IMG!129RNRXPC2F-J@(?&BS;#2_\PP45==)TT
MZ;]F_R&^FWZ.(X>;T  2-GE'%OD0TRP^Y.4B"XRK11(B!WN2)\2QY!9V* &D
M67R/AF#_+.D95J0Q>!4N"=R.MC0=@YJ/I-0T;EQIQ26$RR*NCMS*'=@86Y[9
ML1A9KP[ZK5#_S_?/I:37^@J=++"CFF0@L@NK _<VDZC3?)*9H]U8Y1B2E.%A
M;U\RX_KS91=)96R7%QK7/5SEE)[33/Q3[HC.J3,_3Z]]+;(.O9GT8X$JZY;L
M@!_<SSNTC^UFQH;OF<'PH$"PV\B:CL@S:'TT$?MKFV_0S)K+6EC@<>%%@IK+
MN0_9"^;T10 36NQK=V/<5CMW/+XQY[HJW75L A84P-D :^9D,+EU<]:)/B?9
MJ6;-7N7MYU:U&>H]"5<JO#3&X%QAF&)Q2!RUM$(UR>B!V=D4Q<0V6=\3@MU1
M>)FKBU>%SN^P,#_\$+E,"<%E_1)DMVNV/+<TYTYE,TGNDVEEA5CVUWFP[G;^
MQ+(*S>(RYQ\!EK-5S1^R#O5.]+=/%ARVS7RSDU?(NF4BYA0?_<?_9+G/:0 /
MA06 Y8CE%G,=RTH UAD$ZJ^%O\7OSA%V(U+:7$J6#!;P@:7GN*8K5QF; [MK
M=0&W^X4DG5R#"D)_E<QQU-6\WIS#N@G?<L"H0AEAZZO3U<AU5A @SKX!8&Z\
M[T#\96PXCH+.O;\76/-YB7<8Z(,FU&A3C@?D')RD*UH-&450180 'VMHH'/-
M-OQIE.WGA_CL!1)>I6NP9XX!N&XK6!1$MN@3<EZ:=UGG.VGZ;Y87'PCCJ8F3
M5 Q[;VM.59U,[1J,/],DG>]?Z:#__I3X]?/O<N1M&PVLPV5SAV2P#5 !V&P%
M]JTD_0 SE(#]Q5@(/=1Q#(ACNG53R"!(IP!.EP=10;U.O(^,@8HY6:_5UFE*
M'!UU$5//T7^]W)K,NUO[@BTV]JR5HU85?9S9QT)P"S!^*<>-8/_FVDN )[7>
M.U)U&Q5*E86ZCS3$7[W@TB <M#"R@H:^MPD->[)^;42;_5Q\^KMQ<%;$?; N
M9):M,IGCO8AZC1X^)!X&-9;V(/C,!<<5J@VC'%[K?/E]RF4ZS]0W7/8,[R3M
M)=1Z7/OE>D/@M?.179]YLY.?Q#\FVH/L&/X-U&1^[-_04VC!0=151@*M.:$:
MA8@\^BR0!HTM_'VDQDB?J=A5>':LIBP7)CSEZYJ?W4\[F1VE=F4&)'AY*X_D
MRN^5IA-NYMQYWKNZZ"+N_CHL1$KY?['WIE%-;=O6:,[>NA$044H!(6Y!D5JE
M$D1RE T(" A(741$BA !$9$ (6M;($JYI1"EB@B(E!%("" 0J;<@(K4$(20(
M2B4)15B0ZEN<^]Z/^]US7VNO?>W]>K?!:K0DM)7,N<;LH_>L.?JX'GSEV]82
M<BL3;>'1:)UYM*P]//Q;F(^_WAR3]OTL.O$D2\S$3E+WD<@SM:L^ V)HQT[Z
MG+3_X>OJSI'!%\/QQ,3!BU>I:9T#GP"J)%_L-93Z8K">_*^C.!E"Y^I$1^?.
MD\9WPSWW3!RGU9G'"RHB&G,\:7M!OB*.;WO4;O7LYV9#QNJ^2<^ <]YGXL[9
M/SJGS]>AS!3N>O50(/2ULT_[=8;2I<%3[9+'D>E+]G)8$_ )_>_0:\RM5!.U
MJ*CHURTC+MG^/XG>49=&[W"F=#J5%%IR//L-,"MA+PL$L MC>EJ!T/1=H24B
MY7 2V(/,J8%DT]-8&Z;.[OXTC\GI*:LJ<+7+V#!^627)_J&7CU8EM6NN=++Z
M]R=_\=+_]O*^M-8A=:6Y[H\T?B2<Z;7K3JW309C<8I.&(O$/#OE\Q1X%M68:
M3>4P-EW&68U$/$,&$KC")^JJ,&D]'G$//U\ 2C#HJ^FKML,F^J7!+Q<S4$UG
MEK:8*$./#>IO3Q>8]0B#3H:W^JC&]5,.I8;&61GXNAR;IQ>)V7K%<T4/\K)U
M]!I=M<:?]!CY7'C0IOXEQ@U[PE]]9%3];$ 9Q\UJNJ+L44+C80NEM3>%XL S
MDP%\%F>5JV#(N8"&A@?-))Q9<FRDNN<A @4\FM9ALLM>ECTE+N%EN:<^1Z8E
M*DFRCBPH_;(H+W.O$-)A%F\+[IZR1#%X'G"M:NV0XJ0M5_Z!YY1W==!EC<9J
MD>NS^Q*<>02<HANR-%MRF_V4>PQDE:MX%EM@ZFFH>J?MOXBW\:J]VK[I;M_X
ML<#,I #V</HD:XLKM44?2+L3I[WVO8/V*_97%K+'1WO48?9^APV)A>C8[8)R
M<O!EXS/,1&CHII8?8V]#S5"5?YI#@8*MF7.*RC#1]FH/+QAHBQ;  GE1;(AU
MW@_$AK]EDBJ08#;]*E\!I)<L#$Z<7QX?0XCK_X;O/C3Y6.MG]4QC/?- $:/E
MXIC-)9N!<'\E?+@6*65EZN.)$&,]#$$'8IB5JN08E*.S^G!25CT)<>/GIH/5
MRK6_U1CA)D*Y@\0YE%]KE0(B)EGM"N'LL$>$FLM.^U98=*.&D3?\>PCG%. /
M=-C@!N"3E+4] EC\=V8VQX]O"GR3AB)@*V'7>&1V@*?#/V^R"FX*8) B+H"W
M3"*7JI"S3XL6=[(3-N-T? 8))X9)*9(.-:,;51>_OBGH<1P.O=Y<T_QG;>V3
MJNK"Q* ^C9-W'*^F:O"N =<1DZ+TL)4NSCFL*;C.[/ <_CG>F:/XAI46/Q2+
MV5R%@4.C/_56)3">G3%GIJ=I0>L32\:X(MY?6[5Z'O/QO'R&V(GO5P8WSREP
M$F<]].7?,Z1N+)A-#N5E??4UXAA=,/T4K$O&V=QM!D.>%,GF^!X_V4WD5_GD
M>5H[J[4YQ]MYAXX:JH<4$]G9JV%5;PB] Z"FY<H(_BVP[#=+4,38[]Y!;CV/
MF3&;H?QYEQ!"[P]T:V!%3LTEL'N>5')/,R[IBR%<AK#B+^TC*A?'#:D&%44>
MTWV%J*:L=WW5;IY?!;#?^;]!W"H5F"G7#<ZQ3)AAR;8CX$L>_7.M3TJH:.0^
MO7.Q59;.HZ3#UX:+4K!:<?0@W-BPK4Q^\#V_^J YL7 I\ME&^+GL;X>Y?>*:
MMN)^\M:W7[<0O]OV=ZFJ71R9D]U#T\@^LU5T/$1N<YLL/>=N<.;L$=>Q0(^K
MA<X\GSSU[IR\XD*1[ JY[B*;?/,+G/1DPJH*$$/[M[<GJ\:[2U@>_+]I,MD]
MZ9B8L",ZR[.S7:R\Z4,/'.N9Q:T:\/TD!X::R>F0RJ_>BVR^4H8KQR_H;3#9
MU3C3 U6?NL- ESRS$,!4/'9"15U*GU>4!C=$1M81@Q>;\6:,9JLH0N8Y_9C#
MI8%%KOE" 4WZ=>N($3A_']D/70JT:4$:SR;V;//S&Z!W!':AU4HWLAS3T[F3
MO_&N),KW.\W[J_W;4ZDZNGWQRO$2^KQ_@- :5B$PD+P, 4P.6#0J<VW[KYV2
M.9., 6XZY0G MN="W.[-? E2+FE<M\N0,EXA@"W^D3:XUG+F<A-M0Z,=6#RN
MRXU;XND@9OZ,DI5%,B]!ZO>8S8OYAJ>^X&QHK;U&[U(8BF.%O4XDWO.Q"#A(
MI7:(D9K_^?#1].'"%)>S@Y;;A>,[GL#N3HK'E/_824$<[X[A3)_9W0(FSA$O
M@3X 6+1&. !\BTH4P&J< 9[->_P+!#-2 ./^!4S ^;W?TR 1+#9<L1T%(8*;
M -9["0%I7XX1X2%R)WLAB_<'T#8N@*U!&OP&P-$H@(3LB*$=88[&%X;&K':4
M!RW1Y?G60\ B\K7S#>2:K3V_!7IAH[P;"['&XT1@655- !O&./&N:M 1X$E@
M90E2&L(+'&,P8Q;1>>Y=G&67X;.=U'@F0.^]O%#.M0'_HOKW?TIYV?.M,@/5
M>H28<Y; #61$*\>&'?BAH?E7UYLE<LZ!^$H>@E4T*]XQ,+%%MTSCZW/=6-*E
M\::*6%UF=REC0'HI*IG2,$S\VZ:J)+Y^+M=I;!/]FCQD<KYP0I-:0"$@%Z@G
MLD(BRX)EG@T)8,^CN%)U?!%IEBY?Q(AC'HR4Q?I)%1QAJB9H_>2J,0/I1,FZ
M+QC9]U9E7Z<G>0TJM9Z+/@:L_>F0OI[L3-R34\*]&^./G\#JO\2$71IJM3SZ
MH23G>G2YFJ:BL*I/\!+5!O/Y 1\5-#_V]D'+2(DH/[X+:[D_2>B#>;=[JOH9
MM^ 0-74'BF:-OC)94_]JD9:ZLPNQ4*1^VV]6 .NA).*)JUVK1["WP4%&Q>IA
M[!_@O<J!2G1,R=?TW%BW+]LQN(17[A\T:W[PY9F\^YX_^(J?5T0F@G;.Y[_&
M!R7M%]'8(4%P<)<RDQYU9@ICQA=1Y9@%N3#:3_XDP2<BWGMTD7/#PS$JE*'C
MX"1#47U-7'UZ>@#2W\PROR;W4.W0?-SQ"3-_Q>P_]:<LUZ/X^Z XV9/^CM?<
M>@)H7P(G7GX%.I2Q6N/?WHX7RA-SS%>[\' 4N]ZXA-PQ=8IJ?N*5B:Z?&#\W
M=I;G0IV]U&#LOU+_X&7PT\6MK2BJ^,XQ5$Y [JN%)EQ*$8IM;/>T^ L5E>.2
M]=KC@N_KA9R0AX>H7Q9VXE(JPSTFW"8\NJ1))25$A[:P/>$=^U'RZFF%#*_Y
MP\'V:N\;VKT2"XY=72ZRR-9ZIG2D2<W:P%F/J,9)FL[XMGU E-[TO+?/].-(
MJ7C0X@S=N='^T./Y>4QO\_CMAZI15O53UA74<Q:'V-D5( #-%>'[2.YLSW):
MB'H_[^DN> Y<[P^5^;7,"]-GE^;L]K/Y[?#E^GKJZ8*O_4?K+<A/_1Y/U=GR
MWKNN]0M@0I=Q_3L#:4  X3Z26'"O:'*JB_EK-Y7V"!OYIIT,4 V4#H(4U4=Z
M+2?8*R'$A:J2P143-'U%W-HSW]ZQUON<$\N<5)^_=X2Z0LM:S]-WD:K+4\BU
MLATMSJW/*+,.OS]>^7I6>K01%57(-D%=+,$I?)36^UI6+OW5>6IAL-,QWV)E
M2&JDW/3)Q54T_A[ #)UK::8QG6E_WK;=<^8#BAZ60I9)MY&XQ":+,<.ZQU+.
MOVMZ]BB U-18C_)3GY]F8&P.SSWUY"FCN3D"F*\]-<V1EP2@@7LTXGQNB6TU
MH7U QC:VZH?+@)_T?.., ';H1PSY@4E$D9M7L 'YV=V<U(J9@4-+8_*1RV\E
M_>/"PZ*DZH?-%#\B%P&FS6Q4.XVJ04][R#^%E6>]OC<[ ,/T7:X?(>9'=%"K
M\RLN[$_O.)*=HUU^9[+B[PW*H1]1!W8"'Q-%&Y5'-K2N4U=M1E965D->QY_W
M.=,QZO;55".K2;?#(A%O[IAO79<)#YAU/).RTK_J20^,IW=K/ZQ=#MAKJVEK
M<H.EG3OD6.B2JI07;+F=GJ]F<9=RG!X;T;GI(8 =R0_0.J.(=$XP;\A9M4QR
M;$VR>M?@2);UN!'E6!+?N?C9H[9?_TVBE7-5U=]WKUU[F*8%#'OR17@"V%YA
M,)*S#]?;:OAL%3GX&EQ@>;9/_\X$VL03M@XJN@A@'F.1Y^R7JRR[C)\]#8OU
M.T]YP/T=_<:@J")XW-5@S-&G&O_*DS1=6D9U\P*>K[2T=$UURCS[RS8R,E+/
MA3TVQC(9EY65-.[9?]!,GIC>KY=<TR45/*!<^TKM^C\VSNJ*N^3O#ST1GHD:
MSS_L&.)N_Z7\TVW7:;41AZ;A%U8^"Y-_LY1E+U9K:+4-YP5ZBMI+.C9?_[G
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M;7=TA6 X;==)JQC^+R>M#[M.6G=!1@-HZ@4NM]]U^%Y<<N-GMG[ ,OXJX<:
M6>>E6$VR:G%N>JG'+<=T8LF'A.30<8N5N^_P7P*Y\H17'A<X^[&1+'FK6V$D
M)+6GL^EXYV56[E4B$T+QW0:'[-L7[Q]_$7H\MY.\='O5Y&ESN,>^5_%%+[[S
M\Y:VB__5 G$.#C],65[#'17 %M-Y!>@=3P)^8&H].4X ^\YK_7%!Y_W.3VFK
M6VS';-XO7=RO\[3IR<!M:!QM3I0Y%3A9B)<WWD7CV6P:\U\A9D;$MZ'SD'IX
M60,P8%'AS?C:*D14[02PS+]P7^'L"*0LL*DSLK3S^-]UTPTK #Z<H2Q]^E4
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M#5 #^0H:?!E#KCKR8+#\*O=W!', SGP,M%]@"V 'T#YPC@Y7!<]LYCKPLN:
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M;XJRN4-,JX)A?\7\EWB78F?CJ\,I(FKKZN&A:Z$N7L.Y-CDN*4.)5BIIPPW
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M <R5-1I.H2(\V0U6]#C\J"FA;\ CW@<'5+FTM*3IZ!RCZ&]G:^'7P@0P(:0
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M%>YV(@0<5KD0JUV"PNCB+G[RRH^EPD&@[,,BH1QES)Q]@/'D>>Y7WM; 8#L
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M<6(E#I3K73>AQL]8,:1!0:8I>L:8UA/)8Y"13891Y*XFNV?*ZJ6"!Z=7G87
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M7K]F.0/MI[B0S^$_.X)45T$YV9SC^*DH%B\+/+W"A?0= G%<B.M=!%N/I8K
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M?OF@C[3;R[D"1"'2M<[0#%FJK!>\ <K^K5CF85H\*Y;DS0Y91NQ:2 3Z=WC
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MM&$ZLP[0YG(8 Y+Y#++@JMC<WM'MR5';;\&/R%XT1C/6[TS1I]Y@MR^W8\V
MNG;?,[O:N@<%#R6D'+9&LN^V63TO?T\1="]4?)A$UE0*#+MY\VA@P*)#'B:
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ML["N@?Q9='J/[IZ6\8K:])E@-+QCS'1"8G[2I:X!-D_"BW%&I,2 ^] XXDG
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M@['1IO7GF%..I-2=&>8>[ <2<=V!>8(S!*N5?U[^?=5;F'43O)/M,7<AVO!
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MUCJL$I.B4AM[46/1IZFH5\VC+'4)#$#JTRNQZC(+;,/> .)?]O@C(LE>V.U
M"_=1]U._NA2QE:SOI[?!4I_:=FTK&RO2$1A5E@>K_)F5%S[]T3+\N"]QRJT2
MWUX+WJ[(VRXY '4$\B(^$,EOT7%MID)4-LSOXL<L3%)W)@G[9VU]0[/-BWKF
M+!X$T+O<]"+/M^3&Q)Q?TOL^Y_5N35UG0C9<"X-)]>O0Y7#Q!8E=0[(?6ATW
M6 <X"2P5GMN$QPB^\;8GHZ73%SHL/W=]&_]5-.QU;DSG*=V(::/)43>OZ)OQ
M2\24%)[G09.IB1Z=<NOLEX4VW2TV*'2 %:'/XEL%YE#;KJ[;^^G4W&CKO16Q
M)/L<XX2TY[GTGLX1=DUEN/BIH.'1=_9!C#^C2&^HL)1IYOQB7N,XL_3>@^GO
MTVB'AN$EG\G1F$K7V]3FY&?5-:%';MHD1OOK'$>[=8,%]FBP5N>FW#A89"2D
M%XVI>-*7Q@1W%7QO_WOMEG!/*L='Y9+P]/[8NNN/_T6N^Y:^*2AH0L=M5>'I
M#(7MQC\C".XT+/^4@42Q^/@,=H_@9#5Z>S=ZDG1-"/JG6O+,H+* O4MRO.@]
M@K"?9JV7WM7'GO#&),&&2P4.B51W"O^3ST+^*)FXX*HZEEA]"_Q\Z.V-SMOR
MO]G@A#PMJV6?2Y>=G)_3B@_V.BTP:T=*1(?M$1;;G]!&6S:&[SP1*MMI.=WP
M4[%_;NP]$FC2<5$Q"WUE0M(N8VBG3;E@-!C?+E-*G!*<*F C.+E&@PO$UD(B
M86E33GPV2-2<\PV >S2/K8GUSG5"#WC4Z.H=9Z*P4953DTC36?K%./U"#E0!
M"!<[K?#Z&*E1/F,2E6Q; 61IKA+7Q1;8XQ/N2R;I\71_],07;Z DX'DSJJU8
M&,4_63]S4CB80I6_4+ZF]I](MEI/Z3Q^;\WW\;5^?\:,NH.,[&\!J"H5L><$
M'8;GC#N,[YEECG7!!=<)C_*]3RN7@Q[AE'&#R@UW!D5YU(9F:1] $&H/Y1M2
ME.M\IWRPYS[4O&C,_S)(DEREM%$I_R :5#;E!J,D!RQX>TK$,EYHOPX-*HRZ
M1"^ 9_.LEU4WY>2Q"K'HE^FF?"<9UB>LV>EPQAAUV]*/L,K.ON/2%;[LZVQ^
M]'H$\E&O^W5]?F$_KV?]Y!Z7@'R+WY)JVS]A/'SF$?[:Y%N?C9'GG8G:"T[-
M>=1"+U+YSSU^NZ_<M7U6<_;K^\82]:T'*:Q$G\N^TU;YL\WIGH(.$\MRR^ND
MI#K[,:D(RDEF[\!SK^';(?1;L;_'&LTPG(5XQH04$IRWKXNH]VL.0CZST[2G
MLU#>:3@T(B\'$KK](1;&[3<:\)HGW* .499U;(>=F'Q[I!I\T $P->8MD^(W
MY?PR$^D[N;3&)"^@1\BW>+;$RS7AT@29#,*>Q4E1D^:'@.A &%PQV/R/,U/=
M;R"%9[W?11!NPY"#7_K>SNSY(%4'=&3F I*<"1TM4A5 $FA0SBK(L^7XQ?HD
M;OI)UA4F:KHDX^!$\>LW#>GY)B\ON^2DJ^R"/LH$3.OXWD7'-\J@@9!_7.^G
MMPX\$S1P1&^$*LZ4.AKEJ0=0PAM,J8E(>CW":<BIT5N#P?=@SWZ(A'GYV)I\
MBK<5:K:N9<G'WK31^GDXQXSQR,_7=IYWYN $F]BT8&%WKUP[>-K<^LOAJZ/.
M'4IWWB!L3:YI^(!6X1..Y51JA+^KV\(/S[H)/(?%?FA4M\BNW][3,G0'$M%Z
MG$OH "L\)?LKDY'D&2"I&V>DLA[VS_NQ?7;<7\M/)E0J(P\C#C=_5-C2?\QF
MNR@*'@<7H.@=T5*95;;_*0'S8IZXEP)\(9K7T)7PL \SMJ\=48'8E-M1K;$P
MLS(PHCNYPN)>41E]XP&+#0POFW9?0&*TZ(T4ZL9RC?T1\EH:7]U@I=AMW-J+
MN'1<U0GV;F _KKI0HIG@;J_1=Q1I6PVJMIGLI[E\?I0:N[SKWQ1\WP&E3WC*
M]B0#PD'L-F"*JXYCJFW(=T%W2$\ X9YO&N,F%V9^V(Q*U*H1^3FEHK'7/AX?
M&>&!D09GVZ-08:BS%ZS-%*\,JMW_C&T2HR67*("C6%4Z0MBWLJ86"Y'N79U@
M\Y4; B+#HI0R-FZ/O95Y@T@AH?3KS/P4U<[-"P6%#2W[M5&;VT;0NDLA95XM
MCW3ZB@_9MA[LEC K[<_42P80.E[52S&-SRX?Q%Z9"[TZ5'EZ9O13VHG/,?-(
MK9@O^ )KR7XO+_H'*(=(>&,H+=3*"8,N[^2H[[=BG[W-Z&S^5S!;KO%WKHIY
MZ+.*&<LWA<79N+ZGI ;$W]D;]I42&IV31@=%XI/Q N?5<?X5IEY9D9TBKY7<
MJ?,CY4J"7D1FHJD16;C=J:FQR)V88F+9D#BS-;WCXG*G #'*[(F.#F%L6" 7
M3?I[%L>O5+]_G9>'<_,DZ4F#77\2?N,V9_4*OR*^FL6^7#]O#;(NFKGW!/)5
M9WIZTMWS(YO]<6K"?<*K/RHZ.LK@WFA];NX094S%V%CQK,56VMZ2/@-FL_6!
MH(&EBM+,;Q!9GB5*QV=,9<\OI#-WK07]A@05C/9@9W/@6_P$^NUZ;-V47;5'
ML.\)'QV[X9#O\>4^DS >(44#,NRZMG8R)D:\K.^P*ZBA;RL]Z;OX F3!0KKG
MKPUZ@2ARX]F+C2=F6_&?)"X;%10[-SOAQ>7"I7_A@ 4GEKA&S4L-P/BG9\$!
MCR6(5+U'X9WXXF BN\?KLJ^71R\A!RX(Z5GZ ]))2#,_LM$DU<3@!P1:[?@&
MC#.G5+6><$\/>TD8XT917A],H\P'1+#6Y*&),P>;VEC%-M60DLPNJ2Z3FFZZ
MZ#!FME^5?+3$0:=/>%ZD??I=A\OKZ[E?45_#]<M'RL4MI<\1':5K#VNLE6YJ
MST77RR>\=@[>5:HS>^/(](NL.<<\ZZ53,W5.M$!/XD&$B;NT4I9T"J!O,I/H
M?Z]._,$-?'O1B&6OH4=EY75MRJE$]IN?>@)4\N:2EW7+A(GDL'"U,\/'6.DU
M!*[ZKJ^N"#SW@* G:=E>>40)/RC/_U0I/H)O=Y=J+MX/]T:(H'+0T VOGB*-
M_)5)'\^%*894'IC!(KDQE97(RAB+2F^%76/7&HN@FJBUT[!HD!Y%:*>UGC/V
M4Z9UWM)!2Y*M,BJ\L?'R$PMU] T+&QX@:.%M;:7(;3'.7^W8E-OI":0L9T[6
MW$)0'93F[XLJ[P3 +FNUY1RE>MUHR/=/.*/8.>OQ$/ENP/V]P<((>MG&-26K
M@8CPT-OO.G&$__[PG]'FCF:Z2B8!X[TNIXBM)J:*85$VL55FYPM93_)#EZ?Q
M1#NEKZ0EB%"?P5=9\A/K8*^Q5C?E*-FRCJG;E.M(MUW_3.-K(\LYK1J#G;EN
M)WDQY>FS!3PU'P>[5DA4=$&+3<J,3[%7,JZ2G%%I[U+A0H2D/)^S]_2:>?C<
MM]#0"UP\5*GZ/6@TB>&98_JFKOES^5;#P#$KZL*ODT?*)2_Q[:/00QGQ8BCN
M/?VWJLC* B0Y&7R YB!4\V3JUF09M'UH.X@)55?NCVR\":=<3,MG=R)C6L_.
M\%Q>MPP;($*[6D=6DM'FA8(HR?X6D3]=Z";9*Y;N&A+N5]O!'6X[.:\ZG9$C
MVH"Z-^9Y,^D!]*1%X<V1[RW6-@9B-F71%R+<D_1B0=6NQ9N4HKNJMZ:6:WJC
M]![NA@Q\_L(&R,!H4?1#$-61JF<U, <##@F@'>LH*0$5+2K_/GA(<GEX#:VV
ML"DWN?=A>L1B"WN'+];\F>ZC?*O77GJ6-:H7+^L@X?.5TIU*XC/S^2J2?5,<
M<OO&W\1*+!: \.G*&+*+S[$K60MCHJ3LSOR99]'F>16P$\:#1 #4.:,V]/+)
M4\IRZ)AU?5N*07W;EHUAV2_=OC/JP<2D!>R^4M60AH2I'$)5E]BF+*PB?5 _
M8TVA4V;(PHUF]VLMB@_C49Z&FHF)O]^Q7S<V'2<-0:(OR$#O#YDG#$,>.<_3
M*:#E $%QJ)\76A5[6&#=>;I:]8)_F)E,.&)18=R6F*?$:$N>!1+<U?>*E+'C
M1'W.JM[DBGM RCLM*7=1(I-LG(\0)3A6]IUQKS#(]KPZ(T(,GYU 5S576S""
MW?O'^V/0?0/XWAJ#'W_"+;=^;8\4\)=OFHPY/VQ-\>D)W=H<K S_\LS73=GY
M>O^<X:8<1/!=F]WZ\LO,1D1ICB03_0_2]/E%^P+T1H%*2G&@*)IXV+)*--JZ
M7%:]!M6E<U[3&R))2R"Q"F:Q9UV#% CJQC^*:5/![F:=*')?5>MN.TXMC 2K
M]*C3C,]I$AB9NWLJ,9T?/S(TLB-KYJ6'!:W+&^F#*09SV3_/RQH D@Y,ADCU
M-EY .>4$\*<F&F A/H!!=^,,W@Q'-JTAR&91PC+(CH4BO9$:/<-'-;>RKX]B
MU;CSRU2]RTSIF%OKL,12^$<[)("T8)QE^[<0#VCG+5_DHP$=+<F!O,N M0#\
M3N@61X$<]I0.0.MBJRGKV'SK9'TJ:+_7%^E1('=]-C\O3.9N$+[#OLO2$_5C
MH:2L,5L@C!24GUN\Y[FH^27YN]JO0"& /)3U?#Y=<-GGG,A=H+1<31U+694>
MPNYJ&KLYE/"QZ*PP,SD2R4Z!*AO.>[SX&O&3YA/ H1_^:($O9^C,YZ/ZZQ^3
M8*ARRY)IS_5A&5C_JBR@[[OB5S1*/&SA:9^XYVY:H-H$M<_6*;Z9&:ECTK T
MQ+WYAC!UOLWO>1^[UP0.\G0W&)F_&;[#LO<Y%0$KHOD[6U>;N@?UZDSV;LKU
M1TGV^;]=GUO6D]UMR$;1VNK!7ZN0MZXE=4)4I1]PY\<@RQ$QR9ICM$/%F&R>
M0D:37L+81/7,UTTYWC7?PQGG(PH":4S]M2VC57HO[/1(]9MRL)B6%IB\5X%8
M7!"CHZ837;,*T9_-F!QE,B>-\GFSL[S;5_]NB#L0?3O?[2HO_=!TCLMC"13?
M7@[?X3<JA>*&X8=KOK\[*=/948+*#KC"]W3;(#\DS&M3+L7\5-,8%51KQMRY
M[54^ON/[@[FZ1&LJBZI6@*Q,=:>Z^]$W7FS*Q2?3D:@H4=!&'(2FQ"ET1>GT
M0"GTU&, 5.DS2=157TS"0E%JSF/FQQ<\<95E'SV\)NPB21,(WSV-<5]G ]M8
M-'_L:T3>G4NQD:2[PMV:3^< ;%NVXR>2Q9ZJUO'SW]R>+Q4-$9WTB*@C62OW
M!.F>T=!=-[]A+3]5N';=G)XF.CI_ZF"1WJ]6VWXG'GS'GGDUU229ER4@.J<&
MJ@[E%!/45O$!H F0L]!?.A#5=A2>*%46]#">4KD\_&22-WU$3P^UAHIQ@*DI
MW%MEW"\B;MF+@;YU"#P,";(G\PZ2(^478_2VKPQ._"%5"*@=E2B680I$TT ?
M'[0#PW".:0K%*6-WM@@>U@*A[SLKR[HJL=9"_02^@IKC*';Y6_ ]3W#"RO<"
M3.X%)&0OG)89!0)MRFVCX3IQ:D)Z,NZ4]&.1*=.@%66NLO@-"P;.H_%HA:D@
M]MY0,V@))K5'X\_Z/YQ @15!;7N%5@^*YYU]@U@6NK[Z(RL&4P":TK0%/Z7D
MBLJGE<%.]9Z_\X%AI;//]TQ:Y8WJ4V6L CO??M/LAG.$)I4='0,8_+&,V$-A
MV_>6^VOSM;0>=@PX9VAD:)P-2W7AG_CI_21'VZY1&^&27VY:XRA5HW->T@6H
M@#E9(!/$=['5H;<<4HKT 5*)Q)1I"%?$L+C6G=5G![[Q%-@)$:-%"ZO. OU6
M#NH/!Y:93>67R<"<L'),N*-,%TBG_$@+DS7/JF614(1/J(EA \86TEWE0E5\
M\B1(HOB-WY-,-O/A@I3F-8XW;Q1AO<C3'^&8U(ZB4Q]"],T<8@7=FW)NM&?I
M[/A( @@A/3Z,/37VK77E 4_=?+#COM,,HN@X<XEV<:/"[6?H4Y;(7Q:O6MCS
M;7+-!8QZ\*]X7KS>DR@QF5&EIEY3+M(00)>5HKD 9?H"+"99[SBK)D)G.Y-M
MT=S8R*HQF/C$1.?/=B,Z"SYC*IJD?_SY]O8>PXHAXO+K\60K[5(MQ*MZOE+5
MR9(*"FGGP'[4X8F979F[;D]8(9Y\\WL-5&S*N79SCYXWO7&ZW#G<QMZ)23SO
M,!V5;OID?CC.:6KC:B5P7'9WPS)R\<>=D([!%=?HXX.BJR,TF)] \:I05RHW
MM@;Z_5TE6!G'\CW;5"@Y'_7RA.EE?6*L8&A-IR!=GN$K7PMKI.'O+O+T4(8F
M-9)S)1C\NH_L2^=PH\WTI>1?QZW(2 ZTR]<74701Z'OE@1OTW3H:H@]9(D?H
M>?&,DGD7JO$^KX<COO0//*N<!X,DY_D7-OYPAE6;PA1P"OJSDVL0__HX_&RV
M5"%YX[%!9AJ8ZM )F41WYV\7D9.@M^&[$1\P2N3E -.;$C\@;3(],:?J\E?;
M>D_BW$,SE5*@GN/>2EP,FAQ\1-/BW2B #2\9G*[!W#UL!):/[YIK; ZNND/.
MWFGK2JD4ESNXC$S;L$@[/;Y"$>9NI[K(L)2PQJI[_O]PL6V45P[JP4_7/] -
M_ISY7F@PDF^;8TJMZ#(17ZV(^/A$RQ!2B[^U"AC&,U0)C%9Y^ 9%:H29NP2D
M5JX,&SHDX7\S!.TH*^3JR!?L'37=4\+/5,%8=^4VCR4OA19Z=:J8ZC^4JL5A
M:B)D^#ZV-#K5Y0;?(QN62U!.[J8<&,])-3<'HL0H7#?AH)D?&7M&,)CR=UUF
M]_V*+Q\P8B[^D:'78I^=%@.Z-V+#=+*/(343@-,C$,<%HN**KA<30?='OD^2
M$B4.7-0QENL'%2^I9)''!DZM,F3HCKV^\0 ?DKD-D\]4ZS?Z(0H%6BNF=G:N
MY)H?%9#BJ'AE#,S3O;JFZE,1&@20+88BIV)N-V;(/_O^97GE86ZMG2(_@6?6
M769$&*VH (+7E+0!A'/2FXC@=Y?#TJ+1F&[?Y4\?JQ%-)U=9&9REHERO&W\'
MP>33.X9RL/JFAA4;?C=/64]>CM3JOTTRT<>Y:^X)U#[S\ E*BJ1323VKA_#M
M5S;E4 [*DJ#,#M$Z*'U3+LA!"6LLD&9SQ# "=1+17*6A) AD@$%?7,>$D^UZ
M:Q0M2];RD>& VA31NEY#WKUWT09#H+5?,\G]QMP>68M_EY@-Y2HQS;9S5G<#
MYVR]8L(1O\^WJ0SI1EQ0BALA-2.#+*O3+E^XU]3X9]GX^V]*W]0D[Z&<%!G#
MEP*#LC0)W?B79A92VOQ&0.HL%D8Y-7Y=,Z*PC@/G7@:S%;_W32VFZY;F/N[C
M079]:0Y(R\LZ^2R\.MC4M^!5\C*Y:!2_)E<S\^?STP[Z;YV\*8+QP%/M1L-^
M6JH&)96HK]WQMBNBJ*BF62#:GACLT8WTM2>&A)XUF',L?5YQ^6RG:TZ638P-
M[^7G6SF\+&H^='!5NN<?H!7))TS]:)=)00K_CIYTAV2[(".UJKK_R;U-.:$;
M9LY#",J$W'K38O,Y9D./=K024-KW.66B>LV=^DA9R](KF4X& R?([3'T?\ "
MNU_ 5?,B<UNY2H>><8]G5VGU\7[2(EQES<Z-)ZHC#@0<\DK7<1'VSQ2$J2K'
MG:Z^E3)IH\?40G.T1!G#JU#."X+ #:H^_B5J-18IMI".KZ,[!G<L-/?/5..W
MX'8V"44Y G+[_0SBQ>=YDX5EZ66 ECU3OZ;Z>]/)U,M#R[XLFZD TF3"IIQ#
MZ[EKK @?8X<A"LJ\QX9I4*!F=\Z62>F[JFLP?<[N==P%+W6HPQMJAHZ73&6X
MOZRG4.I33/0X&29^Z<<M'<TLI.]R;C7=8[JTMKJ+RE7#TJ61.JX-Q=CC4C8A
M[&1XR<-*VDD-Q+3MDXI>5]\GKX';[!\4B-O/GS*O&X0?A')_H?H##)*;3C&W
MRWR[^D *^K"2VB.>(NS'S/ZJM2HMCL@^R-<+E)F%B,I5,WFQ+2!Q94#J:+28
M%P?ZOIO\5;11;GAA<*I/NFM.:-K3\6.5-P7/!->;0>7-0!6M,]7AVZHYC_G+
M4"[\@>$^\Q+-(A+I"Z/=U#<U(O?K.U(7=UG#D)(J-NVS3[N4M\,IM8=WYASS
MH+?NIT^BM K;,RTQD.EN<DWK,_HCPT^UM)/;BJAAP,*=ZUX#!VY^8GK1V?:)
ME4CB\*]JIIQLPG9RVQ9\NPE>EHR23$MMT!7M@BA+81'Y]NM2$$F&*4IH0U!*
M<\VS\,-AEPFA+$.0JO?\^L,'M\[!O;ROC:G8'6TJ^ F62:L2<_U)S*#H"X 2
MU-G3&HO8G,&WL;O4;X]\3IMR!UIXH$?4U0,S/>C?=4S-I/L<?O_H$*9;3&(?
M@"'W>U9WS?V@_W^J+ 1]KR+=I<>[&"CJE U.'>Z#"'>P5<9\2<Y IMC14G"N
M767=DEK6I%&'Y-JAK0 0QRM]/TC^+V??NC:6F>'+MK3)NS[!IM.EN5E]8?CR
MZ?[(,)(\N3KPX/M(F.8N]Y1E>IWS/D?<X:S*J$]^W<M_8V(@O:^FFZFOGUZU
M#/YLO=/Z"K4%QS2)H$2UM!9FKD*E.X8$B7,<@D112V0AR"TN\YJ_7T\5O,-I
M!3^V!.6$&VS*J5#[_7FQ3YK+?FH64J]2\,J(7#?'CXWY?4O)98]TN;4IO5."
M0>F>';+V, #V6XU3(W@_APFW[CS<_E$#\04;:! Z10H:51WK'#5V&V+$! BR
M.TREC^\W%!UNC.M_V0)DOO)XAZ[Z3^B21%UIE(!22:TRA"]6,LP/#]'4N700
M8,W(Q4_,: CJDXF8\$LLZ5!DE$A=S>)U \N@!4IE#T;&1HJ\U-R/B"T_]W<-
MB\WZDF>?%5E)//[KW[1;MLON"R.Y \CR56:1J4-JVR$A/@T;6RGQ%$K)I1+'
M>/%VUY%(\-X9H*7SS<)]?(8!6!EQ'YUHN+VIJ/N'PVL?HRG8![\,UM4"F[T_
MUV8#QC_^WJ_C_TT[4MLJ4GN,:&_ =S*?)%H;:C^^ZW;=KK&4N/J57DM>GCL4
MBM+-5,BY-1(T5&AJ\"=U8:!JWF%A.*B[(.%0MP+)L>OTNT9H8+^:>(4]."91
ME&F#7N'JLH^ W8&GN"U[";TZP=LD.X7[#-A* )S[(]' A I-;8,(,BK#PR,A
MR3)^W0N0[B5S=II9DJK+JKD>FH+53K56+_O1XM'(&/7C2T+$.OD+NRL3,#PG
M\ANFG3&#__YK/6&FN;PP7S?+"XYUIP(QP@L,%?TRE41FK$Z[=#]@73%>M9 ]
M]>Z5==7"R>&/%ICF@/&Z&+75+Y!.N(R+EKRXVX,D7F)?:9]4Y?')E&E6)QS<
M=B H(T]QJN#5D8!AB4=(G\'HBX]=^W[[U+#MEFN:,IG0=@3?#J=SGD$5]G]U
MV(>;)/Q!U7SS<- $P/-LVG0OO$B9O%D?AM6M%3[)3YO2Y_W.=H 5).;H_^V>
M)G)[W#[B;,K3M8QRC>MR3LV.>.7("&>EA5:KF9X5U0^==WA6_[T6H:_J;=QQ
MT.Q820I&M?:Z(SFEDW_#M*XPS^!G[C'M!#9#-51;!U;_D2@Y@GN_*4=A+[O)
MS,)_HV$-+H?)[-0X^OH#[K#$N5; 7CXN"/QKS,M; .FD[[P4Z:]!+?\R:?A9
M5/#"!_/R6SNKABSHZ\Z[,^\YD&TX4Z#Q0C1I-TM_,8,GNJ5'5&[*:6!-A*')
MG%45&56?*0<&VU5%.5PX&'$,Y2#=M[@IMR_(^%X^./5[%Y.:OI]_7?JND48=
MK4HL),\K^FP4G0FL<C=[/-,E]=V4:\CLI(.DDVR!$R2][3Q@&2OCV>V)YB;8
M2!;MHH#E^H8967G:S*+$QZX8 '68TCS!R2@#O;O,56]*[>MAL.U(M4'EJ]":
M&6;0\CT)8<&G=-Y552.G+"C?!1S ,H@U[[-E5=,F2&+#1 )*G?A<(_)]MK?=
MIRG&85S(USZ#@JB^XTVW+V)O'"AYPB/9&KRA?K%U?_*B)+K#)%K3I&5QYT"I
MV]G0OER[5Z5W[AS^?#IP7#N2Y*7'N%F\6S''6L>YTLS;BV1"R2JW+3S=][@K
MW!Q3.CLA#60+7.& 9KU,_FQI$VJU.^QH%UOA.WX(05V%BMTSQT=DH09P,8;+
M;\IQ%89HQGAN_[E+-+&7Y#+PP)\' 6S)5/"^=E%,3*'1HH4L8L+?T^(PD2T[
M%9<(@):U1&VL2CI#KR7%T8/5G44O9>RMY\]?1G?7:QP6D"2G=>"/V"%#M$.\
M0H?V[$7VE,R856GJAO1)B44Q<A0Z$24%US7'B\\M7_WA:IP;Y1R]*2<Y3!;>
MQ#^""IRA>S&:A9;DM^1X^JZVPY9;''TO$X*$VW*BA5FS*V%AT6&HR%@S^(%J
M/6+;ZX;7"4LA$5,[JS\WLV[3FJ13>$X!?"<'."[^7?H?J,)+5UBU&@?$2'?P
MMM![_J5(1XA/6C8+Y"O5%W4/=.^L<NO"'1VU(NC\-7;6/36JK;FM%9DZE6E]
MIO_;80WK7#?W5/^P=)?"0-OXT+1BTWJ7:>BM:M4GQR.W+%%#G5# 3VO0YT-)
M!P(Q;@_;//*Z7<JY(U@GQ\[+1&V%YK:IJ=ZOI.3LU(JQ<T.GNBR#L5N 0 %#
MNK-/O!]SG#N7(CTJZ]9=@Z*; "P\G(]/7I_)RM=L_=R6O'53+AF+XOT0K/P[
M627:NW"_=?1-.:+M<%VC4(.2'(DH28=UK@^A+!RE,@P/84_)H%3&EW%,*2M_
M^]*&(-!&&)#$ !\"ZME7 !VQX9?FJGNC]S-%NO>+2F4\18I4>N]I1>2IJ6OH
M.7=I'!]9NU F(#&F_W!H1A[*8ET=EEA72)?Q[2PH56DN#O]KP0F]-BEQ+;7O
MPFJ&AGXKD"#<SWQ7;QDC^,$-'Z]_4(RT_.1XDE CN3SRG;#?W6*W(E1$8-S*
M1Q:<2#P5>9K.&8>,DQF^NS<($K@X%$.R3/S!T^J&[UV<^0WP+Y_Q*F4P\#LE
MH%>%X$ZW^P>8DQ:&-25\AT?W/$5Y/.,,WOHV%G8K=SR$5)<[!Z<0!OMNF+7H
MD3M-7EFU&2NZWFFO>.QZ(^"\EM.HC6UXNLV[[GZGLI'SEL.!Y.>F$VWA"=S#
M6VW\[GY4UGCR[9!3]FS$:589W_K9M_.7"T]?)VW5.M6\]J32RK=7ZP_Q>7Q[
M!7XGJ_V^;XG8'3<$55P#:P3GV^7,DKCX!\K2/8*,!YP-3][D &QZ+X;4HZ$&
M9(;S@R(6'\?*C7($/^*= #.0QK/?O<ZQ<:$R0>@LH_8'YF<V'K:!%_ 4^M(W
MH;$/4"=PZ[A?32G2&:)9$EOSN@83<]TF7\5?%NKF$Q(B -IY'AV$J+U(;$@V
MLU/(>[!J /M9A>8(U@9RPE[Y?(%^ 7E#NL!).#6 +ACD:76@#UF&01^:G\*H
M=+'W2&YL+6&H#\^H">L?O,(@O5,F804Q+9B5$RS#"Z4)<]2FA!,!"-3L7T,-
MA4F\$.;!5Z[5CR*#FLC(2QWY9?/U325;7CY7S62<6(UH>IZ=A6N#Q-W5;E1]
MBC7:YR?<];PU\;1+I?:;JARN:<8-U7(5G? .6(YEF^6VEWS)K\F %H+@!N0@
MCGE?N4Y\2/I!JE/025?&'<38F5D*DKHGAQ]0!S6P!D,G:YG43 5,IGM+VSE,
M4C=N%\H"1K!O468B37_$RW*%H8*G5PM9/GBR]<?:4?CL45GLNB1L(W+ @#9^
M*;YB_DTU ZEQ7@B*@U0'%/'4HK^SP1)S(3X><N*I5_.A*?M,;]76)XKH!A3,
MOC;Z>E4T>-Y!F,FS*A"@N: NA]3)]]<_!LF<KDT-X/.L*K=VS;-0LRRL C?=
MN?/'D,.K:J+8W4*S)D\;=E\78E=QSEY/_QH.QE;DG.:&7ZTR.^"?2MK5^]S)
M\4:@4\3<0<N@)T2E"T%-9<Q:5P^!/=)+_?& >V]->-^B"Z.Y[NZ3STD)VI&(
MWM+"C\0= RZK5<\17;U?4?1O-V4N]:_T@P98^$.BM,I?[0:K]T3ST;]CMHOR
M*(+ET<?<U&G30UA+3N8_^46/.29FT!?!GC4$_,OY33G!8T3;-C%$M-1LU%)V
M*:K"!Y- (1\X?K&^?/V;^ *^W8".! 'Z#IVRJ#[%$*T#CWGP>/8V,_</DY*C
M@L"'W[]PA1I$@6C*R6/9(#/AOG5RR3 E,VE33N%87>/PME2^7KB]T+R.?_$^
MC*SB&S1S),DEK_,^G6LL4<P3^=!E-_Z/= :\HVTWILZII<!"R$ZCHM6Q-\>N
ML;S8'S%JC#_ALH[=D;(^8)3+\!*BB D]B09V=D>RU*&=1<>9JZ''Q(?/+6_*
M.>LI7AFB&98@9,EB]G%9D(;&!X,^!<5+'R)@\CXZ5D,&*.U1'77(5:9!RXX7
M;U@1_4;=.W27='4YB:,#HP>KEWD9!X=4I@>_@992,+H:"I=->C%7F>Y)2J?]
M!'VYRJ6ES_U-OQ)7;?M?.7OZ=#C^Q"GVXAL6;GLDWER 02J?VK=TG&[L44G/
M,_0-N5+<=Y[%N$QOT@A0,65&V=B?DRAL)$(Y#]@[Z7[@J9L,4;[ K0MZ &LE
M<$LTU\"TV (QW$'P)6(/'[]=\I?0 ZTP@W3+'TS\GG[\+Z%1#H11Z-:9KUHK
M:UD399AZ/M2<$;M%J&Z\OO5E"H#U/:>84:XZ7E%#O<I*USQ_@G#".]\U!19M
MTX"LGXI"U7U?VN83UW=J$/2@^/#%0R.%T3(-YLL,UG:B?216/'1RHS@YICC:
M'$LY5>/<^/^J,,]7>:E\/ \]67)IX^%:H8[(E&D.#88?HB&%%MRQ1-0J]#89
M)+D\BM/ZHJ%*:1G&!M0LB)HS&3LTA3+;0>1UN#8KDWGRT7I5*WZC?$'UTK)*
M,JX_;%ULB4ZH>CV>8I)D;QB;?G58% Z<Y/S,RLV$$6,-SX<U!J9UW+Q30;UV
MH=.Q$(R"V3X9N<+[O#T2<6*Z\#OTG9OH7R!='!@\<R*OG4Z=RY"IYF58UR2J
ML/0<QEGTK]"Z"SFXW]W=@[UPUKU+/T%HNFYG/SK <LEVC;DZ,VKR-SW6LGCG
MG;$3FW+V= $J::E.%C4 X#$Z2MCC-(9N.XF;@NXRS!N%<WLRJT,,"D%<Y8R3
M1KZ'@23!6,?HC_6'.'-$(,U]I>W88I3B1PRDDV%)94F.<M)]U>6[?,]*BZ$A
MJ^,]G+QEE@ F$U3"AK\2Q?9MB5]7.W"Z% KKLQ#.R%3J(TV[NP-][0UCH@;'
M\47E,].V6=8GG#P6C.[:^>%WCW[;2Y\5_]>9S61^YH2Q=)>;^(+/?'YG_7IF
M(AT!D<<>%ZY*CO\P'@S@@78 23WW"'O:CB)<A=3NA^O$HN(2>+#S_-Y@WN2'
MA>OSQF.BOR:?NJU^X8_BG_!?^3VI7;+2V'679 6;&(E/FTPZ^_!6^<BG)UI*
M?:?$#>'Q87F?QM/*!67X'%Y8QJ$V194;+)*;XJ&88,6T><OASSDV7:,,\547
MXOEP*^0S*X.*4P/@A4#XG$Q6;#?#>CH<ED7WR]B+@MG1\S>I@)9 JUWC<.M^
MFSOOPGC@0\&>FW*=%Z;Z,!^K*7?J'_"@NR:RMSCH?'2W#]4GWHB;[-O84BEY
MO2F')AP*AE/S) ?&1!DC$6J+R_<=D@G4;:V"U;=C_1OE,='EF!B8, 0JCU,W
MI)8UCYH^T8$D4M"@,D+Q]*9<8+HVJ.[+&TM_5."!Z\!'L"7L3_*C/$921S^[
M-%#F$JAEB:';NC43DY0<\?6YT7[5X6[^WTWW>PMWV-ZU0>.1VFI1#<[B4QOY
MT !8NHI48608)S_SY0RB2 =(%JM*@H$JP?2EE^,SP>:Z0&89IH^__1^TV:7P
M+<9O#J&JJ>"M\XE\Q^V^3(J>C@,K-".G?-YF&P$@;LIMJ\1\-B!,@47_ -&&
MS*D>OL-$+W[?U"5=WHFV89J\4*W=];%7N]IT=X/QT/S,N1'RL<0+.N7,[C&G
M1H_E(W&?0^F-"L>YA$0#4((GO+U?]4(UM#T?PEB$)-YW<?WZ%Z0*>Z8,N N1
M=^_9TA\R^G)ARC91,\.J+FC+?ZI0:?AF\K<N64#>":0Z 9J;<ELQ@ /'#LM
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M],">XU[TZL+O)N;*[TB0DKB5U58]%G;F*P-=;7\#!*6>Y3X9R+@)0W,0^ZO
M%/)R:SC7[NQI0[6^1[IFY_B$-!BW\-3THFJ$:G6O^[S&H29JS(:;':4I;G2
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M"FSTT/;%_*?_BQEK&1Z_TSZFMPWS(%'/DIZ*PLAPXW?.Q$"_XXQ,7[YGV46
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M0?:_Y1/$M*&(2E^R?Z5% H,7']C7N#SUT%-OUAH02Z- .,Z9@ &4?:D2I39
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M,DU@Z40J9)J;)KV PT/+5K.]A/"?2GPQ%=)B_:YV9F,QN1]'+]R)VQ=[ F)
M>G^8>S,'HTB %^@(_WH+A8,R\Z+Q)4 [CF32T_ES7+VE:;[3&WA[14ZS$SQ3
M4-SH7A)Z==UP=5]L_7+J[@7N88LD;]WF2R^_M;L&O<W*<$0>=?OZU:DHN-\X
MT[Q-.>&+FV=9U@^TXS%_5/7\U0]?4I]I@#E LJW,Z[H);<:/JU[+HY)7B9!
M4'"IF_GZAHU-,Y3S2"0!?A.Q;A',][A!$)DSHSO_ %R&P7254#KS/ZC&_H_+
MN)/;1(#&L_C&60%)=IY^!5<3YX2N*1F1N"Y6DX:9;(DCOS6,UX1$Z6GT"@PV
M]+]T_ST_'*Z+FQ/(#>4%Y&Z^G=!A+'^L=,8;V_!0XUGI*J7&0VLK+O"6H_/L
M*KUG_(USO4N?8MV]O$-<M6]7:2_?J; ]Z2JKZ6 NG,RX-^YWE?Y>G[WZ\3LV
M 2>QM9" /8J1XY\9PR>QK$4*;.'=OIC$5B5[[5DATJAP$7D"CE&LSY.X6K-!
M[SVM%]E:HG,.&QOJE'<@^H'?=]SGGX^8UU99!B)V^8L ;_$+W_0CEG&!NR_V
MS/S<:R] D[PP$PM-AC2CH8NCR@!LH/TP3D"LF8?3]9+I8$=Q>KD YE1'\Q^=
MWD"&ZGW)8D)(WVI,75><^UPH-RM=\9YRM%QZU!FPT]7S-/@@(@ 7D'FC6SX#
MK1YR(COC^*?@?SVL)#25P%JF>C<';31>LA74U>.\KV5^GQ6().'BW,;,0C^H
M2;*W]B1F0I1'!A;RPF$.JL0^D!G]E(VYC#[-/?0Y]E#QR^[Q2&]Q6XY!'T1^
M]2.BQ#!>QY[3Z=E5GG(^]J_VA-O=Q;_29$#?=/ZWINP:.'E/ER#3ABMLW7-M
MCZ?[*[J4GNXOB(@NHA>MV(RXI2(+)M-#LCLP 39DX,3CXEB4L4]9O4SZRF3?
M^Z(5XM%-6CG>(5?Q[?W.+W*#&/A@&_A]*?\KMJ<76S_%)O+"4#H[","7=P&M
M.=&M#KCT8BYP=S,QFF?Y=@!TT?OD3)].V3<U->#AYC+N5&<$PXZ ="/2HGR?
MWA7G*<>\'*O>UDF+,,Q"7,:W5&)[?H'\A4W'U=6NT;B!#H+7?+&%D\(K?$>
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M<X;IN Y60=+#V,%AMO/]L,E@_U@>-\?9.:W)<VG4).) 29Q2[A>H9"IY7^R
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M.E6?/$;R=H,C)1R^;SB*H:5%2)6*7<2W+'!J($$&*;C3W6)HN:[ZQZ,#%II
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MH'6=3+9RCC;V(]9?"[UY0O61:O!/?4?W_#3HMO? J!&!DE^"VY0#'\#0_"F
M)+6#F3)$[_% VJ[+@'QK_;RY"-X8((.Y1NW^,V1AV"<>B#9@:\H1C@R",K5I
M6]Q7 M1W4&4WYGLZ&EARZM8!<S9<]?\Q"&$_CIVG717,]5IO!FJ_%;CO>J,(
M#<I6[8_A@71/4R*Y@M50'JC-!?JO9IAQ O_@@3H+Z@'=KB"8#_0E^]-YH&_5
M V/^=%TT(%X$O-)YH*[K3.!]GB\!KY=)D4PD7H8;JD\$L\$^&!XHOA=SYP%T
M99ZV-1/B_$?,#!R-V8"HKN/09O"=/!#1'@%=-=<^R@.-LX!TR"Y+XTK,&_!
M[Z)H@+5[Q\ \T%0I>- FDKW)EL<L?]C&8AN+;2RVL=C&8AN+;2RVL=C&8AN+
M;2RVL=C&8AN+;2RVL=C&8AN+;2RVL=C&8AN+;2RVL?@_& O8#Q]B=A?S-W@*
MU)C-]$S*3!,/]()P1%N N3X!)3)H^HVF/S$+*$MA S?H3L&K[=>8R,9-Z<7G
M^# !?98A_,,H#^0$O^V?LM0:L[!,3;CWD/2$^&UPTSI4Q-%@N0=OF(Z7B%BN
M=X\I^M8W=/GT :LS$0^5S\3*G' I4;"(O!!ZNT^N]5Q555%UW&A*LN G*/-B
M#/>Z$Q7" SG>J\=L!M=@C.(VBEG'V/LX4="[T ,^S?7DG[1/.L^F^4PZ% ZL
M34Z@0D^ Z2K-%CTE/-#"O#ORD4RI:!>_U8G[EV\7O_X6_CO\'J9^FND/>$$,
M&-Z2N067ZNH?<U[N1W/ZLKOP+6:-S=BDF&ZAL$J#-=,"4YW&SUG5!+FZ\=R.
M&/S5(^&C&J&/W"Q=C!^W+)?AU5=MO_OM%ID$R%%1"\9TZ=($N2(!6U2* /^M
MYS$')@10PP6 N +P&K0/%\=!H8PV@*M_UV>S!\;^TR.!+1LPG5@"4QG#CEQS
MFO(8[N;Z *.:\4!0U?64.EW@!5L9%4Q>-4,#S ^$;S'SGOX/NOK<P2O3!5Q^
M' ]TFF.S<9NQ2DB!,H4QG0#I/Y@Y  SE3Z2L<X3A -TIL"U^6G?]J&_MMCY[
M(Y<'>C;# WWF@:P"8%HUD)E([F[P"D#]!6%8) _T-]15_NX(%?^_0=2YC= V
M0ML(;2.TC= V0O\;("02E8?)"N-6 NHBPL'U!P/T/D9;,_W1N^"T#V@!.9UI
MU^!&#?ZS.Z>D GN/4B5_ZS@7K>5L_? JHE+UL#'T60!\E%M+T>@E(0PU>*"G
MVJ85JU9_W9,/U]"AMWUB1.F[X(2TP3G#62\5F&F_C*5JV^.3KQ\G'KT$^N;1
M;@08LE0'736K/0$88KIEB U,\</1S#-]XD-E Q5:B83E1/TCNK*9JI[13YO]
MI,F=FY6$K[VP3BBM=NM[2+J2E"6N,'?+)7'@OW=!%MAP]@:.^Q.4>PUCF\:>
M7XI,P.'6O#"I604I&(H_$Y"?:D0R6XZ]I6KEH7_O*:9C5J8QS%V KPYM]H$!
M18JN9O- N;D< 5WTR@_,-_M1'P<7Q@/A+O! GV0 [P3W Q)<@S4Y-3/#L8=_
M=U&8P3'A 7R J(^@K?- ^S%;ZK@U\D=]_S0?[5+]+:4/@4+GYG@@'3.X)A "
M+!J@]5'!!*;%GW2_A?E[C],$#S3S!2 Y,/CRR;4<:$<M<\-W@P>"P38E0C=F
MN&+D9YCO:6@M8#C<EJ8N2OM!%PLJ!L21T]9);3Q0E"#>;*MD:.O\K[D'/,0D
M;*Q V3LP[)?^+I$K!;7:#@&8OCYNT+M:7R!$UL=QF[)D00PM\\_*13'K1WW<
MSD:@\'@#!!\P^C>=^5L8H/)87EGAYA>LJHJL=+(A!,![77I,/^!JZ%;0.>K_
MJ(\1 .&B@>H"!$3B*? V6;;)LDV6;;)LD^6_1I:_?_D-^S>F6%[A0GP.3B]K
MP;BB>W]/L4.<>GT]1>9KN&Q_AJ,]LW<_Y9%XW9WEI*2=MA:?)MY^F])[\B@6
M5J$U%K80I:DK)Q4;/[MT/ Z'@<[K+) 4IJ!,A"!@8)<^TP. 7&8+<B=]MDKP
M"Q[H>QK[$D"LF"UB%>>C%JJ=V)L)W)T6/-!KR#][<\U19!GW@TO2N!(Z]9A5
M,^XQ $.#/S'LXB2$ QB: QBZ8)9_^BO)BT(W3']P"0\D<)("W93E@0YB:.G_
M(-=W;EL3IC,;,ZX*W0#]U:,VNNC,'U[" P6]IN$XPIA@*-/\SQMFGAC'2>A,
M+X$F@6/_]A>>Y[VKM?C1WQ.O^YAR0Z%$'%M.<XM:&M B.FYE#LX4,.7^\E=?
M6IG!Y7B@OU] 2=_Z,HLNF-+)%4[9BK9D\)!/Y\8:A+T'L/OGOQ \5[8@%@#B
M[U?0ND\ 0?4ND@;(U?VF6ZSJB/QG__PE[OMB8:V8'UWQ(]<S'"YP_0%A^5,V
M0,2]?^'X7.M_GBYI+(@XD(<R@#S4"T3_SFV^;/-EFR_;?-GFR_\ROOS@Z^K+
M@C^ V^:I6A-YM\_C97NKMHF]OZ5A%_E^/G_;)^&JCX/<5.A4]0<O$7.CJ^%Y
M?!L>KPXB=1/N]LFOCLIY6#X+]V\AS98M+;I^?W.XP-#\16S?N]&UR%O5G;6R
M!6$82O:63 585L 5UMYB&1Y,Z]V25P!G!@#.@+<XT_\14^C. ZW, JH1@!*^
MYC3E]U<X,W31=@"<1I2E+3@%,+34?WPLYPS DT%;!^ )(C!O_BF42C!W)P%)
MW?,/YQ+F.EMG_L(WJKS"!)GI A?$ /-' O,7W)H_4I^M"@DF ,Q1!9@3O,6<
MTC26&&"Q-NY/\L?]>7OHK^ BS."B0#":,_VVO %GRZ*WO&$+_<&D!S\";[(*
MR'S R06;Q<L5?R$=RS"46<Z52""2 =)) *33V2*=;=</I\QM; 84=N8_8F *
MLW4W[I_CDG0+UDCX <:1/Y@S0QG*]8?^F2(4N'GL_+^PK_M=K=*/X/W[?/_5
M>1[_')>,.!$ZZ@?@_F"ZG+!(("Q-_Y$F6@''0Q5P_YRX2K+^TXR*7+B-86]B
MMB("MG6'<)M.VW3:IM,VG;;I]/\K.O60#P$ZT+B?,)^<R4U2DB?7"6X<>0!(
MG=%U;HSUP&=2)O4DQ?5QO;_\T@2$F%E>O1S5#Q;ZSJ<@C+UT\[2 \:L;46\_
MF5__?!R **#;09P6$3:K@6HP#3;[Q>U^I6<57?1WJ7J;M! [Z5*5DX:ZXI;#
M2S'8T2EK<G:;X$(&5=KFE@/5Q,'R:&:!])+7\+3LA'-.*'JN50EU?!0[S_&$
MZCH7_ [,\%_W_?QH8\]'PH=B\,8:\Q8PSP=D>^*?7N2!6GP+JED3H4SPC[8P
M_7V;$K?^"V9F@++EP^"!1SP0 #LPN -R29OYKG;OCS8Q_6"?TG\SY,[:"!2(
M.2@[ <O:$G3_V<E$+B@V<_T#1* ;UO[>@ELQP@-)3]>N+(4JC&/^OH/I[QNV
M6/R B3AXH"G7"KR-Q386VUAL8[&-Q386VUAL8[&-Q386VUAL8[&-Q386VUAL
M8[&-Q386VUAL8[&-Q?_66/2Q@7>6)ICS0!\*0C"K*9NUJ041V@(^SZ#'F'-@
ML>\#\=H_]SC5]O=8]'N*W^TM\7.]:GS>=ZHT>K/>*.PRHB^?*CCT+>EZKA<J
MCL/6K6W+NZ"NX35K$1^3&9S!EY]C-FVLLC#@IY*,_9JG8)*$[;M4AO/L?3C@
MP22\"U78U&3^Y92)[;;=MMMV^S^X[=S<QP,] U)P2Q6SD]NF_Y*PMI?I!<\4
MV0 2[JXT'BC&FX[CQ$<*8>8$:7,$$X6-]5#HM[?MF 5Y^.8-TZHVPL@CPMH<
M-)L-[](5X>Q"_VRF*_P3":U&"V8K@E^F[* ),B(9^NPS7!5:^0MH:6T+@P=:
M(# -O-J.B['T%\"((A9JL':8@2OR+^JA:L-B&'^H;61O#O% !X-XH-P7/- 7
M8QYH4ID Y/T'P'JC'OD;@6&K+<H#S;FGPM8*X2GN[_VP4^IY(IH$D34?*V)O
M\G76 54'A%ZFO'>!7JZ5K:V2\MP,(?;7#Q]S+#,<$DIB760;5WHC8B*HSB9R
M\V,+7&#504('.QL(13/L4YNI=,V RS1,"'KXIXGKJZ<I+9[DPT1&8E"7\FHQ
M'OFIV2.COGSSR5MLD!OIN/F8T674 G.FEEE+*,"$D0]H:M$3*)VA7$GF&V%$
M[9GNF>)7ZPOTVR/.F]&1:H8#BFE_O%"KU-VT(]OM^"[E@TYP%R[:R4Y!7Z,)
MA@2(,LD-!,%J..)XPDNV0K;!^SDSG9-8DA[?,<9 O$=L1.:'WH?ORWH5S_A,
M^.8M_AHU$3*4!C=ZH1[DVR&1<>#^I")Q_T:F]-$K$[(&K-+8DT>OJ!NPY$.%
MS.!5,<594>W8<='#Z4Z&2C=STRU'*L[$?W S+L.NOQNN6D\84J]DK3-,.4$$
M2I8F?P%S@"L:S/Z9!QH,4/I((S"<V">AM!C_W,]=J_YV5/)#'NA%%9&KQP-1
M4<6<A(485Q8TD1&T@O[(W5% QC&EUMFO"8"\&++IA:X)TKR>T!V@8O'?UMRM
MY6N)0A*])R52.N*,]+R$[U<H7$T_WI_@[NJ)^&/*4^[N.?<,VV.T1XGNT[%>
MAK-C!R&F%E/P" S-6)!I0=[/1M(O<,5@;"DX+7@63,(-XFCYT")H":8;CZ^.
MI$*8IJK0(DQS$P^DMB &]T EK+C!V_9S,S&NJ U53 2<(8=9A!D73(5^9%Y0
M;9X>"I"OO0.?%T%,'I<U&C++:#.^F:;M8"L\V\CJB:DRL24Q#)2*T:H'E)[>
M3!5T$C>?1F(?5U=,%_BV&CO'APQ_EGT7RMK9\E\]E04*TSZ,J3L'I2#8YVEJ
M#7"F/0 SG/:&B;I!%V1 V0IP*G2!3#TJBBGD@9PQ]9A,3G'+:#D5?*=TY5S5
M9Y.X;SQ0J?>"# ]T@$A;TJ.OLY6@3"! 2MF(3!\=E@SW4"13K[:3P1%L>#K
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M58Q'!TGW)2@$K'^<ZS1RHZ;2\,)F\'<I_]$183]MFK$N D8#AE-2M86=R4>
M7U"8^M,<?!;R"7@00_L-@^+@6&"+CSW59"J0!#SA:E1M_>1BEC9$!I-0:U_5
M68TAIA+F*-"5(QAF6T$>=#P1L^QRXB /5/B\B;P9XR+"\ ZKMGGK(T;4F E'
M6V(X<91.@=ERC=K2+$X\@[5@ZY7TP"XQLG"V?R!A7=MVQYAE1MX*X?K$O<8
M52P=)G2SG<[45-8P3%;T0FN?"'_DHQ$]%8&PR#31'$3T)N&=<RM,3$AEG?E$
MQS_X*,Z6V;J7# ,O=9@ __%1SM"D3]A\M$HJ(1KZ,X;RE;SV"+<10F []E[
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M:?H<K9_N N9G.^%'^8^?Z;'J=2W%'7#!ONBYK?3JS;V)E_B2,F,]ABRU>TS
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MFFFGMYQ'=3U9]>K[;&0!<MV%0;H/*[;;[;R 5TTV'R-9%^ ,_'SQ$<U1Z$.
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MB/=#]O:F4C=UI+(Y</3/3&.*X#.H8 DX^,2^4JR F$Z0^3HL6FKS?6&V?>N
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MR[@)_,<TG:_<<5W06C2Q,32R,6BS*8>$8=>?NA8R"[V @B2"I8IO[V2KB/)
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M4#F3DIKA#E(-!0*>ZD8%"UN9J,^ZVV',-,(O YU@SY GBLYN7!X9UTD)4M#
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MMD'PCUC9^O3E%QCS]0I=1O_IF-5VRW;K*&^RS$B&U.PMP<SI%E#+OK+/)>5
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MY7'45X$9H)*:?Z#]3N:5LS5Y.FG6:"O^*/*!5=1H4N$DQ!#+>$_U3T\JDFM
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M\:/ R> $?K$@XH2>M$IDP//:M"!E= Q#M=!;\]& RG,:Q9R,N;M=].>-7O_
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M5KCC:L;RKV(K- 1%U=<GT78W$Q[O>>>L8JU?0*0KO%==;@N_*7M=82029X-
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M=G8G-N3J?7X RV&>!BFW*PK:YDE%#;A G:1UE</_:AI,)>*[/M[S\^ZTP.+
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MOUB3ZVA0WFF7EC3?JU,0H5I/'Y_GM$UQ3/::;#?OR1F&$=V:*O8I6PTT4YW
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M,WBB4H@;.3_!.M=LWH>4;Y-1^R&YS2GP8V'S_\;>>T8UN77MPMG;+B(6BH+
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M=E/Z^H7KBF5%QWWIJYJ7B]M.X#]0SEGT^5_/L5A\?B0/X_Q<*<^%?_E=P;Q
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MA(Z5()_%O!<]T5#3S66O$JW>;>]3VE_3:OT"#733/8;1VQ=OC-GWJ"%=F/>
MIMNCEJN#?-BB6*WC7Z@EKD9%X?'IJPFZ+GBSN?+N?[-'I3BP'S@;P=R_GP-#
M7$(P1.1!HW]Z%/?'.67^;!S'OFJHS?I-;1%\\0S/.A8!F>\!Z^LYL.ZO2' _
MI'#BT5^!OR#[H[]@#&# 9\B!'>-1Y<#^O(OEP/;>@P8M0WQX JRM\7)@+_H@
M>DNNP?^*[8@? PS5'\('--WLPL\)2'-@]8)XT(5GZ12<Q6J"UNN!W]+9>77!
MC[C$_$5P#:^3-.&THVO8[7WMT&A:4'_*S5VH=J':A6H7JEVH_G.AH@S3#PS^
M+3>%;)IZ!;9WYY<$:9ETDT_L[X'W?,+N+STNWMBR%DX*DMY6*;Q/ZN:Y)$,X
M$FD1JZ-J\UHL+E;GXH-87[%5?<G6K5H]]T8NK=$ LXB[PT3THN*E:];CW[^/
MK[G[U10]\+FUM&  ^6'5S[JBU&1ST6\=A\.O06L]?"P7Z#4HA4;5!<!'T-)"
M#PP@YC"6$$;B" Y,09'- S0HDXC;L$=XAO1'#FR*[\=K_'!-_];TSC'T>%;F
M\/9S^+=/J&D4@Q\%(K>K5RO6&O]#1@&POI@UR'7[[( M;>SZ.N+C$WP[GBJ%
M9Z$WO*?=9L- P7-W($>E.7!@+^,AIO3T_CBN\[8H])E;(WX=U@M0S2%)TW+^
M+SILUY"S2> AR->K,:CY.> >"4@ )DV!+<3"2CNQFX=U4>L]!Z:IVLV!';P
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M&JX]YC.1<0]+< !?8T!;% ^TXOS,GZ=9L-D.53^/A\$74)7%XG\- ?<!;&H
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MR1C$DG^#(3Z@Z>]=P)RPS [7L#N/?.Q:V;6R:V77RJZ572N[5O[3K0Q/@ T
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MT4$GENT^I9VN*F]=.X68R455.B[0T]D/.!B H2BVW#).B541/,)1THN<GIS
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M<$*+==[K!&]I:5&TTCKI:-G*@])W=P;23XVV6+2T1SC9:/R=:9[D.>QK?05
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M'#S2_3CQ6-@979I,%]'UN@%9M?2IFI(+I?FZP4>+HEDQ0\.[:2U*W*,'6?8
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M>KA'^JB(Z+!+G%?2C-!UM@*_D(>C")T0U09?S!9NIO7%;&J="G5%,?[,OM9
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M%JX/4$:Z%^O[^O6Q^!27V2.J]U"S\-6S##MC(ZL6,)I!FK7N@I\@VP>]Q9[
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MHBC6?M1N6'4_M8<=RR RKV*YKZG(G\5[L/!4Q)R,H^HO]44'(#TV4;&!9EJ
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M=08)%%N/_=#/T&3*F;_,YYM8RG ]0,8X0F)W\T(ZM"3)BF>3VLY43Q13!M-
M.0K(#EVT%^V)T(?[::R(^W4@M4Z/P/42,1LOLLAVCS6QQ"+P64*+]'AW9['
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MB%0>@K#D(\?"QH=Y/1"IUPS&JSW!862S32G\9 QUYB/[][BI$W:]UB5/3T5
MMPQ$+B)8T.>INZK.5>:=XF.KYHF95&.W="%HGR'5[-9HD-H3<PV@U"@<K+#\
M<WB$G%M^##V=47T0%6^N]%XOX,.>E$F10K"L,< );+<NH/:[.T6Z'5/]!:N
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MIEMCBW+G;VT>Z6(3^C]3GYQ 3RA(@X!.)D4]&A,:I2[-7BX\[5:YH+J6=K<
MEC;NQ%N3<WMV-\+[T[,"S0,F*PU'H3DX!C_[VRA\VICI^YFK#G6SYIQ0OI8L
MR&-5IQ)5-N^=.9/GT-A$JF@G7+'WCO*&8\Z[%97N2I5@3TB 3:?RG+.E 6J/
MM0H#H[D#%=HP2?JN7"<2O_]AIP;&''8 76SQX$ 4#(3M1O(?=17KA!I$?]+_
M/$8Q+)URJ I43E1)LX?<P0:@6,PK(K+UX06LNE"=E\Y%=6?O0>>SZ8GT?C (
M,.K>GLG<L,D\G&# 6WW*AF@ BRC !G7VXI6*1=P[W+4E'1F$N0U9D&E53(@2
MOI9<F!)U-A&7MUK!!K/F!4N\>Z8L)9(Y+,U:+N%]\9GFH]-(CYS'5 8%R2^P
M:7W2'UCF91N*(ADFX_Z*6PGZ/H;2\(*SW(L,DRV=1#B6M[>G]Z2GIX_/A.>$
M#PT>' P__&"L.3]_N,94,#;&>WEM'T6^U.;PA5-VBB%5:2__D?V&B[%61<H4
MG,M[R82[][QML;*H"#Z$T+&]WT:9Z_BWF:LXTS5(RWN=HN;$;4IUH7UX64B[
M4Y)R<^G2V_<FB+>NSQ:Z=%]&SJP%EL^-W"/<3=/E,<6'(B2"<E!4#+DS"9;'
MF %19S/Y2X*RYKC:,Q@S1A3\-(] "W5;_G=X$::,L2'T7FH.-7=\4J?VQOR,
M!%IYBVMAVWXE,;/M<:^%-L@O[#__?A$:\D$BY;QS%I3*;RU_N6QA*^_A\0R7
MUN;1;M>>]>Y\3)@&NB84[?^5MN*TP\BK*W$^](WH,L&2SRA?GJHIA 4DS$@6
M=MV5FJ@6'^R:E<PMH(S;VY]NLN+1W_89!TGJ5!=>)/&:6_DJ;DUD4FO;*,45
MIY(J])V=O"34*K57*L:_7+JX^&\# M?WU!^U[]W6O8;X0)X99RR)_VVVOQN?
M):DIRVO_ #Y<$(TN+73F=>9R_HV,0QUEH9']YK(IJ1AKDW;?O=Y\Y:?(JJ%R
MA+N'BFFS]W1I?KU.HKWPZY??=J5TP1E4M4YK;->O$'@Y?[PW6ZDE/4%/>)>?
MDB(\61:S%(=BT^5LZI#GOXJ5>2G)QG&7-B]O&$I_=5N$[TO.JYR$39_/67-I
M$X^/DV6O;N]*B6 4=7:H[IOI([SZQ,B3?[9I/:)<+@%\;'U:.X<?&->#%O+;
MG(L-PDRU\'_JZY]4<&JPG#"S[IUZN#SO97."(/O7X_+% -T=KW$<:J+O_,V5
M S8;KD7/IIN^A T[V6!F9/G[3T/ZYO)..[D,_ED-@LH<M(F#OR^KCLT[6U3'
MM1]@9H[\."]M\F[;?!V:!@%W_HR1:VEN!T;Y]6RM;AF?7CM2*U#&/]TU UI9
MS;''39LU%_;BWN>>6-+LMCPP;"3]W%M3<Z2*!P.T^U<.<B$3'H*3HG)KB-"B
MH87*'Z?A4YIF ">4\:[4BH^N>IS':"15=H$U)<#]D6IXS](BO/9L1SS*2(1S
M=#+UOY_C\[V!V@WF0<' V?'E8*YDL,_25Y3X36^*]XJ:$BR%,3RMI 1#C#LP
MS^=8:7''RCC@$VA:-RYFW%A&K5[%IC:$R%[;\^X;VLB.N;](?2A;\+,;(J1M
MDY1SY8ND,K>;^NX&NQI;44?9JN<S%F^^)+[,;7_!/O1GAB8XYMM;9_<,5=><
MK0N7%I?43K1+.V3P(>[;7[S_QC41;/.D;PT_RH SB:YD^Y&,\5.1)0?Z<;?<
MGITT'%Z3_?$^IL$LHP[7WPUNUEINXE1_GNRDT[ D<+?O_04S.\O!MIGK_*B1
MP38UG^<>VD;JE-6+K_[U6$2(4;M2LP0J#T5?WMJY(C0:LXS:.88QXT'?P%AF
M-)=IQ'9PDE#G1,(1P(<?-.3NF(I1J$*''9_EI3PTF8\XC;;K-5<N+%U QFD/
M6][-"7%;V)Y_1%6ASC[$JN]*A1DF0EH$#W=4D+'!O7'92>/?@'D;8(@7T-?,
M&FHNY$6[#%NJ5R'&IDUQ3)^&%X",:P.%UY=7)A.5^WLC/["S)+2DKZ"M:"Z1
M'_OGV_-_OY,[??ROO@&ZC'.4+OO"C23SIQD*N3DOSEU:']!:GM'-J%AUN)$3
MPD>$[_<OF'M]O<5D\!=BP"*S[''_+&*DVM:-J+GON"O1P<@UH[RC)F:$V#^3
M@;A"A*S]R/0JMG[]0U?SLUE:7.I#;!#XX8PB-@2<BITTG$4]G@:-4@(X,A*R
MN? 22'%M8=X%!PV3U ZNUNC-CT6U?]<WSC3<@;HR(M'U]7<*O<:,,\]9##F,
MK\\+]"1<<U4\ &E!]>]*R8K?PZ3%QQ,8V^!,C%,Y&G^[>2SA%\"07?F<K6XM
MJ2+-Z?8J^VJ$M0I Y8B\F2OR+!DUZ>QKKY-#G5??CL74YF,O8P;%<E!@0(L&
M <YF/Z$H!(<3^N/YWSAT&C3YHIU)[R?OER$LZ[(8?O"M]F%N$^[B1 &[KJ@,
MT3ASIBU8X-X>%7 Q?>6:D^P/;Y;]%4*U7%_1/U0$*#M:>3ONH] 4<&+#DDU!
M,:@'6UPOH(E#M+31G$[722)]%M,9"0I3$\B+SW/=6E)ZS.\IO[T7I?^;&6-V
MG7*F\418<.HMJ]K+[XM5F>%)NU)1SB]>N&Y1XUTJ"\EEWZR-+M O\#@U36>Z
M'')*W(O,7[]'.$20E]RKCPV0!^^9*#)]+K=4VX,_!2JZP(SC__Z_MXD"S)W[
M_VTF^ ?^XU[N"WS35A]HC_B#ABZ_1N,(;RNC#B56!@+8E>WL21_04?*NE" ^
M:6@\S5H?,')_Y/'[/=G1H1J<=E*HP7)PXF+4Z^\09_$>S!^\K140SXT-ZT<=
M^-JIP]M*LC8$%&BP(Y@+Y>A)YP8&YA:<O:8,?[#]/BVJ"')]U*3#5*:PR'25
MM>*,KT$\,+IB:<2"W>[2N]_R7:*YNFX(@VO%8S#>K366\\ROG;[.NU(]6-)U
M[$^4XU;OY7 +L_K7[('3[/$FU=-(O[#T&$@RF]K2SO1O;1\-75/SB+=$Q#X6
M/!(9=:H#1DY .&]7Z@T59!R8%)G]$V!!LS[,R)_^Q/JU#96TX:@NUWN'#%_%
ML8X@ ^2SINK"#NLT&UGV8OJV];CZW5\^GJB[X;8]?:Z 7/?%E%/K7/CLIG?C
MUJ(79+5S&X.5F_=<GC&BGW2]*2YYV!-WXERFR?%.Q&B9M YA+6$UV\A7W:;Z
MPW)(:=IWYO(>JJH$OUC P&XY:4=*& YIVNJME\8D\/%9H4(P>U?JV&(TY)!0
M?=;7@\:RH:8&CE";(I&#$B*/<>+)?M[^]]6KEM%52"-IRM$NK=^#6>)[U\G=
MRL.)"0G4Y?^W\I5.^!?6O+5RA$MGP3CCO2!6M V?WG,,HX4B?NW<RV^AJ5MT
MM=VB/A*J2?[NYX57(:JHU 0Y=)-'0_(<C3:VG5^FU-<1FXN,9E5\ED'*,KRO
M? VL-MBFB9E1^>JNN6EE"=$>N$,ZD[<T/$R%#%^HUN68[FZ[G2/^TQ?&$W-[
M2,2^%+U/K+GAP2*W--B@CLE+B%?"7@QL6 +[1.JA3G,T\E<^)-GR O_1&PD@
M<]FA*GWA7^71I9/=8B.&/N8*NW6S&B4#I/1Z:U;,E97"/B)LWS-AU)SW%O^N
MU&<VERB-%E'G84+%O6*9RSOG)'5R27P.;3>[UD<_B+G/1V4(_7EB)L>W'';(
M4FNV%N7$M+Q0)2'F?LK,/T91PD"^VAM$R_AV_>/-S33F]6RW\UUWSW;$78D*
M:@$3=J5 %*4RC E/)='Z!!"Q N9EH_=V:ZCRW!\)J(VB^AVU[C:3_*0*4?6R
M<KXR)&1']K%&],?E>[68H9E@4DO*'SKB,#S/#YQNAE>#S!*Q),V.C#^GO83F
M5%Y*%TS.!YX#0Z@H0!*%%I7>2-/WC0KM+KG]YMFI94A]<P;K@'I9D^=:_>G6
M41/PM5.#?WZO#/#.\QSRAS.JO8=STQU9MHJE7ZI9T?$PW?9/ZY<(E_O^B+'6
MZ#CNAEX<_>K_G;!/^W*<SDB]B:Q2(>%M;>F\^U=L"7VY:<<&@ K(P$^\<4$&
M3RO%,I -D<;<9!A&K<F%8.7U*6:!G)WX<^.W1XU]?&K]F-U^6OS\1Z&B&AQ,
MT/%8N?-49VOZ]<Y&)U=U,W<5UJV"#TH<?%-P=R'X(:R)_F8F<3L*]]%;> ZP
MYWUC RTNH10H&WH([JW_>>NBUV!X:'A\=$RPU71)C/H0?1)%>-V.K"XH(N2R
MEFBURR(R["ZN8D5K.3<:@3?Z[+2):6Y?C+=6FXSW2QE3S3_]D2%8T51<NF_'
M(BN5N^&-[$/R']HHN@?U?R[XW_'X'X@'(238XQ^>6G^!9;$A]#WHB#X_!5YT
MK].I+3_>7 I_SR3M@9]A"Z,V:LC-AMPVNF*IR<$>#S&=80U42'[V\0J2H[OT
M-VEPZ<SH26:4?WR%5T*X^!.$=PTZ<4T@!%9^[!0+ O)V?O^J<8'"HZ9@3K79
MT>J/2SBY4">X' C2_7O9)@O/J7]<?'%4?^YUSOKB*B +KZV@O,:A0VM97GL3
MRH6RP!4V=&+K!^E]F+ OWA8EC0$#,1)*G3RMUCY6Z)3K.Q*)WQ]BJKJOLI9S
M<"/>R(:Q*KQ6W7_'Q"I!3/N=J5^_F=X^^;%&WQVK:64)%7B_8;NK3%I&,7O?
M1M]D? GMPP'>;O"S9!)JA/\G=A)EU&^)&BW+J]#\*\G:PQM:?,BH6G/-\+X1
MIKYF1> R@6[JG5;DJ223J:KHI1ZQ!@_VB&)$N+VD<88?G&Y2:T8K5N6)<X.2
M'3O<?,:CT@NM#.V9M0'['0N7=JKC0N15\F^YX/CTB4(!'K#9\16:%'!!;X8"
M;O#-:/88+P[JX%<_/0JC+M('JN3$MABN0+#Z4@B+ULXD'%C0Z+<P%K$4&Y2)
MC3F+#X^1>\&ZN1U6@A7^R'1[CR=1,RCP'>17:E-6(=<W")*,W9^@B#X;CWRC
M'/O9D+V0H 4P0CWZHL5GQXS3]ZH5!4%_7IR6>M70S/^I#>_4T*!:G*F41WVR
M6D$5MU)G\R 'P;-8H0)>8 '$A!/./JWR$1[YD=Q7>\&S?0*=PD'<QCCQ3ZB<
MH4GY?!G'P*J*KIIXG4X#/MDH#7T.:8G8N-M8=6>]YJQYA8>>K7EX)/%,V:'(
M$UIF.F8Q-U\4-$[FGW=#,!X$GY6V(OX]/Y'L99OA_WA0Q]ED::#U9FV:@+10
M9:-K6W3)NPW^[7UYR7&M?4,JV_ML%#V>Q&O_;S6)_9^8=]=/G.,F_(*Y#,3Q
M@[O-J;0?5KX_\U ]]!^N8'?$TSR['I#,UV(C7E:+*(\X@8R%":C)%+L 8@BK
M0!#65+G ZDB9U*O<T2#X!V)17Z:\N_3B+YDOR:9W<P)5M-E\8]VWYP8&7*M5
MLW0Z%!"F'HQE[KOSC+[9"Q\O#5SUI&AHR1X?,#OFT'&<X9KC358Q9GF32)#^
MRK1=*8]=*2#:3JC %6= !:82MN /:.Y*O;,"\U:S :U^T3'\\@^C<!K/<5?J
M[]@=ZB939E?J5\]LX7'H]IK("B(AE4]"LW:E2HH5))-Q;%<* EM8$-]06L-+
M00+K6;J"*GX4X>&N5'#V(S]K"8E3JQ[TN3S>'2L[^CZ]-+YQD?'68DT9>#GK
M@_;HBCWC82:PC^. 59#>9Y,(^B-'%U4S:R[JI8AL(JD?I06@80.--1M1JH2"
M99Y:_-U[VK'(4( "+A,^6;53[EN"3 B/3CTM@9]*LTW]N\S2I=7UW_+XRVSZ
M80#5M6V"3[$\S18I=$]K,#N'1?A_@ B'5\/&2#!YBHZ-%E@97F\A-Y!W;FV.
M#GWI?[HG9CQ:X9-]&[S\05^+:O_3&NO]?L,KYT8]SL"BC]GAO#?F4^)JLS+,
MDIL$J9QOO\>=83[[\^.#17MX),$=<?Y!1_G"2'/Q4B<^Y<>A#!1PND#R9;;8
M6JD5:.$CN(Y\[ J<*_II(Q[KPJC[@\*K[\8?F+G-@@W-@@]<7]B#V.X0]2;C
M([B08_9ARG-S#-F]-%VY)'@58MI -%F:!M3X&71:''%32"TL\L[V( 4HE?L?
M6#EF U?L\+D?2F4T"JDR^?XZ=UY%CIY3S$^/<89ZC1#UYUU17O;?M:MZ;76!
MH[M2CZJP7W[YD0VU/-0)QBZNB$JJZ9*+G !]MW>BBPI;>B$B2^ HM4U2JOC&
M[.46_GB/:8(!,+5C(OP)Z.=T6-BV\.;P'&P:7MI:77B5+YN=4FM(5G=F7FD:
MH_BRAV"NY.':*'V8^XC^QFL#USZU%3>7]JQ]Q8(Y>Z3P@N@I-1"4F*!I;0P8
M[5Q(H$,.".^RHL:RIO6  )X/F_H7Q2&R<#[1<45OJ5.)-Y;[4MU\W=''RZ#&
M:7RB3H,EC=,*"=#=0#ZIJBG8,5P<C2>,!J8(*+S/<]%;K0FZR.9=*4(__?&%
MBQR;XOC[B>4-'WIW0,%NK/O]!9_F@)BBXO;0]6^&@+;*LM<L;'))X,O?E5I>
MX_JTDGR&_)3X(!I=Y5>F$7":DY $C]^5.A"=%MR4.AH5>I:UN!X/Z8G52S8;
MI9@0D<JF9CAWHE5R@X0&_3V_XK9S!A,G2A?K+N*EL2&0/0@-&?XM/*MN(Z[/
MRP!CQH6"KA%GX.Z=ACSGUB\VJ'H@X.9KYFI"?]S1:Q$R=IK%Q$ "XL&6N_*N
MU%+H;<,>:-+,8;$A$ ;;+_0"HF=A:1KRQ6R#>5Y]#_3 5PU3WJ=Q%UIXJ/J[
M-G!JI AZ/8=C$==>=328##^J5O@D+]'I5(N&(W[L;<R" W[L/%GS_<*W^\XO
M6/;O7^!RMG)N?T ,E3/3Y^YO7"IXS/N^0_!3ZB1F58""JN_'_>Y>7AA.\#[D
M$OT(E5,.,[Y97G&\[A;XFS9@N"NU[YF$,#\7T\4'&6)US$51#06)G!7)]0TZ
M?MC 'P=0;'HOW-A)ZWKJRL80V';46A<PZFN3*&EX<T:^^8.GA$7E[=!D/"J0
MP/*F!?H'[J,.@DG!*_$[U\5CVW.Y'$,6A O)3-!#F,NF+;!.))SJ3-0_;=L,
M,LZ*K ?!35FHE(V=PI3B:S'Q\$J;>(PEF=):Y/_83IS2-B^4AXD/7N#(?#?1
MW96:4/B]Y75NPM<-2#H$;&ETQVS(>'Z003'CN]DS.+1WB\6W<#%_UI@.-$]/
M'RC;PB>">0YT0"ME>:'&&TAGFRT_YY7]SM<H?M(6_$3H2$# CE*NE;=-UA);
MAS=G4MOP&2:^I[8= T/"3&1-UR47?GEUC,-QB8N>CUM*77=PS<-8>USB>(<.
M^?.>!>I8?:_NCB &CZZW?*;G8H[TD-F'#0PM*_048US+^3')I^0S$C2NFWC?
M7(AKOMTPG^8^7/;]#PE"XWZ8I6A ^#.]]#WB:3 8HQ[-KG\T(UOQJ'?FITBP
M(CQ_,((?T'_?QU<K61@/KU@\TB&J?Y0 _F15GV%Y@6.$\A>U<BU0AQ;]5#M'
MC#O4O&=$G>CV[@15_EJ2)706IAJ"BTZEJ$O*$NFGP ].WDS_@\*0B(GZ(PLM
MYM;MI8C\G+WJ8T75\.@"=Y4QQI[<R=N."HDUR)+23D>C=_SCQ?J<ERS\.9<R
M9UE6QJG)--?AU@@S'>>!MU";8U5]D'_^>'Y6Y<P;/5F9T?EGA">UKKJ%1]S#
M79Y5J <<TZXXX$9Y=H<<D?OBB_@/".\F'CBSU@\"M+"]Z@\VC66Q_9 F@XZ7
M]M$\+M<YKW313%7N>2#1KVVA<S^0'G_(EX7VZ/<.^_*J)=V-DL;L<_\@BZ0U
M7N=Z,B(-G^]*!:X!VOB5^IUC'V="=J6:8"LR7%B*QHF1>L*H@5#C X#M\]L7
MZKWXT6MJ21Y0Z-\V3*. X373/G8HV=5Z>.D5HI]FUG-!(=&Y@* &V[PS;JP.
MZMEV$CSD^*K9\^62B#1!O*/-N/&2E8_]R"]R.0<,24M F-XJ^ZAM3DRT_+^%
MPVIA7WY.@ FO2I!R$MNE:WUV*0>=TH-O&/]K8_*[=S 2F])Y%GC.R[VV/_KH
MI6P:^! F?)8J>_7EFP.NZII'IXS4VWK5+N(KN_E!&I7J_M\P:CT3FCI,@FV-
M[OV5<\]T'>3=&"M]SOKM??+>8(6L6;U;)_YHB-D?< )L_*+$N?:VS4'V]TYM
M1@^;ZUI>PKCP[+1VW_"S.1%7^ 42LL8:%/Q'5$?Q17'Q+#LN**-3'YW<OV,3
M^8"ON7'AZ_2)%(]VGREG>G>"$J-V8TT&;0?M:,V2QCOSWF=6>%YD3?3H]Y@^
M:*"))!CKHF)Y=G0P G_4\N1.= *S6&[<4F4V^^?XPAYJ4_U#RVNH'Z>-BDWY
MZ?%9:Q+2HQSE:S G$[>$2FE3SVA"^,EDA2.U,LFM&]E')RG%<HP2Z#&L VRO
MI.QSP#P))9V0S)Q./<!C1Q-CU, W**X6%=2A!RA._ "WX?FL[U$'R.I'USCO
MJ=R82-\@F6=[)F\S<'3/9K*^_[Z-!W*"H>T+GD$8ET,?O>XTOC-^10J6=G;+
M2;IL6P@0&17V;Q6_US$+++9\OF3\,5+@[OAF\SSP=<YK[.*Q99O++U]5'+Q5
M?7 LW5D).5Y_[&;UOXQPPC+COLO]%Z4O-#_CP0ER0)P@"5#G/YJU2UL-NV=Y
MF9_-)F2*51';19D=F>\KRB: <1HN.V7F-N/N2.UJ#:0YTI3JZV.;O\@*J=UT
MU'5,?-RC*Y1(( 1L(H6SM1S';^G#_M1IBKZ[0_.[P,O;2)SV8I]VY'ND:!5'
M?: $L],_QX1&H62!Y+&]$?YQ<,ON@SEK#E3EMKY"HB<+6Z>.3NF'3E0+L*)*
MH4DH&\22F9VGT3,TP,RYUZT,/6$,.][0#_\KI?WWTC8J;XP0'<:J3R:K_7TR
M:YKK\L$P<FEAI6"9\<GR\##>XA1=\YESC9;]&,TC/"+CCS)7A4S&"\/5MWQ,
MX^,7J!"R]CK9,#CMTMT35YP?+XQ[W@LZ[FP\?ZG5E>@<:N;P,GTNL[RUQ/6<
MLQGNSX*+X;M2%V8FLL6''N[$B/LUY O8DE&[(!'8^#<)^W+6Q6*P] R ?5,,
MX;TOC'D)E1VKB"CYBC]*T>7*6M#69Z9H@O:FDLF%7:F0]N+UQ1O,F1G[\$6L
MG'B?I/Q^H\[6=UX$LOE(/SZH!Y1Q :,%1'/U43U8Y<ZSL,656:ALURQ==AI=
M#04\V#JS3?$RSGRMM,V#*_[#F+VS*Z9[6J9/ON8_J"=XP<&3L<O83\Z2[O&S
MA@2V3@NJ[4L/\(W*2?J?<XU7Y A\.VYE2[ETW-^K;PDIF_@TE>W#?Z;>O>F#
MWAAYJ)^1;Z\Z,:@'VBZ:I?\,&+'[DS9@>X66O.QD2^G9>MF)3 BM4YX7]+ "
M#>O>EOTKQSXI*YTMDF/TVS.6>QB#VLT-I,0C9QHO.;WOV;E4?.Y-U_MFWP)M
M[KD%2Z=88YWW[X=:SETDNE;'5CN'V[.@N$_U<[S;,L]';M#FC_<0"H:;*AYU
M<R[<(D[YVFAS3CKD':A5BUQX[^2GT\5R%$97BQ )4L(K/+N5@AVP\#Q?3(#O
M2AT$)T)"LA_&:O:G&X?:A9:WY!=?YJ7!IR_QWM>*LL:>^OCY^$XM>>^O%F7K
MF?)]N^Y'MC_<,SETNUYH428^**%+MEH[:EC.>:&$2LYI=!8 6-X\>ZT;=6 !
M#!(K 0I=U,/"??_$4W>DN\ @H6$IVJC;7$M01XBK7<1/:*CROF05EL&I+._W
M%56+6[M2 8TI*[@BT8JH_WE4E&5CS//5F&NFA&3!3=T;U<G$R[;W7WA_(1[[
MICD85$%W+H0VQD-124" TG]N]<5AW,$*UX[;OM!R5IS#DRIT[IO1T6_EE)"V
M]HMK&IF30HDFF7TIX>$.H P(SWDM37QZ]!Y)']6+;:2F4J#:@#T_[-+DC6;F
M,IE(=IP"L<=[=#_JSZ8[ 4FE<%9\;\W64>\)>+%A<\.NU..4:UD?/\&^>FL-
M[DHU;@D5H8)Q4<8]% D[42](XM?3LN40'LS%@@10" ;"-=S37!MU3V]U\PGF
M(%>DTNL'(HVA],M:DK<\2,._C-0?[;^^XS1"<&1FUF^3$+%!A;7PMN3,F@6!
M>?/3:L^I!5Q='I%U!5NY&!LJ/.H] ]].RARYSYK^.,T:U"=/5;QSO1+^<\XU
M8Y1:(_Y=?1J,9U,/:,[T&<K/H,OZ8 UKM':G !><3.$8$%^#WIH5%YGT4F11
M\[M2_L+3_.B'&Y?F6CUB-H^?8C[==)PSSRH/VP1MX#9>4;RN5FI<PDSNYY^[
MX/*,?>A6@%??@$/%H??RKHSUG$)G[RH;"T,U]3>>+SU;[ZX?[KWSO?S+H5OG
M/$HLS?,;,_7<C]^L8L>?/NZ64::FXQSJNRN%QZZ ):P1(NJ@(E&';Z.UN%LK
M.ER8*G!Q?7O2I9.7A2< CF\2CHV$A>K+YKT>V0"G^*GS\O.(/C9'+J:K+3FF
M*W<&C> FR,IF=L/8V;_QO.O0##S/A9Z!<T\J@7O/)R?L00??)L,RP:K*8\=(
M>!GXA:NXI)D4R\O15:>]EF#RF]6F+4W#QHX6\2X;!:-ZE&L<-6V,Q>%O Z(9
M#$2"]3.25J(KZ=S-K/X42$!V2EO>5&U76QKXB>I6#S3=W.TM)J/V?1+?K2_A
MXK"A_J[4,+>W: YO]<^4]2]@1.LWJC/)2OH:KR\WX!\TTI:!L2J!_T>$=QJ.
MM#*GVS,B 1E*LHRZ>;=:G,7OUW,LBWTI%RJW'DRVIIX]G7Y^Y-5ZR;/9A)K/
MN(SY0\8E]J0"RQ"7B,>?"VA#9W+M!YRTE%]A]F76IR?K0MZ-7;CJ<I_@7'?Z
MB"OE[BJ1KI!Z<_Y0Z(+F,0=G_:JW1Q$.A,<8+7;]3V@WFL8^GE\J 1W<-2W#
M$Z2S(0<!E%VSHY463:S*FRL,+?OJ?;8 ?NP(:X'E7!",] \(/79P'YGB\LNA
M4FHZ!#!L$1ZA<7P+>J''Q9_PC3,/493P6?R3:#H'G(67P)H]N&+7ZW>(_^S5
M<8H=W[W_&L-U?<F/UY)>5_::KY*-NG=O;(>6<+IU% .MMHLH66S+)_RS*Q5*
M\G@7V%I\6J]7[Y9RY><72+?",).2LQ7: XLC=<_*3&K^(%-NEQFVO+]_^VS4
M0[3>U<@1[V*-6N-GO,U3+P*T]4]QWW[2=-II?-3X)2>C3/P;]2<(W# ;UCB?
M267?%=.QRI9(7FX?*.!L05PUVL(3#W4*ML_W7 7;\97SIQ]D<WR/376%8HPS
ML= 1TLB(OA[Y9[+/I*X7>VN&%2$^%+SS0/Q1#$[O!I-@*^I<0PVT*>25\;3,
M*R9%:Q:T;]$-'MV$, ^=:V6#DCO5>=ADX94J3YB3H-#)[C9C4V8GYD[3A=O:
MKQHDVNUK+7]2?-!1,DB61>6;/D58SMIR(:_=G2_[C690P8$>G$3"9"SMJYWV
M#RMNCS])4%S2.#1&+DS*NE0[U$>,CS::H,GFMGM?4]3Y_%_!G:J2\M3I!"_E
M6Y_\@ V8D9Z96=@:BWVL+#;CM_124W$G<C]:#/P</7U,,@BE>Q-41Y9]R_UC
M*A'>3M.%5?_\OBGC6,7)=%N&C-44W\\Z5>=SBS-;H \-2")JFS1FG7++O)D[
M467HG#*/7]229SSF/3/"R?SDZB<RK D@7BV-O0P]>,BM3,=D>"1ZXE_Q2>KL
MLQ^]%)L^PW.!I+-DO\P]XH /B@<3%/BR+V94$@R&@J,J%[:S\)537I^6P'()
M)Y943",\D9"C)H4'?QQ1L<F^T<2S*BY!<6!')]NLTTN!=)$!Y30;"D(K=!<?
MXT$>D_Z-A!U"F]%8ADF61F4^ Y:OX-8:O-7"T/*0MC^.3CF&1^F9JH86D6ON
MWZ8;KS[5==++47Y02$LXSIMY%*ENV#TMSQ.GLJ&'0QX\7=C62K$TJ_ ,B97+
M]I?#5.L;_LY868D463/T\ 8LQO0Q-RW$8=QD??Y[(]Q$1\C;<,%-'5^7?RJ&
M!H?"X._=;S/S\J9RTAPNP!0KMBPM:*_#P#1G>7Q+KT<X^H5CMA9$_[L.,^G+
M@(-*KN/SMZYAKMC#=UQLE+CXW_Z_R SYKYR+_ZD)&2QL_'^:7!4Y2YTYCQ<H
M_ BB>/.Y?U?J-1>[K*"P*U49A-6@\FPAWXW!V5C!?>N?=J5&_3DX$:3^'0@X
M#1;B0/W4G<M@J5VIQ5=\IP3\^+?Z;/QZ^#?PCM0@9/,X^$M]%FS=^\:N5,-^
MCUVIBKM7T[3K^T#]_X\[LZD.D"!HLE:W]3&4TN)8GSZV]SQ-3^?BQ4'_4FPM
M*3U@ME]3\*7]A:+'A"#R3-*I3GO@(&^X\Q2:\6FZ>X@]]',_$6G@<>&3(H8%
M+TF]X;T>J!&B]I95WE/RL\=BZ2G;]!.(JB<OGSPI<3GRZZW_<@:3.O?7#U\P
MW6V5+F>0@(P(#[,N6/UJ_O?M8J.LW-K@P^ZF.K6WM%O]JP9\S7-ZK#0=],0#
MVP8 :H6O)+09>K55EI2'D9:]6A-)3(4S^N>>.B%/6&I:RJG&$KS1?3E%A^ZK
MVRAZ;#P7=?XO?;C_)Y#J_P12_9] JO_??_Y7!%(IB;%@WGV/E2XB!BVJ+1$5
M8#3K:1&\;,&=9%U9[[[N*_K-#?Q^#W(.3'6QH 4<U!*CR<O*BZI$RXT[1U.R
M[49):RKT?1_C[R\RF#M;HV0?69##R&:'.[9Q 6>-CWNY:&9]DRG"T:#-^:OK
MV+.LRW5GUT/9.=!S!RIP3NVG,C^]Q*]G ![E2$@+:N7;;+Q1OP<^8 R+1+':
M?\?W;Q?C40C\Q#HF!*B6X"9S$ZFKK3D<ZK-C#I)';">1DU[@[A0N+\#_T"]B
MVVRO'J&YY6LI9;TL.+L_B<.BZBT2I^$^'JHW%_5-YUDK8#SP,*/VA,9>75KS
MRZ"_"XZ7K]"='Y67.3@O#A?%C@3694^0XWPA*XYB64F[2PP#H@4AHL(-"*N)
M TXQ$W_ DH)30J-JSX4&O1]=LSZ!T>C,1](/A;! >$)_U8)Y2O;&@IZE+V<A
M:3D=>U>LP,!-,YR.\F:PMB9VUYG&4RI.S(U0->A_NP(SKS-(M1<9_Y<K<-98
M/Y2Y'!KPWZ[ VK6U^OJE/UR!LXX%_#Y\TZ_^17_ .2[_5L.MPOO5IHRP17GO
MJR_B;(^0/.)\IYIG/GYY'G^X?F_R&S;GF;9;1N"9FL41Q"822ED<>HLJI9YS
MT#GC\1Y&7EO>*4T8Q39)]Z,F9OQ(PW5W@"8>LT>LS @>GS53#4KE?*\YT\X#
MIY^Q(7?D6.#WHUE,FEB?&5;2U%8\Z#H<:JB_,H<[P$65A=3%1FDYE)_K>OW^
M!=?UJ$_?GSG/O+\YG8T:K3@T\M*%J'0N"OX^[_>.BA]98;#<=/@V?C!;>+1=
M?$"=/RD B:HQ2CO7,;^*RJU5ETP3%#]8HDH1,R#*WED15M(G'W<S>Z>/CU$L
M]A>9I0EO8"P,DU<V:FW7?N/#1XQ%TBX=':W#:K10I4Y\U13BELC.!:8MGL*K
M4-E7$_K 9,.^ V3=S--N// ;;"JK/[F^]NQH:!B7GXN&NC7P?E,>9YVYCX@-
M[%U+7]UPU(Y"!H $UPMDB$Y1P2BD_B>KUR_\#$U[&<6G7(IBB^D@.>\_$YL*
M/V?^4V T5SCFD>ND.W&&\DD.]M>_YY6([)/G/!$)DRH>Q36+9MJ,;!+>Q-[Z
MUH"#]7+,'=S]+^VYV+D(?@ML%!N:#6C;]83":$OAQ&DQ$T;.)_O/3EKH\HG7
M(W>E4K&*GX<QH-*%M@+![?W?]2(SW6P9QH-CP]RX)Z$K<_&7+,@=6$)]'RP3
MM@<2 'DHP?61A', X1H XZ6PLU-J2-5FE!?SRRSG0H'OWFYK%::W?92A/)"\
M/=9E+-I+VT;X(5CEPT]FTUP;_Z7.'93H"0% YE7/@E92>&[<_K[THB#(3T*E
M\2A8VOV%SA.O6D<PUS@H1> TS7NL@[?3;6[L$O,@?\M:B[^)3R;!-]7O?H,.
M&]=:KVZYCJR*Z8C052N)\-&1:',YX,=,VV<.3%0!\SW-JIW/>9-O!+&;]&[Z
M(VMUY$K 52!P-OVFBG=GQTMR;=O96D[<DIIC_+7^8HL.$MFK<VA?!2G6+-FX
M2,V.F; K93JP&.19L_^XF=U/B;06]Q;W.>Z!84*\NK.#3JLQU_GB7(%1^&/J
MV7\OI64Y/AP*K[53P,UYON[+4E]1<C:JMK0)5AI2=:X\:W]5WX'$'M2X=7PD
MI0';=8,Z6XL_\6.+:(+Y, 54]I55_Y?X)W1<3Y,AS3"Q[<2X>58]9^K!VHVV
M5Q\L?;D;3%84WS![-7)R,-[089C$CRA%WY[R^P@@+ I7/+S&R/2O,N(# Y*[
MJO"A4W&A\\"/?-Q0^J'F"OX+&+SX/.#%,_+.!-L"7C^;?G,J1^Y**40^+\NQ
M@G$LZ%:5#96 ^Y(R%F2@=T]SE-/.?_J:*3SY77(O]S.!; &*L2N%4NN0YH*2
M(CN@G)E4H4*<RO(X9RHT  _EU6>0GICHV_4*S.,[1I<?N'?J\@T?*[,M(36[
M4L%3B^X-</.Z[(II3T?.0?\1[(=\2L(O[[3R^RX;[$GO8H]JOXVZNV+^@1A7
M96\=YJ&IZ5Z6P"@?*2MWF]_6./H6/N^&/QKT,>GONU,QW44'JVFRKMF&>B][
M*U0N]79[QE[(;JQPOH'O,%/ZO31-EP-B9K/CQ#(_# 1^D73.1T*8B+0K%0+Y
M"!&X\E5ZO@!>;%D/6QX"K3"K]1?9#FCB7B[A92?N2K'-6L8H-FPU=1A'?RQY
M^C*5OS]3*26Y?D-=P8\W5H$L!W*=1MGMGH7=U" Z8-;^7PEH:@D,:HM!.228
M*EE!IE,#F.=@GUB#O7TG9H3^XQO0O6A8+V[SLTKIA9A_@*/O[/]9:"EP7?10
MS6J(*IFYW2N;G)UPFM(B_B[4X>V\\?LYMT<!#>[2D.?=F]8?WT0I 2\EJA%I
MR]LH/LNW[2#.+,7.IUK^NFV35X@T%Y-K%MN*ZZN1JJFM(U'J4!<JE=**6UWG
M>$%T(;,4V#&%V2WAT35!3K$VR]>#8XMG8Q]MF\><\C03_LJW+:A<8OA:[%=>
M0LU^Q$##D:;]6JYI?5/7G2Z]3EGZ,^:+QZ9EO7[W<->Y)IK_(N=4V;G-0*U#
M$34KQ[J-<N9RG^5YV6 NNE\'#O<G:VO]/1\S9G'DN:65I9]!\E'G&]T?'L<L
MN=)L+K^/("B7[3M@?KX0^&>5*3X-F4W%2V/94=@NZ*[4'T-R\59K).H^0 S+
M\"Y/CXX(U)!PZ$/1OXV(3X68/_[&TGWW;^=YWJY4\LHIDG8H6::]/=3Z>^FK
MMC8<9&.SG@T3R[H!9KM2!\U6KNW882)>PRXRV5I='=)O\@<$>-V!\80+ '%3
M1G>FJ9RH/YY7BM'AZQ>?L:]ABS]\.YL9UH?7PT[9!/>.BNH01*U*-9"#[(,B
M9\30]NN;!.R93(QU]\Z)M%NLIKX W=&,VFJ"_3604L)+$YU;+4&?(S1,><%)
MXM. 4>\,R#*\= +([?*SY/519^DJ0/2-HVJR<=UB;4;=!D0^I*7[^*F_)Q9Q
M3IM3F?^F>9:??\\^8TL#?8[H;9EI;A&JD?FJ(HI:)3I=4"ZI5P^ V;-6!3=W
M)ELZU0F/C0C=:KU,YG*C.#*.Q[5XL'1VR.<FQIJ!/AMPXYO/NZNFPW'@["BK
MJS-7Q6_J5E?T],-0:ZNARS7W:N?:*91VG 72Q]$QA(5,+RQ,?7XR<?J RQ<<
MW/=TFG'P@UNN=K/!?7A 7RNQTU32(_&-**%"O0 Q+NE'I5B%S?@]XO[>@H/[
MG_\C?L?")D<IXNWYA_TN\E/2,DS-Z2F:+04[*BZ4L5J*&8_K4^C+(!59],=V
MK)9&YG];3^7XU-I>\N2>-W+)OY@'M\T[%.[QI89O%)ZL7*-0H.EQAC7GGI?7
MD? +X9$+[:YF5K'O<^8S;L'=\[P\C)/78![]\*M([F5NU4V$!B/Q<0ZFD1+V
M72*H Z" MMDR82<&L(8IBM]3%2)7L#>9_M\P;KR9V^?16 X^\0WRIA&Z\,V6
MQT6$"]S0Y+-R<[$.H_ 6+YD0:Z 762\/\_."70D5%&%?C*_\>)_5);GI_\%V
MF=XSID_2:<WB(X"E= :YNL.5+K#EC_?X\'?,/BXQKX26P[U7MIX0.L8+WEB?
MC+^Z*]5=/LB9>>('WE'YB+'@PN2AAJG+D3LS"V#Q@5Y)\R&_$E'*TP71@,B_
M$@T55'S8 +5\Q36G(P2=RL!D*1K[>R)4?FG,/5QKPM*(6WT:%5,+I'<+EE"E
MOG#&8#7:V2).31]J\V&[Z426XE<H.&_<\]UA'P'1P:@V.;SE8F%*NZM\QR=.
M;H9WH3-^#2P'[=D\QRG)"_[;*["UG*MB\U:!D-*G(Y3#$==<B1;&Q &R#O&*
M@PGV/K5D4;NT\\\=^=(T[;U \Z[4HU>=^IKC&9 _P _=A]_FA!2K KE\I'=>
M^>MU [<?AUEGUP[;*?Y:0<SO 2"]0Y8Y,NE_X9+:NN]QC43M&UIBV8? M5VI
M Q"APJY4+UZA/G(R/1[*1?5G'T,JJ[[XL-@\O.@GRS-]RE[;LR#OK?GIT?6.
M%J805H&Y(EL-EP>9KR[._TYM*^9>\XD#SQ'$<D>!M[M2*MC9*KPJ:2G>AJPO
M,SN>(M; J/*$&2W#,G]\P!C".=E*"P,H+"KTC"Y!:,LOR QU_#7'<YH")7[\
M=)LU8Q.NM64A>;@DX!+^ATT=N%&%]NN'PFK#Q$X5?EC=*T]HI1WH28+6&<D$
M%#K>"PVKQ'T>0G) QQ;=QU7<TKVB9)Y44.,M')&Y!&]17;"XO_M[D!)<[R9Q
M%#>V:N36:P^Y]+Y",YA,R1ZZ:"<JZ[\\;?[V)N_FXH?')/C-RJ^S=[AAN01;
MRK/\A5TI])ID<,)8KFL"B"B+&@)AV5UO^F BBV5'TY9$;MW>V+3*'$/9&6#&
MO;V11W]80^YI&2$A)Z<N+O5N3Z?NF\NM1&P'U==>.PU7M2X)?NG'NFT'2*CI
MS^V2PET6^H@JJ.P*L7;"9/7.)0Q(5$@-!J=8JXR1U]0 4!=$T7C*4:R 50=P
M3F;=JKJ?EB2P.?4)L:5:]YR]IM);CC:B)1P>P;AP,MTM8,OI53Z.A=?'XNW$
M<G' 0-2LX8\#Y\D)*G#FH'I_/RI+0_Z#R=^NG$MEKWG9#_5,L$^BJ_6L_WS=
MMB[T+4$K_Y89^IF4^;"8PYGFZ!ZKVY5ZC@).C0L5L.Z2*TW#A/&E4S#A-4"!
MK2C?6ND3X-:/5:O9B'=T9?KS^Y_H]S^1\,^4S@.-.3.F?R)9F9TEW)],.V]%
MH>30IE@5FY+I!59E1[#E\R\Q0?MCY'35LEP(L?0"^;(A]Z)#]\N.VZ:A"EBC
M.=7.A?"*RS8D1D-G3%'0L]?5>_._9-V2S"+H@2\#MG5G2;KO%7KLM2#^MAK=
M9#_WPHI#:0;ZGT2> ']72OJ0^-,,:2N+XLN;%Q]\N&,*E&)E%DI_8V("D;R(
M'HB:]>7!8 .<NVR,4(G-Y]!_ JZ"FR>1T?D/S,<><<.C@P,"K(:&2EI&21,)
M)A\@LQTS/(^U"1AG^GE)PIAR=()VH>,Z&7)4>!Q8X*G08'LQ;E4AYD/YDP=/
M%73O2H$ZP4#9U<,O6?E)U8X$A'+$[<!ZO<VB2S)'1$L8/<")1Y]->4@R3,8?
MP,A(F+;U'M[H"U-OPR2*9CDK9/M6^0V:HD8$#:EJ,E=R_S]]V\G5F"WS8D)$
MYYI+>UM;CCW^>X8$Z;4D^D^@B79!P)B!T+!BB']%;+;("DX1(@*>FM1:O'$!
M0+ V/C:)X3E[GEZQ9'VRX,TVZ>G4[9K\EMC#3OY[:^<JS@1Y9;YM\&R[''GQ
MNCEM_'YE]<V<ZK2VQWB2A!+8FY9^*G.&=V\]QI]SCJ"T6+WY F1P" H!&H:R
M ]X2JI8/EAIYV6W=5W3L9GA..LXES_N^@*@]\CCF4YE(-J$?3T[IGIE$"F)Y
MTBMJO,0Y'N#1KQR=&E6*X$P;'D%?ZV&9+&][I%J>YO@XQA <?6$VH_I!&>:_
MC^&:GQL4<F3/^M2J>#!1!O%8#J%'5HMM1@,]V952W/QVX$.G*AK4!Y8W*0N/
M#ZWTR=3JZM08P=@1CV_J,IIC(T_1G0J'.MO]0T,*Z[1.:7\:_R9!V'XBLE.3
M(OJ/A#UF[MG>UA'JE(B'#\:P)\].C^>K-I-Y2]TP7LZ<G1.1X'NM$IW@8Q'R
M14=]?7'K[+'/E!S'[&$Z8$#H<ZR7,$.>(YT5X<+4RI<-YB@_^D>HQLSP.#(9
MTTQ5I#A6H'UZ__/[D'&$O6+GWG:^=T<'*?KB[?##'_KO;D4_F#;0,LBT7/0*
M-?VD<3'OF.GJJ#GC45HN8U4>YYI'#K^W?4\CW/R3V>$YRDU$OT%MZLL<DJ^W
M?%4Y5ZW=ML(AM-LLUEX73Z,*CSK2L+PVR62OPC<1TA)^6<1A5"4,1@O]2) '
M/.5:A4&7#66!V)G9Z4R.828K.YUB3X03G!@4DW(;#DC&:V]<_%D\.SUN9U)&
MW=[C^NLX>T@)9%):+'<.:.'.I(U3)6)K-@^V+P@8CP[Y&<I'++&WLJU/(J?U
MGQ6&A/FP4[I6E <=QO0V5HQ<7I.9X[W6%Q]Y.=U'MM:N8-0JW[2YM[[<E3*#
M\!RS/^;V0UIF5J!EPGV\^32,W2QDCQ\ZXM9XYR7T.*W:8J@<H\TP("V0K4S8
M1^W\8V(XF1@ 2V-IUM6UX/Y0G1)ED>,J$>YMQH)Z<3ZV";O<Q=,2V /!99@S
M(KQ8/00,LE0K]^DZT0!_\':;_L3PK@>H#MW>8Z81U,0I2OCR)6_5)#YL?7WM
M'C[XX6Q3FDQ(9_43_N4$-75;=!K8KQXJ>\REJ]4<C3@2\:((,71VT3G65M'U
MRXU'SS;S3#L5'KV*Z332ZW'MXF ;>>3P7.*3=P$@9$;/6^.OO?Z\X=RT"N>B
M"O._"[3,7$N3+-9O00'7,>QL,XQW&S(1W#>M!":-B/48!2XX.HP$Q.U<2W@[
M+0_\5GR!)RC$\!#Y E"%\ (0R"%&5B\<?-4Q&NG[.S0P_,1=QOI8X/.SXG^Q
MLS@J[P8^65)Q+FL38X-<K4>1"Y9:7!!H,7UV+1TK9VC ;:?PH%FA&X/JMI&O
M6GO<$&+Y<7U4V0A&BW,Z- R7^:J#&59"'B=913M)&+ND9_S'N#YY"\MS7$M5
M)60(+8*KT51[((GW'\RIL8K&;VN6NERK:_VL,ZHKH@K.@-K'7B+&)+O?7'/8
MWXI,%SR6'[@7MJ]BJ)Y+%ZI&O01RP.GX9N=4I/7, 018SEIAL>U+2]X=S-K1
M$/%9?CPA*?A;><9BN*CP^KAE #@O^)RGDZ!V.^/^IRL5QI;'7GKJT4_6XES?
M#+^Y>SXOS_05/]/\EH?)L<&IC+NX\)I6G^R+1&F-,"^+[=<G; -SPIW!9^J?
M<R+NG87(KMQLB"CRWM <\'-!N+WXC,M7_Z9-?SK\LIQ+5\0&SB@*XRN%.H _
M'\S):D*93#_E3;Y),.0+JI%AO<&M3(PZ>\6NQV.,=['70H_IO<#H5],SDE\N
MMSFI!EK'2F;QD&3";21,X5L,5VIY 0(DWX,&FX#2Q(=_)-.2P:K(XF,\6&\1
MI"<V.ME2?;9>'J#>,%<::^)384SN:/VDS2/[5W%%H%N)ND57+Z^&6@\H]?#$
M@]BN<+&!8=<,H#FSXD;LJN[,JP;FNV,AW5;'3\F%F00!99Q,E6Z-TXR3DWKG
MCLZ_V<Y.J^RXZ%!E/(EDG&K+'6QJ%<,ALZ,SCY&<;-86E]IG,71R[9[U4:%L
M"NV!:J&*\K9AFE@':''R-;VAK%^YO=,MEN9WY+7FL&]X#1#OCG&NG1#<;O4#
MR8A2"H..X<X3+_EE:;A!MZ*L7MP,E'5M)_JIK[*1D?$3<P&9NU)>ZR<(TJE$
MVR+GV[87%5D.9!5OMSSS?&>'D3_)<=XF:AU%]-5^]]%[QE:Z;F.;7N+!RI#M
M^-7JJD_?W: "I*PURZ=]0%@8,O>Z<* EV=ZRZE0^W'0YS>S^2^S;"'9V+_XG
MS&^2NYP(H 0/@:DZ*!N:HG%:1/P,?.=#W-J;V_AR%2AV,O TG'^M5S72-%'?
M;\EKG.RC7;?A:WK\Y,B0N"D>T7)D6J]1#_]5\KCV!0 #D#<P0 NT\I"O\78E
M4N0 ?M0VGA@9)\A:MVL83]#S@\\<W-"=] \\O%Z[6=? 11[?^%Z1O2P/LT-9
M5_+A#5-O\?,_$HI'1,D4)\F"AT0U%-".]8+*%DXZR:FXA)N=[G>AP=$^3*C&
M:Z%=_-A;OSAVP_=[JFE]-0(G(=4S<D',&RTM?+.T2.20ZS#))]09;:6A2'#.
MES;I&R^LL*^PO>7.RSSG1G3I]9IVKY96@IMI*I9.-JU?6J^]9QO\GR^OO1'-
M)QT\GPS']I4ON1,<THIP")626PZWAQT,G 8THW;8_!VQS-*/EV&BEY0H#NPP
MMNL")+A>7<)*Y8QUES(-G?FH%+$T J^>8+!T6-!XF[78]CX=60HPWXA!,2MZ
M)K*V@[30$B!Y3NW2_.N.L7K7XZ?(WZ^Q[80GKDA6O2(J%!M\0@<+ZDE,:SVO
MK]ZBRCP^F(WJA3[6T !,^%HTT_],>SK5+&P;=_[,H]/:J3)H"IQ/ETT'9FC6
MYY@K9Z@Q]9$R'<V9H2*V4 .XP"L3)  Q[)G'DL4M?V)G)V/E*#HAS;%:299:
ME=<JX1\PU8+"G>9?Q[V;6XCO:N/JT"D>KZGC9)$SLLC#9R1*UF%Q;A76 P4N
ME0ET>(;]NU(?TR5:C&15D%)S!YC9.3\)+S;X(/0*OO/(9]SZF&F+;$HV9E\M
MXL#B-P#ES-P<G'D2>Z<U61!ZVI?WZ17<L(*%)O2LS]R?C3B!:SZ5OR?&5*-8
MF<2]>BR5[*9885KF''7N];<ZN,G0@$N<-9)XJ8_>8CSP.EOV42V.R;GN>_N!
MZHN&6W^21HAW @^%1YUS+;L"G: &*QE X;9^DWFV-QY71&W3=TXDC(,/8L-
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MK04@^%3D(]OQ:7$KN6F88L"Q!;Q8[X\Z?9&S@.J:C2H ),( GINW.S(;]QY
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M+$#[*RMKM+$VWC/R:/T -GA')OL;*VG/"PI9XXOH0P2@D&&I?F/,E0RT[/D
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MME*&M0/PUT-+,2?Z6&D;/<0I&,MNB1TT*S^A+VGJK=!#>+!5?>$WHE$B[TA
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MG":[[+F[]/LYXG%'J4<2>JZEG;[N=]2D\A.CM=_>RF*4J-N4=J7,,?I\T%@
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M P8 [\.!)TZ^F(#;O\X<,,2I ?<YX*Y,#\0T^7.>MZ7D4-R/AA&*<TD7/U=
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MG=/8W>.BR!8H8<"][HCZQ4ZR[:Q'(U6R/_*W\N\,99SY[9':+4VX$+3?$IR
M;D2O!8L+ ALWXJ#[S;1K+J#0%3X?Z>!U(6C.N@/Q"^X=]+?V(SPQ %&.]\=(
M,&&QX= ]F+MB)\;FJ:T-([?GFXEPFNIHM7ZK]J5NP<DV.=]C'+=Z92)*IY5E
M#W.=#"G><>6M,MR3A*"'MS,*):-?K4YI #6997&(KM+MFO ?7C&^)\RE+<![
MA: CD$.3;Y5(V9\.Y2CNFI2I6W]'QFSBALH,5$?E;<A3V3MV/&_"''AUA3,]
M'UN@TL\F,,'=B,3)OU<(=_+LUTOFA""Q(/IZ;CE#PN9$6YZ2LV-=XUC[X/43
MRW+H\)PFQ=I3?\%^G '"^H2@ ^'X)#JX1U=B97N(U..CV9>'(/!,605Z"QS)
MYFY%R($++&TUQ!CO%?%>/3B1U3P>;/8*8C2H_$_^<?"V#[XCQ.#\)A%0C5PC
M1-S^FY+!@[(%CP=-6H_%>@&$N3:%I7%KE=NGTB<%2.T/=9<+_) G<\Z,0']2
M]-\6<6_;I?E%^+GB*+5DLU T=PW,1;&ER)QO5T8_)XM5-R(2O7YNWF/B$U:B
M)-_*Y8C0*FT%IPD]L#DX>/F)M"_;ZA$R*GYT^\KG3>,;X2\\'9"/70@FJ1]5
M%4\M*NC[J8]-+IU^1]5L:6J..MD_'Q7Q[>C/6WD"A\:REBHZ(Y'..2</,$U:
M]*?+]I\K3+.ACTP0\8)N*#L8G(XS!D)H\Y&\PV 6380*4;1N&QTLW*B3NGOH
M>B0G5Z A'Q(A7<USX3 (^@1IY*PRIZFHRL>Z:L7BB,B[?CTMU6ZC_6B6=I@5
M1U3L2[\<$86U$ 08XM"Q$'$S:PZ!>PI(F2<F&PI!X 9SOVZ! 6#-\;*7=@)B
MJS%HRS%9(<B1 @23@9.=%HIC9G8L4Y4F:AMB-P,3:4>=7/VE@;U>50'D2)IV
M"4X(9I[7RH1:W*[3H#;[#MGQ)RYJ)-13V3^"AU"!I+?+VC\(I5CIO\T.OZ"Z
M95:IZW-&*\[?:*M"]-Y=^$0]MQ ^+J-6^6FB'M@O!,6&0-$P6:P,OV(-ZK<A
MBS+ZV<Y."$(:CK/8DT_N1X>I)OPIT/M"-YBM*UYIL6^H'PSV1\VOZ=JTLF&)
M9*W;;HL>M%MLJ:*(:+0_<["T1<!;X;VA0.<&83\[N\"5I)FB#)1]IPF))[)=
MVHPZB)(\TS/-#SI-8;\))N]\P8%'_ _TEWE=NO7W4DM$ZH/3X=,8YFYKU:=!
M"M#-#J""L\L&L&=WL: ]YMA.?=WXPEV<A&[)P(\(.#)GWH:-3FB$'%RVBK'=
M)!<6[*L?N_4-7?,![G5J)>F?9",#6D_X:4J(M/1%PQPH6&Q 3.6SHW[)*6K>
MM:P3VT82R]/&QF 93_]7/.53V/<#G.S3G27!O8>?>I/V-=7VB_]=81#C5(%2
M*29\TQ0!- 7K\)I?!/UY(VYC>AMS"<US%(+DX@32@"\#1MAQ\+$6R,3$/V+G
M#/1U3=)O*Z*#MR2M.U^V9[1@]2PJ:4D856IK>\[ZXC99]&'?<>]*WA#9EJ*X
MP8/U4Z"-2_B7"2*,N.5C]A'9Y]3R8JRA5ARCY@)((J-H<M^):,%P!O[(!R27
M9E(?)'=N"'\K5YU6K[U&_7I?"-K]ENU6M^/X$PGQ_D/07KEF.K=N'D)7@P&U
M\ZBM9%<*[2;;1U#"R>V5]D[3D"\<,4C$GJU4NK@\8'IE<R<Z/^75PHMDQMH!
M/%;D,2_=W;.\WT4V>N.F\F2)-^BI7(C$<4Y#SM*MW 53D0-TV+3N&%N@XV3O
M\Q;? J8=V7YCE]Q8QDCCOE$;;2?#K?JHJKV/[\R*:ZLS_2\,-JN0["2/W&Y*
M,VFZM[Q.(/YS9OC< &;PW%-XH85Q&<SR;>7%@MNW2UJ!2K>B"/S+ZJD?HFGX
MC0RLKD#J$'VPA#'L=^5]_-)&[;MB%NM#FKTBGHC=J]18TU.?I#@P87::/'-_
M(SI2Q#^"OZK$C\[2WW\4@AS<(^_ER#8;??]NR'4S=/OF,^OK,Z342"XK:P@V
MZ!D:ZG[[=P=ZM_K7(?V:1ST*>JT:%2>!5Z),<,"=[$/.$Z;UF$?GL>W'V*1.
MW<1MSV_DDSOZ(E+-0S$+,#%/>W5KVC_.&K.GOCTD(Z_SB74E-HVJ2.@5Z-P\
M?OH#;HCZ\B_^$XI896-M#X/>U.?,[JT9H5,2?@?V/QKRXYSZ$5*6C-K3SBG*
M&V,.M65Q;/1GE6D\OXJI(=)RE&'^W5GEX-SQGE#5VTJJ 4E5MD%N+:D:CB0G
MLE7N%&FC?PWGEO-E.S7!J.3!W$?#ZXF1Z6"P;W[<VNGQLL0JJSCY)O*0^W?'
ME F=\-FDZ1\9?"H^D)B$8'N"@=/X!,HN=O+ZACO;MVA>&SH'79TI&=P]Z>5;
M,,<A7]T>[K9W=K"_R*6?CIB.G\ &LX*QCW6'8QO:I#KYQQK90W$%N<LDWM&3
MI9B37%U^'/4/*J#FWK$SY#O80?<MJP6H[BFK*R&SIU.8D[E*V7U)6,_H8.W&
MAFUJNL4QK#W'*+W17!'6D'\ELSLEM-*\*5V?(74I= W*O@U;%=7P?;D/*#X[
M..REL=!:K%7]1/L1[-X7;74:=,1?#7PO?8X01'@6G?VW(E46DV#3S$Z/NQ^@
M5#!;4 R@>QXI5O&->F]IHOM_]J;TF[\,E:;.E;K/[AUK#*QM&/Z3NE< X1GE
MO1M8%Z DH(=0:AY ?LV@BAYQ=8*F/-T799A=Y8T\_KZK&)EWJ^3,^&9*E1VT
MN,0I&[NQ-YOIOB-K9UMFHWJ+E)AJGJO?4)]]>L(N'Q^TW+I,('0[U<8Q4P=%
M^@1P8MEN(B\ZM62;*=E2/3[%30?)+#EFO99&7G.1?=H$O4N=FR0\J)T;_D";
ME^NM6@G\8]S"$!N4:3-V"ZY^B/5=)'/$]25\=*^^RG4Z2)X9/\UB2 /<40DQ
M7[B]^5J(3K!GB %\$[$T236BSOTMROBQ.3!/&L6]S%;)48.)&-3#%J/NX8/P
MX8!0OPI+%B15SP?K/*'5^%CW6%.[/=PJMV?PF<^E^Y#\F_J/-[\,3]U>F\!?
M0;'T1%K-\RUGHO;?.C)]CS-:K:#R?CT(M6?R=,=?7JV7'!Q4_^/+N])H5S(D
MV!,_1\\45R^FS'_XER\Q__L!I C$?80@]37^:Y'2'*4&ZO)="]5KFU$L7>!T
M)*^DF;LH!-7;\I]1M]PPQ2UW$!N/83MB14(0Z8^[?D+0QU J5TP$,6-Z4 ("
M. GAY8'[J#OG(2 A:/D%QQY'I"WLY1TD".SWSC/X3PE_XK<\,.54V,H/6M_P
M#^,?!/Z?_L3M5,)76I_N#VUU_(=846T8K3MN>=A]?N_\7__#ZJ7,* #MI.>F
MF=F485 VJ6VS%>%_;] ]M9]!#(8^?MAY,7VQ5C/#Y4#1A8^#!2\V-6]4C71=
M7QIH.GG0K4#\\+/7HJ3W?.Y,.MR<M:AZN+6>M#>V>T&>HK-KS\5RM2-IW8Z=
MS#N;Q9_=VD\>=-)_/DJ2H2R[/+TN,U.RA)]",!]-;E68X:O@BW;O3YT)K#CQ
M"MZ&"M2]^_H77W-#H_W[;EC05.Y[=W[@[Z_!=[8KC&&/,_F:77E7+YHJ:8R:
M!KX[\\TD=2CL;+^VP=NRA>R4L[.?=OUY]KW[=[7==]J4#S%YISQEQ&Y\:J]_
MXI[>SE!R.\LEV_:WN#BEB9OHSCBGYBUDY0M!;EBM.2VC!"PD]],UE\7'+@C?
M=YQK]=OO4(D/S:E:JT^?7R^1OWYFVC=MGWW9^:&7R>JU-5"K_Y*0^6<2.BXJ
MM3YXKA4YZM^]("G1*GG]Q$X!(L]T!B*XX ;96@$+'FC:UH?C?^SQP-.JH=O[
MR!ISQ#Y=CMVW@,L6^W[>BIHA^LS29__*9=\::5%Q?]1J+P35MHG"S?9DS?HK
M>VN!U9J1H'VSEJ^>WE3$@0G:AK_J5;%K.=;?S-\EJ]=(__ZO7IW^#V[U7&I<
M0(@+09]")JBK,GA1#IJ;-!%VVG4%;7W?;CD#2U&#FQ9QQ<F:_0;_:APQIB;B
MOYY:06R]&Q,1!MEL]%P"+ZD>_R%D1PBRJ0XB=4-_2$?4;B\B149+V#:S+PDN
M3U%7C6*$H-))@P^B1_)T%G3F"A[]8@V,B "9JA\M>=C1UW/TL*,EZ'^/_YJ!
M;6,2?FAOY_+CL'8B/WR?V)+\#]Z*7( H0P0=ZOBU/@O%.2(?F_OY@"C$_OPO
M:/WQOVK4#HFXCJ;[&B)FYXC@C1"D;'$6$[6 0D!\ MVH4NU'AD+H67*&[29
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MQ#]MPXX@3T^G,Z/Q1PSRLS+,7I,JGK'?Q5\5Z>H@B\_MR\[+D'2M7#0V8YQ
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M+'"6PMI..WGT9L=<5H<Y<^@%+.Y)F8LICLFW;70A.-!;#M9^O>"<:/F=?]T
MM<\YM3R/A0F*L<<@DWH>K/H)K6:Z=;KG,Q'=PS%' D=ESRKO';B=X(T%_YB>
M0Q-U[+6[% ([0?L*2R9.-W?$4^?DVP;!\B%1>'_8SF97<M]@:A$U81#-TGQ.
M=0BC:;*I$($>9RL@?4LIC':6;='#ES!^.A5RL6%I4)A?Z]_A%U+5_;.;OW@^
MK+'Z[$R3#;EP;%KY9'YLWY9(*HW"D4I#C.@J*E]^MA+$AP7)[//1' F;T[[I
MDCE%(-JY"_%SM@[<]!G&[C3&MI_&^XQX9WI H1F-HF_P2W:F59*WT@C7,CU]
MX5X?>X)5M.T1JP?Q]@?%_9/\/F1+DQ6:+!7[;=/K+D7-N0PL#JVD0_L"0HGC
M>V6D(F_ND^&3#FH8#S<Q,R?SGQ%-MW,^;.&>0IB>5@R2U\M? YA\/Q,EOEV6
M(@HY,Q=J8G%^.@+#SILN,*E^G.,II]G.JF<_/R"<GRV8TVT_\&G\A#)##_\F
MW#8N2//+U1;UVKPF'C!6LGX!"K'DO@>'4WF &(6HG=Z0>=6W#5/X(FEXZ#LG
MR1]X@%_PX264*$<OY -)D ?D\260CY;_ CF7G]KRV+"@=]DR^*#$NQ=T*]12
M-K<85L7,?EU'^7:@).<&I]31@4C@M=\S\(R&)A/O$5C+\KR_UE_=Z)QQ->ME
M;XO\L_D'[]OGG!?D?RZ.(Y"G-8T%0QM6F6#5UDKAJT0[9"JD^+:\E+I\]T%8
MP,K@$:B,8J@C=#_:"M[$C,[UHJ^G!<D%BH#5KFYT;5NO04MCPWF'LN-VOVZ)
M:@VM7DD*^*1J.#UEYJ0:41:9LCUJ^M! __WPE*%7E5EK)B>,Q4+I7\)CQT*)
M1FYDL>:]9]P5Z.GOT_L4JM'"A277"_(P[66G/R^1=MQ^I!E0(+#W08M #<TD
M(6FRU+GRZU92ZI3&O5Y\]S$)&<,=&M$/F?T-X]J5O_6XY=](<%*@A#@7]7NX
M6 W.K3A.\?_K*RMR-\+;9*.#Y/*V*R0_]O^[<VC]8R'J(=[B* ^(? A_X0%L
M/*Y ''[;*FK=7\@2YXB6P6;]ZVX\H"_-]S-N+5/'S.X$>N6C/-</\:\=[TX>
MYP'S)X;6-]?R@*E7I(\XCI37ZTG?_1#?NM$5PII&5,Z5.A98K6EF0Y!T3R0[
M2S=YJC!DW[\0Z'4,DC]/CI5[=?%\;HOB5H&#3[G[P.IW$)X'G/OZ80@RO(WB
M4"@3;K @,@O#)=:-$0DN,TEPT@*N?<S'WB/F)A3?*F(M_+B*H5B,U8IZUZG8
MB;_D'W/JO)&5G=AL*4JHID_#]$6C"@WZDJE<;_U 7MQ6['$U0_%]@[!M]-$T
MFTND([Y-XWF3+Z1@L< :TS7YQ*T((3+^$5D!/BAFEJXDV*;#U(1WVR#,46FF
M)+F<,DM,@?VON,"[Z."J=?AZF /7AMZZMNL&"7+ZP ,6P^16]FERE(0"2$NF
M.LBR\(M^S .:UC#TRT0U'I#L->S"D2T0@JU[W/10O:L&W.UY0YS]U4A#BMP*
MWUIA#6GIAT8,LPMI-"9C/'_"!;)""6(F$SVE> "_\B8>$+7T)_WDC =C<A?#
MUL1N4J&S_DA#>^-YH65"(&;R=#A(ST0:->G$?+DW],?A3/( _VO,#CAHXC&5
M&?X9LXJS:Q$%'<902XK-(#-0 &E7'O,%-=VS$_S\5!8).ZR05I%>Z/=TZA]'
MTYT8,4S9.BD.NGPNEZ,G[%EO\O3M2YW4LDKP&/W-HE&(=F1N?US3_6#[4^M[
MWT;S;9)6%[-8+,^+'#&/MOLYS5S02.SP,),9+UL4Z2CI9.;4U*+6%7I[5&*/
M3+861(PYG&0?&3EEE1+STY0E6;T@H]-_[Z?=5E:1-DZT8\G!2N7+3X(57G__
M'U'RU,.6A<$>'/=EIOW__'=&@_LT5<6128T9?['R^Q>\LGZWX_=>GM7,,>?T
MM0D]P=##1A$Q,Q04DH.!OZLH_>'MKK(_[?EEIQ,O(1_<.,^G.4H<,TZK&Z)0
MO\]_IY#_(NC'2B2N_6T@$^Q5_):7U>21^R/G/V;XRTZ!%Q!*2W'E]$7"6O9Y
M7*&D;WGPL&?^H]#_-\I.- /%"2KMX;H5(,;//\T6VL\##MP98DM5(EHF2&:P
MA.!S P2XA 9.5;=G<W8A*M=P61<< J?40Q]B5O=8\(!W"'5(_=$,5@.KT"TR
M-7JBUM$/_E/-_W_S@D)[.L#&OHC6K^%V([/IU++/6=Q?/+-;#6P(1. Q0JV[
MM@9 \CP )[=Z#IFBPUI_YQ3[#RWE,XS *L0SD:3*-5%/?=6(RI ;R[MZU_3#
MTB_V8E#2<-@."+'VK@2-8P.V?4ZL25^E#G5G975M;>^97F67[DX[VQHO=U'S
MY*M&E,F"2\_3^ _KFZB$E$;:FIN6.K5@U"ZD2-15NSZGR^'U#8U4[.)M\)1#
M8:%4^@"*:1JV=AS3V\\#A .'8WC L26PIA0S3$(M70=SB^&#0E5H^-K,;*P2
MF'V=.BDOS .>O@47$7]VLC()<8FO=>1AD6^OV"+^[-OFV,[)?[W4+.C;%M1S
MS&;J:B#%#L*NJ_E^PGQW=#F3!SP&\WE %?I)SZ!L<7X!2VRBVL7??C/DYD&Q
MP;>;:I"<LZ]Z8DZWO>E2GKU56A+]26HB41M_5-Y33!(OX'U33*7VNKRX1$_V
MB8H1Q?Q(NUBGJ4;RK8BNNS'7Z7[5E\(3=([*Q(\P/XGBJ\U*\PM21+NZ8T\5
M;*]ER0<0-4>4^2R9Q2$<3+(GI49R+#76MYC>NAMO)3G^-.LR-DRCV;)=W=@[
M&W.Q(&;3QZ*RXECQ#U\"OR^:S(K OXG#:K\IP&?'^DAJXM4Z#-_$XC/?)(:J
M+>&S);U)X94(37N"V,LJ!:)+IC3A"C>,@[[I>>W87N)!%M\(NH8K?ZVDI.R+
MFM!W1 /FH-^AKW?'3M]3:[NG'$[[S>C(;-;PTQE4WPB;GQN*N<F_96)V=?T$
M\2CDDAT2TN_/<@\,3.G6>42B[7E3/]^->:9[*,*65?#H1G28>BF>GY(3M=G#
MH]G%4;Q_08<'Y-S.B?UUUOFRM^+[CY9&#XOS,YYEG[ MEGTSXO*RSEBI6<&2
MW:DR*RC90RU*\ZOIR/19F-MOHEJQ7%%=S@,8. 0,4%+GN/P3W^-$-0AD.52%
M#]DXW8<,&+BGQ),CU!V&&?C9N6OIAJ\]R=BN!^3*//P-@G%1@6J_VHMK+P6*
M?+X/'G^>)O'_3#_LG0XK?,[D;*3#B?<FQ^-OQ$;>B$R173%15NN8CLVE4[=C
M;J'Z,H<UTM[.8#:!CJ3'U*WJ/H_JE56O=OF*$N680C79QE<Z?HJW.TV>+A[<
MQ83#W--[:QYL^6@5$]ZRV>VQBGZ>8->\A9F)6X*AF\G]^(2(R-&Q0^%YULX5
M>T+RQ+0>3.F=B3IQZ4E%DLEQ/\OEA\_-C1:LWR3IB5I$$ZM&P-XP]C'H%2/;
ML0&W&W/#M.\I0RB4H^<J/?1,Y^8(^#-N.]&:D?UP7NKV$49)-_$LQ=.$!UAW
M'3V07U14^(+0WSAJ3/#\P4I83Y)REDEAFW&CX2V> 5_KAC:#MZ@_8_ATK-,G
M>V3V=>J8,BG#$S74P,K]E<SE 79"QL"D9FR/'_%DJI.UC7IW6BI>R[\^YE1S
M;XM/VE3/_1\[^FP-Q:EF-N5Z'D*W9BSOY84=S-#<:1%N-C9>B(0HA"M'ZP4$
M_$--"?O4MUB_:J8IJG69.):7='J5D*R]*^EZHE;Z]*LK(3H'Z:8R$,&6B7M1
M?IR^(.FI74MS_Q3&,.6'\O4ZB 9TRBZ\YC.'LO;E"H'+1>7MR\Y:TRH.);G4
MPO=%"?R&UV^>R D(QA=T8)'I3KX5VZ76G4'.%S$RK#<\@3P\%.O4\B\+X)&:
MKQ$4 F^S1H+O));!,]O:M9A9D.[M;/@FP,V9/O0,(T'<3Q]F&MW2PVV#3!FZ
M0?1S_O$OU4MO9VZIO?S$<_3G;0U?P/R%V:AU5;@I5L#3@_T00C$GZ'+/V8P>
MLW)F3."1['(#RID8%;MS.F:,]<A2EF/PZ!/\95LL TNPC*6)/J$-GI_+GJ.'
M3#Y22L[1E+"7^52$%K&)+<SHHEBEBA6M.&I*:^&3&LXJ-[_KDKZCL6E+8-;"
MHX)C!8<M/ :_DDU4/&9R*LZ4FS):9]O63W"\R]I<8"W?5F1 E6I#GG<'%SMJ
MBDE[?,4\11CJ@T_QZ8V;:?Y%(:XC@GQ7XHR+*V.[:;:_W;'?-G^C^/&$]6T'
MI;E(JUWQ4XU&NR,1!BT[(N<CC1B,;$VMMY?(5D?%KFW_Y6&YHKYJ2#[67@6K
MK19;VI;:G?Z5!P20^"O%..+,6E]^2)O904<B'W"KGH]'1AT=%9 HR)QXK'-<
M)BU=11U.DGE,=]8T:@]?6TX.S9GO_FQZORTIUD#A_=)VA;3#1M@FY,] $[:H
M?Z!HV:7EQ?'G!_>>.>YW(/SY]4@'T2*S8$/94MFLL"BBY3H_7*NKQ3I4,H*6
M@NMY0![E.1''\#'Y:LM"!Y=;KNMP#K*$@G3.9DV+J-?!E!Q"+-4/K8ZUO53Y
MWB-Q$8:G&=/CCOA;40,AJ/1L9>4CRLY91Y2S9[/N9-,+\O,+ K0)ML;&M[NE
MO D$3\O]3P:WF1T(V/OR8+":A9[EQ2W!BF2K-#TQK8C8%R\OQ:<F9T4EQ^%O
MA[?39$L/'&Y+,?QDD=Y./ESVR6*J>J>+M=?[U-'Y_K+*A9)&:.:#[A8HB8YU
M^ #NYHC3,<\2M[)$C]E"3ZL2M9CC88RA[80B=G'TFG^!9$.@^_JIL^<[Z<74
M@H+*)TK])]NEFFV]?^VZ%:")DX,<U@_Z-J$V<XR(>*8C^SHWT5<8JBN8R98N
MO\)L&"ZN ;_SC)S2;-T<0[O20U2B9\M;:+F/1A?EV5V.H^1?/54@I&;RN=YZ
MTDDAU.:E7T9]Z@@_+E8X/E+N0<1X\$,/0WGWM\;OC$(E.D.OM*5IO<OS-[SD
M]_;T(9I9G(E9OG.F^JW^+PB;>?IWWY'PYV-]SZC#:4.++X;Z27"+$OL)#^BZ
MP@A>?UAYX%MZ%[!)&[P+KJM1:$@4:ND8K$3> G_+;?4N%K7VD.\0AMN Q,,_
M_4KBJJJNOD9( AXS&O!MQXUMI8-0MG3OGJ427 N*(V7( V15V0C1R,NE8[AG
M!ZEI3>O$'EA_+XEUE@=@/ZPFBO* <.\C2%1A"2X?>&>F)S9!.O-WGCX3>YD%
MIH? I3Q@-M1F^1\^F&A3+%<C,/X<JII'*8;S) LSTXWB;K:*NO6'Y/%5F!<X
M1LSXIV=$X6_W(LLBO1J>_CLO5+AZ*.7; <TXA"L_LH8C#>P&?I\_WODL@\3U
M)HTZ6M-QC+!Q[P11LZN''O^=$GXK?[H^I(/PYZ#3&;5"Q'&]P\8_DEGMRS&3
M/@)(9!;N]'<?270%D9AQ%-M-G4D@P_'*BD-50JLBMY#I/[ "1USN,OWW#ID2
M<I$QY9&Y_FCN@>_#6"DPO^]MMJ1"<GE^ZM\=U?^?5%:]:U"+MLOH]>T08FX,
M%S*G)?_BT<)'71T,]\E%'M#_@JA9A5E;13?)?W3CF$"Q$1]#Z)-/4O,4PV:E
M+>B6O=]%W#/\L"G<<%E=G*,L%,0#EM!UB&D4O(08+*5IR<-9]C+-W( 0'E!,
MX@$',#<QJUS,S#BQ@@<(G&6 7 $6./S4 IE%P1CZ;:(I#TCR17-V.9$X+W$7
MVPQZCB']?6?  [X'.<^\#_. UBED]:J.+4 V*!$>,(E#^MTL24:LI]F?^EL+
M"-8M06+DU]LQ$%)W]&R?*0R:KJV2T&#U9P@1Y@P'!_W0A5D]$/:GWJP[U<R6
M/V*X -+MAV]RRS2!7]? GH^KWO">P%ID88HSD+AF:P8/:!3]8W>52<EA.=>0
M_KX/@S?S@-5=;$07I ZXTK%YB%F@BQC^SU1Q>)NZ*7P^Y4^]B2T+BOJX"?&
M'T5!)E+UM\ \$@<F+7_5M><!_DDL#.P/49FGD6A3#_6'SBCIMU-F?@77 ,3,
M/<; YTY%\H"))<3^OEI<^1,T"G_LS>>L'NIJ#=+=%A2''['<^V<116#(7&)K
M#/4/R!C\%= *:^,H^&>DVV&DZDNA#9PW<-[ >0/G#9PW<-[ >0/G#9PW<-[
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M\J%P_R-W)5/CO.7V6CH7N]^(6M:=20Y6>K[T?3#4SRY"'.MCW]^H[XHY2CP
M<@H+ 9F9(!T/5ELC8Y?G7 1%B"[<,N3?!IR#(#,2;#S)= RAYF/R,70T<X$3
M .;#_=PD'K";!Q1RP]=GAZ3^0I\S:3$C,QVA-B>.V#F94Y6-+CMU'6Z.1AA%
M_ ^,.5G&[$!J[*,W7LM?OWDEB^,G$W&!V3OM'ZFS?G6RO-8B=N+KI0QSU3 U
MQ'5,V:N86V-5_RTLQ=2I'/&O,#_*W75+ 5A8KB17VW9:ZBIQ)S<U6[EKW#U4
MTKN,^O0=C58M\3B:,7X[F_YC._:(:^:)CG4EU7\$O'G=0Q;Y_,D2"8!VR/.
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M9N/*HD-@?DD5ET&<)WYP<$,0[(ERX7?60P+^G<8ET=C.^>/,A+Q=HU3,^7_
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M54:APP14A@GEII7R(:_?.'%6@84OY!T;Z71@XPE'B0\9NQNT@^4=>$H-!>V
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M<S QODC9[4*EV(7=RI+1#UDCT 6J3@:%\198*"4=UY_1<AUU8ZR\(QU&RRW
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M%4MLZ)H5>[>_O>RUWV^3-^*^0/=B_\63?AUB?J"7M9=.6&WC7.5>91Z'^O_
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M[1@R=["J[$^*;/VH  2!SG^%)L^] W?/I2!J>^*AOFD)<^(45<Q-YD8L1!&
M+L36,"?M1TVM"5-+KE%SC_41,1/&^*0M]8BM2R$W&_)<@21_]H3G'Q-:H4IU
M.3?& D.37G"3?I63SL^9<%J@@#IJE80*U,XY7.'+HK7S3!OQ0W5I[#"@MORL
M6[$YNGX.66__\UG= [QRGY97AO.7+59?06#'=K!SLGJAZT57X,658D1=D=V3
MLK,+JN:ZMF_*9OR>+PUXZ*VCI]S+OYQRN[HWND?#1@&]JG6XRDK')E4I57,D
MR4%19O!PJ$> I4=S6%GOKTYP #<OE-.;:6G3M?P/T^P" 6C\W,)_R-[_$,6
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MJ^H*(R_,0;U E !4;LV.)2X%47/A@'$<WY;%#.</*=-_E6/19"G66MU./;Z
MJ8U24)AR0AK@=;RDW^8H[7SB0\N(^L]YJ(W:5U2Q+&:V]Y.VT5O?1]JAK+&\
M?,@CD@]Y&5;1!^^[8/O46XH+X_\+W7R(>[?#>P5O@_)</&6(VU3BYI^\9[@O
MPESHL\&YB'^"VWU'UD6LX#RIL@(06$CU/2L$H*70(9$.Q,Z-27[[^;G=H$*^
M&Y[I#/UI.;1&$/Y=@Z< -'+)N!4QW\.5RF,,_3(9^WT-S];EO4*1\"#,598
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MO5TGN38FF%586MJ5J%]L[%TYV:=9IMT&/H7]( "1PN/(JMK=B 1H[<Z:6"$
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MSGF/DR"#HRH "X9TSX;(7 DUB1S)"-2VL_:PFJ9K)X7V#DS&FDH7>SB[N]"
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MLL&XBYF^W;J5#6:I)QOQ!L<,RN%*J3.H:[K*:<+0 ].<NG<%H$Y<_.SOS#=
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M7T(05C(V>V[_=+^U(*K29]G5Y)2C%E)EU'MV+(CW9;+I>,X".F*8<6JVU5T
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MZC])3I(W8:1UBLE=-.S5S@Q ,@9<9V>U=7PSD*:-WM?F--(4%T):+FC@2$.
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MIYF68H>30WJJCZ^?'N9"&?G^*AB+UP'-R;9HX5#WQ%57@=OG1G:XQT/8)D
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M(G.H,5KRU ^=;,05J>#C2WWW0V+VF1?%F&HHAAV$+&/&[^0^9WS^2= ;^A;
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MECCI$AQ3U<@E"037L"6&LEVQOZI-1955E8]:>='_Q=Z;AS65]&V#Z79!1$1
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M0533Q=Y;U5=D^DF_(66[E/5";R;X&0691<[]LQU=SVABU)HM1O ,2!-(B=M
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M=64?6V"HJ9:@C-WC.BDA-3=B< N<H)]EV _7Y(BC+X=O%/1KKQW4:;YR@R2
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M8(M#U4R\O%^+^!#?=D9A^2"(O5)3R_D6%:%=Q#K0=&J[O&)R&5.L_("_H<&
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MX=B+8B'Y<0VC@J :(6(PJL@%A 7ZX1L,KD(+7,M^\F4<">BO23_H]3@PUS9
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MO42<?XMV8P@>I]^A$F,)?<#T JXM/O0&>:X[4:X&KSHK\YZ 5N+I]C&Z^NR
M#N:OT?Z1)OFZX!Q\5DI/EKJAXB\163>.1/Q3ME@,<4T&9& ;ED>"@>T.M/&-
M=FJJ'6!'4>%?Z7L;&%NA=QWI1[L9BX?[? DM'5-R:\N]"6128-P> 5I^2W:J
M.<;?]+,LAOI'J<-;&^/WFX4E9H-R7>UJA6X+^OS9,9RIRYV*O:7OW(O5K*=(
M2W-U#<[$>_A$5!OA=A@J[1>W;B6EV[].:*CD.<_G%E=@7"O?OS-K54JR;&U3
MQFK>K)#OU/(MKLR*APT@_ID-VB@;1*_]MPY?!V5PT #P2.;T^!HBV8832&PY
MW5SV;UW^/#.*T_V)#$D4-0W5HTG#1*)JV"#.'_D<=9L1C:K1ZV1BV"!.]'D?
M6GFT"1%#_><!O-(#9!W+7)Q BGMH?+ NV/R -<ZY:!DVW&Q?M>C;<=ML"&U&
M<]Z!.]FUF%V9+Q]7'[CV)EKL?&9;DN0:XQ7>5D"T;/*A^_U,53A9H=79KW !
MWDN#-VICCZ3U!6W;,;B_+:2@Y,'49\D,?I4N"!CW@?D!\@1_]@Z><9?:';FQ
MNYU$Y*W1O3;="3FOHTD.<4$4,NY0J;5NJ1W.*M3,F)]JJ*R2MZ%O]IS<6@^5
M$R5BOF?*B*FH<7(XK,MO?,X(1=8)G;$1KW2?O1[9PIVVZ!WL:[+1VU-$2$A[
M3(C3^3*MV+8LHE!_R1Z96I.GL:JEYH)RL\D*]C785-W""LL9:?1@%D)\$#YP
M'UWL%X'OR6*5FOL)'="_)8L=ZO^1^E?9]V2Q-<\[KY1UK?VU)G).+Z&%^9XC
M^IF6K?R,&YQXZC$X!34'?'3SX=\8D!9@F::WW2KP0/]%)FW2A&R2+&CTM@<N
MONLS*UT](6*QR4^^?Z]T@0F&>((!R4&&P#Z]ER8UJPU44;7:#8%7(<_VM>HZ
M$%&'.?OM**' )/C2C9DO )%U?CSB-BT7]V+6\7E@1"=:HIIRURLO;KCO :'&
MDB<L\!8;=+(6U:I-&9EB06,AA.;1$C3%/'^0)D8V7HU+Y?KUQ;I2W<?UT-_:
MW1\;U#T919,3KH56AF!O7)T+@<9?1W^.K%+UM"SA,4FQ>FAG$+K:;U)@/.Q3
MQ'AU8.K\PR!UU./.J=CVT0++&?J?'5;MQGY'-H4+KHU-@FO=(3=GDN=5H*3M
M/<\C<47CJJ:1/5.SG6DHR6]&;\ISFGF;17]<6UU555UKI*R\K;PEE<3CZ2Z9
M E]Z=256?,:*#0J9H][B Z1.-A_]Y%X')F1N*I&/3,!3DA1PM( )$#(O;M;=
M/Q9V$A"S,]?#^U2HM3=IN75LBTW%*^K:]$Z-*<$^LH23]MO&T6@84-V5*TY"
MV1 ?0P'IN@VUHW,POO/('P&Q//C<N3-7A(&2!;%FP^XY_D<VU2,UZWEY *8S
M0"NMA3O&DJ3FV:_M6$7E)4;YS81]:I6H<RU6JSF+>4L@+R/-:+O8R%92SB6=
MW3*+ N.*!SC4DP)A:;,LS]G]17F\_TXW^OIAF.C\R\7 ER[?%&JJ1!KLR2M#
M%GYR4*R=F4]DZ6A<&(7N$R7O[.,ODZ<AR)$-L8>GS?4%0?^=8OM].4J8CSS8
MH1(/H9K@IT+('%@@_A#81W%+]N>@A05Q0N\T@"*'(KK"5,8XHY_HCHILF"UA
MOB+CSSY8LQ_ ,K,*X U)>!1=6[ZEN^B!\]R7H!>UU7W@]1-"+:*-[8^> :\[
MC1\$[Y85UPZG8BW4!!WL"[\\G1J5\75Y-M0U3PO4[&G3:%)#JN($L_-$=W%&
MO?(K7ZRFC5:F..-!C@\(,&0(@ED)T.^FC!T/@6D.,.NB<-T;L?F>>J+?I\>>
M@,\&)M\=V>4[MP*N[FYU$G#^[-_(4Z%H-Z26HTBNBR[W-Y6T'=ZFA!]])_(K
MLM7$=TWA8F7:Q:YU]7&:!7ZPO!6\@_J@Q]+N2AN6V\_ZX@"\S2+S1K:5/7+:
M?IST@3,2VR;"P&6Q989"#N=HJF0SX_++)X2X-)V>>TPC\+_DQRFVZ14J4J"
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MOLS<7US(/K5"*,C"^J<UZ<=;J[A/Z84Y4Y.X:L/\(7VADWGZ0HL8H18M)#_
M5[B*9H.ZP0DP'KTS*_9C^7ZA8'N@@L;3!CN[F^-@XP#'.YB0U%2$UPYU<UCY
MM2^^S62)V6$_7/ALJAG?FSCC<2WM:\'IWN?!<IV:1BT]4M,'5]PT+.-SC+K.
M);W/_EH@B/?\8%1(@'OLZYK% =,L"14.) %L4,$&,Y%(DVWA0GWS,63HP%A<
M-#;(</)(#$6!(OG9H"5*[6&E(NN/*C @@^- ]U++MZQU 'QXI@U%U@>SH/VA
MRY.JMMT9;!#U/H?W_+!%X3&!3F?1=1H:&M"*(9Z>J"FW^?)Q86$!K>XSY^Z
M$]%&3] &#RAQ:FZO)LT%JT!,OGEP'.J,GB*\3G2P;?LEZSB06FA_KW;?'O\[
M$D;>%EFM)56EV_#$;Y]=TTHLOW'CUO7RY\:5]Z[_7M@%Q'ZN,/6U*K YOZWE
M&S?N]3AE9#A7EM?>L:9*4*%W?!%GD[WH6O8B(>N]:>ARD+Z@C0%9'UFWP#>=
M2I<#@BBAGJUZ$.8[E"OQ>.!@N^TP/%>2FIP <0='SEZDZ?U1\JL0EK17<=R>
MYI51AH7]6IDHC=TK%'CKKR1RYD8_JKV3#9K'@'=#,55U+*G]5A66MZ)_5$<-
MNGT<7DBR*E4E59NJB:F2;#Q#*I<5N^8I7USCV[K,O32:]*5(9OVJRWZD(5RI
M&^?7ZYJCTE" ;#<3[+;AQ0;%ZE(Y0)45M\L&Q< (T(U66H3-N\]A_"Q.%#D6
M)K>.+E<?%WT23UU?.-4^)^8QE2#ZR%0&JQN=0\:?]PC(_'.5-NVHNYM!_2LC
M]L=^;8,J3>NK>E>X>JT4#>2=>JV*4HR<:K]8&$\=GA7Y)&TD=T<H.KMPV#PJ
MV"+5NT<J+<NKML)U-$!W+4ZNW.S/_+B#+ Z=K<5M^% ''5NHW1VH*1+]"8"B
M.%T__'9OI$EW 94,YM&1KX0?9F2O2N3AYN!:^W'E*ILJY5(9&MM*LG5)(;:O
M+@0.Y=RJMRPQWR%%KNENGNXUF]D4G,PQ'BG&*HS"A^-?6)1HM*I/:JIF[>B]
MR6_:)P]V#D9!1&I<*)!(E$"+!,.22MWQQ2,U:;AH!J* KZ:LN<4?>F;-/N?E
MMV%YT4N#1Z.)D^H_/M+E+C)/<TC(7Y#:6) B0:O-^B$6!7(#"L_2W+@4N\P]
MS%.V"K-,@XHXD>+*WZ='#LSFZ-O,F$J&R:GP3=13XJ39<I>ZUD:8<"TUA[AY
MGAJ'X/\2F.%UR^\U4OMD%#A!S"K3*=/*E>0R+$GPNFUZ*Z/?J[_U_/AHNB_6
M(J<9JTE:LG6DIGDW5CZN)#@$7,?9)WHC7&S2G6W2FG/N#J8WIWUPJ X5>&?^
MM\'_W<Y5B(*Z@(*C)KOGI6?C'])(]-\!::K]44?&?F:8>#503;/]B#GKO;=N
MJG7W\HBRGP-*Q'-*=0K;G#!N,^1L^BBUVTNZ@TM;TE3$(U+6POCG!)QLS4-A
M>6V/C12O2<\J(05+K+!6=92&HK._M(B^4R%>7C5]VLAI;<K$)L15J(VA 110
M!Q>$HYXR_*G)%)4_PN0!R?OUS37O:)GMR<*!J&X)H99&DK?SH'EM-8TOVI_7
M\NZ'^G=-<0X.$P^;@I2\70)E'RP:F,]8P#OK>S1Z;J+A1>@9U3U3_WL^:6XB
M _P)>5+8B_HE!N8>:^8I#? *2],BPBU]00LY.?Q/ .'H%N,X< J1[\3P!^:H
M$?,$?&P1L8XZ,]B)CW4^ _@B*#R)2DJ/1^:'9&C1A +#,E.<8:BK-,.&]QD]
M-LACGT?TRZ\P3S*JBR\2(]:D+IO0PL.P 'QI(6WGU@+LI5H4 -@"Z@P'Y=I]
M/&_^//7%>97?,U=P9,]+24U;.V1=?JM<=,7)H3W(\VK5%<=?![US_F\8?\Z!
M<;,O%3-JGEOE3_X&Y#99Y>DSTA;*^39F6SD'*36IC3;5T"?)^OE-U92Z;F@X
M[-ANS@T8L$"+)[NUYO#8CY@E%ZS#A%HN!YJ09U/+//J\U-;AP4^P%";,L)HX
M8C,P&U+MXJE:=V6*"W<MR+RQA(I;P+6J)(N:X?",LT GM7KA9E3^FJ3AF!H^
M"G*N29HF8#3L_Z0V>L^O&6I!C<:7VTUX*+GYG)BHXB!MJI?.C9=-)><GZ/Z:
MNKCJ[XDV<5(?5$(<<K_4M62T')ZJ+=C432;@-BM0KIN2FTJ><Y-SZ+$Q.H$P
ML:<EE_^6PPZ:2!1<%R8"\T.3KAME.W'N0I@H\A*UJ*!\&O"%TB"=4'' @;P=
M@V^Z$^!2O/8"S9M+H&S:WB5Y$[(JU.^.$GA"E7DR6]#=)B/>"W^\??\A12'!
M55.N[7I:UOL$R[2LC91&Q.<W ^?BLQ=%;BOL<,*52.66:6%FEAN6TY.IF(7E
MC\1D&]&6,NJ-!6@;(N$0%K.MM,L,L0"@-+%6-NC\4U63HWK[I;%NVR9J6'6Y
MPVI=YLV5;]/3SD9G2+<3K[K_A8TI'Y+KY??)=N526I!:D/;W]QOV-,AM_D$@
MZFX)*=OCMGW7LY2TQWC/$OV:/5/W?1MNQ>M*" .,'9'Z5;3EC?I+OXH;=\?V
M3$\J'MFIY:@;C&\1&L5/V1*'AVU:JDEJC=N\@4F#=XGUX=I.QNN_C&UN+**]
M%)@_D4K@%:.UP72/5<98V5]P7#74IF;<:F.\%(Z;+/LNRMO^?YG19&2S0>%X
M5*MEV 54JT88G^-Q?SB%. 6A7(@MT:=ZDOTK^AN=.A4KNG(Q_$CW"O%!NN'O
M2.UBR1J4>YVZL^K8TT+J0!0X\]3+/>(9QCH;=)(-"AN%U?)M9AUI(9\ DT>V
MR >PV*%IQJ-D<G<[%O$C4H^J<VA*C&H2SPN,Z%3W]*0>?93@?3]2[N^)%W.G
M9^R/UTV-] 2]_;_(>^^H)K?V39AC5T1$FH(0E=Y5JHCDM0 " E(C($1%A! A
M("!!0G*4WH_4(PA1((2.=*F1?@"1WD()"2)2(D\$PB,I3/S-/[/F-S-KOO7-
M>K_UK?GCR5H)69N=O:_[OJ]K[WW?>]7AM?/*OGG8>.C!]$<Y<(,^,Q%@N.B8
M+S/1C!!L>;]L.#;,)E[J%T'I.D).7.&,W-=^_395<H[Y89ORRP'%#D7KJ7+F
M D=,LE5OS=WN$RXLZSUR([_E>T.AL5\*AYX;^[,BD7(J%[P$W%Q4Z#[SKKXQ
MBFK27A&-.T6H:TY[4/,Q[E.KT(2!M:RX;3.S5Z"YB'!Z.:W<>T+O338Q>O\%
MH%O]6?R%"B538Y6F%%.-+(^B*]UO%6Q\AL+=KQ@.Q_I860285H][5FR:[O%%
M__G[N@K<UG/2KY>D)W"NORCG,ZY-EH2 2W,G(8 5?GISL;X++CP#DFA1L:H&
M?@20=3_*#/@1IK8<;0!A:'0;GA2>^VXH4OMAJ"8NKD7EUJCV@5J>8)CZ5M-<
M.R9N5>,\'A-:.GBN>\GN?'2G78?EV]5BE2G+TGR"HB6BUS)!*\_3W&ZFI685
M,V'>]<8G)+8HO-VZ>Z3$,KQ2@(88"C\K8Y.MD[OR2,6T/[/4Y:U-[=R/4AY[
M*\R-!0:)QU06*V:6F2U TKHF2PGCQ,DSL%5_8_B>JK8O1# JY\Q8N0,$M,0J
M(6/D\0L:A]L.!.F0(Y9:WY>;"FQ$S]S>W!: M#6B8C!WU,B#-YO0>WPOS9-
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M;@W+-D5NW!S6NIJ@8)1L;E)?ESQI@MSQ%&#G4(Y8VWQ6>:3@<T==[-FW$.-
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M2S2HV)KZ\(JTV% @3FBU2N9?B9D^,<19KZ O"8'7RHJKR.2^ODE='4");\#
M.O(U[OP>WT,>_U176">R0MF/QPR/L:5 ;Y81Z'%_&+.?!H_!GF>8=&X<8VL,
M882HE".@P^+MJK%:-10,V.@6%%L5NZ3SOGR%QW\&\EJ(Y(IWSB59]V)213[\
MG;E5XD P#E1Z.)*&Z)ZM&6VRM*@EJ53!?#HJDMJH)=0/XPR1%5A7GW6'30IF
MFR N*G<@9?J+;DMZ_?15;+\U_',/W7V/[_!5;!\/\6Q4$1K"? $^K.".1]T*
MK!EK]B."G1A5T-^OJ"/(S[O($>WO,HX1I\WY=Z8SI?]U"3GA*I[4\6+XM0+
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M*_!FG,6=@2X4XFM@D0:B[[^_.)%"1<7,2W/>&ARDH@16F.GZ)Z*(;*GAYFN
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M5:+2..M/+J>>?=$8X*8_@@BLO6T-9^Z$0&9P[)/[J8?9RE:@'.G3F?*R<K5
M4NQDC@%(*C>Z5'=)ERV'O3C^U$#%W_-A50U^?0<O&  Y-*_7FG*W0=Q_[@C*
M,D?56PT:CR>;7V<(LD_AN,<X- NW-O*=B4;HIT&RY&VP%F 91_91[E1.&IY
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MA- \N@25?TQ\VQV!@_\R$"\#*_H;JZH;*YN;ZW'KV=5.Y/GIV5EC)T7ULJ7
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M+EEW+?1?.%0X8L_)C#44Q)=^+/O4ZF.]OMT6-@2;L-"TR#NG*>F/UX5R7,&
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MDY!ZQNS0.=?U\^N%!E.M:U$\DGQ*T1S$*R_SZ?:[_ZCK.HOON&BR!V?)@?6
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MA;;(>:Q>CQI3TIVQW#!M9B<LH]!CD8T#25 __!>[KL<#U%4I?">,FTL?2-Q
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M*N,QX2$,"*M 7XDMUYG^8*8G4&T_V<RM25H''MA8%=,F=D"=C1S/_O[I/K/
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M$'S7,;!4_)&!?T8I_-F=^4R?'_:I-\/-S%'AL&V=,S7=Q"]=0@DR?[=P&')
M<"F""Y[3^POO-9NB471=: 3X<:.IYO0\\/71 L3SE<DNHE2KRYY$.E+:)W35
MTW@^Q8_T=8Q9U_2&/!9DI6;_-FG(#3,Q)I2H$>7]C>UL@4(YJUT)Z&/@)V"]
M[^4R& /QT/H=4&(01%'2R?;MFZ:WM*^CN+#BF6D TI6OE#1OB(X(MQ..CFST
M:RID1^AUY@@+_"?L1++4T^L<9:2].)$W-=7:_L%Q9NI#R->O2^S+;7EM*VC?
MQVCC]S,R'OB&-WBGAPL+O/6?5>@U@U!>^\B#[VOA#EK!7;G7?HIL373E N='
MY"BQWHU4MSC+R>SF&TP-5&D[<C6K<<8!7*WN0> NICKF7EC#M^&J5M>@EC"5
M=#5TUJARG'[^2DCNUN^B4SP.B@@U%V'E=N2G.O2E6Y_1\F,]J1Y_-N1;]D08
M7B7.F1$T[L7>:4G2;HC;M*D?WJC +J<TANIN5<+3/WBW-SD(5=39%%\\H)$M
M.*S<D%PZA;,#IJNZ=$L#O5'!& Z?/MNY*HYJY*6[/8>C$+<XF+]:-3S^.%_5
M/;EDHL4]-LKK#ZS"_N@Y,U&S=0<'!@SIQ/%?*SDA3R@'U.?K.'J=^%T YIV[
MO&7M_6"U/+VNQVZ-N4IE5;!2Y\7&4.&)T?M15D@JO-)1-K5B*7LBKE3[K/%4
MYOH+?IJ8:M_%Q$^7NJ_TM#G(];\_TE/>.-90ZFA3JG&LT *NO(S#[#L[_](T
MCRMI$%CZI.(HP^=RM9.C;;Z2^3BJ7]X9^ZG2?_@T7/RR3N#P]U=)0-?Z7S5K
M3[<+C$PK(R=%)'Z;D@0G1Q?[W=@!\9YO5^BT*3 ^ITF$9QMX4[42,0Q*W-9C
MLU+$N,H_HX\U-N/7-_+U/9J'/_X^SS3':'KE[8"&5GEK0/U_%,>J;Y>;:-PH
M.[T99;)+<&M$V[D8[1F'E[)DN%G".-VM\RO78R:GL'$_;L4Q_LSQCC.S1"/Z
MLN*&,#_&1.-V1' 2<H1"?SU;]^E%,$KR$X$.DUK: <D%AWE'6[58[N)0.N$+
MR3B=D,:<9V4+MV8NTP1G/3'&,:'R69D!8;)DM)3BA14_X5BL;=?=2[@/YI%,
M@KK"Y&80R_$E[F=.43IKW>F!8"QMLL<#P*LFX]GZ^;Z)&-\1'T:99=TWZQ:_
M9=*@ZP[(<E8"&VC%P<<9769H')4W/M4Y<> IH_^<GO,AFM6@-C_B8K>BWQT2
MR1&!<,[,FIB8V7T\X4[2^=H:;OROLA,<DA]*Q8_+T14KA4Z"4TKB0"P7[]9H
MR=X!^8O<U9+;$.XHPWPEB':?Z"7LVP'%ALZ=6<9DWV[BA_)Z"G:-P_'>9L:K
M/!)R_JTH66T [[5ZH< YLQXVU(QX>V1](/8\5I6.C&/W=T\+*D(9&E(3"]WR
MCB\\%MQ./[,16'#!*07QUK0L_97J&3\+Q/WA#<-O1D:JUR:]6)4DY\<R%;J\
M^1Q[ARWD9ETZ98W\>1W8E'HS!54W<LO7DH[KZE&+M/!C*C:_KKE[I 5_,7GP
MB[!1Y!6G"3$03@64GDW<%_R6SM<LXU;TS$I':K&R^CUXYH5\[\1B /_/@!&3
M]]T7.>%^$ ACM+E/ *:E[#?#&MJ\.JU[FV3B6QDZOH[<><0$)!1)'%"D>'<)
M*N<Z1<($C#/DF!1[%W;O=Q1SXVS&!K5!J4ZO[Z1[OFT:T?D2K&B[ [J=SF0M
MV%%:WP[[KZRL5)>\S9Y5Z^H=VQK5DTMH&WE@ZOM4E-9*5?]H?::>G6Y"/->Y
M;:G>QTF%.^.4E)Z-4JBI9\I39RO+ \VK4Y<;H4E(P'"72%Q-MI\2_DL!L;W7
M*(PC'!A5*WF+78?$\$,%JO"5#/K /EA@2:XR7X^'%*A1CIIYX)IC>R<IC3I[
ME3[0^ :75_'N>/J45O0JIT4H'D]'2EFS_-L-!#" R(UB3GM?RK5WL^UE6+\D
M1'VFCL&AG6UZM@?_7#YE^57N=S5:\!_(]WB!7 WS%<Y;%/NEPL^Z6_O)$Z3X
MKI^M$ARTZ5_WYC%LK3V Y8UZKNZ+N^@':=]K!7]2N%:MNATK_IJ:$I]F;F4C
M[XE&1^0SQ@WIK,@!?+W8\@9'&^X"=Q6H A<XD^_@;VCTVB@)RD$LIA/NF,NT
M@E\I50X)G$4_%LAGU9;-4H^PX)D;,P7J&5;!RC7K/\E\R '/(Z>+:B7O>37Z
MZ7]HI<%(MZY+LS^DTS")_T(9UU*:XB]$;A@I>T:7:B99/.P2&:>ZS;([+-*T
M.3FT0NA!H8L F_)T7 #=3H=Z]YFGHUI-YR 0W/TQ]NC6RF7M[X*CKU SXIP8
M&NJ5UIL9E889(VXS FDTBZ;E7FDA)VFIVK]86H8!NEIT@",GD.YU!C*"[PVR
MD(HFE[%+5-[C9XT8W\W(PQRW_$3.I&5ME$=8@%*A1RE [!3J-:5M:"R[:9&,
MS:S3CV;#TECXA5GA@;M BRH5 IS56?C+H^WI<N0?.#D 15>EI5O=@L.7W,\T
M#K=K(F=U2'3+W\I]Y6%4V(')Z5F4A+*<04AV(=QMRIB7:]Q6P_NUBK4#N/X_
M&JIYK,8-H/[7AFH<: *)?^3X_]90+9L)2=%P7I0:^!\-U2I- \HG!WXU5'.#
MH^;S>2YN7I#EEQI9=[,RND<<YIL_O&PK.0'--M[]/6O5YAN44]#K,JK!'U[;
MDNJDH7T<XFL[27BH=Q(&,4VJJ]T,QA\7)>P0<,]O*#KF5W%;WH^;(E?U:Q[A
M#E<V5W&N)RNZT\"$0*?L0;HMSO<7-OM=!R9[_T9M)N.EOTA>LHNR-(P=+LR9
MW )J?E2).#-=J'6-JR;<=Y>)%'?Q?83\(C@ P#@T1O+UC&NG8_.K\!ZO<; 1
M)HEOA%)P-=.BWE0GF9\.3_ZW9MF3YN]M2KM35\=@P)4F]8M5:HX9GQN9_6#R
M 1K$ZK'L#WG+"AA58TT9)_PJ<ZN*[^QUBX1BM%OS#*23US*6/+;$1!^/C 27
M1N'OU"C@[)J>%@VWZ^(><77832[15\!Q)I!% VAT0Q-\2O8"$M]I)I92VO0B
MZ>CRBO;PFH,?E<9%<H)V0-U%G-[E8(XA77#H@Y9031"B="J?;O[P;S 8I\E)
MJYY(??F4:GO6JVD,Y\= /-]->R]U.K;K=&7V[PH56N-X0 764=8.PG= \?>1
ML=G-&)Y)_2L!F.-.9J8>'__B8EX,#/2&0#E$8!+61+@5]J"TM8Z+2=*I")^^
M<=DSPZ$ES<^6B?+'J#REI$, @_"Y8^X:VV],Q 1':D?\M=3;#^"D,]R&UT<;
MFZ-H9MS0;J2TVS3K[!]C2JYZV7(STAS\$_^5TMHDR^N)51KN6^@E=)^&7HTF
M?L+(P6 '=/A$ M4)YL1OOI!I<&!10[,,4VKE+CC:*7Q/M\!BHJIN*8'WT^JV
M5U3L64P/K]5(IX00IPAXG5^D*!EVE$/$2T3J;+F+;R% Y56-"67Q/00P(/5)
MQMEJTAFGS(EB)8<9U?9XROY@066"#2T1Z,2^;DUBF%'(&].0;+GV#1&;Z0GN
M$T3B3"#=8@UX8R[JEG*7YC!_"<X:$R:KV2HB.D-VV/A2I$ENSE?^@&'*)K\
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M,!]*UQ/:F3)[ X78P,TO?@=:Z@]ONK^B.])&(_.5/,Y/U)?G]>'E"$[<^6Q
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M*5>\W\45R==.&ZP]Y&+JDK#84)PG64!M>.+FZ)%]Z2=Z7VE<Z</>;,9%QK'
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M!V6"P!F'.A"RC -77J^P@7%3G!H;2.T39@.41@38F;O,[#_?C?KC2'M<)-G
M4X$:].K9<313I@6]\1E%DZH^!GZ>CP"I$R_ 595 Q-75GF=BD=H5V("<_#XV
ML$R/A&Z/1J!7Q<')>@H:MN^;*^8'ZS@IJ,TC-!0L,(EGSO! ,:,'R#,^#63(
M\S?RYE&T-$A)#%1D Y]?L8%X0812;?CK_&&\KFLVH>CQW7<C6?O](MD YW([
M[,W!U/,(P:RJ36"8*E\QK .H6/0?!I$_2AE=:)EXS[0EH)\7[>ZL5'"5'U3B
M<+.\3%9^-$1LS#HM?#_KP1G!>S?$7E"6XW9(WM[_&\\,2Z#C,54_Z.[+W/-2
MXX6?3&K[")BY+[F&W_FYP,TN+K%^)BV2W<E"Q2TFAX@<DJ6BMUX-Q@<<QJFV
M%.X_K&$%2S?FBDH'R\Q9,0.-37>&>DMKIZ6&96F>J+7(#GDSGFZ3K+9*4%'5
M219OT!'^\1G_UA.STYZ-PD%7.@"S'[5VF O\8&X.2 ( D-6A%5@3I==D+<MK
M*_8%?K'U@!WY(W,J[MFI(EW97XVU^/?_AX3KDU9LP%B0Y8-05.'B^7]YE>1K
M3UP1![DV IV7O,&-W59@7RYZ<V^>=.L?3_I\!!XEU\NW)A^$3L)'X"M(O5&/
M_DX74F:@ VLO*L/5JR26Y/.*\G\\Z',@I!Z]N8[^K8U40ZY'?5I7DTPK,_C;
MW5QE"P7#C!@H93TBL8'5Z2S+S+Y7.)DM"F>!!"ES-@ GK<X-H+]!Y,UU5.LK
MHPG"O/SGS<.ADJ13W7\WAQN'$1KT6V(>V'?!B*5B8TY^A%H6;T6":\422_Q=
M#AZA05\->LGSR5EPDJSTZ$>>#;[;R""&U^%HJSX'9$R.1@Q.S.:/NU$3.DQ>
M9L>"HK'6 Z<K6QM_V^4_I.Q87@]&?RV=P] %:/)P]*AEM]*??QE]B?,#&;M2
MV4#I4<CC$;BVC(FY'"J9O_/UWVU@V^7?\,A_>5QV]?!?/["8_0A6WT OB(?
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MXDB8 XBAB\_!<8@V34/T:F3D8"'\:9">@GA^L8E0-B#)R= XTGR/V<@3FJ+
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M,#ELDF5ZCFCHZ28>DWK:)JH<2R1X=_7C9730$Y^T)"UJD>!AF6ZLS%ETST8
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M\$+3:^- 43#W"($O'#M# Q4Q':EQP)XMQ.-T["Y6?S16%,/:U69'8!GJRSF
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MS#+@[\-#4]X"P;3$/7'Z'LW2"/258;\ %1I4\UE*0V8WJJI9 EALD(-L+$4
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M9G"KI2%-V5E92MFA^'UCX_LL;969%).29S)&M\.:S'X=?)#^@/<2L1J/M1/
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M^OY ?!]!_/SF4QL71%\U"^?HP?FOZ:E:476,SWO("_,0?7RC3?E_R'/G/1+
MT,"VEBAU%_]C=@>&=TUC&2(?IALARJ!C+ \+>>"2!O(E2XTWJRB $;3)/-7'
MO ] ZQOXQC4!S">5HUP $\"&M2P)*V?)_;A_J]C9$\S+!69R$2+Z5T"M6=P3
M?>T0@@V8.TLX$(*[AJ,C8KA[*K\Z.7@U[)G.##I(4$O2EP6/,*8WS.('UF9K
MB>1H^H%!EQLS1@ &8"C!?ZU4'*9-R M@(C];U?AQWAL_/A==:I]_USU\(:AL
ML%3'[VB"2XUILD)]Y>B@.19W=Y*><OK3@U!QUYCV>>TPC27K<LF,DF_%O[/$
M[J77.8U>2J1Y+@-F05PIH'4()=3T&UT4<M<90H>:")6"#QF;W=OZB4R_Y^PT
M;H@Y6!W*Y+A &CBXC:]";KPI;F[@VLR<&R$_K;R7,W\7\RI$BO+HDTB#D?3L
M)J63Q@S*7LV\+1UYDM^+JT,EE'#TUPHTWX'HF7W\L?K5;7V_:(A?QINS(S[=
MT1_ZMIWKISJQ^J(F&@/Q.=1$+GL:[.5$<L/']'6Y[HUUI*9W=:0O>E(SS8?7
M]T9'2H=<1J:AU6G"X$/AE<3<5+4U":VPRNHW_6?>CP:M&5L-SYF%?#]=0URC
MO\V]U#8[JGS8U,'[8K'5$>N,T+(?Y0H/C2Q,C$PUI'),F<F5[!\A_7$;]Q]9
M,;7U;EQ\GI"YV'<)+[1Q>T0QP+2H5+M3;S J\]S+;VM77,]5\LT&MB+,*#LM
MV02OL70TM3/^S=?E';M7?C;(NZ5HTD4WA^D_'!UOC([=ZE!WS\S0450R%N-W
M;O'=4,R;\*_K#KPZP*\_RFVWSGDG$H4,"XDU!IM9F>L%.S0S5$S+[K&Z7)ZU
M85-C58Q9W#RKX.4.)NK^G2?.9O'R8P<&IK\:^E[E$79BAOV+O1\2'K\2SS=5
M7QDN]4%+]J65X)SYRQ;]1<A2?,Q7[R]M\R&E<F\8RK=+K9K'U*L&*I<_H8SA
M[#BCE34CDY5#A$X$J*:UYGN7<QYHU>4KHZF1Y1K9[1CJV1,(3P$LECUJ;)[&
MO#;K(]P/.E![V^V#A<,]B]' @34]ZWL-[&S/\(#B$((S,Z),_X5_&76Y'E6;
MR0< 9H#H6H!\)V'B\@U>[J9N>6B3!$?12[3$M>?V&RJ-ZHT[JB^'UC_.0B3Y
MR8:;W4P*EH8/^F*5Z8J;*XD\\[H(SYNL TKJ$RN]3NTA>5>?[+#1L8GVQ==X
M'D3VM\*A!/1WO.U0%*I'\6JZ?FYB+6+U<ZJ$U:4Y0H+9GECB^IIRJ>(GC;>N
M.ON)-WO<M3O\!KA38\MD[C$9OM!8.;\3\1LP Q% <0]BTZ7(050MMT 63)7#
MK*O4$1(V5JQ#6.J-C2^ZG;U^0B!P0/]LR-ZVTE<3XU2JBW<+C&51CI_V23,O
M0QG.HIA_DL=U9MDC/%+DO[B[<S\A]_OHGT_L@!^I]#L7D@:/D=X=@Q0'ET>%
MK"@V#D17X/J@GYX:?>S=T/?[>^.#IDYZ/SEU8=J%PEN <#X0N.?.JP!F"B Y
MN+:9ZRC/6O\0\AWP0OR6>%7'U=B:W B&T]="FY#TQN.^W]=4_<ZQX$^(HH<<
M)QPZU3I&:Z63S^N8\XO0^/.HX!S/PZT>H6X2!5_*KY@=:[0NRY<\Z&9:E&GB
M4UB2GS^P[6%,&?R\X?)#^E6O7;2VP:YI6R_3XWE6";[A?0G1"OJ5=9F;Z%\?
M05W5Y9BA(KMP1/('!-5J<'2'/T9'M8MHV;'D7A2O2E96S[C:"1-$L 8#ZD4:
MWW'W&RI),^:8=B>+G#&2/WHE(M2/^G?61Q<#^1W*HLY\.B-"U(BE^CCB(/Y5
M2*S)$+%7PHHT?7I8/=^I3XJGL_/;6>/3,=_[&%)QW';C\;/?#>\_YE\A\I-P
M3+^QM;O^'&.@59^KP13 VJGK;%*[Z'BP"_"$FA&LC!8O$L#V;XQVB]C316:O
M>=P QL6EC[P#8JF&PU5.4U- 6V.+5GQ0P,F&RJ(Y5M;>@A@X?,^Z97;5VU%^
M=]'#8OD!!9OYU-RWJ0&4O/YQAG^HN4GX\S@>YF#!-#4M2=G0)U@I(U2>F.%U
MU1XU;:I02+Z*</TW]0S%>%%0>X+=.0QX04AE YYZM4SV E$<14?2WX$]/FC5
MT?Y;X(NWXTMAI(ZKWHQI^FV96X-$VRH0N_#I@AKWC/64@[E&?<E0/S]VBW\=
M!6\Y[8T2AW#.!\2_=3-XL_PK44>%>Q-\7+8L/M]1L4Y4.Q'2Y<@2V_HF4N+L
MB*X0&1DM/L\ZI=\WV%Y46E?_1%3U'.>@",6H4NMP?)HY_4VG^CK;T_53@(H6
M.W#9Z"<58SST@WRXFJ@P]U7OV#E&];OXOHJ6J?-GGS;GCM&#O =+?; VLV6U
MR&9>"N"!/,[_2JLCM\''NSXLJ8<1VLGBCDMA614G1?TE8O3D/6J\"RZQ?*EG
MM3EJ,=B+[F4K!U-@[],&E=7E?)YGDH<);&=>%E^8WP7?PU5D2LUH19]ADAXW
MJ0B;G:^ILW<[S4+%J18^UL"= /L=;ZI\&^,Z$CYA#N1D%9^[T'K@D*/7SM6L
M3#I/^>;@>42B**B12)]_QH!/.,\:MZN83BOG]L<B:D>+?%Z&IFF'BSAWMF@S
M"W#Z>,R1CGJ3].N#6Q4*3=D*SYQ7CKXAODMS6*CF;RDPN+Y.S[_^99/SZGJ>
MDJE0'=ZI\.%\6C-.14M,F!#T?H(!CWWON]_1]\^^6TG5VF4CBM>+3+H+I!.3
M0D]3FT*72[N+<2U%YAK?3[_MQ=P8:#(K\N:?9$D_*_'A2X]M]O".NGT):A1V
MM3<:W?2U&W4^97US9+,1Q%</U_6:=H:NKJ^JG<X9W1A%^WX_FW;BE)1% KA)
M#;;H]<Z9TE]8-)?+0:N/Y(25%"Q5EN(6E#F!0*L(1"10,0CB0GM_+*X&O[K&
M,F/@/C2N71]K)POK(8L<IY>IJIETPN'G)5%MDK3DH,5 7Y4MLA -J?_LH2I1
MN:>HV&E\N2&E*.A<]AAZYZ@ MOL?2*E>AL#F3^#>^H3S#&%-E+6+XB8*VL\@
M19 ,97B\DPM9HDGCK??.^A.N(?VJ@=DP]HIF^HP\JR2;<-E;BRTQ&A:Q1457
MKTS#:T;N#F\VYHK(."=R;A>V9!&.S8M5I0KIA*"- D_M)WKN3R^W-#V9ENM7
M^"37WG<#$3H)?D;\:TX;&_99<;33*)!E)G8]62>C]$N1P@B[JB2M<-DTS\G2
MC&H\Z5+)B08*UKDG<1Q''SBDR_P<$9X3BB6I'^ U+;%WZ1.Z$=FC+.\"!.M[
M-)TF$3+D&"+?DC8]XTCMIZ\+4Z=4<_$]9(-A)T6U.DZYV2?REP3RI[OL*58O
M!!W]$\KL"A:_&) K]F?T4Y5G-6M/]31SC.HE4(>:_J#:YJ=Y!R !G^*E!H?:
MH;I<X7C'NK5+HX.MUXWOQS6[G(I-_C,">R,-(V(P21[/1S_\H:9AH2&SI/D
M3$S*/UDN_/1IGMUEL;!ZX-1Y]2N3DLO-;Q?[1X7?.[.U>#EZ2,Z=R"':[V0/
MPKYI@Q)O 4P,ZY1S8Z>)U:_N)!];UZP#M:_@PEB.E$]XJ8>.Q-,Z5XS]3>RK
M8S6.YX./.CO7D2X"99@/\+\10H"'Z-,645"&:=RZ$_R8?Q*$6SB+2!E56?U
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MTFZ'N2IXT-BE'B2\ LDN0[Z!4UIVKAY"FV^P9V8)_YJZAOUY4R;+K*=G4?)
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M##R9?])<P>[UG+2CMKF;WL!HWT3E8\-C=O+_RV>FVL]BN"<A0RLD\BJ [U'
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ML7XC?6Y2'16%U%J8@;^=XBGMX=K\>[XW\$NZ,ZTHYTUT$KY)K <5Y0Z77,^
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ML#%][9/A'G6;#7H^5[)0:C!2<UNVS;BN?>[JK"CUZ"RG8<!0"%HBKX-9E4[
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M*%+=J&>HV"OE ^'/5W=1GX:IX8#@S%3X6C1B')/@[%2WVKP:=;W34[W%8+.
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MTN@]./Z-)B_N!W.-$L-])US/#>FM.1<Q%%,T$%&C.SD!ERO#.-G;$&W*[\B
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M0VZ^SM (M8FF3)U\T-#<TAA_;*3J[=AF.!/!%[O/PQOZ%/K(UG72$G$BA%\
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M:=?"='GK3O;V1_A] #SGM?*!<]C%5U9KF<[J<F/&1(;D> R[D/D*2_J(&,/
M:7E3_I23R^HLC:2@/:1#A8DMRD[6-,L^(5: E]%![9FU.7[W_(+*W@\'=PK)
MYF\("O4:[P]C _09.]"*<P\%K\+%<C6\'FWTY'%OL819)^92&6AG=ZDGK[L$
M#&\71R=<9WG](71 ;;?Y\@HTRG&@YI]*CP6XW]'^$#^5C6&6&5\LG9?&-T"[
M\]6P;;2:=K:"-,M]LK-\NF!4$V/ ZJ$K%^23%!L?S*;2^V.QAT>#>YTHSBB'
M#%9A@]%<XJI&;WZCTDI-[W*0[\MCAT]])+?:DCS!,!-3[06+<C>#\JBRZ93G
MN"85V42SUQ6FJ=8V*>.&8\^#;AI[Q78R^9H2:>:C>%GM"RBQ)%))2LMO)AO#
M+XI5C)VZ[6T#?<4CG_;/:3T#F"%UG;U'U1_"O9'C 71B^^76JIIFED@;[I@P
M*\86R#=.7)6?*E>.9*#@<8W^^'<)IP(O#&N$P ]^]5@\E"!%3O;$O!,B&G$:
MA]N[Z.A,S(HE PH%H=/X5F$4PU71.JWNREG!;X#.,P%_PD7Y<DN[+=^DM\F!
M\U.'6="H:HX (@(F.:VD?]?..8-@[=/GD5^''TLFL8>Z(^[X<#]BG@I?$[QW
M? "W_Z%.>0!I:A]3KZM7Q%3-8 (CQ<KT?;I%SAZ8N#GF@!5EI>=,$Z5]ZYX4
MGM7PWP2@"RY3A=MU@6*J-(</\8M\* FQR3LMM%ZD=J_=S6:AG9(==R-XKVCL
MSXRA]2&&UJZ7MH095UQ%'J'T:4/V]H/T,7O/E5YUA=.VS]*R8FI)GQ_')Y6_
M*S!O\5-<?52AQ,!DMAR;N^P8]]R5_>C+HY=19OMF5A3D9&0#4U.K[;+2T$4]
MO3)O^%UI?&$D%AI^G N^0P"A9K#KP;@R#QXAX A_0)C[FN:<;:AM2:*2GIJ]
MV(H0;=._W;)24),O0\[4BJKNE3.K(KBBI];)G7*OZWK5DVCS>XSH5UY9<RCG
M=P&DU8AP#-QFY-:%,Y+CIO:/81R9,5T*ZB,)A#>,TK7]4ZX3:,!]I$(1J2N
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MF%88LVO]JHFD_:O_:%#_=S>I-E_XNIX/<6N[ %BX$3(Y]K]6RB./&)\3_M+
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M%(CFK+QU3(S^'^ZV8M1W<J\SP[CGD+\J=<$!7R@5(1@+G<6)012$7 4FX1,
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M3!\94;0YU%NO5#>Z9%'Q[NP]M8@;EG<#$.E=S&[@Z4+P)YW[FZ5FMNR@$J5
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MRS.%DSN/88/M_(R83"^-'OM1]G4-:\F:G.$N^IT"3+B F551YY1;1P%EQG1
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MCQUPI]Z1'"KY9*P%N )">Z!#/W=QZX0!"6Y_LWXGW(,LWOQZX'$IMY]8VY[
M-"=!I+E#68BW?CCGL?93')>QM;6UR(Z(8R]U\:)> 4T"0@N3B"U^>"^9,%L
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MSLUQ/8K7TV*!P%S=-(LDAY>P 09TM8F11-?DB!=PC]H:HJ\SO7#J,YV>F)M
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M),*9G%A10F@25.V*,1:SJ+;]0N,)E SO*$J7W4\2@7COE50K=FH&*ISYDI_
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M?]>P7US2Y<NT<^.QW)]'6JZA:=B?>D./?!7RA')Y_;"';7G=T(=RS1$MPFX
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MC?0B8_*=L1(R*KP:&H[8_PR!VI[:B7RZ?.FJY' C?2>0,J>[]E/*=4[P!S$
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MI RFBDA'9YUDH]:0X9<YH;C-E[2+ 8T*Y7"!$_5$W!U&?*R_I6!=>*.^)*C
M\.IKF?M\KL_(9PA_FIX26G? K?QG?OLPE(2ZX-DBNRX_+ZF/@4(C]IS=FP=H
MCK+S_4OL6^_'-YFZ3*S%^H]&SW>@6H%O=$WD'Q#)]?TGILDOR>E-=K&0.Y N
MV7 :<W0P"A(*=JFM\0P-Z'-LQ+B+5;T>@;.DJ)#80B]FLHX,/MRPQ::-:?KT
M5G1%P@6\%V1'U4\33B,%6:)TSA/=EMA%PIO^W!8MD=.W7MK(A[]KN7G&!6YE
M4\-X>[+BJ99._Y.G/F**>JY*%>9.&*M)18?.3W<LO,F933= BF*VP$ZI>Y>T
M!"\I9LDT'!ZXKF!A=T'<(F?13.>26JSK;N+N-^8QYJPJ_!"A'/$*PE9E>G&5
MZ@\ZT]]\$K1OL;J/:$(%HP2*EZ0M,'S@+J/^BB"?>12CLA;M+I;AY#A>18-+
M8N=;U>P,"K"!EUJC'=Y[ZA\LJTYDBW-AKET_X678C\GNJ& H!B,_7)X:5 ="
MN# A78V)AT,^A[,&)UO2'B<6M*0M1\D_?]GO[]8GQ]"O67],/O%H9ZZ_2YY^
MSHA;QKPSVEO*#UXFOV"[H<QI@SR=KMJ&.DZ<GM)4C[!.=1O$W.U:-$6WK/=<
M+LF.4D&W92GV^R\?0(L_5\E3Q;@7HJNL'G].7?HU^&QZ4:';>EC= D6S(*X@
MK,GYN(G@3XUM_9X=!1:^58J9)MK')J7SDJ9&DSXJO'Y]?)VEU[Q:6O/R;?/)
M5D/IM*G]#4?*CTP:9VA79^I87_6U("@EWBX0.V 1JM!XOIH+RRKX>J;$MZN,
MM85Z:#B+F$_IER))8[C=[%Q=E/_D(*."D")+?L Y@XW:N#J$<Z?JV2V;1HUX
M2TW:#>36, I"53&TG[PJ1^*(SLY/O.X3PC0*<]@E[!#$Q$?5X< V"I^Z'C]S
MFK&W@(Z:= ]3_[V<L@_;9TJ'1]>Y3JA&]LXRUQW+\<?[%B"B[9T&ZH[2$/M,
M];/O%8$WD8*MU" =1WW:Y.6AFR'FS[N5$41 $I1O) BS5$NP<!H\%'=JLFL'
M-N'M+.<(/3QF15"I549BJ%C@T=M;_B2A^<<I(V:%;FY1"J85JWGTU".Q;WP,
MCM+1M!26-.+KHU7A-.G%@.:?6?=!5>] =1$NK$F#7D7[,<6/.F\8MS/JXRT7
ML&B"'"554:>UMA=34,49\E!QOQYB%&_:=\W&.DAW5.7MR6LG[PWH?N_E;*TB
MX":=W/5(5MK(R*CP3)MBP,/+':W(]PF&*=;?=?IF=(G]0A^[=>S)Y(?IJ'9&
M'2/_J;8QKOOVG:E0=YV$D.O'.Q/2\^OS#L:' 1/9"+J??',8Z$]B:;$?J"^+
MSC7H,\QB=R3@ AAA/XT?[*G;)I.#<1XHH%>%:OQN;S.DZ^SL>:B*:<JI<'6A
M+FHRV?[B(8Z<MSK^E*DAEG @AT^:H<I\#W;]RAE 5 @]K+N(6&@DHE-D$"\'
M=>_<45X/7Y2?]/"?'^Y,WCVDO&I"$L>>GFZI"5HAB/IO,*/T?.$5V !D_S-_
M/:1%?0^0QX4-;W $-[<J/5@[AU8HHEXHH3H,8\.V9ZF5F<J%">Z@C:J*SP@[
M%*=/2J4\8"E0*=NQ_"W,2$FT'Q&L;5KG)*M[3SF\Z_([:"W,F;"SL[.Q&[6Q
ML;<?MAFV;_9T=_<4^'&P\O'CGF)-YN @_>G%'77[<@P$3ATQ%/5X$O7TUQW6
MVK]-G*PXF7I(ZGGFW0&<SY$WM5952U\<EQ)Q)4_OY+\G[O&QF#8+W^M6_4PG
MSKD%3!-S?HA[=ZN,+R LYAEQ8]S5Q^F':EJF[8#QJ4Q7,_V.=SE12A^1M=KQ
MTMBN)BYLKZXD;3D"?V:PF*4U0=H&NJ 8A&B6P1/)'6$A5(!_UOK^=(1&T:2
M[UOEE7JYMJ7U#ZVBI;MO^#ZJ=49^"<(/D>&<4T"C%1>&&24+SXAKC9 C\"=9
MY^B4QJYA+NRW@/LO-X3"=.'^I,SMU*'0DN55];Y;ZFA)D@8Z?C^8?O5EB''?
M4<:N"%TDS?2\\N 2\SH7=@4ULIT9!)ILF+,4&?*-\#A]Z09&>+.01.5CG"DU
M6E4"V]=XT=94^EK98/D&>LSE-Z<C='*$3)N*1=.;)6\]_^LOZ@(]$ICC--E/
M\Q^0PT,</K'-L\O8B1RE&=1!_6V<SL?X72"1&JWG\ZIY7+D:3&$DMOEY=(/Q
ME^OHG/)U?.HD)2+K>(\*277%U/!J+^%J_!4)A@V*8G_>3]0Z@%^^^T-J/K]B
MG&*]\?6YR:>6=^G,APCGW:.I?AT#L0:+BL<WS.Q\[X1**/E8&/[.T#1,=1\X
M><;.)D83KD2TTKCC=5VQV-16V[?*+./VYSQVK(26D5GYM:?7<'.*PH^6""\D
M%G(GNMX1F,Z@Y88V5G5A[2HH<2Z>LQ^SK]75U=UO$GYP[ID_7 )\"@X/VU2T
MI.67Z35Y+@<>'&*FB54^(CHXOH_5ED58FQM@-;S,*HR3O8PZB;9O\CZL)4V]
MSZ,4>3,7@DSWJ#]?\72>:;3,O92A8!$\HC[;>DG8\6Z4\;)U;;_2ESU0A/.<
M(V7['MS%U -;][]-"XND<6&1%$'53->=XW-=K5*JX;J61.7G1OH?TMJ W>B=
M?-XJ/R5K2(?VR\L=.JW!J4=/Q8_D,O79F0CO^/ :1!-Y!$.EL)2[MGG(G.[C
M?.<I)<22;="ANP_K.A(]LH[0/X:1V(5T+JQE7'30_9,Z1FR>"=RH[G?KD]T
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MP+#.'G<&)F;4H'I0][Q<M%8,R]JO!/MT\I(CYEJ($<$FT:RB/FMP1 )QH<?
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M?*B:0S'%&*J<1(IUO\:?KU!^P6&!C6^SN;"J@R F&%C]A$JZ$,7B&T!,?*"
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MB//5B+/^94/@"KX@8BKI2$ZFMMP8TV2:Y*)]9^^E:=/BH>T_C%$&#^>/NZ]
MH?,.*'0V0M!-4>M\K-M0>RPH?^SD'H-^4 .8D6<T0UUC GR^Z(1A:D(-/G>
M!/7S/&EZ. THMMT<LZ\[S'^L%Z[DD+_APFC'"* <B?TMYPQ +<3\L4&9 $RD
MD5=$0"HT:D3RYK:I-#02OPI80P"L#FWVSLW-WOECC_GK@N$R40R4V*HBD/TE
M0KT$A:*_$EX)L314_M@Y'2:Q83?)4&<_(V]"+OX5\C^VF;\N%P8=)_U&!B/E
M.7Q%$)Z(.#CH9?_'#O@_5Y?3U@',;!?;M!BV_Q\\E6[R]'6?^>MJX>Q_H-\,
M_ZG;PM=;-SW#W[::OZX74HR5Z*J<(T;0+WI!""$GPSE2C_^V"_[G^KXH0ZW#
M6C<C;$=@TP25-TWPZV;SU]7"=7/4 X"Q'\D2L>8$ P<1]/ZJ/W;!_U1;=FP:
M]&L[E3;M>7W^*^P_;,+^=;MY<ZUPK3>*Q;_5X&U9UX5;0YR?3J$@RQE";;JL
MZ*\NZV_[S5^7IQN2K"=06X[>%O5U<2.O;(O:](&<FJ\.@@<;#S8>;#S8>+#Q
M8-L2MO="__)EI'3#5C+]3A445-K2F<1\6R] 6K"CU[[8"=/4%J?[*@"CY@.
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MFQ_Z;V:DU9I'^;R&<X?_!U!+ P04    "  TA*Q:)E_]40TJ P!TKB4 $0
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M-\$D#TG6B!HP$ #%CJ^8AX53VP]I3 V(OS4,::=MP^3%R+3M G^],<T?8,B
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MVY+X=63<'Y/]NAF_"<WGT"R[!7'CP[][$_2VNC1&6"S)#?G4U23=:*T"\8R
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MZ@UF.@2G>8_MLGL*<>T#DSENO6 E,LF29E*GSL5E1%AIQGAI#0Z]K7C4XPJ
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MG&62 A)RG9H9!Y%ZOV")0F",&,VYZ&]'VVNXZ+0,]-Y^:$"D3B>5:V]FJY6
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M*/J.6DYD:_/N#5.E(W/1(X)+#FJ%*)$">P,993$HI5%K^: 3-.XDE7:(%W@
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MSWX>E]1J(6.J-P,R0,$G$PC FL(@!910-O06=8;&!VN00CH )@%R2%&2Y)(
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M) #NI3'D]G%E9PCU?0V4./K_J\/L];C+]<:4R64V\09;<G-T^QE1I1V)PP:
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M*@V"X#I! -AKBA&\6RB,<R (4B2&S]C8)-W_TE\+& "ZY$![ /(#GM',M6,
MMP.8D>.GR="!FX%UD&;Q<_&YJ;],]N>'M\#N"7ED/L1JG NDY9CF%"I*\?.K
MQI</D^?STVX\X>KQS4],QL[LY"O&.C^S&G=BCE"+Z-Q\6[39MH8 H4TL7D+4
MEKZST![.M]1W57@E6WB)&J\7KZ-XZ_O"G;[K8<L\ZTZW#KMDA-7L'MYO,X6;
M7)_.6] Q2X8D%00QYSS2-'J$!2NI3XHU7U'F:C(+FA? C9_KYO@2SV<^*<.Q
MFYVT7B?H[Y<+B]7L2-P5 :UJ$^(VA6;7LE/ZF"9P+8; ,-\#P=[K!.Y<B:S#
MA X4V7\(95= Z(-41/NPALMM75_F41@88T"6!X LPWP/!'M'$[A[E8=SF-B'
M29EWZ&E:&C:O<$E1;"T542(C0HE8- X9CS6B2C@M*3;PRVI<4ID+?IVVU3BT
M[7KZ'JVMS=&@AMXGF[^\?-.GI\R_SFF]CT#E 30O]KW$@00K%=)<<\2,Y_ I
M>J2H\H!^495R19V(YJ3_UTSY+SK"WS#PO'?*&CARF+=AWH9Y6].\?5]BQ@.)
M+%GKJ_8LABM>$RV5RN1=&N)5Q<O"?'-P;_#%N,ZQN=.VB[2"5^\:J5_2D[)N
M\K-&Q^GA7RIX-#RV&,.+U,FU<%2UV4,[-F-7F5'::T^-7-+)[<2,O6E\6Z12
MNY6_JK!3^8/Y\=*@J2&JL*<4^>U1A>U^&(WF1%O\ *28H_NZ)FG7Q\[-HK+_
M!P9;K"O)8$5TL2&!N;<.9A>&$<VY1\2D+H_&!F0CX\@RP4L:L8S8K,A[D^CF
M,OL#WO9K\##N4?N]Q0I6/.'G8S)N53/_D6+%V=Q)/^M>WN90W"4S*5M DJ??
MDT[93FT+MPZ==,H!R&E8E9W.NO$4[>D=IB N&\"UPQ',,+QMK)J#;ABI4NVT
MF2R 5E_1:@:F/02M2\*;'A//[.1X]S?FN.!/"XHI_+W )_Z6R+Y2]\Q,2+S*
M:4? *[.BRCB6EE&"*$_=!%/S!QM+CI@CF)9$:%I>R+@7#L0#PQ%AKDO$I(A(
M6X>1Q)$1%7449;@D$3=7E-E-!65V4^&8]MUTDK5/&/D3X-6JN_W'3[FL3/L$
ME ]7'8#H^/G)Z[>OSLJ5\?0 ^7J"9J<\^84(\E0R^513.@?U^8OV*FNI>[=$
M.>Y,@9V3LCHGA79."NP\+>K3B>ISCH*Z"TORFVH3?]O;GRTH1K=HJBCFZRE8
M[;><F156>+[$V>"KH]G?_P Y!O]V92F!+++VE>^2[V! EV^>7)GD<=:)L\6K
M\2RI0^;/"_,ZRPFY-$_@8H;'>2\/[YP\::"SH?P;@8$<OF[3YW$4OB(/FD-F
MW93^,3T8/P<9#S+\>#L=O>!'Z@8'CYQMN74_S(3%?.;RI0CLY^>'=6<[;S<A
M9;D>A<47.2&!K_>Q$=$C*MIOSI%)-1X!]2# H6:VK&</P-0NY@&IO B'YG/H
M-CF1B9/0;)O1%W/<SG))UD>J*R#-NUE]4^PW2>C]":3 IS1;2U/$8M7 ?&,0
MA;,>C=M9[TVK,JN'.&>?V5+9$8B<]=#57LXB ^GVHOOI-)'8W"U8K1"<SKJ[
MT_%3N+H .SU!E^\JEW]/4NH 5GI^Z24K/Y]L?LG<SA:JEQ1T]\O;FRX4NX<A
MNYG?UI.0RDF8)A>%>%4W7^ C^KVN_TC?<P>X@S,HL9Q22[ZUY\2*C<A5 F:J
MI?'WJ4EE,4;'15>E*)5QA<DZ* A&?R]FI)Q+-.7Y&\WFKSV9OW2.ZQX'QD)3
MV%DD%9@.AZ$3"IU[YG0+ '[/!A5<EX_ '7SFKJ>%:8LOR1$,_Z:;)>])NE.N
M(05<U]TI?(5%GLQNG?8?;OO<K6)G?'SNG3(+^V(_-*$:=^5"P"#*&R,+)X*X
M@5F<U$W:<"PB6'UM<0!VN4W9Z>'@U EUY?QM%7O[H0V+-ZW&1_7H*!1_C.LO
MXSS2Z;C[W%3M'_"&TS3C:8#9U91.Z+I#5P=I"9/]GT92-^WIN.$=VOH@%,ZT
M(97F.J[35=,FOVI3C_)=TLB=29L^Z0C<8FI2@;)V.IK 4Q>G+V7HN_TJ',V&
MW+WE06H_6>6R,+Z*,:2Z(D5LZH.\)12GDVD3EKL?+'%J50;S5^?7&E6=\RRY
M.:Z9R\?+S*\7U_=I<5Q/X6-RM*24VGA\'0.G:0T-W!B&_OFX*W<#_#>ODU =
M7"B= +=,S>,FX<*1MIT>7/C5AE%:V?,_Y\'#TEYRGW2H&D\O^7TZ\N=_]!?/
M"[ V!Y?<MT..\[]^KLWH_&]5FM@+CP(&.?_3"3:=/Y"PZ\)O34C-VR_\7*=5
MK"Z.8JYVA LC:4/XX\)O^Y=-SR2E.%]XY)=J=.%I7\Y<?@HK;07$:9HY4V9D
M/0&6V2O-BW D=IU[]&<,#TL_=]'/?ID ,/@VU_E(##T&,3WK0)B^ISUGH,?V
MM.M]WA9LLGZ_0*ESY+R&M+L6<>$I2(=3^![!ZTPR,C]=/-?85$_BU@Z[%?+T
MF3#R!643GG^ 1B!V4!CEP><Q'%ZA<'9:X1DWQ@($IIY;E_HKLK7]/&,=2@]L
MMRU 2S+B+J#BZ?CQ%N5GB[[>.TR66UP2K!A1E+&28_WGQ?CG/T(XA)&.SMNI
M>9JNF9=D9@";G&Y!+!AM)]5(_GSNKGV1%4FXG]&AFA,].9=2FZ-1WHD+H._
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M8$228RV&VXN\M[$_NMXW\2.4#%S ""5'@I+VZ)+)U_F(T\>U-SZ)24! &;B
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M5-6!J"IBYK"E.1I%/-$LAY2*4<,+XI+R1%A-B9&YBL=ZRLK@2N-U%P4\F.5
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MV7-<[K*INW>PW[;.>V52C[*7VGPA7__0*T\HO#\4'NAS?N__?E5^=1!!=MH
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M5!<"::O_BQH8.Q_P,+]<&MF<_P+6,K'9[.JJ,7V(I?'<%W1#T T9BAMR=+=
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M#ZVWLM4.P)?EHO95G/OXPW+Q?FG/KZ]-;%[<7Y7X[NW?KBU+D#KZO#21"\/
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M"85E5?_6#GX-"K',[ER;%[H:Y\[L$C!)MOJ67'PN>P8Q^FL)J%UVS+IJEG-
M32[4-V!Q)=G,0W#IZY.QASXM7+>2;.@FS]$5,-@L&P>?V4KE8@U!NY]D15L"
M+8% ,S_!W1<Y@Y8]TTF3MG:K+1-L7FJ2N;N)WJ10MO1Y;B\W8LB)YQQ=OX>;
M@.$"GRZV\[Z[B%TV"P7G5_G@%6AS:%.1L<E);#ZYS=3 P'>C>3;YG\7O.6?<
M^(D-,4%</WF_MCGO'&/+QEE,N^+RW7>;*S?ZF?V</.%;BFUS-Z#>\(EES(J4
M?Y_#3'Z !VB< E#1C?JL<A:S71ZN%^>92M>SD*\28-JW2?B=+U"O%OZWLT7.
MNMZH7;]6P;,M?6I^W%7;8SDMD^&<V+SD)4*IB#%:D6B\IEQ24QC616W/M[:N
MZG=IOXPGNXM7I@"QRV*=+?O]#^ V $#6GZKCV1%>>+FZ[R/\2KLK_QES0H8]
M^S\_K<_A 1I%WYN>R=7\3+83U.AJ,['YP_M3NZ^0G9:BF2)R;D'7I"D@LK;6
M$ -1-6',\9)S"'%BZ%!=;RCE9?OS'@5F?4P.'5QY[E2%1DFN5?-AKJ^WN;YK
M.ZP>$LLU"U@NQOG6[VR6>O/EEJ%Q)1I&_N793\^V>?>\5NAS+C OLEQA"S@0
M<''PRNK)U\W'__OERQ^^:9.%%Q=@?0UM+M>SN.W=TOB^K2_0KK[^M!< PR?>
M?,P%!N\;1^<<XLVLDU__].;5-_F[=MFN:.2"Y>K\VH).L]:S=9(>(HNMSV*S
M3]T^V6YL6V>K*0++C@I0>"X8^'T.5P,?L:Y"99=5KE-X"5]OQK4M(VHV%K1I
MC_;)G)VUH=>5]"%&.,^.62M_OV]V]_ 2/O$J[H;#W7!/!!>)N^%P-QSNAL/=
M<+@;#G?#]>+1<#<<[H:[3PIBDVRR^VW;[I=P>E2>BG6]>2_PT@IE*"DUXT1X
M(8DKM"-"%67)K/2RN%4"_Y",25,"OX.'[]I :@<2^QAQQZ:]#O(I8\[&7:'N
M1JZ/0=^33&1\(E[?1,R3^BS&U2>JCS[QU;T '[YT8^6I*2Z.9_"UG*?/:[73
MJR_DS^^GZS=K--LUDJ\WM4W?7-6!@Z,>MZOLL=DZ=&,-/]\3?A'3;7'U_4:]
M7YWUR'LU>)\+P+:>P4-7_-=;G6X2*_7>"[LLS!,33XOYIN[R'-YI4I*;G0^W
MULCF\W6S)/J'XYZ'Z7;I/5?*;I:]0"UMN^(T!;FDO!S:)GU"MHCVJU]O-DPU
MZT3S69-6G^<REYQBRL5T37'KU1>^V:PT+7.YA8]UG5/QV\E*MEI>UZN['NL3
MS[.E[#S6>CV[6X]O*PA\H%J$9FD_YW2WV\;NOL:]M:I7]0&-L!>KG<"K9FM#
MJ'Q;T[@1\_:)<U%WW*R6[FW>2&N8^<MHEWFQKRF=R8N%S8+CMEJC53=X:ZOH
MK6P_FV&\"[%>PSB;#:4;:8IMRC%,\MHE*.KO307[LLI;I79E.ELSNX>^;_*5
MH(CY4UM+?8Q]UF?;9<QEM-NDY#_7\[9D;;-.>X=I/G"L67FW,]%,0JMTGY'4
MQIQOWOAE.TD_QK8::C[Y&QCKA!;D?^'VL^T>E2;-_.95?G^CUZU:WV\EMCOG
M3GK/DA:1**%*(ISR1&NI2: L@ \GF'6W#BYXS'+8+W5\E][4>3L+P#ZZ:3?<
MM+H!B9U\3MKS:FEX5QKRB1629B,T6%9V@*Z6AO):#^!$WA:3]VGMZ#5C[KG]
M+>;](:V(-]7C]?K\HF6>EC53BIMZF';])J\MG;<+,!M[?Y"[,@]W]!S<HN'5
M6/*#-!=OO8V,0_]<A_?M1?97??(SY-*<Q;H=I-\<<CG)NQW;BA1XIKBY]:QJ
MBWBJ;3'HEJ<RDF:.RAM,F_UI;:G]?G'+C9K29O-W4TMZ38!7HX3).@,O9;%L
M=Y=]S,S4EJC-&X?J [#B8EUO:VUN"OZ36^!@J/5BWF1JFTQQ^]C5TJ_/\UY2
M?Y<X\_?RB)L;7RG!#J)_FR]^!R1^'S>2W&Q.G^2--QO1M>R\=6R:3VT7SJ[/
MQV4[K%56KFNUE=MA[40T_8SR-7YMW3H#>5_3JIFFO!2W:FK;\EXO#U 9/E.=
M"2,&M:RG^XNAC1N1=XFUGMN>@DQ;7[#1F\:S;VO'/J$^TROO<?>-NSW'<_#9
MVF!EVOY#VIG(1@#CVU0,YN^>P\R"G+:.:)-Q(8M$UKF(;V\4S4;4?57>CR*
MC=M+Y#8(B^5R\7NS=ZW9<GVM*&ZRLA]W'NQN2^EDLTLX5QG,P&MM/*4LM+P]
M!<*JV.Q5R5]M1_1L\K*M6-SZ<ED!VFV>5V[23:'LIOW8Y!Z8B\%Y3@PK+0&"
MS\T+6"#" '&K4 @CY),S-S_F L27\_#+?ODAIF4^?Y+JKFCSFM1.FO;W-ICO
ME;INK?>/RUSOALVV<J,A[ZO:2[#P;.Q-X)SYY3,4U-90-CD".\E&O,P4;\.'
MW$@B5\3G<>:"S#9"NQTLMY6;=X2ZS_=O^/]=K[==^QQ'YH#P<HOQ>3/K?)V
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MX^*MML&W_3TWGV-S]3]WK1O8)^N<K[UD?ZV-[:+M?0J+;;,8ZUCL]QO 8DG
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MOF^Z'C8YUUZHVU:3[>]M^X3K[B6;IUQEZC:2PW;N+S;:&.8T^7*^6-L/8E/
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M]44/(]NW:+&@5^]9E;937K(_T$[EG+2!ECYBU!<&N0A<T[Q44UJP0D\B^LG
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M<N"& 9^,L0DY+1* &T"#CI:@J#R)@C&&0WIT<,L[1 JX#44'%' KX':4C%W
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MJJ@8($,R0*+000='D(E6(NYRII5A<*XI5BERIJ/>:1C'O+",4(%(2."0^Q3
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M79B[(-I)()JWQDO-.=(X@B.N$Z!3#!X):JC$UA-MZ#:B,2Z<5KF)#@:7G5O
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M =>+1\L8<"\' ^X8>63RN#QR><\\\O$J=@Z^,]]<@8M;(R']5XU4<SK@8P?
MK5K+6.,O@%?-/TU;:)\5BE55]V9W:/HJ??YV1TG.:#Z8FGD-BK3$"QH./DUG
M8P>+\^W5DT9HHN3# 3S0(F@;TW3#P:*"?\4>#U#UH R &G5(?535.<74/^@6
M-J73DUA(_1GP.'%Z61-I3)FLY*.EX&1J(H\Y@V@\# <__!_\K_^LJ/RNSK U
MH?DZSE0?\7&\L%,+A#$S$%,N9B->_?D'^,^WP]33N!LO:N(7L#0/M$EQE9O4
M<NEU?-Q405.3L.'(5;E4]6W3R%['4O\^F7Y"E]-/=?ZSA9:XBF4U43F^ D8:
MUWA.X]OZ73:OYMWO_ZJOKK_[L8';^W83SJN+K@2G57'U8%K5H9J47M ;N'T-
MW%+4T[:>:]#><@T%RW_V=E'73"W3('&5VC0V?A<2+89>QN-TMZ9B"]C(IH3/
MZJ@5QS705%UNW$HU5OY:SU(;S]KS /EBHG@+5BKF!]O@8L:7ZK'HBNP[3]/Q
M%M=A-MW*W\U7>9K("?4VN"-TUZ_X;Y#462<\(L%&F!UBD.*&QX9>4G B#0UA
M,_Y;8E4P[#!RJH!S#(W(J)X@BR/4$U>E8>NMOW_41+LKM?6^:1?<T4'XN$:M
M4VGWW=W OBP5> ]R%GY]@TA\ 6D:2@P3P-H:5DM2:UC+J V(NE1&$?1H-KC1
MXT6*+?P+[C\[8LZQ%05&P94:46 H)'VAD.?"2NZL%62KS>3![-A)0\1.UI^!
M2G^)1'H;:D[LL.:>TJI,G I'KI<>-]G4W6H]Z;6FK, U*5/\X'+]\U$2?Z1:
MQ]J>Z?].8])A7[ "%50X1"6U<=)B@:R5&K::%R7>PO+Q1E,9V]$+"H=3FUK4
M@T4\<$JX<URND*C6\L:-I;DR--?V5??K!V3YP$?H]Y[:=F"&S58:50,/+#QJ
MJA+; L$[ZX-VX/><1@NXQZI47F#DG5-Q-F>)%-4&44VX-Q)^P5M0!D1:P4/!
M$;861\YD2%I5(L*<L[HH F=;\SSWTP)^'W#'D[$MZ@J9QGGM5*LMRT\C#$'C
MP2XSSBVX3FU2+)W9K@N[<EJ3 CA9UN2LH$X4&A$%_$FQT4@K&U!0.!1,\Q#H
MUF2^HA"E=L":BGJPD4UID*1P"5U(H9TBKL0TL^;Q6#-%1E*,)=7?UB&494/0
M1O]/VU658-/@ +#\8J]6;=?$$L^$5/4Q=C!-;_4XSE2,I<C7T_@X"5ZSKN>>
M^'E]C6&W"FVU2\#73^OJAE[6H++>?QED1]=EYGO!]#DD8L^;7*UR[Y4-3\!"
MU.!4218*$'$1URM"3!AC'(IH8(%YP:5V6_ M'N0H]@$)CQFB7E D&8WP>^"$
M*4J(5>+Y*@M[7@>VJBS<% HG6TXH,2TL*01R!06EJCA'\!@"60$&'PG!P*];
M"*&,6? K!"I8;/5G!4,J\*2(K9)22U;P7$[X]'+"%^R:KS4G1'4XCC'_:V"!
M, (ZU;TX:3/&SIXP'8^GG]J^Z VK887!#62/#1=A,6[:1,@N_.V8FU@.J6AL
M&K!0UB)^ WLYG3:YJ,J/Q\-E0#E!5K9^9-3LH]2,FG+"S9B/S8LG0ZDQ;:[T
MW^ D>$]_]ROG\S)E/#:>&2Z5$G [9L<D@ZN[VOA8B>?J9:QG=YR'JUREO%O;
M<P]+;Q8,=ZMI-_$?IV!#U09.Y-AHX02XX[(%?32IYK-%;0XN&Z_NRELUB;DZ
MS7+E?=WJ[WR U[',J'3,HA,"E3AXBOHO.L:M0$S.6\*^Y SUS][,%GJ6>H3)
M1H81>*Q#K#\FP$BS*EKAKU9??[LQA&D["-0]>IN5P1UXUTEFIY[-+QP^3.G+
MJ]@HZ=97N\Q^ UEW)L!KI^86]+.> 64ZDB:Y6Z\Z_D8K3F+GT6Q49S6_73Y9
M*IM<'G.MYPEXH][P"4<4=N4$[5K#\%"+6&:N;6S&3#V[5W&,U=5T[.TBYE!2
MS<]-&FXUK>9I5L45B,^$WUX-7KU[\RM<'+C-3:]B-=A\?-L*_ZL%^.>S*.=!
M-7A@6!#>J6AT.<T)%CV_O?8#.GCU*_WV[@*#NJVX6U_0%A0,!TTWGV^\T;9-
M.3U/W:6<)/ ZM5,Z74<-8*>SZVG*1,-WB\K71[=D&2XU4XK@+,L".IRV(X=_
M_]Q[!!:HIG&=JV;$%?M7W@]B,=Y -F#[J]O6JN2+IW]*S8=K[;V[LNY/2;IO
MS82"G[Y FIWSS-;D2.J.;($'OBA4-H0'6*+3^/J_2)!U$K;-ZLM7M3T5+HJ+
M>O;(UP7,X-7[>@UO'G+6M\-D4'P&YJQ#!PV#?HP-M*N\4DN$19LY^?)25CBI
MNFDE[3)_?.8817?)3EKVO<).Z5RT!;B<@HQ-WA=LY5F"P(D=@O/=S'>](9#O
M\5;Z5;CQPBLW5A;RNFY:!\I><<DR ;\$*XH2M$9VZ%X@"I3VU0_KH8@1V"5J
MNTYX,Y61I50IB/;E!+X%R.?*;]C.\1*I<FRI,>HF=%!&N^N\*O!-_C&]OH2=
M/JKW1%T[ENJ_EE/^0%.Y496*Z#=NF%R!R+.N?<K5PL>Q=5M7L-RHB4&X36?S
MM:5MJZ]-5Z1J8H?3UHE:*NB=V/D]+G>ZJZ'L.)OIV0I_R\<5_M(>;?Z6U1/N
M0%=-IGTZ\P&43^3P8;UO09R/:K289:573#JT8!^GD=IB1$JO"XR,,O"2N&7(
M2"J0\X032PC%VP#R(I B1(ANS85%5 B"E"L%TE88&@P1QOJ=15U GB;%M2\,
M@O)4\EA+5)V[C<,UY(X.^%\7%:.Z-XY'XL&FY&9ER[1-++;;Q%*UK2N19\$2
MJ@.B+9;1%5#H$LZ*UBHX0*GF=M0:UZL SK0&G9V  !\G[3;OX!A%=;'"[]DL
M/KL8_'$OJVZX9IX]L"YB,S=XLLEHX;CP98E1 98'HK!!D=&E1DP2YZBU0HFM
M-GP?"&/">B0,BQ"Y4B!9%C8V\9<&PT['>*L-_[F2T91<T-/8PW=EAU?1X=VV
MRFD7/QA+A9:!(J*H1Q28!?@M@,C'2GA=!@L,N35BQ&G-2XJ1307"#!=(:Q\0
MUEH[IK@+C!VM^$&>3/'#G>4(NRHBX/<4WE[U*LQ'R9E?E20DX$F'U@H68G>J
MC]/'OUZRT/& 5BP_B[Y*K2]:'1=13VK M7DMA^N1)L-!:C(!%P.^;>:)+XVE
M)?Y<>YG1S*$8?[E=M=]L!I[.L#*B5VSXR_I\V8@:>@+R*JC"^5 XY)4N$2V9
M18HZAYSEI2L-6*A^:SJ&9&D*!D6!:;""E2TB0HU&3@B./;>*L]Y,*".G(KUV
M[=2Z:+Q;J+ YJP_^^QL(C-4\KK3C=-7=;?N$L^L..MYPVWM$T_OU,6=DFHQ,
M<T]D&I*1:3(R34:FR<@T&9DF(]/TXM$R,DU&ICED@HJ^N%$E#5!WGQR94X!)
M+K ME! X#I^-P?* @9M""?\24@;K7!FVVEVMY,0P@A%U%,X)'B.IB4),,1Z*
M4&H=7(9)O@,F>6=([V3[&C2VU!D5D)92(RITG';/)!*&<Q&91,NM9D''!+$B
M"$1<%&!4.20)T4B4A34:T\)GF.07 9.<&R^VIT*DDM$H#;KER<U,K&&L)9W9
M45T#G,HV[VS62(6&;3>!7[]:6QO<*1X^6LG@%VH%8P'I_)-O<@V["T.'G;Z3
MY82K&$!=+^YLUA.K45-71ST*Z<M5E6T.HZEJ7+]Z6]/;'9SUM7:/5=G<ZKVT
MJ1I]5Y/'JL?CJXM]2)_'VEH;KFI&NZ2Y);$P+DX>ZJ+$M9/95E6I3;_/EZIP
M6RJFD3^^0[FU5IK-23$[@.NZ/+"LI]O-OJD8?KZ839H]<EI%2J5UQF%"4"BP
M 1,K]M);ZD'#EH3;P+6.P\O752IS!0E.%4BJ,H!/0'&$^BD0*QAEWI>E"OJA
M \_W6+ET,J/.ZR$HA\N_M..$[@7*_Q2_<35GL_4:F5,T!(TT!S:AC@&O8,)0
MR;PQW)F BRT\,TK!N_2E0C;.^P$[+P)(!0^>IL',E]PQ@S<--=BB5Z-4AUL!
M*RW-- M[_\=:I"QF_@/<X_L8F_UFX(&AKF.X;K;P79\UJ>Y1FG/V&J4VLS4O
M?=5X]N+ZTL3%/W6(G-AOC<PGTZ5V<$K] NQS-5G6.IP,80Y@;-835F'_Q-:;
ME<EFFJJC'8BS56,ZK:RQ>I:KOFTGK0U&Z_2-U>TWX)^!-;#>K%?[*QVPI^[-
MZ@O6%[H=IJG08/_.KL91R-:R-<1N&3U9W2^U+,1JF:C?8YDF$*9:A) LOFGL
MU4U=/LNAE5LG7@S>3Z]6$U.7ZZZK7<8CV%WM=9.A.HTEG;-1FF_7&&2C6;N(
M!LXT-3-5\;(QS= \Y2:)TO7;TO%!2A76W0O)6-3=(;6KGIEDK%WISZ.KQ56G
M9JGV %/O\,8 S;46ZNDB3M#UG9'?4[C8W_W*CJO62-!,[VP-V-4 RVYS1#QB
M2>4E\JV=5FTK1'IG8_VI6HSJ!KRZ]"%&:$=7U<98LNK+O+35F9':ZKH&_N;9
MF]#(<0UUWCUV,:9^D  '1RY?<G5#GS7B=2Y]^Z6+Z(\ZFNS+,JN1[UPX,HZ/
MK%BWC33O=S1+I<B+ACCU\$O=O<-TUEEE[2[%H;VQSSUUD*5R-N#4><WH/P))
M/\7>'?C/.LU6+6^7W1LT[3QK3])^!T^SF&GP G-'^$J.ODT!O([R?;$:97-'
MW@"/3X&55VV\J6FYA7T8KEO+#8XW7"TZ \T6O0&!,9U5W>K]"-K0",-)="_&
M'<T5-V.KO3KUD/4%XRZH,;YCM]9*CC486>XF<K8;?)K%S3.)PBQMODZ)9ML'
MO$0R7VW2JBV_7ZJ7I;2XG$T7'VM7==7TF@(.\3$Z(CZU?\,9J;4F+F9<!^Q2
M;VZW^V:M5G13K=4D:Z,;.^ZXKEB2@DJTU=7ZBF*IYR9&1\>%GR<?.H[L78PU
MT &X;%V'?THZ)HEELUQR+=V3''=K0XH7UW$<>TWB:_C]>I9"(;$')-X^.5AN
M,:M+>),4C7=LX$EBB\;8UWIRMO9TFR[5R@7J.%2[G2,AM<'8JPB2J\%]=A0I
MI@P23!C*K(/_;2$Z/<XY6D*NW_@WJ[F:7_>,-MO-[K/BO^*C.51\O4*C[X)=
M7OS3^WGLE/\(+-$&U^)F_+TKMGY8 \Q?@:P<,)6_7SH^@&SIRJ]'<[BO?0 A
M28'9X,/[WW_9#E$>D$J;!4$]4Y:_1%3'R:0N^ERA!FT *73&IZZ0(/BWZX+V
M8PU=TH8]5Z'9%?!1[)5.XR<6M2P%&W%^V[6W_P\(73UX>SV:CB*#-]@<*:R.
M]>^K;][$/HGI9 3F)ESFXTQ?K?5; %VGGV_G4YNBK?4YU9?Q0]KK[)J0D9CF
M77.?;QO?9!=*3)L3Z- KKCV=/P4R@#H8;X([K)=9 XN^VD2'^0+C-E,ZYMY>
M3H"#/G;"SZM(^!?.CP[5HD$"WX5FWQVA'I_DMU]_?X,8QG<W.K:OXY!U8DG@
M]W=/;6(!?8'^ZSL(7L;2/AE&%SKFJY(]"B[]Y&.5\F9@!=87>S7Z-C5$1R,#
MN'XRB9NJY<D NS1F7!N[L3;7)IW$B-,)'*>!7!T#NX'U= OOM+;_ELY_$R.&
MRR?DI!2B6?5;M[YEFAF_[&Z*-U[BC:U=? BKAF5W&:8>7O.QWH6WNX!E89EU
MS]X))$B,YR)(K%!)P.BB)9%(F8 1L1S,L&B4Z2TLQ2)H.%HX%"B-$^@%G&.]
M1\05\+F@N.3K^)N=),B;B?M]2;S-II>]=>KA"W8:.9)1MZNS[8*K&;Y%VDLA
MLL3V7;'>MGQ'[ZS3NY;Z_NJREP1(52>T[?T8N.X#3"P///]E\.13XG'%@3$]
M+5 0)454$HY4*1ABCH22&KAOZ9_,XS\LR74PKBY/EJL3^TYM'3NS_D',Z]<!
M8&J'81?3WGS;]JV.IY_0W=C:F^VI2[6R@1.WW(%QP[RZ^;;&LVQ:7EL#9+,K
MMAXD-KE=8<S%*\WB*A=^/9C<1#ZJW96-1S2PUULW$SA0@AXMU\PK-TV/=K76
MH'?E5U4*:Z H)R F0E'R4&)P_DNM$ V%1%KS@!0U6*H05%'833%AL*>8!(\,
M)P6B1 LDX5CDO994FMCDOCZLY)'"X1Y5 >5IR 90&5&/=2%+#ET?< *EGY([
M490T%1,D: Z-%"L)(@45C"J+C=FJ*."4 FLZBKB. #Q2,61":4%\A0+S@FF&
M[^"]:F?)\$,K.T^L5OBJ6R!\X_NTU).L5BXQURZ4$9I#6425PG&H'T&,>44#
M+T!@;L5Y'\*RRVIE:V<+[WYO5?@/=0(.'(G?E@"4C[.P3JY6>67&U(7*"W_/
MJ,E)%2_OSC?DWO7<N_[DWO5RC<]R[WKN7<^]Z[EW_7$9T]R[GGO7<^_ZO1\T
M]Z[ONW?]X64K+[..XCYU)W4E09K\\Z)K*][[Z_FR<PRWTT,Z<QZ6%1=W3DFZ
MN^!BO8UP%=2S:^]$[W@G@U?U?^YX>VG\2;<,(G7<1?#(@9LM/@[ @O^88)+-
M:)KF5,T:T/@Z,C2:5 U8?U5-[2@IDG3O*#-G$6S?SVYB169U6P%U!J]^^.W]
MM_$6/M:F#T!?CY-4J->ZK$5P_H>W/_Z4:B>C1D\WO%S *ZF'2ZP>7U\O"YW7
M:XV7M9%;M2FUV[^[/*4NUIROBB36Z9MF9ER/IZ-4Z=@:',M1I^V8*_UQ,JW2
MND,SW:5]]4L;95F$\=O[01CY<1VYJM_4W4O?X_VGBWEL5V_C?,MU] L,\T4+
ME$[O:,T8P*/1#J^S8G?4Y,38VTU=^+^*;^G=-2@V59#/EZT8\<)? =UO\@/C
MVTXZ^V:M"W?^:9K*/R*W1G4#USR!!!8F17!&,R0\QXA2XB/\"%@%NE3<BY)Q
M5V[A>RLP(:C6J&0E&!'4"B0=*Q$FC$BC@PQB'7ZDT]NZ)HV7POC_:ZG;9KA^
MGLY^CE3]\&GZ?R--]Y3Q8B<#QAS9>SE9)?4ZI;JE$^ H+6C)(F-@'("C@G)(
M@UV 2B65)T7A?+F5EF*V,+@(!K$"+%*P38$+562PTI#".VD#V0-'?8ATC.RT
MMY(A<B+5%?TJ%ZCG<:]'\Q/#+R$(FF\W1I+%O.]Z;X.^;33$">P+(S0N2+ H
MQ.DE5$N!-"8.<5P"=_O28;ZU+RRWNC#>($ZP1Y09CU0H.3+68*V\=H;SC7V1
MRHS?Q;[(#ZNA<V^732S_#091]Z ]"59^*J4$J<-G5#=$7:\JH%<FPQ>=ALT*
MA)EKS/Z()UW[.VLMB-,O3D(Q>AQ;CP;5I4_3_?I$L V7HG[2$]AEA.*RA(V&
ML&$645 XR(2B0+S 5!:*$DFV=ME#[)DVP[P;KN.GNKCDA6ZJ*-6_-APH%DZG
M0KG:L(%]-;B""UY&P*#(8CNT0JT(NOOUY?AJ]%Z^VH,C@UL->)J6QA9E$8VV
M5,=6P!;0',E"E)1+9DDAGNP&[+;4/JQ:"'_TE9V-$LA13[S1#U_3"(,8O(4M
M'#LG5ZVN4;JGRM11 @.(YGNWN6"T$32CJZ3-9AU#C_C\;0VUU6[-=0P)%^?=
MAM2E<5IH3\I38RF3$=X)%(:UP/3<2T2$+!RSOBCD5J%W5AA/+^BL=]4][:ZU
MB:9?"/W4H= 6ZBQ%?UKTMU$"UJC#-9,5>,=Z/=3VF-S<4_J?[Y?P<LNLR$8.
M9(6,]Z+CEFNCM8=WY$"^/-/ZOGF0!PW>?I5":=UOME\DW&X;\J\[E70YC+<%
M%%AO2VBNMX1HZ([C'?Q*XZA@\'?LW]'BNFV??#E67.\YMQ-Q[[SS?8?=5SR4
MX(]VA-37Q'PSP[ .IY^(-2&,$MP;C HEP9H(VB&5@)FY=88:73B^!<<L/<?2
M@>VM R:(1DQFJ81 !+L@2T>L<YM!GH<&/_<U /="G(9]D7S2MEW8Z&I4M3WD
MLZLM>*_&\P2C_(G\=8=O50:,-94484/@_7*P-0V.)B,/ADKAA-!;>*(.2^(\
MH:C@!4;48Q[1(J.1*B0C#F.'[^")]JG LAS-;G\$5V3]I<;0$THN=SP;Q:P"
M\GUQM]:\HO($G*($Z?-P(.E^8D-WK8^LG/OQZ+^L\*WOLBC?U_C8;R*<1I)G
M#23#GBS-^NH/,SB;)1W0XFSW',CW^]@F32#^% S1E\WL1[%$S\?^#!H,4(\+
M9,M8WRF<1,H+ADC!R^"9*\5VDM$+JC!8%8@6.MH:/I: @ DK#+<XZ*#E0Y/O
M^P8Q*"[X2=B=1S0R75%H@>%-@\^@$"54(,,$04880X*QGLNMN>FET5HXXQ#Q
MQ,"+EQPIS0QBUABKF"SAPQD:F76**<:PS\+ K/IO8/:)H(<Q=K^&SM@/6_?4
M(L_O].SO(V"B57WTTHS\"QR1($I_7M036YX#Y_!H]+N_J]"(-GJ_*OK0$&_#
ME+\/W?\K8K3#)5^]^_TO.TUY^/XK-GQ[]U,TM(Q3!=7>(E$&CB)" 3)%L*!Y
M25%B7&++M@)].HY:\]PB*RQ%U$F'E, :!65+I0M&:.'7]&WD[>I=33GW\W3V
M;N9_:$""=Z<3WRQMX#U%_,B)6%Y)'WT"OS=BIE_6^8>DD9(Z@C4LP97OXS^L
M@^-O 4;^]E_O?B_[Z3P>%!"]Y][CAU4I?LT%J4PO)7AC*48]^&K7?(?$"DU)
M7VWXC-9%:70+3T F89!"M"P(8@;<-ZJ"0UKP$A'FJ"L#%H%MH:N4LK E*2C2
M1402HBD-$0BRSDH3**8NK&/6=>JI?VHI^C8LM>_>,@WX).3.>N]5Q+%/X'/O
M_O)]/?&M6M@(1A46X[JKS,;Y<M$[:C!-5U;]'*SOCWZV+/IOXFXM*Z<A(TE=
M#C>'M=$&G;'AW=,JOPG<"\R\0,"' E$K,9+2:11'W&*L//%V"T!-"<(T5@'Q
M@H#N90I\76\=XM)P$@B3WH@M/?I[0Y\_KN/PTA;#_FWXH?:!.DIT"7FU-UX^
MC2:!R%?_KYZT%0P/G@YZ1H'(M>$MTWK:DFL&P#06\VIX0%(=$8U[662?#-XZ
M9+FJB&@A#MLKK)3-&II=O%8S20/]_J_ZZOJ[']O:V?@;6!U_\W;>3/J)8)CM
M4(J+4]CN#+:TIM8@Y3VHFU)SI I;(&.HTT1H6>(M%64,<Z8L7#WCFMHB($5
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MQDE@*,K/4Q"?UXFL SV.'<<?+]MP?ZO=D_IWHY  :&MHLV@QU*9 KQ[D@8[
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MV\%'("7X%(-/H_GE ';9W_T\OC<W6K(EW"I>:@Y\'5^"GMPF:2N^JX"+O5T
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MY9;'UF=MU ^/35X4(JNRGJ=9<W=G3].L/[<3J!-&K?]\/9KEK&NV8$Y()/6
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M*+.^ZY&^NP-AJX=8._M#/MI!DYV 8O';>-9HLM -H];?K_X-E$N@6G:L*]@
M8?39N_J>Z7YZ-(E@K,T3;F'WK#/K!8LLG=8KTN<.L1NHGYUH*MO(/9MLRFHN
M[:!__0.-)LY_?DV^"V/_&;G1S*>]&"%]%E>3[]RHNA[KV]?QUZW-4B\.;MF$
M:.HOFM?:TCF=BOS$?7<]K4;IVC,_3DGY[H,L=]WG?O>'[)L',5_COW6.NIQM
ML,QH,@9.0M5<SYI7O/X#D'D-ZBF]D&O]T=>Q,:0#//IK/?ZD;ZL&?>=P;+L'
M-GT>B:H'E[.HT?YY/K5_C=2ZMT3J=@NE"X.&F]909J\7L+%F\:W4L=OE5FI>
ME8G(<P="=$M 8=,P^*'^JEJRF-[)9GWF@-U:/_Z^$EU;(NAXDB8AP7U5V*0#
MYC,]J:*5]'IQ?>UG%BRN[YX((HGWQD*__?3'KV]_?S/X<.GAIGX!IE,U'/PR
ML1?/A<2WYS:^?>^QWZ;S!(XX^&.B%RY"S,;=UD =_M"%.OQY--$3.]+CP?LE
MZ.%3II(?_-$&QWW%1[7_[A2,5R )VU-W2,96&+$=LJ<19'V7L \@<>VK=DWB
MQEG51)D2.X4**PRBA%BDF&&(6BF,=X0J3?]*#FS@]0Q?]<V.T:7#B)4Z\X-/
MNAH\11;L>ZW_LFLQ#[C3<XRA)DR04$HDI-3 6+&.WPB.>+""*/C)![<]AEHP
M+C0#\XQA1,NB!$M82T0+7Y8>,VZDW(R'W MC>(E)GB#,JY0C[?X><89!4_Q?
M/U\A$-\90N%K(13VM1!*>7%W>5X?>&D YX_C>XO5V'U:V DP.26Q6\4XY ,#
M.:H$0XJ**$>]5<(:4_JM032/F<;6=R;'\N+N,&$?>&G)Y"#B%Y/9\OGO+)08
M)+, O@33,1TSF%ZOD*]G0.?9R,[;"PRFJX'8P_CK=0S/W/CQ[;!!WH8?OGP=
MN/G5=-(< \0> '%B=[Z]'/F;9(W&M<-CP"GPI%7229/I?' ]FYKH2 Z;,SY%
MA>4_QQ74RS=^T'G@Z8V?#?3@4S.< >EZ.@,<$DVGM,R:R0;7"8(]WO6)&_$.
M/'HE%=?!6%0$(Q#ELD1*VX!(D-@P7)ABNUZM" H'7V!DO.*(4DV1QH&B8"4U
MOO26"_9LFZ?&J/]Y.FN^BL?AM9V"*F]?N\7LUNM93\P<<K&*9&U&47NT7R/%
MTAXY#.])K$1I D>FE %1[S%2<2J"M$*4VC"IS)9U8FRAM<<262_2F!6#3&PD
M<+J@RH/ 9_;YK).3Y+U>F1?DHCB9C;"N4RXV4R&[DAY/\1BWMTLA"J%#E,UQ
MPI"'C2-+C%$9)"V,\1+L^[V,#O$?HZ;[W5]/9_!$'W\<578\K18S?Z)#0 X>
M!,+X8M!0;; DVP,#0^<S(^5M/: D&3$?Z[$E('#!D@VC"=@^NDHV'ERA&6@"
M*TZQK>O9J/(#;<",:ZRH=L[&P $+SCQ\",OXX&A2B]GD!\ =;O1HG$+YT6SS
M-WK<Q%K,;1JU$BVXY>P46%JTFJOX^Y6&AQJ\^N'MC[]^.QS N>TO"'Z)1\82
MZNMH00Z:+]H#8/&3P>7T4S3O=%,0$$7$=#&SOC8M=57YJHI&7%KLQ/J+&"5N
M![\,;D;^4S4813JL3W6!8\$>K'\RBPH(!Y>!)?3?&_-,.1(8^%/6LAC5*I"6
M)4>"6U)PBH6E6][88Z14/;/S;5AR6[,!JS5OJOFRZT?]\MO/VRH:G*E8!%_Y
MR3?_"<_<;S=JNKG!NGY29/8.DEC<8'8,/H5M6KUA;<N_)WXQFU9VY"?1TYA-
M/\[T5057T//!',2-GX-O U<:7'E[J2>CZJK>K_7KCOM,#\QLJL&%B@/K:K?.
M^5GT76 QZ>K7U2UL/1T=K+B+4SJI9O'TL_,?4QMZU*GQ=P]F6;6V1Y;#D9YN
M@W;/C&\=C3ZCRY%S?O+ZY[\RT*<,]"M2*O6E"N!!10S"#!P:HKWSI>F+A/TA
M";.?/GN[2(1[&P+8M;.EQEG[3Q\6#/+UI[??)J<V2L:JGGX%(O>B5ZM\H,K^
MZB2KA^OLIUN)A A-C"E1R<H"T4)[I*TBX-4374C'+;9;3M4^K,0?IN[JW6P*
M%/VO:57]"AL9#,;_/?WT!_A9/X*U.!NED$M/=E 2,#^]7>K9I*P;'5YUE'@C
M4#O:&81<9W1;- 'T^K0VHZL1B+!?XY6CC.Y<.OZYNO8=IX(Q%.V89H_ &J-Y
M4=L1:2DQ5#0>#\91QL?5="R.I0T4[]E8)@:<6E (T0..YU=K)HH%\5\-PF)B
MU\)A.S$IHX+X&W@_C8*()AT8)*EFX]-H?KESH%U"%/$?@3D_3D'Y7J1D[ZB*
M+Z$]"1YXT^*"&\'JJN&2 @MX^G5*[;8#HTJZ7LRNI_%X($UK!L9KKDRPX<#J
MZC(>[.'#/$4+=[Z@2(#*S].WHTE,P$9A6VO&5DG!ZF+<LJJ?I'Y/M=Z]<\3?
MZBDFH&'CQ+YX+; R/S;T ,X9WP*95@2HK^O7+,EHV49#6L_B^LS"17T=><7.
M%T 7>(S%> [7B$\!UYDD,CNXQMTF*WP[2E&0NP84?HDWDO%04^6JWOWQ%;06
M2GP"8)U1O$:4&#$(6M]C8P>,T[-5ESX>KMN1BO7I%U^)%=P]K?/1PK00V&&%
M>,EB%;%22'N!$>>%,ZY003NQWVF=FV+UEQ5[?W_;_/@D-_P 2NN80KR>\VB
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MX)A]%O@LF$>S8.1O><T>$-<^7^;WA6ONL.,:_UV1#76?9\G%<^>2@=*&5NJ
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M\3NZV$QSJ; D;.M*:@] $@BD;H2E[>2M0&=[;2YF<Y.R:"D1PI;J]_F"I?&
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MO"@X=][!YXO2>9.AVOA8([[ON)-WK2%51"[PBW\TAW_O7B]2';&01Z2N$=/
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ML)M\^&@UC<,J@^A>[(@:TNUC.#J6<3>%S[*5)X+/!V<K?D>0O=O'\$38RI.
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M,=[R<,O#3PNC+0_O#@]W_9XWM3S\L7.SX#<&N^T2PVS>?=7KOHFW1LF%_!>
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M@T"S4^KO_< .\!F_^_-WD^\. L=;Y^AU"&]OZN(PC=K;J%0%Y\X[^'M1.F_
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MN?_FMHW4Z+2)HRR<]1[[1N2F;[_1TIBEL8>D,192HKIA^"\Q-+C,(]2*I&0
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M$1ON=O%>=SC\8>.I7;&^_B6R!YC.;\5-G7,G2/(5&@^P@EHTV5.=7G17:9"
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ME;O'1_R4LO#+9^#I&7;?AJ,@$0<H^#8+!\ZSYNOG-#6^2"Z$T%I@WVT=-3$
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M/WU\^UR&RH 8SF6^@R%'>U<AX!8/,/#E>W<PUL>4F,BC"WP$_4L5E?02T2]
M&"RXMJ91YX9F>N6;1U>]6;Q""Y0G;"#^0_5A$*.1%%I_ K+4C-#=QBP9'#];
MGO-,FW@-3LJ&"?3U+M:!)#SU3!I65L_>D]5Z@+3NE*&C% %1Y8JUF27*78$L
M*&:([,Z3RBGR-4O)?$/]0F=7L"S#A(7+O$BC2W1+8$&H>%K1-!O -[_ZN_O'
M/\S]V4ND]O.T#O,0E:$"I%F$ NO97U_!C^<:7XG&E5'8:UI>[%.G-V&* $DJ
MN0 YW/IW/>%;0P:^%("6-)44FR]H8I84"18%K**ZMLK1^( '?S_Q&HJQ!+%)
M$%L40/6KP(DS&C1&)_=/AO<&"1A#_\@2-&_1\?6L^?CY?E(Q[MU#+[[G#7R3
M7O9GN-R%?G9*WO)&.A^NSMN4Q_MU0$.M,NA5?+I,(M57X :D*VM=-,$^8;1]
M:PS.4U;Q9L\=P46XS&10F"$*XK'C!D[.@^_6A*&@<I^?H\9L)#4(=$6UFDO%
M1_BGFD8!9*27' 2K=)0A*OQ_]MZV1VXCR1;^*\2#NX -<'HL>W8\<P4LT+;L
M&=\=K74E^?HSJYA518M%EOG2K?*O?^(U,Y(OU2UY6K+="2QVY.HJ,IF,C(R,
M.'%..,]?3A!@:H]O-0J_CGL+83NC/#CX>N]40(@" [_^(CUA@!%JA63BQ@6
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MM]\?(/SJEV8G%S0"#)Q4$<@=L2EZ4?)]!V]#[N\= %R+]<O_UQ>??18TP?-
MB=QDUZ^?Q\-DV0[_*/ 85]DS)B/!SY'-/".A]>P9+&\B9/OB24XSDIL6C](,
M+O)**%#^Y(NK+XU".0_&-Y*LSX0X$AP'CIOR86 XRNZ.7ZU(ME<..>+H I$P
MWORSJ[_IO<&J?TO:@DV84M9FO\45/Y!N<I&].""'^!=9 T$8.,.NL.+PX%0X
M-/RJ+K9O7A_:KHG"!:2O@.4'"Q&&2,N4L#*K,PWO/-H&V*EK])?3^F:&R8S*
MMLQP#L<JS" L:GXSY@!E/ZSX,'LF]6.(S($;PL=T%I,CAP8ZGF0@G)('DMJ
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M'N=^&) .8#-@RR7RP-\.!ZG[,-NPIEO E/ZGO5%Z\2=_G^HKV84$ T2Z7KP
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MW'1M4<PO?)'L==O6$).1UT6#K%4&/JJ>#2VA/(YN.+2EQ!4A"8495L/31>4
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MW3%0(%[>#-_7.6B)'O,JE]AJ1].$".MPT[<U3(2 8>R "9JC$(NBYDW:D@7
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M#?J6OGI=5V]<71W:MD2/)S"6QXM(_<IMBQ&.+'HVUO>[I/E.QPK_XAEX2=2
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M*R6'6;CGTNL3SK,95YGD(,BA\G'VR*"G*:$(QD(#17T:W ]M4C1-\C@/LA-
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MUB9^$QRZ4')QCI'F<'#AZ_=-NTO*2I3<P4O\/#JK<+V6S+S*7LR30W.?0N-
MA@!*0QW:6[^"T0^+OT8?KMFUD_-2-N+&).7+?@P,#/T'7."$*5APJH+TIN0H
M&2JG1Y=<\N/=XKE(I^]!&\V6MK1?6>_)Y?V&)*9F"@7-.V]4H$J  ?YSQCF
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M3)YG^#,49B.Y:$_)Z?6IA+2**9J,2M>,/G$(MKEX=58LL%<P">ZQ]\QJ(E6
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M7'ML@ TBU!"AA2RW$8$(UWH.;M"@:W###<,B0O4V&6\RW@?7LC/804G(:)X
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M^B$/)T:Y"<.%JZV+.7YAET?Z[TG+CFPI^XXHB]1><!9@@N@H*7Z*66P+KZ%
M-!>+?1PS"A$"/IA)6"B=<>\_][)P5K9L84;PL6RKI_:Z:-=BX]#M8\LS4MZ"
M5_$6+2=>WPNYV+^UWNEP5C>"BV/?$F/(UC7HSA7S8>@\:&><T/K$)!W_'O*!
M]\9*K2RMNQ;378OYMPI"_8UY$MD><$7G/A"Z1Y0N<3G3SLS/ W@5[#VRAP)E
MY6@*W&DX3L%FWJ /\,T/4YZ<&K'F? $L80?>(8'&4QM!("#&;@^XJP^YE.(*
M'_?MH.OF17R/5T(%3(OAF['#+5B)%## J8NQV1Y"69&_ J_N:UA1DOV"&_T/
M^ \B=O[\L\\_X\!RX9N^>L/QAV"O<-R^(0T[NNVC4T"&+/H<6'6AA98Z!ZK&
M-I5_XCE(:@S&X4/%<)5C:-$P+Y9V:_CYP&#W7,8B/P*/MJ_D +"CN/($]Y3N
M@ ."B6'_&;97GV:WV(<Q$F$Y=M(WV37X^3K[_*\Y3L@7/"$^Z-('QL<Y4B<,
MJ4!0 8!YB8JR/0T+D_ZBZ.JJ\+VO9HKA+56U[V+5^66[0QMW:-;S9DX:"MZ(
M_T[WI8G@H*QB3X]?1Y:*(7S3P4C.^'!_Y8<+SP1WS"&4D]Y\8=.S7"1!IH.&
M&MLC;*@C]E?,>\W%G&O,L.(Y(G5@I Z,W]7F]QOKP/A[ZL!('1BI R-U8*0.
MC(_2@?'[I+MY3^8654Q;XR19S8]3SM,0D2A5!$2!=/ZQXBK*-U U(T79_F)\
M,K*-T"%3O\(,S8WBF'+PG]7G?)UM*V0=#0.I&:]/D 2\6M1M;?*9AO+.\%C'
MEX/!%35G5RGWI>59R]@834#<Z&T:V<?&1O?P".#"CWW (7DJUD=+^/)=5,\K
M[INA58/H[RKL,,7L8BD]5QKK7'",.>+7P5BWYQ5^F9@41EECE$5FE23&T]*L
M\=!PE[RAK/&Y/'VDA44:B$3(ZF7)KMBE,@]'MJHYQ@"1Z?]-O#72R*_T3Z'^
M%SP(+::J\'0/DH#)]FU;SMX8]BZ@ M4GVW\\?]%_RF)K0JL1S"0\&H_B'U^_
MZ'U9:U9>$44LK8>8APSN$<G&84;N<FWBS^BFE+R>:F3&Y(T3%N8HY<ZM<C-/
M'<:KS7872*@H[5SW[=1+XLBT7&9+B2'5[HBLFR>-']H:H7C*HU%(DPX33\[/
MA3@_?USIDNTG+N%E-IUT*;'N%VEH''QQ*&"V_[),VVWVF7[L;ARL'+(RS&JU
M335HECQ8N:[Z5>K?1UP/>AY!B(3?-GPB24<+22(!PJB &G;-X+/>K3)^GJSN
M8 H.&1@K5;C[>2R8\;$->GD+WI_EWN%++%$(8P2WLN)4?):9JL6X="EJ\M2M
M"J.:8JUF_EI<'\$:*)?,]'14+N$25ZM\VS/?J,,K2F*SVSIU*M6@&G<E0UDL
M3_T*'\[U%G<:^!AC+GT4YHD7B%A[I,"P[=XP[Y5Z;2$II=):A3S%R+U[SG41
M8?$5QX"N'@&:DWQP>"K[ B>T5I,W.%<(?<1KD9A.[>K8@RD0O)WH1'O+234V
M0AP>Q9R^"!D8A:*HA5Y9'+12T8!0.K JJ/K:;%G(.;XTE0W9"YPSPOM&OK3J
M[0HI51B8TO*])7SR05%$O>PC?&*5BQ]B/B.&C6G.NF2*G\2X9(TQ4!7%U-CV
M23R)' ]0B227#@FR[-"YK<1E^>(;);556$Y;IA$/7I#2_Q8'/1Q@L'WJG4^0
MS ?Q.' J0/$G5B;(:C<0C1C1(P_54"/S,7^6L/7)$A_>$J6#A$GZ6&)'/N=H
M7LX.6L?& &EL%$(4MCP-_6M'!]9=Y5#F6?Z+YNBSI\\<1('/VJU(_'[^Y*DW
M?[AKK,3C=908]<-Y ;E@6AAI83SLPN X9UO=0/R!Y^T.E;L1N*%9S&2"R00?
MU 3[L<<SH;"&D@_4\'DIEY7L,=GCA[#'N#0P;^JF]%/JZDZF^0%-LW,[DG4,
MO9YHJ9,4'9VPJ/52TN7AZV7TO62NR5P_1' Y3:*1U+3I? L)M&W=]MH_>3E%
M/J\</ 6S3P:=#/I!0P.'!5AJF[$"<-34J9Z9U4=8@8^/\@SJ:%D*(/QDEHSP
M77T3A<'4(OQ?V%RTQRH%Z7#% I*4U*]KMX?M[:9J3:MW#2>(;:2[R1,M12A;
M@_=2D5Y$,:.J<W]JM33/5]J[QA$-EE8^J+=@BVU_U *%B?RQ<]-<_AT BX4&
M<R[8322/+P(#\!=^>*(ER?6&"VV8WT5%MKYH%/34.0X6N%)?[9;.8EB7T;.:
MJ&/ IZ/SC*:BTZ&^7+P^S0,W00?AOOA)WT.C[H]C[<_;SK74HD&5(\]E$"N<
ML7KC.Q 82&O4!.5@EM5Z4Q07OG@%G,BT!GM>+UU=+ )/+K6#_^B%9Z2AGWM(
MJC>P5Q[:MLRSIF!E='*@S-&S6Q[O1-:1K5ZZP6VK%J)Y2FQS9WC1C>-KN^U(
M_U%(JY&KJ#RVQDE4;+JV**T&7%^WMUS84,:\HBQ.@[20PJQSJ_7;JA]F#>F"
M*-'^'GQ&[E"+OZ-FD,MR-()7,V'-E;+Y(EPQ*A5N/2!+OLNL2@?JRJ9C1:\;
M'YBL>*)'HB;Y*X01_9*=\2E@Q9:R"<1["^Y/7H=T[M[V"HCS"Q.FGO3.M1/.
MU[QIK>UV4L7@KF"$8UD[W;5C0_Y<-TRL1A"SPA'[TAPVCO$%T>TO7,P8$6I-
M6T.RVZE73WV\T-3[O7<^&=7>>;KXG1*Q W5M>P='$+H27N>F'8=833/ -(.Y
M>)3F  ,AA6N)<L*1;$=@"FQID]<]M)$:)@I66>BI]@'*ERA$:A&NU1.9 MH
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MHG9+1KS:U?MM5S76%#(^ M1$PC#9+JU^IBY^?A0 _:4WBZ2)]^;:O@+VB2.
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MV15)QNHB:=0U82)/7@FKW0,OS*]+GAE6;*J<>K7ZWBSH0[W>"]7'=>7B1X+
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MH<[!K&^R4L^!OQJEC4&^:8#.**ML$Y4Y$&)>A*P7F"\UDA)\:. 1T>3<A5-
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M[*'\J56(*,X@A<_?9K:+96]!=@>0D5R/H1^_S\?@OBUU,#'W=#+Y/:O>A9Y
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M*6VQQBD)N,NB"H.OPQ=)FY9<1"*V0GN8(CI!&1.V]]$EZ!<Q#\GN4XZVX7[
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MCH!KAAYJ6;[+\OUWC'2ULQ:5U&41+XOXDR]BDAXOU]5>@K8(#A'82Y%([#'
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MQGW/ZZ$,MY&+E^N^[=:K7? O26D]#'O?EELV:>0QM2DNS_V2<$7DJ]#(R$*
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M2;#0I"QA0FB@:Q#7.L3LJ<% LE=-II?U'?>B0^TD.B/XB+8^>52QI0YR@#G
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M*;\1ZT-:0!70G<\;<.3/-38A/[5Z!= CBB/DE 3A!^]D<=L+8O/FF>RU."J
M%Y>N<'60F$% :.]FA3GZQI,E1S?C+SC-Q!Q;<:YLIF8F"?4[IN96[N<]91*
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M*I)=/SZ-VJ3#7_]X;9*@+QL3/TY]<<GRLT*XKO@^0SDH,ZOJ\]5Z?F2&_?$
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M62%XE&^NZ6C(9&3SQOY9C6+D,.4!<[L:*TH%Y*7<I+W51A!E36NP$386;(
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MO5I+[D%A/S]/CZ4\I0I#VGJO>Q=YK>25HZ4/ZOTLZ[[7S)@Q3)VP6WE*U=5
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MM 5)(W.6MC#UFVH0JB1L]H$JLC;,R*</M#_A@\S8O^$D28ETD _[ELEZ9!+
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M<+Z[85 ST3IO9#:(FHNIIJE]/8\"2_NQEJ*DV@CX.5RX,BDNS[+CA'AS3/.
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MTQCY*9__J_0OZM=9KS%N1:RD99,N>(Z"]M8@*@Q&,LAQ:H<SKU*P$/Q!@VV
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M<QH)C#\G[U<ZVCC%[=&YV"@G<2Y9 BMA)Y?*!! KF@9FA1"?'2<)J9PV:->
M @PZD2!W"W.]U*K>+9VA")S'0>,7==\G1HXDUF['VNU8NWWEVNWGL78[UF['
MVNU8NQUKM^^D=OOK\2VU/@XK2QG Q0Q)C-JEV&:F85#^GIC9^T$'Z_],*$Q
M=Y5V#KT[DQ&=V13)M5O2D;C[S-BX2T$HW3:2"#I?K4#:PT5:UQM8V-.T%@(K
MJ29./R5IV];YG+(2DNJFI(?)'F[2X7?R9-]K(X#]YS.:L_WG-OOX1L.P[S!U
MV&'$D]NH3E\\?TKLM!(EL%$'%PT@L3ZJ.-U%B(J]EZXQ @?()O3Y]&5RQ %O
M(N_G'#/>.SDB;[=F?,_AGM_28UUA8%#B;(_ '28>KL<4L &'6OE*[0/A%R,(
MB$8<\6'M+F>S)Q*&M:]E@[$]B<1GPFK)'618YXKHHU_?_MP\]B1U<(N>Z#[B
MR$=#9-C$*]ZG5\,+%K7)8$"/*6.W7#8P#!I?U;3AW3%^LZ(H#5PVW!E(S69C
M5LB96>?8[R)+^NMHR=#6F!/74)>[PH_M;+U6B.921]3&G.9SX2%,X*)E:WD(
M&+CE[O:HH5=92N"'V..T[R\I;4IS/^XQP57CRF6P#KA0K,S=_'K3*V.'+R7*
MA?/*FZ+<3"0*-0\@(S3)? [L)N_ACR+MXT4X68%/)$H0),+#/#\%J7OO@?L3
M'X?0E%:I)&"[R[O94-L<J=*U&0AA1!WO,W+Z>;V*QE[Y(1Q3%]*=FJ%[ES<?
MDY]2"LM^,0?)'1SB;P(V<N[Y "]1;VS/,6T$(%R01$K?''N*;HZUY!P-UR_S
M,EW 32D:C9%FATH87#8)XK\:4E?.>]MB8J-'BG8:HL[C928&&Q(8U]R88,":
MRJSI&($?H4NO[0<G&%J["*?^%R-.U^[2>],G=#>C+7/RQO5@HK0%9CXU,AX<
MD+5!W:;M0LZ10VKR(P(V+CV3ONST&FU2_P8B87;M,Z2=@SXD+V$$*+=VG(J_
M"Z28+0?,(\-!=P1S,FPU,]&$+*IR?)B_"7SIE9?IC?5*VVDX&2/-;TX%6O31
MD%DGC2+><*,HF0BX[H0IN;O&9JL6U(67OI'F;;SKEVE>,&DM>E#8R,\I"5Y?
MZB,Y800,/1P;H>*!*B>\6AHV]\-K:+-%TG1PP$E]E<T<V:HOZH50Z:!EMB+4
M$7Q=K?*%R\TUSA!%0A#LM*)M*BQ3]<(K(3\KS\<@?B>I#U?3_J.HYC@S9-S1
MM RVQM#XA[?!@FB4?= KM*_("?'Z:6<=;>34*P1=IE*"9UNN86H4!MF(3K%(
M&28C:V!?D=6^1!Z7!?&7N1]8 6&2Z0D=!(+.;M,Z!ZM\0IO4J.$/?\^K&GY-
MF5U&HF"(R/D@S JCKZ-SPJS88D3C%UTI?B3^D$9N!],X<]N]YE@##/&XR45&
MK'BII];ON^]WDY\DEO2.&QXEWU,A(\YGEA$/G/^RJ,Y@B!V?,O.T_"AXAA6.
M!%%Q.(<%HG)@)+]_K%-"4>$OP >U,-$W39T:9N7Y9[I*I="E(S@,S!%<ZJVO
MM$S4TO6RPE0]G!O,_)U:=XC09[D&!. >1Q>0-PG<R;('B^UI QNIJ_#$VDTP
M2"1!!&?D4=\?<[2Q31#51).FV@XHR"W$]#EXV'+S69%Q#UQNRI.\KLJ5M #L
MRC6^S()5&,M'J,_<H+6MDVWD+4$*3]QT$MS,H1?9T@M@A2H-5CO2;K@72V6[
ML]BV*FP(9#E"1,@]I+\155'PX^3[@CISLI_*S&3KJFFPE0M(H4@5]259D&<>
M/-L]C #!R$R&'7)3$/5:*@\]4X2HT"[<;PA5N-#'ZQKZFMQKG]O7Y5Y+":T:
MZY@02NDS4]@C&0)>0)GD"T2M>=$3ZA760\EY/;5J]/:XP#BT[NCTEU4E8KB%
M4;,,@:0PU X5(,QB[0<FU])>DM87I1EVT0G!9,LQ:?0A+9RKMZ+<#V1($"!L
ML'Q442/*TC8GTW6:=]F1N3Q4[4'9*:\8MG1R,=]$%U2$BZI(,/S3,,CJX9H<
MOQ''FI"EL!=4: <ZVY\')/>]6;=^ZQO>A:<IPFM[??J\'FJCG6L^V*XR6Y?J
M)*TWTO%"5YE@5V@1Z&/RD?80NLS!VM(#L>V.8NSYAG(; KRMUFE>A^U.-@X#
M->$_O.U,G:&\7R0"9Z5>4-@U]I2H-^2'\,W*9I[HS<7UU?ZR4L:!T^'=%-%<
MY /VATM11QES;V!@3J )+H M9*Z! 8S'1[2ZUF\9PQJ:E2%7'N7X^J ZL8<3
M>7VM61R7(*Q'TL:N:\9OWS!0-).6)+'-1H1J1:C6U:%:+R)4*T*U(E0K0K4B
M5"NVV;B%CH68KP?+OJC*(XH?*&3$K$Q-A3$2#Y#Z=(L<H2X6J9\*/\4;G2:K
MCM(+*XQ@4=3-U?%PNH#K$"APN2BJ!B,</MNCNMM2H$*7BMG9>(GP+V2&+]T/
M^>[D[P:Z)SK!^KN#,2XW)#'GR9B*F%<*NC)I2>['<KS\IDE65<959Q+1_5]O
MOW]/98A#0>UQB&@'>4\>.9AET88!&2DY=!FXIY0MK\T)7HSQ(*X"%J#0=;70
MV-]_<?A\W_WO-GF']@_V9L_<_Y[?,Q:B@]UGA[/IL^=/#U[,]I\=/)L=1AHB
MSL!;:76DC#['2FV.L*X3"?TEH),N%E7'%"7+O%YA%!,+Q*0:FN/#<+@S@F,I
M-Q2(HN4Q04"?BQ4[7=_Y<,?D8._@T?RQW<AI/4_AMCMO/Q5F0_L5OIGM[<V2
M1\/O'E\WXUW<77%W?>[N0N1?5JU;:LI!M?0G.1H[WIXB1B("GIX>FY+A3G@(
M>06[K0VN>N$XK$,V:180"C$^BI[(:-\V+[;>D>@_C+MEW#]Q_]SA_ND7<&!B
M<["?;,X8)-R9<[_QYG@MS<U>N<WU%I.8U+6/\_4>5! N.4K;"E,,'69YZ6RK
MJ]:1J7"J79XN='+XTZJV@',^R#R&! ]3G9>4#_507O8.-@_@CD2"%9,1&?=A
MW(?W\!Q30".23'EP!>Q57QC?8?<!N>83.&.M,AT@&<Y-D:Y&*8]2?@U2CA5(
M")&K8*GS4E0ZV&QX3IQ4B,$MMP@UYU+G SI7GQL93Z<C_)A@T>GB&$EHUNF&
M@P?#F %19%Z9]O6KBA8AV''A<491X19,Z98P$?.@-OU@C9:&-D'U4Q#"(1!;
M$%LL0)T5/6"<=T_AQ2D5FQQV\U50$=&QE*:0/G@&K 9TI$O'$RN0(!J1N]!B
MW&Q_&H1-D2AZ1).,.>C["1O/T?;?L8>ED@HEBO7"J,0_\*.T!,CLWV4$8C9:
M97%>306]K$6'A_58#<PP8PNI*@ Y=(0;F6 'OZ9-EO[-3WW_XVO'ZB?UO&S=
M44>)EIPFCAZ?!E T3Q#<^G*YG%U(9#GJZL7EV3"_FGS0_58X=Q"\_W#<B_TB
MTM<PY5AO%Z+7@I!) 2M989IXA&9D33GJ[XED04A1.$%TE:ZJ.QXN:.V/4<+O
M<8VG(46?!' 2!!FELM2&$_G;'ZHLDV]^JM/R8_('XG'?M[4Q;?(.>[0SINNU
M8N-_ P]2@ID8KWPTN %&*OD D]ZE_6&J3G-'@!>W\<JD1LD+=LD)+B@8Y)UU
MXT0'QVGCY=]("U_I[)LP"II*?0FGQ@/LPYWIB.(B JF?\K#/]J&960G^E3!P
MFP;-<.6[$QU,6#Y_*7421QN63ZQQM\P)78L=VR:8=*KA0"VD@D"!PEJUI.1V
M:Y&MH%!Q"R7=AS/DZ8)#Q.0ZF9 VKNZGGK1LPI$E9N1P\0Q>,.9.%>2I2ZQF
MVI.>"K.T]F*%91JBL :W[CT>C5\WGPGX3#G;&(2>X$9.\EJ4< .#0Y\]00@C
MFKE"IGB]KTJ/QJU*/",::9TD#:@S8DSTC_;^F5_9V)%$G73,O2KOL[2S7LJ*
M'*::+;W0LM.:FQ!+WJ^+N) $"C< 84-+(TPI/2/',GLS.> 1E?-)43YMSP*-
MRJ9O XHF&4G&#[6&,XG1;"^;R]M-7Q$K3F!K6TL:B6@FOCJ>2-6$9@,8-,,R
MK%P71CB9;9&%&!I^=AKW#C)T<';-E44MM::TET6@9:,174C5\R;Y2)F+,84?
M:GG2B8TY_VV':?<-8\Z%2%NO0DN):(B)F5E*VCCMH>!N[00D53R]_+ZD2#RN
M6J)EP-=8\.8!YZI ?80ZA=X&X>VP[D?8GIRJGQH-AE$$VO<UX)UXA7#P\RK+
M^;3*M<K&V7LH'WG9]5?)A<Z\J5?7#V]_#!K)Z [CPI]<>;Y!$1]5K ^4L,*I
M=H4N>!*DK\V* ^>ZS)B^'!TM3S/V5 '-T$6$>"*!;BH*QWN28MW&Y*NE8@3Y
MST!\<JHSRJ74$=4(?\?JM!%:C!']R\N&/PU=[)H9<^1LYN<QY,A)L;XK3[W[
M@NO'L>O\<LEUZ^&DH(B<*^9H#N%1A8.A;(![+D__0*1@U_8E:I*,N[>"BI(:
M=M[.'J.R3UZLN'\ONK"E&.\!*^X/9]C.MO8/ZP!1[[&$"HF9E+=)-% IHGV&
M:(\]&-9$RC39./*)=WR*&-]<$]9Z^*M;$ >VEN77PML<-B$)E(8;F%ZF6EK+
M@;WV-<$[6F/>>T?D04H9296@GH;;,IP+X58K*A:RL)!A\\\)$^,OA#J :F6P
MNE;,?TZ68>@(^U@XZ)6-N=JO>*.Y)[L8K:7D?KB"_/U&#P$^4UU>$NN-\H*T
M@Q4O*N?A0S.,8TR&)NA8(3^9@W*\&>8?)T(K$B'B?4#&;C$='0E]>"H@]1=H
M,20=JZA5!7;9]L,CKI9[O@FH,SR&.6S^I)T7I,Z77!QN(\ FQP)/T&57]%[.
M!2.9V  W45JOT/C_45B=J&B8;R7T.&[X7@\W'#XY6\B3[IC<J0IWXNK% @^7
M;'?>Z7(=EX]IE2E%A9CN9'#VA?Y,./S@'6,Q5BS&BL585W[WYWNQ&"L68\5B
MK%B,%8NQOK1BK"^,;/E[M4I].B>V!4?L.^'YD5C'5C,]R+I<3]#VZ\DMOG44
M+6ZN0VB"@9/\&!S.C\2-4)UB'[OCJD8>9,SG8#,S<$Z[4L*,C3)"8=B<^).]
M7R^+JL)HV7%7UYB5H#MLUL<5A9"6G#92BJ]3<(S8FU<.HPDXVAG1YIAUGIE5
MOO#=H#(%>4#\$;D+E-<!.4J;5CI]6I^'@JTJ7]PLTGIIZ,(@J5*U0E'"K%UC
MBJ4$TBB"(=3$-0:/L.\4.E_R/;I@FQ[?#B'0D5!"N7V)7 +9J[(<FQ(W3!\U
M;'-J*8((G9L[?I'A+=RZR<9!]TM: ;O%M3R0<L-:2 \#.BH<O;P-S6#EYE4G
MTZ%/1F>4TX/$C%43B9;@P>SCYY?:Y=X+W.(.?U@0CS<$C%*&2YO#!$%;"YV6
MR]+V<Y+-]J1DCW!%MX&E^:28.<.JQO#A3JJ9_>5!$Q=YS5J](K)^!=D0W!$&
M3S"EXX=7!=;?K:OR.HK<!.#6S[DSY5IYA^5WK),XPNVR#"VWD9>4!====-3Y
M'<X9COUZ4]<2T2 ]_7*34DO[._-I@OVJC_!NDOU1:)Z?I\^J14<_$0(XT]BY
M57Z\!,_'+!]2#3VL<.\?1IL,$@,D<U$I<!;YNKR&*I;O#ZR*CRA## L()MY@
M,A6.+,Y277*9@W0&MR9<.A)#JU,O?D,]$>%[U)!Y>9S/\R'5GBC30C&P;!J/
M]9<4\ 1M'GNH$H/T(FV.T38[Y>BQ;&%'U8_ C:++C%])>^%Y:=S>5:KS4]+]
M3X0/[7)JP3:5IE[C?39'7=VM:[NY],I.O)Z6&+MG]%# $<H93ER(Q<8AL4T;
M*"M<";1%N#,0!EPHFSUV\@F'*G.@71!=/+D^>/'D/'QQP,])NHB)3(?+</G)
M9GZ^?*4%::2$9?-()W-KB^C=%#UG#QV8K2$$Q,OV8>=/ZA7M^9$I94AL\VLA
ME1-.U(?0>N(S.B1= ,^F9(5K\M=;[0^_8.97\!Z$#CY=L(I:UFGW@ V^<= O
M]P4"L;XX^I>Q<FC69 8UXD7QA[2STZ;"0V"C!RSI?S^O>JKW5E@E[%*++!4@
M:D59^A6VV;;=BP-0*[+;@O9<H:81@*X+*; )Z>RPB1A."PR29A,>,ASGB';L
M5K# L!"9_@@'(@V<14U3#I*GL?&Z=,NW#@.!KVCG$W0B3:/K(XZ$Q>7F(O-8
M#;5?_S<3I(AA[%-R7)W"Q!6%-@!"R"3U?G- 2'P])+_60L6JI,-?ULI,I+H%
MCI@."9Q[[-@4%""A@MO:-PPU*8D>F,"*EP#;PQ!HV&L;)(EI(V#TM!!4$3Y#
MK5S2_W ^$4;+1A4(4R?LW<L43)*-PJ?@4LH"(>DP-9#F, (FUJGB"$%O=#*P
MOJ"S <R%]*/IM<D.&Y;3-WV8A!P'< 1E!%FE6(^ZP%:<4X([<2@97AI;/5&>
MNT;AI?,)1Y9S"PGL=6Y]:*3+=@<2W<%PDGZ#A4-E(QW$G0B!T6C!JP7U;1)I
MD;E:Y#5LDA/N*2@5X5BZ!T* H %5G(16Y#(LI)U'T$"!;0<91-:>5I8Z>FVJ
M->]/(B)'@X_/^'_C$0JS4N>9Z4D(\K0N<._!.^,@O:7A\8Q*BM\$2V1L@DOG
M.?L"<;0+2_J?^6))!E!";'/$]FJ0K8<6U"$4'XQ[14'"JO8VIH^ZI<5!RVY!
M8F3M[348J>0,,7"=$"[47:RN":<];O [CUI5G\.U:N<]+0\:^B/.?/U\B-[7
M8PTPB;3!6EIMDC8:,6.\+9Y=Z!X27/,?KU[]-K%%&;V !JDI)R&$)(7C8K76
M#J%XSC$JGWR<%8I&XPY6.38OX=KP,Q:"M$)Y@4TMP-RYQF\]F2V3XQQ]+X[Z
MVT8@D^1C"8<$:%)P'"74>\*N$_Y;V<S885"XG]:>V&.\8KBAGIR>?<*Z%D69
MRM=2#PF=6^:V7X:@I!] FW=-HU'I5]1H*"<9_\G.QNL@<OW.;8.W=AO0#6<O
M7^NN]*@^?M-=B1?_J#.UJWQQ7*YG;\DA=S>A5,F%;TC%*Q+CHA/9Z09'XD$-
M(_%+(@JG&V(,3)91H9WVW-?26IC2+.?*[I1. Z\:Q-8VO??<<U_H:"WM>+M&
MNFN1]&M4^3("IW8*MMC5 4J/27*-T946VV2>\BU[Q>X&W]YN/.(-;W*;4_$F
M1-Y0VBEZISS!#-&L(Z9P3>RTW(!BL:CA_)8\T+A2W-Y")&<M[T^@6-8<:A%$
M82#//72VF.V]VX1%.G+(;QT@F3[4%+D  Y8"ME3'[E)/7D6?[4/&B1L)KFB
M*M>F'EHVK9;[>=76#S@2&AJ.I\;K4@;3@WC1T=[17L'EV2<Y>U,G.0P-[6'0
MA66%U1Q.I6=UNFREIS2I'5$'8&? ]N'3IFN"BC)<0[R;5T6A17EH"'Z2NM%P
M%&';UKQO83".G(K9>DARW14HY4,3!U1\0:E-/^-(74GM]RBK-BHE-&>F/*;9
M=(.52%1366\+?;-E@4>H7"1=B\^><@J$C6/B,7A%7?(4.'ZQD"):]_;'ESJN
MU7F1D_H]DGN>O5(84SY[H5SYGF:'QAOQP-1TNK1G]E53EW]$.T4 < 0 1P#P
MU0' TP@ C@#@" ". . ( /[2 ,!?7MCR+:6+78;)=N#:J''-.6)R6RDZ@/7@
M73T"Q+1]H[$:.&\[J:0LBG2.&I!\SM?OWN+___*V\;+>%*E.;?+ (XN8D-U*
M47Y*:Y$?O=C,T=1LT\5'!AZPJ[NA9,;B^"'CBR6-Z=@7J!NWHCT(=W;>8L/W
M==JT=;=HM;0?_)64 M><#PNK_9"/A9)<F*/@%K1=S1D*YT 03J) KVR"P0.Y
M+T5L5E2)R_ .HISS!_C(*\?LVGXL"5T<NFG'%>DP/$QNX;_JW% _7 \R:^\Z
MZ8>$\/W8G^$\3F\0$OMP_":<,;4R^QCF@+*J-JBOD<^L0L^4HBO25E5:IOH0
M)8GHV@G0+K'X=D<DUQC.(2=PRS0Q\XYU[I!TA:)^62(<IQ84$X:0@D+6B82C
M7;S@5#D'@][.PWWO;]_38_4P+;Q# HCC(W^X,:0?3+.&9W$:3P,=5N"L3EO!
M/N:D=76NII:T;M78>)VO;EW$U%\PD67+SH/JXZ0KD,%"T&BL:2>P2U;ID6#*
M//PYAS6/X2>$)_*5\T0C]^OCO$%"*MO'1Y2W%\2M*+Q@D,3&<%]0[%N[8B#1
M:MUAM.@DKSLEZUBARP)C?61VCW8G"6J2:H6?/,8S Z-(F)!85!DU$R]S+E3(
M8$>EF3?+W+W7CK>I<*BM "%*^J'(.@>!*"TZ_!@A_IRB285_($CNRF8@<@.#
M!ZCDBQ4I05NS/DK+_-^BH?I% %3Z@;G:O%E-J)DWK76_&H3CYZ@2.8/C:D-4
M>Z&\+5M)Y<-HL#ADA1V(\>8L) P%2E[)(EW@U.@=.BX(M<1 &L( )TF!S7%)
M$>'+(^J0\DK>C+O:@A8I+Q2G@/=F D0,/G5:.A$N%4D2SR ROM15M]9XMV;L
MA7LMA?]D)JDY/+E,5A4C,[1\ 91A8P:!4TW)(_= EAQOYG6>):=53:D<KTTX
M'76DBI?IPLX)AOYP7]A=C;VE;0Z>XVX2**X4LXKL8FZB4R%V=WHX/))0[^)$
MZ9!J ^]E*#IM&UL1?5- V561U'8EYPDP.47#A',,RW$*"3?",^",5J4@&:@'
MK+G_$,(0)E?2M1AT J?UX)R/D.C2?SV(66#(,JN"R ?(#1V7C4](,:(CR681
MY:I:;#?YJ:M1J2+HQ"%&**># I7_W6FBSU4_C:FKME)X: ,6?$O*7S>\A/=E
M?RO;8K6$*?+2DHOJB#<D=PPITJ[$9N26,0BL2EAUT_IT- X&C30SBWR=\B'9
M!,/'0\AF!](,1H$_$[ C<SOIR1FRU[F<]M!O<+T@8/OPK"CVA38'JLE/PJ;$
MF#;'VL'6#8+;MKR,C)&@Y0H(-MR[A8L+C%MUP@CIH$1+\.JB7 76/:.AVDIA
M;MX<V:00(Q$E+V-1319B-*';GU1Y)E ?&]YGN''%#;*K^;)K4-OB7*""7B3F
MA$'9H"X+D)[NZ%CU&<(%"I,=&8L:1XEPDY\1GH^L6HMB%C"<G%D3%$.:CLF(
MDT>HL13Q=KD8Q[@X]%I49(?#<#@F<T0B81.YDYXQ/$G("0F9U#R8NZN<T]TN
MK=Y)_&#'@U6Q&F&_\G(B(6#.9QH?<498;2BJG:AJ!#4=_GA(_T8M>RP$S(>3
M*UV\THR1OG&8@&*L\2$+ -$YL:1J31F.'P=J=0V[>%P=8DH'7J6YPC=:.P);
M?P1LU%H*MWRKI4'%)0IF]DL-'()QPD\JX&\N?[5;* ]97UW@ 16PM^UHR#RE
M_4J'7KJ,C*+M"3._#'2T/.0!'Y\_YQ_-:=X829QS6>]5(TJDE^W/*%CA[<SM
M%;Q;V)SH=EP,8HN*S[D+U^OP-^'F%)(^@:<P7BH  FJB]DS3VBNC.$<F91I=
M9.:#U/+AF=4&*&JKS>JAS6$5J*<*2P6V5-1R0##2HL%(/[-WR#:#[ODJ(,1L
MQ'4D3;2NZ<3S -VH"?TH054'@9P@( -?P;]887AA'5N-PUQUC@I/K><E*ZM
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ME6>TD.S!F8B(L(D-Q08VS!.NA!<#A,,YKB)&XEA^O% 64/,S"$N7X 0A[^H
M,0S_X=0XL6!B)$H"7$N.=-G#2.QI#<D-]#>2:9+/QRH&?U1SX0M&.*4-J!I6
M: :+TM 0J7=J4,P:?#/8\ZE6D$DJ$%W40D)^'(*ERWMU,3T"9=4*M!ZXZ84.
M9OP]*$>,\1J8+#843JNZR-2)QYHE"3"X@$D:: IG0.#^AD_2(^/8F+?-GB2)
MV!C!U[5B(;7%BD,>73&A714SQ3.4+O&*_B(H5[_+-HGH3"PI!!N2]*T-([M5
MS[#*M]J(*G8CHEBV\2V@P?@B9#!"!B-D\.J0P5F$#$;(8(0,1LA@A Q&R.!-
M0P;_L(:IG\MDQGH;] ]B$QZ>KPH)B'PH"GE2IW55'F$OZ VG*%U(A>MGQB-0
MBDNRK/P/&0%(\P@&)P=I@SD3(HS1J*JX*V%O [_'%#@DO*HAJ.*XXHBQUV)8
M%A_[Y"AU95YY4<Z*/EACN IFI&/0G*4.\K*)IUB'N&%?VF=$\1XO@(<ETQAX
M?K:V*NQL'P5-@Y\15\:\I:0@D!H$?18<OU=7A0^4/B5^IG?+5CCEU.EG;(B0
M,4,CJA0SN\0&\5^9O3F:"S_UT1^G%%E3";.QG]>*!^:7(VQ!1LE7"S"J;(Z6
M( ="[(+-FN!"8HZUZ"EML"&S[[YHJ!!00ICI46THTV]3^=LG'.$"MN[=2S[8
M//22VLI[,0),/Y9!D'[;4DG';B^NW4-0]B,:6LF'88/26"*0K<F%"==PHD9G
M%5B=EI9\)*]U*3@PHITE=6%VDY]==Q"9)&[D)8N>F24VXE+P!<L SYW#,9R:
M7@,3SBKCE80Q&;EXXK<E&<13O6;2F%.FA<&8!DHM23IE0*H^<R9%;G0=;(\L
M&DAC&B?#LO8(&J >1ZJN.(&%59R.+6:=4GTN[P()U\*4$V+9AFSKBHG_X!+2
MB *P4.6EL2Q#00TOK(:D2-(SN]JZO I6V'H[P@QQC*9B[@]IT(<J$V-%-2EU
M&UK:DF_9JN$8R=;?TKO)+R"7&#_V4A]AKQEZ&#7/L47'A*D9ZR;IY\1[_(G$
MAT#MU\P1L@T6#'MKA+5* F!\%PY9!<%3BAM*;TE2[@V%OS$,%^Q.ZDT9-*0,
M-K(&L?VVW1>+SV^A==S&E7SI?<61M\MOJV;KOG)[*I+JG5<W(2H56<C=Z<)H
MX_Z9XW=W9VB.Q[A ?HPDNKQ5?+A6Z?MSYX:Z1C-^<&YPRPCBPT,+6@,1M$A1
M5*>20"5J.=B-)Q4ZD]+Z;I31,Y5;;"Q_C%NS/J-9F?QDYG6'"O3I))GMS0XG
MU+BL%IPW46 <@XAJ582A%MFH/=G"2"EIV<%)XOHC3OJ@T2%/VB3 EE+XYQ1&
MZ$S0Y/>2ZE_>MP1'^"$7:LW7=(@I?N5]U:&:+MWWV (<5N[_1_,5U*ZA;K%@
ML&LV5;GWW$IQ=VEGP5#P/B>5(VR?%=9C$=_S>T:6XX2RXLE;G 3!__],B=3?
M7,](+02@5P+#\%^VR?,[8=4M<3U6R71OYU^,O73[;3Q73O=A5C]IC7II]7E^
M U#7]S/HJS;IG22]CFAG<0&/'AHAOPB![>H4WWCA0'JV<JAI@]:':K:GKBFD
M_6RL.20APPDA+,TEURQ%!;6>H*QS(<0<&RZ^:@05#+\ZJKP[N5[C&\])L8T;
M-$/=XPFF\UZ: #>F;0LET.#*,\ZIIZ=I+8WKU@463N7+9<P9Q9Q1S!E=/6>T
M'W-&,6<4<T8Q9Q1S1G>2,[H.%%R29__U35>Z-@Y_-FEAFC^KY9\8^VHW?SH/
MYPZ\\8L1YV+1SVP7_!JO&\5[? W4)#_2:_AN"=J%OW.)LW@48;K'$PIXI]5.
M ??<D4)X>J^U)QB!4=5SO4>M)SH!7](R[.#MF^^0Q1(5ZV#!W OO[<Y0,.Z3
M?[Z_N[^__^W+4]!)?$1_]]&8-8RNZ)\7-#5GS,4W__TH?:P+X"E.?LYT;^_;
MWAWO(BYT(4E\9]!$<[(72J0+%5AI<VK-[7A?U;@(VE<>W_D5OHR;\&XWX?SK
MV(1;57O<;$K95((R6H/88_'B] 5%)_>5X_V(HO\4HK*THC::]GYGFCSZ"9N$
M_%KM)B![.\GLV<%L]N+Q@*#^S6]ON23+:X"$I>0KKS<<]:NH#85N*6C+?36X
M.$TJQ"5,!9)78BI3>A>L975=(@N?)W^DU#ME4>=S1WD.%V#WD!:S<A1>I>R/
M- O!L*QMU_>N@]<[F!W ?GAT\-CC&.]%-JM@%I_S+$8==K<Z;/%UZ+ W3=.!
M5/W6U; +FBV&;-1LYYL1MY*E)"<J,]0;I_D3*[O!:RKSJOY2G*?]W>0'&7[R
M^YH4&PY_5-9N///X.9G?ZY>GUB-=OR/)0N7^Y\&?V$,1O/.E :?<%8G>7\'2
MR;J7HT.I/]A-?L$@YWN:4VH%(G/Z<//L6P3^/@PMN8ON46X#OIC_23G)/[WL
M\;W=>RC>A[O)6\)RW>^=>'4NQZ\FNDV&6_X)+_NU6X'WLR"Q^^G/=&86<W,X
MVYE/9_L[!^E\NO/\^6*V\SQ]:EYDSV<'+V9[WQ#B%U[N'2:"7O]Y<'  [[#_
M8F>Q/WV^<Y#-YSOIP=+L/#V83P_-_M/L<#[])BG!#_NO;\PB^^Z7MBX^(,;V
M[?)#G;VJZP]PK^\QQ?-- DY4NH;?M75G[B#C<(GI_V9\ A>'3V>I.7BZ S,%
MDW'X]& ')C'=V7OZ_, LS/+9TQ?3SYU ]!>G>_/#*<S=JZP"CS#[J4B/ODE8
ML$%]? (OA;(+R[1HS):ASA?9 E9T;^=9-C<[!_NS9SO/7SQ=[$QA^.F+],7\
M^6S_<X<*YO$UC?;%,W.8+;)LY^EBNMPY6.P?[,P/S73GF9G-LL6+Y0NS_.S1
M^D/]4*_*]DHC79K%<OH\?;8SWS/PU-ET;^?Y\CELI&=IEJ;/39;N/[_F>;W8
M8._#F?IK9?50,'=7^/O^& JE!<@'+45M(]&4Q9Y 2-2:G E .?"#:[@SM<VK
M_,ZA""+#"H.=\W[X*&VH@7G)X2<ZC0_VGC]:/,:!O;,,),G[G?_].,F8H0$C
M3'];%!O#$AGPI #^\V!N(9ZIOSZWADFXQ*GZ=/?9%PK%N6\F1(2O1?C:?=\S
M]PR^=A#A:Q&^%N%K$;X6X6M?&N5!/S@^/?S3?**JR_L;#O_PXR_)T]WDQWL=
MC)-)?*B1.-B<L#U;TN+;=HYH,1P?/@!>!W^^ P=,U;6^#3#=V]O=^U9_3R6H
MZ\9\UW!7>#.RF;[A < (K/EQDC<Y5]Q\IW>P/X/?96&*^_FWVW8NFQRC%TUW
M]Z]RV=.]*SWL2H_:/;C*9<]W9[.K/>[YTUM[MV<7&N1_/FGKH7#(T8N*=)XN
M/AX1-]^.*),E_6]<F7A8"S9/\8-1N0I.?S)I_7,#/D!F"63?D W-FWS@GGE7
MRDD1@E!4#XSHFN?WPOL8:-X+*9@?69\&ID";W?(TW^RT7DZ#7]5^NO5)NP^R
M&:?QBYA&4"'XW7]]L__-]4^I]9DTS+5NQ:N]GY-]L_KTC>,SH9CX.[,T-7:#
MN4TIW[HDB9RY>_OW='&B0OD"9!S1U=GX)'\%5F!_\\R\W2,3^A 7_5?JRG>7
M6FQV,35V^\;D12?^\ABRNYSB!RSK/U!I!G6$N"^K$<_M*/FW<;17]2HNPYTO
MPP_@/L1EN/-E^&)LGONP%/$(^#J$_I^F-EAY>@4'CQ)?]\7#@]]]3O3Y1A.(
MU^HQ[.].KW_;W.?9NZ>:YKY-F4*7CMMVW7SWY,GIZ>EN8Q:[1]7)DU?UXC@_
M,<T3DQVE]1-L@O9D^OSYX>%L]@1$<CI]L3^='<[V9_O/GAX</,D.#Z8'>T\S
M\VE_NGO<KK:+\[9]?AX"ZN++]VK%W<F1(^>=(0* +'F-2T$]' G<Y**PW(:Q
M25*^:N+QW^:EE/GO#C!07Z4\?$U;Z&+'\#W!A5X,[+GSO^-\7N-\OG@R??$$
M^2[BK$9;X^$JRJ]KRJ+W<0^]CUD4[Z@1;LG[F-VU]_']!EL>1)?BZ]L77Y^Q
M%EV*Z%+<_UF-!L07IBB_KBF++L6]<RD.8I A:H3;%#@+TDZHOU9&#5ZE,J:Q
M@+RO-)_BA_32&YQDEM+VN*:NQS<[J7?N)OI&3?0 OQ U=B]LZSB)<1+C)$8-
M&.4N.GOW5,JOV=F+X9\O2D=\4?FCZ8N]V9-L=C"='NR#8W!PYXX!46$2_18U
MG7E/36<\]%I,''UQ&^)>')K7JI/?[TR?O(HS>KVIHVE,'47;X8&KRJ]KRJ(W
M<>^\B?WI0\L=W7?R@?LV=^I7E*LZW<'\RY]WGH%QYC\R[E-CT+Q<Y.NT2'[\
M9!8=<JDF;[DW #;<"_I -LET/]V9'CQ*'U-)S/0PD[]&VT+^^$F:5E)_R&4"
MKM(!H=FDTT9P__=,;Y[L[\WPMW2KM)ZGI6EVWGXJS$;O,MO;FT7/)1['<<KB
ME,4IBU,6O=MK,,;^3_0ZOA"S&;R.!Q:(B%['YWH==YZ).,/K^"DO4_@G_"MZ
M'?=#?KZFDSI.69RR.&5QRKZ&*8M>1_0Z[LSKF.U._^?#4A?1[?@\MV/V!2<[
MIL^3WW??[[[>M0["=/]P[UPOXL7>T^A%?(4G;YRR.&5QRN*4?0U3%KV(Z$7<
MH1<QBUY$]"(NY45\N<F+Z$7$DS=.69RR.&5QRKZR*8M>1/0B[LH*GNY-=]_\
M^OYA*8SH1]R3N7M3DA/Q?[Y_]W/RIFS:%*F\?J@6W0J^3_[?__%\-IV^).,]
MUV\S_3:KX#7*JDW2]=JD-5+XX@_?H')+%Y2-^"%MTP2;WB9SLTB[1I[4ID=-
MDM8F,:NYR; E";9-LM>[(>FS'M8*?^G':9RR.&5QRN*4?0U3%EV#Z!K<I6OP
M_O4_H\+XDA3&ERYTOOG](?U4E=5JD_SX";YM,)S_?G%L5FGR!]CKR8]JO?^<
MEQ_G:>,\A^9A+4"4V3AE<<KBE,4IN_LIBP9[--COSF _B,KB2U(67[K O:Y.
M$*63'FT+NS^Z:(3]\<-:A2BX<<KBE,4IBU-V]U/V "UV^%<Z+XSWHKV9FL++
M7M>[S\&.-[7]>_=PW0IJ6'[)2_%T]W!\,2XF:S30ISKL+4/['*F\@$S,SGG\
M&5+Q5]>T^7)S5;%PP[F>U_^?R8?CO$D6 5@[72RJ%0P.>6'0COM7E]8@RL4F
M>6?65=TFZZOBKXF)ICE.BX( '7.39,:LP&I$!,@,Q ULR8S^/7V9S#=TMW?F
M*&_:&A^WK&I\]KIJ8&1P2PL0?VX??0%&&^D*;;'@]V$=DCN7P-M[UY&#(,M/
MY/]!;?TG_#=9%&G3P SDGTS&=Z$[I.!0U-_HF.4MZ61(N[;JG16D:'@$S^C?
MW@32S^?5)WP['+$,#V;L4ZBN@OO*84(W@_G#@<I0_KV3@U!]^F[V<EF83SM9
M7K-LPHV+;E6^S/)F7:2;[_#;P7'%@X-'2E2%/Y"%TIFC2W= =%^"_.=T[]H4
M*3IB_HM8+?SI;@ZXNY2C^WN<7_>[/S\\8_\<U[T-DI,COM.TH,=9H,,O0*CX
M8W[4<Q*_-7C['*?;29?PZM^EQ6FZ:5Y^\^1F-^DU;,K;+;KZ'VVU^!-GZ\([
MX92W^;PJLG,KKE1QR%+-BVKQ\69DZ@.:BMSYACYRR=7T=M7T-:KEP)F@[YVB
M'BC<>Z)7KV /W]'IO()UUDM'UEVG^G!D9F69[J7\W,8QDN39?WW3P"=IV]6F
MN>*QXBN2&Y&&]V_^\3EF\HV/[]=7'WY_]^/[2QH!TZ_'@?-+8=$!JLW?'=B>
M!(ZYL%/$%UHWZQB<I*P#=X^@]!E\#2YBS:X?/ :\-A1<^ )<+VR_/3?@T2W5
M7Z,#3'X ?]>F*^$BNA]LNN.JAAEPSM=-FVU74:;G2<=G*%..RE!09JMVDY,&
MQX</@-?!G^^ $5!UK6^G3??V=O>^U=^#!!;INC'?-6:=@C%A1A3>-\-$[DG>
MY/.\R-O-=WJ'T60L/_+@<'<V^W:;AF73</S"JUST[$I/VM]]]OS\"V-:^]YE
M&6^@P(K?(TX?/ B_^Z]O9M_$J;R 66&Z%3ADR0<XO]*UZ6 >FDGRIESL?ND8
MF56>985Y&*L8]4F<OCA]7]?T?3F:]B$MU@_@;GR7_))NDNELDLSV9H=1^.^9
M[G@P7L3WF^]N4_BVHAX2?9^O;XJ?-$^2W]*N2'[>3;Z'"[:4845=?1\7+]HE
M]VWZ'I)/]FNZ,M]=:THA"OW-KUI4]E_HPD6YC]-W=]/W(6^+J.V_N&5[?9R;
MY;#7RV7T?M3U7W))19RU.&MQUFYZUJ+%?!\/OQC*CIKB[J7PO@2QO\*IQ>#U
M+_GB.#4%_+> AZ9E5-!1H<19^RIF[>:BU7$*KS*%4=5&I1%G[:N<M1N,%<<Y
MO'K@=MA>#UD77/N]5XL%J-$6[G:5R&[4R5&[Q%F+L_95S=JU:N%'9W0ZW4)_
M&)-H4>3CK,59B[-V/4FTJ#GO>EWBK,59B[-VGV?M+);0.W^[R#G8E[_(.1@Y
M!R_GK%X[Y^#3N^4<_,\G\RK;_/?_\Y]/CMM5\=__%U!+ P04    "  TA*Q:
M9/O"(V5% 0 I.Q, $0   &YM<F$M,C R-3 S,S$N>'-D[+UI<^1&DB;\?7]%
MO)H/4[(E5<52:W9:-CUKR:N:UBPFA\R2ME>V-@8"D9F0D$ V#I+9O_X-CPN!
M&YF("""KN#;;*I(!]_ X/?QX_#_^]^LF0,\X3OPH_,MW9S]\^ [AT(T\/US]
MY;LOCZ>SQXN;F^_^]W_^C__X_TY/T>7US1VZPR]HYJ;^,[[T$S>(DBS&Z-WC
MY^_1_SE_N$6/[AIO''09N=D&ARDZ1>LTW?[\_OW+R\L/WM(/DRC(4L(N^<&-
M-N_1Z2DG?A%C!WZ/+IT4HY\_?OCXT^F'GT[//B[._NWGC__^\]F??OAP]N>?
M_N>'#S]_^*!\%FUWL;]:I^B=^SV"KPCO,,1!@'?HV@^=T/6= #T*KB?H)G1_
M0+,@0 _P68(><(+C9^S]P(B^)M[/"1,B=>(53N^<#4ZVCHO_\ITB2HBS310[
MZ2L5 _A^^/''L^^0DZ:Q_Y2E^#J*-Y=XZ61!^I?OLO ?F1/X2Q][9(0##$-3
M:*#\F4Q)F/SLI?%INMOBI,#U]2D.?HCBU7ORY_?P9^#\I],/9Z? FWV)7>\T
MR9[D=_2;!+L_K*+G]_R/]#/E@\;&A89D: J]>?F1]N7CAP]G[__/YULV]:)Q
MX(=_U/>=M/_Q/?SYR4FPE!?[]9T@?RAV@OS12XMM.=6?WK,_JDW]ECZ0Q9B2
M]2'[@,-L\[&.\L</[_%KBL/$?PKP*33#,5VLR>E'V#/L\R3.N[5TDB?Z,?EE
MH?M9<KIRG&VU(?]#H7&XB9U>JX[+6QES/D-G?_[SG]_3OW[WG_\#(;K&_<TV
MBE/$EOIMY%)Y6@8+?CH5(W8*OR)[DRR['PBQ[U!8NTD:AOO]L$Z(I7-0)^2Z
M.[038I$!]Y^:^-:NREX<DZ9-*+;N*?S0RK=VK_=F7I*W?>GWD+]C[^PW*)5M
M]1X':0(_M0Y+=3<>-A?B+()_])\'>8(=-@<U1SW].>FUZ.LNB@/'7#VAV+CS
MW_0;^\(!IV$O[+,/!NZ!']^[3N!F 6UV>O9#_7F3E!9^Y2NE TX81BG] _Q*
M_'*[]<-EQ'Y#?@=GU<]Q%. %F4 $__CR<-/C/GB?.J]1&&UV[^&;]T(7NXB(
MIG?OK,A]YY.+O/IKP5BP]C#1UWS:R;,/\/^(-J<H=O1#!%_^Q_MR^Q*E+,'>
M//Q/^N]M3!2ND E_2W[!/^9-6CY41G.O[_)N-7[&?RG&6O<,/!)I,1MKT']]
MC_SHG3L!W(:/:XS3A$U)CW8=<W0&<R3)T$G**2%."C%:;[,V=-;NG9C\>8U3
MGTC9=PJ+'W7,Y\<]YA.]*Y#^_FU^^\^O1Q04[*F#*_^:S)?SK=!99B%IM"&#
MM0:-YAG?1DGR)70RST_A[59> 7K(=JR1'VO6"&-<7"TY:Q0M4<X<.2&T5-@C
MX(_>R1Z\+24]2VF^?$PC]X]U%'@X3J[^D?GI[I)TWO73PQ91+X(=R^=/^RX?
M6#TJVW]%C#%ZQUE__[9TM"^=[GGNN(PTTNY84#_MO:#ZKZ:W.\[4'7?A).OK
M('HY_#JKH="Q4O[MH)L+^"#*Z.V<V>,5**WU\WCEA/X_J1!$\;CUR7XC8[CC
MS\+N=BVS^N<___2GGWZ"=V+N'#A%*B6J;4A:;[/6=]8>L\W&B7?DQO=7H4].
M1B=,9ZX;96'JAZM[LE=<'X,B>>XD/MF-]\I@G96G=ABQCOG_M\K\<W94<<@9
MHIPC$BSIZJ!,H;'*]FVE]%TI<#["'?KL!'!DDEG\[,1_X-1Y"O C=K.8]!,G
ME371][..V?]?E=FGY[5"F<YQ3AOEQ-_FN.\<7SM^_(L39/@S=N!G>CF69[2^
M4<?\_7ME_H ,HG202NAMLOI.EFK^@7=V%-;-5D.KCNGZ<V6Z"D8AE%-ZFZ^^
M\S5SR6&5T,Z0NV^6)+@Z6[5MVN?JIP^5N5*IP(7'Z+S-5.^K+MIL_'3#[ROR
M9@!E H>@252NMY:F'?-V5KW2<F+<>J:0>YN^WCIM2MKBE>_>^BX\^\C$0#2.
M$[MK.D=!X#Q%S$HY6\6X_I8[C$C'E'^LZK""#>)\Z,0+3GP5*+Q0SNQM0?1?
M$&5+5/7I4M.D8S)_K)G,JL'I;9;ZSA)YEBUQ'(/UAPSCKTX<.S7[LJ%5QUS]
MJ3)7D@Z;-20HO<W77KL*@IZHDXF<752<VHU5;=4Q7U5C#Z5S>NXP*UY.Z6V^
M>L\77L&]\8 A2(6H%969*O^]8XYJ##*, I(DWB:G[^3<X12\H_<X?EP[,2[/
M3?G/'5-3M980 LS]2D@@2N-M;OK.S0,.'.:M2G<+<DDDCDN?5N5):FS7,5M5
MVPBGA"@II-)ZF[7^ENVG!/\C(_)?/9/_J=JJBW_NF*.J020G@"B%MYFQX7,0
M?]7I>I TV]? OU4-+3H\$.B=://F;-3LC%C CU63S3[?=BR)&AM.;[<$>L=X
MO$W[,/]$_2RW->V8U*J5IL%7\3:#FIP6]5/8VK9C#JO&F28'QMLDZK2/-QRY
MG1]T3&?5?M-J*W^;4PTVTOJI;&S7,8,-%IU*>-[;Q&DQP[5,7E/;C@FL,?<T
MF.3>)G&P;:YA^NI;=4Q<U1A4L=.]S=C>,W83DF9XX;PVW7G5!AWS5#4#,1*(
MTGB;HJ$VU?IIJF_4,555:U#5OOHV8=I"B&>>1WOH!#?A,HHWM,$E>5#[064^
M#Z+1/MW_JVKX:0X]AO ;R0KY.2_(/*#<WA:$9C./M/W--G"=_1.TFR0EC:4-
M@&41=%,ZWWUV?H_BF_ 9)^1M<9CER%QW.I;I(&-4P9@I>XZ@Z_0KQ00BDB7Z
M$7[:(2H%$F(0Q>,"8EZB>/>V)XSOB?IU!:_EV''3S D^.RG\>M=PGIIFU[&F
MJ[:X0]=TX^I4.H=$[]X6IB;C;'X8TAA4>B,[3WY 1Y\W]&9I?C2&#S Y,7F4
M4&])PZHTRJMC259-BTWFX>*92CO%E079+?&!AYRT<,:&2':.^XW>EJ2>);F/
M-KD_@8[%4S5D-B\>18^\>=,C]7L= %G.RP*BCLU<-\ZP>EPTK(?#"76LBZIY
MM-%?<8H$/WJL,(Z%,^5MA5A8(86,<6W+I99JQ]JI6F:'K)UB)OS;6M*3Z+//
MI;/W]QWKHVH KD\0>KMRQDY"V6>5Z&?0L8RJ]ND!R2MO:\VH[W:_A;37UQVK
MI"90LL[/^S;])J<_US @3"(*:0N!2'T=Q==9"AZJ),E 3>B]+@XCV[Y@_KTF
MJK)^P:B:"^//4W=$#Q!918CU 8E.O*TG71$%+8="OS"#-@(=:Z1JV6Z,/>@Z
M6-[6P<!U(*ULBCN#MIQOJ3[Y"=+HL-=VJ REV;%:ZK)L&U>+8J$KNCC8V<([
M@'@/WHX3[<M(F6=: $+Z!O9<.LUT.I9+0QYOYW)1%P@2+-^.&=WK@]SN:>R[
M*<_X';1&VFEUK).JZ;;?.LF9\B7SME:,GB65/U^]PC_Q W:C50A>[</NICV)
M=ZRF_AG.-:=.72O>$93WY.VR&AZ(N==#>I]O.Y9'C^3JMS>TP7G/G[K\+Q#<
M=Q.Z0095K)1D/_YGOON:_$:ZR7>LGCXAO\4'M?@[C6&4'2ED-8HFHB]ORVQP
M2*J\6^ DS]B8S)?@[G=GH7?I!QG1&DK?-*PPC90[%E?5#EP3_%JXLY0^P(^T
M%]0ZS/M1&SW[MKAT+:YYED*)+(\F0J=D>'PG"'9T[/UGK)CRE*BJ7W&,KU[A
M&,#>=1QM"LNH=OGT79"6>M.QB'M%<!<6L=)OI'0<B9X7;9)J@-H+Z3T2W4=+
MTO_RCGC;!S;P.O;1Y0ZBT;[F_ERU=#?C?+PI=^:@0/;2Z??XM&/Z:XS8)0B1
M;W[2X7_@A4TG(>!U)=4&3NS"EP]XB?@_U:4ARZ3Y8?K>\S?O>9OWY*#^#M%*
ME3^O8[SL7X7Q7Y0OH=[=7[Y+_,TVX'4>-?2,_!N*XT3AJ<>*MA[8ST8ZIGL=
M;1P_'-[I ADS?:8L3C=X\X3C0SM<1\-(;]>$:.QF3_A4#M*!?6ZA-*3GP!@G
M&^<'G,71%OY#.;\G)\Y22O'B>S@^#9TXCE[Z#'H0Q_);('[*?R#2G/W[Z=G9
MZ4=:(_%?ZND>+$ZUQ*+H1 +Z'YQGIWZ*-U4!>I=U_)=Z2NU=%OT]_ JLUFA4
M)8!"P*?B4]K+Q@\,=[1/*</VGO>G,+HHI9)*0^6J)6=12$U%[OH/@U:&TQBH
M?B7<M S1/JRF,3A[%RG3,DX'<IW&D#54WM*UQYII'R9^I; RE?6&[%HR^N19
M#$:7&> SKP18>]U%W%W4^5^Z29J^D3L3U3NOZ-X4K(DRL(A47WFUL+$V*+WK
M)?45?T^"U@1M*!K45ZS6SZT)T51,IZ\4[=];$Z.^QDQ?(=J^MK=OVHJO]-XK
MW43LG8Z'E2/I?2H.(6]Q$&I*</07L?%C:P(T5:?H*T/[]W;GH:9HPUY3T?B]
M/3$JM0QZ"]#PI;6N5Y#^^_:\X4-K'6^&P>\K01<%BPIK"1N^OPI:^^%1:-HY
M=+H-A;O,;6)ZMP"#TZM\%ZF.JX'O*V$/(B-KX_M*U(?*%-3:O==B7U(C:G?[
MRM1%860%Z2!Q.JB,IBSM+4SK]];$J$%<[2M!XZ=C:7W["M#Z^>@FR_: FJ'F
MS#[4)Z9=&$2DU*NP&._H5"=F?UA$0P-_:$?&52ZUP?H-TDXU]V+<(=5SB!Y,
M>F3=OA<6VS#%?P\6$QZ,>M@Q<R/3QF]4MX:>_7(HY6E[#_2,C3'6([Y+=8W,
M(71'%/M 0*##QV,0PY$?^ZU(-\,L #U(CRS\OO NP\;C,&Y3&:(6Z!)-P]+)
M82I#T8'2H6DX>G&9RI#L"T:A<\GLS78T8Z2F"_D JJ.)/!A;X-!1T<1X+*/I
MH&SY RVM&GB./ERV\K^'#K'=?HX>-Z'GY!M"?:QX"TUG_OY$=4:GU\20S\.@
M%+Z]1VAZ@5Z%G-ZX>H^H35[F!,-ZW$#GL*XNG>2)9M E<<JZ2?YQBK&W>7_U
MFD("SU. K\)LP[-[;OVD-0^@0(_U/4@32A2H)[D8P$-#/*&:A?EG)D&(5[ W
M;YTGW"/_&)(?U<\@A?//IV<?3\_^C?:SCEI[=P-H>DO^Q5L#]<8^_\B80T-)
MW4_A TFFR!7#M)!C5TG2EHPCM]"4_.RD44T":'6ZLN1TY3A;9<KX;_()X[_X
M;YF10OJ&;\@_Y7J@/?[+=RT-WX_5Z4O\E-Z$Y!E#\RQGKWY3IVL:CM;IBRA\
MQG%"+U7V\MI $!C[-5F39PTR='\WFDCW@1/>.1M\6<@\+_6_U$A+9\69ZF&?
M]9/\(^\>^>&_KXCF0RV*,29:2T1THN#_^MN+R,.E;G8T'FULS[.$;+0D(<K8
MDQ^R9$P:#[AK&.>6#PX5HJHYP&_^NWIK+TA[_+F0T<][U^.#T898VLO:7)^*
MOY,TN(O"N.#^I%$D#3.BC[[530.!/O&6.R7HL7\!!TZ\:]T][5]I7H%73ASL
MKEYQ[/H)%H.ZNR#C1M;6/3S4H_)QU/^[B5QK !\0.F%ZB1,W]K<U(O7_;C21
M[C+8XC*A/%QQJTC3A=W<?C01Z/OZO.*$>'%B#]Z*[AK/P_JS[Q *FC<*>:_3
M=QSXJQ67P*]^NE;^!+G*S'V[B,[Q50*A-'ZRQE[SD:Z'\)1NU_Q1O"!:^3GA
M^T?_F[;N8\U3.5\N,5P+$%Q&6(<AID8*&/$9N4\Q"X(2K9A%$GLW834<H6X^
M-5*?VD[-M8[S7=[DWMG1-P'L0KYX^<4 -^ZOV%^MB7(](SJVL\+BRKB/?;?I
MMK?%?;P'C).L>Z9P=&R@0RB-MZHJ?OD'# \R=NX];LFJ;WPR=W\Y[F9)%'-Q
MV[(NM!NMRWGQ<Q:+SN-MI:$ZH5E5#7+T_'C\Q\CY3O[SKS[9_[&[WMV2=1.T
MV#EZ?FSI&3$#.),HAD=_S7-!_:OF*[+!CC\G2L?*$=>9VJCN)MR?R&AK9H$W
M\.**=SQ>B&Y5B ?*L61*"Z7MB_&7_DVX)><,7:\?6S7JMB^.3_WH-+T.)SS:
MH-Q&X2K%\0;>J(!5VFHJ;&BL^92H#[J\B\('O,Q"#Q20_\K(QL9QL..C6:LR
M'T1G/%MM 3NA2T-K:CVB];PQ7[/_PVU/(IK7'3MLE?A-$;GY)00XK34&2WG2
M_.3>Z_MQU65VHUQF\%:\)R_&R*.G=3GT#,ZH.WA5$F&6V(=HUF;WTT"RV@\1
MOG@HIB3@H=%CX+,?D,Y$(>8;_A&G:0#O9'CNU!\B!] 9;W+SX"<8Z?/=1> D
MK3;PMB_TBE'U4<ONDQ_(B19YF9O.XT>R?<@[ND:;;FPVWNU)+O#Y\H*<PWYZ
M[;C46MWR#&AL/J))>QMCU^=Q)-L \\14]?75:-7N\>EH@JDA*\QOXRC>+26&
MJ%6/W9?*:.)>;;9!M,/,<M$J4EW+T;K=\);K4K@[/YN0,>HN2G%_#:C_]U8/
MYP4$R<R7>3!4P^E<WVZ\0^#9\0.XRHBB\>@$&-XMN>WR4TRQDF/L!! L#N&3
M3<? WG3&6X".O,O!@C-?*ONC]6W7X\/Q#1 #'/6SIX1FFQN,!9 LK(8#7&!(
MHP_(GL.O?\-EDUESN^.SPW!'C/)JN G9,\.0RZ>.TXC6=9<<,0DY?-A_;T+I
MA+]PMGY*#MOV);X'@5'-"#P OH>UM*GU\2UM]?C)-FSU/?C)']<Q)O.48B);
M^D!TGL]^Z&^RC>[UOB_["6V"^QAO'=^[Y/8PGLY#CN=YNL9Q$=^W<T/T(C:F
M\-$&RT#?[NU>VUJSH67F/?M)%+?8Q4HMQ@@PI:,PC^_CZ-D/*Q$"G<U'GG'0
M*%G>#]BB,G)>Y_4_SO$R*F!_7;V2:8YBSR=/U1U]#1$]Q06HG2@(:&@(V\ZM
MJ\8,1\TK[\YY=EQG"]G3=Y\?9J<_G9V1&5O%SD;D]-6MQAY?C7M]5//I*^?W
M4W>("AETHI<FODN/]:;8=8,,)Q"%D%!;IK_TL5>/-D5V.;5T=KW*!Y$TXJ5@
MB@Z]Q^?A+U&0;<I!23082:0?DA^B>!%=TBN<6ZY_=<B)7#X&C+#0/ *73O"[
MGY[[0?!(3I?U+(NCV&F^?MJ:Z^X9^+FC+2P4.08M%V-;<TNW)*V!UJ!(5/\^
MWL%83(/LL@\V-M<\WQ*^L7F.RTW&?%GE5<+8[<VR3]C_]G#-]OM\/!.X$X=D
M@\N4:YJ_WF0$KVVK>75<9Z&74!W2H^Y@\KBX(%\!QI@",:4< ASJHR$"> @Y
MW7<0)NJ=]XL#?NTG/T@?MU!#BSR89$=$M$6+MWQ?&J,M+&DE$0IBQ\.KN;VE
M0UT4N)R%80:+ Y Q:L[VVF;CV>KA<:T@U;6X46N;ZG[6!HY/-)KPPHF?<92E
M$+O1\L1M;CW>@ :4+O;JK4)\<38-<;^/1W0<I@ZYU3UQD,]<LI8SZA7D%0P;
M78>='^I^IN(4@D+(R>UB[-%G]35Y*H<N>!%:3_R>7XZ>7MRR50M-= \LST43
MR(V5PD^%L6QL/)Y26\9S:K]6&IL?G[6;6P^4I 4V/8;<.%4^X]YR"4]H[9CP
M^K93<,UP=U$EX+$(>-GMM.E)1[OV&D-%GS..T "8*\5PVC:EM=^G)FP^ S;
M+SA)(3B1N3"IVP.:.(%$S$NR@+;X''D4'JTI07NDGDS F CQ[BT774W#\9*Z
MI=Y WXKGNR\)C*A\ES1J'0<0T+S2/SNOX&!D!X X'FC^,L]L3?*!KEN?>WU_
M?!<G"PG+L002ZI=<K)VP&K%0,M92E%FPSDI?K^[;5F_GQ@@^AK ?'E><U 9+
MM;<=3ZO('S%TS&N,=>#1HS'W"^>U2=_8DXKVY,"2W8=<"7Y,/2IU.[VM^8A)
M/!$Y(],=/'N@P@QL"6J+NZMX6GI],I7,Q5Y>LO9OCN V[-#'#R T?L2D6B)%
M!B_VR]UL^U2WM6VSPF%GW846^]L^WT\@.V??:-,<:JHS@%PKC]&&"MX)L*6:
M%6ZUQ13>Q/=./(]IX!!+>BN7,&Y^!3=^.8UL$J:\]<\I*;0?SVG3H,'D<?I_
MC0*P"'TBFANH-?,PC^B?Q7Y"_J0F,G;H3L;8F;%]?#S<]M'YJ6XHN0V.5S!P
M<?22KF&(G7 'NR5+VCW7^WX]8LX0#]%D90BO@^BE2Q5I_62\9TB8^AY',L]7
M=R< :>=GNH&Z&FIPWC9$E?3\:$1?6"&]NO6DKF^K^Y#I*'C3JL@<0F$\F#JE
MU!Q/2LQS];HV<<^/QS^7V'LN+Z77HI6U?V,%*&2!XW)^1%?K,4+2^7_@_"A'
MY[:WG<#SI39\*B\5LN=#93]JNE^>#!]11%(M8M\)"&^BV;C\5Q1QL?;1V?/3
MT=5X?K@HSS_N5.Q0YYN_F\ :;*H)<KXK_*47],4^M+Y"IP&UOAO+I=R7_52"
MC#L<?DVM-9]/YX'C_I&NHSA<D%%SMIBHR2[4LVI^J'5],BXX0@]SPH3,"'=1
M& G[+GO1M\?--;>?P)%9_]!JK"Q5OI?[W^C:&$T*V(?[EL^C.(Y>6-(T^4L%
MI/(@$L=WJ_1-&=9]G?3F>QRH(Y]:[")[TSF^5=2I'-Q%-%X#>V8B!/?F;_6I
M"%EW8>K$NVL_P'%9$VEN9PM'F(R8!Z-V'3AE>.KJWR>365  \J/J/C-B-T#]
M]4Q"V)?JA" 4I ?[%GZ695<:(]WZ?C]^QDZQ0Y"6WOKP[?Y.=Z6FEVBQCK+$
M";W%"Z&_HW67Q*'DDM\0#:H]]61?$OJC=KA!6?%H-O>VK?F(7EQ6&*ETP[:^
M4=J_T5_0"ZK0D*ENK>%5;#.1,DF=[I_&YN-=&++*ZKWC4TQ7&D>JK-BF.Z'[
MPRD PQ7R]ILTJJ;F8\9QY4&(S2%:2AOMGNA*E / G89>R:GV)?33EJS_0\A,
M#2V:96RH'CE1 Z?1?+@_H>-[S51148SF-57YC.F#KLE Y[:O+H]TYY?:DPRJ
MA8R:]VM+Z_$\.T7O:NO]6M_6:GC] RSHVA$N_U7WD:W6D_348^8Q>_H=N^DB
M8JDB/)JPY=0^C)+EC/]KGZ@9F_0JCJ.8:*@Q*Q+7\#SO\=%H"_P3#LE3#-RI
M,V_CAS[$0L!#IMWZWO75B*ZE[3;@F6YJV(<2[]%I7=^'Q+AAE_LZ33H^,I5G
MTA0FWJNXS %4C@]6CJ;4T,;=KF$M] TC!)[]Z<,!"($U7XV^)"%)VH^3E#SW
M_TX^U;1$*U3'3*1:^FG+2T]I,)&233WPBEL^&'.D);K(/@^Z[N^.[[RK]_G,
MEVRF=)]^'=PF$$],Z\"V6LSKVVHW?WID.!D@ /::$D)K6DW3;%(P -UGY(0F
M*X/6!CO$=M)";<Q\9(B,?(AV3J"$#;*:">TNF%Z?CFF#I'Z_/AE>]6TU;PT*
M6$Z/E'L<DA&KK9A:;33FE0D Z[7 ZNTG39\OC\]BV!MXGP4.C15,(]CK/MAQ
MO+F-6HLJEIM,=XJ3_8N)F*ABK[L;$U%#.B^.QN;C82@0VO.E,C4MT<3U;<?S
MB /*.7?_M1J7:QJ.Z,:7C]QGK SE/O5G^U,P::G.(T\@#9C?;O< ^U>/RM7_
MXRG!3W>D5+=],86$?Z9^*]B"S7(T?Z+;LU4J2WN9X4N<N+&_;5HZ'5],*@";
MK^4A =B-)$9<4;7Q@>>[COR3[N\,(2)_QO&**-X]0%E:/YB(U6Y/V(Z>'VM/
M4OQ'YL<4-Q&L;DE2[S2OG82>GTX,-*!WKLCYKIY &WRX08Z3,.,*X-1YS**X
M6 1 #SMNPX<32%VJ?_;414S1MPZ'XNJ'6Z:;B^;-_[>/?\5.D*Y_(=L47FVW
MMQ?-9VYS8ZN)"]1V $FTS_C229UZRTYG\\ED\.2;'()5>:TG\M.O?KKVPWF(
MP5O6A:LYD*CE2!+I&^PL'U%N.5T+S<%)0$74XND!J^[;OQ%M.O6)]OV?Z/M0
MF 0LS&W$,*Q;%)+&YMI?A[1ZJ\0N@N)>H0->@1CR1,A:F2^5Q^G\*?!7K.;C
MXB6J?SP.(6@_!+&A:GW^MZF=7;#[16('I/6TI\WO16/D$@CR,,HW;M.]V=A^
M/.,$>4=AW) M)DI!]M(]#Z$TJO$+;(R0WD)ZW)$?5=?61%T$'D'S94O6NKOV
MR9N6 >-)RU;=R=7SRQ%OD,1/YLM[TDDX2'F2R*._"FE1!"CNYD89M0!1'$._
M.X!T$,FI'8S:86>FI]3MV[_18:8X&G[]B,@H)RI\LHA87IS\.T!EW47IWP$*
MSXW(FOPG&2XJ.7DN\5]!NZ9*QI8[82X/F.S):W^98APNDM@OEZOJE0?<B\0T
M4X48*.LAJ4+\2Q,WS&F/_7U:V>#"7DB.7!&5!0YUHA'S4B2U,=6VN(X)/Q!M
ML,2)[/$\:OMB9"VV564]P@#8NG@@V%]@_(1('.UUY+L9ZDX)B$+72=9%C;L^
M/:6[O;DT .5\(QLVB<(0!]STT8A'N<_G$XGJ@=0$\A_0A9Z= +2@#LS<WI^;
MRR1IOH*KC;Y"M;EH:QS9U#GB RU+_!"@>7,$H-N.JO2MGXP8TORB//SB*"3_
M=%DDX3[UX?<F,P;F\@7YYSQ>1"_E4)BVEE.NZM5J@NG__<AY[!UG?JF1+7"S
MS/,)#:%MUBR8<HOQ?/\\?8_'80HO?IVBT.L3W=$K]+$-;DUR:"^C>,,XA0PK
MIR7VN]^'7^$=RV.T1[QFJSTP\; ^I.O2.)MPFVWS"UH3>2,E>,X/KL#3^:7V
M*@L-['YU8#A3Z:[H48[G8%K30)WJ+A!8TW8\'#;I*9LOB_%,^4.PL@DZW0A#
MJ1[?<5W,RYUE *T.EF'=AW(CG^,;,ID++O =C%47:.$TWK#A%?2/Q4-!D'GD
M;6Z(UO+L>YD3+/PT@/S%^XB] >?QISC*MG/0SS=^FF(,&(A7KRDHZN2@O K)
M%=T*16N.WVA#6./N[SI]6S^Q^MJ\SY[([74=1$YSR*/:1K>^W3/0<+9,R7$3
M0E1(E*W6 O2CR>.IE_;44O-IKS0 &K;0T3S-PJ'3!F53:3-B/D^YB%#'=F[Y
M0/- 7G)%5 P656%Z*+.]OC.<X%4[Z]5&(WO[%LXK3@ 2M[D,>DU#RQ'/D#?5
M$N9,_SR51[ :(M(6I6**BZ6IX;?+[NSC$]5B:J:GTF2TI?[E\5-$'K<AS:+L
M#R3>^=EXX7[U'K;T@KS5=^2\:PN+ZO>MYNWT)73 ) M&*Z)]^!LP%<*U!S48
M$G(N>_! O?9#)X2X1!E0T.>LUT5Z4B'IK9G]+1^,J+O)LL=4Q5I'@8?CI)<7
MH=^WUO%:$]<)1(B9F]65>&EN.\T0KD."M\P$!@/+^!E#\![#YA5NCB]D\\:+
M-6[$SFJQP>JA?+0FG6)4*BU"9<BD4\=ILF$K!X:K3"?#9UX?)S^,X/CF(Q:)
M]QD[8 [RYN$#:%?P6*/1\%_"Z DV,A@T;L)M1L-^0T"*X%@*]'.*<=-Z5QIC
M9\(3RQ 2V87>X7NM:3HBA':EWFKKG#2W'SEMB$80=NB<?;X8<28V&R?>420>
MAJY"M?IE%+.H^DX@\YZ?CP?<Q:NW)9 ?0_,)X&A;2O5>\9O#LDKJ_]2Z.K6R
M&-&Z ^D4T!6)S]1HWJFVU.VG)INDM4)6L8'NHW6SPB&1C6=;M$6UU+<<]6 E
M=SO9DDK-IX["U_7MQW32@V)U'T?/OH>]\]V7!%[J;-&1C<6!.OQ.'](!A":P
M^>"$N""OVQ7XBYOO]3T^G#SR1L<\[DU&.V"3DD[ZN,4NQ:3.<V+Y:%/-I.VH
M.(#,:%-75R>I'=*W[8L)8 Y=+9>88M)(WP1 X19U]CT!A@X@.7I4Z2+B&&+[
MH8\=3&;TD'ZROYZ(LL43I,MU?CM.GCV)C&?<+\ BMF.\UC75C6.>!_B6X+::
M3\?.;\:M@L21[*M^[(9A[OAH3!=NJ=XS3_1(R-:&LZK9H]OQG8$'P#RLSXFH
M:3!& @K_SRTY(CYVI: 4VAZ?O;@NLY.<A)]QNHZ\*(A6G0X;"YSUAW8#^$"?
MW(:FIE,(T &;Q+[NM=Z?6_:P,>_!55A7-J:YW;AIY8JB4,#V%48C<A^+! Y6
MHH&%H9%QIVZHYB-9%_6I/?2Y;4Q]G^_WP*\C,&;>GWI-=N7XU;0]5C#?V0:$
M:1)5"^WQLC'P4\K27Q*V\R 1!M:>L.:R#C8A+/3^?.RB3[WUW0FJNEI5#BW5
M7 YG.*GLA[Q:(_>-_C5Z@9.WN3C!4&KC1[SRT)9S'&+2VZZPUU)K:\_KQNS:
M172.KQ*PSOG)&GN'/,/WI&U),R1Z#H0J/.XV3U%0HQ$6_SYNGD)!A6Y+1"@V
MG-@!R@)Z0($,(6B$W-^T/F$KUM<AE$:]V_.;6$ERS6]L>BBW7>[]OI^.-5@8
M.G'2%@36^9GN *@_W<\^\VK-25MF3'W#"<27Y34&'AZ_M.K^[=^,=P;D7N%B
M1BM[1]Z$"FQWT^;?A\3DP,P[(:PZ/ALO[@5OB);EQ#MVC?3,=^[ZRHR-+>D!
MB=G4].M#2FV8&G/\IN">[2/<+ AX[L)\6<9TI?EZ>_AN-?,;+U$I 6F2U-^0
M<ZCIXBXU,H=TJ-1<),,G=JHL*B(4B.LH7JS]V(,TXKJ]/I#BQ)*L^D6']OMV
M/(.0]WO&XHQ _?/8VP_PX'UR@U\X6Y\<-/6[2,V??L#,7"WV'=M+"AASDWG)
M$O?Q8]RY$80%5VZS=(]J*OO1&&^3*%5F;SM0%NO;ZD>1?2"7PMF'\Y_.9G',
MXN2Q=QTXY2J@G<TG<)/6 %,FYSOEIT6+3VEO,A,S3AQL;&4@Q;]$1)NG@3&T
M3CI+E[%C[6WKP-<UR)< 98-#[Z'JP[7'=U*!E:VVLY8/+"?N7[VZ:Y@ 0!BJ
M,;76-IO @=@</CPH^O- LN.%L0G0\P9#6G.[\3/$536@+9FAL?WQG:#3J&MC
MN7I-(VAEW1L0*@KPH-R.LNA[?3^IFB,R+7<69AEDB['HRUK[F!%&4\D0;:^5
M5]M6;]<[*A)^=EY!5:OM9O7ODXT+/# >< *W&DVK?8"#:;[\DK#<[:X;KO:;
MXZOS4BBF4'2QM-T'NEF->%1LMP'MMA. ^>PZB%YN0AJHT"/'H^_7AE),NU-+
MQSXSRK%WEQ"VU^RE:&AM-4#_ZI7ZXJB=HA:IMK7I%$[G[H-8]X+DD3+*(=":
M?M'6?%)6U!RF]*\^.?=C=]V>(+4?C0F\;UFJ$<4JV?,)V_SEN"'S7;&FA38C
M[M804-,+^70BRAYL3-WAD/M0F%J4?DT6_7Y1^G4$=!]I>17-Q0M9*SN1"J&$
MF_6JP=GUM6G L[G,>ZH+$_)9X6, *R,;FL;0[0%Y=BCMXS.IT/_YA2TZ=M6W
M5D#4Q<+X/=V*D]+67'_/H"Y]E]I0;&-5+[SV QQSC(SR6[>IE6Z]7SJOV4XD
MYS]W7[?G1_?Z;C*9;JT:5D/C\6P(\<H).?I&C@#+0I/5 NL*;%.."=O?/:^=
MC6XW.'_.7Y"FONL$K%LN_^D.9W&4N#XFUY^(M*WUCN]/93IAT'6^MKZQT+7?
MCJ>U16$DS%PL+86[<[HPDSJ_LW1@<_6>X>1"5%=SUF]CT_'?H>RI0O: \G"O
M 90D#<C QP5\R=N.T!B]/,;;@S&LMW0'JF5*^@A*-BMUW"MJKO?G1V[6%;XW
M.>O:BW=WL=,>-+KE0,KSY1<>LWSEQ,%.EEBIM6#O]^U4@N_OG7@>T\N<E901
MQM%^0?B-7T_L";;78TH_2%NN3ZJ^:.&>4  1:M7K/3Z?V+#W=^,KV,XW(7GJ
MAXGOF@P;:.:GNU;$=AE'(3,SL6[4S7%-*ZNOSP>\\D&)"M.&"*K:9KIM2XJ[
M2W%SS</%&L,L.^$N*3I(VZW*FHCJ3I'.TP+(G>!F[%TE0S_J9.CZ9 *6_L[]
MF#1MR'XQOT/I3\9%V:4U-K>?2-8Q!S7=U;QX>GQ@U]>ZP?&*#.:G.'I)UWRW
M-[M;:UMKCQ<3F*J]*JRU-1\O3ICT8L=L"M=9Z+67G6IH/%KG2Q&"Q4 112N
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MG>5IZAIK'L(K\F[8 -2$4M>D'2VK]08<0F[,O(%27<#.JB-[?5HG&)!!KYN
M_"M<_>4[')Y^>?RN("LY:B/R;.NL3GTKXFG^.W@*1.,X"C ;&3(P+R\O/]#!
M@7'Y^.'#C^_AS^\IP>_^4Q)"OP$I1&G]O_]XGS,UT?VBB1N4Q0.[#X103@G]
M!K2,=S^W&\Z7S I%;QT.N(2]LP.ER>FB:(DHY1/$:"-)_.B$2PDU?%LGX5;
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M?(X\?^F[0^"?>^GHYVTE_'BO$>MVCKJ&E)Y+O S1=VBF]OYM0@H[DIG@?64
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MQ*!0YP.<ZL/ =6%7)"G%&U JUMC!3+QRXF GE0]5L7G,GG[';KJ(6&UB7O1
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MBY?H[^13;1?^?B<^6D8Q6D(_(% 4[: GQ@/<+8_4,*T $?:(\J>AP+0'7]D
M:= <:M:1Z8N1'!U+/]41ER>>-;RN)ODQR#CL4,S61YK&_E/&W#!I1)/5HC E
MQ +V+&(P(I9>>X<+'NB7>;K"JJO:5O1EL1H@BTMA\2H'3E6INJ',KV=$CT><
M8C2OD(F7?O:/3)AB8%1)'$1T;XK?:D^NR,782P"@36>PH*#+ -2*SA])^^B$
M*RY$5<+&B+[)OO#JL3WF2[:V!P9_4UHP%IF$6*:#X@#G;V5,]-D-FE&-:*J&
MG9#1:0QJ&4S&TNB>H"L69'=N$<QG*J.M0A]9&^]SB9]D:<B5;&,G60\K7Z&F
M&!-BUBI6:)&AL<RC2V@:S@;UR#+Z''G^TL?>Y0' BI4\5@\YRL+<<-+(([1-
M9[8.E86O)9"!4$*"%+HT"!.IJ>N%($0;_>X5Y%](%+KGI1X 8V+0\Y _JIB^
M3A0>CYQC5X_W]U^)J$*+H?H;8X<8/^[#.,FOR&*"F&!+83R,ZR>\_--#M',"
MI43/+/0&0P^)RE*2]C'*4K#3"<+(RVQDP5)8,XJC>VA";U41 :L, W5C.,-J
M53_;JH-&$7/-MD5 N[JH%NF"#J&.0HBR5="ADK!ZP<:SRNG5?!]C;C6_QR'9
MPX>BXN5T2,<IH6EWNZ375;MOO(@*9>E[W-E(CF(:!437U,!:=YRRS&\"YPD+
M,6+4K;T>#(A8L792287'F(K*RG\(5#NZI6R8VG5+6C)24SECU1_F*:EL5HI0
MFA"R4KQE.Y4I-8[QSPM%Z('Z]T7Y T"XDD4HOM4QTF<IW;/PA/&19^]I'&]N
M(_(&&IY60^N/4UI3[G%0[JPE$+1AO2[;CF3OS1=HZ]J724>"^744+[$/B52R
M\N.OV%^M4^S-R!7LK+#P>5$T)(/[,^EK_%6ZG(. G"#1;<3[+;V%#(KJ6Y\)
M]2P0=$_KATI],%[ .S' #*EGR;IHWO]:M$8/-L-4C.KV8)]U23**:5T( ?5/
MYTME+0\HKJH$ESWCPOU,T^:4GY7B+,6/S%9BE?BD 5$_.:3<H%1T2D@BXUE#
M9BR,F3*N>8;5T+2RYJG,>5A-*C,H<K$4*.C>*]]%M^2T% _O0@AC0Z"G85 [
M-5<[1YC'Z7S)7VT\RDYKRKZ$FM\U <U;S-77*35?Y<5\]+QX *WB.%\*$XN(
M8#Q.64N@6WM.L/E]O=G&>$VV&MG7+(24RKQP7@\^NA2*Y:C4.R8DH7Y2B4>]
M=VQH#1H%5@TO1:EM1*8J,+G,UZ? 3FF 4N21G DO3I;3/B:Y@H)(A8#; DS7
M,<E4=DEU"F?;-:5?6-7%V$-<:ZY&AA+E!^3)$(68/SPO,WR)$S?VMQKT 4E<
MY&6 <QAY.7W#:%Y:9>.[,9=)F"$(6:30/2*1"C$U77-E>N/=UE1LYKJ+\8K-
M0E6S7['9I-3J],YHU6VTA& B#Y$C"-X](*AG(82JH;;<^0[L!X-,!O4U]<!@
M"*0-&P3HCIP%CD].^? SCE<XE@\Z+?9B01LQXOEST>RYJ54D/E6-HMBQXVL5
MJ;"OFN2RFSY$7A_SF"*$>3IB:BII7H0^E/AE'&P'VI@1M34%;$ODI4$X9E<E
ME.4D7&]"FOJ3) ^U^+!#3Q'.!?GAZ9;Q:0PC.$9QQ0GSE8M9.'4F(*N,+"5W
ML.<'&9A6<TC8JU=(X,4>),J!=2%CJW&^O')B>-PD8MN>[^H)#% +5(*% F96
MW -JBJ# ["<'%BU#P\!GM21 YN4 R"G,*^PP\L<GH&J*ZBNEO>1VS<*6X]<*
M.9\,G'C)0#_-6W8>W37V,EH@J=9+G;L3\W(GU#4]<\GF(EU=@/ES, IAG6\_
M=]*<U)=!.4&B$^@WV@UD$Z5PW($K.)VRS08*PY.=41DGP<WH??>WCW_%3I"N
M?R%S!4$*M[<7@YX*?_N(B@01H6CGF:!-E)(*5BN2V4><-E'4M4:(_F(23_F*
MW-Q0")CP=&#IXDLG=8:%0C.22*$)66..K0#HV;/C![#7KR-Z:^3J")1G_.RD
M_*=?_73MA_,0 V*.C(T<4ODQYT1.2M&+TV44GT(_U+A&"%FD_2"7ZBP@YQ%]
MY($:^4CN('*PBC_3?+L3BCF$2%>_KK$KQ$%1B@BLH2:A@U0(<8FB](#!>3H4
M-SP'CF+T1H]R:PIR$[6_19G2A$;W+-9.R,/??J'YW V1;Y\ V@16Y= MHP.*
M4=0:EZ*HD4HR2I')TQJ@2*6BFTW9I6\SV&/C_L*3__L-J3T3U@,.X%"])YMR
M!]6$$X<B]R?Z8JXX!T19()7'6$%7!F4N(L0U"6Y:0!6>_!9N3=@OAYLM\@(/
M1)7/ZS[<1PFM XP$BQ.)U&[!O?'9#R&9X=8GF]RC17B>,>E92G:."_KMBCR!
M%/?U_"GP5[27R>(E.MC%2GFB0#!%+N<**9&<+0R2$M>!HIPS0/Y]/8-2\:D/
M'QQC+P]9ZVC@-JBM=&3%>M=P"\(])PK+KV,\L)93E[V#<T*4E;7B=$9%+V0<
MJ>(9?T305$&I7.27SQ CI<BB552)G+ ERZ0VP8(>,AV-,(5U1M-)6:XHVK"C
MA+QK4[0$$8VZ]V1X!R;<\5S4B[@EG<C#<\6SVH@M4+[9R;^)/DX?-4ZX^U?R
M*)'U,VAW9."R!102"\/!5S/C=%(6]B0/TSZ!J-TG"./RO=P",H(M&6("(:#:
M">X=TMM!5TM."U%BUBX/+4*4 WE528Y"@*)OQY8(5"=5 62_;,F][:Y]_$P5
MBOE2!O=I1*6"JN-.S@3.F8U@<X22!M^"D*6WQ!["&D]8)HJGG\R7]Q#&P#LX
M"[U'?Q7Z2_(6"-.9ZT(((Z"218'O^L.KGU&6(*7*E-N])5N4\T6"L54SBLV!
M:= ENH8#AJQV,(_79DGMA4WYUD=H=6;R?$M69\,S6"B!"=2F:':6F(TX?O;!
M4EDWV!(SEXYK0E]-ZM\OHB2]B]*_X_0!NQ$Y"?Y)9H(.ZG44\U]!NS-3YA#9
M0;'FH4?DMRG:X13EG3KA:YL6_U Z]FV/<BV^@\/79XPAY1P.\X1U'FV-5A%C
MH"HOT6(=90FY-LA-=NTO4XS#11+[/&M:;Q ]5,E).3L&5L$8HL7CPPT*1**V
MG=!ZPZ+S'04B"S:TO-"U*K+(3;<<@F]8='69?_QP]E.#K!9@/6IB?3E@&E68
M#@W_+, (*+3S"MF,//J-_]>JJT^[U(U%H&I$3SC. G<$<OPX9E-DZ"$<;M>"
MJ2M_O9WV4&M.*WJ-B(LF&K_ 6 ;HG?EROESB')-YT%U;+9Q8@#0G"F>BM!/Y
M@ Z[?"4J*2VS* "9MQ0?"-Q.O)LV+I+I#7/= ]OF<)N]O:8WWH4DGDDL3'$D
M,G &Z=/7'1_ D2ELQP04_36#/$W3[&(5CM0BUN@AU5GJ<#3A6H0H<, ;'/1>
M$(186=UWM!RG\2KKTQD*?5::)A!1.<#0/[/%;J,0$.&*OK<#*]?S<2$D3X$F
MBJ23+: >18[<>S3RE(L3,])-8EFK1ZMHNN1N2Z(PQ %7<L%:,+CP;%F;EDRD
M*GUA$E3:M+AM%8E5Y.RM%#OF8E,L[>.;YMHBU-UBGQ;$MHM["46%R7_ F/OL
M!&#&G3V1OSONH0'P<#Y'(36# QP9;&,0/"[B8OYL]FC*ZWYKL6 I]*P51!]D
M?U(+GUNQ+0WNN*KTA#FQX_5^%&/N)^^>*B=%?*L#7Y?+8+$8YY1&I/8VLSLF
MYUGBASA)*-P"B\*_);^X(<_P0Y4O01(I--%O0!51LL9?[G?X10D8B*.0_--E
M&+3,4,O^=VAL!6%3"!4H,!K35&U:_J+=VL6ED(D"0^K#_#O4K_*BK4'T]#RU
M=N9YI$UR0?XYCQ?1R\'8MRRKEI,[01<TTC1&0-)"*;MLDU&5E1XU-9BHPZ"J
MYA<W#?"NUL(IC<E81)&13/BEW()^:]R)3J^1@=H_US9^$V2,S1/LJ%GF^6D4
M"Q/LH:N-49&67.. )NSJ%@#V M/DH!>VNIB$'=]2(2H=4M1J&((R#2*)"D*!
M>NK"DYFF%Z(7/R6/R_24[)S3C1/_0<&A>7MX<_H0L 'UK+(G<J/(OQW%T)20
MA\28R%H%$I?'J(7(A$C%$.T<7XA(1J8')^@<YIBT2GTX^K=E9#A??&%TG3,@
M,1HI!%@$1'4FRW'#A X]JC7J*4G$>+"UO,VYP!AP-H:Q)DW(*(Y613:%.LK)
M6P*?-"%CX2+O%/1X7X_7HK20G@>D)$>/:/RZ!1B]XW]C'SY*8UE\\HGX"HP^
M@X>_DF>#:H)&C%?9RH,\#ADEF962\&05+=$S=0-1%SV#:J)G\O251"2VV(B0
M&6?PU!V,.G;P.=_!J&8'H[PK2/3E:QVSIFW'5]%)W0(R.Q94!SV_R#70(OBQ
M%IV/*[I/;8JNX6UB1$RQ X0>KY!')41K.XJ?&3$+B[:'K$<H8O&1)H0T*DBC
M!+_2VR:5>>,:[<-M"Y2SS?/5OPKI@P,$M^DEL#H8I6/YHODT1B]\4&3%-;1E
M8Y+"F#P%)D_LW'.2,HLPV(,'&FJADEK!O-QH<#=NRM4JGKJ[[\CDQDX:Q<:B
M3437<[B4^;*(0IQ'$554J,'ITQUY>U:3I"V/0+'H)R%0\V2>[&N6K$MR)7/D
MZF26I>LHAFS#\4P&K$?4!LL0"?).??6C6#HQ^#B(PH5+>/C*@H;($8BXU#LA
M3-&3':.YC,'V66&F9'SSU%P)O1:].@(3E+ZA+,7W,_NG@E;(U3#.\&L>D%H#
M\02&!*] 2H;;#.7?(F]S0_KQ['N9$RS\-,"ST!.PH//X4QQEVSF$"&S\-,7X
MSMG@J]<4G/CDI+@*F1IRN(>:]P?)#IV@B_GEYQ.4=PK17E&3NH0K)0<4[1F"
M_J#?\AXAI4O&%8,:2+FANFLM0%YB*>B !=[<4Y?R=1 Y V'Q&2%$*9GU@?7$
M<I\MR?DT#P%J,LI6Z\5+!*#NR<$P'65W9^$"3:"B3)(7"/( -W\C^X(<Z Q%
M@4]9=P \E2+")Q8P!$<=-^%"E>-U+2KP* 65:)V!O ^(=@(J R#>#01(!+0C
M%B!E1AVO@CM6+AM8*G+M_$86S_]CJ^>K'(*BT:YA$.0&,GZ+BD@1[%UF>8(Q
ME8S^32H0K)C]P2JIC(<ANB;C)"&6>'6-@O: ),.C'P%US:N!-(4G"T65PYP%
M?=K07T=F=2FZ$41(FD")&'AWR @WG@=H.#)F:._Y^I2]%G0FW>G:B$)LN.=Y
M+6:)#L*K PW4%!6">8UI>Q9-??*4<$VY)$%.WVQ"W24WAHL50<UY>HWO@D4I
MY-/L%C<A%U]Z4AZYBRAQZ[X4$R*JAT2#G(;+/_"@ &%''ES2@=,3MJJ)=Y\O
ML6/KMKIL\KYO#?>]B >S<%YQ HCC=WA_WY("3<)]9Y0<1S G%"U5'A@N2M F
MQ?2[7_#A0XHYQ1NC)GDF40K$;52-6Y"&0TO% 8UI!GBI2*[6X';/6]P'\A%G
M%2MW(H-80;Q%'LAOR1 VOOS:HU/Y&QBMZ@;3F.8)QP<W">W./CY1R_VA.*/4
MZD_>]&<?WSU]+RR#Q@N0?WG\%)$720A#"2:MW, U/*#NRP^//Z"<O&+M/#:I
M^!Q]>53%*56&M5<>I![K);T@FV5'M/;##B1%(;H02"_T'PJ/$RCX(]@(BYP5
M-<F(S,'^XAZEG"6+@Q"7 OK@G(O1*^=+Z$!R+F1UD"/"WT Z%1BBR T4)N0)
M"R>V)PLU2GA&S98)V0NB7-)NT-P\V@_XE^P(6LJ2D8GLBEG[Q4@#)$XV.3"<
M/9+\D=H!I99FW@7KAI"1QJIPMPT9L#&*J5Y&@$YOKYPJXV>^T*+H&<]G7D>!
M1Z9)"P)"06J5^K\BJ^ (XG5Y[2>N$XA"!FYVJ+%)OE8905'I@9(<%=U\B-+2
M#>EN15'1*E_03[2CDJD1BU[!4SPJ@8K:52-$I&G'FU+I#/H0/V,H=G*=I5F,
MA4/Y"[FAXL4:RR(K<*9)#''"<7@IW@0)[C3*A?'/(2YH#Q#I A)]X!Y]T0L$
MW;"443;*8-67C8O%H('A<\D&3:)C9'30H/ H%H/&'/\Y,#OICH5D7.N#55,R
M\4$=J?KEE78LKZG'X1:K;7V*H^1@F'N-,=[5JF>T9]_ 8-:6)U-+PEL)P^D+
M^GNXDB%0?1L-(L<F6K6 M=MD_*A#-CXZ<2OU%B8A+O<XA_XFV]SZI _DW;R[
MB)XQ>48"2C?@.CHK*%^2;ZGY4^"O6"K"_.#ZLYPG"@13Y'*N ,_$V=)R)LI>
MCG+.R'1A6JN#4@F4&#XXQM-DU2H4.$T^\[KS\_ !S.X0HD)+I7X)HR?0"B!0
M]R;<9K3L7^CZ@4_[>KZCGU\$3I(,,H-0,HC2,6[@R-&N/D<>+1@+HNC#*4,;
MA:P%7++A4HA)8, J"CF+R&/#I:A@C15$,:Y-962C_".#U^XS#WD89AB4]! E
M2 ,@K!G_;C'9D)A6*]%IVV4$CZCS@>@W4#Q!C.88@-"\SO5\N7!>+\A![3/'
M%7FJL4*MFFMIW\UOJ2)#N"'&#A7X':NX0472)@G1;PN:461QCA?D!90LR81
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M$VUKZ;M^^OVQCD@AEK0T[742V\@=9^E/5Z$'L$U#\\9YPO@5&.<L6&O+YBC
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M*HQSO27D+N*:$].3J)5*_?M%E*1W4?IW3''26=SR$#-8AXF(J &B0R*8 7I
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MF+Y$MHV !XO38@0$36TD(^#!XG09 0EATZ*$[AIK,6)>^S%YVG**D^YUOHB
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MLH#CX8;I21L22"9RDPWR<\Q6JYA>7,RQ<5H"=U%RBKZ5T='G/ROEJ:F +I9
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MJK=VQ5:W:JO4,[%G/SA8(E2BAR)EDJINS:^_2+R0( F X"L@L;[,=+< $)D
M$IF)S">=5<!*F2V0*,6TF74,_R38RA6;FN< /";!QH70/);_0A*QN$*6Q>2?
M*W%[-1\-)V5!:'E?J4;_CIQQ8AF2GT>M#07O,S=, J9@(2:0;9 !D/ 3)%1
M-GO?5\U\_(7X =B-^2<F?>;L_L)M4J-\JM.L?P%O5Y_<L6-KC_\=S^@GBC(Y
M^KW*(5V*Q^#E]Z!SRG4. U0,AU5E/*#SJ;5J"?V$P,N*__TZCHC*?_1"*(?^
MHP/WJO[JS&>^$*9.BLJ_KX;^7*HY5^+YXO> JI#^ZZCVR!T%4STF0J+G4XYU
M7//&=#VZ^5? <L\36XL/+61NIW,FO&*EE1F09[HF!0-$=\8'YJ(:-XAB9 Z4
M,$@[D3]U^-B \!?3AY -3 P[N+(Z@],C7+ XF3QY^I'G3I/M2><QX.*):=KY
MI\;UI4Y 8=A(W(4N;2UL39>$3PEG_\N _A?XYNB.M4\HPLH!H,(M_3U6#L#_
M"]4]V.-G+Q<;&YLX2,JC\_SMR3QMHY IGETUK>/>I1#)]80V"'_(_WJ(HQ'R
M)&CH6\(^LCCBKUA)EQB%5JXH$AKYX L8W4;NQ"@DEA0BX[4</58[QU@E;W:Y
M.?6$0H^H@6F6UJRIOD]?#?@2$\+\W>\/7I# 1U<)9L4A3KUPM7V(H]<'6!D*
M[3:@;E%\#U89OO,#^1 #D;L$<L,ZI<F"?TQ*M574M#R1Z#H.\6\QO2U$[Q[%
M#]PH?B9@#E!&+H[2/AE%I<^73@.YR\02M 0],MMYT:+<:>0L(B(:2RA0J^WM
M_A#&)X2(NL;\*X.\:]Z60*!@VR#V*1;%P7#CQKWK1J.VL*\$:"^@DG^" ?CS
M&E23/$Z/1FTI5LV0Y'&S?+T0I>3^R9,N!BI2!P,S7*$\[V+LE.7!B.'7,PRX
MH-=S,>1$Q> &(Z:46"TL2S'NZ&4CWKP@!)%\%R<P@P+]&3+D>@->DR2_8I0/
MB_Q[/VSCY ?XXKE26!(8:1;LR0OL^+"6H]-5JR)M!;R[*!'!*T3T5.AE-2<F
MBF+[V8,J<"]!F#T?H,!$0KS8""K:YZ;:(**]^- BY5\BU4CA4U,9W^-1RU92
MH#+_PH)_HC"_I[D,QJ-6%# "R75"1Z7O*O0VOT(4<G3M)6\H/F:#%8(F0Z]A
MZ 4?FP!6C[L]AR2(;4@5(=/LP"$)$O><BBK;N!FBKL]*L9^&049J@A2E'_W
M2]&?)@1$LL<<53DGP1#*&6(GR/VA9Z$$393[PW0E#V@NV=K[7K@[>VH\+#L-
M#UDJ13:9XU)64P:\5+0N1]=4>UFY'(KV2\<]+ZK*Z;K$[8@/W-Z.SDW.]"X.
ML:J14FCLGCN0XVLOLRP)7HZ4GBP&O.UI?>C#45:I "V,^R\+1$9>_-Y'6VQ?
M9.-5RQF>K!KP=(6HT4AA0&#)KP%6GJ.4:[<_X_V!I54*KU!0'V=0,ZGX7&$<
MO;$/+K;TB],ANXU+.CN) LFY <$_M&!?FMIT&IOT,AX<^]:_&#' CB(CA+9)
M?Z=/3WW8((8SXK$OB<PF9>[#HD*\HI7%=SY>5;07ZA\?9"K OF?T"I][0H<X
MR=UU0\:ZL0\L\B^<)46A@AB;&TY9AFR8=1/P)UVLM39JE;7)L9)SO\!**"!,
MZ@ZR\L&=A$KUZ5!8TKA:J#CD7QKY*7$<2L/*IEUM%^+XI#QO_H7)9.L@%>%:
M9&.JLDL<JB'7)8?V?!.![*U@Y_R@<;-K<\8>7U)LFF)VW;[U59GRH19DK*E.
M=SF0?"!PG%K _.3X.,.2549:J<3"3P:30T-N@R3-IGGO(Y]:V'OU&YG44$&E
M[M%Z&I_$R(17X^7=8T 50"CR90[OKF[&:J(+6-](>'"!RUWJ^AX9K'E4HD7/
MQ&V%6.ESQ@2.\0)$_"X(&01I9Y,VG_=R ^760PXL.[6A7KQR#6ZFEU[0IO0)
M#4^B5=\*'((F=V#Y'T3'( &GN(\V"124N4'T__COX1$TX=OOFQVHU0!O>+O=
MHEXG]4.S _$#.<%5KV+9F4AFO.!37OR>3_I? 4J*S7O!)TZ &1=TZO->"#$(
M$1*5&7^"B!87 [YO9'>'F*X]@7^[FM'<][E44JMDLB?2RA+W4NSJ@103)6\.
M0D0IT;I"R;C(>]_B]2X^IG@GK[_AKYT(!E^>XT!RYH^T&OE@07CXFXN,?721
MD:]2H#XAF87LQ+P.^F'T$+U)^,"V*M#//[:@7V-@BT7.!Z&??W'"R+Y)^"#N
M]A__]..?M71/]@2VVN982H\Q+2#<-Z$S?QB+MXL"J(F//F5"Y^.JUY;%_2<3
MJ)WG6@:XQRP&7A]?PF"S6&&5()E U\P+$-) .  [Z<CQHI0A1WR'P4:#/1J0
M %&14E Q$4S]$,2(R*4 74,0EQG>_HCY>!/BR)\/@/P,F=U0SV!47> AB" !
M/$%^D-UY&_+!I>^3N\L+K^(DB;_!JX]WP#]F7:-GX"L$G)U\9\$_]&%1?&J1
M?VO!/W;.A%?48<Z #67 -F> 5S#@)6? AGUT7'5X9 Z4"L+KJ!S?%_F\0V$X
M2!U#,M+8U0N%7,7DB(50$F]1FA+VW2&47O<*=&>#+L11%S#LA\7U-)'NPY)5
M*9E0T)2BY"W8C!?=7FROM??]WL=3#[;!AISW7GYOMM,@O:(\ZD3>;PI,TC<K
ME@PRH?'3;];EZ/MI &ER?4*P20MXWW[1JH+25;)*A?%M!@B.0GKIG;N9_O'%
M A-H^1L(> J.74U%)A78F,(#$AUU5$6!&]8$$8NA8ZUC9GU3XYLWH;YZY-]'
M+"\^Q2HT/$,"[AV5^P^!]P*Z1D]L!/[%Q09FM4CHM"!R*V!N@0-U"\2\8<#F
M!NY^C\T.ZL*25U)PTWGL:@R+&<Z#KQ5E=1K6CJO<.L/;L+)=R806;$:+=;Q0
M>+$6?%KX#PL^L<6CP%.NR3V,OUV'"CMDV$= PAE%B JSOJ@@T E6HW.TIS"W
ML=D(V;&0' OX-FO<H4>A!I)H"P0L8+ /"QANJD(-Y<#5WCB5E>#5R4!M",0?
MBQ_IDWU/H0)Y( H9R>UY5R]A,O^4S3^ $4>^,3L3\%=*0(1>X4Y[$/E?FO\4
ME9'N@G3CA5 ^X@[_2V=\,3;:@@ZW@/$69$ +\3-8#7G>86T?Y,H]*2! #)B^
MX0<?:J$N']1QDN=+=BA27(^D HK)9ZC8%CYTOB2+CW/MZ;9;7AK4$UXI\EO<
M#\NQ"7<G+X+Y+9[LX7M$LDLE20O21M_'4%* ^"A1NMK>H -$/O0+\Q)&!/\-
M&W.Z:*_A*"H)73E9HU[J3\<0??S3U4\?\<;_'/OX\\B_"[W7GLH)#+OX^*>7
MGW[XN/"29+%G0X^KH0Q%#-MF(A%XQ 4?<O$_,.BX6NY0I)1 &,KTY%8N'W\2
M%_QR@V\9&OH$1ATV[O 4\)_2P&?A%-Q=T=[!*UQKY%L+X6,?%L7G%J7O?<@=
M)*>)KK:Q&1'VX<&Y$U\I5\3)W8B#+WQ(;?(7/OC_$^Z(G Y#[VN4H$W\&D'J
MX-K[?H4BM VR]"D.P[LX(7?]&-AY3_BC$;SC>[R6AC@1\J+(IW(YO.#*G@ A
MH*1Z 5]=L,]:0%GLE1R1IT'P@A*?DOAXP#T@=X<<A"/R5WG0VAA&0_M$E2(9
M)2^#0:9->HH37Q0SGTA*N[P8#4;K-.LPYP4XD$RDY\Q+,N%,&"<(+;QL\8)>
M@XAXM[%(.B%O], -]_EY&_E=N8GP/V,^TG$FP/;9(.2G=TF\OT_3([:ED?3I
ML#O$#QF?!AKS+ZA> L^6VDIHED"RXAWY;"DMQP]5:.7+"^&?0JU76OI,P8D/
MBPAEM&(L5FJ_@1,6"Q(?SN*1GQ(8+"#1;J-ZUJ\A+#1!WG7L=R[P!*$K,,8"
M!AG]/:]X#^\7*BD,-%EP9/_)UPMM, SA*>):"C+JL<4/"/;R30R/OD/'D=.Q
M%_]#1Q\9$XV@PP!R1_*&?&Q-W!T![I,+E*\PD_6.I,X-4;^'8M'PSRVVV*"E
M'RPN#O+)1;:CR70CUX\:G?JP1'@B$KZEA.<B]9@3#MFC4]5I&IT#57B\]IP8
M&=<$WSP0GN&%>44I]L R"+W%\$4A,7#BC(^:/#1A_/XK",K'S9^DIH'?&9BP
MLA=.3=WHV7\"EB+X%^,P\#EPXR,<&+:IA$#C/&&W;XB,^&WB>BV^3O0S\?OE
M,.1B"E-%U=R@-Q3&!$*46(&OQ]#+XN2T/!R2^$W8%<-(+.%SS*#C'UQX[(N3
MU0@<FW2V&ZHD%Q]:\"]-7E%P;-)%*="._C$-EH=X@^VY'?Y,KSP<,LR"C#-1
MYHT,X5! Y.SOPU*!.)903J]RO]65%X)N<99D%ZXF(Z)O*5#_>5(<&A-Z9H1I
M03KCZ<A:1EG@!^$12DT7L'2WWVF /GB3()CGR%6-*GS30\]"4N+G13@_/@'J
M9Q*F0$H+2T"?'L8O.U4I7O@0;%"4HJ&K4+)AIRHXV8L*MHCUV4]=2+(7%8JJ
MD6S,R8J8#5C_H2AC-KX[;*CYA]6IV\SB!+LOH#&C4&R%QV) !=S!:LT)WZ!U
M5<2O3%M^COI^3F$(40.?4?**D@&1F?G "SKR1'C,@Y)3]5JI*!JYCL.0)(4-
MBS.5\T8:0E7UY/3VNLF#J3Y,[X0;A=Q<HJA"Y"9S7HU)I4EXG&1%1]>@*U7E
MR[7DEWM(9O\-8N+3[,I+V^??B8]>,':IB&?^\1^V<?(#?![_&_\D2<B=*C!T
M9"Z$G1EP[I27P(8FI:R(=+QA!BI6RQ@:220FCH\2\LF_2<(<&>B*%TV;$SX-
M _A5+,1Y&A!O(<@S!R1\ /#J/,YY 'BC!Y2F_VM1P"V&!/L[%*,4^%,_00>)
M1\=5'996_JZ2$TA&+<7O3Q2%,2Q=Y>@@%]:/:"#+S2Y ;PP6]_F -B1+1/#C
MT\3O08P!X5MP<E/^M84O/!L@\KUQE<M1B>;^NC*Q^5<6XAL)SZJ?PH 8E>C2
MU6M.^;A&(+B(.<+T$\!.#&/2DKB]'+$\@8%'MF8'(H3?GH2 ''J;##A1T,Q
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M.J7V>9<:.#'E'')2=,^)?CME49CF?DX0.$7F& W9'=2@:/UU)Y@-@I4E%9N
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M *]A,00IOIO ;(= /RH2%-C9XW[)B0W?UU')HH. 2)O^T@[3<(+]$'B7X=E
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M@:F+;O'2[]-.2J%4B;]..R&.1JB>5-YB6B7/ #VLKNKI.DFF+[YZ#?+$>/!
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M[/DQK8\'<AQ^93$V1ESB5CO^F#S:SV2;-<O]AF" 6?')Q%\D%?%_N>C3UT[
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M3KZ;#V;O$3G#WHT)HZ>/G%_O)D2;5YBBV,D[VWH^_A2U4-Y9V>GUJ:B4\L[
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M+,!F8=!VWHKMI>-<S-%*6=YS5%K/OCBO< E5Y@9)%AL YPC"8X;:7N'M1G.
M_&64!3Y,#E_#17[;[?=->,0;[ [+ O N'3/F4FI;U'B$#[DA%]M40^Z\V6:A
M['3CY'#[=B[!$JODU<.WL<?P<AZ"?QXQ![/3TL?_)50*#J4;E'E!>&:W$F0R
ML[>@+]X>_U$H6WP3[[T@4DFIYH[V,N$?5Y_1_@4EBKD7OP\<FJ#:+WCAT7V&
M]M72CX:=!I[EER/0OMI>XZ;!Q@OQ1Q^QXLG^]@4=DSC=!"C:H,<D?DT\^;0[
MC#+LADB33-@,^&_%1L!_^?N3%[TBZ3:H_CKIM#Y[WX/]<:^<6/GWZ3FV_!Y4
ME[O\F]5*UOA@8$-3D#V2Z3:W'RV@5764B9*BCUW5=[7&='%:1;$,.L='X6H3
M\)>+\AD-)LXP8P^\F#GCI2=4VL3>B:A%US^A-U"CR _/AS!0OG4:])Q6+.)K
M0RL62[\[Q/$O<28PC:)]IA"] %OWHS'[&X:Q1["@YK$+GQ@#*<110ST=0>TS
MT!0;AW"!T,<DP$H+LWJ:B2HWMXDBL$'(3\&.XT'N]Q$V4[SP\?@2!AN.@:R@
MR+S_X(7C\3'X!L9H] JF%^#0T;2L_3Y(X1!(]4^3;D.K]XP##'E6KLU7V]BL
M>,>S(.AY6QZS'3;6?T.^8@OH>KA QJ.7K!*B O@DB+'AC)KTM'A<2V#0[2@S
M[&RSKKD<]%H4_%\/1.UC%YUR#=N/9+&"*U2I0C[WG"TWF^/^2+$*T#;8*-4Q
M@X[VUM)+=W6$MV<L%[(U2O8"=)MJ"<T'<,.[:NX3*V'8%4ZGB_9!MW-TY2'H
M79Q.%\U'A8\*&";Q$\V#%:(WAS.BQ*,QV! ZP %C'U?I9<= 3ETJP[HXWLHA
M*TI&7RK+1G'I2;*O&];BTMG;3GN0^QPO.LBLO0+1RM]YT;QK4AK*7M2+9D77
M&Z"B;(S!(Y?$T3C2WN#X7BICAQ1?38\'%QTNVX.1K1XE+KJL^B!,K#QX7'1%
M]>X,:_' <M&5U3LZ@(R>>2ZZ@GI'QM5?G2ZZ;GKW ZI]\+KHXNF#\$S]!G71
MY=/[7 AF3WB774"]S][K\$IXV374NS/3Y.UQE'+J>&5>XG/G7IM'S@F+K)]#
M[<,\^7.Y!XR-WRAB#VXL8$V9C71U^NS](TXXL\\KD:)2F$A5BNAK%+\ (BE0
M?A\=CEDY=?OJ1+J3(FC:](O1/F<USD#8(]H$#GE;>Y#+X&[ AYW(#((TA?DO
M.-3NHS1+CK1<&YY&*O])N]Z#?L(:HS['$3K1HW]WC'S](BL:6]V@8*]69%E#
M50E])P>R6>4SE&4LM.MKC33)QM=DB:A:.[;-:MJ+T3Y[Z)U"UIN<:MG4&_22
M"45!19V!W%@*^EH/8V_[\9M9O%QU&U#9?N#H99G*I4YRT;2V&@J,$CBLC]X!
M)7H50=K6T6/P*8G3%- _O!!V\2>U'M!^''NK!;8]MCRQ"9H"S,XA3H-,OV::
M'N>Q<@!2,L3*D7&LD?SU^5.,S?J(7(:L+@ZQA;&5NB_/6[N>[<=Q9I6+F97G
M:;BXRNY.K&G')71KQ:[C!"JB9*@%-?H^;@1LC.U(J+J])#;W10<;CVFTB[Q5
MV;JS8*Z9K2R'J=$:I)<>/=I@O)9*0@VZ@2^=L89FM<C@]J;K+,YV*]>1R$^-
M97SINZ_1*2#ET^ :P&S8/*+NU.A+N>BHZZFT)X6K9PS>.O2 /=IE)74PS6*C
M=K^M5)K8I0:V3W:T=7[!BXYXG^IX4R_DH*S\*V5EA%XAHL@E9G8^X(VK,,9>
MG--![^!&ONA<C0&/O]H]/0L.3KESM1OU,G-DIE/RM2[\Z;)HSBK.4AXZ>1U'
MQ+=Z],+/7@;_?#I+0&J]I&.D@?M-'W?5>AA'7QZ+F?X29+L@6D7HOY&7Y(Z.
MGN0K!ATX\L1X,;;X>.+)K'=)?'S=K;_%,*U41>RP8P],\VV:!7O0E84P:+T2
MKR6SSW!N7"9=#[:Y&M1\5F;AG^_#Z(&/ZTS<=;TYWDM8C.(RB3,O=$Q-RDEF
M;GVB7!;9)Y+:;=S_O\P*OE:> LY21ZH\<\B)%BC%#;[$4%M,(%P7X#W<^"Y$
MX0K;Y2Y!_SRB:',RB\=5]G2!K/R/?PM0@F75[O2 WE!H1IFNLWWBQ ->GZE9
M7I31&/9)[7'"&BR@03]AKY1/GGD)'@;-YI8T=&32U_AB?P48 G*=Z L3-7=T
M9<N^)SC.*,'QK//V\IU$]D=*+KJ/6@IT/>R3T4.>U]X81K@S'AS(.2.SSXDI
M3 B5MTS9WOYJRW30UAI0M:=]LJPEQXVCI>8GPDRNZ+J^9_U=3M:?["+YL?75
M\Z-M,BXDDT_&VS^W7HT_VR;C/9/K/#.Y^KOI%,'T:@?7;.*]C=QA4O:9^9IF
MP\@!_5&:E(8^1^'2ET+M\2I5&S)P,5TZI]XS96WL2)T[\SW_M<]3AE1@RIQ6
M\V+AD/ZN4C")VDLT+P8W/Y$V:4XUS]1LKI[W?,ZIQ:C""]JHW-=<=/,ZY&/8
MH#)5]=*SX]Y3C-U6.R=,'':.8Z-HG3_.DX4C^^RT[JI+3SSL>+)GGS<\ROG^
M\SQ9./+Y5@#<#)J6>?Y'VCC/\K+36:?9E,/X4<9(?#W_C6R6R3I!MK"#*1I+
MWP\HB??1-D[VY*/GG7=14&P<A2WK8NW%_0O*B#2H%*J24B!OZ\9A-5D0\9@J
MZ)[.$V3W>%YY(12M?-XAK)O$^T,<D12J'$!EN=DD1R3>#V=Y3.MD7..[#$!(
M&G+&&_L-G1=-/WB-6V*S)EPG@1?2LLP;]D^ +5F-C6S5=9P9/^'U!U,#?_$&
M;(CX )*>0D34,+);=+0F$&_WAS ^(?2$2,6T^A90;)GF?O:"H"G''Y-XBTAY
M52^\0TWT-'2R1LPJVZ%$>3X5Q#1TLKTRQG2T(L%&^K.IO"TRS$T%WRS>:#KS
MKTD,S\)CVXI[+>3]+-QAG9C7=+/,PF?3B7--U]@L4,7Z[#D-TX:%"7,0_Z*]
M]?9(UF*',KA1WTVY"4PY_8U\<T3KF%TY>&VR4V=+J3[2&9[M7HR;B\]FN?GG
M,4B) S7-46[<]JBF22:<;?RWXESCO_P=ZPW^<9.M$K:ZDO1/9;-A;3:SB1;H
MET@.6:!O:\_,3!(O>F4^>/*HXQ7_0J ]\7F$;:5-M&H[RL!R]2KT-K]FNSB)
M/J/D%2M/KPDBGU;GL#9UL9N6+IQG3=ZSM*DS$]?FGRL:#[POKKT4K2*DW@7E
M!I/*C2<X'M*957^==%J?O>_!_KA73JS\N[UBZGAL?-$50D9S3.1M[26R0KS'
M:ON<Q9M?M6=$TG#@\X$O(0 <_/$ZCMX@;NHE1(]<%R*?59\<TZX6\X6C+, +
M'F$S*$H#K >RF-H&B*CF?JZ1!!/3;Z3&?M-+/H4^5_QFC<M7QS2(4)H*M]-#
M R*.MHLS%W)Y\1EJ>P*EZ:3;P_#F;CNJ]76]CO<O043MW<BOZ5!ZET'+0:P1
M6SA\)'LSO3H)?]-A?+8>9C3%?KW#&^B CEFP2>^CC8EB+^\R\ P%/P3>"$_H
M]1A"W]/R<$CB-R_\'(0HS>)(AZ?3>HS1N'SM)6\H/F:/H2?'(&QN/X(*O_X6
MZU7XHH%5_*$X4BM-ZG9#,TPN=_,]].B=]O57Y%9=!Y[Q%^_-VW@'?'5H[/5Z
MH_$.<LLS._;Q?#Z%!.+;V+>A[S T=%AE=]P<T0U*-TEPD"@1)CWLW9F9EQ%&
MB8:7QE)0MQ_Z@.#__/11CD8I:3#T]O/P<EUA*>N;G M-ZZ$?4T(O2$B\M>&Q
MT'>P(X:?49:%R+^/ #JDATPNCS,TI_?X^UJEJ])B\&>S78#%+=")3]D!;8)M
M@,07H-LWI,+*[3# 2/O43+?2M!Y:JAQAU-4VWTJ,2[Y4PB@;#SRKG[T([_&7
M(,SN#\D-3Y]6<4O3>I(]6.01L^2/;CM1/\Q(I_DAV* HU<ER14N7'!HRV<C?
ME:L/YYV'&?QJX*M=E>(:*Z>ISVC'D"V^R1DL-W5IFT@]5(#4E9WNHPPEF*/W
M:7I$/K:_X0\:E\A0HUMC#]LWZ3HF5"2(NW98A6 %W8W=1KJ>V*;*U35IXH"Z
M\<"S^GK8)G'5CUXL.DD5DL[0K./@EU;QP(IM%:%N%/V>, 'Y967>?20^8VU6
MX["0M!J#@PDHUH])O,&[71Z"I.2>0=>AS36R-%3>$#ML%?T<A\<]^@4%K[L,
M"Z$WO/U>T6."SPK/;GN$Z*AU#*N<WR^_>/C"EU(V]">F7S,LGK\?0%)T7+BB
MO]V(NJ9(*0B@:PA2NG1TL(X!3GGH86-LT3RR3S11236X1$D0T*7N,J,(P'PO
M5>*1+GKG*&*<N$2JQ!E=-"N,@I9*IZBMS+K4X]4<,Y6?+>-8IC%XY6"Y6>/X
MIS)"26.$T:5N-6ED$I=6)4%VJ1QH$P"EN_-;QQG-0OAW"S\2^=P^IN?2=VK7
M*">1JXI+^=)9IX_6EU@_B@"L69Q=X\#;G&_MP\)FP<CAC''9:^I%(QFTMS2%
ML+F+YHR9D: )U)L%=TRUNG9!A+-@W1!JAMR!=NDX^(9:AB0"=!8;JY=>H50A
M+IMG?56(AFC:60#ZM+H+F@)\9\&Q/E= Q;-TZ;C]C6'4)6U,HK-Q!OUA[L9W
M)>Y[%@>M_96HBT^?!<OZWH@-@?2S &H;PSJJQ/;/@H]#F$H&+U>77BC#\(*H
M)F;,8HNUOR%:YH_,@HM#71H:/^QE U2VNC$TN3:S8%9?\TD>XWCI568,;P%=
MRM0L=M=0-T)#-M<L>-G[7E!DEXV"O^L:\P:(G&E(:)L%&X<P(C1>J#%XZ-*U
MT5X<-F<DSF+?]95]RJ1)QKU_NVCNC14VV)BF.0ON#B$3]2LT!AM=$HMM]V=S
MGBSCV+]?],;K9.=*DG89L_[CG5F<68:YQ(QQ?WUG7"PF:)JF-?.@B,L.K.RT
M\<3D:LZFRPX>:;_-3'*_.>\N^YFQ%>\&ST+G/+YLK_S0^U/(<^<,O/CRTL\9
ME-A^#;@+BL3?YXRYCB'\*Z:W;:&?.%XL96X%/=;?XO4N/J;8H,9?OPNV&4+1
M.DV"JF*IAB5J.\1[\8?L[Y^#2%_\H?3[>_&'#B#D0GFV!_A"'@HNG;VRN5,$
M:(L/:#J\5QTHU;"+CUC88H6<1B?KA+.TK0-8\\+E^H;J5\A&\;-XGYBAT0_V
M(7NUJI-7+V+/C. !B,/ YTG!CX*&L=K>!1$^0($7YD\::4.1@F'&M@BEWGMQ
M:TISA4.#?F*BB@+5IQDIS)QYYS%011OU[ :L4=/^%U@1JS56J'3Y=<U'0PA]
M/H",283RG,W+W:+W6'CUJ0[O6-)JX'G<!4F:]6-BVR%&1OZ7[LC1]^$SVL21
MWX^1K<>PJ2:20KCQR0O%PKGTVN+%KE5:8W/7@1?GT4M^#3 KH]PW]3/^RA'K
M('?'R ^B5X/%:3W&X")8=A.M4;*72V!EZ\GFQ>!E&LIPM.H_\-P;+_K_.GI)
MAI+PQ,7&79P0<;?^%O\W[BJ5-0.,Z@*=ZUV0^#"=P6@L1AR<OJ+:MJ <KU["
MX)5,ZY<@VS75,F\_R"0G"4O%)[3%(@8,Q1I7S4]4PSC6KA+Y:Y8<%]>LC_7#
M,\R!F9R.7M,??=;\0WB5@^0$CW/:>4J:#ZTYX[.4/B;Q6^ C'TNWQP1=XU[!
MQ@OE^W.)Y<E; #J/5(ON,=P8E#VA#0JPP?$5*Z&WW]'F2%TU.6.5-#1V'%RY
MRR\8TWDV=1F!GR)7L'E\"!']Z#5*,B^(9( :*@YW&6H$BF[QO0CPINN836@
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M%/4'0R*YJ'IQ)A<S\GZZH]_+.\6'D)RP0>'7*#]9[_16G=,Z/#E=QUTIHF%
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MREHO^O/>P[UG @=TU'YHU0Y5+ZNKZ)*CI_A>8P+LPTJ]NR&<B38KN.TS6IE
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M/KK>O@_3@@]:;Q+,60Z\1T>,_+#X"/GO"!43CX,F+*T7">#%@PP'H.^T5AW
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MI*\(>H DF9N@_HM'A5AVJ9PP-,%=VM_Z[?&_OZ>(I.2J<O#^W_\'4$L#!!0
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MC,71D@ T0X_Y(V8R^EJ4GX"&O!)J0"2,Q,D=.H5-1#K"!IH$?&L@U8OT$"K
M9HZQ6,"&L[(;=HS;.,8U?RS& 0M%C)@F>BPP7$&ZH3@^UJ7G(@XQ3G":-^-O
M7V8!UHD\*0&V@AP3%%NP.8882LR5<D'!'/UF235:&M@)>84D,HD"R#N%2+;J
MC+7'YV;$0JDFIB"EAAL$O^:HB---9S=:62EQRQ3&K%B[H]?&T>MH*^DUN(/%
M7TU.G3R9IZ%?A:' RWUS8"':9UR#)0."6PPE$&@9H!>&B+<1E2 Q6L^BZ$?7
MV')?*I-A.5*LE72L2+3R(<#;ANTC"0) 5CFD]Z;^B,<WP+H8;JXSB1)VTMO:
M!V>%G?32U8%5O\PHE*#\L?UDEI37RQ#*S=>MD^;B0XM<.QY9'AVW&O7CDU='
MKQO-XZ/C1NN92+7/#[:15>=@L%,0RS;#NA__%4K^?)Z9AQ>A+&P(2)I<D\OK
M5*:Q D3P6!@;DU *8EL/S<L7T:P<$=U*,A(U3^P63*KDT9(>"HQL:(M14@0\
MM88.C0@$UX(:(%SZ:6-T3#5EAE)".YP8FS_:"*8,H$$I1DPJE& O"S^3G (O
M-LL:L4@ML81+5,OY-?X: @EB%V)Y")X>"W<L_\XL'_X +!>TU!F[C) (RVA>
M5$H4'7RQTA6R/[CDPSF/X\18!$1E;E3,*4PC%S)-<T#B-]=!P35DO^!#(44Z
MH^1TG5H:>2PM+>/<H'%'M#2'M-G -&]0DND$&6]L,NW[B!5K@)U-WD",.;)$
MXN,32&A$(1&<*3MRX\@C$HS\.WIO/;W]K:1W;\QE9B,=81_"$&=_8HRH-6MF
M<9@Y/R!FN\OU4SK+8RR(\=:XB>-09>GG=3\DJ^!S::!9<7C_N@T;%O-M.S2!
M\P':TZ'*=U3<=BH&6TG%<X?U5<[0VFH^5;1/EBCY%9&5LF/E^YDF3I12T3OU
M1<JD>(>V-;$6XV,5?[I-";:_(APBH3'.+<GE9OH(4;L(3.O#<3:WY<!9,N)F
MGJM3A+0#  0V=;"MS\/ZC$EQ"S)?$5Z2KSS!(<]#]QV9GWF1J?6S+#+9[;^@
MH'UE$98H2I9IN(A01*>O2,)7)KMH%\>I;JJTF6>\]@96%D4B30'6QOVAPFR:
MG@0";;+%]Y&FR -#81S_TE2[&$_@STR@R78$R6+?KA$?[!:JMCZP;N="55?B
MY V[12#]:.64UF!] 4B6/%N=+QA-T#^4?KK)G$U [334;EL6NQU?1<%\;<<M
M)Z^)9SS @@;FX6P-7?-I*PHC\[ ;*R[[-9CZFBQ"D**[;#/R=&'MCM NL_TA
M"+B=:TA=3&!#C6&F@G0 &Q:14';W/6=>Q66$(AXK.09*"V-^DQ\BT'DDA2B1
M:@;X=#)2+G;R.[Q&'CXQ0ZZN8\C\P)O%%QU1QF[Q&ICQH(/N'"W.[WV#,X;K
M\'Q?_]UW"._A_??/7^JO:IW2<;<7C-%I>;OD]KE#UT,$/&AK'RG YI"XA^C$
M&;\3F0.WBM#-Y1&CDB<&VL8MP\U'@=(Y[#UG %J@"_6T+.@&RG91PUP,Y8*[
M7#EJ51LO/W?NFXZPI\%GR[:JM5>/+=M\0MFC5]57)P\KC#_UJHORD_L6DT/N
MW]YHE<6!EP\*H?VL'Q1*8Y?]]NC&6O<6=+!@K];J]#\"=P[?XXTQ9<0X6\RA
M[> ^%RO07RI9'+>WU7WC\_9/"1P/F^4CI-OLWWS&ZHT*:]0:K?(QTO4 V'GU
M/J^R;^)$%/UI//AVUOZ;@9@/^,6=:@-C)[,[KZQHTUI/K_'*YA[O?Y#O#\WA
MW8/FZWMB-ZQO+GV^S0"T<^(S.#$202#A1W#BRO\*;0\TMVK0?IR?=R/XIO)F
M>VBR<^*/[<3="+[)(_C92$#(>E/P,SJ(PB[=AMUN+/^NJYF/6Z+\F4:?G>]V
MOOL9QN?]*W=@ELO50?K@OE$:?]$&Q'=Y@<'?M]6V!H^??1W/\[Y%I^2^?/_G
M&[R!R.Z&NB,H]'H@A%L6+6TZ+_/%&2>6WERT=IL5XF#-JX=*#9DO64Z_#[TV
M"$<CO024?!/;;E6[CKW[ )U;WO4[<2^0XC?@DAZ/A]C@-I<3/C,V[3D]I+=M
MO7EQ>FC?T_5_4$L#!!0    ( #2$K%K(LB&SR D  +!,   /    ;FUR82UE
M>#,Q7S(N:'1M[5S_<]JX$O^]?X5>;OI>,H,)7T*30JXS-"'OF.DEO93.]/TH
M['70BVSY)!O"_?6W*]G@ &UHDEZAA1^(L5?:U6H_^T52?#I*(_GF!3L= 0_P
M+SM-12KA3>^3UZQ7&Z>'[B<2'.84IT,53)E)IQ)^W4MX$(CXIGV2W'4BKF]$
MW.99JOXEHD3IE,=IYR]/Q '<M6N=1!F1"A6W-4B>BC%T]BS#0(R9+[DQO^Z%
MX@X";R*"=.3Y*DZYB$'O%<P< T]"F%HNG9R[NU.KMD3<L6W;Q_9ZJ.X\(_XB
M^:@SB%,/;^5R>EK<C!;Z<;=<1WMOK& YZV(4C4Z$34=0(EPUK--#;)M_+PPQ
MPC%YA3C+8RP8M5;WN[&Z2@K&(;:FGJ!=KR5IT4&J$K0 ^RSDD9#3]D!$8-@E
M3-BUBGA<$ Y5FJH(:5.X2STNQ0TJ@%@1$VI?\/&55+K]2\U^.I.12,$S"?>A
MG6CP)IHGCMW$S=50R:"S(-N7Q+'/;D''I)%8Q6 GWFDL%&DQ@RA5[VXDAB)E
M#B[4#B<^64LC]9,'I/B"4GSD#GICM7+6NQ[T+_IGW4'_ZI)=7;#WU_W+L_[[
M[CMVT;_LXB5>75T@1>^:O?]X_>%C]W+ !E=?J<%'V]2&J^_ZX[O>!U9O<J]^
MM,\/6/?RG-5;0?[KX^4Y:FWP6X]]Z)U]O.X/^DC<^W3V6_?ROSW6/1N0PNNO
MFT>5G3JM.KL?6/?\ZOV@=UZV-=*>-<]FK4$:LPKM7K_M7O8^>%>?WO7^5^BR
M4:M]-;8;C\<V^>C'ZO*Y5=>OL-^%/^(@\:]$\7A<83[H5(13EHYXVBXKIA2?
M4,#(D\*D'DB(**"0D$DI1@7")))/VZ&$NR75_3\SQ**0Q!)Y)N4Z[5@E>=2_
M:0^Y 2E(_@5USL=3JS:/:HWC^><$0];&:/NHVFH>O^Q,E Z\H09^V[X%2% T
MV2GT(V(:H6?5] 6U[+VI5XNY**4NCDV]5GNYT.'&6!@;\3$P#6,!$PC0J(1A
M?V0X)-!RRJZ!4DFF8G:A=,3J->\/ID+DE$5*<S88 4H&62I\4V']V._,['&>
M@^WL\KO:96,K[?(M3F% =A=-V6VL)A*"&Z@X\]3.* .%?<<J97D"SG@\95F<
MZ@Q0>IY:^R)KY2S"7UIPR4+NXRW-5(1)8ZH<W1)!##X8P_642")^"\BWU*?!
M>P$*@RPEQ4[B002^T'X6(5F,S5&2 #1#C?DC9C+ZFK>?@(:\$QI )(S$^@Z5
MPB8B'>$ 30*^%9#Z17@(%> PQ]@L8,-I60T[Q&T<XIH_%N* A2)&FR9XS&VX
M@G!#<GRL2\]%'&*<X%0ZX[4OLP#[1)R4#+:"&!,46W XAA!*R)5R#L'<^LT"
M:Y0TL#5YA2@RB02(.X66;-D9*X_/S8B%4DU, 4H--VC\FB,C3C>=W"AEI80M
M4PBS).T.7AL'KZ.MA-?@GBW^Q^30R9-Y<OTJ# 7^W#<'UD3[C&NP8$#C%D,)
M9+0,4 M#M+<1M2 R6M*BZ$>_<>2^5";#=L18*^E0D6CE0X"W#=M'$ 2 J'*6
MWKO#ZB*^ =;%<'.=2:2P=6]K'YP4MNZE7P>6_2*BD(+RQ_:345)>,D-3;KYN
MG33G'UKGVN'(XNBXU:@?G[PZ>MUH'A\=-UK/!*I]?K"-J#H'@Y."MFPSK(?M
MOT+)G\\SLWX3RL*&@*#).;F\3F4:.T +'@MC8Q)206S[H;I\'LW*$=$M)B-0
M\\1NCJ1*'BWIH<#(AK(8)47 4ROHT(A <"UH ,*EGS9&Q]139B@EM.[$V/S1
M1C!E  5*,6)2HP1G6?B9Y!1X<5A6B'EJB2U<HEK.K_%J"$2(4XCM(7AZ+-RA
M_#NC?/@#H%S0:F?L,D("+*.ZJ)0H.O/%3I? OG;+]3&/?F(L H(R-RKF%*81
M"YFF&I#PS7508 W1+_A02)%.*3E=Q98\CX6E19QS&O=(2S6DS0;N\@$EF4X0
M\<8FT[Z/MF(%L-7D#<28(TL$/CZ!A#P*D6"E[,"-GD<D&/EW\-YZ>/M;">_>
MF,O,1CJR?0A#K/[$&*W6K*CB,'->(V:[GZM+.HMC;(CQUKC"<:BR]/.\U\DJ
M^(P:J"H.'UZW8<.BWK:N"9P.4)X.=;Z#XK9#,=A**)X[6U_&#*VMYJ6B?;(
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M5&YYT_/$O4*+WX#+]CP>XH#;7$[XU-A\[_20WC?VYL7IH7U3V=]02P,$%
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M#^-[,L2#8ND#4-J'2?0,N5XQA5Z>8]838(/J?:BB9P$11'\9!-_/_/^9B.6
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M2P$"% ,4    "  TA*Q:)E_]40TJ P!TKB4 $0              @ &901<
M;FUR82TR,#(U,#,S,2YH=&U02P$"% ,4    "  TA*Q:9/O"(V5% 0 I.Q,
M$0              @ '5:QH ;FUR82TR,#(U,#,S,2YX<V102P$"% ,4
M"  TA*Q:ZT/#DKH)  "N2P  #P              @ %IL1L ;FUR82UE>#,Q
M7S$N:'1M4$L! A0#%     @ -(2L6LBR(;/("0  L$P   \
M ( !4+L; &YM<F$M97@S,5\R+FAT;5!+ 0(4 Q0    ( #2$K%HY 0'C*08
M /\L   /              "  47%&P!N;7)A+65X,S)?,2YH=&U02P$"% ,4
M    "  TA*Q:^>D_244&  #8+0  #P              @ &;RQL ;FUR82UE
?>#,R7S(N:'1M4$L%!@     '  < L@$   W2&P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>nmra-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nmra="http://www.neumoratx.com/20250331"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nmra-20250331.xsd" xlink:type="simple"/>
    <context id="C_807f1ef6-efe1-47cd-a1ac-f6eebc286522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8546d344-f5a5-49c0-b25a-d7761e6c965c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="C_8581f7af-0c61-4b18-9fa5-437addc36bcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_88db6b5d-3162-4950-a605-ff7e73170e5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8930b52e-d90e-4036-b728-884065a23c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_8983212a-31bb-40e6-aad9-72c31bd8b3ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_89c9cc8c-f7d3-4aa1-8971-7f4acc54dceb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_89d8aeee-2789-4a1f-a31f-e532505c7bf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_8a4d11b0-e864-40f5-af40-5075fb6dcc55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_8ae50382-fe31-444e-adfd-c5c5cf08f02f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_8d55cf2a-ccb9-488d-99f3-88abc8c63dc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_8df9e453-1166-43a2-b750-45ffb91958ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8e618d30-af12-4d65-8977-21df83d2cdd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:FirstVanderbiltSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_900e0f63-0ee4-40ff-a668-3acce016bc69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9061b628-1cbb-40d6-878c-d538a8e5434f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9118ec0b-0a0b-4f37-8864-d70d86430dc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_91940b71-4a64-44b8-8e19-43b82923017e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_93d4bd12-ee53-4993-8268-9e9637ffeca1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_945e63e7-24e2-41e4-b69a-b13ccda12454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_948e3436-40f4-4902-9557-b188a3de6f02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_957f0675-75da-45b6-8d5a-5d4c59c2f42a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_96e4575f-22fb-4510-8c56-dcf2ef26b887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_9725a19f-6026-4597-becd-68b62f258eb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="C_97e950d4-ad65-4370-8e70-5ec2021370e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:Nmra511Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_998e1d41-951a-4a8a-8f7b-eacf68edbd89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_99f5cde7-7246-4eb9-9076-bb614ce418b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nmra:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-09</instant>
        </period>
    </context>
    <context id="C_9a04f240-c069-4dc2-8d21-d62bfc7e531e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9b4cda2e-b933-47c6-a24f-6f190752e6c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_9da9e2d3-d2c9-4624-9a0f-41478107481a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9daa6341-c6b6-4510-aaef-1aaad596df55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:AchievementOfSpecifiedCommercializationEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_9f0723d9-5254-4d08-bff0-43148bf1192a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_a2d3f823-77c5-4f3a-8379-db86ade0a660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_a449de6c-c7c4-4d8d-971a-f9c39a05240e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:ParkinsonsResearchVenturesFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_a4715f31-d2a5-4cb7-8365-aeeabb7b9c1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_a55ca487-0567-4505-9f6f-f91c988a8506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_a586780a-a629-48b7-9844-e31954befa7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-09</instant>
        </period>
    </context>
    <context id="C_a6afc305-12c7-42a2-8ee0-0a5d36ab752d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:Nmra511Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_ad0401b2-4d75-4075-81f0-1c16e959518e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_b021f8a3-fac7-453a-93f0-4243983b574b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b09a7f2f-554f-4ab7-a516-b0464c7db20d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_b1e412fe-b620-42a7-889f-eea848ba3fcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:TwoThousandAndFifteenTsriLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_b2225424-d630-4726-95a9-a1c8ebfb3755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_b67f54a8-a954-4dea-9fa6-8d6747046679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_b7741931-52c1-4814-ba2a-d45dd587fcc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_b89706ed-11c0-4574-9fec-db2b478b98ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b98e4b10-ee87-4bcd-aba7-dfcce8c3e11f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:NavacaprantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_bb5db30d-8a29-4c0f-9230-7f59a4cc1240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:ParkinsonsResearchVenturesFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_bb874d5c-ff29-4fda-8629-e1343f9f7d96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornCarveoutPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_bbcc59cc-72ab-42ea-869f-9a969577ae6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_bc5bd643-a814-479f-a13f-0894453ba0e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bdb2f4d2-eed9-41ee-954a-8febbe7f4b55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EarlyExercisedStockOptionsSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_be0b1b72-5d49-463b-ab77-61e5bac1a983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_bec87db7-aba1-42c1-89de-287859477b6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bedae046-3671-4278-8b1c-24865ff68f64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_bf4dcd0a-343d-4af9-b2ff-82d99b4a270b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bfc6fdc3-c7bf-44aa-8118-ceab97da4350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c1c1147c-6515-43d5-9a5a-39bdb8587234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nmra:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-09</instant>
        </period>
    </context>
    <context id="C_c5716e30-2845-4e75-9c82-0ead8f11e3d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_c6ca0beb-621e-45be-9f36-bcb1a9eadb66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_c7784c8e-e600-439e-b7df-863d51173fcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c7f8c769-dcee-4641-8788-0ecdfd5e085d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c862b521-4d47-4fe1-8a29-5956f0f3aafd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_c9441c9e-5777-498d-b6d5-078a3f0763f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-09</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <context id="C_cac684c1-58c1-4056-87fb-85dffbb9e345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cc122612-07fc-43ba-9703-dd266daba6d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ccb36bdc-b5f6-4cd8-9f8d-4b1d849d2f44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_cd3670e7-bb95-4a95-9b48-6251aef56387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-09</instant>
        </period>
    </context>
    <context id="C_cdd08ec8-fc48-459d-ae7a-3d50a476e424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cf3b1219-8ac1-48e1-966f-2ba7c5539861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d182de24-0601-4e16-8128-a87852d11d16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_d23263c4-414c-41f5-b6d7-7e3e8f52cb59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_d3ac0816-6766-4808-8c6b-73bdf51bb772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d4678025-d799-4a17-bfbf-952b85ed2d13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d572c7f7-2d65-449d-822a-730cba140e6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:VanderbiltIprDAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_d6cdf9f5-5dbc-45cb-b827-e5ec44728d50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_da5dfacb-16f9-419e-9ea3-8176113c5d89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_dca1c4c1-2e7e-4f8b-8535-f8ba404884cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_de855e05-78f1-4034-9dd2-99edd71f6a01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_df815232-6d0e-46d5-858f-73dd8e96a6b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_e0b073e0-9ae4-4fbf-ac18-8ac5ee41c4c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_e34013cc-ec03-4b59-921d-284dfd9952b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nmra:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-09</instant>
        </period>
    </context>
    <context id="C_e5572f63-a9f0-46b3-8d24-1600baa94c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_e6152824-6482-450d-a1ed-1cd75cb82a46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e7491852-40a1-4eee-b2b1-7b6c1fafa82d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:SecondVanderbiltSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="C_e899c8c7-d7d0-4f74-ac13-bf387dd80ce7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_e911e4aa-353a-44c7-8d53-12528baf8f7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_eba48cde-044c-4cf6-83fc-6f6426dd681f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_ebff40d6-3768-4f98-8eb1-4e6b12753e80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ecb47253-5967-4e68-a907-ee441a95567a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_ee1bf88c-a716-432c-9927-f73c12f7dabe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:SharesReservedForOptionsAndRestrictedStockUnitsissuedUnderthePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_ef2557ce-7b57-4e87-830c-4493b126211d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:AchievementOfSpecifiedDevelopmentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_f164d19d-7ff7-4491-8078-1f6420964b6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-01</instant>
        </period>
    </context>
    <context id="C_f17f2417-a74c-4179-81fe-cbc4a177ea8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_f31ea84f-b25c-49d3-b5e0-ea4d01b60c1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_f56f8fbd-ff2d-4bcf-9a02-48dfad75f890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_f63b1f37-86a2-476e-9394-a9737eb501a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_f9669214-3f77-4f65-8703-5b733c4987c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EmployeeStockOptionAndAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_fa6eb452-286f-470e-bfaf-790490cd6700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fc26cf16-194d-42e9-bd78-03837763f10b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_fd27dd1d-0143-49e6-bae8-7ed81f1fc545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">nmra:ServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_fe1ba1ef-7e15-4e74-8545-43b5c9422c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ff586993-3393-4df1-a26e-92ffb8e44664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_ff6c1c0c-dab0-4730-8b13-70db93c2b6cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ffa0d7b0-15ec-4da1-b744-c829194fe468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_0073ad06-94e6-4b3b-840a-a087ad92d314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nmra:CaseTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:CommercialMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_05cc4820-f2b7-4d8d-a300-c73727f10eea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_05db645f-f4bf-46f3-bf4e-7f20ec31940c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_061cf2c5-5b6a-43b7-9349-feb9de83c3de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_069e0991-79db-49f3-896d-022fc3b13a5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_06e547db-6799-4ce2-99ec-f971505c46d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_07657077-ad7d-435a-b4d6-1b88f79c2724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0765bb7b-af0d-4ddb-abe8-4e7b1ecfd1c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:SharesReservedForFutureIssuanceUnderThePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_097e4542-80e5-445f-9968-c8d2e3c75940">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0a97a9b7-374a-4ba2-8c70-91464eb57c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_0c70cc8c-7dc7-4484-8ee0-c0f1aacfc08a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_0cbb0a62-efc0-4cdb-94b9-ad0c8c0323da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_0cd17fb6-6272-4a76-8980-45ff567d9207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0d5d9e12-40b5-47d8-9d2b-14dd033fa5f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:PerformanceRestrictedStockWithPerformanceConditionsToBeEstablishedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_0e450f30-40c2-4a41-84cf-da509f4dece6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nmra:TrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-09</instant>
        </period>
    </context>
    <context id="C_0e64685c-4df1-4cfc-8090-786dde3ed56d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_0f91fe01-be96-44a4-a1f4-fc84be3ec675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_0fa32b7d-f446-4078-9cee-2d0078041367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:TwoThousandAndFifteenTsriLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="C_107c6cfe-84dd-41a5-a2a4-ae925e0ea374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_12814edb-2555-40ce-8b79-cd767af2d069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_139308af-4183-4890-bc4a-2ef55df09c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_19eb528f-0c9a-4741-8410-ab696e22ae8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_1a39b2a9-d6a6-4b5e-bafa-1411d170d3dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_1aca905f-ee26-4555-b248-631ec9df757a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1bc0b95c-7620-484e-a74a-a6ff2b9e28be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_1bef601d-1919-4e4e-87a0-ea9d5c9cb986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_1de420c3-74a2-46db-8f45-5e14a2cb894c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_20182b59-d390-49de-939f-92e912503780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_247cd15b-eac5-41fa-89ce-c12599a45e39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_24e1bd61-fe0a-45a0-b4e5-7e09d0a6cf7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_27e8bd25-1d8a-462a-a5a8-60599bc36dcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_27ed8d77-f3bf-4069-b960-220c0a09b3fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nmra:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-09</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <context id="C_2872bc3f-ac79-4fed-ade2-77671074619e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_28c76f06-1cc1-4845-8c93-25ddca00f65e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nmra:CaseOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_28c81270-b763-4f43-9e26-86aed60a8e6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_29d4b3f4-84bc-4e37-a42c-c5ddac7501e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2a459aad-9b00-4fcc-9e37-26666bf29cc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_2ab6c9e7-ed9e-4fb0-969f-343343d0a2c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2b244c9b-1ded-43bc-820f-3c639a651b27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_2c7eaaa1-bb2c-4bb1-811e-b3ed93a9e5b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_319051d1-d908-4b4b-a4e2-c1ec01693b5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nmra:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenIncLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_33520c04-a8f9-4978-85e4-d1ef14e55fac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_345b87e2-e0de-4a5f-bd10-8a06638a2087">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_34728959-32a0-44fc-a13c-2f71e43ae7e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_3484d184-2e57-4ae8-ae41-4d03630e1535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_34c399d6-b754-4a45-afe8-4f0160c2d7d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmra:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_35521780-703a-4201-9415-b3fff9017474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_3565ca70-6698-469e-afc8-c1986c5cf118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_357567a5-de51-4303-afa8-40e33e156b88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_380c3204-a040-4430-aff2-cdc8bf414df7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:ParkinsonsResearchVenturesFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_389f4cfd-1035-4a63-8472-a8b0535f9979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_39f31af5-0a63-4d36-b5c4-aa045096d63a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-09</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <context id="C_3b83541b-7d35-4924-a941-cdc46db3b104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_3baa7dbd-2e2b-4e86-9a5b-5cbbc95835cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:SecondVanderbiltSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_3c5a3125-1df8-4cfd-82c2-6439f4fce770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3d315f3a-94bd-45c2-a9f2-a8597bd60111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmra:AdditionalSharesOfCapitalStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_3dcb2394-89b3-4597-ac19-7d6a28943660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_434aebe9-f88b-42f1-a3a9-60444626ef43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:NavacaprantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nmra:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_43d828f3-9822-4b63-a7d7-23b01fed21ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_453a453b-8844-4a63-a3ea-cec4fbf05356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_45866c85-796b-42f6-a180-2cc89ed0ddd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_45cdde70-3358-4569-a949-fee006c59617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_467a3e0c-fcaf-44b2-b119-58d8725c65ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_49cf2bec-a0f7-4364-9f41-4d0d4dd7485d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-01</endDate>
        </period>
    </context>
    <context id="C_4a09c9c7-6948-412c-8311-1564f533ec6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nmra:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmra:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">nmra:K2HealthVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-09</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <context id="C_4a189432-6771-4924-b99e-f1ee33b187a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4d3885b7-eb3e-4bdb-9e6c-4fd241fd9a03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4da76cd5-5865-4083-a0ab-47c7fb41907e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_4dc3cc35-4428-4ddc-abab-0af3843650aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_4e37b9ab-9112-4171-96d3-a28df5c5f26d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_4ef13920-7a05-4ac0-99bb-9c2e976e10f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_504593b3-57d4-4b02-8b18-4bdd29a7ac8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_50810541-9cdc-4d75-8385-8446d34bf249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:BlackthornTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_567b6948-dab8-40c8-9463-dba168ab7953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:NavacaprantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_572b967f-2f74-487f-ae14-180bdd868be9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_59e023c8-7631-4420-9721-fe4e193d844b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:ParkinsonsResearchVenturesFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5a79bd11-7094-4ffc-951c-6a83cbffb588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_5b2a4e5c-222a-4ad2-8abc-8bf73b709b4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_5c0b10fb-50d4-4b4e-b9aa-33b20ed8cf2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:AmgenResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_5c2c1eeb-3a09-4d7b-9795-a097550eb2bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EarlyExercisedStockOptionsSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_5cbec31a-e68a-41aa-a5e6-626bf079aa0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_5d02fd90-893f-4a41-a4e0-50545ee339fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_609a5a5a-15b7-4aa9-b8b5-78d98fae8999">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_60c0ef16-d311-4eff-b99d-ea396190548b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_6167264c-1f42-4063-b5e7-f295414754c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmra:LiquidityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_624b06cb-3eb6-4c5a-b6f8-d5c6f733459c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nmra:EmployeeStockOptionAndAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_62cf7b31-5216-483b-b0b1-4177e5c19093">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_635b097b-2010-46d5-b9db-42a97113defc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_64494bd4-6ab5-4895-bf3c-bef01605a51f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:TwoThousandAndFifteenTsriLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_674b4626-69f1-4f21-a46c-b4994d0e271f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_67e82a6b-31f5-4d3a-8d28-c6d447c17553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_69427e48-5aaa-40a8-b2f4-3bbf2e2277d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6c7ce039-4752-4464-8f4e-b470a3b92d07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_6cc3140f-0593-476f-9bc0-70f418f9f63e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <instant>2025-05-05</instant>
        </period>
    </context>
    <context id="C_6d975b6a-1d37-4354-bb12-b6e8b427cd7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nmra:SharesReservedForFutureIssuanceUnderTheEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_76739724-db36-40d3-a0e9-ef80e990e67b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornCarveoutPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7b7d5dac-7754-4da3-bb2b-8b1d57fcd91d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7c050cf9-993c-4fb3-aeca-b255bac5106d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:BlackthornCarveoutPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_7e9a4d20-f83c-40d6-a5ea-7a0380c08cf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nmra:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7f20fb03-a67c-4772-9d37-ac7b4fb27bce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nmra:VanderbiltIprDAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmra:VanderbiltLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Agreements">
        <measure>nmra:Agreements</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Milestones">
        <measure>nmra:Milestones</measure>
    </unit>
    <unit id="U_GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="U_Program">
        <measure>nmra:Program</measure>
    </unit>
    <unit id="U_Segment">
        <measure>nmra:Segment</measure>
    </unit>
    <unit id="U_Tranche">
        <measure>nmra:Tranche</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_bf414cc1-70d4-4935-87df-a16b97268b94">0001885522</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_7d6d31ed-6274-48c4-83c9-f284145996fd">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_4dad036f-1f70-4e65-9ecb-159d2eb2d837">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_2a904c58-ad37-4d3f-85f9-392846bafecb">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      id="F_45e7c1f7-f3df-4a26-b1ce-361952795a76"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      id="F_61c6ee64-fa23-4de8-ba82-cf50486e9efd"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_5ef6507a-991a-417b-a92b-153ec2aede3b">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_c9441c9e-5777-498d-b6d5-078a3f0763f0"
      id="F_c244de65-f8a1-4f33-b839-be154c63280c">2029-05-31</us-gaap:DebtInstrumentMaturityDate>
    <dei:DocumentType
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_3bc3f219-be62-4833-a49e-655490b0a154">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_5d7536cb-ba3a-423b-800f-07c469f5a826">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_772c5c81-7e89-4c65-bd6c-e35c44229ded">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_015bb14e-8a96-46f0-9de7-5543e4f62956">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_628cabf7-2353-4539-9051-f4110dbbd138">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_385183fb-0bb0-424e-8435-a630a9e4a608">001-41802</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_78fc4316-23fe-4946-81a6-52657f20dae6">NEUMORA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_371a24a5-bcf2-4114-bbc3-cdb3e4bf6126">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_7c8a5672-8b8c-494e-a519-c97706ac12dd">84-4367680</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_3a856f4f-f064-49d4-af9b-bf9f9d3d33eb">490 Arsenal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_c50e33bd-1f1e-4d19-b51f-384ca7c9d49e">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_eae7aa30-a562-44b9-8864-204058ef9129">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_96aa3b6a-2b3d-4165-a773-3ed46cda81cf">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_23bdf6ec-9348-497c-8f65-931d493aa156">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_952d4e12-eaf5-45c6-a651-529f79cd488b">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_1eef9c5d-f422-4971-892b-07cfa0326b10">760-0900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_6daf5ed7-1ea9-4bd7-bd2e-55f8568831dd">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_7d39104f-4ff8-444d-8d95-ef3d26031797">NMRA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_31a3825a-cac5-4d84-a8fa-83978b3a0965">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_8ffc11f2-1100-4586-a130-7ea155c64819">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_ed6d140c-8690-4f8a-be66-27ecf5ccb200">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_cdbcf534-7261-4ccd-92fd-06432deced5e">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_20bb26f7-a6e3-4fac-ad09-286c9720afac">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_00e1eb78-9595-4ad5-95fd-828d6d5f8378">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_6a41955d-1afe-4abe-bf45-b46532f07f0a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_6cc3140f-0593-476f-9bc0-70f418f9f63e"
      decimals="INF"
      id="F_90f3b421-25f2-4b3d-bf35-4c1023169235"
      unitRef="U_shares">161747922</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_1c7762c3-c155-446b-ad3a-8600b2b00c02"
      unitRef="U_USD">126860000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_78f92e4d-d243-4e13-982c-bb51f00cc6b1"
      unitRef="U_USD">142148000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_97f18eb5-5773-4519-af47-6d4f451a7e0e"
      unitRef="U_USD">1213000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_696c60c9-bb3b-4738-a3e3-0296c036a964"
      unitRef="U_USD">1213000</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_547ccb8e-52a6-49d1-923e-aebd1243516c"
      unitRef="U_USD">122493000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_efc74190-74b6-4a4a-884e-4ab6d4999772"
      unitRef="U_USD">165430000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_b8cf4bff-93b0-4624-b83d-8c8525c1a5ba"
      unitRef="U_USD">4300000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_a24b037d-7b7a-49c2-9861-c441284a9a1a"
      unitRef="U_USD">5264000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_e622c93e-71b4-4c56-8ce5-b54815b7ca6b"
      unitRef="U_USD">254866000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_6333c106-ebe9-44ba-82cf-756b36b1b24f"
      unitRef="U_USD">314055000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_3f55f5bc-8372-4df9-8604-effb354d7982"
      unitRef="U_USD">982000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_9f37ed48-9427-4b19-bd20-c4c3b13145c5"
      unitRef="U_USD">1140000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_c43d2f2a-2fb5-40f7-a4ee-aef4e64fda49"
      unitRef="U_USD">900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_b0a9f8d7-9f85-4f10-8492-e481a78783c0"
      unitRef="U_USD">1777000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_b209e760-0e34-458b-bc10-9d34f0219b82"
      unitRef="U_USD">256748000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_41015d79-8dd8-4d12-affb-a2dacc336c0b"
      unitRef="U_USD">316972000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_8b4bf8c5-ffb0-42c2-a11a-9ab574cfdba0"
      unitRef="U_USD">1052000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_22067218-48ca-46f1-914e-1ce06cb5aa6f"
      unitRef="U_USD">3307000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_1c7b278e-61f5-4c95-8dcf-0962e7102f01"
      unitRef="U_USD">26272000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_23c17a00-3e4b-4887-b5d5-d9f963b3ebfd"
      unitRef="U_USD">24593000</us-gaap:AccruedLiabilitiesCurrent>
    <nmra:EarlyExerciseLiabilityCurrentPortion
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_eddb0e1a-94f4-42b2-a090-1ec94ed0629a"
      unitRef="U_USD">122000</nmra:EarlyExerciseLiabilityCurrentPortion>
    <nmra:EarlyExerciseLiabilityCurrentPortion
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_4be2f14e-a0dd-40cd-aebe-c423c3c7293c"
      unitRef="U_USD">133000</nmra:EarlyExerciseLiabilityCurrentPortion>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_633bacd2-f1af-4c62-aef0-5cc7c54b1b0e"
      unitRef="U_USD">938000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_30be4811-532a-4fbc-b806-28446aef6f76"
      unitRef="U_USD">1853000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_74e64543-61d4-43fd-b8a7-d1bc12321c12"
      unitRef="U_USD">28384000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_1b448e1b-d9e7-4d8f-b62b-ede52547a29a"
      unitRef="U_USD">29886000</us-gaap:LiabilitiesCurrent>
    <nmra:EarlyExerciseLiabilityNetOfCurrentPortion
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_00fe8ded-e9fc-4aa0-a31c-9fe776117b05"
      unitRef="U_USD">22000</nmra:EarlyExerciseLiabilityNetOfCurrentPortion>
    <us-gaap:Liabilities
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_6af33d6b-60ba-4b69-95f8-c8f69bf256c0"
      unitRef="U_USD">28384000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_f1df33c3-6ccd-4f68-9f74-3f31463a45c9"
      unitRef="U_USD">29908000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_cfb6e7fe-ecf6-46ba-8e0a-2979d80fe903"
      unitRef="U_USD">16000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_bd19bdb4-ae0c-47a7-a4b8-da424f343568"
      unitRef="U_USD">16000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_41b15df7-2f8c-4fca-b939-bc6f27f64f08"
      unitRef="U_USD">1243564000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_2e9f7831-a8cf-49a7-880d-85b7c5d47f1d"
      unitRef="U_USD">1234207000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_fb0ff829-2181-4eb3-991a-a9d8563cb1d7"
      unitRef="U_USD">-3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_f54e55ec-b526-420a-a547-9815d83398bf"
      unitRef="U_USD">62000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_51951d06-9df2-4e0c-8d21-85e6f1890ec9"
      unitRef="U_USD">-1015213000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_57c000e9-39c7-41ab-94e6-9b80fec9d997"
      unitRef="U_USD">-947221000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_35a79b29-7818-4d0e-95bc-a0fc82b64aa1"
      unitRef="U_USD">228364000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_a8a85215-b90b-457b-a604-c3199dbcba07"
      unitRef="U_USD">287064000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_17b6ec15-43e9-47c2-9b2f-60c76fd3b4e6"
      unitRef="U_USD">256748000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_f3f33148-23b6-49a9-82bb-c4bd44271b84"
      unitRef="U_USD">316972000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_1777fdbf-0ff4-4ecf-a336-5187185125f3"
      unitRef="U_USD">52151000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_088a8b54-aba8-4fc2-9781-b6470cf23672"
      unitRef="U_USD">45757000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_29aaeda2-2569-43ae-8c75-834a818c8c16"
      unitRef="U_USD">18785000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_cb880d5e-f3ac-484a-8bc9-53387961f1ce"
      unitRef="U_USD">14317000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_8294971d-6f1d-4644-a9f3-4bdff8410b5c"
      unitRef="U_USD">70936000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_2a2f7871-b205-457f-b3d5-6799250da55e"
      unitRef="U_USD">60074000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_9f7ce1bc-0995-4ad1-a72f-51eb015bdd7b"
      unitRef="U_USD">-70936000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_660056fa-09dd-488a-8efe-84c9822b3ac9"
      unitRef="U_USD">-60074000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_c559b19b-6a10-461e-ac26-916e9017a935"
      unitRef="U_USD">3074000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_95613611-01f4-49fd-b1ab-17a6299e76c7"
      unitRef="U_USD">6365000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_e96c2702-5f90-469a-b4df-0989be79a971"
      unitRef="U_USD">-25000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_d18e3758-cd5e-4e2f-be91-0fed2f332601"
      unitRef="U_USD">-12000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_dc709e29-2087-4d77-8fdb-b816b7d8326a"
      unitRef="U_USD">3049000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_2ea9dc4c-9235-4c43-81e4-0a3a117404fa"
      unitRef="U_USD">6353000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_81a1daf3-72d1-4da3-8fb6-cc93a9715937"
      unitRef="U_USD">-67887000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_8ab4a247-4fde-4cb9-bcf1-53719a6b4425"
      unitRef="U_USD">-53721000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_7878be9a-3a80-48aa-b55e-e557fcd59f5d"
      unitRef="U_USD">105000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_93770844-4614-47a8-b31c-bfe8140d2d36"
      unitRef="U_USD">-67992000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_ea92c1ae-20eb-4295-9a88-ad2428577677"
      unitRef="U_USD">-53721000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_be2e27ee-13d0-47d1-ad09-539d25fbc605"
      unitRef="U_USD">-65000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_91f10e3d-adeb-4f2b-a171-35cf291138e9"
      unitRef="U_USD">-72000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_09a3e384-6761-415b-be15-a50709e7c0e1"
      unitRef="U_USD">-68057000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_0c1ffc72-faab-4745-a2e0-7c68bd212eaf"
      unitRef="U_USD">-53793000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="2"
      id="F_32d0d27f-f8dc-4988-9315-cf7a3701073c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="2"
      id="F_3e38aac0-495b-4ad1-8704-d4792e9cfdb5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="2"
      id="F_ada7d270-88c0-4249-8703-1e2ceda460d5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="2"
      id="F_d1abde46-6048-4027-b014-84004aa8af7b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_d7180f85-445b-46bb-88c4-b5c481015197"
      unitRef="U_shares">161451000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_4e48208a-29ad-4800-8485-d21c7fb8b172"
      unitRef="U_shares">161451000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_cd0bdd46-c401-48a6-8506-56ce9353f416"
      unitRef="U_shares">157943000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_40ec7b2d-e782-437a-9f24-835d9f19cffd"
      unitRef="U_shares">157943000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_cc122612-07fc-43ba-9703-dd266daba6d5"
      decimals="-3"
      id="F_c03825e7-317d-4e95-aa3c-4982f9131d4d"
      unitRef="U_shares">161710000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_cc122612-07fc-43ba-9703-dd266daba6d5"
      decimals="-3"
      id="F_1a6ead74-34eb-4233-a466-313bd874a0a4"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_900e0f63-0ee4-40ff-a668-3acce016bc69"
      decimals="-3"
      id="F_8f770d5e-4926-4edf-a971-91fa061cd93d"
      unitRef="U_USD">1234207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cf3b1219-8ac1-48e1-966f-2ba7c5539861"
      decimals="-3"
      id="F_8f93ea06-c741-4a08-8ffb-9c641d58d9ba"
      unitRef="U_USD">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d6cdf9f5-5dbc-45cb-b827-e5ec44728d50"
      decimals="-3"
      id="F_6a57b59a-567d-41a7-8e55-7eb24d28e021"
      unitRef="U_USD">-947221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_8bb9ec17-c0e2-4281-bb6b-c1e2a502de53"
      unitRef="U_USD">287064000</us-gaap:StockholdersEquity>
    <nmra:ForfeitureOfUnvestedRestrictedCommonStockShares
      contextRef="C_b67f54a8-a954-4dea-9fa6-8d6747046679"
      decimals="-3"
      id="F_5640b99e-3891-4e39-a8e9-9870cd420ea7"
      unitRef="U_shares">-231000</nmra:ForfeitureOfUnvestedRestrictedCommonStockShares>
    <nmra:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits
      contextRef="C_b67f54a8-a954-4dea-9fa6-8d6747046679"
      decimals="-3"
      id="F_6d3f93ed-e3df-4b03-b5a3-fc0a1cc979f3"
      unitRef="U_shares">269000</nmra:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits>
    <nmra:StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase
      contextRef="C_467a3e0c-fcaf-44b2-b119-58d8725c65ac"
      decimals="-3"
      id="F_52cf5843-a38c-4b14-b924-b2ca7102f56e"
      unitRef="U_USD">33000</nmra:StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase>
    <nmra:StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_bf4e5002-d5c5-44ae-82b0-79a4c7e8de92"
      unitRef="U_USD">33000</nmra:StockIssuedDuringPeriodValueVestingOfCommonStockSubjectToRepurchase>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_5cbec31a-e68a-41aa-a5e6-626bf079aa0b"
      decimals="-3"
      id="F_26d26045-9568-4b4d-80e9-9af279aa40f4"
      unitRef="U_USD">-65000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_e655c32b-ce9a-4540-9266-933dda047180"
      unitRef="U_USD">-65000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_467a3e0c-fcaf-44b2-b119-58d8725c65ac"
      decimals="-3"
      id="F_27e987ce-688d-4f03-a75e-4151cace42cf"
      unitRef="U_USD">9324000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_4876e977-7615-4d35-aa99-37dd92148757"
      unitRef="U_USD">9324000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="C_a4715f31-d2a5-4cb7-8365-aeeabb7b9c1e"
      decimals="-3"
      id="F_e1a8da1a-b328-4129-be53-a654b547ea02"
      unitRef="U_USD">-67992000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_e97f4e49-fcc2-430e-9eea-3ef493a275f3"
      unitRef="U_USD">-67992000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_df815232-6d0e-46d5-858f-73dd8e96a6b8"
      decimals="-3"
      id="F_a3b56af9-2c65-4d0f-bc23-453613e153da"
      unitRef="U_shares">161748000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_df815232-6d0e-46d5-858f-73dd8e96a6b8"
      decimals="-3"
      id="F_01f7184f-78d1-4e96-8eba-56f20a34e321"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_139308af-4183-4890-bc4a-2ef55df09c62"
      decimals="-3"
      id="F_faf1cf26-4cb5-480d-9d73-ef0180be28ab"
      unitRef="U_USD">1243564000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1a39b2a9-d6a6-4b5e-bafa-1411d170d3dd"
      decimals="-3"
      id="F_0be0fc7f-37e4-4e49-9c80-e1f4087b9ea9"
      unitRef="U_USD">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3565ca70-6698-469e-afc8-c1986c5cf118"
      decimals="-3"
      id="F_4dfe8c2a-ab47-4cce-b6db-f6f3547dc591"
      unitRef="U_USD">-1015213000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_abf99b77-247c-4175-8ce8-cf18c6b41f6a"
      unitRef="U_USD">228364000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_bfc6fdc3-c7bf-44aa-8118-ceab97da4350"
      decimals="-3"
      id="F_08aae8bf-2551-4923-a75d-1cd7881a7570"
      unitRef="U_shares">158832000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_bfc6fdc3-c7bf-44aa-8118-ceab97da4350"
      decimals="-3"
      id="F_346ceaa8-0fc5-4946-885b-dc01d5ff685c"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bc5bd643-a814-479f-a13f-0894453ba0e4"
      decimals="-3"
      id="F_a839262b-a79e-4a00-adaa-51d412431d53"
      unitRef="U_USD">1172570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20182b59-d390-49de-939f-92e912503780"
      decimals="-3"
      id="F_667b1d93-9dea-4799-a886-8dfeef971dd4"
      unitRef="U_USD">-76000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e6152824-6482-450d-a1ed-1cd75cb82a46"
      decimals="-3"
      id="F_faf85d89-ce40-4d25-9635-b536d54f9923"
      unitRef="U_USD">-703434000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_807f1ef6-efe1-47cd-a1ac-f6eebc286522"
      decimals="-3"
      id="F_cd97cea6-2586-4d63-bde3-1f36fe6fd809"
      unitRef="U_USD">469076000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_4da76cd5-5865-4083-a0ab-47c7fb41907e"
      decimals="-3"
      id="F_a6b016f0-7765-42c5-9277-f7245f3165ea"
      unitRef="U_shares">525000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_069e0991-79db-49f3-896d-022fc3b13a5c"
      decimals="-3"
      id="F_7c775485-8402-412a-a50a-e514f6e72bf5"
      unitRef="U_USD">1845000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_2d4b3fe9-8b0b-4911-b277-dc1bfedb2c3e"
      unitRef="U_USD">1845000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_069e0991-79db-49f3-896d-022fc3b13a5c"
      decimals="-3"
      id="F_bd0d3575-fd82-49b5-9da1-75e8b8e168ca"
      unitRef="U_USD">41000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_4c1fa898-2214-45fd-be8b-a955c372cacc"
      unitRef="U_USD">41000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_33520c04-a8f9-4978-85e4-d1ef14e55fac"
      decimals="-3"
      id="F_7feff954-d84b-41a1-841c-21be8254c1f6"
      unitRef="U_USD">-72000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_52426f68-b0b9-4276-b11b-8763407feb83"
      unitRef="U_USD">-72000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_069e0991-79db-49f3-896d-022fc3b13a5c"
      decimals="-3"
      id="F_c881f494-32fe-4941-af56-8b1e9d349a7e"
      unitRef="U_USD">7373000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_55721930-bf7c-4a81-9576-bac126db69c8"
      unitRef="U_USD">7373000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="C_8df9e453-1166-43a2-b750-45ffb91958ef"
      decimals="-3"
      id="F_422e6d45-b422-48f3-a913-7c4d9de758d2"
      unitRef="U_USD">-53721000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_0eaf5a49-6c47-4a03-b8fa-7ef2a7bd2c17"
      unitRef="U_USD">-53721000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_1bef601d-1919-4e4e-87a0-ea9d5c9cb986"
      decimals="-3"
      id="F_4a632714-be1a-4264-89ec-1c3f1f782a06"
      unitRef="U_shares">159357000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_1bef601d-1919-4e4e-87a0-ea9d5c9cb986"
      decimals="-3"
      id="F_b5c81a4e-540d-4df9-be1f-8e9031309bd0"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9118ec0b-0a0b-4f37-8864-d70d86430dc5"
      decimals="-3"
      id="F_d1658f6c-8b88-4818-b671-dd18d6445015"
      unitRef="U_USD">1181829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bbcc59cc-72ab-42ea-869f-9a969577ae6b"
      decimals="-3"
      id="F_744ed7ed-85e0-469b-aaf0-1b985cd04800"
      unitRef="U_USD">-148000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5b2a4e5c-222a-4ad2-8abc-8bf73b709b4a"
      decimals="-3"
      id="F_909c4df0-594b-458d-9266-230fc953356b"
      unitRef="U_USD">-757155000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d23263c4-414c-41f5-b6d7-7e3e8f52cb59"
      decimals="-3"
      id="F_2d337ae8-cd72-4c99-84f8-c9a2e9a8fb61"
      unitRef="U_USD">424542000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_64e31c0d-24bf-466f-9221-63a78150b730"
      unitRef="U_USD">-67992000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_feafa436-56d7-4294-8fbd-bca98b29c600"
      unitRef="U_USD">-53721000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_99e173c5-acc5-4410-ab88-eb276a58f342"
      unitRef="U_USD">9324000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_fe3e5a86-a2e7-4c54-9e0d-03d132bdee3c"
      unitRef="U_USD">7373000</us-gaap:ShareBasedCompensation>
    <nmra:NoncashOperatingLeaseExpense
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_2803fe57-8213-4b9f-8f74-24ede2b295a5"
      unitRef="U_USD">877000</nmra:NoncashOperatingLeaseExpense>
    <nmra:NoncashOperatingLeaseExpense
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_78d33da1-274d-4675-9954-95ad3268d54b"
      unitRef="U_USD">791000</nmra:NoncashOperatingLeaseExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_45b003f1-fd42-46f1-b0c7-fc292e0d47ac"
      unitRef="U_USD">157000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_b19fa76f-1f73-4d35-8d13-79020cd31e6d"
      unitRef="U_USD">158000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_862dafa4-d42b-49d9-946d-f0375b6812b2"
      unitRef="U_USD">1289000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_bc895e70-9a2e-441d-a9fc-ae7a7b6f359c"
      unitRef="U_USD">1147000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_32bb8818-ddfb-4a2d-9c3c-7280aca90bcf"
      unitRef="U_USD">-966000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_13f79ecc-81a1-4bbe-b48d-3f1841a29052"
      unitRef="U_USD">-7351000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_874c28ac-87c1-4331-a67d-75298bf78d31"
      unitRef="U_USD">-2255000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_b26fdd3b-a628-4356-9f9c-6ced4faeda78"
      unitRef="U_USD">1155000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_10f10d4b-5f78-46b0-b8f4-e9f0356bd6da"
      unitRef="U_USD">1679000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_3425961f-6cf3-4c53-a956-54a3c29a04af"
      unitRef="U_USD">-4113000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_28014d62-ff70-48ff-90d4-0e18393a8468"
      unitRef="U_USD">-915000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_c284669d-dd43-46de-97ae-d9443364c47d"
      unitRef="U_USD">-802000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_91fba0f8-c2b9-4663-890c-6567601810e8"
      unitRef="U_USD">-59448000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_e121ae40-a87a-44a2-aab6-ab010c8df7fa"
      unitRef="U_USD">-42955000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_b8c853fa-e074-4587-9436-60ee03b9040c"
      unitRef="U_USD">44385000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_f5b794bd-e31f-4679-99be-c1428ff5d16a"
      unitRef="U_USD">185804000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_89c37a14-608a-4ab2-9f30-97104fc02d0d"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_52846d03-06d4-44f8-9343-b8f6324140b5"
      unitRef="U_USD">775000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <nmra:ProceedsFromMaturitiesOfMarketableSecurities
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_eb20802b-a5cc-41f6-94ad-cf0ac34171ef"
      unitRef="U_USD">88545000</nmra:ProceedsFromMaturitiesOfMarketableSecurities>
    <nmra:ProceedsFromMaturitiesOfMarketableSecurities
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_36177244-3b62-4062-a000-4529606e79c1"
      unitRef="U_USD">36578000</nmra:ProceedsFromMaturitiesOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_e269eda0-c9e8-466b-810a-1f1f04b16af3"
      unitRef="U_USD">44160000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_735c95ac-7e22-4162-a98d-abaf307fc6c4"
      unitRef="U_USD">-150001000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_db3cdb6e-d3ec-4793-93d2-5fbac1fc1b45"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_8cc4c8aa-71e6-457e-ae20-83291e00b7a7"
      unitRef="U_USD">1845000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_654f65c2-f052-400e-b5ff-5dcc51b42fee"
      unitRef="U_USD">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_2f92d3fd-b745-4253-8bad-3f93ea0b9803"
      unitRef="U_USD">1845000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_32cbe34c-5613-40ac-91fb-f66daad395cc"
      unitRef="U_USD">-15288000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_f422ee89-d92e-46ee-9589-2ee83a08ba56"
      unitRef="U_USD">-191111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_5d49b854-9ef5-4247-844b-24c696e21d50"
      unitRef="U_USD">143361000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_807f1ef6-efe1-47cd-a1ac-f6eebc286522"
      decimals="-3"
      id="F_7ce2cd79-5e37-45cb-a257-5970c1e69299"
      unitRef="U_USD">375251000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_a8283713-3084-4da6-b17f-cfdbb7d9304e"
      unitRef="U_USD">128073000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_d23263c4-414c-41f5-b6d7-7e3e8f52cb59"
      decimals="-3"
      id="F_126d729b-1047-4e94-b5bc-08307c14130b"
      unitRef="U_USD">184140000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_6fad22d3-8cec-4e87-bfe2-f8ed593b6c4c"
      unitRef="U_USD">126860000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d23263c4-414c-41f5-b6d7-7e3e8f52cb59"
      decimals="-3"
      id="F_43e0f5c2-a408-480f-af1d-00677f25487a"
      unitRef="U_USD">182927000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_45860af2-fda4-4d00-b4c2-9ae1f5ede103"
      unitRef="U_USD">1213000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_d23263c4-414c-41f5-b6d7-7e3e8f52cb59"
      decimals="-3"
      id="F_17f9bc40-16d0-4990-942c-bfc6562068e8"
      unitRef="U_USD">1213000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_a8fd7fad-b205-40ba-b770-0a8a44e3a8aa"
      unitRef="U_USD">128073000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_d23263c4-414c-41f5-b6d7-7e3e8f52cb59"
      decimals="-3"
      id="F_f40246fe-127f-42ef-952e-943b73249a99"
      unitRef="U_USD">184140000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_282dcd20-d41e-4e6b-aec4-3def916e031e">&lt;p id="organization_and_liquidity" style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.	&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Organization and Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Neumora Therapeutics, Inc. (the Company), was originally incorporated in the State of Delaware in November 2019, and is headquartered in Watertown, Massachusetts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. The Company&#x2019;s therapeutic pipeline currently consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;seven&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The Company&#x2019;s most advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of major depressive disorder (MDD), which the Company believes has the potential to provide significant advantages relative to the standard of care, if approved. Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company&#x2019;s next most advanced product candidate is NMRA-511, a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer&#x2019;s disease (AD). The Company is advancing a Phase 1b signal-seeking study investigating NMRA-511 initially in healthy elderly adult participants and then people with agitation associated with dementia due to AD. The Company&#x2019;s M4 positive allosteric modular (PAM) franchise comprises multiple novel compounds that each have different chemical composition and what the Company believes are optimal pharmacological properties, which have demonstrated robust activity in preclinical efficacy models and high selectivity for the M4 receptor subtype.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025, the Company has devoted a significant portion of its financial resources and efforts to building its organization, acquiring technologies and companies, executing clinical and preclinical studies, conducting research and development, identifying and developing potential product candidates, building its precision neuroscience tools, organizing and staffing the Company, business planning, establishing, maintaining and protecting its intellectual property portfolio, raising capital and providing general and administrative support for these operations. The Company has not generated revenue from the sale of products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has incurred net losses and negative cash flows from operations since inception and as of March 31, 2025, had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,015.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. As of March 31, 2025, the Company had cash, cash equivalents and marketable securities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which are available to fund future operations. The Company believes that its existing cash, cash equivalents and marketable securities as of March 31, 2025 will be sufficient to support operations for at least the next 12 months from the date these condensed consolidated financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expects to incur additional losses in the future as it continues its research and development efforts, advances its product candidates through preclinical and clinical development, enhances its precision&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;neuroscience approach and programs, expands its product pipeline, potentially seeks regulatory approval, prepares for potential commercialization, as well as hires additional personnel, protects its intellectual property and potentially grows its business. The Company will need to raise additional capital to support its continuing operations and pursue its long-term business plan, including to complete the development and commercialization of its product candidates, if approved. Such activities are subject to significant risks and uncertainties, including clinical failure which can impact the Company&#x2019;s ability to secure additional funding. The Company expects to finance its cash needs through a combination of public or private equity offerings or debt financings or other capital sources, which may include strategic collaborations or other arrangements with third parties, or other sources of financing. However, there is no guarantee that any of these financing or opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <nmra:NumberOfClinicalAndPreclinicalNeurosciencePrograms
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="INF"
      id="F_06df7f0e-77f4-4e64-85c0-8122244d9c14"
      unitRef="U_Program">7</nmra:NumberOfClinicalAndPreclinicalNeurosciencePrograms>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_6167264c-1f42-4063-b5e7-f295414754c1"
      decimals="-5"
      id="F_0452064d-047a-4d3c-8982-0c1a4dd77983"
      unitRef="U_USD">1015200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_6167264c-1f42-4063-b5e7-f295414754c1"
      decimals="-5"
      id="F_98ee860b-7db2-44da-8d4e-5bffb46937b3"
      unitRef="U_USD">249400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_a316f933-a014-4d67-9987-e9c813519092">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.	Summary of Significant Accounting Policies and Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unaudited Interim Condensed Consolidated Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The condensed consolidated balance sheet as of March 31, 2025, condensed consolidated statements of operations and comprehensive loss, statement of stockholders&#x2019; equity (deficit) for the three months ended March 31, 2025 and 2024, and the condensed consolidated statements of cash flows for the three months ended March 31, 2025 and 2024, and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#x2019;s consolidated financial position, results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements as of and for the year ended December 31, 2024 included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 3, 2025.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management&#x2019;s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, the fair value of the Company&#x2019;s common stock, stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the Company's ability to successfully develop, manufacture, and market any approved products; the Company's ability to obtain regulatory approval from the U.S. Food and Drug Administration or foreign regulatory agencies prior to any commercial sales; new technological innovations; dependence on key personnel, protection of intellectual property; compliance with governmental regulations; uncertainty of market acceptance of any approved products; product liability; and the need to obtain additional financing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company invests its excess cash in marketable debt securities with high credit ratings including but not limited to money market funds, securities issued by the U.S. government and its agencies, commercial paper and corporate debt securities that are accounted for as available-for-sale and carried at fair value. Marketable securities are classified as short-term or long-term based on the maturity date and their availability to meet current operating requirements. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income in the consolidated statements of operations and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;comprehensive loss. Realized gains and losses on marketable securities, if any, are included in other income (expense), net. The cost of securities sold is determined based on the trade date using the specific identification method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company periodically assesses its available-for-sale debt securities for impairment. For debt securities in an unrealized loss position, this assessment first considers the Company&#x2019;s intent to sell, or whether it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#x2019;s amortized cost basis is written down to fair value within other income (expense), net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security is considered, among other factors. If this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded in other income (expense), net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as provision for (or reversal of) credit loss expense. Losses are charged against the allowance when management believes the un-collectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. These changes are recorded in other income (expense), net.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company measures fair value by maximizing the use of observable inputs, where available, and minimizing the use of unobservable inputs when measuring fair value. Financial assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized in the fair value hierarchy based upon the lowest level of input that is significant to the fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses primarily consist of internal research and development expense, including personnel-related expenses (such as salaries, benefits and noncash stock-based compensation) and other expenses, including laboratory supplies and other non-capital equipment utilized for in-house research, research and consulting expenses, software development costs, license fees and allocated expenses, including facilities costs and depreciation and amortization; external research and development expenses incurred under arrangements with service providers conducting research and development services on its behalf, such as contract research organizations (CROs), preclinical testing organizations and contract manufacturing organizations (CMOs). Payments made prior to the receipt of goods or services to be used in research and development are capitalized, evaluated for current or long-term classification, and included in prepaid expenses and other current assets or other assets in the consolidated balance sheets based on when the goods are received or the services are expected to be received or consumed, and recognized in research and development expenses when they are realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to estimate expenses resulting from its obligations under contracts with service providers in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in cash flows that do not match the periods over which materials or services are provided. The Company estimates and records&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;accrued expenses for the related research and development activities based on the level of services performed but not yet invoiced pursuant to agreements established with its service providers, according to the progress of preclinical studies, clinical trials or related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the course of a clinical trial, the rate of expense recognition is adjusted if actual results differ from the Company&#x2019;s estimates. The Company estimates accrued expenses as of each balance sheet date in its consolidated financial statements based on the facts and circumstances known at that time. The clinical trial accrual is dependent in part upon the timely and accurate reporting of CROs, CMOs and other service providers. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its estimate may vary from the actual results. To date, the Company has not experienced material differences between its accrued expenses and actual expenses.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity (deficit) that are excluded from net loss, such as unrealized losses on the Company&#x2019;s available-for-sale marketable securities.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company was an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) until December 31, 2024. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has evaluated whether any accounting standards which it previously delayed adopting would have a material impact to the consolidated financial statements or disclosures and concluded that there is no such material impact.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the Financial Accounting Standards Board, or FASB, issued ASU 2024-04, Induced Conversions of Convertible Debt Instruments, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard is effective for annual reporting periods beginning after December 15, 2025, and interim periods within those annual periods. We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which is intended to improve disclosures by requiring additional information about specific expense categories in the notes to the financial statements on an annual and interim basis. The standard will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The standard updates may be applied on either a prospective or retrospective basis. We are currently evaluating the disclosure requirements related to this new standard.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(ASU 2023-09), which requires issuers to make additional disclosures on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, and disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 will be effective for the Company as of January 1, 2025 for annual periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_90e33afe-590a-4aa9-90c1-22b3633ffbed">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <nmra:UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_d36a4791-6823-4c45-b08b-470662a5c504">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unaudited Interim Condensed Consolidated Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The condensed consolidated balance sheet as of March 31, 2025, condensed consolidated statements of operations and comprehensive loss, statement of stockholders&#x2019; equity (deficit) for the three months ended March 31, 2025 and 2024, and the condensed consolidated statements of cash flows for the three months ended March 31, 2025 and 2024, and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#x2019;s consolidated financial position, results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements as of and for the year ended December 31, 2024 included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 3, 2025.&lt;/span&gt;&lt;/p&gt;</nmra:UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_5cc2f84e-7476-4b7c-8858-d12d44a42ab8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management&#x2019;s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, the fair value of the Company&#x2019;s common stock, stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <nmra:RisksAndUncertaintiesPolicyTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_d2bedbc3-926a-4764-852d-493187d04945">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the Company's ability to successfully develop, manufacture, and market any approved products; the Company's ability to obtain regulatory approval from the U.S. Food and Drug Administration or foreign regulatory agencies prior to any commercial sales; new technological innovations; dependence on key personnel, protection of intellectual property; compliance with governmental regulations; uncertainty of market acceptance of any approved products; product liability; and the need to obtain additional financing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</nmra:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_b6fa6560-22a8-449a-8312-70b3a44213f1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All highly liquid investments, including money market funds, with original maturities of three months or less at the time of purchase are considered to be cash equivalents. All of the Company&#x2019;s cash equivalents have liquid markets and high credit ratings. The Company maintains its cash in bank deposits and other accounts.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_3432e995-3f1b-4ef8-884b-f86fc150cac6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash consists of a facility lease agreement collateralized by a letter of credit pursuant to certain banking and lease agreements. Restricted cash, which is unavailable for a period of less than one year from the consolidated balance sheet date, is classified as a current asset.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_b528968c-4095-4a70-8bf2-710533f4dab1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company invests its excess cash in marketable debt securities with high credit ratings including but not limited to money market funds, securities issued by the U.S. government and its agencies, commercial paper and corporate debt securities that are accounted for as available-for-sale and carried at fair value. Marketable securities are classified as short-term or long-term based on the maturity date and their availability to meet current operating requirements. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income in the consolidated statements of operations and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;comprehensive loss. Realized gains and losses on marketable securities, if any, are included in other income (expense), net. The cost of securities sold is determined based on the trade date using the specific identification method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company periodically assesses its available-for-sale debt securities for impairment. For debt securities in an unrealized loss position, this assessment first considers the Company&#x2019;s intent to sell, or whether it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#x2019;s amortized cost basis is written down to fair value within other income (expense), net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security is considered, among other factors. If this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded in other income (expense), net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as provision for (or reversal of) credit loss expense. Losses are charged against the allowance when management believes the un-collectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. These changes are recorded in other income (expense), net.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_cb24736c-7b65-4ae4-81a0-4cb69a4c430c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company measures fair value by maximizing the use of observable inputs, where available, and minimizing the use of unobservable inputs when measuring fair value. Financial assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized in the fair value hierarchy based upon the lowest level of input that is significant to the fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:36pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_d140766e-af4c-4a46-9fd8-d3ef30188da7">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses primarily consist of internal research and development expense, including personnel-related expenses (such as salaries, benefits and noncash stock-based compensation) and other expenses, including laboratory supplies and other non-capital equipment utilized for in-house research, research and consulting expenses, software development costs, license fees and allocated expenses, including facilities costs and depreciation and amortization; external research and development expenses incurred under arrangements with service providers conducting research and development services on its behalf, such as contract research organizations (CROs), preclinical testing organizations and contract manufacturing organizations (CMOs). Payments made prior to the receipt of goods or services to be used in research and development are capitalized, evaluated for current or long-term classification, and included in prepaid expenses and other current assets or other assets in the consolidated balance sheets based on when the goods are received or the services are expected to be received or consumed, and recognized in research and development expenses when they are realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to estimate expenses resulting from its obligations under contracts with service providers in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in cash flows that do not match the periods over which materials or services are provided. The Company estimates and records&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;accrued expenses for the related research and development activities based on the level of services performed but not yet invoiced pursuant to agreements established with its service providers, according to the progress of preclinical studies, clinical trials or related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the course of a clinical trial, the rate of expense recognition is adjusted if actual results differ from the Company&#x2019;s estimates. The Company estimates accrued expenses as of each balance sheet date in its consolidated financial statements based on the facts and circumstances known at that time. The clinical trial accrual is dependent in part upon the timely and accurate reporting of CROs, CMOs and other service providers. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its estimate may vary from the actual results. To date, the Company has not experienced material differences between its accrued expenses and actual expenses.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_219e8103-94a6-44b1-82c1-8c3c2091fc62">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity (deficit) that are excluded from net loss, such as unrealized losses on the Company&#x2019;s available-for-sale marketable securities.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <nmra:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_3e80b321-c55a-4c70-9b7b-f12a2d6b4dc7">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company was an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) until December 31, 2024. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has evaluated whether any accounting standards which it previously delayed adopting would have a material impact to the consolidated financial statements or disclosures and concluded that there is no such material impact.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</nmra:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_fc209ae5-e1ea-4593-8846-ae2292b8e1f8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the Financial Accounting Standards Board, or FASB, issued ASU 2024-04, Induced Conversions of Convertible Debt Instruments, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard is effective for annual reporting periods beginning after December 15, 2025, and interim periods within those annual periods. We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which is intended to improve disclosures by requiring additional information about specific expense categories in the notes to the financial statements on an annual and interim basis. The standard will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The standard updates may be applied on either a prospective or retrospective basis. We are currently evaluating the disclosure requirements related to this new standard.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(ASU 2023-09), which requires issuers to make additional disclosures on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, and disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 will be effective for the Company as of January 1, 2025 for annual periods. The Company is evaluating the impact of this ASU on its condensed consolidated financial statements.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_197b756b-216d-46d7-aeb6-dcecd9d6aac0">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.	Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the amortized cost and fair value of the Company&#x2019;s cash equivalents and marketable securities by major investment category for the periods indicated:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;198,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;198,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;165,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;165,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025, the Company has not realized any material gains or losses on its marketable securities, including any impairment charges on its securities related to expected credit losses. As of March 31, 2025, the aggregate difference between the amortized cost and fair value of each security in an unrealized loss position was de minimis. Since any provision for expected credit losses for a security held is limited to the amount the fair value is less than its amortized cost, no allowance for expected credit loss was deemed necessary at March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (see Note 4).&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_9d789624-11b0-4dd7-a361-3615d76ad771">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the amortized cost and fair value of the Company&#x2019;s cash equivalents and marketable securities by major investment category for the periods indicated:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;198,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;198,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;165,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;165,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9061b628-1cbb-40d6-878c-d538a8e5434f"
      decimals="-3"
      id="F_d12d58d2-0283-47b4-99d1-b5c08a8a01cb"
      unitRef="U_USD">76347000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_e5572f63-a9f0-46b3-8d24-1600baa94c52"
      decimals="-3"
      id="F_e72748fc-d30c-4cb2-81d1-1ae08f6788f2"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_e5572f63-a9f0-46b3-8d24-1600baa94c52"
      decimals="-3"
      id="F_09f099af-b85f-4ced-8ea1-e7c1e53330df"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9061b628-1cbb-40d6-878c-d538a8e5434f"
      decimals="-3"
      id="F_d4b18ff9-68ea-4f40-8129-01a2a5641813"
      unitRef="U_USD">76347000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ffa0d7b0-15ec-4da1-b744-c829194fe468"
      decimals="-3"
      id="F_8b57e7dc-4bb8-4a57-9ae3-0f57cac7daf8"
      unitRef="U_USD">76347000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_34728959-32a0-44fc-a13c-2f71e43ae7e3"
      decimals="-3"
      id="F_a04b4743-1709-4899-92f6-cbf11b0f8a81"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_34728959-32a0-44fc-a13c-2f71e43ae7e3"
      decimals="-3"
      id="F_c0e5d716-ec4a-4264-9eda-15c0cc6818bd"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ffa0d7b0-15ec-4da1-b744-c829194fe468"
      decimals="-3"
      id="F_273d5660-39f5-49f7-a85a-34de641fa168"
      unitRef="U_USD">76347000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2872bc3f-ac79-4fed-ade2-77671074619e"
      decimals="-3"
      id="F_2def81d6-2f9f-48d6-8448-0977764916a5"
      unitRef="U_USD">80630000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_e899c8c7-d7d0-4f74-ac13-bf387dd80ce7"
      decimals="-3"
      id="F_750255af-8c8c-4a80-a64d-f3eed127184a"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_e899c8c7-d7d0-4f74-ac13-bf387dd80ce7"
      decimals="-3"
      id="F_080616dc-16dc-44ad-9da1-6f3f5310ced8"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2872bc3f-ac79-4fed-ade2-77671074619e"
      decimals="-3"
      id="F_0841a631-df83-4fcc-9766-4072b5c02f3d"
      unitRef="U_USD">80627000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4ef13920-7a05-4ac0-99bb-9c2e976e10f2"
      decimals="-3"
      id="F_a9cbea89-08de-4b20-9a89-20a1ec649d28"
      unitRef="U_USD">607000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_3484d184-2e57-4ae8-ae41-4d03630e1535"
      decimals="-3"
      id="F_f5c843c8-684c-4eee-9545-432f4326366d"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_3484d184-2e57-4ae8-ae41-4d03630e1535"
      decimals="-3"
      id="F_3b167686-afbb-4d01-bfd9-46de8aa6c081"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4ef13920-7a05-4ac0-99bb-9c2e976e10f2"
      decimals="-3"
      id="F_46cb08da-7862-4896-8f58-f8af21b7a694"
      unitRef="U_USD">607000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9b4cda2e-b933-47c6-a24f-6f190752e6c8"
      decimals="-3"
      id="F_de07d57e-dfe5-468f-8b4a-2be4419ad3dc"
      unitRef="U_USD">26969000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_e0b073e0-9ae4-4fbf-ac18-8ac5ee41c4c1"
      decimals="-3"
      id="F_12d66d1b-7332-43a7-a8ca-cd07dc0d7d26"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_e0b073e0-9ae4-4fbf-ac18-8ac5ee41c4c1"
      decimals="-3"
      id="F_b8311e92-92a8-4355-bf8d-9d89ba92bc67"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9b4cda2e-b933-47c6-a24f-6f190752e6c8"
      decimals="-3"
      id="F_c0fff5b7-07ec-4880-971a-deec5cf484a3"
      unitRef="U_USD">26970000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f17f2417-a74c-4179-81fe-cbc4a177ea8b"
      decimals="-3"
      id="F_b549b10b-e592-4dbe-ac20-fb1a39c5256c"
      unitRef="U_USD">14290000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_fc26cf16-194d-42e9-bd78-03837763f10b"
      decimals="-3"
      id="F_7645174d-5ea4-466b-838b-75fbda3592f2"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_fc26cf16-194d-42e9-bd78-03837763f10b"
      decimals="-3"
      id="F_c0ee2ab6-ad95-4e6a-983a-883144d6ce4f"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f17f2417-a74c-4179-81fe-cbc4a177ea8b"
      decimals="-3"
      id="F_a2fb6647-6a1c-48df-a61b-f0f7fca46cf0"
      unitRef="U_USD">14289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0cbb0a62-efc0-4cdb-94b9-ad0c8c0323da"
      decimals="-3"
      id="F_6af4793e-af3e-4d3b-89b1-6397b51d064b"
      unitRef="U_USD">122496000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_8ae50382-fe31-444e-adfd-c5c5cf08f02f"
      decimals="-3"
      id="F_a3163dd1-b86f-4554-a248-625fc6c91f85"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_8ae50382-fe31-444e-adfd-c5c5cf08f02f"
      decimals="-3"
      id="F_fa5f6c9c-d64f-4eec-8d6e-ff0b7ef688b0"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0cbb0a62-efc0-4cdb-94b9-ad0c8c0323da"
      decimals="-3"
      id="F_3080a179-5fef-490c-b1e3-a8f322151a31"
      unitRef="U_USD">122493000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_6e215e1a-19ec-497e-b8ff-58424018757d"
      unitRef="U_USD">198843000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_c961b09b-fde8-497a-9297-d0091ff85d36"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_94ff201a-c189-4411-b5d7-52622fe2314d"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_86b5778d-a88f-4d49-9305-010b863e2e0d"
      unitRef="U_USD">198840000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d3ac0816-6766-4808-8c6b-73bdf51bb772"
      decimals="-3"
      id="F_523c1dc2-4c55-47a4-8d13-c3e63ed921e0"
      unitRef="U_USD">94411000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_67e82a6b-31f5-4d3a-8d28-c6d447c17553"
      decimals="-3"
      id="F_9307d7b3-202c-45c0-b437-c33a3e488ec1"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_67e82a6b-31f5-4d3a-8d28-c6d447c17553"
      decimals="-3"
      id="F_93323323-7172-47f6-b09c-7f08176ea472"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d3ac0816-6766-4808-8c6b-73bdf51bb772"
      decimals="-3"
      id="F_ea529026-bba8-4c60-842c-33fb159d1671"
      unitRef="U_USD">94411000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1aca905f-ee26-4555-b248-631ec9df757a"
      decimals="-3"
      id="F_527b2bc2-d3ec-4f53-9aad-9a716f115e63"
      unitRef="U_USD">30875000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_0cd17fb6-6272-4a76-8980-45ff567d9207"
      decimals="-3"
      id="F_ac653eb6-9d39-4e58-88a5-f741b63f354b"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_0cd17fb6-6272-4a76-8980-45ff567d9207"
      decimals="-3"
      id="F_7bd40c81-8e30-49f5-b3b0-d24cbfc888bf"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1aca905f-ee26-4555-b248-631ec9df757a"
      decimals="-3"
      id="F_bb37fd59-fb30-4cb3-9185-9112a29421aa"
      unitRef="U_USD">30881000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d4678025-d799-4a17-bfbf-952b85ed2d13"
      decimals="-3"
      id="F_a117a334-bf01-452d-8d05-809c17dd709e"
      unitRef="U_USD">125286000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_4d3885b7-eb3e-4bdb-9e6c-4fd241fd9a03"
      decimals="-3"
      id="F_d60bcbc9-8b76-4d80-bb4e-75e06160f24d"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_4d3885b7-eb3e-4bdb-9e6c-4fd241fd9a03"
      decimals="-3"
      id="F_e5c7268b-3f7d-4c70-b759-5e2eac3b356c"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d4678025-d799-4a17-bfbf-952b85ed2d13"
      decimals="-3"
      id="F_b30d2aee-172b-4528-83ec-b1940808a086"
      unitRef="U_USD">125292000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_572b967f-2f74-487f-ae14-180bdd868be9"
      decimals="-3"
      id="F_0d90b62e-df9a-44b1-b025-a2f073a281dd"
      unitRef="U_USD">61374000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_69427e48-5aaa-40a8-b2f4-3bbf2e2277d4"
      decimals="-3"
      id="F_d1865044-e2bd-4096-8919-be8e1341bd7b"
      unitRef="U_USD">11000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_69427e48-5aaa-40a8-b2f4-3bbf2e2277d4"
      decimals="-3"
      id="F_b7d7babc-16ac-4678-80a7-3099340ca31a"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_572b967f-2f74-487f-ae14-180bdd868be9"
      decimals="-3"
      id="F_741a2f88-6887-47b3-964e-c4206367e013"
      unitRef="U_USD">61383000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_cac684c1-58c1-4056-87fb-85dffbb9e345"
      decimals="-3"
      id="F_abaf6705-8407-449f-acd5-12ea02f8fb3c"
      unitRef="U_USD">1918000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_609a5a5a-15b7-4aa9-b8b5-78d98fae8999"
      decimals="-3"
      id="F_620c8990-8120-4510-a8db-6fdd5eeb21c1"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_609a5a5a-15b7-4aa9-b8b5-78d98fae8999"
      decimals="-3"
      id="F_a73043a3-a219-434c-8ba2-7ecd7a9b0abe"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_cac684c1-58c1-4056-87fb-85dffbb9e345"
      decimals="-3"
      id="F_14bc3e7f-dfde-4a9f-b3e4-4176889c0100"
      unitRef="U_USD">1918000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_45866c85-796b-42f6-a180-2cc89ed0ddd6"
      decimals="-3"
      id="F_d1d69e9c-bcb8-4071-a6d4-87826ad02f3d"
      unitRef="U_USD">74411000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_05db645f-f4bf-46f3-bf4e-7f20ec31940c"
      decimals="-3"
      id="F_313788a3-b613-40ad-be8b-e9a1c38664f4"
      unitRef="U_USD">36000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_05db645f-f4bf-46f3-bf4e-7f20ec31940c"
      decimals="-3"
      id="F_f1b04699-2596-4543-8247-5849601a2938"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_45866c85-796b-42f6-a180-2cc89ed0ddd6"
      decimals="-3"
      id="F_57cb4d51-2f01-4a6f-ad71-268a4d149e02"
      unitRef="U_USD">74444000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_bf4dcd0a-343d-4af9-b2ff-82d99b4a270b"
      decimals="-3"
      id="F_d4a10dab-23f9-4fbb-a44e-00103ac32cf3"
      unitRef="U_USD">27671000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_91940b71-4a64-44b8-8e19-43b82923017e"
      decimals="-3"
      id="F_a65be563-c326-4e28-9a7c-80a89893280d"
      unitRef="U_USD">17000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_91940b71-4a64-44b8-8e19-43b82923017e"
      decimals="-3"
      id="F_0c0e9d92-be08-4295-807e-ae6f1bb1c405"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bf4dcd0a-343d-4af9-b2ff-82d99b4a270b"
      decimals="-3"
      id="F_38373d98-d4f4-4ebc-99c7-ab57f5c7719e"
      unitRef="U_USD">27685000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3c5a3125-1df8-4cfd-82c2-6439f4fce770"
      decimals="-3"
      id="F_e58d8db1-9ea6-4bbb-a30e-a207fe438e81"
      unitRef="U_USD">165374000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_2c7eaaa1-bb2c-4bb1-811e-b3ed93a9e5b0"
      decimals="-3"
      id="F_d961727f-3355-4536-bd62-cf5bbd66c313"
      unitRef="U_USD">64000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_2c7eaaa1-bb2c-4bb1-811e-b3ed93a9e5b0"
      decimals="-3"
      id="F_4b2182f1-2d64-4db0-b583-f9cbe23de869"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3c5a3125-1df8-4cfd-82c2-6439f4fce770"
      decimals="-3"
      id="F_fe6abfa9-e6e8-4c24-a73d-e8dd90cfb4f4"
      unitRef="U_USD">165430000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_3cd8f73a-29c3-4d90-97fb-9aab9ff7b779"
      unitRef="U_USD">290660000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_cdd08ec8-fc48-459d-ae7a-3d50a476e424"
      decimals="-3"
      id="F_3e9a59a6-8f58-4d3e-936c-1edc9e7a78b0"
      unitRef="U_USD">70000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_cdd08ec8-fc48-459d-ae7a-3d50a476e424"
      decimals="-3"
      id="F_4aabac67-35cd-4637-93aa-57958b73b9e1"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_f09eb14c-b3ca-4ec8-a797-3e999dd1306e"
      unitRef="U_USD">290722000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_9c98d713-4ebf-46de-8873-1e34e10dfa8a">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4.	Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including prepaid expenses and other current assets, accounts payable, accrued liabilities and the current portion of operating lease liabilities approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis by level within the valuation hierarchy:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;198,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds are highly liquid and actively traded marketable securities that generally transact at a stable $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; net asset value representing its estimated fair value. The Company estimates the fair value of its commercial paper, certificates of deposit, U.S. government and agency debt securities, and corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data, and other observable inputs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_c641c61f-69c2-467a-a4a6-968086f0c7e0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis by level within the valuation hierarchy:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;198,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5a79bd11-7094-4ffc-951c-6a83cbffb588"
      decimals="-3"
      id="F_af5c1100-87fa-46a2-ad28-0b68d565a601"
      unitRef="U_USD">76347000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a2d3f823-77c5-4f3a-8379-db86ade0a660"
      decimals="-3"
      id="F_4fd88428-9265-4385-ab33-a8d1b1273960"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_60c0ef16-d311-4eff-b99d-ea396190548b"
      decimals="-3"
      id="F_82a71fd9-86f9-4a7a-9c46-24d03cff87b7"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8983212a-31bb-40e6-aad9-72c31bd8b3ec"
      decimals="-3"
      id="F_0976b9c0-e4af-49c0-a29e-c0c105f08c45"
      unitRef="U_USD">76347000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2b244c9b-1ded-43bc-820f-3c639a651b27"
      decimals="-3"
      id="F_0252935d-44e7-46cb-aabb-3c89ad7370d8"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8930b52e-d90e-4036-b728-884065a23c99"
      decimals="-3"
      id="F_f415ae7d-95a5-418a-aa7a-069dacf4140f"
      unitRef="U_USD">80627000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_be0b1b72-5d49-463b-ab77-61e5bac1a983"
      decimals="-3"
      id="F_98a5a348-a580-4d19-870f-b0da0a81e24c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f31ea84f-b25c-49d3-b5e0-ea4d01b60c1a"
      decimals="-3"
      id="F_de710dde-e69c-4232-b173-57e1279d0657"
      unitRef="U_USD">80627000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dca1c4c1-2e7e-4f8b-8535-f8ba404884cc"
      decimals="-3"
      id="F_6f51d93a-d9ac-4a90-ae31-5c6e93abe677"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c5716e30-2845-4e75-9c82-0ead8f11e3d5"
      decimals="-3"
      id="F_3d983a82-3744-4437-864c-7dbd8a7af741"
      unitRef="U_USD">607000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4e37b9ab-9112-4171-96d3-a28df5c5f26d"
      decimals="-3"
      id="F_1e414534-deda-467a-b37c-d952c5a9f19c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0a97a9b7-374a-4ba2-8c70-91464eb57c67"
      decimals="-3"
      id="F_c2e1d2e2-e7ed-40f2-8a60-f57036b86cd0"
      unitRef="U_USD">607000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2a459aad-9b00-4fcc-9e37-26666bf29cc0"
      decimals="-3"
      id="F_e62846f5-8d20-42cc-beff-50f0f7708a6c"
      unitRef="U_USD">26970000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8a4d11b0-e864-40f5-af40-5075fb6dcc55"
      decimals="-3"
      id="F_6bc6c208-0ef8-48b9-90c4-e0114cd58103"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8581f7af-0c61-4b18-9fa5-437addc36bcf"
      decimals="-3"
      id="F_d4c6f855-fe25-4290-9a1d-4d138e2b7dd7"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f63b1f37-86a2-476e-9394-a9737eb501a9"
      decimals="-3"
      id="F_dab1eaa7-4c4e-4932-96a4-13727c3d7139"
      unitRef="U_USD">26970000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4dc3cc35-4428-4ddc-abab-0af3843650aa"
      decimals="-3"
      id="F_242614fd-2cae-410e-83ff-050a2769b49f"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1de420c3-74a2-46db-8f45-5e14a2cb894c"
      decimals="-3"
      id="F_f26d5fb3-fc78-470d-b4ce-2e0c3822476f"
      unitRef="U_USD">14289000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1bc0b95c-7620-484e-a74a-a6ff2b9e28be"
      decimals="-3"
      id="F_7a6aa5e1-ae38-4821-a775-527cc1d2a83e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f56f8fbd-ff2d-4bcf-9a02-48dfad75f890"
      decimals="-3"
      id="F_aa3e3dfa-5376-4a4f-bcde-f87c95de4e75"
      unitRef="U_USD">14289000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_96e4575f-22fb-4510-8c56-dcf2ef26b887"
      decimals="-3"
      id="F_d51dd7a4-0f6b-4f4e-9dc8-389bfe3c298f"
      unitRef="U_USD">103317000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_345b87e2-e0de-4a5f-bd10-8a06638a2087"
      decimals="-3"
      id="F_ca9c6844-80e6-48f0-8edc-529260ac1892"
      unitRef="U_USD">95523000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ccb36bdc-b5f6-4cd8-9f8d-4b1d849d2f44"
      decimals="-3"
      id="F_dfe21d95-07ed-4cf6-aa39-7c211f5e73a3"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_27e8bd25-1d8a-462a-a5a8-60599bc36dcb"
      decimals="-3"
      id="F_23709699-4570-4939-af4e-5cf741c5a27e"
      unitRef="U_USD">198840000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_453a453b-8844-4a63-a3ea-cec4fbf05356"
      decimals="-3"
      id="F_ecfd3923-2fa7-457e-8082-541e6ad91228"
      unitRef="U_USD">94411000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_89c9cc8c-f7d3-4aa1-8971-7f4acc54dceb"
      decimals="-3"
      id="F_8e5361a2-1a7c-49a9-85d2-bf95196b7f11"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_389f4cfd-1035-4a63-8472-a8b0535f9979"
      decimals="-3"
      id="F_e9419917-e618-41cc-901f-8cb6c010ea7c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_29d4b3f4-84bc-4e37-a42c-c5ddac7501e7"
      decimals="-3"
      id="F_30488188-a88e-40c7-85ad-df43b653cf78"
      unitRef="U_USD">94411000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_93d4bd12-ee53-4993-8268-9e9637ffeca1"
      decimals="-3"
      id="F_9846ff60-e870-4289-91a0-a59f76237e96"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_12814edb-2555-40ce-8b79-cd767af2d069"
      decimals="-3"
      id="F_1a8feb07-a14f-4b21-9f15-e08246133922"
      unitRef="U_USD">30881000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_107c6cfe-84dd-41a5-a2a4-ae925e0ea374"
      decimals="-3"
      id="F_d8596dc5-7770-4381-bc4c-2097b357ffcf"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_957f0675-75da-45b6-8d5a-5d4c59c2f42a"
      decimals="-3"
      id="F_3b0a6c9b-09d6-4a6e-8035-748eed9841ba"
      unitRef="U_USD">30881000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_674b4626-69f1-4f21-a46c-b4994d0e271f"
      decimals="-3"
      id="F_50c3371d-bffa-463c-ac09-6bc4167ba060"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bec87db7-aba1-42c1-89de-287859477b6e"
      decimals="-3"
      id="F_4b338c0e-66ae-4bdd-94a9-a02fdde66343"
      unitRef="U_USD">61383000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_05cc4820-f2b7-4d8d-a300-c73727f10eea"
      decimals="-3"
      id="F_0108a3f5-b95b-417c-8197-ad147fdaf75e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7b7d5dac-7754-4da3-bb2b-8b1d57fcd91d"
      decimals="-3"
      id="F_1f54eef6-a68e-4817-be86-e9536ebf6ecd"
      unitRef="U_USD">61383000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_07657077-ad7d-435a-b4d6-1b88f79c2724"
      decimals="-3"
      id="F_e2b107bb-bafa-41bd-8401-ce4409d6b7ea"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b89706ed-11c0-4574-9fec-db2b478b98ff"
      decimals="-3"
      id="F_a21aa15f-9354-4048-87ec-20669d87a907"
      unitRef="U_USD">1918000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c7f8c769-dcee-4641-8788-0ecdfd5e085d"
      decimals="-3"
      id="F_88667cbb-e8bd-415e-aa52-282baca21268"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9a04f240-c069-4dc2-8d21-d62bfc7e531e"
      decimals="-3"
      id="F_05d90979-5e96-4565-9ae1-b7e10f0eeff6"
      unitRef="U_USD">1918000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_62cf7b31-5216-483b-b0b1-4177e5c19093"
      decimals="-3"
      id="F_d3f643ba-385d-4935-adb0-8727e98b6d60"
      unitRef="U_USD">74444000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7e9a4d20-f83c-40d6-a5ea-7a0380c08cf8"
      decimals="-3"
      id="F_0e016191-6edb-4874-b6ae-6e9772f18c7c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4a189432-6771-4924-b99e-f1ee33b187a1"
      decimals="-3"
      id="F_1829398b-8d8b-494d-988c-813557433e11"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_45cdde70-3358-4569-a949-fee006c59617"
      decimals="-3"
      id="F_fa6beda2-7ad3-41ea-be4e-5c3e16873d98"
      unitRef="U_USD">74444000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_247cd15b-eac5-41fa-89ce-c12599a45e39"
      decimals="-3"
      id="F_db8d6743-9348-4f47-8d34-2e901c135aa8"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_de855e05-78f1-4034-9dd2-99edd71f6a01"
      decimals="-3"
      id="F_264bd2ae-4f3f-44e4-9390-b1cbf6c11f4d"
      unitRef="U_USD">27685000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ff6c1c0c-dab0-4730-8b13-70db93c2b6cd"
      decimals="-3"
      id="F_e2136da1-4c0e-4574-968f-ca1b7ad28e99"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_061cf2c5-5b6a-43b7-9349-feb9de83c3de"
      decimals="-3"
      id="F_0e2d5ec0-4949-47b2-b74a-8d7e05f70777"
      unitRef="U_USD">27685000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_43d828f3-9822-4b63-a7d7-23b01fed21ef"
      decimals="-3"
      id="F_fde979bc-52f0-4fef-a9ea-9fd2096d171b"
      unitRef="U_USD">168855000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_28c81270-b763-4f43-9e26-86aed60a8e6a"
      decimals="-3"
      id="F_01f9d530-0260-486c-ae27-95c18322c7a1"
      unitRef="U_USD">121867000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_948e3436-40f4-4902-9557-b188a3de6f02"
      decimals="-3"
      id="F_50e7146a-0566-4068-972c-409aa07288e5"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9da9e2d3-d2c9-4624-9a0f-41478107481a"
      decimals="-3"
      id="F_3b99a55b-a4d5-4018-a607-c012498edc4d"
      unitRef="U_USD">290722000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:NetAssetValuePerShare
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="2"
      id="F_2bdf12f7-9fb8-4127-b81b-f51e3ab7df0b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1</us-gaap:NetAssetValuePerShare>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_f4c66987-8497-4777-a400-251297578891">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5.	Balance Sheet Components&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:63.473%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.943%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:15.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical trial and preclinical costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development services ($&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;million due to related party in 2025 and 2024, respectively)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_e79c852b-ce62-45c8-bfde-8738f2e73b5f">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:63.473%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.943%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:15.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical trial and preclinical costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development services ($&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;million due to related party in 2025 and 2024, respectively)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <nmra:AccruedClinicalTrialAndPreclinicalCosts
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_85928805-d636-4f90-8cd9-6f212b31fc55"
      unitRef="U_USD">11482000</nmra:AccruedClinicalTrialAndPreclinicalCosts>
    <nmra:AccruedClinicalTrialAndPreclinicalCosts
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_a2dabe00-ac43-4725-8e06-84cd28a37a4f"
      unitRef="U_USD">11606000</nmra:AccruedClinicalTrialAndPreclinicalCosts>
    <nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-5"
      id="F_70ca5226-1720-438d-a9d6-3c5b024d18eb"
      unitRef="U_USD">6300000</nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty>
    <nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-6"
      id="F_799daa3c-660f-4efb-9111-152ca83557d1"
      unitRef="U_USD">0</nmra:AccruedResearchAndDevelopmentServicesDueToRelatedParty>
    <nmra:AccruedResearchAndDevelopmentServices
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_5aa8e5a8-e65e-407a-9912-bed5bca6e4fc"
      unitRef="U_USD">6250000</nmra:AccruedResearchAndDevelopmentServices>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_2e017b20-506d-4341-b1be-3bcaccda9259"
      unitRef="U_USD">6159000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_3142399b-a154-471c-8eff-9a71c8587891"
      unitRef="U_USD">9975000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_4bd030b3-3ed5-401b-afb2-0cfa370ae95f"
      unitRef="U_USD">1972000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_36a38e8f-3744-46aa-aefa-05d508e551cb"
      unitRef="U_USD">2686000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_7acc35b6-3b8d-4d4b-b126-ef300c7906e3"
      unitRef="U_USD">409000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_9993c16e-9144-43a3-8155-a8085d39787e"
      unitRef="U_USD">326000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_41023eb6-2a4d-498a-9a82-667d25aec423"
      unitRef="U_USD">26272000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_907c9317-d7f8-46fd-952b-f6aa7821fdb9"
      decimals="-3"
      id="F_0f151547-cfa3-406e-9727-14fd6c2c4405"
      unitRef="U_USD">24593000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_e8dd9c54-1565-4ac2-b2e4-640324695bda">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6.	Acquisitions of Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;BlackThorn Therapeutics, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2020, the Company entered into an agreement and plan of merger (BlackThorn Merger Agreement) to acquire all of the equity interests of BlackThorn Therapeutics, Inc. (BlackThorn), which became effective in September 2020. The Company acquired BlackThorn for its in-process research and development programs, including an antagonist of the kappa opioid receptor (navacaprant (NMRA-140)) for the treatment of MDD and an antagonist of the vasopressin 1a receptor (NMRA-511) for the treatment of agitation in AD. The Company also gained access to a cloud-based computational psychiatry and data platform that was being developed to support drug target identification, patient stratification and objective clinical trial endpoints. Both navacaprant and NMRA-511 were exclusively licensed to BlackThorn by The Scripps Research Institute (TSRI). The acquisition was accounted for as an acquisition of assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The BlackThorn Merger Agreement requires the Company to pay the former stockholders of BlackThorn contingent consideration (i) with respect to navacaprant, in the form of development and regulatory approval milestones of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;365.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which includes a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant,&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and sales-based milestones of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and (ii) with respect to NMRA-511, in the form of development and regulatory approval milestones of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and sales-based milestones of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (BlackThorn Milestones). At the Company&#x2019;s sole discretion, the BlackThorn Milestone payments may be settled in cash or shares of the Company, or a combination of both, subject to the provisions of the BlackThorn Merger Agreement, other than one development milestone in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which must be settled in cash. None of the BlackThorn Milestones were subject to liability classification and/or derivative accounting and any such contingent consideration will be recognized when the contingency is resolved, and the consideration becomes payable. The Company settled the Phase 3 navacaprant dosing milestone in December 2023 by issuing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,072,445&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock based on the volume weighted average price per share prior to the date the milestone was met and paying cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the former stockholders of BlackThorn and participants in the carveout plan (discussed &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;below). As a result, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in acquired in-process research and developed expenses in the fourth quarter of 2023 related to the BlackThorn Milestones. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ne of the other Blackthorn Milestones have been achieved and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such amounts were deemed due or payable as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;BlackThorn Carveout Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The BlackThorn Merger Agreement required that the Company establish a carveout plan (the BlackThorn Carveout Plan), pursuant to which each BlackThorn stock option holder as of immediately prior to the closing date was allocated a certain number of units (the BlackThorn Carveout Units) based on the number of shares underlying the outstanding options held by each participant at that time. Each BlackThorn Carveout Unit represents a right to receive a portion of the BlackThorn Milestone payment (the BlackThorn Carveout Payments) upon the later of (i) the achievement of a BlackThorn Milestone and (ii) the vesting of the BlackThorn Carveout Unit.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The BlackThorn Carveout Units vest based on time-based schedules that mirror the vesting schedules for the original option awards held by each participant. As of the closing date in September 2020, a portion of the BlackThorn Carveout Units corresponding to the pre-acquisition service periods were fully vested (Vested Carveout Units). The remainder of the BlackThorn Carveout Units had vesting subject to the continued service of the participants, the last of which became fully vested in May 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Vested Carveout Units represent contingent consideration for the acquisition as they are attributable to pre-acquisition services rendered by the participants and continuing service is not required for the participants to receive future payments upon a BlackThorn Milestone being achieved. The Company recognizes the contingent consideration obligation for the Vested Carveout Units when the contingency is resolved, and the consideration becomes payable. The BlackThorn Carveout Units that were unvested as of the closing date are dependent on the continued service of participants and were deemed to be a compensation arrangement. The Company recognizes compensation starting from the time payment becomes probable over each participant&#x2019;s service period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company settled the Phase 3 navacaprant dosing milestone in December 2023. The Company recognized contingent consideration related to Vested Carveout Units, which was included in acquired in-process research and developed expenses in the fourth quarter of 2023 related to the BlackThorn Milestones as described above. In addition, the Company recognized and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in compensation related to the BlackThorn Carveout Units that were a compensatory arrangement in 2023. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ne of the other BlackThorn Milestones had been achieved and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such amounts were deemed due or payable as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amgen Inc. Licenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2021, the Company entered into two license agreements with Amgen Inc. (Amgen) pursuant to which it obtained exclusive, worldwide licenses to develop, manufacture, use, commercialize and distribute products containing compounds that are directed to, in one case, CK1&#x3b4;, and in the other case, glucocerebrosidase (GCase), both for the treatment of neurodegenerative diseases (the Amgen License Agreements) and related know-how and clinical material (collectively, the Amgen IPR&amp;amp;D Assets). The Company accounted for these transactions as acquisitions of assets. Concurrently, the Company also executed a research collaboration agreement as well as a stock purchase agreement with Amgen. Both agreements were deemed to be separate transactions and not accounted for as part of the acquisition of assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total upfront consideration transferred to Amgen of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of the Company&#x2019;s Series A-2 convertible preferred stock, with an acquisition date fair value of $1&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was allocated to the Amgen IPR&amp;amp;D Assets and expensed in 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under these &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; license agreements, Amgen is eligible to receive contingent consideration up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;360.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in commercial milestone payments per product payable in cash with a compound directed to CK1&#x3b4; and up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;360.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in commercial milestone payments per product payable in cash with a compound directed to GCase, in each case, upon the achievement of certain sales thresholds and single digit royalties on potential future net sales, related to CK1&#x3b4; or GCase (the Amgen Milestones). Such contingent consideration was not subject to liability classification and/or derivative accounting and will be recognized when the contingency is resolved, and the consideration becomes payable. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ne of the Amgen Milestones had been achieved and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such amounts were deemed due or payable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, until a specified period of time following the achievement of the first successful Phase 2 clinical trial for any licensed product, if the Company chooses to sell, transfer, sublicense or divest rights to a licensed product in certain major markets, Amgen has a period of time to enter into an agreement with the Company for such rights. The Company determined that these rights of first negotiation were not freestanding instruments from the Amgen License Agreements and did not meet the definition of a derivative.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Vanderbilt License&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2022, the Company and Vanderbilt University (Vanderbilt) entered into a license agreement (Vanderbilt License Agreement). Pursuant to the Vanderbilt License Agreement, as amended, the Company obtained an exclusive, worldwide royalty-bearing, sublicensable (subject to certain restrictions) license under certain patent rights and a non-exclusive, worldwide, royalty-bearing, sublicensable (subject to certain restrictions) license under certain know-how covering small molecule positive allosteric modulators (PAMs) predominantly of the muscarinic acetylcholine receptor subtype 4 (M4) to develop, manufacture, and commercialize products, processes and services covered by such patent rights or that incorporate or use such know-how, for any and uses (the Vanderbilt IPR&amp;amp;D Assets). Concurrently, the Company also executed a sponsored research agreement (see Note 8) with Vanderbilt. The sponsored research agreement was deemed to be a separate transaction and not accounted for as part of the acquisition of assets. The acquisition of Vanderbilt IPR&amp;amp;D Assets became effective in February 2022. In May 2024, the Company and Vanderbilt entered into a second sponsored research agreement with Vanderbilt and concurrently entered into an amendment to the Vanderbilt License Agreement (Second Amendment to the Vanderbilt License Agreement), to extend the rights granted to the Company under the Vanderbilt License Agreement to the data and patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research pursuant to the second sponsored research agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The licensed patent rights are subject to Vanderbilt&#x2019;s right to use the patent rights for research, internal non-commercial use, and educational purposes. The Company intends to develop the PAMs for the treatment of schizophrenia and other neuropsychiatric disorders. The Company has agreed to use commercially reasonable efforts to develop and commercialize licensed products, and to achieve certain development milestones.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company paid Vanderbilt a non-refundable, non-creditable upfront cash payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the Vanderbilt IPR&amp;amp;D Assets, which was immediately recognized as acquired in-process research and development expense in the condensed consolidated statement of operations and comprehensive loss as it was determined to have no alternative future use as of the acquisition date. Under the Vanderbilt License Agreement, Vanderbilt is eligible to receive contingent consideration payable in cash up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of specified development milestones and up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;380.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of commercial milestone events as well as tiered royalties at mid-single digit percentages on potential future net sales, subject to specified reductions for the lack of patent coverage, generic entry and payment obligations for third-party licenses (the Vanderbilt Milestones). Such contingent consideration was not subject to liability classification and/or derivative accounting and will be recognized when the contingency is resolved, and the consideration becomes payable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In October 2023, a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million Vanderbilt Milestone was achieved and settled in cash in November 2023 and was recognized in acquired in-process research and developed expenses in the fourth quarter&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ne of the other Vanderbilt Milestones had been achieved and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such amounts were deemed due or payable as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Company also had an exclusive option, exercisable for a specified period of time, to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research pursuant to the sponsored research agreements between the Company and Vanderbilt, the first of which was entered into at the same time as the Vanderbilt License Agreement and the second of which was executed in May 2024. The Company determined that the right to negotiate was not a freestanding instrument from the Vanderbilt License Agreement and did not meet the definition of a derivative. The Company exercised the above disclosed exclusive option under the first sponsored research agreement and the parties executed an agreement in December 2023 pursuant to which the Company licensed certain patent rights in return for a payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million that was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_434aebe9-f88b-42f1-a3a9-60444626ef43"
      decimals="INF"
      id="F_ec01fb94-bd55-4a02-8eff-29d3c08246c0"
      unitRef="U_USD">365000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <nmra:MilestonePaymentDueDescription
      contextRef="C_567b6948-dab8-40c8-9463-dba168ab7953"
      id="F_8f0c8da0-69c4-469a-b3fa-4977c88b85fc">milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant,</nmra:MilestonePaymentDueDescription>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_b98e4b10-ee87-4bcd-aba7-dfcce8c3e11f"
      decimals="INF"
      id="F_c855e073-08db-474f-8af0-6f09bc171212"
      unitRef="U_USD">450000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_a6afc305-12c7-42a2-8ee0-0a5d36ab752d"
      decimals="INF"
      id="F_8174ef86-c070-40f5-9b27-c8cb5ad3bf7a"
      unitRef="U_USD">100000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_97e950d4-ad65-4370-8e70-5ec2021370e9"
      decimals="INF"
      id="F_1540e9d5-95ce-4c20-8fab-f62d0be909a7"
      unitRef="U_USD">100000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <nmra:ContingentConsiderationMilestonePaymentSettledInCash
      contextRef="C_635b097b-2010-46d5-b9db-42a97113defc"
      decimals="-5"
      id="F_ded6ee91-ba0e-48ff-b1c4-72f158dd1d74"
      unitRef="U_USD">10000000</nmra:ContingentConsiderationMilestonePaymentSettledInCash>
    <nmra:SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet
      contextRef="C_998e1d41-951a-4a8a-8f7b-eacf68edbd89"
      decimals="0"
      id="F_6d2ee0f6-83c3-4cde-a0f8-3f4b39cb7e48"
      unitRef="U_shares">6072445</nmra:SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_fa6eb452-286f-470e-bfaf-790490cd6700"
      decimals="-5"
      id="F_5336aabe-ff05-4b03-855e-d5330b90b920"
      unitRef="U_USD">2300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <nmra:AcquiredInProcessResearchAndDevelopedExpense
      contextRef="C_50810541-9cdc-4d75-8385-8446d34bf249"
      decimals="-5"
      id="F_fefc8743-9b00-4ff5-8a5c-833d8b9304fb"
      unitRef="U_USD">60800000</nmra:AcquiredInProcessResearchAndDevelopedExpense>
    <nmra:NumberOfMilestoneAchieved
      contextRef="C_06e547db-6799-4ce2-99ec-f971505c46d0"
      decimals="INF"
      id="F_e07c876d-8e78-4ec7-b12f-b6147bdfc7c7"
      unitRef="U_Milestones">0</nmra:NumberOfMilestoneAchieved>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_ecb47253-5967-4e68-a907-ee441a95567a"
      decimals="INF"
      id="F_7d1bd066-9864-491d-8065-be47abb4e063"
      unitRef="U_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="C_76739724-db36-40d3-a0e9-ef80e990e67b"
      decimals="-5"
      id="F_11920318-3f32-48d5-b370-b453b6e5be93"
      unitRef="U_USD">1800000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <nmra:NumberOfMilestoneAchieved
      contextRef="C_bb874d5c-ff29-4fda-8629-e1343f9f7d96"
      decimals="INF"
      id="F_6c5c4d1d-43e4-44d4-a63b-311c6e60b801"
      unitRef="U_Milestones">0</nmra:NumberOfMilestoneAchieved>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_7c050cf9-993c-4fb3-aeca-b255bac5106d"
      decimals="INF"
      id="F_23806b17-2713-449a-9788-9d60ad47e311"
      unitRef="U_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <nmra:UpfrontConsiderationTransferredShares
      contextRef="C_319051d1-d908-4b4b-a4e2-c1ec01693b5c"
      decimals="-5"
      id="F_f84dcd7e-2fc8-402b-96b6-46d20628b4ff"
      unitRef="U_shares">20000000</nmra:UpfrontConsiderationTransferredShares>
    <nmra:AcquisitionDateFairValueOfSharesTransferred
      contextRef="C_319051d1-d908-4b4b-a4e2-c1ec01693b5c"
      decimals="-5"
      id="F_1661c701-fd3a-41ec-8e09-e67c86dcc727"
      unitRef="U_USD">57000000</nmra:AcquisitionDateFairValueOfSharesTransferred>
    <nmra:NumberOfLicenseAgreements
      contextRef="C_eba48cde-044c-4cf6-83fc-6f6426dd681f"
      decimals="INF"
      id="F_58d1e050-047d-484c-9a80-cc8ac86e731a"
      unitRef="U_Agreements">2</nmra:NumberOfLicenseAgreements>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_28c76f06-1cc1-4845-8c93-25ddca00f65e"
      decimals="INF"
      id="F_e1939e71-edd9-44f3-94ab-4a26eb8e7118"
      unitRef="U_USD">360000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_0073ad06-94e6-4b3b-840a-a087ad92d314"
      decimals="INF"
      id="F_6504d70a-2971-41ba-a9cf-f91f05a6ff45"
      unitRef="U_USD">360000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <nmra:NumberOfMilestoneAchieved
      contextRef="C_fe1ba1ef-7e15-4e74-8545-43b5c9422c97"
      decimals="INF"
      id="F_a51d85f0-84db-4cdc-bbbd-1d74f5e768ad"
      unitRef="U_Milestones">0</nmra:NumberOfMilestoneAchieved>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_a55ca487-0567-4505-9f6f-f91c988a8506"
      decimals="INF"
      id="F_8140c207-d041-4966-bee7-c7a262ffb0c2"
      unitRef="U_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <nmra:UpfrontCashPayment
      contextRef="C_7f20fb03-a67c-4772-9d37-ac7b4fb27bce"
      decimals="-5"
      id="F_5288ea01-b9b5-46c5-b847-de262c224148"
      unitRef="U_USD">13000000</nmra:UpfrontCashPayment>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_ef2557ce-7b57-4e87-830c-4493b126211d"
      decimals="INF"
      id="F_7d67e331-0217-4414-ba3a-582dd4cc7971"
      unitRef="U_USD">42400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_9daa6341-c6b6-4510-aaef-1aaad596df55"
      decimals="INF"
      id="F_bc47a8f4-294e-4262-baf2-9197ea3fc7d6"
      unitRef="U_USD">380000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <nmra:ContingentConsiderationMilestonePaymentSettledInCash
      contextRef="C_8546d344-f5a5-49c0-b25a-d7761e6c965c"
      decimals="-5"
      id="F_f90def0d-e9a3-435c-94dd-dc63d3bb4feb"
      unitRef="U_USD">2000000</nmra:ContingentConsiderationMilestonePaymentSettledInCash>
    <nmra:NumberOfMilestoneAchieved
      contextRef="C_c862b521-4d47-4fe1-8a29-5956f0f3aafd"
      decimals="INF"
      id="F_01c09771-d537-4ef1-b2f3-b2788fcdd3fa"
      unitRef="U_Milestones">0</nmra:NumberOfMilestoneAchieved>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_d572c7f7-2d65-449d-822a-730cba140e6d"
      decimals="INF"
      id="F_a1c4db9f-a88a-47a5-b958-7b6672b52a85"
      unitRef="U_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <nmra:AcquiredInProcessResearchAndDevelopment
      contextRef="C_5d02fd90-893f-4a41-a4e0-50545ee339fa"
      decimals="-5"
      id="F_3cdbd122-f01b-4d3b-8c4e-a8326cf6aa49"
      unitRef="U_USD">800000</nmra:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_e5d94ffa-a690-4d50-8125-35ebb6dbf10f">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7.	Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Indemnification&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware law. The Company currently has directors&#x2019; and officers&#x2019; insurance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has various manufacturing, clinical, research and other contracts with vendors in the conduct of the normal course of its business. Such contracts are generally terminable with advanced written notice and payment for any products or services received by the Company through the effective time of termination and any non-cancelable and non-refundable obligations incurred by the vendor at the effective time of the termination. In the case of terminating a clinical trial agreement at a particular site, the Company would also be obligated to provide continued support for appropriate medical procedures at that site until completion or termination.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_78ab11e9-4b4a-4ad4-959b-757b45cd5cdd">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8.	Strategic License and Research and Collaboration Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2015 TSRI License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the acquisition of BlackThorn (see Note 6), the Company gained certain exclusive rights to intellectual property related to Kappa Opioid Receptor and V1aR Receptor Antagonist programs as well as an oxytocin receptors positive allosteric modulator program (collectively, the TSRI Programs) under a license agreement between BlackThorn and TSRI originally entered into in November 2015 (as amended, the 2015 TSRI License Agreement). The technology licensed under the 2015 TSRI License Agreement is used in the Company&#x2019;s navacaprant and NMRA-511 research and development programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the 2015 TSRI License Agreement, the Company is obligated, among other things, to pay TSRI (i) a nominal annual license fee due and payable on the first day of each calendar year and after the fourth anniversary creditable against any royalties due for such calendar year, (ii) development and regulatory milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in aggregate for the first product from each TSRI Program, which are contingent upon achieving specific development and regulatory milestone events, (iii) commercial milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in aggregate for each occurrence, which are contingent upon achieving specified commercialization milestone events, (iv) tiered low-single digit royalties on future net sales of each royalty-bearing product and (v) a percentage in the mid-single digits of any sublicensing revenues the Company receives. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the Phase 3 navacaprant dosing milestone was met and the Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to TSRI, which was recognized in acquired in-process research and developed expenses in the fourth quarter of 2023. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ne of the other milestones have&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; been achieved and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; royalties were due under the 2015 TSRI License Agreement as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Collaboration Agreement with Amgen&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2021, and concurrently with the Amgen License Agreements (see Note 6), the Company entered into a research collaboration agreement with Amgen (Amgen Collaboration Agreement) to collectively discover drug targets, biomarkers, and other insights associated with central nervous system (CNS) diseases utilizing Amgen&#x2019;s deCODE genetics and human data research capabilities. The Company received exclusive rights under intellectual property generated in the collaboration to exploit therapeutic compounds and diagnostics for use with therapeutics in the CNS field and Amgen received exclusive rights to exploit therapeutic compounds and diagnostics for use with therapeutics outside of the CNS field.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In return for Amgen performing research and development activities under the agreement, the Company committed to making non-refundable, non-creditable quarterly payments over the first two years totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and for the third year $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025 and December 31, 2024, the Company was obligated to pay Amgen $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and nil, respectively, under the Amgen Collaboration Agreement, which was recorded within current liabilities on the condensed consolidated balance sheets. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and nil of research and development expenses during the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; On May 1, 2025 the Company made a final payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to Amgen under the Amgen Collaboration Agreement for research and development activities. The parties agree that this is the final amount due under the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Sponsored Research Agreement with Vanderbilt&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2022, concurrently with the Vanderbilt License Agreement (see Note 6), the Company entered into a sponsored research agreement with Vanderbilt (First Vanderbilt Research Agreement), pursuant to which Vanderbilt agreed to provide the Company research services to develop a M4 PAM back-up program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In return for Vanderbilt performing research and development activities under the agreement, the Company agreed to make quarterly payments for research up to a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million on an annual basis. The term of the agreement ended in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;September 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In addition, the Company also had an exclusive option to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored research (see Note 6).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2024, concurrently with the Second Amendment to the Vanderbilt License Agreement (see Note 6), the Company entered into a second sponsored research agreement with Vanderbilt (Second Vanderbilt Research Agreement), pursuant to which Vanderbilt agreed to provide the Company additional research and development activities on the M4 PAM back-up program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In return for Vanderbilt performing research and development activities under the agreement, the Company agreed to make payments for research up to a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The term of the agreement ended in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In addition, the Company also has an exclusive option to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored r&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;esearch (see Note 6).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Parkinson&#x2019;s Research Ventures Funding Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2024, the Company entered into a research funding agreement with Parkinson&#x2019;s Research Ventures Limited (PRV), pursuant to which PRV agreed to provide the Company funding up to a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in two tranches to carry out preclinical research and development activities related to the Company&#x2019;s NLPR3 program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The first tranche was due upon execution of the agreement and was received in March 2024, for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company notified PVB of a successful drug candidate nomination, the trigger for the second tranche of funding, in December 2024 and received payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in January 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company concluded the funding arrangement was an obligation to perform services and the funding received is recognized as a contra-R&amp;amp;D expense as project costs are incurred. $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and nil of costs were incurred during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Upon achievement of certain development, regulatory or commercial trigger events, the Company agreed to pay PRV in aggregate an amount equal to no more than four times the funding provided by PRV, i.e., a maximum repayment amount of up to &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The trigger event payments meet the derivative scope exception under ASC 815 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivatives and Hedging,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and therefore do not need to be bifurcated and separately accounted for.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <nmra:DevelopmentAndRegulatoryMilestonePayments
      contextRef="C_0fa32b7d-f446-4078-9cee-2d0078041367"
      decimals="INF"
      id="F_be67f819-32bb-4328-9bf1-2c64dbace3a2"
      unitRef="U_USD">1500000</nmra:DevelopmentAndRegulatoryMilestonePayments>
    <nmra:CommercialMilestonePayments
      contextRef="C_0fa32b7d-f446-4078-9cee-2d0078041367"
      decimals="INF"
      id="F_96d00e40-f734-4826-9375-5d2f34b0003e"
      unitRef="U_USD">3500000</nmra:CommercialMilestonePayments>
    <nmra:MilestonePayments
      contextRef="C_b1e412fe-b620-42a7-889f-eea848ba3fcf"
      decimals="-5"
      id="F_f036f314-93a9-4f08-aa6f-94b189ff900c"
      unitRef="U_USD">300000</nmra:MilestonePayments>
    <nmra:MilestonesAchieved
      contextRef="C_64494bd4-6ab5-4895-bf3c-bef01605a51f"
      decimals="INF"
      id="F_86d70340-4d57-441a-9532-2047549c1bbf"
      unitRef="U_USD">0</nmra:MilestonesAchieved>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="C_64494bd4-6ab5-4895-bf3c-bef01605a51f"
      decimals="INF"
      id="F_316adf3f-1a9c-4991-96b2-55e94f60ff9d"
      unitRef="U_USD">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <nmra:ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears
      contextRef="C_e911e4aa-353a-44c7-8d53-12528baf8f7d"
      decimals="-5"
      id="F_120fdba5-7e61-442e-b2f4-9a396e7356d3"
      unitRef="U_USD">50000000</nmra:ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears>
    <nmra:ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear
      contextRef="C_5c0b10fb-50d4-4b4e-b9aa-33b20ed8cf2d"
      decimals="INF"
      id="F_a743553a-11f1-4f9d-a021-3989e200de3f"
      unitRef="U_USD">12500000</nmra:ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear>
    <nmra:RelatedPartyTransactionObligationWithRelatedParty
      contextRef="C_c6ca0beb-621e-45be-9f36-bcb1a9eadb66"
      decimals="-5"
      id="F_b7a102fc-fd37-4a87-a12d-613f2de3d16f"
      unitRef="U_USD">6300000</nmra:RelatedPartyTransactionObligationWithRelatedParty>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e911e4aa-353a-44c7-8d53-12528baf8f7d"
      decimals="-5"
      id="F_24133a10-1b5c-4e20-bf00-60148094282f"
      unitRef="U_USD">6300000</us-gaap:ResearchAndDevelopmentExpense>
    <nmra:CollaborationAgreementTerminationDescription
      contextRef="C_e911e4aa-353a-44c7-8d53-12528baf8f7d"
      id="F_a43bc030-11f9-4f00-8da6-80734685c207">The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024.</nmra:CollaborationAgreementTerminationDescription>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e911e4aa-353a-44c7-8d53-12528baf8f7d"
      decimals="-5"
      id="F_9e4bc458-a83c-4cc6-86e8-2780d5ce008e"
      unitRef="U_USD">6300000</us-gaap:ResearchAndDevelopmentExpense>
    <nmra:ResearchAndCollaborationAgreementQuarterlyPayments
      contextRef="C_8e618d30-af12-4d65-8977-21df83d2cdd6"
      decimals="-5"
      id="F_7b976eb1-098c-4fad-988a-46cdb4ba0d65"
      unitRef="U_USD">1700000</nmra:ResearchAndCollaborationAgreementQuarterlyPayments>
    <nmra:ResearchAgreementExpiryDate
      contextRef="C_d182de24-0601-4e16-8128-a87852d11d16"
      id="F_3f11a484-1b22-4658-b1c7-86fb487d77a9">2023-09</nmra:ResearchAgreementExpiryDate>
    <nmra:ResearchAndCollaborationAgreementPayments
      contextRef="C_e7491852-40a1-4eee-b2b1-7b6c1fafa82d"
      decimals="INF"
      id="F_fab97e10-c34a-47d8-9e75-2063fe5d376f"
      unitRef="U_USD">600000</nmra:ResearchAndCollaborationAgreementPayments>
    <nmra:ResearchAgreementExpiryDate
      contextRef="C_3baa7dbd-2e2b-4e86-9a5b-5cbbc95835cb"
      id="F_d00a7175-df89-4247-b572-b7bb2fbce686">2025-03</nmra:ResearchAgreementExpiryDate>
    <nmra:FundsProvidedForPreClinicalResearchAndDevelopmentActivities
      contextRef="C_a449de6c-c7c4-4d8d-971a-f9c39a05240e"
      decimals="-5"
      id="F_bd904aec-73f6-494b-b0fc-422031131c55"
      unitRef="U_USD">2600000</nmra:FundsProvidedForPreClinicalResearchAndDevelopmentActivities>
    <nmra:PaymentsForExecutionOfAgreement
      contextRef="C_380c3204-a040-4430-aff2-cdc8bf414df7"
      decimals="-5"
      id="F_194b4302-5bb1-49fd-a763-25d4d3f17f5d"
      unitRef="U_USD">1100000</nmra:PaymentsForExecutionOfAgreement>
    <nmra:FundReceivedUponCompletionOfCertainDevelopmentMilestone
      contextRef="C_9725a19f-6026-4597-becd-68b62f258eb7"
      decimals="-5"
      id="F_f6e715e7-80c7-4c81-88da-c862119e2ecc"
      unitRef="U_USD">1500000</nmra:FundReceivedUponCompletionOfCertainDevelopmentMilestone>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_bb5db30d-8a29-4c0f-9230-7f59a4cc1240"
      decimals="-5"
      id="F_519ea4cb-9ee0-43a6-90c0-bb4da27a831d"
      unitRef="U_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_59e023c8-7631-4420-9721-fe4e193d844b"
      decimals="-5"
      id="F_c964ad1c-39f6-461f-93e6-0d3bfc662d96"
      unitRef="U_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <nmra:MaximumRepaymentAmountAgreedToPay
      contextRef="C_bb5db30d-8a29-4c0f-9230-7f59a4cc1240"
      decimals="-5"
      id="F_155f8a51-63ad-433a-94df-950a341c0af5"
      unitRef="U_GBP">8400000</nmra:MaximumRepaymentAmountAgreedToPay>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_35af6c7b-58f1-4709-a8ca-481479e12c91">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9.	Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's board of directors has the authority to issue up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of preferred stock in one or more series with rights, preferences and privileges to be determined. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of preferred stock issued and outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock outstanding in the condensed consolidated balance sheet and condensed consolidated statement of stockholders&#x2019; equity as of March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; includes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136,920&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of restricted stock that vest based on service conditions and are subject to the Company&#x2019;s right of repurchase upon termination of services. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:78.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:18.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for options and restricted stock units issued under the equity plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for future issuance under the equity plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for future issuance under the employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Company may be required to issue additional shares of its capital stock if certain milestone conditions are met pursuant to the contingent consideration associated with the Company&#x2019;s acquisitions of assets (see Note 6). In December 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,072,445&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were issued related to BlackThorn Merger Agreement upon achievement of the Phase 3 navacaprant dosing milestone that was met in October 2023. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares have been reserved for potential future issuances as no other BlackThorn Milestones have been achieved.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="INF"
      id="F_627b82b2-8c27-4552-ab8d-9ce50f8feb0e"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="INF"
      id="F_a32671bf-e245-45ea-8125-f24778e2e77f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="INF"
      id="F_68bf5f45-811f-484e-94a0-43f28215e3c7"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_fd27dd1d-0143-49e6-bae8-7ed81f1fc545"
      decimals="0"
      id="F_3d964ed4-cc25-4a56-9266-cf26d674c70a"
      unitRef="U_shares">136920</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <nmra:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_f961e3de-bc20-416e-83bc-cc4a070c67ea">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:78.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:18.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for options and restricted stock units issued under the equity plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for future issuance under the equity plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for future issuance under the employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</nmra:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ee1bf88c-a716-432c-9927-f73c12f7dabe"
      decimals="-3"
      id="F_af8e4a50-21ba-42ff-9cde-02df44cb175c"
      unitRef="U_shares">25187000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0765bb7b-af0d-4ddb-abe8-4e7b1ecfd1c2"
      decimals="-3"
      id="F_b82b0662-0a20-422b-8f01-2a6594d51f98"
      unitRef="U_shares">18389000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6d975b6a-1d37-4354-bb12-b6e8b427cd7f"
      decimals="-3"
      id="F_729d019b-895f-4c69-9436-506d55101841"
      unitRef="U_shares">4681000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e2a1d014-20d2-44f9-b860-5500f8f6d49e"
      decimals="-3"
      id="F_cd2258c7-0688-47c6-8367-77ca2d5e1b9c"
      unitRef="U_shares">48257000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <nmra:SharesIssuedUponAchievementOfMilestone
      contextRef="C_b021f8a3-fac7-453a-93f0-4243983b574b"
      decimals="INF"
      id="F_c6a6e228-ac4c-4519-af6e-3767391b9964"
      unitRef="U_shares">6072445</nmra:SharesIssuedUponAchievementOfMilestone>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3d315f3a-94bd-45c2-a9f2-a8597bd60111"
      decimals="INF"
      id="F_1dc37b11-5d57-4c6a-ae6c-0ca80061e85a"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_a29b31d9-0c7b-422c-95b5-4c87bed249a4">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10.	Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2023 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2023, the Company adopted the 2023 Equity Incentive Plan (2023 Plan). The 2023 Plan provides for the grant of stock options, restricted stock awards, restricted stock unit awards, and other stock-based awards to employees, directors, and non-employee service providers of the Company. The 2023 Plan replaced the Company&#x2019;s 2020 Equity Incentive Plan (&#x201c;2020 Plan&#x201d; and together with the 2023 Plan, Plans). The Company no longer grants stock options or other awards under its 2020 Plan, but any stock options outstanding under the 2020 Plan remain outstanding and effective in accordance with their terms. Awards granted under the 2023 Plan expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of grant. The price of stock options shall not be less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the estimated fair value on the date of grant and typically vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period although may be granted with different vesting terms.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2023 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company&#x2019;s outstanding shares of common stock as of the last day of the prior year. On January 1, 2025, the number of shares of common stock available for issuance under the 2023 Plan increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,085,495&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares as a result of the automatic increase provision of the 2023 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2023 Employee Share Purchase Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2023, the Company adopted the 2023 Employee Share Purchase Plan (ESPP). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may hold one or more offering periods each year during which employees will be able to purchase shares under the ESPP through payroll deductions made over the term of the offering. The per-share purchase price at the end of each offering period is equal to the lesser of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the closing price of the Company's common stock at the beginning or end of the offering period. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 1, 2025, the number of shares of common stock available for issuance under the ESPP increas&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ed by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,617,099&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares as a result of the automatic increase provision of the ESPP. No shares were issued under the ESPP during the year the three months ended March 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:41.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:11.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands, except per share amounts and years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Canceled and forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable as of March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The stock option activity table above excludes options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;446,068&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock that were originally granted with market conditions to one of the Company&#x2019;s executives.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Plans allow for the grant of restricted common stock and restricted stock units to certain employees, executives, non-employee scientific advisors, and third-party service providers. The restrictions lapse over time primarily according to service-based vesting conditions of each award. In the event of a voluntary or involuntary termination of the holder&#x2019;s continuous provision of services to the Company, any unvested portion of the restricted stock award is automatically forfeited.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s restricted stock activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:45.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:11.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares of&lt;br/&gt;Restricted&lt;br/&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares of&lt;br/&gt;Restricted&lt;br/&gt;Stock&lt;br/&gt;Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding and unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited and expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding and unvested as of March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes total stock-based compensation included in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.434%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.163%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.911000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.465%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:14.027000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025, there was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized stock-based compensation related to stock options and restricted stock outstanding, respectively, including stock options and restricted common stock for which achievement of milestones was not probable, which were expected to be recognized over a weighted-average remaining service period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0c70cc8c-7dc7-4484-8ee0-c0f1aacfc08a"
      id="F_6ce2fc9b-34b1-41fe-8118-d2ca5008da54">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_b09a7f2f-554f-4ab7-a516-b0464c7db20d"
      decimals="INF"
      id="F_249dd7ec-9742-4248-9f57-2a347a9e1639"
      unitRef="U_pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0c70cc8c-7dc7-4484-8ee0-c0f1aacfc08a"
      id="F_b6e3baa7-479e-4dfe-828f-274b1e62644d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <nmra:Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease
      contextRef="C_b09a7f2f-554f-4ab7-a516-b0464c7db20d"
      decimals="INF"
      id="F_bc6623ae-b357-4bba-a4bc-5840cede6a2b"
      unitRef="U_pure">0.05</nmra:Share-BasedCompensationArrangementByShare-BasedPaymentAwardPercentageOfAnuualIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_34c399d6-b754-4a45-afe8-4f0160c2d7d0"
      decimals="INF"
      id="F_a1f5930d-2c7f-487a-b036-1c42b9bc940a"
      unitRef="U_shares">8085495</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <nmra:Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod
      contextRef="C_8d55cf2a-ccb9-488d-99f3-88abc8c63dc6"
      decimals="INF"
      id="F_f9743ab6-e533-436d-b5d9-188a62fc4898"
      unitRef="U_pure">0.85</nmra:Share-BasedCompensationArrangementByShare-BasedPaymentAwardPerShareOfPurchasePriceOfOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_19eb528f-0c9a-4741-8410-ab696e22ae8b"
      decimals="INF"
      id="F_3b6c08d6-ef1c-4084-9e0e-c2e6c1d67145"
      unitRef="U_shares">1617099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_51d2826f-850d-42b8-95b1-38c996013269">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:41.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:11.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands, except per share amounts and years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Canceled and forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable as of March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_504593b3-57d4-4b02-8b18-4bdd29a7ac8f"
      decimals="-3"
      id="F_62687563-0229-40a6-8b86-3b561f0d4f0a"
      unitRef="U_shares">13927000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_504593b3-57d4-4b02-8b18-4bdd29a7ac8f"
      decimals="2"
      id="F_0b36c41f-c9a4-465c-8c88-92ce790f2cf8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_2ab6c9e7-ed9e-4fb0-969f-343343d0a2c0"
      id="F_b7b2f553-d258-4e6c-8634-27bfed77c101">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_504593b3-57d4-4b02-8b18-4bdd29a7ac8f"
      decimals="-3"
      id="F_179a1b71-5c40-49e2-98e0-2aa469779f6c"
      unitRef="U_USD">44953000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660"
      decimals="-3"
      id="F_534b9394-dd3d-4e90-8fd9-f57b75042fc3"
      unitRef="U_shares">11995000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660"
      decimals="2"
      id="F_d19dbc6b-7ce8-407f-ad48-403834e48cbc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660"
      decimals="-3"
      id="F_1e53a34d-a1ea-4412-b46b-9828da92c1fc"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660"
      decimals="0"
      id="F_0acf88c4-ef97-44ae-b3d1-90210029bd82"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660"
      decimals="-3"
      id="F_8e9ad7ce-0030-47a1-9532-5060da7c0866"
      unitRef="U_shares">2166000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660"
      decimals="2"
      id="F_9d39747b-f962-48ad-96ce-4ad39fea4e15"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660"
      decimals="-3"
      id="F_b7a70e2d-9020-46ed-a488-fc0338da337f"
      unitRef="U_shares">121000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660"
      decimals="2"
      id="F_593b2038-1c45-4850-974b-8ff40025a960"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b2225424-d630-4726-95a9-a1c8ebfb3755"
      decimals="-3"
      id="F_b8213a50-7156-40c4-b858-49f2beee4c4b"
      unitRef="U_shares">23635000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_b2225424-d630-4726-95a9-a1c8ebfb3755"
      decimals="2"
      id="F_b2df767c-6888-44e2-855f-540d90ae2cff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660"
      id="F_5956a6ed-a691-447b-ba5b-9df033b833ec">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_b2225424-d630-4726-95a9-a1c8ebfb3755"
      decimals="-3"
      id="F_3f055c60-0a77-497d-93a9-55aa7afcddd8"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_b2225424-d630-4726-95a9-a1c8ebfb3755"
      decimals="-3"
      id="F_c4803b81-95cd-45f2-889c-93bb88a87f63"
      unitRef="U_shares">6490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_b2225424-d630-4726-95a9-a1c8ebfb3755"
      decimals="2"
      id="F_9128318b-dcb2-4069-a213-873aa612515b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_3dcb2394-89b3-4597-ac19-7d6a28943660"
      id="F_23836285-a2de-4206-afe1-292616830435">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_b2225424-d630-4726-95a9-a1c8ebfb3755"
      decimals="-3"
      id="F_98eefbcd-cc14-417a-a15b-7480d9f05bb3"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_0e64685c-4df1-4cfc-8090-786dde3ed56d"
      decimals="INF"
      id="F_d93b4751-0bfc-4cd5-a774-c4fe49e1cc9f"
      unitRef="U_shares">446068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_eae948f1-1123-4e6a-af83-4ad7c47c9e69">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s restricted stock activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:45.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:11.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares of&lt;br/&gt;Restricted&lt;br/&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares of&lt;br/&gt;Restricted&lt;br/&gt;Stock&lt;br/&gt;Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding and unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited and expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding and unvested as of March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_097e4542-80e5-445f-9968-c8d2e3c75940"
      decimals="-3"
      id="F_25a796b2-8575-494b-9af1-425378fc4cd9"
      unitRef="U_shares">371000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_097e4542-80e5-445f-9968-c8d2e3c75940"
      decimals="2"
      id="F_52f91698-d02d-4192-b1a8-545a67505bbd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_ebff40d6-3768-4f98-8eb1-4e6b12753e80"
      decimals="-3"
      id="F_4646330f-c1c7-4061-81c2-3970ff674e8f"
      unitRef="U_shares">1441000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_ebff40d6-3768-4f98-8eb1-4e6b12753e80"
      decimals="2"
      id="F_cfc81987-ba3a-4f8f-bb7f-292a1ccea9c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8"
      decimals="-3"
      id="F_88eefb45-2d6e-4d4e-8a97-6e15fc6c4012"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8"
      decimals="0"
      id="F_ceba66be-06c0-495c-ac1b-86267b06cdd4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_35521780-703a-4201-9415-b3fff9017474"
      decimals="-3"
      id="F_d740ed64-9e33-4933-86eb-bdbd0086dc81"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_35521780-703a-4201-9415-b3fff9017474"
      decimals="0"
      id="F_2072702a-ca69-4425-8d6c-a7ab42a390ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8"
      decimals="-3"
      id="F_12b2315d-e902-4bf6-942d-099c454928c4"
      unitRef="U_shares">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8"
      decimals="2"
      id="F_8611a7c2-bf7f-4c90-948e-bdc520e99cd3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_35521780-703a-4201-9415-b3fff9017474"
      decimals="-3"
      id="F_1dc11f71-6902-468b-a797-2c1f0961d02b"
      unitRef="U_shares">269000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_35521780-703a-4201-9415-b3fff9017474"
      decimals="2"
      id="F_5189fe1b-d321-44ce-974f-2b1e6db9c633"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8"
      decimals="-3"
      id="F_7b5b20aa-e3bb-4ceb-bf76-299aba73e911"
      unitRef="U_shares">231000</nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8"
      decimals="2"
      id="F_c65bbcb1-edcf-4f1c-be89-c7bf89359100"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.87</nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue>
    <nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="C_35521780-703a-4201-9415-b3fff9017474"
      decimals="-3"
      id="F_6ee339df-a967-4dda-b98e-7849f6a71476"
      unitRef="U_shares">66000</nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_35521780-703a-4201-9415-b3fff9017474"
      decimals="2"
      id="F_d9db4f39-3311-4b75-ad37-628e91dc9160"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.07</nmra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_9f0723d9-5254-4d08-bff0-43148bf1192a"
      decimals="-3"
      id="F_391df976-7b3a-4fd8-8699-1cd601b2af34"
      unitRef="U_shares">111000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_9f0723d9-5254-4d08-bff0-43148bf1192a"
      decimals="2"
      id="F_c42b57b3-88c3-49af-aaac-eb96a2ed78ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_ff586993-3393-4df1-a26e-92ffb8e44664"
      decimals="-3"
      id="F_98c6625d-4918-466b-a3c5-ea51f55021d6"
      unitRef="U_shares">1106000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_ff586993-3393-4df1-a26e-92ffb8e44664"
      decimals="2"
      id="F_4151b746-9581-4a85-993e-e7afd233bed8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_389cbeed-1d44-4b2e-9f28-e649c63eec51">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes total stock-based compensation included in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.434%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.163%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.911000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.465%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:14.027000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3b83541b-7d35-4924-a941-cdc46db3b104"
      decimals="-3"
      id="F_231e5ee5-e0c4-42fb-ab02-e2c6aac222e3"
      unitRef="U_USD">3748000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_945e63e7-24e2-41e4-b69a-b13ccda12454"
      decimals="-3"
      id="F_6f3d6c47-b60e-48a2-a82f-c66a015a4105"
      unitRef="U_USD">2812000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_89d8aeee-2789-4a1f-a31f-e532505c7bf2"
      decimals="-3"
      id="F_59653870-751a-41e9-a1ac-369c34db57d0"
      unitRef="U_USD">5576000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_88db6b5d-3162-4950-a605-ff7e73170e5d"
      decimals="-3"
      id="F_898d03c1-fd7e-436b-85d6-8d0bc491688e"
      unitRef="U_USD">4561000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_5577d24e-c81d-4dfc-bcdc-c1f1720dda6f"
      unitRef="U_USD">9324000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_ee983b67-5f06-4524-92f8-43412dd2f0ec"
      unitRef="U_USD">7373000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_357567a5-de51-4303-afa8-40e33e156b88"
      decimals="-5"
      id="F_d2572f38-788a-4ca2-ab76-6fc72972fefd"
      unitRef="U_USD">73600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_9f0723d9-5254-4d08-bff0-43148bf1192a"
      decimals="-5"
      id="F_42f3d6bd-ef5b-4975-9475-4cec97cbb3e6"
      unitRef="U_USD">18300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0f91fe01-be96-44a4-a1f4-fc84be3ec675"
      id="F_9896afbc-0fb7-4683-9acf-2f81b510b08e">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_bc0aae18-ce73-4dfb-b51a-da049eec95c8"
      id="F_81973bf6-b38f-4ee1-9d44-8c773ab589bd">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_80707aff-2f93-4ef6-8311-3f840bbe84ca">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment related to the development of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5ef6507a-991a-417b-a92b-153ec2aede3b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (CEO) serves as the CODM.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CEO manages and allocates resources to the operations of the Company on a consolidated basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#x2019;s strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, cash forecasting, allocating resources and setting incentive targets. The CEO bases this assessment on the Company&#x2019;s consolidated net loss. Through this analysis, the CEO assesses performance by comparing budget to actual results, and then decides how to allocate resources to invest in the Company&#x2019;s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below is a summary of the segment loss, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Program expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Navacaprant (NMRA-140) program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;M4 PAM programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;NMRA-511 program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Preclinical programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development personnel-related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) Includes other research and development costs, provision for income taxes, and other income (expense).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="INF"
      id="F_e59d2f58-bcc5-4220-a836-76c206417c46"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_227a2bb3-3530-40ae-ac92-9a2a08d6c1cd">The CEO manages and allocates resources to the operations of the Company on a consolidated basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#x2019;s strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, cash forecasting, allocating resources and setting incentive targets. The CEO bases this assessment on the Company&#x2019;s consolidated net loss. Through this analysis, the CEO assesses performance by comparing budget to actual results, and then decides how to allocate resources to invest in the Company&#x2019;s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_22071d19-6358-4399-ae71-660dbd09fad7">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below is a summary of the segment loss, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Program expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Navacaprant (NMRA-140) program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;M4 PAM programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;NMRA-511 program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Preclinical programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development personnel-related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) Includes other research and development costs, provision for income taxes, and other income (expense).&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <nmra:NavacaprantNMRA-140ProgramExpenses
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_72b3e118-3c6a-4bad-93f1-d9e52a20e704"
      unitRef="U_USD">24493000</nmra:NavacaprantNMRA-140ProgramExpenses>
    <nmra:NavacaprantNMRA-140ProgramExpenses
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_37810957-ba77-4d50-a4b4-e7c83253302e"
      unitRef="U_USD">24319000</nmra:NavacaprantNMRA-140ProgramExpenses>
    <nmra:M4PAMProgramsExpenses
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_24edb14c-9f8f-4908-aa89-00eee9f698e3"
      unitRef="U_USD">2882000</nmra:M4PAMProgramsExpenses>
    <nmra:M4PAMProgramsExpenses
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_c2da78c1-2806-4068-b5fb-24a185928ce8"
      unitRef="U_USD">3524000</nmra:M4PAMProgramsExpenses>
    <nmra:NavacaprantNMRA-511ProgramExpenses
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_3ce561fb-37e7-406f-8f04-eb6d4556e7aa"
      unitRef="U_USD">2580000</nmra:NavacaprantNMRA-511ProgramExpenses>
    <nmra:NavacaprantNMRA-511ProgramExpenses
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_bd136785-352d-47c8-97ac-6fb9f96d23b0"
      unitRef="U_USD">1887000</nmra:NavacaprantNMRA-511ProgramExpenses>
    <nmra:PreclinicalProgramsExpenses
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_344e0853-d5fc-470f-b410-edca55971544"
      unitRef="U_USD">1002000</nmra:PreclinicalProgramsExpenses>
    <nmra:PreclinicalProgramsExpenses
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_2d9f4f8d-6fe5-493e-878a-0c3f09c528ea"
      unitRef="U_USD">2409000</nmra:PreclinicalProgramsExpenses>
    <nmra:ResearchAndDevelopmentPersonnelRelatedCosts
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_10a91ede-bf1f-4ddb-9c84-5050e7bd9d86"
      unitRef="U_USD">12326000</nmra:ResearchAndDevelopmentPersonnelRelatedCosts>
    <nmra:ResearchAndDevelopmentPersonnelRelatedCosts
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_9ab12f41-2e90-480c-983b-598b6c79580e"
      unitRef="U_USD">10875000</nmra:ResearchAndDevelopmentPersonnelRelatedCosts>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_034b0471-de22-4444-9f31-c48cf24bed0b"
      unitRef="U_USD">18785000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_eb7abb83-d468-492c-83e1-bc4e266a6600"
      unitRef="U_USD">14317000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_14dda382-8264-4beb-b17b-d944f118a099"
      unitRef="U_USD">3074000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_b19ec3c2-a0cd-4a1e-824e-d820b49170de"
      unitRef="U_USD">6365000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <nmra:OtherSegmentItems
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_338b5abd-d5ba-4acd-9834-3af999a45efe"
      unitRef="U_USD">8998000</nmra:OtherSegmentItems>
    <nmra:OtherSegmentItems
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_afd64794-3f3f-44b3-a05c-f17ef3eabec5"
      unitRef="U_USD">2755000</nmra:OtherSegmentItems>
    <us-gaap:NetIncomeLoss
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_7438873d-54a3-4536-9775-c03692263e32"
      unitRef="U_USD">-67992000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_90611b52-ec38-4c7b-a41b-b07140656bd1"
      unitRef="U_USD">-53721000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_40991cf4-f17e-4b90-a5c9-6d2039d09ff8">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12.	Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:58.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.279999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.419999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;161,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options and restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Performance restricted stock (with performance conditions to be established)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_4ae5773e-4e0c-47d5-807b-0d86f6fa84f1">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:58.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.279999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.419999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;161,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_c4c178e3-c2f1-402c-a58d-6ecf7e55d721"
      unitRef="U_USD">-67992000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_cd4b775b-833b-430b-b756-222c9b37c9cc"
      unitRef="U_USD">-53721000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_6675b482-8136-415d-8ff3-63698ed4b95b"
      unitRef="U_shares">161451000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_1598f811-2987-4fb7-9177-3ba3b1c288d6"
      unitRef="U_shares">161451000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_5b3c5527-a96c-4011-b791-7746e8a7bae7"
      unitRef="U_shares">157943000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_04168446-e1ce-4db3-a881-86f9b90d925d"
      unitRef="U_shares">157943000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="2"
      id="F_75c17561-7d17-4a28-9c63-bd7cb232b7ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="2"
      id="F_c4f4b542-cf51-47c3-8ce0-a65b9d9ee7ce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="2"
      id="F_f4f4bc77-772a-448d-9b87-6f50a92afd2b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="2"
      id="F_3e8a70c7-c2b4-414e-92d3-a5db7bc047c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_f572e454-baaa-428f-82d6-eab5f24eaec6">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options and restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Performance restricted stock (with performance conditions to be established)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f9669214-3f77-4f65-8703-5b733c4987c2"
      decimals="-3"
      id="F_b4fe711a-2cec-4260-9887-5f40a1acb7c8"
      unitRef="U_shares">25187000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_624b06cb-3eb6-4c5a-b6f8-d5c6f733459c"
      decimals="-3"
      id="F_f2696f5c-e516-41fd-a256-25e642d18ba7"
      unitRef="U_shares">17084000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5c2c1eeb-3a09-4d7b-9795-a097550eb2bf"
      decimals="-3"
      id="F_90fc4c7e-08c8-40b5-9a7a-113d79366f0f"
      unitRef="U_shares">26000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bdb2f4d2-eed9-41ee-954a-8febbe7f4b55"
      decimals="-3"
      id="F_6a77d8c3-895c-4cc6-9b81-4c7dac12494b"
      unitRef="U_shares">55000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_da5dfacb-16f9-419e-9ea3-8176113c5d89"
      decimals="-3"
      id="F_3094e629-1591-49c8-8781-09cf671f6718"
      unitRef="U_shares">111000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b7741931-52c1-4814-ba2a-d45dd587fcc8"
      decimals="-3"
      id="F_d686e93d-bd7b-46e6-bc80-01b5dbbdb178"
      unitRef="U_shares">650000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0d5d9e12-40b5-47d8-9d2b-14dd033fa5f5"
      decimals="-3"
      id="F_381b2813-4954-4d18-9140-65a68f1fe9d3"
      unitRef="U_shares">255000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_24e1bd61-fe0a-45a0-b4e5-7e09d0a6cf7f"
      decimals="-3"
      id="F_fef22623-ef1a-434e-86fa-948f02c97beb"
      unitRef="U_shares">272000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      decimals="-3"
      id="F_fe21f909-fd49-42e7-a8ab-29d156513efb"
      unitRef="U_shares">25596000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6c7ce039-4752-4464-8f4e-b470a3b92d07"
      decimals="-3"
      id="F_683f8c15-daa0-43a7-a96f-e31c1469e184"
      unitRef="U_shares">18044000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_aae49879-c595-4c0a-a2fa-f7d7599aaeda">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13.	Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025 and December 31, 2024, the Company was obligated to pay Amgen $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, under the Amgen Collaboration Agreement, which was recorded within current liabilities on the condensed consolidated balance sheets. During the three months ended March 31, 2025 and 2024, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, of research and development expenses with Amgen.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <nmra:RelatedPartyTransactionObligationWithRelatedParty
      contextRef="C_c6ca0beb-621e-45be-9f36-bcb1a9eadb66"
      decimals="-5"
      id="F_5ae6ae2f-d65a-410f-a518-ffeb5a8a6bbb"
      unitRef="U_USD">6300000</nmra:RelatedPartyTransactionObligationWithRelatedParty>
    <nmra:RelatedPartyTransactionObligationWithRelatedParty
      contextRef="C_c7784c8e-e600-439e-b7df-863d51173fcb"
      decimals="-6"
      id="F_94fd2344-c59a-4865-96d5-3589b780661c"
      unitRef="U_USD">0</nmra:RelatedPartyTransactionObligationWithRelatedParty>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e911e4aa-353a-44c7-8d53-12528baf8f7d"
      decimals="-5"
      id="F_1ebf712e-6a31-4eb6-b4ba-eae5cd727c17"
      unitRef="U_USD">6300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_bedae046-3671-4278-8b1c-24865ff68f64"
      decimals="-6"
      id="F_43ed7e5a-d9f7-4bf3-8545-2f18ce0b0a58"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_07594a85-9a35-4339-8f32-6efd0798b426">&lt;p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14.	Subsequent Event&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 9, 2025 (the &#x201c;Closing Date&#x201d;) the Company, entered into a loan and security agreement (the &#x201c;Loan Agreement&#x201d;) with K2 HealthVentures LLC (&#x201c;K2HV&#x201d;) that provides up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million principal in term loans (the &#x201c;Term Loans&#x201d;) over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; tranches. The first tranche consists of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million with $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million funded on the Closing Date and an option for an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million at the Company&#x2019;s request through December 31, 2025. The second tranche commitment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million is available to be drawn at the Company&#x2019;s option through September 30, 2026, subject to the achievement of certain clinical and regulatory milestones and receipt of not less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in net cash proceeds from certain financing activities, with at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from an equity financing. A third tranche commitment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million is available to be drawn at the Company&#x2019;s option from December 1, 2027 through December 31, 2027, subject to certain regulatory approvals. A fourth and final tranche commitment of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million is available subject to K2HV&#x2019;s review of certain information from the Company and discretionary approval by the Lenders.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Term Loan matures on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_c244de65-f8a1-4f33-b839-be154c63280c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;May 1, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company is obligated to make interest only payments for the first 36 months, or 48 months if the second tranche is funded, and then interest and principal payments for the next 12 months.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Term Loan bears a variable interest rate equal to the greater of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, and (ii) the sum of (A) the prime rate as quoted in The Wall Street Journal and (B) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our obligations under the Loan Agreement are secured by a security interest in substantially all of our assets, other than certain intellectual property assets. The Loan Agreement includes customary affirmative and negative covenants, as well as standard events of default, including an event of default based on the occurrence of a material adverse event. The negative covenants include, among others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying cash dividends or making other distributions, making investments, creating liens, selling assets and making any payment on subordinated debt, in each case subject to certain exceptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Beginning January 1, 2026, the Company is subject to a minimum liquidity covenant. Depending on the Company&#x2019;s achievement of milestones and/or exceeding a specified market capitalization, the minimum liquidity amount will be one of the following: (i) four months cash runway, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the outstanding obligations under the Loan Agreement, (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the outstanding obligations under the Loan Agreement or (iv) waived (i.e., zero).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may prepay, at its option, all, but not less than all, of the Term Loan then outstanding plus the accrued and unpaid interest on the portion of principal so repaid, subject to a prepayment premium and end of term fee. K2HV may elect prior to the full repayment of the term loans to convert up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of outstanding principal of the term loans into shares of the Company&#x2019;s common stock, at a conversion price of the lesser of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8774&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and the lowest effective price per share of the Company&#x2019;s next equity financing. There will be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; prepayment penalty for any principal amount converted into common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company granted K2HV the right, prior to repayment of the term loans, to invest up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in the aggregate in future offerings of the Company&#x2019;s capital stock subject to certain exceptions and conditions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_cd3670e7-bb95-4a95-9b48-6251aef56387"
      decimals="INF"
      id="F_4c67afe6-76d3-42b7-b1b5-17073376a4d5"
      unitRef="U_USD">125000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <nmra:NumberOfTranches
      contextRef="C_c9441c9e-5777-498d-b6d5-078a3f0763f0"
      decimals="INF"
      id="F_330746ad-6634-4665-8371-9e365055d6fc"
      unitRef="U_Tranche">4</nmra:NumberOfTranches>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_99f5cde7-7246-4eb9-9076-bb614ce418b2"
      decimals="INF"
      id="F_a72b7a16-5b60-4cd1-87c6-8fb9d286a417"
      unitRef="U_USD">40000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_99f5cde7-7246-4eb9-9076-bb614ce418b2"
      decimals="-6"
      id="F_e283c3b2-27e6-4bc2-9d07-860a238561ee"
      unitRef="U_USD">20000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <nmra:LineOfCreditFacilityAdditionalBorrowingCapacity
      contextRef="C_99f5cde7-7246-4eb9-9076-bb614ce418b2"
      decimals="-6"
      id="F_c797c971-3ec9-4f2e-b523-f88a9060f260"
      unitRef="U_USD">20000000</nmra:LineOfCreditFacilityAdditionalBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_c1c1147c-6515-43d5-9a5a-39bdb8587234"
      decimals="INF"
      id="F_c2bba2a1-1e90-40e0-8904-f4a1ab8a1432"
      unitRef="U_USD">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <nmra:NetCashProceedsFromFinancingActivities
      contextRef="C_27ed8d77-f3bf-4069-b960-220c0a09b3fc"
      decimals="INF"
      id="F_c1507c87-e000-4c1b-a14e-8030391f14e9"
      unitRef="U_USD">175000000</nmra:NetCashProceedsFromFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_27ed8d77-f3bf-4069-b960-220c0a09b3fc"
      decimals="INF"
      id="F_2315a3b0-0707-408b-8ca5-150a0547b16f"
      unitRef="U_USD">150000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_e34013cc-ec03-4b59-921d-284dfd9952b9"
      decimals="INF"
      id="F_d2439587-8562-475a-852c-e9d22b678279"
      unitRef="U_USD">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0e450f30-40c2-4a41-84cf-da509f4dece6"
      decimals="INF"
      id="F_249b09b7-7441-4866-b5ae-8f5db24c1524"
      unitRef="U_USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms
      contextRef="C_ad0401b2-4d75-4075-81f0-1c16e959518e"
      id="F_5a528946-d477-4295-9c91-12f81b89aab7">Company is obligated to make interest only payments for the first 36 months, or 48 months if the second tranche is funded, and then interest and principal payments for the next 12 months.</us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms>
    <us-gaap:LineOfCreditFacilityInterestRateDescription
      contextRef="C_ad0401b2-4d75-4075-81f0-1c16e959518e"
      id="F_bc019c2d-aa9f-40d7-9937-e3dbc01ed823">The Term Loan bears a variable interest rate equal to the greater of (i) 10.45%, and (ii) the sum of (A) the prime rate as quoted in The Wall Street Journal and (B) 2.95%.</us-gaap:LineOfCreditFacilityInterestRateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_f164d19d-7ff7-4491-8078-1f6420964b6a"
      decimals="INF"
      id="F_ac7875dc-08a9-4370-b494-1694ea7c6469"
      unitRef="U_pure">0.1045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_49cf2bec-a0f7-4364-9f41-4d0d4dd7485d"
      decimals="4"
      id="F_40abd0b7-044a-4ecc-b990-f6e4d580a20c"
      unitRef="U_pure">0.0295</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCovenantDescription
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_cd4bb77f-5dee-42e2-b234-7f9377c56b1c">Beginning January 1, 2026, the Company is subject to a minimum liquidity covenant. Depending on the Company&#x2019;s achievement of milestones and/or exceeding a specified market capitalization, the minimum liquidity amount will be one of the following: (i) four months cash runway, (ii) 50% of the outstanding obligations under the Loan Agreement, (iii) 105% of the outstanding obligations under the Loan Agreement or (iv) waived (i.e., zero).</us-gaap:DebtInstrumentCovenantDescription>
    <nmra:MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne
      contextRef="C_39f31af5-0a63-4d36-b5c4-aa045096d63a"
      decimals="2"
      id="F_69112e18-2528-40c9-b224-d3e06278c76d"
      unitRef="U_pure">0.50</nmra:MinimumLiquidityCovenantPercentageOfOutstandingObligationsOne>
    <nmra:MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo
      contextRef="C_39f31af5-0a63-4d36-b5c4-aa045096d63a"
      decimals="2"
      id="F_196c6c0e-3f5b-4cf0-a56b-ab4ab9d8b347"
      unitRef="U_pure">1.05</nmra:MinimumLiquidityCovenantPercentageOfOutstandingObligationsTwo>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="C_4a09c9c7-6948-412c-8311-1564f533ec6d"
      decimals="INF"
      id="F_519afbab-c0da-4a03-a628-c116f31fab74"
      unitRef="U_USD">10000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_a586780a-a629-48b7-9844-e31954befa7a"
      decimals="4"
      id="F_390a31d2-72ce-4b15-b74d-a48f47beb46c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.8774</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nmra:PrepaymentPenalty
      contextRef="C_c9441c9e-5777-498d-b6d5-078a3f0763f0"
      decimals="INF"
      id="F_902dcadf-d210-4bf8-b660-317ee5e58266"
      unitRef="U_USD">0</nmra:PrepaymentPenalty>
    <nmra:MaximumFutureCapitalStockOfferingsInvestment
      contextRef="C_cd3670e7-bb95-4a95-9b48-6251aef56387"
      decimals="INF"
      id="F_2e15aa5c-22d5-4aff-b4ce-10c226e8b093"
      unitRef="U_USD">5000000</nmra:MaximumFutureCapitalStockOfferingsInvestment>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_a2ecbe52-b123-4ab1-88c2-8a6e9d824920">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ne of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_c562ae46-4928-4564-ab1a-0684ecef7691">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_bcdc8240-7dbe-4327-896c-1e46a9a9b823">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_97e5dcdd-6c1f-4c34-b5e1-7e22dc9f9ef3">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_444ace39-c318-4dbb-a4fe-64b15e36d5b1"
      id="F_fecf18a7-b0e8-4210-8f81-87adaa8eda38">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
